<SEC-DOCUMENT>0001628280-24-012230.txt : 20240320
<SEC-HEADER>0001628280-24-012230.hdr.sgml : 20240320
<ACCEPTANCE-DATETIME>20240320163320
ACCESSION NUMBER:		0001628280-24-012230
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		172
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240320
DATE AS OF CHANGE:		20240320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alvotech
		CENTRAL INDEX KEY:			0001898416
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981629342
		STATE OF INCORPORATION:			N4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41421
		FILM NUMBER:		24768223

	BUSINESS ADDRESS:	
		STREET 1:		9, RUE DE BITBOURG
		CITY:			LUXEMBOURG
		STATE:			N4
		ZIP:			L-1273
		BUSINESS PHONE:		354 422-4500

	MAIL ADDRESS:	
		STREET 1:		9, RUE DE BITBOURG
		CITY:			LUXEMBOURG
		STATE:			N4
		ZIP:			L-1273

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alvotech Lux Holdings S.A.S.
		DATE OF NAME CHANGE:	20211209
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>alvo-20231231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0f568319-c84c-47ce-b7c2-396cc2b09ac1,g:54c4089e-eaa8-4b46-9747-283b5fa757be,d:e527079dad0a4810aa92569387637e3d-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:srt="http://fasb.org/srt/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:alvo="http://www.alvotech.com/20231231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>alvo-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-42">0001898416</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-43">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-44">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-45">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-797" name="alvo:ThresholdDaysForDeterminingTheSharePrice" id="f-2302">P10D</ix:nonNumeric><ix:nonNumeric contextRef="c-797" name="alvo:NumberOfConsecutiveTradingDays" id="f-2303">P20D</ix:nonNumeric><ix:nonNumeric contextRef="c-798" name="alvo:ThresholdDaysForDeterminingTheSharePrice" id="f-2305">P10D</ix:nonNumeric><ix:nonNumeric contextRef="c-798" name="alvo:NumberOfConsecutiveTradingDays" id="f-2306">P20D</ix:nonNumeric><ix:nonNumeric contextRef="c-807" name="alvo:ThresholdDaysForDeterminingTheSharePrice" id="f-2320">P10D</ix:nonNumeric><ix:nonNumeric contextRef="c-807" name="alvo:NumberOfConsecutiveTradingDays" id="f-2321">P20D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-797" decimals="2" name="alvo:VestingPercentageOfShares" scale="-2" id="f-2505">50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-798" decimals="2" name="alvo:VestingPercentageOfShares" scale="-2" id="f-2506">50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-910" decimals="2" name="alvo:VestingPercentageOfShares" scale="-2" id="f-2507">50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-911" decimals="2" name="alvo:VestingPercentageOfShares" scale="-2" id="f-2508">50</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="alvo-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:ClassOfStocksAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:ClassOfStocksAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:VestedEarnOutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:VestedEarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:VestedEarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PennyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PennyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PennyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:OtherShareBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:OtherShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementsTypeAxis">alvo:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:OacbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares2"><xbrli:measure>alvo:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ClassesOfCommonStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:ClassesOfCommonStockAxis">alvo:ClassBCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">alvo:BusinessCombinationAndPipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechGermanyGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechGermanyGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechGermanyGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechSwissAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechSwissAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechSwissAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHannoverGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHannoverGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHannoverGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMaltaLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMaltaLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMaltaLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUsaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUsaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUsaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUkLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUkLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUkLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMancoEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMancoEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMancoEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechBiosciencesIndiaPrivateLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechBiosciencesIndiaPrivateLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechBiosciencesIndiaPrivateLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:FasteignafelagiSmundurHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:FasteignafelagiSmundurHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:FasteignafelagiSmundurHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechCchnBiopharmaceuticalCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechCchnBiopharmaceuticalCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechCchnBiopharmaceuticalCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AztiqPharmaPartnersSarlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AztiqPharmaPartnersSarlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:OtherSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:OtherSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-23</xbrli:startDate><xbrli:endDate>2024-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="iskPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ISK</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segement"><xbrli:measure>alvo:segement</xbrli:measure></xbrli:unit><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:ProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:ProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:ProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:LicenseRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:LicenseRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:LicenseRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:DevelopmentAndOtherServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:DevelopmentAndOtherServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:DevelopmentAndOtherServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:NotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:NotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="individuals"><xbrli:measure>alvo:Individuals</xbrli:measure></xbrli:unit><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:CostOfProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:CostOfProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:CostOfProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TemporaryDifferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TemporaryDifferenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:TaxYearsAxis">alvo:TwoThousandTwentyFourToTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:TaxYearsAxis">alvo:TwoThousandTwentySevenToTwoThousandTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:TaxYearsAxis">alvo:LaterPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:LU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AssetsAcquisitionAxis">alvo:SaemundurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AssetsAcquisitionAxis">alvo:SaemundurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AssetsAcquisitionAxis">alvo:SaemundurMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagidEyjolfurHf.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagidEyjolfurHf.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:GeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:GeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:GeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntangibleAssetsWithFiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntangibleAssetsWithFiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntangibleAssetsWithFiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntangibleAssetsWithFiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:KashivMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:KashivMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:KashivMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:KashivMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:ClassAAndClassBOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfPredecessorOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfPredecessorOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfClassAOacbOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:ClassAOacbOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfClassAOacbOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:ClassBOacbOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfClassAOacbOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfClassAOacbOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:SaleOfStockAxis">alvo:PrivatePlacementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-10</xbrli:startDate><xbrli:endDate>2023-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:SaleOfStockAxis">alvo:PrivatePlacementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PennyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:A2022ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:A2022ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:BcaFrameworkAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-07</xbrli:startDate><xbrli:endDate>2021-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:EventAxis">alvo:PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:BcaFrameworkAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-07</xbrli:startDate><xbrli:endDate>2021-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:BcaFrameworkAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:FinanceIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleShareholderLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:BcaFrameworkAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleShareholderLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:ComponentOfDebtConvertedIntoEquityAxis">alvo:PrincipalAndAccruedInterestComponent.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ComponentOfDebtConvertedIntoEquityAxis">alvo:PremiumComponentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AdditionalBondsIssuanceAxis">alvo:IssuedToANewBondHolderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AdditionalBondsIssuanceAxis">alvo:IssuedToTheExistingNoteholderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AdditionalBondsIssuanceAxis">alvo:IssuedToTheExistingAndANewBondHolderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AdditionalBondsIssuanceAxis">alvo:IssuedToTheExistingAndANewBondHolderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:EventAxis">alvo:SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:EventAxis">alvo:SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:ComponentOfBondsPayableAxis">alvo:PrincipalComponentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:ComponentOfBondsPayableAxis">alvo:InterestComponentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:NatureOfFeesAxis">alvo:ConsentFeesToBondholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:EventAxis">alvo:ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:EventAxis">alvo:ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:EventAxis">alvo:IncreaseInTheFaceValueOfTheBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:DetailsAxis">alvo:BeforeTheTermsOfTheSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:DetailsAxis">alvo:AfterTheTermsOfTheSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ContingentlyIssuablePennyWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>alvo:tranche</xbrli:measure></xbrli:unit><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ContingentlyIssuablePennyWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ContingentlyIssuablePennyWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranch"><xbrli:measure>alvo:tranch</xbrli:measure></xbrli:unit><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-20</xbrli:startDate><xbrli:endDate>2022-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-24</xbrli:startDate><xbrli:endDate>2023-07-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-31</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-31</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="isk"><xbrli:measure>iso4217:ISK</xbrli:measure></xbrli:unit><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alvo:ATPHoldingEhf.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-31</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:AztiqConversionFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alvo:AztiqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:BorrowingsTrancheAxis">alvo:BorrowingsTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-22</xbrli:startDate><xbrli:endDate>2022-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:BorrowingsTrancheAxis">alvo:BorrowingsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-22</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:BorrowingsTrancheAxis">alvo:BorrowingsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:BorrowingsTrancheAxis">alvo:BorrowingsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityAndAztiqFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityAndAztiqFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="loan"><xbrli:measure>alvo:Loan</xbrli:measure></xbrli:unit><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-11</xbrli:startDate><xbrli:endDate>2022-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-12</xbrli:startDate><xbrli:endDate>2022-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenSubordinatedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenSubordinatedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenLoanWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenSubordinatedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-20</xbrli:startDate><xbrli:endDate>2022-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:ArionBankiHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>alvo:agreement</xbrli:measure></xbrli:unit><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-09</xbrli:startDate><xbrli:endDate>2022-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RiskExposuresAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:FinalMaturityInDecember2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RiskExposuresAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:FinalMaturityInDecember2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsFinancialInstitutionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">alvo:UsdSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsFinancialInstitutionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">alvo:UsdSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsFinancialInstitutionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">alvo:UsdSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:VariableRatesAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:VariableRatesAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:VariableRatesAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnApril2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnApril2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:VariableRatesAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnApril2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:ThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:ThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:FormerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:FormerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:FormerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:FormerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:ExistingEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:ExistingEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:ExistingEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="litigation_case"><xbrli:measure>alvo:litigation_case</xbrli:measure></xbrli:unit><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LeaseFacilityAxis">alvo:April2023LeaseFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FlokiFasteignirEhf.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FlokiFasteignirEhf.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:LeaseFacilityAxis">alvo:Remaining15LeaseFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FlokiArtEhf.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsSRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsSRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AtpHoldingsEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AtpHoldingsEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqConsultingEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqConsultingEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiArtEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiArtEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenUKSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenUKSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenFinanceB.VMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenFinanceB.VMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusInternationalPteltdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusInternationalPteltdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoUKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiInvestEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiInvestEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiHoldingsS.aR.lMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiHoldingsS.aR.lMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenSpainSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenSpainSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:NorwichClinicalServicesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:NorwichClinicalServicesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignaflagiEyjlfurhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignaflagiEyjlfurhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiFasteignirEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiFasteignirEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsSRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsSRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqConsultingEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqConsultingEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AtpHoldingsEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AtpHoldingsEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiEyjolfurEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiEyjolfurEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusInternationalPteltdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusInternationalPteltdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenKoreaCo.LtdSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenKoreaCo.LtdSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenSpainSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenSpainSlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:NorwichClinicalServicesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:NorwichClinicalServicesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenPharmaPvtLtdSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenPharmaPvtLtdSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiFasteignirEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiFasteignirEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:L41EhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:L41EhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:Lambahagavegur7EhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:Lambahagavegur7EhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsS.aR.lSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqPharmaPartnersS.aR.l.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenAztiqABSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenUKSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenKoreaCo.LtdSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenPharmaPvtLtdSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:HRJAFEhfSisterCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:L41EhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:Lambhagavegur7EhfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RichardDaviesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RichardDaviesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AnnMerchantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AnnMerchantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ArniHararsonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ArniHararsonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FaysalKalmouaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FaysalKalmouaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LindaMcgoldrickMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LindaMcgoldrickMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LisaGraverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LisaGraverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ThomasEkmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ThomasEkmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:NetCompensationExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:NetCompensationExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:OtherExecutiveTeamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RichardDaviesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RichardDaviesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AnnMerchantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AnnMerchantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ArniHararsonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ArniHararsonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FaysalKalmouaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FaysalKalmouaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LindaMcgoldrickMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LindaMcgoldrickMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LisaGraverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LisaGraverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ThomasEkmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ThomasEkmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:HirofumiImaiBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:HirofumiImaiBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:NetCompensationExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:NetCompensationExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:MarkLevickCeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:OtherExecutiveTeamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:A2022ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:A2022ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:ConversionPriceOfBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:ConversionPriceOfBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:DividendYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:DividendYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:RiskyYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:RiskyYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:VariableInterestRateFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:VariableInterestRateFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:CashEquivalentsAndCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:CashEquivalentsAndCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-891"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-894"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:HumiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-26</xbrli:startDate><xbrli:endDate>2024-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-26</xbrli:startDate><xbrli:endDate>2024-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-12</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-12</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001898416</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie527079dad0a4810aa92569387637e3d_1"></div><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">WASHINGTON, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">____________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">20-F</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">____________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="f-2">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">OR </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-3">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-5"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">OR </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">OR </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="f-7">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Date of event requiring this shell company report </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">001-41421</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">____________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-9">ALVOTECH</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Exact name of Registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">____________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Not applicable</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-10">Grand Duchy of Luxembourg</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Translation of Registrant&#8217;s name into English)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Jurisdiction of incorporation or organization)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-11">9</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-12">Rue de Bitbourg</ix:nonNumeric>, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">L-<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">1273</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-14">Luxembourg</ix:nonNumeric>, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-15">Grand Duchy of Luxembourg</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelName" id="f-16">Robert Wessman</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressAddressLine1" id="f-17">S&#230;mundargata 15-19</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressPostalZipCode" id="f-18">102</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCityOrTown" id="f-19">Reykjav&#237;k</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-20">Iceland</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">+<ix:nonNumeric contextRef="c-2" name="dei:CityAreaCode" id="f-21">354</ix:nonNumeric> <ix:nonNumeric contextRef="c-2" name="dei:LocalPhoneNumber" id="f-22">422 4500</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Securities registered or to be registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:31.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-23">Ordinary Shares</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-24">ALVO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-25">Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-26">Warrants</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-27">ALVOW</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-28">Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Securities registered or to be registered pursuant to Section 12(g) of the Act: None </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">____________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual company report: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-29">266,821,844</ix:nonFraction> Ordinary Shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="alvo:ClassOfWarrantsOrRightsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">10,363,094</ix:nonFraction> Warrants to purchase Ordinary Shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-31">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">x </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-32">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-33">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-34">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-35">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-36">x</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-37">o</ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:18.5pt">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-38">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-39">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:19.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">US GAAP </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAccountingStandard" id="f-40">International Financial Reporting Standards</ix:nonNumeric> as issued</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">by the International Accounting Standards Board</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"> &#174;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item17 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> Item18 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-41">x</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TABLE OF CONTENTS </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.265%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_13">GENERAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_13">1</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_16">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_16">1</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_19">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_22">Item 1. Identity of Directors, Senior Management and Advisers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_25">Item 2. Offer Statistics and Expected Timetable</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_28">Item 3. Key Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_31">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_31">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_34">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_34">Capitalization and indebtedness</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_34">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_37">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_37">Reasons for the offer and use of proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_37">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_40">D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_40">Risk factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_40">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_43">Item 4. Information on the Company </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_43">67</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_46">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_46">History and Development of the Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_46">67</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_49">B</a>.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_49">Business Overview</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_49">68</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_52">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_52">Organizational Structure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_52">98</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_55">D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_55">Property, Plants and Equipment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_55">98</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_58">Item 4A. Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_58">100</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_61">Item 5. Operating and Financial Review and Prospects</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_61">100</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_64">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_64">Operating Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_64">104</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_67">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_67">Liquidity and Capital Resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_67">115</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_70">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_70">Research and Development, Patents and Licenses, etc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_70">119</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_73">D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_73">Trend Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_73">119</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_76">E.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_76">Critical Accounting Policies and Estimates</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_76">119</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_79">Item 6. Directors, Senior Management and Employees </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_79">121</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_82">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_82">Directors and senior management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_82">121</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_85">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_85">Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_85">123</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_88">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_88">Board Practices</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_88">126</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_91">D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_91">Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_91">128</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_94">E.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_94">Share Ownership</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_94">129</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_97">F.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_97">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_97">129</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_100">Item 7. Major Shareholders and Related Party Transactions </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_100">129</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_103">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_103">Major Shareholders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_103">129</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_106">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_106">Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_106">131</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_109">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_109">Interests of Experts and Counsel</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_109">132</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_112">Item 8. Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_112">132</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_115">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_115">Consolidated Statements and Other Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_115">132</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_118">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_118">Significant Changes</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_118">133</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_121">Item 9. The Offer and Listing </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_121">133</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_124">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_124">Offer and Listing Details</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_124">133</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_127">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_127">Plan of Distribution</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_127">133</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_130">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_130">Markets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_130">133</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_133">D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_133">Selling Shareholders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_133">133</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_136">E.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_136">Dilution</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_136">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_139">F.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_139">Expenses of the Issue</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_139">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_142">Item 10. Additional Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_142">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_145">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_145">Share Capital</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_145">134</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_148">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_148">Memorandum and Articles of Association</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_148">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_151">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_151">Material Contracts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_151">134</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_154">D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_154">Exchange Controls</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_154">136</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_157">E.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_157">Taxation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_157">136</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_160">F.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_160">Dividends and Paying Agents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_160">141</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_163">G.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_163">Statement by Experts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_163">141</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_166">H.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_166">Documents on Display</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_166">141</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_169">I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_169">Subsidiary Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_169">142</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_172">J.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_172">Annual Report to Security Holders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_172">142</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_175">Item 11. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_175">142</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_178">Item 12. Description of Securities Other than Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_178">143</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_181">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_181">Debt Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_181">143</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_184">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_184">Warrants and Rights</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_184">143</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_187">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_187">Other Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_187">143</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_190">D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_190">American Depositary Shares</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_190">143</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_193">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_193">144</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_196">Item 13. Defaults, Dividend Arrearages and Delinquencies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_196">144</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_199">Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_199">144</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_202">Item 15. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_202">144</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_205">A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_205">Disclosure Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_205">144</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_208">B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_208">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_208">144</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_211">C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_211">Attestation Report of the Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_211">146</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_214">D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_214">Changes in Internal Control Over Financial Reporting</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_214">146</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_217">Item 16. [Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_217">146</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_220">Item 16A. Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_220">146</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_223">Item 16B. Code of Ethics</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_223">146</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_226">Item 16C. Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_226">146</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_229">Item 16D. Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_229">147</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_232">Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_232">147</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_235">Item 16F. Change in Registrant&#8217;s Certifying Accountant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_235">147</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_238">Item 16G. Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_238">147</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_241">Item 16H. Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_241">148</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_244">Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_244">148</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_944">Item 16J.</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_944"> In</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_944">sider Tra</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_944">ding P</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_944">olicy</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_944">148</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_865">Item 16K</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_865">. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_865">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_865">148</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_247">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_247">150</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_250">Item 17. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_250">150</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_253">Item 18. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_253">150</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_256">Item 19. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_256">150</a></span></div></td></tr></table></div><div id="ie527079dad0a4810aa92569387637e3d_10"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">GENERAL INFORMATION </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless context otherwise requires, all references in this Annual Report on Form 20-F (&#8220;Annual Report&#8221;) to &#8220;Alvotech,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Alvotech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and, where appropriate, its consolidated subsidiaries. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this Annual Report appear without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. </span></div><div id="ie527079dad0a4810aa92569387637e3d_16"></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 20-F (including information incorporated by reference herein, the &#8220;Annual Report&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contains or may contain forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">involve significant risks and uncertainties. All statements other than statements of historical facts are forward-looking</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">statements. These forward-looking statements include information about our possible or assumed future results of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">operations or our performance. Words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;targets&#8221;, &#8220;possible,&#8221; &#8220;project,&#8221; and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;predict&#8221; and variations of such words and similar expressions are intended to identify the forward-looking statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise stated or unless the context otherwise requires, references to &#8220;Alvotech&#8221; or the &#8220;Company&#8221; are to the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">registrant named &#8220;Alvotech&#8221;, previously known as Alvotech Lux Holdings S.A.S. and its subsidiaries after the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consummation of the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(the &#8220;Business Combination&#8221;), whereas references to &#8220;Alvotech Holdings&#8221; are to Alvotech Holdings S.A. and its</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">subsidiaries prior to the consummation of the Business Combination (the &#8220;Closing&#8221;) on 15 June 2022 (the &#8220;Closing</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#8221;). Forward-looking statements in this Annual Report may include, for example, statements about:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Development and projections relating to our competitors and industry, including the estimated growth of the industry; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The timing of, and our ability to obtain and maintain regulatory approval for our product candidates of the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), European Commission and comparable national or regional authorities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The timing of the announcement of clinical study results, the commencement of patient studies, regulatory applications, approvals and market launches; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our expectations regarding regulatory review and interactions, including the timing and results of the facility inspection by the FDA or other foreign regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our financial performance; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Changes in our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our strategic advantages and the impact those advantages will have on future financial and operational results; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our expansion plans and opportunities, </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our ability to grow our business in a cost-effective manner; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The implementation, market acceptance and success of our business model; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Developments and projections relating to our competitors and industry, including the estimated growth of the industry; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our approach and goals with respect to technology; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Changes in applicable laws or regulations; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The outcome of any known and unknown litigation and regulatory proceedings; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our ability to maintain the listing of our ordinary shares, with a nominal value of $0.01 per share (&#8220;Ordinary Shares &#8221;), or warrants (the &#8220;Warrants&#8221;) on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) and the Nasdaq Main Market in Iceland (&#8220;Nasdaq Iceland Main Market&#8221;);</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our ability to comply with all applicable laws and regulations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our ability to successfully launch our products in certain markets after obtaining regulatory approval for such market; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our estimates of expenses and profitability; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our ability to raise additional adequate funds through equity or debt financing; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our ability to identify and successfully develop new product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our relationship with third party providers for clinical and non-clinical studies, supplies, and manufacturing of our products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our ability to manage our manufacturing risks; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The impact of worsening or unpredictable macroeconomic conditions, including rising inflation, interest rates and cost of energy, and general market conditions, global geopolitical tension, including regions affected by Russia's invasion of Ukraine and conflicts in the Middle East, or public health emergencies, on the business, financial position, strategy and anticipated milestones; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our relationship with partners for the commercialization of our product candidates. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These forward-looking statements are based on information available as of the date of this Annual Report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You should not place undue reliance on these forward-looking statements in deciding to invest in our securities. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The outcome of any legal proceedings that may be instituted against us or others following the Business Combination; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The outcome of any legal or regulatory proceedings; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The ability to raise substantial additional funding, which may not be available on acceptable terms or at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The ability to maintain the listing of Ordinary Shares on The Nasdaq Stock Market LLC and Nasdaq Iceland Main Market; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Changes in applicable laws or regulations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The effects of public health emergencies on our business;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The inherent uncertainty of projected financial information with respect to us, and the possibility that the assumption underlying such projects ultimately prove incorrect; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The effects of competition on our future business; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our position in the market against current and future competitors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our expansion into new products, services, technologies or geographic regions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our ability to implement business plans, forecasts and other expectations, and identify and realize additional opportunities and to continue as a going concern; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The risk of downturns and the possibility of rapid change in the highly competitive industry in which we operate; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The risk that we and our current and future commercial partners are unable to successfully develop, seek regulatory approval for, and commercialize our products or services, or experience significant delays in doing so; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The risk that we may never achieve or sustain profitability; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The risk that we may need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The risk that we experience difficulties in managing our growth and expanding operations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The risk that we have identified a material weakness in our internal control over financial reporting which, if not corrected, could affect the reliability of our financial statements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The risk that we are unable to secure or protect our intellectual property; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The risk that estimated growth of the industry does not occur, or does not occur at the rates or timing we have assumed based on third-party estimates and on our own internal analyses; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The possibility that we may be adversely affected by other economic, business, and/or competitive factors. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You should refer to the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 3.D Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART I </span></div><div id="ie527079dad0a4810aa92569387637e3d_22"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Identity of Directors, Senior Management and Advisers. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Offer Statistics and Expected Timetable. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Key Information. </span></div><div id="ie527079dad0a4810aa92569387637e3d_31"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17.84pt">[Reserved] </span></div><div id="ie527079dad0a4810aa92569387637e3d_34"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Capitalization and indebtedness. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_37"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Reasons for the offer and use of proceeds. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_40"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D. &#160;&#160;&#160;&#160;Risk factors. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">An investment in our securities carries a significant degree of risk. In addition to the other information contained in this Annual Report on Form 20-F, including the matters addressed under the heading &#8220;Forward-Looking Statements,&#8221; you should carefully consider the following risk factors in deciding whether to invest in our securities. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect relating to our business, financial condition, and results of operations and future prospects, in which event the market price of our securities could decline, and you could lose part or all of your investment. Additional risks and uncertainties of which we are not presently aware or that we currently deem immaterial could also affect our business operations and financial condition. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary Risk Factors </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to a number of risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in this section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; in Part I, Item 3.D. of this Annual Report. Set forth below is a summary list of the principal risk factors as of the date of the filing of this Annual Report: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">We have a limited operating history in a highly regulated environment on which to assess our business, have incurred significant losses since inception and anticipate that we may continue to incur significant losses for the immediate future. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">We have substantial indebtedness and expect to continue to use leverage in executing our business strategy, which could have important consequences on our business and adversely affect the return on our assets. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">We may need to raise substantial additional funding from shareholders or third parties. This additional funding may not be available on acceptable terms or at all. Failure to obtain such necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The regulatory approval processes of the FDA, European Commission, Health Canada and comparable other national or regional authorities are lengthy and time consuming and we cannot give any assurance that marketing authorization applications for any of our product candidates will receive regulatory approval. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our product candidates may cause unexpected side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following regulatory approval, if granted. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our commercial products will remain subject to continuous subsequent regulatory obligations and scrutiny. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">We rely on third parties to conduct our nonclinical and clinical studies, to manufacture aspects of clinical and commercial supplies of our product candidates, and to store critical components of our product candidates. If these third parties do not successfully carry out their contractual duties, or are not compliant with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">We are subject to a multitude of risks related to manufacturing. Any adverse developments affecting the manufacturing operations of our biosimilar products could substantially increase our costs and limit supply for our products, or could affect the approval status of our products. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our biosimilar product candidates, if approved, will face significant competition from the reference products, from other biosimilar products that reference the same reference products including those which may have regulatory exclusivities, and from other medicinal products approved for the same indication(s) as the reference products. Our failure to effectively compete may prevent us from achieving significant market penetration and expansion. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">We currently have no marketing and sales organization. We are dependent on our partners for the commercialization of our biosimilar products in certain markets, and their failure to commercialize in those markets could have a material adverse effect on our business and operating results. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">If we, or one of our partners, infringe or are alleged to infringe the intellectual property rights of third parties, our business could be harmed.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Our recurring losses raise substantial doubt as to our ability to continue as a going concern. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we experience additional material weaknesses in the future or otherwise are unable to develop and maintain an effective system of internal controls in the future, we may not be able to produce timely and accurate financial statements or comply with applicable laws and regulations, which may adversely affect investor confidence in us and, as a result, the value of Ordinary Shares.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Future issuances of debt securities and equity securities, including by selling shareholders with resales covered by effective shelf registration statements, may adversely affect us, including the market price of our Ordinary Shares and may be dilutive to existing shareholders. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Financial Position and Need for Capital </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a limited operating history in a highly regulated environment on which to assess our business, have incurred significant losses since inception and anticipate that we may continue to incur significant losses for the immediate future. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a biotech company with a limited operating history. We have incurred losses in each year since inception in 2013, including losses of $551.7 million, $513.6 million, and $101.5 million for the years ended 31&#160;December 2023, 2022, and 2021, respectively. We had an accumulated deficit of $2,205.8 million as of 31&#160;December 2023.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have devoted substantially all of our financial resources to identify and develop our product candidates, including conducting, among other things, analytical characterization, process development and manufacture, formulation and clinical studies and providing general and administrative support for these operations. To date, we have financed our operations primarily through the sale of equity securities, debt financing by way of shareholder loans (convertible and non-convertible) and the issuance of bond instruments (convertible and non-convertible) to third party investors and related parties, as well as through milestone payments received under certain license and development agreements with our partners, for example Teva Pharmaceuticals International GmbH (&#8220;Teva&#8221;), STADA Arzneimittel AG (&#8220;STADA&#8221;), and Mercury Pharma Group Limited (&#8220;Advanz&#8221;). The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings or strategic collaborations. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no guarantee that we will receive regulatory approval for our product candidates in any country. If we obtain regulatory approval to market a biosimilar product candidate, our future revenue will depend upon the therapeutic indications for which approval is granted, the size of any markets in which our product candidates may receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors and adequate market share for our product candidates in those markets. However, even if one or more of our product candidates gain regulatory approval and is commercialized, we may never become profitable. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to continue to incur significant expenses, which could lead to increasing operating losses for the immediate future. We anticipate that our expenses will increase substantially if and as we: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">prepare for commercial launch of our products which have received approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">continue our analytical, nonclinical and clinical development of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">incur costs associated with being a public company; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">expand the scope of our current clinical studies for our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">advance our programs into more expensive clinical studies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">initiate additional analytical, nonclinical, clinical or other studies for our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">change or add contract manufacturers, clinical research service providers, testing laboratories, device suppliers, legal service providers or other vendors or suppliers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">establish a sales and marketing infrastructure; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">seek to identify, assess, acquire and/or develop other biosimilar product candidates or products that may be complementary to our products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">make upfront, milestone, royalty or other payments under any license agreements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">seek to create, maintain, protect, expand and enforce our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">engage legal counsel and technical experts to help evaluate and avoid infringing any valid and enforceable intellectual property rights of third parties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">engage in litigation including patent litigation with reference product companies or others that may hold patents allegedly infringed by us; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">seek to attract and retain skilled personnel; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">experience any delays or encounters issues with any of the above, including but not limited to failed studies, conflicting results, safety issues, supply chain issues, and other delays, whether or not due to public health emergencies, litigation or regulatory challenges that may require longer follow-up of existing studies, additional major studies or additional supportive studies in order to obtain regulatory approval. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year such that a period-to-period comparison of our results of operations may not be a good indication of our future performance quarter-to-quarter and year-to-year due to factors including the timing of clinical trials, any litigation that we may file or that may be filed against us, the execution of collaboration, licensing or other agreements, and the timing of any payments we make or receive thereunder. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our product revenues have been limited and we may never be profitable. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we have received upfront payments, milestone and other contingent payments and/or funding for development from some of our collaboration and license agreements, and some product revenue since we launched AVT02 in Canada, Europe and Australia in 2022 and 2023, we generated limited revenue from product sales. Our ability to generate revenue and achieve profitability depends on the ability of our strategic collaboration partners, to successfully commercialize our approved biosimilars and our ability to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, as well as successfully commercialize, our biosimilar candidates. We cannot predict if and when we will begin generating revenue from product sales outside of Canada, Europe and Australia, as this depends heavily on our success in many areas, including but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">launching and commercializing product candidates for which we obtain regulatory approval, either directly or with collaboration partners or distributors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">obtaining adequate third-party payor coverage and reimbursements for our approved products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">obtaining market acceptance of biosimilar pharmaceuticals as viable treatment options; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">addressing any competing technological and market developments, including the development of new formulations of the originator biologic or new biologics which can be used to treat the indications for approved biosimilars or biosimilar candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">completing analytical, nonclinical and clinical development of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">developing and testing of our product formulations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">obtaining and retaining regulatory approvals for product candidates for which we complete clinical studies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">developing a sustainable and scalable manufacturing process for any approved product candidates that is compliant with regulatory manufacturing requirements;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">establishing and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market demand for our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">identifying, assessing and developing (or acquiring/in-licensing) new product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">negotiating favorable or commercially reasonable terms in any collaboration, licensing or other arrangements into which we may enter; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">attracting, hiring and retaining qualified personnel; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the result of potential litigation including patent litigation with reference product companies or others that may allege infringement by us. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if product candidates that we develop are approved for commercial sale, we may incur significant costs in order to manufacture and commercialize any such product. Our expenses could increase beyond our expectations if we are required by the FDA, the European Commission, the European Medicines Agency (the "EMA"), other comparable regulatory authorities, domestic or foreign, or by any unfavorable outcomes in intellectual property litigation filed against us, to change our manufacturing processes or assays or to perform clinical, nonclinical, analytical or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining regulatory approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the timing of our entry into a particular market or territory, the number of biosimilar competitors in such markets and whether any have regulatory exclusivity, the national laws governing substitution, the accepted price for the product, the ability to get reimbursement at any price, the nature and degree of competition from the reference product and other biosimilar companies (including competition from large pharmaceutical companies entering the biosimilar market that may be able to gain advantages in the sale of biosimilar products based on brand recognition and/or existing relationships with customers and payors), our ability to manufacture sufficient quantities of the product of sufficient quality and at a reasonable cost and whether we own (or has partnered to own) the commercial rights   for that territory. If the market for our product candidates (or its share of that market) is not as significant as we expect, the regulatory approval is narrower in scope than we expect (e.g., for a narrow indication or set of indications) or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are unable to successfully complete development and obtain regulatory approval for our product candidates in significant markets, our business may suffer. Additionally, if we are not able to generate substantial revenue from the sale of any approved products or the costs necessary to generate revenues increase significantly, we may never become profitable. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating and financial results are subject to concentration risk. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operational and financial results are subject to concentration risk. Our success will depend significantly on the development of a limited number of product candidates, their regulatory approval in a limited number of jurisdictions and their commercialization by a limited number of commercial partners. Even if we are successful in developing and commercializing all of these products, our revenue will be dependent on a limited number of products that would account for a significant majority of our revenues. This concentration risk would increase to the extent we are successful in developing and commercializing fewer products as we would be dependent on a lower number of products for the significant majority of our revenues. Unfavorable changes or the non-occurrence of certain anticipated events with respect to any of these limited number of products, jurisdictions or commercial partners may disproportionally affect our global results. As of 31&#160;December 2023, we have only generated product revenue through sales of AVT02 in Canada, Australia and nineteen select European markets since 2022 through certain commercialization partners. See also &#8220;&#8212;We are dependent on our partners, such as Teva, STADA and Advanz for the commercialization of our biosimilars and biosimilar candidates in certain major markets, and their failure to commercialize in those markets could have a material adverse effect on our revenue, business and operating results.&#8221;</span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unable to generate sufficient cash flow to satisfy our significant debt service obligations, which would adversely affect our financial condition and results of operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to make principal and interest payments on and to refinance our indebtedness will depend on our ability to generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors that may be beyond our control. If our business does not generate sufficient cash flow, if currently anticipated costs and revenues are not realized on schedule, in the amounts projected or at all, or if future borrowings are not available to us in amounts sufficient to enable us to pay our indebtedness or to fund our other liquidity </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">needs, our financial condition and results of operations may be adversely affected. Furthermore, our debt obligations are secured by substantially all of our intellectual property. If we cannot service our debt payments under the senior bonds</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">issued by Alvotech Holdings on 14 December 2018, as amended and restated on 16 November 2022 (the &#8220;Senior Bonds"), the bondholders may take possession, sell, exchange, license or otherwise dispose of our intellectual property, which we have pledged as collateral for the Senior Bonds. If we cannot generate sufficient cash flow to make scheduled principal and interest payments on our debt obligations in the future, we may need to refinance all or a portion of our indebtedness on or before maturity, sell assets, delay capital expenditures or seek additional equity. If we are unable to refinance any of our indebtedness on commercially reasonable terms or at all or to effect any other action relating to our indebtedness on satisfactory terms or at all, we may be forced to reduce or discontinue operations or seek protection of the bankruptcy laws, our business may be harmed and our securityholders may lose some or all of their investment. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may need to raise substantial additional funding from shareholders or third parties. This additional funding may not be available on acceptable terms or at all. Failure to obtain such necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing our product candidates is expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates through clinical studies. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, we had cash and cash equivalents, excluding restricted cash, of $11.2 million. In February 2024, we accepted an offer for the sale of 10,127,132 Ordinary Shares for gross proceeds of approximately $166 million.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, even with the aforementioned cash as of 31&#160;December 2023 and the proceeds from the February 2024 private placement, management has determined that there is a material uncertainty that may cast significant doubt about our ability to continue as a going concern. The audited consolidated financial statements appearing elsewhere in this Annual Report on Form 20-F have been prepared on a going concern basis without adjustments that might result from the outcome of this uncertainty and the report of our independent registered public accounting firm thereon includes an explanatory paragraph to that effect. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may require significant additional funding to obtain regulatory approval for, and to successfully commercialize, our product candidates. In addition, our operating plans may change as a result of many factors that are currently unknown to us, and we may need to seek additional funding sooner than planned. Our future funding requirements will depend on many factors, including but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the scope, rate of progress, results and cost of our analytical studies, clinical studies, nonclinical testing and other related activities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the cost of manufacturing clinical supplies and establishing commercial supplies, of our product candidates and any products that we may develop; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the number and characteristics of product candidates that we pursue; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the cost, timing and outcomes of regulatory approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the cost and timing of establishing sales, marketing and distribution capabilities and launching our products that have received regulatory approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the terms and timing of any collaborative, licensing and other arrangements that we may establish, including any milestone and royalty payments thereunder; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the cost, timing and outcomes of any litigation that we may file or that may be filed against us by third parties; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the product revenue, if any, derived from our sales of approved products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute the share ownership of our existing shareholders. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">earlier stage than otherwise would be desirable and to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or for specific strategic considerations. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all. In addition, the perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to obtain sufficient funding on a timely basis and on acceptable terms and continue as a going concern, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidates or to otherwise reduce or discontinue our operations. In general, we may be unable to expand our operations or otherwise capitalize on business opportunities, and defend against and prosecute litigation necessary to commercialize our product candidates as desired, which could materially affect our business, financial condition and results of operations. If we are ultimately unable to continue as a going concern, we may have to seek the protection of bankruptcy laws or liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that our securityholders will lose all or a part of their investment. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to obtain sufficient funding on a timely basis, on acceptable terms, or at all. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given the recent inflation, interest rates and volatility on the capital markets, we may be unable to raise sufficient funding on a timely basis, on acceptable terms, or at all. Failure to obtain additional funding could have a material adverse effect on our business, prospects and financial condition and may require us to significantly curtail, delay or discontinue one or more of our development programs or the commercialization of any product candidates or to otherwise reduce or discontinue our operations. Even if we were able to obtain additional funding, the terms on which such funding could be obtained may be unfavorable to us and our securityholders, including higher interest rates, which would burden us with higher debt service obligations and may impact our prospects of becoming profitable, a lower share price at which new equity would be issued, which may cause significant dilution to existing shareholders, and/or we may be required to provide additional incentives to potential investors, such as penny warrants, which also may cause significant dilution to existing shareholders. See also &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future issuances of debt securities and equity securities may adversely affect us, including the market price of our Ordinary Shares and may be dilutive to existing shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; and &#8220;&#8212;W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">e have substantial indebtedness and expect to continue to use leverage in executing our business strategy, which could have important consequences on our business and adversely affect the return on our assets.&#8221;</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have substantial indebtedness and expect to continue to use leverage in executing our business strategy, which could have important consequences on our business and adversely affect the return on our assets. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of 31&#160;December 2023, we had $960.2 million in outstanding indebtedness, consisting of $549.4 million in Senior Bonds, $155.9 million in  Tranche A and Tranche B Convertible Bonds issued by Alvotech on 20 December 2022 (the "2022 Convertible Bonds"), $80.7&#160;million in the convertible bonds issued by Alvotech to Aztiq Pharma Partners S.&#224; r.l. ("Aztiq") on 16 November 2022 (also known as the "Aztiq Convertible Bond"), $76.6 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">from loans from Alvogen, and $97.6 million in bank loans, including the mortgage on our Reykjavik facility and loans to help finance equipment purchases. In addition, we may incur additional indebtedness in order to finance our operations, make acquisitions or to repay existing indebtedness. Our board of directors will consider a number of factors when evaluating our level of indebtedness and when making decisions regarding the incurrence of new indebtedness, including the purchase price of assets to be acquired with debt financing, the estimated market value of our assets and the ability of particular assets, and our ability as a whole, to generate cash flow to cover the expected debt service. Our articles of incorporation do not contain a limitation on the amount of debt we may incur, and the board of directors may change our target debt levels at any time without the approval of shareholders. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This substantial indebtedness, as well as any future indebtedness we may incur, could have important consequences for our business and holders of our securities, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">making it more difficult for us to satisfy our obligations with respect to our debt or to our trade or other creditors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">causing us to pay higher interest rates upon refinancing indebtedness if interest rates rise; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">increasing our vulnerability to adverse economic or industry conditions; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">limiting our ability to obtain additional financing to fund capital expenditures and acquisitions, particularly when the availability of financing in the capital markets is limited; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">requiring a substantial portion of our cash flows from operations for the payment of interest on our debt and reducing our ability to use our cash flows to fund working capital, capital expenditures, acquisitions, stock repurchases, and general corporate requirements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">limiting our flexibility in planning for, or reacting to, changes in our business and the homebuilding industry; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">placing us at a competitive disadvantage to less leveraged competitors. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will be available to us through capital markets financings or under our debt or credit facilities or otherwise in an amount sufficient to enable us to pay our indebtedness, or to fund our other liquidity needs. If we cannot service our debt, we may have to take actions such as selling assets, seeking additional debt or equity or reducing or delaying capital expenditures, strategic acquisitions, investments and alliances. We cannot assure you that any such actions, if necessary, could be effected on commercially reasonable terms, or at all, or on terms that would be advantageous to our securityholders or on terms that would not require us to breach the terms and conditions of our existing or future debt agreements</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may need to refinance all or a portion of our indebtedness and cannot assure you that refinancing will be available on commercially reasonable terms, or at all. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, we had $960.2 million in outstanding indebtedness, that matures between June 2025 and December 2029. We may need to refinance all or a portion of our indebtedness, on or before its maturity. </span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that we will be able to refinance any of our indebtedness on commercially reasonable terms, or at all. . If we are unable to refinance any of our indebtedness on commercially reasonable terms or at all or to effect any other action relating to our indebtedness on satisfactory terms or at all, we may be forced to reduce or discontinue operations or seek protection of the bankruptcy laws, our business may be harmed and our securityholders may lose some or all of their investment.</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">As a European public company with limited liability with registered office in Luxembourg, we will be subject to the sustainability disclosure requirements set out in the EU Corporate Sustainability Reporting Directive and the disclosure requirements set out in the EU Taxonomy Regulation.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 18 June 2020 the EU adopted Directive 2020/852/EU (the "Taxonomy Regulation"). The goal of the Taxonomy Regulation was to create a uniform, credible, science-based system to classify activities that are environmentally sustainable by determining (among other conditions) if they substantially contribute to specific environmental objectives. The broader objective of the EU Taxonomy is to help financial market participants and other relevant actors to identify which economic operators carry out environmentally sustainable economic activities, and make it easier for these relevant actors to raise funding for these activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 5 January 2023, the EU adopted Directive 2022/2464/EU (the &#8220;Corporate Sustainability Reporting Directive&#8221;), which amends the non-financial reporting requirements set out in Directive 2013/34/EU (the  &#8220;Accounting Directive&#8221;). The CSRD introduces new mandatory reporting obligations that will require in-scope entities to publish audited sustainability information in their Management Reports addressing environmental, social and governance (&#8220;ESG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) matters in line with new mandatory European sustainability reporting standards (&#8220;ESRS&#8221;) that will be adopted by the European Commission through secondary legislation. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The EU Taxonomy Regulation took effect on 1 June 2023. The CSRD requirements will become effective in stages, based on the characteristics of undertakings, with earliest application from 1 January 2024 (reporting in 2025 on 2024 data). As a European public company with limited liability with registered office in Luxembourg, we will fall under the scope of application of the new sustainability-related reporting requirements. This will involve setting up processes to gather the relevant data, conduct materiality assessments and prepare a CSRD-compliant report, which will likely be a time-consuming and costly exercise.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain disclosures for large EU reporting entities are mandatory, even if the entity considers that there are no material impacts, risks or opportunities. Materiality&#8217; under the CSRD must be assessed following the double materiality principle. Double materiality means that the reporting entity should consider both financial materiality (i.e., sustainability matters which from the investor perspective are material to the company&#8217;s development, performance and position) and impact materiality (i.e., the impact of corporate activity on sustainability matters from the perspective of citizens, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consumers, employees etc.). Impacts, risks and opportunities are material if they satisfy one or both of these materiality tests. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The disclosure requirements under the CSRD will apply alongside the EU Taxonomy Regulation, which (a) creates a classification system to determine when an economic activity qualifies as &#8220;environmentally sustainable&#8221; and (b) requires companies in scope of the EU Accounting Directive, including those brought into  scope by the CSRD, to disclose the proportion of turnover, capital and operational expenditure directed towards activities that qualify as &#8220;environmentally sustainable&#8221; (this information should be disclosed even if the contribution is none). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All EU reporting entities must have the sustainability section of their management report audited by a third-party accredited auditor to confirm that it has been prepared in accordance with the relevant ESRS and Article 8 of the Taxonomy Regulation. By Luxembourg Law of 23 July 2016 the non-financial statement may be disclosed either in the management report or in a separate report, under the condition that this separate report is published together with the management report or made available within six months after the balance sheet date on the given entity&#8217;s website.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The disclosures set out in the CSRD and the EU Taxonomy Regulation should be also considered together with the adjusted proposal of the EU Directive on Corporate Sustainability Due Diligence (&#8220;CSDDD&#8221;), which has been agreed by the European Council on 15 March 2024. Whilst the final text of the CSDDD remains to be voted on by the European Parliament and formalized by the European Commission by April 2024, the agreed proposal of the CSDDD sets out new due diligence duties for large companies with (a) more than 1000 employees and (b) a net worldwide turnover of over EUR 450 million generated in the last financial year for which financial statements have been prepared. The due diligence obligations under the agreed proposal of the CSDDD shall also apply to companies entering into franchising or licensing agreements in return for royalties of more than EUR 22.5 million, provided that the company has a net worldwide turnover of over EUR 80 million generated in the last financial year for which financial statements have been prepared. The requirements of this directive may apply to us. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The CSDDD will impose substantive due diligence obligations and also influence the information gathering process required by entities that are also subject to the CSRD. It will also have an impact on the mandatory disclosures to be made under the CSRD on the entity&#8217;s due diligence process (which will need to show compliance with the CSDDD if the entity is subject to both the CSRD and CSDDD).</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Once the CSDDD has been adopted, EU Member States, including Luxembourg, will have two years to transpose the Directive into national law. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A disruption at our main manufacturing facility could materially and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, we acquired the Reykjavik manufacturing and research facility through the purchase of the shares in Fasteignaf&#233;lagi&#240; S&#230;mundur hf. (&#8220;Saemundur&#8221;) from ATP Holdings ehf., a related party. Simultaneously, we entered into a loan facility for $48.8 million with Landsbankinn hf., secured with a first priority mortgage over the facility, resulting in the extinguishment of the old loan on the manufacturing and research facility. As owners of the manufacturing and research facility, we are responsible for the maintenance, upkeep and improvements of the facility, for obtaining and maintaining all permits related to the facility and activities therein, and a significant disruption at the facility, whether it be due to fire, natural disaster, power loss, intentional acts of vandalism, climate change, war, terrorism, insufficient quality, or cyber-attacks could materially and adversely affect our business. In addition, failure to make timely payments under the loan facility with Landsbankinn hf. may lead disruptions of our manufacturing facility and to the loss of the facility and equipment therein. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Covenants under our existing debt instruments, and any future debt arrangements may result in the acceleration of outstanding indebtedness and limit the manner in which we operate. </span></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our existing debt instruments, including the Senior Bonds, the Aztiq Convertible Bond and the 2022 Convertible Bonds, contain customary terms and covenants, as well as customary events of default, including but not limited to defaults related to payment compliance, undertaking and covenant compliance, bankruptcy and insolvency proceedings, judgments against the Company, and delisting events. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, these bonds contain, and any future indebtedness we incur may contain, various negative covenants that restrict or may restrict, among other things, our ability to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">incur additional indebtedness, guarantee indebtedness or issue disqualified shares or preferred shares; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">declare or pay dividends on, repurchase or make distributions in respect of, capital stock or make other restricted payments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">make certain investments or acquisitions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">create certain liens; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">enter into agreements restricting certain subsidiaries&#8217; ability to pay dividends or make other intercompany transfers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">consolidate, merge, sell or otherwise dispose of all or substantially all of our assets and the assets of our restricted subsidiaries; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">enter into certain transactions with affiliates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">sell, transfer or otherwise convey certain assets; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">conduct our business and may be unable to engage in favorable business activities, repurchase our ordinary shares or finance future operations or capital needs. </span></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Servicing these bonds requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt. </span></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. If we are unable to make our installment payments in cash, we may be forced to issue a significant number of Ordinary Shares which could dilute existing shareholders. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to the Development of Our Product Candidates </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The regulatory review and approval processes of the FDA, European Commission and comparable national or regional authorities are lengthy, time consuming and have uncertain outcomes. If we and our collaboration partners are unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We cannot give any assurance that marketing authorization applications for any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future success is dependent on our ability to develop, obtain regulatory approval for, and then commercialize and obtain adequate third-party coverage and reimbursement for one or more product candidates. We currently only have marketing authorization for AVT02 in the United States, the EEA (comprising the 27 EU Member States, Norway,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liechtenstein, and Iceland), the UK, Switzerland, Canada, Australia and Saudi Arabia. We also received regulatory</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approval for AVT04 in Japan, Canada, and the EEA. We do not have marketing authorization for other product candidates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or in other countries, and may never be able to develop or commercialize a marketable product other than AVT02 and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVT04 in those countries.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, marketing, distribution, post-approval monitoring and reporting and export and import of biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States, by the European Commission, the EMA and the National Competent Authorities of the EEA countries, and by other comparable regulatory authorities in other countries, which regulations differ from country to country. Neither we nor any collaboration partner is permitted to market our product candidates before receiving market authorization/approval from the appropriate regulatory authorities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The time required to seek and obtain market authorization/approval by the FDA and comparable foreign regulatory authorities is unpredictable, may take many years following the completion of clinical studies and depends upon numerous factors. In addition, approval requirements, regulations, or considerations with respect to the type and amount of clinical, nonclinical and analytical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the submission of an application for marketing authorization/approval, the authorization or approval, or the decision not to approve an application. Other than the regulatory approval received in the United States, 52 countries, including the EEA, the UK, Switzerland, Canada, Australia, Israel, Morocco, Egypt, Saudi Arabia, South Africa and part of Latin America for AVT02 and in Japan, Canada </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the EEA for AVT04, neither we nor any collaboration partner has obtained regulatory approval for any of our product candidates in the United States, the EEA or in additional other countries where we or our partners have commercial rights, and it is possible that none of our current or future product candidates will ever obtain regulatory approval.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These lengthy approval processes, as well as the unpredictability of the results of analytical, nonclinical, and clinical studies, may result in our failure to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, prospects and financial condition. Moreover, any delays in the commencement or completion of product testing could significantly impact our product development costs and could result in the need for additional financing. For example, our clinical trials must use reference products as comparators, and such supplies may not be available on a timely basis to support such trials. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Most of our product candidates are in varying stages of development and will require additional clinical development, management of analytical, nonclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supplies, commercial organization and significant marketing efforts before we may generate any revenue from product sales. Since 2021, we, directly or through our partners, received regulatory approval for AVT02 in 52 countries. The countries where AVT02 has been approved include European countries (such as the EEA, the UK, Switzerland and several Balkan states), Canada, Australia, Israel, Morocco, Egypt, Saudi Arabia, South Africa and parts of Latin America. In February 2024, the FDA approved AVT02 in the United States. AVT02 is currently marketed in 21 countries: in Europe, Canada and Australia. In 2023 AVT04 was approved in Japan and Canada, and, in January 2024, in the EEA. In November 2023, we announced that the FDA had accepted a resubmitted BLA for AVT04 for review. We anticipate that the FDA's review will be completed in April 2024. We have completed, or are expecting to complete, clinical studies for AVT03, AVT05, and AVT06 in 2024, while AVT23 has recently entered a confirmatory efficacy study. In addition we currently have five biosimilar candidates in pre-clinical development.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot be certain that any of our product candidates will receive additional regulatory approval. If we and our collaboration partners do not receive regulatory approvals for enough of our product candidates in sufficiently large markets, we may not be able to continue our operations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the data collected from analytical, nonclinical, or clinical studies of our product candidates may not be sufficient to support an application for regulatory approval as a biosimilar; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the FDA or comparable supranational, national or regional regulatory authorities may disagree with the design or implementation, or sufficiency of our analytical, nonclinical, or clinical studies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the FDA or comparable regulatory authorities may disagree with our interpretation of data from analytical and bioanalytical studies, nonclinical studies or clinical studies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">we may be unable to provide adequate scientific justification to the FDA or comparable regulatory authorities for extrapolation of a product candidate to each proposed indication; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the FDA or comparable regulatory authorities may identify significant deficiencies with the manufacturing processes, test procedures and specifications, facilities or third-party manufacturers with which we contract for clinical and commercial supplies. For example, prior to receiving approval for AVT02 from the FDA, we received multiple CRLs, noting certain deficiencies related to the Reykjavik facility and stating that satisfactory resolution of the deficiencies was required before the FDA approved AVT02 and before the FDA may approve AVT04;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the regulatory exclusivity held by a competing manufacturer; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the approval requirements, policies, or regulations of the FDA or comparable regulatory authorities may significantly change in a manner rendering our clinical, nonclinical, analytical, or chemistry, manufacturing, and control data insufficient for approval. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we change the regulatory pathway through which we intend to seek approval of any of our product candidates, we may have to conduct additional clinical trials, which may delay our ability to submit a marketing application for the product. Even if we or our collaboration partners were to obtain approval for any of our product candidates, the FDA or comparable regulatory authorities may limit the scope of such approval, e.g., for fewer or more limited indications than those for which we have sought licensure, may grant approval contingent on the completion of costly additional clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The UK&#8217;s withdrawal from the EEA on 31 January 2020, commonly referred to as Brexit, has created significant uncertainty and such uncertainty may make it more difficult for us to achieve regulatory approval in the UK. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the EU, the UK, was subject to a transition period until 31 December 2020, or the Transition Period, during which EU rules continued to apply. The UK and the EU have signed an EU-UK Trade and Cooperation Agreement, or TCA, which became provisionally applicable on 1 January 2021 and entered into force on 1 May 2021. This agreement provides details on how some aspects of the UK and EU&#8217;s relationship will operate going forward though many uncertainties remain. The TCA primarily focuses on ensuring free trade between the EEA and the UK in relation to goods, including medicinal products. Although the body of the TCA includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an annex to the TCA. The annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Among the changes that will now occur is that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will continue to follow the EU regulatory rules. The TCA also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The UK has unilaterally agreed to accept EEA batch testing and batch release. However, the EEA continues to apply EU laws that require batch testing and batch release to take place in the EEA territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EEA market for commercial use. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As regards marketing authorizations, Great Britain will have a separate regulatory submission process, approval process and a separate national MA. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the European Commission. For example, the scope of a marketing authorization for a medicinal product granted by the European Commission or by the competent authorities of EEA countries will no longer encompass Great Britain (England, Scotland and Wales). In these circumstances, a separate marketing authorization granted by the UK competent authorities is required to place medicinal products on the market in Great Britain. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On 27 February 2023, the UK Government and the European Commission reached a political agreement on the so-called &#8220;Windsor Framework&#8221;. The Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is intended to revise the Northern Ireland Protocol to address some of the perceived shortcomings in its operation. The agreement was adopted at the Withdrawal Agreement Joint Committee on 24 March 2023. If the changes are adopted in the form proposed, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">medicinal products to be placed on the market in the UK will be authorized solely in accordance with UK laws. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Northern Ireland would be reintegrated back into a UK-only regulatory environment under the authority of the MHRA with respect to all medicinal products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The implementation of the Windsor Framework would occur in stages, with new arrangements relating to the supply of medicinal products into Northern Ireland anticipated to take effect in 2025.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since a significant proportion of the regulatory framework in the UK applicable to our business and our product candidates is derived from EU Directives and Regulations, Brexit, following the Transition Period, could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the UK or the EU, now that UK legislation has the potential to diverge from EU legislation. All of these changes could increase our costs and otherwise adversely affect our business. Any delay in obtaining, or an inability to obtain, any regulatory approvals for our product candidates, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the UK or the EEA and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the EEA. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approvals for our pro in the UK or the EEA for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the foregoing, among other factors, there can be no assurance that we would be able to achieve our plan to commercialize our product candidates on our expected timeline, or at all. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are not able to demonstrate biosimilarity of our biosimilar product candidates to the satisfaction of the FDA or comparable national or regional regulatory authorities, we will not obtain regulatory approval for commercialization of our biosimilar product candidates and our future results of operations and ability to generate revenue would be adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future results of operations depend, to a significant degree, on our ability to obtain regulatory approval for and to commercialize our biosimilar product candidates. Any inability to obtain regulatory approval could impact and delay the development timeline of our product candidates. To obtain regulatory approval for the commercialization of these product candidates, we will be required to demonstrate to the satisfaction of the FDA or comparable national regulatory authorities, among other things, that our proposed products are highly similar to biological reference products already approved by the applicable regulatory authority pursuant to approved marketing applications/authorizations, notwithstanding minor differences in clinically inactive components, and that they have no clinically meaningful differences as compared to the marketed biological products in terms of the safety, purity and potency of the products. Each individual jurisdiction may apply different criteria to assess biosimilarity, based on of the data that can be interpreted subjectively in some cases. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is uncertain if regulatory authorities will grant the reference biosimilar product candidates the same labeling than the labeling approved for the reference product if the reference biosimilar product candidates are approved. For example, an infliximab (Remicade) biosimilar molecule was approved in the EEA with the same label as the reference product, but it did not receive approval initially for the same labeling reference in Canada. A similar outcome could occur with respect to one or more of our product candidates. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event that the FDA or comparable regulatory authorities require us to generate additional data, including by conducting additional clinical trials or other lengthy processes or otherwise change their criteria and requirements for the approval of biosimilar products, the approval and commercialization of our proposed biosimilar products could be delayed or prevented. Delays in the commercialization of or the inability to obtain regulatory approval for these products could adversely affect our operating results by restricting or significantly delaying the introduction of new biosimilars. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The structure of complex proteins used in protein-based therapeutics is inherently variable and highly dependent on the processes and conditions used to manufacture them. If we are unable to develop manufacturing processes that demonstrate that our product candidates are highly similar to their reference products, and within a range of variability considered acceptable by regulatory authorities, we may not be able to obtain regulatory approval for our products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Protein-based therapeutics are inherently heterogeneous and their structures are highly dependent on the manufacturing process and conditions. Products from one manufacturing facility can differ from those produced in another facility. Similarly, physicochemical differences can also exist among different lots produced within a single facility. The physicochemical complexity and size of biologic therapeutics can create significant technical and scientific challenges in the context of their replication as biosimilar products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The inherent variability in protein structure from one production lot to another is a fundamental consideration with respect to establishing biosimilarity to a reference product to support regulatory approval requirements. For example, the glycosylation of the protein, meaning the manner in which sugar molecules are attached to the protein backbone of a therapeutic protein when it is produced in a living cell, is critical to half-life (how long the drug stays in the body), efficacy and even safety of the therapeutic and is therefore a key consideration for biosimilarity. Defining and understanding the variability of a reference product in order to match its glycosylation profile requires significant skill in cell biology, protein purification and analytical protein chemistry. Variations in the glycosylation profile and other analytical characterizations important for determining biosimilarity to the reference product molecule are risks unique to biosimilar manufacturers. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are extraordinary technical challenges in developing complex protein-based therapeutics that not only must achieve an acceptable degree of similarity to the reference product in terms of relevant quality attributes such as glycosylation patterns, but also the ability to develop manufacturing processes that can replicate the necessary structural characteristics within an acceptable range of variability sufficient to satisfy regulatory authorities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, the manufacturing process of our products may be susceptible to non-ideal product variability without well-characterized and well-controlled master and working cell banks. A cell bank is a collection of ampoules of uniform composition stored under defined conditions, each containing an aliquot of a single pool of cells. The master cell bank is generally derived from the selected cell clone containing the expression construct that has been encoded to produce the protein of interest, such as a specific monoclonal antibody with a defined amino acid sequence. This unique aliquot of cells allows for a consistent high quality biologic medicine to be produced. The working cell bank is derived by expansion of one or more ampoules of the master cell bank and is used for routine manufacturing. Both the master cell bank and working cell bank are central to obtaining regulatory approval for manufacturing and marketing biologic medicine. The quality of the manufactured biologic product is dependent on the quality of the cells used for its manufacturing, and having </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a sufficient supply of master and working cell banks is important for a consistent manufacturing process. Should our cell banks be compromised, we would be unable to produce usable products for patients in any market. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given the challenges caused by the inherent variability in protein production, we may not be successful in our application for approval of our products if regulators conclude that we have not demonstrated that our product candidates are highly similar to their reference products, or that the processes we use to manufacture our products are unable to produce the products within an acceptable range of variability (including situations where the reference product sponsor changes its manufacturing process and such changes impact the characteristics of the product). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the foregoing factors complicate scaling of our manufacturing capabilities. To the extent that we are unable to scale our manufacturing capabilities to produce sufficient quantities of our products at the required specifications and at an acceptable cost, we may be unable to meet demand for our approved product candidates and our business, financial condition, reputation and results of operations may suffer. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical drug development involves a lengthy and expensive process, and we may encounter substantial delays in our clinical studies or may fail to demonstrate safety, purity and efficacy/potency to the satisfaction of applicable regulatory authorities. Additionally, the impact of public health emergencies or the occurrence of unforeseen geopolitical events such as the Russia-Ukraine conflict, the Middle Eastern conflicts and the resulting instability in these regions, may delay the conduct and completion of clinical studies. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before obtaining regulatory approval from regulatory authorities for the sale of our product candidates, we (and/or our collaboration partners) must conduct clinical studies to demonstrate the safety, purity, and potency (safety and efficacy) of the product candidates in humans. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical studies are expensive and can take many years to complete, and their outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies, including comparative analytical assessments of our product candidates, may not be predictive of the results of clinical studies. The success of clinical studies cannot be predicted. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. As a result of public health emergencies, such as the COVID-19 pandemic, and/or the occurrence of unforeseen geopolitical events, such as the Russia-Ukraine conflict and the Middle Eastern conflicts, and the resulting instability in these regions, timelines could be extended. A failure of one or more clinical studies can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include but are not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical studies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">delays in reaching a consensus with regulatory authorities on study design; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">delays in obtaining required Institutional Review Board, or IRB, approval or Ethics Committee positive opinion as part of the single decision on the authorization of the clinical trial issued by EU Member States including input from the national competent authorities and Ethics Committee in relation each clinical study site; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">imposition of a clinical hold by regulatory authorities, after review of an investigational new drug, or IND, application or amendment or equivalent application or amendment, or an inspection of its clinical study operations or study sites or as a result of adverse events reported during a clinical trial; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">delays in administering studies as a result of adverse events or complaints; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">delays in recruiting suitable or sufficient numbers of patients to participate in its clinical studies sponsored by us or our partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">difficulty collaborating with patient groups and investigators; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">failure by its CROs, clinical study sites, other third parties or us to adhere to clinical study requirements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">failure to perform in accordance with the FDA&#8217;s good clinical practices requirements or applicable regulatory guidelines and good clinical practice requirements in other countries; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">delays in having patients complete participation in a study or return for post-treatment follow-up, or patients dropping out of a study; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">difficulties justifying the scientific relevance of non-U.S. comparators for use in studies intended to support regulatory approval by FDA; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">questions with regard to the scientific justification for extrapolation of findings across indications; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">changes in regulatory requirements or policies that require amending or submitting new clinical protocols; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the cost of clinical studies of its product candidates being greater than what we anticipate; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">clinical studies of our product candidates producing negative or inconclusive results, which may result in us deciding or regulators requiring us to conduct additional clinical studies or to abandon product development programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">delays in manufacturing, testing, releasing, validating or importing/exporting and/or distributing sufficient stable quantities of our product candidates and reference products for use in clinical studies or the inability to do any of the foregoing; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">staffing shortages and limitation on the movement of people as a result of public health emergencies, the Russia-Ukraine conflict, the various conflicts in the Middle East, and the resulting instability in the regions, and local, national or international governmental restrictions imposed or enforced as a result of these or other health-related or geopolitical events; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">delays or interruptions to preclinical studies, clinical trials, our receipt of services from third-party service providers or our supply chain due to public health emergencies or the occurrence of unforeseen geopolitical events such as the Russia-Ukraine conflict and the conflicts in the Middle East, and the resulting instability in these regions, or otherwise. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any inability to successfully complete analytical, nonclinical, or clinical development could result in additional costs to us or impair our ability to achieve regulatory approval and generate revenue. Even if we are successful, the regulatory approval processes and action dates of the FDA, EMA and the European Commission and comparable regulatory authorities may be delayed or continue to be delayed due to impact of public health emergencies or other emergencies in the world. As a result, we may be delayed in obtaining regulatory approvals for our products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. If we intend to alter the manufacturing process for a particular product candidate, we will need to provide data to the FDA and comparable regulatory authorities demonstrating the comparability of the pre- and post-change product candidate. If we are unable to make that demonstration to the FDA or comparable regulatory authorities, we could face significant delays or fail to obtain regulatory approval to market the product, which could significantly harm our business, prospects and financial condition. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our product candidates may cause unexpected side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following regulatory approval, if granted. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As with most pharmaceutical products, use of our product candidates could be associated with side effects or adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our product candidates may be observed at any time, including in clinical trials or when a product is commercialized. Undesirable or unexpected side effects caused by our product candidates that must be reported to the FDA or other regulators could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable regulatory authorities. Results of our studies could reveal a high and unacceptable severity and prevalence of side effects or other safety issues and, if different from the severity and prevalence of side effects for the reference products, could preclude the demonstration of biosimilarity. Such adverse event findings also could require us or our collaboration partners to perform additional studies or halt development or sale of these product candidates or expose us to product liability lawsuits which will harm our business, prospects and financial condition. In such an event, we may be precluded from seeking licensure through the regulatory pathway for biosimilars, or could be required by the FDA or other comparable regulatory authorities to conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated or our studies could be suspended, varied or terminated, and the FDA or comparable regulatory authorities could order us to cease further development of or deny, vary, or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">withdraw approval of our product candidates for any or all intended indications. There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any comparable regulatory authority in a timely manner, if ever, which could harm our business, prospects and financial condition. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Drug-related side effects could affect patient recruitment for clinical trials, the ability of enrolled patients to complete our studies or result in potential product liability claims against which we would need to mount a defense. We currently carry product liability insurance, and we are required to maintain clinical trial insurance pursuant to certain of our license agreements. We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect the results of our operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, if one or more of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such products (or caused by the reference products or other biosimilars based on the applicable reference products), a number of potentially significant negative consequences could result, including but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">regulatory authorities may suspend, withdraw or vary approvals of such product; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">regulatory authorities may request or require that the product be recalled or removed from the market; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">regulatory authorities may require additional warnings on the label or otherwise require labeling to be updated or narrowed; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">we may be required to agree to a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), or a shared system REMS, or comparable foreign strategy, which could include a medication guide for distribution to patients outlining the risks of side effects, a communication plan for healthcare providers and/or other elements to assure safe use; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">we could be sued and potentially held liable for harm caused to patients; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our reputation may suffer. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, prospects and financial condition. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As our product candidates receive approval, regulatory authorities including the FDA, European Commission, Icelandic Medicines Agency ("IMA"), EMA, National Competent Authorities of EEA countries and other comparable foreign regulatory authorities regulations will require that we regularly report certain information, including information about adverse events that may have been caused by or contributed by those products. The timing of adverse event reporting obligations would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, European Commission, the IMA, the EMA, the National Competent Authorities of EEA countries or other comparable foreign regulatory authorities could take action that may include criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or suspension or variation of market approval, and delay in approval or clearance of future products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a condition to granting marketing authorization or approval of a product, the FDA or other comparable foreign regulatory authorities may require additional clinical trials or other studies. The results generated in these trials could result in the loss of regulatory approval, changes in labeling, and/or new or increased concerns about the side effects, efficacy or safety. Regulatory authorities in countries outside the United States often have similar regulations and may impose comparable requirements. Post-marketing studies, whether conducted by us or by others, whether mandated by regulatory authorities or conducted voluntarily, and other emerging data about products, such as adverse event reports, may also adversely affect the availability or commercial potential of our products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on certain participants for our clinical trials could cause delays in ongoing studies or the development of our products if such participants prove to be too limited or a substantial portion of participants in the studies withdraw. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to be successful and pursue market authorization for our products in various countries, we must be able to gather health data on the basis of populations from around the world. To the extent participants in clinical trials are too limited to certain populations, our clinical research may be adversely affected. Additionally, we depend on the willingness of these volunteers to participate in studies, and there is always the risk that they may no longer be willing to participate or revoke the consents necessary for us to process their medical data. For example, due to reasons beyond our control, including public health emergencies, the Russia-Ukraine conflict, the conflict in the Middle East, and the resulting instability in the region, participants and our key employees and advisors may no longer be able to travel or cross country borders to participate in our studies. If, for any reason, a substantial portion of participants in the studies were to withdraw their consent or discontinue their participation, we may not be able to continue our clinical studies for some or all of our product candidates which may cause delays in the development or approval of our product candidates. If our ability to gather and use sufficient data is impaired, we also may not be able to fulfill some contractual obligations with our partners. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The development, manufacture and commercialization of biosimilar products under various regulatory pathways pose unique risks related to regulatory approvals across various jurisdictions. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. Regulatory Framework for Biosimilars </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and our collaboration partners intend to pursue market authorization globally. In the United States, an abbreviated pathway for approval of biosimilar products was established by the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), as part of the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act (together, the &#8220;PPACA&#8221;). The BPCIA established this abbreviated pathway under section 351(k) of the Public Health Service Act (the &#8220;PHSA&#8221;) for biological products shown to be biosimilar to or interchangeable with an FDA-licensed reference biological product. Subsequent to the enactment of the BPCIA, the FDA has issued numerous guidance documents explaining its current thinking regarding the demonstration of biosimilarity and interchangeability as well as the submission and review of such BLA. Market success of biosimilar products will depend on demonstrating to patients, physicians, payors and relevant authorities that such products are similar in quality, safety and efficacy as compared to the reference product. If biosimilar product applications do not continue to be approved and the markets in which we operate do not widely accept the commercialization of biosimilar products, our business will be harmed. How the BPCIA is applied and interpreted by the FDA may have a material impact on our chances of obtaining FDA approval for our biosimilar product candidates, and our business operations after obtaining approval. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will continue to analyze and incorporate into our product development plans any additional final regulations issued by the FDA, pharmacy substitution policies enacted by state governments and other applicable requirements. The costs of development and approval, along with the probability of success for our biosimilar product candidates, will be dependent upon application of any laws and regulations issued by the relevant regulatory authorities. The costs of developing our products may increase due to uncertainties or changes in guidance provided by regulatory authorities like the FDA, and we may not have adequate funding and resources to pursue market authorization for all of our biosimilar products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biosimilar products may also be subject to extensive patent clearances and patent infringement litigation, which may delay and could prevent the commercial launch of a product. Moreover, the PHSA prohibits the FDA from filing an application for a biosimilar candidate to a reference product for four years of the date of first licensure of the reference product by the FDA, and from approving an application for a biosimilar candidate for 12 years from the date of first licensure of the reference product. For example, the FDA would not be able to approve a BLA submitted for a biosimilar that references a specific drug until 12 years after the date of first licensure of the BLA, i.e., the date that reference product BLA was approved. Depending on the product, that regulatory exclusivity period may be further extended by a six-month pediatric exclusivity. The US regulatory exclusivity in the case of AVT02, a biosimilar to Humira (adalimumab), would be 31 December 2014, in the case of AVT04, a biosimilar candidate to Stelara (ustekinumab), would be 25 September 2021, in the case of AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), would be 24 April 2021, and in the case of AVT06, a biosimilar candidate to Eylea (aflibercept), would be 18 May 2024. Interchangeable biosimilar approvals may also be blocked by periods of first interchangeable exclusivity ranging from 12 to 42 months in duration. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Regulatory Framework for Biosimilars Outside the United States </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The European Commission approved the first biosimilar medicinal product in 2006. Since then the European Commission and the EMA have acquired extensive experience in the review and approval of biosimilars, and developed guidelines related to the authorization procedure for these products, including data requirements needed to support approval. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The EU provides opportunities for data and market exclusivity related to certain types of marketing authorizations. Upon grant of related marketing authorization, innovative medicinal products generally benefit from eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EEA from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EEA until 10 years have elapsed from the initial marketing authorization of the reference product in the EEA. The overall ten year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A new pharmaceutical form does not trigger a new data exclusivity. It could trigger orphan exclusivity, provided, however, that the targeted disease is a rare disease and that the new pharmaceutical form meets the high threshold for being considered as bringing a significant benefit to patients. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other regions, including Canada, China, Japan and Korea, also have their own legislation outlining a regulatory pathway for the approval of biosimilars. In some cases, other countries have either adopted European Union guidance (Singapore and Malaysia) or are following guidance issued by the World Health Organization (Cuba and Brazil). While there is overlap in the regulatory requirements across regions, there are also some areas of non-overlap. Additionally, we cannot predict whether countries that we may wish to market in, which do not yet have an established or tested regulatory framework could decide to issue regulations or guidance and/or adopt a more conservative viewpoint than other regions. Therefore, it is possible that even if we obtain agreement from one health authority to an accelerated or optimized development plan, we will need to defer to the most conservative view to ensure global harmonization of the development plan. Also, for regions where regulatory authorities do not yet have sufficient experience in the review and approval of a biosimilar product, these authorities may rely on the approval from another region (for example, the United States), which could delay its approval in that region. In addition, regulatory approval may be delayed as a result of laws in any applicable jurisdiction that provide for stay of regulatory approval related to patent coverage and subsequent litigation. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If other companies&#8217; biosimilar candidates for certain reference products are determined to be interchangeable before ours, or our biosimilar product candidates for these same reference products are not determined to be interchangeable, our business could be negatively impacted. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA may determine that a proposed biosimilar product is &#8220;interchangeable&#8221; with a reference product, meaning that the biosimilar product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, if the application includes sufficient information to show that the product is biosimilar to the reference product and that it can be expected to produce the same clinical result as the reference product in any given patient. In addition, if the biosimilar product may be administered more than once to a patient, the applicant must demonstrate that the risk in terms of safety or diminished efficacy of alternating or switching between the biosimilar product candidate and the reference product is not greater than the risk of using the reference product without such alternation or switch. To make a final determination of biosimilarity or interchangeability, the FDA may require additional confirmatory information beyond what we plan to initially submit in our applications for approval, such as more in-depth analytical characterization, animal testing or further clinical studies. Provision of sufficient information for approval may prove difficult and expensive. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict whether any of our biosimilar product candidates will meet regulatory requirements for approval as a biosimilar product or as an interchangeable product. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The concept of &#8220;interchangeability&#8221; is important because, in the United States for example, the first biosimilar approved as interchangeable with a particular reference product for any condition of use is eligible for a period of market exclusivity during which time the FDA cannot approve a second or subsequent biosimilar product interchangeable with that reference product for any condition of use. The relevant period of exclusivity will end upon the earlier of: (1) one year </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">after the first commercial marketing of the first interchangeable product; (2) 18 months after resolution of a patent infringement suit instituted under 42 U.S.C. &#167; 262(l)(6) against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; (3) 42 months after approval of the first interchangeable product, if a patent infringement suit instituted under 42 U.S.C. &#167; 262(l)(6) against the applicant that submitted the application for the first interchangeable product is still ongoing; or (4) 18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued under 42 U.S.C. &#167; 262(l)(6). Thus, a determination that another company&#8217;s product is interchangeable with the reference biologic made before we obtain approval of our corresponding biosimilar product candidates may delay the potential approval of our products as interchangeable with the reference product, which could materially adversely affect the results of operations and delay, prevent or limit our ability to generate revenue. Even if we are awarded interchangeable exclusivity for a product, that award may be challenged by third parties. Any successful challenge to our exclusivity will negatively impact our ability to market and sell the related product. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EEA, the approval of a biosimilar for marketing is based on a positive opinion issued by the EMA and a related decision issued by the European Commission. The regulatory approval is valid throughout the entire EEA. However, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for marketing authorization. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product. In addition, rules governing the interchangeability, switching and substitution of a reference medicinal products by its biosimilar are provided by the national law of individual EEA countries, and many of them do not permit the automatic substitution of a reference medicinal products by  its biosimilar. Therefore, even if we obtain regulatory approval for one of our product candidates in the EEA, we may not receive a positive decision from the National Competent Authorities of EEA countries in relation to the interchangeability, switching or substitution of a reference products with our approved product candidate in one or more EEA countries, thereby restricting our ability to market our products in those jurisdictions. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our commercial products will remain subject to continuous subsequent regulatory obligations and scrutiny. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our product candidates are approved, they will be subject to ongoing regulatory requirements for pharmacovigilance, manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies (if any) and submission of other post-market information, including both federal and state requirements in the United States and equivalent requirements of comparable foreign regulatory authorities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (&#8220;cGMP&#8221;), regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any marketing authorization application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any regulatory approvals that we or our collaboration partners receive for our product candidates may be subject to limitations on the approved conditions of use for which the product may be marketed or to the conditions of approval or may contain requirements for potentially costly additional data generation, including clinical trials. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities, and to conduct surveillance to monitor the safety and efficacy of the product candidate. Any new legislation addressing drug safety or biologics or biosimilars issues could result in delays in product development, approval or commercialization or increased costs to assure compliance. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions that vary throughout the world and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products in ways that are not consistent with FDA-approved labeling, e.g., for indications or uses for which they do not have approval. Equivalent limitations are provided both at EU level and national level in the individual EU Member States. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our product candidates are approved, the company must submit new or supplemental applications and obtain prior approval for certain changes to the licensed approved, therapeutic indications, product labeling and manufacturing process. These changes may require submission of substantial data packages that may include clinical data. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a regulatory authority discovers previously unknown problems with a biosimilar product (or with the reference product or related biosimilars) such as adverse events of unanticipated severity or frequency, or if there are problems with the facility where the product is manufactured or the regulatory authority disagrees with the advertising, promotion, marketing or labeling of a product, such regulatory authority may impose restrictions on that product or us. If we fail to comply with applicable regulatory requirements, a regulatory authority such as FDA may, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">issue warning or untitled letters; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">refer a case to the U.S. Department of Justice, or comparable authorities, to impose civil or criminal penalties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">begin proceedings to suspend or withdraw regulatory approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">issue an import alert; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">suspend our ongoing clinical studies or put our investigational new drug application (&#8220;IND&#8221;) on clinical hold; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">refuse to approve pending applications (including supplements to approved applications) submitted by us; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">ask us to initiate a product recall; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">refer a case to the U.S. Department of Justice, or comparable authorities, to seize and forfeit products or obtain an injunction imposing restrictions on our operations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with EU and EU Member State laws that govern conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of the marketing authorization, or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any government investigation of alleged violations of law or regulations could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, our value and our operating results will be adversely affected. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adverse events involving a reference product, or other biosimilars of such reference product, may result in negative publicity for our biosimilar product or ultimately result in the removal of our biosimilar product from the market. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event that use of a reference product, or another biosimilar for such reference product, results in unanticipated side effects or other adverse events, it is likely that our biosimilar product candidate will be viewed comparably and may become subject to the same scrutiny and regulatory actions as the reference product or other biosimilar, as applicable. Accordingly, we may become subject to, for example, safety labeling change orders, clinical holds, voluntary or mandatory product recalls or other regulatory actions for matters outside of our control that affect the reference product, or other biosimilars, as applicable, potentially until we are able to demonstrate to the satisfaction of our regulators that our biosimilar product candidate is not subject to the same issues leading to the regulatory action as the reference product or other biosimilar, as applicable. Any recall or safety alert or safety labeling change relating to our product (either voluntary or required by regulatory bodies) could ultimately result in the removal of our product from the market. Any recall could result in significant cost as well as negative publicity that could reduce overall demand for our products. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are highly dependent on the services of our key executives and personnel, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our operations and future performance will suffer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are highly dependent on the principal members of our management and scientific and technical staff. The loss of service of any of our management or key scientific and technical staff could harm our business, prospects and financial condition. In addition, we will need to expand and effectively manage our managerial, scientific, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. The pharmaceutical industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to retain our management and to attract, retain and motivate on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and results of operations. Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have been and will need to continue to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, we had 1,026 employees, including 27 contractors. Additionally, we rely on a number of temporary workers from time to time, as needed. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. In addition, our success depends on our ability to attract and retain a talented workforce with a specialized set of skills. A significant part of our employees are expatriates and may need to obtain work visas in the country of operations. Changes to immigration laws or other restrictions on the movement of persons might make it more difficult for us to attract and retain talented employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected and our ability to generate and/or grow revenue could be reduced and our ability to implement business strategy may suffer. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Reliance on Third Parties </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have relied upon and plans to continue to rely upon third-party CROs to monitor and manage data for our ongoing nonclinical and clinical programs. We rely on these parties for execution of our nonclinical and clinical studies and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with relevant practices that may include cGMP, current good clinical practices (&#8220;cGCP&#8221;) and Good Laboratory Practices (&#8220;GLP&#8221;), which are regulations and guidelines required by the FDA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities monitor these regulations through periodic inspections of study sponsors, principal investigators, study sites and other contractors. If we, any of our CROs, service providers or investigators fail to comply with applicable regulations or cGCPs, the data generated in our nonclinical and clinical studies may be deemed unreliable and the FDA, European Commission, EMA or comparable regulatory authorities may require us to perform additional nonclinical and clinical studies before approving our marketing applications. We cannot provide assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any clinical investigator for any of our clinical studies comply with cGCP regulations. In addition, our clinical studies must be conducted with product produced in compliance with cGMP regulations. Failure to comply with these regulations by us or any of the participating parties may require us to generate new data, repeat clinical studies, and potentially undergo re-inspection, which would delay the regulatory approval process. Further, if any accidents occur or there are process mistakes at the facilities of CROs or other vendors that handle reference products, there may be product loss which could further delay our nonclinical and clinical programs. Moreover, our business may be implicated if our CRO or any other participating parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws whether in the United States or equivalent foreign laws and obligations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under the agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going nonclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">data they obtain is compromised due to the failure to adhere to protocols, regulatory requirements, delays caused by public health emergencies or for other reasons, our clinical studies may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, the results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switching or adding additional CROs involves additional costs and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We partly rely on third parties to manufacture clinical and commercial supplies of our product candidates and to store critical components of our product candidates (including procuring and providing reference product). Our business could be harmed if those third parties fail to provide us with sufficient quantities of product candidates or fail to do so at acceptable quality levels, prices and agreed upon time frame. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We partly rely on third-party manufacturers (contract manufacturing organizations, or &#8220;CMOs&#8221;) to manufacture and supply our product candidates for our preclinical and clinical studies. We also rely on third parties to manufacture nonclinical and clinical supplies of our product candidates, to store critical components of our product candidates and perform various services related to the product candidates&#8217; compliance with regulatory requirements. Successfully transferring complicated manufacturing techniques to contract manufacturing organizations and scaling up these techniques for commercial quantities is time consuming, and we may not be able to achieve such transfer or do so in a timely manner. Moreover, the availability of contract manufacturing services for protein-based therapeutics is highly variable and there are periods of relatively abundant capacity alternating with periods in which there is little available capacity. If our need for contract manufacturing services increases during a period of industry-wide production capacity shortage, we may not be able to produce our product candidates on a timely basis or on commercially viable terms. Moreover, our manufacturing processes utilize single-use processing technology to manufacture drug substance and drug product. Although we will plan accordingly and generally does not begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete such study, any significant delay, whether due to supply chain interruptions in connection with public health emergencies or otherwise, or discontinuation in the supply of a product candidate for an ongoing clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates, which could harm our business and results of operations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reliance on third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, commercial manufacturing must be produced in compliance with cGMP regulations. Failure to comply by any CMO may require us to generate new data, repeat clinical studies, and potentially undergo re-inspection, which would delay the regulatory approval process. In addition, if a CMO does not comply with cGMP, our failure or the failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, license suspension or revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or any other product candidates or products that we may develop. Any failure or refusal to supply the components for our product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected products or product candidates could be delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and the expenses relating to the transfer of necessary technology and processes could be significant. In addition, any changes in our manufacturers could necessitate generation of new data and pre-license facility inspections. Changes made during the pendency of a BLA before FDA, or during the marketing authorization application, could result in delay in approval of the BLA or the marketing authorization. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of our product candidates are approved, in order to produce the quantities necessary to meet anticipated market demand, any contract manufacturer that we engage may need to increase manufacturing capacity. If we are unable to produce our product candidates in sufficient quantities to meet the requirements for the launch of these products or to meet future demand, our revenue and gross margins could be adversely affected. Although we believe that we will not have any material supply issues, we cannot be certain that we will be able to obtain long-term supply arrangements for our product candidates or materials used to produce them on acceptable terms, if at all. If we are unable to arrange for third-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">party manufacturing, or to do so on commercially reasonable terms, we may not be able to complete development or commercialization of or products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our reliance also extends to in-licensing. For AVT23, a biosimilar candidate referencing Xolair (omalizumab), which we have in-licensed, both manufacturing and clinical studies involve external stakeholders. Any failure on their part to meet regulatory requirements or maintain necessary drug availability puts us at risk of delays and potential breaches of our downstream commercial commitments.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we engage external transport companies to ship our products between the different supply points used to manufacture the finished product. Delays in shipment, damage of materials during shipment or any other events leading to late delivery or not full amount of ordered quantities could have a significant impact on project timelines, stock on markets and sales. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time we, or our suppliers located in Europe, may require materials and equipment originating in Asia. Conflicts in the Middle East, which have in recent months disrupted shipments through the Suez Canal, may cause delays in shipments originating in Asia or cause the cost of materials originating in Asia to rise unexpectedly. This may cause delays or disruption in our operations or impair the ability of our suppliers to ship materials and equipment to us on time and on budget. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with third parties in connection with the development of certain of our product candidates. Even if we believe that the development of our technology and product candidates is promising, our partners may choose not to proceed with such development if we materially deviate from the original program timelines, the contractual terms, or breach the contractual terms. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have or may have future collaborations with various partners for the development and commercialization of some of our biosimilar candidates. Our existing and future agreements with our collaboration partners are generally subject to termination by the counterparty under certain circumstances. Accordingly, even if we believe that the development of certain product candidates is worth pursuing, our partners may choose not to continue with such development, if we materially deviate from the original program timelines, the contractual terms, or breach the contractual terms. If any of our collaborations are terminated, we may be required to devote additional resources to the development of our product candidates or seek a new collaboration partner, and the terms of any additional collaborations or other arrangements that we establishes may not be favorable to us, available under commercially reasonable terms or available at all. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also at risk that our collaborations or other arrangements may not be successful. Factors that may affect the success of our collaborations include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our collaboration partners may incur financial, legal or other difficulties that force them to limit or reduce their participation in our joint projects; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our collaboration partners may be pursuing alternative technologies or developing alternative products that are competitive to our technology and products, either on their own or in partnership with others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our collaboration partners may terminate the collaborations, which could make it difficult for us to attract new partners or adversely affect our reputation in the business and financial communities; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our collaboration partners may pursue higher priority programs or change the focus of their development programs, which could affect their commitment to us. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we cannot maintain successful collaborations, our business, financial condition and operating results may be adversely affected. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are dependent on our partners, such as Teva, STADA and Advanz for the commercialization of our biosimilars and biosimilar candidates in certain major markets, and their failure to commercialize in those markets could have a material adverse effect on our revenue, business and operating results. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not currently have direct sales, marketing, and distribution capabilities. Instead, we have chosen to market and commercialize our products through partnerships with multiple regional partners. For example, Teva is responsible for commercialization of, among others, AVT02 and our biosimilar candidates AVT04, AVT05, AVT06 and AVT16 in the United States, Advanz for commercialization of, among others, our biosimilar candidates AVT05 and AVT16 in Europe, and STADA for commercialization of, among others, AVT02 and AVT04 and our AVT06 biosimilar candidate in Europe. If our commercial partners fail to exercise commercially reasonable efforts to market and sell our products in their respective licensed jurisdictions (timely or at all) or are otherwise ineffective in doing so, our business will be harmed and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">we may not be able to adequately remedy the harm through negotiation, litigation, arbitration or termination of the license agreements. Moreover, any disputes with our collaboration partners concerning the adequacy of their commercialization efforts will substantially divert the attention of our senior management from other business activities, and will require us to incur substantial legal costs to fund litigation or arbitration proceedings, and perhaps lead to delayed license-related payments to us. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to a multitude of risks related to manufacturing. Any adverse developments affecting the manufacturing operations of our biosimilar products could substantially increase costs and limit supply. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The process of manufacturing our products is complex, highly regulated and subject to several risks, including but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">raw material and/or consumable shortages from external suppliers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">product loss due to contamination, equipment failure, or operator error;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">equipment installation and qualification failures, equipment breakdowns, labor shortages, natural disasters, power failures and numerous other factors associated with the manufacturing facilities in which our products are produced; </span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:18.65pt">disruption of supply chains for critical and specialized raw materials, delays in regulatory inspections of supplies, manufacturing and testing facilities; and</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:18.65pt">inventory shortages, lack of spare parts, or reduced manufacturing capacities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">due to local or global events such as disruptions of air traffic, maritime transport, volcanic eruptions, earthquakes, pandemics and international conflict.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even minor deviations from normal manufacturing processes for any of our products could result in reduced production yields, product defects and other supply disruptions; additionally, FDA will inspect our manufacturing facilities for these issues, and ensure that the processes are satisfactory, before it licenses a BLA made at these facilities. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, manufacturing facilities for an extended period of time to investigate and remedy the contamination, and any such findings pre-licensure could impact FDA&#8217;s ability to license a BLA. Further, any defects or contaminations, or inadequate disclosure relating to the risk of using our products post-approval could lead to recalls or safety alerts, or other enforcement action by regulatory authorities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We operate our main R&amp;D and manufacturing facility in Iceland which is an island with a relatively limited number of ports of entry by sea or air which may impact logistics. Geologic activity, in particular volcanic eruptions could impact transport and cause disruptions to our supply chain or ability to export product. </span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our main R&amp;D and manufacturing facility is located in Reykjavik. Our operations dependent on supplies which are shipped in either by sea or air and we transport our products to our clients by similar means. </span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Recently, volcanic activity has increased in the region near Reykjavik. While this activity is localized and is not expected to pose a direct threat to our facility and operations, logistics could be disrupted as a consequence of these earthquakes or volcanic eruptions. Volcanic activity could suddenly increase in other parts of Iceland which are geologically active.</span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Major natural disasters, which could include strong earthquakes, can damage the electrical grid, district heating systems or infrastructure which is vital to a well-functioning transport and supply system. </span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">While our facilities are designed to withstand earthquakes and volcanic activity are not expected to impact our operations directly, it is possible that any impact to third-parties, damage to infrastructure or the disruption of air traffic and other logistics, could have an impact on our ability to maintain stable operations and therefore cause delays in our development timelines, increase costs or and cause a loss of revenue. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We currently engage single suppliers for some manufacture, clinical trial services, formulation development and product testing of our product candidates. The loss of any of these suppliers or vendors could materially and adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The biologic drug substance used in all of our programs is currently manufactured at the facility of Alvotech hf. in Reykjavik. In addition, we rely on certain single third-party suppliers for services, such as safety device assembly and associated finished packaging. Prior to engaging any contract manufacturer for services, we perform a qualification of the site, including a verification of our status with regard to the relevant regulations. In addition, we perform regular audits as per our contractor management procedures once the contractor is qualified. Prior to any approval inspection, we engage external partners to help prepare for a successful inspection. We cannot be certain that identifying and establishing relationships with such would not result in significant delay in the development of our product candidates. Additionally, we may not be able to enter into arrangements with alternative vendors on commercially reasonable terms or at all. A delay in the development of our product candidates or having to enter into a new agreement with a different third-party on less favorable terms than what we have with our current suppliers could have a material adverse impact upon on our business. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to obtain or renew certain approvals, licenses, permits and certificates required may result in our inability to continue our operations or may result in enforcement actions with the respective regulatory authorities which would materially and adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are required to obtain and maintain various approvals, licenses, permits and certificates from relevant authorities to operate our business. Any failure to obtain any approvals, licenses, permits and certificates necessary for our operations may result in enforcement actions thereunder, including the relevant regulatory authorities ordering us to cease operations, implement potentially costly corrective measures or any other action which could materially disrupt our business operations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, some of these approvals, permits, licenses and certificates are subject to periodic renewal and/or reassessment by the relevant authorities, and the standards of such renewal and/or reassessment may change from time to time. We cannot give reassurance that we will be able to successfully procure such renewals and/or reassessment when due, and any failure to do so could severely disrupt our business. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, if the interpretation or implementation of existing laws and regulations changes or new regulations come into effect requiring us to obtain any additional approvals, permits, licenses or certificates that were previously not required to operate our existing businesses, we cannot provide assurance that we will successfully obtain them, which in turn could restrict the scope of permitted business activities and constrain our drug development and revenue generation capability. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of the above developments could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We and our collaboration partners and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not meet or continue to meet regulatory requirements or may not be able to meet supply demands. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We, our collaboration partners or our contract manufacturers must supply all necessary documentation in support of a market application on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA and other comparable foreign regulatory authorities through their facilities inspection program. Not all contractors supporting our product candidates may be registered or approved for commercial pharmaceutical production. The facilities and quality systems of some or all of our collaboration partners and third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we oversee our contract manufacturers, we cannot control the implementation of the manufacturing process by the contract manufacturing partners. If these facilities do not pass a pre-approval plant inspection, regulatory approval of our products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our collaboration partners and third-party contractors to monitor and ensure compliance with cGMP. Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement and that may include the invalidation of drug product lots or processes, the temporary or permanent suspension of a clinical study or commercial sales or import or the temporary or permanent closure of a facility and that may require re-inspection thereby causing delays. In some cases, a product recall may be warranted or required, which would materially affect our ability to supply and market products. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business, prospects and financial condition. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we, our collaboration partners or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable foreign regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new biologic product, or suspension, variation or revocation of an approval. As a result, our business, financial condition and results of operations may be materially harmed. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, if supply from one approved manufacturer is interrupted, registration of an alternative manufacturer would require submissions of variations to the marking authorization which could result in further delay. The regulatory authorities may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and prior regulatory approval and is likely to result in a delay in our desired clinical and commercial timelines. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These factors could incur higher costs and cause the delay or termination of clinical studies, regulatory submissions, required approvals or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we is unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential revenue from sales of an approved product. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaboration partners, advisors, employees and consultants prior to beginning research or disclosing proprietary information, such as trade secrets. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be successful in our efforts to identify, develop or commercialize additional product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although a substantial amount of our effort will focus on the continued testing, potential approval and commercialization of our existing product candidates, the success of our business also depends upon our ability to identify, develop and commercialize additional product candidates (in addition to the lead candidates). Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our development efforts may fail to yield additional product candidates suitable for development and/or commercialization for a number of reasons, including but not limited to the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">we may not be successful in identifying potential product candidates that pass our strict screening criteria; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">we may not be able to overcome technological hurdles to development or a product candidate may not be capable of producing commercial quantities at an acceptable cost or at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">we may not be able to assemble sufficient resources to acquire or discover additional product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our product candidates may not succeed in analytical, nonclinical, or clinical testing; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our potential product candidates may fail to show biosimilarity to reference products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">we may not be successful in overcoming intellectual property obstacles in a timely manner or at all; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">competitors may develop alternatives that render our product candidates obsolete or less attractive or the market for a product candidate may change such that a product candidate may not justify further development. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs or we may not be able to identify, develop or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on certain significant shareholders and affiliated entities for certain key services in the execution of our strategy and business operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have entered into various service agreements with our direct and indirect significant shareholders and related entities, such as Alvogen, Aztiq, Alvogen Malta (Out-Licensing) Ltd. (&#8220;Adalvo&#8221;) and Floki Invest ehf. (&#8220;Floki&#8221;). These services include, among others, IT services, corporate administrative, legal, financial, facility management, portfolio and market intelligence research, regulatory compliance, quality audit, and publishing services, and certain administrative and financial services related to our Reykjavik facility. These services are key to our ability to continue to execute on our business strategy and to keep our business operations uninterrupted. Any interruption in the provision of these services may materially harm our business. In addition, because the providers of the services are direct or indirect significant shareholders and related entities, we may not be able or willing to enforce our contractual rights under the service agreements the same way we would if the service providers were unrelated third-party providers. See also &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;We currently rely on Alvogen&#8217;s ERP solution and other components of Alvogen&#8217;s IT infrastructure and will continue to do so for the foreseeable future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Competition and Industry </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our biosimilar product candidates, if approved, will face significant competition from the reference products, other biosimilars, and from other medicinal products approved for the same indication(s) as the reference products. Our failure to effectively compete may prevent us from achieving significant market penetration and expansion. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to enter highly competitive markets. We expect other companies to seek approval to manufacture and market biosimilars to Humira (AVT02), Prolia/Xgeva (AVT03), Stelara (AVT04), Simponi/Simponi Aria (AVT05), Eylea (AVT06), Entyvio (AVT16), Xolair (AVT23), and Keytruda (AVT33). If other biosimilars to these or other non-reference products in the same therapeutic spaces are approved and successfully commercialized before AVT03, AVT04, AVT05, AVT06, AVT16, AVT23 and AVT33, respectively, we may never achieve significant market share for these products, our revenue would be reduced and, as a result, our business, prospects and financial condition could suffer. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Successful competitors in the market have demonstrated the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as an ability to effectively commercialize, market and promote approved products. Numerous companies, universities and other research institutions are engaged in developing, patenting, manufacturing and marketing of products competitive with those that we are developing. Many of these potential competitors are large, experienced pharmaceutical companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources. These companies also have greater brand recognition and more experience in conducting preclinical testing and clinical trials of product candidates and obtaining FDA and other regulatory approvals of products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If an improved version of a reference product, is developed or if the market for the reference product significantly declines, sales or potential sales of our biosimilar product candidates may suffer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Companies may develop improved versions, treatment regimens, combinations and/or doses of a reference product as part of a life cycle extension strategy and may obtain regulatory approval of the improved version under a new or supplemental BLA, or equivalent foreign procedure, filed with the applicable regulatory authority. Should the company manufacturing the reference product for any of our candidate products succeed in obtaining an approval of an improved biologic product, it may capture a significant share of the market for the reference product in the applicable jurisdiction and significantly reduce the market for the reference product and thereby the potential size of the market for our biosimilar product candidates. In addition, the improved product may be protected by additional regulatory exclusivity or patent rights that may subject our follow-on biosimilar to claims of infringement. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biologic reference products may also face competition as technological advances are made that may offer patients a more convenient form of administration or increased efficacy or as new products are introduced. As new products are approved that compete with the reference product for our biosimilar product candidates, sales of the reference products may be adversely impacted or rendered obsolete. If the market for the reference product is impacted, we may lose significant market share or experience limited market potential for our approved biosimilar products or product candidates, and the value of our product pipeline could be negatively impacted. As a result of the above factors, our business, prospects and financial condition could suffer.</span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">If efforts by manufacturers of reference products to prevent, delay or limit the use of biosimilars are successful, our business may be negatively affected, including but not limited to the sales of our biosimilar products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many manufacturers of reference products have increasingly used legislative, regulatory and other means to prevent or delay regulatory approval and to seek to restrict competition from manufacturers of biosimilars. These efforts may include or have included: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">settling patent lawsuits with biosimilar companies, resulting in such patents remaining an obstacle for biosimilar approval by others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">submitting Citizen Petitions to request the FDA Commissioner to take administrative action with respect to prospective and submitted biosimilar applications or to elaborate or amend the standard of review for such biosimilar applications; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">appealing denials of Citizen Petitions in U.S. federal district courts and seeking injunctive relief to reverse approval of biosimilar applications; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">restricting access to reference brand products for equivalence and biosimilarity testing that interferes with timely biosimilar development plans; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">attempting to influence potential market share by conducting medical education with physicians, payors, regulators and patients claiming that biosimilar products are too complex for biosimilar approval or are too dissimilar from reference products to be trusted as safe and effective alternatives; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">implementing payor market access tactics that benefit their brands at the expense of biosimilars; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">seeking state law restrictions on the substitution of biosimilar products at the pharmacy without the intervention of a physician or through other restrictive means such as excessive recordkeeping requirements or patient and physician notification; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">seeking federal or state regulatory restrictions, or equivalent foreign restrictions, on the use of the same non-proprietary name as the reference brand product for a biosimilar or interchangeable biologic; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">seeking changes to the U.S. Pharmacopeia, an industry recognized compilation of drug and biologic standards, or equivalent international or foreign standards; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">obtaining new patents covering existing products or processes which could extend patent exclusivity for a number of years or otherwise delay the launch of biosimilars; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">originator could compete with us by manufacturing or commercializing their own proprietary biosimilar product to the reference product they sponsor; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">influencing legislatures so that they attach special patent extension amendments to unrelated federal legislation. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2012, Abbott Laboratories filed a Citizen Petition with the FDA asking the agency to refrain from accepting biosimilar applications under the BPCIA arguing that to approve such applications, without compensation to the reference </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">product sponsor, would constitute an unconstitutional taking of a reference company&#8217;s valuable trade secrets under the fifth amendment of the U.S. constitution. The FDA denied this citizen petition in 2016. Other reference companies may file Citizen Petitions in an effort to restrict or prevent the introduction of biosimilars. If the FDA or a federal court determines that biosimilar applications under the BPCIA should be limited, our business may be negatively impacted. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face intense competition and rapid technological changes and the possibility that our competitors and originators such as AbbVie and Janssen may develop therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and the ability to successfully commercialize our product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. Some of the pharmaceutical and biotechnology companies developing biosimilars we expect to compete with include companies such as Celltrion Healthcare Co., Ltd. (&#8220;Celltrion&#8221;), Coherus, Amgen, Pfizer Inc. (&#8220;Pfizer&#8221;), Samsung Bioepis, Ltd. (&#8220;Samsung Bioepis&#8221;), and Sandoz International GmbH (&#8220;Sandoz&#8221;), as well as other companies. These companies may develop biosimilars or other products in the same therapeutic space as our products. For example, based on publicly available information, we expect AbbVie (the originator), Amgen, Boehringer Ingelheim GmbH, Biocon/Fujifilm, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Coherus, and Sandoz to be our main competitors for AVT02, a biosimilar to Humira (adalimumab); Janssen (the originator), Amgen, Celltrion, Bio-Thera, Formycon, Dong-A/Meiji Seika, Samsung Bioepis, and Biocon to be our main competitors for AVT04, a biosimilar to Stelara (ustekinumab); Amgen (the originator), Sandoz, Celltrion, Fresenius Kabi, Samsung Bioepis, Gedeon Richter, mAbxience, Biocon, Henlius and Teva to be our main competitors for AVT03, a biosimilar candidate to Prolia / Xgeva (denosumab); Janssen (the originator), and Bio-thera to be our main competitors for AVT05, a biosimilar candidate of Simponi and Simponi Aria (golimumab); and Regeneron/Bayer Health Care (the originator), Amgen, Celltrion, Formycon, Altos, Sam Chun Dang, Samsung Bioepis, Sandoz, and Viatris/Biocon, to be our main competitors for AVT06, a biosimilar candidate to Eylea (aflibercept); and Genentech (the originator), Celltrion and Teva, to be our main competitors for AVT23, a biosimilar candidate to Xolair (omalizumab). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of our competitors have substantially greater financial, technical and other resources, such as larger research and development team and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop; they may also obtain patent protection that could block our products; and they may obtain regulatory approval, product commercialization and market penetration earlier than we do. Additionally, our competitors may have more resources in order to effectively pursue, defend against or settle with regard to potential or ongoing litigation. Biosimilar product candidates developed by our competitors may render our potential product candidates uneconomical, less desirable or obsolete, and we may not be successful in marketing our product candidates against competitors. Competitors may also assert in their marketing or medical education programs that their biosimilar products demonstrate a higher degree of biosimilarity to the reference products than do our or other competitor&#8217;s biosimilar products, thereby seeking to influence health care practitioners to select their biosimilar products, versus those of us or other competitors. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our competitors may also succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than our biosimilar candidates. They may also obtain exclusivity by regulators that could block or limit the marketability of our products for shorter or longer periods of time; and they may obtain regulatory approval, achieve commercialization and significant market penetration earlier than we do.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Furthermore, our competitors may develop products that are easier to administer than our products, which could adversely affect our results. Many of our biosimilar candidates need to be administered by a physician. Patients may demonstrate a preference for medications which can be administered by the patient at home or for pharmaceuticals that can be administered more rapidly in the clinic. Our competitors could develop proprietary technology that we are unable to replicate allowing competing medications to be self-administered or for sub cutaneous injection.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Development of such alternative and competitive technologies and products may limit our success in commercializing our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to establish effective sales and marketing capabilities in jurisdictions for which we choose to retain commercialization rights or if we are unable to enter into agreements with third parties to market and sell our product candidates, and we are unable to establish and maintain a marketing and sales organization, we may be unable to generate substantial or any revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have no marketing or sales organization. We have no experience selling and marketing our product candidates. To successfully commercialize any products that may result from our development programs, we will need to develop these capabilities, either on our own or with others. If our product candidates receive regulatory approval, we might establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in major markets where we may choose to retain commercialization rights. Doing so will be expensive, difficult and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, given our lack of prior experience in marketing and selling biopharmaceutical products, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such, we may be required to hire substantially more sales representatives to adequately support the commercialization of our product candidates or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaboration partners do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We expect competition from companies such as Celltrion, Sandoz, Amgen, Pfizer, Fresenius Kabi, Boehringer Ingelheim, Samsung Bioepis, Coherus and Viatris that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third-party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may need to enter into alliances with other companies that can provide capabilities and funds for the development and commercialization of our product candidates. If we are unsuccessful in forming or maintaining these alliances on sufficiently favorable terms, our business could be adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our manufacturing facility in Reykjavik to be able to scale up its capabilities for commercial production. Nevertheless, we are expected to retain contract manufacturing organization services as a second source of supply, including for business continuity risk mitigation. In addition, because we have limited capabilities for late-stage product development, manufacturing, sales, marketing and distribution, we have found it necessary to enter into alliances with other companies. We entered into a collaboration agreement with Teva for the development and commercialization of AVT02 in the United States. Similarly, we entered into a collaboration agreement with STADA for the development and commercialization of AVT02 in Europe. In the future, we may also find it necessary to form alliances or joint ventures with major pharmaceutical companies to jointly develop and/or commercialize specific biosimilar product candidates. In such alliances, we would expect our collaboration partners to provide substantial capabilities in clinical development, manufacturing, regulatory affairs, sales and marketing. We may not be successful in entering into any such alliances. Even if we do succeed in securing such alliances, we may not be able to maintain them if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. If we are unable to secure or maintain such alliances we may not have the capabilities necessary to continue or complete development of our product candidates and bring them to market, which may have an adverse effect on our business. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to product development and commercialization capabilities, we may depend on our alliances with other companies to provide substantial additional funding for development and potential commercialization of our product candidates. We may not be able to obtain funding on favorable terms from these alliances, and if we are not successful in doing so, we may not have sufficient funds to develop a particular product candidate internally or to bring product candidates to market. Failure to bring our product candidates to market will prevent us from generating sales revenue, and this may substantially harm our business, prospects and financial condition. Furthermore, any delay in entering into these alliances could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. As a result, our business and operating results may be adversely affected. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our product candidates will depend in part on the medical community, patients and third-party payors accepting our product candidates as medically useful, cost-effective and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of any of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the safety and efficacy of the product as demonstrated in clinical studies and through the demonstration of biosimilarity; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">any potential advantages over competing biosimilars and/or other treatments in the same therapeutic space(s); </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the clinical indications for which approval is granted; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the possibility that a competitor may achieve interchangeability in the United States, and we may not; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">relative convenience and ease of administration; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the extent to which our product may be more or less similar to the reference product than competing biosimilar product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">policies and practices governing the naming of biological product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">prevalence of the disease or condition for which the product is approved; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the cost of treatment, particularly in relation to competing treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the strength of marketing and distribution support and timing of market introduction of competitive products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">publicity concerning our products or competing products and treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the extent to which third-party payors provide adequate third-party coverage and reimbursement for our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">our ability to maintain compliance with regulatory requirements. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if a potential biosimilar product is expected to have a highly similar efficacy and safety profile to the reference product, as demonstrated through analytical, nonclinical, and clinical studies, market acceptance of the product will not be fully known until after it is launched and may be negatively affected by a potential poor safety experience and the track record of other biosimilar product candidates. Our efforts to educate the medical community and third-party payors on the benefits of the product candidates may require significant resources, may be under-resourced compared to large well-funded pharmaceutical entities and may never be successful. If our product candidates are approved but fail to achieve an adequate level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient revenue to become or remain profitable. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The third-party coverage and reimbursement status of newly-approved products is uncertain. Failure of our third-party commercial partners to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and generate revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pricing, coverage and reimbursement of our biosimilar product candidates, if approved, may not be adequate to support our commercial infrastructure. Our per-patient prices may not be sufficient to recover our development and manufacturing costs and potentially achieve profitability. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford expensive treatments such as our products, if approved. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations or reimbursed by government authorities, private health insurers and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reimbursement amount may not be adequate to allow us to establish or maintain pricing sufficient to realize a return on investment. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our biosimilar product candidates, if approved. In addition, in the United States, no uniform policy of coverage and reimbursement for biologics exists among third-party payors. Therefore, coverage and reimbursement for biologics can differ significantly from payor to payor. As a result, the process for obtaining favorable coverage determinations often is time-consuming and costly and may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outside the United States, pharmaceutical companies, products and distributors are generally subject to extensive governmental price controls and other market regulations. We believe the increasing emphasis on cost-containment initiatives in EEA, Canada and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to control healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Certain cost containment practices may adversely affect our product sales. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our third-party commercial partners are unable to establish or sustain coverage and adequate reimbursement for any of our product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect our ability to market or sell those product candidates, if approved.</span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Measures to contain healthcare costs, including the U.S. Inflation Reduction Act, may reduce the addressable market for our products, affect the prices that our commercial partners are able to obtain and have a material adverse effect on our business and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A number of legislative initiatives in the U.S. and other markets, often intended to contain healthcare costs, may impact our cost of obtaining market approval and ability to successfully commercialize our products. In the U.S. the Inflation Reduction Act (IRA), requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap. As the U.S. Secretary of the Department of Health and Human Services (HHS) is given significant flexibility to implement different provisions of the IRA it is currently unclear how this particular legislation will work and what impact it will have on the market for biosimilars in the near future.</span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a reference product becomes subject to the IRA negotiation provision and related price cap, this may significantly alter the economics for biosimilars to that product. In 2023, HHS added Stelara, the reference product for AVT04, to the list of drugs for the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) Medicare price negotiations. At this point it is unclear whether this will have any impact on the pricing of Stelara or on the competitive position of biosimilars to Stelara, as the Medicare drug price negotiation program is currently subject to legal challenges.</span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Any reduction in reimbursement for reference products from Medicare, other government programs in the U.S. or similar cost reimbursement systems in other countries, may result in a price reduction for biosimilars. The implementation of cost containment measures or other healthcare reforms may therefore prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the EU, similar political, economic, and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our biosimilar product candidates, if approved, could face price competition from other biosimilars of the same reference products for the same indication. This price competition could exceed our capacity to respond, detrimentally affecting its market share and revenue as well as adversely affecting the overall financial health and attractiveness of the market for the biosimilar. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to enter highly competitive biosimilar markets. Successful competitors in the biosimilar market have the ability to effectively compete on price through payors and their third-party administrators who exert downward pricing pressure. It is possible our biosimilar competitors&#8217; compliance with price discounting demands in exchange for market share could exceed our capacity to respond in kind and reduce market prices beyond our expectations. Such practices may limit our and our collaboration partners&#8217; ability to increase market share and will also impact profitability. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Intellectual Property </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we or one of our partners infringes or is alleged to infringe the intellectual property rights of third parties, our business could be harmed. Avoiding and defending against infringement claims could be expensive and time consuming, which may in turn prevent or delay our development and commercialization efforts. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success depends in large part on avoiding infringement of the valid and enforceable patents and proprietary rights of third parties and invalidating or rendering unenforceable other patent and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the pharmaceutical industry, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the pharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights, or other intellectual property rights, of third parties. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research, development and commercialization activities may be claimed or held to infringe or otherwise violate patents owned or controlled by other parties. The companies that originated the products for which we intend to introduce biosimilar versions, such as AbbVie, Amgen, Janssen, Genentech and Regeneron as well as other competitors (including other companies developing biosimilars) often have developed worldwide patent portfolios of varying sizes and breadth, many of which are in fields relating to our business, and it may not always be clear to industry participants, including us, which patents cover various types of products, methods of use, methods of manufacturing, etc. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. While we have conducted freedom to operate analyses with respect to our lead product candidates, we cannot guarantee that any of our analyses will ensure that claims will not be brought or won against us, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates. Moreover, because patent applications can take up to 18 months after initial priority filing date to publish and issue, there may be currently pending patent applications with claims not yet filed that may later result in issued patents covering our product candidates. We have not yet completed a freedom-to-operate analysis on products we are evaluating for inclusion in our future biosimilar product pipeline, and therefore we do not know whether or to what extent that development of these products may be influenced by unexpired patents and pending applications. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There may also be patent applications that have been filed but not published and if such applications issue as patents, they could be asserted against us. For example, in most cases, a patent filed today would not become known to industry participants for at least 18 months given patent rules applicable in most jurisdictions which typically do not publish patent applications until 18 months from the application&#8217;s prior date. Moreover, we may face claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. In addition, coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to convince a judicial authority that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid and/or unenforceable, and we may not be able to do this. Proving to a judicial authority that a patent claim is invalid or unenforceable can be difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">presumption of validity enjoyed by issued patents. Also in proceedings before courts in Europe, the burden of proving invalidity of the patent usually rests on the party alleging invalidity. Further, proving the invalidity or unenforceability of a patent claim in the jurisdictions in which we operate may also depend on changes in the relevant law. Attempts to resolve intellectual property disputes may require substantial efforts including, but not limited to, validity challenges in patent offices, court litigation and arbitration. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a desired conclusion. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties could bring claims against us that would cause us to incur substantial expenses to defend against and, if successful against us, could cause us to pay substantial monetary damages if our product candidate is on the market. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Ultimately, we could be prevented from commercializing a product or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, We are unable to enter into licenses on commercially acceptable terms or at all. If, as a result of patent infringement claims or to avoid potential claims, we choose or is required to seek licenses from third parties, these licenses may not be available on acceptable terms or at all. Even if we are able to obtain a license, the license may obligate us to pay substantial license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively delay or block our ability to further develop and commercialize one or more of our product candidates. For example, companies that originated the products for which we intend to introduce biosimilar versions may seek damages for their loss of profits and/or market share. Defense of these claims, regardless of their merit, would likely involve substantial litigation expense and would likely be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may, in addition to being blocked from the market, have to pay substantial monetary damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future products. An unfavorable outcome in any such proceedings could require us to delay or cease using the related technology or to attempt to license rights to it from the prevailing party or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we may jointly develop intellectual property with certain parties, and disagreements may therefore arise as to the ownership of the intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BLA holders may submit applications for patent term extensions in the United States or other jurisdictions where similar extensions are available and/or Supplementary Protection Certificates in the EEA countries, and an equivalent process in Switzerland, seeking to extend certain patent protection which, if approved, may interfere with or delay the launch of one or more of our biosimilar products. Further, patent laws in the various jurisdictions in which we do business are subject to change and any future changes in patent laws may be less favorable for us. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Patent litigation and other proceedings may fail, and even if successful, may result in substantial costs and distract our management and other employees. The companies that originated the products for which we intend to introduce biosimilar versions, as well as other competitors (including other biosimilar companies) may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings (either filed against Alvotech or one of its partners) could impair our ability to compete in the applicable marketplace. For example, we were in legal proceedings adverse to AbbVie, and our Canadian partner JAMP continues to be, relating to AVT02. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">So called &#8220;submarine&#8221; patents may be granted to our competitors that may significantly alter our launch timing expectations, reduce our projected market size, cause us to modify our product or process or block us from the market altogether. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The term &#8220;submarine&#8221; patent has been used in the pharmaceutical industry and in other industries to denote a patent issuing from an application that was not published, publicly known or available (including unfiled continuation, continuation-in-part, and divisional applications, and the like) at a critical time during which development and/or commercial decisions are made. Submarine patents add uncertainty to our business, e.g., because key decisions may be made during a period of time during which a pending applications has not yet published and such applications may only become known after those key decisions have already been made and perhaps even acted on. Submarine patents may issue to our competitors covering key aspects of our biosimilar product candidates or our pipeline candidates and thereby cause significant market entry delay, lead to unexpected licensing fees, defeat our ability to market our products or cause us to abandon development and/or commercialization of a molecule. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The issuance of one or more submarine patents may harm our business by causing substantial delays in our ability to introduce a biosimilar candidate into the U.S. market. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not timely identify, or identify at all, relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent which might adversely affect our ability to develop and market our products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are 100% accurate and/or exhaustive, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction (timely or at all). The scope of a patent claim is determined by a judicial authority&#8217;s interpretation under controlling law. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect and/or different from that of a judicial authority, which may negatively impact our ability to market our products or pipeline molecules. We may determine that our products are not covered by a third-party patent, but a judicial authority may hold otherwise. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many patents may cover a marketed product, including but not limited to the composition of the product, methods of use, formulations, cell line constructs, vectors, growth media, production processes and purification processes. The identification of all patents and their expiration dates relevant to the production and sale of a reference product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction and interactive monitoring and analyzing of the patent landscape. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. Our determination of the expiration date of any patent in the United States or abroad that we consider (timely or at all) relevant may be incorrect which may negatively impact our ability to develop and market our products. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal proceedings that carry risk may occur from time to time, and their outcome may be uncertain. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have been, and may in the future be involved, directly or through our partners, in various legal proceedings, including patent litigation and challenges, other intellectual property disputes, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment, tax litigation and other legal proceedings that arise from time to time in the ordinary course of our business. See, for example, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> &#8212;We may be involved in lawsuits to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">unsuccessful." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">addition, we were in legal proceedings adverse to AbbVie relating to AVT02, which resulted in settlements (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 4.B</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Business Overview&#8212;Material Agreements, Partnerships and Suppliers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), and our Canadian partner JAMP continues to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">be in proceedings adverse to AbbVie relating to AVT02. Litigation is inherently unpredictable, and excessive verdicts do occur. We could incur judgments and/or enter into settlements, which could require us to make payments to the proceedings&#8217; counterparties or limit or discontinue certain of our activities, or could otherwise have a material adverse effect on our business operations. In addition, even if such legal proceedings are ultimately resolved in our favor, they may be costly and time-consuming to conduct, which may materially adversely affect our business, financial condition and results of operations. The cost and resource requirements, including management attention, associated with conducting such legal proceedings may lead us to settle certain actions on terms that are materially adverse to us, even if we believe that the ultimate resolution of the proceedings is likely to be favorable. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if we cannot obtain a license from the prevailing party on commercially reasonable terms. Our defense of litigation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development partnerships that would help us bring our product candidates to market. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be involved in lawsuits to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may discover that competitors are infringing one or more of our patents after they issue. Expensive and time-consuming litigation may be required to abate such infringement. Although we are not currently involved in any litigation to enforce patents, if we or one of our collaboration partners, such as Teva or STADA, were to initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including but not limited to lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone involved in the prosecution of the patent withheld relevant or material information related to the patentability of the invention from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, and although there are protections in place, there is a risk that some of our confidential information could be compromised by disclosure during any litigation we initiate to enforce our patents. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, they could have a material adverse effect on the price of Ordinary Shares. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers or third parties. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We employ individuals, retains independent contractors and consultants and members on our board of directors or scientific advisory board who were previously employed at universities or other pharmaceutical companies, including our competitors or potential competitors. Although we have several mechanisms in place to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. For example, in March 2021, AbbVie brought a suit, which is now dismissed, against Alvotech hf. alleging that Alvotech hf. misappropriated trade secrets through the hiring of a former AbbVie employee. If we fail in defending against any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs or delay and be a distraction to management and other employees. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to obtain and maintain effective intellectual property rights, including patent rights, for our product candidates or any future product candidates, we may not be able to prevent competitors from using technologies we consider important to successful development and commercialization of our product candidates, resulting in loss of any potential competitive advantage our intellectual property rights may have otherwise afforded us. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our principal focus in matters relating to intellectual property is to avoid infringing the valid and enforceable rights of third parties, we also rely upon a combination of intellectual property protection and confidentiality agreements to protect our own intellectual property related to our product candidates and development programs. Our ability to enjoy any competitive advantages afforded by our own intellectual property depends in large part on our ability to obtain and maintain patents and other intellectual property protection in the United States and in other countries with respect to various proprietary elements of our product candidates, such as, for example, our product formulations and processes for manufacturing our products and our ability to maintain and control the confidentiality of trade secrets and confidential information critical to our business. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our products that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. There is no guarantee that any patent application we file will result in an issued patent having claims that protect our products. Additionally, while the basic requirements for patentability are similar across jurisdictions, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">each jurisdiction has its own specific requirements for patentability. We cannot guarantee that we will obtain identical or similar, or any, patent protection covering our products in all jurisdictions where we file patent applications. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The patent positions of biopharmaceutical companies generally are highly uncertain and involve complex legal and factual questions for which legal principles remain unresolved. As a result, the patent applications that we own or licenses may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries for many reasons. There is no assurance that all potentially relevant prior art relating to our patents and patent applications have been found, considered or cited during patent prosecution, which can be used to invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patent claims being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competitors from using the technologies claimed in any patents issued to us, which may have an adverse impact on our business. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant and, in addition, may be challenged before national courts at any time. From time to time, we may be involved in these anonymous or &#8220;straw man&#8221; oppositions. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we hold, license or pursue with respect to our product candidates is threatened, it could threaten our ability to prevent third parties from using the same technologies that we use in our product candidates. In addition, changes to the patent laws of the United States provide additional procedures for third parties to challenge the validity of issued patents based on patent applications filed after 15 March 2013. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is challenged, then it could threaten our ability to prevent competitive products using our proprietary technology. Further, because patent applications in the United States and most other countries are confidential for a period of time, typically for 18 months after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before 16 March 2013 or patents issuing from such applications, an interference proceeding can be provoked by a third-party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of 16 March 2013, the United States transitioned to a &#8220;first-inventor-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications claiming the same invention are filed by different parties. A third-party that files a patent application in the USPTO before us could therefore be awarded a patent covering our invention. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The change to &#8220;first-inventor-to-file&#8221; from &#8220;first-to-invent&#8221; is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;), signed into law on 16 September 2011. Among some of the other significant changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. We have filed patent applications, which are in various stages of prosecution/issuance, and plan to pursue additional applications, covering various aspects of our product candidates (e.g., formulations and bioprocesses). We cannot offer any assurances about which or where, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened or infringed by third parties. Any successful actions by third parties to challenge the validity or enforceability of any patents which may issue to us could deprive us the ability to prevent others from using the technologies claimed in such issued patents. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is based primarily on the timing of our biosimilar product launches to occur after the expiration of relevant patents and/or regulatory exclusivity. We file patent applications directed to our proprietary formulations for our product candidates when we believe securing such patents may afford a competitive advantage. For example, the company that originated Humira (AbbVie) owns patents directed to formulations for these products. We have developed our own proprietary formulations for this product and have filed patent applications covering our formulations. We cannot guarantee that our proprietary formulations will avoid infringement of third-party patents, or that the patent applications filed on our proprietary formulations will be found patentable and/or upheld as valid. Moreover, because competitors may be able to develop their own proprietary product formulations, it is uncertain whether issuance of any of our pending patent applications directed to formulations of ATV02, a biosimilar candidate to Humira (adalimumab), would cover the formulations of any competitors. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not consider it necessary for us or our competitors to obtain or maintain a proprietary patent position in order to engage in the business of biosimilar development and commercialization. Hence, while our ability to secure patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">coverage on our own proprietary developments may improve our competitive position with respect to the product candidates we intend to commercialize, we do not view our own patent filings as a necessary or essential requirement for conducting our business nor do we rely on patent filings or the potential for any commercial advantage they may provide us as a basis for our success. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Obtaining and maintaining our patent protection depends on compliance with various procedural requirements, document submissions, actions within prescribed deadlines, overcoming substantial and procedural examination requirements, fee payments and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to adequately protect our intellectual property rights throughout the world. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filing, prosecuting, defending and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Further, licensing partners may choose not to file patent applications in certain jurisdictions in which we may obtain commercial rights (to the extent those partners have a contractual right to do so), thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or importing products made using our inventions into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but the ability to enforce our patents is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many companies have encountered significant problems in obtaining, protecting and defending intellectual property rights in certain non-U.S. jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that it initiates and the damages or other remedies awarded, if any, may not be commercially meaningful. Governments of some foreign countries may force us to license our patents to third parties on terms that are not commercially reasonable or acceptable to us (not timely or not at all). Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license in certain jurisdictions. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in the patent laws of the United States and other jurisdictions in which we do business could diminish the value of patents obtainable in such jurisdictions, thereby impairing our ability to protect our products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As is the case with other biopharmaceutical companies, our success for any given product could be heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain effective (non-patent) proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we have filed patent applications to protect certain aspects of our own proprietary formulation and process developments, we also rely on trade secret protection and confidentiality agreements to protect proprietary scientific, business and technical information and know-how that is not or may not be patentable or that we elect not to patent. However, confidential information and trade secrets can be difficult to protect. Moreover, the information embodied in our trade secrets and confidential information may be independently and legitimately developed or discovered by third parties without any improper use of or reference to information or trade secrets. We seek to protect the scientific, technical and business information supporting our operations, as well as the confidential information relating specifically to our product candidates by entering into confidentiality agreements with parties to whom we need to disclose our confidential information, for example, our employees, consultants, scientific advisors, board members, contractors, potential collaborators and financial investors. However, we cannot be certain that such agreements have been entered into with all relevant parties, or that any such agreements would not be violated. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. Further, from time-to-time we may be subject to anonymous Freedom of Information Act (&#8220;FOIA&#8221;), requests. To the extent the company needs to respond to such requests, our management&#8217;s attention and the company&#8217;s resources may be diverted from normal business operations. As a result of either security breaches or FOIA requests, our confidential information and trade secrets thus may become known by our competitors in ways we cannot prevent or remedy. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we require all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. We cannot guarantee that our employees, former employees or consultants will not file patent applications claiming our inventions. Because of the &#8220;first-to-file&#8221; laws in the United States (and in other jurisdictions), such unauthorized patent application filings may defeat our attempts to obtain patents on our inventions. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims challenging the inventorship or ownership of our patent filings and other intellectual property. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we are not currently aware of any claims challenging the inventorship of our patent applications or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patent applications or patents we may be granted or other intellectual property as an inventor or co-inventor. For example, we may have inventorship or ownership disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates, or which result from an improper assignment of ownership. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be successful in obtaining or maintaining necessary intellectual property rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have or are pursuing rights to certain intellectual property, through licenses from third parties for various technologies relevant to the manufacture and commercialization of biologics. Because we may find that our programs require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on investment. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, our business and financial condition could suffer. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to market our products in the United States may be significantly delayed or prevented by the BPCIA patent information exchange mechanism. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BPCIA created an elaborate and complex, private, pre-litigation patent information exchange mechanism for biosimilars to focus issues for patent litigation and/or facilitate dispute resolution with the reference product sponsor before litigation commences/ends. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BPCIA provides for a detailed and complex mechanism for exchange of confidential and business-sensitive information between a reference product sponsor and a biosimilar candidate (pre-approval) that is demanding, time-sensitive and, to date, not fully tested and therefore unpredictable. This pre-litigation private information exchange is colloquially known as the &#8220;patent dance.&#8221; </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The patent dance requires the biosimilar applicant to disclose not only the regulatory application but also the applicant&#8217;s manufacturing process before litigation (and therefore significantly earlier than would normally be required in patent litigation), has the potential to afford the reference product sponsor an easier path than traditional infringement litigation for developing any factual grounds they may require to support allegations of infringement. The rules established in the BPCIA&#8217;s patent dance procedures could place biosimilar firms at a significant disadvantage by affording the reference product sponsor a much easier mechanism for factual discovery, thereby increasing the risk that a biosimilar product could be blocked from the market more quickly than under traditional patent infringement litigation processes and in certain cases could outweigh advantages provided to biosimilar firms by the patent dance. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preparing for and conducting the patent information exchange, briefing and negotiation process under the BPCIA will require sophisticated legal counseling and extensive planning, all under extremely tight deadlines. We cannot guarantee the outcome of the patent dance will be a successful path to commercialization of our biosimilar products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible for a biosimilar firm to skip the patent dance before any corresponding patent litigation. But this too could place a biosimilar firm at a significant disadvantage by ceding all control of the number of patents and the timing for the start of litigation to the reference product sponsor, thereby increasing the uncertainty before approval and launch and increasing the chances for possible delays. In certain circumstances, the advantages of participating in the patent dance could outweigh the advantages of skipping the patent dance. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regardless of whether a biosimilar firm chooses to participate in the patent dance, the BPCIA&#8217;s information disclosure procedure adds significantly to expense, complexity, uncertainty, and risk. For example, a biosimilar firm may be subject to an allegation of violating the BPCIA independent of the patent issues, given that what could be a violation still has not been fully vetted. Moreover, the complexity of the patent dance and subsequent biosimilar litigation requires highly qualified law firms and the conflict space for such firms is very crowded, with biosimilar firms competing not only with other biosimilar firms but also with reference product sponsors for the engagement of suitable law firms. It may be difficult for us to secure such legal support if large, well-funded references have already entered into engagements with highly qualified law firms or if the most highly qualified law firms choose not to represent biosimilar applicants due to their long-standing relationships with references. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Canadian partner, JAMP, is involved in legal proceedings adverse to AbbVie that may have an impact on our AVT02 product in Canada. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our legal proceedings adverse to AbbVie related to our biosimilar adalimumab product, AVT02, have been settled or otherwise resolved in the United States, the Netherlands, and Japan, and before the European Patent Office, proceedings between our Canadian partner JAMP and AbbVie are pending in Canada. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 31 March 2021, AbbVie filed four actions in the Federal Court of Canada (T-557-21, T-559-21, T-560-21 and T-561-21, collectively, the &#8220;NOC Actions&#8221;) against JAMP Pharma Corporation (&#8220;JAMP Pharma&#8221;), which is our exclusive Canadian partner for AVT02 (adalimumab solution for injection). No Alvotech entity is a named party in the NOC </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actions. AbbVie is seeking declarations pursuant to the Patented Medicines (Notice of Compliance) Regulations and the Patent Act that JAMP Pharma&#8217;s adalimumab solution for subcutaneous injection (the &#8220;JAMP Pharma Products&#8221;) would directly or indirectly infringe the asserted claims of Canadian Patent Nos. 2,898,009; 2,904,458; 2,504,868; 2,847,142; 2,801,917 and 2,385,745. JAMP Pharma counterclaimed, in each of the four actions, alleging that the asserted claims of each of the six patents are invalid. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 6 April 2021, JAMP Pharma commenced four actions in the Federal Court of Canada (T-572-21, T-573-21, T-577-21 and T-581-21, collectively, the &#8220;Impeachment Actions&#8221;) seeking declarations that all claims of Canadian Patent Nos. 2,898,009; 2,904,458; 2,504,868; 2,847,142; 2,801,917 and 2,385,745 are invalid, void and of no force or effect, and declarations that the making, using or selling of the JAMP Pharma Products by JAMP Pharma in Canada will not infringe any valid claim of Canadian Patent Nos. 2,898,009; 2,904,458; 2,504,868; 2,847,142; 2,801,917 and 2,385,745. No Alvotech entity is a named party in the Impeachment Actions. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 4 June 2021, JAMP Pharma amended its Statements of Claim in the Impeachment Actions to only seek declarations that the specific claims asserted in the NOC Actions are invalid, void and of no force or effect, and declarations that the making, using or selling of the JAMP Pharma Products by JAMP Pharma in Canada will not infringe the asserted claims. AbbVie has counterclaimed for declarations that the asserted claims of the patents are valid and that they will be infringed by JAMP Pharma. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trial of the Impeachment Actions and the NOC Actions commenced on 14 November 2022, and concluded with closing arguments on 14 December 2022. During the course of the proceedings, the patents-at-issue were limited to Canadian Patent Nos. 2,904,458; 2,504,868; and 2,801,917. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, Justice McVeigh issued her trial decision, which invalidated AbbVie&#8217;s 868 Patent (dosing to treat Crohn&#8217;s disease and UC) and 917 Patent (dosing to treat HS). While AbbVie&#8217;s 458 Patent (bufferless formulation) was held to be valid and infringed by JAMP Pharma, Justice McVeigh declined to issue a permanent injunction and instead determined that JAMP Pharma could continue to market AVT02 in Canada and compensate AbbVie by way of a running royalty (to be determined by way of a future trial).  AbbVie appealed the trial decision and JAMP Pharma cross-appealed (regarding the validity/infringement of the 458 Patent).  The appeal and cross-appeal are in the early stages and are unlikely to be heard before the fourth quarter of 2024. Even if JAMP Pharma is successful in defending against AbbVie&#8217;s patent infringement claims, litigation could result in substantial cost and distraction to management and other employees. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In December 2021, Health Canada informed JAMP Pharma that the 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI are not subject to the 24-month statutory stay pursuant to the Patented Medicines (Notice of Compliance) Regulations because AbbVie elected to not market the equivalent high-concentration versions to Canadian patients. In January 2022, JAMP Pharma received notices of compliance for the 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI. AbbVie has commenced applications to judicially review Health Canada&#8217;s decision in the Federal Court of Canada, and a hearing took place on 16-17 May 2022. On 17 August 2022, the court issued a decision, finding that Health Canada&#8217;s interpretation of the regulations was reasonable and dismissing AbbVie&#8217;s applications for judicial review. On 3 October 2022, AbbVie issued a Notice of Appeal. The appeal will be heard by the Federal Court of Appeal on 9 April 2024.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event that an appellate court finds in AbbVie&#8217;s favor, then market access of SIMLANDI in Canada may be impacted. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Potential patent conflict with Johnson &amp; Johnson ("J&amp;J") related to our biosimilar ustekinumab product, AVT04, have been settled or otherwise resolved in the United States, Japan, Canada, and Europe (Europe being resolved January 2024).</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, we, directly or through our partners, may become involved in legal proceedings adverse to other originators or market participants. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Legal and Regulatory Compliance Matters </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently enacted and future legislation, including healthcare legislative reform measures, may have a material adverse effect on our business and results of operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system, including initiatives to contain healthcare costs. For example, in March 2010, the PPACA, was passed, which substantially changed the way health care is financed by both governmental and private insurers and continues to significantly impact the U.S. pharmaceutical industry. The PPACA, among other things, created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, added a provision to increase the Medicaid rebate for line extensions or reformulated drugs, established annual fees and taxes on manufacturers of certain branded prescription drugs and promotes a new Medicare Part D coverage gap discount program. The PPACA also includes the BPCIA, which created, among other things, a regulatory framework for the approval of biosimilars and interchangeables. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been executive, judicial and Congressional challenges to repeal or replace certain aspects of the PPACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the PPACA such as removing penalties, starting 1 January 2019, for not complying with the PPACA&#8217;s individual mandate to carry health insurance and eliminating the implementation of certain PPACA-mandated fees. Additionally, on 17 June 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on 28 January 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the PPACA marketplace, which began 15 February 2021 and remained open through 15 August 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. On 16 August 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges, and the healthcare reform measures of the Biden administration, will impact the PPACA, including the BPCIA. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. For example, on 2 August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect on 1 April 2013 and will stay in effect until 2032, unless additional Congressional action is taken. On 2 January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012 which, among other things, further reduced Medicare payments to certain providers, including physicians, hospitals and cancer treatment centers. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; which expressed its intent to pursue certain policy initiatives to reduce pharmaceutical prices. For example, the executive order expressed the Biden administration&#8217;s support of legislative reforms to lower prescription drug prices, including by allowing Medicare&#8217;s negotiation of drug prices. In response to Biden&#8217;s executive order, on 9 September 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA directs the HHS Secretary to establish a Drug Price Negotiation Program (the &#8220;Program&#8221;) to lower prices for certain high-expenditure, single-source prescription drugs and biologics covered under Medicare Part B and Part D that have been approved by the FDA for at least 7 years for prescription drugs and at least 11 years for biologics. Under the Program, the HHS Secretary will publish a list of &#8220;selected drugs,&#8221; and will then negotiate maximum fair prices (&#8220;MFP&#8221;) with their manufacturers. The Program will be implemented in stages. Beginning in 2026, 10 Medicare Part D &#8220;selected drugs&#8221; will be subject to price negotiations. By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and biologics covered under Medicare Part B and Part D. Agreements between HHS and manufacturers will remain in place until a drug or biologic is no longer considered a &#8220;selected drug&#8221; for negotiation purposes. Manufacturers who do not comply with the negotiated prices set under the Program will be subject to an excise tax based on a percentage of total sales of a &#8220;selected drug&#8221; up to 95% and potential civil monetary penalties. On 29 August 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, including Stelara, the reference product for AVT04, although the Medicare drug </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">price negotiation program is currently subject to legal challenges. Further, beginning in October 2023, the IRA will require manufacturers that increase prices of certain Medicare Part B and Part D drugs or biologics at a rate greater than inflation to pay rebates to the Centers for Medicare &amp; Medicaid Services or be subject to civil monetary penalties. The IRA also provides certain incentives for the development and manufacture of biosimilars. For example, the Secretary can grant a one-year delay from price negotiations for biosimilars that have a &#8220;high likelihood&#8221; of a competing biosimilar product entering the market within the requested delay period. In addition, certain Part B biosimilars qualify for an increase in Medicare payments, to 8% of the 5-year Average Sales Price, from 6% under current law. The HHS Secretary has been directed to promulgate regulations to implement the Program and other IRA health reform measures. In response to the Biden administration&#8217;s October 2022 executive order, on 14 February 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the state level, individual states have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many EU Member States periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. We expect that legislators, policymakers and healthcare insurance funds in the EU Member States will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 and will apply as of January 2025, is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and will permit EU  Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the policies of the FDA, the competent authorities of the EU Member States, the EMA, the European Commission and other comparable regulatory authorities with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on 31 January 2022. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each EU Member State, leading to a single decision for each EU Member State. The assessment procedure for the authorization of clinical trials has been harmonized as well, including a joint assessment by all EU Member States concerned, and a separate assessment by each EU Member State with respect to specific requirements related to its own territory, including ethics rules. Each EU Member State&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the clinical trial approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials in relation to which application for approval was made on the basis of the Clinical Trials Directive before 31 January 2023, the Clinical Trials Directive will continue to apply on a transitional basis until January 31, 2025. By 31 January 2025. all ongoing trials will become subject to the provisions of the CTR. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is currently unclear to what extent the UK will seek to align its regulations with the EU in the future. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On 17 January 2022, the UK Medicines and Healthcare products Regulatory Agency, or MHRA, launched an eight-week consultation on reframing the UK legislation for clinical trials. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">UK Government published its response to the consultation on 21 March 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the CTR. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications. A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization in the EU for our product candidates on the basis of clinical trials conducted in the UK. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, on 26 April 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation. If adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to federal and state healthcare laws, including those governing fraud and abuse, false claims, physician payment transparency and health information privacy and security laws, and comparable foreign law equivalents. If we are unable to comply or have not fully complied with such laws, we could face substantial penalties including administrative, civil and criminal penalties, damages, fines, and exclusion from participation in government health care programs. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations may be subject to various civil and criminal fraud and abuse laws. In the United States, federal fraud and abuse laws include, without limitation, the False Claims Act (&#8220;FCA&#8221;), the Anti-Kickback Statute (&#8220;AKS&#8221;), the Exclusions Law, and the Civil Monetary Penalties Law (&#8220;CMPL&#8221;). Many states have similar state laws. These laws may impact, among other things, our research activities as well as our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the federal Anti-Kickback Statute, which prohibits, among other things, any individual or entity from knowingly and willfully soliciting, offering or paying remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce another individual or entity to : (a) refer an individual to a person for the furnishing (or arranging for the furnishing) of any item or service for which payment may be made under a federal health care program; (b) purchase or order any covered item or service; (c) arrange for the purchase or order of any covered item or service; or (d) recommend the purchase or order of any covered item or service; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">federal civil and criminal false claims laws and civil monetary penalties laws, including the FCA and the CMPL, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented false, fictitious, or fraudulent claims for payment to the U.S. government; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of health information that allows identification of individual patients on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable health information, as well as their covered subcontractors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Federal and state transparency laws and regulations, such as the federal Physician Payments Sunshine Act. The federal Physician Payment Sunshine Act which requires certain manufacturers of drugs, devices, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value made by such manufacturers to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members in such manufacturers; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the national or federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; national or state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and national or state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outside the United States, interactions between pharmaceutical companies and healthcare professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, health care reform legislation has strengthened these laws. For example, in the United States the PPACA, among other things, amended the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes, such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Moreover, one or more of our commercial partners may be subject to the above law and may be investigated or sued for any one or more of the previous concerns which may in turn materially impact us by virtue of our association with such commercial partner(s). </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The international aspects of our business expose us to business, regulatory, political, operational, financial and economic risks. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have international operations and a number of international collaborations. Doing business internationally involves a number of risks, including but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">failure by us or our collaboration partners to obtain and maintain regulatory approvals for the use of our products in various countries; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">additional potentially relevant third-party patent rights; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">complexities and difficulties in obtaining protection and enforcing our intellectual property; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">difficulties in staffing and managing foreign operations by us or our collaboration partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems by our collaboration partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">limits in our ability or our collaboration partners&#8217; ability to penetrate international markets; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">foreign exchange risk, as we have significant asset and liabilities denominated in foreign currencies (mainly in EUR, GBP, ISK, and CHF), and a 10% fluctuation of the exchange rate of ISK against the USD can significantly impact us; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">natural disasters, political and economic instability, including wars such as the Russia-Ukraine conflict, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">certain expenses including, among others, expenses for travel, translation and insurance; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, specifically our books and records provisions or its anti-bribery provisions. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to anti-corruption laws and regulations, export and import controls, and sanctions laws and regulations of the United States and other countries. Compliance with these legal standards could impair our ability to compete in international markets. We could face criminal liability and other serious consequences for violations, which could harm our business, prospects and financial condition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and other state and national anti-bribery laws in jurisdictions in which we may conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value improperly to or from recipients in the public or private sector. We have engaged third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, the FCPA imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which requires such companies to maintain complete and accurate books and records and maintain a system of internal accounting controls. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, as well as by comparable import, export, and sanctions laws and regulations in other jurisdictions. Compliance with applicable regulatory requirements regarding the import and export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export our products to some countries or persons altogether. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any changes in the laws and regulations described above, shift in the enforcement or scope of existing laws and regulations, or change in the countries, governments, persons, or technologies targeted by such laws and regulations, could result in decreased ability to export our product candidates internationally. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our confidential information in internal systems or those used by third party collaborator partners or other contractors or consultants, could compromise the confidentiality, integrity and availability of our confidential information in information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To achieve our business objectives, we rely on sophisticated information technology systems, including software, mobile applications, cloud services and network-connected control systems, some of which are managed, hosted, provided or serviced by third parties. Internal or external events that compromise the confidentiality, integrity and availability of our systems and data may significantly interrupt the operation of our business, result in significant costs and/or adversely affect </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our reputation and/or place us at a competitive disadvantage resulting from the improper disclosure or theft of confidential information or intellectual property. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our information technology systems are highly integrated into our business, including our research and development (&#8220;R&amp;D&#8221;) efforts, our clinical and commercial manufacturing processes and our product sales and distribution processes. Further, as certain employees are working remotely, our reliance on our and third-party information technology systems has increased substantially and is expected to continue to increase. The complexity and interconnected nature of our systems make them potentially vulnerable to breakdown or other service interruptions. Our systems are subject to frequent attempted cyberattacks. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity and are becoming increasingly difficult to detect. Such attacks could include the use of harmful and virulent malware, including ransomware or other denials of service, that can be deployed through various means, including the software supply chain, e-mail, malicious websites and/or the use of social engineering. Attacks such as those experienced by governmental entities (including those that approve and/or regulate our products, such as the FDA, the European Commission or EMA) and other multi-national companies, including some of our peers, could leave us unable to utilize key business systems or access or protect important data, and could have a material adverse effect on our ability to operate our business, including developing, gaining regulatory approval for, manufacturing, selling and/or distributing our products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our systems and possibly those of permissible third parties also contain and utilize a high volume of sensitive data, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials and/or personal information belonging to us, our staff, customers and/or other parties. In some cases, we and/or permissible third parties may use third-party service providers to process, store, manage or transmit such data, which may increase our risk. Intentional or inadvertent data privacy or security breaches (including cyberattacks) or lapses by employees, service providers (including providers of information technology-specific services), nation states (including groups associated with or supported by foreign intelligence agencies), organized crime organizations, &#8220;hacktivists&#8221; or others, create risks that our sensitive data may be exposed to unauthorized persons, our competitors, or the public. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Domestic and global government regulators, our business partners, suppliers with whom it does business, vendors and law firms that host our documents and information in connection with transactions or proceedings, companies that provide us or our partners with business services and companies that we may acquire may face similar risks, and security breaches of their systems could adversely affect our security, leave us without access to important systems, products, raw materials, components, services or information or expose our confidential data. As a part of our business, we share confidential information with third parties, such as commercial partners, consultants, advisors and vendors. We are at risk of our confidential data being disclosed without our consent or lost if these third parties&#8217; servers or databases experience security breaches of their systems. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have experienced system downtime and attacks but we do not believe such downtime and attacks have had, either individually or in the aggregate, a material adverse effect on our business or results of operations. We continue to invest in the monitoring, protection and resilience of our critical and/or sensitive data and systems and have a Security Operations Center ("SOC") provider and 24/7 monitoring of our systems. However, there can be no assurances that our efforts will detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks, and/or breaches of our systems that could adversely affect our business and operations and/or result in the loss or exposure of critical, proprietary, private, confidential or otherwise sensitive data, which could result in material financial, legal, business or reputational harm or negatively affect our share price. While we maintain cyber-liability insurance, our insurance is not sufficient to cover it against all losses that could potentially result from a service interruption, breach of our systems or loss of critical or sensitive data. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. For example, in the EEA, we are subject to the General Data Protection Regulation (&#8220;GDPR&#8221;), which became effective in May 2018, imposes strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting and which provides for substantial penalties for non-compliance. Other jurisdictions where we operate have enacted or proposed similar legislation and/or regulations. Failure to comply with these current and future laws could result in significant penalties, liability for damages incurred by individuals whose privacy is violated, and could have a material adverse effect on our business and results of operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We and our service providers may be subject to evolving data protection and security laws, including in the EEA and the UK, in relation to certain processing of personal data. The actual or perceived failure to comply with such laws could harm our financial condition and operating results and involve distraction from other aspects of our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. For example, in the EEA we are subject to the EU&#8217;s General Data Protection Regulation (&#8220; EU GDPR&#8221;), which became effective in May 2018, and in the United Kingdom, to the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;). Both regulations impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting and which provides for substantial penalties for non-compliance.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data privacy and security laws are rapidly evolving, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, related obligations may be subject to interpretations which may vary from one country to another. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the EU and UK GDPR, require our customers to impose specific contractual restrictions on their service providers. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, because of the remote work policies we implemented due to the COVID-19 pandemic, information that is normally protected, including company confidential information, may be less secure. Cybersecurity and data security threats continue to evolve and raise the risk of an incident that could affect our operations or compromise our business information or sensitive personal data, including health data. We may also need to collect more extensive health-related information from our employees to manage our workforce. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other jurisdictions where we operate have enacted or proposed similar legislation and/or regulations. If we or our third-party partners fail to comply or are alleged to have failed to comply with data protection and privacy laws and regulations, or if we were to experience a data breach involving personal data, we could be subject to government enforcement actions. In addition, under the EU GDPR, companies may face private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. Any associated claims, inquiries, or investigations or other government actions could lead to unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other remedies that harm our business, including orders that we modify or cease existing business practices. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We currently rely on Alvogen&#8217;s ERP solution and other components of Alvogen's IT infrastructure and will continue to do so for the foreseeable future. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently rely on certain IT infrastructure and software owned and/or operated by Alvogen. A service agreement is in place between us and Alvogen addressing confidentiality, service and fees and other customary matters, and the two companies have entered into an agreement regarding the ownership, access rights and retention of shared data, pursuant to which Alvogen stores our data separate from Alvogen data. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have signed a separate license agreement for our own ERP system and are in the process of implementing and migrating to the new platform in an environment separate from Alvogen&#8217;s. This environment set up is underway and the system is expected to go live during the second half of 2024. However, in the meantime, we are relying on Alvogen&#8217;s platform and licenses. In addition, we also use a small number of applications related to ERP, that are licensed through Alvogen. We plan to stop using these applications during the second half of 2024. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also currently relying on Alvogen&#8217;s Azure (cloud) environment and have moved or migrated the majority of our data into a dedicated separate environment. While our components of the environment have been logically separated from Alvogen&#8217;s components and are operated by us, a limited number of Alvogen IT administrators continue to have read-only access to our Azure subscriptions for to monitor usage billing purposes. Although we plan to physically separate the remaining resources and have our ERP platform go live by the end of 2024, following the migration of the Azure environment, there can be no assurance that this project will be successful at all or will be achieved on schedule. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is a risk that other issues due to the shared infrastructure between the companies have not yet been identified, posing a risk to our business operations which are currently relying on the confidentiality, integrity and availability of critical information systems and our data stored on Alvogen&#8217;s IT infrastructure. For more information on the service agreements between us and Alvogen, please see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 7.B Related Party Transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The implementation of an ERP system is a complex and time-consuming project that requires transformations of business and finance processes to reap the benefits of the ERP system. Any such transformation involves risk inherent in the conversion to a new system, including loss of information and potential disruption to normal operations. Delays or the failure to fully implement the ERP system and fully separate the IT infrastructure, or interruptions in service or operational difficulties during or following the full implementation of the ERP system, may adversely impact our financial results and could lead to business disruption and loss of business. In addition, the failure or abandonment of any part of the ERP system could result in a write-off of part or all of the costs that have been capitalized on the project, which could adversely affect our results of operations and financial condition. Further, if the ERP system does not operate as intended, the effectiveness of our internal control over financial reporting could be adversely affected or our ability to assess those controls adequately could be delayed. Significant delays in documenting, reviewing and testing our internal control over financial reporting could cause us to fail to comply with SEC reporting obligations related to our management&#8217;s assessment of internal control over financial reporting. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our IT Governance (ITG) and Information Security Management System (ISMS) may not be sufficient to ensure the effective and efficient use of IT in enabling the organization to achieve business objectives and secure the confidentiality, integrity and availability of critical information technology systems and data. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently do not have a fully implemented ITG and ISMS in place. At the end of 2022, we hired an Information Security Officer who reports to the General Counsel to strengthen ISMS. The Information Security Officer will introduce an information security (&#8220;InfoSec&#8221;) program, which includes revising and updating the ISMS, and, together with the CIO, the ITG. The InfoSec program plans to introduce enhanced policies and procedures. We currently have in place ITIL aligned procedures, covering access management, change management, incident management, business continuity and disaster recovery, which will be further reviewed and revised and aligned to the ISO 27001 framework. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not currently have a data retention policy in place. We have established procedures for IT business continuity and disaster management, with restore tests conducted quarterly. The full implementation of ITG and ISMS may not be successfully completed during 2024, or at all, due to lack of capabilities, resources or funding, prioritization, or other reasons. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of our critical systems and data are hosted on premise in one data center, without a secondary data center for redundancy. Force majeure events impacting the data center such as fire, flood, earthquake, or power outage can therefore pose a risk to our operation and may compromise the confidentiality, integrity and availability of those systems and data. A new data center has been completed as part of the extension build at Saemundargata 19, Reykjavik, Iceland, which will be taken into use in the Spring of 2024 and implementation of the equipment is in progress. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we have invested, and continue to invest, in ITG and ISMS, there can be no assurance that our efforts will be sufficient to ensure the effective and efficient use of IT, which could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business or reputational harm. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ISMS may be subject to security breaches or other incidents that could result in misappropriation of funds, disruption to operations, disclosure of commercially or personally sensitive information, legal or regulatory breaches and liability, as well as other costs and reputational damage. Given the increasing sophistication and evolving nature of these threats, the possibility of security breaches occurring in the future cannot be ruled out. An extended failure of critical system components, caused by accidental or malicious actions, including those resulting from a cybersecurity attack, could result in a significant commercial loss, interruption to operations, loss of access to critical data or systems, unfavorable publicity, damage to reputation, regulatory investigations, fines or penalties, litigation or other claims by affected parties and possible financial obligations for liabilities and damages related to the theft or misuse of our information and other business delays or disruptions, any of which could have an adverse effect on our business, financial condition, results of operations and reputation. Further, we may be forced to expend significant financial and operational resources in response to a security breach, including repairing system damage, increasing security protection costs by  deploying additional personnel and modifying or enhancing protection technologies, investigating and remediating any information security vulnerabilities and defending against and resolving legal and regulatory claims, all of which could divert resources and the attention of management and key personnel away from business operations and adversely affect our business, financial condition and results of operations. See also &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our confidential information in internal systems or those used by third party collaborator partners or other contractors or consultants, could compromise the confidentiality, integrity and availability of our confidential information in information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our facilities and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect from a serious disaster. Our manufacturing facility and inventories are located in Reykjavik, Iceland and any severe natural or other disaster or disruption at this site could have a material adverse effect on our financial condition and results of operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our corporate headquarters, manufacturing site and a large part of our R&amp;D division are located in Reykjavik, Iceland. Iceland is geographically isolated and has in the past experienced severe earthquakes and other natural disasters, such as volcanic eruptions. Earthquakes or other natural disasters could severely disrupt our operations or those of our collaboration partners and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure (such as the manufacturing facilities of our third-party providers of power or water supplies) or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our current lack of business continuity insurance, could have a material adverse effect on our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business could be materially disrupted by strikes, work stoppages or other labor actions in Iceland or elsewhere. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under applicable Icelandic labor laws, members of a labor union are required to participate in a strike called by the labor union or work stoppage called by an employers association. As many of our employees in Iceland are members of Icelandic labor unions, we may be faced with strikes, work stoppages or other labor actions in Iceland which may materially disrupt our business at our headquarters, manufacturing site, and the local part of our R&amp;D division. Work stoppages, strikes or other labor actions at other companies or industries within Iceland, including international air traffic, could also have an adverse effect on our ability to operate and may impact earnings and other key business metrics. In addition, work stoppages, strikes or other labor actions of our employees outside of Iceland may affect our operations at those sites outside of Iceland, and work stoppages, strikes or other labor actions of employees of our vendors, suppliers or partners may affect the performance of our partners, our supply chain, our ability to sell our products and our operations generally. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Iceland&#8217;s implementation of EEA rules may not be comprehensive or may be delayed, which may result in certain risks and uncertainty for us and our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have significant assets, including our subsidiary Alvotech hf., in Iceland. Many of our assets and material agreements are therefore governed by Icelandic law and subject to the jurisdiction of the Icelandic courts. As an EEA country, Iceland is obligated to implement important parts of EU law relating to the &#8220;four freedoms&#8221; within the EU single market. Certain aspects of our operations are subject to laws originating from such implementation. If the Icelandic state fails to draft national legislation which conforms with such EU rules, Icelandic individuals and legal persons may not be able to rely on the relevant EU rules and the Icelandic courts could be restricted from applying them unless the Icelandic legislation can be interpreted in a way which conforms with EU rules. This could negatively affect us or other individuals or legal persons who conduct business with us in Iceland. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we experience additional material weaknesses in the future or otherwise are unable to develop and maintain an effective system of internal controls in the future, we may not be able to produce timely and accurate financial statements or comply with applicable laws and regulations, which may adversely affect investor confidence in us and, as a result, the value of Ordinary Shares. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have identified material weaknesses in the design and operating effectiveness of our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. In connection with the preparation of the consolidated financial statements covered by this report, we identified material weaknesses as follows: (i) we did not have a sufficient number of trained professionals with an appropriate level of internal control knowledge, training and experience; (ii) we did not consistently operate all controls, specifically related to consistent execution, adequate review procedures, and maintaining documentation to evidence control performance, including assessing the accuracy and completeness of information used in the execution of controls; and (iii) we did not implement effective controls over the segregation of duties and certain information technology general controls for information systems that are relevant to the preparation of our financial statements. These material weaknesses could result in a misstatement of our accounts or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon identifying the material weaknesses, we began taking steps intended to address the underlying causes of the control deficiencies in order to remediate the material weaknesses, which included the following activities during 2022 and 2023: (i) hired qualified individuals with strong technical accounting, internal control and SEC reporting experience and continued training control owners to reaffirm expectations as it relates to the control design and execution of such controls, including enhancements to the documentation to evidence the execution of the controls; (ii) enhanced the Company's governance and oversight processes by establishing a formal control governance structure, ensuring clear roles and responsibilities for control oversight, conducting regular meetings to review control performance, and implementing a system for reporting control-related matters to the Audit Committee; (iii) implemented formal documentation of certain policies and procedures, and/or redesigned entity level controls, business process-level controls across all significant accounts and information technology general controls across all relevant domains; (iv) developed and executed a risk-based testing plan to cover all identified controls through a mix of design assessment, independent testing of operating effectiveness and management self-certification. The Company has engaged outside consultants to assist in evaluating our internal controls, develop remediation plans to address control deficiencies identified, and actively measure compliance and remediation progress through a quarterly scorecard; and (v) continued implementation of a new enterprise resource planning (&#8220;ERP&#8221;) system including the engagement of outside consultants to help design and implement automated controls and enhance our information technology general controls environment as part of the ERP system implementation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the above actions, we expect to engage in additional activities to enhance our control environment including but not limited to: (i) complete the implementation of a new ERP system, which includes increased automated functionality and controls for the preparation of the financial statements to prevent, among other things, unauthorized overrides, and enhance user access controls, segregation of duties with the system, and audit trails to track and monitor activities; (ii) implement stronger IT controls to ensure the integrity and security of financial information, including enhancing access and change management controls and implementing regular system monitoring and testing; (iii) continue focusing on consistent control execution, adequate review procedures, and improving control documentation, including the accuracy and completeness of information used in the performance of controls; and (iv) continue engaging outside consultants to assist in evaluating the internal controls, and actively measure compliance and remediation through quarterly scorecard. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure that the measures we have taken to date, and are continuing to implement, will be sufficient to remediate the material weaknesses identified and avoid potential future material weaknesses. If the steps we take do not remediate the material weaknesses in a timely manner, we will be unable to conclude that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to remediate our existing material weaknesses, identify new material weaknesses in our internal controls over financial reporting, are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, are unable to conclude that our internal controls over financial reporting are effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal controls over financial reporting when we are no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of the Ordinary Shares could be negatively affected. As a result of such failures, we could also become subject to investigations by the stock exchanges on which our securities are listed, the Securities and Exchange Commission (&#8220;SEC&#8221;), or other regulatory authorities, and become subject to litigation from investors and shareholders, which could harm our reputation and financial condition or divert financial and management resources from our regular business activities. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Ownership of our Ordinary Shares and Warrants and our Status as a Public Company </span></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have and will incur increased costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will continue to incur significant legal, accounting and other expenses as a public company, and these expenses may increase even more if and when we are no longer an emerging growth company, as defined in Section 2(a) of the Securities Act. As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, as  well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. The increased costs will increase our net loss. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be forced to accept reduced policy limits or incur substantially higher costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on our board advisors or as executive officers. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The market price and trading volume of our Ordinary Shares and Warrants may be volatile and could decline significantly. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The stock markets, including Nasdaq and Nasdaq Iceland Main Market on which Ordinary Shares and Warrants are listed under the symbols ALVO and ALVOW, respectively, have from time to time experienced significant price and volume fluctuations. The market price of Ordinary Shares and Warrants may be volatile and could decline significantly. In addition, the trading volume in Ordinary Shares and Warrants may fluctuate and cause significant price variations to occur. Additionally, any substantial amount of trading or sales in Ordinary Shares could make it difficult for us to raise capital through the issuance of debt or equity securities in the future. Generally, securities of biopharmaceutical companies tend to be volatile and experience significant price and volume fluctuations. We cannot guarantee that the market price of Ordinary Shares and Warrants will not fluctuate widely or decline significantly in the future in response to a number of factors, including, among others, the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the realization of any of the risk factors presented in this Annual Report on Form 20-F;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">actual or anticipated differences in our estimates, or in the estimates of analysts, for our revenues, results of operations, liquidity or financial condition; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">regulatory decisions with respect to our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">additions and departures of key personnel; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">failure to comply with the requirements of Nasdaq U.S. and Nasdaq Iceland Main Market; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">failure to comply with the Sarbanes-Oxley Act or other laws or regulations in the United States, Luxembourg and Iceland; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">future issuances, sales or resales, or anticipated issuances, sales or resales, of Ordinary Shares; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">publication of research reports about us; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the performance and market valuations of other similar companies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">broad disruptions in the financial markets, including sudden disruptions in the credit markets; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">material and adverse impact of public health emergencies and other world emergencies on the markets and the broader global economy; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">speculation in the press or investment community; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">actual, potential or perceived control, accounting or reporting problems; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">changes in accounting principles, policies and guidelines. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, securities class-action litigation has often been instituted against companies following periods of volatility in the market price of their shares. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources, which could have a material adverse effect on us. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The dual listing of Ordinary Shares may adversely affect the liquidity and value of those ordinary shares. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Ordinary Shares are listed on both The Nasdaq Stock Market in the United States (&#8220;Nasdaq&#8221;) and Nasdaq Iceland Main Market in Iceland. The trading of Ordinary Shares in these markets takes place in different currencies (U.S. dollars on Nasdaq and Icelandic Krona on Nasdaq Iceland Main Market), at different times (resulting from different time zones, different trading days and different public holidays in the United States and Iceland) and with different settlement mechanics. The trading prices of Ordinary Shares on these two markets may differ due to these and other factors. Any decrease in the price of Ordinary Shares on Nasdaq Iceland Main Market could cause a decrease in the trading price of Ordinary Shares on Nasdaq and vice versa. Investors could seek to sell or buy Ordinary Shares to take advantage of any price differences between the markets through a practice referred to as arbitrage. Any arbitrage activity could create unexpected volatility in both the trading prices on one exchange and Ordinary Shares available for trading on the other exchange. Further, the dual listing of Ordinary Shares may reduce the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for Ordinary Shares in the United States. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The listing of Ordinary Shares on Nasdaq Iceland Main Market may result in increased additional compliance risk, which could have a material effect on our business, results of operations and financial condition, or may delay or discourage a takeover attempt. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ordinary shares are listed on both the Nasdaq and Nasdaq Iceland Main Market. Nasdaq Iceland Main Market a regulated market in Iceland operated by Nasdaq Iceland, the Icelandic stock exchange. Issuers on Nasdaq Iceland Main Market are subject to the rules of Nasdaq Iceland Main Market and the relevant rules and regulations given the fact that the securities of the issuer are admitted to trading on a regulated market. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a dual-listed Luxembourg company listed on Nasdaq Iceland Main Market and Nasdaq, we are subject to reporting requirements and certain other applicable requirements under Luxembourg law, U.S. law and Icelandic law, including, but not limited to, Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014, on market abuse, as amended (&#8220;MAR&#8221;), the Directive 2004/109/EC of the European Parliament and of the Council of 15 December 2004 on the harmonization of transparency requirements in relation to information about issuers whose securities are admitted to trading on a regulated market, as amended (the &#8220;Transparency Directive&#8221;), the Luxembourg law of 23 December 2016, on market abuse, as amended (&#8220;Luxembourg Market Abuse Law&#8221;), the Luxembourg law of 11 January 2008 on transparency requirements for issuers, as amended (the &#8220;Luxembourg Transparency Law&#8221;), the Grand-Ducal regulation of 11 January 2008, on transparency requirements for issuers of securities, as amended (the &#8220;Luxembourg Transparency Regulation&#8221;), Directive 2004/25/EC of the European Parliament and of the Council of 21 April 2004, on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">takeover bids, as amended (the &#8220;Takeover Directive&#8221;) and the Luxembourg law of 19 May 2006, on takeover bids, as amended (the &#8220;Luxembourg Takeover Law&#8221;). </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Transparency Regime </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of shares and other financial instruments may be subject to notification obligations pursuant to the Luxembourg Transparency Law. The following description summarizes these obligations. Holders are advised to consult with their own legal advisors to determine whether the notification obligations apply to them. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Luxembourg Transparency Law and Luxembourg Transparency Regulation provide that, once the Shares are admitted to listing and trading on Nasdaq Iceland Main Market, if a person acquires or disposes of a shareholding in the Company, and if following the acquisition or disposal the proportion of voting rights held by the person reaches, exceeds or falls below one of the thresholds of 5%, 10%, 15%, 20%, 25%, 33 1/3%, 50% and 66 2/3% (each a &#8220;Relevant Threshold&#8221;) of the total voting rights existing when the situation giving rise to a declaration occurs, such person must simultaneously notify the Company and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Luxembourg Commission de Surveillance du Secteur Financier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (the &#8220;CSSF&#8221;) of the proportion of voting rights held by it further to such event. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A person must also notify the Company and the CSSF of the proportion of his or her voting rights if that proportion reaches, exceeds or falls below a Relevant Threshold as a result of events changing the breakdown of voting rights and on the basis of the information disclosed by the Company. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The same notification requirements apply to a natural person or legal entity to the extent he/she/it is entitled to acquire, to dispose of, or to exercise voting rights in any of the cases or a combination of them stated in Article 9 of the Luxembourg Transparency Law. The notification requirements set out above also apply to a natural person or legal entity that holds, directly or indirectly: (i) financial instruments that, on maturity, give the holder, under a formal agreement, either the unconditional right to acquire or the discretion as to his or her right to acquire the Ordinary Shares, to which voting rights are attached, already issued by the Company; or (ii) financial instruments which are not included in point (i) but which are referenced to the Ordinary Shares referred to in that point and with an economic effect similar to that of the financial instruments referred to in that point, whether or not they confer a right to a physical settlement. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The number of voting rights shall be calculated as specified in Article 12 and 12a of the Luxembourg Transparency Law. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notification to the Company and the CSSF must be effected promptly, but not later than four trading days after the date on which the shareholder, or the natural person or legal entity referred to above learns of the acquisition or disposal or of the possibility of exercising voting rights, or on which, having regard to the circumstances, should have learned of it, regardless of the date on which the acquisition, disposal or possibility of exercising voting rights takes effect, as specified in the Luxembourg Transparency Law and the related guidelines of the CSSF. Upon receipt of the notification, but not later than three trading days thereafter, the Company must make public all the information contained in the notification as regulated information within the meaning of the Luxembourg Transparency Law. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As long as the notifications have not been made to the Company in the manner prescribed, the exercise of voting rights relating to the shares exceeding the fraction that should have been notified is suspended. The suspension of the exercise of voting rights is lifted as of the moment the shareholder makes the notification. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Where within the fifteen days preceding the date for which the general meeting has been convened, the Company receives a notification or becomes aware of the fact that a notification has to be or should have been made in accordance with the Luxembourg Transparency Law, the board of directors may postpone the general meeting. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Market Abuse Regime </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rules on preventing market abuse set out in the MAR and the Luxembourg Market Abuse Law are applicable to the Company, persons discharging managerial responsibilities within the Company (including the members of the board of directors) (the &#8220;PDMRs&#8221;), persons closely associated with PDMRs, other insiders and persons performing or conducting transactions in the Company&#8217;s financial instruments. Certain important market abuse rules set out in the MAR and the Luxembourg Market Abuse Law that are relevant for investors are described hereunder. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is required to make inside information public. Pursuant to the MAR, inside information is information of a precise nature, which has not been made public, relating, directly or indirectly, to the Company or to one or more financial instruments, and which, if it were made public, would be likely to have a significant effect on the prices of those </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">financial instruments or on the price of related derivative financial instruments. Unless an exception applies, the Company must without delay publish the inside information by means of a press release and post and maintain it on its website for at least five years. The Company must also provide Nasdaq Iceland and the CSSF with its press release that contains inside information at the time of publication. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is prohibited for any person to make use of inside information by acquiring or disposing of, for its own account or for the account of a third party, directly or indirectly, financial instruments to which that information relates, as well as an attempt thereto (insider dealing). In addition, it is prohibited for any person to disclose inside information to anyone else (except where the disclosure is made in the normal exercise of an employment, profession or duties) or, whilst in possession of inside information, to recommend or induce anyone to acquire or dispose of financial instruments to which the information relates. Furthermore, it is prohibited for any person to engage in or attempt to engage in market manipulation, for instance by conducting transactions which give, or are likely to give, false or misleading signals as to the supply of, the demand for or the price of a financial instrument. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-compliance with the notification obligations under the Market Abuse Regulation, set out in the paragraphs above, is an economic offense and could lead to the imposition of criminal prosecution, administrative fines, imprisonment or other sanctions. Nasdaq Iceland Main Market may impose administrative penalties or a cease-and-desist order under penalty for non-compliance. If criminal charges are pressed, Nasdaq Iceland Main Market is no longer allowed to impose administrative penalties and vice versa, Nasdaq Iceland Main Market is no longer allowed to seek criminal prosecution if administrative penalties have been imposed. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to Article 19 of the MAR and the Luxembourg Market Abuse Law, PDMRs must notify the CSSF and the Company of any transactions conducted for his or her own account relating to shares or any debt instruments of the Company or to derivatives or other financial instruments linked thereto. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A PDMR within the Company shall not conduct any transactions on its own account or for the account of a third party, directly or indirectly, relating to the Ordinary Shares or debt instruments of the Company or to derivatives or other financial instruments linked to them during a closed period of 30 calendar days before the announcement of an interim financial report or a year-end report which must be made publicly available. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, pursuant to the MAR and the regulations promulgated thereunder as well as the Luxembourg Market Abuse Law, certain persons who are closely associated with persons discharging managerial responsibilities (PDMRs) as defined in Article 1 (26) of the MAR, are also required to notify the CSSF and the Company of any transactions conducted for their own account relating to shares or any debt instruments of the Company or to derivatives or other financial instruments linked thereto in accordance with MAR. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Takeover Regime and Squeeze-out and Sell-out Procedures </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Takeover Directive has been implemented in Luxembourg in the Luxembourg Takeover Law. The Luxembourg Takeover Law provides that if a person, acting alone or in concert, acquires shares in a company which, when added to any existing holdings of a company&#8217;s shares, result in such person having voting rights representing at least 33 1/3% of all of the voting rights attached to the issued and outstanding shares in a company, this person is obliged to make a mandatory takeover bid, at a fair price, for the remaining shares in the company. Where the aforementioned percentage-threshold is met, the person acquiring such voting rights will be deemed to have control over the Issuer in accordance with Luxembourg Takeover Law. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Luxembourg Takeover Law provides that, when a mandatory or voluntary takeover offer is made to all holders of voting shares in a company and after such offer the offeror holds at least 95% of the capital of that company carrying voting rights and 95% of the voting rights of the company, the offeror may require the holders of the remaining shares to sell those shares to the offeror. The price offered for such shares must be a fair price. The price offered in a voluntary offer would be considered a fair price in the squeeze-out proceedings if 90% of the shares of the company carrying voting rights were acquired in such a voluntary offer, in accordance with Luxembourg Takeover Law. The price paid in a mandatory takeover offer is deemed to be a fair price pursuant to Luxembourg Takeover Law. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Luxembourg Takeover Law provides that, when a mandatory or voluntary takeover bid is made to all holders of voting shares in a company and if after such offer the offeror (together with any person acting in concert with the offeror) holds shares carrying more than 90% of the voting rights, the remaining shareholders may require that the offeror purchase the remaining shares. The price offered in a voluntary offer would be considered a fair price in the sell-out proceedings if 90% of the shares of the company carrying voting rights were acquired in such a voluntary takeover offer, in accordance with Luxembourg Takeover Law. Where the offeree company has issued more than one class of shares, the right of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">squeeze-out and sell-out referred to above can be exercised only in the class in which the relevant threshold has been reached. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if there has not been an offer pursuant to the Luxembourg Takeover Law, the Luxembourg law of 21 July 2012 on the squeeze-out and sell-out of securities of companies admitted or having been admitted to trading on a regulated market or which have been subject to a public offer (the &#8220;Luxembourg Mandatory Squeeze-Out and Sell-Out Law&#8221;) provides that if any individual or legal entity, acting alone or in concert with another, becomes the direct or indirect holder (otherwise than by way of a voluntary or mandatory takeover bid pursuant to the Luxembourg Takeover Law) of shares or other voting securities representing at least 95% of the voting share capital and 95% of the voting rights of a company, (i) such shareholder may require the holders of the remaining shares or other voting securities to sell those remaining securities; and (ii) the holders of the remaining shares or securities may require such shareholder to purchase those remaining shares or other voting securities (the &#8220;Mandatory Sell-Out&#8221;). The Mandatory Squeeze-Out and the Mandatory Sell-Out must be exercised at a fair price according to objective and adequate methods applying to asset disposals in accordance with the Luxembourg Mandatory Squeeze-Out and Sell-Out Law. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adherence to the requirements of these rules and regulations may increase our legal, accounting and financial compliance costs, make certain activities more difficult, time consuming and costly, place additional strain on resources and divert management&#8217;s attention away from other business matters. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the applicable legal requirements or the interpretation of such requirements by regulators and courts in each of these jurisdictions may differ or conflict which could expose us to additional costs, sanctions and/or fines. Any of these factors could have a material effect on our business, results of operations and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The issuance or resale of a substantial number of Ordinary Shares in the public market could occur at any time. These issuances and sales, or the perception in the market that these issuances or sales may occur, could increase the volatility of the market price of Ordinary Shares or result in a significant decline in the public trading price of Ordinary Shares. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future issuances of debt securities and equity securities may adversely affect us, including the market price of our Ordinary Shares and may be dilutive to existing shareholders. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant additional capital will be needed in the future to continue our planned research, development and business operations. In the future, we may incur debt or issue equity ranking senior to our ordinary shares. Those securities will generally have priority upon liquidation. Such securities also may be governed by an indenture or other instrument containing covenants restricting our operating flexibility. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of Ordinary Shares. Because our decision to issue debt or equity in the future will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, nature or success of our future capital raising efforts. As a result, future capital raising efforts may reduce the market price of Ordinary Shares and be dilutive to existing shareholders. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The sale and issuance of our Ordinary Shares to investors, holders of warrants or convertible bonds will cause dilution to our existing shareholders, and the sale of Ordinary Shares acquired by them, or the perception that such sales may occur, could cause the price of our Ordinary Shares to drop. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, we and the bondholders amended and restated certain terms and conditions of existing senior bonds and issued new senior bonds in an aggregate principal amount equal to $70,000,000 (the &#8220;Senior Bonds&#8221;). Pursuant to the terms of the amended Senior Bonds, we issued 4,198,807 warrants to the bondholders on 31 December 2022. Each new warrant entitles the bondholders, upon exercise, to receive from us one fully paid and non-assessable Ordinary Share, at the exercise price of one cent ($0.01) per share. Pursuant to the terms of the warrant, we registered Ordinary Shares underlying the warrants for resale on 14 July 2023. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we issued convertible bonds, such as the Aztiq Convertible Bond and the 2022 Convertible Bonds during 2022 and 2023. Under the terms of these convertible bond agreements, bondholders have the right to convert their bonds into Ordinary Shares credited as fully paid on 31 December, 2023, 30 June 2024, or when the bond has been called or put up for optional or mandatory redemption, for a conversion price of $10.00 per share. If the bondholders decide to convert the debt into Ordinary Shares, the share ownership of our existing shareholders will be diluted as a result of the issuance of new Ordinary Shares to the bondholders. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given the substantial number of Ordinary Shares expected to be registered for potential resale by bondholders, the sale of shares by the bondholders, or the perception in the market that the holders of a large number of shares intend to sell </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">their shares, could increase the volatility of the market price of Ordinary Shares or result in a significant decline in the public trading price of Ordinary Shares. In addition, if the holders of the Senior Bonds exercise their warrants and/or holders of the Aztiq Convertible Bond and our 2022 Convertible Bonds elect to convert the bonds into ordinary shares and we issue new Ordinary Shares, the existing shareholders will be diluted. Existing shareholders could also experience dilution if we issue Ordinary Shares pursuant to our standby equity purchase agreement, dated as of 18 April 2022, by and among Alvotech and YA II PN, LTD. See also &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Our Warrants are exercisable for Ordinary Shares and certain Bonds are convertible into Ordinary Shares, the exercise of which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#8221;  </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following these issuances described above and following the expiration of lock-ups of certain other restricted shareholders and as restrictions on resale end and registration statements are available for use, the market price of our Ordinary Shares could decline if the holders of restricted or locked up shares sell them or are perceived by the market as intending to sell them. As such, sales of a substantial number of Ordinary Shares in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of Ordinary Shares. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have issued and expect to issue in the future additional Ordinary Shares, including under our Management Incentive Plan. Any such issuances would dilute the interest of our shareholders and likely present other risks. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have adopted the Alvotech Management Incentive plan in 2022 (the &#8220;2022 Plan&#8221;) under which restricted stock units (&#8220;RSUs&#8221;) and options have been granted in 2022 and 2023. Subject to certain vesting and other terms and conditions, the RSUs and options may be settled in Ordinary Shares. If all RSUs and options vest and are exchanged for Ordinary Shares, the combined grants, excluding forfeitures and deliveries, may result in an aggregate of 5,505,941 Ordinary Shares</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary Shares reserved issued under the 2022 Plan become eligible for sale in the public market once those shares are issued, subject to provisions relating to various vesting agreements, lock-up agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144, as applicable. The aggregate number of Ordinary Shares initially reserved for issuance under the 2022 Plan is 16,802,386 shares. In August 2022, we filed a registration statement on Form S-8 under the Securities Act to register Ordinary Shares or other securities convertible into or exchangeable for Ordinary Shares pursuant to the 2022 Plan, and we may file additional registration statements on Form S-8 in the future. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, shares registered under such registration statements may be immediately available for sale in the open market. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any such issuances of additional Ordinary Shares or securities convertible into Ordinary Shares: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">may significantly dilute the equity interests of our investors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">may subordinate the rights of holders of Ordinary Shares if securities are issued with rights senior to those afforded Ordinary Shares; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">may adversely affect prevailing market prices for Ordinary Shares. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to issue a substantial number of Ordinary Shares or other securities convertible into or exchangeable for Ordinary Shares, including under our 2022 Plan. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Warrants are exercisable for Ordinary Shares and certain Bonds are convertible into Ordinary Shares, the exercise of which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the Business Combination being consummated, outstanding warrants to purchase an aggregate of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,916,647 Ordinary Shares became exercisable in accordance with the terms of the warrant agreement, dated 21</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2020 by and between OACB and Continental Stock Transfer &amp; Trust Company, as warrant agent, governing</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OACB&#8217;s outstanding warrants, which was assigned to and assumed by Alvotech pursuant to that certain Assignment,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assumption and Amendment Agreement dated as of 15 June 2022 (the &#8220;Warrant Agreement&#8221;).</span></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These warrants became exercisable on 15 July 2022. The exercise price of these warrants is $11.50 per share, or approximately $125.5 million, assuming none of the warrants are exercised through &#8220;cashless&#8221; exercise. To the extent such warrants are exercised, additional Ordinary Shares will be issued, which will result in dilution to the holders of Ordinary Shares and increase the number of shares eligible for resale in the public market. On 8 March 2024, there were 9,943,434 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">warrants entitling the holders to acquire one Ordinary Share at a price of $11.50 (the "Warrants") outstanding, the last reported sales price of our ordinary shares was $15.60 per share and the last reported sales price of our Public Warrants was $4.45 per warrant. Sales of substantial numbers of such shares in the public market or the fact that such warrants may be exercised could adversely affect the market price of Ordinary Shares. See &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The warrants may not continue to be in the money, and they may expire worthless and the terms of the Public Warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, on 16 November 2022, we and the bondholders amended and restated certain terms of existing Senior Bonds and issued new senior bonds in an aggregate principal amount equal to $70.0 million. Pursuant to the terms of the amended Senior Bonds, we were required to use commercially reasonable endeavors to raise new funding through issuance of additional Ordinary Shares (by way of ordinary shares, structured equity and/or preference shares) and/or unsecured convertible bond(s), for net proceeds of at least $75.0 million of net proceeds by 15 December 2022, and are required to raise $150.0 million in net proceeds by 31 March 2023. We failed to raise at least $75.0 million by 15 December 2022, so we were required to grant penny warrants representing 1.5% of the ordinary share capital to the bondholders, and if we had failed to raise at least $150.0 million by 31 March 2023, we would have been required to grant penny warrants representing 1.00% of the ordinary share capital to the bondholders. Since we had not raised $75.0 million of net proceeds by 15 December 2022, we issued 4,198,807 warrants to the bondholders on 31 December 2022. Each new warrant entitles the bondholders, upon exercise, to receive from us one fully paid and non-assessable Ordinary Share, at the exercise price of one cent ($0.01) per share. If the bondholders exercise their warrants and we issue new Ordinary Shares, the existing shareholders will be diluted. Following the issuance of the 2022 Convertible Bonds and the closing of the private placement of Ordinary Shares for gross proceeds of $137.0 million on 10 February 2023, we are not obligated to issue the additional 1.00% warrants to the bondholders. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The Warrants may not continue to be in the money, and they may expire worthless and the terms of the Public Warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is no guarantee that the Warrants will continue to be in the money and, as such, the Warrants may expire</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">worthless. For example, between 1 January 2023 and 29 February 2024, the last reported sales prices of our ordinary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">shares on Nasdaq fluctuated between $6.90 on 29 June 2023 and $17.27 on 26 February 2024.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Warrants were issued in registered form under a warrant agreement between Continental Stock Transfer &amp; Trust Company, as warrant agent, and Oaktree Acquisition Corp. II (&#8220;OACB&#8221;), and were assumed at the time of the Closing by us, pursuant to a warrant assignment, assumption and amendment agreement by and between us, OACB, Continental Stock Transfer &amp; Trust Company, Computershare Inc. and Computershare Trust Company. Computershare is currently the warrant agent. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity, correct any defective provision or correct any mistake, amend the definition of &#8220;Ordinary Cash Dividend&#8221; or add or change any provisions with respect to matters or questions arising under the warrant as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the rights of the warrant holders, but requires the approval by the holders of at least 50% of the then-outstanding Public Warrants to make any change that adversely affects the interests of the registered holders of Public Warrants. Accordingly, we may amend the terms of the Public Warrants in a manner adverse to a holder if holders of at least 50% of the then-outstanding Public Warrants approve of such amendment and, solely with respect to any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the private placement warrants, 50% of the number of the then outstanding Private Placement Warrants. Although our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then-outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert the warrants into cash, shorten the exercise period or decrease the number of Ordinary Shares purchasable upon exercise of a warrant. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may redeem the Warrants prior to their exercise at a time that is disadvantageous to the holder, thereby making such warrants worthless. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may redeem the Warrants prior to their exercise at a time that is disadvantageous to the holder, thereby making such warrants worthless. We have the ability to redeem outstanding Public Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the closing price of Ordinary Shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading day period ending on the third trading day prior to the date on which a notice of redemption is sent to the warrant holders. We will not redeem the warrants as described above unless a registration statement under the Securities Act covering Ordinary Shares issuable upon exercise of such warrants is effective and a current prospectus relating to those Ordinary Shares is available throughout the 30-day redemption period. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If and when the Public Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding Public Warrants could force holders (i) to exercise the Public Warrants and pay the exercise price therefor at a time when it may be disadvantageous to do so, (ii) to sell the Public Warrants at the then-current market price when holders might otherwise wish to hold the Public Warrants, or (iii) to accept the nominal redemption price which, at the time the outstanding Public Warrants are called for redemption, is likely to be substantially less than the market value of the Public Warrants. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we will have the ability to redeem the outstanding Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.10 per warrant if, among other things, the closing price of Ordinary Shares equals or exceeds $10.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) on the trading day prior to the date on which a notice of redemption is sent to the warrant holders. Recent trading prices for Ordinary Shares have exceeded the $10.00 per share threshold at which the Warrants would become redeemable. In such a case, the holders will be able to exercise their Warrants prior to redemption for a number of Ordinary Shares determined based on the redemption date and the fair market value of Ordinary Shares. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The value received upon exercise of the Warrants (1) may be less than the value the holders would have received if they had exercised their Warrants at a later time when the underlying share price is higher and (2) may not compensate the holders for the value of the Warrants. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The JOBS Act permits &#8220;emerging growth companies&#8221; like Alvotech to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, which may make our Ordinary Shares less attractive to investors. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently qualify as an &#8220;emerging growth company&#8221; as defined in Section 2(a)(19) of the Securities Act, as modified by the Jumpstart Its Business Startups Act of 2012, which is referred to as the &#8220;JOBS Act.&#8221; As such, we take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies for as long as it continues to be an emerging growth company, including the exemption from the auditor attestation requirements with respect to internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act. As a result, our shareholders may not have access to certain information they deem important. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict if investors will find Ordinary Shares less attractive because we rely on these exemptions. If some investors find Ordinary Shares less attractive as a result, there may be a less active trading market and share price for Ordinary Shares may be more volatile. We may incur increased legal, accounting and compliance costs associated with Section 404 of the Sarbanes-Oxley Act. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Investment in a Luxembourg Company and Our Status as a Foreign Private Issuer </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">As a foreign private issuer, we are exempt from a number of U.S. securities laws and rules promulgated thereunder and is permitted to publicly disclose less information than U.S. public companies must. This may limit the information available to holders of Ordinary Shares. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We qualify as a &#8220;foreign private issuer,&#8221; as defined in the SEC&#8217;s rules and regulations, and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. For example, some of our key executives may sell a significant amount of Ordinary Shares and such sales are not required to be disclosed as promptly as public companies organized within the United States would have to disclose. Accordingly, once such sales are eventually disclosed, the price of Ordinary Shares may decline significantly. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. We are also not subject to Regulation FD under the Exchange Act, which prohibits companies from selectively disclosing material nonpublic information to certain persons without concurrently making a widespread public disclosure of such information. Accordingly, there may be less publicly available information concerning Alvotech than there is for U.S. public companies. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a foreign private issuer, we will file an Annual Report on Form 20-F within four months of the close of each fiscal year ended December 31 and furnish reports on Form 6-K relating to certain material events promptly after we publicly announce these events. However, because of the above exemptions for foreign private issuers, which we rely on, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our shareholders are not afforded the same information generally available to investors holding shares in public companies that are not foreign private issuers. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a foreign private issuer, we are also permitted to follow home country practice in lieu of certain corporate governance rules of the Nasdaq, including those that require listed companies to have a majority of independent directors and independent director oversight of executive compensation, nomination of directors and corporate governance matters. As of 31&#160;December 2023, three of our eight directors are independent as defined in Nasdaq listing standards and applicable SEC rules. As long as we rely on the foreign private issuer exemption, a majority of our board of directors will not be required to be independent directors and our compensation committee will not be required to be composed entirely of independent directors. Accordingly, holders of our securities may not have the same protections afforded to shareholders of listed companies that are subject to all of the applicable corporate governance requirements. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses. This would subject us to U.S. GAAP reporting requirements which may be difficult for us to comply with. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a &#8220;foreign private issuer,&#8221; we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and related rules and regulations. Under those rules, the determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter, and, accordingly, the next determination will be made with respect to our status on 30 June 2024. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the future, we could lose our foreign private issuer status if a majority of our Ordinary Shares are held by residents in the United States and any of the following three circumstances applies: (1) the majority of our executive officers or directors are U.S. citizens or residents; (2) more than 50% of our assets are located in the United States; or (3) our business is administered principally in the United States. Although we intend to follow certain practices that are consistent with U.S. regulatory provisions applicable to U.S. companies, our loss of foreign private issuer status would make such provisions mandatory. The regulatory and compliance costs to us under U.S. securities laws if we are deemed a U.S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. For example, we would become subject to the Regulation FD, aimed at preventing issuers from making selective disclosures of material information. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also may be required to modify certain policies to comply with good governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional costs. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements of Nasdaq that are available to foreign private issuers. For example, Nasdaq&#8217;s corporate governance rules require listed companies to have, among other things, a majority of independent board members and independent director oversight of executive compensation, nomination of directors, and corporate governance matters. As a foreign private issuer, we are permitted to follow home country practice in lieu of the above requirements. We intend to follow Luxembourg practice with respect to quorum requirements for shareholder meetings in lieu of the requirement under Nasdaq Listing Rules that the quorum be not less than 33 1/3% of the outstanding voting shares. Under our articles of association, at an ordinary general meeting, there is no quorum requirement and resolutions are adopted by a simple majority of validly cast votes. In addition, under our articles of association, for any resolutions to be considered at an extraordinary general meeting of shareholders, the quorum shall be at least one half of our issued share capital unless otherwise mandatorily required by law and resolutions are adopted with a majority of at least two thirds of the validly cast votes. As long as we rely on the foreign private issuer exemption to certain of Nasdaq&#8217;s corporate governance standards, a majority of the directors on our board of directors are not required to be independent directors, our remuneration committee is not required to be comprised entirely of independent directors, and we will not be required to have a nominating and corporate governance committee. Also, we would be required to change our basis of accounting from the International Financial Reporting Standards as adopted by the International Accounting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Standards Board (&#8220;IFRS&#8221;) to United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), which may be difficult and costly for us to comply with. If we lose our foreign private issuer status and fail to comply with U.S. securities laws applicable to U.S. domestic issuers, we may have to de-list from Nasdaq and could be subject to investigation by the SEC, Nasdaq and other regulators, among other materially adverse consequences. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are organized under the laws of Luxembourg and a substantial amount of our assets are not located in the United States. It may be difficult to obtain or enforce judgments or bring original actions against us or the members of our board of directors in the United States. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are organized under the laws of Luxembourg. In addition, a substantial amount of our assets are located in Iceland and elsewhere outside the United States. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, some of the members of our board of directors and officers reside outside the United States and a substantial portion of our assets are located in Iceland and elsewhere outside the U.S. Investors may not be able to effect service of process within the United States upon us or these persons or enforce judgments obtained against us or these persons in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the U.S. federal securities laws. Likewise, it also may be difficult for an investor to enforce in U.S. courts judgments obtained against us or these persons in courts located in jurisdictions outside the United States, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws. Awards of punitive damages in actions brought in the United States or elsewhere are generally not enforceable in Luxembourg. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As there is no treaty in force on the reciprocal recognition and enforcement of judgments in civil and commercial matters between the United States and Luxembourg other than arbitral awards rendered in civil and commercial matters, courts in Luxembourg will not automatically recognize and enforce a final judgment rendered by a U.S. court. A valid judgment obtained from a court of competent jurisdiction in the United States may be entered and enforced through a court of competent jurisdiction in Luxembourg, subject to the applicable enforcement procedures (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">exequatur</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) as set out in the relevant provisions of the Luxembourg New Civil Procedure Code and in Luxembourg case law. Pursuant to Luxembourg case law, the granting of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">exequatur</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is subject to the following requirements: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the judgment of the U.S. court is final and enforceable (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ex&#233;cutoire</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) in the United States and has not been fully enforced in the United States and/or in any other jurisdiction; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the U.S. court had full jurisdiction over the subject matter leading to the judgment (that is, its jurisdiction was in compliance both with Luxembourg private international law rules and with the applicable domestic U.S. federal or state jurisdictional rules); </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the U.S. court applied to the dispute the substantive law which is designated by the Luxembourg conflict of laws rules or, at least, such court&#8217;s order must not contravene the principles underlying those rules (based on recent case law and legal doctrine, it is not certain that this condition would still be required for an exequatur to be granted by a Luxembourg court); </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the judgment was granted following proceedings where the counterparty had the opportunity to appear and, if it appeared, to present a defense, and the decision of the foreign court must not have been obtained by fraud, but in compliance with the rights of the defendant; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the U.S. court acted in accordance with its own procedural laws; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the judgment of the U.S. court does not contradict an already issued judgment of a Luxembourg court, and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the decisions and the considerations of the U.S. court must not be contrary to Luxembourg international public policy rules (as such term is interpreted under the laws of Luxembourg) or have been given in proceedings of a tax or criminal nature or rendered subsequent to an evasion of Luxembourg law (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">fraude &#224; la loi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). Awards of damages made under civil liabilities provisions of the U.S. federal securities laws, or other laws, which are classified by Luxembourg courts as being of a penal or punitive nature (for example, fines or punitive damages), might not be recognized by Luxembourg courts. Ordinarily, an award of monetary damages would not be considered as a penalty, but if the monetary damages include punitive damages, such punitive damages may be considered a penalty and therefore not enforceable in Luxembourg. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Similarly, as Alvotech hf., a subsidiary of Alvotech, has significant assets in Iceland, investors may seek to enforce judgments obtained in the United States against Alvotech in Iceland. As there is no treaty in force on the reciprocal recognition and enforcement of judgments in civil and commercial matters between the United States and Iceland other than arbitral awards entered in civil and commercial matters, courts in Iceland will not automatically recognize and enforce a final judgment rendered by a U.S. court. Based on recent Icelandic case law, a valid judgment obtained from a court of competent jurisdiction in the United States will not be directly recognized and enforceable in Iceland. Instead, the judgment creditor would need to issue fresh legal proceedings against the judgment debtor in Iceland in which the U.S. judgment would serve as evidence, in addition to other evidence and legal arguments regarding the merits of the case, which will be adjudicated by the Icelandic courts. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an original action is brought in Luxembourg or Iceland, without prejudice to specific conflict of law rules, Luxembourg courts or Icelandic courts may refuse to apply the designated law (i) if the choice of such foreign law was not made bona fide or (ii) if the foreign law was not pleaded and proved or (iii) if pleaded and proved, such foreign law is contrary to mandatory Luxembourg or Icelandic laws or incompatible with Luxembourg or Icelandic public policy rules. In an action brought in Luxembourg or Iceland on the basis of U.S. federal or state securities laws, Luxembourg courts or Icelandic courts may not have the requisite power to grant the remedies sought. Also, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">exequatur</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> may be refused by a Luxembourg court in respect of punitive damages. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In practice, Luxembourg courts tend not to review the merits of a foreign judgment, although there is no clear statutory prohibition of such review. A contractual provision allowing the service of process against a party to a service agent could be overridden by Luxembourg or Icelandic statutory provisions allowing the valid serving of process against a party in accordance with applicable laws at the domicile of the party. Further, in the event any proceedings are brought in a Luxembourg court in respect of a monetary obligation payable in a currency other than the Euro, a Luxembourg court would have the power to give judgment as an order to pay the obligation in a currency other than the Euro. However, enforcement of the judgment against any party in Luxembourg would be available only in Euros and, for such purposes, all claims or debts would be converted into Euros. Similarly, in the event any proceedings are brought in an Icelandic court in respect of a monetary obligation payable in a currency other than the Icelandic Krona, an Icelandic court would have the power to give judgment as an order to pay the obligation in a currency other than the Icelandic Krona. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, actions brought in a Luxembourg court against Alvotech, the members of our board of directors, our officers, or the experts named herein to enforce liabilities based on U.S. federal securities laws may be subject to certain restrictions. In particular, Luxembourg courts generally do not award punitive damages. Litigation in Luxembourg also is subject to rules of procedure that differ from the U.S. rules, including, with respect to the taking and admissibility of evidence, the conduct of the proceedings and the allocation of costs. Proceedings in Luxembourg would have to be conducted in the French or German language, and all documents submitted to the court would, in principle, have to be translated into French or German. For these reasons, it may be difficult for a U.S. investor to bring an original action in a Luxembourg court predicated upon the civil liability provisions of the U.S. federal securities laws against Alvotech, the members of our board of directors, our officers, or the experts named herein. In addition, even if a judgment against Alvotech, the non-U.S. members of our board of directors, our officers, or the experts named in this Annual Report on Form 20-F based on the civil liability provisions of the U.S. federal securities laws is obtained, a U.S. investor may not be able to enforce it in United States or Luxembourg courts. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our directors and officers might enter into indemnification agreements with Alvotech. Under such agreements, the directors and officers could be entitled to indemnification from Alvotech to the fullest extent permitted by Luxemburg law against liability and expenses reasonably incurred or paid by him or her in connection with any claim, action, suit, or proceeding in which he or she would be involved by virtue of his or her being or having been a director or officer and against amounts paid or incurred by him or her in the settlement thereof. Luxembourg law permits us to keep directors indemnified against any expenses, judgments, fines and amounts paid in connection with liability of a director towards Alvotech or a third-party for management errors i.e., for wrongful acts committed during the execution of the mandate (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">mandat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) granted to the director by Alvotech, except in connection with criminal offenses, gross negligence or fraud. The rights to and obligations of indemnification among or between Alvotech and any of our current or former directors and officers are generally governed by the laws of Luxembourg and subject to the jurisdiction of the Luxembourg courts, unless such rights or obligations do not relate to or arise out of such persons&#8217; capacities listed above. Although there is doubt as to whether U.S. courts would enforce this indemnification provision in an action brought in the United States under U.S. federal or state securities laws, this provision could make it more difficult to obtain judgments outside Luxembourg or from non-Luxembourg jurisdictions that would apply Luxembourg law against our assets in Luxembourg. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Luxembourg, Icelandic and European Union insolvency and bankruptcy laws are substantially different from U.S. insolvency and bankruptcy laws and may offer our shareholders less protection than they would have under U.S. insolvency and bankruptcy laws. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a company organized under the laws of Luxembourg and with its registered office in Luxembourg, we are subject to Luxembourg insolvency and bankruptcy laws in the event any insolvency proceedings are initiated against us including, among other things, Council and European Parliament Regulation (EU) 2015/848 of May 20, 2015, on insolvency proceedings (recast). Should courts in another EU Member State determine that the insolvency and bankruptcy laws of that country apply to us in accordance with and subject to such EU regulations, the courts in such EU Member State could have jurisdiction over the insolvency proceedings initiated against us. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the parent company of Alvotech hf., our main operating subsidiary. As a company organized under the laws of Iceland and with its registered office in Iceland, Alvotech hf. is subject to Icelandic insolvency and bankruptcy laws in the event any insolvency proceedings are initiated against it. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insolvency and bankruptcy laws in Luxembourg, Iceland or the relevant other EU Member State, if any, may offer our shareholders less protection than they would have under U.S. insolvency and bankruptcy laws and make it more difficult for them to recover the amount they could expect to recover in a liquidation under U.S. insolvency and bankruptcy laws. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rights of our shareholders and responsibilities of our directors and officers are governed by Luxembourg or Icelandic law and differ in some respects from the rights and responsibilities of shareholders under other jurisdictions, including jurisdictions in the United States or Iceland. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our corporate affairs are governed by our articles of association, and by the laws governing companies incorporated in Luxembourg, including the Luxembourg law of August 10, 1915 on commercial companies, as amended (the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Luxembourg Company Law&#8221;). The rights of our shareholders and the responsibilities of our directors and officers under Luxembourg law differ in some respects from those of a company incorporated under other jurisdictions, including jurisdictions in the U.S. corporate laws governing Luxembourg companies may not be as extensive as those in effect in U.S. jurisdictions and the Luxembourg Company Law in respect of corporate governance matters might not be as protective of shareholders as the corporate law and court decisions interpreting the corporate law in Delaware, where the majority of U.S. public companies are incorporated. Further, under Luxembourg law there may be less publicly available information about us than would otherwise be published by or about U.S. issuers. In addition, we anticipate that all of our shareholder meetings will take place in Luxembourg. Our shareholders may have more difficulty in protecting their interests in connection with actions taken by our directors and officers or our principal shareholders than they would as shareholders of a corporation incorporated in a jurisdiction in the United States. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations regarding Ordinary Shares and Warrants adversely, then the price and trading volume of Ordinary Shares and Warrants could decline. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for Ordinary Shares and Warrants is influenced by the research and reports that industry or securities analysts may publish about us, our business, our market, or our competitors. If any of the analysts who may cover us change their recommendation regarding Ordinary Shares and Warrants adversely, cease to provide coverage or provide more favorable relative recommendations about our competitors, the price of Ordinary Shares and Warrants would likely decline. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Only two majority shareholders may have significant influence over the outcome of matters submitted to shareholders for approval, which may prevent us from engaging in certain transactions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the date hereof, our two largest shareholders, Alvogen and Aztiq, own approximately 71.6% of our Ordinary Shares. As a result of their ownership interest and other contractual rights, these shareholders exercise significant influence over all matters requiring shareholder approval, including the appointment of directors and the approval of significant corporate transactions. Such corporate action might be taken even if other shareholders oppose them. This ownership and control may also have the effect of delaying or preventing a future change in control, impeding a merger, consolidation, takeover or other business combination that may be in the best interest of us and any other shareholder. This ownership and control may be used to prevent us from raising additional funds through the sale of equity which may make it more difficult for us to finance our operations. </span></div><div style="margin-top:18pt;text-indent:35.43pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on certain significant shareholders and affiliated entities for certain key services in the execution of our strategy and business operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have entered into various service agreements with our direct and indirect significant shareholders and related entities, such as Alvogen, Aztiq, Alvogen Malta (Out-Licensing) Ltd. (&#8220;Adalvo&#8221;) and Floki Invest ehf. (&#8220;Floki&#8221;). These services include, among others, IT services, corporate administrative, legal, financial, facility management, portfolio and market intelligence research, regulatory compliance, quality audit, and publishing services, and certain administrative and financial services related to our Reykjavik facility. These services are key to our ability to continue to execute on our business strategy and to keep our business operations uninterrupted. Any interruption in the provision of these services may materially harm our business. In addition, because the providers of the services are direct or indirect significant shareholders and related entities, we may not be able or willing to enforce our contractual rights under the service agreements the same way we would if the service providers were unrelated third-party providers. See also &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We currently </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">rely on Alvogen&#8217;s ERP solution and other components of Alvogen&#8217;s IT infrastructure and will continue to do so for the foreseeable future&#8221;.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Taxation </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are treated as a &#8220;passive foreign investment company&#8221; for any taxable year, U.S. investors could be subject to adverse U.S. federal income tax consequences. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A non-U.S. corporation generally will be treated as a &#8220;passive foreign investment company&#8221; (&#8220;PFIC&#8221;) for U.S. federal income tax purposes if either (i) at least 75% of its gross income in a taxable year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income or (ii) at least 50% of its assets in a taxable year (ordinarily determined based on fair market value and averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business), and gains from the disposition of passive assets. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our analysis of our income, assets, activities and market capitalization, we believe that we were not treated as a PFIC for our taxable year ended 31&#160;December 2023. However, the determination of whether a non-U.S. corporation is a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. In particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change. In addition, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of Ordinary Shares from time to time, which may fluctuate considerably. As a result, there can be no assurance with respect to our status as a PFIC for any taxable year, and our U.S. counsel expresses no opinion with respect to our PFIC status for any taxable year. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are treated as a PFIC, U.S. investors may be subject to certain adverse U.S. federal income tax consequences, including additional reporting requirements. For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, as well as certain elections that may be available to U.S. investors, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 10.E Taxation-Material U.S. Federal Income Tax Considerations for U.S. Holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#8221; U.S. investors should consult their tax advisors regarding the application of the PFIC rules in their particular circumstances. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we or any of our subsidiaries is treated as a &#8220;controlled foreign corporation,&#8221; certain U.S. investors could be subject to adverse U.S. federal income tax consequences. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Generally, under the Internal Revenue Code of 1986, as amended (the "Code"), if a U.S. investor owns or is treated as owning, directly, indirectly, or constructively, 10% or more of the total value or total combing voting power of our stock, the U.S. investor may be treated as a &#8220;United States shareholder&#8221; with respect to each controlled foreign corporation (&#8220;CFC&#8221;) in our corporate structure, if any. A non-U.S. corporation generally will be a CFC if United States shareholders own, directly, indirectly, or constructively, 10% or more of the total value or total combined voting power of the stock of such corporation. Because our corporate structure includes a U.S. corporate subsidiary, our non-U.S. corporate subsidiaries, including any non-U.S. corporate subsidiaries that may be formed or acquired in the future, will be treated as CFCs, regardless of whether we are treated as a CFC. A United States shareholder of a CFC may be required to annually report and include in its U.S. taxable income its pro rata share of the CFC&#8217;s &#8220;Subpart F income&#8221;, &#8220;global intangible low-taxed income,&#8221; and investments of earnings in U.S. property, regardless of whether the CFC makes any distributions to its shareholders. Furthermore, an individual United States shareholder with respect to a CFC generally will not be allowed certain tax deductions and foreign tax credits that are allowed to a corporate United States shareholder. Failure to comply with CFC reporting obligations may also subject a United States shareholder to significant penalties. There can be no assurance that the Company will provide to any United States shareholder information that may be necessary for the United States shareholder to comply with its CFC reporting and tax paying obligations. U.S. investors should consult their tax advisors regarding the application of the CFC rules in their particular circumstances. </span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in tax laws and unanticipated tax liabilities could adversely affect us. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to tax in Luxembourg and in other jurisdictions, and significant judgment is required in determining our provision for income taxes. Likewise, we are subject to audit by tax authorities in various jurisdictions. In such audits, our interpretation of tax legislation may be challenged and there would be a potential risk of an adverse effect on our consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The integrated nature of our worldwide operations can produce conflicting claims from tax authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">subsidiaries charge one another for intercompany transactions, known as transfer pricing. Most of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation, although such mechanisms for resolving such conflicting claims can be expected to be very lengthy.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our tax liabilities could be adversely affected in the future by a number of factors, including changes in accounting standards, changes in the valuation of deferred tax assets and liabilities, and changes in tax laws such as corporate income tax rates and changes in tax treatment of specific items.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other international tax measures, such as the Organization for Economic Cooperation and Development&#8217;s (&#8220;OECD&#8217;s&#8221;) base erosion and profit shifting (&#8220;BEPS&#8221;) project and the global minimum taxation regime (&#8220;Pillar two&#8221;) contribute to increased uncertainty and may adversely affect our tax provision. The BEPS project contemplates changes to numerous international tax principles, as well as national tax incentives, and these changes, when adopted by individual countries, could adversely affect our provision for income taxes. Pillar two, was announced by the EU Council on 12 December 2022, and introduces the minimum taxation component of 15% as part of the OECD&#8217;s reform of international taxation. Multinational groups are subjected to these rules upon meeting certain criteria, and we continuously monitor whether compliance with these rules becomes applicable. These rules are fairly new and further guidance is progressively sought, as a result of which it remains difficult to predict the magnitude of the eventual effect of such new rules on our financial results.</span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to fully utilize some of our Icelandic NOL carryforwards. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of 31&#160;December 2023, Alvotech hf., the Icelandic operational entity, had net operating loss (&#8220;NOL&#8221;) carryforwards. There can be no certainty that we will generate revenues, in the foreseeable future, if ever, and we may never achieve profitability. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. In the absence of their utilization, any increased liabilities could adversely affect our business, results of operations, financial position and cash flows. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Termination or expiration of governmental programs or tax benefits, could adversely affect us.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Some entities forming part of the group benefit from governmental programs or tax benefits. The termination, change or expiration of governmental programs or tax benefits, or a change in our business, could adversely affect our overall effective tax rate</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">. </span></div><div id="ie527079dad0a4810aa92569387637e3d_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Information on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div id="ie527079dad0a4810aa92569387637e3d_46"></div><div style="margin-top:6pt;padding-left:21.25pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:12.1pt">History and Development of the Company </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech hf. was founded in 2013 in Reykjavik, Iceland with the aim of creating a highly integrated platform company focused exclusively on developing and manufacturing biosimilars for the global market. Over the past eleven years, we have invested steadily and methodically in building a fully integrated platform, enabling us to control quality, cost and speed to market of our developed products, representing a key competitive advantage in the biosimilar business.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech, previously known as Alvotech Lux Holdings S.A.S., was incorporated under the laws of the Grand Duchy of Luxembourg on August 23, 2021, as a simplified joint stock company. On 15 June 2022, the legal form of Alvotech changed from a simplified joint stock company (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">soci&#233;t&#233; par actions simplifi&#233;e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) to a public limited liability company (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) under Luxembourg law. We own no material assets other than our interests in Alvotech hf. and other subsidiaries and do not operate any business. Our business is conducted through Alvotech hf., our direct, wholly-owned subsidiary and its subsidiaries. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal place of business is at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg. The mailing address of our group&#8217;s principal executive office is S&#230;mundargata 15-19, 102 Reykjav&#237;k, Iceland, and our telephone number is +354 422 4500. Our principal website address is www.alvotech.com. The information contained on, or accessible through, our websites is not incorporated by reference into this Annual Report, and you should not consider it a part of this Annual Report. The SEC maintains an Internet site that contains reports, proxy information statements and other information regarding issuers that file electronically with the SEC. The address of that site is http://www.sec.gov. Our agent for service of process in the United States is Alvotech USA Inc., 1602 Village Market Blvd., Suite 280, Leesburg, Virginia 20175.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our actual capital expenditures for the years ended 31&#160;December 2023,  2022, and 2021 amounted to $33.2 million, $37.9 million and $20.5 million, respectively. These capital expenditures primarily consisted of property, plant and equipment, leasehold improvements, lab equipment, and computer equipment  in Iceland. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:21.25pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:12.1pt">Business Overview </span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Overview </span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a vertically integrated biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Our purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. Since our inception, we have built our company with key characteristics we believe will help us capture the substantial global market opportunity in biosimilars: a leadership team that has brought numerous successful biologics and biosimilars to market around the world; a purpose-built biosimilars R&amp;D and manufacturing platform; commercial partnerships in global markets; and a diverse, expanding portfolio and pipeline addressing many of the largest disease areas and health challenges globally. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A biosimilar is a biological medicine that is highly similar to and has no clinically meaningful differences from an existing approved biological, or reference product. Much as generics do for off-patent small-molecule drugs, biosimilars provide a cost-effective alternative with no clinically meaningful difference to biologic medicines whose patent exclusivity has expired. Many patient, policy, industry and regulatory organizations share our view that the availability of quality, affordable biosimilars is critical to the long-term sustainability of health systems and medical innovation globally. Cost savings generated by biosimilars can be used to treat more people and to sustain the cost of investment in the next generations of innovative therapies. We see both the discovery of novel therapies, which is the focus of many biopharmaceutical companies, and innovating access to medicines, which is our core focus, as critical to the purpose of the pharmaceutical industry as a whole&#8212;to deliver breakthrough, life-changing medicines to as many patients as possible, whoever and wherever they are. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We aim to achieve our mission by becoming a leading supplier of biosimilars globally. To do this, we have built a distinctive and comprehensive platform for developing and manufacturing biosimilars at scale. Our platform is designed to enable us to execute the product development and scale-up process in-house: from identifying therapeutic areas and target product candidates with significant unmet patient and market need through R&amp;D, leveraging gold-standard host cell lines, cell-culture processes and Good Manufacturing Practice (&#8220;GMP&#8221;) manufacturing, clinical testing, and regulatory approvals. In order to give our products global reach with local expertise, we have formed strategic commercialization partnerships with leading pharmaceutical companies covering global markets. We license our intellectual property to partners in exchange for milestone payments and royalties. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing and manufacturing biosimilars is a time-consuming, capital intensive, complex and historically uncertain undertaking. We currently have two approved products and an additional nine product candidates in our portfolio and pipeline targeting serious diseases with unmet patient and market need. Product candidates in our pipeline address reference products treating autoimmune, eye, and bone disorders, as well as cancer. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Pipeline </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Product selection </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the nature and quality of our platform enable us to innovate and systematically produce high quality biosimilars for treating a broad range of serious diseases. We believe that our ability to generate and capture efficiencies across research and development, manufacturing and commercialization gives us key advantages in quality, cost and speed to market when competing with both originator and other biosimilar companies. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our fully integrated capabilities provide us wide breadth and flexibility in deciding which biosimilar opportunities to pursue, optimizing the commercial, scientific and medical impact of each program as part of our portfolio. We evaluate a rigorous set of six criteria to select our candidates: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Competitive situation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Evaluates originator value, brand and longevity, as well as competition from biosimilars and originators alike, on an ongoing basis. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Launch timing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Aims to be among the first wave of biosimilars to every reference product. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Portfolio fit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Seeking balance across the portfolio, assesses volume/price ratio and the ability to leverage the breadth of our R&amp;D and manufacturing capabilities. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Differentiation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Seeks opportunities where platform differentiation can be applied and exploited, for example, in potential for interchangeability (for the U.S. market), delivery device and product presentations. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Feasibility and cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Ongoing assessment for technical, clinical, intellectual property and regulatory issues as well as cost and time analysis for CMC, clinical and potential for interchangeability. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Partner insights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Strategic input from commercial partners taken into account at every stage. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the above, our platform is built for flexibility that may allow us to expand into other healthcare products areas such as respiratory and primary care products. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Our Pipeline </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Through our rigorous product selection and development platform, we have been able to build a pipeline comprising two launched products and nine disclosed biosimilar candidates, covering a variety of therapeutic areas, including autoimmune, eye, and bone disorders, as well as cancer. Our lead program, AVT02, a high concentration formulation biosimilar to Humira, has received regulatory approval in over 50 markets and has been launched in over 20 markets globally. We expect to launch AVT02 in the United States during the first half of 2024. We also have a second approved biosimilar, AVT04, which uses the same SP2/0 host cell line as the reference biologic Stelara. AVT04 has been approved in Japan, Canada and the EEA and was launched in Canada on 1 March 2024. Launches of AVT04 in Japan and Europe are expected, respectively, in Q2 2024 and Q3 2024. We anticipate that the FDA&#8217;s review of our BLA for AVT04 will be completed by 16 April 2024. Clinical programs for AVT03, AVT05 and AVT06 are at an advanced stage, and we expect to file marketing applications for these biosimilar candidates in 2024. We are also developing, AVT23, that is in clinical development, as well as AVT16 and AVT33, in addition to three undisclosed programs, all of which are in pre-clinical development. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Our Programs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVT02, our high-concentration biosimilar to Humira</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Humira (adalimumab) inhibits tumor necrosis factor (&#8220;TNF&#8221;), which is a protein in the body that can cause inflammation. Developed and predominantly marketed by AbbVie, adalimumab is prescribed to treat a variety of inflammatory conditions including, rheumatoid arthritis, psoriatic arthritis, Crohn&#8217;s disease, ulcerative colitis, plaque psoriasis among other indications. Humira is approved and marketed in a high concentration formation (100 mg/mL) across four doses (10 mg, 20 mg, 40 mg, 80 mg) which account for roughly 80% of the U.S. Humira market. In 2023, Humira worldwide net revenues were approximately $14.4 billion. A lower concentration formulation (50 mg/mL) is also approved and marketed across three strengths (10 mg, 20mg, 40mg). Adalimumab has many of the core characteristics we look for in selecting a candidate for development. We are aiming to have the first interchangeable high-concentration citrate-free biosimilar to Humira in the United States. Additionally, adalimumab fits well within our immunology portfolio and manufacturing capabilities. The competitive landscape and broad market opportunity for adalimumab is attractive to us and our commercial partners.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">We have directly or through our partners, received regulatory approval for AVT02 in 52 countries. These include the EEA, UK and Switzerland, Canada, Australia, Israel, Morocco, Egypt, Saudi Arabia, South Africa and parts of Latin America. AVT02 is currently marketed in Europe, Canada and Australia. On 23 February 2024, we received U.S. FDA approval for AVT02 as an interchangeable high-concentration citrate-free biosimilar to Humira, AVT02 also qualifies for exclusivity as a high-concentration biosimilar. We expect to launch AVT02 with our partner Teva in the United States during the first half of 2024. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVT04, our proposed biosimilar to Stelara</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stelara (ustekinumab) is a human IgG1k monoclonal antibody against the human interleukin-12 and -23 cytokines. Marketed by Janssen, Stelara is prescribed to treat a variety of inflammatory conditions including psoriatic arthritis, Crohn&#8217;s disease, ulcerative colitis, plaque psoriasis among other indications. In 2023, global net revenues from Stelara were approximately $10.8 billion. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are using an SP2/0 host cell line, which is the same manufacturing host cell line as Stelara. Developing our biosimilar in the same host cell line as the originator for a product that requires such a long half-life, de-risks the approval process and creates potential differentiation relative to other biosimilar developers.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, we announced that AVT04 had been approved in Japan and Canada. In early 2024, we announced that it has also been approved in the EEA. We anticipate that the FDA&#8217;s review of our BLA for AVT04 will be completed by 16 April 2024. We also announced that we have reached settlement agreements with the manufacturer of the reference product Stelara, Johnson &amp; Johnson, launched AVT04 in March 2024 in Canada, and expect launches in Q2 2024 in Japan, Q3 2024 in Europe, and in February 2025 in the U.S., pending FDA approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVT06, our proposed biosimilar to Eylea</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Eylea (aflibercept) is a recombinant fusion protein formulated for intravitreal administration consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Developed and marketed by Bayer and Regeneron, Eylea is prescribed to treat conditions including age-related macular degeneration, macular edema, and diabetic retinopathy.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Both the reference product as well as our proposed biosimilar AVT06 are produced in recombinant Chinese hamster ovary cells. In July 2022, we initiated the confirmatory clinical study for AVT06 and, in January 2024, we announced positive topline results from the confirmatory study.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVT03, our proposed biosimilar to both Xgeva and Prolia</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Xgeva and Prolia have the same active ingredient, denosumab, but the products are approved for different indications, patient populations, doses and frequencies of administration. Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL, receptor activator of nuclear factor kappa-B ligand. Developed and predominately marketed by Amgen, Xgeva is prescribed to prevent bone fracture, spinal cord compression or the need for radiation or bone surgery in patients with certain types of cancer, and Prolia is prescribed to prevent bone loss and increase bone mass. In 2023 cumulative global sales of Prolia and Xgeva were approximately $6.2 billion. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Both the reference product as well as our proposed biosimilar AVT03 are produced in recombinant Chinese hamster ovary cells. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVT03 is in the clinical phase and has been developed to have a high degree of analytical similarity to the originator. Further we have engaged with global regulatory authorities on our development strategy in order to align our program with expectations from regulatory authorities and further limit development risk. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our clinical program consists of two pharmacokinetic (PK) studies in healthy volunteers and a confirmatory efficacy and safety study in patients with post-menopausal osteoporosis. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, we announced the positive top-line results from a PK study for AVT03 compared to Prolia in healthy adult subjects. In August 2023, we announced the initiation of a second PK study, which is still ongoing, comparing AVT03 to Xgeva. In August 2022, we announced the initiation of a confirmatory patient study for AVT03, which is also ongoing. The objective of the confirmatory study is to demonstrate clinical similarity of AVT03 to Prolia in terms of efficacy, safety, immunogenicity, and PK in postmenopausal women with osteoporosis. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVT05, our proposed biosimilar to Simponi and Simponi Aria</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Simponi / Simponi Aria (golimumab), inhibits TNF, which is a protein in the body that can cause inflammation. Simponi / Simponi Aria are prescribed to treat a variety of inflammatory conditions including, RA, psoriatic arthritis, ulcerative colitis among others. Simponi is a sterile solution of golimumab antibody supplied for subcutaneous use. Simponi Aria injection is a sterile solution supplied for intravenous use. We are developing both forms of the product. AVT05 is expressed in an SP2/0 host cell line, which matches the cell used by the developer of the originator. AVT05 is in clinical development. We have developed AVT05 to match the host cell line used by the developer of the originator and we intend to pursue interchangeability designation. In November 2023, we announced positive topline results from our pharmacokinetic study for AVT05. In May 2023, Alvotech announced the initiation of a clinical study to compare the efficacy, safety, and immunogenicity of AVT05 and Simponi in adult patients with moderate to severe rheumatoid arthritis. We expect to announce top-line results from the clinical efficacy study in 2024. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVT23 (also called ADL018), our proposed biosimilar to Xolair</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Xolair (omalizumab) is an antibody that targets free IgE and is used to treat patients with allergic asthma, chronic spontaneous urticaria (CSU) and nasal polyp. Xolair, the only currently approved product containing omalizumab, was first approved in 2003. In 2023, we announced an agreement with Kashiv Biosciences LLC ("Kashiv") to in-license AVT23. The agreement covers all 27 countries of the European Union, the UK, Australia, Canada, and New Zealand. Under terms of the agreement, Alvotech will receive an exclusive license to commercialize AVT23, which will be developed and manufactured by Kashiv.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVT23 is currently in clinical development. A pharmacokinetic (PK) comparability study has been completed, with results demonstrating that AVT23&#8217;s bioavailability, safety, tolerability and immunogenicity are comparable to those of Xolair. A confirmatory clinical efficacy study comparing AVT23 to Xolair is currently ongoing.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently in early phase development for five additional products, three for which the reference biologic remains unnamed, in addition to AVT16, a proposed biosimilar to Entyvio (vedolizumab) and AVT33, a proposed biosimilar to Keytruda (pembrolizumab).</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Market Opportunity </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Background on Biologics </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biologic medicines (biologics) are complex pharmaceutical products that typically contain one or more active substances made by or derived from a biological source. Conventional medicines are typically chemically synthesized small molecules that are easily identified and characterized; in contrast, biologics are large, complex molecules that require unique characterization techniques and generally tend to be sensitive to heat and microbial contamination. The creation innovation and advancement of biologics are the result of cutting-edge research and these medicines have provided novel treatments for a variety of illnesses such as rheumatoid arthritis, Crohn&#8217;s disease, ulcerative colitis, psoriasis, multiple sclerosis, age-related macular degeneration, diabetic macular edema and numerous types of cancer. Biologics are designed to have very specific effects and to interact with specific targets in the patient&#8217;s body, mainly on the outside of cells. A more targeted mechanism of action leads to a greater chance of the medicine having the desired effect against the disease and results in fewer side effects compared to traditional medicines. The effectiveness of biologics has led to an increase of investment in R&amp;D within the pharmaceutical sector for biologic medicines. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Background on Biosimilars </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A biosimilar is a biological medicine that is highly similar to and has no clinically meaningful differences from an existing approved biological, or reference product. Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines and typically have the same amino acid sequence. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biosimilars offer a lower cost alternative to their name-brand reference products, and have no clinically meaningful difference in terms of safety, purity or potency when compared to reference products. Because they are designed to be highly similar to already approved biologics, the success rate for developing biosimilars is considerably higher, and the R&amp;D cost proportionally much lower. While the average originator biologic takes an average of 12 years to develop at a cost of more than $2.5 billion, the average biosimilar can usually be developed six to nine years and at a cost of between $100.0 to 200.0 million. Further, this is significantly different to generics, which are simpler to manufacture, can typically developed in two years or less at a cost of less than $10 million, and without needing clinical trials. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The availability of biologics and their rapidly increasing prices have forced healthcare systems and payors around the world, public and private alike, into difficult tradeoffs in the effort to balance the best quality of care, accessibility, sustainability and cost. As biosimilars provide a more affordable alternative to payors and patients, they offer the potential to improve the accessibility of many life-altering treatments to many more patients. More broadly, lower costs for existing treatments can make healthcare systems more sustainable and free up resources to pay for the next generation of innovative brand-name therapies, and the R&amp;D infrastructure that sustains future drug discovery. In this way, we believe that biosimilars can also help to sustain the global biomedical innovation ecosystem as a whole. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While biosimilars share similarities with generics, there are significant differences, including the complexity of development and manufacturing. For traditional medications, generic products can generally be considered identical to the branded product in form and function. In the case of biologics and biosimilars, the complexity of a biologic molecule means that the biosimilar product is not identical in form to the branded product, and some variability from the branded reference product is considered inherent to the process. However, there is no clinically meaningful functional difference between a biosimilar and the reference product in safety, purity or potency. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Strategy </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategy is to leverage our integrated platform to develop and manufacture high quality biosimilars and to then work with our global network of partners to commercialize the portfolio and pipeline into markets around the world. We are advancing multiple product candidates towards regulatory approval and intend to launch our portfolio and pipeline into over 90 markets around the world. Our strategy can be summarized by the following; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Platform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: At the heart of our strategy is our fully integrated biosimilars platform. We have a purpose-built facility with a footprint of approximately 280,000 square feet that includes R&amp;D, process, quality, manufacturing and headquarters in Reykjavik, Iceland. Additionally, we have cell line, process, analytics and glycoprotein characterization sites in Germany; a regulatory, legal and government affairs office in the United States; and an R&amp;D, clinical, and regulatory strategy center in Switzerland. This infrastructure and know-how enables us to have a full set of capabilities and control, from analysis of reference products and cell line development through fill-and-finish GMP manufacturing and regulatory approvals. Further, it provides us the ability to innovate efficiencies in every step of the process and project those cost-savings throughout our portfolio. We have demonstrated manufacturing capabilities using both of the two most widely-used host cell lines &#8212; Chinese hamster ovary (&#8220;CHO&#8221;) and SP2/0 &#8212; as well as cell culture processes, fed batch and perfusion.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Portfolio and Pipeline:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In addition to two approved biosimilars, we are currently advancing a portfolio and pipeline of  nine biosimilar candidates through the development and global regulatory process. Our portfolio and pipeline covers a variety of therapeutic areas, including autoimmune disorders, eye disorders, bone disease, respiratory disease, and cancer. Where possible, we seek to develop differentiated products as is the case with the company&#8217;s first launched product, AVT02, a biosimilar to Humira. For the U.S. market, our biosimilar was developed as a high-concentration form, which is the predominant product profile that is marketed by the originator company. Additionally, we sought and have been given  an interchangeability designation for AVT02 in the U.S. market, with exclusivity. By end of 2023, we had begun commercialization of AVT02, through our commercial partners, in Canada, Australia, and 19 markets across Europe. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Commercial Partnerships: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have formed a global network of strategic commercial partnerships to ensure that our products can reach the patients in geographies across the world. Our partners include Teva (US), STADA (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Medpro (Australia, New Zealand, South Africa/Africa), JAMP Pharma (Canada), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS (Middle East and Africa), Abdi Ibrahim (Turkey), Kamada (Israel), MegaLabs, Stein, Libbs, Tuteur and Saval (Latin America), Advanz Pharma (EEA, U.K., Switzerland, Canada, Australia and New Zealand), among others. Our partners&#8217; deep knowledge of the markets and economic, regulatory, payor and reimbursement landscapes in the countries they serve optimizes our commercial opportunity and ability to reach patients in these markets in a way we could not do on our own. We partner only with trusted, market leaders and develop close strategic relationships with these partners that align our interests and the partners&#8217; interests for success. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">People: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31 December 2023, we employ over 1000 people around the world. Over 85% of our workforce is dedicated to manufacturing and development of biosimilars. We seek to attract and retain the highest quality talent in order to achieve our mission and execute our strategy. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">ESG and corporate responsibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: We aim to maintain and further develop our commitment to sustainability and corporate responsibility beyond our fundamental mission of expanding access to medicines while lowering costs for patients. We are developing and implementing a comprehensive environmental, social and governance (&#8220;ESG&#8221;) framework to collect, monitor and report data that assess our environmental and social impact as well as provide transparent disclosures on governance. </span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that we have certain intrinsic business and operational qualities that may favorably position us to optimize our ESG impact, including the location of our headquarters and manufacturing in Iceland. This enables us to minimize our environmental impact by conducting our principal operations using nearly 100% renewable energy and in a geography with abundant cold and hot water. We intend to make a difference for patients around the world by working strategically towards increasing patient access to medicines, supporting the sustainability of health systems and, where feasible, conducting clinical trials in areas with relatively lower access to healthcare. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Platform </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the nature and quality of our platform enable us to innovate and systematically develop and manufacture biosimilar medicines. We consider this ability, and that our platform can generate and capture efficiencies all along the research and development, manufacturing and sales and marketing chain, to be fundamental advantages when competing with both originator and other biosimilar companies in quality, cost and speed to market. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The challenges of biosimilars development </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Making biosimilars&#8212;biologic medicines that are highly similar to and without clinically meaningful differences from their reference products in terms of safety, purity and potency&#8212;is a fundamentally complex task. It requires, among other things, highly specialized expertise and infrastructure, time, and significant capital. Success in the biosimilar space is largely determined by the ability to make biosimilars efficiently and consistently. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that these same barriers to entry also create opportunities for differentiation. The capital investment, sophisticated infrastructure and scientific/technical expertise required are principal reasons that the biosimilar divisions of large originator biopharmaceutical companies, who have access to all of these, have dominated the sector&#8217;s early years. But these biosimilars divisions within larger organizations have competing internal demands for resources, including people, R&amp;D and manufacturing facilities. As a result, biosimilars are often viewed as a secondary business. Such internal competition makes consistent and replicable operational control and efficiencies more difficult and costly to achieve, and biosimilars also tend to receive less focus in marketing and distribution. Conversely, smaller companies may not have all of the internal capabilities needed for development or the capital resources to invest in such capabilities. These constraints may require these smaller companies to outsource key parts of the R&amp;D and manufacturing process, thereby potentially losing control over quality or the ability to innovate and control costs. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research &amp; Development </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development is solely focused on the development of biosimilar medicines, which require considerable time and substantial financial investment. We intend to continue to commit significant resources in financial and human capital to development activities going forward, with the aim of offering more affordable biologic medicines, globally. We also strive to identify opportunities where a level of differentiation can be applied to the development program to enable improved commercial success. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biosimilar medicines are highly similar to their reference products and typically have identical primary amino acid structure. They are held to the same high-quality standards as innovative biopharmaceuticals. The ultimate goal in the development of biosimilar medications is to develop therapeutics that are highly similar to and have no clinically meaningful difference from their reference products. In order to demonstrate this, we apply rigorous processes in the development of our product candidates. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A biosimilarity claim must demonstrate totality of evidence with respect to physiochemical characteristics, biologic activity, pharmacokinetics, clinical safety and efficacy, and therapeutic indication. Extensive analytical comparisons to the reference products are conducted, followed by nonclinical and clinical pharmacokinetic (&#8220;PK&#8221;) and pharmacodynamic (&#8220;PD&#8221;) studies, as required. Finally, a clinical efficacy and safety study is conducted to resolve any remaining uncertainty that the product is biosimilar. This process is described in more detail below. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Early phase development </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In this phase of development it is vital to establish a manufacturing process that delivers highly similar product to the reference product. This starts with cell line development activities, where clones having characteristics similar to the reference product with acceptable productivity are selected. Following this a competitive commercial manufacturing process for drug substance and drug product is developed to deliver a product that is highly similar to the reference product, enabling future investment in GMP manufacturing. Numerous characterization methods are also applied to ensure our biosimilar candidate is highly similar to the reference product in structure and function. Significant time and effort is spent on this similarity evaluation to enable a streamlined clinical program in subsequent development phases with a higher probability of success. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Pre-clinical development and GMP manufacturing</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In this phase, the manufacturing process is scaled-up up from small pilot scale batches to commercial scale in a commercial site. The goal is to manufacture product with a high degree of analytical similarity to the reference product while also confirming the highest quality product is produced. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In parallel, regulatory authorities in the U.S., EU, and other geographies are engaged to discuss the overall development strategy, in order to ensure the ultimate submission package is approvable in all major regions. Non-clinical studies may also be conducted as required, based on the individual biosimilar program and alignments with regulatory authorities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Clinical studies</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical studies are conducted in this phase to support product registration. Typically, a PK study is performed to demonstrate PK equivalence of the proposed biosimilar to the approved reference products such as those available in both the U.S. and EU. A global, confirmatory clinical efficacy and safety study is typically also performed to demonstrate that there are no clinically meaningful differences between the proposed biosimilar and the reference product. Depending on the specific program, these two studies may be conducted within one larger study or, conversely, additional small studies may need to be performed to support registration. When both a PK and confirmatory efficacy and safety study is required, we take the calculated risk to execute these studies in parallel (where feasible), which enables the fast track to licensing application submission for the program. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In parallel to the clinical studies being conducted, manufacturing process characterization and validation is completed, in addition to completion of the analytical similarity assessment supporting registration. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Interchangeability</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When practical and commercially relevant in the U.S. market and other countries and regions, we seek interchangeability designation such as is the case with our lead product, AVT02, a biosimilar to Humira. Interchangeability is a U.S. regulatory construct and according to the FDA, an interchangeable product will have met additional data requirements and so may be substituted for the reference product without the intervention of a prescriber. The substitution may occur at the pharmacy, much as generic drugs are substituted for brand name drugs, subject to varying U.S. state pharmacy laws. Biosimilars, including those designated as interchangeable products, have the potential to reduce health care costs. The concept of interchangeability for biosimilars was signed into law through the Biologics Price Competition and Innovation Act in 2010. In order to be considered interchangeable, a biosimilar must meet additional requirements, including the execution of a &#8220;switching study,&#8221; utilizing the reference product and biosimilar product in patients. The vast majority of states have passed laws regarding substitution for interchangeable products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Submission and approval</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ultimate goal is to submit a globally vetted, high-quality dossier that enables first-pass approval based on the totality of evidence for the comparative analytical, Chemistry, Manufacturing and Controls, (&#8220;CMC&#8221;), and clinical data. Extrapolation principles also allow for attaining a full label matching the reference product other than indications specifically protected by regulatory exclusivity. We work closely with health authorities through the review process to enable approval at the earliest possible time after dossier submission, ensuring we can remain competitive with market entry. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Manufacturing &amp; Supply </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Manufacturing Facilities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our corporate headquarters, main manufacturing site and a large part of our R&amp;D division are located in Reykjavik, Iceland. This facility provides us with purpose-built GMP and has highly integrated capabilities for producing biosimilars at scale. The facility is currently approximately 140,000 square feet and utilizes single-use technology to manufacture drug substance and drug product. It houses our R&amp;D, quality control and quality assurance teams and has an active and valid GMP certificate issued by the Icelandic Medicines Authority authorizing Investigational Medicinal Product and commercial manufacturing. In December 2020, we broke ground on an expansion of our Reykjavik facility that will double the total footprint, adding another 140,000 square feet. The expansion provides space for R&amp;D activities, and is expected to be completed in 2024. It is also is expected to give additional redundancy in drug product capacity, assembly of combination products and devices, and secondary packaging. Additionally, the expansion will support increased warehousing and other supportive functions. With the expansion of the Reykjavik facility&#8217;s manufacturing capabilities, we expect our capabilities to be able to meet the demand for our products, after obtaining regulatory approval and commercial launch, in the near future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Third Party Suppliers, Manufacturers, and Raw Materials</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our manufacturing processes utilize single-use processing technology for both drug substance and drug product. Our manufacturing is therefore reliant on the availability of single-use components to complete production. We source these components from various reputable third-party suppliers. However, the price of these materials and components is subject to market forces and competing demands. Increases in the cost of components would have an adverse effect on our forecasted cost of goods. In certain cases, we may rely on only one approved source for a particular component and shortages may significantly impact our ability to manufacture drug substance and drug product. Finding alternative suppliers may not be possible or cause material delay to development plans or commercial production. We have the ability and are currently evaluating opportunities for redundancies in our manufacturing processes in order to mitigate risk and control costs. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also require the use of certain reagents and materials in order to develop and produce biologic medicines. We acquire these reagents and materials through reputable third parties that specialize in the production and sourcing of these reagents and materials. These materials are widely available commodities. However, unforeseen shortages in these materials may have an adverse effect on either the price of these materials or could cause delays in our development or commercialization timelines. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVT02 and certain other products within our pipeline require the use of auto-injector devices. We work closely with our vendor in order to assure availability and manage risk through inventory management and relationship management. Our current arrangement with our supplier utilizes a proprietary design. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Master cell banks and working cell banks are critical components in biologic medicine manufacturing. A cell bank is a collection of ampoules of uniform composition stored under defined conditions, each containing an aliquot of a single pool of cells. The master cell bank is generally derived from the selected cell clone containing the expression construct that has been encoded to produce the protein of interest, such as a specific monoclonal antibody with a defined amino acid sequence. This unique aliquot of cells allows for a consistent high quality biologic medicine to be produced. The working cell bank is derived by expansion of one or more ampoules of the master cell bank and is used for routine manufacturing. Both the master cell bank and working cell bank are central to obtaining regulatory approval for manufacturing and marketing biologic medicine. Without well-characterized and well-controlled master and working cell banks, the manufacturing process could be susceptible to non-ideal product variability. The quality of the manufactured biologic product is dependent on the quality of the cells used for our manufacturing, and having a sufficient supply of master and working cell banks is important for a consistent manufacturing process. The master cell banks and working cell banks for our lead product candidates are produced at either an EU or U.S.-based contract manufacturing organization and then transferred internally to both the Reykjavik site in Iceland and J&#252;lich site in Germany for supply continuity and redundancy. The availability of master cell banks is critical to our ability to manufacture products for the commercial market. Should our cell banks (despite any redundancies) be compromised, we would be unable to produce usable products for patients in any market. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sales and Marketing </span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have launched AVT02 in over 20 markets globally, including in select European countries under the trade name Hukyndra and in Canada under the trade name SIMLANDI. We aim to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">meet patient demand in our major markets, and to launch in further markets in 2024, including in the United States </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the first half of 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. A breakdown of product revenue from the sale of AVT02 is presented by region below.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.878%"><tr><td style="width:1.0%"/><td style="width:18.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Product Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Product Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Europe</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Asia and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,699&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have chosen to market and commercialize our products through numerous strategic partnerships rather than sell a single global license to an individual commercial partner. By partnering with multiple leading regional partners who would likely be able place a higher value on licenses due to their core market(s) focus, we believe we can achieve higher return for the rights of our products. This also better ensures focus from partners on our portfolio. Additionally, by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partnering with multiple partners, we are able to enhance local market knowledge and expand our geographic reach by mitigating our risk of being dependent on one single partner. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By outsourcing sales and marketing, we believe we are able to realize and leverage the following benefits: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Global reach: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By commercializing through best-in-class partners, we can reach nearly all markets around the world, including key markets in the U.S., Europe, Japan, Canada, Australia, and various international markets across regions such as Latin America and Asia. This global approach provides diversification and opportunities for growth often overlooked by companies that focus solely on the U.S. and Europe.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Local expertise: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial strategy allows us to leverage the expertise from our partners. Our partners&#8217; expertise in managing numerous local regulatory and commercial landscapes has been built up over many years and would be difficult, to replicate internally across all global markets. We believe our partners will enable us to bring our products to market more effectively, than if we were to pursue a commercial strategy on our own.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Portfolio scale:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our commercial strategy also allows us to combine our products with larger portfolios (via our partners) which, through the benefit of cross-selling, should enhance the attractiveness of our products. Furthermore, through a portfolio approach, we are able to receive the benefits of our partners established relationships with payors and providers.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Product selection flexibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: As a company focused only on developing and manufacturing biosimilars, our product selection model is not complicated by an in-house set of innovator products, nor is it confined to specific therapeutic areas. We do not need to make product selection decisions to fit a pre-existing commercial strategy or sales and marketing infrastructure, but rather we can take a flexible approach to product selection, evaluating candidates based on their clinical merits, partner preferences and commercial opportunity. We are able to access markets through an existing network or create a new network through our partnership model in various therapeutic areas and various geographies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Platform leveragability: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial strategy also allows for the creation of a highly leverageable platform. Products may be added without significant changes in Sales and Marketing or G&amp;A infrastructure. We believe this leveragability, after achieving critical mass through our launches, can create a company more profitable than we would otherwise be, had we decided to create a global commercial infrastructure and distribute our product through that network. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Milestones: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to receive milestone payments from our partners at the time of signature of the commercial agreement and at various points in time through development and in some cases, post approval. Milestones offset the cost of development and create a shared risk alignment with our partners. We further view milestones as a consistent and repeating revenue opportunity, as we fully expect to continue to add product candidates to our pipeline, and subsequently out-license them in order to maximize the value of our dedicated biosimilar development and manufacturing infrastructure. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of our strategic decision to form commercial partnerships, we do not currently have direct sales, marketing, and distribution capabilities. In order for us to commercialize any product on our own, we would need to either develop an infrastructure to facilitate sales, marketing and distribution or contract with third parties that have the requisite capabilities. Our in-house strategic sales and marketing expertise is currently focused on relationships with our existing partners and finding new partner relationships. As of 31&#160;December 2023, we have contracted with 17 partners to sell, market, and distribute our products in certain agreed upon territories. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Commercial partnerships</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have formed strategic commercialization partnerships with leading pharmaceutical companies covering global markets. A commercialization partnership generally consists of two components. First, under the licensing component, we and the partner agree that we will develop the product candidate and that the partner will have the exclusive right to market, distribute and sell our product in a certain territory once the product has been approved by the relevant regulator. In return, the partner agrees to make certain upfront or milestone payments to us, which can be any or a combination of the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Upfront payments upon the signing of the agreement;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Milestone payments related to the development of the products, for example upon the completion of a clinical trial with respect to the relevant product candidate;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Milestone payments related to the regulatory approval process of the products, for example upon submitting an application for approval with or receiving approval from the relevant regulator for the relevant product candidate;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Milestone payments related to the launch or first commercial sale of the product in the relevant territory; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Milestone payments related to achieving sales targets in the territory. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the supply component of the partnership agreements, we will generally manufacture, supply and deliver the product to each partner, and the partner will exclusively buy the product from us. The purchase price for each commercial partner, unless specifically noted otherwise in the description of the partnership agreements below, is a royalty of approximately 40% (between 35% and 45%) of the estimated net selling price or an agreed-upon applicable floor price, whichever is higher, for the duration of the agreements. The floor price is a minimum price per unit specific to each presentation to be paid by the commercial partner for the product, and is determined per each presentation and product taking into consideration Cost of Goods of manufacturing, supply and commercial market environment. Under certain partnership agreements, we may be eligible to receive additional royalty payments in periods where sales exceed certain targets. As is customary, the partnerships are concluded for durations of ten to twenty years. We recognized $48.7 million of product revenue and $42.7 million of license and other revenue, resulting from the commercial partnerships, for the year ended 31&#160;December 2023. Refer to Note 5 of the consolidated financial statements included elsewhere in this Form 20-F for further details on the revenue recognized under these agreements. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amounts in upfront and milestone payments and the royalty rates are negotiated between parties and depend in part on the estimated addressable market for the product and the size of the territory. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a principal matter, we grant our partners access to the dossier, which includes our dossier of data, information and know-how relating to the relevant products that enable our partners to apply for and obtain marketing authorization in the various territories. Marketing authorizations obtained with the help of the dossier remain with the partners after the expiry of the partnership. Partners only return the marketing authorization to us when we terminate the agreement for cause. Certain partners may also get access to our trademarks. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal partners and partnerships include: </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">United States&#8212;Teva</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License and Development Agreement with Teva Pharmaceuticals International GmbH </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, we entered into a license and development agreement with Teva which was amended in June 2021, and again in February 2023, for the commercialization of certain biosimilar products in certain territories (the &#8220;LDA&#8221;). Under the LDA, we granted Teva an exclusive license (even as to us and our affiliates), with the right to sublicense through multiple tiers, to use, import, commercialize, and market products containing AVT02, AVT04, AVT05, AVT06, and AVT16 in the United States and each of its territories, districts and possessions, including the Commonwealth of Puerto Rico. Under the LDA, Teva has the exclusive right to reference (i) our registration dossiers of certain biosimilar products for its BLA approval, and (ii) all clinical studies conducted by or on our behalf with respect to the development of certain biosimilar products for purposes of obtaining applicable BLA approvals. Under the LDA, we granted Teva the right of first negotiation for commercialization and marketing rights in certain territories for our future biosimilar products (with some exceptions) for five (5) years from the effective date of the agreement. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The LDA expires on a product-by-product basis ten (10) years from the first commercial sale of a product, subject to possible one-year extensions. Either party may terminate the LDA on a product-by-product basis for any material breach by the other party that is not remedied within a specified time period, if either party reasonably believes that there is a material safety issue with respect to such product, or in certain other circumstances. Teva may terminate the LDA on a product-by-product basis within certain time periods, if Teva reasonably demonstrates a lack of commercial viability for such product in which case we retain already paid milestone payments and are allowed to partner with someone else. Either party may also terminate the LDA upon the insolvency of the other party. The LDA will automatically terminate as a whole upon the termination of the Teva Product Supply Agreement, or in part with respect to any product if the Teva Product Supply Agreement is terminated with respect to such product. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, we announced that the FDA had accepted the resubmitted biologics license application for AVT04. We anticipate that the FDA&#8217;s review will be completed by 16 April 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 27 February 2023, Alvotech and Teva signed an amendment to the LDA. As part of that amendment, Alvotech agreed to provide future financial consideration to Teva to assist with the cost of launching and marketing the licensed biosimilar products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 24 July 2023, Alvotech announced that it had expanded its strategic partnership agreement with Teva. The expanded agreement pertained to the exclusive commercialization in the U.S. by Teva of two new biosimilar candidates to be developed and manufactured by Alvotech and line extensions of two current biosimilar candidates in the partnership, also to be developed and manufactured by Alvotech. The agreement includes milestone payments, the majority paid following product approvals and upon achieving significant sales milestones. Teva and Alvotech will share profit from the commercialization of the biosimilars. Teva also agreed to acquire Tranche B Convertible Bonds which were issued by Alvotech pursuant to a convertible bond instrument, dated 20 December 2022, for $40 million.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As consideration for the rights granted to Teva under the LDA, Teva made upfront payments of $40.0 million and $37.5 million in development milestone payments up to 31&#160;December 2023. Additionally, we are eligible to receive aggregate payments of up to an additional $552.5 million upon the achievement of certain regulatory, commercial, manufacturing and sales milestones. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2024, the FDA approved our BLA supporting interchangeability for AVT02 in the United</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">States for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">spondylitis, Crohn&#8217;s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to launch AVT02 through Teva under the trade name SIMLANDI in the U.S. in the first half of 2024.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Product Supply Agreement with Teva Pharmaceuticals International GmbH </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the LDA, we entered into a product supply agreement with Teva in August 2020 for the exclusive manufacture and supply of each product during such product&#8217;s respective product supply term (the &#8220;PSA&#8221;). Under the PSA, we will manufacture and supply each product exclusively to Teva for marketing in the territory. We will meet purchase orders for the product that have been accepted or deemed accepted by us. Teva has agreed to a minimum order quantity for each product. Subject to some limitations, as consideration for supply of product Alvotech will receive 40% of the value of Teva&#8217;s net sales of the products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The PSA remains in force on a product-by-product basis for 10 years from launch, then continuing until terminated by either party with 12 months&#8217; notice. Either party may terminate the PSA on a product-by-product basis for any material breach by the other party that is not remedied within a specified time period. Either party may terminate the agreement with respect to a product if the BLA approval for a product in the territory is revoked by a regulatory authority due to a health, safety or efficacy concern. With exceptions, Teva may require us to purchase any and all unsold quantities of products ordered by Teva prior to termination. We may terminate the PSA if Teva fails to purchase certain minimum quantities of each product. Additionally, either party may terminate the PSA with respect to a product if a margin split event occurred which results in a negative margin for a period of four (4) consecutive calendar quarters. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Europe&#8212;STADA</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From August to November of 2019, we entered into similar license and supply agreements (&#8220;out-license contracts&#8221;) with STADA which were amended in March 2020, pursuant to which we granted STADA exclusive licenses (even as to us and our affiliates) to import, commercialize and market certain products containing AVT02, AVT03, AVT04, AVT05, AVT06, and AVT16 in the European Union and certain other countries. Under the amended agreements, STADA also received joint ownership of certain of our intellectual property covering such products in the EU and certain other countries under certain conditions. Pursuant to the amended agreements, we are required to provide, and STADA is required to obtain, all of STADA&#8217;s requirements of the licensed products for a defined period of time. We are also obligated to develop the licensed products, including performing all pre-clinical and clinical activities required to submit grants to obtain marketing authorizations for the licensed products in the EU and certain other countries, whereas STADA is required to use all commercially reasonable efforts to sell, market, import and store the licensed products and we have the right to terminate if STADA does not launch after fulfillment of certain conditions. STADA will remit approximately 40% of its in-market sales to us in the form of sales-based royalties. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain conditions, the consideration paid to us is subject to a partial or full refund to STADA on a product-by-product basis if (i) the net sales of a product fall below certain specified thresholds, (ii) the manufacture, marketing or sale of such product would result in patent infringement, or (iii) we materially breach the agreement and fail to cure within 60 days of receiving notice from STADA. The licenses granted to STADA will remain exclusive until the fifth anniversary of STADA&#8217;s first sale of a product in a country, on a product-by-product and country-by-country basis. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">STADA may extend the exclusivity period up to three times for an additional five years by providing written notice one year prior to the expiration of the exclusivity period. Upon expiration of the exclusivity period for a product in a country, STADA will retain a non-exclusive license to import, commercialize and market such product in the country, and will be granted a worldwide, non-exclusive license to manufacture such product for sale in such country. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, we entered into a second amendment of the AVT02 agreement to, among other things, expand the agreement to include an additional product and provide certain additional terms for the development, licensing and commercialization of such product. Under the amended agreement, we granted STADA a perpetual, exclusive license to import, commercialize and market the additional product in the EU and certain other countries. If STADA grants us a non-exclusive license to import, commercialize and market the additional product, we will be required to reimburse a portion of the milestone payments received for the development of the additional product. Upon expiration of the exclusive license of any AVT02 product in a country, STADA will be granted a worldwide, non-exclusive license to manufacture the additional product for sale in such country. </span></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the completion of development of the additional product, STADA may terminate its rights to the additional product upon 10 days written notice. Upon such termination, we would no longer be eligible for payments for the subsequent completion of milestones for the additional product. </span></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 19 May 2023, Alvotech entered into three termination agreements (the &#8220;Termination STADA Agreements&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">with STADA to terminate the license and supply agreements between Alvotech and STADA pertaining to Alvotech&#8217;s</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">product candidates AVT03, AVT05, and AVT16. Pursuant to the terms of the Termination STADA Agreements, Alvotech repaid the aggregate amount of &#8364;17.4 million that Alvotech had previously received from STADA under the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Terminated STADA Agreements. Any and all rights, title and/or interest in respect of the products which became jointly</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">owned as a result of the Agreements with STADA, excluding any trademarks of STADA and/or any of its affiliates,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">fully reverted back to the entire and sole ownership alone by Alvotech. STADA has no further rights or licenses under the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Terminated STADA Agreements. The other agreements between Alvotech and STADA, that pertain to AVT02, AVT04 and AVT06, were not terminated or amended.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of these agreements, STADA made upfront payments of $4.9 million and $62.4 million in development milestone payments up to 31&#160;December 2023. Additionally, we are eligible to receive aggregate payments of up to an additional $57.2 million upon the achievement of certain, regulatory, commercial, manufacturing and sales milestones. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Europe - Advanz</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 6 February 2023, Alvotech announced that it had entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23, a proposed biosimilar to Xolair (omalizumab).  The agreement covers the European Economic Area, UK, Switzerland, Canada, Australia and New Zealand. According to the agreement, Alvotech will be responsible for development and manufacture, while Advanz Pharma will handle registration and commercialization.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On 24 May 2023, Alvotech announced that the two companies had extended their exclusive partnership agreement, adding the supply and commercialization of five biosimilar candidates in Europe. Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe. The agreement includes candidate biosimilars to Simponi (golimumab) and Entyvio (vedolizumab) and also includes three additional early-stage, undisclosed biosimilar candidates. In conjunction with this agreement, which includes three biosimilar candidates previously licensed to STADA, Advanz Pharma agreed to make upfront payments of $61 million and agreed to make additional payments for an aggregate amount of up to $287.5 million, upon the achievement of certain development and commercial milestones,</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Under the terms of these agreements, Advanz Pharma made upfront payments of $75.3 million and $15.1 million in development milestone payments up to 31&#160;December 2023. Additionally, we are eligible to receive aggregate payments of up to an additional $351.0 million upon the achievement of certain, regulatory, commercial, manufacturing and sales milestones. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Japan &#8211; Fuji Pharma</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 2 April 2019, Alvotech and Fuji Pharma entered into a license agreement, as amended on June 23, 2020 to reflect a delay in the development process and therefore, among others, amended and restated the milestone payments, (the &#8220;Fuji Pharma AVT04 License Agreement&#8221;) and a supply agreement (the &#8220;Fuji Pharma AVT04 Supply Agreement&#8221;). Under the Fuji Pharma AVT04 License Agreement, Alvotech will develop AVT04 and compile and provide a dossier of data, information and know-how relating to AVT04 to Fuji Pharma. Alvotech retains full ownership of all intellectual property </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rights in AVT04 and the AVT04 dossier. Fuji Pharma has the exclusive right to use the dossier to obtain and maintain regulatory approvals for AVT04 and to import, finish, market, promote, sell and distribute AVT04 in Japan. Fuji Pharma made a one-time payment on the signature date of $4.6 million and will make an additional milestone payment to Alvotech upon the launch of the product, subject to certain conditions. If Fuji Pharma achieves annual sales in excess of certain target volumes, it will pay Alvotech an additional royalty on the net sales above the target. Under the Fuji Pharma AVT04 Supply Agreement, Alvotech will manufacture, supply and deliver the AVT04 product. Fuji Pharma will pay Alvotech a royalty or the applicable floor price, whichever is higher, for the duration of the agreement. All invoices are payable within thirty business days, in U.S. dollar and by wire transfer. The agreements terminate 20 years after the first commercial sale of AVT04 in Japan. They can be terminated by either party if the other party: (i) withholds any monies due to the other party for more than two months; (ii) commits or permits any substantial breach of any material term of the agreement; (iii) has a receiver or administrator appointed in respect of any of its assets or enters into any agreement with its creditors; or (iv) goes into liquidation. The agreements can be terminated by Fuji Pharma if (i) a competing product obtains reimbursement approval (Fuji Pharma AVT04 License Agreement) before AVT04 obtains reimbursement approval; (ii) AVT04 does not obtain reimbursement approval by 30 November 2023; or (iii) AVT04 obtains reimbursement approval at the same time two competing products obtain reimbursement approval. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 18 November 2020, Alvotech and Fuji Pharma entered into four binding term sheets with respect to AVT06, two proposed AVT03 biosimilar products and AVT05. On 10 February 2022, Alvotech and Fuji Pharma expanded their strategic partnership and entered into an additional binding term sheet with respect to a new undisclosed biosimilar candidate currently in early phase development, and in January 2023 we announced the expansion with another undisclosed biosimilar candidate. Under the binding term sheets, Alvotech will develop the product candidates and provide a dossier of data, information and know-how relating to the relevant product to Fuji Pharma. Fuji Pharma has the exclusive right to use the dossier to obtain and maintain regulatory approvals and to import, finish, market, promote, sell and distribute the relevant product in Japan. As of 31 December 2022, Fuji Pharma made one-time payments on the signing dates of the binding term sheets of $3.0 million and agreed to make additional payments upon the achievement of certain regulatory and development milestones. Alvotech and Fuji Pharma will enter into license and supply agreements for each product at a later date, subject to fulfilling of certain conditions related to the development of that product and the absence of the commercial launch of competing products in Japan at that time. Fuji Pharma will exclusively buy the relevant biosimilar candidate from Alvotech at a royalty or the applicable floor price, whichever is higher, for the duration of the agreement. The license and supply agreements will terminate 20 years after the first commercial sale of the relevant product in Japan. They can be terminated by either party in case a party (i) withholds any monies due to the other party for more than two months; (ii) commits or permits any substantial breach of any material term of the agreement; (iii) has a receiver or administrator appointed in respect of any of its assets or enters into any agreement with its creditors; or (iv) goes into liquidation. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In September 2023, Fuji Pharma received marketing approval for AVT04 from the Japanese Ministry of Health, Labor and Welfare. In February 2024, Alvotech announced that, following settlement agreements with the manufacturer of the originator biologics, Johnson &amp; Johnson,  marketing of AVT04 in Japan was expected to commence after the upcoming round of National Health Insurance reimbursement price listings, in May 2024.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Canada &#8211; JAMP Pharma</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">JAMP Pharma has a portfolio with more than 290 molecules and is a leader in the pharmaceutical industry in Canada. In December 2019, Alvotech entered into five license and supply agreements with JAMP Pharma with respect to AVT02, AVT03, AVT04, AVT05 and AVT06. Under the terms of the agreements, Alvotech will develop the product candidates and provide the dossier of data, information and know-how relating to the relevant product candidate to JAMP Pharma. Alvotech retains full ownership of all intellectual property rights in the product candidates and the dossiers. JAMP Pharma has the exclusive right and obligation to use the dossier to try to obtain and maintain regulatory approvals for the relevant product and to market, sell, and distribute the products in Canada. Alvotech will manufacture, supply and deliver the product to JAMP Pharma and JAMP Pharma will exclusively buy the relevant biosimilar candidate from Alvotech at a royalty or the applicable floor price, whichever is higher, for the duration of the agreement. If the agreed remittance is less than the floor price, JAMP Pharma has the option to turn the supply price for that product into a profit share arrangement. All invoices are payable within sixty days, in euros and by wire transfer. The agreements terminate 20 year after the first commercial sale of the relevant product and are subject to certain customary early termination rights. They can be terminated by either party if the other party (i) commits or permits any substantial breach of any material term or provision of the agreement; (ii) has a receiver or administrator appointed in respect of any of its assets, or enter into any arrangement or composition with its creditors; or (iii) goes into liquidation. The agreements can be terminated by JAMP Pharma (i) in case of Phase III study failure; (ii) in case the dossier is delayed by more than 12 months from the target date; (iii) if, following the agreed launch date, Alvotech&#8217;s formulation of the product or the process used in the manufacture of the product violates any third-party patent in Iceland or Canada; (iv) in case of GMP or quality failures hindering registration or launch in the Canada; (v) if Health Canada rejects or does not provide regulatory approval within 18 months of filing; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(vi) if the results of due diligence performed by JAMP Pharma are not satisfactory; (viii) if 50% of the market for the product is not converted to certain product specifications at the time of launch by JAMP Pharma; or (ix) if Alvotech fails to deliver the launch order for the product within 12 months from the placing of the launch and, due to Alvotech&#8217;s non- or late delivery of products, JAMP Pharma is out of stock for more than 12 consecutive months. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, Health Canada granted marketing authorization to JAMP Pharma for AVT02. In April 2022, JAMP Pharma launched AVT02, under the trade name SIMLANDI, in Canada. In November 2023, Health Canada granted marketing authorization to JAMP Pharma for AVT04 under the trade name JAMTEKI. JAMP Pharma launched JAMTEKI in Canada on 1 March 2024. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 29 August 2022, Alvotech and JAMP Pharma entered into additional license and supply agreements on substantially the same terms and thereby expanded their partnership with two additional biosimilar candidates, AVT16 and AVT33. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under these agreements, JAMP Pharma made upfront payments of $18.0 million and $0.5 million in development milestone payments up to 31&#160;December 2023. Additionally, we are eligible to receive aggregate payments of up to an additional $56.2 million upon the achievement of certain regulatory, commercial, manufacturing and sales milestones. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, Alvotech has commercialization partnerships with, among others, Cipla/Cipla Gulf/Cipla Medpro (Australia, New Zealand, South Africa/Africa), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS (Middle East and Africa), Abdi Ibrahim (Turkey), Kamada (Israel), MegaLabs, Stein, Libbs, Tuteur and Saval (Latin America), and Advanz Pharma (EEA, U.K., Switzerland, Canada, Australia and New Zealand). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Kashiv Biosciences for AVT23</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, Alvotech announced that it had entered into an exclusive licensing agreement for AVT23 (also called ADL018), a proposed biosimilar to Xolair (omalizumab), which is currently in clinical development.  The agreement covers all 27 countries of the European Union, the UK, Australia, Canada, and New Zealand. Under terms of the agreement, Alvotech will receive an exclusive license to commercialize AVT23, which will be developed and manufactured by Kashiv Biosciences ("Kashiv"). Kashiv received an upfront payment of $6.0 million and is eligible for subsequent milestone payments up to $34.0 million and royalties.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Material Agreements, Partnerships and Suppliers </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">China Joint Venture </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2018, Alvotech created a 50-50 joint venture with the Joint Venture Partner, Changchun High &amp; New Technology Industries (Group) Inc. ("CCHN") to develop, manufacture and commercialize Alvotech&#8217;s biosimilar medicines in China and for the China market. Pursuant to a joint venture agreement, as amended on 17 February 2019, the Joint Venture Partner is investing $100 million in cash to build a state-of-the-art biologic medicine manufacturing facility in Changchun, and Alvotech is contributing the same value via a combination of additional capital and the granting of market licenses for six of its biosimilar medicines in the China market under a separate technology license contract. These capital contributions are made in installments pursuant to the contribution schedule in the joint venture agreement. There are no other anticipated payments under the joint venture agreement aside from the aforementioned capital contributions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31 December 2023, Alvotech is in discussions with CCHN to buy back Alvotech's interests in the joint venture. See further information on the accounting considerations for the China JV in note 27 of the consolidated financial statements included elsewhere in this 20-F.</span></div><div style="margin-top:18pt;padding-left:27pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. AbbVie Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 8 March 2022 Alvotech entered into the AbbVie U.S. Agreement with AbbVie Inc. and AbbVie Biotechnology Ltd with respect to AVT02 for the U.S. market. Pursuant to the settlement component of the AbbVie U.S. Agreement, the parties agreed to stipulate to the dismissal of all claims, counterclaims and potential claims in the pending litigation, with each party to bear its own fees and costs, in the U.S. For more information about the U.S. litigation that was terminated, please refer to &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 8.A Consolidated Statements and Other Financial Information&#8212;Legal Proceedings&#8212;U.S. Litigations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; The parties further agreed to release each other from certain claims and demands. Under the licensing component of the AbbVie U.S. Agreement, AbbVie granted Alvotech a license effective 1 July 2023 to make, import, use, distribute, sell and offer for sale AVT02 in the U.S. and a license to manufacture, import and store a reasonable amount of AVT02 in anticipation of the commercial launch of AVT02 in the U.S. Under the agreement, Alvotech may sublicense </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">certain rights to Teva, as a commercialization partner, and may also sublicense to other parties subject to certain conditions. In return, Alvotech is obligated to pay a royalty to AbbVie in the single-digits of the net sales of AVT02 in the U.S. The agreement does not provide for upfront or milestone payments. The obligation of Alvotech to pay royalties shall terminate on the earlier of (i) 11 February 2025; or (ii) a determination that licensed patents are invalid or unenforceable, at which time the license granted will be deemed fully paid up and irrevocable. Each party has the right to terminate the agreement upon breach of certain terms of the agreement that remains uncured for a certain period of time. Additionally, AbbVie may terminate the agreement if Alvotech takes certain actions concerning the patentability, validity, or enforceability of AbbVie&#8217;s patents in the U.S. with respect to AVT02. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">European AbbVie Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 4 April 2022, Alvotech entered into the European AbbVie Agreement with AbbVie Biotechnology Ltd with respect to the sale of AVT02 in Europe and selected markets outside of Europe (the &#8220;European AbbVie Agreement&#8221;). Pursuant to the settlement component, the parties resolved all intellectual property disputes between Alvotech and AbbVie relating to AVT02 in those territories. For more information about those legal disputes, please refer to &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 8.A Consolidated Statements and Other Financial Information&#8212;Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; The parties further agreed to release each other from certain claims and demands. Under the licensing component of the European AbbVie Agreement, AbbVie granted Alvotech a license effective immediately to make, import, use, distribute, sell and offer for sale AVT02 in Europe and selected markets outside of Europe. Under the agreement, Alvotech may sublicense certain rights to STADA, as a commercialization partner, and may also sublicense to other parties subject to certain conditions. In return, Alvotech is obligated to pay royalties to AbbVie with respect to certain indications that are covered by AbbVie patents, on an indication-by-indication and territory-by-territory basis. For purposes of calculating royalties due under the agreement, the parties agreed that in any territory, a certain percentage of AVT02 sold in such territory is covered by the indication, bringing the effective royalty rate in the single-digit to low-teens percentage range of net sales of AVT02 in the territories. The agreement does not provide for upfront or milestone payments. The royalty payments terminated or will terminate, on an indication-by-indication basis, on 5 June 2022, 11 April, 2025, and 3 June 2031, respectively, at which time the license granted for that indication will be deemed fully paid up and irrevocable. Alvotech&#8217;s royalty obligation will terminate earlier if, on a territory-by-territory and indication-by-indication basis, no valid AbbVie patent rights remain. Each party has the right to terminate the agreement upon breach of certain terms of the agreement that remains uncured for a certain period of time. Additionally, AbbVie may terminate the agreement if Alvotech takes certain actions concerning the patentability, validity, or enforceability of AbbVie&#8217;s patents in Europe with respect to AVT02. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended 31&#160;December 2023, we paid $1.7 million in royalties to AbbVie. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our focus on biosimilars, investment in our platform, and global market reach endow us with a differentiated set of strategic advantages in the dynamic and competitive biosimilars marketplace. These features include substantial control over quality and capacity allocation; the ability to find and exploit operational and process efficiencies across R&amp;D and manufacturing; and the agility to rapidly, flexibly and efficiently pivot to new opportunities to advance a broad portfolio of product candidates. We believe these advantages expand our opportunity and support our commercial and medical goals of accelerating the development of cost-effective biosimilars that are as close to the reference products as possible, and then getting them to the patients around the world who need them. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The specific characteristics of the competitive landscape for each of our publicly announced product development programs include but are not limited to: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVT02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We expect AbbVie (the originator) as well as Amgen, Boehringer Ingelheim GmbH, Biocon/FujiFilm, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Coherus, and Sandoz to be our main competitors for AVT02, a biosimilar product candidate to Humira (adalimumab). Most of these companies have either launched or disclosed development plans for a 50 mg/mL Humira biosimilar in the U.S., EU, or both, as well as in some other global markets. Celltrion, Sandoz and Alvotech are the only companies with regulatory approval in the EU for a 100 mg/mL biosimilar version of adalimumab. In the US, Amgen, Samsung Bioepis, Celltrion and Sandoz received approval from FDA for a 100 mg/mL biosimilar version of adalimumab and Boehringer Ingelheim has a BLA pending FDA approval. Companies that announced plans to seek U.S. interchangeability designation for a 100 mg/mL biosimilar version of adalimumab include Amgen, Samsung Bioepis, and Celltrion. On 23 February 2024, the FDA gave market U.S. approval to AVT02 under the tradename SIMLANDI, and announced that SIMLANDI qualified for interchangeability designation and with exclusivity in the U.S. market for an undetermined length of time. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVT04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We expect Janssen (the originator) as well as Amgen, Celltrion, Bio-Thera, Formycon, Dong-A/Meiji Seika, Samsung Bioepis and Biocon to be our main competitors for AVT04, a biosimilar candidate to Stelara (ustekinumab), all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of which have disclosed development plans for a Stelara biosimilar. Janssen is also attempting to defend against biosimilar competition by expanding the label for Stelara and by launching follow-on drugs. We have reached settlement agreements with the originator to enable launches in the U.S., Europe, Canada and Japan. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVT06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We expect Regeneron (the originator) Amgen, Celltrion, Formycon, Altos, Sam Chun Dang, Samsung Bioepis, Sandoz and Viatris/Biocon to be our main competitors for AVT06, a biosimilar candidate to Regeneron&#8217;s Eylea (aflibercept). As the originator, Regeneron is currently working to expand the label for Eylea and developing higher-concentration formulations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVT03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We expect Amgen (the originator), Sandoz, Celltrion, Fresenius Kabi, Samsung Bioepis, Gedeon Richter, mAbxience, Biocon, Henlius and Teva to be our main competitors for AVT03, a biosimilar candidate to Prolia/Xgeva (denosumab), as they have all disclosed development plans for a Prolia/Xgeva biosimilar. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVT05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We expect Janssen (the originator), and Bio-Thera to be our main competitors for AVT05, a biosimilar candidate to Janssen&#8217;s Simponi (golimumab). The originator, Janssen, is solidifying the reference product&#8217;s market position by actively expanding the label and by winning approvals in Japan and China. We believe that the originator&#8217;s success in expanding the market for the reference product will prove to be a benefit to AVT05&#8217;s commercial positioning. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVT23.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We expect Genentech (the originator), Celltrion and Teva to be our main competitors for AVT23, a biosimilar candidate to Genentech&#8217;s Xolair (omalizumab), as they have all disclosed development plans for a Xolair biosimilar. As the originator, Genentech is currently working to expand the label for Xolair. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The branded pharmaceutical industry relies on patent protection as one of several means to maintain exclusivity on the market. As a biosimilar-focused company, our success will depend in part on our ability to avoid infringement of, to invalidate, and/or to license any relevant and material intellectual property rights of third parties. We expect all branded companies that market products in which we are developing a biosimilar to vigorously protect what they view as their proprietary rights. We fully understand that efforts to market our products may result in patent litigation, which may determine whether a particular patent at issue is valid and whether We have infringed such a patent. Timelines for resolution to patent disputes are difficult to estimate and are very specific to a particular situation (including, for example, the jurisdiction). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our principal focus in matters relating to intellectual property is to avoid infringing the valid and enforceable rights of third parties, we also use a combination of intellectual property protection and confidentiality agreements to protect our own intellectual property related to our product candidates and development programs. We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including by seeking, maintaining, enforcing and defending trademarks, trade secrets, patent rights, and other intellectual property rights for our products and processes, whether developed internally or licensed from third parties. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are actively building our own intellectual property portfolio around our product candidates and platform technologies, including our manufacturing processes, and intend to identify and obtain, directly or through a license, as appropriate, patents that provide protection to our intellectual property and technology base. With respect to these pending and any future applications, we cannot be sure that patents will be granted in any or all jurisdictions, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products. In addition to patents, We also rely on trademarks, trade secrets, know-how, continuing technological innovation, confidentiality agreements, and IP assignment agreements in place with our employees to develop and maintain our proprietary position and ensure the future commercial success of our products. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulatory Landscape </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Regulation and Product Approval </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government authorities at the federal, state and local level in the United States and in other countries extensively regulate, among other things, the research, development, testing, clinical trials manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in other countries, along with subsequent obligation of compliance with applicable statutes and regulations, can vary widely and can require the expenditure of substantial time and financial resources. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">FDA Approval Process </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of our current product candidates are subject to extensive pre- and post-market regulation in the United States by the FDA as biological products, or biologics. The Public Health Service Act, or PHSA, the Federal Food, Drug and Cosmetic Act, or FFDCA, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, post-approval changes, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending Biologics License Applications, or BLAs, withdrawal of approvals or revocation or suspension of licenses, clinical holds, warning letters, product recalls, product seizures, injunctions, fines, civil penalties or criminal penalties. The PHSA and its implementing regulations provides FDA authority to immediately suspend licenses in certain situations where FDA determines that there exists a danger to health, and to promulgate and enforce regulations to prevent the introduction or spread of communicable diseases in the United States and between states. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The process required by the FDA before a new biologic may be marketed in the United States is long, expensive and inherently uncertain. In order to establish the safety, purity and potency (effectiveness) of the biologic, biologics development in the United States typically involves, among other things, pre-clinical laboratory and animal tests, the submission to the FDA of an investigational new drug application, or IND, which must become effective before U.S. clinical investigations in humans may commence, and adequate and well-controlled clinical trials to establish the safety, purity and potency of the biologic for the conditions of use for which FDA approval is sought. Developing the data to satisfy FDA approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pre-clinical tests include laboratory evaluation of product chemistry, formulation and toxicology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the pre-clinical tests must comply with federal regulations and requirements, including good laboratory practices. An IND must be submitted to the FDA to administer an investigational new drug to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies, although the IND must also include safety data, e.g., the results of pre-clinical testing and animal testing assessing the toxicology and pharmacology of the product along with other information, including information about product chemistry, manufacturing and controls and a proposed clinical trial protocol. Long term pre-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An IND must become effective before United States clinical trials may begin. There is generally a 30-day waiting period after the IND submission, after which clinical investigations can begin, unless the FDA notifies the sponsor of concerns or questions related to a clinical hold. If that happens, the sponsor and the FDA must resolve the hold issue(s) before the clinical investigation can begin. Otherwise, the clinical trial proposed in the IND may begin at the conclusion of this 30-day period. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials involve the administration of the investigational new drug to volunteers or patients all under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with federal regulations on good clinical practice, or GCP, including, for example, regulations regarding the protection of human subjects, defining, the roles of clinical trial sponsors, administrators and monitors, and governing protocols detailing the objectives of the trial and, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA may order the temporary or permanent discontinuation of a clinical trial at any if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients, among other reasons. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or may impose other conditions. The study sponsor may also suspend a clinical trial at any time on various grounds, including a determination that the subjects or patients are being exposed to an unacceptable health risk. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials to support BLAs for regulatory approval of a reference biologic product under the 351(a) pathway are typically conducted in three sequential phases, but the phases may overlap or be combined. In Phase 1, the biologics are initially introduced into patients or healthy human subjects and the biologic is tested to assess the safety/tolerability, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the biologic for a particular indication, dosage tolerance and optimum dosage and to identify common adverse effects and safety risks. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a product candidate demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials are undertaken to obtain additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites. These Phase 3 clinical trials are intended to establish data sufficient to demonstrate substantial evidence of the efficacy and safety of the product to permit the FDA to evaluate the overall benefit-risk relationship of the biologic and to provide adequate information for the labeling of the biologic. Trials conducted outside of the United States under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to the FDA in support of product licensing. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sponsors of clinical trials for investigational drugs generally must publicly disclose certain clinical trial information, including detailed trial design and trial results in a public database administered by the U.S. Department of Health and Human Services. These requirements are subject to specific timelines and apply to most clinical trials of FDA-regulated products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After completion of the required clinical testing in accordance with all applicable regulatory requirements, detailed information regarding the investigational product is prepared and submitted to the FDA in the form of a BLA requesting approval to market the product for one or more indications or conditions of use. FDA review and approval of the BLA is required before marketing of the product may begin in the United States. The BLA will include the results of pre-clinical, clinical and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture and controls and must demonstrate the continued safety, purity, and potency (efficacy) of the product based on these data. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Manufacturing controls and conformance to current good manufacturing practices (&#8220;cGMPs&#8221;) are considered very important for biological products. The BLA must also contain extensive manufacturing information. The FDA will inspect the facility or the facilities at which the biologic is manufactured to ensure conformance to cGMPs. This can include reviewing a firm&#8217;s previous compliance history, using information sharing from trusted foreign regulatory partners through mutual recognition agreements and other confidentiality agreements, requesting records &#8220;in advance of or in lieu of&#8221; facility inspections or voluntarily from facilities and sites, and conducting remote interactive evaluations where appropriate. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most original BLAs is subject to a multi-million dollar application user fee, as well as annual fees, both of which are typically increased annually. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has agreed to certain performance goals in the review of BLAs. First, the FDA has agreed to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to enable substantive review within 60 days from its receipt of a BLA. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA&#8217;s stated goal is to review most original BLA applications for standard review biologics within ten months from the date the application is accepted for filing. Although the FDA often meets its user fee performance goals, the review goal date can be extended in the event of a &#8220;major amendment,&#8221; or can be extended by requests for additional information or clarification, and FDA review may not occur on a timely basis at all. Additionally, as a result of public health emergencies, such as the COVID-19 pandemic, review timelines may be delayed even further. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA often refers applications for novel biologics or biologics which present difficult questions of safety or efficacy, to an advisory committee &#8212; typically a panel that includes clinicians and other experts &#8212; for review, evaluation and a recommendation as to whether the application should be approved and/or specific use and approvability questions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. After the FDA evaluates the BLA, including the facilities listed in the BLA, it issues either an approval letter or a complete response letter. A complete response letter outlines the deficiencies in the submission. Remedying those deficiencies may require substantial additional testing or information in order for the FDA to consider the resubmitted application for approval. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction such that a resubmitted BLA is approvable, the FDA will issue an approval letter. The FDA has committed to user fee goals of reviewing such resubmissions in two or six months depending on the type of information included. The FDA approval is never guaranteed, and the FDA may refuse to approve a BLA if applicable regulatory criteria are not satisfied.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the PHSA, the FDA will approve a BLA if it determines, among other things, that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. The approval for a biologic may be significantly more limited than requested in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">application, including limitations on the specific conditions of use, which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings or precautions be included in the product labeling. In addition, under certain circumstances, the FDA may require a risk evaluation and mitigation strategy, or REMS, as a condition of approval, if necessary to ensure that the benefits of the biologic outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the biologic. Moreover, product approval may include post-marketing commitments and/or post-marketing-requirements, including, for example, pediatric studies, safety monitoring, and Phase 4 trials. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain types of biologics may also be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. After approval of biologics, manufacturers must address any safety issues that arise, may be subject to recalls or a halt in manufacturing under certain circumstances, and are subject to periodic inspection after approval. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because biologically-sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Abbreviated Licensure Pathway of Biological Products as Biosimilars under 351(k) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, amended the PHSA and created an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological products. This pathway was established as a way to provide more treatment options, increase access to lifesaving medications, and potentially lower health care costs through competition. Under the 351(k) (biosimilar) approval pathway, an application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following (unless a specific element is waived by FDA): </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">animal studies (including the assessment of toxicity and immunogenicity); and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, an application submitted under the 351(k) pathway must include information demonstrating that: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the route of administration, the dosage form and the strength of the proposed biosimilar product are the same as those for the reference product; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the biological product continues to be safe, pure, and potent. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biosimilarity, as defined in PHSA &#167;351(i), means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. In addition, section 351(k)(4) of the PHSA provides for a designation of &#8220;interchangeability&#8221; between the reference and biosimilar products if certain additional criteria are met, whereby the biosimilar may be substituted for the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reference product without the intervention of the health care provider who prescribed the reference product. An application seeking licensure as an interchangeable must include information sufficient to demonstrate that: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the proposed product is biosimilar to the reference product; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the proposed product is expected to produce the same clinical result as the reference product in any given patient; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">for a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As with other biological products, FDA approval of a BLA is required before a biosimilar may be marketed in the United States. Biosimilar BLAs (or &#8220;351(k) BLAs&#8221;) are not required to duplicate the entirety of the data package used to establish the safety and effectiveness of the reference product. Rather, a 351(k) BLA will be approved based on a demonstration of biosimilarity to the reference product, including the information outlined above, and does not require an independent showing of safety and effectiveness. Because a biosimilar can rely in part on FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, biosimilar applicants generally do not need to conduct as many clinical trials. Biosimilar products also may be approved for an indication without direct studies of the biosimilar in that indication, with sufficient scientific justification for extrapolation. However, the FDA may not approve a 351(k) BLA if there is insufficient information to show that the biosimilar is &#8220;highly similar&#8221; to the reference product or that there are no clinically meaningful differences between the biosimilar product and the reference product. In addition, as with innovator BLAs, biosimilar BLAs will not be approved unless the product is manufactured in facilities designed to assure and preserve the biological product&#8217;s safety, purity and potency. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The process for filing and review of a BLA submitted through the 351(k) pathway is very similar to that of a BLA submitted through the 351(a) pathway, although there is a period of statutory exclusivity during which time the FDA is precluded from filing a 351(k) BLA that references a protected reference product. Subsequently, the FDA will accept the application for filing if it meets the regulatory criteria. The FDA may refuse to file applications that it finds are incomplete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons, any applicable user fees assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case the sponsor may choose to conduct further analytical, preclinical or clinical studies and resubmit the BLA to demonstrate biosimilarity under section 351(k). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for 12 years from the date of first licensure of the reference product. A reference product may also be entitled to exclusivity under other statutory provisions. For example, a reference product with orphan drug exclusivity for a particular orphan &#8220;disease or condition&#8221; may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved until either the end of the 12-year period provided under &#167;351(k)(7), and no biosimilar may be approved for the orphan disease or condition until the end of the seven-year orphan drug exclusivity period. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent and thus block &#167;351(k) applications from being approved on or after the patent expiration date. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The first biological product determined to be interchangeable with a branded reference product for any condition of use is also eligible for a period of exclusivity, during which time the FDA may not determine that another product is interchangeable with the same reference product for any condition of use. This exclusivity period lasts until the earlier of: (1) one year after the first commercial marketing of the first interchangeable product; (2) 18 months after resolution of a patent infringement suit instituted under 42 U.S.C. &#167; 262(l)(6) against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; (3) 42 months after approval of the first interchangeable product, if a patent infringement suit instituted under 42 U.S.C. &#167; 262(l)(6) against the applicant that submitted the application for the first interchangeable product is still ongoing; or (4) 18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued under 42 U.S.C. &#167; 262(l)(6). </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Advertising and Promotion </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FFDCA prohibits the marketing, promotion, or advertising of an investigational drug as if it has been demonstrated to be safe and effective for the uses for which it is being studied. Once a BLA is approved, a product will be subject to continuing post-approval regulatory requirements, including, among other things, requirements relating to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse events. For instance, the FDA closely regulates the post-approval advertising, marketing and promotion of drugs, including biologics, including, for example, direct-to-consumer advertising, off-label promotion, and industry-sponsored scientific and educational activities. Violations of the FDA&#8217;s requirements around advertising, marketing, and promotion of drugs can result in significant enforcement activities, including the issuance of warning letters or untitled letters, which may direct a company to correct deviations from FDA, and federal and state investigations, which can lead to civil and criminal penalties, lawsuits, and prosecutions. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As with all drugs, biologics may be marketed only as consistent with FDA-approved labeling. After approval, most changes require submission and FDA approval supplemental BLA before the change can be implemented. This includes changes to labeling or manufacturing processes (including changes to facilities), which typically require prior approval of a supplement. A supplement for a 351(a) BLA seeking to add a new indication typically requires new clinical data, and the FDA generally uses the same procedures and actions in reviewing BLA supplements with clinical data as it does in reviewing BLAs. There are also continuing reporting requirements for marketed drug products. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adverse Event Reporting and GMP Compliance </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to regular periodic reports following FDA approval of a BLA and compliance with any post-marketing commitments or post-marketing requirements, license-holders also must comply with adverse event reporting requirements and must continue to conform to cGMPs, as described above. Manufacture, packaging, labeling, storage, and distribution procedures must continue to conform to cGMP after approval, and FDA conducts periodic surveillance inspections intended to ensure such ongoing compliance. Biologics manufacturers and their manufacturing subcontractors are generally required to register their establishments with the FDA and certain state agencies. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Post-approval discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency or issues with manufacturing processes or cGMP compliance, or other failures to comply with regulatory requirements, may lead the FDA to, for example: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">require revisions to approved labeling to add new safety information; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">require post-market studies to assess new safety risks; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">issue fines, warning letters, or untitled letters; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">place post-approval clinical trials on hold; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">detain or refusal to permit the import or export of products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">request voluntary calls; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">seek injunctions, civil forfeiture, civil money penalties, or other civil relief; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">seek criminal penalties or prosecution. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under certain circumstances, FDA may initiate proceedings to suspend or revoke a license or recall the product from the market. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Healthcare Laws and Compliance Requirements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we currently do not have any products on the market or engage with any licensed health care providers in the United States, our current and future business operations are subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we conduct our business. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal Anti-Kickback Statute (&#8220;AKS&#8221;) prohibits any individual or entity from knowingly and willfully offering or paying &#8220;remuneration,&#8221; directly or indirectly, overtly or covertly, in cash or in kind to induce another individual or entity to: (a) refer an individual to a person for the furnishing (or arranging for the furnishing) of any item or service for which payment may be made under a federal health care program; (b) purchase or order any covered item or service; (c) arrange for the purchase or order of any covered item or service; or (d) recommend the purchase or order of any covered item or service. It also is illegal under the Anti-Kickback Statute to solicit or receive remuneration for such purposes. &#8220;Remuneration&#8221; is generally defined to include any transfer of value, in cash or in kind, including gifts or free product, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">meals, discounts, rebates, and other price concessions. Courts have broadly construed the AKS to include virtually anything of value given to an individual or entity if one purpose of the remuneration is to influence the recipient&#8217;s reason or judgment relating to referrals. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are statutory exceptions and regulatory safe harbors specifying certain payment practices that will not be considered to violate the AKS. Such exceptions and safe harbors include, among others, protection for payments for personal services and management contracts, and for certain discounts. If a payment practice falls squarely within one of the exceptions or safe harbors, it will be immune from criminal prosecution and civil exclusion under the AKS. Importantly, the failure of an arrangement to fall within a statutory exception or regulatory safe harbor does not mean that it necessarily violates the AKS; however, the legality of such arrangements may be closely scrutinized by federal authorities on a facts and circumstances basis and are not protected. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, states have enacted similar kickback statutes that may apply to healthcare services reimbursed by private insurance, not just those reimbursed by a federal or state health care program. The specific scope of these laws vary. However, in many instances, activities that are protected from scrutiny under the federal statute would not violate the state statutes. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, pursuant to changes made under the PPACA, any claims submitted to Medicare or Medicaid as a result of an illegal kickback constitutes a false or fraudulent claims under the federal False Claims Act (&#8220;FCA&#8221;). Additionally, the ACA amended the intent requirement of the AKS so that a person or entity no longer needs to have actual knowledge of the AKS, or the specific intent to violate it, to have violated the statute. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The civil false claims laws, including the FCA, prohibits, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the FCA may be brought by the government or as a qui tam action by a private individual in the name of the government. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free products to customers with the expectation that the customers would bill federal programs for the products; providing consulting fees and other benefits to physicians to induce them to prescribe products;  and engaging in promotion for unapproved uses. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal Health insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created additional federal criminal statutes that prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of some of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. For instance, the federal Physician Payments Sunshine Act (&#8220;Sunshine Act&#8221;) requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments or other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors, other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals and to report annually specified ownership and investment interests held by physicians and their immediate family members. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) and their implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity and their covered subcontractors. HITECH also </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The shifting commercial compliance environment and the need to build and maintain robust systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may violate one or more of the requirements. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil, and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">International Regulation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, marketing authorization procedures and commercial sales and distribution of pharmaceutical products. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval. In the EU, the approval of a biosimilar for marketing is based on an opinion issued by the European Medicines Agency, or EMA, and a related decision issued by the European Commission. However, the subsequent substitutability of a reference medicinal product for the biosimilar is a decision that is made at the national level on a country-by-country basis in individual EU Member States. Other regions, including Canada, Japan and Korea, also have their own regulatory pathways governing the approval and marketing of biosimilars. Some third countries (such as Singapore and Malaysia) have adopted EU guidance. Other countries (such as (Cuba and Brazil) follow guidance issued by the World Health Organization. While there are some similarities between the regulatory requirements across regions, some areas of substantial difference remain. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Trials in the EU </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014, or CTR, which entered into application on 31 January 2022, repealing and replacing the former Clinical Trials Directive 2001/20, or CTD, and related national implementing legislation of EU Member States. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increasing their transparency. Specifically, the Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the EU portal, the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The extent to which on-going clinical trials will be governed by the CTR will depend on the duration of the individual clinical trial. Sponsors could choose to submit a clinical trial application under either the CTD or the CTR until 31 January 2023. For clinical trials in relation to which application for approval was made on the basis of the CTD before 31 January 2023, if authorized, those clinical trials will be governed by the CTD until 31 January 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the clinical trial has already transitioned to the CTR framework. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">EU Review and Approval Process </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, medicinal products can only be commercialized after a related marketing authorization, or MA, has been granted. A company may submit a marketing authorization application, or MAA, either on the basis of the centralized, or decentralized procedure or mutual recognition procedure. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To obtain an MA for a product in the EU, which is valid throughout the EEA, an applicant must submit an MAA either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The centralized procedure provides for the grant of a single MA by the European Commission that is valid for all EU Member States. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs, and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EU Member States. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the eCTD (Common Technical Document) providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five-year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i) the benefit-risk balance of the medicinal product is positive; (ii) it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii) the medicinal product fulfils an unmet medical need; and (iv) the benefit of the immediate availability to patients of the medicinal product is greater than the risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA and approved by the European Commission, the MA will cease to be renewed. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA will be withdrawn if the risk-benefit ratio is no longer favorable. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Post-approval Requirements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. Although general requirements for advertising and promotion of medicinal products are established under EU legislation, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">with the SmPC is considered off-label and is prohibited in the EU. Direct-to-consumer advertising of prescription medicinal products is also prohibited in the EU. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Data and marketing exclusivity </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The EU also provides opportunities for market exclusivity. Upon receiving an MA in the EU, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from referencing the innovator&#8217;s pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization during a period of eight years from the date on which the reference product was first authorized in the EU. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity period. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for marketing authorization. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pediatric Development </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, Regulation (EC) No 1901/2006 provides that all marketing authorization applications for new medicinal products must include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which marketing authorization is being sought. The PDCO may grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Furthermore, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six-month extension to the Supplementary Protection Certificate, or SPC, if any is in effect at the time of authorization or, in the case of orphan medicinal products, a two-year extension of orphan market exclusivity. For other countries outside of the EU, such as certain countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product approval, pricing and reimbursement vary from country to country. In all cases, the clinical trials are to be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pharmaceutical Coverage, Pricing and Reimbursement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S. and other countries, sales of our products will depend on the availability and extent of coverage and reimbursement from third-party payors, including government healthcare programs and private insurance plans. Patients who are provided medical treatment for their conditions generally rely on third party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, or comparable foreign programs and commercial payors are critical to new product acceptance. Governments and private payors continue to pursue initiatives to manage drug utilization and contain costs. These payors are increasingly focused on the effectiveness, benefits, and costs of similar treatments, which could result in lower reimbursement rates for our products or narrower populations for whom payors will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payor dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which could adversely affect our business. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S., no uniform product coverage and reimbursement policy exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Obtaining coverage and reimbursement approval of a product from a government or other third-party payor can be a time-consuming and costly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">process that can require provision of supporting scientific, clinical and cost-effectiveness data, with no assurance that coverage or specific levels of reimbursement will be obtained. Third-party payors are increasingly examining the medical necessity and cost-effectiveness of products and services in addition to their safety and efficacy. Accordingly, significant uncertainty exists as to the reimbursement status of newly approved products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Both private and government payors use formularies to manage access and utilization of drugs. A drug&#8217;s inclusion and favorable positioning on a formulary are essential to ensure patients have access to a particular drug. Even when access is available, some patients abandon their prescriptions for economic reasons. Third-party payors continue to institute cost reduction and containment measures that lower drug utilization and/or spending altogether and/or shift a greater portion of the costs to patients. Such measures include, but are not limited to, more-limited benefit plan designs, higher patient co-pays or coinsurance obligations, limitations on patients&#8217; use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs), stricter utilization management criteria before a patient may get access to a drug, higher-tier formulary placement that increases the level of patient out-of-pocket costs and formulary exclusion, which effectively encourages patients and providers to seek alternative treatments or pay 100% of the cost of a drug. The use of such measures by pharmacy benefit managers (&#8220;PBMs&#8221;) and insurers has continued to intensify and could limit use and sales of our products. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Over the past few years, many PBMs and insurers have consolidated, resulting in a smaller number of PBMs and insurers overseeing a large portion of total covered lives in the United States. As a result, PBMs and insurers have greater market power and negotiating leverage to mandate stricter utilization criteria and/or exclude drugs from their formularies in favor of competitor drugs or alternative treatments. In highly competitive treatment markets, PBMs are also able to exert negotiating leverage by requiring incremental rebates from manufacturers in order for them to gain and/or maintain their formulary position. Moreover, third-party coverage policies and reimbursement rates are dynamic, meaning that our products could be subject to less favorable coverage policies and/or reimbursement rates over time, making prospective reimbursement and coverage status of our products difficult to predict. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Other countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, some EU Member States may approve a specific price for a product, or they may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many EU Member States have increased the amount of discounts that pharmaceutical companies are requirement to offer. These efforts could continue as countries attempt to manage healthcare expenditures. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products onto national markets. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Healthcare Reform </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Like third-party payors, the U.S. federal government, state legislatures and foreign governments have continually implemented cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for generic substitution. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. State laws may permit or require substitution of interchangeable products, too, when approved interchangeable products are available in the future. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit our net revenue and results. Decreases in third-party reimbursement for our products or decisions by certain third-party payors to not cover specific products, or implement coverage restrictions (e.g. prior authorization, step-edit requirements) could reduce provider utilization and have a material adverse effect on sales, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S. and some other countries, particularly over the past few years, a number of legislative and regulatory proposals have been introduced in an attempt to lower drug prices and restrict or regulate post-approval activities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S., in addition to market actions taken by private and government payors, there has been heightened government, media, and public scrutiny over the manner in which drug manufacturers set prices for their marketed products, resulting in several presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on 9 September 2021, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA directs the HHS Secretary to establish a Drug Price Negotiation Program to lower prices for certain high-expenditure, single-source prescription drugs and biologics covered under Medicare Part B and Part D that have been approved by the FDA for at least 7 years for prescription drugs and at least 11 years for biologics. Under the Program, the HHS Secretary will publish a list of &#8220;selected drugs,&#8221; and will then negotiate maximum fair prices with their manufacturers. The Program will be implemented in stages. Beginning in 2026, 10 Medicare Part D &#8220;selected drugs&#8221; will be subject to price negotiations. By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and biologics covered under Medicare Part B and Part D. Agreements between HHS and manufacturers will remain in place until a drug or biologic is no longer considered a &#8220;selected drug&#8221; for negotiation purposes. Manufacturers who do not comply with the negotiated prices set under the Program will be subject to an excise tax based on a percentage of total sales of a &#8220;selected drug&#8221; up to 95% and potential civil monetary penalties. On 29 August 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, including Stelara, the reference product for AVT04, although the Medicare drug price negotiation program is currently subject to legal challenges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, beginning in October 2023, the IRA will require manufacturers that increase prices of certain Medicare Part B and Part D drugs or biologics at a rate greater than inflation to pay rebates to the Centers for Medicare &amp; Medicaid Services or be subject to civil monetary penalties. The IRA also provides certain incentives for the development and manufacture of biosimilars. For example, the Secretary can grant a one-year delay from price negotiations for biosimilars that have a &#8220;high likelihood&#8221; of a competing biosimilar product entering the market within the requested delay period. In addition, certain Part B biosimilars qualify for an increase in Medicare payments, to 8% of the 5-year Average Sales Price, from 6% under current law. The HHS Secretary has been directed to promulgate regulations to implement the Program and other IRA health reform measures. In response to the Biden administration&#8217;s October 2022 executive order, on 14 February 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In this dynamic environment, we are unable to predict which or how many government policy, legislative, regulatory, executive or administrative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that these or other federal government initiatives further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our products, or limit our ability to offer co-pay payment assistance to commercial patients, such actions could have a material adverse effect on our business and results of operations. Individual states have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In many countries outside the United States, government-sponsored healthcare systems are the primary payors for drugs. With increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payors in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls; price referencing; therapeutic-reference pricing; increases in mandates; incentives for generic substitution and biosimilar usage and government-mandated price cuts. In this regard, many countries have health technology assessment agencies that use formal economic metrics such as cost-effectiveness to determine prices, coverage and reimbursement of new therapies; and these agencies are expanding in both established and emerging markets. For example, some EEA countries may require the completion of studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies. This Health Technology Assessment, or HTA, process is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. In December 2021 the EU HTA Regulation was adopted. The purpose of the Regulation is to introduce joint clinical assessments at EU level. When it enters into application in 2025 the Regulation will be intended to harmonize the clinical benefit assessment of HTA across </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the EU. Many countries also limit coverage to populations narrower than those specified on our product labels or impose volume caps to limit utilization. We expect that countries will continue taking aggressive actions to seek to reduce expenditures on drugs. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Brexit </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The UK, withdrawal from the EU on 31 January 2020, commonly referred to as Brexit, has created significant uncertainty concerning the future relationship between the UK and the EU. The Medicines and Healthcare products Regulatory Agency ("MHRA"), is now the UK&#8217;s standalone regulator. On 24 December 2020, the EU and UK reached an agreement in principle on the framework for their future relationship, the EU-UK Trade and Cooperation Agreement, or Agreement. The Agreement primarily focuses on ensuring free trade between the EU and the UK in relation to goods, including medicinal products. Although the body of the Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Among the changes that will now occur are that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. As part of the Agreement, the EU and the UK will recognize GMP inspections carried out by the other party and the acceptance of official GMP documents issued by the other party. The Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to accept EU batch testing and batch release. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). However, it is currently unclear to what extent the UK will seek to align its regulations with the EU following entry into application of the Clinical Trials Regulation on 31 January 2022. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Marketing authorizations in the UK are governed by the Human Medicines Regulations (SI 2012/1916), as amended. Since 1 January 2021, an applicant for the EU centralized procedure marketing authorization can no longer be established in the UK. As a result, since this date, companies established in the UK cannot use the EU centralized procedure and instead must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain a marketing authorization to market products in the UK. All existing EU marketing authorizations for centrally authorized products were automatically converted or grandfathered into UK marketing authorization, effective in Great Britain only, free of charge on 1 January 2021, unless the marketing authorization holder opted-out of this possibility. Northern Ireland currently remains within the scope of EU authorizations in relation to centrally authorized medicinal products. Accordingly, until the Windsor Framework is implemented in Northern Ireland on 1 January 2025, products falling within the scope of the EU centralized procedure can only be authorized through UK national authorization procedures in Great Britain.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The MHRA has also introduced changes to national marketing authorization procedures. This includes introduction of procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment route, a rolling review procedure and the International Recognition Procedure. Since 1 January, 2024, the MHRA may rely on the International Recognition Procedure, or IRP, when reviewing certain types of marketing authorization applications. This procedure is available for applicants for marketing authorization who have already received an authorization for the same product from a reference regulator. These include the FDA, the EMA, and national competent authorities of individual EEA countries. A positive opinion from the EMA and CHMP, or a positive end of procedure outcome from the mutual recognition or decentralized procedures are considered to be authorizations for the purposes of the IRP.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is no pre-marketing authorization orphan designation for medicinal products in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same as those in the EU, but have been tailored for the market. This includes the criterion that prevalence of the condition in Great Britain, rather than the EU, must not be more than five in 10,000. Upon the grant of a marketing authorization with orphan status, the medicinal product will benefit from up to 10 years of market exclusivity from similar products in the approved orphan indication. The start of this market exclusivity period will be set from the date of first approval of the product in Great Britain.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Data Privacy and Security </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to stringent and evolving United States and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security, including the EU&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;) and the United Kingdom&#8217;s General Data Protection Regulation (&#8220;UK GDPR&#8221;). New privacy rules are being enacted in the United States and globally, and existing ones are being expanded, updated and strengthened. For example, the EU GDPR which went into effect in May 2018 introduced strict requirements regarding the processing of personal data, including health-related data. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The collection and use of personal health data in the EEA is governed by the EU GDPR, which became effective on 25 May 2018. The EU GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The EU GDPR enhances data protection obligations for controllers and processors of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct privacy impact assessments for high-risk processing, limitations on retention of personal data and mandatory data breach notification and privacy by design requirements, and creates direct obligations on service providers acting as data processors. The EU GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, such as the U.S. Failure to comply with the requirements of the EU GDPR and the related national data protection laws of the EEA countries may result in fines up to 20 million Euros or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the EU GDPR grants data subjects the right to claim compensation for damages resulting from infringement of the EU GDPR. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the United Kingdom&#8217;s withdrawal and the expiration of the transition period, from 31 January 2020, companies doing business in the EU and the UK will be obliged to comply with both the GDPR and the UK GDPR. The UK has implemented legislation similar to the EU GDPR, the UK GDPR, including the UK Data Protection Act, which provides for fines of up to the greater of 17.5 million British Pounds or 4% of a company&#8217;s worldwide turnover, whichever is higher. Additionally, the relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear following Brexit, including with respect to regulation of data transfers between EU Member States and the UK. On 28 June 2021, the European Commission announced a decision of &#8220;adequacy&#8221; concluding that the UK ensures an equivalent level of data protection to the EU GDPR, which provides some relief regarding the legality of continued personal data flows from the EEA to the UK. Some uncertainty remains, however, as this adequacy determination must be renewed after four years and may be modified or revoked in the interim. We cannot fully predict how the Data Protection Act, the UK GDPR, and other UK data protection laws or regulations may develop in the medium to longer term nor the effects of divergent laws and guidance regarding how data transfers to and from the UK will be regulated. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Organizational Structure </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Structure </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following diagram illustrates our corporate structure as of 31&#160;December 2023. </span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><img src="alvo-20231231_g1.jpg" alt="Image02.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:599px"/></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech hf., Alvotech Manco ehf., and Fasteignaf&#233;lagi&#240; S&#230;mundur hf. are incorporated in Iceland; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech Malta Limited is incorporated in Malta; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech UK Ltd. is incorporated in the United Kingdom; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech Hannover GmbH and Alvotech Germany GmbH are incorporated in Germany; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech Swiss AG is incorporated in Switzerland; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech USA Inc. is incorporated in Virginia, United States; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech Biosciences India Private Limited is incorporated in India. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech hf. also has a 50% stake in a joint venture, Alvotech &amp; CCHN Biopharmaceutical Limited Liability Company, which is incorporated in China and is not reflected in the above organizational chart. Alvotech is in discussions with CCHN to buy back Alvotech's interests in the joint venture.</span></div><div id="ie527079dad0a4810aa92569387637e3d_55"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">Property, Plants and Equipmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">t </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our office, research, laboratory and manufacturing facilities, including the ongoing expansion of the Reykjavik facility, are sufficient to meet our current needs. However, as a high-growth company we are constantly evaluating our needs for expanding and or adding to our facilities. We are not aware of, and do not anticipate, environmental issues that may affect our utilization of the facilities described below. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registered Office in Grand Duchy of Luxembourg </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our registered office is at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg, where it has approximately 19 square meters of office space. This location is used for administrative functions only. We are currently leasing this office space. The lease expires in August 2023 but the agreement provides for automatic renewal for one year until termination of the agreement. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Offices and Manufacturing Facility in Iceland </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our corporate headquarters, main manufacturing site and a large part of our R&amp;D division are located in Reykjavik, Iceland. This facility, which we own through a subsidiary, provides us with purpose-built GMP, and has highly integrated capabilities for producing biosimilars at scale. The facility is currently approximately 140,000 square feet and utilizes single-use technology to manufacture drug substance and drug product. It houses our R&amp;D, quality control and quality assurance teams and has an active and valid GMP certificate issued by the Icelandic Medicines Authority authorizing Investigational Medicinal Product and commercial manufacturing. In December 2020, we broke ground on an expansion of our Reykjavik facility that will double the total footprint, adding another 140,000 square feet. The expansion is expected to be completed in 2024 and will give additional redundancy in drug product capacity, assembly of combination products and devices, and secondary packaging. Additionally, the expansion will support increased warehousing and other supportive functions. With the expansion of the Reykjavik facility&#8217;s manufacturing capabilities, we expect our capabilities to be able to meet the demand for our products, after obtaining regulatory approval and commercial launch, in the near future. During this expansion, our R&amp;D functions have temporarily moved to another facility in Reykjavik. Permits from the Icelandic EPA (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Umhverfisstofnun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) and the city of Reykjavik have been granted for the operations in Klettagardar. These facilities have no known additional environmental risks that might impact our operations or utilization of facilities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we have a warehouse of approximately 36,000 square feet in Reykjavik which is used for warehousing, office space and laboratories to sample incoming materials. We are leasing this office space and warehouse until 2038. We also rent office space in Kopavogur, Iceland, for approximately 10,000 square feet, on a lease that expires in 2027. Until the expansion of our Reykjavik facility is completed, we also have short term leases for office space, R&amp;D activities and storage space in Reykjavik, for approximately 57,000 square feet in total, with the leases expiring in 2024. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hold operational permits from the city of Reykjavik for our facilities in Iceland. The permits address potential environmental impact from our operations. They also address factors that could impact our neighboring communities, such as noise pollution, handling of hazardous substances, air emissions, handling of solid waste and wastewater. We are also required to hold permits from the Icelandic EPA (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Umhverfisstofnun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) for the use of GMOs in our facilities. We are subject to Icelandic law and regulations, many of whom are set by the Icelandic EPA (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Umhverfisstofnun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) and the Icelandic Administration of Occupational Safety and Health (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vinnueftirliti&#240;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Offices </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have a facility in J&#252;lich, Germany that focuses on cell line, media, process and analytical development, including tailored clone creation and selection. The J&#252;lich site also serves as a warehouse for supply continuity of master cell banks and working cell banks for our lead product candidates that are produced at contract manufacturing organizations. This facility is approximately 15,000 square feet and is not used for manufacturing. We are holding the space through seven lease agreements, two of which expire in 2024 and provides for automatic renewal until the termination of the agreement, and the other five lease agreements can be terminated at any time with a three-month notice period. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have a facility in Hannover, Germany that houses our capabilities in analytical glycoprotein characterization. This facility is approximately 14,000 square feet and is not used for manufacturing. We are currently leasing this office space. The lease agreement can be terminated at any time with a 12-month notice period. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Virginia, USA office houses our U.S. regulatory, government policy and legal affairs functions. Having recently moved from Arlington, Virginia, to Leesburg, Virginia, the current office is approximately 950 square feet and is not used for manufacturing. We are currently leasing this office space. The lease expires in March 2026.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our London office houses employees working in London for the Group. Alvotech uses the premises for its employees, strategic meetings and meetings with shareholders and potential investors. The office is approximately 5,500 square feet and the group leases 30% of the premises, containing approximately 1,645 square feet of space. The lease expires in 2028. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our office in Zurich, Switzerland features our strategic clinical and Medical Affairs R&amp;D center that focuses on late-stage development and regulatory filings. This facility is approximately 3,800 square feet and is not used for manufacturing. We are currently leasing this office space. The lease expires in August 2026. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have a facility in Bangalore, India that focuses on research and development. This facility is approximately 6,100 square feet and is not used for manufacturing. We are currently leasing this office space. The lease expires in December 2025. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we use a small part of a 6,000 square feet office in Malta that for administrative functions. We are currently leasing this office space. The leases expire in August 2025. </span></div><div id="ie527079dad0a4810aa92569387637e3d_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 4A.&#160;&#160;&#160;&#160;Unresolved Staff Comments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 5.&#160;&#160;&#160;&#160;Operating and Financial Review and Prospects </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion and analysis of our audited financial condition and results of operations together with our consolidated financial statements appearing elsewhere in this Annual Report on Form 20-F. This Annual Report on Form 20-F contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; or similar language. All forward-looking statements included in this Annual Report on Form 20-F are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. In evaluating our business, you should carefully consider the information provided under &#8220;Item 3.D. Risk Factors.&#8221; Actual results could differ materially from those projected in the forward-looking statements. The terms &#8220;Company,&#8221; &#8220;Alvotech,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; as used herein refer to Alvotech and its consolidated subsidiaries unless otherwise stated or indicated by context. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">All amounts discussed are in U.S. dollars, unless otherwise indicated. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Overview </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech is a highly integrated biopharmaceutical company committed to developing and manufacturing high quality biosimilar medicines for patients globally. Our purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. Since our inception, we have built our company with key characteristics we believe will help us capture the substantial global market opportunity in biosimilars: a leadership team that has brought numerous successful biologics and biosimilars to market around the world; a purpose-built biosimilars R&amp;D and manufacturing platform; top commercial partnerships in global markets; and a diverse, expanding pipeline addressing many of the biggest disease areas and health challenges globally. Alvotech is a company committed to constant innovation: we focus our platform, people and partnerships on finding new ways to drive access to more affordable biologic medicines. Alvotech, which was founded in 2013, is led by specialists in biopharmaceutical product creation from around the world that bring extensive combined knowledge and expertise to its mission. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech currently has two approved biosimilars and an additional nine product candidates in its pipeline for serious diseases with unmet patient and market need. Product candidates in our pipeline address reference products treating autoimmune, eye, and bone disorders, as well as cancer, with combined estimated peak global sales of originator products of more than $130 billion. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">In 2022, Alvotech&#8217;s commercial partners launched AVT02 in Canada and Europe and in 2023, in Australia. On 23 February 2024, Alvotech announced the receipt of FDA approval for marketing AVT02 in the U.S. Alvotech expects to launch AVT02 with Teva Pharmaceuticals in the U.S. in the first half of 2024. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">In the fourth quarter of 2023, Alvotech's commercialization partners Fuji Pharma and JAMP Pharma received approval for AVT04,  a biosimilar to Stelara (ustekinumab) in Japan and Canada. In January 2024, Alvotech's  commercialization partner STADA received approval for AVT04 in the EEA. Alvotech anticipates that the FDA&#8217;s review of the BLA for AVT04 will be completed in April 2024. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech is in late stage clinical studies for four biosimilar candidates. These are AVT03, a biosimilar candidate to Prolia / Xgeva (denosumab), AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT06, a biosimilar candidate to Eylea (aflibercept), and AVT23, a biosimilar candidate to Xolair (omalizumab). </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech also has a number of other programs in earlier phases of development that it plans to advance over the coming years. The combined anticipated peak sales for the reference products for these biosimilar candidates in pre-clinical development is over $105 billion. The two most advanced of these, AVT16, a proposed biosimilar to Entyvio (vedolizumab), and AVT33, a proposed biosimilar to Keytruda (pembrolizumab). </span></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception, Alvotech has incurred significant operating losses. Alvotech&#8217;s loss for the years ended 31&#160;December 2023, 2022, and 2021 was $551.7 million, $513.6 million, and $101.5 million, respectively. Alvotech&#8217;s Adjusted EBITDA was  ($291.0) million, ($205.2) million, and ($180.7) million for the years ended 31&#160;December 2023, 2022, and 2021, respectively. Alvotech expects to continue to incur further expenses for the immediate future, as it advances its products through preclinical and clinical development and seeks regulatory approvals, manufactures drug product and drug supply, maintains and expands its intellectual property portfolio, hires additional personnel, and pays for accounting, audit, legal, regulatory and consulting services and costs associated with maintaining compliance with exchange listing rules and the requirements of the SEC, director and officer liability insurance premiums, investor and public relations activities and other expenses associated with operating as a public company. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We may need to raise substantial additional funding from shareholders or third parties. This additional funding may not be available on acceptable terms or at all. Failure to obtain such necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.&#8221;</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Factors Affecting Alvotech&#8217;s Performance </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pharmaceutical industry is highly competitive and highly regulated. As a result, Alvotech faces a number of industry-specific factors and challenges, which can significantly impact its results. For a more detailed explanation of Alvotech&#8217;s business and its risks see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Item 3.D. Risk Factors.&#8221;</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The regions in which Alvotech conducts business and the pharmaceutical industry in general is highly competitive. Alvotech faces significant competition from a wide range of companies in a highly regulated industry, including competition from both biosimilar developers and manufacturers as well as competition from branded pharmaceutical developers and manufacturers. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and development uncertainty </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development within the pharmaceutical industry has a high degree of uncertainty, and likewise there is uncertainty with respect to the probability of success of Alvotech&#8217;s biosimilar programs and the timing of the requisite preclinical and clinical steps to achieve regulatory approval of its biosimilar product candidates. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reliance on commercial partners </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech has partnered with several third parties to commercialize its biosimilar product candidates, once approved by the appropriate regulatory agencies. Alvotech does not currently have the capabilities or the necessary infrastructure to commercialize its products independently. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Impact of Geopolitics and Global Economic Conditions </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group is subject to additional risks and uncertainties arising from changes to the macroeconomic environment and geopolitical events, including inflation, political instability in particular foreign economies and markets, such as the instability caused by geopolitical conflicts including the war in Ukraine and hostilities in the Middle East, or public health issues or pandemics, such as the COVID-19 pandemic. Global financial markets have experienced volatility and disruption due to macroeconomic and geopolitical events such as rising inflation, the risk of a recession and ongoing conflicts in other countries. In addition, if equity and credit markets deteriorate, including as a result of past and potential future bank failures, it may make any future debt or equity financing more difficult to obtain on favorable terms, and potentially more dilutive to its existing stockholders. The Group cannot predict at this time to what extent it and its collaborators, employees, suppliers, contract manufacturers and/or vendors could potentially be negatively impacted by these events. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that inflation will have a general impact on the business in line with overall price increases, increases in the cost of borrowing, and operating in an inflationary economy. We cannot predict the timing, strength, or duration of any inflationary period or economic slowdown or its ultimate impact on the Company. If the conditions in the general economy significantly deviate from present levels and continue to deteriorate it could have a material adverse effect on the Group&#8217;s business, financial condition, results of operations and growth prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Components of Operations </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Product Revenue </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended 31&#160;December 2023, the Company recognized revenue from product sales resulting from the launch of Alvotech&#8217;s AVT02 product, in select European countries, Canada and Australia. The Company expects to continue to recognize product revenue as products are successfully launched into the marketplace. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License and Other Revenue </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech generates a significant portion of its revenue from upfront and milestone payments pursuant to long-term out-license contracts which provide its partners with an exclusive right to market and sell Alvotech&#8217;s biosimilar product candidates in a particular territory once such products are approved for commercialization. These contracts typically include commitments to continue development of the underlying compound and to provide supply of the product to the partner upon commercialization. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the future, revenue may include new out-license contracts and additional milestone payments. Alvotech expects that any revenue it generates will fluctuate from period to period as a result of the timing and amount of license, research and development services, and milestone and other payments. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Operating Expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Cost of product revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product revenue includes the cost of inventory sold, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as shipping and freight costs and royalty costs related to in-license agreements. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Research and development expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses consist primarily of costs incurred in connection with Alvotech&#8217;s research, development and pre-commercial manufacturing activities prior to commercialization of our products. These costs include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">personnel expenses, including salaries, benefits and other compensation expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">costs of funding the execution of studies performed both internally and externally; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">costs of purchasing laboratory supplies and non-capital equipment used in designing, developing and manufacturing preclinical study and clinical trial materials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">expenses related to quality control and other advancement development; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">consultant fees; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">expenses related to regulatory activities, including filing fees paid to regulatory agencies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">facility costs including rent, depreciation and maintenance expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">fees for maintaining licenses under third party licensing agreements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">expenses incurred in preparation for commercial launch, such as designing and developing commercial-scale manufacturing capabilities and processes, quality control processes, production asset valuation and other related activities; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">costs related to amortization, depreciation and impairment losses related to software and property, plant and equipment used in research and development activities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenditures related to research and development activities are generally recognized as an expense in the period in which they are incurred. Due to significant regulatory uncertainties and other uncertainties inherent in the development of pharmaceutical products, Alvotech did not capitalize any research and development expenses as internally developed intangible assets during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development activities will continue to be central to Alvotech&#8217;s business model and will vary significantly based upon the success of its programs. Alvotech plans to substantially increase research and development expenses in the near term, as it continues to advance the development of its biosimilar product candidates. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of development, primarily due to the increased size and duration of later-stage clinical trials. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The duration, costs and timing of clinical trials of Alvotech&#8217;s products in development and any other product candidates will depend on a variety of factors that include, but are not limited to, the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the number of trials required for approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the per patient trial costs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the number of patients who participate in the trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the number of sites included in the trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the countries in which the trials are conducted; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the length of time required to enroll eligible patients; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the dose that patients receive; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the drop-out or discontinuation rates of patients; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the potential additional safety monitoring or other studies requested by regulatory agencies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the duration of patient follow-up;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the timing and receipt of regulatory approvals; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the efficacy and safety profile of the product candidates. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the probability of success of Alvotech&#8217;s products in development and any other product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. Alvotech may never succeed in achieving regulatory approval of its product candidates for any indication in any country. As a result of the uncertainties discussed above, the estimated duration and completion costs of any clinical trial that Alvotech conducts is subject to change. Alvotech is also unable to determine with certainty when and to what extent it will generate revenue from the commercialization and sale of products in development or other product candidates, if at all. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and administrative expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses primarily consist of personnel-related expenses, including salaries, bonuses and other related compensation expenses, and external consulting service costs for corporate and other administrative and operational functions including finance, human resources, information technology and legal, as well as facility-related costs not otherwise included in research and development expenses. These costs relate to the operation of the business and are not related to research and development initiatives. General and administrative costs are expensed as incurred. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech expects general and administrative expenses to continue to increase as Alvotech increases its headcount and incurs external costs associated with operating as a public company, including expenses related to legal, accounting, tax, consulting services and regulatory matters, maintaining compliance with requirements of exchange listings and of the SEC, director and officer liability insurance premiums and investor relations activities and other expenses associated with operating as a public company. Though expected to increase, Alvotech expects these expenses to decrease as a percentage of revenue in the long-term, as revenue increases. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share of net loss / profit of joint venture </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech currently holds a 50% ownership interest in the Joint Venture. Alvotech accounts for its ownership interest in the Joint Venture using the equity method of accounting. Under the equity method of accounting, investments in joint ventures are initially recognized at cost and the carrying amount is subsequently adjusted for Alvotech&#8217;s share of the profit or loss of the Joint Venture, as well as any distributions received from the Joint Venture. Alvotech&#8217;s profit or loss includes its share of the profit or loss of the Joint Venture and, to the extent applicable, other comprehensive income or loss for Alvotech will include its share of other comprehensive income or loss of the Joint Venture. The carrying amount of equity-accounted investments is assessed for impairment and impairment losses will be recognized as impairment loss on investment in joint venture in the statements of profit or loss and other comprehensive income or loss if there is objective evidence of impairment as a result of loss events that have an impact on estimated future cash flows and that can be reliably estimated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Finance income and finance costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income consists of changes in the fair value of derivative financial liabilities and interest income. Alvotech recognizes interest income from a financial asset when it is probable that the economic benefits will flow to Alvotech, and the amount of income can be measured reliably. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance costs consist of interest expenses related to lease liabilities and borrowings, changes in the fair value of derivative financial liabilities, accretion of Alvotech&#8217;s borrowings and amortization of deferred financing fees. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exchange rate differences </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group uses the US dollar as its reporting currency and conducts business on a global basis in various currencies. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Icelandic and UK market currencies, as well as in the Swiss franc. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Gain / Loss on extinguishment of financial liabilities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech recognizes a gain / loss on extinguishment of financial liabilities in connection with the substantial modification or extinguishment of outstanding financial liabilities. The gain / loss is calculated as the difference between the carrying amount of the liability extinguished and the fair value of the consideration paid. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income tax benefit </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax benefit consists of current tax and deferred tax benefit recorded in the consolidated statement of profit or loss and other comprehensive income or loss. </span></div><div id="ie527079dad0a4810aa92569387637e3d_64"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Operating Results </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Comparison of the Years Ended 31&#160;December 2023 and 2022 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth Alvotech&#8217;s results of operations for the years ended 31 December: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.151%"><tr><td style="width:1.0%"/><td style="width:62.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">USD in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(160,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(64,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(210,827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(180,622)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(76,559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(186,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(354,860)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(346,442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share of net loss of joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment loss on investment in joint venture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(267,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(188,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exchange rate differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Loss) / gain on extinguishment of financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(27,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-operating (loss) / profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(296,189)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(205,205)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(651,049)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(551,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss for the year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(551,731)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(513,580)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Product revenue </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Product revenue </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company successfully launched the AVT02 product in Canada and select European countries during the second quarter 2022 and increased sales volume predominantly in Europe during 2023 resulting in $48.7 million of product revenue recognized during the year ended 31&#160;December 2023, almost doubling the product revenue from 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License and other revenue </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">License and other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,458)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">License and other revenue decreased by $15.5 million, or 26.6%, from $58.2 million for the year ended 31&#160;December 2022, to $42.7 million for the year ended 31&#160;December 2023. The decrease in license and other revenue was primarily driven by the recognition of $44.5 million research and development milestone during the same period in the prior year, due to the completion of the AVT04 main clinical program. This was partially offset by the recognition of $31.6 million research and development milestone during 2023 due to the CES completion of the AVT06 program. The remainder of the decrease is mainly due to the net impact of the changes in licensing arrangements during the year ended 31&#160;December 2023.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other income </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income remained consistent between 31&#160;December 2023, and 31&#160;December 2022. It mainly included in income from a grant received from the Icelandic government to promote research &amp; development activities in Iceland.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product revenue </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">160,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:27pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company successfully launched AVT02 in select European countries and Canada during the year ended 31&#160;December 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result, the Company recognized cost of product revenue in the amount of $64.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and $160.9 million during the year ended 31&#160;December 2022 and 2023, respectively. Cost of product revenue includes both variable and fixed manufacturing costs associated with commercial manufacturing. Cost of product revenue for the period is disproportionate relative to product revenue due to the timing of new launches and elevated production-related charges, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">resulting in higher costs than revenues recognized for the period. Prior to the recognition of cost of product revenues, costs from pre-commercial manufacturing activities were reported as R&amp;D expenses.</span></div><div style="margin-top:18pt;padding-left:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.121%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.213%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT02 development program expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,187)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(51.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT03 development program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT04 development program expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(69.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT05 development program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT06 development program expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salary and other employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation, amortization and impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Total research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">210,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">180,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Other research and development expenses include other project costs, facility costs and other operating expenses recognized as research and development expenses during the period. </span></div><div style="margin-top:6pt;text-indent:21.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses increased by $30.2 million, or 16.7%, from $180.6 million for the year ended 31&#160;December 2022, to $210.8 million for the year ended 31&#160;December 2023. The increase was primarily driven by a charge of $18.5 million relating to the termination of the co-development agreement with Biosana for AVT23, and a $42.5 million increase in direct program expenses mainly from three biosimilar candidates, AVT03, AVT05 and AVT06, that entered clinical development in 2022. These increases were partially offset by a decrease of $21.8 million primarily related to programs which have completed clinical phase (i.e., AVT02 and AVT04 programs). In addition, upon the launch of AVT02 during the second quarter of 2022, the Company commenced recognizing pre-commercial manufacturing activities as cost of product revenue. As a result, research and development expenses during the year ended 31&#160;December 2022 included $8.8 million of costs relating to AVT02 which have since been recognized as cost of product revenue.  </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">General and administrative expenses </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">General and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(110,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(59.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses decreased by $110.2 million, or 59.0%, from $186.7 million for the year ended 31&#160;December 2022, to $76.6 million for the year ended 31&#160;December 2023. The decrease in general and administrative expenses was primarily attributable to a $83.4 million non-cash share listing expense and $22.9 million of transaction costs as a result of the Business Combination recognized as of 31&#160;December 2022 (see Note 1.1 of the consolidated financial statements included elsewhere in this 20-F for additional information). The Company also incurred $13.4 million of IP-related legal expenses during the year ended 31&#160;December 2022, compared to $2.3 million during the year ended 31&#160;December 2023. This decrease was partially offset by a $3.7 million net increase in other general administrative expenses due to costs from operating as a public company in both the U.S. and Iceland. Lastly, the Company recognized $10.8 million of general and administrative expenses for share-based payments, resulting from the granting of RSUs during the year ended 31&#160;December 2023, against $6.5 million during the year ended 31&#160;December 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Share of net loss of joint venture and impairment loss on investment in joint venture</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.090%"><tr><td style="width:1.0%"/><td style="width:40.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Share of net loss of joint venture</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">176.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Impairment loss on investment in joint venture</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,519)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,519)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">nm</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">nm = not meaningful, refer to explanation below</span></div><div style="margin-top:12pt;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share of net loss of joint venture increased by $4.6 million, or 176.2%, from $2.6 million for the year ended 31&#160;December 2022, to $7.2 million for the year ended 31&#160;December 2023. The increase in losses incurred by the Joint Venture was mainly due to higher depreciation and amortization expense for the year ended 31&#160;December 2023. In 2023, the Group impaired their share of the joint venture, the impairment amounted to $21.5 million, based on discussions between Alvotech and CCHN to buy back Alvotech's interests in the joint venture. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group estimates the recoverable amount using value in use where the recoverable amount is estimated as the future cash flows expected to arise from dividends to be received from the investment and from its ultimate disposal.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Finance income </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Finance income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">89.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income increased by 2.3 million, or 89.2%, from $2.5 million for the year ended 31&#160;December 2022, to $4.8 million for the year ended 31&#160;December 2023. The increase in finance income is primarily driven by interest received on cash and cash equivalent held in our bank accounts. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Finance costs </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Finance costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">267,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">188,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance costs increased by $78.7 million, or 41.8%, from $188.4 million for the year ended 31&#160;December 2022, to $267.2 million for the year ended 31&#160;December 2023.The increase in finance costs is primarily related to a $49.2 million increase in interest on debt and borrowings due to the additional financing obtained since 31&#160;December 2022, including the annualized impact of prior year financing, and a $35.4 million increase in fair value of derivative liabilities mainly driven by the OACB Warrants, the Predecessors and OACB Earn Out shares and the Tranche A Conversion Feature, including the additional Tranche A Convertible Bonds secured in 2023. This is partially offset by $16.0 million in charges related to the closing of the Business Combination in 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exchange rate differences </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Exchange rate differences</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,749)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(149.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Exchange rate differences decreased by $15.7 million from a gain of $10.6 million for the year ended 31&#160;December 2022, to a loss of $5.2 million for the year ended 31&#160;December 2023. The decrease was primarily driven by the movements in the exchange rate of foreign currencies, predominantly Icelandic krona and euros. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Loss) / Gain on extinguishment of financial liabilities </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Loss) / Gain on extinguishment of financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(27,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">nm</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">nm = not meaningful, refer to explanation below</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech recognized a loss on extinguishment of financial liabilities of $27.3 million during the year ended December 31, 2022, primarily as a result of the following transactions: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$40.9 million loss resulting from the amendment and upsizing of the Senior Bonds. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$3.9 million loss resulting from the extinguishment of the lease on the Alvotech facility resulting from the Share Purchase Agreement for the Saemundur manufacturing facility. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$17.8 million gain resulting from the settlement of related party loans with Aztiq and Alvogen, in which the parties agreed to settle outstanding loan amounts through the issuance of Ordinary Shares. </span></div><div style="margin-top:18pt;padding-left:27pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income tax benefit </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">160.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The income tax benefit increased by $61.3 million for the year ended 31&#160;December 2023, compared to the same period for 2022. This increase was mainly driven by $34.7 million deferred tax credit corresponding to an increase in operating losses and a favorable $26.7 million foreign currency translation of the deferred tax asset recognized on Icelandic tax loss carry-forwards denominated in Icelandic Krona, that the Company expects to fully utilize against future taxable profits.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Comparison of the Years Ended December 31, 2022, and 2021 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth Alvotech&#8217;s results of operations for the years ended December 31: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.151%"><tr><td style="width:1.0%"/><td style="width:62.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">USD in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(64,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(180,622)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(191,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(186,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(84,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(346,442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(235,456)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share of net loss of joint venture</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,418)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(188,419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(117,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exchange rate differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Loss) / Gain on extinguishment of financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(27,311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">151,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non&#8211;operating (loss) profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(205,205)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(551,647)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(149,198)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss for the year</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(513,580)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(101,504)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Product revenue </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">nm</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nm = not meaningful, refer to explanation below </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company successfully launched the AVT02 product in Canada and select European countries resulting in $24.8 million of product revenue recognized during the year ended 31 December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License and other revenue </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022 </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">License and other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License and other revenue increased by $21.4 million, or 58.2%, from $36.8 million for the year ended 31 December 2021, to $58.2 million for the year ended 31 December 2022. The company recognized revenue of $44.5 million and $11.6 million resulting from license and milestone payments for AVT04 and AVT05, respectively, for the year ended 31 December 2022. During the year ended 31 December 2021, the Company recognized $20.8 million, $8.6 million, and $7.2 million from license and milestone payments for AVT06, AVT02, and AVT03, respectively. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other income </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022 </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(924)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income decreased by $0.9 million, or 31.7%, from $2.9 million for the year ended 31 December 2021, to $2.0 million for the year ended 31 December 2022. The decrease in other income was driven by a decrease in income generated from services performed pursuant to Alvotech&#8217;s support service arrangements with Alvogen, a related party, during the year ended 31 December 2022, as compared to the year ended 31 December 2021. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of product revenue </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">nm</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nm = not meaningful, refer to explanation below </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company successfully launched AVT02 in select European countries and Canada during the year ended 31 December 2022. As a result, the Company commenced recognizing cost of product revenue in the same period. Cost of product revenue for the year ended 31 December 2022, was $64.1 million, which includes both variable and fixed manufacturing costs associated with commercial manufacturing. Cost of product revenue is disproportionate relative to product revenue due to the timing of new launches, resulting in higher costs than revenues recognized for the period. The Company expects this to normalize as it increases in scale and expands on new product launches. Ultimately, the increase in volumes will result in the absorption of fixed manufacturing costs. Prior to the recognition of cost of product revenues, these costs were reported as research and development expenses as pre-commercial manufacturing activities. </span></div><div style="margin-top:18pt;padding-left:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:115%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021 to 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT02 development program expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,624)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT03 development program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT04 development program expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT05 development program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">nm</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AVT06 development program expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salary and other employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18,626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation, amortization and impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,024)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">180,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">191,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10,384)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">nm = not meaningful, refer to explanation below </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Other research and development expenses include other project costs, facility costs and other operating expenses recognized as research and development expenses during the period. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses decreased by $10.4 million, or 5.4%, from $191.0 million for the year ended 31 December 2021, to $180.6 million for the year ended 31 December 2022. During the year ended 31 December 2022, the following resulted in an overall decrease to total research and development expenses: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">AVT02 development program expenses decreased by $16.6 million, or 62.5%, as a result of decreased R&amp;D activities. The Company obtained marketing authorization for AVT02 in the EEA, the UK, Switzerland, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Canada, Australia and Saudi Arabia, resulting in the conclusion of pre-launch R&amp;D studies and the recognition of cost of product revenue. As a result, the AVT02 development program expenses decreased during the year ended 31 December 2022. The Company expects these expenses to continue to decrease as the Company seeks to obtain marketing authorization in other jurisdictions, including the US. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">AVT04 development program expenses decreased by $11.9 million, or 33.2%. During the year ended 31 December 2022, the Company completed significant R&amp;D activities related to AVT04. Subsequent to 31 December 2022, in January 2023, Alvotech announced that the FDA had accepted for review a BLA for AVT04 and in November that the FDA had accepted for review its resubmitted BLA for AVT04 with an expected goal date in April 2024. In February 2023, Alvotech announced that the EMA had accepted a Marketing Authorization Application for AVT04, which was approved in February 2024. As a result, the company recognized less R&amp;D expense related to AVT04 as R&amp;D studies entered late stages. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Salary and other employee expenses decreased by $18.6 million, or 26.0%. This decrease is a result of costs being classified as manufacturing costs subsequent to the Company obtaining marketing authorization for AVT02. Previously, these costs were reported as pre-commercial manufacturing activities within research and development. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Depreciation, amortization and impairment expenses decreased by $15.0 million, or 69.0%. This decrease is a result of costs being classified as manufacturing costs subsequent to the Company obtaining marketing authorization for AVT02. Previously, these costs were reported as pre-commercial manufacturing activities within research and development. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">The increases in development program expenses of $9.0 million, $25.2 million, and $7.5 million for AVT03, AVT05, and AVT06, respectively, are a result of these biosimilar candidates initiating the clinical phase of development. The Company expects to continue to incur R&amp;D expense as they seek commercialization of these biosimilar candidates. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Other research and development expenses increased by $10.5 million, or 76.6%. The increase is due to an increase in costs of $4.3 million and $4.2 million for AVT23 and AVT16, respectively. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and administrative expenses </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">General and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses increased by $102.6 million, or 122.0%, from $84.1 million for the year ended 31 December 2021, to $186.7 million for the year ended 31 December 2022. The increase in general and administrative expenses was primarily attributable to the $83.4 million non-cash share listing expense and $10.4 million of additional transaction costs recognized as a result of the Business Combination. See Note 1.1 of the consolidated financial statements included elsewhere in this Form 20-F. The Company also recognized $5.8 million of general and administrative expenses for share-based payments, resulting from the granting of RSUs during the year ended 31 December 2022. Lastly, the company recognized $3.3 million in salary expense related to severance agreements, associated with a management reorganization, and had an increase of $13.6 million on other general administrative expenses related to IT and other third-party services. These increases were offset by $17.4 million less of long-term incentive plan expense recognized during the year ended 31 December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share of net loss of joint venture </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Share of net loss of joint venture</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share of net loss of joint venture increased by $0.2 million, or 7.1%, from $2.4 million for the year ended 31 December 2021, to $2.6 million for the year ended 31 December 2022. The increase in the share of net loss of joint venture was due to an increase in losses incurred by the Joint Venture during the year ended 31 December 2022, as compared to 31 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 2021. The increase in losses incurred by the Joint Venture was due to lower interest income combined with higher depreciation and amortization expense for the year ended 31 December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Finance income </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Finance income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(49.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">95.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income decreased by $49.0 million, or 95.1%, from $51.6 million for the year ended 31 December 2021, to $2.6 million for the year ended 31 December 2022. The decrease in finance income was primarily attributable to $48.7 million in income resulting from a favorable fair value remeasurement of derivative financial liabilities associated with the convertible shareholder loans during the year ended 31 December 2021. In connection with the Business Combination Agreement, on 7 December 2021, the Group&#8217;s shareholders entered into the BCA Framework Agreement resulting in the exercise of the conversion, warrant, and funding rights associated with the convertible shareholder loans. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Finance costs </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Finance costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">188,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance costs increased by $71.1 million, or 60.5%, from $117.4 million for the year ended 31 December 2021, to $188.4 million for the year ended 31 December 2022. The increase in finance costs is primarily related to a $94.2 million increase in finance costs resulting from the change in fair value of derivative liabilities. For the year ended 31 December 2022, the Company recognized finance costs for the following derivatives: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$48.7 million in finance costs resulting from the increase in fair value of the Predecessor Earn Out Shares; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$29.9 million in finance costs resulting from the increase in fair value of the Senior Bond Warrants; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$13.2 million in finance costs resulting from the increase in fair value of the Tranche A Conversion Feature; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$3.7 million in finance costs resulting from the decrease in fair value of the derivative asset relates to the Senior bond interest feature; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$1.4 million in finance costs resulting from the increase in fair value of the OACB Earn Out Shares. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the company recognized $13.9 million in finance costs related to the consenting fee and remeasurement of the bonds as result of the terms being amended in association with the closing of the Business Combination with OACB. These increases in finance costs were offset by $35.0 million less of finance costs related to the interest on debt and borrowings. The company incurred less interest costs on borrowings due to the extinguishment of the convertible shareholder loans on 7 December 2021, resulting in less finance costs for the year ended 31 December 2022. During the year ended 31 December 2021, the Company recognized $30.7 million of finance costs related to interest on the convertible shareholders loans. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exchange rate differences </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Exchange rate differences</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">294.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exchange rate differences increased by $7.9 million, or 294.1%, from $2.7 million for the year ended 31 December 2021, to $10.6 million for the year ended 31 December 2022. The increase was primarily driven by a change in financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assets and liabilities denominated in Icelandic Krona and Euros, along with the weakening of the Icelandic Krona compared to the US dollar, during the year ended 31 December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Loss) / Gain on extinguishment of financial liabilities </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Loss) / Gain on extinguishment of financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(27,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">151,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">nm</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">nm = not meaningful, refer to explanation below</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech recognized a loss on extinguishment of financial liabilities of $27.3 million during the year ended 31 December 2022, primarily as a result of the following transactions: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$40.9 million loss resulting from the amendment and upsizing of the Senior Bonds; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$3.9 million loss resulting from the extinguishment of the lease on the Alvotech facility resulting from the Share Purchase Agreement for the Saemundur manufacturing facility; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">$17.8 million gain resulting from the settlement of related party loans with Aztiq and Alvogen, in which the parties agreed to settle outstanding loan amounts through the issuance of Ordinary Shares. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech recognized a gain on extinguishment of financial liabilities of $151.8 million during the year ended 31 December 2021, in connection with the substantial modification to the terms and conditions of the convertible bonds, as well as the exercise of the conversion, warrant and funding rights associated with the convertible shareholder loans. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income tax benefit </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,627)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes for the year ended 31 December 2022, resulted in an income tax benefit of $38.1 million compared to an income tax benefit of $47.7 million for the year ended 31 December 2021. This decrease in income tax benefit was mainly driven by a $10.1 million foreign currency impact due to the continued weakening of the Icelandic Krona against the US dollar, decreasing the US dollar value of tax loss carry-forwards that Alvotech expects to fully utilize against future taxable profits. </span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reconciliation of non-IFRS financial measure </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to its operating results, as calculated in accordance with IFRS, Alvotech uses Adjusted EBITDA when monitoring and evaluating operational performance. Adjusted EBITDA is defined as profit or loss for the relevant period, as adjusted for certain items that Alvotech management believes are not indicative of ongoing operating performance. The adjusting items consist of the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Income tax benefit; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Total net finance costs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Depreciation and amortization of property, plant, and equipment, right-of-use assets and intangible assets; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Impairment and loss on sale of property, plant, and equipment and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Charge related to contract termination;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Long-term incentive plan expense; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Share of net loss of joint venture; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Impairment loss on investment in joint venture;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Exchange rate differences; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Share listing expense; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Loss (Gain) on extinguishment of financial liabilities; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Transaction costs. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech believes that this non-IFRS measure assists its shareholders because it enhances the comparability of results each period, helps to identify trends in operating results and provides additional insight and transparency on how management evaluates the business. Alvotech&#8217;s executive management team uses this non-IFRS measure to evaluate financial measures to budget, update forecasts, make operating and strategic decisions, and evaluate performance. This non-IFRS financial measure is not meant to be considered alone or as a substitute for IFRS financial measures and should be read in conjunction with Alvotech&#8217;s consolidated financial statements prepared in accordance with IFRS. Additionally, this non-IFRS measure may not be comparable to similarly titled measures used by other companies. The most directly comparable IFRS measure to this non-IFRS measure is loss for the year. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table reconciles loss for the year to Adjusted EBITDA for the years ended 31&#160;December 2023, 2022, and 2021, respectively: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"/><td style="width:51.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.112%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">USD in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss for the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(551,731)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(513,580)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(101,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(99,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(47,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total net finance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">262,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">185,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment and loss on sale of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Charge related to contract termination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Incentive plan expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share of net loss of joint venture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment loss on investment in joint venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exchange rate differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,681)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share listing expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss (Gain) on extinguishment of financial liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(151,788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Transactions costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Adjusted EBITDA</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(290,977)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(205,178)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(180,717)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.84pt">Represents expense related to employee incentive plans, reported within cost of product revenue, research and development expenses and general and administrative expenses.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.84pt">Represents impairment loss on investment in joint venture due to uncertainties around the economic conditions in China. The Group estimated the recoverable amount using value in use where the recoverable amount is estimated as the future cash flows expected to arise from dividends to be received from the investment and from its ultimate disposal.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.84pt">Represents the share listing expense reported within general and administrative expenses, which was recorded in accordance with IFRS 2 as the excess of the fair value of Alvotech shares issued at the Closing Date over the fair value of OACB&#8217;s identifiable net assets acquired.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.84pt">Represents transaction costs incurred in 2021 and 2022 in connection with the Business Combination and the Icelandic Main Board listing, and, in 2023, with any remaining services reported within general and administrative expenses.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.84pt">Represents a charge in relation to the termination of the co-development agreement with Biosana for AVT23.</span></div><div style="text-indent:-4.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Liquidity and Capital Resources </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of 31&#160;December 2023 and 2022, Alvotech had cash and cash equivalents, excluding restricted cash, of $11.2 million and $66.4 million, respectively. Since its inception, Alvotech has incurred operating losses, including net losses of $551.7 million and $513.6 million for the years ended 31&#160;December 2023 and 2022, respectively, and had an accumulated deficit of $2,205.8 million and $1,654.1 million as of 31&#160;December 2023 and 2022, respectively. The Company has financed its activities through successive capital increases, borrowings, and upfront and milestone payments under agreements with its commercial partners. During the year ended 31&#160;December 2023, the Company used $312.2 million cash in operating activities and $46.3 million cash in investing activities, and its financing activities provided $301.3 million cash.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sources of Liquidity </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Alvotech began to generate revenue from product sales in the second quarter of 2022 in conjunction with the commercialization of AVT02 in Canada and select European countries. AVT02 has received regulatory approval in over 50 markets and has been launched in over 20 markets globally to date. Alvotech expects to launch AVT02 in the United States during the first half of 2024. The Company also has a second biosimilar, AVT04, which has been approved in Japan, Canada and the EEA and was launched in Canada in March 2024. Launches of AVT04 in Japan and Europe are expected in Q2 2024 and Q3 2024, respectively. Alvotech anticipates that the FDA&#8217;s review of its BLA for AVT04 will be completed by 16 April 2024.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February and March 2022, Alvotech received $25.0 million from each of Alvogen and Aztiq pursuant to interest free loan advances provided by both significant shareholders, who agreed to settle these outstanding amounts in Ordinary Shares rather than cash in July 2022. The closing of the Business Combination and the PIPE Financing provided the Company with $131.9 million of net proceeds that was used to finance the continuing development and commercialization of its biosimilar product candidates. Additionally, during the year ended 31 December 2022, the Company received $110.0 million in cash proceeds from the loans issued by Alvogen (including the Alvogen Facility), successfully amended and upsized the outstanding Senior Bonds resulting in  $57.9&#160;million of net cash proceeds, along with net cash proceeds of $73.4 million from the issuance of the Tranche A and Tranche B 2022 Convertible Bonds and Facility Loans, of which $50.0&#160;million was used to repay amounts drawn under the Alvogen Facility.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In January 2023, the Company issued an additional $10.0&#160;million of Tranche B under the 2022 Convertible Bonds agreement. Holders of the Tranche B Convertible Bonds may elect, at their sole discretion, to convert all or part of the principal amount and accrued interest into Alvotech Ordinary Shares at a conversion price of $10.00 per share on 31 December 2023, 30 June 2024, or upon optional or mandatory redemption of the bonds. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2023, Alvotech completed a private placement for gross proceeds of $137.0&#160;million, and transaction costs of $4.1&#160;million, of its Ordinary Shares at a purchase price of $11.57 per Ordinary Share. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On 6 February 2023, Alvotech announced that it had entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23 in the European Economic Area, UK, Switzerland, Canada, Australia and New Zealand. On 24 May 2023, Alvotech announced that the two companies had extended their exclusive partnership agreement, adding the supply and commercialization of five biosimilar candidates in Europe. Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe. The agreement includes candidate biosimilars to Simponi (golimumab) and Entyvio (vedolizumab) and also includes three additional early-stage, undisclosed biosimilar candidates. Under the terms of the current agreements with Advanz Pharma, Alvotech received upfront payments of $75.3 million and development milestone payments of $15.1 million up to 31&#160;December 2023. Additionally, Alvotech is eligible to receive aggregate payments of up to an additional $351.0 million upon the achievement of certain, regulatory, commercial, manufacturing and sales milestones.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In July 2023, in conjunction with the Company's expansion of its existing partnership agreement with Teva, Teva also acquired Tranche B Convertible Bonds pursuant to the 2022 Convertible Bonds agreement, in principal amount of $40&#160;million. The expanded agreement pertained to the exclusive commercialization in the U.S. by Teva of two new biosimilar candidates and line extensions of two current biosimilar candidates in the partnership. Additionally, Alvotech received upfront payments of $40.0 million and $37.5 million in development milestone payments up to 31 December 2023 and is eligible to receive aggregate payments of up to an additional $552.5 million upon the achievement of certain regulatory, commercial, manufacturing and sales milestones under the entire partnership with Teva.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also in July 2023, the Company secured a private placement of the December 2022 Convertible Bonds denominated in Icelandic krona and US dollar for a principal amount of $100&#160;million. As part of this private placement, ATP Holdings ehf., an affiliated of Aztiq, acquired Tranche A Convertible Bonds in principal amount of $30&#160;million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2024, the Company announced the sale of 10,127,132 Ordinary Shares for an approximate value of $166&#160;million, par value USD 0.01 per share, at a purchase price of $16.41 per Share, or ISK 2,250 per share at foreign exchange rates on February 23, 2024.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For the foreseeable future, Alvotech&#8217;s Board of Directors will maintain a capital structure that supports Alvotech&#8217;s strategic objectives through managing the budgeting process, maintaining strong investor relations and managing financial risks. Consequently, management and the Board of Directors believe that Alvotech will have sufficient funds, and access to sufficient funds, to continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. However, although management continues to pursue these plans, there is no assurance that Alvotech will be successful in obtaining sufficient funding on terms acceptable to Alvotech management to fund continuing operations, if at all. Alvotech&#8217;s future capital requirements will depend on many factors, including the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the progress, results, and costs of preclinical studies for any programs that Alvotech may develop; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the costs, timing, and outcome of regulatory review of program candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Alvotech&#8217;s ability to establish and maintain collaborations, licensing, and other agreements with commercial partners on favorable terms, if at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the achievement of milestones or occurrence of other developments that trigger payments under the agreements that Alvotech has entered into or may enter into with third parties or related parties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the extent to which Alvotech is obligated to reimburse clinical trial costs under collaboration agreements, if any; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the costs of preparing, filing and prosecuting patent applications and maintaining, defending and enforcing Alvotech&#8217;s intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the extent to which Alvotech acquires or invests in businesses, products, technologies, or other joint ventures;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the costs of performing commercial-scale manufacturing in-house and, if needed, securing manufacturing arrangements for commercial production of its program candidates; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the costs of establishing or contracting for sales and marketing capabilities if Alvotech obtains regulatory approvals to market program candidates. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash Flows </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Comparison of the Years Ended 31&#160;December 2023 and 2022 </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.303%"><tr><td style="width:1.0%"/><td style="width:38.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022 to 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">USD in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">($312,185)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">($312,389)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(46,340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(63,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Cash generated from financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">301,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">424,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(123,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Operating activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities decreased by $0.2 million, or 0.1%, from $312.4 million for the year ended 31&#160;December 2022, to $312.2 million for the year ended 31&#160;December 2023. This was primarily driven by a $54.7 million increase in operating cash outflows before considering movements in working capital, $74.2 million increase in cash flows from movements in working capital, and $21.9 million in additional interest paid during 2023 compared to 2022. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The $54.7 million increase in operating cash flow before movements in working capital is mostly due to an increased loss of $38.2 million, $18.5 million allowance for receivables, $21.5 million impairment loss on investment in joint venture and $78.7 million increase in finance costs. This was offset by $61.3 million change in income tax benefit and $83.4 million change in share-listing expense in non-cash expenses. The $74.2 million increase in cash flows from movements in working capital is du to a $21.1 million decrease in cash outflow to inventories, $16.4 million increase in cash inflow from other assets, $31.5 million increase in cash inflow from trade and other payables and other liabilities and a $16.0 million increase in contract liabilities partially offset by a $8.2 million increase in contract assets. Other major change in net cash used in the operating cash flow are due to an increase in paid interests of $21.9 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Investing activities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in investing activities decreased by $17.2 million, or 27.1%, from $63.5 million for the year ended 31&#160;December 2022, to $46.3 million for the year ended 31&#160;December 2023. The decrease in investing activities was driven by a $4.6 million decrease in cash outflow for the acquisition of property, plant and equipment. Additionally, the Group had a $14.9 million cash outflow in 2022 resulting from the amended bond agreement, whereby Alvotech is required to maintain a minimum of $25.0 million of restricted cash in a separate liquidity account per the terms of their debt agreements. These decreases were partially offset by a $2.1 million increase in cash outflows related to the acquisition of intangible assets as the Group acquired intellectual property rights of AVT23 from Kashiv and continued investing in its SAP project during the year ended December 31, 2023. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financing activities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash generated from financing activities decreased by $123.6 million, or 29.1%, from $424.9 million for the year ended 31&#160;December 2022, to $301.3 million for the year ended 31&#160;December 2023. In 2023 the Company received $269.8 million in proceeds from new borrowings, thereof $26.9 million from related parties. Additionally, the Group received net $132.7 million from the private placement closed during Q1 2023 and $6.4 million in proceeds from warrants. Repayments of borrowings amounted to $99.4 million and repayments of leases amount to $8.3 million compared to $34.7 million and $11.1 million repayments in 2022, respectively. </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Material Cash Requirements for Known Contractual Obligations and Commitments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a description of commitments for known and reasonably likely cash requirements as of 31&#160;December 2023. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Borrowings </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech&#8217;s debt consists of interest-bearing borrowings from both financial institutions and related parties. The amount of the outstanding borrowings as of 31&#160;December 2023, was $960.2 million, including payment-in-kind interest. The timing of future payments on the outstanding borrowing amounts, by year, as well as additional information regarding Alvotech&#8217;s borrowings and rights conveyed to the lenders, can be found in Note 21 of the audited consolidated financial statements, included elsewhere in this Form 20-F.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Senior Bonds </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of 31 December 2023, the carrying amount of the Senior Bonds was $549.4&#160;million. The Senior Bonds mature in June 2025 and the Group has the option, at any time, to prepay all or any part of the outstanding bonds in exchange for the payment of the redemption premium pursuant to the terms of the agreement.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">2022 Convertible Bonds</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of 31&#160;December 2023, the Tranche A and Tranche B Convertible Bonds was $107.1 million and $48.8 million, respectively. Holders of both the Tranche A and Tranche B of the 2022 Convertible Bonds, may elect, at their sole discretion, to convert all or part of the principal amount and accrued interest into Alvotech Ordinary Shares at a conversion price of $10.00 per share on 31 December 2023, 30 June 2024, or upon optional or mandatory redemption of the bonds.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Aztiq Convertible Bond</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of 31&#160;December 2023, the carrying amount of the Aztiq Convertible Bond was  $80.7 million. The maturity date of the convertible bond is the later of the (i) 16 November 2025, or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Bondholders have the right to convert their outstanding bonds into ordinary shares of Alvotech on 31 December 2023, 30 June 2024, or upon optional or mandatory redemption, for a conversion price of $10.00 per share.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Alvogen Facility</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Facility Loans is $48.5 million. Accrued interest on the Facility Loans as of 31&#160;December 2023 is $0.3 million. The first loan includes annuity payments that are due monthly with a final maturity in December 2029 and a variable interest rate of USD Secured Overnight Funding Rate ("SOFR") plus a margin </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 4.75%. The second loan is a bullet loan with a final maturity in December 2027 and a variable interest rate of USD SOFR plus a margin of 3.75%</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other borrowings</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 22 February 2022, the Group entered into a credit facility agreement with Landsbankinn hf. with the ability to draw down an amount up to $8 million. The credit facility is in place to help finance equipment purchases in the future. Per the terms of the credit facility, any borrowings are required to be paid by 1 August 2024 and have a variable interest rate of USD SOFR plus a margin of 4.95%. As of 31&#160;December 2023, the outstanding balance on the credit facility was $7.8&#160;million. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 22 February 2022, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $3.2 million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in March 2029. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $2.5&#160;million.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 5 August 2022, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $1.8 million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in August 2029. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $1.6&#160;million. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 4 August 2023, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $11.5&#160;million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in August 2030. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $11.0&#160;million.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 14 December 2023, the Group entered into a qualified receivable financing agreement with Landsbankinn hf. for a principal amount of $25.0 million. The qualified receivable financing arrangement has a variable interest rate of USD SOFR plus a margin of 3.50% and a maturity of April 2024. As of 31&#160;December 2023, the outstanding balance on the loan was $25.0&#160;million.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech&#8217;s future undiscounted payments pursuant to lease agreements totaled $155.4&#160;million as of 31&#160;December 2023, compared to $48.4 million as of 31&#160;December 2022. The timing of these future payments can be found in Note 13 of the audited consolidated financial statements included elsewhere in this Form 20-F.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other long-term liability to a related party </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech acquired certain rights for the commercialization of its biosimilar Adalimumab product in certain territories in Asia from Lotus Pharmaceutical Co. Ltd., a related party, during the year ended 31 December 2020. Pursuant to the terms of the asset acquisition, Alvotech is required to pay $7.4 million upon the commercial launch of Adalimumab in China which became due on 31&#160;December 2023.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Purchase obligations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended 31&#160;December 2023, 2022, and 2021, Alvotech did not have any purchase obligations. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While Alvotech does not have legally enforceable commitments with respect to capital expenditures, Alvotech expects to continue to make substantial investments in preparation for commercial launch of its biosimilar product candidates. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Operating Capital Requirements</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the Company had cash and cash equivalents, excluding restricted cash, of $11.2 million. In February 2024, Alvotech accepted an offer for the sale of 10,127,132 Ordinary Shares for gross proceeds of approximately $166&#160;million. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, even with the aforementioned cash as of 31&#160;December 2023 and the proceeds from the February 2024 private placement, Alvotech&#8217;s management has determined that there is a material uncertainty that may cast significant </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">doubt about its ability to continue as a going concern as described in Note 1.4 of the audited consolidated financial statements included elsewhere in this Annual Report on Form 20-F. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech&#8217;s future funding requirements will depend on many factors as detailed elsewhere in this Annual Report. See the risk factor entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;We may need to raise substantial additional funding from shareholders or third parties. This additional funding may not be available on acceptable terms or at all. Failure to obtain such necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.&#8221; in Item 3.D.</span></div><div id="ie527079dad0a4810aa92569387637e3d_70"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Research and Development, Patents and Licenses, etc. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Full details of our research and development activities and expenditures are given in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Item 4.B. Information on the Company&#8212;Business Overview&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Item 5 Operating and Financial Review and Prospects&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sections of this Annual Report on Form 20-F above. </span></div><div id="ie527079dad0a4810aa92569387637e3d_73"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">Trend Information </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other than as described elsewhere in this Annual Report on Form 20-F, we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material adverse effect on our revenue, income from continuing operations, profitability, liquidity or capital resources, or that would cause our reported financial information not necessarily to be indicative of future operation results or financial condition. </span></div><div id="ie527079dad0a4810aa92569387637e3d_76"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech has prepared its financial statements in accordance with IFRS. The preparation of these financial statements requires Alvotech to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and related disclosures at the date of the financial statements, as well as revenue and expense recorded during the reporting periods. Alvotech evaluates its estimates and judgments on an ongoing basis. Alvotech bases its estimates on historical experience and other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably possible could materially impact the financial statements. Alvotech&#8217;s significant accounting policies are described in more detail in Note 2 of the audited consolidated financial statements as of 31&#160;December 2023, and for the three years ended 31&#160;December 2023, included elsewhere in this Annual Report on Form 20-F. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Revenue recognition </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Product revenue </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue from the sale of its biosimilar product to commercial partners, identified as the customer, when control is transferred, and the performance obligations have been satisfied. This is when the title passes to the customer, which is upon shipment of the product. At that point, the commercial partner has full discretion over the channel and price to sell the products. Revenue is recognized based on the net selling price from the commercial partners, which is considered to be the transaction price and includes estimated rebates, returns and chargebacks, and other forms of variable consideration recognized by the Customer. Variable consideration is accounted for by the Company only to the extent that it is highly probable that a significant reversal in the revenue recognized will not occur. Variable consideration, which includes any adjustments to the net selling price, is estimated based on the most likely amount method on a contract-by-contract basis. The Company uses historical and market data in determining the most likely amount of variable consideration. These estimates are reviewed each reporting period and involve inherent uncertainty and management&#8217;s judgement. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Out-licensing revenue </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consideration to which Alvotech is entitled pursuant to these contracts generally includes upfront payments and payments based upon the achievement of development and regulatory milestones. All contracts include a potential refund obligation whereby Alvotech must refund the consideration paid by the partner in the event of a technical failure or the occurrence of certain other matters that result in partial or full cancellation of the contract. As such, the entire transaction price is comprised of variable consideration, which is estimated using the most likely amount method due to the binary nature of the outcomes under these contracts. Such variable consideration is included in the transaction price only when it </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">is highly probable that doing so will not result in a significant reversal of cumulative revenue recognized when the underlying uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standalone selling prices of the development services and the license to intellectual property are not directly observable and, therefore, are estimated. The standalone selling price of the development services is estimated using the expected cost plus a margin approach, using various data points such as the underlying development budget, contractual milestones, and performance completed at the time of entering into the contract with a partner. The standalone selling price of the license is estimated using the residual approach on the basis that the Alvotech licenses intellectual property for a broad range of amounts and has not previously licensed intellectual property on a standalone basis. Therefore, Alvotech first allocates the transaction price to the development services and subsequently allocates the remainder of the transaction price to the license. Inputs used to determine the standalone selling price of the development services are reviewed by management each reporting period. Changes to these inputs, including changes to the underlying development budget, could impact the timing in which revenue is recognized. The Company has not made any changes to the inputs used in determining the standalone selling price. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Valuation of derivative financial instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech recognized derivative financial liabilities related to warrants, earn out shares and conversion features. The fair values of the derivative liabilities were determined using an option pricing-based approach that incorporated a range of inputs that are both observable and unobservable in nature. The observable and unobservable inputs used in the initial and subsequent fair value measurements relate to (i) the fair value of Ordinary Shares, (ii) the volatility of the Ordinary Shares, (iii) a risk-adjusted discount rate corresponding to the credit risk associated with the repayment of the host debt instruments, and (iv) the probabilities of each derivative being exercised by the holder and the timing of such exercises. The probabilities are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The assumptions underlying the valuations represent Alvotech&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if Alvotech used significantly different assumptions or estimates, its finance costs for prior periods could have been materially different. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Valuation of deferred tax assets </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech recognizes deferred tax assets for all deductible temporary differences and unused tax losses to the extent that it is probable that taxable profits will be available against the deductible temporary differences that can be utilized after consideration of all available positive and negative evidence. Estimation of the level of future taxable profits and the application of relevant jurisdictional tax legislation regarding loss expiry rules, non-deductible expenses, and other guidance are required in order to determine the appropriate carrying value of deferred tax assets. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech&#8217;s estimation of the level of future taxable profits is primarily driven by an evaluation of executed out-license contracts and the expected timing of revenue recognition from such contracts. Alvotech considers the amount of revenues that relate to the various phases of development for its biosimilar product candidates, with greater certainty attributed to revenues earned upon contract execution and before later-stage clinical trials and no certainty attributed to revenues that relate to future sales targets on the basis that such amounts are dependent on events that are not within Alvotech&#8217;s control. These forecasts are also evaluated to incorporate potential uncertainty associated with the amount and timing of expected future revenues, driven by factors such as potential competition and the inherent risk associated with biosimilar product development. Changes to these forecasts, and the inputs used in determining the underlying cash flows involve inherent uncertainties and the application of management&#8217;s judgement. As a result, if Alvotech used significantly different assumptions or estimates, its valuation of deferred tax assets for current and prior periods could have been materially different. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amount of deferred tax assets is reviewed at the end of each reporting period and is reduced to the extent it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.  </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Determination of recoverable amounts of investments in joint venture</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After application of the equity method, the Group determines whether it is necessary to recognise an impairment loss on its investment in its joint venture. At each reporting date, the Group determines whether there is objective evidence that the investment in the joint venture is impaired. The Group determined that, considering the uncertainties around the economic conditions in China, there were indicators of potential impairment. The Group calculates the amount of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">impairment as the difference between the recoverable amount of the joint venture and its carrying value. The Group estimated the recoverable amount based on estimated future cash flows from the ultimate disposal of the investment.</span></div><div id="ie527079dad0a4810aa92569387637e3d_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 6.&#160;&#160;&#160;&#160;Directors, Senior Management and Employees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div id="ie527079dad0a4810aa92569387637e3d_82"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Directors and senior management. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the executive officers and directors of Alvotech. Unless otherwise noted, the business address of each of the directors and executive officers of Alvotech is 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Executive Officers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer and Executive Chairman of the Board of Directors</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tanya Zharov</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Joseph E. McClellan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Scientific Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Operating Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Joel Morales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%">Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director and Deputy Chairman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Arni Hardarson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Executive Officers </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Robert Wessman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is the founder and has served as Executive Chairman and member of the board of directors of Alvotech since January 2019, and chief executive officer since January 2023. Since November 2018, he has also served as Director at Fuji Pharma and chairman of the board of directors of Lotus Pharmaceuticals and since May 2009, he has served as a member of the board of directors of Aztiq and as a member of the board of directors of Aztiq GP, the general partner of Aztiq Fund I SCSp, a Luxembourg alternative investment fund, and the parent company of Aztiq. Mr. Wessman is also the founder and main partner of the Aztiq group. Mr. Wessman founded Alvogen in July 2009, and served as its Executive Chairman and Chief Executive Officer until June 2022. He continues to serve as Alvogen&#8217;s chairman since July 2022. Between 1999 and 2008, Mr. Wessman served as the Chief Executive Officer of Actavis. He has a Bachelor of Science degree in Business Administration from the University of Iceland. We believe Mr. Wessman is qualified to serve on Alvotech&#8217;s board of directors due to the perspective he brings as Alvotech&#8217;s founder and his experience in top executive positions in the pharmaceutical industry. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tanya Zharov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has served as our General Counsel since January 2023 and Deputy Chief Executive Officer between May 2020 and December 2022. Prior to joining Alvotech, between 2016 and 2020, Ms. Zharov served as Deputy Chief Executive Officer and compliance officer of deCODE genetics. Prior to that, Ms. Zharov held various management positions, including as General Counsel and Deputy Chief Executive Officer at Virding hf from January 2014 to January 2016, as General Counsel and Deputy Chief Executive Officer at Audur Capital from January 2008 to December 2013, as Board Secretary, corporate counsel and Vice President Corporate Governance and Administration at deCODE genetics from July 2003 to December 2007, and as tax partner at PricewaterhouseCoopers from June 1996 to December 1998. Ms. Zharov holds a law degree from the University of Iceland and is a European Patent Attorney. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Joseph E. McClellan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has served as our Chief Scientific Officer since October 2019. Prior to joining Alvotech, Mr. McClellan served for over 17 years in various roles at Pfizer Inc., including as Global Head of Biosimilars Development and Medicine/Asset Team Leader of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IXIFI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (biosimilar infliximab). Mr. McClellan holds a PhD degree in Chemistry, with a focus in Analytical Chemistry and Mass Spectrometry, from the University of Florida, and he was a Postdoctoral Fellow in Mass Spectrometry and Analytical Biochemistry at the Boston University School of Medicine. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Joel Morales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has served as our Chief Financial Officer since February 2020 after serving as Chief Financial Officer at our affiliated company Alvogen since 2017. Prior to joining Alvotech he held various positions of increasing responsibility with Endo International plc., from January 2015 to September 2017, with his last position as Senior Vice President of the Generics Business Segment and Global Finance Operations. Prior to that, Mr. Morales spent ten years working for large multinational pharmaceutical companies, including Merck and Schering Plough. Mr. Morales began his career at KPMG as a licensed certified public accountant in the State of New Jersey and has a Bachelor of Science degree in Accounting from Rutgers University. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Faysal Kalmoua</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has served as Chief Operating Officer since September 2023 and as one of Alvotech&#8217;s directors since June 2020. Mr. Kalmoua has also served as a partner of the Aztiq group since June 2022. Between April 2020 and June 2022, Mr. Kalmoua served as Executive Vice President of Portfolio, Business Development and Research and Development for Alvogen Iceland ehf. and Alvogen, Inc. Between November 2015 and March 2020, Mr. Kalmoua served as Executive Vice President of Portfolio for Alvogen, Inc. Prior to joining Alvogen, Mr. Kalmoua served in various management positions for Synthon for nearly 16 years. Mr. Kalmoua holds a Master&#8217;s degree in Chemistry from the Radboud University Nijmegen and an executive MBA from Insead. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Non-Executive Directors </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Richard Davies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">has served Deputy Chairman of Alvotech&#8217;s board, previously Chairman of Alvotech&#8217;s board, and as one of Alvotech&#8217;s directors since January 2019. Since November 2018, he has served as Chief Executive Officer of Auregen Bio Therapeutics SA. Prior to joining Auregen Bio Therapeutics, Mr. Davies served as Chief Executive Officer of Bonesupport AB between 2016 and 2018, as Senior Vice President and Chief Commercial Officer of Hospira Inc. between 2012 and 2015, and in various leadership roles at Amgen Inc between 2003 and 2012. Mr. Davies holds an MBA from the University of Warwick and Bachelor of Science in applied chemistry from the University of Portsmouth. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tomas Ekman </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">has served as one of Alvotech&#8217;s directors since January 2019. Since November 2014 he has served as a partner at CVC Capital Partners where he is a member of the CVC Nordics team and is based in Stockholm. Prior to joining CVC in 2014, Mr. Ekman was a partner and Managing Director at 3i, responsible for its Nordic business. Mr. Ekman holds MSc degrees from the University of Strathclyde and Chalmers University of Technology, and an MBA from IMD, Switzerland. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ann Merchant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has served as one of Alvotech&#8217;s directors since June 2022. Since 2018, she has served as Vice President for MorphoSys, and as Head of Global Supply Chain since January 2019. Prior to joining MorphoSys, from September 2011 to August 2018, Ms. Merchant served as the President for Schreiner Medipharm. Between 1994 and 2011, Ms. Merchant held various roles at Amgen, including Vice President, Head of International Supply Chain and Site Head between 2007 and 2011. Ms. Merchant holds an MBA from the Henley Business School and a Bachelor of Science in Languages from Georgetown University. We believe Ms. Merchant is qualified to serve on Alvotech&#8217;s board of directors because of her experience in executive positions with several pharmaceutical companies and expertise in financial planning, new product launches and creating and executing international strategies to increase market share. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Arni Hardarson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has served as one of Alvotech&#8217;s directors since June 2022. Mr. Hardarson is a co-founder and partner of the Aztiq group. Between 2009 and June 2022, he served as Deputy to the Chief Executive Officer and General Counsel of Alvogen. Prior to joining Alvogen, Mr. Hardarson was Vice President of Tax and Structure at Actavis, and as partner, member of the executive management committee, and served as a head of tax and legal at Deloitte. Mr. Hardarson holds a Master&#8217;s degree in law from the University of Iceland. We believe Mr. Hardarson is qualified to serve on Alvotech&#8217;s board of directors because of his extensive expertise in financial and legal matters and his past experience in top executive positions. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lisa Graver </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">has served as one of Alvotech&#8217;s directors since June 2022. Ms. Graver has served in various leadership positions for Alvogen since June 2010, including as President of Alvogen Inc, a subsidiary of Alvogen, since August 2015, as Executive Vice President and Deputy to the Chief Executive Officer of Alvogen Inc. since February 2013, and as Vice president Intellectual Property of Alvogen since June 2010. Prior to joining Alvogen, Ms. Graver was Vice President Intellectual Property and Senior Director Intellectual Property at Actavis Inc. between 2006 and 2008. Ms. Graver holds a BSc in Biology from Lakehead University and a law degree from the Case Western Reserve University School of Law. We believe Ms. Graver is qualified to serve on Alvotech&#8217;s board of directors because of her extensive expertise in intellectual property and the pharmaceutical industry. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Linda McGoldrick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> has served as one of Alvotech&#8217;s directors since June 2022. In 1985, Dr. McGoldrick founded, and currently serves as Chairman and Chief Executive Officer of, Financial Health Associates International, a strategic consulting company specializing in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and life sciences. Since January 2020, she has served as the Chief Executive </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Officer for 2Enable Health LLC. Prior to joining 2Enable Health LLC, Dr. McGoldrick served as interim CEO at Zillion between June 2019 and December 2019. Over her professional career, Dr. McGoldrick has served in a number of leadership roles, including Senior Vice President and National Development Director for the Healthcare and Life Sciences Industry Practices at Marsh-MMC Companies, International Operations and Marketing Director of Veos plc, and Managing Director Europe for Kaiser Permanente International. In 2018, Dr. McGoldrick was appointed by the Governor of Massachusetts to serve on the state&#8217;s Health Information Technology Commission. Dr. McGoldrick has served as a director of numerous publicly traded and private held companies and non-profit organizations in the U.S., UK and Europe, including as director for Compass Pathways since September 2020. In 2012, Dr. McGoldrick was named as one of the Top 100 Corporate Directors of Fortune 100 Companies by the Financial Times. Dr. McGoldrick holds a Master&#8217;s Degree in Healthcare from the University of Pennsylvania and an MBA from Wharton. We believe Dr. McGoldrick is qualified to serve on Alvotech&#8217;s board of directors because of her extensive expertise in financial matters and the healthcare and life sciences industry. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Diversity of the Board of Directors </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below provides certain information regarding the diversity of our board of directors as of the date of this Annual Report. </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board Diversity Matrix (As of December 31, 2023)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Country of Principal Executive Offices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Luxembourg</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Foreign Private Issuer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Yes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Disclosure Prohibited under Home Country Law</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">No</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total Number of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Female</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Male</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-Binary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Did Not</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disclose</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Gender</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Part I: Gender Identity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr><tr><td colspan="27" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Part II: Demographic Background</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Underrepresented Individual in Home Country Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">LGBTQ+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Did Not Disclose Demographic Background</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Family Relationships </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are no family relationships among any of our executive officers or directors. </span></div><div style="margin-top:18pt"><span><br/></span></div><div id="ie527079dad0a4810aa92569387637e3d_85"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Compensation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Compensation of Executive Officers </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of our executive officers has entered into an employment agreement with us for an indefinite period of time. The agreements provide the terms of each individual&#8217;s employment or service with us, as applicable. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each employment agreement contains provisions regarding non-competition, non-solicitation, confidentiality of information and assignment of inventions. The enforceability of the non-competition covenants is subject to limitations. Either we or the executive officer may terminate the applicable executive officer&#8217;s employment or service by giving advance written notice to the other party. We may also terminate an executive officer&#8217;s employment or services agreement for cause (as defined in the applicable employment or services agreement). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our executive compensation program reflects its compensation policies and philosophies, as they may be modified and updated from time to time. In addition to a base salary and certain performance-based bonuses, executive officers can be eligible to receive awards under our 2022 equity incentive plan, the Alvotech Management Incentive Plan (the &#8220;2022 Plan&#8221;), as further described below. Decisions with respect to the compensation of our executive officers, including our named executive officers, are made by the compensation committee of our board of directors. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth information regarding compensation earned by Robert Wessman, our Chief Executive Officer and our other members of the leadership team during the years ended 31&#160;December 2023. </span></div><div style="margin-top:12pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Key employees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Salaries and benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Termination benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long- term benefits</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman CEO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.37pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Members of the Leadership Team</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">372&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth information regarding compensation earned by Mark Levick, our former Chief Executive Officer until December 31, 2022, and our other executive officers during the years ended 31 December 2022. </span></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Key employees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Salaries and benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Termination benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long- term benefits</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mark Levick CEO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.37pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Members of the Leadership Team</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">820&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">608&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Compensation of Directors </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the Annual General Meeting of Alvotech on 6 June 2023 &#8211; the shareholders approved the compensation for the board of directors which applies to the independent directors, additionally the shareholders approve a remuneration policy under Lux law.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All vesting of the restricted stock units is subject to the non-employee director&#8217;s continuous service on the applicable vesting date. However, for each eligible director who remains in continuous service until immediately prior to the occurrence of a change in control (as such term is defined in the 2022 Plan), the shares subject to his or her then-outstanding restricted stock unit awards will become fully vested immediately prior to the closing of such change in control event. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will also reimburse our non-employee directors for their reasonable out-of-pocket expenses in connection with attending board and committee meetings. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables sets forth information regarding compensation earned by each of our directors during the years ended 31&#160;December 2023 and 2022: </span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"><tr><td style="width:1.0%"/><td style="width:45.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors&#8217; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Board fees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension <br/>contribution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">year-end**</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman, Chairman of the board*</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies, Vice-Chairman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,143,713</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant, Board Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#193;rni Har&#240;arson, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua, Board Member*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick, Board Member</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver, Board Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">421&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">416&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,175,459</span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Waived their board compensation (both cash and equity)</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Direct share ownership </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"><tr><td style="width:1.0%"/><td style="width:45.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors&#8217; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Board fees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long-term benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">year-end**</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman, Chairman of the board</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies, Vice-Chairman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,133,131</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#193;rni Har&#240;arson, Board Member (from 16.6.2022)*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua, Board Member*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Hirofumi Imai, Board member (until 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">927&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,133,131</span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Waived their board compensation (both cash and equity) </span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Direct share ownership </span></div><div style="margin-top:18pt;padding-left:27pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Management Incentive Plan </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 13 June 2022, our chairman adopted, and our shareholders approved, a new 2022 equity incentive plan, the Management Incentive Plan (the &#8220;2022 Plan&#8221;). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The 2022 Plan will provide for the grant of shares, restricted shares units, options or any combination of the foregoing including such other Awards that may be denominated or payable in, value in whole or in part, by reference to or otherwise based upon, or related to, shares (the &#8220;Awards&#8221;) to our employees, directors, and consultants and any of our affiliates&#8217; employees and consultants. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Authorized Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Initially, the maximum number of Ordinary Shares that may be issued under the 2022 Plan after it becomes effective will not exceed 5.79% of our share capital on a fully diluted basis. In addition, the number of Ordinary Shares reserved for issuance under the 2022 Plan may be increased by our board of directors by up to 1% annually over ten (10) years from the date of approval of the 2022 Plan. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Plan Administration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our board of directors, or any person or persons or committee to whom decision-making authority with respect to the 2022 Plan is delegated by our board of directors (the &#8220;Administrator&#8221;) will administer the 2022 Plan. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Plan Amendment or Termination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our board of directors and the Administrator have the authority to amend or, suspend, the 2022 Plan at any time and from time to time, and our board of directors has the authority to terminate the 2022 Plan provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our shareholders. No Awards may be granted after the tenth anniversary of the date our board of directors adopted the 2022 Plan. No Awards may be granted under the 2022 Plan while it is suspended or after it is terminated. Rights under any Award granted before suspension or termination of the 2022 Plan shall not be impaired by such suspension or termination. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 1 December 2022, our Remuneration Committee authorized the grant of restricted stock units (&#8220;RSUs&#8221;) to certain employees, executive officers and directors under the 2022 Plan. Subject to certain vesting and other terms and conditions, the RSUs may be settled in Ordinary Shares. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Annual General Meeting of the shareholders approved the Remuneration Policy and the Remuneration of the Alvotech board.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the year 2023, our Remuneration Committee authorized the grant of a total of 820,602 RSUs to certain employees and executive officers under the 2022 Plan</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">If all RSUs vest and are exchanged for Ordinary Shares, the combined grants may result in an aggregate of 6,891,717 Ordinary Shares. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management Share Appreciation Rights Agreements </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of its long-term incentive program, Alvotech hf. had entered into &#8220;phantom share agreements,&#8221; which were defined as Share Appreciation Rights (&#8220;SARs&#8221;) for financial purposes, with certain members of management. The vesting conditions of the SARs under the phantom share agreements were linked to certain milestones in our operations and the payment amounts were determined by the increase in our market value from the grant date of the SARs until the triggering event occurred. The SARs did not give the beneficiaries dividend rights, voting rights or the right to purchase shares of Alvotech but required Alvotech to pay the beneficiaries a cash payment associated with the occurrence of certain designated triggering events. In conjunction with the Business Combination, Alvotech terminated deferred compensation arrangements by entering into settlement agreements with the three former employees and one current employee that had outstanding rights under the phantom share agreements of $38.1 million as of the Closing. Alvotech further agreed with the two other former employees to settle each of their respective claims of $17.5 million, as may be reduced by any applicable tax withholdings, through the allocation of a number of Ordinary Shares by dividing their respective claims by a per share price of $10.00, rounded to the nearest whole share. The shares were allocated to them on 16 June 2023, one year and one day following the Closing which was settled in cash on 16 June 2023.</span></div><div id="ie527079dad0a4810aa92569387637e3d_88"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Board Practices </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Composition of Our Board of Directors </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors is currently composed of eight members. In accordance with our articles of association, the board of directors is not divided into classes of directors. Each director was appointed at the closing of the Business Combination on 15 June 2022, to serve as director until the end of the general meeting of shareholders called to approve our annual accounts for the 2024 financial year. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Three of eight directors are independent as defined in Nasdaq listing standards and applicable SEC rules and our board of directors has an independent audit and risk committee, a nominating committee, a compensation committee. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Non-Executive Director Appointment Letters </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our independent non-executive directors are engaged on letters of appointment that set out their duties and responsibilities. The non-executive directors do not receive benefits upon termination or resignation from their respective positions as directors. Under the non-executive director appointment letters, our non-executive directors are entitled to receive annual fees in accordance with our Director Compensation Policy, as discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 6.B Compensation&#8212;Compensation of Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Committees of our Board of Directors </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors has five standing committees: an audit and risk committee, a compensation committee, a nominating and corporate governance committee, a strategy committee and a Corporate Sustainability Committee. The board has adopted written charters that are available to shareholders on our website at https://investors.alvotech.com/corporate-governance/documents-charters for the audit and risk committee, the compensation committee, and the nominating and corporate governance committees. The reference to our website address in this Annual Report on Form 20-F does not include or incorporate by reference the information on our website into this Annual Report on Form 20-F.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Audit and Risk Committee </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The members of our audit and risk committee are Dr. McGoldrick (Chair), Ms. Merchant and Mr. Davies. Each member of our audit and risk committee qualifies as independent directors according to the rules and regulations of the SEC and Nasdaq with respect to audit and risk committee membership. In addition, all audit and risk committee members meet the requirements for financial literacy under applicable SEC and Nasdaq rules and at least one of the audit and risk committee members qualifies as an &#8220;audit and risk committee financial expert,&#8221; as such term is defined in Item 407(d) of Regulation S-K. The audit and risk committee is responsible for, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">appointing, compensating, retaining, evaluating, terminating and overseeing our independent registered public accounting firm; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">discussing with our independent registered public accounting firm their independence from management; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">reviewing, with our independent registered public accounting firm, the scope and results of their audit; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">approving all audit and permissible non-audit services to be performed by our independent registered public accounting firm; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the annual financial statements that we file with the SEC; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">overseeing our financial and accounting controls and compliance with legal and regulatory requirements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">reviewing our policies on risk assessment and risk management; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">reviewing related party transactions; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal controls or auditing matters. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Compensation Committee </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The members of our compensation committee are Mr. Davies (Chair), Mr. Hardarson and Mr. Ekman. Mr. Davies qualifies as independent directors according to the rules and regulations of the SEC and Nasdaq with respect to compensation committee membership, including the heightened independence standards for members of a compensation committee. The compensation committee is responsible for, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">reviewing and approving the corporate goals and objectives, evaluating the performance of and reviewing and approving, (either alone or, if directed by the board of directors, in conjunction with a majority of the independent members of the board of directors) the compensation of our chief executive officer; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">overseeing an evaluation of the performance of and reviewing and setting or making recommendations to our board of directors regarding the compensation of our other executive officers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">reviewing and approving or making recommendations to our board of directors regarding our incentive compensation and equity-based plans, policies and programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">reviewing and approving all employment agreement and severance arrangements for our executive officers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">making recommendations to our shareholders regarding the compensation of our directors; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">retaining and overseeing any compensation consultants. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Nominating and Corporate Governance Committee </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The members of our nominating and corporate governance committee are Mr. Davies (Chair), Ms. Merchant and Dr. McGoldrick. The nominating committee is responsible for, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">identifying individuals qualified to become members of our board of directors, consistent with criteria approved by our board of directors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">overseeing succession planning for our Chief Executive Officer and other executive officers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">periodically reviewing our board of directors&#8217; leadership structure and recommending any proposed changes to our board of directors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">overseeing an annual evaluation of the effectiveness of our board of directors and its committees; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">developing and recommending to our board of directors a set of corporate governance guidelines. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Corporate Sustainability Committee </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The members of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Corporate Sustainability Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are Ms. Merchant (Chair), Mr. Hardarson and Mr. Wessman. The ESG committee is responsible for, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">reviewing, monitoring and setting strategy in the area of corporate responsibility; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">overseeing our activities in the area of corporate responsibility that may have an impact on the Company&#8217;s reputation and operations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">periodically assess our compliance obligations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">monitor and review matters of health and safety and report findings to the broader board; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">review and evaluate environmental, social and political issues and trends and their relevance to our business and make recommendations to the board regarding those trends and issues. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Strategy Committee </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Strategy committee is responsible for, among other things, reviewing, monitoring and setting strategy for our business. The members of our Strategy committee are Mr. Faysal Kalmoua (Chair), Ms. Lisa Graver and Mr. Wessman. </span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk Oversight</span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The board of directors is responsible for overseeing our risk management process. The board of directors focuses on</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our general risk management strategy, the most significant risks, and oversees the implementation of risk mitigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategies by management. The audit and risk committee is also responsible for discussing our policies with respect to risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assessment and risk management. The board of directors believes its administration of its risk oversight function has not</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">negatively affected the board of directors&#8217; leadership structure.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Code of Business Conduct</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors adopted a Code of Business Conduct applicable to the directors, executive officers and team</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">members that complies with the rules and regulations of Nasdaq and the SEC. The Code of Ethics is available on our</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">website. In addition, we posted on the Corporate Governance section of our website all disclosures that are required by law</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the Code of Ethics. The</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reference to our website address in this Annual Report does not include or incorporate by reference the information on our</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">website into this Annual Report.</span></div><div id="ie527079dad0a4810aa92569387637e3d_91"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">Employees </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, we had 1,026 employees, including 27 contractors, 87% of whom were devoted to R&amp;D, quality and technical operations, and 13% to administration and support roles. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our Iceland-based employees are members of Icelandic labor unions and as such the bargaining agreements which these unions enter into with the Icelandic Confederation of Employers, of which Alvotech hf. is a member. We have not experienced any work stoppages and consider our relationship with our employees and the labor unions to be good. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">At 31 December</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Function:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">575</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">512</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">360</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">129</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">320</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">268</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">1,026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">947</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">732</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Geography:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">745</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">557</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">European Union</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Elsewhere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">1,026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">947</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">732</span></td></tr></table></div><div id="ie527079dad0a4810aa92569387637e3d_94"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Share Ownership </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For information regarding the share ownership of our directors and executive officers, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 7.A Major Shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 6.B Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for a discussion of the 2023 Plan. </span></div><div id="ie527079dad0a4810aa92569387637e3d_97"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation. </span></div><div style="margin-top:6pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7.&#160;&#160;&#160;&#160;Major Shareholders and Related Party Transactions </span></div><div id="ie527079dad0a4810aa92569387637e3d_103"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Major Shareholders </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth information regarding the beneficial ownership of Ordinary Shares as of 15 February 2024 by: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">each person known by us to be the beneficial owner of more than 5% of Ordinary Shares; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">each of our directors and executive officers; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">all our directors and executive officers as a group. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except as otherwise noted herein, the number and percentage of Ordinary Shares beneficially owned is determined in accordance with Rule 13d-3 of the Exchange Act, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, beneficial ownership includes any Ordinary Shares as to which the holder has sole or shared voting power or investment power and also any Ordinary Shares which the holder has the right to acquire within 60 days of 15 February 2024 through the exercise of any option, warrant or any other right. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except as otherwise indicated, all of the shares reflected in the table are ordinary shares and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have based percentage ownership on 266,821,844 Ordinary Shares outstanding as of 15 February 2024. </span></div><div style="margin-top:12pt;padding-left:54pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.151%"><tr><td style="width:1.0%"/><td style="width:65.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name and Address of Beneficial Owners</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Directors and Executive Officers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Richard Davies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,153,634</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:114%;position:relative;top:-4.2pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Arni Hardarson</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:114%;position:relative;top:-4.2pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:114%;position:relative;top:-4.2pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,503</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:114%;position:relative;top:-4.2pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,683</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tanya Zharov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:114%;position:relative;top:-4.2pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,166</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Joseph E. McClellan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:114%;position:relative;top:-4.2pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">277,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Joel Morales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:114%;position:relative;top:-4.2pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">208,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">All Directors and Executive Officers as a group (11 persons)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,845,102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Five Percent Holders Post-Business Combination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvogen Lux Holdings S.&#224; r.l.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,005,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Aztiq Pharma Partners S.&#224; r.l.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101,165,374</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">___________</span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Indicates beneficial ownership of less than 1% of the total ordinary shares outstanding.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Unless otherwise noted, the business address of each of the directors and executive officers is 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Consists of 97,880 unvested Earn Out Shares and 9,921 vested RSUs held by Richard Davis. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Consists of 9,921 vested RUSs held by Ann Merchant.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Consists of 9,921 vested RSUs held by Lisa Graver.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Consists of 9,921 vested RSUs held by Linda McGoldrick.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Consists of 39,683 vested RSUs held by Faysal Kalmoua.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Consists of 104,166 vested RSUs held by Tanya Zharov.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Consists of 277,778 vested RSUs held by Joseph McClellan.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Consists of 208,332 vested RSUs held by Joel Morales.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.34pt">Represents shares held by Alvogen Lux Holdings S.&#224; r.l. (&#8220;Alvogen&#8221;). Through intermediary holding entities, Alvogen is a wholly-owned subsidiary of Celtic Holdings SCA (&#8220;Celtic Holdings&#8221;). Investment and voting decisions with respect to the shares held by Alvogen are made by the directors of Celtic Holdings. Carmen Andre, Tomas Ekman, Arni Hardarson, Park Jung Ryun, Christoffer Sj&#248;qvist and Robert Wessman are the directors of Celtic Holdings and may be deemed to have shared voting and dispositive power with respect to the shares held by Alvogen. Carmen Andre, Tomas Ekman, Arni Hardarson, Park Jung Ryun, Christoffer Sj&#248;qvist and Robert Wessman each disclaim any beneficial ownership of any such shares, except to the extent of their pecuniary interest therein, if any. The address of Alvogen is 5, rue Heienhaff, L-1736 Senningerberg, Luxembourg, Grand-Duchy of Luxembourg and the address of Celtic Holdings is 20, avenue Monterey, L-2163 Luxembourg, Grand-Duchy of Luxembourg.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.34pt">Represents shares held by Aztiq Pharma Partners S.&#224; r.l. (&#8220;APP&#8221;). APP is a wholly-owned subsidiary of Aztiq Fund I SCSp (&#8220;Aztiq Fund&#8221;). Investment and voting decisions at Aztiq Fund are made by its general partner, Floki GP S.&#224; r.l. (&#8220;Aztiq GP&#8221;). Investment and voting decisions with respect to the shares held by APP are made by the members of the board of managers of Aztiq GP. Arni Hardarson, Johann Johannsson, Danny Major, Marc Levebvre and Robert Wessman are members of the board of managers of Aztiq GP and may be deemed to have shared voting and dispositive power with respect to the shares held by APP in Alvotech. Arni Hardarson, Johann Johannsson, Danny Major, Marc Levebvre and Robert Wessman each disclaim any beneficial ownership of any such shares, except to the extent of their pecuniary interest therein, if any. The address of APP is 5, rue Heienhaff, L-1736 Senningerberg, Grand-Duchy of Luxembourg and the address of Aztiq Fund and Aztiq GP is at 4 rue Robert Stumper, L-2557 Luxembourg, Grand-Duchy of Luxembourg.</span></div><div style="text-indent:-9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Voting Rights </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The voting rights of the principal shareholders do not differ from the voting rights of other shareholders. </span></div><div style="margin-top:18pt;padding-left:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Shareholders in the United States </span></div><div style="margin-top:6pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31 January 2024, to the best of our knowledge 67,081,130 of our outstanding ordinary shares were held by eight shareholders of record in the United States. The actual number of holders is greater than these numbers of record holders, and includes beneficial owners whose ordinary shares are held in street name by brokers and other nominees. This number of holders of record also does not include holders whose shares may be held in trust by other entities. </span></div><div id="ie527079dad0a4810aa92569387637e3d_106"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Related Party Transactions </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Policies and Procedures for Related Person Transactions </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board of Directors has adopted a written related person transaction policy that sets forth certain policies and procedures for the review and approval or ratification of transactions involving us in which a related person has or will have a direct or indirect material interest, as determined by the audit and risk committee of the Board. A &#8220;related person&#8221; for purposes of the policy means: (i) enterprises that directly or indirectly through one or more intermediaries, control or are controlled by, or are under common control with, us; (ii) Associates (defined as, unconsolidated enterprises in which we have a Significant Influence or which has Significant Influence over us); (iii) individuals owning, directly or indirectly, an interest in the voting power of us that gives them Significant Influence over us, and close members of any such individual&#8217;s family; (iv) key management personnel (i.e., having authority and responsibility for planning, directing and controlling our activities), including Directors and close members of such individuals&#8217; families; and (v) enterprises in which a substantial interest in the voting power is owned, directly or indirectly, by any person described in (iii) or (iv) above or over which such a person is able to exercise Significant Influence, including enterprises owned by our Directors or major shareholders and enterprises that have a member of key management in common with us. &#8220;Significant Influence&#8221; for purposes of the policy means the power to participate in the financial and operating policy decisions of an enterprise but is less than control over those policies, provided that shareholders beneficially owning a 10% or more interest in the voting power of the enterprise concerned are presumed to have a significant influence on such enterprise. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the policy, each executive director, nominee for the position of executive director and executive officer shall promptly notify the designated contact of any transaction involving us and a related person. The designated contact will present any new related person transactions, and proposed transactions involving related persons, to the Audit and Risk Committee of the Board at its next occurring regular meeting. If the Audit and Risk Committee determines that the related person involved has a direct or indirect material interest in the transaction, and there therefore that the transaction is a related party transaction, the Audit and Risk Committee shall consider all relevant facts and circumstances, including the commercial reasonableness of the terms, the benefit and perceived benefit, or lack thereof, to the Company, opportunity costs of alternate transactions, the materiality and character of the Related Person&#8217;s direct or indirect interest, and the actual or apparent conflict of interest of the Related Person. The Audit and Risk Committee will not approve or ratify a Related Person Transaction unless it shall have determined that, upon consideration of all relevant information, the Transaction is in, or not inconsistent with, our best interests . On an annual basis, the Audit and Risk Committee shall review previously approved related person transactions, under the standard described above, to determine whether such transactions should continue. If after the review described above, the Audit and Risk Committee determines not to approve or ratify a related person transaction (whether such transaction is being reviewed for the first time or has previously been approved and is being reviewed), the transaction will not be entered into or continued. </span></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Lease agreements with related parties</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Lease agreement with Fasteignafelagid Eyjolfur hf.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Group entered into a lease agreement with Fasteignafelagid Eyjolfur hf. in April 2023 for a new facility in Iceland with remaining lease terms of approximately 15 years as of 31 December 2023. The building is 140,000 square feet and is currently in construction. The expansion is close to being finalized and is expected to be completed in 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Lease liabilities as of 31 December 2023 amount to $69.7 million. </span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Lease agreement with Fl&#243;ki Fasteignir ehf. (HRJ&#193;F ehf.)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Group entered into seven separate lease agreements with Fl&#243;ki Fasteignir ehf. (HRJAF ehf.) in 2023 for a group of apartment buildings in Iceland used for temporary housing of employees and third-party contractors. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">remaining lease terms leases approximate 8 years, on average, as of 31 December 2023. Lease liabilities as of 31 December 2023 for the new leases amount to $2.6 million.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Lease agreement with Alvogen UK Ltd.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Group entered into office sublease sharing agreement with Alvogen UK Ltd. in August 2023. The agreement was effective from 1 January 2023 and shall terminate upon the expiration or termination of the lease. The office is approximately 5,500 square feet and the group leases 30% of the premises, containing approximately 1,645 square feet of space. Lease liabilities as of 31 December 2023 amount to $0.6 million.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Lease agreement with Fl&#243;ki-Art ehf. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Group entered into an art lease agreement with Fl&#243;ki-Art ehf. in January 2023, as a result of the Share Purchase Agreement pursuant to which the Group rent pieces of art located in S&#230;mundargata 15-19, Reykjavik. The remaining lease term for the leased asset is 15 years as of 31 December 2023. Lease liabilities as of 31 December amount to $0.4 million.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Shareholder Loans and Financing </span></div><div style="margin-top:18pt;padding-left:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Aztiq Tranche A Convertible Bond </span></div><div style="margin-top:6pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 31 July 2023, as part of a private placement of subordinated convertible bonds for a principal amount of $100 million, ATP Holdings ehf., an affiliate of Aztiq, acquired Tranche A convertible bonds in an aggregate principal amount equal to $30.0 million (excluding any amount resulting from capitalization of PIK interest accrued) pursuant to the terms thereof) (the &#8220;Aztiq Tranche A Convertible Bond&#8221;). These Tranche A convertible bonds are ISK denominated and carries an annual payment-in-kind interest rate of 15% per year. The maturity date of the convertible bonds is the later of the (i) 20 December 2025 or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Holders of both the Tranche A convertible bonds, may elect, at their sole discretion, to convert all or part of the principal amount and accrued interest into Alvotech Ordinary Shares at a conversion price of $10.00 per share on 31 December 2023, or 30 June 2024, or upon optional or mandatory redemption of the bonds.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of 31&#160;December 2023, the outstanding carrying amount on the Aztiq Tranche A Convertible Bond was $15.9 million.</span></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div id="ie527079dad0a4810aa92569387637e3d_109"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Interests of Experts and Counsel </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 8.&#160;&#160;&#160;&#160;Financial Information. </span></div><div id="ie527079dad0a4810aa92569387637e3d_115"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Consolidated Statements and Other Financial Information </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our consolidated financial statements are appended at the end of this Annual Report, starting at page F-1.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividend Distribution Policy </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From the annual net profits of Alvotech, at least 5% shall each year be allocated to the reserve required by applicable laws (the &#8220;Legal Reserve&#8221;). That allocation to the Legal Reserve will cease to be required as soon and as long as the Legal Reserve amounts to 10% of the amount of the share capital of Alvotech. The legal reserve is not available for distribution. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not anticipate paying any cash dividends in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business and product candidates. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the Luxembourg law of August 10, 1915, on commercial companies, as amended (&#8220;Luxembourg Company Law&#8221;), the general meeting of shareholders, by a simple majority vote and based on the recommendation of our board of directors, shall resolve how the remainder of the annual net profits, after allocation to the Legal Reserve, will be disposed of by allocating the whole or part of the remainder to a reserve or to a provision, by carrying it forward to the next following financial year or by distributing it, together with carried forward profits, distributable reserves or share premium to the shareholders, each Ordinary Share entitling to the same proportion in such distributions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The board of directors may resolve that Alvotech pays out an interim dividend to the shareholders, subject to the conditions of article 461-3 of the Luxembourg Company Law and Alvotech&#8217;s articles of association. The board of directors shall set the amount and the date of payment of the interim dividend. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any share premium, assimilated premium or other distributable reserve may be freely distributed to the shareholders subject to the provisions of the Luxembourg Company Law and Alvotech&#8217;s articles of association. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions may be lawfully declared and paid only if our net profits and/or distributable reserves are sufficient under Luxembourg Company Law. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thus, in case of a dividend payment, each shareholder is entitled to receive a dividend right pro rata according to his or her respective shareholding. The dividend entitlement lapses upon the expiration of a five-year prescription period from the date of the dividend distribution. The unclaimed dividends return to Alvotech&#8217;s accounts. However, Alvotech does not anticipate paying cash dividends on our Ordinary shares in the foreseeable future. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Luxembourg withholding tax of 15% is generally due on dividends and similar distributions made by us to our shareholders, unless a reduced treaty rate or the participation exemption applies. No withholding tax is levied on capital gains and liquidation proceeds </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Legal Proceedings </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">operations. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8220;Item 3. Key Information&#8212;D. Risk factors&#8212;Legal proceedings that carry risk may occur from time to time, and their outcome may be uncertain&#8221; and &#8220;Item 3. Key Information&#8212;D. Risk factors&#8212;Our Canadian partner, JAMP, is involved in legal proceedings adverse to AbbVie that may have an impact on our AVT02 product in Canada.&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="ie527079dad0a4810aa92569387637e3d_118"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Significant Changes </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see Note 30. Subsequent Events, included in the audited consolidated financial statements starting at page F-1 included elsewhere in this Form 20-F. Other than the events included in this note, no significant changes have occurred. </span></div><div id="ie527079dad0a4810aa92569387637e3d_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9. &#160;&#160;&#160;&#160;The Offer and Listing. </span></div><div id="ie527079dad0a4810aa92569387637e3d_124"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Offer and Listing Details </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary Shares and Warrants are listed on The Nasdaq Stock Market LLC under the symbols ALVO and ALVOW, respectively. Ordinary Shares are also listed on the Nasdaq Iceland Main Market under the ticker symbol &#8220;ALVO&#8221; since 8 December 2022, and, prior to that, on the Nasdaq First North Growth Market since 23 June 2022 until their admission to trading to the Nasdaq Iceland Main Market. Prior to 15 June 2022, there was no public trading market for Alvotech&#8217;s Ordinary Shares or Warrants. </span></div><div id="ie527079dad0a4810aa92569387637e3d_127"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Plan of Distribution </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_130"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Markets </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary Shares and Warrants are listed on The Nasdaq Stock Market LLC under the symbol &#8220;ALVO&#8221; and &#8220;ALVOW&#8221;, respectively, since 16 June 2022. Ordinary Shares are also listed on the Nasdaq Iceland Main Market under the ticker symbol &#8220;ALVO&#8221; since 8 December 2022 and, prior to that, on the Nasdaq First North Growth Market since 23 June 2022 until their admission to trading to the Nasdaq Iceland Main Market. </span></div><div id="ie527079dad0a4810aa92569387637e3d_133"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">Selling Shareholders </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">133</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Dilution </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_139"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Expenses of the Issue </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_142"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 10. &#160;&#160;&#160;&#160;Additional Information. </span></div><div id="ie527079dad0a4810aa92569387637e3d_145"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Share Capital </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_148"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Memorandum and Articles of Association </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A copy of our Amended and Restated Articles of Association have been previously filed as Exhibit 99.3 to our report on Form 6-K filed with the SEC on 6 June, 2023, and is incorporated by reference into this Annual Report. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information set forth in Exhibit 2.11 is incorporated herein by reference. There are no limitations on the rights to own securities, including the rights of non-resident or foreign shareholders to hold or exercise voting rights on the securities imposed by the laws of Luxembourg or by our Articles. </span></div><div id="ie527079dad0a4810aa92569387637e3d_151"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Material Contracts </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the contracts described elsewhere in this Annual Report, the following are summaries of each material contract to which we are a party for the two years preceding the date of this Annual Report. For additional information on our material contracts, please see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 4. Information on the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 6. Directors, Senior Management and Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 7.B Related Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; of this Annual Report. </span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Amendment to the Senior Bonds </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 14 December 2018, Alvotech Holdings issued $300.0 million in convertible bonds. The offering included $125.0 million of Tranche A bonds (the &#8220;Tranche A Senior Bonds&#8221;) that included a guarantee from Alvogen Lux Holdings S.&#224; r.l. (&#8220;Alvogen&#8221;) and a 10% bonus if the bondholders converted at the time of an initial public offering (&#8220;IPO&#8221;). In addition, $175.0 million of Tranche B bonds (the &#8220;Tranche B Senior Bonds&#8221; and, together with the Tranche A Senior Bonds, the &#8220;Existing Senior Bonds&#8221;, which includes, for the avoidance of doubt, the additional bonds issued in June 2021 as further described below) were issued that did not have a guarantee but included a 25% bonus if the bondholders elected to convert at the time of an Initial Public Offering (the "IPO"). The bonds offered a 15% payment-in-kind interest rate and a put option to sell the bonds back to Alvotech if an IPO had not occurred within three years from the original date of issuance. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 24 June 2021, holders of the Existing Senior Bonds converted $100.7 million of principal and accrued interest and $4.8 million of additional premium offered by Alvotech Holdings to the bondholders into 455,687 Class A ordinary shares of Alvotech Holdings. Following the conversion, certain bondholders elected to redeem their remaining Existing Senior Bonds for cash, resulting in the payment of $54.1 million in outstanding principal and accrued interest plus an additional $6.1 million of premium that the bondholders elected to be paid in cash. The remaining unconverted and unredeemed Existing Senior Bonds were rolled over into new bonds with an extended maturity of June 2025 and the elimination of conversion rights, among other amendments to the terms and conditions. Such Existing Senior Bonds, including an additional premium of $2.6 million and an extension premium of $8.1 million offered to the bondholders in the form of additional bonds, totaled $280.9 million. Alvotech Holdings also issued an additional $113.8 million of Existing Senior Bonds to one previous bondholder and one new bondholder. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January and June of 2022, Alvotech Holdings amended the terms of the outstanding bonds. The amendments resulted in the interest rate on the bonds ranging from 7.5% to 10.0%, depending on the amount of aggregate net proceeds following the closing of the business combination by and among Oaktree Acquisition Corp. II, Alvotech Holdings and Alvotech (the &#8220;Business Combination&#8221;). Additionally, Alvotech made a payment of a $5.0 million consent fee to the bondholders who did not vote against the Business Combination Agreement dated as of 7 December 2021, as amended, by and among OACB, Alvotech Holdings and Alvotech. The payment was made in July 2022. The amendment also included a requirement for Alvotech to maintain a minimum of $25.0 million of restricted cash in a separate liquidity account. As a result of the closing of the Business Combination, there was a change in cash flows on the bonds related to the increase in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interest rate from 7.5% to 10.0%. Alvotech remeasured the carrying value in accordance with IFRS 9 to the present value of the revised cash flows and recognized a $6.5 million loss on the remeasurement of the Existing Senior Bonds. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, Alvotech and the bondholders amended and restated certain terms and conditions of the Existing Senior Bonds and issued new senior bonds in an aggregate principal amount equal to $70.0 million (the &#8220;New Senior Bonds&#8221; and, together with the Existing Senior Bonds, the &#8220;Senior Bonds&#8221;). The New Senior Bonds were issued subject to the terms of the Existing Senior Bonds, as amended and restated. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The coupon rate applicable to the Senior Bonds is 12.00% per annum, that, subject to certain step down provisions, may be lowered to 11.375% (if Alvotech raises more than $75.0 million but less than $150.0 million in net proceeds from the issuance of new equity) or 10.75% (if Alvotech raises more than $150.0 million in net proceeds from the issuance of new equity). Alvotech shall use commercially reasonable endeavors to procure that the aggregate amount of the net proceeds of all new equity is (i) not less than $75.0 million by 15 December 2022, and (ii) not less than $150.0 million by 31 March 2023, inclusive of any net proceeds raised in (i). This step down provision is subject to certain further conditions, including the FDA approval of a biologics license application for AVT02 on or before 31 March 2023. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For interest accrued until (and including) 15 December 2023, Alvotech has the option to elect that interest accrued in excess of 8.50% per annum be capitalized and added to the outstanding principal amount of the Senior Bonds then outstanding. Interest accrued as of (and including) 16 December 2023 will be payable in cash in arrears on each coupon payment date. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, Alvotech is required to (i) grant the bondholders penny warrants representing 1.5% of its fully diluted ordinary share capital outstanding as at 15 December 2022 if the aggregate amount of the net proceeds of all new equity issuances from November 16, 2022 through 15 December 2022 is less than $75.0 million; and (ii) grant the bondholders penny warrants representing 1.00% of its fully diluted ordinary share capital outstanding as at 31 March 2023 if the aggregate amount of the net proceeds of all new equity issuances from 16 November 2022 through 31 March 2023 (inclusive of any net proceeds raised in (i)) is less than $15.0 million. Each warrant will entitle the bondholders, upon exercise, to receive from Alvotech one fully paid and non-assessable ordinary share of Alvotech, at the exercise price of one cent ($0.01) per share. Since Alvotech had not raised $75.0 million by 15 December 2022, Alvotech issued 4,198,807 warrants to the bondholders on 31 December 2022. Each new warrant entitles the bondholders, upon exercise, to receive from Alvotech one fully paid and non-assessable Ordinary Share, at the exercise price of one cent ($0.01) per share. Pursuant to the terms of the warrant, Alvotech is required to register Ordinary Shares underlying the warrants for resale on or before 15 July 2023. Following the issuance of the 2022 Convertible Bonds and the closing of the private placement of Ordinary Shares for gross proceeds of $137.0 million on 10 February 2023, we are not obligated to issue the additional 1.00% warrants to the bondholders. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The bondholders will be entitled to appoint one observer to receive all information provided to, and attend meetings of, Alvotech&#8217;s board of directors (and any committees or groups thereunder). </span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Convertible Bonds</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 20, 2022, the Company issued two tranches of convertible bonds, Tranche A is ISK denominated with a principal balance of $59.1 million, of which $3.5 million in cash proceeds were received subsequent to December 31, 2022, and carries an annual payment-in-kind interest rate of 15% per year, while tranche B is USD denominated with a principal balance of $0.6 million and carries an annual payment-in-kind interest rate of 12.5% per year. The maturity date of the convertible bonds is the later of the (i) 20 December 2025 or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Holders of both the Tranche A and Tranche B convertible bonds, may elect, at their sole discretion, to convert all or part of the principal amount and accrued interest into Alvotech Ordinary Shares at a conversion price of $10.00 per share on December 31, 2023, June 30, 2024. or when the bond has been called or put up for redemption, including on the maturity date </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 25 January 2023, the Company issued an additional $10.0&#160;million of Tranche B Convertible Bonds. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 24 July 2023, Alvotech announced that Teva and Alvotech have agreed to expand their existing strategic partnership agreement. As part of the agreement, Teva acquired Tranche B Convertible Bonds in principal amount of $40&#160;million. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 31 July 2023, Alvotech completed a private placement of Tranche A Convertible Bonds for a total principal amount of $100&#160;million, or approximately ISK 13&#160;billion at current exchange rates. As part of this private placement, ATP Holdings ehf., which is affiliated with Aztiq, acquired Tranche A Convertible Bonds in principal amount of $30&#160;million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span><br/></span></div><div id="ie527079dad0a4810aa92569387637e3d_154"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">Exchange Controls </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are no foreign exchange controls or foreign exchange regulations under the currently applicable laws of the Grand Duchy of Luxembourg. </span></div><div id="ie527079dad0a4810aa92569387637e3d_157"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Taxation </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Material Luxembourg Tax Considerations </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tax Residency </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A holder of Ordinary Shares or Warrants will not become resident, nor be deemed to be resident, in Luxembourg solely by virtue of holding and/or disposing of Ordinary Shares or Warrants or the execution, performance, delivery and/or enforcement of his or her rights thereunder. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Tax </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the purposes of this section, a &#8220;disposal&#8221; may include a sale, an exchange, a contribution, a redemption and any other kind of alienation of Ordinary Shares or Warrants. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Luxembourg Non-Residents</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Non-resident holders of Ordinary Shares or Warrants, who have neither a permanent establishment nor a permanent representative in Luxembourg to which or whom Ordinary Shares or Warrants are attributable, are not liable to any Luxembourg income tax, whether they receive payments of dividends or realize capital gains on the disposal of Ordinary Shares or Warrants, except with respect to capital gains realized on a substantial participation before the acquisition or within the first six months of the acquisition thereof, or where the non-resident holder has been a former Luxembourg resident for more than 15 years and has become a non-resident, at the time of transfer, less than five years ago, that are subject to income tax in Luxembourg at ordinary rates (subject to the provisions of any relevant double tax treaty). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-resident holders of Ordinary Shares or Warrants having a permanent establishment or a permanent representative in Luxembourg to which or whom Ordinary Shares or Warrants are attributable, must include any income received, as well as any gain realized on the disposal of Ordinary Shares or Warrants, in their taxable income for Luxembourg tax assessment purposes, unless the conditions of the participation exemption regime, as described below, are satisfied. If the conditions of the participation exemption regime are not fulfilled, 50% of the gross amount of dividends received by a Luxembourg permanent establishment or permanent representative are however exempt from income tax. Taxable gains are determined as being the difference between the price for which Ordinary Shares have been disposed of and the lower of their cost or book value. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Under the participation exemption regime (subject to the relevant anti-abuse rules), dividends derived from Ordinary Shares may be exempt from income tax if cumulatively (i) Ordinary Shares are attributable to a qualified permanent establishment (&#8220;Qualified Permanent Establishment&#8221;) and (ii) at the time the dividend is put at the disposal of the Qualified Permanent Establishment, it holds or commits itself to hold for an uninterrupted period of at least 12 months Ordinary Shares or Warrants representing either (a) a direct participation in the share capital of Alvotech of at least 10% or (b) a direct participation of an acquisition price of at least &#8364;1.2 million. A Qualified Permanent Establishment means (a) a Luxembourg permanent establishment of a company covered by Article 2 of the Parent-Subsidiary Directive, (b) a Luxembourg permanent establishment of a capital company (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">soci&#233;t&#233; de capitaux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">) resident in a State having a double tax treaty with Luxembourg and (c) a Luxembourg permanent establishment of a capital company (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">soci&#233;t&#233; de capitaux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">) or  a cooperative company (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">soci&#233;t&#233; coop&#233;rative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">) resident in an EEA country other than an EU Member State. Liquidation proceeds are assimilated to a received dividend and may be exempt under the same conditions. Ordinary Shares held through a tax transparent entity are considered as being a direct participation proportionally to the percentage held in the net assets of the transparent entity. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the participation exemption regime (subject to the relevant anti-abuse rules), capital gains realized on Ordinary Shares or Warrants may be exempt from income tax (save for the recapture rules) if cumulatively (i) Ordinary Shares or Warrants are attributable to a Qualified Permanent Establishment and (ii) at the time the capital gain is realized, the Qualified Permanent Establishment holds or commits itself to hold for an uninterrupted period of at least 12 months Ordinary Shares or Warrants representing either (a) a direct participation in the share capital of Alvotech of at least 10% or (b) a direct participation of an acquisition price of at least &#8364;6 million. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net Worth Tax </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Luxembourg resident as well as a non-resident who has a permanent establishment or a permanent representative in Luxembourg to which Ordinary Shares or Warrants are attributable, are subject to Luxembourg NWT (subject to the application of the participation exemption regime) on such Ordinary Shares or Warrants, except if the holder of Ordinary Shares or Warrants is (i) a resident or non-resident individual taxpayer, (ii) a securitization company governed by the amended law of 22 March 2004 on securitization, (iii) a company governed by the amended law of 15 June 2004 on venture capital vehicles, (iv) a professional pension institution governed by the amended law of 13 July 2005, (v) a specialized investment fund governed by the amended law of 13 February 2007, (vi) a family wealth management company governed by the law of 11 May 2007, (vii) an undertaking for collective investment governed by the amended law of 17 December 2010 or (viii) a reserved alternative investment fund governed by the amended law of 23 July 2016. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, (i) a securitization company governed by the amended law of 22 March 2004 on securitization, (ii) a company governed by the amended law of 15 June 2004 on venture capital vehicles (iii) a professional pension institution governed by the amended law dated 13 July 2005 and (iv) an opaque reserved alternative investment fund treated as a venture capital vehicle for Luxembourg tax purposes and governed by the amended law of 23 July 2016 remain subject to the minimum NWT. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Taxes </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under current Luxembourg tax laws, no registration tax or similar tax is in principle payable by the holder of Ordinary Shares or Warrants upon the acquisition, holding or disposal of Ordinary Shares or Warrants. However, a fixed or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ad valorem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> registration duty may be due upon the registration of Ordinary Shares or Warrants in Luxembourg in the case where Ordinary Shares or Warrants are physically attached to a public deed or to any other document subject to mandatory registration, as well as in the case of a registration of Ordinary Shares or Warrants on a voluntary basis. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No inheritance tax is levied on the transfer of Ordinary Shares or Warrants upon death of a holder in cases where the deceased was not a resident of Luxembourg for inheritance tax purposes at the time of his death. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gift tax may be due on a gift or donation of Ordinary Shares or Warrants if the gift is recorded in a Luxembourg notarial deed or otherwise registered in Luxembourg. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Material U.S. Federal Income Tax Considerations for U.S. Holders </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a discussion of certain material U.S. federal income tax considerations generally applicable to the acquisition, ownership, and disposition of Ordinary Shares by a &#8220;U.S. Holder.&#8221; This discussion applies only to Ordinary Shares that are held by a U.S. Holder as &#8220;capital assets&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not describe all U.S. federal income tax considerations that may be relevant to a U.S. Holder in light of such U.S. Holder&#8217;s particular circumstances, nor does it address any state, local, or non-U.S. tax considerations, any non-income tax (such as gift or estate tax) considerations, the alternative minimum tax, the special tax accounting rules under Section 451(b) of the Code, the Medicare contribution tax on net investment income, or any tax consequences that may be relevant to U.S. Holders that are subject to special tax rules, including, without limitation: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">banks or other financial institutions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">insurance companies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">mutual funds; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">pension or retirement plans; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">S corporations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">broker or dealers in securities or currencies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">traders in securities that elect mark-to-market treatment; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">regulated investment companies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">real estate investment trusts; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">trusts or estates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">tax-exempt organizations (including private foundations); </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">persons that hold Ordinary Shares as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion,&#8221; &#8220;synthetic security,&#8221; &#8220;constructive sale,&#8221; or other integrated transaction for U.S. federal income tax purposes; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">persons that have a functional currency other than the U.S. dollar; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">certain U.S. expatriates or former long-term residents of the United States; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">persons owning (directly, indirectly, or constructively) 5% (by vote or value) or more of our stock; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">persons that acquired Ordinary Shares pursuant to an exercise of employee stock options or otherwise as compensation; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">partnerships or other entities or arrangements treated as pass-through entities for U.S. federal income tax purposes and investors in such entities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">&#8220;controlled foreign corporations&#8221; within the meaning of Section 957(a) of the Code; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">&#8220;passive foreign investment companies&#8221; within the meaning of Section 1297(a) of the Code; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">corporations that accumulate earnings to avoid U.S. federal income tax. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds Ordinary Shares, the tax treatment of a partner in such partnership generally will depend on the status of the partner and the activities of the partnership and the partner. Partnerships holding Ordinary Shares should consult their tax advisors regarding the tax consequences in their particular circumstances. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This discussion is based on the Code, the U.S. Treasury regulations promulgated thereunder, administrative rulings, and judicial decisions, all as currently in effect and all of which are subject to change or differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax consequences described herein. Furthermore, there can be no assurance that the Internal Revenue Service (the &#8220;IRS&#8221;) will not challenge the tax considerations described herein and that a court will not sustain such challenge. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of Ordinary Shares, that is, for U.S. federal income tax purposes: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">an individual who is a U.S. citizen or resident of the United States; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">a corporation (including an entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">a trust (i) if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more &#8220;United States persons&#8221; within the meaning of Section 7701(a)(30) of the Code have the authority to control all substantial decisions of the trust or (B) that has in effect a valid election under applicable U.S. Treasury regulations to be treated as a United States person. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">THIS DISCUSSION IS FOR GENERAL INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. U.S. HOLDERS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE TAX CONSEQUENCES OF THE ACQUISTION, OWNERSHIP, AND DISPOSITION OF ORDINARY SHARES IN THEIR PARTICULAR CIRCUMSTANCES. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions on Ordinary Shares </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the PFIC rules discussed below under &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Passive Foreign Investment Company Rules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; distributions on Ordinary Shares generally will be taxable as a dividend for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Such distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the applicable U.S. Holder&#8217;s adjusted tax basis in its Ordinary Shares. Any remaining excess will be treated as gain realized on the sale or other taxable disposition of Ordinary Shares and will be treated as described below under &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sale or Other Taxable Disposition of Ordinary Shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; The amount of any such distributions will include any amounts required to be withheld by us (or another applicable withholding agent) in respect of any non-U.S. taxes. Any such amount treated as a dividend will be treated as foreign-source dividend income. Any such dividends received by a corporate U.S. Holder generally will not qualify for the dividends-received deduction generally allowed to U.S. corporations in respect of dividends received from other U.S. corporations. With respect to non-corporate U.S. Holders, any such dividends generally will be taxed at currently preferential long-term capital gains rates only if (i) Ordinary Shares </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">are readily tradable on an established securities market in the United States or we are eligible for benefits under an applicable tax treaty with the United States, (ii) we are not treated as a PFIC with respect to the applicable U.S. Holder at the time the dividend was paid or in the preceding year, and (iii) certain holding period and other requirements are met. Any such dividends paid in a currency other than the U.S. dollar generally will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of actual or constructive receipt. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted above and subject to applicable limitations, taxing jurisdictions other than the United States may withhold taxes from distributions on Ordinary Shares, and a U.S. Holder may be eligible for a reduced rate of withholding to the extent there is an applicable tax treaty between the applicable taxing jurisdiction and the  United States and/or may be eligible for a foreign tax credit against the U.S. Holder&#8217;s U.S. federal income tax liability. Recently issued U.S. Treasury regulations, which apply to foreign taxes paid or accrued in taxable years beginning on or after 28 December 2021, may in some circumstances prohibit a U.S. Holder from claiming a foreign tax credit with respect to certain foreign taxes that are not creditable under applicable tax treaties. In lieu of claiming a foreign tax credit, a U.S. Holder may, at such U.S. Holder&#8217;s election, deduct foreign taxes in computing such U.S. Holder&#8217;s taxable income, subject to generally applicable limitations under U.S. tax law. An election to deduct foreign taxes in lieu of claiming a foreign tax credit applies to all foreign taxes paid or accrued in the taxable year in which such election is made. The foreign tax credit rules are complex and U.S. Holders should consult their tax advisers regarding the application of such rules, including the creditability of foreign taxes, in their particular circumstances. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sale or Other Taxable Disposition of Ordinary Shares </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the PFIC rules discussed below under &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Passive Foreign Investment Company Rules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; upon any sale or other taxable disposition of Ordinary Shares, a U.S. Holder generally will recognize gain or loss in an amount equal to the difference, if any, between (i) the sum of (A) the amount of cash and (B) the fair market value of any other property received in such sale or disposition and (ii) the U.S. Holder&#8217;s adjusted tax basis in the Ordinary Shares. Any such gain or loss generally will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for such Ordinary Shares exceeds one year. Long-term capital gain recognized by non-corporate U.S. Holders generally will be taxed at currently preferential long-term capital gains rates. The deductibility of capital losses is subject to limitations. For foreign tax credit purposes, any such gain or loss generally will be treated as U.S. source gain or loss. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the consideration received by a U.S. Holder upon a sale or other taxable disposition of Ordinary Shares is not paid in U.S. dollars, the amount realized will be the U.S. dollar value of such payment calculated by reference to the exchange rate in effect on the date of such sale or disposition. A U.S. Holder may have foreign currency gain or loss to the extent of the difference, if any, between (i) the U.S. dollar value of such payment on the date of such sale or disposition and (ii) the U.S. dollar value of such payment calculated by reference to the exchange rate in effect on the date of settlement. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. Holders should consult their tax advisors regarding the tax consequences of a sale or other taxable disposition of Ordinary Shares, including the creditability of foreign taxes imposed on such sale or disposition by a taxing jurisdiction other than the United States, in their particular circumstances. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Passive Foreign Investment Company Rules </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. federal income tax treatment of U.S. Holders could be materially different from that described above if we are treated as a PFIC for U.S. federal income tax purposes. A non-U.S. corporation generally will be treated as a PFIC for U.S. federal income tax purposes if either (i) at least 75% of its gross income in a taxable year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income or (ii) at least 50% of its assets in a taxable year (ordinarily determined based on fair market value and averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business), and gains from the disposition of passive assets. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our analysis of our income, assets, activities and market capitalization, we believe that we were not treated as a PFIC for our taxable year, ended 31 December 2023. However, the determination of whether a non-U.S. corporation is a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. In particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change. In addition, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of Ordinary Shares from time to time, which may fluctuate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">considerably. As a result, there can be no assurance with respect to our status as a PFIC for any taxable year, and our U.S. counsel expresses no opinion with respect to our PFIC status for any taxable year. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although PFIC status is generally determined annually, if we are determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder in its Ordinary Shares and the U.S. Holder did not make either a mark-to-market election or a qualifying electing fund (&#8220;QEF&#8221;) election or, which are referred to collectively as the &#8220;PFIC Elections&#8221; for purposes of this discussion, for the first taxable year in which we are treated as a PFIC, and in which the U.S. Holder held (or was deemed to hold) Ordinary Shares, or the U.S. Holder does not otherwise make a purging election, as described below, the U.S. Holder generally will be subject to special and adverse rules with respect to (i) any gain recognized by the U.S. Holder on the sale or other taxable disposition of its Ordinary Shares and (ii) any &#8220;excess distribution&#8221; made to the U.S. Holder (generally, any distributions to the U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by the U.S. Holder in respect of its Ordinary Shares during the three preceding taxable years of the U.S. Holder or, if shorter, the U.S. Holder&#8217;s holding period in its Ordinary Shares). </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under these rules: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the U.S. Holder&#8217;s gain or excess distribution will be allocated ratably over the U.S. Holder&#8217;s holding period in its Ordinary Shares; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the amount allocated to the U.S. Holder&#8217;s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, and to any period in the U.S. Holder&#8217;s holding period before the first day of the first taxable year in which we are treated as a PFIC, will be taxed as ordinary income; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in the U.S. Holder&#8217;s holding period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable to each such other taxable year of the U.S. Holder. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">PFIC Elections </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are treated as a PFIC and Ordinary Shares constitute &#8220;marketable stock,&#8221; a U.S. Holder may avoid the adverse PFIC tax consequences discussed above if such U.S. Holder makes a mark-to-market election with respect to its Ordinary Shares for the first taxable year in which the U.S. Holder holds (or is deemed to hold) Ordinary Shares and each subsequent taxable year. Such U.S. Holder generally will include for each of its taxable years as ordinary income the excess, if any, of the fair market value of its Ordinary Shares at the end of such year over its adjusted tax basis in its Ordinary Shares. The U.S. Holder also will recognize an ordinary loss in respect of the excess, if any, of its adjusted tax basis in its Ordinary Shares over the fair market value of its Ordinary Shares at the end of its taxable year (but only to the extent of the net amount of previously included income as a result of the mark-to-market election). The U.S. Holder&#8217;s adjusted tax basis in its Ordinary Shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable disposition of its Ordinary Shares will be treated as ordinary income. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The mark-to-market election is available only for &#8220;marketable stock,&#8221; generally, stock that is regularly traded on a national securities exchange that is registered with the Securities and Exchange Commission, including the Nasdaq (on which Ordinary Shares are currently listed), or on a foreign exchange or market that the IRS determines has rules sufficient to ensure that the market price represents a legitimate and sound fair market value. As such, such election generally will not apply to any of our non-U.S. subsidiaries, unless the shares in such subsidiaries are themselves &#8220;marketable stock.&#8221; As such, U.S. Holders may continue to be subject to the adverse PFIC tax consequences discussed above with respect to any lower-tier PFICs, as discussed below, notwithstanding their mark-to-market election with respect to Ordinary Shares. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If made, a mark-to-market election would be effective for the taxable year for which the election was made and for all subsequent taxable years unless Ordinary Shares cease to qualify as &#8220;marketable stock&#8221; for purposes of the PFIC rules or the IRS consents to the revocation of the election. U.S. Holders should consult their tax advisors regarding the availability and tax consequences of a mark-to-market election with respect to Ordinary Shares in their particular circumstances. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The tax consequences that would apply if we were a PFIC and a U.S. Holder made a valid QEF election would also be different from the adverse PFIC tax consequences described above. In order to comply with the requirements of a QEF election, however, a U.S. Holder generally must receive a PFIC Annual Information Statement from us. If we are determined to be a PFIC for any taxable year, we do not currently intend to provide the information necessary for U.S. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders to make or maintain a QEF election. As such, U.S. Holders should assume that a QEF election will not be available with respect to Ordinary Shares. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are treated as a PFIC and a U.S. Holder failed or was unable to timely make a PFIC Election for prior periods, the U.S. Holder might seek to make a purging election to rid its Ordinary Shares of the PFIC taint. Under the purging election, the U.S. Holder will be deemed to have sold its Ordinary Shares at their fair market value and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a result of the purging election, the U.S. Holder will have a new adjusted tax basis and holding period in Ordinary Shares solely for purposes of the PFIC rules. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Related PFIC Rules </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are treated as a PFIC and, at any time, has a non-U.S. subsidiary that is treated as a PFIC, a U.S. Holder generally would be deemed to own a proportionate amount of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge described above if we receive a distribution from, or sell or otherwise dispose of all or part of our interest in, such lower-tier PFIC, or the U.S. Holder otherwise was deemed to have sold or otherwise disposed of an interest in such lower-tier PFIC. U.S. Holders should consult their tax advisors regarding the application of the lower-tier PFIC rules in their particular circumstances. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that owns (or is deemed to own) shares in a PFIC during any taxable year, may have to file an IRS Form 8621 (whether or not a QEF election or a mark-to-market election is made) and to provide such other information as may be required by the U.S. Treasury Department. Failure to do so, if required, will extend the statute of limitations applicable to such U.S. Holder until such required information is furnished to the IRS and could result in penalties </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">THE PFIC RULES ARE VERY COMPLEX AND U.S. HOLDERS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE APPLICATION OF SUCH RULES IN THEIR PARTICULAR CIRCUMSTANCES. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Information Reporting and Backup Withholding </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries are subject to information reporting, and may be subject to backup withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient or (ii) in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the U.S. Holder&#8217;s U.S. federal income tax liability and may entitle the U.S. Holder to a refund, provided that the required information is timely furnished to the IRS. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. Holders should consult their tax advisors regarding the information reporting requirements and the application of the backup withholding rules in their particular circumstances. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">THIS DISCUSSION IS FOR GENERAL INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. U.S. HOLDERSSHOULD CONSULT THEIR TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE, AND LOCAL AND NON-U.S. INCOME AND NON-INCOME TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF ORDINARY SHARES, INCLUDING THE IMPACT OF ANY POTENTIAL CHANGE IN LAW, IN THEIR PARTICULAR CIRCUMSTANCES. </span></div><div id="ie527079dad0a4810aa92569387637e3d_160"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Dividends and Paying Agents </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_163"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">Statement by Experts </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_166"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:16.73pt">Documents on Display </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and under those requirements will file reports with the SEC. Those reports may be inspected without charge at the locations described below. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. Nevertheless, we will file with the SEC an Annual Report on Form 20-F containing financial statements that have been examined and reported on, with and opinion expressed by an independent registered public accounting firm. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain a corporate website at www.alvotech.com. We intend to post our Annual Report on our website promptly following it being filed with the SEC. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Securities and Exchange Commission maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding registrants, such as us, that file electronically with the SEC. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to references made in this Annual Report to any contract or other document of our Company, such references are not necessarily complete, and you should refer to the exhibits attached or incorporated by reference to this Annual Report for copies of the actual contract or document. </span></div><div id="ie527079dad0a4810aa92569387637e3d_169"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:20.61pt">Subsidiary Information </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_172"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">J.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:19.5pt">Annual Report to Security Holders </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to submit any annual report provided to security holders in electronic format as an exhibit to a current report on Form 6-K.</span></div><div id="ie527079dad0a4810aa92569387637e3d_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 11. &#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to market risks that may result in changes of foreign currency exchange rates and interest rates, as well as the overall change in economic conditions in the countries where we conduct business. As of 31&#160;December 2023, and 2022, we had cash and cash equivalents of $11.2 million and $66.4 million, respectively, excluding restricted cash. Our cash and cash equivalent include both cash in banks and cash on hand. Additional information regarding the Group's management of financial risks relating to its operations can be found in Note 28 of the audited consolidated financial statements, included elsewhere in this Form 20-F.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Foreign currency exchange risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to foreign exchange risk in our operations, as some of our financial assets and financial liabilities are denominated in currencies other than the functional currency of our subsidiaries. Any strengthening or weakening of our significant foreign currencies against the USD could impact the measurement of financial instruments in a foreign currency and affect equity. Our significant asset and liabilities denominated in foreign currencies as 31&#160;December 2023, and 31&#160;December 2022 are denominated in EUR, GBP, ISK and CHF. We analyze at the end of each year the sensitivity to foreign currency exchange changes. Specifically, we have performed an analysis to understand the impact of an increase or decrease of a 10% strengthening or weakening of each significant foreign currency, keeping all other variables consistent, as of 31&#160;December 2023. Through this analysis, we note that the only foreign currency that had a material impact was ISK, while all other currencies did not significantly fluctuate. Refer to Note 28 of the consolidated financial statements included elsewhere in this Annual Report on Form 20-F for further information. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Interest rate risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our interest-bearing investments and borrowings are subject to interest rate risk. The majority of our borrowings are subject to fixed interest rate. Our exposure to the risk of fluctuations in market interest rates primarily relates to the cash in banks that is denominated with floating interest rates. We analyze at the end of each year the sensitivity to interest rate changes. Specifically, we have performed an analysis to understand the impact of an increase or decrease of a one hundred basis point on the interest rates, keeping all other variables consistent, as of 31&#160;December 2023. Through this analysis, we note that the impacts of the interest rate sensitivity did not have a significant effect on loss before tax. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Credit risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to credit risk from our operating activities, primarily trade receivables, and cash, cash equivalents and deposits held with banks and financial institutions. Cash, cash equivalents and deposits are maintained with high-quality financial institutions in Iceland, Europe and United States. We are also potentially subject to concentrations of credit risk in our trade receivables. Concentrations of credit risk are with respect to trade receivables owed by a limited number of companies comprising our customer base. Our exposure to credit losses is low, however, owing largely to the credit quality of our collaboration partners which are significantly larger than us. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continually monitor our positions with, and the credit quality of, the financial institutions and corporations, which are counterparts to our financial instruments and do not anticipate non-performance. The maximum default risk corresponds to the carrying amount of the financial assets shown in the statement of financial position. We monitor the risk of a liquidity shortage. The main factors considered here are the maturities of financial assets as well as expected cash flows from equity measures. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity Risk </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see Item 5.B and risk factors, including &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We may be unable to generate sufficient cash flow to satisfy our significant debt service obligations, which would adversely affect our financial condition and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;  of this Annual Report. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inflation Risk </span></div><div style="margin-top:6pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that inflation will have a general impact on our business in line with overall price increases, increases in the cost of borrowing, and operating in an inflationary economy. We cannot predict the timing, strength, or duration of any inflationary period or economic slowdown or its ultimate impact on the Company. If the conditions in the general economy significantly deviate from present levels and continue to deteriorate it could have a material adverse effect on the Group&#8217;s business, financial condition, results of operations and growth prospects. </span></div><div style="margin-top:6pt;text-indent:24.48pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Interim Periods</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Safe Harbor</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and as defined in the Private Securities Litigation Reform Act of 1995. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Special Note Regarding Forward-Looking Statements".</span></div><div id="ie527079dad0a4810aa92569387637e3d_178"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 12.&#160;&#160;&#160;&#160;Description of Securities Other than Equity Securities. </span></div><div id="ie527079dad0a4810aa92569387637e3d_181"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Debt Securities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_184"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Warrants and Rights </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_187"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Other Securities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_190"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">American Depositary Shares </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">143</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_193"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART II </span></div><div id="ie527079dad0a4810aa92569387637e3d_196"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 13.&#160;&#160;&#160;&#160;Defaults, Dividend Arrearages and Delinquencies. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_199"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 14.&#160;&#160;&#160;&#160;Material Modifications to the Rights of Security Holders and Use of Proceeds. </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Not applicable. </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Not applicable. </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Not applicable. </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">Not applicable. </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Use of Proceeds. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_202"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 15.&#160;&#160;&#160;&#160;Controls and Procedures. </span></div><div id="ie527079dad0a4810aa92569387637e3d_205"></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Disclosure Controls and Procedures </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in the Company&#8217;s reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of 31&#160;December 2023. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the material weaknesses described below, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of 31&#160;December 2023, our disclosure controls and procedures were not effective. After giving full</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consideration to these material weaknesses, and the additional analyses and other procedures that we performed to ensure</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that our consolidated financial statements included in this Annual Report on Form 20-F were prepared in accordance with</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IFRS, our management has concluded that our consolidated financial statements present fairly, in all material respects, our</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">financial position, results of operations and cash flows for the periods disclosed in conformity with IFRS.</span></div><div id="ie527079dad0a4810aa92569387637e3d_208"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act and for the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assessment of the effectiveness of our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our internal control system was designed to provide reasonable assurance to our management and board of directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regarding the reliability of financial reporting and the preparation and fair presentation of published financial statements for</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">external purposes in accordance with IFRS Accounting Standards as issued by the IASB. Because of its inherent</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">limitations, internal control over financial reporting, no matter how well designed, cannot provide absolute assurance of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">achieving financial reporting objectives and may not prevent or detect misstatements. Therefore, even if the internal control</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">over financial reporting is determined to be effective it can provide only reasonable assurance with respect to financial</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management has assessed the effectiveness of our internal control over financial reporting as of 31 December 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">using criteria described in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Organizations of the Treadway Commission. Based on its assessment, management concluded that our internal control over</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">financial reporting was not effective due to the identified material weaknesses in internal control over financial reporting as</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">described below. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Identified Material Weakness </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Alvotech has identified material weaknesses in the design and operating effectiveness of its internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the preparation of the consolidated financial statements covered by this Annual Report, we identified the following material weaknesses: </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i) the Company did not have a sufficient number of trained professionals with an appropriate level of internal control knowledge, training and experience; </span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii) the Company did not consistently operate all controls, specifically related to consistent execution, adequate review procedures, and maintaining documentation to evidence control performance, including assessing the accuracy and completeness of information used in the execution of controls; and</span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)  the Company did not implement effective controls over the segregation of duties and certain information technology general controls for information systems that are relevant to the preparation of our financial statements.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These material weaknesses could result in a misstatement of Alvotech&#8217;s accounts or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected. </span></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Remediation Activities </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">During the period covered by this Annual Report, we began implementing a remediation plan that is reasonably likely to materially affect, our internal control over financial reporting. This plan includes further developing and implementing formal policies, processes, internal controls and documentation relating to our financial reporting working towards the goal of effective control over financial reporting.</span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">As part of this plan, we began taking steps intended to address the underlying causes of the control deficiencies in order to remediate the material weaknesses, which included the following activities during 2022 and 2023: </span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">(i) Hired qualified individuals with strong technical accounting, internal control and SEC reporting experience and continued training control owners to reaffirm expectations as it relates to the control design and execution of such controls, including enhancements to the documentation to evidence the execution of the controls; </span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">(ii) Enhanced the Company's governance and oversight processes by establishing a formal control governance structure, ensuring clear roles and responsibilities for control oversight, conducting regular meetings to review control performance, and implementing a system for reporting control-related matters to the Audit Committee; </span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">(iii) Implemented formal documentation of certain policies and procedures, and/or redesigned entity level controls, business process-level controls across all significant accounts and information technology general controls across all relevant domains; </span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iv) Developed and executed a risk-based testing plan to cover all identified controls through a mix of design assessment, independent testing of operating effectiveness and management self-certification. The Company has engaged outside consultants to assist in evaluating our internal controls, develop remediation plans to address control deficiencies identified, and actively measure compliance and remediation progress through a quarterly scorecard; and </span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">(v) Continued implementation of a new enterprise resource planning (&#8220;ERP&#8221;) system including the engagement of outside consultants to help design and implement automated controls and enhance our information technology general controls environment as part of the ERP system implementation.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">In addition to the above actions, we expect to continue engaging in the following additional remediation measures:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">(i) Complete the implementation of a new ERP system, which includes increased automated functionality and controls for the preparation of the financial statements to prevent, among other things, unauthorized overrides, and enhance user access controls, segregation of duties with the system, and audit trails to track and monitor activities; </span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">(ii) Implement stronger IT controls to ensure the integrity and security of financial information, including enhancing access and change management controls and implementing regular system monitoring and testing; </span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">(iii) Continue focusing on consistent control execution, adequate review procedures, and improving control documentation, including the accuracy and completeness of information used in the performance of controls; and</span></div><div style="padding-left:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">(iv) Continue engaging outside consultants to assist in evaluating the internal controls, and actively measure compliance and remediation through quarterly scorecard. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">The Company believes that this structured and phased approach is essential in order to establish effective internal controls over financial reporting in a sustainable manner, which will also enable us to support and adapt to the Company&#8217;s continuous growth path. Management may also determine that it is necessary to modify the above-mentioned remediation efforts depending on the circumstances and Company needs. However, we cannot assure that our efforts will be effective, that we will be able to remedy these material weaknesses or that we will be able to prevent any future material weaknesses in our internal control over financial reporting. We plan to continue to address the material weaknesses identified by further improving our internal control over financial reporting, including designing and implementing additional procedures within our finance, manufacturing and supply chain, human resources and information technology departments.</span></div><div style="text-indent:28.34pt"><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We will not be able to conclude that we have remediated the material weaknesses until all relevant controls are fully implemented and have operated effectively for a sufficient period of time. See also &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Item 3. Key Information&#8212;D. Risk factors&#8212;We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we experience additional material weaknesses in the future or otherwise are unable to develop and maintain an effective system of internal controls in the future, we may not be able to produce timely and accurate financial statements or comply with applicable laws and regulations, which may adversely affect investor confidence in us and, as a result, the value of Ordinary Shares.&#8221;</span></div><div id="ie527079dad0a4810aa92569387637e3d_211"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.84pt">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report does not include an attestation report of the Company&#8217;s registered public accounting firm on management&#8217;s assessment of the Company&#8217;s internal control over financial reporting since we are an emerging growth company. </span></div><div id="ie527079dad0a4810aa92569387637e3d_214"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:17.28pt">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 15.A Disclosure Controls and Procedures&#8212;Remediation Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; above for the changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period covered by this Annual Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div id="ie527079dad0a4810aa92569387637e3d_217"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16.&#160;&#160;&#160;&#160;[Reserved]</span></div><div id="ie527079dad0a4810aa92569387637e3d_220"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16A.&#160;&#160;&#160;&#160;Audit Committee Financial Expert</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Board has determined that Dr. McGoldrick (Chair), Ms. Merchant and Mr. Davies each qualify as an &#8220;audit committee financial expert&#8221; as defined by SEC rules and have the requisite financial sophistication under the applicable rules and regulations of the Nasdaq Stock Market. Dr. McGoldrick (Chair), Ms. Merchant and Mr. Davies are independent as such term is defined in Rule 10A-3 under the Exchange Act and under the listing standards of the Nasdaq Stock Market. </span></div><div id="ie527079dad0a4810aa92569387637e3d_223"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16B.&#160;&#160;&#160;&#160;Code of Ethics</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech&#8217;s board of directors adopted a Code of Business Conduct applicable to the directors, executive officers and other team members that complies with the rules and regulations of Nasdaq, and Nasdaq Iceland Main Market, and the SEC. The Code of Ethics is available on Alvotech&#8217;s website. In addition, Alvotech posted on the Corporate Governance section of its website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the Code of Ethics. The reference to Alvotech&#8217;s website address in this Annual Report on Form 20-F does not include or incorporate by reference the information on Alvotech&#8217;s website into this Annual Report on Form 20-F.</span></div><div id="ie527079dad0a4810aa92569387637e3d_226"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16C.&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deloitte ehf. has served as our independent registered public accountant since 2013 and has audited our consolidated financial statements for the years ended 31&#160;December 2023 and 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the aggregate fees for services rendered by Deloitte ehf. to us and our subsidiaries, in the fiscal years ended 31&#160;December 2023 and 2022. </span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.000%"><tr><td style="width:1.0%"/><td style="width:61.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended 31 December</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Audit Fees</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Audit-Related Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax Fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.030%"><tr><td style="width:1.0%"/><td style="width:50.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Auditor Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Auditor Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Auditor Firm ID</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-46">Deloitte ehf.</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-47">K&#243;pavogur, Iceland</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-48">1490</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Audit fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Audit fees consisted of fees for the audit of our annual financial statements and other professional services provided in connection with the statutory and regulatory filings or engagements, including fees for the review of our interim financial information. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Audit-related fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Audit-related fees included fees for review of our current and historical financial information included in our SEC registration statements, including services that generally only the independent accountant can reasonably provide. </span></div><div style="margin-top:12pt;padding-left:28.34pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tax Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Tax fees included fees for tax compliance, tax advice, and tax planning. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Audit and Risk Committee Pre-Approval Policies and Procedures </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit and risk committee reviews and pre-approves the scope and the cost of audit services related to us and permissible non-audit services performed by the independent auditors. All of the services related to us provided by Deloitte during the last fiscal year have been pre-approved by the audit and risk committee. </span></div><div id="ie527079dad0a4810aa92569387637e3d_229"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16D.&#160;&#160;&#160;&#160;Exemptions from the Listing Standards for Audit Committees.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_232"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16E.&#160;&#160;&#160;&#160;Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_235"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16F.&#160;&#160;&#160;&#160;Change in Registrant&#8217;s Certifying Accountant.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_238"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16G.&#160;&#160;&#160;&#160;Corporate Governance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a &#8220;foreign private issuer,&#8221; as defined by the SEC. As a result, in accordance with Nasdaq rules, we comply with home country governance requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. While we expect to voluntarily follow most Nasdaq corporate governance rules, we may choose to take advantage of the following limited exemptions: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Exemption from quorum requirements for shareholder meetings. Luxembourg practice with respect to quorum requirements for shareholder meetings in lieu of the requirement under Nasdaq Listing Rules that the quorum be not less than 33 1/3% of the outstanding voting shares; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Exemption from the Nasdaq rules applicable to domestic issuers requiring disclosure within four business days of any determination to grant a waiver of the code of business conduct and ethics to directors and officers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Exemption from the requirement to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans and approval of other securities issuances; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Exemption from the requirement that our audit and risk committee have review and oversight responsibilities over all &#8220;related party transactions,&#8221; as defined in Item 7.B of this Annual Report on Form 20-F;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Exemption from the requirement that a majority of the board of directors must be comprised of Independent Directors as defined in the Nasdaq listing standards. Three of our eight directors are independent as defined in Nasdaq listing standards and applicable SEC rules, and our board of directors has an independent audit and risk committee. In addition, the independence rules applicable to companies listed on the Icelandic Main Market differ from the rules of Nasdaq. One additional director is considered independent under the Icelandic rules but not under the Nasdaq listing rules; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Exemption from the requirements related to the composition of our compensation committee and nominating</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and corporate governance committee.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, Nasdaq Rule 5615(a)(3) provides that a foreign private issuer, such as Alvotech, may rely on home country corporate governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d), provided that we nevertheless comply with Nasdaq&#8217;s Notification of Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640) and that we have an audit and risk committee that satisfies Rule 5605(c)(3), consisting of committee members that meet the independence requirements of Rule 5605(c)(2)(A)(ii). Although Alvotech is permitted to follow certain corporate governance rules that conform to Luxembourg requirements in lieu of many of the Nasdaq corporate governance rules, we comply with the Nasdaq corporate governance rules applicable to foreign private issuers. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, our shareholders may not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq. We may utilize these exemptions for as long as we continue to qualify as a foreign private issuer. </span></div><div id="ie527079dad0a4810aa92569387637e3d_241"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16H.&#160;&#160;&#160;&#160;Mine Safety Disclosure.</span></div><div style="margin-top:6pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_244"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16I.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:6pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_944"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16J. &#160;&#160;&#160;&#160;Insider Trading Policy.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div id="ie527079dad0a4810aa92569387637e3d_865"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16K.&#160;&#160;&#160;&#160;Cybersecurity.</span></div><div style="margin-top:18pt;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cybersecurity Risk management and strategy  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cybersecurity risk management program aims to fully identify threats, to present and evaluate them transparently, to mitigate, and manage them proactively. We have developed and implemented a cybersecurity risk management process intended to protect the confidentiality, integrity, and availability of our critical systems and information.  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cybersecurity risk management process guides us in making cybersecurity risk-informed decisions and provides the basis for evaluating and monitoring the cybersecurity risk profile of the Company. This process provides a shared understanding and promotes a consistent approach to cybersecurity risk management within the Company in line with our information security policy and includes a cybersecurity incident response plan. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our cybersecurity risk management program, we review industry best practices, including the NIST (National Institute of Standards and Technology) Cybersecurity Framework and ISO (International Organization for Standardization) 27001 to manage information security.  We periodically conduct ongoing internal and external vulnerability analyses, including simulated attack as well as external testing via a third-party to evaluate the effectiveness of our cybersecurity process and controls.  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an effort to minimize third-party risk, we have established a process to assess the security practices of third-party vendors and service providers and related risks. Our process includes a security assessment informed by vendor questionnaires and contractual security requirements related to data privacy for certain vendors. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The SOC is responsible for investigating all security incidents and alerts including determining the threat type, incident scope and incident severity. Where appropriate, major incidents are escalated according to cybersecurity incident process. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employee awareness and training are essential to our ability as a company to thwart cyber-attacks. We continuously raise employees&#8217; risk awareness with mandatory, regular online training for all employees and complimentary awareness campaigns.  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, we did not identify any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. Despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurance that we have not experienced an undetected cybersecurity incident. For more information about these risks, please see &#8220; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Legal and Regulatory Compliance Matters -  A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our confidential information in internal systems or those used by third party collaborator partners or other contractors or consultants, could compromise the confidentiality, integrity and availability of our confidential information in information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8221; in Item 3. Key Information &#8211; D. Risk Factors. </span></div><div><span><br/></span></div><div style="text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cybersecurity Governance </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors has overall oversight responsibility for our risk management strategy, and delegates information security and related risk management oversight to the Audit and Risk Committee. Members of the audit and risk committee receive regular updates from management, including the CIO and the Cybersecurity and Risks Council, regarding cybersecurity related matters. This includes existing and new cybersecurity risks, how management is addressing, managing and/or mitigating those risks, cybersecurity and data privacy incidents (if relevant), and the status of key information security initiatives. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cybersecurity and Risks Council overseas regular review of cybersecurity risk management activities, is responsible for the management of our cyber risk exposure and monitoring the effectiveness of the cybersecurity program, including but not limited to, our cybersecurity tools and controls, and is responsible for establishing and reviewing our risk tolerance for our cyber risk framework.  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The cybersecurity and Risks Council includes the CIO, the Director of Corporate Security, the Director of IT Infrastructure and Operations, the Enterprise architect, the Director of Cybersecurity, and Cybersecurity specialist. Those employees have decades of experience in cybersecurity and operations, cybersecurity education, and certifications from various organizations. The Cybersecurity and Risks Council is responsible for mobilizing the Materialization Board, which includes representatives from Legal and Finance, to review identified incident.</span></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">149</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_247"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART III </span></div><div id="ie527079dad0a4810aa92569387637e3d_250"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 17. &#160;&#160;&#160;&#160;Financial Statements. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See pages F-1 through F-66 of this Annual Report. </span></div><div id="ie527079dad0a4810aa92569387637e3d_253"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 18. &#160;&#160;&#160;&#160;Financial Statements. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div id="ie527079dad0a4810aa92569387637e3d_256"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 19.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT INDEX </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.033%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Incorporation By Reference</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Schedule/</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">File</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">File Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523161736/d500322dex993.htm">Amended and Restated Articles of Association.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">06.06.2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1820931/000119312520250390/d74733dex41.htm">Warrant Agreement, dated as of September 21, 2020, between Continental Stock Transfer &amp; Trust Company and OACB </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">001-39526</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">09.22.2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522287821/d408752dex994.htm">Amended and Restated Convertible Bond Instrument (Tranche A), dated November 16, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">6-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">99.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">11.17.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522287821/d408752dex995.htm">Amended and Restated Convertible Bond Instrument (Tranche B), dated November 16, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">6-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">99.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">11.17.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522178843/d358835dex27.htm">Warrant Assignment, Assumption and Amendment Agreement by and between OACB, Alvotech, Continental Stock Transfer &amp; Trust Company, Computershare Inc. and Computershare Trust Company, dated June 15, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">06.22.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522287821/d408752dex999.htm">Convertible Bond Instrument by and between Alvotech and the Bondholders named therein, dated November 16, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">6-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">99.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">11.17.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523056506/d454484dex211.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03.01.2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523056506/d454484dex29.htm">December 2022 Convertible Bond Instrument (Tranche A) by and between Alvotech and the Bondholders named therein, dated December 20, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03.01.2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523056506/d454484dex210.htm">December 2022 Convertible Bond Instrument (Tranche B) by and between Alvotech and the Bondholders named therein, dated December 20, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03.01.2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.1&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex101.htm">License and supply agreement between Alvotech hf. and STADA for AVT02 (Adalimumab), dated August 30, 2019 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.2&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex102.htm">First Amendment to the license and supply agreement between Alvotech hf. and STADA for AVT02 (Adalimumab) dated August 30, 2019 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.3&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex103.htm">Second Amendment to the license and supply agreement between Alvotech hf. and STADA for AVT02 (Adalimumab) dated August 30, 2019, dated May 3, 2021 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.4&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex106.htm">License and supply agreement between Alvotech hf. and STADA for AVT04 (Ustekinumab), dated November 6, 2019 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.5&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex107.htm">First Amendment to the license and supply agreement between Alvotech hf. and STADA for AVT04 (Ustekinumab) dated November 6, 2019, dated March 13, 2020 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.033%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Incorporation By Reference</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Schedule/</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">File</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">File Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.6&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex1010.htm">License and supply agreement between Alvotech hf. and STADA for AVT06 (Aflibercept), dated November 6, 2019 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.7&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex1011.htm">First Amendment to the license and supply agreement between Alvotech hf. and STADA for AVT06 (Aflibercept), dated March 13, 2020 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.8&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex1012.htm">License and supply agreement between Alvotech hf. and STADA for AVT16, dated November 6, 2019 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.9&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex1013.htm">First Amendment to the license and supply agreement between Alvotech hf. and STADA for AVT16, dated November 6, 2019, dated March 13, 2020 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.10&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex1016.htm">Product Supply Agreement between Alvotech hf. and Teva, dated August 5, 2020 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.11&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex1017.htm">License and Development Agreement between Alvotech hf. and Teva, dated August 5, 2020 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.12&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex1018.htm">Settlement Agreement, Release and Amendment to the License and Development Agreement between Alvotech hf. and Teva dated August 5, 2020, dated June 28, 2021 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.13&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001898416/000119312522109589/d193995dex1017.htm">Amended and Restated Services Agreement between Alvogen and Alvotech, dated April 11, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.14+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312521362501/d193995dex1022.htm">BCA Framework Agreement between Alvotech Holdings S.A., Alvotech Lux Holdings S.A.S., Floki Holdings S.&#224; r.l, and certain other shareholders dated December 7, 2021 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001898416/000119312522028704/d193995dex1025.htm">Product Rights Agreement between Alvotech hf. and Alvogen, dated January 22, 2018 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.16&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001898416/000119312522028704/d193995dex1026.htm">First Amendment to the Product Rights Agreement between Alvotech hf. and Alvogen dated January 22, 2018, dated December 14, 2018 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.20.2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.17&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522074698/d193995dex1029.htm">Settlement and License Agreement between Alvotech hf. and AbbVie, dated March 8, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">03.14.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.18&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001898416/000119312522109589/d193995dex1031.htm">Settlement and License Agreement between Alvotech hf. and AbbVie, dated April 4, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">04.19.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.19&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522135361/d193995dex1034.htm">Standby Equity Purchase Agreement between Alvotech and YA II PN, LTD., dated April 18, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-261773</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.34</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">05.02.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.20#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522178843/d358835dex439.htm">Management Incentive Plan. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">06.22.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.033%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Incorporation By Reference</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Schedule/</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">File</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">File Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001898416/000119312522193874/d364319dex1037.htm">Investor Rights and Lock-Up Agreement between Alvotech and certain Investors, dated June 15, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">F-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">333-266136</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">10.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">07.14.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522287821/d408752dex997.htm">Warrant Agreement by and between Alvotech and Alvogen Lux Holdings S.&#224; r.l., dated November 16, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">a6-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">99.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">11.17.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523056506/d454484dex442.htm">Form of Share Purchase Agreement by and between Alvotech and Investor., dated February 26, 2024</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523056506/d454484dex442.htm">. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/1/2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1898416/000119312522287821/d408752dex9910.htm">Transition Services Agreement between Alvotech and Aztiq Consulting ehf., dated November 16, 2022 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">6-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">11.17.2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523056506/d454484dex446.htm">Form of Indemnification Agreement between Alvotech and Non-Executive Directors </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03.01.2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4.26&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523056506/d454484dex447.htm">Second amendment to the License and Development Agreement between Alvotech hf. and Teva dated August 5, 2020, dated February 27, 2023 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03.01.2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000093041323001851/c106704_ex99-4.htm">Master License and Supply Agreement by and between Alvotech and Mercury Pharma Group Limited (trading as Advanz Pharma Holdings), dated as of May 22, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">07.12.2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt 0 10pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">8.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1898416/000119312523056506/d454484dex81.htm">Subsidiaries of the Registrant </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-41421</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">03.01.2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="alvo-20231231xexx121.htm">Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">12.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="alvo-20231231xexx122.htm">Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">13.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="alvo-20231231xexx131.htm">Certification by the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">15.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="alvo-20231231xexx151.htm">Consent of Deloitte ehf., independent registered accounting firm for Alvotech. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97*</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="alvo-20231231xexx97.htm">Incentive Compensation Recoupment Policy. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">__________</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Filed herewith.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Furnished herewith.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Certain schedules and exhibits to this Exhibit have been omitted pursuant to Company S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8224;&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:21.37pt">Certain schedules and exhibits to this Exhibit have been omitted pursuant to Regulation S-K Item 601(a)(5). The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Indicates a management contract or any compensatory plan, contract or arrangement </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">152</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_259"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES </span></div><div style="margin-top:12pt;text-indent:24.48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this report on its behalf. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20&#160;March 2024 </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ALVOTECH</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">/s/ Robert Wessman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name:</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">153</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_262"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:120pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">Alvotech </span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:50%">_____________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Financial Statements as </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 31&#160;December, 2023 and 2022 and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for the years ended 31&#160;December 2023, 2022, and 2021 </span></div><div style="margin-top:240pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Table of Contents </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_265">Report of Independent Registered Accounting Firm (PCAOB ID: </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-49">1490</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_265">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_265">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_268">Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_268">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_271">Consolidated Statements of Financial Position</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_271">4</a> - F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i823aa1bfad674e8d9979f682bbc51608_357">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_274">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_274">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_277">Consolidated Statements of Changes in Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_277">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_280">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie527079dad0a4810aa92569387637e3d_280">8</a> - F-64</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-1</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_265"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div style="margin-bottom:16.63pt;margin-top:16.63pt"><img src="alvo-20231231_g2.jpg" alt="1.jpg" style="height:20px;margin-bottom:5pt;vertical-align:text-bottom;width:114px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the shareholders and the Board of Directors of Alvotech</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated statements of financial position of Alvotech and subsidiaries (the "Company") as of December 31, 2023 and 2022, the related consolidated statements of profit or loss and other comprehensive income or loss, changes in equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board and adopted by the EU.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Going concern</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1.4 to the financial statements, the Company has suffered recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1.4. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Deloitte ehf.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">K&#243;pavogur, Iceland</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> March 20, 2024</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company's auditor since 2013.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-2</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_268"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss for the years ended 31&#160;December 2023, 2022, and 2021 </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">USD in thousands, except for per share amounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="3" id="f-50">48,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="3" id="f-51">24,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="3" id="f-52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:LicenceFeeIncome" format="ixt:num-dot-decimal" scale="3" id="f-53">42,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:LicenceFeeIncome" format="ixt:num-dot-decimal" scale="3" id="f-54">58,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:LicenceFeeIncome" format="ixt:num-dot-decimal" scale="3" id="f-55">36,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="3" id="f-56">1,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="3" id="f-57">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="3" id="f-58">2,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="3" id="f-59">160,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="3" id="f-60">64,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:fixed-zero" scale="3" id="f-61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-62">210,827</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-63">180,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-64">191,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-65">76,559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-66">186,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-67">84,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-68">354,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-69">346,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-70">235,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of net loss of joint venture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-71">7,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-72">2,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-73">2,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment loss on investment in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-74">21,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-77">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-78">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-79">51,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-80">267,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-81">188,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-82">117,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange rate differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-83">5,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-84">10,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-85">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) / gain on extinguishment of financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" format="ixt:fixed-zero" scale="3" id="f-86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" format="ixt:num-dot-decimal" scale="3" id="f-87">27,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" format="ixt:num-dot-decimal" scale="3" id="f-88">151,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-operating (loss) / profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-89">296,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:OtherGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-90">205,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:OtherGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-91">86,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-92">651,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-93">551,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-94">149,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-95">99,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-96">38,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-97">47,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss for the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-98">551,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-99">513,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-100">101,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income / (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Item that will be reclassified to profit or loss in subsequent periods:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange rate differences on translation of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-101">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-102">6,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-103">305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-104">551,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-105">519,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-106">101,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss for the year per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-107"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-108">2.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-109"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-110">2.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-111"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-112">0.92</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-3</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_271"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Financial Position as of 31&#160;December 2023 and 2022 </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">USD in thousands </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Non-current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-113">236,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-114">220,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-115">119,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-116">47,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-117">12,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-118">11,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-119">19,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-120">25,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-121">10,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-122">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Investment in joint venture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-123">18,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-124">48,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-125">2,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-126">5,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-127">26,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-128">25,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-129">309,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-130">209,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-131">755,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-132">597,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="f-133">74,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="f-134">71,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-135">41,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-136">32,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-137">35,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-138">25,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-139">31,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-140">32,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Receivables from related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" scale="3" id="f-141">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-142">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-143">11,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-144">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-145">194,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-146">230,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-147">950,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-148">828,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Financial Position as of 31&#160;December 2023 and 2022 </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">USD in thousands </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share capital</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-149">2,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-150">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share premium</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-151">1,229,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-152">1,058,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-153">42,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-154">30,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-155">1,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-156">1,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-157">2,205,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-158">1,654,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-159">932,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-160">564,416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-161">922,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-162">744,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-163">520,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-164">380,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other long-term liability to related party</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentPayablesToRelatedParties" format="ixt:fixed-zero" scale="3" id="f-165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentPayablesToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-166">7,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-167">105,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-168">35,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term incentive plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" format="ixt:fixed-zero" scale="3" id="f-169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" scale="3" id="f-170">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-171">73,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-172">57,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-173">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" scale="3" id="f-174">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-175">1,621,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-176">1,225,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-177">80,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-178">49,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-179">9,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-180">5,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current maturities of borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentPortionOfLongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-181">38,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentPortionOfLongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-182">19,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Liabilities to related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-183">9,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-184">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-185">59,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-186">36,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="3" id="f-187">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="3" id="f-188">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-189">62,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-190">54,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-191">260,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-192">167,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-193">1,882,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-194">1,392,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total equity and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-195">950,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-196">828,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these Consolidated Financial <span id="i823aa1bfad674e8d9979f682bbc51608_357"></span>Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-5</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_274"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Cash Flows for the years ended 31&#160;December 2023, 2022, and 2021 </span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">USD in thousands </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Loss for the year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">551,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">513,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-199">101,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Adjustments for non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gain on extinguishment of SARs liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains" format="ixt:fixed-zero" scale="3" id="f-200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains" format="ixt:num-dot-decimal" scale="3" id="f-201">4,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains" format="ixt:fixed-zero" scale="3" id="f-202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Share-listing expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AdjustmentsForSharelistingExpense" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AdjustmentsForSharelistingExpense" format="ixt:num-dot-decimal" scale="3" id="f-204">83,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:AdjustmentsForSharelistingExpense" format="ixt:fixed-zero" scale="3" id="f-205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long-term incentive plan expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="3" id="f-206">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-207">5,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-208">17,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-209">24,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-210">20,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-211">18,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Impairment of property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-214">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Impairment of other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-215">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-216">2,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-217">3,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Change in allowance for receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-218">18,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Change in inventory reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:ChangesInInventoryReserves" format="ixt:num-dot-decimal" scale="3" id="f-221">8,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:ChangesInInventoryReserves" format="ixt:fixed-zero" scale="3" id="f-222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:ChangesInInventoryReserves" format="ixt:fixed-zero" scale="3" id="f-223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Loss on disposal of property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment" scale="3" id="f-224">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Impairment loss on investment in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-227">21,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Share of net loss of joint venture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">27</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-230">7,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-231">2,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-232">2,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Finance income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-233">4,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-234">2,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-235">51,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Finance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-236">267,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-237">188,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-238">117,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Loss/(Gain) on extinguishment of financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" format="ixt:num-dot-decimal" scale="3" id="f-240">27,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" format="ixt:num-dot-decimal" scale="3" id="f-241">151,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Share-based payments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-242">18,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-243">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:fixed-zero" scale="3" id="f-244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exchange rate difference</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="3" id="f-245">5,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="3" id="f-246">10,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="3" id="f-247">2,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncomeTaxExpense" format="ixt:num-dot-decimal" scale="3" id="f-248">99,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncomeTaxExpense" format="ixt:num-dot-decimal" scale="3" id="f-249">38,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncomeTaxExpense" format="ixt:num-dot-decimal" scale="3" id="f-250">47,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating cash flow before movement in working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-251">283,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-252">228,861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-253">193,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Increase in inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-254">11,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-255">32,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-256">29,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Increase in trade receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-257">8,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-258">3,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-259">28,813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Increase / (decrease) in liabilities with related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-260">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" scale="3" id="f-261">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" scale="3" id="f-262">453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Increase) / decrease in contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-263">17,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-264">9,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-265">15,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Increase in other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="3" id="f-266">802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-267">17,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-268">4,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Increase in trade and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-269">31,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-270">16,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-271">14,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Increase in contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-272">35,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-273">19,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-274">21,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Decrease) / increase in other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-275">5,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-276">21,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-277">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash used in operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-278">257,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-279">276,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-280">200,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-281">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="f-282">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="f-283">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-284">57,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-285">35,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-286">28,004</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-287">1,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="f-288">834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="f-289">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-290">312,185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-291">312,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-292">228,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Acquisition of property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-293">33,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-294">37,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-295">20,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Disposal of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-296">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-297">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Acquisition of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-299">13,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-300">11,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-301">20,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash in connection with amended bond agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:RestrictedCashInConnectionWithAmendedBondAgreement" format="ixt:fixed-zero" scale="3" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:RestrictedCashInConnectionWithAmendedBondAgreement" format="ixt:num-dot-decimal" scale="3" id="f-303">14,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:RestrictedCashInConnectionWithAmendedBondAgreement" format="ixt:fixed-zero" scale="3" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-305">46,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-306">63,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-307">40,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Repayments of borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-308">99,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-309">34,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-310">37,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Repayments of principal portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-311">8,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-312">11,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-313">7,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from new borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-314">278,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-315">193,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-316">113,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Transaction cost from new borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-317">9,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gross proceeds from private placement equity offering</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" format="ixt:num-dot-decimal" scale="3" id="f-318">136,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" format="ixt:fixed-zero" scale="3" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gross private placement equity offering fee</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-321">4,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from warrants </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-324">6,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds on issue of equity shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-329">185,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Transaction costs for amended borrowing agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-330">12,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:PaymentsForDebtIssueCosts" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gross proceeds from the PIPE Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:GrossProceedsFromThePipeFinancing" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:GrossProceedsFromThePipeFinancing" format="ixt:num-dot-decimal" scale="3" id="f-333">174,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:GrossProceedsFromThePipeFinancing" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gross PIPE Financing fees paid</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:GrossPipeFinancingFeesPaid" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:GrossPipeFinancingFeesPaid" format="ixt:num-dot-decimal" scale="3" id="f-336">5,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:GrossPipeFinancingFeesPaid" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the Capital Reorganization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:ProceedsFromTheCapitalReorganization" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:ProceedsFromTheCapitalReorganization" format="ixt:num-dot-decimal" scale="3" id="f-339">9,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:ProceedsFromTheCapitalReorganization" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from loans from related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-342">160,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Repayment of loans from related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-345">50,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash generated from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-347">301,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-348">424,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-349">254,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Increase / (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="f-350">57,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="f-351">48,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="f-352">13,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents at the beginning of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-353">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-354">17,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-355">31,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of movements in exchange rates on cash held</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-356">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-357">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-358">161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash and cash equivalents at the end of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-359">11,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-360">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-361">17,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow disclosures (Note 29) </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-6</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_277"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Changes in Equity for the years ended 31&#160;December 2023, 2022, and 2021 </span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">USD in thousands </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:37.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share<br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share<br/>premium </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>reserves</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Translation<br/>reserve </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total equity </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">At 1 January 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-362">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-363">166,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-365">4,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-366">1,039,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-367">867,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss for the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-368">101,504</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-369">101,504</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency translation differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-370">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-371">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total comprehensive loss</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-372">305</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-373">101,504</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-374">101,809</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increase in share capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-375">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-376">833,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-377">833,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">At 31 December 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-378">135</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-379">1,000,118</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-381">4,669</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-382">1,140,534</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-383">135,612</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss for the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-384">513,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-385">513,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-386">6,111</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-387">6,111</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-388">6,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-389">513,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-390">519,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">PIPE Financing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="alvo:IncreaseDecreaseThroughPipeFinancing" scale="3" id="f-391">175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="alvo:IncreaseDecreaseThroughPipeFinancing" format="ixt:num-dot-decimal" scale="3" id="f-392">169,193</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:IncreaseDecreaseThroughPipeFinancing" format="ixt:num-dot-decimal" scale="3" id="f-393">169,368</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of SARs with shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-394">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-395">30,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-396">30,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capital Reorganization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="alvo:IncreaseDecreaseThroughCapitalReorganization" format="ixt:num-dot-decimal" scale="3" id="f-397">1,731</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="alvo:IncreaseDecreaseThroughCapitalReorganization" format="ixt:num-dot-decimal" scale="3" id="f-398">173,296</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:IncreaseDecreaseThroughCapitalReorganization" format="ixt:num-dot-decimal" scale="3" id="f-399">171,565</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of related party loans with Ordinary Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" scale="3" id="f-400">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-401">32,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-402">32,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-403">14,548</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-404">14,548</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of equity component of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-405">16,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-406">16,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">At 31 December 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-407">2,126</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-408">1,058,432</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-409">30,582</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-410">1,442</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-411">1,654,114</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-412">564,416</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss for the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-413">551,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-414">551,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-415">86</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-416">86</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-417">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-418">551,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-419">551,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capital contribution</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="f-420">118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="f-421">132,618</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="f-422">132,736</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested earn-out shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-423">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-424">8,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-425">8,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Penny warrants exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-426">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-427">27,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-428">27,184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Public warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-429">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-430">7,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-431">7,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-432">16,985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-433">16,985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of RSUs with shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="f-434">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-435">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-436">5,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="f-437">678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of SARs with shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="f-438">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-439">9,526</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-440">4,231</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-441">13,767</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of equity component of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-442">5,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-443">5,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">At 31 December 2023</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-444">2,279</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-445">1,229,690</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-446">42,911</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-447">1,528</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-448">2,205,845</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-449">932,493</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-7</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_280"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div><span><br/></span></div><div id="ie527079dad0a4810aa92569387637e3d_283"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-450" continuedAt="f-450-1" escape="true">General information </ix:nonNumeric></span></div><ix:continuation id="f-450-1" continuedAt="f-450-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech (the &#8220;Parent&#8221; or the &#8220;Company&#8221; or &#8220;Alvotech&#8221;), previously known as Alvotech Lux Holdings S.A.S., the surviving company after the Business Combination (as defined below) with, among other parties, Alvotech Holdings S.A. (the &#8220;Predecessor&#8221;), is a Luxembourg public limited company (soci&#233;t&#233; anonyme) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg and is registered with the Luxembourg Trade and Companies&#8217; Register under number B 258884. The Company was incorporated on 23 August 2021. These consolidated financial statements were approved by the Group&#8217;s Board of Directors, and authorized for issue, on 20 March 2024. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company and its subsidiaries (collectively referred to as the &#8220;Group&#8221;) are a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide. The Group has commercialized a certain biosimilar product and has multiple biosimilar molecules. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1 Capital Reorganization </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 15 June 2022 (the &#8220;Closing Date&#8221;), the Company consummated the capital reorganization with Alvotech Holdings S.A. and OACB (the &#8220;Business Combination&#8221; or &#8220;Capital Reorganization&#8221;) pursuant to the business combination agreement, dated as of 7 December 2021, as amended by an amendment agreement dated 18 April 2022 and 7 June 2022 (the &#8220;Business Combination Agreement&#8221;), by and among the Company, Oaktree Acquisition Corp. II (&#8220;OACB&#8221;) and the Predecessor. The closing of the Business Combination resulted in the following transactions: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">OACB merged with and into the Company, whereby (i) all of the outstanding ordinary shares of OACB (&#8220;OACB Ordinary Shares&#8221;) were exchanged for ordinary shares of Alvotech (&#8220;Ordinary Shares&#8221;) on a <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="alvo:NumberOfSharesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-451">one</ix:nonFraction>-for-one basis, pursuant to a share capital increase of Alvotech and (ii) all of the outstanding warrants of OACB ceased to represent a right to acquire OACB Ordinary Shares and now represent a right to be issued <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="alvo:NumberOfSharesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-452">one</ix:nonFraction> Ordinary Share, with Alvotech as the surviving company in the merger. Prior to the merger OACB shares were redeemed, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="alvo:ProceedsFromTheCapitalReorganization" format="ixt:num-dot-decimal" scale="6" id="f-453">9.8</ix:nonFraction> million of cash proceeds from the OACB trust account; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Alvotech redeemed and canceled the initial shares held by the initial sole shareholder of Alvotech pursuant to a share capital reduction of Alvotech; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The legal form of Alvotech changed from a simplified joint stock company (soci&#233;t&#233; par actions simplifi&#233;e) to a public limited liability company (soci&#233;t&#233; anonyme) under Luxembourg law; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Predecessor merged with and into the Parent, whereby all outstanding ordinary shares of the Predecessor (&#8220;Predecessor Ordinary Shares&#8221;) were exchanged for Ordinary Shares, pursuant to a share capital increase of Alvotech, with Alvotech as the surviving company in the merger. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrently with the execution of the Business Combination Agreement, OACB and Alvotech entered into subscription agreements (&#8220;Subscription Agreements&#8221;) with certain investors (the &#8220;PIPE Financing&#8221;). On 15&#160;June 2022, immediately prior to the closing of the Business Combination, the PIPE Financing was closed, pursuant to the Subscription Agreements, in which subscribers collectively subscribed for <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="alvo:CommonStockSharesSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-454">17,493,000</ix:nonFraction> Ordinary Shares at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="INF" name="alvo:CommonStockSubscriptionPricePerShare" scale="0" id="f-455">10.00</ix:nonFraction> per share for an aggregate subscription price equal to $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="alvo:CommonStockValueSubscriptions" format="ixt:num-dot-decimal" scale="6" id="f-456">174.9</ix:nonFraction> million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Business Combination, Predecessor shareholders were granted a total of <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-457">38,330,000</ix:nonFraction> Ordinary Shares subject to certain vesting conditions (&#8220;Predecessor Earn Out Shares&#8221;). Former OACB shareholders were granted a total of <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-458">1,250,000</ix:nonFraction> Ordinary Shares subject to certain vesting conditions (&#8220;OACB Earn Out Shares&#8221;). Additionally, as part of the Business Combination the Company assumed the <ix:nonFraction unitRef="shares2" contextRef="c-72" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-459">10,916,647</ix:nonFraction> outstanding warrants (&#8220;OACB Warrants&#8221;), on substantially the same contractual terms and conditions as were in effect immediately prior to the Business Combination. See Note 28 for further details. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Business Combination was accounted for as a capital reorganization. Under this method of accounting, OACB was treated as the &#8220;acquired&#8221; company for financial reporting purposes, with Alvotech Holdings S.A. being the accounting acquirer and accounting predecessor. Accordingly, the capital reorganization was treated as the equivalent of Alvotech issuing shares at the closing of the Business Combination for the net assets of OACB as of the Closing Date, accompanied by a recapitalization. The capital reorganization, which was not within the scope of IFRS 3 since OACB did not meet the definition of a business in accordance with that guidance, was accounted for within the scope of IFRS 2. In accordance with IFRS 2, Alvotech recorded a one-time non-cash share listing expense of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="alvo:ReorganizationShareListingExpense" format="ixt:num-dot-decimal" scale="6" id="f-460">83.4</ix:nonFraction> million, recognized as a general and administrative expense, based on the excess of the fair value of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-450-2" continuedAt="f-450-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech shares issued, at the Closing Date, over the fair value of OACB&#8217;s identifiable net assets acquired. <ix:nonNumeric contextRef="c-1" name="alvo:ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" id="f-461" continuedAt="f-461-1" escape="true">The fair value of shares issued was estimated based on a market price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-73" decimals="2" name="alvo:FairValueOfSharesIssuedMarketPricePerShare" scale="0" id="f-462">9.38</ix:nonFraction> per share as of 15&#160;June 2022. </ix:nonNumeric></span></div><ix:continuation id="f-461-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(in 000s) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class A Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" format="ixt:num-dot-decimal" scale="0" id="f-463">976,505</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class B Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" format="ixt:num-dot-decimal" scale="0" id="f-464">5,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" format="ixt:num-dot-decimal" scale="0" id="f-465">1,250,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Alvotech Shares issued to OACB shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" format="ixt:num-dot-decimal" scale="0" id="f-466">7,226,505</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of Shares issued to OACB as of 15 June 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" format="ixt:num-dot-decimal" scale="3" id="f-467">56,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of OACB Earn Out Shares issued to OACB as of 15 June 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" format="ixt:num-dot-decimal" scale="3" id="f-468">9,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Estimated fair market value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" format="ixt:num-dot-decimal" scale="3" id="f-469">65,160</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjusted net liabilities of OACB as of 15 June 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="alvo:AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" format="ixt:num-dot-decimal" scale="3" id="f-470">18,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Difference &#8211; being the share listing expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="alvo:ReorganizationShareListingExpense" format="ixt:num-dot-decimal" scale="3" id="f-471">83,411</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Business Combination and PIPE Financing, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-472">28.5</ix:nonFraction> million of transaction costs, which represent legal, financial advisory, and other professional fees in connection with the Business Combination and PIPE Financing, during the year ended December&#160;31, 2022. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="alvo:ExpenseCapitalized" format="ixt:num-dot-decimal" scale="6" id="f-473">5.6</ix:nonFraction> million represented equity issuance costs related to PIPE Financing that were capitalized in share premium. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-474">22.9</ix:nonFraction> million was recognized as general and administrative expense. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" id="f-475" continuedAt="f-475-1" escape="true"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2 Information about subsidiaries and joint ventures </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"/><td style="width:37.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.137%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Entity name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Principal </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">activity</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issued and </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">paid capital </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(presented in </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">whole shares)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Place of </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">establishment</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proportion of ownership </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">and voting power held by </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Alvotech </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31.12.2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31.12.2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech hf</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-476">3,893,650</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-477">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-478">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Germany GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-479">31,182</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Germany</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-480">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-481">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Swiss AG</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-482">153,930</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Switzerland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-483">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-484">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Hannover GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-485">29,983</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Germany</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-486">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-487">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Malta Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-488">80,450</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Malta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-489">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-490">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech USA Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" id="f-491">10</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">USA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-492">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-493">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech UK Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" id="f-494">135</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">UK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-495">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-496">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Manco ehf</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-497">215,390</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-498">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-102" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-499">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Biosciences India Private Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-500">96,113</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-104" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-501">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-502">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignafelagi&#240; S&#230;mundur hf</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Real estate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-503">12,965,337</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-504">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-505">100.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech &amp; CCHN Biopharmaceutical Co. Ltd*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-506">110,000,021</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-507">50.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-508">50.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><ix:continuation id="f-475-1" continuedAt="f-475-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt"><ix:continuation id="f-475-2">Alvotech &amp; CCHN Biopharmaceutical Co. Ltd. is an unconsolidated joint venture (see Note 27).</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.3 Information about shareholders </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant shareholders of the Company are Aztiq Pharma Partners S.&#224; r.l. (Aztiq) and Alvogen Lux Holdings S.&#224; r.l. (Alvogen), with <ix:nonFraction unitRef="number" contextRef="c-112" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-509">37.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-113" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-510">33.7</ix:nonFraction>% ownership interest as of 31&#160;December 2023, and  <ix:nonFraction unitRef="number" contextRef="c-114" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-511">40.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-115" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-512">35.8</ix:nonFraction>% ownership interest as of 31&#160;December 2022, respectively. The remaining <ix:nonFraction unitRef="number" contextRef="c-116" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-513">28.4</ix:nonFraction>% ownership interest is held by various entities, with no single shareholder holding more than <ix:nonFraction unitRef="number" contextRef="c-116" decimals="INF" name="alvo:MaximumPercentageOfOwnershipInterestHeldByEachShareholder" scale="0" id="f-514">2.4</ix:nonFraction>% ownership interest as of 31&#160;December 2023. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-450-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The remaining <ix:nonFraction unitRef="number" contextRef="c-117" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-515">23.5</ix:nonFraction>% ownership interest was held by various entities, with no single shareholder holding more than <ix:nonFraction unitRef="number" contextRef="c-117" decimals="INF" name="alvo:MaximumPercentageOfOwnershipInterestHeldByEachShareholder" scale="0" id="f-516">2.4</ix:nonFraction>% ownership interest as of 31&#160;December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.4 Going concern </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group has primarily funded its operations with proceeds from the issuance of ordinary shares and the issuance of loans and borrowings to both related parties and third parties. The Group has also incurred recurring losses since its inception, including net losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-517">551.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-518">513.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-519">101.5</ix:nonFraction> million for the years ended 31&#160;December 2023, 2022, and 2021, respectively, and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="6" id="f-520">2,205.8</ix:nonFraction>&#160;million as of 31&#160;December 2023. The Group has not generated positive operational cash flow, largely due to the continued focus on biosimilar product development and expansion efforts. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the Group had cash and cash equivalents, excluding restricted cash, of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-521">11.2</ix:nonFraction>&#160;million and current assets less current liabilities of ($<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="ifrs-full:CurrentAssetsLiabilities" scale="6" id="f-522">66.1</ix:nonFraction>) million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, the development of and regulatory approval of commercially viable biosimilar products, the need to raise adequate additional financing necessary to fund the development and commercialization of its biosimilar products.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company announced in February 2024 that the U.S. Food and Drug Administration ("FDA") has approved SIMLANDI (adalimumab) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn&#8217;s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. Teva is Alvotech&#8217;s strategic partner for the exclusive commercialization of SIMLANDI in the United States. SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA, and will qualify for interchangeable exclusivity for the 40mg/0.4ml injection. This approval is an important milestone for the Company to access the U.S. market with a unique positioning. The Company expects to launch AVT02 with its partner Teva in the United States during the first half of 2024. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, in February 2024, the Company announced it has reached settlement agreements with Johnson &amp; Johnson in Japan, Canada and in the European Economic Area (EEA) for AVT04, a biosimilar to Stelara (ustekinumab). Regulatory approval for AVT04 in these markets has already been granted. Market applications for AVT04 are currently pending in additional global markets, including in the U.S. Market entry of AVT04 in Canada started in March 2024. Launch of AVT04 in Japan is anticipated after the upcoming round of National Health Insurance reimbursement price listings, in May 2024. Entry to the first European markets is expected as soon as possible after the expiration date of the European Supplementary Protection Certificate for Stelara, which is in late July 2024. These approvals represent another significant milestone for the Company to tap into the Stelara market.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The closing of the private placement equity offering in February 2024 provided the Group with gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-523">166</ix:nonFraction>&#160;million (net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="6" id="f-524">160</ix:nonFraction>&#160;million) that is expected to be used to finance general corporate purposes and working capital, to strengthen its production capacity, and to support expected biosimilars launches. As part of the transaction, the Group sold <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-525">10,127,132</ix:nonFraction> Ordinary Shares, par value USD <ix:nonFraction unitRef="usdPerShare" contextRef="c-121" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-526">0.01</ix:nonFraction> per share, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-527">16.41</ix:nonFraction> per share, or ISK <ix:nonFraction unitRef="iskPerShare" contextRef="c-120" decimals="0" name="ifrs-full:WeightedAverageSharePrice2019" format="ixt:num-dot-decimal" scale="0" id="f-528">2,250</ix:nonFraction> per share, at foreign exchange rates on 23 February 2024.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Group expects to continue to source its financing during the development of its biosimilar products from existing out-license contracts with commercial partners. In light of these conditions and events management evaluated whether there is substantial doubt about the Group&#8217;s ability to continue as a going concern for at least one year after the date that the consolidated financial statements are issued. Based on the cash on hand, funding received, and projected future cash flows, management concluded that the Group has the ability to continue as a going concern for at least one year after the date that the consolidated financial statements are issued. As such, the consolidated financial statements have been prepared on a going concern basis</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, although management continues to pursue these plans, there is no assurance that the Group will be successful in obtaining sufficient funding on terms acceptable to the Group to fund continuing operations, if at all. If financing is obtained, the terms of such financing may adversely affect the holdings or the rights of the Group&#8217;s shareholders. The ability to obtain funding, therefore, is outside of management&#8217;s control and is a material uncertainty that may cast significant doubt upon the Group&#8217;s ability to continue as a going concern. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-10</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_286"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="f-529" continuedAt="f-529-1" escape="true">Summary of significant accounting policies </ix:nonNumeric></span></div><ix:continuation id="f-529-1" continuedAt="f-529-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-530" continuedAt="f-530-1" escape="true">Basis of preparation </ix:nonNumeric></span></div><ix:continuation id="f-530-1" continuedAt="f-530-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements of the Group have been prepared in accordance and in compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), which comprise all standards and interpretations approved by the IASB, and as adopted by the European Union ("EU"). </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All amendments to IFRSs issued by the IASB that are effective for annual periods that begin on or after 1 January 2023 have been adopted as further described within the footnotes to the consolidated financial statements. The Group has not adopted any standards or amendments to standards in issue that are available for early adoption. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-530-2">The consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and financial liabilities which have been measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The consolidated financial statements are presented in U.S. Dollar ("USD") and all values are rounded to the nearest thousand unless otherwise indicated.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.2 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory" id="f-531" continuedAt="f-531-1" escape="true">Basis of consolidation </ix:nonNumeric></span></div><ix:continuation id="f-531-1" continuedAt="f-531-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">has power over the investee; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">is exposed, or has rights, to variable returns from its involvement with the investee; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">has the ability to use its power to affect its returns. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company&#8217;s voting rights in an investee are sufficient to give it power, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the size of the Company&#8217;s holding of voting rights relative to the size and dispersion of holdings of the other vote holders; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">potential voting rights held by the Company, other vote holders or other parties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">rights arising from other contractual arrangements; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders&#8217; meetings. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income or loss from the date the Company gains control until the date when the Company ceases to control the subsidiary. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-531-2">All intra-group transactions, balances, income and expenses are eliminated in full in consolidation.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentsInJointVentures" id="f-532" continuedAt="f-532-1" escape="true">Investments in joint ventures </ix:nonNumeric></span></div><ix:continuation id="f-532-1" continuedAt="f-532-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent the Group concludes that it does not control, and thus consolidate, a joint venture, the Group accounts for its interest in joint ventures using the equity method of accounting. As such, investments in a joint venture are initially recognized at cost and the carrying amount is subsequently adjusted for the Group&#8217;s share of the profit or loss of the joint venture, as well as any distributions received from the joint venture. The Group carries its ownership interest in a joint venture as &#8220;Investment in joint venture&#8221; on the consolidated statements of financial position. The Group&#8217;s profit or loss includes its share of the profit or loss of the joint venture and, to the extent applicable, other comprehensive income or loss for the Group includes its share of other comprehensive income or loss of the joint venture. The Group&#8217;s share of a joint venture&#8217;s profit or loss in a particular year is presented as &#8220;Share of net loss of joint venture&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-2" continuedAt="f-529-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-532-2">The carrying amount of equity-accounted investments is assessed for impairment as a single asset. Impairment losses are incurred only if there is objective evidence of impairment as a result of loss events that have an impact on estimated future cash flows and that can be reliably estimated. Losses expected as a result of future events are not recognized. The Group  recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-533">21.5</ix:nonFraction>&#160;million related to its investment in the joint venture for the year ended 31&#160;December 2023. <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="0" id="f-534"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="0" id="f-535">No</ix:nonFraction></ix:nonFraction> impairment losses were recognized in 2022 or 2021.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4 <ix:nonNumeric contextRef="c-1" name="alvo:DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" id="f-536" continuedAt="f-536-1" escape="true">Critical accounting judgments and key sources of estimation uncertainty </ix:nonNumeric></span></div><ix:continuation id="f-536-1" continuedAt="f-536-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the consolidated financial statements in conformity with IFRS requires Group management to make judgments, estimates and assumptions about the reported amounts of assets, liabilities, income and expenses that are not readily apparent from other sources. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and other factors that are considered to be relevant. Judgments and assumptions involving key estimates are primarily made in relation to the measurement and recognition of revenue, the impairment of the investment in the joint venture, the valuation of derivative financial liabilities, the valuation of restricted share units (&#8220;RSUs&#8221;), and the valuation of deferred tax assets. Apart from those involving estimations, critical accounting judgments include the Group&#8217;s evaluation as to whether it controls its joint venture in China  and material uncertainties with respect to the Group&#8217;s going concern assessment. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Existing circumstances and assumptions may change due to events arising that are beyond the Group&#8217;s control. Therefore, actual results may differ from these estimates. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-536-2">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.5 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="f-537" continuedAt="f-537-1" escape="true">Segment reporting </ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-537-1">The Group operates and manages its business as <ix:nonFraction unitRef="segement" contextRef="c-5" decimals="INF" name="alvo:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-538">one</ix:nonFraction> operating segment based on the manner in which the Chief Executive Officer, the Group&#8217;s chief operating decision maker, assesses performance and allocates resources across the Group.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.6 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="f-539" continuedAt="f-539-1" escape="true">Revenue recognition </ix:nonNumeric></span></div><ix:continuation id="f-539-1" continuedAt="f-539-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Product revenue</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue from the sale of its biosimilar product to commercial partners, identified as the customer, when control is transferred, and the performance obligations have been satisfied. This is when the title passes to the customer, which is upon shipment of the product. At that point, the commercial partner has full discretion over the channel and price to sell the products. Revenue is recognized based on the net selling price from the commercial partners, which is considered to be the transaction price and includes estimated rebates, returns and chargebacks, and other forms of variable consideration recognized by the customer. Variable consideration is accounted for by the Company only to the extent that it is highly probable that a significant reversal in the revenue recognized will not occur. Variable consideration, which includes any adjustments to the net selling price, is estimated based on the most likely amount method on a contract-by-contract basis. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Out-licensing revenue</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant part of the Group&#8217;s revenue is generated from long-term out-license contracts which provide the customer with an exclusive right to market and sell products in a particular territory once such products are approved for commercialization. These contracts typically include the Group&#8217;s promises to continue development of the underlying compound and to provide supply of the product to the customer upon commercialization. The Group concludes that the license, development services and commercial supply are separate performance obligations. This is because customers generally have the capabilities to perform the necessary development, manufacturing and commercialization activities on their own or with readily available resources and have the requisite expertise in the industry and the territory for which the license has been granted. Further, the intellectual property is generally in a later phase of development at the time the license is granted such that any subsequent development activities performed by the Group are not expected to significantly modify or transform the intellectual property. The fact that the Group is contractually obligated to perform development activities for and provide commercial supply to the </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-539-2" continuedAt="f-539-3"><ix:continuation id="f-529-3" continuedAt="f-529-4"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">customer does not impact this conclusion. The Group&#8217;s promise to provide commercial supply to its customers is contingent upon the achievement of regulatory approval in the particular territory for which the license has been granted. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consideration to which the Group is entitled pursuant to these contracts generally includes upfront payments and payments based upon the achievement of development and regulatory milestones. All contracts include a potential refund obligation whereby the Group must refund the consideration paid by the customer in the event of a technical failure or the occurrence of certain other matters that result in partial or full cancellation of the contract. As such, the entire transaction price is comprised of variable consideration, which is estimated using the most likely amount method due to the binary nature of the outcomes under these contracts. Such variable consideration is included in the transaction price only when it is highly probable that doing so will not result in a significant reversal of cumulative revenue recognized when the underlying uncertainty associated with the variable consideration is subsequently resolved. The Group does not account for a significant financing component since a substantial amount of consideration promised by the customer is variable and the amount or timing of that consideration varies on the basis of a future event that is not substantially within the control of either party. Certain contracts also include commercialization milestones upon the first commercial sale of a product in a particular territory, as well as royalties. Commercialization milestones and royalties are accounted for as sales-based royalties; therefore, such amounts are not included in the transaction price and recognized as revenue until the underlying sale that triggers the milestone or royalty occurs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upfront payments, when applicable, are received in advance of transferring control of all goods and services. Therefore, a portion of upfront payments is recorded as a contract liability upon receipt. Due to the existence of refund provisions, upfront payments and certain development milestone payments are generally included in the transaction price upon submission of the first clinical trial application to the respective regulatory agency, since it is at this point in time that a significant reversal of cumulative revenue recognized related to such payments is no longer highly probable. Other development and regulatory milestones may not be included in the transaction price until such milestones are achieved due to the degree of uncertainty associated with achieving these milestones. Contract liabilities are presented on the consolidated statements of financial position as either current or non-current based upon forecasted performance. In certain contracts, the Group may transfer control of goods and services, and thus recognize revenue, prior to having the right to invoice the customer. In these circumstances, the Group recognizes contract assets for revenue recognized, and subsequently reclasses the contract asset to trade receivables upon issuing an invoice and the right to consideration is only conditional on the passage of time. Contract assets are presented on the consolidated statements of financial position as either current or non-current based upon the expected timing of settlement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standalone selling prices of the development services and the license to intellectual property are not directly observable and, therefore, are estimated. The standalone selling price of the development services is estimated based on the expected costs to be incurred during the development period, using various data points such as the underlying development budget, contractual milestones and performance completed at the time of entering into the contract with a customer. The standalone selling price of the license is estimated using the residual approach on the basis that the Group licenses intellectual property for a broad range of amounts and has not previously licensed intellectual property on a standalone basis. Therefore, the Group first allocates the transaction price to the development services and subsequently allocates the remainder of the transaction price to the license. If the product is still in early phase of development and the constraint on variable consideration has not been resolved, all the transaction price is allocated to the development service. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standalone selling price of the commercial supply is directly observable and the stated prices in the Group&#8217;s supply contracts reflect the standalone selling price of such goods. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The licenses to intellectual property are right of use licenses on the basis that the ongoing development work performed by the Group does not significantly affect the intellectual property to which the customer has rights. Therefore, control of the license transfers to the customer at the point in time when the right to use the license is granted to the customer. The license is generally granted to the customer at the time the contract is executed with the customer. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group satisfies its performance obligation related to the development services over time as the Group&#8217;s performance enhances the value of the licensed intellectual property controlled by the customer throughout the performance period. The Group recognizes revenue using a cost-based input measure since this measure best reflects the progress of the development services and, therefore, the pattern of transfer of control of the services to the customer. In certain instances, the Group may subcontract services to other parties for which the Group is ultimately responsible. Costs incurred for such subcontracted services are included in the Group&#8217;s measure of progress for </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-4" continuedAt="f-529-5"><ix:continuation id="f-539-3" continuedAt="f-539-4"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">satisfying its performance obligation. Changes in the total estimated costs to be incurred in measuring the Group&#8217;s progress toward satisfying its performance obligation may result in adjustments to cumulative revenue recognized at the time the change in estimate occurs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the achievement of regulatory approval and the commencement of commercial sale of its products, the Group will satisfy its performance obligation related to commercial supply at the point in time when control of the manufactured product is transferred to the customer. Transfer of control for such goods will occur in accordance with the stated shipping terms. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group does not incur incremental costs of obtaining a contract with a customer that would require capitalization. Costs to fulfill performance obligations are not incurred in advance of performance and, as such, are expensed when incurred. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other revenue</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-539-4">Other revenue primarily consists of clinical trial support services rendered by the Group for its customers, which is recognized as the service is provided. Revenue for such services is presented in the consolidated statements of profit or loss and other comprehensive income or loss net of any discounts.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.7 <ix:nonNumeric contextRef="c-1" name="alvo:DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" id="f-540" continuedAt="f-540-1" escape="true">Cost of product revenue </ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-540-1">Cost of product revenue includes the cost of inventory sold, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as shipping and freight costs and royalty costs related to in-license agreements.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.8 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="f-541" continuedAt="f-541-1" escape="true">Research and development expenses </ix:nonNumeric></span></div><ix:continuation id="f-541-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses primarily consist of personnel costs, material and other lab supply costs, facility costs and internal and external costs related to the execution of studies and other development program advancement initiatives. Such expenses also include costs incurred in preparation for commercial launch, such as designing and developing commercial-scale manufacturing capabilities and processes, quality control processes, production asset validation and other related activities. The costs also include amortization, depreciation and impairment losses related to software, property, plant and equipment, and right-of-use assets used in research and development activities and pre-commercial manufacturing and quality control activities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An internally generated intangible asset arising from the Group&#8217;s development is recognized only if the Group can demonstrate: the technical feasibility of completing the intangible asset so that it will be available for use or sale; the intent to complete the intangible asset and use or sell it; how the intangible asset will generate probable future economic benefits; the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and the ability to measure reliably the expenditure attributable to the intangible asset during its development. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount initially recognized for internally-generated intangible assets is the sum of the expenditures incurred from the date when the intangible asset first meets the aforementioned recognition criteria. If an internally-generated intangible asset cannot be recognized, the related development expenditure is charged to profit or loss in the period in which it is incurred. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenditures related to research and development activities are generally recognized as an expense in the period in which they are incurred. The Company did not capitalize any development expenses as intangible assets during the years ended 31&#160;December 2023, 2022, and 2021 as not all the criteria in paragraph 57 of IAS 38 have been met.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.9 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory" id="f-542" continuedAt="f-542-1" escape="true">General and administrative expenses </ix:nonNumeric></span></div><ix:continuation id="f-542-1" continuedAt="f-542-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administration expenses primarily consist of personnel-related costs, including salaries and other related compensation expense, for corporate and other administrative and operational functions including finance, human resources, information technology and legal, as well as facility-related costs. These costs relate to the operation of the business and are not related to research and development initiatives. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-542-2">Expenditures related to general and administration activities are recognized as an expense in the period in which they are incurred.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-5" continuedAt="f-529-6"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.10 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" id="f-543" continuedAt="f-543-1" escape="true">Finance income and finance cost </ix:nonNumeric></span></div><ix:continuation id="f-543-1" continuedAt="f-543-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income consists of changes in the fair value of derivative financial liabilities and interest income. Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset&#8217;s net carrying amount on initial recognition. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-543-2">Finance cost consists of changes in the fair value of derivative financial liabilities, interest expense related to lease liabilities and borrowings, accretion of borrowings and amortization of deferred debt issue costs.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.11 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="f-544" continuedAt="f-544-1" escape="true">Foreign currency translation </ix:nonNumeric></span></div><ix:continuation id="f-544-1" continuedAt="f-544-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements are presented in U.S. Dollars, which is the Group&#8217;s presentation currency. The Group maintains the financial statements of each entity within the Group in its respective functional currency. The majority of the Group&#8217;s expenses are incurred in U.S. Dollars and Icelandic Krona, and the majority of the Company&#8217;s cash and cash equivalents are held in a combination of Icelandic Krona, Euros and U.S. Dollars. Transactions in currencies other than the Group&#8217;s presentation currency (foreign currencies) are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non- monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognized in profit or loss in the period in which they arise. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-544-2">Exchange differences arising on translation of a foreign controlled subsidiary are recognized in other comprehensive income or loss and accumulated in a translation reserve within equity. The cumulative translation amount is reclassified to profit or loss if and when the net investment in the foreign controlled subsidiary is disposed.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.12 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="f-545" continuedAt="f-545-1" escape="true">Fair value measurements </ix:nonNumeric></span></div><ix:continuation id="f-545-1" continuedAt="f-545-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group measures certain financial liabilities at fair value through profit or loss (FVTPL) at each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure the fair values of such financial liabilities, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques, as follows: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 1: quoted prices in active markets for identical assets and liabilities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (e.g., prices) or indirectly (e.g., derived from prices); and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 3: inputs for the asset or liability that are unobservable. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amounts of cash and cash equivalents, restricted cash, trade receivables, other current assets, contract assets, trade and other payables and other current liabilities in the Group&#8217;s consolidated statements of financial position approximate their fair value because of the short maturities and nature of these instruments. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-545-2">For liabilities that are measured at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by reassessing the inputs used in determining fair value at the end of each reporting period.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-6" continuedAt="f-529-7"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.13 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="f-546" continuedAt="f-546-1" escape="true">Goodwill and other intangible assets </ix:nonNumeric></span></div><ix:continuation id="f-546-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Goodwill and business combinations</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisitions are first reviewed to determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not meet the definition of a business, the Group will account for the transaction as an asset acquisition. If the definition of a business combination is met, the Group will account for the transaction using the acquisition method of accounting. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange fo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">r control of the acquiree. Acquisition-related costs are recognized in the consolidated statements of profit or loss and other comprehensive income or loss as incurred.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of the purchase price of the business combination over the Group&#8217;s interest in the net fair value of the identifiable assets, liabilities, contingent liabilities, the amount of any noncontrolling interests in the acquiree and the fair value of the acquirer&#8217;s previously held equity interest in the acquiree. Goodwill is reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the initial accounting for a business combination is incomplete by the end of the reporting period in which the business combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period, or as additional assets or liabilities are recognized, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group did not complete any business combinations during the years ended 31&#160;December 2023. Refer to Note 1.1 for the Business Combination completed during the year ended 31&#160;December 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other intangible assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other intangible assets consist of software, customer relationships, and intellectual property rights. Intangible assets acquired in a business combination are identified and recognized separately from goodwill if they satisfy the definition of an intangible asset and their fair values can be reliably measured. The cost of intangible assets is their fair value at the acquisition date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with finite useful lives are reported at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over an asset&#8217;s estimated useful life. The estimated useful life and amortization method are reviewed at each balance sheet date, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" id="f-547" continuedAt="f-547-1" escape="true">The following useful lives are used in the calculation of amortization: </ix:nonNumeric></span></div><ix:continuation id="f-547-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"/><td style="width:78.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-122" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-548">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-123" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-549">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-124" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-550">7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intellectual property rights*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-125" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-551">10</ix:nonNumeric> years</span></td></tr></table></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">From launch date</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with indefinite useful lives are reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-7" continuedAt="f-529-8"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.14 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="f-552" continuedAt="f-552-1" escape="true">Income tax </ix:nonNumeric></span></div><ix:continuation id="f-552-1" continuedAt="f-552-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax includes the current tax and deferred tax charge recorded in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Current tax</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current tax expense is based on taxable profit for the year. Taxable profit differs from &#8216;profit before tax&#8217; as reported in the consolidated statements of profit or loss and other comprehensive income or loss because it excludes items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group&#8217;s current tax expense is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accruals for tax contingencies are made when it is not probable that a tax authority will accept the tax position, based upon management&#8217;s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Accruals for tax contingencies are measured using either the most likely amount or the expected value amount depending on which method the entity expects to better predict the resolution of the uncertainty. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Deferred tax</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax is provided in full for all temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit, except to the extent the temporary difference arises from: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The initial recognition of an asset or a liability in a transaction that is not a business combination and that affects neither the taxable profit nor accounting profit; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The initial recognition of residual goodwill (for deferred tax liabilities only); or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Investments in subsidiaries, branches, associates and joint ventures, where the Group is able to control the timing of the reversal of the temporary difference and it is not probable that it will reverse in the foreseeable future. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and deferred tax assets reflects the tax consequences that would follow from the manner in which the Group expects, at the balance sheet date, to recover or settle the carrying amount of the assets and liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax is charged or credited to the consolidated statements of profit or loss and other comprehensive income or loss, except when the tax arises from a business combination or it relates to items charged or credited directly to equity, in which case the deferred tax is also taken directly to equity. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-552-2">Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis in that taxation authority.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.15 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="f-553" continuedAt="f-553-1" escape="true">Property, plant and equipment </ix:nonNumeric></span></div><ix:continuation id="f-553-1" continuedAt="f-553-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment is recognized as an asset when it is probable that future economic benefits associated with the asset will flow to the Group and the cost of the asset can be measured in a reliable manner. Property, plant and equipment which qualifies for recognition as an asset are initially measured at cost. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cost of property, plant and equipment includes an asset&#8217;s purchase price and any directly attributable costs of bringing the asset to working condition for its intended use. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-8" continuedAt="f-529-9"><ix:continuation id="f-553-2" continuedAt="f-553-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation is calculated and recognized as an expense on a straight-line basis over an asset&#8217;s estimated useful life. The estimated useful lives, residual values and depreciation method are reviewed at each balance sheet date, with the effect of any changes in estimate accounted for on a prospective basis. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" id="f-554" continuedAt="f-554-1" escape="true">The following useful lives are used in the calculation of depreciation: </ix:nonNumeric></span></div><ix:continuation id="f-554-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"/><td style="width:78.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-126" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-555">40</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-127" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-556">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c-128" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-557">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-129" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-558">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-130" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-559">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-131" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-560">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-132" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-561">5</ix:nonNumeric> years</span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of the Group&#8217;s property, plant and equipment assets have been pledged to secure borrowings as further described in Note 21. Significant disposals of pledged assets are subject to lender approval. Upon disposal or retirement of an asset, the difference between the sales proceeds, if applicable, and the carrying amount of the asset is recognized in the consolidated statements of profit or loss and other comprehensive income or loss at the time of disposal or retirement. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-553-3">At the end of each reporting period, or sooner if events triggering an interim impairment assessment occur, the Group reviews the carrying amounts of its property, plant and equipment to determine whether there is any indication that the value of such assets are impaired. Triggering events that warrant an interim impairment assessment include, but are not limited to, the technical obsolescence of equipment or failure of such equipment to meet regulatory requirements. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss and the carrying amount of the asset is reduced to its recoverable amount, which is the higher of fair value less costs of disposal and value in use.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.16 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="f-562" continuedAt="f-562-1" escape="true">Inventories </ix:nonNumeric></span></div><ix:continuation id="f-562-1" continuedAt="f-562-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories, which consist of raw materials and supplies, work in progress and finished goods are stated at the lower of cost or net realizable value. Net realizable value is the expected sales price less completion costs and costs to be incurred in marketing, selling and distributing the inventory. Cost is calculated using the weighted average cost method or the first-in,first-out method, depending on the nature of the inventory. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories include direct costs for raw materials and supplies and, as applicable, direct and indirect labor and overhead expenses that have been incurred to bring inventories to their present location and condition.  </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the net realizable value is lower than the carrying amount, a write-down of inventory is recognized for the amount by which the carrying amount exceeds net realizable value.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-562-2">The Group does not pledge inventories as collateral to secure its liabilities.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.17 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="f-563" continuedAt="f-563-1" escape="true">Financial assets </ix:nonNumeric></span></div><ix:continuation id="f-563-1" continuedAt="f-563-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Recognition of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets are recognized when the Group becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets, other than financial assets measured at FVTPL, are added to or deducted from the fair value of the financial assets, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets at FVTPL are recognized immediately in profit or loss. There were no transaction costs related to the acquisition of financials assets in 2023, 2022, or 2021. All of the Group&#8217;s financial assets are measured at amortized cost as of 31&#160;December 2023 and 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial assets measured at amortized cost</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets measured at amortized cost are debt instruments that give rise to contractual cash flows that are solely payments of principal and interest on the principal amount outstanding. The Group&#8217;s financial assets measured at amortized cost are trade receivables, certain other current assets, receivables from related parties, restricted cash and cash and cash equivalents. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-9" continuedAt="f-529-10"><ix:continuation id="f-563-2" continuedAt="f-563-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income is recognized by applying the effective interest rate, except for short-term receivables when the effect of discounting is immaterial. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Impairment of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognizes a loss allowance for expected credit losses ("ECL") on its trade receivables and other debt instruments that are measured at amortized cost. In addition, although contract assets are not financial assets, a loss allowance for ECL are also recognized for such assets. ECL is based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group always recognizes lifetime ECL for trade receivables and contract assets. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group&#8217;s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecasted direction of conditions at the reporting date, including time value of money where appropriate. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group writes off a financial asset when there is no reasonable expectation of recovery, such as information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. A trade receivable or contract asset that is considered uncollectible is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognized in profit or loss. The Group did not write off any trade receivables or contract assets during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group estimates impairment for related party receivables on an individual basis. No impairment is recognized for restricted cash or cash and cash equivalents as management has estimated that the effects of any calculated ECL would be immaterial. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derecognition of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Group neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Group recognizes its retained interest in the asset as well as an associated liability. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-563-3">On derecognition of a financial asset, the difference between the asset&#8217;s carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognized in other comprehensive income or loss and accumulated in equity is recognized in profit or loss.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.18 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="f-564" continuedAt="f-564-1" escape="true">Financial liabilities </ix:nonNumeric></span></div><ix:continuation id="f-564-1" continuedAt="f-564-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s financial liabilities consist of trade and other payables, certain other current liabilities loans and borrowings, lease liabilities, derivative financial instruments, long-term incentive plans, share appreciation right plans and other long-term liability to a related party. All financial liabilities are initially measured at fair value. Loans and borrowings are recorded net of directly attributable transaction costs and less the value attributable to any embedded derivative financial instruments, if applicable. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group derecognizes financial liabilities when, and only when, the Group&#8217;s obligations are discharged, cancelled, substantially modified or have expired. Additionally, management elected, as part of its accounting policy, to recognize the difference between the carrying amount of the financial liabilities and the fair value of the consideration paid for the extinguishment in the consolidated statement of profit or loss and other comprehensive income or loss. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-564-2" continuedAt="f-564-3"><ix:continuation id="f-529-10" continuedAt="f-529-11"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities subsequently measured at amortized cost</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After initial recognition, financial liabilities other than derivative financial instruments and awards issued pursuant to long-term incentive plans are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that discounts all estimated future cash payments through the expected life of the financial liability, or a shorter period if appropriate, to the amortized cost of a financial liability. The effective interest rate includes the effects of any discount or premium on acquisition of the financial liability, as well as any fees or costs incurred upon acquisition. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities subsequently measured at FVTPL</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivative financial instruments </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain rights and features pursuant to borrowing arrangements and other contracts may provide the counterparty with one or more financial instruments that need to be evaluated and potentially accounted for separately by the Group. These financial instruments are either embedded in a host instrument or are treated as a separate financial instrument if they are contractually transferable independent from the host instrument. Such rights and features pursuant to the Group&#8217;s contracts with both third parties and related parties include earn out rights, conversion rights and warrant rights. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity conversion features within host debt instruments that meet the definition of a derivative and have economic and risk characteristics that are not closely related to the host instrument are embedded derivatives that are separated from the host instrument and accounted for separately. As part of the accounting for embedded derivatives or separate financial instruments, management considers the appropriate accounting classification under IAS 32. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Embedded derivatives and separate financial instruments that meet the fixed-for-fixed criteria are classified as equity and initially measured at fair value. Warrant rights that provide the holder with an option to purchase ordinary shares at a specified price or pursuant to a specified formula are generally separate derivative financial instruments that are accounted for as derivative liabilities. Earn Out Shares grant the holder with a variable number of Ordinary Shares based on certain vesting conditions tied to the stock price and are accounted for as derivative liabilities. In the event that the fair value of any derivative liabilities, determined using unobservable inputs, exceeds the transaction price of a borrowing arrangement, the Group records a deferred loss at the inception of the borrowing arrangement for the difference between the fair value of the derivative liabilities and the transaction price of the borrowing arrangement. Such deferred losses are recognized over the term of the related borrowing arrangement using the straight-line method of amortization. The deferred loss is netted against derivative financial liabilities on the consolidated statements of financial position. Amortization of the deferred loss is recognized as a component of &#8220;Finance costs&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognized derivative liabilities related to the Predecessor Earn Out Shares, OACB Earn Out Shares and assumed OACB warrants. Additionally, the Group recognized an embedded derivative for the conversion feature associated with the Tranche A Convertible Bonds, as further described in Note 21. These features are liability-classified, rather than equity-classified, because the Group is obligated to issue a variable number of ordinary shares to the holder upon conversion or exercise of the feature. Therefore, these derivative liabilities were initially recorded at fair value and remeasured to fair value at each reporting period with gains and losses arising from changes in the fair value recognized in finance income or finance costs, as appropriate. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of the derivative liabilities were determined using a valuation approach that incorporated a range of inputs that are both observable and unobservable in nature. The inputs used in the initial and subsequent fair value measurements predominantly relate to (i) the price of the Group&#8217;s Ordinary Shares (ii) the volatility of the Group&#8217;s Ordinary Shares, (ii) a risky discount rate corresponding to the credit risk associated with the repayment of the host debt instruments, and (iii) the probabilities of each derivative being exercised by the holder and the timing of such exercises. The probabilities are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group will derecognize any derivative liabilities if and when the rights are exercised by the holders or the time period during which the rights can be exercised expires. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Liabilities to related parties </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Group&#8217;s liabilities to related parties arose from its acquisition of rights for the commercialization of the Group&#8217;s biosimilar Adalimumab product in certain territories in Asia from Lotus Pharmaceutical Co. Ltd., a </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-11" continuedAt="f-529-12"><ix:continuation id="f-564-3" continuedAt="f-564-4"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related party, during the year ended 31&#160;December 2021. Pursuant to the terms of the asset acquisition, the Group made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="alvo:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-565">1.9</ix:nonFraction> million and is required to pay $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-566">7.4</ix:nonFraction> million upon the commercial launch of Adalimumab in China which became due on 31 December 2023. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Long-term incentive plans </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Share appreciation rights</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group issued to certain current and former employees share appreciation rights ("SARs") that require settlement in connection with the occurrence of specified, future triggering events. Grants occurred from 2015 through 2020. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. The individuals retain their vested awards upon termination of employment with the Group. Settlement amounts are determined by the change in the Group&#8217;s market value from the grant date of the SAR until the triggering events occur. The SARs do not expire at a specific date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the terms of the SAR agreements, management determined that the Group cannot avoid paying cash to settle the awards and, therefore, SARs are liability-classified in the consolidated statements of financial position. Accordingly, SARs were recorded at fair value and were subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. The fair value of the SARs was determined using the Black-Scholes-Merton pricing model. In connection with the closing of the Business Combination, the Company reached a settlement agreement for share appreciation rights previously awarded to certain current and former employees. The remaining share appreciation rights were settled through the issuance of fully vested RSUs under the Management Incentive Plan on 1 December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Employee incentive plan</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group also sponsors an employee incentive plan for certain qualifying employees. Under the plans, such employees are entitled to cash payments upon achievement of key milestones, such as a research and development milestone or the occurrence of an exit event. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. Since the Group cannot avoid paying cash to settle the awards, the employee incentive plan is liability-classified in the consolidated statements of financial position. Accordingly, awards issued pursuant to the employee incentive plan are recorded at fair value and are subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. Employee incentive plan liabilities are presented as either current or non-current on the consolidated statements of financial position based on the anticipated timing of settlement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the employee incentive plan awards is determined by estimating the probability of success in reaching the specified milestones and other levers, such as the anticipated timing of potential milestone achievement. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Management Incentive Plan</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-564-4">The Group can issue share options, restricted share units (&#8220;RSUs&#8221;), and other share-based awards under the Company&#8217;s new incentive plan (the &#8220;Management Incentive Plan&#8221;) which was approved by the Board in June 2022. Awards issued under the Management Incentive Plan are accounted for in accordance with IFRS 2. Share-based payments are classified as equity-settled share-based payments as the Company intends to settle the awards with equity and has the commercial substance to do so. Share-based payments are measured at the grant date fair value of the instruments issued and recognized over the expected vesting periods. The number of shares expected to vest are reviewed and adjusted at the end of each reporting period such that the amount of expense recognized shall be based on the number of equity instruments that will eventually vest.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.19 <ix:nonNumeric contextRef="c-1" name="alvo:DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" id="f-567" continuedAt="f-567-1" escape="true">Litigation and other contingencies </ix:nonNumeric></span></div><ix:continuation id="f-567-1" continuedAt="f-567-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group may, from time to time, become involved in legal proceedings arising out of the normal course of its operations. For instance, as a developer and manufacturer of biosimilars, the Group may be subject to lawsuits alleging patent infringement or other similar claims filed by the reference product sponsor. Similarly, the Group may utilize patent challenge procedures to challenge the validity, enforceability or infringement of the reference product </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-12" continuedAt="f-529-13"><ix:continuation id="f-567-2" continuedAt="f-567-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sponsor&#8217;s patents. Other parties may also file patent infringement claims against the Group alleging that the Group&#8217;s products or manufacturing process techniques infringe their patents. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group establishes reserves for specific legal matters when it determines that the likelihood of an unfavorable outcome is probable and the loss is reasonably estimable. When such conditions are not met for a specific legal matter, no reserve is established. Although management currently believes that resolving claims against the Group, including claims where an unfavorable outcome is reasonably possible, will not have a material impact on the liquidity, results of operations, or financial condition of the Group, these matters are subject to inherent uncertainties and management&#8217;s view of these matters may change in the future. It is possible that an unfavorable outcome of a lawsuit or other contingency could have a material impact on the liquidity, results of operations, or financial condition of the Group. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount of loss can be reasonably estimated. Accruals are based only on information available at the time of the assessment, due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Group&#8217;s results of operations in a given period. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-567-3">The Group maintains liability insurance coverages for various claims and exposures. The Group&#8217;s insurance coverage limits its maximum exposure on claims; however, the Group is responsible for any uninsured portion of losses. Management believes that present insurance coverage is sufficient to cover potential exposures.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.20 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="f-568" continuedAt="f-568-1" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="f-568-1" continuedAt="f-568-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for those with a lease term of twelve months or less and leases of low value assets. For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The Group&#8217;s leased assets consist of various real estate, fleet and equipment leases. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets reflect the initial measurement of the lease liability, lease payments made at or before the lease commencement date and any initial direct costs less lease incentives that may have been received by the Group. These assets are subsequently measured at cost less accumulated depreciation, impairment losses and remeasurements of the underlying lease liability. Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the underlying asset. If a lease transfers ownership of the underlying asset to the Group or the lease includes a purchase option that the Group is reasonably certain to exercise, the related right-of-use asset is depreciated over the useful life of the underlying asset. Depreciation starts at the commencement date of the lease. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate, which is the rate of interest that the Group would need to pay to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term in a similar economic environment based on information available at the commencement date of the lease. The lease payments included in the measurement of the lease liability comprise fixed payments (including in-substance fixed payments) less any incentives, variable lease payments that depend on an index or rate, expected residual guarantees and the exercise price of purchase options reasonably certain to be exercised by the Group. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability, using the effective interest method, and by reducing the carrying amount to reflect payments made during the lease term. The Group remeasures the lease liability if the lease term has changed, when lease payments based on an index or rate change or when a lease contract is modified and the modification is not accounted for as a separate lease. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable payments that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-568-2">As a practical expedient, lessees are not required to separate non-lease components from lease components, and instead account for any lease and associated non-lease components as a single lease component. The Group has used this practical expedient.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-529-13"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.21 <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="f-569" continuedAt="f-569-1" escape="true">Loss per share </ix:nonNumeric></span></div><ix:continuation id="f-569-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of the Predecessor Earn Out Shares and OACB Earn Out Shares have equal dividend and participation rights to the ordinary shareholders. However, these participating securities are classified as liabilities and as such, the shares held are not included in the weighted average number of ordinary shares outstanding in the basic loss per share calculation. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The calculation of basic loss per share is based on the loss for the year attributable to ordinary shareholders of the Group and the weighted average number of ordinary shares outstanding during the period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted loss per share is computed by dividing the loss for the year attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding in the basic loss per share calculation, both of which are adjusted for the effects of all dilutive potential ordinary shares. Antidilutive effects of potential ordinary shares, which result in an increase in earnings per share or a reduction in loss per share, are not recognized in the computation of diluted loss per share.</span></div></ix:continuation></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_289"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-571" continuedAt="f-571-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFirstTimeAdoptionExplanatory" id="f-570" continuedAt="f-570-1" escape="true">New accounting standards </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-571-1" continuedAt="f-571-2"><ix:continuation id="f-570-1" continuedAt="f-570-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">New standards and interpretations adopted and effective during the periods</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following new IFRS standards have been adopted by the Group effective 1 January 2023: </span></div><div style="margin-top:5.1pt;padding-left:27.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IFRS 17 - Insurance Contracts</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2017, the IASB issued IFRS 17, Insurance Contracts, which replaces IFRS 4, Insurance Contracts. This standard sets out principles for the recognition, measurement, presentation and disclosure of insurance contracts that are within the scope of IFRS 17. In June 2020, the IASB issued Amendments to IFRS 17, which addresses concerns and implementation challenges that were identified after IFRS 17, Insurance Contracts, was published in 2017. The amendments are effective for annual periods beginning on or after 1 January 2023. IFRS 17 requires fundamental accounting changes to how insurance contracts are measured and accounted for. It introduces the general measurement model, based on a risk-adjusted present value of future cash flows that will arise as the insurance contract is fulfilled. This new measurement model aims to provide relevant information of the future cash flows. The general measurement model is modified for the measurement of reinsurance contracts held, direct participating contracts, and investment contracts with discretionary participation features. Also, while the general measurement model applies to all groups of insurance contracts in scope of IFRS 17, a simplified approach (a premium allocation approach) may be used to measure contracts that meet certain criteria. IFRS 17 also includes new disclosure requirements, providing more clarity and transparency for users of financial statements. The adoption of the standard did not have a material impact on the consolidated financial statements of the Group.</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:27.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 1 (Amendment) - Disclosure of Accounting Policies</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued Disclosure of Accounting Policies (Amendments to IAS 1) and IFRS Practice Statement 2 Making Materiality Judgements. The amendments replace the requirement for entities to disclose their significant accounting policies with the requirement to disclose their material accounting policy information. The amendments also include guidance to help entities apply the definition of material in making decisions about accounting policy disclosures.  The adoption of these amendments did not have a material impact on the consolidated financial statements of the Group.</span></div><div><span><br/></span></div><div style="padding-left:27.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 8 (Amendments) - Definition of Accounting Estimates</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments on IAS 8 to help entities to distinguish between accounting policies and accounting estimates. The amendments clarify how companies distinguish changes in accounting policies from changes in accounting estimates, with a primary focus on the definition of and clarifications on accounting estimates. The distinction between the two is important because changes in accounting policies are applied retrospectively, while changes in accounting estimates are applied prospectively. The amendments further clarify that accounting estimates are monetary amounts in the financial statements and are subject to measurement uncertainty. The amendments also clarify the relationship between accounting policies and accounting estimates by specifying that a company develops accounting estimates to achieve the objective set out by an accounting policy. The amendments are reflected in all financial statements and disclosures of the Group. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-571-2"><ix:continuation id="f-570-2"><div style="margin-top:7.95pt;padding-left:27.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 12 (Amendments) - Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments on IAS 12, which clarifies how companies shall account for deferred tax on transactions such as leases and decommissioning obligations, with a focus on reducing diversity in practice. The amendments narrow the scope of the initial recognition exemption in paragraphs 15 and 24 of IAS 12 so that it does not apply to transactions that give rise to equal and offsetting temporary differences. As a result, companies will need to recognize deferred tax assets and a deferred tax liability for temporary differences arising on initial recognition of a lease and a decommissioning provision. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.</span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 12 (Amendments) - International Tax Reform&#8212;Pillar Two Model Rules</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, the OECD released technical guidance on its 15% global minimum tax agreed as the second &#8216;pillar&#8217; of a project to address the tax challenges arising from digitalisation of the economy. This guidance elaborates on the application and operation of the Global Anti-Base Erosion (GloBE) Rules agreed and released in December 2021 which lay out a co-ordinated system to ensure that multinational enterprises with revenues above &#8364;750 million pay tax of at least 15% on the income arising in each of the jurisdictions in which they operate. In May 2023, the IASB issued amendments to IAS12 Income Taxes to introduce a temporary exception to the requirements to recognise and disclose information about deferred tax assets and liabilities related to Pillar Two income taxes. As the Company does not meet the revenue thresholds, this guidance had no impact on the Group's consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">New and revised IFRS standards in issue but not yet effective</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following new standards are not yet adopted by or effective for the Group and have not been applied in preparing these consolidated financial statements. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 1 (Amendments) &#8211; Classification of Liabilities as Current or Non-Current </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments to IAS 1, which affect the presentation of liabilities as current or non-current in the statement of financial position. The amendment does not impact the amount or timing of recognition of any asset, liability, income or expenses, or the information disclosed about those items. The amendments clarify that the classification of liabilities as current or non-current is based on rights that are in existence at the end of the reporting period, specify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, explain that rights are in existence if covenants are complied with at the end of the reporting period, and introduce a definition of &#8216;settlement&#8217; to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. The Group currently evaluates the impact of these amendments on the consolidated financial statements. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 1 (Amendments) &#8211; Non-current Liabilities with Covenants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These amendments clarify how conditions with which an entity must comply within twelve months after the reporting period affect the classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these conditions. The amendments also respond to stakeholders&#8217; concerns about the classification of such a liability as current or non-current. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group currently evaluates the impact of these amendments on the consolidated financial statements.</span></div><div style="margin-top:1pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IFRS 16 (Amendment) - Lease Liability in a Sale and Leaseback</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This amendment adds subsequent measurement requirements for sale and leaseback transactions. This amendment includes requirements for sale and leaseback transactions in IFRS 16 to explain how an entity accounts for a sale and leaseback after the date of the transaction. Sale and leaseback transactions where some or all the lease payments are variable lease payments that do not depend on an index or rate are most likely to be impacted. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group anticipates that the application of this amendment will not have a material impact on the consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="margin-top:1pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-24</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_292"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="f-572" continuedAt="f-572-1" escape="true">Segment reporting </ix:nonNumeric></span></div><ix:continuation id="f-572-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As disclosed in Note 2, the Group operates and manages its business as <ix:nonFraction unitRef="segement" contextRef="c-5" decimals="INF" name="alvo:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-573">one</ix:nonFraction> operating segment. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant portion of the Group&#8217;s revenue is generated from long-term out-license contracts which provide the customer with exclusive rights to a particular territory, which generally span multiple countries or a particular continent, as well as the Group&#8217;s promises to continue development of the underlying compound and to provide supply of the product to the customer upon commercialization. Therefore, based on the nature of the customer agreements, revenue information is not currently available on a country-by-country basis. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="f-574" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from customers based on the geographic market in which the revenue is earned, which predominantly aligns with the rights conveyed to the Group&#8217;s customers pursuant to its out-license contracts, is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Europe</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-575">63,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-576">39,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-577">20,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-578">18,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-579">30,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-580">11,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Asia and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-581">9,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-582">12,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-583">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-584">91,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-585">83,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-586">36,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" id="f-587" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current assets, excluding financial instruments and deferred tax assets, based on the location of the asset is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.272%"><tr><td style="width:1.0%"/><td style="width:63.998%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Europe</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-588">415,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-589">334,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-590">5,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" scale="3" id="f-591">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Asia and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-592">6,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-593">3,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-594">426,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-595">338,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory" id="f-596" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from transactions with individual customers that exceeds ten percent or more of the Group&#8217;s total revenue is as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"><tr><td style="width:1.0%"/><td style="width:18.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-597">9,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-150" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-598">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-599">17,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-151" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-600">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-601">10,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-152" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-602">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-603">46,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-153" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-604">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-605">38,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-154" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-606">46.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-607">18,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-608">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-609">8,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-156" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-610">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-611">12,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-157" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-612">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-613">1,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-158" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-614">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-615">16,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-159" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-616">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="ifrs-full:Revenue" format="ixt:fixed-zero" scale="3" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-160" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" format="ixt:fixed-zero" scale="-2" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="ifrs-full:Revenue" format="ixt:fixed-zero" scale="3" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="3" name="ifrs-full:PercentageOfEntitysRevenue" format="ixt:fixed-zero" scale="-2" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_295"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" id="f-621" continuedAt="f-621-1" escape="true">Revenue </ix:nonNumeric></span></div><ix:continuation id="f-621-1" continuedAt="f-621-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Disaggregated revenue </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="f-622" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Groups&#8217; revenue from contracts with customers, disaggregated by the type of good or service and timing of transfer of control of such goods and services to customers: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue (point in time revenue recognition)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-623">48,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-624">24,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License revenue (point in time revenue recognition)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-626">12,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="f-627">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-628">1,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Development and other service revenue (over time revenue recognition)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-629">30,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-630">57,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-631">35,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-632">91,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-633">83,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-634">36,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-621-2" continuedAt="f-621-3"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reassessment of variable consideration </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to revenue in the period of change. The Group updates variable consideration estimates on a quarterly basis. The quarterly changes in estimates did not result in material adjustments to the Group&#8217;s previously reported revenue or trade receivables during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="f-635" escape="true"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contract assets and liabilities </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Contract </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Assets </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Contract </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liabilities </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="ifrs-full:ContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-636">19,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-637">74,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract asset additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-638">29,823</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts transferred to trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="alvo:ContractAssetsAdditionsAmountsTransferredToTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-639">19,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer prepayments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="alvo:ContractLiabilityCustomerPrepayments" format="ixt:num-dot-decimal" scale="3" id="f-640">46,127</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-641">26,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" sign="-" name="alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment" scale="3" id="f-642">915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment" scale="3" id="f-643">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December  2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="ifrs-full:ContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-644">28,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-645">93,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract asset additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-646">19,634</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts transferred to trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="alvo:ContractAssetsAdditionsAmountsTransferredToTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-647">2,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="alvo:ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" format="ixt:fixed-zero" scale="3" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition of contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="alvo:ContractLiabilitiesAdditionsDerecognitionOfContractLiability" format="ixt:num-dot-decimal" scale="3" id="f-649">42,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="alvo:ContractLiabilityCustomerPrepayments" format="ixt:num-dot-decimal" scale="3" id="f-650">100,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-651">23,101</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment" scale="3" id="f-652">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-653">3,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December 2023</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="ifrs-full:ContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-654">46,049</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-655">132,444</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The net increase in contract assets as of 31&#160;December 2023 is due to revenue recognized when the performance obligation has been met which is offset by the transfer of such amounts to trade receivables on the basis that the Group&#8217;s right to that consideration is no longer contingent on its performance. The net increase in contract liabilities as of 31&#160;December 2023 is due to customer prepayments in advance of the Group&#8217;s performance. As of 31&#160;December 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ifrs-full:NoncurrentContractAssets" format="ixt:num-dot-decimal" scale="6" id="f-656">10.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ifrs-full:CurrentContractAssets" format="ixt:num-dot-decimal" scale="6" id="f-657">35.2</ix:nonFraction> million are recorded as non-current contract assets and current contract assets, respectively. Non-current contract assets will materialize over the next <ix:nonNumeric contextRef="c-181" name="alvo:NoncurrentContractAssetsMaterializePeriod" format="ixt-sec:duryear" id="f-658">2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-182" name="alvo:NoncurrentContractAssetsMaterializePeriod" format="ixt-sec:duryear" id="f-659">3</ix:nonNumeric> years. As of 31&#160;December 2023, $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-660">73.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-661">59.2</ix:nonFraction> million are recorded as non-current contract liabilities and current contract liabilities, respectively. Non-current contract liabilities will</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> be recognized as revenue over the next <ix:nonNumeric contextRef="c-181" name="alvo:NoncurrentContractLiabilitiesRevenueRecognitionPeriod" format="ixt-sec:duryear" id="f-662">2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-182" name="alvo:NoncurrentContractLiabilitiesRevenueRecognitionPeriod" format="ixt-sec:duryear" id="f-663">6</ix:nonNumeric> years as either services are rendered or contractual milestones are achieved, depending on the performance obligation to which the payment relates. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Remaining performance obligations </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><ix:continuation id="f-621-3" continuedAt="f-621-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the long-term nature of the Group&#8217;s out-license contracts, the Group&#8217;s obligations pursuant to such contracts represent partially unsatisfied performance obligations at year-end. The revenues under existing out-license contracts with original expected durations of more than one year are estimated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to be $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations" format="ixt:num-dot-decimal" scale="6" id="f-664">383.0</ix:nonFraction> million. The</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-621-4"> Group expects to recognize the majority of these revenues over the next <ix:nonNumeric contextRef="c-184" name="alvo:TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" format="ixt-sec:duryear" id="f-665">5</ix:nonNumeric> years.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-26</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_298"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" id="f-666" continuedAt="f-666-1" escape="true">Salaries and other employee expenses </ix:nonNumeric></span></div><ix:continuation id="f-666-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The average number of individuals employed by the Group during the years ended 31&#160;December 2023, 2022, and 2021 was <ix:nonFraction unitRef="individuals" contextRef="c-1" decimals="-3" name="ifrs-full:AverageNumberOfEmployees" scale="3" id="f-667">999</ix:nonFraction>, <ix:nonFraction unitRef="individuals" contextRef="c-6" decimals="-3" name="ifrs-full:AverageNumberOfEmployees" scale="3" id="f-668">858</ix:nonFraction>, and <ix:nonFraction unitRef="individuals" contextRef="c-7" decimals="-3" name="ifrs-full:AverageNumberOfEmployees" scale="3" id="f-669">645</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" id="f-670" continuedAt="f-670-1" escape="true">The aggregate salary and other employee expenses incurred by the Group for these employees were as follows: </ix:nonNumeric></span></div><ix:continuation id="f-670-1" continuedAt="f-670-2"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salary expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="f-671">107,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="f-672">92,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="f-673">67,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Defined contribution plan expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" format="ixt:num-dot-decimal" scale="3" id="f-674">11,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" format="ixt:num-dot-decimal" scale="3" id="f-675">10,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" format="ixt:num-dot-decimal" scale="3" id="f-676">7,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term incentive plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherLongtermBenefits" scale="3" id="f-677">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:OtherLongtermBenefits" format="ixt:num-dot-decimal" scale="3" id="f-678">5,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:OtherLongtermBenefits" format="ixt:num-dot-decimal" scale="3" id="f-679">17,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share-based payments (see Note 23)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-680">18,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-681">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:fixed-zero" scale="3" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other employee expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-683">19,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-684">11,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-685">10,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Temporary labor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:TemporaryLabourExpense" format="ixt:num-dot-decimal" scale="3" id="f-686">8,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:TemporaryLabourExpense" format="ixt:num-dot-decimal" scale="3" id="f-687">5,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:TemporaryLabourExpense" format="ixt:num-dot-decimal" scale="3" id="f-688">6,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-689">164,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-690">135,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-691">109,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><ix:continuation id="f-670-2" continuedAt="f-670-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.43pt"><ix:continuation id="f-670-3">Defined contribution plan expense consists of costs incurred by the Group for employees of certain subsidiaries that are required by local laws to participate in pension schemes. These pension schemes are not sponsored or administered by the Group. Pursuant to the requirements of the schemes, the Group is required to contribute a certain percentage of its payroll costs to the pension schemes. Such contributions are charged to the consolidated statements of profit or loss and other comprehensive income or loss as they are incurred in accordance with the rules of the pension schemes.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" id="f-692" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salaries and other employee expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-693">76,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-694">42,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:fixed-zero" scale="3" id="f-695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-696">44,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-697">52,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-698">71,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-699">43,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-700">39,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-701">37,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total salary and other employee expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-702">164,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-703">135,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-704">109,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_301"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="f-705" continuedAt="f-705-1" escape="true">Finance income and finance costs </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExplanatory" id="f-706" escape="true"><ix:continuation id="f-705-1" continuedAt="f-705-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income earned during the years ended 31&#160;December 2023, 2022 and 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in the fair value of derivatives (see Note 28)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-708">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-709">51,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income from cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-710">4,547</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="f-711">556</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="f-712">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestIncomeOnOtherFinancialAssets" scale="3" id="f-713">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:InterestIncomeOnOtherFinancialAssets" scale="3" id="f-714">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:InterestIncomeOnOtherFinancialAssets" scale="3" id="f-715">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-716">4,823</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-717">2,549</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-718">51,568</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceCostExplanatory" id="f-719" escape="true"><ix:continuation id="f-705-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance costs incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in the fair value of derivatives (see Note 28)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-720">132,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-721">96,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-722">2,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on debt and borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-723">129,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-724">71,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-725">106,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consenting fee (see Note 21)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:ConsentingFee" format="ixt:fixed-zero" scale="3" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:ConsentingFee" format="ixt:num-dot-decimal" scale="3" id="f-727">7,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:ConsentingFee" format="ixt:fixed-zero" scale="3" id="f-728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss on remeasurement of bonds (see Note 21)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:LossOnRemeasurementOfBonds" format="ixt:fixed-zero" scale="3" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:LossOnRemeasurementOfBonds" format="ixt:num-dot-decimal" scale="3" id="f-730">6,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:LossOnRemeasurementOfBonds" format="ixt:fixed-zero" scale="3" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities (see Note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-732">3,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-733">6,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-734">6,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of deferred debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AmortizationOfDeferredDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-735">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AmortizationOfDeferredDebtIssuanceCosts" scale="3" id="f-736">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:AmortizationOfDeferredDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-737">1,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-738">267,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-739">188,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-740">117,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ie527079dad0a4810aa92569387637e3d_304"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" id="f-741" continuedAt="f-741-1" escape="true">Depreciation, amortization and impairment </ix:nonNumeric></span></div><ix:continuation id="f-741-1"><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" id="f-742" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation, amortization and impairment expenses incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and impairment of property, plant and equipment (see Note 12)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-743">14,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-744">9,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-745">10,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation of right of use assets (see Note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-746">8,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-747">9,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-748">8,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization and impairment of intangible assets (see Note 15)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AmortizationAndImpairmentOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-749">2,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AmortizationAndImpairmentOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-750">3,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:AmortizationAndImpairmentOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-751">4,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-752">25,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-753">23,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-754">24,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" id="f-755" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation, amortization and impairment expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-756">15,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-757">10,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-758">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-759">6,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-760">9,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-761">21,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-762">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-763">3,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-764">2,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total depreciation, amortization and impairment expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-765">25,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-766">23,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-767">24,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_307"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfAuditFeesExplanatoryTextBlock" id="f-768" continuedAt="f-768-1" escape="true">Audit fees </ix:nonNumeric></span></div><ix:continuation id="f-768-1" continuedAt="f-768-2"><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" id="f-769" escape="true"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financial Statement audit fees</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AuditorsRemunerationForAuditServices" format="ixt:num-dot-decimal" scale="3" id="f-770">2,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AuditorsRemunerationForAuditServices" format="ixt:num-dot-decimal" scale="3" id="f-771">2,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AuditorsRemunerationForAuditServices" format="ixt:num-dot-decimal" scale="3" id="f-772">5,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other fees, including tax services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AuditorsRemunerationForTaxServices" scale="3" id="f-773">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AuditorsRemunerationForTaxServices" scale="3" id="f-774">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AuditorsRemunerationForTaxServices" scale="3" id="f-775">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total fees</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AuditorsRemuneration" format="ixt:num-dot-decimal" scale="3" id="f-776">3,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AuditorsRemuneration" format="ixt:num-dot-decimal" scale="3" id="f-777">3,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AuditorsRemuneration" format="ixt:num-dot-decimal" scale="3" id="f-778">5,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial Statements audit fees consist of fees for the audit of our annual financial statements and other professional services provided in connection with the statutory and regulatory filings or engagements, including fees for the review of our interim financial information. </span></div><div style="margin-top:12pt;padding-left:28.34pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other fees, including tax services, include fees for review of our current and historical financial information included in our SEC registration statements, fees for tax compliance, tax advice, and tax planning. </span></div></ix:continuation><div style="margin-top:12pt;padding-left:28.34pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-768-2">Audit fees for 2021 included fees for the audit of the consolidated financial statements for 2019 and 2020.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-28</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_310"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-779" continuedAt="f-779-1" escape="true">Income tax </ix:nonNumeric></span></div><ix:continuation id="f-779-1" continuedAt="f-779-2"><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" id="f-780" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxation recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct taxes - current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="f-781">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="f-782">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="f-783">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct taxes &#8211; prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="3" id="f-784">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="3" id="f-785">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="3" id="f-786">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total current tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" format="ixt:num-dot-decimal" scale="3" id="f-787">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="3" id="f-788">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" format="ixt:num-dot-decimal" scale="3" id="f-789">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="f-790">89,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="f-791">54,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="f-792">48,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods" format="ixt:num-dot-decimal" scale="3" id="f-793">10,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods" format="ixt:num-dot-decimal" scale="3" id="f-794">15,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods" scale="3" id="f-795">477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" format="ixt:num-dot-decimal" scale="3" id="f-796">100,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" format="ixt:num-dot-decimal" scale="3" id="f-797">38,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" format="ixt:num-dot-decimal" scale="3" id="f-798">48,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-799">99,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-800">38,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-801">47,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The prior year deferred tax impact of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods" format="ixt:num-dot-decimal" scale="6" id="f-802">10.7</ix:nonFraction> million mainly relates to foreign currency impact on losses denominated in Icelandic krona. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The factors affecting the tax benefit during the years ended 31&#160;December 2023 and 2022 relate to the recognition of a deferred tax asset on accumulated tax losses, as management assessed that it was probable that the accumulated tax losses would be fully utilized in the coming years, as further described below. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no accruals for tax contingencies during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate for the year of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-803">15.3</ix:nonFraction>% (2022: <ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-804">6.9</ix:nonFraction>%, 2021: <ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-805">32.0</ix:nonFraction>%) is lower than the applicable Luxembourgish statutory rate of corporation tax. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" id="f-806" continuedAt="f-806-1" escape="true">The reconciling items between the statutory rate and the effective tax rate are as follows: </ix:nonNumeric></span></div><ix:continuation id="f-806-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-807">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-808">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-809">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effect of tax rate in foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-810">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-811">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-812">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="-2" id="f-813">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="-2" id="f-814">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="-2" id="f-815">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-recognition of tax losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="alvo:TaxRateEffectOfNonrecognitionOfTaxLosses" scale="-2" id="f-816">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="alvo:TaxRateEffectOfNonrecognitionOfTaxLosses" scale="-2" id="f-817">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="alvo:TaxRateEffectOfNonrecognitionOfTaxLosses" scale="-2" id="f-818">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-819">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-820">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-821">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-822">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-823">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-824">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" id="f-825" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The movement in net deferred taxes during the years ended 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-826">209,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-827">170,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax credited to profit or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-828">100,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-829">38,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-830">309,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-831">209,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NetDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-832">309,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NetDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-833">209,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NetDeferredTaxLiabilities" scale="3" id="f-834">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NetDeferredTaxLiabilities" scale="3" id="f-835">309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Where there is a right of offset of deferred tax balances within the same tax jurisdiction, IAS 12 requires these to be presented after such offset in the consolidated statements of financial position. The closing deferred tax balances included above are after offset; however, the disclosure of deferred tax assets by category below are presented before such offset. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-779-2"><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" id="f-836" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount of deferred tax recognized in the consolidated statements of financial position as of 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets attributable to temporary differences in respect of tax losses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="ifrs-full:NetDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-837">301,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="ifrs-full:NetDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-838">205,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets attributable to other temporary differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="ifrs-full:NetDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-839">11,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="ifrs-full:NetDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-840">6,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities attributable to other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="ifrs-full:NetDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-841">3,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="ifrs-full:NetDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-842">2,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-843">309,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-844">209,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A deferred tax liability has been recognized in relation to ordinary timing differences arising from depreciation, amortization, other provisions and difference in measurement basis of customer relationships. A deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="ifrs-full:NetDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-845">3.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="ifrs-full:NetDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-846">2.9</ix:nonFraction> million has been recognized as of 31&#160;December 2023 and 2022, respectively. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A deferred tax asset has been recognized in relation to ordinary timing differences arising from various provisions, reserves, employee benefits and tax losses carried forward in the Group. The deferred tax asset on tax losses relates to tax losses arising in Iceland, and management considers probable that future forecasted profit associated with product and out-licensing revenue will be available to offset the cumulative tax losses as of 31&#160;December 2023. No deferred tax asset is recognized on tax losses arising in Luxembourg as their recoverability is unlikely to be realized. A deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-847">309.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-848">209.5</ix:nonFraction> million is recognized as of 31&#160;December 2023 and 2022, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" id="f-849" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These tax losses expire as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"/><td style="width:78.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024-2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-850">68,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027-2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-851">289,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Later</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-852">1,155,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-853">1,513,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 2023, the Group has total unused tax losses of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="f-854">1,514</ix:nonFraction> million which is comprised of $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="f-855">1,501</ix:nonFraction> million of accumulated tax losses in Iceland and $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="6" id="f-856">13</ix:nonFraction> million accumulated tax losses in Luxembourg.</span></div></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_313"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-857" continuedAt="f-857-1" escape="true">Loss per share </ix:nonNumeric></span></div><ix:continuation id="f-857-1" continuedAt="f-857-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic loss per share is computed by dividing loss for the year by the weighted average number of ordinary shares outstanding during the period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted loss per share is computed by adjusting the calculation of basic loss per share for the effects of dilutive potential ordinary shares from financial instruments that may be converted or exercised into ordinary shares of the Group. For the years ended 31&#160;December 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" format="ixt:num-dot-decimal" scale="0" id="f-858">86,745,377</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" format="ixt:num-dot-decimal" scale="0" id="f-859">148,857,998</ix:nonFraction>, respectively, potential ordinary shares pursuant to the RSUs, Senior Bond Warrants, Aztiq Convertible Bond, 2022 Convertible Bonds, OACB Warrants, Predecessor Earn Out Shares, and OACB Earn Out Shares (as defined and discussed in Notes 21 and 28) were excluded in the calculation of diluted loss per share, since the effect of doing so would result in a reduction of loss per share and thus be antidilutive. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> For the year ended 31&#160;December 2021, there were <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="alvo:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" format="ixt-sec:numwordsen" scale="0" id="f-860">no</ix:nonFraction> potential ordinary shares pursuant to such agreements as all conversion, warrant and funding rights associated with these agreements had been exercised or otherwise expired (refer to Note 22 for further details). Therefore, the calculation of diluted loss per share did not differ from the calculation of basic loss per share. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-861" escape="true"><ix:continuation id="f-857-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The calculation of basic and diluted loss per share for the years ended 31&#160;December 2023, 2022, and 2021 is as follows (in thousands, except for share and per share amounts):</span></div><div style="margin-top:12pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss for the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-862">551,731</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-863">513,580</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-864">101,504</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of ordinary shares outstanding</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-865"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-866">227,256,469</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-867"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-868">197,721,710</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-869"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-870">110,673,309</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-871"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-872">2.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-873"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-874">2.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-875"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-876">0.92</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ie527079dad0a4810aa92569387637e3d_316"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-877" continuedAt="f-877-1" escape="true">Property, plant and equipment </ix:nonNumeric></span></div><ix:continuation id="f-877-1" continuedAt="f-877-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment consists of facility and computer equipment, furniture, fixtures and leasehold improvements. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="f-878" continuedAt="f-878-1" escape="true">Movements within property, plant and equipment during the years ended 31&#160;December 2023 and 2022 are as follows: </ix:nonNumeric></span></div><ix:continuation id="f-878-1" continuedAt="f-878-2"><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"><tr><td style="width:1.0%"/><td style="width:28.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.390%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.390%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.390%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.390%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Facility</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;Equipment </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Furniture, <br/>fixtures and <br/>leasehold <br/>improvements </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Computer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">equipment </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-879">115,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-880">145,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-881">9,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-882">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-883">271,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-885">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="3" id="f-886">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="3" id="f-887">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-888">2,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-889">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-890">29,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-891">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-892">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-893">31,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-895">1,233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-896">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-897">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-898">1,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-900">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-901">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-902">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-903">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-904">115,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-905">176,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-906">10,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-907">2,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-908">304,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-909">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-910">46,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-911">3,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-912">1,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-913">51,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-915">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="3" id="f-916">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="3" id="f-917">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-918">3,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-919">2,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-920">10,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-921">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-922">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-923">14,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-925">737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-926">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-927">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-928">895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-930">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-931">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-932">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-933">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-934">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-935">59,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-936">3,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-937">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-938">68,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-939">111,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-940">117,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-941">7,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-942">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-943">236,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-877-2" continuedAt="f-877-3"><ix:continuation id="f-878-2"><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"><tr><td style="width:1.0%"/><td style="width:28.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.390%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.390%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.390%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.390%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Facility</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;Equipment </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Furniture, <br/>fixtures and <br/>leasehold <br/>improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Computer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">equipment </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-945">88,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-946">32,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-947">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-948">122,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-950">25,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-951">25,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-954">115,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-955">35,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-956">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-957">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-958">153,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-960">2,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-963">2,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-965">1,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-966">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-967">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-968">1,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-969">115,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-970">145,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-971">9,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-972">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-973">271,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-975">33,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-976">8,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-977">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-978">43,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-980">5,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-981">5,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-984">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-985">8,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-986">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-987">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-988">9,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-990">2,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-993">2,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-995">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-996">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-997">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-998">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-999">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1000">46,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1001">3,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1002">1,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1003">51,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1004">114,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1005">99,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1006">6,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-1007">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1008">220,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, the Group entered into a share purchase agreement (the &#8220;Share Purchase Agreement&#8221;) relating to shares in Fasteignaf&#233;lagi&#240; S&#230;mundur hf. (&#8220;Saemundur&#8221;) with ATP Holdings ehf., an affiliate of Aztiq. Pursuant to the Share Purchase Agreement, Alvotech purchased <ix:nonFraction unitRef="number" contextRef="c-263" decimals="4" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" id="f-1009">99.99</ix:nonFraction>% of the shares in Saemundur through the issuance the Aztiq Convertible Bond, as defined and discussed in Note 21, and the assumption of debt. At the time of closing, Saemundur&#8217;s only asset was the property where Alvotech&#8217;s Reykjavik manufacturing and research facility (the &#8220;Facility&#8221;) are located. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Share Purchase Agreement was accounted for as an asset acquisition under IFRS 3 as all of the fair value of the gross assets acquired from Saemundur were concentrated in the Alvotech Facility. As a result, the purchase price was determined to be $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="alvo:AssetAcquisitionsConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-1010">115.0</ix:nonFraction> million, which consists of $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="alvo:AssetAcquisitionConsiderationTransferredConvertibleBond" format="ixt:num-dot-decimal" scale="6" id="f-1011">80.0</ix:nonFraction> million related to the fair value of the Aztiq Convertible Bond, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="alvo:AssetAcquisitionConsiderationTransferredLoansAssumed" format="ixt:num-dot-decimal" scale="6" id="f-1012">30.0</ix:nonFraction> million in loans assumed by the Company, and $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="alvo:AssetAcquisitionConsiderationTransferredSettlements" format="ixt:num-dot-decimal" scale="6" id="f-1013">5.0</ix:nonFraction> million associated with the settlement of the pre-existing relationship with Saemundur. The entire purchase price was allocated to the Facility as it was the only asset acquired. Additionally, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="alvo:LossOnExtinguishmentOfTheLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1014">3.9</ix:nonFraction> million loss on the extinguishment of the lease liability related to the Facility. See Note 21 for further details. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-877-3">The Group pledged $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity" format="ixt:num-dot-decimal" scale="6" id="f-1015">127.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity" format="ixt:num-dot-decimal" scale="6" id="f-1016">122.4</ix:nonFraction> million of property, plant and equipment as collateral to secure bank loans with third parties as of 31&#160;December 2023 and 2022, respectively.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-32</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_319"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfLeasesExplanatory" id="f-1017" continuedAt="f-1017-1" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="f-1017-1" continuedAt="f-1017-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s leased assets consist of facilities, fleet and equipment pursuant to both arrangements with third parties and related parties. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="f-1018" continuedAt="f-1018-1" escape="true">The carrying amounts of the Group&#8217;s right-of-use assets and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: </ix:nonNumeric></span></div><ix:continuation id="f-1018-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1019">47,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1020">126,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjustments for indexed leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AdjustmentsForIndexedLeasesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1021">7,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AdjustmentsForIndexedLeasesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1022">10,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1023">74,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1024">9,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:CancellationsRightOfUseAssets" scale="3" id="f-1025">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:CancellationsRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="f-1026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition due to acquisition of Alvotech Facility (see Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:DecreaseThroughDerecognitionRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="f-1027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:DecreaseThroughDerecognitionRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1028">88,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:ReclassificationRightOfUseAssets" scale="3" id="f-1029">443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="alvo:ReclassificationRightOfUseAssets" id="f-1030"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1031">8,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1032">9,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:TranslationDifferenceRightOfUseAssets" scale="3" id="f-1033">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:TranslationDifferenceRightOfUseAssets" scale="3" id="f-1034">274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1035">119,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1036">47,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group entered into lease agreement with Fasteignafelagid Eyjolfur hf. in April 2023 for a facility expansion in Iceland with remaining lease terms of approximately <ix:nonNumeric contextRef="c-266" name="alvo:WeightedAverageRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1037">15</ix:nonNumeric> years as of 31 December 2023. The building is <ix:nonFraction unitRef="sqft" contextRef="c-267" decimals="-3" name="alvo:AreaOfProperty" format="ixt:num-dot-decimal" scale="0" id="f-1038">140,000</ix:nonFraction> square feet and is currently in construction. The expansion is close to being finalized and is expected to be completed in 2024. The lease amount is in substance fixed and is based on construction cost, adjusted monthly. Righ-of-use asset as of 31&#160;December 2023 amounts to $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1039">68.5</ix:nonFraction>&#160;million.</span></div><div style="padding-left:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" id="f-1040" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s right-of-use assets as of 31&#160;December 2023 and 2022 are comprised of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1041">110,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1042">41,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fleet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-1043">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-1044">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1045">8,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1046">5,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1047">119,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1048">47,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1017-2" continuedAt="f-1017-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" id="f-1049" continuedAt="f-1049-1" escape="true">The Group&#8217;s lease liabilities and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: </ix:nonNumeric></span></div><ix:continuation id="f-1049-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"/><td style="width:64.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1050">40,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1051">122,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjustments for indexed leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:LeaseLiabilitiesAdjustmentsForIndexedLeases" format="ixt:num-dot-decimal" scale="3" id="f-1052">7,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:LeaseLiabilitiesAdjustmentsForIndexedLeases" format="ixt:num-dot-decimal" scale="3" id="f-1053">10,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1054">72,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1055">7,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:LeaseLiabilitiesCancelledLease" scale="3" id="f-1056">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:LeaseLiabilitiesCancelledLease" format="ixt:fixed-zero" scale="3" id="f-1057">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Installment payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="3" id="f-1058">7,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="3" id="f-1059">7,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition due to acquisition of Alvotech Facility (see Note 12)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:DerecognitionDueToAssetsAcquisition" format="ixt:fixed-zero" scale="3" id="f-1060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:DerecognitionDueToAssetsAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-1061">80,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:LeaseLiabilitiesForeignCurrencyAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-1062">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:LeaseLiabilitiesForeignCurrencyAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-1063">11,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="alvo:LeaseLiabilitiesTranslationDifference" scale="3" id="f-1064">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:LeaseLiabilitiesTranslationDifference" scale="3" id="f-1065">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1066">115,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1067">40,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1068">9,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1069">5,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1070">105,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1071">35,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" id="f-1072" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amounts recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 in relation to the Group&#8217;s lease arrangements are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation expense from right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1073">7,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1074">9,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1075">8,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fleet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-1076">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-1077">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-1078">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1079">1,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-1080">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-1081">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total depreciation expense from right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1082">8,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1083">9,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1084">8,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1085">3,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1086">6,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1087">6,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency difference on lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="alvo:ForeignCurrencyDifferenceOnLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1088">1,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:ForeignCurrencyDifferenceOnLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1089">11,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:ForeignCurrencyDifferenceOnLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1090">3,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from extinguishment of lease agreement (see Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:LossFromExtinguishmentOfLeaseLiabilities" scale="3" id="f-1091">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:LossFromExtinguishmentOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1092">3,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:LossFromExtinguishmentOfLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-1093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total amount recognized in profit and loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:LeaseCostRecognizedInProfitAndLoss" format="ixt:num-dot-decimal" scale="3" id="f-1094">14,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:LeaseCostRecognizedInProfitAndLoss" format="ixt:num-dot-decimal" scale="3" id="f-1095">8,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:LeaseCostRecognizedInProfitAndLoss" format="ixt:num-dot-decimal" scale="3" id="f-1096">11,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" id="f-1097" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The maturity analysis of undiscounted lease payments as of 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less than one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1098">14,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1099">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1100">51,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1101">20,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1102">89,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1103">22,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1104">155,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1105">48,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1017-3">The Group&#8217;s lease liabilities as of 31&#160;December 2023 and 2022 do not include $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="alvo:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" format="ixt:num-dot-decimal" scale="6" id="f-1106">0.7</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="alvo:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" format="ixt:num-dot-decimal" scale="6" id="f-1107">0.1</ix:nonFraction> million, respectively, of costs for short-term leases and low value leases.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-34</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_322"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGoodwillExplanatory" id="f-1108" continuedAt="f-1108-1" escape="true">Goodwill </ix:nonNumeric></span></div><ix:continuation id="f-1108-1" continuedAt="f-1108-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory" id="f-1109" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s goodwill balances as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1110">11,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1111">12,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" scale="3" id="f-1112">415</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" scale="3" id="f-1113">724</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1114">12,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1115">11,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill is recognized at the Group level, which is determined to be the smallest cash-generating unit. The recoverable amount of the cash-generating unit is determined based on a value in use calculation which uses cash flow projections based on the financial forecast for the period 2024-2030 which reflect the recent business developments of the Group and has been approved by management and the Board of Directors. The Group determined that the terminal growth rate and the discount rate are the key assumptions used in determining the current estimate of value in use. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash flows beyond 2030 have been extrapolated using a negative <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" scale="-2" id="f-1116"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" scale="-2" id="f-1117">5</ix:nonFraction></ix:nonFraction>% terminal rate in both the 2023 and 2022 value in use calculations, respectively. A discount rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" scale="-2" id="f-1118">25.0</ix:nonFraction>% (2022: <ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" scale="-2" id="f-1119">27.6</ix:nonFraction>%) per annum was used in determining the current estimate of value in use. Since the recoverable amount of the cash-generating unit was substantially in excess of its carrying amount as of 31&#160;December 2023 and 2022, management believes that any reasonably possible change in the key assumptions on which the recoverable amount of the cash-generating unit is based would not cause the carrying amount of the cash-generating unit to exceed its recoverable amount. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1108-2">There were <ix:nonFraction unitRef="usd" contextRef="c-289" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" format="ixt:fixed-zero" scale="0" id="f-1120"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" format="ixt:fixed-zero" scale="0" id="f-1121">no</ix:nonFraction></ix:nonFraction> goodwill impairment charges recognized in the consolidated statements of profit or loss and other comprehensive income or loss in any prior periods.</ix:continuation> </span></div><div id="ie527079dad0a4810aa92569387637e3d_325"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="f-1122" continuedAt="f-1122-1" escape="true">Other Intangible assets </ix:nonNumeric></span></div><ix:continuation id="f-1122-1" continuedAt="f-1122-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other intangible assets consist of software, customer relationships, and licensed intellectual property rights. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="f-1123" continuedAt="f-1123-1" escape="true">Movements in intangible assets during the years ended 31&#160;December 2023 and 2022 are as follows: </ix:nonNumeric></span></div><ix:continuation id="f-1123-1" continuedAt="f-1123-2"><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Software </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Customer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">relationships </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Intellectual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">property </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">rights</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1124">13,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1125">2,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1126">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1127">30,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1128">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1131">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1132">4,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1134">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1135">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1136">1,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1139">1,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Retirement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1142">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1143">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1144">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1145">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1147">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1148">17,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1149">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1150">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1151">25,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1152">3,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1153">1,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1155">5,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1156">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1157">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1159">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1160">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1161">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1163">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1164">3,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1165">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1167">6,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1168">13,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1170">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1171">19,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1122-2"><ix:continuation id="f-1123-2"><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Software </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Customer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">relationships </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Intellectual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">property </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">rights</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1172">8,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1173">2,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1174">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1175">26,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1176">7,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1179">7,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1180">2,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1183">2,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1184">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1185">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1187">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1188">13,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1189">2,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1190">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1191">30,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1192">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1193">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1195">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1196">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1197">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1199">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1200">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1201">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1203">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1204">3,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1205">1,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1207">5,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1208">10,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-1209">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1210">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1211">25,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions during the year ended 31&#160;December 2023 were primarily comprised of licensed intellectual property rights from Kashiv as detailed below. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" id="f-1212" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense for amortization of the Group&#8217;s intangible assets is included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1213">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1214">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1216">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1217">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1218">324</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1219">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1220">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1221">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1222">944</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1223">733</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-1224">923</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At 31&#160;December 2023 and 2022, the Group performed a review of its intangible assets and determined certain software development had been abandoned. In assessing recoverable amount, the Group determined the market for resale was non-existent. Management therefore determined to fully impair the assets, resulting in an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="ifrs-full:ImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1225">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-5" name="ifrs-full:ImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1226">2.8</ix:nonFraction> million during the years ended 31&#160;December 2023 and 2022, respectively. The impairment charge was recognized as an expense within &#8220;General and administrative expense&#8221;. For the year ended 31&#160;December 2022, the impairment was recognized as an expense as follows: $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="ifrs-full:ImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1227">2.1</ix:nonFraction> million in "Cost of product revenue" and $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="ifrs-full:ImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1228">0.7</ix:nonFraction> million in "General and administrative expense".</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At 31&#160;December 2023, following the termination of the agreement with Biosana, the Group derecognized $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="alvo:DerecognitionIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1229">15.0</ix:nonFraction>&#160;million of other intangible assets relating to intellectual property rights for the co-development and commercialization of AVT23. A corresponding receivable was recognized to reflect the claim against Biosana for full reimbursement. See further information on the receivable in Note 18.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech entered into an exclusive product licensing and supply agreement with Kashiv for the development and commercialization of AVT23 in September 2023. Under the terms of the agreement, Kashiv granted Alvotech an exclusive right for AVT23 which will be produced using Kashiv&#8217;s proprietary process technology and commercialized by Alvotech in specific territories. In exchange, Alvotech made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="alvo:PaymentForContractualCommitment" format="ixt:num-dot-decimal" scale="6" id="f-1230">3.0</ix:nonFraction>&#160;million upon the signing of the agreement, with an additional $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="alvo:PaymentForContractualCommitment" format="ixt:num-dot-decimal" scale="6" id="f-1231">3.0</ix:nonFraction>&#160;million due upon the beginning of Phase 3 which coincides with the clinical trial application ("CTA") submission.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, Alvotech may be obligated to pay Kashiv up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="ifrs-full:ContractualCapitalCommitments" format="ixt:num-dot-decimal" scale="6" id="f-1232">25</ix:nonFraction>&#160;million (including the $<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="alvo:PaymentForContractualCommitment" format="ixt:num-dot-decimal" scale="6" id="f-1233">6</ix:nonFraction>&#160;million upfront payments mentioned above), payable upon the achievement of various development and regulatory milestones, as well as certain tiered royalty payments up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="alvo:ContractualCapitalCommitmentContingentLiability" format="ixt:num-dot-decimal" scale="6" id="f-1234">15</ix:nonFraction>&#160;million based on commercial sales of AVT23. The agreement terminates <ix:nonNumeric contextRef="c-346" name="alvo:ContractualCapitalCommitmentsTerm" format="ixt-sec:duryear" id="f-1235">10</ix:nonNumeric> years after the launch of AVT23 and is subject to certain customary termination rights.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-36</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_328"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="f-1236" continuedAt="f-1236-1" escape="true">Cash and cash equivalents </ix:nonNumeric></span></div><ix:continuation id="f-1236-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Cash and cash equivalents</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents include both cash in banks and on hand. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" id="f-1237" continuedAt="f-1237-1" escape="true">Cash and cash equivalents as of 31&#160;December 2023 and 2022 are as follows: </ix:nonNumeric></span></div><ix:continuation id="f-1237-1"><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents denominated in US dollars</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1238">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1239">10,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents denominated in other currencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1240">9,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1241">56,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1242">11,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1243">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Restricted cash</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Restricted cash relates to cash that may only be used pursuant to certain of the Group&#8217;s borrowing arrangements. Therefore, these deposits are not available for general use by the Group. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" id="f-1244" continuedAt="f-1244-1" escape="true">Movements in restricted cash balances during the years ended 31&#160;December 2023 and 2022 are as follows: </ix:nonNumeric></span></div><ix:continuation id="f-1244-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1245">25,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1246">10,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AdditionRestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-1247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AdditionRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1248">14,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:InterestIncomeOnCash" scale="3" id="f-1249">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:InterestIncomeOnCash" scale="3" id="f-1250">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1251">26,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1252">25,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s restricted cash is available for use after one year or later.</span></div></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_331"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="f-1253" continuedAt="f-1253-1" escape="true">Inventories </ix:nonNumeric></span></div><ix:continuation id="f-1253-1" continuedAt="f-1253-2"><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" id="f-1254" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s inventory balances as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:RawMaterialsAndConsumablesUsed" format="ixt:num-dot-decimal" scale="3" id="f-1255">51,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:RawMaterialsAndConsumablesUsed" format="ixt:num-dot-decimal" scale="3" id="f-1256">41,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="3" id="f-1257">33,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="3" id="f-1258">29,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:FinishedGoods" scale="3" id="f-1259">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-1260">2,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:InventoryReserves" format="ixt:num-dot-decimal" scale="3" id="f-1261">10,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:InventoryReserves" format="ixt:num-dot-decimal" scale="3" id="f-1262">2,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="f-1263">74,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="f-1264">71,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The increase in inventory from 31&#160;December 2022 to 31&#160;December 2023 is due to the expansion of the commercial launch of certain of the Group&#8217;s biosimilar products.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognised $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-3" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1265">42.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-3" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1266">20.9</ix:nonFraction> million within cost of goods sold during the years ended 31&#160;December 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1253-2">During the years ended 31&#160;December 2023, 2022, and 2021, write-down of inventories amounted to $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:InventoryWritedown2011" format="ixt:num-dot-decimal" scale="6" id="f-1267">10.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="ifrs-full:InventoryWritedown2011" format="ixt:num-dot-decimal" scale="6" id="f-1268">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="ifrs-full:InventoryWritedown2011" format="ixt:num-dot-decimal" scale="6" id="f-1269">1.2</ix:nonFraction> million, respectively, due to product expiration and results from quality control inspections. There were <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ifrs-full:ReversalOfInventoryWritedown" format="ixt-sec:numwordsen" scale="6" id="f-1270"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ifrs-full:ReversalOfInventoryWritedown" format="ixt-sec:numwordsen" scale="6" id="f-1271"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="ifrs-full:ReversalOfInventoryWritedown" format="ixt-sec:numwordsen" scale="6" id="f-1272">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> reversals of inventory write-downs during the years ended 31&#160;December 2023, 2022, and 2021.</ix:continuation> </span></div><div style="margin-top:12pt;padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-37</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_334"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" id="f-1273" continuedAt="f-1273-1" escape="true">Other current assets </ix:nonNumeric></span></div><ix:continuation id="f-1273-1"><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" id="f-1274" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other current assets as of 31&#160;December 2023 and 2022 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value-added tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1275">8,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1276">6,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1277">22,035</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1278">20,601</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds receivable from Convertible Bonds (see Note 21)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:ProceedsReceivableFromConvertibleBonds" format="ixt:fixed-zero" scale="3" id="f-1279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:ProceedsReceivableFromConvertibleBonds" format="ixt:num-dot-decimal" scale="3" id="f-1280">3,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:DerivaiveAssets" format="ixt:fixed-zero" scale="3" id="f-1281">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:DerivaiveAssets" scale="3" id="f-1282">851</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other short-term receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1283">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1284">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1285">31,871</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1286">32,949</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year, the Group terminated the co-development agreement with Biosana for AVT23 and derecognized $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="alvo:DerecognitionIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1287">15.0</ix:nonFraction>&#160;million of other intangible assets and $<ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="alvo:DerecognitionPrepaidDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="f-1288">3.5</ix:nonFraction>&#160;million of prepaid development costs. A receivable of $<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1289">18.5</ix:nonFraction>&#160;million was recognized under other current assets which was fully reserved due to the uncertainty that it would be collected.</span></div></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_337"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIssuedCapitalExplanatory" id="f-1290" continuedAt="f-1290-1" escape="true">Share capital </ix:nonNumeric></span></div><ix:continuation id="f-1290-1" continuedAt="f-1290-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all liabilities. Equity instruments issued by a Group entity are recognized in the amount of the proceeds received, net of direct issue costs.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the Capital Reorganization the Group&#8217;s equity consisted of Class A and Class B ordinary shares (together the &#8220;Predecessor Ordinary Shares&#8221;). The Group&#8217;s authorized share capital was $<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-5" name="alvo:SharesAuthorizedValue" format="ixt:num-dot-decimal" scale="6" id="f-1291">99.7</ix:nonFraction> million, consisting of the equivalent of <ix:nonFraction unitRef="shares" contextRef="c-358" decimals="INF" name="ifrs-full:NumberOfSharesAuthorised" format="ixt:num-dot-decimal" scale="0" id="f-1292">99,961,829</ix:nonFraction> Class A or Class B ordinary shares with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-358" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-1293">0.01</ix:nonFraction> per share. All share capital issued as of 31&#160;December 2023 and 2022 was fully paid.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Capital Reorganization resulted in the following share capital activity: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">All of the outstanding Predecessor Ordinary Shares were exchanged for <ix:nonFraction unitRef="shares" contextRef="c-359" decimals="INF" name="alvo:CapitalReorganizationEventSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1294">180,600,000</ix:nonFraction> Ordinary Shares and <ix:nonFraction unitRef="shares" contextRef="c-360" decimals="INF" name="alvo:CapitalReorganizationEventSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1295">38,330,000</ix:nonFraction> Predecessor Earn Out Shares; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"><ix:nonFraction unitRef="shares" contextRef="c-361" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1296">976,505</ix:nonFraction> of Class A OACB Ordinary Shares were exchanged for Ordinary Shares; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"><ix:nonFraction unitRef="shares" contextRef="c-362" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1297">6,250,000</ix:nonFraction> of Class B OACB Ordinary Shares were exchanged for <ix:nonFraction unitRef="shares" contextRef="c-363" decimals="INF" name="alvo:CapitalReorganizationSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1298">5,000,000</ix:nonFraction> Ordinary Shares and <ix:nonFraction unitRef="shares" contextRef="c-364" decimals="INF" name="alvo:CapitalReorganizationSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1299">1,250,000</ix:nonFraction> OACB Earn Out Shares; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="alvo:StockIssuedUnderPipeFinancingShares" format="ixt:num-dot-decimal" scale="0" id="f-1300">17,493,000</ix:nonFraction> Ordinary Shares were issued in the PIPE Financing. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="ifrs-full:DividendsPaid" format="ixt:fixed-zero" scale="0" id="f-1301"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="ifrs-full:DividendsPaid" format="ixt:fixed-zero" scale="0" id="f-1302"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="ifrs-full:DividendsPaid" format="ixt:fixed-zero" scale="0" id="f-1303">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> dividends were paid or declared during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-1304" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share capital and share premium of the Group&#8217;s Ordinary Shares issued as of 31&#160;December 2023, and 2022 are as follows (in thousands, except for share amounts): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-365" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1305">266,821,844</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" name="alvo:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-1306">1,231,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-366" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1307">252,160,087</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="alvo:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-1308">1,060,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total share capital and share premium</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1309">266,821,844</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-1310">1,231,969</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1311">252,160,087</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-1312">1,060,558</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 10 February 2023, the Company completed a private placement equity offering for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="6" id="f-1313">137.0</ix:nonFraction>&#160;million, and transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="6" id="f-1314">4.1</ix:nonFraction>&#160;million, of its ordinary shares, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-368" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-1315">0.01</ix:nonFraction> per share, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-368" decimals="INF" name="alvo:SaleOfStockIssuePricePerShare" scale="0" id="f-1316">11.57</ix:nonFraction> per share. The shares were delivered from previously issued ordinary shares held by Alvotech&#8217;s subsidiary, Alvotech Manco ehf. As a result of proceeds raised from the private placement offering, the Company extinguished the derivative financial liability related to the Senior Bond Warrants since the Company has not anymore the obligation to issue the penny warrants representing <ix:nonFraction unitRef="number" contextRef="c-369" decimals="INF" name="alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" scale="-2" id="f-1317">1.0</ix:nonFraction>% of the fully diluted ordinary share capital. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1290-2" continuedAt="f-1290-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This was accounted for as an extinguishment of a derivative financial liability in the consolidated statements of profit or loss and other comprehensive income or loss. See Notes 21 and 28 for further information.</span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" id="f-1318" escape="true"><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s Class A and Class B ordinary shares, share capital and share premium during the years ended 31&#160;December 2023, 2022, and 2021 are as follows (in thousands, except for share amounts): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:37.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ordinary </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Predecessor </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ordinary </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-370" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1319">7,259,139</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-1320">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1321">166,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1322">166,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share issue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-372" decimals="INF" name="alvo:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-1323">6,222,660</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="alvo:IssueOfEquities" scale="3" id="f-1324">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="alvo:IssueOfEquities" format="ixt:num-dot-decimal" scale="3" id="f-1325">833,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="alvo:IssueOfEquities" format="ixt:num-dot-decimal" scale="3" id="f-1326">833,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-374" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1327">13,481,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-1328">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1329">1,000,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1330">1,000,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Elimination of Predecessor Ordinary Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-376" decimals="INF" sign="-" name="alvo:EliminationOfPredecessorOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="f-1331">13,481,799</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="alvo:EliminationOfPredecessorOrdinaryValue" scale="3" id="f-1332">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="alvo:EliminationOfPredecessorOrdinaryValue" scale="3" id="f-1333">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="alvo:EliminationOfPredecessorOrdinaryValue" format="ixt:fixed-zero" scale="3" id="f-1334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of Ordinary Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="alvo:IssuanceOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="f-1335">186,576,505</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="alvo:IssuanceOfOrdinaryValue" format="ixt:num-dot-decimal" scale="3" id="f-1336">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="alvo:IssuanceOfOrdinaryValue" format="ixt:num-dot-decimal" scale="3" id="f-1337">63,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="alvo:IssuanceOfOrdinaryValue" format="ixt:num-dot-decimal" scale="3" id="f-1338">65,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">PIPE Financing (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="alvo:IncreaseThroughPipeFinancingShares" format="ixt:num-dot-decimal" scale="0" id="f-1339">17,493,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="alvo:IncreaseThroughPipeFinancingValue" scale="3" id="f-1340">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="alvo:IncreaseThroughPipeFinancingValue" format="ixt:num-dot-decimal" scale="3" id="f-1341">174,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="alvo:IncreaseThroughPipeFinancingValue" format="ixt:num-dot-decimal" scale="3" id="f-1342">174,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Transaction costs arising on share issue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-1343">5,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-1344">5,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="alvo:IssueOfPredecessorEarnOutShares" format="ixt:num-dot-decimal" scale="0" id="f-1345">38,330,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="alvo:IssueOfPredecessorEarnOutSharesValue" format="ixt:num-dot-decimal" scale="3" id="f-1346">227,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" sign="-" name="alvo:IssueOfPredecessorEarnOutSharesValue" format="ixt:num-dot-decimal" scale="3" id="f-1347">227,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="alvo:IssueOfOacbEarnOutShares" format="ixt:num-dot-decimal" scale="0" id="f-1348">1,250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="alvo:IssueOfOacbEarnOutSharesValue" format="ixt:num-dot-decimal" scale="3" id="f-1349">9,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" sign="-" name="alvo:IssueOfOacbEarnOutSharesValue" format="ixt:num-dot-decimal" scale="3" id="f-1350">9,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">SARs Settlement (Note 22)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsShares" format="ixt:num-dot-decimal" scale="0" id="f-1351">3,510,582</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue" scale="3" id="f-1352">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue" format="ixt:num-dot-decimal" scale="3" id="f-1353">30,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue" format="ixt:num-dot-decimal" scale="3" id="f-1354">30,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of related party loans with Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares" format="ixt:num-dot-decimal" scale="0" id="f-1355">5,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue" scale="3" id="f-1356">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue" format="ixt:num-dot-decimal" scale="3" id="f-1357">32,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue" format="ixt:num-dot-decimal" scale="3" id="f-1358">32,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1359">252,160,087</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1360">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1361">1,058,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1362">1,060,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capital contribution</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="alvo:CapitalContributionSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1363">11,834,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="alvo:CapitalContributionValue" scale="3" id="f-1364">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="alvo:CapitalContributionValue" format="ixt:num-dot-decimal" scale="3" id="f-1365">132,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="alvo:CapitalContributionValue" format="ixt:num-dot-decimal" scale="3" id="f-1366">132,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested earn-out shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="alvo:VestedEarnoutSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1367">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="alvo:VestedEarnoutSharesValue" scale="3" id="f-1368">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="alvo:VestedEarnoutSharesValue" format="ixt:num-dot-decimal" scale="3" id="f-1369">8,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="alvo:VestedEarnoutSharesValue" format="ixt:num-dot-decimal" scale="3" id="f-1370">8,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Penny warrants (Note 28)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1371">2,479,962</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-1372">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1373">27,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1374">27,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Public warrants (Note 28)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1375">553,552</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-1376">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1377">7,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1378">7,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of RSUs with shares (Note 23)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1379">838,919</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-1380">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1381">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1382">5,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of SARs with shares (Note 22)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" sign="-" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1383">1,044,737</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="ifrs-full:IssueOfEquity" scale="3" id="f-1384">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1385">9,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-3" sign="-" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-1386">9,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1387">266,821,844</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1388">2,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1389">1,229,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1390">1,231,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1290-3">Alvotech Manco ehf., a subsidiary of Alvotech hf., owns <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="alvo:CommonStockHeldBySubsidiaries" format="ixt:num-dot-decimal" scale="0" id="f-1391">22,905,618</ix:nonFraction> Ordinary Shares in Alvotech. Such shares are intended for the future issuance of Ordinary Shares under the Management Incentive Plan and other equity offerings.</ix:continuation> </span></div><div id="ie527079dad0a4810aa92569387637e3d_2748779070348"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherLiabilitiesExplanatory" id="f-1392" continuedAt="f-1392-1" escape="true">Other reserves </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="alvo:ScheduleOfOtherReservesTableTextBlock" id="f-1393" escape="true"><ix:continuation id="f-1392-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other reserves as of 31&#160;December 2023 and 2022 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity component of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1394">21,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1395">16,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:ReserveOfSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-1396">21,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:ReserveOfSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-1397">14,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-1398">42,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-1399">30,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-39</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_340"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBorrowingsExplanatory" id="f-1400" continuedAt="f-1400-1" escape="true">Borrowings </ix:nonNumeric></span></div><ix:continuation id="f-1400-1" continuedAt="f-1400-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="f-1401" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s debt consists of interest-bearing borrowings from financial institutions, related parties and third parties. Outstanding borrowings, net of transaction costs, presented on the consolidated statements of financial position as current and non-current as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-1402">549,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-1403">530,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-1404">155,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-1405">32,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-1406">80,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-1407">65,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-3" name="ifrs-full:LoansReceived" format="ixt:num-dot-decimal" scale="3" id="f-1408">76,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="ifrs-full:LoansReceived" format="ixt:num-dot-decimal" scale="3" id="f-1409">64,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1410">97,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1411">71,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total outstanding borrowings, net of debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1412">960,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1413">764,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current portion of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentPortionOfLongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1414">38,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentPortionOfLongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1415">19,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total non-current borrowings</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1416">922,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1417">744,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Convertible shareholder loans </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Business Combination Agreement (see Note 1.1), on 7&#160;December 2021, the Group&#8217;s shareholders entered into the BCA Framework Agreement resulting in the exercise of the conversion, warrant, and funding rights associated with the convertible shareholder loans. As a result, the following issuances of Class A ordinary shares occurred: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"><ix:nonFraction unitRef="shares" contextRef="c-393" decimals="INF" name="alvo:StockSharesIssuedDuringThePeriodExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1418">1,522,103</ix:nonFraction> shares from the exercise of warrant and funding rights in exchange for $<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="6" id="f-1419">101.3</ix:nonFraction> million of cash;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"><ix:nonFraction unitRef="shares" contextRef="c-394" decimals="INF" name="alvo:StockSharesIssuedDuringThePeriodExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1420">1,137,248</ix:nonFraction> shares from the exercise of warrant rights in exchange for the settlement of $<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="6" id="f-1421">73.7</ix:nonFraction> million of accrued payment-in-kind interest; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"><ix:nonFraction unitRef="shares" contextRef="c-393" decimals="INF" name="alvo:StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-1422">2,306,555</ix:nonFraction> shares resulting from the conversion of $<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="ifrs-full:IssueOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1423">166.8</ix:nonFraction> million of outstanding principal and accrued payment-in-kind interest.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with these exercises, for the year ended 31 December 2021, the Group recognized finance income of $<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-5" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="6" id="f-1424">48.7</ix:nonFraction> million resulting from the remeasurement of the derivative liabilities at the date of extinguishment and a $<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-5" name="alvo:GainLossOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1425">149.2</ix:nonFraction> million gain on extinguishment of financial liabilities, which primarily reflects the difference between the carrying amount of the pre-transaction convertible shareholder loans and the related derivative financial liabilities and the fair value of the ordinary shares issued. In addition, the gain on extinguishment of financial liabilities includes transaction costs incurred as part of the extinguishment, the acceleration of previously deferred debt issue costs incurred in connection with the issuance of the convertible shareholder loans and the acceleration of previously unamortized accretion of the convertible shareholder loans. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Bonds </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 24&#160;June 2021, holders of the Group&#8217;s convertible bonds converted $<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="ifrs-full:IssueOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1426">100.7</ix:nonFraction> million of principal and accrued interest and $<ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-5" name="ifrs-full:IssueOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1427">4.8</ix:nonFraction> million of additional premium offered by the Group to the bondholders into <ix:nonFraction unitRef="shares" contextRef="c-399" decimals="INF" name="alvo:StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-1428">455,687</ix:nonFraction> Class A ordinary shares. Following the conversion, certain bondholders elected to redeem their remaining bonds for cash, resulting in the payment of $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="ifrs-full:RepaymentsOfBondsNotesAndDebentures" format="ixt:num-dot-decimal" scale="6" id="f-1429">55.3</ix:nonFraction> million in outstanding principal and accrued interest plus an additional $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="alvo:PremiumPaymentOnBonds" format="ixt:num-dot-decimal" scale="6" id="f-1430">6.1</ix:nonFraction> million of premium that the bondholders elected to be paid in cash. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The remaining unconverted and unredeemed bonds were replaced with new bonds with an extended maturity of June 2025 and the elimination of conversion rights, among other amendments to the terms and conditions. The Group offered the holders of the replaced bonds an extension premium of $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="alvo:ExtensionPremiumToBondHolders" format="ixt:num-dot-decimal" scale="6" id="f-1431">8.1</ix:nonFraction> million for their agreement to extend the maturity of the replaced bonds to June 2025, as well as an additional premium of $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="alvo:AdditionalExtensionPremiumToBondholders" format="ixt:num-dot-decimal" scale="6" id="f-1432">2.6</ix:nonFraction> million, both of which were granted to the bondholders in the form of additional bonds. The Group also issued an additional $<ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-5" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" format="ixt:num-dot-decimal" scale="6" id="f-1433"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" format="ixt:num-dot-decimal" scale="6" id="f-1434">113.8</ix:nonFraction></ix:nonFraction> million of bonds to one previous bondholder and one new bondholder. On the date of issuance, the fair value and the nominal value of the bonds was $<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5" name="ifrs-full:IssuesFairValueMeasurementLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1435">358.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1436">397.4</ix:nonFraction> million, respectively. The difference between the nominal value and fair value was recognized as a discount that will be amortized over the term of the bonds. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group determined that the 24 June 2021 transaction was a substantial modification to its convertible bonds and the associated derivative financial liability and accounted for the transaction as an extinguishment. As a result, the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1400-2" continuedAt="f-1400-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Group recognized a gain on extinguishment of financial liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-5" name="ifrs-full:GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1437">2.6</ix:nonFraction> million during the year ended 31 December 2021, primarily driven by the difference between the fair value of the post-transaction bonds and the carrying amount of the pre-transaction bonds. The gain on extinguishment of financial liabilities also includes the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Transaction costs and fees incurred as part of the extinguishment; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The acceleration of previously deferred debt issue costs incurred in connection with the issuance of the pre-transaction bonds; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The acceleration of previously unamortized accretion of the pre-transaction bonds. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the extinguishment of the convertible bonds and as noted above, the bondholders had the option to convert the bonds into Class A ordinary shares up to <ix:nonNumeric contextRef="c-397" name="alvo:BorrowingConversionPeriodPriorToExtinguishment" format="ixt-sec:durwordsen" id="f-1438">fourteen days</ix:nonNumeric> prior to maturity. This conversion right was separately accounted for as a derivative financial liability. During the period from 1 January 2021 to 24 June 2021, there was <ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-6" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="0" id="f-1439">no</ix:nonFraction> change in fair value of the derivative financial liability. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31 December 2021, the carrying amount of the bonds was $<ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-5" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1440">363.1</ix:nonFraction> million. Accrued interest on the bonds as of 31 December 2021 is $<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-5" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1441">31.0</ix:nonFraction> million. The Group has the option, at any time, to prepay all or any part of the outstanding bonds. If the Group elects to prepay the bonds within the first <ix:nonNumeric contextRef="c-397" name="alvo:BorrowingPrepaymentPeriodWithAdditionalPremium" format="ixt-sec:durwordsen" id="f-1442">three years</ix:nonNumeric> of the bond agreement, the bondholders are entitled to be paid an additional premium of at least <ix:nonFraction unitRef="number" contextRef="c-409" decimals="3" name="alvo:PrepaymentPenaltyPercentageOnBonds" scale="-2" id="f-1443">2.0</ix:nonFraction>% of the outstanding principal at the time of such prepayment.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January and June of 2022, the Group amended the terms of the outstanding bonds. The amendments resulted in the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Following the close of the Business Combination, the interest rate will range from <ix:nonFraction unitRef="number" contextRef="c-410" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1444">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-411" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1445">10.0</ix:nonFraction>% depending on the amount of aggregate net proceeds, as defined by the terms of the amended bond agreement; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A $<ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-5" name="ifrs-full:FeeAndCommissionExpense" format="ixt:num-dot-decimal" scale="6" id="f-1446">7.4</ix:nonFraction>&#160;million consent fee, recognized as finance costs, paid to the bondholders who did not vote against the Business Combination Agreement; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The requirement for Alvotech to maintain a minimum of $<ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-5" name="alvo:MinimumAmountOfRestrictedCashToBeMaintained" scale="6" id="f-1447">25.0</ix:nonFraction> million of restricted cash in a separate liquidity account; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A decrease in the interest rate to <ix:nonFraction unitRef="number" contextRef="c-414" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1448">7.5</ix:nonFraction>%, following the closing of the Business Combination, if the Company issues additional shares within <ix:nonNumeric contextRef="c-415" name="alvo:BorrowingSharesIssuancePeriodForInterestDecrease" format="ixt-sec:durwordsen" id="f-1449">six months</ix:nonNumeric> of the Closing Date, resulting in the Company exceeding the amount of aggregate net proceeds, as defined in the bond agreement.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the closing of the Business Combination, there was a change in future cash flows on the bonds related to the increase in interest rate from <ix:nonFraction unitRef="number" contextRef="c-410" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1450">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-411" decimals="2" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1451">10.0</ix:nonFraction>%. The Company remeasured the carrying value in accordance with IFRS 9 to the present value of the revised cash flows and recognized a $<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="ifrs-full:GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1452">6.5</ix:nonFraction> million loss on the remeasurement of the bonds. The outstanding bonds were subsequently amended as described below.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Senior Bonds </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16&#160;November 2022, the Group amended and upsized the outstanding bonds by $<ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1453">70.0</ix:nonFraction> million. The amended bond agreement (the &#8220;Senior Bonds&#8221;) resulted in the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">An increase in principal from $<ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1454">455.7</ix:nonFraction>&#160;million at the time of the amendment, to $<ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1455">525.7</ix:nonFraction> million;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">An increase in the interest rate, resulting in a range from <ix:nonFraction unitRef="number" contextRef="c-420" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1456">10.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-421" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1457">12.0</ix:nonFraction>% depending on the occurrence of certain events, as defined by the terms of the agreement. The Group accounted for this interest rate feature (the &#8220;Senior Bond Interest Rate Feature&#8221;) as an embedded derivative, classified as an other current asset in the consolidated statement of financial position as of 31 December 2022; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Amended the terms of the related party loans from Alvogen, setting forth subordination conditions; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Contingently issuable penny warrants (exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-422" decimals="2" name="alvo:ClassOfWarrantsOrRightsExercisePricePerShare" scale="0" id="f-1458">0.01</ix:nonFraction>) to the bondholders (the &#8220;Senior Bond Warrants&#8221;) if certain events occur, issuable in <ix:nonFraction unitRef="tranche" contextRef="c-5" decimals="INF" name="alvo:NumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-1459">two</ix:nonFraction> tranches representing <ix:nonFraction unitRef="number" contextRef="c-423" decimals="INF" name="alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" scale="-2" id="f-1460">1.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-424" decimals="INF" name="alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" scale="-2" id="f-1461">1.0</ix:nonFraction>% of the fully diluted ordinary share capital, as defined in the Senior Bonds agreement (see Note 28). </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group determined that the 16 November 2022 transaction was a substantial modification to its bonds and accounted for the transaction as an extinguishment. As a result, the Group recognized a loss on extinguishment of financial liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="alvo:GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1462">40.9</ix:nonFraction> million, including $<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="alvo:TransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-1463">12.1</ix:nonFraction> million of transaction costs, during the year ended 31 </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1400-3" continuedAt="f-1400-4"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 2022, primarily driven by the difference between the fair value of the post-transaction Senior Bonds and the Senior Bond Warrants and the carrying amount of the pre-transaction bonds. The loss on extinguishment of financial liabilities includes the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Extinguishment of bonds with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-5" name="alvo:CarryingValueOfDebtExtinguished" format="ixt:num-dot-decimal" scale="6" id="f-1464">440.1</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="alvo:AccruedInterestOnDebtExtinguished" format="ixt:num-dot-decimal" scale="6" id="f-1465">4.8</ix:nonFraction> million of accrued interest;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="alvo:NetCashProceedsFromTheTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1466">57.9</ix:nonFraction>&#160;million, including transaction costs paid of $<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="alvo:TransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-1467">12.1</ix:nonFraction> million;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Recognition of a $<ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-5" name="alvo:RecognitionOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="f-1468">4.6</ix:nonFraction>&#160;million derivative asset for the Senior Bond Interest Rate Feature;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Recognition of $<ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="alvo:RecognitionOfDerivativeLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1469">528.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="alvo:RecognitionOfDerivativeLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1470">15.4</ix:nonFraction> million representing the fair value of the new Senior Bonds and Senior Bond Warrants (see Note 28), respectively.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of proceeds raised from the private placement offering executed in February 2023, the Company extinguished the liability related to the senior bond warrants since the Company has not anymore the obligation to issue the penny warrants representing the <ix:nonFraction unitRef="number" contextRef="c-369" decimals="INF" name="alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" scale="-2" id="f-1471">1.0</ix:nonFraction>% Senior Bond Warrants (see Note 28 for further information).</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Senior Bonds is $<ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1472">549.4</ix:nonFraction>&#160;million, compared to $<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1473">530.5</ix:nonFraction>&#160;million as of 31&#160;December 2022. The Group has the option, at any time, to prepay all or any part of the outstanding bonds in exchange for the payment of the redemption premium pursuant to the terms of the agreement.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group has pledged its intellectual property as collateral for the Senior Bonds. Additionally, the Group has pledged the Facility of up to $<ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity" format="ixt:num-dot-decimal" scale="6" id="f-1474">600</ix:nonFraction>&#160;million over the Facility as collateral for the Senior Bonds (2nd lien pledge), as further described in Note 12.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">2022 Convertible Bonds </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 20&#160;December 2022, the Group issued <ix:nonFraction unitRef="tranch" contextRef="c-430" decimals="INF" name="alvo:NumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-1475">two</ix:nonFraction> tranches of convertible bonds (the &#8220;2022 Convertible Bonds&#8221;). Tranche A is ISK denominated with a principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1476">59.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1477">3.5</ix:nonFraction> million in cash proceeds were received in February 2023, and carries an annual payment-in-kind interest rate of <ix:nonFraction unitRef="number" contextRef="c-431" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1478">15</ix:nonFraction>% per year, while Tranche B is USD denominated with a principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1479">0.6</ix:nonFraction> million and carries an annual payment-in-kind interest rate of <ix:nonFraction unitRef="number" contextRef="c-433" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1480">12.5</ix:nonFraction>% per year. The maturity date of the Convertible Bonds is the later of the (i) 20 December 2025 or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Holders of both the Tranche A and Tranche B of the 2022 Convertible Bonds, may elect, at their sole discretion, to convert all or part of the principal amount and accrued interest into Alvotech Ordinary Shares at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-434" decimals="INF" name="alvo:BorrowingsRedemptionConversionPrice" scale="0" id="f-1481">10.00</ix:nonFraction> per share on 31 December 2023, 30 June 2024, or upon mandatory or optional redemption of the bonds. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conversion features (the &#8220;Tranche A Conversion Feature&#8221; and &#8220;Tranche B Conversion Feature&#8221;) for both the Tranche A and Tranche B of the 2022 Convertible Bonds were determined to be embedded derivatives as the economic characteristics and risks are not closely related to the debt host. The Group classified the Tranche A Conversion Feature as a liability due to the variability created by conversion rates resulting from the tranche being denominated in ISK and was determined to have a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-5" name="alvo:BorrowingsConversionFeatureFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1482">24.9</ix:nonFraction> million at issuance date (see Note 28 for further details). The Group classified the Tranche B Conversion Feature as equity due to the conversion price having preservation and passage of time adjustments that meet the fixed-for-fixed criteria.</span></div><div style="margin-top:8.4pt;padding-left:27.5pt;padding-right:7.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">On 25 January 2023, the Company issued an additional $<ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-5" name="ifrs-full:DebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1483">10.0</ix:nonFraction>&#160;million of Tranche B Convertible Bonds. The Tranche B Conversion Feature associated with this additional issuance was determined to have a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-5" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1484">1.4</ix:nonFraction>&#160;million at issuance date.</span></div><div style="margin-top:8.4pt;padding-left:27.5pt;padding-right:7.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">On 24 July 2023, Alvotech announced that Teva and Alvotech have agreed to expand their existing partnership agreement. As part of the agreement, Teva acquired Tranche B Convertible Bonds in principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-6" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" format="ixt:num-dot-decimal" scale="6" id="f-1485">40</ix:nonFraction>&#160;million. The Tranche B Conversion Feature associated with this additional issuance was determined to have a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-5" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1486">3.9</ix:nonFraction>&#160;million at issuance date.</span></div><div style="padding-right:7.75pt;text-align:justify"><span><br/></span></div><div style="padding-left:28.34pt;padding-right:7.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 31 July 2023, Alvotech completed a private placement of Tranche A Convertible Bonds for a total principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-6" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" format="ixt:num-dot-decimal" scale="6" id="f-1487">100</ix:nonFraction>&#160;million, or approximately ISK <ix:nonFraction unitRef="isk" contextRef="c-439" decimals="-8" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" format="ixt:num-dot-decimal" scale="9" id="f-1488">13</ix:nonFraction>&#160;billion at current exchange rates. As part of this private placement, ATP Holdings ehf., an affiliated of Aztiq, acquired Tranche A Convertible Bonds in principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-6" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" format="ixt:num-dot-decimal" scale="6" id="f-1489">30</ix:nonFraction>&#160;million. The Tranche A Conversion Feature associated with these additional issuances was determined to have a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-5" name="alvo:BorrowingsConversionFeatureFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1490">45.6</ix:nonFraction>&#160;million at issuance date (see Note 28 for further details). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1400-4" continuedAt="f-1400-5"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of 31&#160;December 2023, the carrying amount of the Tranche A and Tranche B of the 2022 Convertible Bonds is $<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1491">107.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-5" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1492">48.8</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Aztiq Convertible Bond </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, the Group issued a convertible bond (also known as the &#8220;Aztiq Convertible Bond&#8221;) to ATP Holdings ehf, an affiliate of Aztiq, for the Share Purchase Agreement and the acquisition of the Alvotech Facility (See Note 12). The Aztiq Convertible Bond has a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1493">80.0</ix:nonFraction> million and carries an interest rate of <ix:nonFraction unitRef="number" contextRef="c-444" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1494">12.50</ix:nonFraction>% per annum. Interest is payable in six-month intervals and is capitalized and added to the outstanding principal amount of the bonds. The maturity date of the convertible bond is the later of the (i) 16 November 2025 or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Bondholders have the right to convert their outstanding bonds into ordinary shares of Alvotech on 30 December 2023, 30 June 2024, or when the bond has been called or put up for mandatory or optional redemption, for a conversion price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-444" decimals="2" name="alvo:BorrowingsRedemptionConversionPrice" scale="0" id="f-1495">10.00</ix:nonFraction> per share. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conversion feature (the &#8220;Aztiq Conversion Feature&#8221;) was determined to be an embedded derivative as the economic characteristics and risks are not closely related to the debt host. The Group classified the Aztiq Conversion Feature as equity due to the conversion price having preservation and passage of time adjustments that meet fixed-for-fixed criteria. As a result, the Group recognized the following related to the Aztiq Convertible Bond: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1496">64.0</ix:nonFraction>&#160;million related to the debt host;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1497">16.0</ix:nonFraction>&#160;million related to the Aztiq Conversion Feature; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-5" name="alvo:AssetAcquisitionConsiderationLoansAssumed" format="ixt:num-dot-decimal" scale="6" id="f-1498">30.0</ix:nonFraction>&#160;million related to the loans (the &#8220;Facility Loans&#8221;) on the building, which were assumed by the Group as part of the asset acquisition.</span></div><div style="margin-top:0.35pt;padding-left:28.34pt;padding-right:7.9pt;text-align:justify;text-indent:-0.05pt"><span><br/></span></div><div style="margin-top:0.35pt;padding-left:28.34pt;padding-right:7.9pt;text-indent:-0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">In April 2023, we were communicated that ATP Holdings ehf. sold a portion of the Aztiq Convertible Bond to Mitsui &amp; Co., Ltd. ("Mitsui"), a global trading and investment company headquartered in Japan, and Shinhan Healthcare fund 5 ("Shinhan"), a fund established under the laws of the Republic of Korea.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Aztiq Convertible Bond was  $<ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-5" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1499">80.7</ix:nonFraction>&#160;million and includes $<ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1500">15.1</ix:nonFraction> million held by ATP Holdings ehf. The carrying amount of the Aztiq Convertible Bond was $<ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-5" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-1501">65.8</ix:nonFraction>&#160;million as of 31&#160;December 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Alvogen Facility</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with an undertaking by Alvotech shareholders to ensure that Alvotech was sufficiently funded through the closing of the Business Combination by providing at least $<ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1502">50.0</ix:nonFraction> million for the operations of the Group, Alvogen and Aztiq provided interest free loan advances to Alvotech. On 22&#160;February 2022, Alvotech borrowed $<ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1503">15.0</ix:nonFraction> million under the facility from Alvogen, as lender. On 29&#160;March 2022, Alvotech withdrew an additional amount of $<ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1504">10.0</ix:nonFraction> million under the facility, for aggregate indebtedness of $<ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1505">25.0</ix:nonFraction> million. On 11&#160;March 2022, Alvotech borrowed $<ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1506">15.0</ix:nonFraction> million under the facility from Aztiq, as lender. On 31&#160;March 2022, Alvotech withdrew an additional amount of $<ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1507">10.0</ix:nonFraction> million under the facility, for aggregate indebtedness of $<ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1508">25.0</ix:nonFraction> million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 12 July 2022, the Company entered into settlement agreements with both Aztiq and Alvogen for the $<ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="alvo:BorrowingsRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1509"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-5" name="alvo:BorrowingsRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1510">25.0</ix:nonFraction></ix:nonFraction> million in related party loans provided by each party. As a result of the settlement agreements, Aztiq and Alvogen each received <ix:nonFraction unitRef="shares" contextRef="c-458" decimals="INF" name="alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares" format="ixt:num-dot-decimal" scale="0" id="f-1511"><ix:nonFraction unitRef="shares" contextRef="c-459" decimals="INF" name="alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares" format="ixt:num-dot-decimal" scale="0" id="f-1512">2,500,000</ix:nonFraction></ix:nonFraction> Ordinary Shares. The settlement was accounted for as an extinguishment of financial liabilities. In accordance with IFRS 9, the difference between the fair value of the consideration paid for the settlement, which was determined to be $<ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-5" name="alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue" format="ixt:num-dot-decimal" scale="6" id="f-1513">32.2</ix:nonFraction> million, and the extinguished financial liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="alvo:BorrowingsRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1514">50.0</ix:nonFraction> million was recognized as a gain on the extinguishment of financial liabilities in the consolidated statement of profit or loss and other comprehensive income or loss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 11&#160;April 2022, Alvotech entered into a loan agreement with Alvogen, as lender, for a loan of up to $<ix:nonFraction unitRef="usd" contextRef="c-462" decimals="INF" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1515">40.0</ix:nonFraction> million bearing an interest rate of <ix:nonFraction unitRef="number" contextRef="c-462" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1516">10</ix:nonFraction>% per annum. The loan was drawable in <ix:nonFraction unitRef="loan" contextRef="c-462" decimals="INF" name="alvo:NumberOfSeparateInstallments" format="ixt-sec:numwordsen" scale="0" id="f-1517">two</ix:nonFraction> separate installments of $<ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1518">20.0</ix:nonFraction> million each. On 12&#160;April 2022, Alvotech withdrew the first installment of $<ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1519">20.0</ix:nonFraction> million. Alvotech withdrew a second installment of $<ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1520">20.0</ix:nonFraction> million on 9&#160;May 2022 for aggregate indebtedness of $<ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-5" name="alvo:AggregateBorrowingsIndebtedness" format="ixt:num-dot-decimal" scale="6" id="f-1521">40.0</ix:nonFraction> million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 1&#160;June 2022, Alvotech also entered into a loan agreement with Alvogen, as lender, for a loan of $<ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1522">20.0</ix:nonFraction> million bearing an interest rate of <ix:nonFraction unitRef="number" contextRef="c-467" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1523">10</ix:nonFraction>% per annum. Alvotech withdrew the entire loan amount of $<ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1524">20.0</ix:nonFraction> million on 1&#160;June 2022. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1400-5" continuedAt="f-1400-6"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the 16 November 2022 Senior Bonds amendment, Alvotech entered into a subordinated loan agreement with Alvogen (the &#8220;Alvogen Facility&#8221;). As part of the subordinated loan agreement, the Group agreed to the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Rollover the $<ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1525">63.3</ix:nonFraction>&#160;million outstanding, which includes $<ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" name="ifrs-full:InterestPayable" format="ixt:num-dot-decimal" scale="6" id="f-1526">3.3</ix:nonFraction> million of accrued interest, under the Alvogen loans, into the new subordinated loan agreement, and withdraw an additional $<ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1527">50.0</ix:nonFraction> million in loans;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The interest rate was increased from <ix:nonFraction unitRef="number" contextRef="c-466" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1528">10</ix:nonFraction>% per annum to <ix:nonFraction unitRef="number" contextRef="c-469" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1529">17.5</ix:nonFraction>% per annum on the outstanding amounts under the loan facility;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A repayment date of 91 days after the full redemption or the final maturity date of the Senior Bonds; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Contingently issuable penny warrants to the bondholders (the &#8220;Alvogen Facility Warrants&#8221;) if certain events occur, representing <ix:nonFraction unitRef="number" contextRef="c-471" decimals="INF" name="alvo:PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" scale="-2" id="f-1530">4.0</ix:nonFraction>% of the fully diluted ordinary share capital, as defined in the Alvogen Facility agreement.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group determined that the 16 November 2022 transaction was a substantial modification to its related party loans and accounted for the transaction as an extinguishment. As a result, the Group recognized the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Extinguishment of bonds with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-5" name="alvo:ExtinguishmentOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1531">63.2</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-5" name="alvo:ExtinguishmentOfBorrowingsAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1532">3.2</ix:nonFraction> million of accrued interest;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1533">50.0</ix:nonFraction>&#160;million; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Recognition of $<ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1534">113.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1535">1.3</ix:nonFraction> million representing the fair value of the new Alvogen Facility and Alvogen Facility Warrants, respectively.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 20&#160;December 2022, the Company repaid $<ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1536">50.0</ix:nonFraction> million under the Alvogen Facility, with proceeds from the 2022 Convertible Bonds. As a result, Alvotech extinguished the liability to issue the Alvogen Facility Warrants. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Alvogen Facility is $<ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-5" name="ifrs-full:LoansReceived" format="ixt:num-dot-decimal" scale="6" id="f-1537">76.6</ix:nonFraction>&#160;million, compared to $<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-5" name="ifrs-full:LoansReceived" format="ixt:num-dot-decimal" scale="6" id="f-1538">64.6</ix:nonFraction>&#160;million as of 31&#160;December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Facility Loans </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted above, the Group assumed the Facility Loans as part of the asset acquisition for the Facility. On 9&#160;December 2022, the Group extinguished the assumed loans from Arion banki hf., with an outstanding balance of $<ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-5" name="alvo:BorrowingsRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="f-1539">30.9</ix:nonFraction> million, with <ix:nonFraction unitRef="agreement" contextRef="c-475" decimals="INF" name="alvo:NumberOfLoans" format="ixt-sec:numwordsen" scale="0" id="f-1540">two</ix:nonFraction> new loans from Landsbankinn hf. for $<ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1541">48.8</ix:nonFraction> million, with variable interest rate, currently <ix:nonFraction unitRef="number" contextRef="c-477" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1542">8.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-478" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1543">9.3</ix:nonFraction>% per annum. The refinancing resulted in net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-5" name="alvo:ProceedsFromBorrowingsNetOfTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-1544">17.2</ix:nonFraction> million after transaction costs paid. The Group has pledged the facility as collateral to secure these loans (1st lien pledge), as further described in Note 12.</span></div><div style="margin-top:0.35pt;padding-left:27.5pt;padding-right:7.9pt"><span><br/></span></div><div style="margin-top:0.35pt;padding-left:27.5pt;padding-right:7.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">These <ix:nonFraction unitRef="agreement" contextRef="c-475" decimals="INF" name="alvo:NumberOfLoans" format="ixt-sec:numwordsen" scale="0" id="f-1545">two</ix:nonFraction> loans were denominated in Icelandic Krona and included a conversion clause to convert them into USD. The conversion of these <ix:nonFraction unitRef="agreement" contextRef="c-475" decimals="INF" name="alvo:NumberOfLoans" format="ixt-sec:numwordsen" scale="0" id="f-1546">two</ix:nonFraction> loans took place in March 2023.</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="padding-left:27.5pt;padding-right:7.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">Under the terms of the loan agreements after conversion, the first loan includes annuity payments that are due monthly with a final maturity in December 2029 and a variable interest rate of USD </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">Secured Overnight Funding Rate ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">SOFR") plus a margin of <ix:nonFraction unitRef="number" contextRef="c-480" decimals="4" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1547">4.75</ix:nonFraction>%. The second loan is a bullet loan with a final maturity in December 2027 and a variable interest rate of USD SOFR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-481" decimals="4" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1548">3.75</ix:nonFraction>%</span></div><div style="margin-top:0.55pt"><span><br/></span></div><div style="padding-left:27.5pt;padding-right:7.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">The Group determined that conversion to USD of the <ix:nonFraction unitRef="agreement" contextRef="c-475" decimals="INF" name="alvo:NumberOfLoans" format="ixt-sec:numwordsen" scale="0" id="f-1549">two</ix:nonFraction> loans was a substantial modification to loan agreements and accounted for the transaction as an extinguishment. No gain or loss was recognized as part of the extinguishment.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Facility Loans is $<ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1550">48.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Other borrowings </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2015 and 2016, the Group entered into several term loan agreements with a financial institution for a total principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1551">25.9</ix:nonFraction> million. The loan agreements set forth terms and conditions between the Group and the financial institution, inclusive of certain representations and non-financial covenants. Per the terms of the loan </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1400-6" continuedAt="f-1400-7"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">agreements, the loans mature throughout 2024, depending on the issuance date of each loan. Interest on the loans is based on variable interest rate of USD SOFR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-483" decimals="INF" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1552">4.95</ix:nonFraction>%, payable on a monthly basis. Interest accrued and unpaid at the end of each interest period increases the principal obligations owed by the Group to the financial institution. As of 31&#160;December 2023, the outstanding balance on the loans is $<ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1553">0.5</ix:nonFraction>&#160;million, compared to a balance of $<ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1554">3.2</ix:nonFraction>&#160;million as of 31&#160;December 2022. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 22 February 2022, the Group entered into a credit facility agreement with Landsbankinn hf. with the ability to draw down an amount up to $<ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1555">8</ix:nonFraction>&#160;million. The credit facility is in place to help finance equipment purchases in the future. Per the terms of the credit facility, any borrowings are required to be paid by 1 August 2024 and have a variable interest rate of USD SOFR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-486" decimals="INF" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1556">4.95</ix:nonFraction>%. As of 31&#160;December 2023, the outstanding balance on the credit facility was $<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1557">7.8</ix:nonFraction>&#160;million, compared to $<ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1558">13.9</ix:nonFraction>&#160;million as of 31&#160;December 2022. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 22 February 2022, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1559">3.2</ix:nonFraction> million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in March 2029. The loan has a variable interest rate of USD SOFR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-490" decimals="INF" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1560">4.25</ix:nonFraction>%. As of 31&#160;December 2023, the outstanding balance on the loan was $<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1561">2.5</ix:nonFraction>&#160;million, compared to $<ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1562">2.9</ix:nonFraction>&#160;million as of 31&#160;December 2022.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 5 August 2022, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1563">1.8</ix:nonFraction> million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in August 2029. The loan has a variable interest rate of USD SOFR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-494" decimals="INF" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1564">4.25</ix:nonFraction>%. As of 31&#160;December 2023, the outstanding balance on the loan was $<ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1565">1.6</ix:nonFraction>&#160;million, compared to $<ix:nonFraction unitRef="usd" contextRef="c-496" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1566">1.8</ix:nonFraction>&#160;million as of 31&#160;December 2022. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 4 August 2023, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1567">11.5</ix:nonFraction>&#160;million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in August 2030. The loan has a variable interest rate of USD SOFR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-494" decimals="INF" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1568">4.25</ix:nonFraction>%. As of 31&#160;December 2023, the outstanding balance on the loan was $<ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1569">11.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group is in compliance with all representations and non-financial covenants required by these agreements. In addition, the Group has pledged equipment as collateral to secure these borrowings, as further described in Note 12. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 14 December 2023, the Group entered into a qualified receivable financing agreement with Landsbankinn hf. for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1570">25.0</ix:nonFraction>&#160;million. The qualified receivable financing arrangement has a variable interest rate of USD SOFR plus a margin of <ix:nonFraction unitRef="number" contextRef="c-500" decimals="INF" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-1571">3.50</ix:nonFraction>% and a maturity of April 2024. As of 31&#160;December 2023, the outstanding balance on the loan was $<ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1572">25.0</ix:nonFraction>&#160;million. The Group has pledged $<ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-3" name="ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1573">25</ix:nonFraction>&#160;million of its trade receivables to secure this financing.</span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" id="f-1574" continuedAt="f-1574-1" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s outstanding borrowings during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1575">764,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1576">400,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of deferred debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:PaymentsForDebtIssueCost" format="ixt:num-dot-decimal" scale="3" id="f-1577">6,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:PaymentsForDebtIssueCost" format="ixt:num-dot-decimal" scale="3" id="f-1578">2,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accretion/derecognition of borrowings discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AccretionderecognitionOfBorrowingsDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1579">15,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AccretionderecognitionOfBorrowingsDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1580">35,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of new borrowings discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:RecognitionOfNewBorrowingsDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1581">50,953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:RecognitionOfNewBorrowingsDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1582">43,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds from new borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:ProceedsFromBorrowingClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1583">275,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:ProceedsFromBorrowingClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1584">467,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loans from related party converted to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:LoansFromRelatedPartyConvertedToEquity" format="ixt:fixed-zero" scale="3" id="f-1585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:LoansFromRelatedPartyConvertedToEquity" format="ixt:num-dot-decimal" scale="3" id="f-1586">50,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Repayments of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:RepaymentsOfBorrowingClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1587">99,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:RepaymentsOfBorrowingClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1588">83,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:DebtInstrumentIncreaseAccruedInterests" format="ixt:num-dot-decimal" scale="3" id="f-1589">58,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:DebtInstrumentIncreaseAccruedInterests" format="ixt:num-dot-decimal" scale="3" id="f-1590">40,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of deferred debt issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AmortizationOfDeferredDebtIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-1591">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AmortizationOfDeferredDebtIssueCosts" scale="3" id="f-1592">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency exchange difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1593">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1594">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1595">960,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1596">764,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average interest rates of outstanding borrowings for the years ended 31&#160;December 2023, 2022, and 2021 are <ix:nonFraction unitRef="number" contextRef="c-502" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1597">12.73</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-503" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1598">12.41</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="c-504" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-1599">14.83</ix:nonFraction>%, respectively.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1400-7"><ix:continuation id="f-1574-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below details the changes in the Group&#8217;s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group&#8217;s consolidated cash flow statement as cash flows from financing activities.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.280%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1 January <br/>2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Financing Cash flows (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Capitalized loan cost changes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair value changes, including accretion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other changes (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign exchange impact</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds and Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1600">98,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1601">145,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-3" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1602">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-3" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:num-dot-decimal" scale="3" id="f-1603">36,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-3" name="alvo:NonCashChangesInOtherChanges" format="ixt:num-dot-decimal" scale="3" id="f-1604">27,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-1605">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1606">236,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds (including related party)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1607">530,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-1608">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-1609">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" scale="3" id="f-1610">888</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="alvo:NonCashChangesInOtherChanges" format="ixt:num-dot-decimal" scale="3" id="f-1611">18,017</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-1612">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1613">549,411</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1614">71,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1615">25,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-1616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:fixed-zero" scale="3" id="f-1617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" sign="-" name="alvo:NonCashChangesInOtherChanges" scale="3" id="f-1618">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1619">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1620">97,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1621">64,588</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-1622">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-1623">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:fixed-zero" scale="3" id="f-1624">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="alvo:NonCashChangesInOtherChanges" format="ixt:num-dot-decimal" scale="3" id="f-1625">11,968</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-1626">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1627">76,556</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1628">764,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1629">170,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1630">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:num-dot-decimal" scale="3" id="f-1631">35,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:NonCashChangesInOtherChanges" format="ixt:num-dot-decimal" scale="3" id="f-1632">57,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1633">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1634">960,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Other changes include interest accruals and effects of payments including $<ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="ifrs-full:ProceedsFromCurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1635">3.5</ix:nonFraction>&#160;million in cash received from borrowings from the 2022 Convertible Bonds and transaction cost of $<ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="ifrs-full:PaymentsForDebtIssueCosts" format="ixt:num-dot-decimal" scale="6" id="f-1636">9</ix:nonFraction>&#160;million paid in 2023.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.242%"><tr><td style="width:1.0%"/><td style="width:19.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 January <br/>2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing Cash flows (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized loan cost changes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value changes, including accretion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other changes (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion to Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-cash movements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds and Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-3" name="ifrs-full:Borrowings" format="ixt:fixed-zero" scale="3" id="f-1637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1638">55,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" sign="-" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1639">2,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:num-dot-decimal" scale="3" id="f-1640">40,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" name="alvo:NonCashChangesInOtherChanges" format="ixt:num-dot-decimal" scale="3" id="f-1641">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-1642">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" name="ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity" format="ixt:fixed-zero" scale="3" id="f-1643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" name="alvo:NonCashChangesInOtherNonCashMovements" format="ixt:num-dot-decimal" scale="3" id="f-1644">83,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1645">98,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds (including related party)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1646">394,129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1647">70,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-3" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-1648">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-3" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:num-dot-decimal" scale="3" id="f-1649">32,069</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-3" name="alvo:NonCashChangesInOtherChanges" format="ixt:num-dot-decimal" scale="3" id="f-1650">34,308</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-1651">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-3" name="alvo:NonCashChangesInOtherNonCashMovements" format="ixt:fixed-zero" scale="3" id="f-1652">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1653">530,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1654">6,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1655">33,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-3" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-1656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-3" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:fixed-zero" scale="3" id="f-1657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-3" name="alvo:NonCashChangesInOtherChanges" scale="3" id="f-1658">762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-1659">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-3" name="alvo:NonCashChangesInOtherNonCashMovements" format="ixt:num-dot-decimal" scale="3" id="f-1660">29,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1661">71,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-3" name="ifrs-full:Borrowings" format="ixt:fixed-zero" scale="3" id="f-1662">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1663">110,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-3" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-1664">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-3" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:fixed-zero" scale="3" id="f-1665">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-3" name="alvo:NonCashChangesInOtherChanges" format="ixt:num-dot-decimal" scale="3" id="f-1666">4,588</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-1667">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-3" name="ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity" format="ixt:num-dot-decimal" scale="3" id="f-1668">50,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-3" name="alvo:NonCashChangesInOtherNonCashMovements" format="ixt:fixed-zero" scale="3" id="f-1669">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1670">64,588</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1671">400,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1672">268,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:InterestCostsCapitalizedPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1673">2,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" format="ixt:num-dot-decimal" scale="3" id="f-1674">8,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:NonCashChangesInOtherChanges" format="ixt:num-dot-decimal" scale="3" id="f-1675">41,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1676">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity" format="ixt:num-dot-decimal" scale="3" id="f-1677">50,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:NonCashChangesInOtherNonCashMovements" format="ixt:num-dot-decimal" scale="3" id="f-1678">113,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1679">764,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Other changes include interest accruals and payments.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="alvo:ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" id="f-1680" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of principal amounts on the Group&#8217;s outstanding borrowings as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1681">38,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1682">19,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within two years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1683">867,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1684">3,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1685">4,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1686">696,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within four years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1687">37,857</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1688">3,374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1689">12,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1690">40,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1691">960,159</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1692">764,570</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-46</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_343"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" id="f-1693" continuedAt="f-1693-1" escape="true">Long-term incentive plans </ix:nonNumeric></span></div><ix:continuation id="f-1693-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Share appreciation rights</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to 2020, the Group granted SARs to three former employees. During the year ended 31&#160;December 2021 and 2020, the Group granted SARs to one and two current employees, respectively. There were <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1694"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1695">no</ix:nonFraction></ix:nonFraction> new granted SARs in the years ended 31&#160;December 2023 and 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Settlement of SARs </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the closing of the Business Combination, the Company reached a settlement agreement for share appreciation rights previously awarded to certain current and former employees. The rights were settled as follows: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"><ix:nonFraction unitRef="number" contextRef="c-529" decimals="0" name="ifrs-full:NumberOfEmployees" format="ixt-sec:numwordsen" scale="0" id="f-1696">two</ix:nonFraction> former employees will each receive <ix:nonFraction unitRef="shares" contextRef="c-530" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1697">1,755,291</ix:nonFraction> Ordinary Shares to be issued <ix:nonNumeric contextRef="c-531" name="alvo:NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" format="ixt-sec:durwordsen" id="f-1698">one year</ix:nonNumeric> after the Closing Date. In accordance with IFRS 2, the settlements were accounted for as a modification of a share-based payment transaction that changes the awards classification from cash-settled to equity-settled; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">one former employee will receive a $<ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1699">1.5</ix:nonFraction> million cash payment in July 2022; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"><ix:nonFraction unitRef="number" contextRef="c-533" decimals="0" name="ifrs-full:NumberOfEmployees" format="ixt-sec:numwordsen" scale="0" id="f-1700">one</ix:nonFraction> current employee can elect to receive a cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1701">1.5</ix:nonFraction> million or <ix:nonFraction unitRef="shares" contextRef="c-535" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1702">150,000</ix:nonFraction> Ordinary Shares to be issued <ix:nonNumeric contextRef="c-534" name="alvo:NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" format="ixt-sec:durwordsen" id="f-1703">one year</ix:nonNumeric> after the Closing Date. The Company recognized the cash settlement option as a liability with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="alvo:LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1704">0.8</ix:nonFraction> million and the share settlement option as equity with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="alvo:DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1705">0.7</ix:nonFraction> million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The settlement agreements resulted in a net $<ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1706">36.8</ix:nonFraction> million decrease in the SARs liability, a $<ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-5" name="ifrs-full:ChangesInEquity" format="ixt:num-dot-decimal" scale="6" id="f-1707">31.0</ix:nonFraction> million increase in equity equal to the fair value of the Ordinary Shares issued to the two former employees, a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="alvo:IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1708">1.5</ix:nonFraction> million increase in other current liabilities, and income of $<ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-5" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="f-1709">4.3</ix:nonFraction> million in "General and administrative expense" recognized for the difference between the extinguished liabilities and the fair value of consideration paid to the current and former employees. As of 31&#160;December 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" format="ixt:num-dot-decimal" scale="6" id="f-1710">0.7</ix:nonFraction> million as an other current liability related to the remaining SARs liability. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All liabilities described above have been fully settled in 2023 as follows:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Shares were delivered to the <ix:nonFraction unitRef="number" contextRef="c-529" decimals="0" name="ifrs-full:NumberOfEmployees" format="ixt-sec:numwordsen" scale="0" id="f-1711">two</ix:nonFraction> former employees, on a net basis after tax withholding, resulting in a total of <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="alvo:NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1712">2,465,845</ix:nonFraction> shares which has been reflected accordingly in Note 19.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The employee who could choose between receiving $<ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="alvo:IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1713">1.5</ix:nonFraction>&#160;million or <ix:nonFraction unitRef="shares" contextRef="c-535" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1714">150,000</ix:nonFraction> Ordinary Shares elected to receive the cash payment. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Employee incentive plan</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" id="f-1715" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s employee incentive plan liabilities during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="f-1716">12,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="f-1717">14,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset" scale="3" id="f-1718">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-1719">5,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-1720">11,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-1721">7,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December prior to reclassification</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="f-1722">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="f-1723">12,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassified to other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-3" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="f-1724">659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="f-1725">11,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="f-1726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="f-1727">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_346"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="f-1728" continuedAt="f-1728-1" escape="true">Share-based payments </ix:nonNumeric></span></div><ix:continuation id="f-1728-1" continuedAt="f-1728-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 1 December 2022, the Renumeration Committee authorized and the Group granted RSUs to employees, executives, and directors granting rights to Ordinary Shares once vesting conditions are met. Compensation expense for RSUs is determined based upon the market price of the Ordinary Shares underlying the awards on the date of grant and expensed over the vesting period, which is generally a <ix:nonNumeric contextRef="c-544" name="alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement" format="ixt-sec:duryear" id="f-1729">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-545" name="alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement" format="ixt-sec:duryear" id="f-1730">4</ix:nonNumeric>-year period, with a <ix:nonNumeric contextRef="c-546" name="alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement" format="ixt-sec:duryear" id="f-1731">1</ix:nonNumeric>-year cliff vesting period </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1728-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and subsequent monthly vesting, resulting from participants completing a service condition. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="f-1732" continuedAt="f-1732-1" escape="true">Movements in RSUs during the year ended 31&#160;December 2023 are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1732-1"><div style="margin-top:12pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.030%"><tr><td style="width:1.0%"/><td style="width:41.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">RSUs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-547" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1733">6,979,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-547" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" scale="0" id="f-1734">6.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-548" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-548" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" format="ixt:fixed-zero" scale="0" id="f-1736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New grants during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-549" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1737">820,602</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-549" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" scale="0" id="f-1738">8.79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-550" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1739">7,659,044</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-550" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" scale="0" id="f-1740">6.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-549" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1741">1,587,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-549" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" scale="0" id="f-1742">7.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-550" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-550" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" format="ixt:fixed-zero" scale="0" id="f-1744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-549" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1745">2,466,374</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-549" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" scale="0" id="f-1746">6.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-550" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1747">679,562</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-550" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" scale="0" id="f-1748">6.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-551" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1749">3,745,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-551" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" scale="0" id="f-1750">7.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-547" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1751">6,979,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-547" decimals="2" name="alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" scale="0" id="f-1752">6.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" id="f-1753" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recogniz</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ed $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="6" id="f-1754">18.0</ix:nonFraction> million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="6" id="f-1755">10.3</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of shar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e-based payment expense during the years ended 31&#160;December 2023 and 2022, respectively, as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"/><td style="width:64.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1756">3,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1757">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1758">3,991</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1759">2,994</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1760">10,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1761">5,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1762">18,033</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-1763">10,317</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_349"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfLitigationSettlementsExplanatoryTextBlock" id="f-1764" continuedAt="f-1764-1" escape="true">Litigation </ix:nonNumeric></span></div><ix:continuation id="f-1764-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group was involved in <ix:nonFraction unitRef="litigation_case" contextRef="c-5" decimals="INF" name="alvo:NumberOfLitigations" format="ixt-sec:numwordsen" scale="0" id="f-1765">four</ix:nonFraction> litigations (all now dismissed) in the United States adverse to AbbVie arising out of the development of Alvotech&#8217;s AVT02 product, and the filing of a biologics license application with the U.S. Food and Drug Administration seeking regulatory approval (the &#8220;AbbVie Litigations&#8221;).</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech entered into the AbbVie U.S. Agreement with AbbVie Inc. and AbbVie Biotechnology Ltd with respect to AVT02 for the U.S. market. Pursuant to the settlement component of the AbbVie U.S. Agreement, the parties agreed to stipulate to the dismissal of all claims, counterclaims and potential claims in the <ix:nonFraction unitRef="litigation_case" contextRef="c-5" decimals="INF" name="alvo:NumberOfLitigations" format="ixt-sec:numwordsen" scale="0" id="f-1766">four</ix:nonFraction> U.S. litigations, with each party to bear its own fees and costs. The parties further agreed to release each other from certain claims and demands. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group incurred approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="alvo:LegalCost" format="ixt:fixed-zero" scale="6" id="f-1767">0.0 million</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="alvo:LegalCost" format="ixt:num-dot-decimal" scale="6" id="f-1768">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="alvo:LegalCost" format="ixt:num-dot-decimal" scale="6" id="f-1769">13.5</ix:nonFraction> million in legal expenses during the years ended 31&#160;December 2023, 2022, and 2021, respectively, in preparation for, and/or in relation to, these litigations. Aside from this matter, the Group is not currently a party to any material litigation or similar matters.</span></div></ix:continuation><div id="ie527079dad0a4810aa92569387637e3d_352"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-1770" continuedAt="f-1770-1" escape="true">Related parties </ix:nonNumeric></span></div><ix:continuation id="f-1770-1" continuedAt="f-1770-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related parties are those parties which have considerable influence over the Group, directly or indirectly, including a parent company, owners or their families, large investors, key management personnel and their families and parties that are controlled by or dependent on the Group, such as affiliates and joint ventures. Key management personnel include the Group&#8217;s executive officers and directors, since these individuals have the authority and responsibility for planning, directing and controlling the activities of the Group. Interests in subsidiaries are set out in Note 1. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Transactions with related parties</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A related party transaction is a transfer of resources, services or obligations between the Group and a related party, regardless of whether a price is charged. The Group engages with related parties for both purchased and sold services, loans and other borrowings and other activities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group entered into lease agreement with Fasteignaf&#233;lagi&#240; Eyj&#243;lfur hf. in April 2023 for a new facility in Iceland with remaining lease terms of approximately <ix:nonNumeric contextRef="c-558" name="alvo:WeightedAverageRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1771">15</ix:nonNumeric> years as of 31 December 2023 (see Note 13). The Group also entered into <ix:nonFraction unitRef="agreement" contextRef="c-559" decimals="INF" name="alvo:NumberOfLeaseAgreementsEnteredInto" format="ixt-sec:numwordsen" scale="0" id="f-1772">seventeen</ix:nonFraction> separate lease agreements with Fl&#243;ki Fasteignir ehf. (HRJAF ehf.) throughout 2020, 2021 and 2023 for a group of apartment buildings in Iceland used for temporary housing of employees and third party </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1770-2" continuedAt="f-1770-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contractors. <ix:nonFraction unitRef="agreement" contextRef="c-560" decimals="INF" name="alvo:NumberOfLeasesTerminated" format="ixt-sec:numwordsen" scale="0" id="f-1773">Two</ix:nonFraction> of the leases were terminated during the year ended 31&#160;December 2021. The remaining lease terms for the other <ix:nonFraction unitRef="agreement" contextRef="c-561" decimals="INF" name="alvo:NumberOfLeaseAgreements" format="ixt-sec:numwordsen" scale="0" id="f-1774">fifteen</ix:nonFraction> leases approximate <ix:nonNumeric contextRef="c-562" name="alvo:WeightedAverageRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1775">7</ix:nonNumeric> years, on average, as of 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group entered into office sublease sharing agreement with Alvogen UK Ltd. in August 2023. The agreement was effective from 1 January 2023 and shall terminate upon the expiration or termination of the Lease.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group entered into art lease agreement with Fl&#243;ki-Art ehf. in January 2023, as a result of the Share Purchase Agreement (see Note 12). The leased asset is located in S&#230;mundargata 15-19, Reykjavik. The remaining lease term for the leased asset is <ix:nonNumeric contextRef="c-563" name="alvo:WeightedAverageRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1776">15</ix:nonNumeric> years, as of 31 December 2023.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group provides and receives certain support services through arrangements with Aztiq, Alvogen, and Alvogen Malta (Outlicensing) Ltd. (Adalvo). Services provided to Alvogen consist of finance, administrative, legal and human resource services. Services received from Alvogen primarily consist of marketing, salary processing, and information technology support services. Services received from Adalvo primarily consist of legal, regulatory, supply chain management, and portfolio and market intelligence services. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchased service includes rental fees and service expenses, as described above. Rental fees and service expenses with related parties are presented as &#8220;General and administrative expenses&#8221; or &#8220;Research and development expenses&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss, depending on the nature of the service performed and expense incurred by the Group. Rental liabilities from lease arrangements with related parties are presented as a component of &#8220;Lease liabilities&#8221; on the consolidated statements of financial position. Service payables are presented as &#8220;Liabilities to related parties&#8221; on the consolidated statements of financial position. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest includes interest expense on borrowings. Interest expenses on loans from related parties are presented as &#8220;Finance costs&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. Borrowings are presented as &#8220;Borrowings&#8221; and &#8220;Current maturities of borrowings&#8221; on the consolidated statements of financial position. See Note 21 for further details on the borrowing arrangements with related parties. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sold service includes services provided to related parties, as described above. Income from related parties for such services are presented as &#8220;Other income&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. Amounts receivable for such activities are presented as &#8220;Receivables from related parties&#8221; on the consolidated statements of financial position. The Group has not recorded bad debt provisions for its receivables from related parties. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-1777" continuedAt="f-1777-1" escape="true"><ix:continuation id="f-1770-3" continuedAt="f-1770-4"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions as of and for the year ended 31&#160;December 2023 are as follows:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"/><td style="width:39.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Purchased service /</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">interest</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Sold service</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Payables/ </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">borrowings</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1778">11,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1781">76,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ATP Holdings ehf. - Sister company (a)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1782">9,193</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1783">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1784">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1785">49,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1787">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Consulting ehf. &#8211; Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1790">178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1791">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1792">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1793">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki-Art ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1794">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1797">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1798">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1799">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1800">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1801">484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1803">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1804">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen UK - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1806">273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1807">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1808">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1809">581</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Finance B.V. - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1810">3,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1813">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1814">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1815">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-583" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1816">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-583" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1817">7,440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus International Pte. Ltd. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1819">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-585" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-585" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1822">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1823">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1824">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1825">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1826">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1829">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1830">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1831">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1832">758</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1833">539</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo Limited - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1834">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1835">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1836">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1837">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo UK - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1838">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1839">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1840">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1841">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki Invest ehf - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1842">680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1845">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Floki Holdings S.&#224; r.l. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1846">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1847">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1848">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1849">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1852">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Spain SL - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1854">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1855">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1856">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1857">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Norwich Clinical Services Ltd - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1858">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1861">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company (d)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1862">3,807</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1863">102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1864">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1865">69,732</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki fasteignir ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1866">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1869">11,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1870">32,781</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1871">597</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1872">896</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1873">217,956</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). In relation to the private placement of Tranche A Convertible Bonds in July, the Company paid underwriters fee to APT Holding amounting to $<ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="6" id="f-1874">3.3</ix:nonFraction>&#160;million. The underwriter&#8217;s fee is accounted for as a transaction cost that is amortized through profit and loss over the life of the instrument.  </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Payables to Lotus Pharmaceuticals Co. Ltd. consists of the other current liability as further described in Note 2. This other current liability is presented as &#8220;Liabilities to related party&#8221; on the consolidated statements of financial position. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The amount receivable from Alvotech &amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Refer to Note 13 for the details of the new lease. </span></div></ix:continuation></ix:nonNumeric><div style="padding-left:18pt;text-indent:-9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1777-1" continuedAt="f-1777-2"><ix:continuation id="f-1770-4" continuedAt="f-1770-5"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions as of and for the year ended 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"/><td style="width:39.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchased service / <br/>interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sold service</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payables/ <br/>borrowings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1875">5,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1878">64,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1879">216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1880">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1881">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1882">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Consulting ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1883">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1886">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ATP Holdings ehf. - Sister company (a)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1887">1,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1888">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1889">765</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1890">81,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company (e)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1891">7,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1895">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1896">196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1897">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1898">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1899">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1900">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1902">484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1903">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1904">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-625" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1905">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-625" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1906">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1908">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1909">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1910">7,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus International Pte. Ltd. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1911">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1912">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1913">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1914">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1915">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Korea co. Ltd - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1919">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1920">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1921">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1922">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1923">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1924">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1925">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1926">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1927">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1928">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-637" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1929">758</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-637" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1930">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo Limited - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-638" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1931">1,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-638" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1932">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-639" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-639" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1934">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1935">603</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1936">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1937">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1938">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Spain SL - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1939">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1941">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Norwich Clinical Services Ltd - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1943">301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1944">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1945">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" id="f-1946">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Pharma Pvt Ltd - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1947">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1950">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki fasteignir ehf. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1951">1,516</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1952">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1953">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1954">8,876</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">L41 ehf.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1955">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lambhagavegur 7 ehf. (d)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1959">537</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1960">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1961">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1962">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1963">21,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1964">818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1965">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1966">163,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities including discount and accretion (see Note 21). </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#8220;Other long-term liability to related party&#8221; on the consolidated statements of financial position. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The amount receivable from Alvotech &amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Lambahagavegur is no longer a related party as it was sold during the year ended 31&#160;December 2023. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. was acquired as part of the Share Purchase Agreement, with ATP Holdings ehf., on 16 November 2022. The related party transactions reflect activity until the acquisition date. See Note 12 and Note 21 for further details.  </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1770-5" continuedAt="f-1770-6"><ix:continuation id="f-1777-2" continuedAt="f-1777-3"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions for the year ended 31&#160;December 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"><tr><td style="width:1.0%"/><td style="width:59.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchased service / <br/>interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sold <br/>service</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1967">9,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Pharma Partners S.&#224; r.l. &#8211; Sister company (a) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1969">16,048</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1970">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Aztiq AB &#8211; Sister company (a) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1971">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. (a) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1973">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1974">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company  </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1975">7,762</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1976">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1977">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1978">2,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company  </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1979">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1980">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen UK - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1981">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1983">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1984">312</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1985">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Korea co. Ltd - Sister company </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1987">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1988">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1989">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1990">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1991">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" scale="3" id="f-1992">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Pharma Pvt Ltd - Sister Company </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1993">491</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1994">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">HRJ&#193;F ehf - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1995">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">L41 ehf. </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1997">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-1998">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lambhagavegur 7 ehf. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" scale="3" id="f-1999">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="f-2000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:ServicesReceivedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-2001">39,940</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-2002">3,715</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). </span></div></ix:continuation><div style="padding-left:54pt;text-indent:-27pt"><ix:continuation id="f-1777-3" continuedAt="f-1777-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"><ix:continuation id="f-1777-4">Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#8220;Other long-term liability to related party&#8221; on the consolidated statements of financial position.</ix:continuation> </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Commitments and guarantees</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group does not have any contractual commitments with its related parties other than the receivables, loans and payables previously disclosed. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Key management personnel</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At 31&#160;December 2023 and 2022 there are <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:LoansToRelatedParties" format="ixt:fixed-zero" scale="3" id="f-2003"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:LoansToRelatedParties" format="ixt:fixed-zero" scale="3" id="f-2004">no</ix:nonFraction></ix:nonFraction> loans to the members of the Board of Directors and the CEO. In addition, there were no transactions carried out between the Group and members of the Board of Directors nor the CEO in the years ended 31&#160;December 2023 and 2022. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" id="f-2005" continuedAt="f-2005-1" escape="true">The Board of Directors&#8217; remuneration is shown in the table below. </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2005-1"><ix:continuation id="f-1770-6"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"><tr><td style="width:1.0%"/><td style="width:45.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors&#8217; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Board fees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension <br/>contribution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">year-end**</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman, Chairman of the board*</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-3" name="alvo:DirectorFees" format="ixt:fixed-zero" scale="3" id="f-2006">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="3" id="f-2008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-672" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2009">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies, Vice-Chairman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2010">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="f-2012">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-674" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2013">1,143,713</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant, Board Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2014">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="f-2016">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-676" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2017">10,582</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#193;rni Har&#240;arson, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-3" name="alvo:DirectorFees" format="ixt:fixed-zero" scale="3" id="f-2018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="3" id="f-2020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-678" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2021">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua, Board Member*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-3" name="alvo:DirectorFees" format="ixt:fixed-zero" scale="3" id="f-2022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="3" id="f-2024">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-680" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2025">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick, Board Member</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2026">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="f-2028">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-682" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2029">10,582</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver, Board Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2030">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="f-2032">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-684" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2033">10,582</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-3" name="alvo:DirectorFees" format="ixt:fixed-zero" scale="3" id="f-2034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="3" id="f-2036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-686" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2037">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2038">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="f-2040">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-688" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2041">1,175,459</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Waived their board compensation (both cash and equity)</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Direct share ownership </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Key employees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Salaries and benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Termination benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long- term benefits</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman CEO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2042">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="f-2043">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="3" id="f-2044">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="3" id="f-2045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Executive Team Members (9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2046">5,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="f-2047">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="3" id="f-2048">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2049">9,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2050">6,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="f-2051">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="3" id="f-2052">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2053">9,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"><tr><td style="width:1.0%"/><td style="width:45.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors&#8217; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Board fees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long-term benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">year-end**</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman, Chairman of the board</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2054">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="0" id="f-2055">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="0" id="f-2056">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-692" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2057">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies, Vice-Chairman</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2058">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="0" id="f-2059">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="0" id="f-2060">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-694" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2061">1,133,131</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2062">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="0" id="f-2063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="0" id="f-2064">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-696" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2065">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#193;rni Har&#240;arson, Board Member (from 16.6.2022)*</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-3" name="alvo:DirectorFees" format="ixt:fixed-zero" scale="3" id="f-2066">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="0" id="f-2067">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="0" id="f-2068">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-698" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2069">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua, Board Member*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-3" name="alvo:DirectorFees" format="ixt:fixed-zero" scale="3" id="f-2070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="0" id="f-2071">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="0" id="f-2072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-700" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2073">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick, Board Member (from 16.6.2022)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2074">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="0" id="f-2075">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="0" id="f-2076">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-702" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2077">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2078">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="0" id="f-2079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="0" id="f-2080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-704" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2081">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman, Board Member*</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-3" name="alvo:DirectorFees" format="ixt:fixed-zero" scale="3" id="f-2082">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2083">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="3" id="f-2084">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-706" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2085">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Hirofumi Imai, Board member (until 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-3" name="alvo:DirectorFees" format="ixt:fixed-zero" scale="3" id="f-2086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="0" id="f-2087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="0" id="f-2088">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-708" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-2089">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-3" name="alvo:DirectorFees" scale="3" id="f-2090">927</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" format="ixt:fixed-zero" scale="3" id="f-2091">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="3" id="f-2092">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-710" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2093">1,133,131</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Waived their board compensation (both cash and equity)</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Direct share ownership </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Key employees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Salaries and benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Termination benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long- term benefits</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mark Levick CEO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" id="f-2094">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="f-2095">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2096">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:fixed-zero" scale="3" id="f-2097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Executive Team Members (9)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2098">5,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="f-2099">446</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="3" id="f-2100">820</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2101">5,015</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2102">6,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="f-2103">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2104">1,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2105">5,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-53</span></div></div></div><div id="ie527079dad0a4810aa92569387637e3d_355"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory" id="f-2106" continuedAt="f-2106-1" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other current liabilities </span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" id="f-2107" continuedAt="f-2107-1" escape="true"><ix:continuation id="f-2106-1" continuedAt="f-2106-2"><div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other current liabilities as of 31&#160;December 2023 and 2022 is as follows: </span></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt;text-align:center"><ix:continuation id="f-2107-1"><ix:continuation id="f-2106-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unpaid salary and salary related expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:CurrentAccruedSalaryAndSalaryRelatedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-2108">31,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:CurrentAccruedSalaryAndSalaryRelatedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-2109">15,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:CurrentAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-2110">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:CurrentAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-2111">2,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued vacation leave</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:CurrentAccruedVacation" format="ixt:num-dot-decimal" scale="3" id="f-2112">6,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:CurrentAccruedVacation" format="ixt:num-dot-decimal" scale="3" id="f-2113">5,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee incentive plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:CurrentEmployeeIncentivePlan" scale="3" id="f-2114">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:CurrentEmployeeIncentivePlan" format="ixt:num-dot-decimal" scale="3" id="f-2115">12,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2116">21,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2117">18,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2118">62,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2119">54,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:115%"> </span></div><div id="ie527079dad0a4810aa92569387637e3d_358"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfJointVenturesExplanatory" id="f-2120" continuedAt="f-2120-1" escape="true">Interests in joint ventures </ix:nonNumeric></span></div><ix:continuation id="f-2120-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2018, Alvotech hf., a subsidiary of the Group, entered into a joint venture agreement with Changchun High &amp; New Technology Industries (Group) Inc. (the &#8220;joint venture partner&#8221;, "CCHN") to form a newly created joint venture entity, Alvotech &amp; CCHN Biopharmaceutical Co., Ltd. (the &#8220;joint venture&#8221; or &#8220;JVCO&#8221;). The purpose of the JVCO is to develop, manufacture and sell biosimilar products in the Chinese market. The JVCO&#8217;s place of business is also the country of incorporation. </span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" id="f-2121" escape="true"><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"><tr><td style="width:1.0%"/><td style="width:33.210%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.486%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.486%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.486%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.486%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%;text-decoration:underline">Name of entity</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Place of business</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Ownership interest </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech &amp; CCHN Biopharmaceutical Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-713" name="ifrs-full:PrincipalPlaceOfBusinessOfJointVenture" id="f-2122">China</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-713" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-2123">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-714" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-2124">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-2125">18,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-2126">48,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The proportion of ownership interest is the same as the proportion of voting rights held by the Group. Management evaluated whether the Group&#8217;s voting rights are sufficient for providing a practical ability to direct the relevant activities and strategic objectives of JVCO unilaterally. As the Group does not hold a majority of the voting rights, the Group does not control JVCO. As a result, the Group&#8217;s investment in JVCO is accounted for using the equity method. </span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" id="f-2127" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the change in the Group&#8217;s investment in a joint venture during the years ended 31&#160;December 2023 and 2022: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-2128">48,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-2129">55,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share in losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-2130">7,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-2131">2,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment loss on investment in joint venture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-2132">21,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-2133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="alvo:ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-2134">1,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="alvo:ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-2135">4,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-2136">18,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="f-2137">48,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Group did <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2138"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2139"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2140">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> receive any dividends from JVCO during the years ended 31&#160;December 2023, 2022, and 2021. The Group had a $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="ifrs-full:CommitmentsInRelationToJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-2141">5.0</ix:nonFraction> million commitment to provide a cash contribution to JVCO as of 31&#160;December 2020, which was paid during the year ended 31&#160;December 2021. Similarly, the joint venture partner had a $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="alvo:CommitmentsOfJointVenturePartnersInRelationToJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-2142">50.0</ix:nonFraction> million commitment to provide a cash contribution to JVCO as of 31&#160;December 2020, which was also paid during the year ended 31&#160;December 2021. The Group does <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CommitmentsInRelationToJointVentures" format="ixt:fixed-zero" scale="3" id="f-2143"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CommitmentsInRelationToJointVentures" format="ixt:fixed-zero" scale="3" id="f-2144">not</ix:nonFraction></ix:nonFraction> have any remaining commitments to JVCO as of 31&#160;December 2023 and 2022. Furthermore, the Group does <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" format="ixt:fixed-zero" scale="3" id="f-2145"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" format="ixt:fixed-zero" scale="3" id="f-2146">not</ix:nonFraction></ix:nonFraction> have any contingent liabilities relating to its interests in JVCO as of 31&#160;December 2023 or 2022. While there are no significant restrictions resulting from contractual arrangements with JVCO, entities in China are subject to local exchange control regulations. These regulations provide for restrictions on exporting capital from those countries, other than dividends</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. As of 31 December 2023, it had become clear that there were uncertainties around the economic conditions in China. Accordingly, the Group recorded an impairment loss on its investment in JVCO based on discussions between Alvotech and CCHN to buy back Alvotech&#180;s interest in the joint venture. The Group estimated the recoverable amount using value in use where the recoverable amount is estimated as the future cash flows expected to arise from dividends to be received from the investment and from its ultimate disposal.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div><span><br/></span></div><div id="ie527079dad0a4810aa92569387637e3d_361"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="f-2147" continuedAt="f-2147-1" escape="true">Financial instruments </ix:nonNumeric></span></div><ix:continuation id="f-2147-1" continuedAt="f-2147-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Accounting classification and carrying amounts</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="f-2148" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets as of 31&#160;December 2023 and 2022, all of which are measured at amortized cost, are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2149">11,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2150">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2151">26,132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2152">25,187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-2153">41,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-2154">32,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:OtherCurrentAsset" format="ixt:num-dot-decimal" scale="3" id="f-2155">1,035</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:OtherCurrentAsset" format="ixt:num-dot-decimal" scale="3" id="f-2156">5,880</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Receivables from related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" scale="3" id="f-2157">896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-2158">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other long-term assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:OtherNoncurrentAsset" scale="3" id="f-2159">336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:OtherNoncurrentAsset" format="ixt:num-dot-decimal" scale="3" id="f-2160">4,484</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:FinancialAssetsAtAmortisedCost" format="ixt:num-dot-decimal" scale="3" id="f-2161">80,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:FinancialAssetsAtAmortisedCost" format="ixt:num-dot-decimal" scale="3" id="f-2162">136,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="f-2163" escape="true"><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial liabilities as of 31&#160;December 2023 and 2022 are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-2164">960,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-2165">764,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial liabilities (measured at FVTPL)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2166">520,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2167">380,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other long-term liability to related party (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentPayablesToRelatedParties" format="ixt:fixed-zero" scale="3" id="f-2168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentPayablesToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-2169">7,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term incentive plan (measured at FVTPL)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" format="ixt:fixed-zero" scale="3" id="f-2170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" scale="3" id="f-2171">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade and other payables (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-2172">80,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-2173">49,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities (measured at amortized cost)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2174">115,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2175">40,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Liabilities to related parties (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-2176">9,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-2177">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:OtherCurrentLiability" format="ixt:num-dot-decimal" scale="3" id="f-2178">61,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:OtherCurrentLiability" format="ixt:num-dot-decimal" scale="3" id="f-2179">53,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-2180">1,748,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-2181">1,297,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is management&#8217;s estimate that the carrying amounts of financial assets and financial liabilities carried at amortized cost approximate their fair value, with the exception of the Senior Bonds, Aztiq Convertible Bond, 2022 Convertible Bonds, and Alvogen Facility, since any applicable interest receivable or payable is either close to current market rates or the instruments are short-term in nature. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" id="f-2182" continuedAt="f-2182-1" escape="true">Material differences between the fair values and carrying amounts of these borrowings are identified as follows: </ix:nonNumeric></span></div><ix:continuation id="f-2182-1" continuedAt="f-2182-2"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2183">549,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2184">559,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2185">80,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2186">84,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2187">155,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2188">217,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2189">76,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2190">82,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2191">862,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2192">944,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2147-2" continuedAt="f-2147-3"><ix:continuation id="f-2182-2"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2193">530,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2194">535,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2195">65,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2196">65,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2197">32,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2198">52,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2199">64,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2200">66,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="3" id="f-2201">693,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="alvo:BondsIssuedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2202">720,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Fair value measurements</span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" id="f-2203" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables illustrate the fair value measurement hierarchy of the Group&#8217;s financial instruments measured at fair value on a recurring basis as of 31&#160;December 2023 and 2022: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Bond Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2204">19,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-725" xsi:nil="true" name="ifrs-full:DerivativeFinancialLiabilities" id="f-2205"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2207">19,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2210">118,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2211">118,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2213">349,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2215">349,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2217">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2219">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2220">25,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-743" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2223">25,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2224">45,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2225">356,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2226">118,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2227">520,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bond Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2230">45,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2231">45,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2234">38,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2235">38,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bond Interest Rate Feature (included in other current assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-2238">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-2239">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2241">276,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2243">276,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2245">10,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-765" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-766" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2247">10,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2248">10,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2251">10,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2252">10,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2253">286,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2254">84,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2255">381,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="f-2256" escape="true"><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of Level 3 financial instruments:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.818%"><tr><td style="width:1.0%"/><td style="width:49.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Senior Bond Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Senior Bond Interest Rate Feature</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 January  2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2257">45,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2258">38,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="f-2259">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-3" name="ifrs-full:IssuesFairValueMeasurementLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2260">45,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-3" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="3" id="f-2261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-3" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2262">35,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer to Level 1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-3" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2263">45,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-3" name="ifrs-full:SettlementsFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="3" id="f-2264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-776" decimals="-3" name="ifrs-full:SettlementsFairValueMeasurementLiabilities" scale="3" id="f-2265">851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-2266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-2267">118,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-777" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-2268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2147-3" continuedAt="f-2147-4"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognized the transfer of the Senior Bond Warrants from Level 3 to Level 1 for $<ix:nonFraction unitRef="usd" contextRef="c-778" decimals="-3" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2269">19.7</ix:nonFraction>&#160;million<ix:nonFraction unitRef="usd" contextRef="c-725" xsi:nil="true" name="ifrs-full:DerivativeFinancialLiabilities" id="f-2270"></ix:nonFraction> (2022: $<ix:nonFraction unitRef="usd" contextRef="c-779" decimals="-3" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2271">45.3</ix:nonFraction> million) during the year ended 31&#160;December 2023 due to the lift of the lock-up period for the un-exercised Senior Bond Warrants. The Group did not recognize any transfer of assets or liabilities between levels of the fair value hierarchy during the years ended 31&#160;December 2022 and 2021. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, the Group amended and upsized the outstanding bonds by $<ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-5" name="alvo:IncreaseInOutstandingBondsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-2272">70.0</ix:nonFraction>&#160;million. The amended bond agreement of the Senior Bonds resulted in, among other things, an increase in the interest rate, resulting in a range from <ix:nonFraction unitRef="number" contextRef="c-780" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2273">10.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-781" decimals="3" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2274">12.0</ix:nonFraction>% depending on the occurrence of certain events, as defined by the terms of the agreement (see Note 21). The Group accounted for this interest rate feature (the &#8220;Senior Bond Interest Rate Feature&#8221;) as an embedded derivative, classified as an "Other current assets" in the consolidated statement of financial position as of 31 December 2022. Since the conditions to adjust the coupon rate have not been met as of 31 March 2023 per the terms of the agreement, the interest rate on the Senior Bonds is now fixed and the embedded derivative previously recorded has been extinguished during the year ended 31&#160;December 2023, resulting in a loss on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-776" decimals="-5" name="ifrs-full:SettlementsFairValueMeasurementLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2275">0.9</ix:nonFraction>&#160;million recorded in finance costs.</span></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Senior Bond Warrants</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted in Note 21, as a result of proceeds raised from the private placement offering executed in February 2023, the Company extinguished the derivative financial liability related to the senior bond warrants since the Company has not anymore the obligation to issue the <ix:nonFraction unitRef="number" contextRef="c-369" decimals="INF" name="alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" scale="-2" id="f-2276">1.0</ix:nonFraction>% Senior Bond Warrants, resulting in a gain on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-5" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2277">6.5</ix:nonFraction> million. In January and February 2023, the Senior Bond Warrant holders (also known as penny warrant holders) elected to exercise their warrants. As a result, <ix:nonFraction unitRef="shares" contextRef="c-782" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2278">2,479,962</ix:nonFraction> ordinary shares were issued in exchange for the exercising of the penny warrants. The Company received an immaterial amount of cash and recognized the transaction as an extinguishment of the derivative financial liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Senior Bond Warrants was derived from the publicly quoted trading price of the Ordinary Shares at the valuation date. As of 31&#160;December 2023, the Company had <ix:nonFraction unitRef="shares" contextRef="c-727" decimals="INF" name="alvo:ClassOfWarrantsOrRightsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2279">1,718,845</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-727" decimals="INF" name="alvo:ConversionPrice" scale="0" id="f-2280">0.01</ix:nonFraction>, representing the <ix:nonFraction unitRef="number" contextRef="c-782" decimals="3" name="alvo:TrancheOfSeniorBondWarrantsPercentage" scale="-2" id="f-2281">1.5</ix:nonFraction>% tranche of Senior Bond Warrants. The Senior Bond Warrants had a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-5" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2282">19.7</ix:nonFraction>&#160;million as of 31&#160;December 2023. The change in fair resulted in $<ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-5" sign="-" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-2283">8.1</ix:nonFraction> million of finance costs for the year ended 31&#160;December 2023.  </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Tranche A Conversion Feature </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted in Note 21, in connection with the Convertible Bonds the Group classified the Tranche A Conversion Feature as an embedded derivative liability due to the variability created by conversion rates resulting from the tranche being denominated in ISK. The conversion feature had a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-5" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2284">118.8</ix:nonFraction>&#160;million as of 31&#160;December 2023. The change in fair resulted in $<ix:nonFraction unitRef="usd" contextRef="c-783" decimals="-5" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-2285">35.2</ix:nonFraction>&#160;million of finance costs for the year ended 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Tranche A Conversion Feature was determined using a lattice model that incorporated inputs and assumptions as further described below. The inputs and assumptions associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" id="f-2286" continuedAt="f-2286-1" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the Tranche A Conversion Feature: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.787%"><tr><td style="width:1.0%"/><td style="width:55.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.550%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="number" contextRef="c-784" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2287">11.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="number" contextRef="c-785" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2288">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Conversion price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="number" contextRef="c-786" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2289">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="number" contextRef="c-787" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2290">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-788" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2291">57.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-789" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2292">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-790" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2293">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-791" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2294">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-792" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2295">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-793" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2296">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risky yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-794" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2297">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-795" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2298">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2147-4" continuedAt="f-2147-5"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Predecessor Earn Out Shares </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Business Combination, Predecessor shareholders were granted a total of <ix:nonFraction unitRef="shares" contextRef="c-796" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2299">38,330,000</ix:nonFraction> Ordinary Shares subject to certain vesting conditions (&#8220;Predecessor Earn Out Shares&#8221;). One half of the Predecessor Earn Out Shares will vest if, at any time during the <ix:nonNumeric contextRef="c-797" name="alvo:AggregatePeriodForDeterminingTheSharePrice" format="ixt-sec:durwordsen" id="f-2300">five years</ix:nonNumeric> following the closing of the Business Combination, the Alvotech ordinary share price is at or above a volume weighted average price (&#8220;VWAP&#8221;) of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-797" decimals="2" name="alvo:SharesPrice" scale="0" id="f-2301">15.00</ix:nonFraction> per share for any <span style="-sec-ix-hidden:f-2302">ten</span> trading days within any <span style="-sec-ix-hidden:f-2303">twenty</span>-trading day period, with the other half vesting at a VWAP of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-798" decimals="2" name="alvo:SharesPrice" scale="0" id="f-2304">20.00</ix:nonFraction> per share for any <span style="-sec-ix-hidden:f-2305">ten</span> trading days within any <span style="-sec-ix-hidden:f-2306">twenty</span>-trading day period. The Predecessor Earn Out Shares are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The Predecessor Earn Out Shares had a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2307">349.9</ix:nonFraction> million as of 31&#160;December 2023, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-799" decimals="-5" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-2308">73.7</ix:nonFraction>&#160;million of finance costs during the year ended 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Predecessor Earn Out Shares was determined using Monte Carlo analysis that incorporated inputs and assumptions as further described below. The inputs and assumptions associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><ix:continuation id="f-2286-1" continuedAt="f-2286-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the Predecessor Earn Out Shares: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-735" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2309">38,330,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-762" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2310">38,330,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="number" contextRef="c-800" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2311">11.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="number" contextRef="c-801" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2312">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-802" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2313">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-803" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2314">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-804" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2315">3.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-805" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2316">4.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">OACB Earn Out Shares </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Former OACB shareholders were granted a total of <ix:nonFraction unitRef="shares" contextRef="c-806" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2317">1,250,000</ix:nonFraction> Ordinary Shares subject to certain vesting conditions (&#8220;OACB Earn Out Shares&#8221;). One half of the OACB Earn Out Shares will vest if, at any time during the <ix:nonNumeric contextRef="c-807" name="alvo:AggregatePeriodForDeterminingTheSharePrice" format="ixt-sec:durwordsen" id="f-2318">five years</ix:nonNumeric> following the closing of the Business Combination, the Alvotech ordinary share price is at or above a VWAP of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-807" decimals="2" name="alvo:SharesPrice" scale="0" id="f-2319">12.50</ix:nonFraction> per share for any <span style="-sec-ix-hidden:f-2320">ten</span> trading days within any <span style="-sec-ix-hidden:f-2321">twenty</span>-trading day period, with the other half vesting at a VWAP of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-808" decimals="2" name="alvo:SharesPrice" scale="0" id="f-2322">15.00</ix:nonFraction> per share.  On 17 February 2023, the first half of OACB Earn Out Shares vested resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-809" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2323">625,000</ix:nonFraction> ordinary shares by the Group. The OACB Earn Out Shares are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The OACB Earn Out Shares had a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2324">6.2</ix:nonFraction> million as of 31&#160;December 2023, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-806" decimals="-5" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-2325">4.0</ix:nonFraction>&#160;million of finance costs during the year ended 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the OACB Earn Out Shares was determined using a Monte Carlo analysis that incorporated inputs and assumptions as further described below. Assumptions and inputs associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><ix:continuation id="f-2286-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the OACB Earn Out Shares: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-810" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2326">625,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-811" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2327">1,250,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="number" contextRef="c-812" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2328">11.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="number" contextRef="c-813" decimals="2" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="f-2329">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Volatility rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-814" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2330">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-815" decimals="3" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2331">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-816" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2332">3.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-817" decimals="4" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-2333">4.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2147-5" continuedAt="f-2147-6"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">OACB Warrants </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, as part of the Business Combination the Company assumed the <ix:nonFraction unitRef="shares" contextRef="c-818" decimals="INF" name="alvo:ClassOfWarrantsOrRightsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2334">10,916,647</ix:nonFraction> outstanding OACB Warrants, on substantially the same contractual terms and conditions as were in effect immediately prior to the Business Combination, including an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-818" decimals="2" name="alvo:ClassOfWarrantsOrRightsExercisePricePerShare" scale="0" id="f-2335">11.50</ix:nonFraction>. Each warrant entitles the holder to purchase <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="alvo:NumberOfSharesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-2336">one</ix:nonFraction> Alvotech ordinary share.  During 2023, holders of the OACB warrants exercised their warrant rights for an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-743" decimals="2" name="alvo:ClassOfWarrantsOrRightsExercisePricePerShare" scale="0" id="f-2337">11.50</ix:nonFraction> for the rights to <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="alvo:NumberOfSharesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-2338">one</ix:nonFraction> ordinary share per warrant. The exercises resulted in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-743" decimals="INF" name="ifrs-full:NumberOfSharesIssued" scale="0" id="f-2339">553.552</ix:nonFraction> ordinary shares and cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-819" decimals="-5" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="6" id="f-2340">6.3</ix:nonFraction>&#160;million. The OACB warrants are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The OACB warrants had a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-743" decimals="-5" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-2341">25.9</ix:nonFraction>&#160;million as of 31&#160;December 2023. The fair value of the warrants was derived from the publicly quoted trading price at the valuation date. The change in fair value of the OACB Warrants resulted in $<ix:nonFraction unitRef="usd" contextRef="c-819" decimals="-5" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-2342">17.0</ix:nonFraction>&#160;million of finance costs during the year ended 31&#160;December 2023. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Capital management</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The capital structure of the Group consists of equity, debt and cash. For the foreseeable future, the Board of Directors will maintain a capital structure that supports the Group&#8217;s strategic objectives through managing the budgeting process, maintaining strong investor relations and managing the financial risks of the Group, as further described below. No changes were made in the objectives, policies or processes for managing capital during the years ended 31&#160;December 2023 and 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial risk management</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s corporate treasury function provides services across the organization, coordinates access to domestic and international financial markets, monitors and manages the financial risks relating to the Group&#8217;s operations through internal risk reports which analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Interest rate risk</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group&#8217;s exposure to the risk of fluctuations in market interest rates primarily relates to the cash in bank and borrowings that are subject to floating interest rates. </span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" id="f-2343" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides an interest rate sensitivity analysis for the effect on loss before tax: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-rate financial instruments +100</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-820" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2344">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-821" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2345">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-rate financial instruments -100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-820" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2346">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-821" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2347">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Foreign currency risk</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group uses the US dollar as its reporting currency and conducts business on a global basis in various currencies. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Icelandic and UK market currencies, as well as in the Swiss franc. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2147-6" continuedAt="f-2147-7"><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" id="f-2348" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below are the foreign currencies that have the most significant impact on the Group&#8217;s operations. </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"/><td style="width:23.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.455%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Closing rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Average rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-822" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2349">1.105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-823" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2350">1.061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-824" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2351">1.091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-825" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2352">1.052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-824" decimals="3" name="alvo:PercentageChangeInForeignExchangeRate" scale="-2" id="f-2353">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-826" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2354">1.275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-827" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2355">1.204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-828" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2356">1.266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-829" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2357">1.233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-828" decimals="3" name="alvo:PercentageChangeInForeignExchangeRate" scale="-2" id="f-2358">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-830" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2359">0.007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-831" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2360">0.007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-832" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2361">0.007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-833" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2362">0.007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-832" decimals="3" name="alvo:PercentageChangeInForeignExchangeRate" scale="-2" id="f-2363">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-834" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2364">1.188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-835" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2365">1.071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-836" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2366">1.156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-837" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2367">1.047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-836" decimals="3" name="alvo:PercentageChangeInForeignExchangeRate" scale="-2" id="f-2368">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-838" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2369">0.012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-839" decimals="3" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-2370">0.012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-840" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2371">0.012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-841" decimals="3" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-2372">0.013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-840" decimals="3" name="alvo:PercentageChangeInForeignExchangeRate" scale="-2" id="f-2373">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" id="f-2374" escape="true"><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2023 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>assets </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-822" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-2375">36,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-822" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2376">46,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-822" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2377">9,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-826" decimals="-3" name="ifrs-full:Assets" scale="3" id="f-2378">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-826" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2379">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-826" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2380">3,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-830" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-2381">3,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-830" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2382">144,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-830" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2383">141,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-834" decimals="-3" name="ifrs-full:Assets" scale="3" id="f-2384">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-834" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2385">7,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-834" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2386">7,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-838" decimals="-3" name="ifrs-full:Assets" scale="3" id="f-2387">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-838" decimals="-3" name="ifrs-full:Liabilities" scale="3" id="f-2388">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-838" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" scale="3" id="f-2389">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"/><td style="width:48.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net <br/>assets </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-823" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-2390">36,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-823" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2391">26,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-823" decimals="-3" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2392">9,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-827" decimals="-3" name="ifrs-full:Assets" scale="3" id="f-2393">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-827" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2394">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-827" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2395">1,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-831" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-2396">49,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-831" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2397">109,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-831" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2398">60,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-835" decimals="-3" name="ifrs-full:Assets" scale="3" id="f-2399">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-835" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2400">7,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-835" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2401">7,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-839" decimals="-3" name="ifrs-full:Assets" scale="3" id="f-2402">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-839" decimals="-3" name="ifrs-full:Liabilities" scale="3" id="f-2403">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-839" decimals="-3" sign="-" name="ifrs-full:NetAssetsLiabilities" scale="3" id="f-2404">506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reasonable possible strengthening or weakening of the Group&#8217;s significant foreign currencies against the USD would affect the measurement of financial instruments denominated in a foreign currency and affect profit or loss and equity by the amount shown in the sensitivity analysis table below. <ix:nonNumeric contextRef="c-1" name="alvo:DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" id="f-2405" continuedAt="f-2405-1" escape="true">The analysis assumes that all other variables, such as interest rates, remain constant. </ix:nonNumeric></span></div><ix:continuation id="f-2405-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">EUR </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">GBP </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">ISK </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">CHF </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">INR </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Year ended 31 December 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">-<ix:nonFraction unitRef="number" contextRef="c-842" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2406">10</ix:nonFraction>% weakening</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-843" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2407">974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-844" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2408">341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-845" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2409">14,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-846" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2410">715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-847" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2411">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">+<ix:nonFraction unitRef="number" contextRef="c-842" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2412">10</ix:nonFraction>% strengthening</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-843" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2413">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-844" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2414">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-845" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2415">14,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-846" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2416">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-847" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2417">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Year ended 31 December 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">-<ix:nonFraction unitRef="number" contextRef="c-848" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" scale="-2" id="f-2418">10</ix:nonFraction>% weakening</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-849" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2419">991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-850" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2420">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-851" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2421">6,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-852" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2422">724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-853" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2423">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">+<ix:nonFraction unitRef="number" contextRef="c-848" decimals="2" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" scale="-2" id="f-2424">10</ix:nonFraction>% strengthening</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-849" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2425">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-850" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2426">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-851" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2427">6,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-852" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2428">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-853" decimals="-3" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" scale="3" id="f-2429">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2147-7" continuedAt="f-2147-8"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Credit risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Credit risk it the risk that a counterparty will not fulfill its contractual obligations under a financial instrument contract, leading to a financial loss for the Group. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCreditRiskExposureExplanatory" id="f-2430" continuedAt="f-2430-1" escape="true">The maximum credit risk exposure for the Group&#8217;s financial assets as of 31&#160;December 2023 and 2022 is as follows: </ix:nonNumeric></span></div><ix:continuation id="f-2430-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"/><td style="width:64.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-854" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="f-2431">11,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-855" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="f-2432">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-856" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="f-2433">26,132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-857" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="f-2434">25,187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-858" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="f-2435">43,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-859" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="f-2436">44,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="f-2437">80,848</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:MaximumExposureToCreditRisk" format="ixt:num-dot-decimal" scale="3" id="f-2438">136,498</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s cash and cash equivalents and restricted cash are deposited with high-quality financial institutions. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Group has not experienced any losses on its deposits of cash and cash equivalents and restricted cash yet monitors the credit rating of these financial institutions on a periodic basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets primarily consist of other current assets, as described in Note 18, and trade receivables and contract assets recognized in connection with the Group&#8217;s performance pursuant to its contracts with customers, all of which are large multinational pharmaceutical companies. In 2023, the Group recognized a receivable of $<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2439">18.5</ix:nonFraction>&#160;million in other current assets following the termination of the co-development agreement with Biosana which was fully reserved as of 31&#160;December 2023 due to the uncertainty of its collection (see Note 18). There are no other significant amounts past due as of 31&#160;December 2023 and 2022 and the Group concludes that any expected credit losses with respect to these assets, except as described above, is immaterial. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Liquidity risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. </span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" id="f-2440" continuedAt="f-2440-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of financial assets and liabilities as of 31&#160;December 2023 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one<br/>year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">One to two<br/>years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-860" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2441">43,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-861" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-2442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-862" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-2443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-863" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2444">43,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-864" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2445">11,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-865" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-2446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-866" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2447">26,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-867" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2448">37,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2449">54,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-2450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-868" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2451">26,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2452">80,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-869" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2453">142,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-870" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-871" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-872" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2456">142,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2457">66,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-874" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2458">1,101,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-875" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-876" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2460">1,167,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-877" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-878" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2462">520,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-879" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2464">520,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2465">44,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2466">10,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2467">65,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2468">121,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2469">253,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2470">1,631,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-868" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2471">65,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2472">1,951,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2440-1"><ix:continuation id="f-2147-8" continuedAt="f-2147-9"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of financial assets and liabilities as of 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one<br/>year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">One to two<br/>years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2473">40,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-886" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-2474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-887" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-2475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-888" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2476">40,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-889" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2477">66,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-890" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-2478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-891" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2479">29,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-892" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2480">96,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2481">106,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-2482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-893" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2483">29,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-2484">136,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-894" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2485">104,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-895" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-896" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2487">7,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-897" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2488">112,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-898" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2489">45,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-899" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2490">66,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-900" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2491">896,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-901" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2492">1,008,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-902" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-903" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-2494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-904" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2495">380,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-905" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2496">380,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-906" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2497">25,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-907" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2498">8,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-908" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2499">59,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-909" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2500">92,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2501">175,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2502">74,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-893" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2503">1,344,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2504">1,593,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-2147-9">Refer to Note 13 for the maturity analysis of the Group&#8217;s undiscounted lease payments.</ix:continuation> </span></div><div id="ie527079dad0a4810aa92569387637e3d_367"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="alvo:DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" id="f-2509" continuedAt="f-2509-1" escape="true">Supplemental cash flow information </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="alvo:DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" id="f-2510" escape="true"><ix:continuation id="f-2509-1"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplement cash flow information for the years ended 31&#160;December 2023, 2022, and 2021 is included below (see Note 21 for non-cash movements in borrowings).</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"><tr><td style="width:1.0%"/><td style="width:50.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.438%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of property, plant and equipment in trade payables and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid" format="ixt:num-dot-decimal" scale="3" id="f-2511">2,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid" format="ixt:num-dot-decimal" scale="3" id="f-2512">4,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid" format="ixt:num-dot-decimal" scale="3" id="f-2513">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of intangibles in trade payables and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid" scale="3" id="f-2514">930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid" format="ixt:num-dot-decimal" scale="3" id="f-2515">4,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid" format="ixt:fixed-zero" scale="3" id="f-2516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets obtained through new operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2517">74,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2518">9,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2519">18,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Purchase of Facility through Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond" format="ixt:fixed-zero" scale="3" id="f-2520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond" format="ixt:num-dot-decimal" scale="3" id="f-2521">115,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond" format="ixt:fixed-zero" scale="3" id="f-2522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-cash issuance of Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:NonCashIssuanceOfConvertibleBond" format="ixt:fixed-zero" scale="3" id="f-2523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:NonCashIssuanceOfConvertibleBond" format="ixt:num-dot-decimal" scale="3" id="f-2524">80,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:NonCashIssuanceOfConvertibleBond" format="ixt:fixed-zero" scale="3" id="f-2525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity issued through conversion of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:OrdinarySharesValueIssuedConversionOfBorrowings" format="ixt:fixed-zero" scale="3" id="f-2526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:OrdinarySharesValueIssuedConversionOfBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-2527">32,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:OrdinarySharesValueIssuedConversionOfBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-2528">346,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of other intangible assets through financing agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" format="ixt:fixed-zero" scale="3" id="f-2529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" format="ixt:fixed-zero" scale="3" id="f-2530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" scale="3" id="f-2531">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of RSUs with shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares" scale="3" id="f-2532">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares" format="ixt:fixed-zero" scale="3" id="f-2533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-912" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares" format="ixt:fixed-zero" scale="3" id="f-2534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of SARs with shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares" format="ixt:num-dot-decimal" scale="3" id="f-2535">13,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-913" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares" format="ixt:fixed-zero" scale="3" id="f-2536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-914" decimals="-3" name="alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares" format="ixt:fixed-zero" scale="3" id="f-2537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ie527079dad0a4810aa92569387637e3d_370"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-2538" continuedAt="f-2538-1" escape="true">Subsequent events </ix:nonNumeric></span></div><ix:continuation id="f-2538-1" continuedAt="f-2538-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group evaluated subsequent events through 20 March 2024, the date the consolidated financial statements were available to be issued. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 15 February 2024, the Company announced it has reached settlement agreements with Johnson &amp; Johnson in Japan, Canada and in the EEA for AVT04, a biosimilar to Stelara (ustekinumab). Regulatory approval for AVT04 in these markets has already been granted. Market applications for AVT04 are currently pending in additional global markets, including in the U.S. Alvotech's commercialization partner in Canada, JAMP Pharma, launched AVT04 in Canada on March 1, 2024. Launch of AVT04 in Japan is anticipated after the upcoming round of National Health Insurance reimbursement price listings, in May 2024. Entry to the first European markets is expected as soon as possible after the expiration date of the European Supplementary Protection Certificate (SPC) for Stelara, which is in late July 2024.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 23 February 2024, the Company announced that the FDA has approved SIMLANDI (adalimumab) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn&#8217;s disease, adult ulcerative colitis, adult plaque psoriasis, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#ie527079dad0a4810aa92569387637e3d_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements </span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2538-2"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest-grossing pharmaceutical products in the world, with sales in the U.S. of nearly $<ix:nonFraction unitRef="usd" contextRef="c-915" decimals="-8" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="9" id="f-2539">12.2</ix:nonFraction>&#160;billion. Teva is Alvotech&#8217;s strategic partner for the exclusive commercialization of SIMLANDI in the United States.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 26 February 2024, the Company announced the sale of <ix:nonFraction unitRef="shares" contextRef="c-916" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2540">10,127,132</ix:nonFraction> Ordinary Shares for an approximate value of $<ix:nonFraction unitRef="usd" contextRef="c-916" decimals="-6" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-2541">166</ix:nonFraction>&#160;million (net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-917" decimals="-6" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="6" id="f-2542">160</ix:nonFraction>&#160;million), par value USD <ix:nonFraction unitRef="usdPerShare" contextRef="c-918" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-2543">0.01</ix:nonFraction> per share, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-919" decimals="INF" name="alvo:SaleOfStockIssuePricePerShare" scale="0" id="f-2544">16.41</ix:nonFraction> per share, or ISK <ix:nonFraction unitRef="iskPerShare" contextRef="c-919" decimals="INF" name="alvo:SaleOfStockIssuePricePerShare" format="ixt:num-dot-decimal" scale="0" id="f-2545">2,250</ix:nonFraction> per share at the foreign exchange rates on 23 February 2024. The Shares will be delivered to the Investors from previously issued treasury shares held by Alvotech&#8217;s subsidiary, Alvotech Manco ehf. The Transaction took place on the Nasdaq Iceland Exchange.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 12 February 2024, the second tranche of OACB Earn Out Shares vested resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-920" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2546">625,000</ix:nonFraction> Ordinary Shares. The issuance of Ordinary Shares for the second tranche will be accounted for as an extinguishment of a financial liability in the consolidated statements of profit or loss and other comprehensive income or loss.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 12 February 2024, the first tranche of Predecessor Earn Out Shares vested resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-921" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2547">19,165,000</ix:nonFraction> Ordinary Shares. The issuance of Ordinary Shares for the first tranche will be accounted for as an extinguishment of a financial liability in the consolidated statements of profit or loss and other comprehensive income or loss.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent to 31&#160;December 2023, Senior Bond Warrant holders elected to exercise their warrants. As a result,  <ix:nonFraction unitRef="shares" contextRef="c-922" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2548">1,501,599</ix:nonFraction> Ordinary Shares were issued in exchange for the exercising of the penny warrants. The Company received an immaterial amount of cash and will recognize the transaction as an extinguishment of the derivative financial liabilities. The difference between the equity issued and carrying value of the derivative financial liabilities will be recognized in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent to 31&#160;December 2023, holders of the OACB Warrants exercised their warrant rights for an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-923" decimals="2" name="alvo:ClassOfWarrantsOrRightsExercisePricePerShare" scale="0" id="f-2549">11.50</ix:nonFraction> for the rights to <ix:nonFraction unitRef="shares" contextRef="c-923" decimals="INF" name="alvo:NumberOfSharesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-2550">one</ix:nonFraction> Ordinary Share per warrant. The exercises result in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-924" decimals="INF" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2551">419,660</ix:nonFraction> Ordinary Shares and cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-924" decimals="-5" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-2552">4.8</ix:nonFraction>&#160;million. The Company will recognize the transaction as an extinguishment of the derivative financial liabilities. The difference between the equity issued and carrying value of the derivative financial liabilities will be recognized in the consolidated statements of profit or loss and other comprehensive income or loss.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> F-63</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>alvo-20231231xexx121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if0ef6fc42f3b4bdfb3222ef16ada34c0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 12.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Certification by the Principal Executive Officer pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Securities Exchange Act Rules 13a-14(a) and 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, Robert Wessman, certify that&#58; </font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">I have reviewed this annual report on Form 20-F of Alvotech (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">&#91;Intentionally omitted&#93;&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March&#160;20, 2024 </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.545%"><tr><td style="width:1.0%"></td><td style="width:8.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Robert Wessman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>alvo-20231231xexx122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic0a632572dec44a4a71e7d0b8d759a4f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 12.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Certification by the Principal Financial Officer pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Securities Exchange Act Rules 13a-14(a) and 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, Joel Morales, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. I have reviewed this annual report on Form 20-F of Alvotech (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;)&#59; </font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">&#91;Intentionally omitted&#93;&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.5pt">The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March&#160;20, 2024 </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.545%"><tr><td style="width:1.0%"></td><td style="width:8.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Joel Morales</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Joel Morales</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>alvo-20231231xexx131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6506207c085640f8b21b67c7560b71e3_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 13.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Certification by the Principal Executive Officer and Principal Financial Officer pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18 U.S.C. Section 1350, as adopted pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Section 906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Annual Report on Form 20-F of Alvotech (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) for the fiscal year ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Robert Wessman, Chief Executive Officer of the Company and Joel Morales, Chief Financial Officer of the Company, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each hereby certifies that, to the best of his knowledge&#58; </font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March&#160;20, 2024 </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Robert Wessman</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Joel Morales</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>5
<FILENAME>alvo-20231231xexx151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i896f35855c7a4191940e0f926a57b78e_1"></div><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="background-color:#ffffff;color:#666666;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:190%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="background-color:#ffffff;color:#666666;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We consent to the incorporation by reference in Registration Statement No. 333-266881 on Form S-8 and Registration Statement Nos. 333-266136, 333-275111 and 333-273262 on Form F-3 of our report dated March 20, 2024, relating to the financial statements of Alvotech appearing in this Annual Report on Form 20-F for the year ended December 31, 2023.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#47;s&#47; Deloitte ehf.  </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#666666;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Deloitte ehf. </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#666666;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">K&#243;pavogur, Iceland </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#666666;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">March 20, 2024</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>6
<FILENAME>alvo-20231231xexx97.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iccd1ef3b31fa4de98830735a487a5ede_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Introduction</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of ALVOTECH, a public limited liability company (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">soci&#233;t&#233; anonyme</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) incorporated and existing under the laws of the Grand Duchy of Luxembourg (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) providing for the Company&#8217;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Rule 10D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Nasdaq Listing Rule 5608 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Listing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Effective Date</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Incentive Compensation is deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; in the Company&#8217;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Definitions</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Accounting Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Compensation Committee or, in the absence of such committee, the Board.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Covered Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each current and former Executive Officer.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Nasdaq Stock Market.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Nova',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including Company share price and total shareholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). A measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Lookback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Recoverable Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on share price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the share price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Recoupment</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Applicability of Policy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv)&#160;during the Lookback Period. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Recoupment Generally.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#8217;s obligation to </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Nova',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.  </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Impracticability of Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Recoupment may be determined to be impracticable if, and only if&#58;</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation&#59; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards&#59;</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">recoupment of the applicable Recoverable Incentive Compensation would violate home country law where that law was adopted prior to November 28, 2022&#59; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on violation of home country law, the Company shall obtain an opinion of home country counsel, acceptable to the Exchange, that recoupment would result in such a violation, and shall provide such opinion to the Exchange in accordance with the Listing Standards&#59; or</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Sources of Recoupment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date&#58; (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer&#59; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid)&#59; (iii) cancelling or offsetting against any planned future cash or equity-based awards&#59; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A&#59; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">No Indemnification of Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#8217;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Indemnification of Administrator.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Nova',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">No &#8220;Good Reason&#8221; for Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#8220;good reason&#8221; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Administration</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy.  Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Severability</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Impairment of Other Remedies</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#8217;s obligations to the Company, including, without limitation, termination of employment and&#47;or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SOX 304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and&#47;or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time&#59; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and&#47;or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Amendment&#59; Termination</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Successors</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and&#47;or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Required Filings</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Nova',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Approved by the Board of Directors of the Company on 28 November 2023.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Nova',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</font></div></div></div><div id="iccd1ef3b31fa4de98830735a487a5ede_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>alvo-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0f568319-c84c-47ce-b7c2-396cc2b09ac1,g:54c4089e-eaa8-4b46-9747-283b5fa757be-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:alvo="http://www.alvotech.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alvotech.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alvo-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alvo-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alvo-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alvo-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.alvotech.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.alvotech.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss" roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss">
        <link:definition>0000003 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofFinancialPosition" roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition">
        <link:definition>0000004 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinEquity" roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Generalinformation" roleURI="http://www.alvotech.com/role/Generalinformation">
        <link:definition>0000007 - Disclosure - General information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.alvotech.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary Of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingStandards" roleURI="http://www.alvotech.com/role/NewAccountingStandards">
        <link:definition>0000009 - Disclosure - New Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.alvotech.com/role/SegmentReporting">
        <link:definition>0000010 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.alvotech.com/role/Revenue">
        <link:definition>0000011 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SalariesAndOtherEmployeeExpenses" roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpenses">
        <link:definition>0000012 - Disclosure - Salaries And Other Employee Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinanceIncomeAndFinanceCosts" roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCosts">
        <link:definition>0000013 - Disclosure - Finance Income And Finance Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DepreciationAmortizationAndImpairment" roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairment">
        <link:definition>0000014 - Disclosure - Depreciation, Amortization And Impairment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditFees" roleURI="http://www.alvotech.com/role/AuditFees">
        <link:definition>0000015 - Disclosure - Audit Fees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTax" roleURI="http://www.alvotech.com/role/IncomeTax">
        <link:definition>0000016 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShare" roleURI="http://www.alvotech.com/role/LossPerShare">
        <link:definition>0000017 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipment">
        <link:definition>0000018 - Disclosure - Property, Plant And Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.alvotech.com/role/Leases">
        <link:definition>0000019 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.alvotech.com/role/Goodwill">
        <link:definition>0000020 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleassets" roleURI="http://www.alvotech.com/role/OtherIntangibleassets">
        <link:definition>0000021 - Disclosure - Other Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalents" roleURI="http://www.alvotech.com/role/CashAndCashEquivalents">
        <link:definition>0000022 - Disclosure - Cash And Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.alvotech.com/role/Inventories">
        <link:definition>0000023 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentAssets" roleURI="http://www.alvotech.com/role/OtherCurrentAssets">
        <link:definition>0000024 - Disclosure - Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.alvotech.com/role/ShareCapital">
        <link:definition>0000025 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Otherreserves" roleURI="http://www.alvotech.com/role/Otherreserves">
        <link:definition>0000026 - Disclosure - Other reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.alvotech.com/role/Borrowings">
        <link:definition>0000027 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlans" roleURI="http://www.alvotech.com/role/LongTermIncentivePlans">
        <link:definition>0000028 - Disclosure - Long-Term Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.alvotech.com/role/ShareBasedPayments">
        <link:definition>0000029 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.alvotech.com/role/Litigation">
        <link:definition>0000030 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.alvotech.com/role/RelatedParties">
        <link:definition>0000031 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilities" roleURI="http://www.alvotech.com/role/OtherCurrentLiabilities">
        <link:definition>0000032 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestsInJointVentures" roleURI="http://www.alvotech.com/role/InterestsInJointVentures">
        <link:definition>0000033 - Disclosure - Interests In Joint Ventures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.alvotech.com/role/FinancialInstruments">
        <link:definition>0000034 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.alvotech.com/role/SupplementalCashFlowInformation">
        <link:definition>0000035 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.alvotech.com/role/SubsequentEvents">
        <link:definition>0000036 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary Of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralinformationTables" roleURI="http://www.alvotech.com/role/GeneralinformationTables">
        <link:definition>9954472 - Disclosure - General information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTable" roleURI="http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesTable">
        <link:definition>9954473 - Disclosure - Summary Of Significant Accounting Policies (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.alvotech.com/role/SegmentReportingTables">
        <link:definition>9954474 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.alvotech.com/role/RevenueTables">
        <link:definition>9954475 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SalariesAndOtherEmployeeExpensesTables" roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesTables">
        <link:definition>9954476 - Disclosure - Salaries And Other Employee Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinanceIncomeAndFinanceCostsTables" roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsTables">
        <link:definition>9954477 - Disclosure - Finance Income And Finance Costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DepreciationAmortizationAndImpairmentTables" roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentTables">
        <link:definition>9954478 - Disclosure - Depreciation, Amortization And Impairment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditFeesTables" roleURI="http://www.alvotech.com/role/AuditFeesTables">
        <link:definition>9954479 - Disclosure - Audit Fees (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxTables" roleURI="http://www.alvotech.com/role/IncomeTaxTables">
        <link:definition>9954480 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareTables" roleURI="http://www.alvotech.com/role/LossPerShareTables">
        <link:definition>9954481 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>9954482 - Disclosure - Property, Plant And Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.alvotech.com/role/LeasesTables">
        <link:definition>9954483 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.alvotech.com/role/GoodwillTables">
        <link:definition>9954484 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleassetsTables" roleURI="http://www.alvotech.com/role/OtherIntangibleassetsTables">
        <link:definition>9954485 - Disclosure - Other Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsTables" roleURI="http://www.alvotech.com/role/CashAndCashEquivalentsTables">
        <link:definition>9954486 - Disclosure - Cash And Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.alvotech.com/role/InventoriesTables">
        <link:definition>9954487 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentAssetsTables" roleURI="http://www.alvotech.com/role/OtherCurrentAssetsTables">
        <link:definition>9954488 - Disclosure - Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.alvotech.com/role/ShareCapitalTables">
        <link:definition>9954489 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherreservesTables" roleURI="http://www.alvotech.com/role/OtherreservesTables">
        <link:definition>9954490 - Disclosure - Other reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.alvotech.com/role/BorrowingsTables">
        <link:definition>9954491 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansTables" roleURI="http://www.alvotech.com/role/LongTermIncentivePlansTables">
        <link:definition>9954492 - Disclosure - Long-Term Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.alvotech.com/role/ShareBasedPaymentsTables">
        <link:definition>9954493 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesTables" roleURI="http://www.alvotech.com/role/RelatedPartiesTables">
        <link:definition>9954494 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilitiesTables" roleURI="http://www.alvotech.com/role/OtherCurrentLiabilitiesTables">
        <link:definition>9954495 - Disclosure - Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestsInJointVenturesTables" roleURI="http://www.alvotech.com/role/InterestsInJointVenturesTables">
        <link:definition>9954496 - Disclosure - Interests In Joint Ventures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.alvotech.com/role/FinancialInstrumentsTables">
        <link:definition>9954497 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.alvotech.com/role/SupplementalCashFlowInformationTables">
        <link:definition>9954498 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralinformationAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails">
        <link:definition>9954499 - Disclosure - General information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails" roleURI="http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails">
        <link:definition>9954500 - Disclosure - General Information - Schedule of fair value of shares issued and non-cash share listing expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails" roleURI="http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails">
        <link:definition>9954501 - Disclosure - General Information - Disclosure of Subsidiaries and Joint Ventures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954502 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails" roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails">
        <link:definition>9954503 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails" roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails">
        <link:definition>9954504 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails" roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails">
        <link:definition>9954505 - Disclosure - Segment Reporting - Summary Of Detailed Information About Revenue From Customers Based On Geographical Market (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails" roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails">
        <link:definition>9954506 - Disclosure - Segment Reporting - Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails" roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails">
        <link:definition>9954507 - Disclosure - Segment Reporting - Summary Of Detailed Information About Revenue From Transactions With Individual Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails" roleURI="http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails">
        <link:definition>9954508 - Disclosure - Revenue - Summary Of The Groups' Revenue From Contracts With Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails" roleURI="http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails">
        <link:definition>9954509 - Disclosure - Revenue - Summary Of Reconciliation Of Contract Assets And Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalinformationDetails" roleURI="http://www.alvotech.com/role/RevenueAdditionalinformationDetails">
        <link:definition>9954510 - Disclosure - Revenue - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SalariesAndOtherEmployeeExpensesAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesAdditionalInformationDetails">
        <link:definition>9954511 - Disclosure - Salaries And Other Employee Expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails" roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails">
        <link:definition>9954512 - Disclosure - Salaries And Other Employee Expenses - Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails" roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails">
        <link:definition>9954513 - Disclosure - Salaries And Other Employee Expenses - Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails" roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails">
        <link:definition>9954514 - Disclosure - Finance Income And Finance Costs - Summary Of Detailed Information About Finance Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails" roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails">
        <link:definition>9954515 - Disclosure - Finance Income And Finance Costs - Summary Of Detailed Information About Finance Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails" roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails">
        <link:definition>9954516 - Disclosure - Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails">
        <link:definition>9954517 - Disclosure - Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails" roleURI="http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails">
        <link:definition>9954518 - Disclosure - Audit Fees - Summary Of Detailed Information About Audit Fees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails">
        <link:definition>9954519 - Disclosure - Income Tax - Schedule Of Taxation Recognized In The Consolidated Statements Of Profit Or Loss And Other Comprehensive Income Or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails">
        <link:definition>9954520 - Disclosure - Income Tax - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails" roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails">
        <link:definition>9954521 - Disclosure - Income Tax - Schedule Of The Reconciling Items Between The Statutory Rate And The Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails" roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails">
        <link:definition>9954522 - Disclosure - Income Tax - Schedule Of The Movement In Net Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails" roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails">
        <link:definition>9954523 - Disclosure - Income Tax - Schedule Of Deferred Tax Recognized In The Consolidated Statements Of Financial Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails" roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails">
        <link:definition>9954524 - Disclosure - Income Tax - Schedule Of Expiration Of Unused Tax Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/LossPerShareAdditionalInformationDetails">
        <link:definition>9954525 - Disclosure - Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareSummaryofBasicandDilutedLossPerShareDetails" roleURI="http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails">
        <link:definition>9954526 - Disclosure - Loss Per Share - Summary of Basic and Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails">
        <link:definition>9954527 - Disclosure - Property, Plant And Equipment - Summary Of Property, Plant And Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails">
        <link:definition>9954528 - Disclosure - Property, Plant And Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails" roleURI="http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails">
        <link:definition>9954529 - Disclosure - Leases - Summary of Leases Assets About Right-Of-Use Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9954530 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofClassesofRightOfUseAssetsDetails" roleURI="http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails">
        <link:definition>9954531 - Disclosure - Leases - Summary of Classes of Right-Of-Use Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofLeaseLiabilitiesDetails" roleURI="http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails">
        <link:definition>9954532 - Disclosure - Leases - Summary of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryOfLeaseCostDetails" roleURI="http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails">
        <link:definition>9954533 - Disclosure - Leases - Summary Of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails" roleURI="http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails">
        <link:definition>9954534 - Disclosure - Leases - Summary of Maturity Analysis For Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillSummaryofGoodwillDetails" roleURI="http://www.alvotech.com/role/GoodwillSummaryofGoodwillDetails">
        <link:definition>9954535 - Disclosure - Goodwill - Summary of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/GoodwillAdditionalInformationDetails">
        <link:definition>9954536 - Disclosure - Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails" roleURI="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails">
        <link:definition>9954537 - Disclosure - Other Intangible assets - Summary of Detailed Information About Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails" roleURI="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails">
        <link:definition>9954538 - Disclosure - Other Intangible assets - Summary of Impairment Loss and Reversal of Impairment Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleassetsAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails">
        <link:definition>9954539 - Disclosure - Other Intangible assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails" roleURI="http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails">
        <link:definition>9954540 - Disclosure - Cash And Cash Equivalents - Summary of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsSummaryofRestrictedCashDetails" roleURI="http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails">
        <link:definition>9954541 - Disclosure - Cash And Cash Equivalents - Summary of Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesSummaryofInventoriesDetails" roleURI="http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails">
        <link:definition>9954542 - Disclosure - Inventories - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/InventoriesAdditionalInformationDetails">
        <link:definition>9954543 - Disclosure - Inventories - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails" roleURI="http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails">
        <link:definition>9954544 - Disclosure - Other Current Assets - Summary of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentAssetsAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails">
        <link:definition>9954545 - Disclosure - Other Current Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalAdditionalinformationDetails" roleURI="http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails">
        <link:definition>9954546 - Disclosure - Share Capital - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryofShareCapitalandSharePremiumDetails" roleURI="http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails">
        <link:definition>9954547 - Disclosure - Share Capital - Summary of Share Capital and Share Premium (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails" roleURI="http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails">
        <link:definition>9954548 - Disclosure - Share Capital - Summary of Movements in Ordinary Shares, Share Capital and Share Premium (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherreservesDetails" roleURI="http://www.alvotech.com/role/OtherreservesDetails">
        <link:definition>9954549 - Disclosure - Other reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails" roleURI="http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails">
        <link:definition>9954550 - Disclosure - Borrowings - Summary of consolidated statements of financial position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails">
        <link:definition>9954551 - Disclosure - Borrowings - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails" roleURI="http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails">
        <link:definition>9954552 - Disclosure - Borrowings - Summary of movements in the group's outstanding borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails" roleURI="http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails">
        <link:definition>9954553 - Disclosure - Borrowings - Summary of non-cash changes in the group&#8217;s outstanding borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails" roleURI="http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails">
        <link:definition>9954554 - Disclosure - Borrowings - Schedule of maturities of outstanding borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails">
        <link:definition>9954555 - Disclosure - Long-Term Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails" roleURI="http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails">
        <link:definition>9954556 - Disclosure - Long-Term Incentive Plans - Schedule Of Movements In The Group's Employee Incentive Plan Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofMovementsinRSUsDetails" roleURI="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails">
        <link:definition>9954557 - Disclosure - Share-Based Payments - Summary of Movements in RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails">
        <link:definition>9954558 - Disclosure - Share-Based Payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails" roleURI="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails">
        <link:definition>9954559 - Disclosure - Share-Based Payments - Summary of share-based payment expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/LitigationAdditionalInformationDetails">
        <link:definition>9954560 - Disclosure - Litigation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesAdditionalinformationDetails" roleURI="http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails">
        <link:definition>9954561 - Disclosure - Related Parties - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesSummaryofRelatedPartyTransactionsDetails" roleURI="http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails">
        <link:definition>9954562 - Disclosure - Related Parties - Summary of Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesScheduleofRelatedPartyTransactionsDetails" roleURI="http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails">
        <link:definition>9954563 - Disclosure - Related Parties - Schedule of Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails" roleURI="http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails">
        <link:definition>9954564 - Disclosure - Related Parties - Schedule of Information About Board of Directors Remuneration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails" roleURI="http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails">
        <link:definition>9954565 - Disclosure - Other Current Liabilities - Schedule of Composition of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails" roleURI="http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails">
        <link:definition>9954566 - Disclosure - Interests In Joint Ventures - Schedule of Information About Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails" roleURI="http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails">
        <link:definition>9954567 - Disclosure - Interests In Joint Ventures - Schedule of Changes in Groups Investment in a Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestsInJointVenturesAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails">
        <link:definition>9954568 - Disclosure - Interests In Joint Ventures - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails">
        <link:definition>9954569 - Disclosure - Financial Instruments - Summary of Financial Assets Measured at Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofFinancialLiabilitiesDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails">
        <link:definition>9954570 - Disclosure - Financial Instruments - Summary of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails">
        <link:definition>9954571 - Disclosure - Financial Instruments - Summary of Material Differences Between the Fair Value and Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails">
        <link:definition>9954572 - Disclosure - Financial Instruments - Summary of Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails">
        <link:definition>9954573 - Disclosure - Financial Instruments - Schedule of Provides a Reconciliation of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails">
        <link:definition>9954574 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofAssumptionsandInputsDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails">
        <link:definition>9954575 - Disclosure - Financial Instruments - Summary of Assumptions and Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails">
        <link:definition>9954576 - Disclosure - Financial Instruments - Summary of Interest Rate Sensitivity Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails">
        <link:definition>9954577 - Disclosure - Financial Instruments - Summary of Impact on the Groups Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails">
        <link:definition>9954578 - Disclosure - Financial Instruments - Summary of Groups Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails">
        <link:definition>9954579 - Disclosure - Financial Instruments - Summary of Analysis Assumes that all Other Variables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails">
        <link:definition>9954580 - Disclosure - Financial Instruments - Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails" roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails">
        <link:definition>9954581 - Disclosure - Financial Instruments - Summary of Contractual Maturities of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails" roleURI="http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails">
        <link:definition>9954582 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>9954583 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="alvo_EarnoutWarrantsMember" abstract="true" name="EarnoutWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AdjustmentsForSharelistingExpense" abstract="false" name="AdjustmentsForSharelistingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_TaxYearsDomain" abstract="true" name="TaxYearsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_EventDomain" abstract="true" name="EventDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_EventAxis" abstract="true" name="EventAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AggregateBorrowingsIndebtedness" abstract="false" name="AggregateBorrowingsIndebtedness" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AlvogenFinanceB.VMember" abstract="true" name="AlvogenFinanceB.VMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IncreaseDecreaseThroughCapitalReorganization" abstract="false" name="IncreaseDecreaseThroughCapitalReorganization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CashAndCashEquivalentsRollForward" abstract="true" name="CashAndCashEquivalentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AggregatePeriodForDeterminingTheSharePrice" abstract="false" name="AggregatePeriodForDeterminingTheSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_ComponentOfBondsPayableAxis" abstract="true" name="ComponentOfBondsPayableAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DebtInstrumentIncreaseAccruedInterests" abstract="false" name="DebtInstrumentIncreaseAccruedInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" abstract="false" name="AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AztiqMember" abstract="true" name="AztiqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" abstract="false" name="DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_SaleOfStockIssuePricePerShare" abstract="false" name="SaleOfStockIssuePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_OrdinarySharesValueIssuedConversionOfBorrowings" abstract="false" name="OrdinarySharesValueIssuedConversionOfBorrowings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_TaxRateEffectOfNonrecognitionOfTaxLosses" abstract="false" name="TaxRateEffectOfNonrecognitionOfTaxLosses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="alvo_IssueOfOacbEarnOutShares" abstract="false" name="IssueOfOacbEarnOutShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" abstract="false" name="DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AgreementOneAxis" abstract="true" name="AgreementOneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_TaxYearsAxis" abstract="true" name="TaxYearsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DerecognitionDueToAssetsAcquisition" abstract="false" name="DerecognitionDueToAssetsAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AztiqFacilityLoansMember" abstract="true" name="AztiqFacilityLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AsiaAndOtherMember" abstract="true" name="AsiaAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ConversionPriceOfBondsMember" abstract="true" name="ConversionPriceOfBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfForeignExchangeRateTable" abstract="true" name="DisclosureInTabularFormOfForeignExchangeRateTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AmortizationAndImpairmentOfIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid" abstract="false" name="CapitalExpenditureIntangibleAssetsIncurredButNotPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_FurnitureFixturesAndLeaseholdImprovementsMember" abstract="true" name="FurnitureFixturesAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares" abstract="false" name="IssueOfSharesOnSettlementOfShareAppreciationRightsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_AdditionalBondsIssuanceAxis" abstract="true" name="AdditionalBondsIssuanceAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_GrossProceedsFromThePipeFinancing" abstract="false" name="GrossProceedsFromThePipeFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_OtherCurrentLiability" abstract="false" name="OtherCurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_StockPriceMember" abstract="true" name="StockPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment" abstract="false" name="ContractAssetsLiabilitiesForeignCurrencyAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities" abstract="false" name="RepaymentsOfPrincipalPortionOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ProceedsFromTheCapitalReorganization" abstract="false" name="ProceedsFromTheCapitalReorganization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DetailsDomain" abstract="true" name="DetailsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_GrossPipeFinancingFeesPaid" abstract="false" name="GrossPipeFinancingFeesPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities" abstract="false" name="ProceedsFromBorrowingClassifiedAsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CapitalContributionValue" abstract="false" name="CapitalContributionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" abstract="false" name="FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NumberOfTranches" abstract="false" name="NumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alvo_AlvogenFacilityAndAztiqFacilityMember" abstract="true" name="AlvogenFacilityAndAztiqFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants" abstract="false" name="StockSharesIssuedDuringThePeriodExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_RecognitionOfDerivativeLiabilitiesAtFairValue" abstract="false" name="RecognitionOfDerivativeLiabilitiesAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ComponentOfBondsPayableDomain" abstract="true" name="ComponentOfBondsPayableDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" abstract="false" name="LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_FasteignafelagiSmundurHfMember" abstract="true" name="FasteignafelagiSmundurHfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_OtherCurrentAsset" abstract="false" name="OtherCurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_VestedEarnOutSharesMember" abstract="true" name="VestedEarnOutSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AztiqConvertibleBondMember" abstract="true" name="AztiqConvertibleBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_StockExchangeDescriptionAxis" abstract="true" name="StockExchangeDescriptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ScheduleOfOtherReservesTableTextBlock" abstract="false" name="ScheduleOfOtherReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DisclosureOfIncomeTaxAbstract" abstract="true" name="DisclosureOfIncomeTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfGoodwillLineItems" abstract="true" name="DisclosureOfGoodwillLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems" abstract="true" name="DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems" abstract="true" name="DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_LossOnRemeasurementOfBonds" abstract="false" name="LossOnRemeasurementOfBonds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_LaterThanTwoYearsMember" abstract="true" name="LaterThanTwoYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ComponentOfDebtConvertedIntoEquityDomain" abstract="true" name="ComponentOfDebtConvertedIntoEquityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable" abstract="true" name="ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_OtherCurrentAssetsLineItems" abstract="true" name="OtherCurrentAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_StockExchangeDescriptionDomain" abstract="true" name="StockExchangeDescriptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_PrivatePlacementsMember" abstract="true" name="PrivatePlacementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ConsentFeesToBondholdersMember" abstract="true" name="ConsentFeesToBondholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ClassOfStocksAxis" abstract="true" name="ClassOfStocksAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_EliminationOfPredecessorOrdinaryValue" abstract="false" name="EliminationOfPredecessorOrdinaryValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ArniHararsonMember" abstract="true" name="ArniHararsonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract" abstract="true" name="WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_SeniorBondWarrantsMember" abstract="true" name="SeniorBondWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" abstract="false" name="FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" abstract="false" name="ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_BcaFrameworkAgreementMember" abstract="true" name="BcaFrameworkAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfIncomeTaxTable" abstract="true" name="DisclosureOfIncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_AVT23Member" abstract="true" name="AVT23Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_TrancheAMember" abstract="true" name="TrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable" abstract="true" name="DisclosureInEntiretyOfSupplementalCashFlowInformationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward" abstract="true" name="NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_CompensationStatusAxis" abstract="true" name="CompensationStatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfGoodwillTable" abstract="true" name="DisclosureOfGoodwillTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_BusinessCombinationAndPipeFinancingMember" abstract="true" name="BusinessCombinationAndPipeFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ExchangeOfClassAOacbOrdinarySharesMember" abstract="true" name="ExchangeOfClassAOacbOrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_PaymentsForDebtIssueCost" abstract="false" name="PaymentsForDebtIssueCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NumberOfOperatingSegments1" abstract="false" name="NumberOfOperatingSegments1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_IncreaseInOutstandingBondsFairValue" abstract="false" name="IncreaseInOutstandingBondsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_LindaMcgoldrickMember" abstract="true" name="LindaMcgoldrickMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IncomeStatementsLocationAxis" abstract="true" name="IncomeStatementsLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_IssueOfPredecessorEarnOutShares" abstract="false" name="IssueOfPredecessorEarnOutShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AccruedInterestOnDebtExtinguished" abstract="false" name="AccruedInterestOnDebtExtinguished" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable" abstract="true" name="DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems" abstract="true" name="ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_VariableRatesDomain" abstract="true" name="VariableRatesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CompensationWaivedMember" abstract="true" name="CompensationWaivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" abstract="false" name="DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DecreaseThroughDerecognitionRightOfUseAssets" abstract="false" name="DecreaseThroughDerecognitionRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_PredecessorEarnoutSharesMember" abstract="true" name="PredecessorEarnoutSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenEhf.SisterCompanyMember" abstract="true" name="AlvogenEhf.SisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclousreOfGoodwillAbstract" abstract="true" name="DisclousreOfGoodwillAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AccretionderecognitionOfBorrowingsDiscount" abstract="false" name="AccretionderecognitionOfBorrowingsDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CommonStockValueSubscriptions" abstract="false" name="CommonStockValueSubscriptions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DevelopmentAndOtherServiceRevenueMember" abstract="true" name="DevelopmentAndOtherServiceRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ExchangeOfPredecessorOrdinarySharesMember" abstract="true" name="ExchangeOfPredecessorOrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingsRepurchasedFaceAmount" abstract="false" name="BorrowingsRepurchasedFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_LotusPharmaceuticalCo.LtdMember" abstract="true" name="LotusPharmaceuticalCo.LtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ClassOfWarrantsOrRightsExercisePricePerShare" abstract="false" name="ClassOfWarrantsOrRightsExercisePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_EarnoutSharesMember" abstract="true" name="EarnoutSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_OacbWarrantsMember" abstract="true" name="OacbWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ClassesOfCommonStockMember" abstract="true" name="ClassesOfCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" abstract="false" name="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_AmortizationOfDeferredDebtIssueCosts" abstract="false" name="AmortizationOfDeferredDebtIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AlvotechMancoEhfMember" abstract="true" name="AlvotechMancoEhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables" abstract="false" name="ContractAssetsAdditionsAmountsTransferredToTradeReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable" abstract="true" name="DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_CurrentAccruedInterest" abstract="false" name="CurrentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfAuditFeesAbstract" abstract="true" name="DisclosureOfAuditFeesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_RevenueFromContractsWithCustomersAbstract" abstract="true" name="RevenueFromContractsWithCustomersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AssetAcquisitionsConsiderationTransferred" abstract="false" name="AssetAcquisitionsConsiderationTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_IssuedToTheExistingAndANewBondHolderMember" abstract="true" name="IssuedToTheExistingAndANewBondHolderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NonCashChangesInOtherNonCashMovements" abstract="false" name="NonCashChangesInOtherNonCashMovements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_LoansToRelatedParties" abstract="false" name="LoansToRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_LeaseLiabilitiesRollForward" abstract="true" name="LeaseLiabilitiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember" abstract="true" name="TwoThousandTwentyFourToTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember" abstract="true" name="AlvotechAndCchnBiopharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LeaseFacilityDomain" abstract="true" name="LeaseFacilityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ContractLiabilityCustomerPrepayments" abstract="false" name="ContractLiabilityCustomerPrepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AztiqFjrfestingarEhfMember" abstract="true" name="AztiqFjrfestingarEhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NetCompensationExpenseMember" abstract="true" name="NetCompensationExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FlokiFasteignirEhfMember" abstract="true" name="FlokiFasteignirEhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities" abstract="false" name="RepaymentsOfBorrowingClassifiedAsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_VestingPercentageOfShares" abstract="false" name="VestingPercentageOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="alvo_AlvogenMaltaSh.ServicesSisterCompanyMember" abstract="true" name="AlvogenMaltaSh.ServicesSisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CostOfProductRevenueMember" abstract="true" name="CostOfProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IntangibleAssetsWithFiniteLivedMember" abstract="true" name="IntangibleAssetsWithFiniteLivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ConvertibleLoanNotesMember" abstract="true" name="ConvertibleLoanNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ClassOfStockAxis" abstract="true" name="ClassOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" abstract="false" name="IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_LossFromExtinguishmentOfLeaseLiabilities" abstract="false" name="LossFromExtinguishmentOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfShareBasedPaymentArrangementsAbstract" abstract="true" name="DisclosureOfShareBasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable" abstract="true" name="DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue" abstract="false" name="IssueOfSharesOnSettlementOfRelatedPartyLoansValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_TrancheOfSeniorBondWarrantsPercentage" abstract="false" name="TrancheOfSeniorBondWarrantsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="alvo_BorrowingsRepurchaseAmount" abstract="false" name="BorrowingsRepurchaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfAuditFeesExplanatoryTextBlock" abstract="false" name="DisclosureOfAuditFeesExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_TrancheAConversionFeatureMember" abstract="true" name="TrancheAConversionFeatureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NonCashChangesInOtherChanges" abstract="false" name="NonCashChangesInOtherChanges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_IssueOfSharesCapitalRollForward" abstract="true" name="IssueOfSharesCapitalRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_SubscriptionAgreementsMember" abstract="true" name="SubscriptionAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_GeneralAndAdministrativeExpensesMember" abstract="true" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenInc.SisterCompanyMember" abstract="true" name="AlvogenInc.SisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenMember" abstract="true" name="AlvogenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_TrancheBMember" abstract="true" name="TrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" abstract="false" name="DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_InterestComponentMember" abstract="true" name="InterestComponentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BeforeTheTermsOfTheSecondAmendmentMember" abstract="true" name="BeforeTheTermsOfTheSecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems" abstract="true" name="ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_NotLaterThanFiveYearsMember" abstract="true" name="NotLaterThanFiveYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AgreementOneDomain" abstract="true" name="AgreementOneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingsRollForward" abstract="true" name="BorrowingsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfNewAccountingStandardsAbstract" abstract="true" name="DisclosureOfNewAccountingStandardsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_LitigationAbstract" abstract="true" name="LitigationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_IntangibleAssetsOtherThanGoodwillRollForward" abstract="true" name="IntangibleAssetsOtherThanGoodwillRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="DisclosureOfSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DetailsAxis" abstract="true" name="DetailsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" abstract="false" name="DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_SharesAuthorizedValue" abstract="false" name="SharesAuthorizedValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_Remaining15LeaseFacilitiesMember" abstract="true" name="Remaining15LeaseFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_MaturedOnMarch2029Member" abstract="true" name="MaturedOnMarch2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DeferredTaxAbstract" abstract="true" name="DeferredTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ClassBCommonStockMember" abstract="true" name="ClassBCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AssetAcquisitionConsiderationTransferredSettlements" abstract="false" name="AssetAcquisitionConsiderationTransferredSettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_PrincipalComponentMember" abstract="true" name="PrincipalComponentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems" abstract="true" name="DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_StockIssuedUnderPipeFinancingShares" abstract="false" name="StockIssuedUnderPipeFinancingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_RecognitionOfNewBorrowingsDiscount" abstract="false" name="RecognitionOfNewBorrowingsDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_FlokiArtEhf.Member" abstract="true" name="FlokiArtEhf.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AssetAcquisitionConsiderationTransferredConvertibleBond" abstract="false" name="AssetAcquisitionConsiderationTransferredConvertibleBond" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ClassAAndClassBOrdinarySharesMember" abstract="true" name="ClassAAndClassBOrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_GeneralInformationAboutFinancialStatementsLineItems" abstract="true" name="GeneralInformationAboutFinancialStatementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" abstract="false" name="NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" abstract="false" name="GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NumberOfLeaseAgreements" abstract="false" name="NumberOfLeaseAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alvo_ContractualCapitalCommitmentContingentLiability" abstract="false" name="ContractualCapitalCommitmentContingentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_VestedEarnoutSharesIssued" abstract="false" name="VestedEarnoutSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_VariableRatesAxis" abstract="true" name="VariableRatesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_FleetMember" abstract="true" name="FleetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ExcerciseOfWarrantsMember" abstract="true" name="ExcerciseOfWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenPharmaPvtLtdSisterCompanyMember" abstract="true" name="AlvogenPharmaPvtLtdSisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_MaturedOnAugust2029Member" abstract="true" name="MaturedOnAugust2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CurrentEmployeeIncentivePlan" abstract="false" name="CurrentEmployeeIncentivePlan" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ConsentingFee" abstract="false" name="ConsentingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NumberOfLeasesTerminated" abstract="false" name="NumberOfLeasesTerminated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alvo_LeaseCostRecognizedInProfitAndLoss" abstract="false" name="LeaseCostRecognizedInProfitAndLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ConvertibleBondMember" abstract="true" name="ConvertibleBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ContractAssetMember" abstract="true" name="ContractAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IssueOfEquityShares" abstract="false" name="IssueOfEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_IssueOfOacbEarnOutSharesValue" abstract="false" name="IssueOfOacbEarnOutSharesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DerivativeFinancialLiabilitiesRollForward" abstract="true" name="DerivativeFinancialLiabilitiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AmortizationMember" abstract="true" name="AmortizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract" abstract="true" name="DisclosureOfDepreciationAmortizationAndImapirmentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder" abstract="false" name="MaximumPercentageOfOwnershipInterestHeldByEachShareholder" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="alvo_LoanAgreementMember" abstract="true" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AssetAcquisitionConsiderationTransferredLoansAssumed" abstract="false" name="AssetAcquisitionConsiderationTransferredLoansAssumed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ContractualCapitalCommitmentsTerm" abstract="false" name="ContractualCapitalCommitmentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_IncreaseInTheFaceValueOfTheBondsMember" abstract="true" name="IncreaseInTheFaceValueOfTheBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_VestedEarnoutSharesValue" abstract="false" name="VestedEarnoutSharesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CarryingValueOfDebtExtinguished" abstract="false" name="CarryingValueOfDebtExtinguished" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember" abstract="true" name="AlvogenLuxHoldingsS.aR.lSisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" abstract="false" name="StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems" abstract="true" name="DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_LeaseLiabilitiesForeignCurrencyAdjustment" abstract="false" name="LeaseLiabilitiesForeignCurrencyAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable" abstract="true" name="DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_CommonStockHeldBySubsidiaries" abstract="false" name="CommonStockHeldBySubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_PrincipalAndAccruedInterestComponent.Member" abstract="true" name="PrincipalAndAccruedInterestComponent.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LossOnExtinguishmentOfTheLeaseLiability" abstract="false" name="LossOnExtinguishmentOfTheLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ComponentOfDebtConvertedIntoEquityAxis" abstract="true" name="ComponentOfDebtConvertedIntoEquityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_OtherExecutiveTeamMember" abstract="true" name="OtherExecutiveTeamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" abstract="false" name="IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AlvotechHfMember" abstract="true" name="AlvotechHfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DerecognitionPrepaidDevelopmentCosts" abstract="false" name="DerecognitionPrepaidDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_FlokiHoldingsS.aR.lMember" abstract="true" name="FlokiHoldingsS.aR.lMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_TranslationDifferenceRightOfUseAssets" abstract="false" name="TranslationDifferenceRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CapitalReorganizationSharesIssued" abstract="false" name="CapitalReorganizationSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" abstract="false" name="DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable" abstract="true" name="DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_PremiumComponentMember" abstract="true" name="PremiumComponentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" abstract="false" name="AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CustomerDMember" abstract="true" name="CustomerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IssueOfEquities" abstract="false" name="IssueOfEquities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ExtensionPremiumToBondHolders" abstract="false" name="ExtensionPremiumToBondHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable" abstract="true" name="DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_LaterPeriodMember" abstract="true" name="LaterPeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ContingentlyIssuablePennyWarrantsMember" abstract="true" name="ContingentlyIssuablePennyWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_PercentageChangeInForeignExchangeRate" abstract="false" name="PercentageChangeInForeignExchangeRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="alvo_HumiraMember" abstract="true" name="HumiraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenUKSisterCompanyMember" abstract="true" name="AlvogenUKSisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" abstract="false" name="DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ClassOfStock1Domain" abstract="true" name="ClassOfStock1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ATPHoldingEhf.Member" abstract="true" name="ATPHoldingEhf.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfCashAndCashEquivalentsTable" abstract="true" name="DisclosureOfCashAndCashEquivalentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AdalvoLimitedMember" abstract="true" name="AdalvoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract" abstract="true" name="DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember" abstract="true" name="ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable" abstract="true" name="ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_RecognitionOfDerivativeAsset" abstract="false" name="RecognitionOfDerivativeAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures" abstract="false" name="CommitmentsOfJointVenturePartnersInRelationToJointVentures" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AztiqFacilityMember" abstract="true" name="AztiqFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable" abstract="true" name="DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AlvotechBiosciencesIndiaPrivateLtdMember" abstract="true" name="AlvotechBiosciencesIndiaPrivateLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BondsIssuedAtFairValue" abstract="false" name="BondsIssuedAtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_Lambhagavegur7EhfMember" abstract="true" name="Lambhagavegur7EhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_Lambahagavegur7EhfMember" abstract="true" name="Lambahagavegur7EhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable" abstract="true" name="DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AdditionalExtensionPremiumToBondholders" abstract="false" name="AdditionalExtensionPremiumToBondholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_CapitalContributionSharesIssued" abstract="false" name="CapitalContributionSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_NumberOfConsecutiveTradingDays" abstract="false" name="NumberOfConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_IssuedCapitalAndSharePremiumMember" abstract="true" name="IssuedCapitalAndSharePremiumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_MaturedOnApril2024Member" abstract="true" name="MaturedOnApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" abstract="false" name="WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" abstract="false" name="DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_OtherNoncurrentAsset" abstract="false" name="OtherNoncurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" abstract="false" name="WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_GeneralAndAdministrativeMember" abstract="true" name="GeneralAndAdministrativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NetCashProceedsFromTheTransaction" abstract="false" name="NetCashProceedsFromTheTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_CommonStockSubscriptionPricePerShare" abstract="false" name="CommonStockSubscriptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_FairValueOfSharesIssuedMarketPricePerShare" abstract="false" name="FairValueOfSharesIssuedMarketPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_DisclosureOfFinanceIncomeAbstract" abstract="true" name="DisclosureOfFinanceIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_OacbEarnoutSharesMember" abstract="true" name="OacbEarnoutSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows" abstract="false" name="FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_TrancheAConvertibleDebtMember" abstract="true" name="TrancheAConvertibleDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DeferredTaxLiabilityAssetRollForward" abstract="true" name="DeferredTaxLiabilityAssetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_NumberOfLoans" abstract="false" name="NumberOfLoans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses" abstract="false" name="CurrentAccruedSalaryAndSalaryRelatedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_FasteignafelagidEyjolfurHf.Member" abstract="true" name="FasteignafelagidEyjolfurHf.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingsRedemptionConversionPrice" abstract="false" name="BorrowingsRedemptionConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_FacilityLoansMember" abstract="true" name="FacilityLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingsTrancheDomain" abstract="true" name="BorrowingsTrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ThresholdDaysForDeterminingTheSharePrice" abstract="false" name="ThresholdDaysForDeterminingTheSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_VariableInterestRateFinancialLiabilitiesMember" abstract="true" name="VariableInterestRateFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AgreementAxis" abstract="true" name="AgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_CurrentTaxAbstract" abstract="true" name="CurrentTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_GeneralInformationAboutFinancialStatementsTable" abstract="true" name="GeneralInformationAboutFinancialStatementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_RestrictedCashMember" abstract="true" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FinanceIncomeMember" abstract="true" name="FinanceIncomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_MaturityMonthAndYearAxis" abstract="true" name="MaturityMonthAndYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_TwoLeaseFacilitiesMember" abstract="true" name="TwoLeaseFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LiabilityAssetOfDefinedBenefitPlansRollForward" abstract="true" name="LiabilityAssetOfDefinedBenefitPlansRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ShareAppreciationRightsMember" abstract="true" name="ShareAppreciationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IssuanceOfOrdinaryShares" abstract="false" name="IssuanceOfOrdinaryShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_AlvotechUkLtdMember" abstract="true" name="AlvotechUkLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ProceedsReceivableFromConvertibleBonds" abstract="false" name="ProceedsReceivableFromConvertibleBonds" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_BorrowingsTrancheOneMember" abstract="true" name="BorrowingsTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond" abstract="false" name="AdditionOfTheLoanFacilitiesThroughConvertibleBond" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NonInterestBearingFinancialAssetsMember" abstract="true" name="NonInterestBearingFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingsConversionFeatureFairValue" abstract="false" name="BorrowingsConversionFeatureFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" abstract="false" name="DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ProceedsFromBorrowingsNetOfTransactionCosts" abstract="false" name="ProceedsFromBorrowingsNetOfTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" abstract="false" name="WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_NumberOfLeaseAgreementsEnteredInto" abstract="false" name="NumberOfLeaseAgreementsEnteredInto" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alvo_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_VariableInterestBearingFinancialAssetsMember" abstract="true" name="VariableInterestBearingFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ProductRevenueMember" abstract="true" name="ProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LeaseLiabilitiesTranslationDifference" abstract="false" name="LeaseLiabilitiesTranslationDifference" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AlvogenLoanMember" abstract="true" name="AlvogenLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NumberOfLitigations" abstract="false" name="NumberOfLitigations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alvo_LeaseFacilityAxis" abstract="true" name="LeaseFacilityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DerecognitionIntangibleAssetsOtherThanGoodwill" abstract="false" name="DerecognitionIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfCashAndCashEquivalentsLineItems" abstract="true" name="DisclosureOfCashAndCashEquivalentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_InvestmentsAccountedForUsingEquityMethodRollForward" abstract="true" name="InvestmentsAccountedForUsingEquityMethodRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_IncreaseThroughPipeFinancingShares" abstract="false" name="IncreaseThroughPipeFinancingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_FacilityMember" abstract="true" name="FacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems" abstract="true" name="DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_MaturityMonthAndYearDomain" abstract="true" name="MaturityMonthAndYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ConversionPrice" abstract="false" name="ConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="alvo_PennyWarrantsMember" abstract="true" name="PennyWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AreaOfProperty" abstract="false" name="AreaOfProperty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="alvo_CashEquivalentsAndCashMember" abstract="true" name="CashEquivalentsAndCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NonCashIssuanceOfConvertibleBond" abstract="false" name="NonCashIssuanceOfConvertibleBond" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" abstract="false" name="TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_AtpHoldingsEhfMember" abstract="true" name="AtpHoldingsEhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenLoanWarrantsMember" abstract="true" name="AlvogenLoanWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AdditionalBondsIssuanceDomain" abstract="true" name="AdditionalBondsIssuanceDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember" abstract="true" name="AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AssetAcquisitionConsiderationLoansAssumed" abstract="false" name="AssetAcquisitionConsiderationLoansAssumed" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_FasteignaflagiEyjlfurhfMember" abstract="true" name="FasteignaflagiEyjlfurhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_SeniorBondInterestRateFeatureMember" abstract="true" name="SeniorBondInterestRateFeatureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ArionBankiHfMember" abstract="true" name="ArionBankiHfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_PropertyPlantAndEquipmentRollForward" abstract="true" name="PropertyPlantAndEquipmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ExtinguishmentOfBorrowingsAccruedInterest" abstract="false" name="ExtinguishmentOfBorrowingsAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AmortizationOfDeferredDebtIssuanceCosts" abstract="false" name="AmortizationOfDeferredDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_EliminationOfPredecessorOrdinaryShares" abstract="false" name="EliminationOfPredecessorOrdinaryShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" abstract="false" name="AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_BorrowingsTrancheTwoMember" abstract="true" name="BorrowingsTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LoansFromRelatedPartyConvertedToEquity" abstract="false" name="LoansFromRelatedPartyConvertedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AlvotechUsaIncMember" abstract="true" name="AlvotechUsaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DividendYieldMember" abstract="true" name="DividendYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FinalMaturityInDecember2029Member" abstract="true" name="FinalMaturityInDecember2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable" abstract="true" name="DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_OtherShareBasedPaymentsMember" abstract="true" name="OtherShareBasedPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IntellectualPropertyRightsMember" abstract="true" name="IntellectualPropertyRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FlokiInvestEhfMember" abstract="true" name="FlokiInvestEhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_TemporaryLabourExpense" abstract="false" name="TemporaryLabourExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" abstract="false" name="DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ThereafterMember" abstract="true" name="ThereafterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_FormerEmployeesMember" abstract="true" name="FormerEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingSharesIssuancePeriodForInterestDecrease" abstract="false" name="BorrowingSharesIssuancePeriodForInterestDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_AdjustmentsForIndexedLeasesRightOfUseAssets" abstract="false" name="AdjustmentsForIndexedLeasesRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems" abstract="true" name="DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AlvotechGermanyGmbhMember" abstract="true" name="AlvotechGermanyGmbhMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract" abstract="true" name="DisclosureOfSalariesAndOtherEmployeeExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfInventoriesTable" abstract="true" name="DisclosureOfInventoriesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_UsdSofrMember" abstract="true" name="UsdSofrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_LegalCost" abstract="false" name="LegalCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_FasteignafelagiEyjolfurEhfMember" abstract="true" name="FasteignafelagiEyjolfurEhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_RobertWessmanMember" abstract="true" name="RobertWessmanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LenderNameAxis" abstract="true" name="LenderNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_IssuedToANewBondHolderMember" abstract="true" name="IssuedToANewBondHolderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenSpainSlMember" abstract="true" name="AlvogenSpainSlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfIncomeTaxLineItems" abstract="true" name="DisclosureOfIncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AlvogenFacilityMember" abstract="true" name="AlvogenFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FinancialAssetsUndiscountedVariableInterestBearingLoansReceivable" abstract="false" name="FinancialAssetsUndiscountedVariableInterestBearingLoansReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AgreementDomain" abstract="true" name="AgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_KashivMember" abstract="true" name="KashivMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ClassACommonStockMember" abstract="true" name="ClassACommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember" abstract="true" name="AlvotechCchnBiopharmaceuticalCo.LtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue" abstract="false" name="IssueOfSharesOnSettlementOfShareAppreciationRightsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember" abstract="true" name="TwoThousandTwentySevenToTwoThousandTwentyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" abstract="false" name="DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_IncreaseThroughPipeFinancingValue" abstract="false" name="IncreaseThroughPipeFinancingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember" abstract="true" name="ConvertibleBondAgreementTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" abstract="false" name="DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_FlokiArtEhfMember" abstract="true" name="FlokiArtEhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenIcelandEhf.SisterCompanyMember" abstract="true" name="AlvogenIcelandEhf.SisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FasteignafelagiSmundurHf.SisterCompanyMember" abstract="true" name="FasteignafelagiSmundurHf.SisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_WeightedAverageRemainingLeaseTerm" abstract="false" name="WeightedAverageRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains" abstract="false" name="AdjustmentsForExtinguishmentOfLiabilityLossesGains" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_FinancialAssetsUndiscountedNonInterestBearingLoansReceivable" abstract="false" name="FinancialAssetsUndiscountedNonInterestBearingLoansReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable" abstract="true" name="DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability" abstract="false" name="ContractLiabilitiesAdditionsDerecognitionOfContractLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AztiqConversionFeatureMember" abstract="true" name="AztiqConversionFeatureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvotechSwissAgMember" abstract="true" name="AlvotechSwissAgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_MarkLevickCeoMember" abstract="true" name="MarkLevickCeoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NatureOfFeesDomain" abstract="true" name="NatureOfFeesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_RestrictedCashInConnectionWithAmendedBondAgreement" abstract="false" name="RestrictedCashInConnectionWithAmendedBondAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NoncurrentContractAssetsMaterializePeriod" abstract="false" name="NoncurrentContractAssetsMaterializePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_IncreaseDecreaseThroughPipeFinancing" abstract="false" name="IncreaseDecreaseThroughPipeFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DetailsOfFinanceIncomeAbstract" abstract="true" name="DetailsOfFinanceIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ClassAOacbOrdinarySharesMember" abstract="true" name="ClassAOacbOrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CurrentAccruedVacation" abstract="false" name="CurrentAccruedVacation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member" abstract="true" name="SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvotechHannoverGmbhMember" abstract="true" name="AlvotechHannoverGmbhMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember" abstract="true" name="AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable" abstract="true" name="DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_PaymentForContractualCommitment" abstract="false" name="PaymentForContractualCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NumberOfSeparateInstallments" abstract="false" name="NumberOfSeparateInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alvo_AztiqPharmaPartnersSarlMember" abstract="true" name="AztiqPharmaPartnersSarlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_April2023LeaseFacilityMember" abstract="true" name="April2023LeaseFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_RiskyYieldMember" abstract="true" name="RiskyYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CompensationStatusDomain" abstract="true" name="CompensationStatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ResearchAndDevelopmentExpensesMember" abstract="true" name="ResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ConvertibleOrdinarySharesMember" abstract="true" name="ConvertibleOrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_HRJAFEhfSisterCompanyMember" abstract="true" name="HRJAFEhfSisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ReclassificationRightOfUseAssets" abstract="false" name="ReclassificationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" abstract="false" name="ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ExtinguishmentOfBorrowings" abstract="false" name="ExtinguishmentOfBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_TrancheDomain" abstract="true" name="TrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_RightOfUsedAssetsRollForward" abstract="true" name="RightOfUsedAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" abstract="false" name="ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember" abstract="true" name="SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares" abstract="false" name="IssueOfSharesOnSettlementOfRelatedPartyLoansShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_SaemundurMember" abstract="true" name="SaemundurMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares" abstract="false" name="IncreaseDecreaseThroughSettlementOfLiabilityWithShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" abstract="false" name="PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ShareCapitalAndSharePremium" abstract="false" name="ShareCapitalAndSharePremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement" abstract="false" name="VestingPeriodOfRequirementsForShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_LandsbankinnHfMember" abstract="true" name="LandsbankinnHfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ContractLiabilitiesMember" abstract="true" name="ContractLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember" abstract="true" name="EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IssuedToTheExistingNoteholderMember" abstract="true" name="IssuedToTheExistingNoteholderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ClassOfStocksDomain" abstract="true" name="ClassOfStocksDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems" abstract="true" name="DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ContractAssetsRollForward" abstract="true" name="ContractAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutLeaseCostLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_RichardDaviesMember" abstract="true" name="RichardDaviesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenEmergingMarketsSisterCompanyMember" abstract="true" name="AlvogenEmergingMarketsSisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" abstract="false" name="RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AlvogenLuxHoldingsSRLMember" abstract="true" name="AlvogenLuxHoldingsSRLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NonInterestBearingUndiscountedCashFlowsLiabilities" abstract="false" name="NonInterestBearingUndiscountedCashFlowsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_InterestIncomeOnCash" abstract="false" name="InterestIncomeOnCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfCreditRiskLineItems" abstract="true" name="DisclosureOfCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_MinimumAmountOfRestrictedCashToBeMaintained" abstract="false" name="MinimumAmountOfRestrictedCashToBeMaintained" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_HirofumiImaiBoardMember" abstract="true" name="HirofumiImaiBoardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid" abstract="false" name="CapitalExpenditureTangibleAssetsIncurredButNotPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfInventoriesLineItems" abstract="true" name="DisclosureOfInventoriesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" abstract="false" name="FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_AlvogenKoreaCo.LtdSisterCompanyMember" abstract="true" name="AlvogenKoreaCo.LtdSisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember" abstract="true" name="LotusPharmaceuticalsCo.Ltd.SisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IncomeStatementsLocationDomain" abstract="true" name="IncomeStatementsLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_FixedInterestBearingBorrowingsMember" abstract="true" name="FixedInterestBearingBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod" abstract="false" name="NoncurrentContractLiabilitiesRevenueRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_PredecessorOrdinarySharesMember" abstract="true" name="PredecessorOrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_MaturedOnAugust2030Member" abstract="true" name="MaturedOnAugust2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingPrepaymentPeriodWithAdditionalPremium" abstract="false" name="BorrowingPrepaymentPeriodWithAdditionalPremium" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" abstract="false" name="ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_PublicWarrantsMember" abstract="true" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_VariableInterestBearingBorrowingsMember" abstract="true" name="VariableInterestBearingBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember" abstract="true" name="AztiqPharmaPartnersS.aR.l.SisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems" abstract="true" name="DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems" abstract="true" name="DisclosureInTabularFormOfForeignExchangeRateLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_OtherSubsidiariesMember" abstract="true" name="OtherSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CapitalReorganizationEventSharesIssued" abstract="false" name="CapitalReorganizationEventSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_AlvogenSubordinatedLoanMember" abstract="true" name="AlvogenSubordinatedLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_PremiumPaymentOnBonds" abstract="false" name="PremiumPaymentOnBonds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ContractLiabilitiesRollForward" abstract="true" name="ContractLiabilitiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" abstract="false" name="AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_OtherCurrentLiabilitiesAbstract" abstract="true" name="OtherCurrentLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_L41EhfMember" abstract="true" name="L41EhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DirectorFees" abstract="false" name="DirectorFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NumberOfSharesCalledByEachWarrantOrRight" abstract="false" name="NumberOfSharesCalledByEachWarrantOrRight" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment" abstract="false" name="DepreciationAndImpairmentOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ChangesInInventoryReserves" abstract="false" name="ChangesInInventoryReserves" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ClassesOfCommonStockAxis" abstract="true" name="ClassesOfCommonStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ExistingEmployeesMember" abstract="true" name="ExistingEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DerivaiveAssets" abstract="false" name="DerivaiveAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ClassBOacbOrdinarySharesMember" abstract="true" name="ClassBOacbOrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_SharesPrice" abstract="false" name="SharesPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="alvo_InventoryReserves" abstract="false" name="InventoryReserves" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember" abstract="true" name="PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AdditionRestrictedCashAndCashEquivalents" abstract="false" name="AdditionRestrictedCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_GainLossOnExtinguishmentOfDebt" abstract="false" name="GainLossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_DisclosureOfCreditRiskTable" abstract="true" name="DisclosureOfCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" abstract="false" name="DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_FinalMaturityInDecember2027Member" abstract="true" name="FinalMaturityInDecember2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ExpenseCapitalized" abstract="false" name="ExpenseCapitalized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_OtherCurrentAssetsTable" abstract="true" name="OtherCurrentAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AgreementsTypeDomain" abstract="true" name="AgreementsTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvotechMaltaLtdMember" abstract="true" name="AlvotechMaltaLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LotusInternationalPteltdMember" abstract="true" name="LotusInternationalPteltdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingsTrancheAxis" abstract="true" name="BorrowingsTrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_FacilityEquipmentMember" abstract="true" name="FacilityEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_IssuanceOfOrdinaryValue" abstract="false" name="IssuanceOfOrdinaryValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_LisaGraverMember" abstract="true" name="LisaGraverMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_OtherCurrentAssetsAbstract" abstract="true" name="OtherCurrentAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_OtherBorrowingsMember" abstract="true" name="OtherBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FaysalKalmouaMember" abstract="true" name="FaysalKalmouaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AztiqConsultingEhfMember" abstract="true" name="AztiqConsultingEhfMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ConvertibleShareholderLoanMember" abstract="true" name="ConvertibleShareholderLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_NonInterestBearingFinancialLiabilitiesMember" abstract="true" name="NonInterestBearingFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_LenderNameDomain" abstract="true" name="LenderNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AnnMerchantMember" abstract="true" name="AnnMerchantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_AlvogenAztiqABSisterCompanyMember" abstract="true" name="AlvogenAztiqABSisterCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_PrepaymentPenaltyPercentageOnBonds" abstract="false" name="PrepaymentPenaltyPercentageOnBonds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" abstract="false" name="DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FlokiFasteignirEhf.Member" abstract="true" name="FlokiFasteignirEhf.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutLeaseCostTable" abstract="true" name="DisclosureOfDetailedInformationAboutLeaseCostTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" abstract="false" name="ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_AfterTheTermsOfTheSecondAmendmentMember" abstract="true" name="AfterTheTermsOfTheSecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_GoodwillBalancesRollForward" abstract="true" name="GoodwillBalancesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock" abstract="false" name="DisclosureOfLitigationSettlementsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_NatureOfFeesAxis" abstract="true" name="NatureOfFeesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" abstract="false" name="WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems" abstract="true" name="DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AssetAcquisitionsDomain" abstract="true" name="AssetAcquisitionsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_DisclosureOfLongtermIncentivePlansAbstract" abstract="true" name="DisclosureOfLongtermIncentivePlansAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_AdalvoUKMember" abstract="true" name="AdalvoUKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_ReorganizationShareListingExpense" abstract="false" name="ReorganizationShareListingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_LicenseRevenueMember" abstract="true" name="LicenseRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_BorrowingConversionPeriodPriorToExtinguishment" abstract="false" name="BorrowingConversionPeriodPriorToExtinguishment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alvo_LeaseLiabilitiesCancelledLease" abstract="false" name="LeaseLiabilitiesCancelledLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ForeignCurrencyDifferenceOnLeaseLiability" abstract="false" name="ForeignCurrencyDifferenceOnLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_ThomasEkmanMember" abstract="true" name="ThomasEkmanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CancellationsRightOfUseAssets" abstract="false" name="CancellationsRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_SeniorBondsMember" abstract="true" name="SeniorBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_OtherBorrowingsFinancialInstitutionMember" abstract="true" name="OtherBorrowingsFinancialInstitutionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_CommonStockSharesSubscribed" abstract="false" name="CommonStockSharesSubscribed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_TrancheAxis" abstract="true" name="TrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" abstract="false" name="DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="alvo_ClassOfWarrantsOrRightsOutstanding" abstract="false" name="ClassOfWarrantsOrRightsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alvo_AgreementsTypeAxis" abstract="true" name="AgreementsTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases" abstract="false" name="LeaseLiabilitiesAdjustmentsForIndexedLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_IssueOfPredecessorEarnOutSharesValue" abstract="false" name="IssueOfPredecessorEarnOutSharesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_AssetsAcquisitionAxis" abstract="true" name="AssetsAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alvo_GeneralInformationAboutFinancialStatementsAbstract" abstract="true" name="GeneralInformationAboutFinancialStatementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alvo_InterestCostsCapitalizedPeriodIncreaseDecrease" abstract="false" name="InterestCostsCapitalizedPeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alvo_NorwichClinicalServicesLtdMember" abstract="true" name="NorwichClinicalServicesLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_TrancheBConvertibleDebtMember" abstract="true" name="TrancheBConvertibleDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="alvo_A2022ConvertibleBondsMember" abstract="true" name="A2022ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>alvo-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0f568319-c84c-47ce-b7c2-396cc2b09ac1,g:54c4089e-eaa8-4b46-9747-283b5fa757be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_7019a514-9959-4330-b6bb-fe523c6187f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_758e4138-530c-48c8-8efd-d55ed1f14dd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_7019a514-9959-4330-b6bb-fe523c6187f6" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_758e4138-530c-48c8-8efd-d55ed1f14dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicenceFeeIncome_6b9cd004-de07-4705-8319-f048ee4bb7e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicenceFeeIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_7019a514-9959-4330-b6bb-fe523c6187f6" xlink:to="loc_ifrs-full_LicenceFeeIncome_6b9cd004-de07-4705-8319-f048ee4bb7e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_485f5e5b-dfa8-4e8a-9d1a-efed70057131" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_7019a514-9959-4330-b6bb-fe523c6187f6" xlink:to="loc_ifrs-full_OtherRevenue_485f5e5b-dfa8-4e8a-9d1a-efed70057131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_b1941d95-247d-4e1d-9995-6aad73a4f113" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_7019a514-9959-4330-b6bb-fe523c6187f6" xlink:to="loc_ifrs-full_CostOfSales_b1941d95-247d-4e1d-9995-6aad73a4f113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_5dd3d192-efa3-45a0-922c-8a400e9fe196" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_7019a514-9959-4330-b6bb-fe523c6187f6" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_5dd3d192-efa3-45a0-922c-8a400e9fe196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_7c2d48c6-f0a6-420d-86e5-48d34eeec093" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_7019a514-9959-4330-b6bb-fe523c6187f6" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_7c2d48c6-f0a6-420d-86e5-48d34eeec093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_de8032f8-d809-4a96-9713-5779de07798b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_8e83e6dd-b516-441e-b6c6-4e6bd5a2fc12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_de8032f8-d809-4a96-9713-5779de07798b" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_8e83e6dd-b516-441e-b6c6-4e6bd5a2fc12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_94d9ce54-2b6d-4ea5-a2a1-02513a7cfeaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_de8032f8-d809-4a96-9713-5779de07798b" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_94d9ce54-2b6d-4ea5-a2a1-02513a7cfeaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_c8aa92cf-169a-454b-ac51-92a9f1557242" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_47b3434a-0033-4d11-9d14-ee2471514af3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_c8aa92cf-169a-454b-ac51-92a9f1557242" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_47b3434a-0033-4d11-9d14-ee2471514af3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_bda678d3-9be5-4368-8e03-de473998d5f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherGainsLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_c8aa92cf-169a-454b-ac51-92a9f1557242" xlink:to="loc_ifrs-full_OtherGainsLosses_bda678d3-9be5-4368-8e03-de473998d5f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_d56b1818-41d9-4129-9876-949c14317329" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherGainsLosses"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_c79c38e5-6726-4783-bf93-b021da7da895" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_d56b1818-41d9-4129-9876-949c14317329" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_c79c38e5-6726-4783-bf93-b021da7da895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_9c8b9524-6ffa-4b11-84cb-6bdd9e10da6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_d56b1818-41d9-4129-9876-949c14317329" xlink:to="loc_ifrs-full_FinanceCosts_9c8b9524-6ffa-4b11-84cb-6bdd9e10da6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_ea39ece9-7c59-4c0c-9e2f-b566c778dba9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_d56b1818-41d9-4129-9876-949c14317329" xlink:to="loc_ifrs-full_FinanceIncome_ea39ece9-7c59-4c0c-9e2f-b566c778dba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_380eaffc-0e3f-4cfa-ac6e-5f114a547b3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_d56b1818-41d9-4129-9876-949c14317329" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_380eaffc-0e3f-4cfa-ac6e-5f114a547b3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_774ea558-5d59-4396-9b16-72c1f423b05a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_d56b1818-41d9-4129-9876-949c14317329" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_774ea558-5d59-4396-9b16-72c1f423b05a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_605df642-3955-4f3a-89d9-96d61119b910" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_d56b1818-41d9-4129-9876-949c14317329" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_605df642-3955-4f3a-89d9-96d61119b910" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofFinancialPosition"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_55a939a2-116d-4a02-bc55-f94938eae31c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_f79e1422-7cce-41d0-9297-4433e05879a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_55a939a2-116d-4a02-bc55-f94938eae31c" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_f79e1422-7cce-41d0-9297-4433e05879a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_83e8c0e0-4c37-4042-9523-630d081d68ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_55a939a2-116d-4a02-bc55-f94938eae31c" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_83e8c0e0-4c37-4042-9523-630d081d68ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_df79832e-1c68-4289-8331-564818a36521" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_55a939a2-116d-4a02-bc55-f94938eae31c" xlink:to="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_df79832e-1c68-4289-8331-564818a36521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_e8068249-ee0d-4fde-a4ed-4a64119a52ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_55a939a2-116d-4a02-bc55-f94938eae31c" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_e8068249-ee0d-4fde-a4ed-4a64119a52ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_f46648a3-d897-4e37-bc4e-8530dafbbccb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_55a939a2-116d-4a02-bc55-f94938eae31c" xlink:to="loc_ifrs-full_CurrentContractLiabilities_f46648a3-d897-4e37-bc4e-8530dafbbccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_097f3378-e8a1-41ad-a250-7598a792fdd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_55a939a2-116d-4a02-bc55-f94938eae31c" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_097f3378-e8a1-41ad-a250-7598a792fdd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_bee7739d-9feb-4e41-83b7-3c585512fd8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_55a939a2-116d-4a02-bc55-f94938eae31c" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_bee7739d-9feb-4e41-83b7-3c585512fd8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_67ae76b9-892c-48f7-8c94-f9b32eaa502d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_80472cd0-4400-4080-98b1-36cd5a52f053" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_67ae76b9-892c-48f7-8c94-f9b32eaa502d" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_80472cd0-4400-4080-98b1-36cd5a52f053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractAssets_8191e7a5-7b52-4f03-b9ea-8f4dc1beb34d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_67ae76b9-892c-48f7-8c94-f9b32eaa502d" xlink:to="loc_ifrs-full_CurrentContractAssets_8191e7a5-7b52-4f03-b9ea-8f4dc1beb34d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_48ca8530-5b2e-48d3-8661-0bcfbf3ddbf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_67ae76b9-892c-48f7-8c94-f9b32eaa502d" xlink:to="loc_ifrs-full_CurrentTradeReceivables_48ca8530-5b2e-48d3-8661-0bcfbf3ddbf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_c579ae3c-3109-40cc-ab56-0fc64d9f343b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_67ae76b9-892c-48f7-8c94-f9b32eaa502d" xlink:to="loc_ifrs-full_CashAndCashEquivalents_c579ae3c-3109-40cc-ab56-0fc64d9f343b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_fd88f0d1-b5f9-4b43-bb4b-c3cbd5ba2dd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_67ae76b9-892c-48f7-8c94-f9b32eaa502d" xlink:to="loc_ifrs-full_Inventories_fd88f0d1-b5f9-4b43-bb4b-c3cbd5ba2dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_ceb02c80-52a5-4e67-b628-803bd3d74c8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_67ae76b9-892c-48f7-8c94-f9b32eaa502d" xlink:to="loc_ifrs-full_OtherCurrentAssets_ceb02c80-52a5-4e67-b628-803bd3d74c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_990a92e7-6aa6-4944-a831-2e3675513e69" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_b42bb6bc-a3a3-477d-a270-39a4a96ae25f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_990a92e7-6aa6-4944-a831-2e3675513e69" xlink:to="loc_ifrs-full_NoncurrentLiabilities_b42bb6bc-a3a3-477d-a270-39a4a96ae25f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_7d04929e-b68a-4ac0-bce0-d94ec6195888" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_990a92e7-6aa6-4944-a831-2e3675513e69" xlink:to="loc_ifrs-full_CurrentLiabilities_7d04929e-b68a-4ac0-bce0-d94ec6195888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_53a53f99-e24b-4e72-a321-7c15c796f268" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_d428529f-b79d-4906-8d08-5bcba839f966" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_53a53f99-e24b-4e72-a321-7c15c796f268" xlink:to="loc_ifrs-full_OtherReserves_d428529f-b79d-4906-8d08-5bcba839f966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_0c49cd2b-5686-4c2a-8c9e-a582d8fdd254" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_53a53f99-e24b-4e72-a321-7c15c796f268" xlink:to="loc_ifrs-full_RetainedEarnings_0c49cd2b-5686-4c2a-8c9e-a582d8fdd254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_f616a901-92d4-42fd-bf41-00683f0f3c74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_53a53f99-e24b-4e72-a321-7c15c796f268" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_f616a901-92d4-42fd-bf41-00683f0f3c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_dc2ec328-f3c9-4f30-be23-5e74c0271843" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_53a53f99-e24b-4e72-a321-7c15c796f268" xlink:to="loc_ifrs-full_IssuedCapital_dc2ec328-f3c9-4f30-be23-5e74c0271843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_505290a3-8964-4309-948b-7069920b9ea5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_53a53f99-e24b-4e72-a321-7c15c796f268" xlink:to="loc_ifrs-full_SharePremium_505290a3-8964-4309-948b-7069920b9ea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_940f50cf-b4cb-41af-b732-b7b213d2409e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_48a53800-05c5-4cb1-aeed-d7eeb3554333" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_940f50cf-b4cb-41af-b732-b7b213d2409e" xlink:to="loc_ifrs-full_Equity_48a53800-05c5-4cb1-aeed-d7eeb3554333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_1b43b9c3-f6c7-400e-a814-ef2f28bea28f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_940f50cf-b4cb-41af-b732-b7b213d2409e" xlink:to="loc_ifrs-full_Liabilities_1b43b9c3-f6c7-400e-a814-ef2f28bea28f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_afb43973-25a1-4bf1-83b2-63a68284848d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_0de2ca1c-3a39-4fee-939d-f943fb2c2c9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_afb43973-25a1-4bf1-83b2-63a68284848d" xlink:to="loc_ifrs-full_LongtermBorrowings_0de2ca1c-3a39-4fee-939d-f943fb2c2c9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_728ce79b-fb18-4418-a130-f4e1d84b60cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_afb43973-25a1-4bf1-83b2-63a68284848d" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_728ce79b-fb18-4418-a130-f4e1d84b60cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPayablesToRelatedParties_e5910526-f0d8-455f-838d-456a5100752a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPayablesToRelatedParties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_afb43973-25a1-4bf1-83b2-63a68284848d" xlink:to="loc_ifrs-full_NoncurrentPayablesToRelatedParties_e5910526-f0d8-455f-838d-456a5100752a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_0b7c6708-28ce-43f6-abcd-c0042ba57e28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_afb43973-25a1-4bf1-83b2-63a68284848d" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_0b7c6708-28ce-43f6-abcd-c0042ba57e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_68529ebd-b6e4-4ca3-aee0-6932fd4631b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_afb43973-25a1-4bf1-83b2-63a68284848d" xlink:to="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_68529ebd-b6e4-4ca3-aee0-6932fd4631b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_bc773535-867e-4d64-b2ae-f43a48acbd9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_afb43973-25a1-4bf1-83b2-63a68284848d" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_bc773535-867e-4d64-b2ae-f43a48acbd9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_2ed84115-cbb9-4531-89f0-5c6cb75fb8c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_afb43973-25a1-4bf1-83b2-63a68284848d" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_2ed84115-cbb9-4531-89f0-5c6cb75fb8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_afe22019-5369-45dd-a086-0359a60d69f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_75be5678-4844-4002-ac9e-2aa660ef10ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_afe22019-5369-45dd-a086-0359a60d69f0" xlink:to="loc_ifrs-full_NoncurrentAssets_75be5678-4844-4002-ac9e-2aa660ef10ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_02416a59-7333-4f75-b446-fcfe2b89ab52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_afe22019-5369-45dd-a086-0359a60d69f0" xlink:to="loc_ifrs-full_CurrentAssets_02416a59-7333-4f75-b446-fcfe2b89ab52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_e9d2e6d0-f24f-40c2-ad75-246ebfc7cb74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_RightofuseAssets_e9d2e6d0-f24f-40c2-ad75-246ebfc7cb74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_d0055558-98f7-4b55-b132-7a1dc1c0798c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_d0055558-98f7-4b55-b132-7a1dc1c0798c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_18511633-9e0b-41f6-ab19-29764f2dc98a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_Goodwill_18511633-9e0b-41f6-ab19-29764f2dc98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_630c179e-47ad-4f9d-9bc5-e9efadd98d7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_630c179e-47ad-4f9d-9bc5-e9efadd98d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_0335d982-84be-4acd-b96a-62bf7445a813" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_DeferredTaxAssets_0335d982-84be-4acd-b96a-62bf7445a813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractAssets_c1b387ac-f3ba-40c5-87ad-3faabf0436e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_NoncurrentContractAssets_c1b387ac-f3ba-40c5-87ad-3faabf0436e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_c1d27d72-1d3c-4975-b5a5-006b45861e0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_c1d27d72-1d3c-4975-b5a5-006b45861e0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_03c551ce-b93e-404c-a131-0efde54f4fc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_03c551ce-b93e-404c-a131-0efde54f4fc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_de195287-d48f-4c85-a99f-9b6b76f69675" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_7c972505-e1a1-4961-a0c6-5defd37f2be0" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_de195287-d48f-4c85-a99f-9b6b76f69675" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_84ea3af5-2dee-44b1-b239-d0ebc1fa8dab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_84ea3af5-2dee-44b1-b239-d0ebc1fa8dab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_4c7eefcf-4af3-410c-887f-5b8a87837732" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_4c7eefcf-4af3-410c-887f-5b8a87837732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_35cfd441-1c3a-4e8a-ac12-9983827bca31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_35cfd441-1c3a-4e8a-ac12-9983827bca31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains_da1a4e87-af6c-4472-83e6-de0c76b4e5f0" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains_da1a4e87-af6c-4472-83e6-de0c76b4e5f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForSharelistingExpense_5783eaa0-bb2a-4745-9867-608fb6c66401" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForSharelistingExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_alvo_AdjustmentsForSharelistingExpense_5783eaa0-bb2a-4745-9867-608fb6c66401" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_683b47cb-cc93-4919-a833-498da539e27a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_683b47cb-cc93-4919-a833-498da539e27a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_f5ee81ca-fca3-428c-bef7-5fe72fc2e98a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_f5ee81ca-fca3-428c-bef7-5fe72fc2e98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ChangesInInventoryReserves_963e971e-899c-43fc-bfbf-0bba1aa2ea1e" xlink:href="alvo-20231231.xsd#alvo_ChangesInInventoryReserves"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_alvo_ChangesInInventoryReserves_963e971e-899c-43fc-bfbf-0bba1aa2ea1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_fc872f8a-444e-4778-ae81-0320a0f2e171" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_fc872f8a-444e-4778-ae81-0320a0f2e171" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7b43695d-e89e-443a-89ac-4e0e35cca1cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_ProfitLoss_7b43695d-e89e-443a-89ac-4e0e35cca1cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_2f2f47e6-bd37-4e7e-bbfe-02a456167a07" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_2f2f47e6-bd37-4e7e-bbfe-02a456167a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets_304ca090-c9da-4dc3-8c39-94041b66d852" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets_304ca090-c9da-4dc3-8c39-94041b66d852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_470c6b79-05d0-4a7c-8d7e-e6b50831729f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_470c6b79-05d0-4a7c-8d7e-e6b50831729f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_36548ef7-862b-4a36-9282-23af9316bd8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_36548ef7-862b-4a36-9282-23af9316bd8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_976424fc-d2b7-4b84-b8a5-bb9ae423622b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_976424fc-d2b7-4b84-b8a5-bb9ae423622b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_58fd096f-dc1b-4942-917c-40b570a2ef7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_58fd096f-dc1b-4942-917c-40b570a2ef7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_293ed1eb-d7bc-4d45-9373-237d93439ca8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_293ed1eb-d7bc-4d45-9373-237d93439ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_b8440fc5-e6ec-4309-9d2c-a8917a7235bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_eb39a76b-db25-4255-8f3d-dab9ab7dd81c" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_b8440fc5-e6ec-4309-9d2c-a8917a7235bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_a65f6535-16d7-4d7b-bc94-663620b44c80" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_a65f6535-16d7-4d7b-bc94-663620b44c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_99146cb7-e7e2-4298-b9cd-544a574468b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_99146cb7-e7e2-4298-b9cd-544a574468b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_87642734-39f5-44ee-a2c8-4d9096b8bf55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_87642734-39f5-44ee-a2c8-4d9096b8bf55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GrossPipeFinancingFeesPaid_03d20e9b-9e15-4cdb-a501-ee3c06331a4d" xlink:href="alvo-20231231.xsd#alvo_GrossPipeFinancingFeesPaid"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_alvo_GrossPipeFinancingFeesPaid_03d20e9b-9e15-4cdb-a501-ee3c06331a4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts_01b59d58-298b-4b3f-88b9-d0a6cbabb5c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForDebtIssueCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_PaymentsForDebtIssueCosts_01b59d58-298b-4b3f-88b9-d0a6cbabb5c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_bd41f289-b9c4-4618-9fb6-8783ced23fd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_bd41f289-b9c4-4618-9fb6-8783ced23fd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties_4467c170-5458-4c6a-8a7b-422620bbf029" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties_4467c170-5458-4c6a-8a7b-422620bbf029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_d4a65ef6-e48d-4028-9926-2d03ad6955fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_d4a65ef6-e48d-4028-9926-2d03ad6955fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_ebdc0907-6ce8-42ff-ad02-126aac51cb0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_ebdc0907-6ce8-42ff-ad02-126aac51cb0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities_5c583250-89c0-4f28-bd7c-4ac39b07172b" xlink:href="alvo-20231231.xsd#alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities_5c583250-89c0-4f28-bd7c-4ac39b07172b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_3a62d90c-1ad2-4636-9ab3-f8455ab9e8ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_3a62d90c-1ad2-4636-9ab3-f8455ab9e8ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromTheCapitalReorganization_d0604bf2-53d6-41b1-bbfb-88c6bec87dea" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromTheCapitalReorganization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_alvo_ProceedsFromTheCapitalReorganization_d0604bf2-53d6-41b1-bbfb-88c6bec87dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GrossProceedsFromThePipeFinancing_6c926886-9ebb-4d97-a48b-1df89b284d2c" xlink:href="alvo-20231231.xsd#alvo_GrossProceedsFromThePipeFinancing"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5204f62e-aa1e-469f-b60c-7adae3bf55b4" xlink:to="loc_alvo_GrossProceedsFromThePipeFinancing_6c926886-9ebb-4d97-a48b-1df89b284d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7e78bbee-4716-49c7-b60a-e3a5e03dab0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_836daa87-6d84-43e9-8a64-7a8c657f0223" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7e78bbee-4716-49c7-b60a-e3a5e03dab0d" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_836daa87-6d84-43e9-8a64-7a8c657f0223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_bf505be0-0627-4c40-b7ae-c3469f8cd439" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7e78bbee-4716-49c7-b60a-e3a5e03dab0d" xlink:to="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_bf505be0-0627-4c40-b7ae-c3469f8cd439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_62f0eefb-3600-4922-b2cf-3357b37b5eff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7e78bbee-4716-49c7-b60a-e3a5e03dab0d" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_62f0eefb-3600-4922-b2cf-3357b37b5eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RestrictedCashInConnectionWithAmendedBondAgreement_c6237934-66cc-4cea-9bde-9cf7c0351ae0" xlink:href="alvo-20231231.xsd#alvo_RestrictedCashInConnectionWithAmendedBondAgreement"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7e78bbee-4716-49c7-b60a-e3a5e03dab0d" xlink:to="loc_alvo_RestrictedCashInConnectionWithAmendedBondAgreement_c6237934-66cc-4cea-9bde-9cf7c0351ae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_79741a7b-a6ee-4b5d-b828-4033a986bad0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_79741a7b-a6ee-4b5d-b828-4033a986bad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_55117af8-5695-4c90-a537-b2ac4771ab5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_55117af8-5695-4c90-a537-b2ac4771ab5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_7da9f72a-9641-4b4c-93c7-940108d73068" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_7da9f72a-9641-4b4c-93c7-940108d73068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets_14926655-e0ae-434f-8b7b-7a0a4b525244" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets_14926655-e0ae-434f-8b7b-7a0a4b525244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_402581ed-77aa-4db5-bf65-fce569798de4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_402581ed-77aa-4db5-bf65-fce569798de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_24edb13c-76df-49d7-91c4-59a920a75834" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_24edb13c-76df-49d7-91c4-59a920a75834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_f41ad448-58e3-49d2-a2f3-788556bbdc59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_f41ad448-58e3-49d2-a2f3-788556bbdc59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_bc53381d-4862-4dc7-ad39-e2108c6af397" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_bc53381d-4862-4dc7-ad39-e2108c6af397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties_ce83c8ad-b9fe-46da-b326-e3d6c89b12de" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4af17ea4-e529-4701-aa18-e258ebb547e2" xlink:to="loc_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties_ce83c8ad-b9fe-46da-b326-e3d6c89b12de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_d1416684-5cd8-4b73-a493-6c95a1b2cad8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_a73cc4ee-d6a1-4bbd-82ae-db370608667c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_d1416684-5cd8-4b73-a493-6c95a1b2cad8" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_a73cc4ee-d6a1-4bbd-82ae-db370608667c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_e5bf527d-05e2-4842-b9ae-1e979c3db54f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_d1416684-5cd8-4b73-a493-6c95a1b2cad8" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_e5bf527d-05e2-4842-b9ae-1e979c3db54f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_ad8a9158-c0db-4f9c-9f42-b480f9c83e8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_d1416684-5cd8-4b73-a493-6c95a1b2cad8" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_ad8a9158-c0db-4f9c-9f42-b480f9c83e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_80170f01-754d-4f2c-a192-a09581171db7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_d1416684-5cd8-4b73-a493-6c95a1b2cad8" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_80170f01-754d-4f2c-a192-a09581171db7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_980febbb-0d96-4719-896d-9946cfad94ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_01ca5cdc-ad96-48ea-bccd-162cc3bd90c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_980febbb-0d96-4719-896d-9946cfad94ee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_01ca5cdc-ad96-48ea-bccd-162cc3bd90c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_f383076d-2257-4553-a055-723135b074dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_980febbb-0d96-4719-896d-9946cfad94ee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_f383076d-2257-4553-a055-723135b074dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2b6dc772-3c0f-4c85-bbe0-1f60125abeea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_980febbb-0d96-4719-896d-9946cfad94ee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_2b6dc772-3c0f-4c85-bbe0-1f60125abeea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_2d61080e-f316-416c-b8db-87fbdf2ce64e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4ef671e3-a186-4c58-94cb-c8c6a16a5e3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_2d61080e-f316-416c-b8db-87fbdf2ce64e" xlink:to="loc_ifrs-full_ProfitLoss_4ef671e3-a186-4c58-94cb-c8c6a16a5e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ba51f0da-357f-4606-b3a7-f7ab2e9f42ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_2d61080e-f316-416c-b8db-87fbdf2ce64e" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ba51f0da-357f-4606-b3a7-f7ab2e9f42ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_77747eb7-6ca6-4860-bbf9-8629663bf7f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_dc4f0ccd-e7ee-414c-9f5b-7bff6da1d046" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_77747eb7-6ca6-4860-bbf9-8629663bf7f1" xlink:to="loc_ifrs-full_WagesAndSalaries_dc4f0ccd-e7ee-414c-9f5b-7bff6da1d046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_8cda3245-ee6a-4201-b5a2-0f31c7877418" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_77747eb7-6ca6-4860-bbf9-8629663bf7f1" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_8cda3245-ee6a-4201-b5a2-0f31c7877418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermBenefits_bfe28996-bfec-4214-9c4e-9ead171c63c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_77747eb7-6ca6-4860-bbf9-8629663bf7f1" xlink:to="loc_ifrs-full_OtherLongtermBenefits_bfe28996-bfec-4214-9c4e-9ead171c63c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_3c0f8a1e-0bfe-4d88-8182-75642588301d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_77747eb7-6ca6-4860-bbf9-8629663bf7f1" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_3c0f8a1e-0bfe-4d88-8182-75642588301d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_032ece48-8668-4c59-8083-d99c4fd5dcdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_77747eb7-6ca6-4860-bbf9-8629663bf7f1" xlink:to="loc_ifrs-full_OtherEmployeeExpense_032ece48-8668-4c59-8083-d99c4fd5dcdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TemporaryLabourExpense_e2d8ffda-95fb-4ee6-bdd0-8949b158c585" xlink:href="alvo-20231231.xsd#alvo_TemporaryLabourExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_77747eb7-6ca6-4860-bbf9-8629663bf7f1" xlink:to="loc_alvo_TemporaryLabourExpense_e2d8ffda-95fb-4ee6-bdd0-8949b158c585" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_4a2bc751-ed76-4705-b4e6-f2b76573e141" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_4106e7d5-094e-4322-893f-bdfd75441a62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_4a2bc751-ed76-4705-b4e6-f2b76573e141" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_4106e7d5-094e-4322-893f-bdfd75441a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_25c99a5b-1c6b-4e41-9050-91dc879a1c43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_4a2bc751-ed76-4705-b4e6-f2b76573e141" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_25c99a5b-1c6b-4e41-9050-91dc879a1c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets_96558af1-98da-4193-8562-2d3b2fa33e99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnOtherFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_4a2bc751-ed76-4705-b4e6-f2b76573e141" xlink:to="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets_96558af1-98da-4193-8562-2d3b2fa33e99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_c520da93-9626-480a-afdd-bb7da3842de6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_58ba7d83-1add-45b6-a67c-2e143e93300e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_c520da93-9626-480a-afdd-bb7da3842de6" xlink:to="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_58ba7d83-1add-45b6-a67c-2e143e93300e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_7479e1a4-f813-4e28-aa91-a8121e81efd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_c520da93-9626-480a-afdd-bb7da3842de6" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_7479e1a4-f813-4e28-aa91-a8121e81efd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConsentingFee_c201bdb2-4c05-407d-8d72-5c9047509330" xlink:href="alvo-20231231.xsd#alvo_ConsentingFee"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_c520da93-9626-480a-afdd-bb7da3842de6" xlink:to="loc_alvo_ConsentingFee_c201bdb2-4c05-407d-8d72-5c9047509330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossOnRemeasurementOfBonds_3977912f-35a8-4a08-b1a2-93d8d342de26" xlink:href="alvo-20231231.xsd#alvo_LossOnRemeasurementOfBonds"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_c520da93-9626-480a-afdd-bb7da3842de6" xlink:to="loc_alvo_LossOnRemeasurementOfBonds_3977912f-35a8-4a08-b1a2-93d8d342de26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_3d0762ac-90d7-4540-9036-bde6ef709e77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_c520da93-9626-480a-afdd-bb7da3842de6" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_3d0762ac-90d7-4540-9036-bde6ef709e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationOfDeferredDebtIssuanceCosts_94cba366-6fc9-4420-a41f-04d211653334" xlink:href="alvo-20231231.xsd#alvo_AmortizationOfDeferredDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_c520da93-9626-480a-afdd-bb7da3842de6" xlink:to="loc_alvo_AmortizationOfDeferredDebtIssuanceCosts_94cba366-6fc9-4420-a41f-04d211653334" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_c2e3f65f-89e6-40bb-858f-addefdaa15e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_c786ff28-7b5e-4700-ba09-ddb6112d51a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_c2e3f65f-89e6-40bb-858f-addefdaa15e2" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_c786ff28-7b5e-4700-ba09-ddb6112d51a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment_0ae4f99a-5139-414d-9d95-203c1d77431a" xlink:href="alvo-20231231.xsd#alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_c2e3f65f-89e6-40bb-858f-addefdaa15e2" xlink:to="loc_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment_0ae4f99a-5139-414d-9d95-203c1d77431a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationAndImpairmentOfIntangibleAssets_109e8ecb-a6b4-449b-9631-625d18afdc7a" xlink:href="alvo-20231231.xsd#alvo_AmortizationAndImpairmentOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_c2e3f65f-89e6-40bb-858f-addefdaa15e2" xlink:to="loc_alvo_AmortizationAndImpairmentOfIntangibleAssets_109e8ecb-a6b4-449b-9631-625d18afdc7a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration_fbe25035-adfd-4347-aad3-c20834f8f282" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_0dbe6028-c9cc-4f49-9e57-acc1440a0aaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration_fbe25035-adfd-4347-aad3-c20834f8f282" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_0dbe6028-c9cc-4f49-9e57-acc1440a0aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices_4ad1e036-7648-4fbb-80e6-178aed5e1ece" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration_fbe25035-adfd-4347-aad3-c20834f8f282" xlink:to="loc_ifrs-full_AuditorsRemunerationForTaxServices_4ad1e036-7648-4fbb-80e6-178aed5e1ece" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_abbeef4e-a8a5-464b-9e01-b7f64954241d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_8e9b9fd6-768f-44e4-91ff-a68a47792a33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_abbeef4e-a8a5-464b-9e01-b7f64954241d" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_8e9b9fd6-768f-44e4-91ff-a68a47792a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_3fe511fc-f3a5-4b65-b6b3-8ddd51d892c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_abbeef4e-a8a5-464b-9e01-b7f64954241d" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_3fe511fc-f3a5-4b65-b6b3-8ddd51d892c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_f6be2194-7f2f-4876-a489-55a299288927" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_12b2fdbc-bac4-4441-a21f-f364184ddc14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_f6be2194-7f2f-4876-a489-55a299288927" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_12b2fdbc-bac4-4441-a21f-f364184ddc14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_b57f147e-ab69-4ba2-94ae-e894223e401d" xlink:href="alvo-20231231.xsd#alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_f6be2194-7f2f-4876-a489-55a299288927" xlink:to="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_b57f147e-ab69-4ba2-94ae-e894223e401d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_89ded0d4-ef35-4477-9806-ee29fdd04baa" xlink:href="alvo-20231231.xsd#alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_6f682c8f-b2c2-40ac-b93b-06bba9910855" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_89ded0d4-ef35-4477-9806-ee29fdd04baa" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_6f682c8f-b2c2-40ac-b93b-06bba9910855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_71883e36-b275-4cd3-96db-e1300eb4cdc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_89ded0d4-ef35-4477-9806-ee29fdd04baa" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_71883e36-b275-4cd3-96db-e1300eb4cdc2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_60a19969-9f26-48f8-9de3-f53b5d5d79c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_30ebaaba-0d87-4b19-9ead-014ea1e9c9f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_60a19969-9f26-48f8-9de3-f53b5d5d79c0" xlink:to="loc_ifrs-full_ApplicableTaxRate_30ebaaba-0d87-4b19-9ead-014ea1e9c9f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_e866e13b-3b3a-441d-bd95-667b3c42c046" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_60a19969-9f26-48f8-9de3-f53b5d5d79c0" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_e866e13b-3b3a-441d-bd95-667b3c42c046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_10957e81-46a6-4b4f-bf47-bf69bf5ff846" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_60a19969-9f26-48f8-9de3-f53b5d5d79c0" xlink:to="loc_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_10957e81-46a6-4b4f-bf47-bf69bf5ff846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses_31fc0e26-c276-4c71-8d9b-5bb6e1b6ad8d" xlink:href="alvo-20231231.xsd#alvo_TaxRateEffectOfNonrecognitionOfTaxLosses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_60a19969-9f26-48f8-9de3-f53b5d5d79c0" xlink:to="loc_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses_31fc0e26-c276-4c71-8d9b-5bb6e1b6ad8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_d7db83ef-8825-4525-b74e-6c9468e42cab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_60a19969-9f26-48f8-9de3-f53b5d5d79c0" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_d7db83ef-8825-4525-b74e-6c9468e42cab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_b4fe1682-d60e-439a-8d67-6f1476cffddd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets_7321e8fa-e99e-42a0-91d3-f9fa38933a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset_b4fe1682-d60e-439a-8d67-6f1476cffddd" xlink:to="loc_ifrs-full_NetDeferredTaxAssets_7321e8fa-e99e-42a0-91d3-f9fa38933a2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities_1baec178-7e9d-46bb-8a88-d9a0f29bdd55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset_b4fe1682-d60e-439a-8d67-6f1476cffddd" xlink:to="loc_ifrs-full_NetDeferredTaxLiabilities_1baec178-7e9d-46bb-8a88-d9a0f29bdd55" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_c1a5dd54-a04b-4841-a386-60320f39e10f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_cc298180-ea8b-49b1-9545-d042060032d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_c1a5dd54-a04b-4841-a386-60320f39e10f" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_cc298180-ea8b-49b1-9545-d042060032d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_c553b8e4-fbd3-46e9-99d2-cd2d4a767ded" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_c1a5dd54-a04b-4841-a386-60320f39e10f" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_c553b8e4-fbd3-46e9-99d2-cd2d4a767ded" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryOfLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseCostRecognizedInProfitAndLoss_f7e3d9c3-bbb8-4a22-abc4-69269700448b" xlink:href="alvo-20231231.xsd#alvo_LeaseCostRecognizedInProfitAndLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_3f44c262-f28e-4cbd-a741-caf4f4ad8254" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_LeaseCostRecognizedInProfitAndLoss_f7e3d9c3-bbb8-4a22-abc4-69269700448b" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_3f44c262-f28e-4cbd-a741-caf4f4ad8254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossFromExtinguishmentOfLeaseLiabilities_17c99276-2df0-4c89-bcc0-f816cc128a7a" xlink:href="alvo-20231231.xsd#alvo_LossFromExtinguishmentOfLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_LeaseCostRecognizedInProfitAndLoss_f7e3d9c3-bbb8-4a22-abc4-69269700448b" xlink:to="loc_alvo_LossFromExtinguishmentOfLeaseLiabilities_17c99276-2df0-4c89-bcc0-f816cc128a7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ForeignCurrencyDifferenceOnLeaseLiability_ad4c0748-38fc-41cc-9931-d23b581d88b8" xlink:href="alvo-20231231.xsd#alvo_ForeignCurrencyDifferenceOnLeaseLiability"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_LeaseCostRecognizedInProfitAndLoss_f7e3d9c3-bbb8-4a22-abc4-69269700448b" xlink:to="loc_alvo_ForeignCurrencyDifferenceOnLeaseLiability_ad4c0748-38fc-41cc-9931-d23b581d88b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_47667e7e-6da9-45ec-8934-ee85bbf454b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_LeaseCostRecognizedInProfitAndLoss_f7e3d9c3-bbb8-4a22-abc4-69269700448b" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_47667e7e-6da9-45ec-8934-ee85bbf454b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_8b6644fe-ff32-43d9-8930-0a04b96dcf4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_496bc77c-f42c-43cb-989c-a37791dbb9fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_8b6644fe-ff32-43d9-8930-0a04b96dcf4e" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_496bc77c-f42c-43cb-989c-a37791dbb9fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_b8b3f1a0-7623-4787-be43-5c3c285e604e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_8b6644fe-ff32-43d9-8930-0a04b96dcf4e" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_b8b3f1a0-7623-4787-be43-5c3c285e604e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_55682ea9-a542-4972-a4fd-a9b8197553db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_8b6644fe-ff32-43d9-8930-0a04b96dcf4e" xlink:to="loc_ifrs-full_OtherCurrentReceivables_55682ea9-a542-4972-a4fd-a9b8197553db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerivaiveAssets_fd9b47cb-6916-4c58-9ae3-2c06bb5b6dac" xlink:href="alvo-20231231.xsd#alvo_DerivaiveAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_8b6644fe-ff32-43d9-8930-0a04b96dcf4e" xlink:to="loc_alvo_DerivaiveAssets_fd9b47cb-6916-4c58-9ae3-2c06bb5b6dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsReceivableFromConvertibleBonds_e215c8a1-2ed4-4614-b197-10665ec3300d" xlink:href="alvo-20231231.xsd#alvo_ProceedsReceivableFromConvertibleBonds"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_8b6644fe-ff32-43d9-8930-0a04b96dcf4e" xlink:to="loc_alvo_ProceedsReceivableFromConvertibleBonds_e215c8a1-2ed4-4614-b197-10665ec3300d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherreservesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherreservesDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/OtherreservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_ba2c0478-7ee0-41da-a72d-80ebc8b43d3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPayments_0940b9f5-dd3c-4dc7-99b2-be22a16fca63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherReserves_ba2c0478-7ee0-41da-a72d-80ebc8b43d3a" xlink:to="loc_ifrs-full_ReserveOfSharebasedPayments_0940b9f5-dd3c-4dc7-99b2-be22a16fca63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments_95c9fe18-a27e-4f0f-bca7-aac403078333" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherReserves_ba2c0478-7ee0-41da-a72d-80ebc8b43d3a" xlink:to="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments_95c9fe18-a27e-4f0f-bca7-aac403078333" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_ac4e069d-f64f-4293-be94-d827c779b9bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_32d79f95-a97c-489d-b6bb-0e16be07c85e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_ac4e069d-f64f-4293-be94-d827c779b9bc" xlink:to="loc_ifrs-full_BondsIssued_32d79f95-a97c-489d-b6bb-0e16be07c85e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_36c23a31-89a4-4c37-b633-fab1066c35eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_ac4e069d-f64f-4293-be94-d827c779b9bc" xlink:to="loc_ifrs-full_LoansReceived_36c23a31-89a4-4c37-b633-fab1066c35eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_2aa16c42-9a04-4aba-99be-2fa7982ec667" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_ac4e069d-f64f-4293-be94-d827c779b9bc" xlink:to="loc_ifrs-full_OtherBorrowings_2aa16c42-9a04-4aba-99be-2fa7982ec667" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_34389e72-0e09-4f5a-bd9c-a85a36e4d0ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses_203635a3-1709-4506-a271-7803831ed804" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_34389e72-0e09-4f5a-bd9c-a85a36e4d0ea" xlink:to="loc_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses_203635a3-1709-4506-a271-7803831ed804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedInterest_76d30d16-cbac-4f50-95e9-83c83b5e139a" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_34389e72-0e09-4f5a-bd9c-a85a36e4d0ea" xlink:to="loc_alvo_CurrentAccruedInterest_76d30d16-cbac-4f50-95e9-83c83b5e139a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedVacation_f2a56e04-fc24-445a-bb80-22a10a8b6356" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedVacation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_34389e72-0e09-4f5a-bd9c-a85a36e4d0ea" xlink:to="loc_alvo_CurrentAccruedVacation_f2a56e04-fc24-445a-bb80-22a10a8b6356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentEmployeeIncentivePlan_48f34cf4-dbbb-4bb7-ac09-4b3d11b36261" xlink:href="alvo-20231231.xsd#alvo_CurrentEmployeeIncentivePlan"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_34389e72-0e09-4f5a-bd9c-a85a36e4d0ea" xlink:to="loc_alvo_CurrentEmployeeIncentivePlan_48f34cf4-dbbb-4bb7-ac09-4b3d11b36261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_e523696a-6184-4a0c-bda6-7514a65c2dac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_34389e72-0e09-4f5a-bd9c-a85a36e4d0ea" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_e523696a-6184-4a0c-bda6-7514a65c2dac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCost_6e6ca21f-edd7-41e4-a1d6-dd5158d34b4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4044ebdb-429c-4da1-9ede-383d845532cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCost_6e6ca21f-edd7-41e4-a1d6-dd5158d34b4d" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4044ebdb-429c-4da1-9ede-383d845532cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_d92ccf5d-38d1-4c7e-a757-44cb313d2bbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCost_6e6ca21f-edd7-41e4-a1d6-dd5158d34b4d" xlink:to="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_d92ccf5d-38d1-4c7e-a757-44cb313d2bbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_a358c557-b5b1-4061-85ba-f7dd04a320dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCost_6e6ca21f-edd7-41e4-a1d6-dd5158d34b4d" xlink:to="loc_ifrs-full_CurrentTradeReceivables_a358c557-b5b1-4061-85ba-f7dd04a320dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAsset_8fb55c54-55c1-4fbe-b8d7-093f20154baf" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCost_6e6ca21f-edd7-41e4-a1d6-dd5158d34b4d" xlink:to="loc_alvo_OtherCurrentAsset_8fb55c54-55c1-4fbe-b8d7-093f20154baf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_aad65c70-c67b-435e-a12a-a8dfc8b601ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCost_6e6ca21f-edd7-41e4-a1d6-dd5158d34b4d" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_aad65c70-c67b-435e-a12a-a8dfc8b601ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherNoncurrentAsset_aaff312a-25da-42d6-b39d-a814b037ff67" xlink:href="alvo-20231231.xsd#alvo_OtherNoncurrentAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCost_6e6ca21f-edd7-41e4-a1d6-dd5158d34b4d" xlink:to="loc_alvo_OtherNoncurrentAsset_aaff312a-25da-42d6-b39d-a814b037ff67" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_689ea072-3194-45de-8662-556c55e52218" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinancialAssetsUndiscountedNonInterestBearingLoansReceivable_d860ea7e-7442-476f-992b-79885b946a09" xlink:href="alvo-20231231.xsd#alvo_FinancialAssetsUndiscountedNonInterestBearingLoansReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_689ea072-3194-45de-8662-556c55e52218" xlink:to="loc_alvo_FinancialAssetsUndiscountedNonInterestBearingLoansReceivable_d860ea7e-7442-476f-992b-79885b946a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinancialAssetsUndiscountedVariableInterestBearingLoansReceivable_71539037-de60-4a74-9a86-d598806c64ad" xlink:href="alvo-20231231.xsd#alvo_FinancialAssetsUndiscountedVariableInterestBearingLoansReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_689ea072-3194-45de-8662-556c55e52218" xlink:to="loc_alvo_FinancialAssetsUndiscountedVariableInterestBearingLoansReceivable_71539037-de60-4a74-9a86-d598806c64ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows_f7fc684f-127c-4c57-a0c6-d8bae9156c5a" xlink:href="alvo-20231231.xsd#alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonInterestBearingUndiscountedCashFlowsLiabilities_1954a9e0-8372-4a4f-baf3-190c67ac3851" xlink:href="alvo-20231231.xsd#alvo_NonInterestBearingUndiscountedCashFlowsLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows_f7fc684f-127c-4c57-a0c6-d8bae9156c5a" xlink:to="loc_alvo_NonInterestBearingUndiscountedCashFlowsLiabilities_1954a9e0-8372-4a4f-baf3-190c67ac3851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_4b3690ba-2fdc-4aac-8b43-a27ba88d4e15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows_f7fc684f-127c-4c57-a0c6-d8bae9156c5a" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_4b3690ba-2fdc-4aac-8b43-a27ba88d4e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssuedUndiscountedCashFlows_6f717c4a-337e-4c66-874e-6eb4ad19e168" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssuedUndiscountedCashFlows"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows_f7fc684f-127c-4c57-a0c6-d8bae9156c5a" xlink:to="loc_ifrs-full_BondsIssuedUndiscountedCashFlows_6f717c4a-337e-4c66-874e-6eb4ad19e168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_f495fb50-526b-452f-8d4a-1c9a743ec54f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows_f7fc684f-127c-4c57-a0c6-d8bae9156c5a" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_f495fb50-526b-452f-8d4a-1c9a743ec54f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>alvo-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0f568319-c84c-47ce-b7c2-396cc2b09ac1,g:54c4089e-eaa8-4b46-9747-283b5fa757be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.alvotech.com/role/CoverPage" xlink:type="simple" xlink:href="alvo-20231231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_7368cf59-3fa8-4e93-a1fe-7eba56b137e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_7368cf59-3fa8-4e93-a1fe-7eba56b137e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_7368cf59-3fa8-4e93-a1fe-7eba56b137e2_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_7368cf59-3fa8-4e93-a1fe-7eba56b137e2" xlink:to="loc_dei_AddressTypeDomain_7368cf59-3fa8-4e93-a1fe-7eba56b137e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_b43335de-6957-4972-8c3c-9cd04a666de2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_7368cf59-3fa8-4e93-a1fe-7eba56b137e2" xlink:to="loc_dei_AddressTypeDomain_b43335de-6957-4972-8c3c-9cd04a666de2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_1528f110-4f23-43e7-9fe6-1e9102e98387" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_b43335de-6957-4972-8c3c-9cd04a666de2" xlink:to="loc_dei_BusinessContactMember_1528f110-4f23-43e7-9fe6-1e9102e98387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStocksAxis_5481295b-04a6-4f5e-8566-2cc2d8f9ae10" xlink:href="alvo-20231231.xsd#alvo_ClassOfStocksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:to="loc_alvo_ClassOfStocksAxis_5481295b-04a6-4f5e-8566-2cc2d8f9ae10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStocksDomain_5481295b-04a6-4f5e-8566-2cc2d8f9ae10_default" xlink:href="alvo-20231231.xsd#alvo_ClassOfStocksDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_ClassOfStocksAxis_5481295b-04a6-4f5e-8566-2cc2d8f9ae10" xlink:to="loc_alvo_ClassOfStocksDomain_5481295b-04a6-4f5e-8566-2cc2d8f9ae10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStocksDomain_ab0d9b79-4afd-4fe0-9f8d-5212643c9dad" xlink:href="alvo-20231231.xsd#alvo_ClassOfStocksDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_ClassOfStocksAxis_5481295b-04a6-4f5e-8566-2cc2d8f9ae10" xlink:to="loc_alvo_ClassOfStocksDomain_ab0d9b79-4afd-4fe0-9f8d-5212643c9dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_3729d015-b2c5-4a89-bf65-3206ff1688c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ClassOfStocksDomain_ab0d9b79-4afd-4fe0-9f8d-5212643c9dad" xlink:to="loc_ifrs-full_OrdinarySharesMember_3729d015-b2c5-4a89-bf65-3206ff1688c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_98d1a515-c32b-4c40-a97f-10d671e2f900" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ClassOfStocksDomain_ab0d9b79-4afd-4fe0-9f8d-5212643c9dad" xlink:to="loc_ifrs-full_WarrantsMember_98d1a515-c32b-4c40-a97f-10d671e2f900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_055c7176-cfde-47cb-8132-eb2ef32c862a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentType_055c7176-cfde-47cb-8132-eb2ef32c862a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_da473fa2-5a88-4506-8538-e8caa4155d4f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentRegistrationStatement_da473fa2-5a88-4506-8538-e8caa4155d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7de0f182-d5b5-4b07-b7c3-c7310f2c5760" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentAnnualReport_7de0f182-d5b5-4b07-b7c3-c7310f2c5760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f58bf877-fc9f-43ca-9797-97165e5bce27" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_CurrentFiscalYearEndDate_f58bf877-fc9f-43ca-9797-97165e5bce27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d84bb72a-23d0-45e6-b8dd-99076231ce7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentPeriodEndDate_d84bb72a-23d0-45e6-b8dd-99076231ce7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_092efdca-07e0-46f9-8117-7308b8f59782" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentTransitionReport_092efdca-07e0-46f9-8117-7308b8f59782" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_931f71ad-f9ed-49c2-99d6-6787e413bf5d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentShellCompanyReport_931f71ad-f9ed-49c2-99d6-6787e413bf5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f6b04066-84b3-459b-b0f0-1299ef54c7d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityFileNumber_f6b04066-84b3-459b-b0f0-1299ef54c7d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a6b4973c-0ed1-478f-9a49-eb5af4418d3b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityRegistrantName_a6b4973c-0ed1-478f-9a49-eb5af4418d3b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0db558e9-8c5f-41f3-83d5-e6d145298afb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0db558e9-8c5f-41f3-83d5-e6d145298afb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_db6b3c8e-4196-4024-b7cb-f143b6334566" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressAddressLine1_db6b3c8e-4196-4024-b7cb-f143b6334566" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f21ff1b7-90f9-41e4-b174-42e0fca113ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressAddressLine2_f21ff1b7-90f9-41e4-b174-42e0fca113ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9dacfd2d-7058-4098-8325-430ab5614043" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressPostalZipCode_9dacfd2d-7058-4098-8325-430ab5614043" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6428a717-9a70-4f53-8fcb-a5e289763484" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressCityOrTown_6428a717-9a70-4f53-8fcb-a5e289763484" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_e118383f-0ec9-454c-9582-82aed6176cf1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressCountry_e118383f-0ec9-454c-9582-82aed6176cf1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_aa377f6f-6e52-4634-a530-bac33cbe7cb7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_ContactPersonnelName_aa377f6f-6e52-4634-a530-bac33cbe7cb7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_06e11079-664e-4b07-b706-a0a81af2edc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_CityAreaCode_06e11079-664e-4b07-b706-a0a81af2edc8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_678b8124-0f2e-432a-9656-d5c1bb0c91b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_LocalPhoneNumber_678b8124-0f2e-432a-9656-d5c1bb0c91b4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6d7b5c8b-8ce5-41f2-8d0e-be819910a9ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_Security12bTitle_6d7b5c8b-8ce5-41f2-8d0e-be819910a9ed" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_764adabc-58a2-4ed9-8694-06b4ba29d592" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_TradingSymbol_764adabc-58a2-4ed9-8694-06b4ba29d592" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_288988c7-d4e6-483b-88a9-ff2134c9c6ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_SecurityExchangeName_288988c7-d4e6-483b-88a9-ff2134c9c6ec" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f6d34484-3c86-4a6b-aaa3-cd455c573eb2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f6d34484-3c86-4a6b-aaa3-cd455c573eb2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsOutstanding_d2de7d24-895a-4627-b56c-74932b31563c" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_alvo_ClassOfWarrantsOrRightsOutstanding_d2de7d24-895a-4627-b56c-74932b31563c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_d88db6bf-07b1-4d9c-ac5e-dc438bb69403" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_d88db6bf-07b1-4d9c-ac5e-dc438bb69403" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_6dce1658-6f0a-49d8-b2ee-8f8ec4589e35" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityVoluntaryFilers_6dce1658-6f0a-49d8-b2ee-8f8ec4589e35" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c28b1f48-2a58-4966-b1b9-d385e0d35a16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityCurrentReportingStatus_c28b1f48-2a58-4966-b1b9-d385e0d35a16" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cf1c3eef-4730-4f6b-93eb-6f404881d7b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityInteractiveDataCurrent_cf1c3eef-4730-4f6b-93eb-6f404881d7b3" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_dd5a38fa-1ea9-42b7-833c-28303af60f00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityFilerCategory_dd5a38fa-1ea9-42b7-833c-28303af60f00" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_73e8f6ea-d1b1-462b-837c-d3e58f3accc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityEmergingGrowthCompany_73e8f6ea-d1b1-462b-837c-d3e58f3accc8" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_28577fb7-3f8d-4b52-af88-58f4f46691a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityExTransitionPeriod_28577fb7-3f8d-4b52-af88-58f4f46691a3" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9c02cc4d-9f40-4845-a25d-bad2a87f55fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9c02cc4d-9f40-4845-a25d-bad2a87f55fd" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_657d60e0-e0a2-42f5-82ad-9211e667e2c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_657d60e0-e0a2-42f5-82ad-9211e667e2c5" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_78ba7abf-7e55-43fc-b3f8-e16e3407ca89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentAccountingStandard_78ba7abf-7e55-43fc-b3f8-e16e3407ca89" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ce9b955e-566a-44eb-a2de-df4c900c31f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityShellCompany_ce9b955e-566a-44eb-a2de-df4c900c31f2" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_02b5260f-3cad-4693-9b92-8a92963793a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityCentralIndexKey_02b5260f-3cad-4693-9b92-8a92963793a0" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2c9b5fe0-0209-4791-8a3e-81f0741612a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2c9b5fe0-0209-4791-8a3e-81f0741612a8" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_84e8b036-6f2a-4116-88ab-d21a2dc64eb4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_AmendmentFlag_84e8b036-6f2a-4116-88ab-d21a2dc64eb4" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_74ee989e-2ee9-4ea7-b965-b4f8ba4d39ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentFiscalYearFocus_74ee989e-2ee9-4ea7-b965-b4f8ba4d39ef" xlink:type="arc" order="37"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_32163db0-35b0-4c2e-a191-fd25095b9a00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_32163db0-35b0-4c2e-a191-fd25095b9a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_32163db0-35b0-4c2e-a191-fd25095b9a00_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_32163db0-35b0-4c2e-a191-fd25095b9a00" xlink:to="loc_ifrs-full_EquityMember_32163db0-35b0-4c2e-a191-fd25095b9a00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_32163db0-35b0-4c2e-a191-fd25095b9a00" xlink:to="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_e6ec63cc-bb47-431d-81cf-656bcd22bd99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_IssuedCapitalMember_e6ec63cc-bb47-431d-81cf-656bcd22bd99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_eaa7c3d0-f9b7-487b-b5ee-29d5d214b050" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_SharePremiumMember_eaa7c3d0-f9b7-487b-b5ee-29d5d214b050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_83789010-aecb-4356-883e-3d9e1d7dfa97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_OtherReservesMember_83789010-aecb-4356-883e-3d9e1d7dfa97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ce9a189c-ec50-42c7-8f04-636881692f56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ce9a189c-ec50-42c7-8f04-636881692f56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_3bbd671c-acd0-4f7c-ad9a-c98281e58bc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_RetainedEarningsMember_3bbd671c-acd0-4f7c-ad9a-c98281e58bc4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_229a88f0-58a7-42be-859a-a10643087674" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_229a88f0-58a7-42be-859a-a10643087674" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_229a88f0-58a7-42be-859a-a10643087674_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_229a88f0-58a7-42be-859a-a10643087674" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_229a88f0-58a7-42be-859a-a10643087674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_229a88f0-58a7-42be-859a-a10643087674" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PennyWarrantsMember_6c1ce34d-5cb1-4e2f-8b13-3d688edb347c" xlink:href="alvo-20231231.xsd#alvo_PennyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_PennyWarrantsMember_6c1ce34d-5cb1-4e2f-8b13-3d688edb347c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PublicWarrantsMember_d5665955-d5f7-498f-ad08-fa60facf1e91" xlink:href="alvo-20231231.xsd#alvo_PublicWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_PublicWarrantsMember_d5665955-d5f7-498f-ad08-fa60facf1e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_711a4aae-8f61-43dc-adeb-9773759cc133" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_711a4aae-8f61-43dc-adeb-9773759cc133" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember_cb2a8cb0-8cda-4940-9039-c5bc52ef6bb9" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_ShareAppreciationRightsMember_cb2a8cb0-8cda-4940-9039-c5bc52ef6bb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnOutSharesMember_bc6031b9-aba7-4870-9ebb-f09f160ddc40" xlink:href="alvo-20231231.xsd#alvo_VestedEarnOutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_VestedEarnOutSharesMember_bc6031b9-aba7-4870-9ebb-f09f160ddc40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherShareBasedPaymentsMember_eaff886a-82d3-48f7-9c97-fa29aa79a5c8" xlink:href="alvo-20231231.xsd#alvo_OtherShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_OtherShareBasedPaymentsMember_eaff886a-82d3-48f7-9c97-fa29aa79a5c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_1d207a29-06fc-48ae-943a-6df7306290c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_Equity_1d207a29-06fc-48ae-943a-6df7306290c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9cf60d14-cead-414b-b28b-e391b9246c21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_ProfitLoss_9cf60d14-cead-414b-b28b-e391b9246c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47942090-eec6-4915-a979-44a3e80ed303" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47942090-eec6-4915-a979-44a3e80ed303" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_f62e5f91-b334-4ae3-bfea-b70a8a8c87cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_ComprehensiveIncome_f62e5f91-b334-4ae3-bfea-b70a8a8c87cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_10ec41ca-8e7c-42e2-b550-73be2ddaa620" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IssueOfEquity_10ec41ca-8e7c-42e2-b550-73be2ddaa620" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughPipeFinancing_1962cfdf-708b-4b8d-aa0b-e00ef3865fbf" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughPipeFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_alvo_IncreaseDecreaseThroughPipeFinancing_1962cfdf-708b-4b8d-aa0b-e00ef3865fbf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughCapitalReorganization_142bac18-da67-43de-9c31-a89fecf52611" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughCapitalReorganization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_alvo_IncreaseDecreaseThroughCapitalReorganization_142bac18-da67-43de-9c31-a89fecf52611" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares_eaca617b-8017-4b8f-af51-4d75e474bab6" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares_eaca617b-8017-4b8f-af51-4d75e474bab6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_859894a2-bb4b-4283-bd4e-3408e780cd4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_859894a2-bb4b-4283-bd4e-3408e780cd4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_af42ab98-3515-438f-9f05-76f59ee794d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_af42ab98-3515-438f-9f05-76f59ee794d7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_e6beaf07-b3ae-471e-b991-6fc3060b616d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_e6beaf07-b3ae-471e-b991-6fc3060b616d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_d457e1f0-1d32-484a-b4b9-6433ef65a1b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_d457e1f0-1d32-484a-b4b9-6433ef65a1b8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e9a7d081-1dc4-45d9-a813-2a84813acf1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GeneralinformationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_4485781f-b0db-4eeb-8986-f690039770d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_4485781f-b0db-4eeb-8986-f690039770d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_f59549bc-bcdb-4d83-a773-a613d0aa6ab3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_4485781f-b0db-4eeb-8986-f690039770d4" xlink:to="loc_ifrs-full_OrdinarySharesMember_f59549bc-bcdb-4d83-a773-a613d0aa6ab3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_9dbf14b0-3f06-46b4-935b-0b87efe9c374" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_9dbf14b0-3f06-46b4-935b-0b87efe9c374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_9dbf14b0-3f06-46b4-935b-0b87efe9c374_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_9dbf14b0-3f06-46b4-935b-0b87efe9c374" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_9dbf14b0-3f06-46b4-935b-0b87efe9c374_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_631cd352-fbf4-402d-820e-44e2404f0dc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_9dbf14b0-3f06-46b4-935b-0b87efe9c374" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_631cd352-fbf4-402d-820e-44e2404f0dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_00538a95-8876-472b-a521-e88536044269" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_631cd352-fbf4-402d-820e-44e2404f0dc3" xlink:to="loc_alvo_EarnoutWarrantsMember_00538a95-8876-472b-a521-e88536044269" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementsTypeAxis_8094e302-a44b-4e24-9547-de178432fe8a" xlink:href="alvo-20231231.xsd#alvo_AgreementsTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_alvo_AgreementsTypeAxis_8094e302-a44b-4e24-9547-de178432fe8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementsTypeDomain_8094e302-a44b-4e24-9547-de178432fe8a_default" xlink:href="alvo-20231231.xsd#alvo_AgreementsTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_AgreementsTypeAxis_8094e302-a44b-4e24-9547-de178432fe8a" xlink:to="loc_alvo_AgreementsTypeDomain_8094e302-a44b-4e24-9547-de178432fe8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementsTypeDomain_70bfc345-4d6e-4e00-ba35-57201e61901d" xlink:href="alvo-20231231.xsd#alvo_AgreementsTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_AgreementsTypeAxis_8094e302-a44b-4e24-9547-de178432fe8a" xlink:to="loc_alvo_AgreementsTypeDomain_70bfc345-4d6e-4e00-ba35-57201e61901d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SubscriptionAgreementsMember_b8987b3d-5c3b-4095-9244-72597e6e84f1" xlink:href="alvo-20231231.xsd#alvo_SubscriptionAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AgreementsTypeDomain_70bfc345-4d6e-4e00-ba35-57201e61901d" xlink:to="loc_alvo_SubscriptionAgreementsMember_b8987b3d-5c3b-4095-9244-72597e6e84f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_db7432e5-d573-4607-94f2-90675062b92b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_db7432e5-d573-4607-94f2-90675062b92b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_db7432e5-d573-4607-94f2-90675062b92b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_db7432e5-d573-4607-94f2-90675062b92b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_db7432e5-d573-4607-94f2-90675062b92b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_e7fd5ad3-e210-4c30-ae38-e6054835f14f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_db7432e5-d573-4607-94f2-90675062b92b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_e7fd5ad3-e210-4c30-ae38-e6054835f14f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_2e212a31-b831-41b9-a935-4dbb84882fe6" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e7fd5ad3-e210-4c30-ae38-e6054835f14f" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_2e212a31-b831-41b9-a935-4dbb84882fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_7278304c-8ab8-4018-a84d-fbfae955e1b4" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e7fd5ad3-e210-4c30-ae38-e6054835f14f" xlink:to="loc_alvo_EarnoutSharesMember_7278304c-8ab8-4018-a84d-fbfae955e1b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c5652203-4bd8-4fb5-bf8c-13541854ad7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c5652203-4bd8-4fb5-bf8c-13541854ad7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c5652203-4bd8-4fb5-bf8c-13541854ad7b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c5652203-4bd8-4fb5-bf8c-13541854ad7b" xlink:to="loc_ifrs-full_EquityMember_c5652203-4bd8-4fb5-bf8c-13541854ad7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_55f0349a-6cef-463c-809e-5d5a52016182" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c5652203-4bd8-4fb5-bf8c-13541854ad7b" xlink:to="loc_ifrs-full_EquityMember_55f0349a-6cef-463c-809e-5d5a52016182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbWarrantsMember_9a55165d-f8c7-43cc-98e8-f86883806045" xlink:href="alvo-20231231.xsd#alvo_OacbWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_55f0349a-6cef-463c-809e-5d5a52016182" xlink:to="loc_alvo_OacbWarrantsMember_9a55165d-f8c7-43cc-98e8-f86883806045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_f2a65901-4e35-49dd-a9fd-77cb1b70fa92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_f2a65901-4e35-49dd-a9fd-77cb1b70fa92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_f2a65901-4e35-49dd-a9fd-77cb1b70fa92_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_f2a65901-4e35-49dd-a9fd-77cb1b70fa92" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_f2a65901-4e35-49dd-a9fd-77cb1b70fa92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_b97ef570-b69c-45a3-8b4b-05c89b7792c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_f2a65901-4e35-49dd-a9fd-77cb1b70fa92" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_b97ef570-b69c-45a3-8b4b-05c89b7792c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BusinessCombinationAndPipeFinancingMember_81f83a27-a563-4f84-a3e3-e088df512c3e" xlink:href="alvo-20231231.xsd#alvo_BusinessCombinationAndPipeFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_b97ef570-b69c-45a3-8b4b-05c89b7792c7" xlink:to="loc_alvo_BusinessCombinationAndPipeFinancingMember_81f83a27-a563-4f84-a3e3-e088df512c3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b04e650e-7c84-4494-a082-fc69c276e03d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b04e650e-7c84-4494-a082-fc69c276e03d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b04e650e-7c84-4494-a082-fc69c276e03d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b04e650e-7c84-4494-a082-fc69c276e03d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b04e650e-7c84-4494-a082-fc69c276e03d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b04e650e-7c84-4494-a082-fc69c276e03d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqPharmaPartnersSarlMember_6288f2ef-fea8-4313-aa65-dbc331733a6c" xlink:href="alvo-20231231.xsd#alvo_AztiqPharmaPartnersSarlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:to="loc_alvo_AztiqPharmaPartnersSarlMember_6288f2ef-fea8-4313-aa65-dbc331733a6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenMember_05b1adf0-bacc-4730-bd09-4437b4882968" xlink:href="alvo-20231231.xsd#alvo_AlvogenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:to="loc_alvo_AlvogenMember_05b1adf0-bacc-4730-bd09-4437b4882968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherSubsidiariesMember_07fa2cb7-d024-48b3-92bf-526ca3a0166a" xlink:href="alvo-20231231.xsd#alvo_OtherSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:to="loc_alvo_OtherSubsidiariesMember_07fa2cb7-d024-48b3-92bf-526ca3a0166a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0b48a9f4-e14f-4c73-b344-83514f540ed5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0b48a9f4-e14f-4c73-b344-83514f540ed5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_0b48a9f4-e14f-4c73-b344-83514f540ed5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0b48a9f4-e14f-4c73-b344-83514f540ed5" xlink:to="loc_ifrs-full_NonadjustingEventsMember_0b48a9f4-e14f-4c73-b344-83514f540ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_6c5dde5e-b4be-467c-8dd5-895e6a497553" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0b48a9f4-e14f-4c73-b344-83514f540ed5" xlink:to="loc_ifrs-full_NonadjustingEventsMember_6c5dde5e-b4be-467c-8dd5-895e6a497553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_d30849db-3170-446e-8b6c-be534f235108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_6c5dde5e-b4be-467c-8dd5-895e6a497553" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_d30849db-3170-446e-8b6c-be534f235108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_8e75de81-24b6-4902-a1a8-5087a0cf8513" xlink:href="alvo-20231231.xsd#alvo_NumberOfSharesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_8e75de81-24b6-4902-a1a8-5087a0cf8513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromTheCapitalReorganization_c6523d07-905e-47cf-bcc6-0e64e4df9c6d" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromTheCapitalReorganization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_ProceedsFromTheCapitalReorganization_c6523d07-905e-47cf-bcc6-0e64e4df9c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockSharesSubscribed_f665035b-ea4d-4544-ac35-a50e3d79ee95" xlink:href="alvo-20231231.xsd#alvo_CommonStockSharesSubscribed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_CommonStockSharesSubscribed_f665035b-ea4d-4544-ac35-a50e3d79ee95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockSubscriptionPricePerShare_bc736114-ba22-4440-8df1-ab5a0d8074f0" xlink:href="alvo-20231231.xsd#alvo_CommonStockSubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_CommonStockSubscriptionPricePerShare_bc736114-ba22-4440-8df1-ab5a0d8074f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockValueSubscriptions_e14f1fe3-53dc-446e-82b9-9b222becd4c0" xlink:href="alvo-20231231.xsd#alvo_CommonStockValueSubscriptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_CommonStockValueSubscriptions_e14f1fe3-53dc-446e-82b9-9b222becd4c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_19efb52a-ed48-4793-aa34-71e020ab7644" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_19efb52a-ed48-4793-aa34-71e020ab7644" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_a2bf2eef-0129-4c92-a48f-dd6c206a8090" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_a2bf2eef-0129-4c92-a48f-dd6c206a8090" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReorganizationShareListingExpense_dc79ab58-4d07-435e-9bbe-4a8c967a6e08" xlink:href="alvo-20231231.xsd#alvo_ReorganizationShareListingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_ReorganizationShareListingExpense_dc79ab58-4d07-435e-9bbe-4a8c967a6e08" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedMarketPricePerShare_f7474af6-d833-40bf-9d9b-0bf32438ea73" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedMarketPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_FairValueOfSharesIssuedMarketPricePerShare_f7474af6-d833-40bf-9d9b-0bf32438ea73" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_408b293a-a8ff-40c5-ae6f-11ac844d4cbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_408b293a-a8ff-40c5-ae6f-11ac844d4cbd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExpenseCapitalized_05de6b3a-312d-4ffc-9221-68b16fce45ae" xlink:href="alvo-20231231.xsd#alvo_ExpenseCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_ExpenseCapitalized_05de6b3a-312d-4ffc-9221-68b16fce45ae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_a3477c90-62b9-48f1-affa-1068bf3e64b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_a3477c90-62b9-48f1-affa-1068bf3e64b6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_241f9bd3-8675-4cc1-bd94-7046524d6332" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_241f9bd3-8675-4cc1-bd94-7046524d6332" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder_245b247c-9c27-4768-80fd-852681cb6c60" xlink:href="alvo-20231231.xsd#alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder_245b247c-9c27-4768-80fd-852681cb6c60" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_d601dd8a-032d-4005-939f-0f3138db6b60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_ProfitLoss_d601dd8a-032d-4005-939f-0f3138db6b60" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_697cc6f7-ef67-434d-967e-918f05d3355d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_RetainedEarnings_697cc6f7-ef67-434d-967e-918f05d3355d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_65baee6a-05fe-41bb-820d-0a599269819c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_CashAndCashEquivalents_65baee6a-05fe-41bb-820d-0a599269819c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities_d2ccb0ed-26bc-4b50-b873-c85ff78ffe17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_CurrentAssetsLiabilities_d2ccb0ed-26bc-4b50-b873-c85ff78ffe17" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_ca8ec701-1898-4a2f-b3a7-002cf7f9801a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_IssueOfEquity_ca8ec701-1898-4a2f-b3a7-002cf7f9801a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_1c3f4894-0427-4684-b8b8-201730842167" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_1c3f4894-0427-4684-b8b8-201730842167" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_e023d582-91f0-49ea-b26c-23f1383f2924" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_e023d582-91f0-49ea-b26c-23f1383f2924" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_01645b5f-6bd8-4180-966a-a02ffce6c93a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_ParValuePerShare_01645b5f-6bd8-4180-966a-a02ffce6c93a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_901077e6-318c-43b5-83fe-0fbf4b80becc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_901077e6-318c-43b5-83fe-0fbf4b80becc" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_448bb195-3bde-492c-8c14-35439dfdb98e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_448bb195-3bde-492c-8c14-35439dfdb98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_448bb195-3bde-492c-8c14-35439dfdb98e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_448bb195-3bde-492c-8c14-35439dfdb98e" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_448bb195-3bde-492c-8c14-35439dfdb98e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_ebf72cda-4029-4bc9-ab02-1abc9b89948e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_448bb195-3bde-492c-8c14-35439dfdb98e" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_ebf72cda-4029-4bc9-ab02-1abc9b89948e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_2d1931ce-f7b1-4ed7-97d1-16b8ec13c92b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_ebf72cda-4029-4bc9-ab02-1abc9b89948e" xlink:to="loc_ifrs-full_OrdinarySharesMember_2d1931ce-f7b1-4ed7-97d1-16b8ec13c92b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassesOfCommonStockAxis_e3e6c4a6-42c3-475b-b25d-58e91b02eba1" xlink:href="alvo-20231231.xsd#alvo_ClassesOfCommonStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:to="loc_alvo_ClassesOfCommonStockAxis_e3e6c4a6-42c3-475b-b25d-58e91b02eba1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassesOfCommonStockMember_e3e6c4a6-42c3-475b-b25d-58e91b02eba1_default" xlink:href="alvo-20231231.xsd#alvo_ClassesOfCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_ClassesOfCommonStockAxis_e3e6c4a6-42c3-475b-b25d-58e91b02eba1" xlink:to="loc_alvo_ClassesOfCommonStockMember_e3e6c4a6-42c3-475b-b25d-58e91b02eba1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassesOfCommonStockMember_eea33a31-2645-4935-b6bd-c6534f138961" xlink:href="alvo-20231231.xsd#alvo_ClassesOfCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_ClassesOfCommonStockAxis_e3e6c4a6-42c3-475b-b25d-58e91b02eba1" xlink:to="loc_alvo_ClassesOfCommonStockMember_eea33a31-2645-4935-b6bd-c6534f138961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassACommonStockMember_df3102cf-721e-44f9-919b-45c01c1da6a7" xlink:href="alvo-20231231.xsd#alvo_ClassACommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ClassesOfCommonStockMember_eea33a31-2645-4935-b6bd-c6534f138961" xlink:to="loc_alvo_ClassACommonStockMember_df3102cf-721e-44f9-919b-45c01c1da6a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassBCommonStockMember_bd92fcba-3fbc-464e-bbd1-4a9d9f376e13" xlink:href="alvo-20231231.xsd#alvo_ClassBCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ClassesOfCommonStockMember_eea33a31-2645-4935-b6bd-c6534f138961" xlink:to="loc_alvo_ClassBCommonStockMember_bd92fcba-3fbc-464e-bbd1-4a9d9f376e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_aee08f6c-7f24-49dd-9154-aecbc494c24e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_aee08f6c-7f24-49dd-9154-aecbc494c24e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_aee08f6c-7f24-49dd-9154-aecbc494c24e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_aee08f6c-7f24-49dd-9154-aecbc494c24e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_aee08f6c-7f24-49dd-9154-aecbc494c24e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_f7228cce-6399-429e-a0b5-e320325863e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_aee08f6c-7f24-49dd-9154-aecbc494c24e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_f7228cce-6399-429e-a0b5-e320325863e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_aadfdc23-2bac-4f81-b581-e66666eec023" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_f7228cce-6399-429e-a0b5-e320325863e3" xlink:to="loc_alvo_EarnoutSharesMember_aadfdc23-2bac-4f81-b581-e66666eec023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2_5f0fdde6-6d2d-4018-8225-a8c114b4838b" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2_5f0fdde6-6d2d-4018-8225-a8c114b4838b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2_1527b7b0-5d7f-44a0-9426-2b042693427e" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2_1527b7b0-5d7f-44a0-9426-2b042693427e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2_b0bc4243-c3cb-4425-86f0-15de24b74e72" xlink:href="alvo-20231231.xsd#alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2_b0bc4243-c3cb-4425-86f0-15de24b74e72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReorganizationShareListingExpense_34dc9731-b60c-4f10-a7c3-a81314c5a4b6" xlink:href="alvo-20231231.xsd#alvo_ReorganizationShareListingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_ReorganizationShareListingExpense_34dc9731-b60c-4f10-a7c3-a81314c5a4b6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2af2d2a1-5397-4165-be6e-efffe8bee4f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2af2d2a1-5397-4165-be6e-efffe8bee4f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2af2d2a1-5397-4165-be6e-efffe8bee4f4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2af2d2a1-5397-4165-be6e-efffe8bee4f4" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2af2d2a1-5397-4165-be6e-efffe8bee4f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2af2d2a1-5397-4165-be6e-efffe8bee4f4" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechHfMember_56920944-d2e6-4bad-9074-c33b5f7ba100" xlink:href="alvo-20231231.xsd#alvo_AlvotechHfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechHfMember_56920944-d2e6-4bad-9074-c33b5f7ba100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechGermanyGmbhMember_cacccf5a-503a-4022-9de4-8c37c9b1ffef" xlink:href="alvo-20231231.xsd#alvo_AlvotechGermanyGmbhMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechGermanyGmbhMember_cacccf5a-503a-4022-9de4-8c37c9b1ffef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechSwissAgMember_27eec329-1ce2-4efc-a271-4bae663eccdb" xlink:href="alvo-20231231.xsd#alvo_AlvotechSwissAgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechSwissAgMember_27eec329-1ce2-4efc-a271-4bae663eccdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechHannoverGmbhMember_77dfc2c8-e642-44f7-a272-f2ac8367774a" xlink:href="alvo-20231231.xsd#alvo_AlvotechHannoverGmbhMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechHannoverGmbhMember_77dfc2c8-e642-44f7-a272-f2ac8367774a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechMaltaLtdMember_762254ad-f881-4bcc-b117-075d4e0a9cef" xlink:href="alvo-20231231.xsd#alvo_AlvotechMaltaLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechMaltaLtdMember_762254ad-f881-4bcc-b117-075d4e0a9cef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechUsaIncMember_b1e38604-a98e-42fa-8fd7-2b41e3c7f64c" xlink:href="alvo-20231231.xsd#alvo_AlvotechUsaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechUsaIncMember_b1e38604-a98e-42fa-8fd7-2b41e3c7f64c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechUkLtdMember_0116f429-a59c-46a8-b156-fcb233a91bd9" xlink:href="alvo-20231231.xsd#alvo_AlvotechUkLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechUkLtdMember_0116f429-a59c-46a8-b156-fcb233a91bd9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechMancoEhfMember_e2947693-9d0b-476f-9fe6-56155540578d" xlink:href="alvo-20231231.xsd#alvo_AlvotechMancoEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechMancoEhfMember_e2947693-9d0b-476f-9fe6-56155540578d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechBiosciencesIndiaPrivateLtdMember_d04b3d2f-2b94-4f64-b435-328cccdd09a6" xlink:href="alvo-20231231.xsd#alvo_AlvotechBiosciencesIndiaPrivateLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechBiosciencesIndiaPrivateLtdMember_d04b3d2f-2b94-4f64-b435-328cccdd09a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHfMember_377a0700-2800-4b61-89d9-3561fe86efd9" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_FasteignafelagiSmundurHfMember_377a0700-2800-4b61-89d9-3561fe86efd9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_858ddc7d-f507-4a54-be51-4278c6c4340d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:to="loc_ifrs-full_JointVenturesAxis_858ddc7d-f507-4a54-be51-4278c6c4340d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_858ddc7d-f507-4a54-be51-4278c6c4340d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_858ddc7d-f507-4a54-be51-4278c6c4340d" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_858ddc7d-f507-4a54-be51-4278c6c4340d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_45bfe90a-8d31-4cad-be24-dd727f9a0966" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_858ddc7d-f507-4a54-be51-4278c6c4340d" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_45bfe90a-8d31-4cad-be24-dd727f9a0966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember_162ba2d6-995e-42d0-b323-6dd200bfd305" xlink:href="alvo-20231231.xsd#alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_45bfe90a-8d31-4cad-be24-dd727f9a0966" xlink:to="loc_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember_162ba2d6-995e-42d0-b323-6dd200bfd305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_e3a0147e-81fe-460f-9ab9-2c61d25bcc71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_e3a0147e-81fe-460f-9ab9-2c61d25bcc71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_f028bb95-edae-48bd-a406-7111ed1ba595" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_f028bb95-edae-48bd-a406-7111ed1ba595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_2760b9f8-73db-4a06-ab4a-23ccc4726108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_2760b9f8-73db-4a06-ab4a-23ccc4726108" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_af0d774e-0a56-475c-ad8c-409eb71df639" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_af0d774e-0a56-475c-ad8c-409eb71df639" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_af0d774e-0a56-475c-ad8c-409eb71df639" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0a616be0-6b6a-4293-9c6d-a9bc0658e062" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0a616be0-6b6a-4293-9c6d-a9bc0658e062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusPharmaceuticalCo.LtdMember_50cc0113-f84d-4e00-96b3-d6cf69bf303d" xlink:href="alvo-20231231.xsd#alvo_LotusPharmaceuticalCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0a616be0-6b6a-4293-9c6d-a9bc0658e062" xlink:to="loc_alvo_LotusPharmaceuticalCo.LtdMember_50cc0113-f84d-4e00-96b3-d6cf69bf303d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_f779f3b8-f48e-4a0e-b2f4-ea38c0698440" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_f779f3b8-f48e-4a0e-b2f4-ea38c0698440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfOperatingSegments1_8789a901-446e-48a4-9feb-55397c59c064" xlink:href="alvo-20231231.xsd#alvo_NumberOfOperatingSegments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_alvo_NumberOfOperatingSegments1_8789a901-446e-48a4-9feb-55397c59c064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_UpfrontPayment_5a6b4482-7608-4538-882c-7c72be104f0d" xlink:href="alvo-20231231.xsd#alvo_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_alvo_UpfrontPayment_5a6b4482-7608-4538-882c-7c72be104f0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7be99bb0-e829-4495-9f24-9700484c4bfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7be99bb0-e829-4495-9f24-9700484c4bfb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c25bbc7a-0830-4ca6-827e-a8921343c360" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c25bbc7a-0830-4ca6-827e-a8921343c360" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_61572556-dcca-4da7-ba55-b457fd26606c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_61572556-dcca-4da7-ba55-b457fd26606c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_61572556-dcca-4da7-ba55-b457fd26606c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_61572556-dcca-4da7-ba55-b457fd26606c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_61572556-dcca-4da7-ba55-b457fd26606c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_61572556-dcca-4da7-ba55-b457fd26606c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_dfe39cc2-3658-4be6-bf45-a529d5283346" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:to="loc_ifrs-full_ComputerSoftwareMember_dfe39cc2-3658-4be6-bf45-a529d5283346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember_86910c83-4257-4884-826e-a8e60a0eff8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CustomerrelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:to="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember_86910c83-4257-4884-826e-a8e60a0eff8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntellectualPropertyRightsMember_cb35ce5c-f92d-4373-bc25-730c40314174" xlink:href="alvo-20231231.xsd#alvo_IntellectualPropertyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:to="loc_alvo_IntellectualPropertyRightsMember_cb35ce5c-f92d-4373-bc25-730c40314174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_c93ba5c8-ce01-479d-87c0-84a7c1ae8254" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:to="loc_ifrs-full_RangeAxis_c93ba5c8-ce01-479d-87c0-84a7c1ae8254" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_c93ba5c8-ce01-479d-87c0-84a7c1ae8254_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_c93ba5c8-ce01-479d-87c0-84a7c1ae8254" xlink:to="loc_ifrs-full_RangesMember_c93ba5c8-ce01-479d-87c0-84a7c1ae8254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_0dbe0af9-0072-4f66-9bdc-ce22b7ead306" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_c93ba5c8-ce01-479d-87c0-84a7c1ae8254" xlink:to="loc_ifrs-full_RangesMember_0dbe0af9-0072-4f66-9bdc-ce22b7ead306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_678319bb-47f2-4a54-a01b-709c79dd2a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_0dbe0af9-0072-4f66-9bdc-ce22b7ead306" xlink:to="loc_ifrs-full_BottomOfRangeMember_678319bb-47f2-4a54-a01b-709c79dd2a2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_751975b4-9965-42bb-a505-8cf7de74462d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_0dbe0af9-0072-4f66-9bdc-ce22b7ead306" xlink:to="loc_ifrs-full_TopOfRangeMember_751975b4-9965-42bb-a505-8cf7de74462d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_0732dad3-433a-4f2d-9a22-bf96e92dce69" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c25bbc7a-0830-4ca6-827e-a8921343c360" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_0732dad3-433a-4f2d-9a22-bf96e92dce69" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_714421f2-127a-4691-91c1-63d136bdd78d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_714421f2-127a-4691-91c1-63d136bdd78d" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5bf369d7-a4a7-4682-a117-5da00e3e650f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5bf369d7-a4a7-4682-a117-5da00e3e650f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_5bf369d7-a4a7-4682-a117-5da00e3e650f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5bf369d7-a4a7-4682-a117-5da00e3e650f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_5bf369d7-a4a7-4682-a117-5da00e3e650f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5bf369d7-a4a7-4682-a117-5da00e3e650f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityMember_6d539d63-b90c-4b9e-8aad-bc9eac816797" xlink:href="alvo-20231231.xsd#alvo_FacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_alvo_FacilityMember_6d539d63-b90c-4b9e-8aad-bc9eac816797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityEquipmentMember_886175c2-3317-444a-8b4a-52b96e2d573b" xlink:href="alvo-20231231.xsd#alvo_FacilityEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_alvo_FacilityEquipmentMember_886175c2-3317-444a-8b4a-52b96e2d573b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_2f31efdf-9721-472e-ba2b-a29e53bd05ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_ifrs-full_ComputerEquipmentMember_2f31efdf-9721-472e-ba2b-a29e53bd05ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_2b34c2c6-0b04-4925-86a0-2360735f93ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_2b34c2c6-0b04-4925-86a0-2360735f93ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_0ad95a9e-5210-4058-839b-cc89004cc032" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_0ad95a9e-5210-4058-839b-cc89004cc032" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_6e31c0dc-9ee4-45d2-a842-009c022733f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:to="loc_ifrs-full_RangeAxis_6e31c0dc-9ee4-45d2-a842-009c022733f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_6e31c0dc-9ee4-45d2-a842-009c022733f0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_6e31c0dc-9ee4-45d2-a842-009c022733f0" xlink:to="loc_ifrs-full_RangesMember_6e31c0dc-9ee4-45d2-a842-009c022733f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_62da08b5-ac4b-47dc-bb85-b021663b15bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_6e31c0dc-9ee4-45d2-a842-009c022733f0" xlink:to="loc_ifrs-full_RangesMember_62da08b5-ac4b-47dc-bb85-b021663b15bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_5e6b8d4b-8171-4183-8f68-67318f8108aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_62da08b5-ac4b-47dc-bb85-b021663b15bf" xlink:to="loc_ifrs-full_BottomOfRangeMember_5e6b8d4b-8171-4183-8f68-67318f8108aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_ae86b21e-5b0a-484b-b908-4714cec0aba3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_62da08b5-ac4b-47dc-bb85-b021663b15bf" xlink:to="loc_ifrs-full_TopOfRangeMember_ae86b21e-5b0a-484b-b908-4714cec0aba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_562fecfb-0f39-4a89-aada-933c8e54f558" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_714421f2-127a-4691-91c1-63d136bdd78d" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_562fecfb-0f39-4a89-aada-933c8e54f558" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_badf9f55-e474-4b55-bd65-518befd533a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_e38aa574-cc62-433b-a7e0-4cce40f1053b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_badf9f55-e474-4b55-bd65-518befd533a3" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_e38aa574-cc62-433b-a7e0-4cce40f1053b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_5db8cce7-51d4-476d-8b93-11be908a58ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_e38aa574-cc62-433b-a7e0-4cce40f1053b" xlink:to="loc_ifrs-full_GeographicalAreasAxis_5db8cce7-51d4-476d-8b93-11be908a58ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_5db8cce7-51d4-476d-8b93-11be908a58ca_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_5db8cce7-51d4-476d-8b93-11be908a58ca" xlink:to="loc_ifrs-full_GeographicalAreasMember_5db8cce7-51d4-476d-8b93-11be908a58ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_5db8cce7-51d4-476d-8b93-11be908a58ca" xlink:to="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2f1461d2-02db-4521-b4b6-ccae0aef2875" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:to="loc_srt_EuropeMember_2f1461d2-02db-4521-b4b6-ccae0aef2875" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_885c0625-fd8d-4901-a23a-5f6da86c46fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:to="loc_srt_NorthAmericaMember_885c0625-fd8d-4901-a23a-5f6da86c46fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AsiaAndOtherMember_5b668966-8565-47e7-b96b-89ccf37ee95e" xlink:href="alvo-20231231.xsd#alvo_AsiaAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:to="loc_alvo_AsiaAndOtherMember_5b668966-8565-47e7-b96b-89ccf37ee95e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_363bde3f-c897-4709-9b61-9ea0a826e028" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_badf9f55-e474-4b55-bd65-518befd533a3" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_363bde3f-c897-4709-9b61-9ea0a826e028" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_4ef5f21b-5ebd-47e9-a0d1-78eab01fe116" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_18eb070a-b2c6-432b-96cb-8efaef2bb590" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_4ef5f21b-5ebd-47e9-a0d1-78eab01fe116" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_18eb070a-b2c6-432b-96cb-8efaef2bb590" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_2f33eb93-edf5-4da4-91ca-d77c52c10e7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_18eb070a-b2c6-432b-96cb-8efaef2bb590" xlink:to="loc_ifrs-full_GeographicalAreasAxis_2f33eb93-edf5-4da4-91ca-d77c52c10e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_2f33eb93-edf5-4da4-91ca-d77c52c10e7b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2f33eb93-edf5-4da4-91ca-d77c52c10e7b" xlink:to="loc_ifrs-full_GeographicalAreasMember_2f33eb93-edf5-4da4-91ca-d77c52c10e7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2f33eb93-edf5-4da4-91ca-d77c52c10e7b" xlink:to="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0c1425b8-6c4b-4fb9-9c75-c307f77f88a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:to="loc_srt_EuropeMember_0c1425b8-6c4b-4fb9-9c75-c307f77f88a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_fa80d91a-8049-4876-9660-9eb593946631" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:to="loc_srt_NorthAmericaMember_fa80d91a-8049-4876-9660-9eb593946631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AsiaAndOtherMember_754bfb61-5613-4c3a-8237-579ac9cc3ece" xlink:href="alvo-20231231.xsd#alvo_AsiaAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:to="loc_alvo_AsiaAndOtherMember_754bfb61-5613-4c3a-8237-579ac9cc3ece" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_968897f5-1c2e-4f0c-8c21-a7850422d68c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_4ef5f21b-5ebd-47e9-a0d1-78eab01fe116" xlink:to="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_968897f5-1c2e-4f0c-8c21-a7850422d68c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMajorCustomersLineItems_93103b0f-2d13-45d4-af81-aab33b73feb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMajorCustomersTable_5da3c142-a194-4ec0-92c1-de9c46df1298" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMajorCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersLineItems_93103b0f-2d13-45d4-af81-aab33b73feb5" xlink:to="loc_ifrs-full_DisclosureOfMajorCustomersTable_5da3c142-a194-4ec0-92c1-de9c46df1298" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_a4194d4f-da54-46bc-98a4-93d73b8f52ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersTable_5da3c142-a194-4ec0-92c1-de9c46df1298" xlink:to="loc_ifrs-full_MajorCustomersAxis_a4194d4f-da54-46bc-98a4-93d73b8f52ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_a4194d4f-da54-46bc-98a4-93d73b8f52ee_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MajorCustomersAxis_a4194d4f-da54-46bc-98a4-93d73b8f52ee" xlink:to="loc_ifrs-full_MajorCustomersMember_a4194d4f-da54-46bc-98a4-93d73b8f52ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MajorCustomersAxis_a4194d4f-da54-46bc-98a4-93d73b8f52ee" xlink:to="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerAMember_849f9ac0-cc5e-4e0c-991c-12b261bd337a" xlink:href="alvo-20231231.xsd#alvo_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:to="loc_alvo_CustomerAMember_849f9ac0-cc5e-4e0c-991c-12b261bd337a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerBMember_05224c4c-0257-41c7-bd42-fd95640db125" xlink:href="alvo-20231231.xsd#alvo_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:to="loc_alvo_CustomerBMember_05224c4c-0257-41c7-bd42-fd95640db125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerCMember_dcb443ce-9f62-4a3b-bcab-9d955df02ba9" xlink:href="alvo-20231231.xsd#alvo_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:to="loc_alvo_CustomerCMember_dcb443ce-9f62-4a3b-bcab-9d955df02ba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerDMember_44d7e200-7477-4303-b4ba-db581f4bd14b" xlink:href="alvo-20231231.xsd#alvo_CustomerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:to="loc_alvo_CustomerDMember_44d7e200-7477-4303-b4ba-db581f4bd14b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_e3a5bbcc-3b2c-4b72-b484-6893a1956a29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersLineItems_93103b0f-2d13-45d4-af81-aab33b73feb5" xlink:to="loc_ifrs-full_Revenue_e3a5bbcc-3b2c-4b72-b484-6893a1956a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_fff35f0e-f136-48c3-843a-853f34eb2d63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersLineItems_93103b0f-2d13-45d4-af81-aab33b73feb5" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_fff35f0e-f136-48c3-843a-853f34eb2d63" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d97ed54a-122b-41a3-a8cc-cf3db3d40fe3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d97ed54a-122b-41a3-a8cc-cf3db3d40fe3" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_82fde80c-50df-462c-8e20-397474fb1d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_82fde80c-50df-462c-8e20-397474fb1d52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_82fde80c-50df-462c-8e20-397474fb1d52_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_82fde80c-50df-462c-8e20-397474fb1d52" xlink:to="loc_ifrs-full_ProductsAndServicesMember_82fde80c-50df-462c-8e20-397474fb1d52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_82fde80c-50df-462c-8e20-397474fb1d52" xlink:to="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProductRevenueMember_b734addb-935b-4af5-866a-d0a2bcd6180c" xlink:href="alvo-20231231.xsd#alvo_ProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:to="loc_alvo_ProductRevenueMember_b734addb-935b-4af5-866a-d0a2bcd6180c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LicenseRevenueMember_d1de40d2-9890-4ffa-bf03-1b70dc5b4904" xlink:href="alvo-20231231.xsd#alvo_LicenseRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:to="loc_alvo_LicenseRevenueMember_d1de40d2-9890-4ffa-bf03-1b70dc5b4904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DevelopmentAndOtherServiceRevenueMember_87b70524-0f77-4e80-970b-646f505b1bdd" xlink:href="alvo-20231231.xsd#alvo_DevelopmentAndOtherServiceRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:to="loc_alvo_DevelopmentAndOtherServiceRevenueMember_87b70524-0f77-4e80-970b-646f505b1bdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_54555790-bb6f-4fa4-bdb5-8929b2f63bcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_54555790-bb6f-4fa4-bdb5-8929b2f63bcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_aba3da4b-5d28-401a-b3c3-e365d11a142a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_54555790-bb6f-4fa4-bdb5-8929b2f63bcc" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_aba3da4b-5d28-401a-b3c3-e365d11a142a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_dba4a322-275f-4be1-a73b-b953130f2862" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_54555790-bb6f-4fa4-bdb5-8929b2f63bcc" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_dba4a322-275f-4be1-a73b-b953130f2862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_151d25b8-0f33-47c7-9931-26bcffb37e50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d97ed54a-122b-41a3-a8cc-cf3db3d40fe3" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_151d25b8-0f33-47c7-9931-26bcffb37e50" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_818d3db5-835e-47f6-9512-65eee3495368" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_bda422a0-01a7-4ed8-976f-9ae3e9339205" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_818d3db5-835e-47f6-9512-65eee3495368" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_bda422a0-01a7-4ed8-976f-9ae3e9339205" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_f67ea609-7e86-4378-9972-61c62e3593b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_bda422a0-01a7-4ed8-976f-9ae3e9339205" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_f67ea609-7e86-4378-9972-61c62e3593b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_f67ea609-7e86-4378-9972-61c62e3593b3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_f67ea609-7e86-4378-9972-61c62e3593b3" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_f67ea609-7e86-4378-9972-61c62e3593b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_6acb6098-37ef-4ff2-b06e-c8635bcfeb6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_f67ea609-7e86-4378-9972-61c62e3593b3" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_6acb6098-37ef-4ff2-b06e-c8635bcfeb6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetMember_8b9d2983-6968-4944-810c-30268929a42b" xlink:href="alvo-20231231.xsd#alvo_ContractAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_6acb6098-37ef-4ff2-b06e-c8635bcfeb6c" xlink:to="loc_alvo_ContractAssetMember_8b9d2983-6968-4944-810c-30268929a42b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesMember_b1330e8e-43e0-4a5b-8d69-007235020441" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_6acb6098-37ef-4ff2-b06e-c8635bcfeb6c" xlink:to="loc_alvo_ContractLiabilitiesMember_b1330e8e-43e0-4a5b-8d69-007235020441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_818d3db5-835e-47f6-9512-65eee3495368" xlink:to="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractAssets_ae7a000e-d228-4e87-bf84-2b656154b6c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:to="loc_ifrs-full_ContractAssets_ae7a000e-d228-4e87-bf84-2b656154b6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets_399dfeb2-edab-4650-83f8-3aaf47edc5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets_399dfeb2-edab-4650-83f8-3aaf47edc5f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables_1fee69a3-1211-41c6-a2eb-762d544678ba" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:to="loc_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables_1fee69a3-1211-41c6-a2eb-762d544678ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractAssets_3874261e-b879-49b0-b9ea-753fcfaf5578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_818d3db5-835e-47f6-9512-65eee3495368" xlink:to="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_a3300dba-4b0e-46c5-99d5-dfe11a7249d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_ifrs-full_ContractLiabilities_a3300dba-4b0e-46c5-99d5-dfe11a7249d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables_9c74e565-e639-4c79-82d9-8a4eec16e8c3" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables_9c74e565-e639-4c79-82d9-8a4eec16e8c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability_bcf859ff-c0c2-46a4-ab17-c91e88d4eb72" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability_bcf859ff-c0c2-46a4-ab17-c91e88d4eb72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilityCustomerPrepayments_047a265e-9836-4bd7-ad4c-3b26bd60e21f" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilityCustomerPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_alvo_ContractLiabilityCustomerPrepayments_047a265e-9836-4bd7-ad4c-3b26bd60e21f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities_8d8648d4-735a-4e5d-80ac-16fea41a375a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities_8d8648d4-735a-4e5d-80ac-16fea41a375a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment_b07fc157-30c6-40d7-9453-1ef54124e216" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment_b07fc157-30c6-40d7-9453-1ef54124e216" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_20a418d8-4ff3-42f3-87c6-b7eb23ea84c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RevenueAdditionalinformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RevenueAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/RevenueAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_197c79a5-fe48-42fd-a10f-689cc88fc029" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:to="loc_ifrs-full_RangeAxis_197c79a5-fe48-42fd-a10f-689cc88fc029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_197c79a5-fe48-42fd-a10f-689cc88fc029_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_197c79a5-fe48-42fd-a10f-689cc88fc029" xlink:to="loc_ifrs-full_RangesMember_197c79a5-fe48-42fd-a10f-689cc88fc029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_84e7d2e4-7ce4-470b-91a4-5722b51e4cae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_197c79a5-fe48-42fd-a10f-689cc88fc029" xlink:to="loc_ifrs-full_RangesMember_84e7d2e4-7ce4-470b-91a4-5722b51e4cae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_a1c15705-e8c9-4138-a7a8-6727068ba8f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_84e7d2e4-7ce4-470b-91a4-5722b51e4cae" xlink:to="loc_ifrs-full_BottomOfRangeMember_a1c15705-e8c9-4138-a7a8-6727068ba8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_1d4c4552-62cd-4d51-957a-f910ad7f6710" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_84e7d2e4-7ce4-470b-91a4-5722b51e4cae" xlink:to="loc_ifrs-full_TopOfRangeMember_1d4c4552-62cd-4d51-957a-f910ad7f6710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_4145ef70-cfb8-4f81-9868-4455dda1f3f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:to="loc_ifrs-full_MaturityAxis_4145ef70-cfb8-4f81-9868-4455dda1f3f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_4145ef70-cfb8-4f81-9868-4455dda1f3f7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_4145ef70-cfb8-4f81-9868-4455dda1f3f7" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_4145ef70-cfb8-4f81-9868-4455dda1f3f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_91890b49-cf2d-404f-bf15-a59c7cd1bdcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_4145ef70-cfb8-4f81-9868-4455dda1f3f7" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_91890b49-cf2d-404f-bf15-a59c7cd1bdcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NotLaterThanFiveYearsMember_a5e16ff0-d42f-47f8-9410-3bce207b9eca" xlink:href="alvo-20231231.xsd#alvo_NotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_91890b49-cf2d-404f-bf15-a59c7cd1bdcb" xlink:to="loc_alvo_NotLaterThanFiveYearsMember_a5e16ff0-d42f-47f8-9410-3bce207b9eca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsAxis_f15157bf-5222-4460-a149-e96efb4ec60e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:to="loc_ifrs-full_PerformanceObligationsAxis_f15157bf-5222-4460-a149-e96efb4ec60e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsMember_f15157bf-5222-4460-a149-e96efb4ec60e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_PerformanceObligationsAxis_f15157bf-5222-4460-a149-e96efb4ec60e" xlink:to="loc_ifrs-full_PerformanceObligationsMember_f15157bf-5222-4460-a149-e96efb4ec60e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsMember_00a9f2b8-273d-4291-80fd-2584033dafc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_PerformanceObligationsAxis_f15157bf-5222-4460-a149-e96efb4ec60e" xlink:to="loc_ifrs-full_PerformanceObligationsMember_00a9f2b8-273d-4291-80fd-2584033dafc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_be22510d-df56-49ba-bdb3-e8596f8d584e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PerformanceObligationsMember_00a9f2b8-273d-4291-80fd-2584033dafc3" xlink:to="loc_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_be22510d-df56-49ba-bdb3-e8596f8d584e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractAssets_5f3cf7a9-9e22-414b-b02c-ace0b77bf606" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_NoncurrentContractAssets_5f3cf7a9-9e22-414b-b02c-ace0b77bf606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractAssets_65ba858b-7dc4-4d5a-a9af-432e98f2b8e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_CurrentContractAssets_65ba858b-7dc4-4d5a-a9af-432e98f2b8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NoncurrentContractAssetsMaterializePeriod_eb64e60c-3b35-4537-b1c9-b2d755c76cbb" xlink:href="alvo-20231231.xsd#alvo_NoncurrentContractAssetsMaterializePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_alvo_NoncurrentContractAssetsMaterializePeriod_eb64e60c-3b35-4537-b1c9-b2d755c76cbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_f6224a69-bd4e-486f-82e9-b2c6dbb365a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_f6224a69-bd4e-486f-82e9-b2c6dbb365a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_039853fb-f380-4305-be2b-0a4bb3476a82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_CurrentContractLiabilities_039853fb-f380-4305-be2b-0a4bb3476a82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod_3f4e2fe3-e082-4cc8-beb6-6ffac512e26d" xlink:href="alvo-20231231.xsd#alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod_3f4e2fe3-e082-4cc8-beb6-6ffac512e26d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_338152cf-5583-42dc-be72-e0198bc409d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_338152cf-5583-42dc-be72-e0198bc409d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod_acada7da-8c05-450c-8831-7821c0fcbe1e" xlink:href="alvo-20231231.xsd#alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod_acada7da-8c05-450c-8831-7821c0fcbe1e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_cde9ce3a-7739-4279-8914-faf935a81fa8" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_b5cbdc3c-c81a-43a3-9888-0f2d958ddf8e" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_cde9ce3a-7739-4279-8914-faf935a81fa8" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_b5cbdc3c-c81a-43a3-9888-0f2d958ddf8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_eb2f75cc-0006-427c-b94a-b20a155ff065" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_b5cbdc3c-c81a-43a3-9888-0f2d958ddf8e" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_eb2f75cc-0006-427c-b94a-b20a155ff065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_eb2f75cc-0006-427c-b94a-b20a155ff065_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_eb2f75cc-0006-427c-b94a-b20a155ff065" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_eb2f75cc-0006-427c-b94a-b20a155ff065_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_eb2f75cc-0006-427c-b94a-b20a155ff065" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CostOfProductRevenueMember_db618429-f1b5-40e4-8efb-c7bbcb09ff37" xlink:href="alvo-20231231.xsd#alvo_CostOfProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:to="loc_alvo_CostOfProductRevenueMember_db618429-f1b5-40e4-8efb-c7bbcb09ff37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentExpensesMember_69ad7a9c-7f1f-4ab2-8cce-31e9b4ea3253" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:to="loc_alvo_ResearchAndDevelopmentExpensesMember_69ad7a9c-7f1f-4ab2-8cce-31e9b4ea3253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember_0a42c758-127e-4c77-a5dc-85a93bc31ac4" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:to="loc_alvo_GeneralAndAdministrativeExpensesMember_0a42c758-127e-4c77-a5dc-85a93bc31ac4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_651b70ba-edc3-496b-a49d-b475c2a81e37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_cde9ce3a-7739-4279-8914-faf935a81fa8" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_651b70ba-edc3-496b-a49d-b475c2a81e37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_d3af45a4-ad19-4e73-aae1-5a6dc968fd29" xlink:href="alvo-20231231.xsd#alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_2a3b9068-db86-400d-9f10-b914a390efa6" xlink:href="alvo-20231231.xsd#alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_d3af45a4-ad19-4e73-aae1-5a6dc968fd29" xlink:to="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_2a3b9068-db86-400d-9f10-b914a390efa6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_26466cbe-4457-4225-be41-17ce5123a835" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_2a3b9068-db86-400d-9f10-b914a390efa6" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_26466cbe-4457-4225-be41-17ce5123a835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_26466cbe-4457-4225-be41-17ce5123a835_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_26466cbe-4457-4225-be41-17ce5123a835" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_26466cbe-4457-4225-be41-17ce5123a835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_26466cbe-4457-4225-be41-17ce5123a835" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CostOfProductRevenueMember_8e569007-ec3a-4b3a-9fb1-f09cf6f12a7e" xlink:href="alvo-20231231.xsd#alvo_CostOfProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:to="loc_alvo_CostOfProductRevenueMember_8e569007-ec3a-4b3a-9fb1-f09cf6f12a7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentExpensesMember_d5d6de87-7dd3-4153-8c2f-3dba4ba45289" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:to="loc_alvo_ResearchAndDevelopmentExpensesMember_d5d6de87-7dd3-4153-8c2f-3dba4ba45289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember_0b15ca43-51ce-4cd1-9183-190d24854db2" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:to="loc_alvo_GeneralAndAdministrativeExpensesMember_0b15ca43-51ce-4cd1-9183-190d24854db2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_ed9263d3-3e7c-4fb5-ae1e-3de85168cb63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_d3af45a4-ad19-4e73-aae1-5a6dc968fd29" xlink:to="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_ed9263d3-3e7c-4fb5-ae1e-3de85168cb63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_81d2ec82-3c09-4654-a93e-09b70866bea4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_81d2ec82-3c09-4654-a93e-09b70866bea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_81d2ec82-3c09-4654-a93e-09b70866bea4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_81d2ec82-3c09-4654-a93e-09b70866bea4" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_81d2ec82-3c09-4654-a93e-09b70866bea4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_acc89e5e-07b9-4d28-86ef-170f35dcf512" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_81d2ec82-3c09-4654-a93e-09b70866bea4" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_acc89e5e-07b9-4d28-86ef-170f35dcf512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_b746588a-693a-40af-8067-899acd9c1b51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_acc89e5e-07b9-4d28-86ef-170f35dcf512" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_b746588a-693a-40af-8067-899acd9c1b51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceMember_6d316a69-3dc0-4dbc-83b5-1ce5aeb136e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_acc89e5e-07b9-4d28-86ef-170f35dcf512" xlink:to="loc_ifrs-full_TemporaryDifferenceMember_6d316a69-3dc0-4dbc-83b5-1ce5aeb136e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_43510af9-6dea-4288-a8c2-2d9c058a01e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:to="loc_srt_StatementGeographicalAxis_43510af9-6dea-4288-a8c2-2d9c058a01e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_43510af9-6dea-4288-a8c2-2d9c058a01e9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_43510af9-6dea-4288-a8c2-2d9c058a01e9" xlink:to="loc_srt_SegmentGeographicalDomain_43510af9-6dea-4288-a8c2-2d9c058a01e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_79fff4fe-623c-4005-80f8-cfa70b2c606b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_43510af9-6dea-4288-a8c2-2d9c058a01e9" xlink:to="loc_srt_SegmentGeographicalDomain_79fff4fe-623c-4005-80f8-cfa70b2c606b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IS_1a96e06d-cb8b-4381-bd82-078217918f28" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_79fff4fe-623c-4005-80f8-cfa70b2c606b" xlink:to="loc_country_IS_1a96e06d-cb8b-4381-bd82-078217918f28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_LU_42107cc4-1546-4700-9b6f-9f2f5d9d4295" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_LU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_79fff4fe-623c-4005-80f8-cfa70b2c606b" xlink:to="loc_country_LU_42107cc4-1546-4700-9b6f-9f2f5d9d4295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_4b6a65c8-cc89-4b47-a170-1cb51f753885" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_4b6a65c8-cc89-4b47-a170-1cb51f753885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_24fe7d2d-d813-4e6a-b743-999f5b840590" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_24fe7d2d-d813-4e6a-b743-999f5b840590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities_91c671f3-8cc7-4011-8c62-ca802c14143d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_NetDeferredTaxLiabilities_91c671f3-8cc7-4011-8c62-ca802c14143d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_f6062073-a1a5-4ceb-b009-89deeb7dc091" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_DeferredTaxAssets_f6062073-a1a5-4ceb-b009-89deeb7dc091" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_7a17e7cb-ea68-4c2b-9118-dabd9b121445" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_7a17e7cb-ea68-4c2b-9118-dabd9b121445" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_36fb06eb-74a4-4e95-95ae-80b516059528" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_36fb06eb-74a4-4e95-95ae-80b516059528" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_36fb06eb-74a4-4e95-95ae-80b516059528" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2e9398f9-3bb8-4a8b-b1ad-c2994192e4ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2e9398f9-3bb8-4a8b-b1ad-c2994192e4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_b3417242-e715-463d-a80a-78ce57980889" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2e9398f9-3bb8-4a8b-b1ad-c2994192e4ba" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_b3417242-e715-463d-a80a-78ce57980889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_95a82f54-84e2-40c1-b506-53e725110c09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2e9398f9-3bb8-4a8b-b1ad-c2994192e4ba" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_95a82f54-84e2-40c1-b506-53e725110c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets_5a873b88-367e-4d5f-a266-2507090b7626" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:to="loc_ifrs-full_NetDeferredTaxAssets_5a873b88-367e-4d5f-a266-2507090b7626" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities_971acf0a-6c75-4d5f-8db1-40bca989b68e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:to="loc_ifrs-full_NetDeferredTaxLiabilities_971acf0a-6c75-4d5f-8db1-40bca989b68e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_65361188-f5f9-4a56-8d1f-948844ac1608" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_65361188-f5f9-4a56-8d1f-948844ac1608" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxLineItems_fa4e34c1-9405-4b5a-b284-42cf5f8579b1" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxTable_33f02ab2-79f7-4b45-bca4-f09325af89c4" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_fa4e34c1-9405-4b5a-b284-42cf5f8579b1" xlink:to="loc_alvo_DisclosureOfIncomeTaxTable_33f02ab2-79f7-4b45-bca4-f09325af89c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxYearsAxis_9b1311e2-26de-4380-a53a-dbfa827c739c" xlink:href="alvo-20231231.xsd#alvo_TaxYearsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable_33f02ab2-79f7-4b45-bca4-f09325af89c4" xlink:to="loc_alvo_TaxYearsAxis_9b1311e2-26de-4380-a53a-dbfa827c739c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxYearsDomain_9b1311e2-26de-4380-a53a-dbfa827c739c_default" xlink:href="alvo-20231231.xsd#alvo_TaxYearsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_TaxYearsAxis_9b1311e2-26de-4380-a53a-dbfa827c739c" xlink:to="loc_alvo_TaxYearsDomain_9b1311e2-26de-4380-a53a-dbfa827c739c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:href="alvo-20231231.xsd#alvo_TaxYearsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_TaxYearsAxis_9b1311e2-26de-4380-a53a-dbfa827c739c" xlink:to="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember_7118d442-f833-4c7c-bb85-80319f34b675" xlink:href="alvo-20231231.xsd#alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:to="loc_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember_7118d442-f833-4c7c-bb85-80319f34b675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember_a59fc00f-220c-42df-8d9d-c8ab3dbdb86f" xlink:href="alvo-20231231.xsd#alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:to="loc_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember_a59fc00f-220c-42df-8d9d-c8ab3dbdb86f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LaterPeriodMember_f998c8bb-b430-4b75-af21-f2312e2e6fe3" xlink:href="alvo-20231231.xsd#alvo_LaterPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:to="loc_alvo_LaterPeriodMember_f998c8bb-b430-4b75-af21-f2312e2e6fe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_8f3fc3ae-9206-4f62-8644-2737cfe93746" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_fa4e34c1-9405-4b5a-b284-42cf5f8579b1" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_8f3fc3ae-9206-4f62-8644-2737cfe93746" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LossPerShareSummaryofBasicandDilutedLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable_9e8ac3f8-e64d-4421-b4db-6e16e2d08223" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_EarningsPerShareTable_9e8ac3f8-e64d-4421-b4db-6e16e2d08223" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_e3a15166-a717-426c-a2ff-5a91bfde27cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_ProfitLoss_e3a15166-a717-426c-a2ff-5a91bfde27cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_476ba450-cb45-4728-b81b-286c41c67951" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_WeightedAverageShares_476ba450-cb45-4728-b81b-286c41c67951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_d0aebb8a-92d7-4ca2-a271-e21c86653571" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_d0aebb8a-92d7-4ca2-a271-e21c86653571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_45ed73e2-e53f-46b8-80d1-7efac2708873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_45ed73e2-e53f-46b8-80d1-7efac2708873" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_3dc71a15-7c64-49fd-8966-70c521a5a311" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_3dc71a15-7c64-49fd-8966-70c521a5a311" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0b2c6804-329a-43a3-806d-4e2b1cfe1767" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0b2c6804-329a-43a3-806d-4e2b1cfe1767" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9037609e-4ca5-4f61-9e87-24e1ffd358cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9037609e-4ca5-4f61-9e87-24e1ffd358cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_9037609e-4ca5-4f61-9e87-24e1ffd358cb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9037609e-4ca5-4f61-9e87-24e1ffd358cb" xlink:to="loc_ifrs-full_CarryingAmountMember_9037609e-4ca5-4f61-9e87-24e1ffd358cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_bcbdc428-e325-44df-b629-a9133d0b9b1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9037609e-4ca5-4f61-9e87-24e1ffd358cb" xlink:to="loc_ifrs-full_CarryingAmountMember_bcbdc428-e325-44df-b629-a9133d0b9b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_a6670314-86ff-4cbc-8a4b-27b45b588d4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_bcbdc428-e325-44df-b629-a9133d0b9b1d" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_a6670314-86ff-4cbc-8a4b-27b45b588d4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_db662e0e-a737-4637-ad74-26c037663fca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_bcbdc428-e325-44df-b629-a9133d0b9b1d" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_db662e0e-a737-4637-ad74-26c037663fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_a35da168-1ba1-435f-81a7-b30c725ea98a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_a35da168-1ba1-435f-81a7-b30c725ea98a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_a35da168-1ba1-435f-81a7-b30c725ea98a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_a35da168-1ba1-435f-81a7-b30c725ea98a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_a35da168-1ba1-435f-81a7-b30c725ea98a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_a35da168-1ba1-435f-81a7-b30c725ea98a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityMember_20235103-10a9-4ae2-a9d9-0627c7e8118e" xlink:href="alvo-20231231.xsd#alvo_FacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:to="loc_alvo_FacilityMember_20235103-10a9-4ae2-a9d9-0627c7e8118e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityEquipmentMember_871408f9-1ca1-4c13-8c93-2e31b13ba8be" xlink:href="alvo-20231231.xsd#alvo_FacilityEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:to="loc_alvo_FacilityEquipmentMember_871408f9-1ca1-4c13-8c93-2e31b13ba8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FurnitureFixturesAndLeaseholdImprovementsMember_f47750c8-caf1-45d9-b52f-60f09312d130" xlink:href="alvo-20231231.xsd#alvo_FurnitureFixturesAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:to="loc_alvo_FurnitureFixturesAndLeaseholdImprovementsMember_f47750c8-caf1-45d9-b52f-60f09312d130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_ccf4f53e-08d5-4677-a6f6-af36371b3189" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:to="loc_ifrs-full_ComputerEquipmentMember_ccf4f53e-08d5-4677-a6f6-af36371b3189" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:href="alvo-20231231.xsd#alvo_PropertyPlantAndEquipmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0b2c6804-329a-43a3-806d-4e2b1cfe1767" xlink:to="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_d9f3360f-243d-42c3-ab70-879def06cb01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_d9f3360f-243d-42c3-ab70-879def06cb01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_994fe3ca-4b03-4152-bbd0-4c9138fd42ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_994fe3ca-4b03-4152-bbd0-4c9138fd42ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f52328ca-bf00-4a0c-a569-f5f48d025c99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f52328ca-bf00-4a0c-a569-f5f48d025c99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_fa0d5e4f-bee1-482d-89b2-08f4d88d5d27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_fa0d5e4f-bee1-482d-89b2-08f4d88d5d27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_f1803eb0-4b54-486b-a246-38e5d08f9609" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_f1803eb0-4b54-486b-a246-38e5d08f9609" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_e4dbca62-9c06-4155-b907-fbb995f0839e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_e4dbca62-9c06-4155-b907-fbb995f0839e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9cf2bb32-030d-4f0c-99ce-e35e69001cf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#PropertyPlantAndEquipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetsAcquisitionAxis_9aa953b1-1cac-4eec-8fda-23100afab36f" xlink:href="alvo-20231231.xsd#alvo_AssetsAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:to="loc_alvo_AssetsAcquisitionAxis_9aa953b1-1cac-4eec-8fda-23100afab36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionsDomain_9aa953b1-1cac-4eec-8fda-23100afab36f_default" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_AssetsAcquisitionAxis_9aa953b1-1cac-4eec-8fda-23100afab36f" xlink:to="loc_alvo_AssetAcquisitionsDomain_9aa953b1-1cac-4eec-8fda-23100afab36f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionsDomain_15261457-82a6-4605-9af5-6d2bc1bd7225" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_AssetsAcquisitionAxis_9aa953b1-1cac-4eec-8fda-23100afab36f" xlink:to="loc_alvo_AssetAcquisitionsDomain_15261457-82a6-4605-9af5-6d2bc1bd7225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaemundurMember_39b7d770-5f73-4324-9153-557c93ce27c6" xlink:href="alvo-20231231.xsd#alvo_SaemundurMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AssetAcquisitionsDomain_15261457-82a6-4605-9af5-6d2bc1bd7225" xlink:to="loc_alvo_SaemundurMember_39b7d770-5f73-4324-9153-557c93ce27c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_9c77efd7-f5fd-43cf-b325-4264100e6b8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_9c77efd7-f5fd-43cf-b325-4264100e6b8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_9c77efd7-f5fd-43cf-b325-4264100e6b8e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_9c77efd7-f5fd-43cf-b325-4264100e6b8e" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_9c77efd7-f5fd-43cf-b325-4264100e6b8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_a9de1ee4-2d6c-4d6c-843b-effbd2f35171" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_9c77efd7-f5fd-43cf-b325-4264100e6b8e" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_a9de1ee4-2d6c-4d6c-843b-effbd2f35171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityMember_1f7f8f05-a188-4939-9c72-bf24a7a78e6d" xlink:href="alvo-20231231.xsd#alvo_FacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_a9de1ee4-2d6c-4d6c-843b-effbd2f35171" xlink:to="loc_alvo_FacilityMember_1f7f8f05-a188-4939-9c72-bf24a7a78e6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_c2f08ba6-0352-44ec-8bf6-68f5602d2614" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_c2f08ba6-0352-44ec-8bf6-68f5602d2614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionsConsiderationTransferred_c61f7e04-a1c6-4f0d-b687-01180230778e" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionsConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_AssetAcquisitionsConsiderationTransferred_c61f7e04-a1c6-4f0d-b687-01180230778e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond_87fc2b2c-8e46-4578-96d5-c80212261e88" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredConvertibleBond"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond_87fc2b2c-8e46-4578-96d5-c80212261e88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed_e8f4be7a-063c-4d3d-8d22-180a116551ea" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredLoansAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed_e8f4be7a-063c-4d3d-8d22-180a116551ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredSettlements_f9510177-1a08-4154-acf2-c4fe0e0d867b" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_AssetAcquisitionConsiderationTransferredSettlements_f9510177-1a08-4154-acf2-c4fe0e0d867b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossOnExtinguishmentOfTheLeaseLiability_38f5f7db-b97d-4739-bdfe-cd88cf2cf8d4" xlink:href="alvo-20231231.xsd#alvo_LossOnExtinguishmentOfTheLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_LossOnExtinguishmentOfTheLeaseLiability_38f5f7db-b97d-4739-bdfe-cd88cf2cf8d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_66c10599-320b-438f-98f2-ee30b2a1cd72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_66c10599-320b-438f-98f2-ee30b2a1cd72" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:to="loc_srt_CounterpartyNameAxis_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acb4db7c-72ae-4026-bf5d-a588c534f8b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acb4db7c-72ae-4026-bf5d-a588c534f8b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagidEyjolfurHf.Member_240c72e9-3c64-4cd9-9c8b-92599f8bf13c" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagidEyjolfurHf.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acb4db7c-72ae-4026-bf5d-a588c534f8b0" xlink:to="loc_alvo_FasteignafelagidEyjolfurHf.Member_240c72e9-3c64-4cd9-9c8b-92599f8bf13c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_67a52cae-9351-4515-ab48-13cd1763b2a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:to="loc_srt_StatementGeographicalAxis_67a52cae-9351-4515-ab48-13cd1763b2a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_67a52cae-9351-4515-ab48-13cd1763b2a3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_67a52cae-9351-4515-ab48-13cd1763b2a3" xlink:to="loc_srt_SegmentGeographicalDomain_67a52cae-9351-4515-ab48-13cd1763b2a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0e9ed4ae-7bd3-4042-9c97-3d8dfbf99aa5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_67a52cae-9351-4515-ab48-13cd1763b2a3" xlink:to="loc_srt_SegmentGeographicalDomain_0e9ed4ae-7bd3-4042-9c97-3d8dfbf99aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IS_ac36bb05-4b7a-447b-9fa2-32b033f14795" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0e9ed4ae-7bd3-4042-9c97-3d8dfbf99aa5" xlink:to="loc_country_IS_ac36bb05-4b7a-447b-9fa2-32b033f14795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageRemainingLeaseTerm_afff09c9-0104-4f6b-bd86-021208aee59b" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_alvo_WeightedAverageRemainingLeaseTerm_afff09c9-0104-4f6b-bd86-021208aee59b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AreaOfProperty_0d3b40c6-9626-462c-84e0-0b71b384f89b" xlink:href="alvo-20231231.xsd#alvo_AreaOfProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_alvo_AreaOfProperty_0d3b40c6-9626-462c-84e0-0b71b384f89b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_e96ca346-7dc0-45c8-9ade-dc0f9c279319" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_ifrs-full_RightofuseAssets_e96ca346-7dc0-45c8-9ade-dc0f9c279319" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_2e7efd2b-6ae9-406f-83ef-836799c7d38b" xlink:href="alvo-20231231.xsd#alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_2e7efd2b-6ae9-406f-83ef-836799c7d38b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryofClassesofRightOfUseAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_f8d1ab1d-99f5-4c56-9574-4cdad6e0d2bd" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_51d81d0d-79a9-45ed-972b-770f9f0de1dd" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_f8d1ab1d-99f5-4c56-9574-4cdad6e0d2bd" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_51d81d0d-79a9-45ed-972b-770f9f0de1dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_165d396c-cfc5-484a-9bc6-2503ecc7f291" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_51d81d0d-79a9-45ed-972b-770f9f0de1dd" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_165d396c-cfc5-484a-9bc6-2503ecc7f291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_165d396c-cfc5-484a-9bc6-2503ecc7f291_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_165d396c-cfc5-484a-9bc6-2503ecc7f291" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_165d396c-cfc5-484a-9bc6-2503ecc7f291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_165d396c-cfc5-484a-9bc6-2503ecc7f291" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilitiesMember_7e505bdf-c8ab-44c7-9f91-78fd74516f11" xlink:href="alvo-20231231.xsd#alvo_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:to="loc_alvo_FacilitiesMember_7e505bdf-c8ab-44c7-9f91-78fd74516f11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FleetMember_14120bc2-7bac-4971-9458-a6e7c21dbe67" xlink:href="alvo-20231231.xsd#alvo_FleetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:to="loc_alvo_FleetMember_14120bc2-7bac-4971-9458-a6e7c21dbe67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_bb399644-e4d8-4c10-8209-3a1db443f2e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:to="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_bb399644-e4d8-4c10-8209-3a1db443f2e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_3ee80f09-a965-42cb-8088-859895f12462" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_f8d1ab1d-99f5-4c56-9574-4cdad6e0d2bd" xlink:to="loc_ifrs-full_RightofuseAssets_3ee80f09-a965-42cb-8088-859895f12462" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryOfLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_5219180b-479c-4c93-a614-2da47a82681e" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_5219180b-479c-4c93-a614-2da47a82681e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_4c19fac2-3282-4cae-b88c-6610948cf9da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_5219180b-479c-4c93-a614-2da47a82681e" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_4c19fac2-3282-4cae-b88c-6610948cf9da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_4c19fac2-3282-4cae-b88c-6610948cf9da_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_4c19fac2-3282-4cae-b88c-6610948cf9da" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_4c19fac2-3282-4cae-b88c-6610948cf9da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_4c19fac2-3282-4cae-b88c-6610948cf9da" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilitiesMember_2ee4f4ee-7597-423e-b8e5-257ca9c6638a" xlink:href="alvo-20231231.xsd#alvo_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:to="loc_alvo_FacilitiesMember_2ee4f4ee-7597-423e-b8e5-257ca9c6638a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FleetMember_9b2da623-8f31-4525-900f-642c885fe9e2" xlink:href="alvo-20231231.xsd#alvo_FleetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:to="loc_alvo_FleetMember_9b2da623-8f31-4525-900f-642c885fe9e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_b7a8c1e3-037c-44dc-a0ba-5102d99b26a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:to="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_b7a8c1e3-037c-44dc-a0ba-5102d99b26a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_ccc34b1e-796d-4430-9b26-572bff045e33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_ccc34b1e-796d-4430-9b26-572bff045e33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_08ed03ab-752f-44ef-9399-dfc2b12b14f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_08ed03ab-752f-44ef-9399-dfc2b12b14f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ForeignCurrencyDifferenceOnLeaseLiability_d8d77034-738a-49ba-b051-e3d917c942ef" xlink:href="alvo-20231231.xsd#alvo_ForeignCurrencyDifferenceOnLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_alvo_ForeignCurrencyDifferenceOnLeaseLiability_d8d77034-738a-49ba-b051-e3d917c942ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossFromExtinguishmentOfLeaseLiabilities_6a6615f6-8cec-4a84-88c8-d859c8ad0bc3" xlink:href="alvo-20231231.xsd#alvo_LossFromExtinguishmentOfLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_alvo_LossFromExtinguishmentOfLeaseLiabilities_6a6615f6-8cec-4a84-88c8-d859c8ad0bc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseCostRecognizedInProfitAndLoss_8f2227d5-3349-4de7-b238-87e9e83b3cdd" xlink:href="alvo-20231231.xsd#alvo_LeaseCostRecognizedInProfitAndLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_alvo_LeaseCostRecognizedInProfitAndLoss_8f2227d5-3349-4de7-b238-87e9e83b3cdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_f118824b-7d1e-4b34-829d-2f3cb85ab133" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_ifrs-full_RightofuseAssets_f118824b-7d1e-4b34-829d-2f3cb85ab133" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_d6a48431-24f3-4f29-b576-e017fec1913a" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_8afe0404-758f-4f8c-925e-f7b1b0ea4f9f" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_d6a48431-24f3-4f29-b576-e017fec1913a" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_8afe0404-758f-4f8c-925e-f7b1b0ea4f9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_c1b147d0-0c9a-4b6e-8b72-089ad5313776" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_8afe0404-758f-4f8c-925e-f7b1b0ea4f9f" xlink:to="loc_ifrs-full_MaturityAxis_c1b147d0-0c9a-4b6e-8b72-089ad5313776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c1b147d0-0c9a-4b6e-8b72-089ad5313776_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_c1b147d0-0c9a-4b6e-8b72-089ad5313776" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c1b147d0-0c9a-4b6e-8b72-089ad5313776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_c1b147d0-0c9a-4b6e-8b72-089ad5313776" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_811e498c-2640-4152-bef1-f75c50c6b20b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_811e498c-2640-4152-bef1-f75c50c6b20b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_d98d1b91-4df4-4b18-a324-abe3fd62fc9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_d98d1b91-4df4-4b18-a324-abe3fd62fc9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_4764b751-2aa0-41a7-a784-54bb1300f81c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_4764b751-2aa0-41a7-a784-54bb1300f81c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_1e485b82-34dc-4afa-8929-e009cdd3d4bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_d6a48431-24f3-4f29-b576-e017fec1913a" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_1e485b82-34dc-4afa-8929-e009cdd3d4bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/GoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfGoodwillTable_425ee260-4624-42cf-927a-c285171605e2" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:to="loc_alvo_DisclosureOfGoodwillTable_425ee260-4624-42cf-927a-c285171605e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfGoodwillTable_425ee260-4624-42cf-927a-c285171605e2" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_7020c94d-a070-4a14-bad2-a3a55553a823" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_7020c94d-a070-4a14-bad2-a3a55553a823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_937158f8-d23e-47ae-a59d-14841b8bc4a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_7020c94d-a070-4a14-bad2-a3a55553a823" xlink:to="loc_ifrs-full_GoodwillMember_937158f8-d23e-47ae-a59d-14841b8bc4a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_32e9d0e8-3e3f-4587-8ab1-8c737e0bb2df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:to="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_32e9d0e8-3e3f-4587-8ab1-8c737e0bb2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_781a0132-ca2e-423c-a6cb-723a8fb3d1c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_781a0132-ca2e-423c-a6cb-723a8fb3d1c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_49768db5-ae73-4632-84ad-0692b3db6770" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_49768db5-ae73-4632-84ad-0692b3db6770" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_a792ceae-c8ea-4c4c-ba29-5df667fc8b21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_a792ceae-c8ea-4c4c-ba29-5df667fc8b21" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc169c4c-fcec-4ec8-a516-a9419f1a0e36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc169c4c-fcec-4ec8-a516-a9419f1a0e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_fc169c4c-fcec-4ec8-a516-a9419f1a0e36_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc169c4c-fcec-4ec8-a516-a9419f1a0e36" xlink:to="loc_ifrs-full_CarryingAmountMember_fc169c4c-fcec-4ec8-a516-a9419f1a0e36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_2216fdbb-ccbc-436e-8ec2-08e714737c74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc169c4c-fcec-4ec8-a516-a9419f1a0e36" xlink:to="loc_ifrs-full_CarryingAmountMember_2216fdbb-ccbc-436e-8ec2-08e714737c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_f4b936f0-40c4-4e8d-affc-da5e050b389c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_2216fdbb-ccbc-436e-8ec2-08e714737c74" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_f4b936f0-40c4-4e8d-affc-da5e050b389c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationMember_1b13bd15-f0c8-4e2c-914c-f54870d91610" xlink:href="alvo-20231231.xsd#alvo_AmortizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_2216fdbb-ccbc-436e-8ec2-08e714737c74" xlink:to="loc_alvo_AmortizationMember_1b13bd15-f0c8-4e2c-914c-f54870d91610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_062322e5-be33-44c0-92f9-c01d58cd93d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_062322e5-be33-44c0-92f9-c01d58cd93d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_062322e5-be33-44c0-92f9-c01d58cd93d1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_062322e5-be33-44c0-92f9-c01d58cd93d1" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_062322e5-be33-44c0-92f9-c01d58cd93d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_062322e5-be33-44c0-92f9-c01d58cd93d1" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_b7b8a1b9-e8a7-4409-9c35-9554550bd61d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:to="loc_ifrs-full_ComputerSoftwareMember_b7b8a1b9-e8a7-4409-9c35-9554550bd61d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember_9ba07377-51ce-422e-817f-762784a09ad1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CustomerrelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:to="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember_9ba07377-51ce-422e-817f-762784a09ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_84731698-1dc8-4a99-a800-34c9f228bd65" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_84731698-1dc8-4a99-a800-34c9f228bd65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:href="alvo-20231231.xsd#alvo_IntangibleAssetsOtherThanGoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_a792ceae-c8ea-4c4c-ba29-5df667fc8b21" xlink:to="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1b88e66c-ff30-47bd-bf34-870a8ccd9219" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1b88e66c-ff30-47bd-bf34-870a8ccd9219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4a5572d3-30be-4afa-b59c-719c40607c98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4a5572d3-30be-4afa-b59c-719c40607c98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ca0aa162-aab3-49f1-a94b-b43cd4b4a603" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ca0aa162-aab3-49f1-a94b-b43cd4b4a603" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_c72494be-3103-4752-b8d9-56a00d3740e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_c72494be-3103-4752-b8d9-56a00d3740e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_660ef786-1aeb-4198-9cdd-7829b0da91fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_660ef786-1aeb-4198-9cdd-7829b0da91fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_9cd4035d-02ed-40c3-85cf-4d75ae9a1814" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_9cd4035d-02ed-40c3-85cf-4d75ae9a1814" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_03756fd1-9675-4ae0-88b0-7abf4fd7de85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_03756fd1-9675-4ae0-88b0-7abf4fd7de85" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_05cd0965-f168-4975-8093-a5b95ef872e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_d4103ba5-db92-419c-916a-c78e629dba2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_936d3ab1-1642-4a92-9b3c-ae813c93d456" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_d4103ba5-db92-419c-916a-c78e629dba2f" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_936d3ab1-1642-4a92-9b3c-ae813c93d456" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_18f5d644-f32f-4643-ad3e-e083e39fcff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_936d3ab1-1642-4a92-9b3c-ae813c93d456" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_18f5d644-f32f-4643-ad3e-e083e39fcff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_18f5d644-f32f-4643-ad3e-e083e39fcff0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_18f5d644-f32f-4643-ad3e-e083e39fcff0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_18f5d644-f32f-4643-ad3e-e083e39fcff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_18f5d644-f32f-4643-ad3e-e083e39fcff0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_b0212c0f-45e8-425c-a73b-b9a49338f66e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:to="loc_ifrs-full_CostOfSalesMember_b0212c0f-45e8-425c-a73b-b9a49338f66e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentMember_5caf101c-8d11-47f4-ad8e-9dd9850372bc" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:to="loc_alvo_ResearchAndDevelopmentMember_5caf101c-8d11-47f4-ad8e-9dd9850372bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeMember_3a6eea43-fa07-40d4-803a-a0a1331169e5" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:to="loc_alvo_GeneralAndAdministrativeMember_3a6eea43-fa07-40d4-803a-a0a1331169e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_334b4e0d-102e-4ed2-a065-258d3010d8fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_d4103ba5-db92-419c-916a-c78e629dba2f" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_334b4e0d-102e-4ed2-a065-258d3010d8fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherIntangibleassetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7f055ccb-fcb7-4fbf-9673-3b1b30e66480" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7f055ccb-fcb7-4fbf-9673-3b1b30e66480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7f055ccb-fcb7-4fbf-9673-3b1b30e66480_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7f055ccb-fcb7-4fbf-9673-3b1b30e66480" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7f055ccb-fcb7-4fbf-9673-3b1b30e66480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_762d2eb7-7706-460d-a0c5-eeaac59c2010" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7f055ccb-fcb7-4fbf-9673-3b1b30e66480" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_762d2eb7-7706-460d-a0c5-eeaac59c2010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntangibleAssetsWithFiniteLivedMember_3dcfbaae-639d-438a-a32b-00cec39cb064" xlink:href="alvo-20231231.xsd#alvo_IntangibleAssetsWithFiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_762d2eb7-7706-460d-a0c5-eeaac59c2010" xlink:to="loc_alvo_IntangibleAssetsWithFiniteLivedMember_3dcfbaae-639d-438a-a32b-00cec39cb064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntellectualPropertyRightsMember_de4d149d-e447-46de-8b2e-50af39110261" xlink:href="alvo-20231231.xsd#alvo_IntellectualPropertyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_762d2eb7-7706-460d-a0c5-eeaac59c2010" xlink:to="loc_alvo_IntellectualPropertyRightsMember_de4d149d-e447-46de-8b2e-50af39110261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationAxis_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_alvo_IncomeStatementsLocationAxis_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8_default" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_IncomeStatementsLocationAxis_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8" xlink:to="loc_alvo_IncomeStatementsLocationDomain_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_f2a306c7-984f-448f-8115-cc4cec04f401" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_IncomeStatementsLocationAxis_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8" xlink:to="loc_alvo_IncomeStatementsLocationDomain_f2a306c7-984f-448f-8115-cc4cec04f401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_53fce948-9ba9-4f23-be19-4cef2ac6e141" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IncomeStatementsLocationDomain_f2a306c7-984f-448f-8115-cc4cec04f401" xlink:to="loc_ifrs-full_CostOfSalesMember_53fce948-9ba9-4f23-be19-4cef2ac6e141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember_a8f4f4a1-d8b2-4969-aec2-7a796c6acf21" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IncomeStatementsLocationDomain_f2a306c7-984f-448f-8115-cc4cec04f401" xlink:to="loc_alvo_GeneralAndAdministrativeExpensesMember_a8f4f4a1-d8b2-4969-aec2-7a796c6acf21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ba2a0334-f758-4c75-b4ba-458a875d1213" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_srt_ProductOrServiceAxis_ba2a0334-f758-4c75-b4ba-458a875d1213" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ba2a0334-f758-4c75-b4ba-458a875d1213_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ba2a0334-f758-4c75-b4ba-458a875d1213" xlink:to="loc_srt_ProductsAndServicesDomain_ba2a0334-f758-4c75-b4ba-458a875d1213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5118f31f-958e-47c5-9431-c3c812da2a31" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ba2a0334-f758-4c75-b4ba-458a875d1213" xlink:to="loc_srt_ProductsAndServicesDomain_5118f31f-958e-47c5-9431-c3c812da2a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AVT23Member_7f17c4af-3972-4426-8ca8-ede631319f02" xlink:href="alvo-20231231.xsd#alvo_AVT23Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5118f31f-958e-47c5-9431-c3c812da2a31" xlink:to="loc_alvo_AVT23Member_7f17c4af-3972-4426-8ca8-ede631319f02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_898d0a7b-548e-488b-9296-14de2c4ac9c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_srt_CounterpartyNameAxis_898d0a7b-548e-488b-9296-14de2c4ac9c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_898d0a7b-548e-488b-9296-14de2c4ac9c6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_898d0a7b-548e-488b-9296-14de2c4ac9c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_898d0a7b-548e-488b-9296-14de2c4ac9c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65de5cae-842f-4f2f-bf99-d47d382035b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_898d0a7b-548e-488b-9296-14de2c4ac9c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65de5cae-842f-4f2f-bf99-d47d382035b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_KashivMember_fb1e1d6f-95d0-4e51-86f5-ac5f1704e42a" xlink:href="alvo-20231231.xsd#alvo_KashivMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65de5cae-842f-4f2f-bf99-d47d382035b0" xlink:to="loc_alvo_KashivMember_fb1e1d6f-95d0-4e51-86f5-ac5f1704e42a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_srt_StatementScenarioAxis_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_565d112b-0a55-46a7-a5e9-13d6c7b17825" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_565d112b-0a55-46a7-a5e9-13d6c7b17825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ba472a4c-24ac-438e-a8d2-97da8ed06c16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_565d112b-0a55-46a7-a5e9-13d6c7b17825" xlink:to="loc_srt_ScenarioForecastMember_ba472a4c-24ac-438e-a8d2-97da8ed06c16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLoss_c04d89be-50cd-49e3-91c4-d8ac0fd155df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_ifrs-full_ImpairmentLoss_c04d89be-50cd-49e3-91c4-d8ac0fd155df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_a7e6fbd1-2735-47cb-a3af-0d8c7d571031" xlink:href="alvo-20231231.xsd#alvo_DerecognitionIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_a7e6fbd1-2735-47cb-a3af-0d8c7d571031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PaymentForContractualCommitment_70fd83c3-316d-48d6-a5c7-f5ed52d9f065" xlink:href="alvo-20231231.xsd#alvo_PaymentForContractualCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_alvo_PaymentForContractualCommitment_70fd83c3-316d-48d6-a5c7-f5ed52d9f065" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_f12f2a73-1f69-47e7-82ad-6b5026c43a61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_f12f2a73-1f69-47e7-82ad-6b5026c43a61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractualCapitalCommitmentContingentLiability_028dd2ea-c0df-4e22-bcf3-f00bdadd22af" xlink:href="alvo-20231231.xsd#alvo_ContractualCapitalCommitmentContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_alvo_ContractualCapitalCommitmentContingentLiability_028dd2ea-c0df-4e22-bcf3-f00bdadd22af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractualCapitalCommitmentsTerm_a4475642-220b-4f05-a9ca-ee0ade9b13c3" xlink:href="alvo-20231231.xsd#alvo_ContractualCapitalCommitmentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_alvo_ContractualCapitalCommitmentsTerm_a4475642-220b-4f05-a9ca-ee0ade9b13c3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCashAndCashEquivalentsLineItems_6d924f31-e6a3-49dc-a01f-2ddbc06608a3" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCashAndCashEquivalentsTable_2c173d8d-b987-45e2-a8fa-afd9d01595f4" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfCashAndCashEquivalentsLineItems_6d924f31-e6a3-49dc-a01f-2ddbc06608a3" xlink:to="loc_alvo_DisclosureOfCashAndCashEquivalentsTable_2c173d8d-b987-45e2-a8fa-afd9d01595f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a44e02c1-ed6d-453c-ac99-9b2037655ced" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfCashAndCashEquivalentsTable_2c173d8d-b987-45e2-a8fa-afd9d01595f4" xlink:to="loc_srt_StatementGeographicalAxis_a44e02c1-ed6d-453c-ac99-9b2037655ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a44e02c1-ed6d-453c-ac99-9b2037655ced_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a44e02c1-ed6d-453c-ac99-9b2037655ced" xlink:to="loc_srt_SegmentGeographicalDomain_a44e02c1-ed6d-453c-ac99-9b2037655ced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c5cf91e8-b628-430b-966f-f946b3b55d3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a44e02c1-ed6d-453c-ac99-9b2037655ced" xlink:to="loc_srt_SegmentGeographicalDomain_c5cf91e8-b628-430b-966f-f946b3b55d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b9d99750-824b-40ee-abd2-9d5c442f51e0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5cf91e8-b628-430b-966f-f946b3b55d3c" xlink:to="loc_country_US_b9d99750-824b-40ee-abd2-9d5c442f51e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignCountriesMember_d1efafb7-71f0-4757-831d-be950c341d93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5cf91e8-b628-430b-966f-f946b3b55d3c" xlink:to="loc_ifrs-full_ForeignCountriesMember_d1efafb7-71f0-4757-831d-be950c341d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_821a9107-b6c7-4bfb-8660-145199ff42ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfCashAndCashEquivalentsLineItems_6d924f31-e6a3-49dc-a01f-2ddbc06608a3" xlink:to="loc_ifrs-full_CashAndCashEquivalents_821a9107-b6c7-4bfb-8660-145199ff42ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InventoriesAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#InventoriesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/InventoriesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfInventoriesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfInventoriesTable_44dca31d-148d-44a8-94be-4974222ade03" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfInventoriesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:to="loc_alvo_DisclosureOfInventoriesTable_44dca31d-148d-44a8-94be-4974222ade03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_3d8d1b50-5dc4-4243-b458-665836c930f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfInventoriesTable_44dca31d-148d-44a8-94be-4974222ade03" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_3d8d1b50-5dc4-4243-b458-665836c930f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_3d8d1b50-5dc4-4243-b458-665836c930f7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_3d8d1b50-5dc4-4243-b458-665836c930f7" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_3d8d1b50-5dc4-4243-b458-665836c930f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_9aed1e9f-b326-42c5-8146-b4d2041e56ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_3d8d1b50-5dc4-4243-b458-665836c930f7" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_9aed1e9f-b326-42c5-8146-b4d2041e56ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_5188c723-a8cb-40d3-b83b-f7c991f43213" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_9aed1e9f-b326-42c5-8146-b4d2041e56ac" xlink:to="loc_ifrs-full_CostOfSalesMember_5188c723-a8cb-40d3-b83b-f7c991f43213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_ac1cc0a0-a8eb-4c6a-815d-7f2e48c101d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:to="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_ac1cc0a0-a8eb-4c6a-815d-7f2e48c101d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoryWritedown2011_46f013f3-9c49-4383-bd95-55607f6b4b85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:to="loc_ifrs-full_InventoryWritedown2011_46f013f3-9c49-4383-bd95-55607f6b4b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfInventoryWritedown_27464887-4483-4b0c-ab53-8a8b3a0077ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfInventoryWritedown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:to="loc_ifrs-full_ReversalOfInventoryWritedown_27464887-4483-4b0c-ab53-8a8b3a0077ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:to="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_968f78e1-a849-46f0-8937-a66ea08c12d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:to="loc_srt_ProductOrServiceAxis_968f78e1-a849-46f0-8937-a66ea08c12d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_968f78e1-a849-46f0-8937-a66ea08c12d3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_968f78e1-a849-46f0-8937-a66ea08c12d3" xlink:to="loc_srt_ProductsAndServicesDomain_968f78e1-a849-46f0-8937-a66ea08c12d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a39b5cb1-832d-49ea-916d-5f55d484739e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_968f78e1-a849-46f0-8937-a66ea08c12d3" xlink:to="loc_srt_ProductsAndServicesDomain_a39b5cb1-832d-49ea-916d-5f55d484739e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AVT23Member_c3007138-90be-4a33-94f7-8beca9d37ade" xlink:href="alvo-20231231.xsd#alvo_AVT23Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a39b5cb1-832d-49ea-916d-5f55d484739e" xlink:to="loc_alvo_AVT23Member_c3007138-90be-4a33-94f7-8beca9d37ade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7ca12449-83d4-4c2b-bec0-e063af60d150" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7ca12449-83d4-4c2b-bec0-e063af60d150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntellectualPropertyRightsMember_f5ff62f5-3b92-41d1-8a03-f8e61d5a958a" xlink:href="alvo-20231231.xsd#alvo_IntellectualPropertyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7ca12449-83d4-4c2b-bec0-e063af60d150" xlink:to="loc_alvo_IntellectualPropertyRightsMember_f5ff62f5-3b92-41d1-8a03-f8e61d5a958a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_3681efc2-5b24-4ab6-b8a9-f2612afb9350" xlink:href="alvo-20231231.xsd#alvo_DerecognitionIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:to="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_3681efc2-5b24-4ab6-b8a9-f2612afb9350" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionPrepaidDevelopmentCosts_362411de-acf9-4d77-9dcf-3ff3e35c5a2a" xlink:href="alvo-20231231.xsd#alvo_DerecognitionPrepaidDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:to="loc_alvo_DerecognitionPrepaidDevelopmentCosts_362411de-acf9-4d77-9dcf-3ff3e35c5a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_e7f0e4cc-9247-4881-880a-bd7ab56f7e2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:to="loc_ifrs-full_OtherCurrentAssets_e7f0e4cc-9247-4881-880a-bd7ab56f7e2b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareCapitalAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_842b606e-ff17-408e-bbe4-eeb2a9cceb64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_842b606e-ff17-408e-bbe4-eeb2a9cceb64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_842b606e-ff17-408e-bbe4-eeb2a9cceb64_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_842b606e-ff17-408e-bbe4-eeb2a9cceb64" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_842b606e-ff17-408e-bbe4-eeb2a9cceb64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_842b606e-ff17-408e-bbe4-eeb2a9cceb64" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassAAndClassBOrdinarySharesMember_d350cd36-e9b6-4f86-878c-6160b021e74a" xlink:href="alvo-20231231.xsd#alvo_ClassAAndClassBOrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_ClassAAndClassBOrdinarySharesMember_d350cd36-e9b6-4f86-878c-6160b021e74a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_f8218550-f357-4ef4-be16-0b5513c4fb1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_ifrs-full_OrdinarySharesMember_f8218550-f357-4ef4-be16-0b5513c4fb1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_2dd6049b-3ce7-4711-9cde-5560992671e8" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_2dd6049b-3ce7-4711-9cde-5560992671e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassAOacbOrdinarySharesMember_336bf40c-f953-4876-98ae-a68d765018ff" xlink:href="alvo-20231231.xsd#alvo_ClassAOacbOrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_ClassAOacbOrdinarySharesMember_336bf40c-f953-4876-98ae-a68d765018ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassBOacbOrdinarySharesMember_ba446065-fd9f-401b-be58-ba8f32095167" xlink:href="alvo-20231231.xsd#alvo_ClassBOacbOrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_ClassBOacbOrdinarySharesMember_ba446065-fd9f-401b-be58-ba8f32095167" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_e4ecd157-3e23-49fe-b35c-245bab11f18c" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_EarnoutSharesMember_e4ecd157-3e23-49fe-b35c-245bab11f18c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockExchangeDescriptionAxis_05770a67-8646-4398-889e-50f862090110" xlink:href="alvo-20231231.xsd#alvo_StockExchangeDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_alvo_StockExchangeDescriptionAxis_05770a67-8646-4398-889e-50f862090110" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockExchangeDescriptionDomain_05770a67-8646-4398-889e-50f862090110_default" xlink:href="alvo-20231231.xsd#alvo_StockExchangeDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_StockExchangeDescriptionAxis_05770a67-8646-4398-889e-50f862090110" xlink:to="loc_alvo_StockExchangeDescriptionDomain_05770a67-8646-4398-889e-50f862090110_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockExchangeDescriptionDomain_dbbfc157-5b9b-4995-bf1a-3eb682aae535" xlink:href="alvo-20231231.xsd#alvo_StockExchangeDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_StockExchangeDescriptionAxis_05770a67-8646-4398-889e-50f862090110" xlink:to="loc_alvo_StockExchangeDescriptionDomain_dbbfc157-5b9b-4995-bf1a-3eb682aae535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExchangeOfPredecessorOrdinarySharesMember_b153e043-92d6-47a6-8489-12ad0ff10eb2" xlink:href="alvo-20231231.xsd#alvo_ExchangeOfPredecessorOrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_StockExchangeDescriptionDomain_dbbfc157-5b9b-4995-bf1a-3eb682aae535" xlink:to="loc_alvo_ExchangeOfPredecessorOrdinarySharesMember_b153e043-92d6-47a6-8489-12ad0ff10eb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExchangeOfClassAOacbOrdinarySharesMember_a19657f4-2a11-4d45-9d32-8b423dd38041" xlink:href="alvo-20231231.xsd#alvo_ExchangeOfClassAOacbOrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_StockExchangeDescriptionDomain_dbbfc157-5b9b-4995-bf1a-3eb682aae535" xlink:to="loc_alvo_ExchangeOfClassAOacbOrdinarySharesMember_a19657f4-2a11-4d45-9d32-8b423dd38041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockAxis_379edf4b-f1a2-40ab-8f74-361edfc03f4f" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_alvo_SaleOfStockAxis_379edf4b-f1a2-40ab-8f74-361edfc03f4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockDomain_379edf4b-f1a2-40ab-8f74-361edfc03f4f_default" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_SaleOfStockAxis_379edf4b-f1a2-40ab-8f74-361edfc03f4f" xlink:to="loc_alvo_SaleOfStockDomain_379edf4b-f1a2-40ab-8f74-361edfc03f4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockDomain_207e4c30-9dcf-4ebe-99bd-d2126a67acd3" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_SaleOfStockAxis_379edf4b-f1a2-40ab-8f74-361edfc03f4f" xlink:to="loc_alvo_SaleOfStockDomain_207e4c30-9dcf-4ebe-99bd-d2126a67acd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrivatePlacementsMember_eef418b1-0dfa-4c33-a6bf-177597c565f6" xlink:href="alvo-20231231.xsd#alvo_PrivatePlacementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_SaleOfStockDomain_207e4c30-9dcf-4ebe-99bd-d2126a67acd3" xlink:to="loc_alvo_PrivatePlacementsMember_eef418b1-0dfa-4c33-a6bf-177597c565f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_0cdb01af-6d7d-4f68-9ba1-561841a11259" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_0cdb01af-6d7d-4f68-9ba1-561841a11259" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_0cdb01af-6d7d-4f68-9ba1-561841a11259_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_0cdb01af-6d7d-4f68-9ba1-561841a11259" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_0cdb01af-6d7d-4f68-9ba1-561841a11259_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_56daa20d-00ab-4dbe-ade7-2bb678348e4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_0cdb01af-6d7d-4f68-9ba1-561841a11259" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_56daa20d-00ab-4dbe-ade7-2bb678348e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_f69bc88c-99bc-40d1-b8ff-c7e902a2375b" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_56daa20d-00ab-4dbe-ade7-2bb678348e4d" xlink:to="loc_alvo_SeniorBondWarrantsMember_f69bc88c-99bc-40d1-b8ff-c7e902a2375b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2b0a62e6-2937-4f32-bb8d-285a5d1b370a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_srt_StatementGeographicalAxis_2b0a62e6-2937-4f32-bb8d-285a5d1b370a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2b0a62e6-2937-4f32-bb8d-285a5d1b370a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2b0a62e6-2937-4f32-bb8d-285a5d1b370a" xlink:to="loc_srt_SegmentGeographicalDomain_2b0a62e6-2937-4f32-bb8d-285a5d1b370a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2247f900-d3cf-4872-b758-dc3ebe9c1bd7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2b0a62e6-2937-4f32-bb8d-285a5d1b370a" xlink:to="loc_srt_SegmentGeographicalDomain_2247f900-d3cf-4872-b758-dc3ebe9c1bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignCountriesMember_b268f0c6-9c3a-4c84-9a64-375ececa8576" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2247f900-d3cf-4872-b758-dc3ebe9c1bd7" xlink:to="loc_ifrs-full_ForeignCountriesMember_b268f0c6-9c3a-4c84-9a64-375ececa8576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SharesAuthorizedValue_cde68196-ec11-4273-8cb6-3765c038dc8c" xlink:href="alvo-20231231.xsd#alvo_SharesAuthorizedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_SharesAuthorizedValue_cde68196-ec11-4273-8cb6-3765c038dc8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_39c187b2-c0f5-4069-8e17-05d9a6ce537a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_39c187b2-c0f5-4069-8e17-05d9a6ce537a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_47286a52-6455-42e7-9723-95292c6f2d12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_47286a52-6455-42e7-9723-95292c6f2d12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_6488f9d8-9f20-4d7b-a496-8d8f2350cb45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_ParValuePerShare_6488f9d8-9f20-4d7b-a496-8d8f2350cb45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalReorganizationEventSharesIssued_f919722b-1918-4164-b2d0-be54b1e93eb7" xlink:href="alvo-20231231.xsd#alvo_CapitalReorganizationEventSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_CapitalReorganizationEventSharesIssued_f919722b-1918-4164-b2d0-be54b1e93eb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1d7eda76-99c6-4353-8071-732bd3e044bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_1d7eda76-99c6-4353-8071-732bd3e044bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalReorganizationSharesIssued_e0857732-77e9-4545-9a2b-7a8cef2c5c17" xlink:href="alvo-20231231.xsd#alvo_CapitalReorganizationSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_CapitalReorganizationSharesIssued_e0857732-77e9-4545-9a2b-7a8cef2c5c17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockIssuedUnderPipeFinancingShares_ab29698e-3c46-4c69-ac68-6654c9e07f19" xlink:href="alvo-20231231.xsd#alvo_StockIssuedUnderPipeFinancingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_StockIssuedUnderPipeFinancingShares_ab29698e-3c46-4c69-ac68-6654c9e07f19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaid_ccbd2501-535d-4ff7-b969-5c2f16e63ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_DividendsPaid_ccbd2501-535d-4ff7-b969-5c2f16e63ac2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_17aa09df-2904-49b9-b0fb-8fc8ece2a09c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_17aa09df-2904-49b9-b0fb-8fc8ece2a09c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockIssuePricePerShare_150592bd-b6cd-4260-87c7-b97a25dcb409" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockIssuePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_SaleOfStockIssuePricePerShare_150592bd-b6cd-4260-87c7-b97a25dcb409" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_a8a4a6fc-a992-49ec-96e2-d3723c183482" xlink:href="alvo-20231231.xsd#alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_a8a4a6fc-a992-49ec-96e2-d3723c183482" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockHeldBySubsidiaries_f4250bf4-e23e-4f5c-bdbd-eba58dc0a887" xlink:href="alvo-20231231.xsd#alvo_CommonStockHeldBySubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_CommonStockHeldBySubsidiaries_f4250bf4-e23e-4f5c-bdbd-eba58dc0a887" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d86e901e-60e7-413c-b4cf-ebbd5236d845" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d86e901e-60e7-413c-b4cf-ebbd5236d845" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareCapitalSummaryofShareCapitalandSharePremiumDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_009b3598-f4d4-411e-988b-d229d55a55f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7574a384-ddfa-4903-90f2-4dff83649868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_009b3598-f4d4-411e-988b-d229d55a55f3" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7574a384-ddfa-4903-90f2-4dff83649868" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_61bc2f74-2a20-4325-894a-6894556b4e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7574a384-ddfa-4903-90f2-4dff83649868" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_61bc2f74-2a20-4325-894a-6894556b4e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_61bc2f74-2a20-4325-894a-6894556b4e22_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_61bc2f74-2a20-4325-894a-6894556b4e22" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_61bc2f74-2a20-4325-894a-6894556b4e22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_5c42d62f-c0cb-4783-a765-6f2db0851e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_61bc2f74-2a20-4325-894a-6894556b4e22" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_5c42d62f-c0cb-4783-a765-6f2db0851e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_63282242-0d78-4601-b496-29154b2bb30f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_5c42d62f-c0cb-4783-a765-6f2db0851e6e" xlink:to="loc_ifrs-full_OrdinarySharesMember_63282242-0d78-4601-b496-29154b2bb30f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_8c986114-e73d-472c-8211-1cdc5f26e1e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_009b3598-f4d4-411e-988b-d229d55a55f3" xlink:to="loc_ifrs-full_NumberOfSharesIssued_8c986114-e73d-472c-8211-1cdc5f26e1e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareCapitalAndSharePremium_eced371d-d013-4ac9-8773-d79b680d2c3a" xlink:href="alvo-20231231.xsd#alvo_ShareCapitalAndSharePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_009b3598-f4d4-411e-988b-d229d55a55f3" xlink:to="loc_alvo_ShareCapitalAndSharePremium_eced371d-d013-4ac9-8773-d79b680d2c3a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_28bf7754-c93d-4150-b384-1a9a79717cc2" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_28bf7754-c93d-4150-b384-1a9a79717cc2" xlink:to="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_972b8cbd-de9b-4248-830f-4baa9cb495fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_972b8cbd-de9b-4248-830f-4baa9cb495fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_972b8cbd-de9b-4248-830f-4baa9cb495fb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_972b8cbd-de9b-4248-830f-4baa9cb495fb" xlink:to="loc_ifrs-full_EquityMember_972b8cbd-de9b-4248-830f-4baa9cb495fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_972b8cbd-de9b-4248-830f-4baa9cb495fb" xlink:to="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_b2234379-6945-4c89-bd1d-42dbfc3913c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:to="loc_ifrs-full_IssuedCapitalMember_b2234379-6945-4c89-bd1d-42dbfc3913c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_e640f52f-cbdb-4a3f-b81f-74670d0e0dea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:to="loc_ifrs-full_SharePremiumMember_e640f52f-cbdb-4a3f-b81f-74670d0e0dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedCapitalAndSharePremiumMember_cfdcda6f-ad23-48d9-93d2-b1292c844079" xlink:href="alvo-20231231.xsd#alvo_IssuedCapitalAndSharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:to="loc_alvo_IssuedCapitalAndSharePremiumMember_cfdcda6f-ad23-48d9-93d2-b1292c844079" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f2abda2d-f33e-4ee2-a31d-767a4ae481d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f2abda2d-f33e-4ee2-a31d-767a4ae481d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_f2abda2d-f33e-4ee2-a31d-767a4ae481d5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f2abda2d-f33e-4ee2-a31d-767a4ae481d5" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_f2abda2d-f33e-4ee2-a31d-767a4ae481d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f2abda2d-f33e-4ee2-a31d-767a4ae481d5" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PennyWarrantsMember_5b300385-16ef-4e46-b02f-13f69a0156de" xlink:href="alvo-20231231.xsd#alvo_PennyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:to="loc_alvo_PennyWarrantsMember_5b300385-16ef-4e46-b02f-13f69a0156de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PublicWarrantsMember_efd0ef2a-e8e1-4eca-a774-271429d776aa" xlink:href="alvo-20231231.xsd#alvo_PublicWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:to="loc_alvo_PublicWarrantsMember_efd0ef2a-e8e1-4eca-a774-271429d776aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_d88b41a4-1bfb-496c-9304-808184edb6d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_d88b41a4-1bfb-496c-9304-808184edb6d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember_efa1703f-b22d-4197-900b-fc28bc5b84d4" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:to="loc_alvo_ShareAppreciationRightsMember_efa1703f-b22d-4197-900b-fc28bc5b84d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_45279e54-69b4-4824-8d85-506eefcfb2ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_45279e54-69b4-4824-8d85-506eefcfb2ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_45279e54-69b4-4824-8d85-506eefcfb2ed_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_45279e54-69b4-4824-8d85-506eefcfb2ed" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_45279e54-69b4-4824-8d85-506eefcfb2ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_49649ccc-d243-436d-a77a-2611a26e5655" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_45279e54-69b4-4824-8d85-506eefcfb2ed" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_49649ccc-d243-436d-a77a-2611a26e5655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorOrdinarySharesMember_5d4f7e2c-0b32-4197-8644-a0bee93390c6" xlink:href="alvo-20231231.xsd#alvo_PredecessorOrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_49649ccc-d243-436d-a77a-2611a26e5655" xlink:to="loc_alvo_PredecessorOrdinarySharesMember_5d4f7e2c-0b32-4197-8644-a0bee93390c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesCapitalRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_28bf7754-c93d-4150-b384-1a9a79717cc2" xlink:to="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_650d8a4d-152d-4788-908d-eac1346d54fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_650d8a4d-152d-4788-908d-eac1346d54fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f4c1da32-ed71-4356-8c3d-aec2fd10b555" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_Equity_f4c1da32-ed71-4356-8c3d-aec2fd10b555" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfEquityShares_da464d23-f0b8-41a0-8f6b-a0ab028335aa" xlink:href="alvo-20231231.xsd#alvo_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfEquityShares_da464d23-f0b8-41a0-8f6b-a0ab028335aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfEquities_59e89fc1-07e9-495b-9b8b-efda0ecc0b24" xlink:href="alvo-20231231.xsd#alvo_IssueOfEquities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfEquities_59e89fc1-07e9-495b-9b8b-efda0ecc0b24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EliminationOfPredecessorOrdinaryShares_7c7fcc04-0b1e-41b3-abd5-d7bee801c89a" xlink:href="alvo-20231231.xsd#alvo_EliminationOfPredecessorOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_EliminationOfPredecessorOrdinaryShares_7c7fcc04-0b1e-41b3-abd5-d7bee801c89a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EliminationOfPredecessorOrdinaryValue_0eeb3f14-381a-40d1-8dc2-70aec416952b" xlink:href="alvo-20231231.xsd#alvo_EliminationOfPredecessorOrdinaryValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_EliminationOfPredecessorOrdinaryValue_0eeb3f14-381a-40d1-8dc2-70aec416952b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuanceOfOrdinaryShares_b98a2000-e369-4178-9fa7-5ecc5d152646" xlink:href="alvo-20231231.xsd#alvo_IssuanceOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssuanceOfOrdinaryShares_b98a2000-e369-4178-9fa7-5ecc5d152646" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuanceOfOrdinaryValue_430b76e9-90d2-4a1b-ad41-6c23b22a807b" xlink:href="alvo-20231231.xsd#alvo_IssuanceOfOrdinaryValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssuanceOfOrdinaryValue_430b76e9-90d2-4a1b-ad41-6c23b22a807b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseThroughPipeFinancingShares_7bae9be6-0dbb-4d3d-bb25-78a4249eff91" xlink:href="alvo-20231231.xsd#alvo_IncreaseThroughPipeFinancingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IncreaseThroughPipeFinancingShares_7bae9be6-0dbb-4d3d-bb25-78a4249eff91" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseThroughPipeFinancingValue_95c33891-de89-4608-8b31-92caeac7c6e2" xlink:href="alvo-20231231.xsd#alvo_IncreaseThroughPipeFinancingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IncreaseThroughPipeFinancingValue_95c33891-de89-4608-8b31-92caeac7c6e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_79b71d3f-09ad-4645-81b7-3c5bfc7b6724" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_79b71d3f-09ad-4645-81b7-3c5bfc7b6724" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfPredecessorEarnOutShares_876ed378-d991-4714-a851-c2c4b4f78b0c" xlink:href="alvo-20231231.xsd#alvo_IssueOfPredecessorEarnOutShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfPredecessorEarnOutShares_876ed378-d991-4714-a851-c2c4b4f78b0c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfPredecessorEarnOutSharesValue_f57d8b7f-d97a-427f-b466-e906275622fe" xlink:href="alvo-20231231.xsd#alvo_IssueOfPredecessorEarnOutSharesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfPredecessorEarnOutSharesValue_f57d8b7f-d97a-427f-b466-e906275622fe" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfOacbEarnOutShares_240d8d7a-d549-4604-8e5a-d7a4c948582d" xlink:href="alvo-20231231.xsd#alvo_IssueOfOacbEarnOutShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfOacbEarnOutShares_240d8d7a-d549-4604-8e5a-d7a4c948582d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfOacbEarnOutSharesValue_df2a6d1f-27ae-40f4-8196-c2b2e2b5a652" xlink:href="alvo-20231231.xsd#alvo_IssueOfOacbEarnOutSharesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfOacbEarnOutSharesValue_df2a6d1f-27ae-40f4-8196-c2b2e2b5a652" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares_2ed183f4-ddf1-4ec8-bed3-3f1b1a5e19f8" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares_2ed183f4-ddf1-4ec8-bed3-3f1b1a5e19f8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue_13d8d7da-7fc7-4999-8f7b-f99be1f6373c" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue_13d8d7da-7fc7-4999-8f7b-f99be1f6373c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_14e602bc-0672-40df-b492-8104f203287e" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_14e602bc-0672-40df-b492-8104f203287e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_5b987f1c-97c3-4ad8-b1fb-c74407dc37a8" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_5b987f1c-97c3-4ad8-b1fb-c74407dc37a8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalContributionSharesIssued_8be5eb93-818f-4aa6-9e05-bd1eea2ac457" xlink:href="alvo-20231231.xsd#alvo_CapitalContributionSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_CapitalContributionSharesIssued_8be5eb93-818f-4aa6-9e05-bd1eea2ac457" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalContributionValue_15cb4a42-8721-4338-a7df-296f97172a08" xlink:href="alvo-20231231.xsd#alvo_CapitalContributionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_CapitalContributionValue_15cb4a42-8721-4338-a7df-296f97172a08" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnoutSharesIssued_98ddc9c1-956f-4606-970f-5bc838a8cd09" xlink:href="alvo-20231231.xsd#alvo_VestedEarnoutSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_VestedEarnoutSharesIssued_98ddc9c1-956f-4606-970f-5bc838a8cd09" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnoutSharesValue_598c9114-ca7c-40b7-97d9-96560480645d" xlink:href="alvo-20231231.xsd#alvo_VestedEarnoutSharesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_VestedEarnoutSharesValue_598c9114-ca7c-40b7-97d9-96560480645d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_87c01efe-d902-4dca-8569-96ff6fc4dc6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_87c01efe-d902-4dca-8569-96ff6fc4dc6c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_4a7d0c6b-852a-4d5c-970f-2b71c5ea4c33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_IssueOfEquity_4a7d0c6b-852a-4d5c-970f-2b71c5ea4c33" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_65e9245e-cce0-484b-83eb-46331c3d3499" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_9eb89b2e-21ef-42c6-8cd2-fe7ef49c0e87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_dd38fd29-eac5-42a2-9403-19fa5804a422" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_dd38fd29-eac5-42a2-9403-19fa5804a422" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_8215ba89-6aef-4077-9500-93278efc583a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_dd38fd29-eac5-42a2-9403-19fa5804a422" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_8215ba89-6aef-4077-9500-93278efc583a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_8215ba89-6aef-4077-9500-93278efc583a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_8215ba89-6aef-4077-9500-93278efc583a" xlink:to="loc_ifrs-full_BorrowingsByNameMember_8215ba89-6aef-4077-9500-93278efc583a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_8215ba89-6aef-4077-9500-93278efc583a" xlink:to="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_474a400e-648a-4b29-8878-5cb0bfa545f3" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:to="loc_alvo_SeniorBondsMember_474a400e-648a-4b29-8878-5cb0bfa545f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_A2022ConvertibleBondsMember_bc39aaba-0c83-49e6-b35e-da72cdebb5bd" xlink:href="alvo-20231231.xsd#alvo_A2022ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:to="loc_alvo_A2022ConvertibleBondsMember_bc39aaba-0c83-49e6-b35e-da72cdebb5bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConvertibleBondMember_8d741c24-8d12-4ee8-88b0-d8ea57724e42" xlink:href="alvo-20231231.xsd#alvo_AztiqConvertibleBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:to="loc_alvo_AztiqConvertibleBondMember_8d741c24-8d12-4ee8-88b0-d8ea57724e42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember_62ce8e8b-597a-4e0a-8984-bd7b1d96af3b" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:to="loc_alvo_AlvogenFacilityMember_62ce8e8b-597a-4e0a-8984-bd7b1d96af3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_b6e2e4bc-6336-425f-aa6a-d4555f8339cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_BondsIssued_b6e2e4bc-6336-425f-aa6a-d4555f8339cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_e3428838-0469-4169-8857-b739d0ede92d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_LoansReceived_e3428838-0469-4169-8857-b739d0ede92d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_6d933bd9-f42b-4972-9c84-48b5ce92fffd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_OtherBorrowings_6d933bd9-f42b-4972-9c84-48b5ce92fffd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_4d0e413d-6501-4513-9214-8d1de031531e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_Borrowings_4d0e413d-6501-4513-9214-8d1de031531e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_1617edf3-659a-4b87-8a9e-6e2ff686995e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_1617edf3-659a-4b87-8a9e-6e2ff686995e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_1f139e4c-0062-4a1c-9eb5-04ff5d230f59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_LongtermBorrowings_1f139e4c-0062-4a1c-9eb5-04ff5d230f59" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStockAxis_0c47441c-7737-4fd1-8772-786352beb64f" xlink:href="alvo-20231231.xsd#alvo_ClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_ClassOfStockAxis_0c47441c-7737-4fd1-8772-786352beb64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStock1Domain_0c47441c-7737-4fd1-8772-786352beb64f_default" xlink:href="alvo-20231231.xsd#alvo_ClassOfStock1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_ClassOfStockAxis_0c47441c-7737-4fd1-8772-786352beb64f" xlink:to="loc_alvo_ClassOfStock1Domain_0c47441c-7737-4fd1-8772-786352beb64f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStock1Domain_ba569623-fa73-4591-bf39-bdcfd6dd0795" xlink:href="alvo-20231231.xsd#alvo_ClassOfStock1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_ClassOfStockAxis_0c47441c-7737-4fd1-8772-786352beb64f" xlink:to="loc_alvo_ClassOfStock1Domain_ba569623-fa73-4591-bf39-bdcfd6dd0795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassACommonStockMember_1ce9ebd4-31a2-4e13-b2d4-b0637e3dfb2a" xlink:href="alvo-20231231.xsd#alvo_ClassACommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ClassOfStock1Domain_ba569623-fa73-4591-bf39-bdcfd6dd0795" xlink:to="loc_alvo_ClassACommonStockMember_1ce9ebd4-31a2-4e13-b2d4-b0637e3dfb2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementAxis_fd7a77c7-d604-4e15-96d0-c8270af290c5" xlink:href="alvo-20231231.xsd#alvo_AgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_AgreementAxis_fd7a77c7-d604-4e15-96d0-c8270af290c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementDomain_fd7a77c7-d604-4e15-96d0-c8270af290c5_default" xlink:href="alvo-20231231.xsd#alvo_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_AgreementAxis_fd7a77c7-d604-4e15-96d0-c8270af290c5" xlink:to="loc_alvo_AgreementDomain_fd7a77c7-d604-4e15-96d0-c8270af290c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementDomain_9424ae03-ba98-42b7-a810-ffb463952e8a" xlink:href="alvo-20231231.xsd#alvo_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_AgreementAxis_fd7a77c7-d604-4e15-96d0-c8270af290c5" xlink:to="loc_alvo_AgreementDomain_9424ae03-ba98-42b7-a810-ffb463952e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BcaFrameworkAgreementMember_cd1fc3db-238a-415a-927f-169935f32acc" xlink:href="alvo-20231231.xsd#alvo_BcaFrameworkAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AgreementDomain_9424ae03-ba98-42b7-a810-ffb463952e8a" xlink:to="loc_alvo_BcaFrameworkAgreementMember_cd1fc3db-238a-415a-927f-169935f32acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_74d45f5e-804d-4e6b-befe-09b0981368a9" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AgreementDomain_9424ae03-ba98-42b7-a810-ffb463952e8a" xlink:to="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_74d45f5e-804d-4e6b-befe-09b0981368a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_61f85c27-3743-483a-8851-162e74c4219c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_61f85c27-3743-483a-8851-162e74c4219c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_61f85c27-3743-483a-8851-162e74c4219c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_61f85c27-3743-483a-8851-162e74c4219c" xlink:to="loc_ifrs-full_BorrowingsByNameMember_61f85c27-3743-483a-8851-162e74c4219c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_61f85c27-3743-483a-8851-162e74c4219c" xlink:to="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleOrdinarySharesMember_bfe8d500-bc4e-4699-8072-50c18493bfcc" xlink:href="alvo-20231231.xsd#alvo_ConvertibleOrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_ConvertibleOrdinarySharesMember_bfe8d500-bc4e-4699-8072-50c18493bfcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleShareholderLoanMember_a1e5453a-bf0c-44f6-8090-f448565948aa" xlink:href="alvo-20231231.xsd#alvo_ConvertibleShareholderLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_ConvertibleShareholderLoanMember_a1e5453a-bf0c-44f6-8090-f448565948aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondMember_5da35493-e8a3-46d0-889b-a7d064d78111" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_ConvertibleBondMember_5da35493-e8a3-46d0-889b-a7d064d78111" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_19860c35-d9e7-4b3b-9e92-8b16b431829c" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_SeniorBondsMember_19860c35-d9e7-4b3b-9e92-8b16b431829c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConvertibleDebtMember_d4ef8116-ca7f-45b6-92ac-d71835632962" xlink:href="alvo-20231231.xsd#alvo_TrancheAConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_TrancheAConvertibleDebtMember_d4ef8116-ca7f-45b6-92ac-d71835632962" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheBConvertibleDebtMember_8eba8f00-4305-4c0f-af0e-6528552e29a3" xlink:href="alvo-20231231.xsd#alvo_TrancheBConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_TrancheBConvertibleDebtMember_8eba8f00-4305-4c0f-af0e-6528552e29a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConvertibleBondMember_ac3d404f-382c-434e-a367-38b27ac25ecf" xlink:href="alvo-20231231.xsd#alvo_AztiqConvertibleBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AztiqConvertibleBondMember_ac3d404f-382c-434e-a367-38b27ac25ecf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFacilityLoansMember_cd5c2a93-884e-4ef2-8cbf-6275e6ba1a78" xlink:href="alvo-20231231.xsd#alvo_AztiqFacilityLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AztiqFacilityLoansMember_cd5c2a93-884e-4ef2-8cbf-6275e6ba1a78" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember_7b40b32a-6451-4b0c-a6cc-9cecf8670d16" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenFacilityMember_7b40b32a-6451-4b0c-a6cc-9cecf8670d16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFacilityMember_740146e5-699b-49dd-92b3-cabc86de749b" xlink:href="alvo-20231231.xsd#alvo_AztiqFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AztiqFacilityMember_740146e5-699b-49dd-92b3-cabc86de749b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityAndAztiqFacilityMember_27e4ac6e-86f3-4da0-b1c7-4c325fc3cf6d" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityAndAztiqFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenFacilityAndAztiqFacilityMember_27e4ac6e-86f3-4da0-b1c7-4c325fc3cf6d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLoanMember_3bab6ec1-1993-4482-b39f-21fdf8eabfa0" xlink:href="alvo-20231231.xsd#alvo_AlvogenLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenLoanMember_3bab6ec1-1993-4482-b39f-21fdf8eabfa0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LoanAgreementMember_d58595a6-bc9d-46c1-baa8-ad45505b0e01" xlink:href="alvo-20231231.xsd#alvo_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_LoanAgreementMember_d58595a6-bc9d-46c1-baa8-ad45505b0e01" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenSubordinatedLoanMember_1bef3ab5-7936-4c21-b2ab-cbc96627b3ba" xlink:href="alvo-20231231.xsd#alvo_AlvogenSubordinatedLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenSubordinatedLoanMember_1bef3ab5-7936-4c21-b2ab-cbc96627b3ba" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLoanWarrantsMember_af1342ae-98f5-4b79-a0b3-be4400f0de75" xlink:href="alvo-20231231.xsd#alvo_AlvogenLoanWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenLoanWarrantsMember_af1342ae-98f5-4b79-a0b3-be4400f0de75" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityLoansMember_423f832b-c1ed-4dd6-b769-8747de296577" xlink:href="alvo-20231231.xsd#alvo_FacilityLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_FacilityLoansMember_423f832b-c1ed-4dd6-b769-8747de296577" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherBorrowingsFinancialInstitutionMember_ddfed47a-0654-4353-b119-6b438cf5cbfb" xlink:href="alvo-20231231.xsd#alvo_OtherBorrowingsFinancialInstitutionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_OtherBorrowingsFinancialInstitutionMember_ddfed47a-0654-4353-b119-6b438cf5cbfb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_4d4a1fc0-3d8b-4a3c-b647-7a646b4e0700" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_4d4a1fc0-3d8b-4a3c-b647-7a646b4e0700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_ab15a8dd-f519-41b4-803a-841fe6057663" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_4d4a1fc0-3d8b-4a3c-b647-7a646b4e0700" xlink:to="loc_ifrs-full_OrdinarySharesMember_ab15a8dd-f519-41b4-803a-841fe6057663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EventAxis_2710bdf3-0485-4217-8818-094b602736bd" xlink:href="alvo-20231231.xsd#alvo_EventAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_EventAxis_2710bdf3-0485-4217-8818-094b602736bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EventDomain_2710bdf3-0485-4217-8818-094b602736bd_default" xlink:href="alvo-20231231.xsd#alvo_EventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_EventAxis_2710bdf3-0485-4217-8818-094b602736bd" xlink:to="loc_alvo_EventDomain_2710bdf3-0485-4217-8818-094b602736bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:href="alvo-20231231.xsd#alvo_EventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_EventAxis_2710bdf3-0485-4217-8818-094b602736bd" xlink:to="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember_256a4b56-a244-400c-b763-84c92f85b461" xlink:href="alvo-20231231.xsd#alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:to="loc_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember_256a4b56-a244-400c-b763-84c92f85b461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember_e2e276cf-f0e0-45a5-9d0c-8313046c57f2" xlink:href="alvo-20231231.xsd#alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:to="loc_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember_e2e276cf-f0e0-45a5-9d0c-8313046c57f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember_2a351995-ca0d-46b9-855b-085cc7a925a5" xlink:href="alvo-20231231.xsd#alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:to="loc_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember_2a351995-ca0d-46b9-855b-085cc7a925a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseInTheFaceValueOfTheBondsMember_4a10416b-6a37-4e32-93b5-f4f4475fa0fb" xlink:href="alvo-20231231.xsd#alvo_IncreaseInTheFaceValueOfTheBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:to="loc_alvo_IncreaseInTheFaceValueOfTheBondsMember_4a10416b-6a37-4e32-93b5-f4f4475fa0fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationAxis_1683582a-36bc-4bc5-aaed-3d18e9ce5c75" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_IncomeStatementsLocationAxis_1683582a-36bc-4bc5-aaed-3d18e9ce5c75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_1683582a-36bc-4bc5-aaed-3d18e9ce5c75_default" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_IncomeStatementsLocationAxis_1683582a-36bc-4bc5-aaed-3d18e9ce5c75" xlink:to="loc_alvo_IncomeStatementsLocationDomain_1683582a-36bc-4bc5-aaed-3d18e9ce5c75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_9003bf9e-0732-4eca-88fb-ac9f3294a733" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_IncomeStatementsLocationAxis_1683582a-36bc-4bc5-aaed-3d18e9ce5c75" xlink:to="loc_alvo_IncomeStatementsLocationDomain_9003bf9e-0732-4eca-88fb-ac9f3294a733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinanceIncomeMember_c32b7941-6917-48f9-bc21-17f2e4f9bd49" xlink:href="alvo-20231231.xsd#alvo_FinanceIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IncomeStatementsLocationDomain_9003bf9e-0732-4eca-88fb-ac9f3294a733" xlink:to="loc_alvo_FinanceIncomeMember_c32b7941-6917-48f9-bc21-17f2e4f9bd49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0" xlink:href="alvo-20231231.xsd#alvo_ComponentOfDebtConvertedIntoEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0_default" xlink:href="alvo-20231231.xsd#alvo_ComponentOfDebtConvertedIntoEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0" xlink:to="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_2bcbfdff-3f2d-453f-9338-c150515f1ece" xlink:href="alvo-20231231.xsd#alvo_ComponentOfDebtConvertedIntoEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0" xlink:to="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_2bcbfdff-3f2d-453f-9338-c150515f1ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrincipalAndAccruedInterestComponent.Member_12f125dc-5380-444c-b535-91c80a5997ec" xlink:href="alvo-20231231.xsd#alvo_PrincipalAndAccruedInterestComponent.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_2bcbfdff-3f2d-453f-9338-c150515f1ece" xlink:to="loc_alvo_PrincipalAndAccruedInterestComponent.Member_12f125dc-5380-444c-b535-91c80a5997ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PremiumComponentMember_652cfcb9-ce99-4681-a04a-cc1d6879420e" xlink:href="alvo-20231231.xsd#alvo_PremiumComponentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_2bcbfdff-3f2d-453f-9338-c150515f1ece" xlink:to="loc_alvo_PremiumComponentMember_652cfcb9-ce99-4681-a04a-cc1d6879420e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalBondsIssuanceAxis_77b97080-65e6-40eb-8634-11468b74137e" xlink:href="alvo-20231231.xsd#alvo_AdditionalBondsIssuanceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_AdditionalBondsIssuanceAxis_77b97080-65e6-40eb-8634-11468b74137e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalBondsIssuanceDomain_77b97080-65e6-40eb-8634-11468b74137e_default" xlink:href="alvo-20231231.xsd#alvo_AdditionalBondsIssuanceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_AdditionalBondsIssuanceAxis_77b97080-65e6-40eb-8634-11468b74137e" xlink:to="loc_alvo_AdditionalBondsIssuanceDomain_77b97080-65e6-40eb-8634-11468b74137e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:href="alvo-20231231.xsd#alvo_AdditionalBondsIssuanceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_AdditionalBondsIssuanceAxis_77b97080-65e6-40eb-8634-11468b74137e" xlink:to="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToANewBondHolderMember_12d789b3-7a37-4af2-a1e6-2c83d3223063" xlink:href="alvo-20231231.xsd#alvo_IssuedToANewBondHolderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:to="loc_alvo_IssuedToANewBondHolderMember_12d789b3-7a37-4af2-a1e6-2c83d3223063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToTheExistingNoteholderMember_45883b07-08cd-4989-bd5f-6fa9dcdab798" xlink:href="alvo-20231231.xsd#alvo_IssuedToTheExistingNoteholderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:to="loc_alvo_IssuedToTheExistingNoteholderMember_45883b07-08cd-4989-bd5f-6fa9dcdab798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToTheExistingAndANewBondHolderMember_0693bdbf-31c7-4cc5-bc14-f6bfede7e10c" xlink:href="alvo-20231231.xsd#alvo_IssuedToTheExistingAndANewBondHolderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:to="loc_alvo_IssuedToTheExistingAndANewBondHolderMember_0693bdbf-31c7-4cc5-bc14-f6bfede7e10c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfBondsPayableAxis_68af5291-3a3c-4e39-a520-337c02921e59" xlink:href="alvo-20231231.xsd#alvo_ComponentOfBondsPayableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_ComponentOfBondsPayableAxis_68af5291-3a3c-4e39-a520-337c02921e59" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfBondsPayableDomain_68af5291-3a3c-4e39-a520-337c02921e59_default" xlink:href="alvo-20231231.xsd#alvo_ComponentOfBondsPayableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_ComponentOfBondsPayableAxis_68af5291-3a3c-4e39-a520-337c02921e59" xlink:to="loc_alvo_ComponentOfBondsPayableDomain_68af5291-3a3c-4e39-a520-337c02921e59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfBondsPayableDomain_4bdcb192-4e33-4e0f-b7eb-83855fb93cf5" xlink:href="alvo-20231231.xsd#alvo_ComponentOfBondsPayableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_ComponentOfBondsPayableAxis_68af5291-3a3c-4e39-a520-337c02921e59" xlink:to="loc_alvo_ComponentOfBondsPayableDomain_4bdcb192-4e33-4e0f-b7eb-83855fb93cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrincipalComponentMember_b997e2c2-7911-4794-926a-c644102ef65e" xlink:href="alvo-20231231.xsd#alvo_PrincipalComponentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ComponentOfBondsPayableDomain_4bdcb192-4e33-4e0f-b7eb-83855fb93cf5" xlink:to="loc_alvo_PrincipalComponentMember_b997e2c2-7911-4794-926a-c644102ef65e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InterestComponentMember_cd57e5ce-ea0f-4778-a4a4-49dfa0333195" xlink:href="alvo-20231231.xsd#alvo_InterestComponentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ComponentOfBondsPayableDomain_4bdcb192-4e33-4e0f-b7eb-83855fb93cf5" xlink:to="loc_alvo_InterestComponentMember_cd57e5ce-ea0f-4778-a4a4-49dfa0333195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneAxis_fc0adda3-304f-4e7f-8bcb-426965ee39c1" xlink:href="alvo-20231231.xsd#alvo_AgreementOneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_AgreementOneAxis_fc0adda3-304f-4e7f-8bcb-426965ee39c1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneDomain_fc0adda3-304f-4e7f-8bcb-426965ee39c1_default" xlink:href="alvo-20231231.xsd#alvo_AgreementOneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_AgreementOneAxis_fc0adda3-304f-4e7f-8bcb-426965ee39c1" xlink:to="loc_alvo_AgreementOneDomain_fc0adda3-304f-4e7f-8bcb-426965ee39c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneDomain_d7ef03dc-3147-4e10-81e4-e6142d4410d0" xlink:href="alvo-20231231.xsd#alvo_AgreementOneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_AgreementOneAxis_fc0adda3-304f-4e7f-8bcb-426965ee39c1" xlink:to="loc_alvo_AgreementOneDomain_d7ef03dc-3147-4e10-81e4-e6142d4410d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember_2bd04bb1-6d6e-4bf4-90a6-933af798d96b" xlink:href="alvo-20231231.xsd#alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AgreementOneDomain_d7ef03dc-3147-4e10-81e4-e6142d4410d0" xlink:to="loc_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember_2bd04bb1-6d6e-4bf4-90a6-933af798d96b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_3fd5847b-9c98-4543-934e-d615663ffb8a" xlink:href="alvo-20231231.xsd#alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AgreementOneDomain_d7ef03dc-3147-4e10-81e4-e6142d4410d0" xlink:to="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_3fd5847b-9c98-4543-934e-d615663ffb8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_d3e80adc-0ccd-483b-b4bf-aef0577fe940" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_RangeAxis_d3e80adc-0ccd-483b-b4bf-aef0577fe940" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_d3e80adc-0ccd-483b-b4bf-aef0577fe940_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_d3e80adc-0ccd-483b-b4bf-aef0577fe940" xlink:to="loc_ifrs-full_RangesMember_d3e80adc-0ccd-483b-b4bf-aef0577fe940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_d3e80adc-0ccd-483b-b4bf-aef0577fe940" xlink:to="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c7b11ade-06b7-4ac5-80f8-8a9001d63eb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:to="loc_ifrs-full_BottomOfRangeMember_c7b11ade-06b7-4ac5-80f8-8a9001d63eb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_b71a7efe-3817-4d5b-94b8-94c92f721f60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:to="loc_ifrs-full_TopOfRangeMember_b71a7efe-3817-4d5b-94b8-94c92f721f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageMember_c7edaa61-da6b-468b-ae0c-dcedaba45421" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:to="loc_ifrs-full_WeightedAverageMember_c7edaa61-da6b-468b-ae0c-dcedaba45421" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NatureOfFeesAxis_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b" xlink:href="alvo-20231231.xsd#alvo_NatureOfFeesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_NatureOfFeesAxis_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NatureOfFeesDomain_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b_default" xlink:href="alvo-20231231.xsd#alvo_NatureOfFeesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_NatureOfFeesAxis_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b" xlink:to="loc_alvo_NatureOfFeesDomain_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NatureOfFeesDomain_a87c66fa-8b4c-41cf-be23-bee4a7d7bde7" xlink:href="alvo-20231231.xsd#alvo_NatureOfFeesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_NatureOfFeesAxis_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b" xlink:to="loc_alvo_NatureOfFeesDomain_a87c66fa-8b4c-41cf-be23-bee4a7d7bde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConsentFeesToBondholdersMember_a2cbc651-64a2-4936-9abd-db27de5518fc" xlink:href="alvo-20231231.xsd#alvo_ConsentFeesToBondholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_NatureOfFeesDomain_a87c66fa-8b4c-41cf-be23-bee4a7d7bde7" xlink:to="loc_alvo_ConsentFeesToBondholdersMember_a2cbc651-64a2-4936-9abd-db27de5518fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsAxis_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc" xlink:href="alvo-20231231.xsd#alvo_DetailsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_DetailsAxis_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsDomain_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc_default" xlink:href="alvo-20231231.xsd#alvo_DetailsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_DetailsAxis_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc" xlink:to="loc_alvo_DetailsDomain_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsDomain_40ea0c80-1378-4dae-a7df-845caadac704" xlink:href="alvo-20231231.xsd#alvo_DetailsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_DetailsAxis_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc" xlink:to="loc_alvo_DetailsDomain_40ea0c80-1378-4dae-a7df-845caadac704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BeforeTheTermsOfTheSecondAmendmentMember_cfb6a747-eaa9-4dbd-8fea-bd3bed01e866" xlink:href="alvo-20231231.xsd#alvo_BeforeTheTermsOfTheSecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DetailsDomain_40ea0c80-1378-4dae-a7df-845caadac704" xlink:to="loc_alvo_BeforeTheTermsOfTheSecondAmendmentMember_cfb6a747-eaa9-4dbd-8fea-bd3bed01e866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AfterTheTermsOfTheSecondAmendmentMember_a1366c99-c591-4b54-aad3-f07ff14d8634" xlink:href="alvo-20231231.xsd#alvo_AfterTheTermsOfTheSecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DetailsDomain_40ea0c80-1378-4dae-a7df-845caadac704" xlink:to="loc_alvo_AfterTheTermsOfTheSecondAmendmentMember_a1366c99-c591-4b54-aad3-f07ff14d8634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContingentlyIssuablePennyWarrantsMember_681d34bb-4ee2-4bff-8ab4-da350bd237c8" xlink:href="alvo-20231231.xsd#alvo_ContingentlyIssuablePennyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:to="loc_alvo_ContingentlyIssuablePennyWarrantsMember_681d34bb-4ee2-4bff-8ab4-da350bd237c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondInterestRateFeatureMember_2a5e8b71-1c83-4e0b-9aa3-7e711c0a700e" xlink:href="alvo-20231231.xsd#alvo_SeniorBondInterestRateFeatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:to="loc_alvo_SeniorBondInterestRateFeatureMember_2a5e8b71-1c83-4e0b-9aa3-7e711c0a700e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_66dddf52-3210-46a5-954c-07bebf0a6de0" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:to="loc_alvo_SeniorBondWarrantsMember_66dddf52-3210-46a5-954c-07bebf0a6de0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConversionFeatureMember_1654f8a6-101d-4ff2-bedf-ef4b69f4dddf" xlink:href="alvo-20231231.xsd#alvo_AztiqConversionFeatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:to="loc_alvo_AztiqConversionFeatureMember_1654f8a6-101d-4ff2-bedf-ef4b69f4dddf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAxis_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506" xlink:href="alvo-20231231.xsd#alvo_TrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_TrancheAxis_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506_default" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_TrancheAxis_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506" xlink:to="loc_alvo_TrancheDomain_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_71938d88-63b7-4229-aca5-00f77ed30ce8" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_TrancheAxis_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506" xlink:to="loc_alvo_TrancheDomain_71938d88-63b7-4229-aca5-00f77ed30ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAMember_253a079e-0e69-41da-b3c1-dd9889eb4dd4" xlink:href="alvo-20231231.xsd#alvo_TrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TrancheDomain_71938d88-63b7-4229-aca5-00f77ed30ce8" xlink:to="loc_alvo_TrancheAMember_253a079e-0e69-41da-b3c1-dd9889eb4dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheBMember_23ef9d7d-19f3-4d45-8c74-87de4f0f5189" xlink:href="alvo-20231231.xsd#alvo_TrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TrancheDomain_71938d88-63b7-4229-aca5-00f77ed30ce8" xlink:to="loc_alvo_TrancheBMember_23ef9d7d-19f3-4d45-8c74-87de4f0f5189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_dba10c8b-9469-4136-a073-7820e61c28fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_dba10c8b-9469-4136-a073-7820e61c28fd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_dba10c8b-9469-4136-a073-7820e61c28fd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_dba10c8b-9469-4136-a073-7820e61c28fd" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_dba10c8b-9469-4136-a073-7820e61c28fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_1c843362-618d-49b7-8774-52c46afe7f39" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_dba10c8b-9469-4136-a073-7820e61c28fd" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_1c843362-618d-49b7-8774-52c46afe7f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_ccbc5ca8-d5cc-4d2e-a61a-854355993cc4" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_1c843362-618d-49b7-8774-52c46afe7f39" xlink:to="loc_alvo_SeniorBondWarrantsMember_ccbc5ca8-d5cc-4d2e-a61a-854355993cc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_40c9c3fc-ccd6-4223-9d39-f3b6bec48135" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_1c843362-618d-49b7-8774-52c46afe7f39" xlink:to="loc_alvo_SeniorBondsMember_40c9c3fc-ccd6-4223-9d39-f3b6bec48135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_a9d19bff-843d-4027-8c52-5553f4668292" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_a9d19bff-843d-4027-8c52-5553f4668292" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_a9d19bff-843d-4027-8c52-5553f4668292_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_a9d19bff-843d-4027-8c52-5553f4668292" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_a9d19bff-843d-4027-8c52-5553f4668292_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_3c093a7d-3727-4dea-b3c7-c200da5ee393" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_a9d19bff-843d-4027-8c52-5553f4668292" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_3c093a7d-3727-4dea-b3c7-c200da5ee393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_4ec3e19d-d6ee-4f9d-b2b5-6d8415f50975" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_3c093a7d-3727-4dea-b3c7-c200da5ee393" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_4ec3e19d-d6ee-4f9d-b2b5-6d8415f50975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ccba0edd-8822-4e56-a784-5090957a8763" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ccba0edd-8822-4e56-a784-5090957a8763" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_ccba0edd-8822-4e56-a784-5090957a8763_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ccba0edd-8822-4e56-a784-5090957a8763" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_ccba0edd-8822-4e56-a784-5090957a8763_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_e39a004c-e2a3-4e8f-9fe9-7f90755de476" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ccba0edd-8822-4e56-a784-5090957a8763" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_e39a004c-e2a3-4e8f-9fe9-7f90755de476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_0eaa5165-3f45-460c-9528-48f0074c1ab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_e39a004c-e2a3-4e8f-9fe9-7f90755de476" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_0eaa5165-3f45-460c-9528-48f0074c1ab4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5cfdf885-d37d-4aa3-94fa-ec747aa6a358" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_dei_LegalEntityAxis_5cfdf885-d37d-4aa3-94fa-ec747aa6a358" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5cfdf885-d37d-4aa3-94fa-ec747aa6a358_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5cfdf885-d37d-4aa3-94fa-ec747aa6a358" xlink:to="loc_dei_EntityDomain_5cfdf885-d37d-4aa3-94fa-ec747aa6a358_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e35efc4d-a991-414e-8f85-f0b7763c2ad2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5cfdf885-d37d-4aa3-94fa-ec747aa6a358" xlink:to="loc_dei_EntityDomain_e35efc4d-a991-414e-8f85-f0b7763c2ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqMember_2ec048ba-ebc8-4766-bb8e-06582deb4de4" xlink:href="alvo-20231231.xsd#alvo_AztiqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e35efc4d-a991-414e-8f85-f0b7763c2ad2" xlink:to="loc_alvo_AztiqMember_2ec048ba-ebc8-4766-bb8e-06582deb4de4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ATPHoldingEhf.Member_4822ea63-a9cf-446e-924b-6cdb89c45e30" xlink:href="alvo-20231231.xsd#alvo_ATPHoldingEhf.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e35efc4d-a991-414e-8f85-f0b7763c2ad2" xlink:to="loc_alvo_ATPHoldingEhf.Member_4822ea63-a9cf-446e-924b-6cdb89c45e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheAxis_4884beef-0583-4437-a957-9c0ff9a7a855" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_BorrowingsTrancheAxis_4884beef-0583-4437-a957-9c0ff9a7a855" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheDomain_4884beef-0583-4437-a957-9c0ff9a7a855_default" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_BorrowingsTrancheAxis_4884beef-0583-4437-a957-9c0ff9a7a855" xlink:to="loc_alvo_BorrowingsTrancheDomain_4884beef-0583-4437-a957-9c0ff9a7a855_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheDomain_fbff7610-f482-4f73-9d68-b0815c1fd72f" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_BorrowingsTrancheAxis_4884beef-0583-4437-a957-9c0ff9a7a855" xlink:to="loc_alvo_BorrowingsTrancheDomain_fbff7610-f482-4f73-9d68-b0815c1fd72f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheOneMember_a85147d4-86f7-4ae2-811c-bd276746d0b3" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsTrancheDomain_fbff7610-f482-4f73-9d68-b0815c1fd72f" xlink:to="loc_alvo_BorrowingsTrancheOneMember_a85147d4-86f7-4ae2-811c-bd276746d0b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheTwoMember_a045b2f8-0cb9-4bb0-8940-ab83739574f4" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsTrancheDomain_fbff7610-f482-4f73-9d68-b0815c1fd72f" xlink:to="loc_alvo_BorrowingsTrancheTwoMember_a045b2f8-0cb9-4bb0-8940-ab83739574f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LenderNameAxis_136ffd55-6102-48b9-8f70-dd60c96315be" xlink:href="alvo-20231231.xsd#alvo_LenderNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_LenderNameAxis_136ffd55-6102-48b9-8f70-dd60c96315be" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LenderNameDomain_136ffd55-6102-48b9-8f70-dd60c96315be_default" xlink:href="alvo-20231231.xsd#alvo_LenderNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_LenderNameAxis_136ffd55-6102-48b9-8f70-dd60c96315be" xlink:to="loc_alvo_LenderNameDomain_136ffd55-6102-48b9-8f70-dd60c96315be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LenderNameDomain_6c164edb-c91c-45eb-91b4-6705c7001416" xlink:href="alvo-20231231.xsd#alvo_LenderNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_LenderNameAxis_136ffd55-6102-48b9-8f70-dd60c96315be" xlink:to="loc_alvo_LenderNameDomain_6c164edb-c91c-45eb-91b4-6705c7001416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ArionBankiHfMember_8e33b832-a3cd-4690-9194-b1e3dc757058" xlink:href="alvo-20231231.xsd#alvo_ArionBankiHfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_LenderNameDomain_6c164edb-c91c-45eb-91b4-6705c7001416" xlink:to="loc_alvo_ArionBankiHfMember_8e33b832-a3cd-4690-9194-b1e3dc757058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LandsbankinnHfMember_b288361c-e6d2-47f4-840d-f6037fecadf9" xlink:href="alvo-20231231.xsd#alvo_LandsbankinnHfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_LenderNameDomain_6c164edb-c91c-45eb-91b4-6705c7001416" xlink:to="loc_alvo_LandsbankinnHfMember_b288361c-e6d2-47f4-840d-f6037fecadf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_44a1598b-79d1-480e-a6a1-a465b320bcb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_MaturityAxis_44a1598b-79d1-480e-a6a1-a465b320bcb5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_44a1598b-79d1-480e-a6a1-a465b320bcb5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_44a1598b-79d1-480e-a6a1-a465b320bcb5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_44a1598b-79d1-480e-a6a1-a465b320bcb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_db516481-874f-477a-b925-d03b74c2ed96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_44a1598b-79d1-480e-a6a1-a465b320bcb5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_db516481-874f-477a-b925-d03b74c2ed96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinalMaturityInDecember2029Member_00d99b96-1c99-4482-91c3-d7375391b10d" xlink:href="alvo-20231231.xsd#alvo_FinalMaturityInDecember2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_db516481-874f-477a-b925-d03b74c2ed96" xlink:to="loc_alvo_FinalMaturityInDecember2029Member_00d99b96-1c99-4482-91c3-d7375391b10d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinalMaturityInDecember2027Member_ece9918a-30c1-4059-aacd-691d32fca87f" xlink:href="alvo-20231231.xsd#alvo_FinalMaturityInDecember2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_db516481-874f-477a-b925-d03b74c2ed96" xlink:to="loc_alvo_FinalMaturityInDecember2027Member_ece9918a-30c1-4059-aacd-691d32fca87f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposuresAxis_99db7f43-8849-468a-a06e-fb663c7ed3d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposuresAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_RiskExposuresAxis_99db7f43-8849-468a-a06e-fb663c7ed3d1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposuresMember_99db7f43-8849-468a-a06e-fb663c7ed3d1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposuresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RiskExposuresAxis_99db7f43-8849-468a-a06e-fb663c7ed3d1" xlink:to="loc_ifrs-full_RiskExposuresMember_99db7f43-8849-468a-a06e-fb663c7ed3d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposuresMember_d3a28093-8640-46a5-bf79-24bec48f20a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposuresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RiskExposuresAxis_99db7f43-8849-468a-a06e-fb663c7ed3d1" xlink:to="loc_ifrs-full_RiskExposuresMember_d3a28093-8640-46a5-bf79-24bec48f20a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_df28740e-2af0-4485-bf99-1fa1087bf20d" xlink:href="alvo-20231231.xsd#alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RiskExposuresMember_d3a28093-8640-46a5-bf79-24bec48f20a2" xlink:to="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_df28740e-2af0-4485-bf99-1fa1087bf20d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_39ef2a81-d826-4b0a-8858-cc2bbb730a6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_39ef2a81-d826-4b0a-8858-cc2bbb730a6b" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_39ef2a81-d826-4b0a-8858-cc2bbb730a6b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_39ef2a81-d826-4b0a-8858-cc2bbb730a6b" xlink:to="loc_ifrs-full_InterestRateTypesMember_39ef2a81-d826-4b0a-8858-cc2bbb730a6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_ecd90ea1-d9f4-4264-a7ac-ba4c64a02f75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_39ef2a81-d826-4b0a-8858-cc2bbb730a6b" xlink:to="loc_ifrs-full_InterestRateTypesMember_ecd90ea1-d9f4-4264-a7ac-ba4c64a02f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_UsdSofrMember_459c4193-121b-4647-8926-85c6e1912f1f" xlink:href="alvo-20231231.xsd#alvo_UsdSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_ecd90ea1-d9f4-4264-a7ac-ba4c64a02f75" xlink:to="loc_alvo_UsdSofrMember_459c4193-121b-4647-8926-85c6e1912f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableRatesAxis_f43ed206-657c-41fe-bd97-d28500c5799e" xlink:href="alvo-20231231.xsd#alvo_VariableRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_VariableRatesAxis_f43ed206-657c-41fe-bd97-d28500c5799e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableRatesDomain_f43ed206-657c-41fe-bd97-d28500c5799e_default" xlink:href="alvo-20231231.xsd#alvo_VariableRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_VariableRatesAxis_f43ed206-657c-41fe-bd97-d28500c5799e" xlink:to="loc_alvo_VariableRatesDomain_f43ed206-657c-41fe-bd97-d28500c5799e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableRatesDomain_461deff6-ae10-4a6f-9236-025a94ffc231" xlink:href="alvo-20231231.xsd#alvo_VariableRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_VariableRatesAxis_f43ed206-657c-41fe-bd97-d28500c5799e" xlink:to="loc_alvo_VariableRatesDomain_461deff6-ae10-4a6f-9236-025a94ffc231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_659829ac-d6a9-49b9-9993-adbf631a938d" xlink:href="alvo-20231231.xsd#alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_VariableRatesDomain_461deff6-ae10-4a6f-9236-025a94ffc231" xlink:to="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_659829ac-d6a9-49b9-9993-adbf631a938d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturityMonthAndYearAxis_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b" xlink:href="alvo-20231231.xsd#alvo_MaturityMonthAndYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_MaturityMonthAndYearAxis_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturityMonthAndYearDomain_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b_default" xlink:href="alvo-20231231.xsd#alvo_MaturityMonthAndYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_MaturityMonthAndYearAxis_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b" xlink:to="loc_alvo_MaturityMonthAndYearDomain_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:href="alvo-20231231.xsd#alvo_MaturityMonthAndYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_MaturityMonthAndYearAxis_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b" xlink:to="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnMarch2029Member_d96a3230-a507-4e58-bc65-a0fd88ff434c" xlink:href="alvo-20231231.xsd#alvo_MaturedOnMarch2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:to="loc_alvo_MaturedOnMarch2029Member_d96a3230-a507-4e58-bc65-a0fd88ff434c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnAugust2029Member_91ffa96a-e8ba-4691-af05-806b50a45c78" xlink:href="alvo-20231231.xsd#alvo_MaturedOnAugust2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:to="loc_alvo_MaturedOnAugust2029Member_91ffa96a-e8ba-4691-af05-806b50a45c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnAugust2030Member_9f9cab8c-9f19-4d71-99a6-33d5a4cf7416" xlink:href="alvo-20231231.xsd#alvo_MaturedOnAugust2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:to="loc_alvo_MaturedOnAugust2030Member_9f9cab8c-9f19-4d71-99a6-33d5a4cf7416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnApril2024Member_321d8c48-7a95-4697-8e60-fd1f323168a7" xlink:href="alvo-20231231.xsd#alvo_MaturedOnApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:to="loc_alvo_MaturedOnApril2024Member_321d8c48-7a95-4697-8e60-fd1f323168a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis_3cafa7b6-da0f-4831-a633-f0bf24c69c35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsAxis_3cafa7b6-da0f-4831-a633-f0bf24c69c35" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsTypeMember_3cafa7b6-da0f-4831-a633-f0bf24c69c35_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_3cafa7b6-da0f-4831-a633-f0bf24c69c35" xlink:to="loc_ifrs-full_FinancialAssetsTypeMember_3cafa7b6-da0f-4831-a633-f0bf24c69c35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsTypeMember_d2e7f6be-d19e-4e5e-b129-b1d7d8e1244c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_3cafa7b6-da0f-4831-a633-f0bf24c69c35" xlink:to="loc_ifrs-full_FinancialAssetsTypeMember_d2e7f6be-d19e-4e5e-b129-b1d7d8e1244c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_dead2cfe-9b3b-451c-8ec6-e8ffb3da4f55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsTypeMember_d2e7f6be-d19e-4e5e-b129-b1d7d8e1244c" xlink:to="loc_ifrs-full_TradeReceivablesMember_dead2cfe-9b3b-451c-8ec6-e8ffb3da4f55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants_0ad11ce4-7dba-44e2-8868-b8590a295205" xlink:href="alvo-20231231.xsd#alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants_0ad11ce4-7dba-44e2-8868-b8590a295205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_90cf85be-0460-4c45-adb1-d8b41383a531" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_90cf85be-0460-4c45-adb1-d8b41383a531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities_04f0d629-2081-4c95-b084-d119370ce5b6" xlink:href="alvo-20231231.xsd#alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities_04f0d629-2081-4c95-b084-d119370ce5b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfConvertibleInstruments_da9228d2-07bd-43fe-99cf-b74384da4c85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_IssueOfConvertibleInstruments_da9228d2-07bd-43fe-99cf-b74384da4c85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_722911bc-fb08-48f2-845c-7b97c85fd0bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_722911bc-fb08-48f2-845c-7b97c85fd0bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GainLossOnExtinguishmentOfDebt_cc3d683a-f564-4def-a2a0-b332d89620f8" xlink:href="alvo-20231231.xsd#alvo_GainLossOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_GainLossOnExtinguishmentOfDebt_cc3d683a-f564-4def-a2a0-b332d89620f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_f47452a8-f37e-4111-8a8b-cdd2a5a34f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_f47452a8-f37e-4111-8a8b-cdd2a5a34f11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PremiumPaymentOnBonds_61c140d9-b252-496d-b267-0caa51bd38ed" xlink:href="alvo-20231231.xsd#alvo_PremiumPaymentOnBonds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_PremiumPaymentOnBonds_61c140d9-b252-496d-b267-0caa51bd38ed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtensionPremiumToBondHolders_bd007f42-9a98-4d7c-9ca9-a76d639a1ea5" xlink:href="alvo-20231231.xsd#alvo_ExtensionPremiumToBondHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ExtensionPremiumToBondHolders_bd007f42-9a98-4d7c-9ca9-a76d639a1ea5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalExtensionPremiumToBondholders_d19667db-ea6f-49dc-9158-dafff0ff9ee2" xlink:href="alvo-20231231.xsd#alvo_AdditionalExtensionPremiumToBondholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_AdditionalExtensionPremiumToBondholders_d19667db-ea6f-49dc-9158-dafff0ff9ee2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_a57abea6-a92b-4030-b379-66c684d29b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_a57abea6-a92b-4030-b379-66c684d29b26" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuesFairValueMeasurementLiabilities_f3efa5de-4b7c-4e24-b23d-54105ed5c194" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuesFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_IssuesFairValueMeasurementLiabilities_f3efa5de-4b7c-4e24-b23d-54105ed5c194" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_87f4dead-bc39-42b0-b478-01f38f5c1270" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_NotionalAmount_87f4dead-bc39-42b0-b478-01f38f5c1270" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities_9a2ef073-4fc8-41ab-bee0-bf1afb833257" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities_9a2ef073-4fc8-41ab-bee0-bf1afb833257" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingConversionPeriodPriorToExtinguishment_e41f1468-fbc4-4ed3-a79e-fad57ce3049e" xlink:href="alvo-20231231.xsd#alvo_BorrowingConversionPeriodPriorToExtinguishment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingConversionPeriodPriorToExtinguishment_e41f1468-fbc4-4ed3-a79e-fad57ce3049e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_8e5b0e8b-ef52-44e2-af2e-be52fe068373" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_BondsIssued_8e5b0e8b-ef52-44e2-af2e-be52fe068373" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium_db60e5a0-c3dd-4da2-824f-eb3571c33fd9" xlink:href="alvo-20231231.xsd#alvo_BorrowingPrepaymentPeriodWithAdditionalPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium_db60e5a0-c3dd-4da2-824f-eb3571c33fd9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrepaymentPenaltyPercentageOnBonds_121bae40-0813-4b25-b1b9-20998ed2acea" xlink:href="alvo-20231231.xsd#alvo_PrepaymentPenaltyPercentageOnBonds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_PrepaymentPenaltyPercentageOnBonds_121bae40-0813-4b25-b1b9-20998ed2acea" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_66c4dd90-8063-45aa-b7c0-973c7b2d0aa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_BorrowingsInterestRate_66c4dd90-8063-45aa-b7c0-973c7b2d0aa2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_82f9c3da-357e-441b-8048-de88d6db4433" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_FeeAndCommissionExpense_82f9c3da-357e-441b-8048-de88d6db4433" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MinimumAmountOfRestrictedCashToBeMaintained_9bf491af-e9dc-4e2e-9907-8afff592b210" xlink:href="alvo-20231231.xsd#alvo_MinimumAmountOfRestrictedCashToBeMaintained"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_MinimumAmountOfRestrictedCashToBeMaintained_9bf491af-e9dc-4e2e-9907-8afff592b210" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingSharesIssuancePeriodForInterestDecrease_35bc76be-b292-4e5d-aaa2-1b19e383ace8" xlink:href="alvo-20231231.xsd#alvo_BorrowingSharesIssuancePeriodForInterestDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingSharesIssuancePeriodForInterestDecrease_35bc76be-b292-4e5d-aaa2-1b19e383ace8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_27780319-69b6-49e5-af9c-6c070b45595a" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_27780319-69b6-49e5-af9c-6c070b45595a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_b6d6242d-3def-418d-934e-8198153effcf" xlink:href="alvo-20231231.xsd#alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_b6d6242d-3def-418d-934e-8198153effcf" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue_75379e23-c5d8-4b07-918d-76322a8126d2" xlink:href="alvo-20231231.xsd#alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue_75379e23-c5d8-4b07-918d-76322a8126d2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TransactionCosts_06065397-b3c9-4ef2-b6eb-18b496dd3108" xlink:href="alvo-20231231.xsd#alvo_TransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_TransactionCosts_06065397-b3c9-4ef2-b6eb-18b496dd3108" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CarryingValueOfDebtExtinguished_efcfe2ef-fba2-4692-bdfd-05cb5f7c1e11" xlink:href="alvo-20231231.xsd#alvo_CarryingValueOfDebtExtinguished"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_CarryingValueOfDebtExtinguished_efcfe2ef-fba2-4692-bdfd-05cb5f7c1e11" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AccruedInterestOnDebtExtinguished_3176a0af-4760-494e-b2e6-0b56573a5e9d" xlink:href="alvo-20231231.xsd#alvo_AccruedInterestOnDebtExtinguished"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_AccruedInterestOnDebtExtinguished_3176a0af-4760-494e-b2e6-0b56573a5e9d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NetCashProceedsFromTheTransaction_9cd182d4-da55-4d18-88fe-13fa9da2bfd1" xlink:href="alvo-20231231.xsd#alvo_NetCashProceedsFromTheTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_NetCashProceedsFromTheTransaction_9cd182d4-da55-4d18-88fe-13fa9da2bfd1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RecognitionOfDerivativeAsset_34d9af03-9f48-4fb7-9e11-1d282c4977ee" xlink:href="alvo-20231231.xsd#alvo_RecognitionOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_RecognitionOfDerivativeAsset_34d9af03-9f48-4fb7-9e11-1d282c4977ee" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue_7a11815a-f9c3-4946-8c9b-457e8ead2e8f" xlink:href="alvo-20231231.xsd#alvo_RecognitionOfDerivativeLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue_7a11815a-f9c3-4946-8c9b-457e8ead2e8f" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_dfa3b757-dba2-47c0-94de-7f820a3e7b1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_dfa3b757-dba2-47c0-94de-7f820a3e7b1e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfTranches_5b3811a6-2b68-4947-8ef0-7fa4571f6e5a" xlink:href="alvo-20231231.xsd#alvo_NumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_NumberOfTranches_5b3811a6-2b68-4947-8ef0-7fa4571f6e5a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_220ac598-adca-41ba-a771-7d4719d1b178" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_220ac598-adca-41ba-a771-7d4719d1b178" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRedemptionConversionPrice_e7e58aba-3d8e-4216-96d9-55d38bc85371" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRedemptionConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingsRedemptionConversionPrice_e7e58aba-3d8e-4216-96d9-55d38bc85371" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsConversionFeatureFairValue_816f1e45-26af-476c-bbee-6c9f9fc388b1" xlink:href="alvo-20231231.xsd#alvo_BorrowingsConversionFeatureFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingsConversionFeatureFairValue_816f1e45-26af-476c-bbee-6c9f9fc388b1" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecurities_5a711ef7-4801-4ae5-92ac-7b21934baeae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_DebtSecurities_5a711ef7-4801-4ae5-92ac-7b21934baeae" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_0d2c5e86-e03d-4a5c-a62d-ec7ff613f341" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_0d2c5e86-e03d-4a5c-a62d-ec7ff613f341" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationLoansAssumed_100d03fe-a44e-4e4c-8c3c-03e208e6caf8" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationLoansAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_AssetAcquisitionConsiderationLoansAssumed_100d03fe-a44e-4e4c-8c3c-03e208e6caf8" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRepurchasedFaceAmount_5e3aa53c-3db9-4604-811c-71653f56ad3b" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingsRepurchasedFaceAmount_5e3aa53c-3db9-4604-811c-71653f56ad3b" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_08f2143d-f690-4579-ba36-80621debcc73" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_08f2143d-f690-4579-ba36-80621debcc73" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_87f96372-27b6-4416-b4d5-ecea304bc146" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_87f96372-27b6-4416-b4d5-ecea304bc146" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSeparateInstallments_abfdfdb3-921c-41fd-9bb5-5e406faa94b8" xlink:href="alvo-20231231.xsd#alvo_NumberOfSeparateInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_NumberOfSeparateInstallments_abfdfdb3-921c-41fd-9bb5-5e406faa94b8" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AggregateBorrowingsIndebtedness_e3c7172d-d9f4-4503-8ea6-18e7be8a8c6a" xlink:href="alvo-20231231.xsd#alvo_AggregateBorrowingsIndebtedness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_AggregateBorrowingsIndebtedness_e3c7172d-d9f4-4503-8ea6-18e7be8a8c6a" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPayable_da67b624-621d-44a4-8a90-1e50400db6ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_InterestPayable_da67b624-621d-44a4-8a90-1e50400db6ac" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare_2629bb54-a1cf-47f8-82ad-a70b8d2bccb6" xlink:href="alvo-20231231.xsd#alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare_2629bb54-a1cf-47f8-82ad-a70b8d2bccb6" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtinguishmentOfBorrowings_bce3b2e8-0114-4266-ab50-955ca5d11c90" xlink:href="alvo-20231231.xsd#alvo_ExtinguishmentOfBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ExtinguishmentOfBorrowings_bce3b2e8-0114-4266-ab50-955ca5d11c90" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtinguishmentOfBorrowingsAccruedInterest_ac879f86-c36c-4af8-a64d-7ded71af2f6f" xlink:href="alvo-20231231.xsd#alvo_ExtinguishmentOfBorrowingsAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ExtinguishmentOfBorrowingsAccruedInterest_ac879f86-c36c-4af8-a64d-7ded71af2f6f" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_732faf58-b23f-427f-8c5e-6beb460859e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_Borrowings_732faf58-b23f-427f-8c5e-6beb460859e8" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_da848cf3-6f09-41db-84e5-f666c8d8c124" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_da848cf3-6f09-41db-84e5-f666c8d8c124" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_c91d6587-9fda-4830-a090-b103ccf2ce4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_LoansReceived_c91d6587-9fda-4830-a090-b103ccf2ce4d" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRepurchaseAmount_2b2d2fb8-a340-4eb8-abaf-6c7296aca735" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingsRepurchaseAmount_2b2d2fb8-a340-4eb8-abaf-6c7296aca735" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLoans_7857c547-2cf1-4ed8-b96c-8b8d5f8edc7a" xlink:href="alvo-20231231.xsd#alvo_NumberOfLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_NumberOfLoans_7857c547-2cf1-4ed8-b96c-8b8d5f8edc7a" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromBorrowingsNetOfTransactionCosts_bc01f004-4c21-468a-85ad-5dc21543da86" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromBorrowingsNetOfTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ProceedsFromBorrowingsNetOfTransactionCosts_bc01f004-4c21-468a-85ad-5dc21543da86" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_313ccd6c-9eb7-48d3-8e40-9d07cb9fc77f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_313ccd6c-9eb7-48d3-8e40-9d07cb9fc77f" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_fb899a53-81fd-46f3-b0d6-488295bf2300" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_fb899a53-81fd-46f3-b0d6-488295bf2300" xlink:type="arc" order="55"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_14258eef-b831-45a1-9ec3-7d81dedc4456" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1f82928d-f299-4608-9a42-c94472c1ddac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_14258eef-b831-45a1-9ec3-7d81dedc4456" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1f82928d-f299-4608-9a42-c94472c1ddac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_a4146015-7a81-4e65-bcb0-ee6005956f24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1f82928d-f299-4608-9a42-c94472c1ddac" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_a4146015-7a81-4e65-bcb0-ee6005956f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_a4146015-7a81-4e65-bcb0-ee6005956f24_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a4146015-7a81-4e65-bcb0-ee6005956f24" xlink:to="loc_ifrs-full_BorrowingsByNameMember_a4146015-7a81-4e65-bcb0-ee6005956f24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a4146015-7a81-4e65-bcb0-ee6005956f24" xlink:to="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleLoanNotesMember_9f64d526-4329-4a63-9892-67816832f3fe" xlink:href="alvo-20231231.xsd#alvo_ConvertibleLoanNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:to="loc_alvo_ConvertibleLoanNotesMember_9f64d526-4329-4a63-9892-67816832f3fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_a454db1d-e5ef-4abb-87c9-210d3dc89862" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:to="loc_alvo_SeniorBondsMember_a454db1d-e5ef-4abb-87c9-210d3dc89862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherBorrowingsMember_42b02ebe-8f99-49d9-953e-b3ce2c3dbca7" xlink:href="alvo-20231231.xsd#alvo_OtherBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:to="loc_alvo_OtherBorrowingsMember_42b02ebe-8f99-49d9-953e-b3ce2c3dbca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember_07723a56-b7c2-4f09-8736-67faa0ae68a7" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:to="loc_alvo_AlvogenFacilityMember_07723a56-b7c2-4f09-8736-67faa0ae68a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_14258eef-b831-45a1-9ec3-7d81dedc4456" xlink:to="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_e203ab54-1c55-4a88-8499-9cd969fac7fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_Borrowings_e203ab54-1c55-4a88-8499-9cd969fac7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_0c532775-7522-4999-bb2a-fe5d9cdc9c68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_0c532775-7522-4999-bb2a-fe5d9cdc9c68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease_3ba8fb5a-a33f-44aa-af8f-46a79a0ee7a4" xlink:href="alvo-20231231.xsd#alvo_InterestCostsCapitalizedPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease_3ba8fb5a-a33f-44aa-af8f-46a79a0ee7a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement_8870f893-dabc-4636-8274-079cb9444a24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement_8870f893-dabc-4636-8274-079cb9444a24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashChangesInOtherChanges_4fece731-fbc3-43f8-9d67-8551086a02f0" xlink:href="alvo-20231231.xsd#alvo_NonCashChangesInOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_alvo_NonCashChangesInOtherChanges_4fece731-fbc3-43f8-9d67-8551086a02f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_a882e5a9-e738-4325-8599-e71df412118e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_a882e5a9-e738-4325-8599-e71df412118e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity_98e40728-e307-4f8d-b793-1a0bfa8b2cb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity_98e40728-e307-4f8d-b793-1a0bfa8b2cb1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashChangesInOtherNonCashMovements_ac7f18bd-c6d3-4fc1-b6c1-189ed541d1b1" xlink:href="alvo-20231231.xsd#alvo_NonCashChangesInOtherNonCashMovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_alvo_NonCashChangesInOtherNonCashMovements_ac7f18bd-c6d3-4fc1-b6c1-189ed541d1b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_63eeb9c8-1943-4b00-9f49-8aceadfee04f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings_1379be72-0976-4000-8490-a944590f8492" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_ProceedsFromCurrentBorrowings_1379be72-0976-4000-8490-a944590f8492" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_655d8dcc-55d7-4f33-9b6c-acb279480229" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_655d8dcc-55d7-4f33-9b6c-acb279480229" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts_07099426-81b7-4e84-975a-2d14faa5a5ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForDebtIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_14258eef-b831-45a1-9ec3-7d81dedc4456" xlink:to="loc_ifrs-full_PaymentsForDebtIssueCosts_07099426-81b7-4e84-975a-2d14faa5a5ba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_aa47283b-f677-4fc8-aeed-9284c568294b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0ee4b454-d596-4fd1-b736-9da0b78095df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_aa47283b-f677-4fc8-aeed-9284c568294b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0ee4b454-d596-4fd1-b736-9da0b78095df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_c9efdacf-091d-45d5-8005-ffe36f8e8e6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0ee4b454-d596-4fd1-b736-9da0b78095df" xlink:to="loc_ifrs-full_MaturityAxis_c9efdacf-091d-45d5-8005-ffe36f8e8e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c9efdacf-091d-45d5-8005-ffe36f8e8e6c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_c9efdacf-091d-45d5-8005-ffe36f8e8e6c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c9efdacf-091d-45d5-8005-ffe36f8e8e6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_c9efdacf-091d-45d5-8005-ffe36f8e8e6c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_afe6efba-1cad-44e5-953c-4dd04985fbfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_afe6efba-1cad-44e5-953c-4dd04985fbfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1b9b1070-111c-4db5-a753-7e7221a7455f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1b9b1070-111c-4db5-a753-7e7221a7455f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_094d74e6-5088-4f5f-9dcf-ec92b117f354" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_094d74e6-5088-4f5f-9dcf-ec92b117f354" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_89d96fa9-a17b-4c44-9acd-af539fae0827" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_89d96fa9-a17b-4c44-9acd-af539fae0827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThereafterMember_a70df2f0-4715-4d78-a1a4-f32431b9fa53" xlink:href="alvo-20231231.xsd#alvo_ThereafterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_alvo_ThereafterMember_a70df2f0-4715-4d78-a1a4-f32431b9fa53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_ad263c91-8c55-4a0f-b75a-b6ba9bd1374c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_aa47283b-f677-4fc8-aeed-9284c568294b" xlink:to="loc_ifrs-full_Borrowings_ad263c91-8c55-4a0f-b75a-b6ba9bd1374c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LongTermIncentivePlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_31138ca0-fef8-4c12-ace9-cdf124c43a61" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_srt_TitleOfIndividualAxis_31138ca0-fef8-4c12-ace9-cdf124c43a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_31138ca0-fef8-4c12-ace9-cdf124c43a61_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_31138ca0-fef8-4c12-ace9-cdf124c43a61" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_31138ca0-fef8-4c12-ace9-cdf124c43a61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5b8619af-5e16-4375-ad96-07fca409cc8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_31138ca0-fef8-4c12-ace9-cdf124c43a61" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5b8619af-5e16-4375-ad96-07fca409cc8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FormerEmployeesMember_c20accbb-4cde-4c9c-bd94-baa36245fbb4" xlink:href="alvo-20231231.xsd#alvo_FormerEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5b8619af-5e16-4375-ad96-07fca409cc8e" xlink:to="loc_alvo_FormerEmployeesMember_c20accbb-4cde-4c9c-bd94-baa36245fbb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExistingEmployeesMember_c0a0ef46-c8b5-4620-8642-2faa587cc654" xlink:href="alvo-20231231.xsd#alvo_ExistingEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5b8619af-5e16-4375-ad96-07fca409cc8e" xlink:to="loc_alvo_ExistingEmployeesMember_c0a0ef46-c8b5-4620-8642-2faa587cc654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_d011bfd9-abfd-4b8b-9528-a47ccfe57324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_d011bfd9-abfd-4b8b-9528-a47ccfe57324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_2ce7c5f8-3123-41c1-a950-36d7a70adcb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_d011bfd9-abfd-4b8b-9528-a47ccfe57324" xlink:to="loc_ifrs-full_OrdinarySharesMember_2ce7c5f8-3123-41c1-a950-36d7a70adcb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_623425e8-e133-4069-a696-b19c0ed9b73c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_623425e8-e133-4069-a696-b19c0ed9b73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember_85e40fde-9548-4412-ba8e-92fbf2ca2366" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_623425e8-e133-4069-a696-b19c0ed9b73c" xlink:to="loc_alvo_ShareAppreciationRightsMember_85e40fde-9548-4412-ba8e-92fbf2ca2366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_18f26ac2-e7a6-4771-83d0-20c5969cbeb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_18f26ac2-e7a6-4771-83d0-20c5969cbeb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_18f26ac2-e7a6-4771-83d0-20c5969cbeb4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_18f26ac2-e7a6-4771-83d0-20c5969cbeb4" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_18f26ac2-e7a6-4771-83d0-20c5969cbeb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_509e945b-d333-4d50-a4e1-180d79744341" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_18f26ac2-e7a6-4771-83d0-20c5969cbeb4" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_509e945b-d333-4d50-a4e1-180d79744341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_46169514-d868-4039-8862-9863501c9dcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_509e945b-d333-4d50-a4e1-180d79744341" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_46169514-d868-4039-8862-9863501c9dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_06bb608c-2f3a-47c8-ad68-bb6cb7828f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_06bb608c-2f3a-47c8-ad68-bb6cb7828f0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_6a6c08f6-99c2-40f3-8adc-a43f76e4ff59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_NumberOfEmployees_6a6c08f6-99c2-40f3-8adc-a43f76e4ff59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_405302e8-f5df-4242-8588-a0ee11925366" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_405302e8-f5df-4242-8588-a0ee11925366" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination_77b3f35e-90a5-4a76-b235-d216915e2774" xlink:href="alvo-20231231.xsd#alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination_77b3f35e-90a5-4a76-b235-d216915e2774" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_7c132a45-2bd6-4575-a99a-28a768221e9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_7c132a45-2bd6-4575-a99a-28a768221e9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue_52544203-725a-4a21-823e-871fb276e94f" xlink:href="alvo-20231231.xsd#alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue_52544203-725a-4a21-823e-871fb276e94f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue_9cdece47-d30a-4fb9-825a-0f589260fe8d" xlink:href="alvo-20231231.xsd#alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue_9cdece47-d30a-4fb9-825a-0f589260fe8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_172bb982-665d-4b7d-b996-83bf1cd96fc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_172bb982-665d-4b7d-b996-83bf1cd96fc2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity_2a1dd53f-7cab-4726-a5eb-af65f1072dcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_ChangesInEquity_2a1dd53f-7cab-4726-a5eb-af65f1072dcb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset_332e9b2f-81a7-41cd-870d-6d5d92e72f29" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset_332e9b2f-81a7-41cd-870d-6d5d92e72f29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_cc17af30-170f-4c80-9180-87ebc04e37bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_cc17af30-170f-4c80-9180-87ebc04e37bd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_cadcdbfa-9e57-447e-8a6a-0c14b7d608fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_cadcdbfa-9e57-447e-8a6a-0c14b7d608fa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement_f510ecca-bde2-4189-80cb-7af7bf169e29" xlink:href="alvo-20231231.xsd#alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement_f510ecca-bde2-4189-80cb-7af7bf169e29" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_f0bc3169-8618-446a-930c-b233875a21d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_bb5f0884-58d7-41de-aad1-71ef453599f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_f0bc3169-8618-446a-930c-b233875a21d0" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_bb5f0884-58d7-41de-aad1-71ef453599f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_dacc618b-6b39-4a40-bb02-d24684535934" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_bb5f0884-58d7-41de-aad1-71ef453599f3" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_dacc618b-6b39-4a40-bb02-d24684535934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_dacc618b-6b39-4a40-bb02-d24684535934_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_dacc618b-6b39-4a40-bb02-d24684535934" xlink:to="loc_ifrs-full_RestatedMember_dacc618b-6b39-4a40-bb02-d24684535934_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_d2dfcd9f-4297-4811-a4c9-c854d4fddac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_dacc618b-6b39-4a40-bb02-d24684535934" xlink:to="loc_ifrs-full_RestatedMember_d2dfcd9f-4297-4811-a4c9-c854d4fddac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreviouslyStatedMember_3f219747-7498-4c11-9a78-4cac9ba90a98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestatedMember_d2dfcd9f-4297-4811-a4c9-c854d4fddac9" xlink:to="loc_ifrs-full_PreviouslyStatedMember_3f219747-7498-4c11-9a78-4cac9ba90a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember_286e0346-a9e0-4829-92cc-9ec0e03455b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestatedMember_d2dfcd9f-4297-4811-a4c9-c854d4fddac9" xlink:to="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember_286e0346-a9e0-4829-92cc-9ec0e03455b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:href="alvo-20231231.xsd#alvo_LiabilityAssetOfDefinedBenefitPlansRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_f0bc3169-8618-446a-930c-b233875a21d0" xlink:to="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_3ca580fc-ad0c-4cd5-bc44-6e43d40ed7f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_3ca580fc-ad0c-4cd5-bc44-6e43d40ed7f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_36175c65-4401-423d-a04a-181637ffb675" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:to="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_36175c65-4401-423d-a04a-181637ffb675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d8da3ad5-73d4-40ed-8249-880440175351" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d8da3ad5-73d4-40ed-8249-880440175351" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_5bf9775e-9f87-4bcc-b63d-0d6114c41fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareBasedPaymentsSummaryofMovementsinRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_47d5522d-8407-4366-a493-b4263337d0cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_531b566b-7de6-44fc-9440-9668eaf448da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_47d5522d-8407-4366-a493-b4263337d0cd" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_531b566b-7de6-44fc-9440-9668eaf448da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fb2fc671-745d-4aff-9076-98c9cfaa65b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_531b566b-7de6-44fc-9440-9668eaf448da" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fb2fc671-745d-4aff-9076-98c9cfaa65b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb2fc671-745d-4aff-9076-98c9cfaa65b2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fb2fc671-745d-4aff-9076-98c9cfaa65b2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb2fc671-745d-4aff-9076-98c9cfaa65b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2a94830c-7e1f-4a36-adbd-2150b33eeda1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fb2fc671-745d-4aff-9076-98c9cfaa65b2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2a94830c-7e1f-4a36-adbd-2150b33eeda1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_f0bb8e4c-3be9-4b27-913a-bc62f4845b68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2a94830c-7e1f-4a36-adbd-2150b33eeda1" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_f0bb8e4c-3be9-4b27-913a-bc62f4845b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:href="alvo-20231231.xsd#alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_47d5522d-8407-4366-a493-b4263337d0cd" xlink:to="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b2325121-0d39-48db-b4d5-2ed1de8eaf2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b2325121-0d39-48db-b4d5-2ed1de8eaf2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_92036a4a-18f7-4cfa-b35d-83d6625246f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_92036a4a-18f7-4cfa-b35d-83d6625246f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e319a152-bfd2-4d99-89da-2aa1b3ce8f8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e319a152-bfd2-4d99-89da-2aa1b3ce8f8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_d6ce9fa7-e22f-4eb1-83d1-4629d2a62214" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_d6ce9fa7-e22f-4eb1-83d1-4629d2a62214" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_fecdb804-2a93-4cae-8f27-69d77b12b664" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_47d5522d-8407-4366-a493-b4263337d0cd" xlink:to="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_a38d0108-ed24-4938-87d1-8dccce3c5a29" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_a38d0108-ed24-4938-87d1-8dccce3c5a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted_07aaf5dd-e3b6-4031-8781-1c3e62237ed7" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted_07aaf5dd-e3b6-4031-8781-1c3e62237ed7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited_cd1d8132-4130-4f0e-b3b7-d56ef26c379a" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited_cd1d8132-4130-4f0e-b3b7-d56ef26c379a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested_8cb449b9-4818-42b5-a63e-e1ad7846d207" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested_8cb449b9-4818-42b5-a63e-e1ad7846d207" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_ab0b50be-3913-4696-b4bc-0eaeec47fee6" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_92952b5d-caae-46f3-aaf9-a41cb9bb507f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c81360c8-3d75-4e22-8999-fd4390bb8402" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_92952b5d-caae-46f3-aaf9-a41cb9bb507f" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c81360c8-3d75-4e22-8999-fd4390bb8402" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77e082e8-62ce-4211-803b-b240ad3313b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c81360c8-3d75-4e22-8999-fd4390bb8402" xlink:to="loc_srt_RangeAxis_77e082e8-62ce-4211-803b-b240ad3313b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77e082e8-62ce-4211-803b-b240ad3313b6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_77e082e8-62ce-4211-803b-b240ad3313b6" xlink:to="loc_srt_RangeMember_77e082e8-62ce-4211-803b-b240ad3313b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83ba829e-67ab-4364-89dd-6b3172fcb000" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_77e082e8-62ce-4211-803b-b240ad3313b6" xlink:to="loc_srt_RangeMember_83ba829e-67ab-4364-89dd-6b3172fcb000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5ed55fba-411e-477a-a156-160e643e7e3d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_83ba829e-67ab-4364-89dd-6b3172fcb000" xlink:to="loc_srt_MinimumMember_5ed55fba-411e-477a-a156-160e643e7e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b0b66b90-6d8f-4a68-8d99-033f552b6478" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_83ba829e-67ab-4364-89dd-6b3172fcb000" xlink:to="loc_srt_MaximumMember_b0b66b90-6d8f-4a68-8d99-033f552b6478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement_2be87731-f550-4207-a503-25fcb51699a9" xlink:href="alvo-20231231.xsd#alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_92952b5d-caae-46f3-aaf9-a41cb9bb507f" xlink:to="loc_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement_2be87731-f550-4207-a503-25fcb51699a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8657e07d-1732-4d16-ae70-b7261719ebe2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_92952b5d-caae-46f3-aaf9-a41cb9bb507f" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8657e07d-1732-4d16-ae70-b7261719ebe2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aba806e3-a0e9-41c3-9b95-76c2bde821e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_73ed8fc6-7035-4bd1-b36a-c37fe96a4a4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aba806e3-a0e9-41c3-9b95-76c2bde821e8" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_73ed8fc6-7035-4bd1-b36a-c37fe96a4a4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationAxis_3cb3f1bd-c4e9-4eff-b021-859846914d7c" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_73ed8fc6-7035-4bd1-b36a-c37fe96a4a4e" xlink:to="loc_alvo_IncomeStatementsLocationAxis_3cb3f1bd-c4e9-4eff-b021-859846914d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_3cb3f1bd-c4e9-4eff-b021-859846914d7c_default" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_IncomeStatementsLocationAxis_3cb3f1bd-c4e9-4eff-b021-859846914d7c" xlink:to="loc_alvo_IncomeStatementsLocationDomain_3cb3f1bd-c4e9-4eff-b021-859846914d7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_IncomeStatementsLocationAxis_3cb3f1bd-c4e9-4eff-b021-859846914d7c" xlink:to="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_6db0d1eb-fa5b-45ea-8f48-bfb950ac585b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:to="loc_ifrs-full_CostOfSalesMember_6db0d1eb-fa5b-45ea-8f48-bfb950ac585b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentExpensesMember_891ead7d-2a16-4e5c-957f-129e6f2a615c" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:to="loc_alvo_ResearchAndDevelopmentExpensesMember_891ead7d-2a16-4e5c-957f-129e6f2a615c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember_6360c1e5-d364-44ce-9b12-92b3c05c11ec" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:to="loc_alvo_GeneralAndAdministrativeExpensesMember_6360c1e5-d364-44ce-9b12-92b3c05c11ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_579de708-06f5-4aa0-99cb-74a0576843b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aba806e3-a0e9-41c3-9b95-76c2bde821e8" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_579de708-06f5-4aa0-99cb-74a0576843b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2f77fcc5-58c6-4d89-8741-1c98fb07806b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:to="loc_srt_CounterpartyNameAxis_2f77fcc5-58c6-4d89-8741-1c98fb07806b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f77fcc5-58c6-4d89-8741-1c98fb07806b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2f77fcc5-58c6-4d89-8741-1c98fb07806b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f77fcc5-58c6-4d89-8741-1c98fb07806b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2f77fcc5-58c6-4d89-8741-1c98fb07806b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_d17dbb01-6021-4f63-878d-306bdc191502" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHf.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:to="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_d17dbb01-6021-4f63-878d-306bdc191502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiFasteignirEhf.Member_721fa112-978f-49c7-9937-40bfd38add57" xlink:href="alvo-20231231.xsd#alvo_FlokiFasteignirEhf.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:to="loc_alvo_FlokiFasteignirEhf.Member_721fa112-978f-49c7-9937-40bfd38add57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiArtEhf.Member_863e8239-ae43-41c3-93aa-eb22fd802a31" xlink:href="alvo-20231231.xsd#alvo_FlokiArtEhf.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:to="loc_alvo_FlokiArtEhf.Member_863e8239-ae43-41c3-93aa-eb22fd802a31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseFacilityAxis_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d" xlink:href="alvo-20231231.xsd#alvo_LeaseFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:to="loc_alvo_LeaseFacilityAxis_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseFacilityDomain_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d_default" xlink:href="alvo-20231231.xsd#alvo_LeaseFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_LeaseFacilityAxis_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d" xlink:to="loc_alvo_LeaseFacilityDomain_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:href="alvo-20231231.xsd#alvo_LeaseFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_LeaseFacilityAxis_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d" xlink:to="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoLeaseFacilitiesMember_f73f3230-8b68-46b5-86c2-69cf49a39c3b" xlink:href="alvo-20231231.xsd#alvo_TwoLeaseFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:to="loc_alvo_TwoLeaseFacilitiesMember_f73f3230-8b68-46b5-86c2-69cf49a39c3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_April2023LeaseFacilityMember_13fd71da-4bb0-46c9-ac49-1bcc0d602ad1" xlink:href="alvo-20231231.xsd#alvo_April2023LeaseFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:to="loc_alvo_April2023LeaseFacilityMember_13fd71da-4bb0-46c9-ac49-1bcc0d602ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Remaining15LeaseFacilitiesMember_5c6c2933-7594-468c-926b-d238f4e7796d" xlink:href="alvo-20231231.xsd#alvo_Remaining15LeaseFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:to="loc_alvo_Remaining15LeaseFacilitiesMember_5c6c2933-7594-468c-926b-d238f4e7796d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeaseAgreementsEnteredInto_a8f70729-5139-4ff1-ac9b-9cf3cb13c93d" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeaseAgreementsEnteredInto"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_NumberOfLeaseAgreementsEnteredInto_a8f70729-5139-4ff1-ac9b-9cf3cb13c93d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageRemainingLeaseTerm_6a30755b-9c8e-4055-9480-026fe56df90e" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_WeightedAverageRemainingLeaseTerm_6a30755b-9c8e-4055-9480-026fe56df90e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeasesTerminated_403b44e0-1fc9-44be-a999-810504a53afd" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeasesTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_NumberOfLeasesTerminated_403b44e0-1fc9-44be-a999-810504a53afd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeaseAgreements_cf39ea6e-d955-473a-9388-4b327b061980" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_NumberOfLeaseAgreements_cf39ea6e-d955-473a-9388-4b327b061980" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LoansToRelatedParties_8ef19f40-533e-4228-825e-59f33f8286ae" xlink:href="alvo-20231231.xsd#alvo_LoansToRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_LoansToRelatedParties_8ef19f40-533e-4228-825e-59f33f8286ae" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesSummaryofRelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7c32c1e2-88e9-4675-b6c6-594091928ebf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7c32c1e2-88e9-4675-b6c6-594091928ebf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9da972ca-fb84-4d1a-9e56-75c4df1b6747" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7c32c1e2-88e9-4675-b6c6-594091928ebf" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9da972ca-fb84-4d1a-9e56-75c4df1b6747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9da972ca-fb84-4d1a-9e56-75c4df1b6747_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9da972ca-fb84-4d1a-9e56-75c4df1b6747" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9da972ca-fb84-4d1a-9e56-75c4df1b6747_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9da972ca-fb84-4d1a-9e56-75c4df1b6747" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLuxHoldingsSRLMember_0b36d9c9-45d2-40c7-8920-4c7bfd7284cd" xlink:href="alvo-20231231.xsd#alvo_AlvogenLuxHoldingsSRLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenLuxHoldingsSRLMember_0b36d9c9-45d2-40c7-8920-4c7bfd7284cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AtpHoldingsEhfMember_ffdc8581-e23b-47d4-b2f1-0d0ff843886c" xlink:href="alvo-20231231.xsd#alvo_AtpHoldingsEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AtpHoldingsEhfMember_ffdc8581-e23b-47d4-b2f1-0d0ff843886c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFjrfestingarEhfMember_a1c19332-a7e4-4533-b43d-cd1857f6fa22" xlink:href="alvo-20231231.xsd#alvo_AztiqFjrfestingarEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AztiqFjrfestingarEhfMember_a1c19332-a7e4-4533-b43d-cd1857f6fa22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_8a4cadb2-e430-4f88-8afa-4e30c230b913" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHf.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_8a4cadb2-e430-4f88-8afa-4e30c230b913" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiEyjolfurEhfMember_60d03009-0fa9-4f02-a560-6c024da47df2" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiEyjolfurEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FasteignafelagiEyjolfurEhfMember_60d03009-0fa9-4f02-a560-6c024da47df2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConsultingEhfMember_c9862b00-bef2-41cf-8f10-4e829b9a753f" xlink:href="alvo-20231231.xsd#alvo_AztiqConsultingEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AztiqConsultingEhfMember_c9862b00-bef2-41cf-8f10-4e829b9a753f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiArtEhfMember_b7815af3-f47a-4c53-9322-ffeac8f6aa68" xlink:href="alvo-20231231.xsd#alvo_FlokiArtEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FlokiArtEhfMember_b7815af3-f47a-4c53-9322-ffeac8f6aa68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember_6315f512-2c3c-4952-a640-13d64fd4fea1" xlink:href="alvo-20231231.xsd#alvo_AlvogenIcelandEhf.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember_6315f512-2c3c-4952-a640-13d64fd4fea1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEhf.SisterCompanyMember_89711954-d4ea-45bf-9ce3-18a693af222c" xlink:href="alvo-20231231.xsd#alvo_AlvogenEhf.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenEhf.SisterCompanyMember_89711954-d4ea-45bf-9ce3-18a693af222c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenUKSisterCompanyMember_6ba7fd22-7808-4e10-8a78-e7faec788fe2" xlink:href="alvo-20231231.xsd#alvo_AlvogenUKSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenUKSisterCompanyMember_6ba7fd22-7808-4e10-8a78-e7faec788fe2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFinanceB.VMember_270d97e8-4258-45b1-abe4-7b4ebba90e51" xlink:href="alvo-20231231.xsd#alvo_AlvogenFinanceB.VMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenFinanceB.VMember_270d97e8-4258-45b1-abe4-7b4ebba90e51" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_d9803858-726e-4e8e-893b-ad85bb69384b" xlink:href="alvo-20231231.xsd#alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_d9803858-726e-4e8e-893b-ad85bb69384b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusInternationalPteltdMember_571a625a-3a1a-42d3-a63f-a3c53fc97767" xlink:href="alvo-20231231.xsd#alvo_LotusInternationalPteltdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_LotusInternationalPteltdMember_571a625a-3a1a-42d3-a63f-a3c53fc97767" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember_559f509b-c093-4a9f-a2c5-4aaf9409991b" xlink:href="alvo-20231231.xsd#alvo_AlvogenEmergingMarketsSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember_559f509b-c093-4a9f-a2c5-4aaf9409991b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_63be4742-69ef-478c-90b7-b7301ec575a8" xlink:href="alvo-20231231.xsd#alvo_AlvogenKoreaCo.LtdSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_63be4742-69ef-478c-90b7-b7301ec575a8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenInc.SisterCompanyMember_3a0685c4-a084-451d-87bb-d354b1209def" xlink:href="alvo-20231231.xsd#alvo_AlvogenInc.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenInc.SisterCompanyMember_3a0685c4-a084-451d-87bb-d354b1209def" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_e411ece4-fabc-48cf-b084-87966b33d969" xlink:href="alvo-20231231.xsd#alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_e411ece4-fabc-48cf-b084-87966b33d969" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdalvoLimitedMember_56e73611-49d6-41a9-b02c-d2b747c1e7e6" xlink:href="alvo-20231231.xsd#alvo_AdalvoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AdalvoLimitedMember_56e73611-49d6-41a9-b02c-d2b747c1e7e6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdalvoUKMember_c0488ec7-bfd7-419d-b43c-eddbbffcb1c6" xlink:href="alvo-20231231.xsd#alvo_AdalvoUKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AdalvoUKMember_c0488ec7-bfd7-419d-b43c-eddbbffcb1c6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiInvestEhfMember_5a560699-8929-4722-b150-f2a85a1e930b" xlink:href="alvo-20231231.xsd#alvo_FlokiInvestEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FlokiInvestEhfMember_5a560699-8929-4722-b150-f2a85a1e930b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiHoldingsS.aR.lMember_173f59ae-f142-4064-b92f-5c474ff918b6" xlink:href="alvo-20231231.xsd#alvo_FlokiHoldingsS.aR.lMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FlokiHoldingsS.aR.lMember_173f59ae-f142-4064-b92f-5c474ff918b6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_L41EhfMember_68f5a6b4-9b5d-4b5e-a987-2b131a7ca77e" xlink:href="alvo-20231231.xsd#alvo_L41EhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_L41EhfMember_68f5a6b4-9b5d-4b5e-a987-2b131a7ca77e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_df783559-1745-4fda-b4a9-473f5ed33128" xlink:href="alvo-20231231.xsd#alvo_AlvogenMaltaSh.ServicesSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_df783559-1745-4fda-b4a9-473f5ed33128" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenSpainSlMember_8f22e66b-5be8-4de0-b2b2-f81f34c93185" xlink:href="alvo-20231231.xsd#alvo_AlvogenSpainSlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenSpainSlMember_8f22e66b-5be8-4de0-b2b2-f81f34c93185" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NorwichClinicalServicesLtdMember_d3264a05-cda2-47aa-953f-1c2c7810e11a" xlink:href="alvo-20231231.xsd#alvo_NorwichClinicalServicesLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_NorwichClinicalServicesLtdMember_d3264a05-cda2-47aa-953f-1c2c7810e11a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignaflagiEyjlfurhfMember_64ece6f8-73d0-44c4-b816-ee4b2d09afb3" xlink:href="alvo-20231231.xsd#alvo_FasteignaflagiEyjlfurhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FasteignaflagiEyjlfurhfMember_64ece6f8-73d0-44c4-b816-ee4b2d09afb3" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiFasteignirEhfMember_60b1320d-ff6e-4bbe-b5ce-8ad150597d1c" xlink:href="alvo-20231231.xsd#alvo_FlokiFasteignirEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FlokiFasteignirEhfMember_60b1320d-ff6e-4bbe-b5ce-8ad150597d1c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_8b0c8e17-750c-4b2a-8b51-a7d105aa7e65" xlink:href="alvo-20231231.xsd#alvo_AlvogenPharmaPvtLtdSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_8b0c8e17-750c-4b2a-8b51-a7d105aa7e65" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Lambahagavegur7EhfMember_3c435b96-253b-473e-ad94-9d7a1f5755c5" xlink:href="alvo-20231231.xsd#alvo_Lambahagavegur7EhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_Lambahagavegur7EhfMember_3c435b96-253b-473e-ad94-9d7a1f5755c5" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_0f043c7e-44c2-4751-bac1-9d59187a329c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_0f043c7e-44c2-4751-bac1-9d59187a329c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_1a6d75d5-d0b5-49eb-9688-77f2cb3d455e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_1a6d75d5-d0b5-49eb-9688-77f2cb3d455e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_bd0fe2f0-4c0a-4cbe-bde6-69c7d9e946a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_bd0fe2f0-4c0a-4cbe-bde6-69c7d9e946a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_405eb4a8-9e2c-4b20-8403-3c25277cf9fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_405eb4a8-9e2c-4b20-8403-3c25277cf9fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1ebd866c-0d46-471e-8fef-66444246e58a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_1ebd866c-0d46-471e-8fef-66444246e58a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesScheduleofRelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_193a4ec1-0be9-4295-bbd9-e07060e87ad6" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_021e0c17-8a2e-481f-b0b1-9f53c77c4131" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_193a4ec1-0be9-4295-bbd9-e07060e87ad6" xlink:to="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_021e0c17-8a2e-481f-b0b1-9f53c77c4131" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_6e1f19ee-5ed9-4f07-b00c-570de0b69963" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_021e0c17-8a2e-481f-b0b1-9f53c77c4131" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_6e1f19ee-5ed9-4f07-b00c-570de0b69963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_6e1f19ee-5ed9-4f07-b00c-570de0b69963_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_6e1f19ee-5ed9-4f07-b00c-570de0b69963" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_6e1f19ee-5ed9-4f07-b00c-570de0b69963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_6e1f19ee-5ed9-4f07-b00c-570de0b69963" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember_81763b40-46be-4d08-8f6f-937c74843880" xlink:href="alvo-20231231.xsd#alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember_81763b40-46be-4d08-8f6f-937c74843880" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember_aa018c2a-2118-40a9-8f42-94b4772f2bca" xlink:href="alvo-20231231.xsd#alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember_aa018c2a-2118-40a9-8f42-94b4772f2bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenAztiqABSisterCompanyMember_02340af5-d7ef-416c-a355-c7677f4b03c6" xlink:href="alvo-20231231.xsd#alvo_AlvogenAztiqABSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenAztiqABSisterCompanyMember_02340af5-d7ef-416c-a355-c7677f4b03c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFjrfestingarEhfMember_eb2020c9-6f9e-42c5-b46f-5a214e9c20fa" xlink:href="alvo-20231231.xsd#alvo_AztiqFjrfestingarEhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AztiqFjrfestingarEhfMember_eb2020c9-6f9e-42c5-b46f-5a214e9c20fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_799369df-d9ea-4ff2-8b61-536ec8ecd31a" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHf.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_799369df-d9ea-4ff2-8b61-536ec8ecd31a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember_add0306b-2abb-4306-b112-93645e3ea1d0" xlink:href="alvo-20231231.xsd#alvo_AlvogenIcelandEhf.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember_add0306b-2abb-4306-b112-93645e3ea1d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEhf.SisterCompanyMember_c9cd6ee4-7922-4ffd-ad87-e6a78f9ec892" xlink:href="alvo-20231231.xsd#alvo_AlvogenEhf.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenEhf.SisterCompanyMember_c9cd6ee4-7922-4ffd-ad87-e6a78f9ec892" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenUKSisterCompanyMember_e5086ad6-4574-43be-9c65-315474206f4b" xlink:href="alvo-20231231.xsd#alvo_AlvogenUKSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenUKSisterCompanyMember_e5086ad6-4574-43be-9c65-315474206f4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_88614146-ddce-41ad-8d9f-7195b3b2e8b1" xlink:href="alvo-20231231.xsd#alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_88614146-ddce-41ad-8d9f-7195b3b2e8b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember_4b77dca8-02c3-4555-99a6-dc200cf67070" xlink:href="alvo-20231231.xsd#alvo_AlvogenEmergingMarketsSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember_4b77dca8-02c3-4555-99a6-dc200cf67070" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_13da9074-d8bb-4f62-8fd9-c013538da46f" xlink:href="alvo-20231231.xsd#alvo_AlvogenKoreaCo.LtdSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_13da9074-d8bb-4f62-8fd9-c013538da46f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenInc.SisterCompanyMember_f84bfdf8-f00a-4451-a3bb-4b545d8ddca3" xlink:href="alvo-20231231.xsd#alvo_AlvogenInc.SisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenInc.SisterCompanyMember_f84bfdf8-f00a-4451-a3bb-4b545d8ddca3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_2b1dbe6c-fecd-4c7b-b4a2-b982f03c75ef" xlink:href="alvo-20231231.xsd#alvo_AlvogenMaltaSh.ServicesSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_2b1dbe6c-fecd-4c7b-b4a2-b982f03c75ef" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_a3f8ce9a-6a5d-4533-86b6-3825ba3df806" xlink:href="alvo-20231231.xsd#alvo_AlvogenPharmaPvtLtdSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_a3f8ce9a-6a5d-4533-86b6-3825ba3df806" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HRJAFEhfSisterCompanyMember_8c6f0376-89d2-4dde-ade2-eac8fd703351" xlink:href="alvo-20231231.xsd#alvo_HRJAFEhfSisterCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_HRJAFEhfSisterCompanyMember_8c6f0376-89d2-4dde-ade2-eac8fd703351" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_L41EhfMember_e51b248c-0515-48db-9df3-12b3d88d38a4" xlink:href="alvo-20231231.xsd#alvo_L41EhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_L41EhfMember_e51b248c-0515-48db-9df3-12b3d88d38a4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Lambhagavegur7EhfMember_015be8e3-9cda-4038-9a8d-b9fa0805e20b" xlink:href="alvo-20231231.xsd#alvo_Lambhagavegur7EhfMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_Lambhagavegur7EhfMember_015be8e3-9cda-4038-9a8d-b9fa0805e20b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_9d51f9e8-9bfb-4319-928f-306f982b4171" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_193a4ec1-0be9-4295-bbd9-e07060e87ad6" xlink:to="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_9d51f9e8-9bfb-4319-928f-306f982b4171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_2ac796a0-0211-47af-a52f-349c2570dad3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_193a4ec1-0be9-4295-bbd9-e07060e87ad6" xlink:to="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_2ac796a0-0211-47af-a52f-349c2570dad3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RobertWessmanMember_d876e890-41bf-42e5-a6e9-8230d04f915f" xlink:href="alvo-20231231.xsd#alvo_RobertWessmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_RobertWessmanMember_d876e890-41bf-42e5-a6e9-8230d04f915f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RichardDaviesMember_0f707890-1b8b-455d-ba91-7b12b54234d0" xlink:href="alvo-20231231.xsd#alvo_RichardDaviesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_RichardDaviesMember_0f707890-1b8b-455d-ba91-7b12b54234d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AnnMerchantMember_9e50adaa-8f15-4192-934f-8c45457b5d9f" xlink:href="alvo-20231231.xsd#alvo_AnnMerchantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_AnnMerchantMember_9e50adaa-8f15-4192-934f-8c45457b5d9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ArniHararsonMember_3dc00d17-a0a9-4657-aba8-8b3c8b9f7197" xlink:href="alvo-20231231.xsd#alvo_ArniHararsonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_ArniHararsonMember_3dc00d17-a0a9-4657-aba8-8b3c8b9f7197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FaysalKalmouaMember_cdeb3a3f-c36a-4106-a1e9-e6e7367b49f4" xlink:href="alvo-20231231.xsd#alvo_FaysalKalmouaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_FaysalKalmouaMember_cdeb3a3f-c36a-4106-a1e9-e6e7367b49f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LindaMcgoldrickMember_65be12cf-8489-41d9-a2f2-a6621105786a" xlink:href="alvo-20231231.xsd#alvo_LindaMcgoldrickMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_LindaMcgoldrickMember_65be12cf-8489-41d9-a2f2-a6621105786a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LisaGraverMember_b7e3e513-cf91-40f9-80a5-60efd17b6c40" xlink:href="alvo-20231231.xsd#alvo_LisaGraverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_LisaGraverMember_b7e3e513-cf91-40f9-80a5-60efd17b6c40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThomasEkmanMember_302f44fc-cd26-43a7-8f69-f5872f49731b" xlink:href="alvo-20231231.xsd#alvo_ThomasEkmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_ThomasEkmanMember_302f44fc-cd26-43a7-8f69-f5872f49731b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MarkLevickCeoMember_6ac587cb-ccce-4084-af4a-4217309d89b9" xlink:href="alvo-20231231.xsd#alvo_MarkLevickCeoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_MarkLevickCeoMember_6ac587cb-ccce-4084-af4a-4217309d89b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherExecutiveTeamMember_99a7cfe9-d382-4cc0-92ef-b154e532cb03" xlink:href="alvo-20231231.xsd#alvo_OtherExecutiveTeamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_OtherExecutiveTeamMember_99a7cfe9-d382-4cc0-92ef-b154e532cb03" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HirofumiImaiBoardMember_b510395c-50ba-4e97-8aab-bd70c358517d" xlink:href="alvo-20231231.xsd#alvo_HirofumiImaiBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_HirofumiImaiBoardMember_b510395c-50ba-4e97-8aab-bd70c358517d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationStatusAxis_cb04569a-3e9d-4f54-93f3-4603e3a911a2" xlink:href="alvo-20231231.xsd#alvo_CompensationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:to="loc_alvo_CompensationStatusAxis_cb04569a-3e9d-4f54-93f3-4603e3a911a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationStatusDomain_cb04569a-3e9d-4f54-93f3-4603e3a911a2_default" xlink:href="alvo-20231231.xsd#alvo_CompensationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_CompensationStatusAxis_cb04569a-3e9d-4f54-93f3-4603e3a911a2" xlink:to="loc_alvo_CompensationStatusDomain_cb04569a-3e9d-4f54-93f3-4603e3a911a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationStatusDomain_f571058c-ed31-49b0-9c83-91b95799754c" xlink:href="alvo-20231231.xsd#alvo_CompensationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_CompensationStatusAxis_cb04569a-3e9d-4f54-93f3-4603e3a911a2" xlink:to="loc_alvo_CompensationStatusDomain_f571058c-ed31-49b0-9c83-91b95799754c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationWaivedMember_e5c2acdb-05f4-4db3-8eac-4d327cf09b1b" xlink:href="alvo-20231231.xsd#alvo_CompensationWaivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_CompensationStatusDomain_f571058c-ed31-49b0-9c83-91b95799754c" xlink:to="loc_alvo_CompensationWaivedMember_e5c2acdb-05f4-4db3-8eac-4d327cf09b1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NetCompensationExpenseMember_134c1f16-8e5a-4291-b790-14530af6a0b2" xlink:href="alvo-20231231.xsd#alvo_NetCompensationExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_CompensationStatusDomain_f571058c-ed31-49b0-9c83-91b95799754c" xlink:to="loc_alvo_NetCompensationExpenseMember_134c1f16-8e5a-4291-b790-14530af6a0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DirectorFees_acf991d5-26b0-42f1-95a0-6c4dd8dcb7a8" xlink:href="alvo-20231231.xsd#alvo_DirectorFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_alvo_DirectorFees_acf991d5-26b0-42f1-95a0-6c4dd8dcb7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_58f3160a-7396-4fd4-bae7-b2e422f5b524" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_58f3160a-7396-4fd4-bae7-b2e422f5b524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_f091675c-0705-48e1-9487-a97434bd886d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_f091675c-0705-48e1-9487-a97434bd886d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_3a570c4a-65bb-4c36-9cf4-755c51e49460" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_3a570c4a-65bb-4c36-9cf4-755c51e49460" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_7a184c2c-e882-4d88-87b9-1edd53a17ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_7a184c2c-e882-4d88-87b9-1edd53a17ecd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_ab069e28-77ce-4161-a3ec-371f72972466" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_ab069e28-77ce-4161-a3ec-371f72972466" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_c46a7554-b032-4496-923b-eb551eb51dc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesTable_c46a7554-b032-4496-923b-eb551eb51dc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_6c8d1b08-de04-48b6-9a03-3a26b934e0db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_c46a7554-b032-4496-923b-eb551eb51dc4" xlink:to="loc_ifrs-full_JointVenturesAxis_6c8d1b08-de04-48b6-9a03-3a26b934e0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_6c8d1b08-de04-48b6-9a03-3a26b934e0db_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_6c8d1b08-de04-48b6-9a03-3a26b934e0db" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_6c8d1b08-de04-48b6-9a03-3a26b934e0db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_b92fc86e-6b59-4754-a6a2-8f6bdb14a4b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_6c8d1b08-de04-48b6-9a03-3a26b934e0db" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_b92fc86e-6b59-4754-a6a2-8f6bdb14a4b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_2eb9a0d1-9161-40b2-959a-59282018d351" xlink:href="alvo-20231231.xsd#alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_b92fc86e-6b59-4754-a6a2-8f6bdb14a4b0" xlink:to="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_2eb9a0d1-9161-40b2-959a-59282018d351" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture_cc7d84a8-e84f-4617-a4ef-944648c72422" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PrincipalPlaceOfBusinessOfJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:to="loc_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture_cc7d84a8-e84f-4617-a4ef-944648c72422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_54ea4d05-a9c7-40d7-aff9-4d069fb5cd87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_54ea4d05-a9c7-40d7-aff9-4d069fb5cd87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_21c1d617-af5a-4c9b-88cf-1dc6717ce450" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_21c1d617-af5a-4c9b-88cf-1dc6717ce450" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_df597256-a945-4a88-a598-51d97584ed05" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_e37ada93-0412-4fef-9781-73325212bd8c" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_df597256-a945-4a88-a598-51d97584ed05" xlink:to="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_e37ada93-0412-4fef-9781-73325212bd8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_e37ada93-0412-4fef-9781-73325212bd8c" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_330c9f72-ed37-4c7c-9055-92cf6f3b9f8b" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:to="loc_alvo_SeniorBondsMember_330c9f72-ed37-4c7c-9055-92cf6f3b9f8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConvertibleBondMember_a79fa7e0-7903-452e-ad09-64651cd29228" xlink:href="alvo-20231231.xsd#alvo_AztiqConvertibleBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:to="loc_alvo_AztiqConvertibleBondMember_a79fa7e0-7903-452e-ad09-64651cd29228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_A2022ConvertibleBondsMember_24af089b-3c44-4f96-8819-12d7d72ae3ca" xlink:href="alvo-20231231.xsd#alvo_A2022ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:to="loc_alvo_A2022ConvertibleBondsMember_24af089b-3c44-4f96-8819-12d7d72ae3ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember_fdca43c7-d3e5-48e2-b070-19e20e452922" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:to="loc_alvo_AlvogenFacilityMember_fdca43c7-d3e5-48e2-b070-19e20e452922" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_d69703f2-505a-44ad-9594-97c8cd67a183" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_df597256-a945-4a88-a598-51d97584ed05" xlink:to="loc_ifrs-full_BondsIssued_d69703f2-505a-44ad-9594-97c8cd67a183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BondsIssuedAtFairValue_78faa7b5-6b1f-4c57-89e9-b6b8e96397f7" xlink:href="alvo-20231231.xsd#alvo_BondsIssuedAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_df597256-a945-4a88-a598-51d97584ed05" xlink:to="loc_alvo_BondsIssuedAtFairValue_78faa7b5-6b1f-4c57-89e9-b6b8e96397f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_401c34bf-807f-4e78-8de4-2d199c52b6df" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_401c34bf-807f-4e78-8de4-2d199c52b6df" xlink:to="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_3713722b-51d7-43df-98a8-89bfd93ac38d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_3713722b-51d7-43df-98a8-89bfd93ac38d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_3713722b-51d7-43df-98a8-89bfd93ac38d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_3713722b-51d7-43df-98a8-89bfd93ac38d" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_3713722b-51d7-43df-98a8-89bfd93ac38d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_3713722b-51d7-43df-98a8-89bfd93ac38d" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_47e3e48c-7cb5-4f8a-a324-b22823c71742" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_SeniorBondWarrantsMember_47e3e48c-7cb5-4f8a-a324-b22823c71742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConversionFeatureMember_598599a5-1f3c-4acd-8a5b-d73c9fdfd266" xlink:href="alvo-20231231.xsd#alvo_TrancheAConversionFeatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_TrancheAConversionFeatureMember_598599a5-1f3c-4acd-8a5b-d73c9fdfd266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondInterestRateFeatureMember_f01d456f-e551-4147-9d1b-3eaebe966b5b" xlink:href="alvo-20231231.xsd#alvo_SeniorBondInterestRateFeatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_SeniorBondInterestRateFeatureMember_f01d456f-e551-4147-9d1b-3eaebe966b5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_cac60ba6-46c4-41ac-a33d-2d684a1d300f" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_cac60ba6-46c4-41ac-a33d-2d684a1d300f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_118a1fdd-734d-4b12-ad1d-7e3d3ba26076" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_EarnoutSharesMember_118a1fdd-734d-4b12-ad1d-7e3d3ba26076" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_d638dbdb-b972-4c58-bb39-889d0facd9b0" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_EarnoutWarrantsMember_d638dbdb-b972-4c58-bb39-889d0facd9b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1cb557a3-e686-41fa-8404-adf659766647" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1cb557a3-e686-41fa-8404-adf659766647" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1cb557a3-e686-41fa-8404-adf659766647_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1cb557a3-e686-41fa-8404-adf659766647" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_1cb557a3-e686-41fa-8404-adf659766647_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1cb557a3-e686-41fa-8404-adf659766647" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_7183e3ee-63a4-4813-8af8-1759a41fee15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_7183e3ee-63a4-4813-8af8-1759a41fee15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_b8d6be6a-679a-4874-96bc-b26d7de102ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_b8d6be6a-679a-4874-96bc-b26d7de102ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_9567e6b7-b542-414a-8574-64f7a69af25d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_9567e6b7-b542-414a-8574-64f7a69af25d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_5bd4da80-b504-4b14-b08a-f7cd80b7072b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_401c34bf-807f-4e78-8de4-2d199c52b6df" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_5bd4da80-b504-4b14-b08a-f7cd80b7072b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_59317a24-1a43-4eba-bf28-d00accf1fb37" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_59317a24-1a43-4eba-bf28-d00accf1fb37" xlink:to="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_3295a0a4-b533-48a0-8d98-59e4e9235a01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_3295a0a4-b533-48a0-8d98-59e4e9235a01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_c72cb07e-8cd7-465a-a232-6104456ac3ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_c72cb07e-8cd7-465a-a232-6104456ac3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_be9784ec-079f-4d36-be91-6a65c008489d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_be9784ec-079f-4d36-be91-6a65c008489d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4cf7f097-651e-4f0e-8ab5-b3d8152cc254" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4cf7f097-651e-4f0e-8ab5-b3d8152cc254" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_4cf7f097-651e-4f0e-8ab5-b3d8152cc254_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4cf7f097-651e-4f0e-8ab5-b3d8152cc254" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_4cf7f097-651e-4f0e-8ab5-b3d8152cc254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4cf7f097-651e-4f0e-8ab5-b3d8152cc254" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_264bd524-908f-4055-b768-a5fc296390ff" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_SeniorBondWarrantsMember_264bd524-908f-4055-b768-a5fc296390ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConversionFeatureMember_746bd69b-b4cf-45d5-8ba9-21fa8e63476b" xlink:href="alvo-20231231.xsd#alvo_TrancheAConversionFeatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_TrancheAConversionFeatureMember_746bd69b-b4cf-45d5-8ba9-21fa8e63476b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondInterestRateFeatureMember_8a498e98-aa45-495e-8aa9-b480a1b13672" xlink:href="alvo-20231231.xsd#alvo_SeniorBondInterestRateFeatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_SeniorBondInterestRateFeatureMember_8a498e98-aa45-495e-8aa9-b480a1b13672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_cb32fad9-56c4-46df-9a13-415a90b9d1e1" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_cb32fad9-56c4-46df-9a13-415a90b9d1e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_b297d89a-4f42-4a61-ba53-87468d5425bf" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_EarnoutSharesMember_b297d89a-4f42-4a61-ba53-87468d5425bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_aeda224f-6947-42a9-a3e7-9ed41bfe11c9" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_EarnoutWarrantsMember_aeda224f-6947-42a9-a3e7-9ed41bfe11c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:href="alvo-20231231.xsd#alvo_DerivativeFinancialLiabilitiesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_59317a24-1a43-4eba-bf28-d00accf1fb37" xlink:to="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_35599bc6-364f-4901-8e23-9bcf53031698" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_35599bc6-364f-4901-8e23-9bcf53031698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuesFairValueMeasurementLiabilities_49fdcdcf-5d53-46bb-84d3-7a59de818e5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuesFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_IssuesFairValueMeasurementLiabilities_49fdcdcf-5d53-46bb-84d3-7a59de818e5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_964c039f-fac7-4399-8453-e297d9711633" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_964c039f-fac7-4399-8453-e297d9711633" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_f6cad003-bc8f-42ab-b005-e2962fe32619" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_f6cad003-bc8f-42ab-b005-e2962fe32619" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities_0262911f-0eea-4e54-b1bc-62720723f196" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettlementsFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities_0262911f-0eea-4e54-b1bc-62720723f196" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_4e9bccf0-4d44-41c0-a899-3f38b610a0eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5463aa3f-30c2-4f44-84a7-a0d0f1b3ce12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5463aa3f-30c2-4f44-84a7-a0d0f1b3ce12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_bc82100c-9f22-4334-ac4b-6e9d4cb99868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5463aa3f-30c2-4f44-84a7-a0d0f1b3ce12" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_bc82100c-9f22-4334-ac4b-6e9d4cb99868" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_db941ce0-6788-4c7f-9a12-f13b48478e36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5463aa3f-30c2-4f44-84a7-a0d0f1b3ce12" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_db941ce0-6788-4c7f-9a12-f13b48478e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4db9fb30-5d5c-4c3e-90b6-213b93902222" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4db9fb30-5d5c-4c3e-90b6-213b93902222" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_4db9fb30-5d5c-4c3e-90b6-213b93902222_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4db9fb30-5d5c-4c3e-90b6-213b93902222" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_4db9fb30-5d5c-4c3e-90b6-213b93902222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4db9fb30-5d5c-4c3e-90b6-213b93902222" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_37425d73-b3c9-4e8f-b92c-98f221aebbbd" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_SeniorBondWarrantsMember_37425d73-b3c9-4e8f-b92c-98f221aebbbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConversionFeatureMember_840b65d6-fc55-4743-b18c-ecebeaece0d0" xlink:href="alvo-20231231.xsd#alvo_TrancheAConversionFeatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_TrancheAConversionFeatureMember_840b65d6-fc55-4743-b18c-ecebeaece0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_dcb17c29-155a-4049-ad4d-ea4d27d1b145" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_dcb17c29-155a-4049-ad4d-ea4d27d1b145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbEarnoutSharesMember_c53f5c01-b8bc-4118-ae87-ad7b65966f64" xlink:href="alvo-20231231.xsd#alvo_OacbEarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_OacbEarnoutSharesMember_c53f5c01-b8bc-4118-ae87-ad7b65966f64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_cb63e1e8-16fb-4723-a0f5-fae49c4bbd2c" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_EarnoutSharesMember_cb63e1e8-16fb-4723-a0f5-fae49c4bbd2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbWarrantsMember_fb752a1a-4be6-4315-8272-b3624e7b265a" xlink:href="alvo-20231231.xsd#alvo_OacbWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_OacbWarrantsMember_fb752a1a-4be6-4315-8272-b3624e7b265a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_e6bfc5c0-07d8-4078-9a91-d42270b265f9" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_EarnoutWarrantsMember_e6bfc5c0-07d8-4078-9a91-d42270b265f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_f80d1f7d-d66e-4b5b-956a-50b340735399" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_f80d1f7d-d66e-4b5b-956a-50b340735399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_f80d1f7d-d66e-4b5b-956a-50b340735399_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_f80d1f7d-d66e-4b5b-956a-50b340735399" xlink:to="loc_ifrs-full_BorrowingsByNameMember_f80d1f7d-d66e-4b5b-956a-50b340735399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_b629136f-1810-4e8d-9504-7f05c2ed1c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_f80d1f7d-d66e-4b5b-956a-50b340735399" xlink:to="loc_ifrs-full_BorrowingsByNameMember_b629136f-1810-4e8d-9504-7f05c2ed1c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondMember_3268198b-f507-4beb-bd6a-8de6822177a8" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_b629136f-1810-4e8d-9504-7f05c2ed1c9f" xlink:to="loc_alvo_ConvertibleBondMember_3268198b-f507-4beb-bd6a-8de6822177a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_d63e5d49-e76c-4419-922a-16fdde20d301" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_RangeAxis_d63e5d49-e76c-4419-922a-16fdde20d301" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_d63e5d49-e76c-4419-922a-16fdde20d301_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_d63e5d49-e76c-4419-922a-16fdde20d301" xlink:to="loc_ifrs-full_RangesMember_d63e5d49-e76c-4419-922a-16fdde20d301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_bd59f0dc-6981-455e-970b-3011e214c43a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_d63e5d49-e76c-4419-922a-16fdde20d301" xlink:to="loc_ifrs-full_RangesMember_bd59f0dc-6981-455e-970b-3011e214c43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_adc6fc80-c6e1-41e6-b3d8-8a643f5b767d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_bd59f0dc-6981-455e-970b-3011e214c43a" xlink:to="loc_srt_MinimumMember_adc6fc80-c6e1-41e6-b3d8-8a643f5b767d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56d6c85c-7367-4680-a7bb-1401db26e364" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_bd59f0dc-6981-455e-970b-3011e214c43a" xlink:to="loc_srt_MaximumMember_56d6c85c-7367-4680-a7bb-1401db26e364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneAxis_0ae79a0b-7986-4ee5-902a-4df312de64ba" xlink:href="alvo-20231231.xsd#alvo_AgreementOneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_alvo_AgreementOneAxis_0ae79a0b-7986-4ee5-902a-4df312de64ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneDomain_0ae79a0b-7986-4ee5-902a-4df312de64ba_default" xlink:href="alvo-20231231.xsd#alvo_AgreementOneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_AgreementOneAxis_0ae79a0b-7986-4ee5-902a-4df312de64ba" xlink:to="loc_alvo_AgreementOneDomain_0ae79a0b-7986-4ee5-902a-4df312de64ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneDomain_dfd1583f-4f50-45fe-bd72-eb0bd7c956fc" xlink:href="alvo-20231231.xsd#alvo_AgreementOneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_AgreementOneAxis_0ae79a0b-7986-4ee5-902a-4df312de64ba" xlink:to="loc_alvo_AgreementOneDomain_dfd1583f-4f50-45fe-bd72-eb0bd7c956fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_a4e094d9-3046-427f-b065-896d47413c9b" xlink:href="alvo-20231231.xsd#alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AgreementOneDomain_dfd1583f-4f50-45fe-bd72-eb0bd7c956fc" xlink:to="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_a4e094d9-3046-427f-b065-896d47413c9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAxis_8de97105-4e86-451f-9d6e-73ae12a6d1f2" xlink:href="alvo-20231231.xsd#alvo_TrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_alvo_TrancheAxis_8de97105-4e86-451f-9d6e-73ae12a6d1f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_8de97105-4e86-451f-9d6e-73ae12a6d1f2_default" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_TrancheAxis_8de97105-4e86-451f-9d6e-73ae12a6d1f2" xlink:to="loc_alvo_TrancheDomain_8de97105-4e86-451f-9d6e-73ae12a6d1f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_TrancheAxis_8de97105-4e86-451f-9d6e-73ae12a6d1f2" xlink:to="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheBMember_d8c45b06-26c3-4d0c-8022-3782f4ca9fdd" xlink:href="alvo-20231231.xsd#alvo_TrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:to="loc_alvo_TrancheBMember_d8c45b06-26c3-4d0c-8022-3782f4ca9fdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheOneMember_021993de-bafd-4ab0-b0a2-aa5b2e6d3d1f" xlink:href="alvo-20231231.xsd#alvo_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:to="loc_alvo_TrancheOneMember_021993de-bafd-4ab0-b0a2-aa5b2e6d3d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheTwoMember_5b6a161f-bd8d-4d09-bb29-3ed5cf4ce70d" xlink:href="alvo-20231231.xsd#alvo_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:to="loc_alvo_TrancheTwoMember_5b6a161f-bd8d-4d09-bb29-3ed5cf4ce70d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementAxis_0c797132-7e10-4107-aa32-07cd639fc1da" xlink:href="alvo-20231231.xsd#alvo_AgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_alvo_AgreementAxis_0c797132-7e10-4107-aa32-07cd639fc1da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementDomain_0c797132-7e10-4107-aa32-07cd639fc1da_default" xlink:href="alvo-20231231.xsd#alvo_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_AgreementAxis_0c797132-7e10-4107-aa32-07cd639fc1da" xlink:to="loc_alvo_AgreementDomain_0c797132-7e10-4107-aa32-07cd639fc1da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementDomain_e1ddc568-63ba-4027-84d0-e26af15e24b1" xlink:href="alvo-20231231.xsd#alvo_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_AgreementAxis_0c797132-7e10-4107-aa32-07cd639fc1da" xlink:to="loc_alvo_AgreementDomain_e1ddc568-63ba-4027-84d0-e26af15e24b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_b4b84b6c-0891-4919-a2c1-a04387b581dc" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_AgreementDomain_e1ddc568-63ba-4027-84d0-e26af15e24b1" xlink:to="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_b4b84b6c-0891-4919-a2c1-a04387b581dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_480e88e6-e54c-440c-ac8a-b874d3432335" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_480e88e6-e54c-440c-ac8a-b874d3432335" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_480e88e6-e54c-440c-ac8a-b874d3432335_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_480e88e6-e54c-440c-ac8a-b874d3432335" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_480e88e6-e54c-440c-ac8a-b874d3432335_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_c2e74485-7a24-442a-9859-ddbab9ebc74f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_480e88e6-e54c-440c-ac8a-b874d3432335" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_c2e74485-7a24-442a-9859-ddbab9ebc74f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContingentlyIssuablePennyWarrantsMember_8095d831-ff62-446e-97a3-4a4b7bd154e5" xlink:href="alvo-20231231.xsd#alvo_ContingentlyIssuablePennyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_c2e74485-7a24-442a-9859-ddbab9ebc74f" xlink:to="loc_alvo_ContingentlyIssuablePennyWarrantsMember_8095d831-ff62-446e-97a3-4a4b7bd154e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PennyWarrantsMember_a902bd82-f347-4a58-aff5-708431488311" xlink:href="alvo-20231231.xsd#alvo_PennyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_c2e74485-7a24-442a-9859-ddbab9ebc74f" xlink:to="loc_alvo_PennyWarrantsMember_a902bd82-f347-4a58-aff5-708431488311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_9d961e6b-5ad7-49ee-a950-e4aec92b48f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_9d961e6b-5ad7-49ee-a950-e4aec92b48f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_9e82900d-7e07-46fa-9f16-e124b044e449" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9d961e6b-5ad7-49ee-a950-e4aec92b48f8" xlink:to="loc_ifrs-full_OrdinarySharesMember_9e82900d-7e07-46fa-9f16-e124b044e449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_8b48923e-fb32-49e4-842e-2a773c46ae51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_8b48923e-fb32-49e4-842e-2a773c46ae51" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_8b48923e-fb32-49e4-842e-2a773c46ae51_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_8b48923e-fb32-49e4-842e-2a773c46ae51" xlink:to="loc_ifrs-full_NonadjustingEventsMember_8b48923e-fb32-49e4-842e-2a773c46ae51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_8b339c1d-f599-45b3-97c6-64bb2421085a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_8b48923e-fb32-49e4-842e-2a773c46ae51" xlink:to="loc_ifrs-full_NonadjustingEventsMember_8b339c1d-f599-45b3-97c6-64bb2421085a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExcerciseOfWarrantsMember_c9e2b95f-3cff-49d7-a478-97ac822c7a61" xlink:href="alvo-20231231.xsd#alvo_ExcerciseOfWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_8b339c1d-f599-45b3-97c6-64bb2421085a" xlink:to="loc_alvo_ExcerciseOfWarrantsMember_c9e2b95f-3cff-49d7-a478-97ac822c7a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_208de23d-b90b-4317-867f-69f1173542b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_208de23d-b90b-4317-867f-69f1173542b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_d73079a6-138b-490f-8fd0-04de8ab75fd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_d73079a6-138b-490f-8fd0-04de8ab75fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseInOutstandingBondsFairValue_e7f2774e-5d68-4fb7-b839-acdfb31eadeb" xlink:href="alvo-20231231.xsd#alvo_IncreaseInOutstandingBondsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_IncreaseInOutstandingBondsFairValue_e7f2774e-5d68-4fb7-b839-acdfb31eadeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_f9940f47-5ec5-4508-9b59-8139f728cc6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_BorrowingsInterestRate_f9940f47-5ec5-4508-9b59-8139f728cc6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_0788d075-b5c6-4be4-9454-b5fc7635aa72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_0788d075-b5c6-4be4-9454-b5fc7635aa72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_21b8fddf-69db-4aa9-8f53-0f0bb970d845" xlink:href="alvo-20231231.xsd#alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_21b8fddf-69db-4aa9-8f53-0f0bb970d845" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities_694c22ec-fc31-414d-b76c-488c14f0da48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettlementsFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities_694c22ec-fc31-414d-b76c-488c14f0da48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_06c99425-fd81-4344-b50e-75a659a3f374" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_06c99425-fd81-4344-b50e-75a659a3f374" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsOutstanding_0a3a0f63-93f9-4a67-b790-5c4fd1eea560" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_ClassOfWarrantsOrRightsOutstanding_0a3a0f63-93f9-4a67-b790-5c4fd1eea560" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConversionPrice_7e2b1080-ce1d-463a-8520-3acb5ef9ff33" xlink:href="alvo-20231231.xsd#alvo_ConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_ConversionPrice_7e2b1080-ce1d-463a-8520-3acb5ef9ff33" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheOfSeniorBondWarrantsPercentage_c3ea4840-cdeb-4e3f-839c-1f81f18c4d5f" xlink:href="alvo-20231231.xsd#alvo_TrancheOfSeniorBondWarrantsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_TrancheOfSeniorBondWarrantsPercentage_c3ea4840-cdeb-4e3f-839c-1f81f18c4d5f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_3e59327c-578f-4e37-b051-0f1298d21578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_3e59327c-578f-4e37-b051-0f1298d21578" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_72882718-8fc0-49f6-9a84-3be413b0ed67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_FinanceCosts_72882718-8fc0-49f6-9a84-3be413b0ed67" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AggregatePeriodForDeterminingTheSharePrice_323d41ee-fe1a-4a00-b7ce-ecea12c7e2e8" xlink:href="alvo-20231231.xsd#alvo_AggregatePeriodForDeterminingTheSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_AggregatePeriodForDeterminingTheSharePrice_323d41ee-fe1a-4a00-b7ce-ecea12c7e2e8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SharesPrice_2ee9d85e-7764-4917-939c-35ef053f9933" xlink:href="alvo-20231231.xsd#alvo_SharesPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_SharesPrice_2ee9d85e-7764-4917-939c-35ef053f9933" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThresholdDaysForDeterminingTheSharePrice_90907751-a87e-4898-b27f-7605dba4f9c6" xlink:href="alvo-20231231.xsd#alvo_ThresholdDaysForDeterminingTheSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_ThresholdDaysForDeterminingTheSharePrice_90907751-a87e-4898-b27f-7605dba4f9c6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfConsecutiveTradingDays_067c1818-f0ea-4dc8-a52e-614d74865399" xlink:href="alvo-20231231.xsd#alvo_NumberOfConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_NumberOfConsecutiveTradingDays_067c1818-f0ea-4dc8-a52e-614d74865399" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_5a292c95-72bf-4104-bcbd-1a728c908934" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_5a292c95-72bf-4104-bcbd-1a728c908934" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_89b7d992-de9e-444a-b0db-1db6e3e9ef50" xlink:href="alvo-20231231.xsd#alvo_NumberOfSharesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_89b7d992-de9e-444a-b0db-1db6e3e9ef50" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_d387c650-87fc-42e5-927a-a472ffea836c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_d387c650-87fc-42e5-927a-a472ffea836c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_4fae936b-fba4-4957-b4ac-c74ddf8078a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_Liabilities_4fae936b-fba4-4957-b4ac-c74ddf8078a2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestingPercentageOfShares_647e6514-7798-4ae8-959e-e8fa9837f08d" xlink:href="alvo-20231231.xsd#alvo_VestingPercentageOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_VestingPercentageOfShares_647e6514-7798-4ae8-959e-e8fa9837f08d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_f039446c-46fa-47f4-a60f-57e9a35b6b8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_NumberOfSharesIssued_f039446c-46fa-47f4-a60f-57e9a35b6b8f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_f4eec38a-b5e8-4161-9ce0-49c5dec2cc2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_f4eec38a-b5e8-4161-9ce0-49c5dec2cc2d" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofAssumptionsandInputsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_253b03d2-94db-48f0-85f8-b752bc3d1027" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_253b03d2-94db-48f0-85f8-b752bc3d1027" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:to="loc_ifrs-full_UnobservableInputsAxis_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54" xlink:to="loc_ifrs-full_UnobservableInputsMember_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54" xlink:to="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockPriceMember_19712e27-d5cc-42f0-8d03-5969eb55e6d6" xlink:href="alvo-20231231.xsd#alvo_StockPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_alvo_StockPriceMember_19712e27-d5cc-42f0-8d03-5969eb55e6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConversionPriceOfBondsMember_26530166-314a-440c-bb38-36b52a870eeb" xlink:href="alvo-20231231.xsd#alvo_ConversionPriceOfBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_alvo_ConversionPriceOfBondsMember_26530166-314a-440c-bb38-36b52a870eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2bad5fc3-be1c-400f-a273-9bdecc51fd19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2bad5fc3-be1c-400f-a273-9bdecc51fd19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember_8bc7b05b-733c-48fc-9b1b-fa6725f41409" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_ifrs-full_InterestRateMeasurementInputMember_8bc7b05b-733c-48fc-9b1b-fa6725f41409" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DividendYieldMember_c5e14367-78d0-4413-956e-9a125121579c" xlink:href="alvo-20231231.xsd#alvo_DividendYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_alvo_DividendYieldMember_c5e14367-78d0-4413-956e-9a125121579c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RiskyYieldMember_4873ec30-f5fa-4c65-80b8-ccef4c8384c3" xlink:href="alvo-20231231.xsd#alvo_RiskyYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_alvo_RiskyYieldMember_4873ec30-f5fa-4c65-80b8-ccef4c8384c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_af0f54ae-48de-405a-b062-01be73dc1e66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_af0f54ae-48de-405a-b062-01be73dc1e66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_af0f54ae-48de-405a-b062-01be73dc1e66_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_af0f54ae-48de-405a-b062-01be73dc1e66" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_af0f54ae-48de-405a-b062-01be73dc1e66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_af0f54ae-48de-405a-b062-01be73dc1e66" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember_9479bff9-374e-424e-9725-5c700e34dff3" xlink:href="alvo-20231231.xsd#alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:to="loc_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember_9479bff9-374e-424e-9725-5c700e34dff3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_ec226b04-2a5d-4880-abe5-9c942ea3070c" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_ec226b04-2a5d-4880-abe5-9c942ea3070c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbEarnoutSharesMember_9a15a2d2-1e5b-44e2-8722-b6c612706ec6" xlink:href="alvo-20231231.xsd#alvo_OacbEarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:to="loc_alvo_OacbEarnoutSharesMember_9a15a2d2-1e5b-44e2-8722-b6c612706ec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_883a2341-98a5-4dae-8f37-063a02044b50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_253b03d2-94db-48f0-85f8-b752bc3d1027" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_883a2341-98a5-4dae-8f37-063a02044b50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_294dd5f8-b0bb-43be-b688-1af4c63fb354" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_253b03d2-94db-48f0-85f8-b752bc3d1027" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_294dd5f8-b0bb-43be-b688-1af4c63fb354" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_a4ff7dc7-3f06-47bc-821e-a603a998382d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:to="loc_ifrs-full_TypesOfRisksAxis_a4ff7dc7-3f06-47bc-821e-a603a998382d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_a4ff7dc7-3f06-47bc-821e-a603a998382d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_a4ff7dc7-3f06-47bc-821e-a603a998382d" xlink:to="loc_ifrs-full_TypesOfRisksMember_a4ff7dc7-3f06-47bc-821e-a603a998382d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_18bb73bb-7465-4953-8b7e-71eba8316ef3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_a4ff7dc7-3f06-47bc-821e-a603a998382d" xlink:to="loc_ifrs-full_TypesOfRisksMember_18bb73bb-7465-4953-8b7e-71eba8316ef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_b5756c8a-00db-4e5b-b3f6-bddf36bcedf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_18bb73bb-7465-4953-8b7e-71eba8316ef3" xlink:to="loc_ifrs-full_InterestRateRiskMember_b5756c8a-00db-4e5b-b3f6-bddf36bcedf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_f6aa6f69-b060-4c05-abf3-40e989c70b6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_f6aa6f69-b060-4c05-abf3-40e989c70b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_f6aa6f69-b060-4c05-abf3-40e989c70b6e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_f6aa6f69-b060-4c05-abf3-40e989c70b6e" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_f6aa6f69-b060-4c05-abf3-40e989c70b6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_f5211e09-99eb-4708-ba0d-5c0fee6c6239" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_f6aa6f69-b060-4c05-abf3-40e989c70b6e" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_f5211e09-99eb-4708-ba0d-5c0fee6c6239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestRateFinancialLiabilitiesMember_2164b18b-26fb-4043-8793-e0d04b97d213" xlink:href="alvo-20231231.xsd#alvo_VariableInterestRateFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_f5211e09-99eb-4708-ba0d-5c0fee6c6239" xlink:to="loc_alvo_VariableInterestRateFinancialLiabilitiesMember_2164b18b-26fb-4043-8793-e0d04b97d213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_d063e82b-32f0-44ec-93bb-042963d6e7f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_d063e82b-32f0-44ec-93bb-042963d6e7f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_1e9a29b5-636e-45e6-8809-0f0d82f209b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_1e9a29b5-636e-45e6-8809-0f0d82f209b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_be320a1d-63f4-4450-9889-90b5b99579c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_be320a1d-63f4-4450-9889-90b5b99579c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_47818a46-0de9-4d50-bb5c-7c0a857bc2d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_47818a46-0de9-4d50-bb5c-7c0a857bc2d4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_b2c06703-ddbe-4537-8ac3-55e4df942800" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfForeignExchangeRateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:to="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_b2c06703-ddbe-4537-8ac3-55e4df942800" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_57205420-04f7-4a19-b678-8b08bf819f47" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_b2c06703-ddbe-4537-8ac3-55e4df942800" xlink:to="loc_srt_CurrencyAxis_57205420-04f7-4a19-b678-8b08bf819f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_57205420-04f7-4a19-b678-8b08bf819f47_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_57205420-04f7-4a19-b678-8b08bf819f47" xlink:to="loc_currency_AllCurrenciesDomain_57205420-04f7-4a19-b678-8b08bf819f47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_57205420-04f7-4a19-b678-8b08bf819f47" xlink:to="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_edb60053-3fa4-4cb8-a548-eb13223cf5c0" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_EUR_edb60053-3fa4-4cb8-a548-eb13223cf5c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_970bc941-1b79-47a4-b6a0-dfd4387e9eb7" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_GBP_970bc941-1b79-47a4-b6a0-dfd4387e9eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_ISK_a0fbf990-6671-4fe5-9f99-89ec22cad92a" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ISK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_ISK_a0fbf990-6671-4fe5-9f99-89ec22cad92a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_7d0bebe9-46f3-4f75-a70b-22008314c528" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_CHF_7d0bebe9-46f3-4f75-a70b-22008314c528" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_INR_e7fe1e51-3468-481f-a0c0-b5e8c48edfc6" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_INR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_INR_e7fe1e51-3468-481f-a0c0-b5e8c48edfc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_fb985f65-fe39-4ce8-b28e-680b0717e7d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_fb985f65-fe39-4ce8-b28e-680b0717e7d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_6b595008-8503-483f-bb5f-7175044abf06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_6b595008-8503-483f-bb5f-7175044abf06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PercentageChangeInForeignExchangeRate_dacb58af-4bdb-48d7-8575-dbd40e2b0b0c" xlink:href="alvo-20231231.xsd#alvo_PercentageChangeInForeignExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:to="loc_alvo_PercentageChangeInForeignExchangeRate_dacb58af-4bdb-48d7-8575-dbd40e2b0b0c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:to="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_c1c388af-42fd-4f1c-b24d-66606aef0aeb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:to="loc_srt_CurrencyAxis_c1c388af-42fd-4f1c-b24d-66606aef0aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_c1c388af-42fd-4f1c-b24d-66606aef0aeb_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_c1c388af-42fd-4f1c-b24d-66606aef0aeb" xlink:to="loc_currency_AllCurrenciesDomain_c1c388af-42fd-4f1c-b24d-66606aef0aeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_c1c388af-42fd-4f1c-b24d-66606aef0aeb" xlink:to="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_87939d0b-55c5-4707-840d-2dfdfbf8eb1e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_EUR_87939d0b-55c5-4707-840d-2dfdfbf8eb1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_04434245-9033-464b-bdc6-511aa10919f2" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_GBP_04434245-9033-464b-bdc6-511aa10919f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_ISK_b27b969c-594b-4c52-9588-3d8b7fcda4d6" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ISK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_ISK_b27b969c-594b-4c52-9588-3d8b7fcda4d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_bae63013-3696-4189-8e61-b8b0d32e6d1f" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_CHF_bae63013-3696-4189-8e61-b8b0d32e6d1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_INR_db807fc0-fc75-4e7e-818b-85296ccf91e8" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_INR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_INR_db807fc0-fc75-4e7e-818b-85296ccf91e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a4a46cc9-ab35-4cad-b5a0-7c35cb582423" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a4a46cc9-ab35-4cad-b5a0-7c35cb582423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_a4a46cc9-ab35-4cad-b5a0-7c35cb582423_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a4a46cc9-ab35-4cad-b5a0-7c35cb582423" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_a4a46cc9-ab35-4cad-b5a0-7c35cb582423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_c1e7dc0f-1b69-4d8f-8000-342695eb6362" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a4a46cc9-ab35-4cad-b5a0-7c35cb582423" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_c1e7dc0f-1b69-4d8f-8000-342695eb6362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbWarrantsMember_56a0135c-60d1-47fd-aaf0-9ee1af39369f" xlink:href="alvo-20231231.xsd#alvo_OacbWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_c1e7dc0f-1b69-4d8f-8000-342695eb6362" xlink:to="loc_alvo_OacbWarrantsMember_56a0135c-60d1-47fd-aaf0-9ee1af39369f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_626ddd8d-8065-4afc-964a-854baa4ea9a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_626ddd8d-8065-4afc-964a-854baa4ea9a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_626ddd8d-8065-4afc-964a-854baa4ea9a1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_626ddd8d-8065-4afc-964a-854baa4ea9a1" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_626ddd8d-8065-4afc-964a-854baa4ea9a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9127d957-8f17-4af8-9e9d-c69de058e8fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_626ddd8d-8065-4afc-964a-854baa4ea9a1" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9127d957-8f17-4af8-9e9d-c69de058e8fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_966bf59b-7411-48c5-9ddd-44b30d1acf4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9127d957-8f17-4af8-9e9d-c69de058e8fd" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_966bf59b-7411-48c5-9ddd-44b30d1acf4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_fdd3b2d9-dad7-4fba-816f-c1ddf38d77c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:to="loc_ifrs-full_Assets_fdd3b2d9-dad7-4fba-816f-c1ddf38d77c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_82113128-8aff-48e1-83a9-9bf8d70923e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:to="loc_ifrs-full_Liabilities_82113128-8aff-48e1-83a9-9bf8d70923e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_e86af3f3-2684-481f-8b14-dccc4cedbb59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:to="loc_ifrs-full_NetAssetsLiabilities_e86af3f3-2684-481f-8b14-dccc4cedbb59" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_9b04d982-f5bd-4a29-80fa-74a1c7cde37e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:to="loc_ifrs-full_TypesOfRisksAxis_9b04d982-f5bd-4a29-80fa-74a1c7cde37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_9b04d982-f5bd-4a29-80fa-74a1c7cde37e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_9b04d982-f5bd-4a29-80fa-74a1c7cde37e" xlink:to="loc_ifrs-full_TypesOfRisksMember_9b04d982-f5bd-4a29-80fa-74a1c7cde37e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_fc997d78-d49f-4c75-907e-e182b428d97b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_9b04d982-f5bd-4a29-80fa-74a1c7cde37e" xlink:to="loc_ifrs-full_TypesOfRisksMember_fc997d78-d49f-4c75-907e-e182b428d97b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_51403a31-b30c-475d-bfac-0263a19b47a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_fc997d78-d49f-4c75-907e-e182b428d97b" xlink:to="loc_ifrs-full_CurrencyRiskMember_51403a31-b30c-475d-bfac-0263a19b47a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_06ef794d-337e-430f-a5a4-a5e153b6bebc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:to="loc_srt_CurrencyAxis_06ef794d-337e-430f-a5a4-a5e153b6bebc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_06ef794d-337e-430f-a5a4-a5e153b6bebc_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_06ef794d-337e-430f-a5a4-a5e153b6bebc" xlink:to="loc_currency_AllCurrenciesDomain_06ef794d-337e-430f-a5a4-a5e153b6bebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_06ef794d-337e-430f-a5a4-a5e153b6bebc" xlink:to="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_cbbc0e7d-e0bd-4981-9ae4-4dc2ac8d79ef" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_EUR_cbbc0e7d-e0bd-4981-9ae4-4dc2ac8d79ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_306a2c3a-3282-4011-84ab-3bd9fb3c0aa7" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_GBP_306a2c3a-3282-4011-84ab-3bd9fb3c0aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_ISK_02f1dcaa-f6d9-42ab-8359-401e41246e49" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ISK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_ISK_02f1dcaa-f6d9-42ab-8359-401e41246e49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_35d87b0c-4c6a-44ff-8364-7d0f88304083" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_CHF_35d87b0c-4c6a-44ff-8364-7d0f88304083" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_INR_040d6b3b-ae9f-4b50-8a03-ee4375d6e8f5" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_INR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_INR_040d6b3b-ae9f-4b50-8a03-ee4375d6e8f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_93e3ffab-1186-4e92-984b-703da7897eee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_93e3ffab-1186-4e92-984b-703da7897eee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_7e184d96-4f3a-44fc-8677-799ab020b86c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_7e184d96-4f3a-44fc-8677-799ab020b86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_44ee88ca-86ee-477b-ac8f-13bdfe3e3adf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_44ee88ca-86ee-477b-ac8f-13bdfe3e3adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_4ff29dc9-8339-4644-a832-bf14e842b23d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_4ff29dc9-8339-4644-a832-bf14e842b23d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCreditRiskLineItems_ea6d4aa7-4bb9-456a-a526-04c865354d08" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCreditRiskTable_efe99dca-b827-4bed-ac3e-738ff735b25a" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfCreditRiskLineItems_ea6d4aa7-4bb9-456a-a526-04c865354d08" xlink:to="loc_alvo_DisclosureOfCreditRiskTable_efe99dca-b827-4bed-ac3e-738ff735b25a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_67433c1d-dd43-44e5-a095-3f0e21001e42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfCreditRiskTable_efe99dca-b827-4bed-ac3e-738ff735b25a" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_67433c1d-dd43-44e5-a095-3f0e21001e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_67433c1d-dd43-44e5-a095-3f0e21001e42_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_67433c1d-dd43-44e5-a095-3f0e21001e42" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_67433c1d-dd43-44e5-a095-3f0e21001e42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_67433c1d-dd43-44e5-a095-3f0e21001e42" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CashEquivalentsAndCashMember_1031492d-cc07-4697-b3b9-f26a8bdc9028" xlink:href="alvo-20231231.xsd#alvo_CashEquivalentsAndCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:to="loc_alvo_CashEquivalentsAndCashMember_1031492d-cc07-4697-b3b9-f26a8bdc9028" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RestrictedCashMember_bc8cf14a-d41b-4771-b65e-aa72dca0069e" xlink:href="alvo-20231231.xsd#alvo_RestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:to="loc_alvo_RestrictedCashMember_bc8cf14a-d41b-4771-b65e-aa72dca0069e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsMember_27bdcff0-6508-4a0d-9ae3-f6ba4c3dda05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:to="loc_ifrs-full_OtherAssetsMember_27bdcff0-6508-4a0d-9ae3-f6ba4c3dda05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk_ee022395-1507-4c73-bf61-5fe8eee95e88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfCreditRiskLineItems_ea6d4aa7-4bb9-456a-a526-04c865354d08" xlink:to="loc_ifrs-full_MaximumExposureToCreditRisk_ee022395-1507-4c73-bf61-5fe8eee95e88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_fc1537f3-199c-4c07-a1b5-1164cfc23361" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_fc1537f3-199c-4c07-a1b5-1164cfc23361" xlink:to="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:to="loc_ifrs-full_MaturityAxis_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_c231f3ee-0659-461a-b053-a2fa6155c8de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_c231f3ee-0659-461a-b053-a2fa6155c8de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_e8a11067-1519-4c26-b12f-7845307cf108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_e8a11067-1519-4c26-b12f-7845307cf108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LaterThanTwoYearsMember_809e61bd-e928-4aa2-ab47-d5c8ca6f71d7" xlink:href="alvo-20231231.xsd#alvo_LaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:to="loc_alvo_LaterThanTwoYearsMember_809e61bd-e928-4aa2-ab47-d5c8ca6f71d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_f84c7efb-0de8-4bed-9e0f-070831dfba57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_f84c7efb-0de8-4bed-9e0f-070831dfba57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonInterestBearingFinancialAssetsMember_f8ebff54-3e1b-4ae0-8ce6-9e00f96a909c" xlink:href="alvo-20231231.xsd#alvo_NonInterestBearingFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f84c7efb-0de8-4bed-9e0f-070831dfba57" xlink:to="loc_alvo_NonInterestBearingFinancialAssetsMember_f8ebff54-3e1b-4ae0-8ce6-9e00f96a909c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestBearingFinancialAssetsMember_24d8f84b-8f61-46f2-b62d-8dafd8be0a71" xlink:href="alvo-20231231.xsd#alvo_VariableInterestBearingFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f84c7efb-0de8-4bed-9e0f-070831dfba57" xlink:to="loc_alvo_VariableInterestBearingFinancialAssetsMember_24d8f84b-8f61-46f2-b62d-8dafd8be0a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_81586b2c-1d92-4c8c-afaf-cae07f7daabb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_81586b2c-1d92-4c8c-afaf-cae07f7daabb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_81586b2c-1d92-4c8c-afaf-cae07f7daabb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_81586b2c-1d92-4c8c-afaf-cae07f7daabb" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_81586b2c-1d92-4c8c-afaf-cae07f7daabb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_81586b2c-1d92-4c8c-afaf-cae07f7daabb" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonInterestBearingFinancialLiabilitiesMember_99394ee9-0d58-4c43-891c-433e9b0d5727" xlink:href="alvo-20231231.xsd#alvo_NonInterestBearingFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:to="loc_alvo_NonInterestBearingFinancialLiabilitiesMember_99394ee9-0d58-4c43-891c-433e9b0d5727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FixedInterestBearingBorrowingsMember_3c288ad2-4051-4076-8e9b-6d8cfa0c2a0d" xlink:href="alvo-20231231.xsd#alvo_FixedInterestBearingBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:to="loc_alvo_FixedInterestBearingBorrowingsMember_3c288ad2-4051-4076-8e9b-6d8cfa0c2a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_eff1954d-6acf-46d7-a077-e9a2a69786f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:to="loc_ifrs-full_DerivativesMember_eff1954d-6acf-46d7-a077-e9a2a69786f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestBearingBorrowingsMember_f86c6b0c-8071-4163-bce9-677280542c33" xlink:href="alvo-20231231.xsd#alvo_VariableInterestBearingBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:to="loc_alvo_VariableInterestBearingBorrowingsMember_f86c6b0c-8071-4163-bce9-677280542c33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_e4875ff3-a150-49b3-8515-dc2159aab362" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_fc1537f3-199c-4c07-a1b5-1164cfc23361" xlink:to="loc_ifrs-full_FinancialAssets_e4875ff3-a150-49b3-8515-dc2159aab362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_e509069c-6d3b-4434-bdae-66db498fc07f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_fc1537f3-199c-4c07-a1b5-1164cfc23361" xlink:to="loc_ifrs-full_FinancialLiabilities_e509069c-6d3b-4434-bdae-66db498fc07f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_09ef14ad-cfc8-4c13-87af-d9bc646b7f28" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_09ef14ad-cfc8-4c13-87af-d9bc646b7f28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d0026f68-1acf-4f90-a8d9-7d729f71cf8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_09ef14ad-cfc8-4c13-87af-d9bc646b7f28" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d0026f68-1acf-4f90-a8d9-7d729f71cf8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d0026f68-1acf-4f90-a8d9-7d729f71cf8b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d0026f68-1acf-4f90-a8d9-7d729f71cf8b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d0026f68-1acf-4f90-a8d9-7d729f71cf8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_0208a8b2-a715-4f2d-8f6c-60c80aa4e7f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d0026f68-1acf-4f90-a8d9-7d729f71cf8b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_0208a8b2-a715-4f2d-8f6c-60c80aa4e7f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_eeec9b20-7456-43d9-a79d-f2e5cf9dcc71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0208a8b2-a715-4f2d-8f6c-60c80aa4e7f6" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_eeec9b20-7456-43d9-a79d-f2e5cf9dcc71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember_4ae879df-8b73-4e55-a067-14abd6377521" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0208a8b2-a715-4f2d-8f6c-60c80aa4e7f6" xlink:to="loc_alvo_ShareAppreciationRightsMember_4ae879df-8b73-4e55-a067-14abd6377521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid_b884e126-6812-4580-a286-27ffdf3133b1" xlink:href="alvo-20231231.xsd#alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid_b884e126-6812-4580-a286-27ffdf3133b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid_ff57657b-9bed-4746-8b94-cd67cf8111d0" xlink:href="alvo-20231231.xsd#alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid_ff57657b-9bed-4746-8b94-cd67cf8111d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities_26978cb7-3ea6-4ff6-8c08-2929b2454f09" xlink:href="alvo-20231231.xsd#alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities_26978cb7-3ea6-4ff6-8c08-2929b2454f09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond_d7251b15-df26-4429-b5d5-66cfaea32d20" xlink:href="alvo-20231231.xsd#alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond_d7251b15-df26-4429-b5d5-66cfaea32d20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashIssuanceOfConvertibleBond_97271712-0bbe-4e12-9f10-a421717a37cd" xlink:href="alvo-20231231.xsd#alvo_NonCashIssuanceOfConvertibleBond"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_NonCashIssuanceOfConvertibleBond_97271712-0bbe-4e12-9f10-a421717a37cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OrdinarySharesValueIssuedConversionOfBorrowings_dc9bb0fd-2847-48ff-8390-f419aab7e3c3" xlink:href="alvo-20231231.xsd#alvo_OrdinarySharesValueIssuedConversionOfBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_OrdinarySharesValueIssuedConversionOfBorrowings_dc9bb0fd-2847-48ff-8390-f419aab7e3c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements_6a976b88-18f6-4b43-ba15-dbc386e16a6c" xlink:href="alvo-20231231.xsd#alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements_6a976b88-18f6-4b43-ba15-dbc386e16a6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares_e4e73ca6-e8f2-4ea2-b4a9-8d676678cfe8" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares_e4e73ca6-e8f2-4ea2-b4a9-8d676678cfe8" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da7d0530-8da3-4596-8f5b-15806d44e606" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_srt_ProductOrServiceAxis_da7d0530-8da3-4596-8f5b-15806d44e606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da7d0530-8da3-4596-8f5b-15806d44e606_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_da7d0530-8da3-4596-8f5b-15806d44e606" xlink:to="loc_srt_ProductsAndServicesDomain_da7d0530-8da3-4596-8f5b-15806d44e606_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_49bc6a2f-6368-4bc1-a594-4ef87218007f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_da7d0530-8da3-4596-8f5b-15806d44e606" xlink:to="loc_srt_ProductsAndServicesDomain_49bc6a2f-6368-4bc1-a594-4ef87218007f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HumiraMember_6b7028fc-b309-4ef6-adde-b4a5090f87ff" xlink:href="alvo-20231231.xsd#alvo_HumiraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49bc6a2f-6368-4bc1-a594-4ef87218007f" xlink:to="loc_alvo_HumiraMember_6b7028fc-b309-4ef6-adde-b4a5090f87ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_59e3eab2-0c0e-4040-910d-415bd976db6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_59e3eab2-0c0e-4040-910d-415bd976db6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_59e3eab2-0c0e-4040-910d-415bd976db6a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_59e3eab2-0c0e-4040-910d-415bd976db6a" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_59e3eab2-0c0e-4040-910d-415bd976db6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_c99d81c1-199d-42d9-b572-f3a0235b5f18" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_59e3eab2-0c0e-4040-910d-415bd976db6a" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_c99d81c1-199d-42d9-b572-f3a0235b5f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_b3866e8f-872c-4bfd-8e87-1e0e1411771b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_c99d81c1-199d-42d9-b572-f3a0235b5f18" xlink:to="loc_ifrs-full_OrdinarySharesMember_b3866e8f-872c-4bfd-8e87-1e0e1411771b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5198e1a6-f3c3-4174-ad13-05e8885cdeeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5198e1a6-f3c3-4174-ad13-05e8885cdeeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_5198e1a6-f3c3-4174-ad13-05e8885cdeeb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5198e1a6-f3c3-4174-ad13-05e8885cdeeb" xlink:to="loc_ifrs-full_NonadjustingEventsMember_5198e1a6-f3c3-4174-ad13-05e8885cdeeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_29e598a9-09a0-44d9-966a-39ba8af7b1c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5198e1a6-f3c3-4174-ad13-05e8885cdeeb" xlink:to="loc_ifrs-full_NonadjustingEventsMember_29e598a9-09a0-44d9-966a-39ba8af7b1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_d1859032-8156-40ff-8771-00163a51e133" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_29e598a9-09a0-44d9-966a-39ba8af7b1c0" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_d1859032-8156-40ff-8771-00163a51e133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAxis_c6752c28-d25c-4990-a405-ce156c77c102" xlink:href="alvo-20231231.xsd#alvo_TrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_alvo_TrancheAxis_c6752c28-d25c-4990-a405-ce156c77c102" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_c6752c28-d25c-4990-a405-ce156c77c102_default" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alvo_TrancheAxis_c6752c28-d25c-4990-a405-ce156c77c102" xlink:to="loc_alvo_TrancheDomain_c6752c28-d25c-4990-a405-ce156c77c102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_aabef385-7737-4f46-9297-9f829c60821d" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alvo_TrancheAxis_c6752c28-d25c-4990-a405-ce156c77c102" xlink:to="loc_alvo_TrancheDomain_aabef385-7737-4f46-9297-9f829c60821d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheTwoMember_7194adde-f256-45d9-b339-d9d8d05deaa2" xlink:href="alvo-20231231.xsd#alvo_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TrancheDomain_aabef385-7737-4f46-9297-9f829c60821d" xlink:to="loc_alvo_TrancheTwoMember_7194adde-f256-45d9-b339-d9d8d05deaa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheOneMember_2371b812-75b8-433c-940d-8b01e3c850f5" xlink:href="alvo-20231231.xsd#alvo_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alvo_TrancheDomain_aabef385-7737-4f46-9297-9f829c60821d" xlink:to="loc_alvo_TrancheOneMember_2371b812-75b8-433c-940d-8b01e3c850f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_62748741-2e07-4a96-983b-9613818a0670" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_62748741-2e07-4a96-983b-9613818a0670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_ee9dedc2-432a-427c-9fe2-cacf98fbd1fc" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_62748741-2e07-4a96-983b-9613818a0670" xlink:to="loc_alvo_EarnoutSharesMember_ee9dedc2-432a-427c-9fe2-cacf98fbd1fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4ad6713a-0767-4773-ba10-3be12e216b7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4ad6713a-0767-4773-ba10-3be12e216b7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_4ad6713a-0767-4773-ba10-3be12e216b7d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4ad6713a-0767-4773-ba10-3be12e216b7d" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_4ad6713a-0767-4773-ba10-3be12e216b7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_594a7fe7-5abd-42de-9367-630a35692452" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4ad6713a-0767-4773-ba10-3be12e216b7d" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_594a7fe7-5abd-42de-9367-630a35692452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_0ecf980b-41ea-405c-9376-c770fd9a9d91" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_594a7fe7-5abd-42de-9367-630a35692452" xlink:to="loc_alvo_SeniorBondWarrantsMember_0ecf980b-41ea-405c-9376-c770fd9a9d91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_34192361-2908-4db1-8d27-b6badb8d9a02" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_594a7fe7-5abd-42de-9367-630a35692452" xlink:to="loc_alvo_EarnoutWarrantsMember_34192361-2908-4db1-8d27-b6badb8d9a02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_c7c53123-7700-4fdd-86c3-dc6a52af9aa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_Revenue_c7c53123-7700-4fdd-86c3-dc6a52af9aa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_cb5e2a96-4cb1-4113-bb92-be8092b485a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_cb5e2a96-4cb1-4113-bb92-be8092b485a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_626e5aca-3626-472b-a994-6bc367a4ad4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_IssueOfEquity_626e5aca-3626-472b-a994-6bc367a4ad4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_ae6e238c-0d06-4531-a63a-2791b5360fbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_ae6e238c-0d06-4531-a63a-2791b5360fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_e8f52c55-a2fb-46cd-91a1-7e47df835ab6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_ParValuePerShare_e8f52c55-a2fb-46cd-91a1-7e47df835ab6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockIssuePricePerShare_d504a8a0-971a-4da9-8652-6339998b643b" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockIssuePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_alvo_SaleOfStockIssuePricePerShare_d504a8a0-971a-4da9-8652-6339998b643b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_4a133b52-080b-4a8a-9b2f-e116b0c10ecf" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_4a133b52-080b-4a8a-9b2f-e116b0c10ecf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_6c2d86a9-8128-4d97-a4bc-e49795c8ac71" xlink:href="alvo-20231231.xsd#alvo_NumberOfSharesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_6c2d86a9-8128-4d97-a4bc-e49795c8ac71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_5495bd0e-5f48-435d-9ad2-764ffa2435d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_5495bd0e-5f48-435d-9ad2-764ffa2435d3" xlink:type="arc" order="8"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>alvo-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0f568319-c84c-47ce-b7c2-396cc2b09ac1,g:54c4089e-eaa8-4b46-9747-283b5fa757be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_NumberOfEmployees_fbae02b4-f181-4ed5-af87-4b15f31189c5_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_ifrs-full_NumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfEmployees" xlink:to="lab_ifrs-full_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AssetAcquisitionsConsiderationTransferred_146dc1fc-191d-4e40-8524-6510858c0514_terseLabel_en-US" xlink:label="lab_alvo_AssetAcquisitionsConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration transferred</link:label>
    <link:label id="lab_alvo_AssetAcquisitionsConsiderationTransferred_label_en-US" xlink:label="lab_alvo_AssetAcquisitionsConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisitions Consideration Transferred</link:label>
    <link:label id="lab_alvo_AssetAcquisitionsConsiderationTransferred_documentation_en-US" xlink:label="lab_alvo_AssetAcquisitionsConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration transferred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionsConsiderationTransferred" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionsConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AssetAcquisitionsConsiderationTransferred" xlink:to="lab_alvo_AssetAcquisitionsConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FacilityEquipmentMember_b036a370-942e-47ba-9f15-79a2400e3aad_verboseLabel_en-US" xlink:label="lab_alvo_FacilityEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Facility equipment</link:label>
    <link:label id="lab_alvo_FacilityEquipmentMember_b34bd096-9015-409b-9e76-9e0e79a42f39_terseLabel_en-US" xlink:label="lab_alvo_FacilityEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Equipment</link:label>
    <link:label id="lab_alvo_FacilityEquipmentMember_label_en-US" xlink:label="lab_alvo_FacilityEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Equipment [Member]</link:label>
    <link:label id="lab_alvo_FacilityEquipmentMember_documentation_en-US" xlink:label="lab_alvo_FacilityEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityEquipmentMember" xlink:href="alvo-20231231.xsd#alvo_FacilityEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FacilityEquipmentMember" xlink:to="lab_alvo_FacilityEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_cee24215-fc94-4d44-b954-1823e90ba478_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseInOutstandingBondsFairValue_5f1c3ce4-9882-4c18-b05a-ae0753518329_terseLabel_en-US" xlink:label="lab_alvo_IncreaseInOutstandingBondsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in outstanding bonds fair value</link:label>
    <link:label id="lab_alvo_IncreaseInOutstandingBondsFairValue_label_en-US" xlink:label="lab_alvo_IncreaseInOutstandingBondsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Outstanding Bonds Fair Value</link:label>
    <link:label id="lab_alvo_IncreaseInOutstandingBondsFairValue_documentation_en-US" xlink:label="lab_alvo_IncreaseInOutstandingBondsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase In Outstanding Bonds Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseInOutstandingBondsFairValue" xlink:href="alvo-20231231.xsd#alvo_IncreaseInOutstandingBondsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseInOutstandingBondsFairValue" xlink:to="lab_alvo_IncreaseInOutstandingBondsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_WeightedAverageRemainingLeaseTerm_62c8206d-1407-4848-bd8d-d01c862f019f_terseLabel_en-US" xlink:label="lab_alvo_WeightedAverageRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease remaining lease term</link:label>
    <link:label id="lab_alvo_WeightedAverageRemainingLeaseTerm_label_en-US" xlink:label="lab_alvo_WeightedAverageRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Lease Term</link:label>
    <link:label id="lab_alvo_WeightedAverageRemainingLeaseTerm_documentation_en-US" xlink:label="lab_alvo_WeightedAverageRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee operating lease remaining lease term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageRemainingLeaseTerm" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_WeightedAverageRemainingLeaseTerm" xlink:to="lab_alvo_WeightedAverageRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PropertyPlantAndEquipmentRollForward_70bc71a6-a59a-4cc3-adbb-d6f3c2040966_terseLabel_en-US" xlink:label="lab_alvo_PropertyPlantAndEquipmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Roll Forward]</link:label>
    <link:label id="lab_alvo_PropertyPlantAndEquipmentRollForward_label_en-US" xlink:label="lab_alvo_PropertyPlantAndEquipmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Roll Forward]</link:label>
    <link:label id="lab_alvo_PropertyPlantAndEquipmentRollForward_documentation_en-US" xlink:label="lab_alvo_PropertyPlantAndEquipmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PropertyPlantAndEquipmentRollForward" xlink:href="alvo-20231231.xsd#alvo_PropertyPlantAndEquipmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward" xlink:to="lab_alvo_PropertyPlantAndEquipmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NatureOfFeesDomain_4b5ebafe-9b25-42cb-b7d6-98f8214695d4_terseLabel_en-US" xlink:label="lab_alvo_NatureOfFeesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature Of Fees [Domain]</link:label>
    <link:label id="lab_alvo_NatureOfFeesDomain_label_en-US" xlink:label="lab_alvo_NatureOfFeesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature Of Fees [Domain]</link:label>
    <link:label id="lab_alvo_NatureOfFeesDomain_documentation_en-US" xlink:label="lab_alvo_NatureOfFeesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nature of fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NatureOfFeesDomain" xlink:href="alvo-20231231.xsd#alvo_NatureOfFeesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NatureOfFeesDomain" xlink:to="lab_alvo_NatureOfFeesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VariableInterestRateFinancialLiabilitiesMember_f968cee6-6b29-409a-bc75-b977c51cb8f6_terseLabel_en-US" xlink:label="lab_alvo_VariableInterestRateFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable interest rate financial liabilities</link:label>
    <link:label id="lab_alvo_VariableInterestRateFinancialLiabilitiesMember_label_en-US" xlink:label="lab_alvo_VariableInterestRateFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Rate Financial Liabilities [Member]</link:label>
    <link:label id="lab_alvo_VariableInterestRateFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_alvo_VariableInterestRateFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable interest rate financial liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestRateFinancialLiabilitiesMember" xlink:href="alvo-20231231.xsd#alvo_VariableInterestRateFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VariableInterestRateFinancialLiabilitiesMember" xlink:to="lab_alvo_VariableInterestRateFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BondsIssued_9a38d92b-a03b-4b26-bdad-53c654727ad9_verboseLabel_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
    <link:label id="lab_ifrs-full_BondsIssued_e636f0dd-c30f-4a59-a9a3-38a112d97a7d_terseLabel_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
    <link:label id="lab_ifrs-full_BondsIssued_label_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BondsIssued" xlink:to="lab_ifrs-full_BondsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PerformanceObligationsAxis_52d029ba-03b4-4ab8-9bb0-127ef073fa78_terseLabel_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations [axis]</link:label>
    <link:label id="lab_ifrs-full_PerformanceObligationsAxis_label_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance obligations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PerformanceObligationsAxis" xlink:to="lab_ifrs-full_PerformanceObligationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForJointVenturesMember_71f4e0ce-5c67-4338-b487-1246100ed8a0_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for joint ventures [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForJointVenturesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for joint ventures [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:to="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_1f3a2289-3b4f-4845-8348-3581698e6e77_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_82453229-7836-4df3-acd4-49e4f3094e72_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_1fa16f62-b598-47ca-9d84-6bc907e15d74_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Salaries And Other Employee Expenses [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Salaries And Other Employee Expenses [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of salaries and other employee expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract" xlink:to="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherCurrentLiabilitiesAbstract_47a0c927-08a5-4985-8940-114626dece83_terseLabel_en-US" xlink:label="lab_alvo_OtherCurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Abstract]</link:label>
    <link:label id="lab_alvo_OtherCurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_alvo_OtherCurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Abstract]</link:label>
    <link:label id="lab_alvo_OtherCurrentLiabilitiesAbstract_documentation_en-US" xlink:label="lab_alvo_OtherCurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentLiabilitiesAbstract" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract" xlink:to="lab_alvo_OtherCurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_8142c5a2-aad3-45cb-945e-b9cfa7b46bc3_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value-added tax</link:label>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value added tax receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_b56af8c8-1d0f-42bc-a67b-2a64f16caedb_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants_1c1ca3d2-c5e9-4d2a-b8e0-06c91dfc16dd_terseLabel_en-US" xlink:label="lab_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock shares issued during the period exercise of warrants (in shares)</link:label>
    <link:label id="lab_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants_label_en-US" xlink:label="lab_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Shares Issued During The Period Exercise Of Warrants</link:label>
    <link:label id="lab_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants_documentation_en-US" xlink:label="lab_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock shares issued during the period exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants" xlink:href="alvo-20231231.xsd#alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants" xlink:to="lab_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TaxYearsAxis_88288487-9c46-4f88-90b9-2f2e152f9564_terseLabel_en-US" xlink:label="lab_alvo_TaxYearsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax years [Axis]</link:label>
    <link:label id="lab_alvo_TaxYearsAxis_label_en-US" xlink:label="lab_alvo_TaxYearsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax years [Axis]</link:label>
    <link:label id="lab_alvo_TaxYearsAxis_documentation_en-US" xlink:label="lab_alvo_TaxYearsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxYearsAxis" xlink:href="alvo-20231231.xsd#alvo_TaxYearsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TaxYearsAxis" xlink:to="lab_alvo_TaxYearsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_31b5cd17-0dc6-40cc-ae45-5ca421797ae0_negatedLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_217d8009-203c-4d75-883b-25269ca12501_terseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractLiabilityCustomerPrepayments_9e8e54f9-2319-4a17-a2ef-c9789ff863ae_terseLabel_en-US" xlink:label="lab_alvo_ContractLiabilityCustomerPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer prepayments</link:label>
    <link:label id="lab_alvo_ContractLiabilityCustomerPrepayments_label_en-US" xlink:label="lab_alvo_ContractLiabilityCustomerPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer prepayments</link:label>
    <link:label id="lab_alvo_ContractLiabilityCustomerPrepayments_documentation_en-US" xlink:label="lab_alvo_ContractLiabilityCustomerPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract liability C\customer prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilityCustomerPrepayments" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilityCustomerPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractLiabilityCustomerPrepayments" xlink:to="lab_alvo_ContractLiabilityCustomerPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties_d370031b-1821-4c09-9621-fddc9da830a5_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from loans from related parties</link:label>
    <link:label id="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties_label_en-US" xlink:label="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash advances and loans from related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:to="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WagesAndSalaries_86d035fc-e730-41e5-bd1e-9b8997ee1738_terseLabel_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary expense</link:label>
    <link:label id="lab_ifrs-full_WagesAndSalaries_label_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wages and salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses_a0af37cb-a862-40bd-b44f-a0a9e11925e4_verboseLabel_en-US" xlink:label="lab_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unpaid salary and salary related expenses</link:label>
    <link:label id="lab_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses_label_en-US" xlink:label="lab_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Accrued Salary And Salary Related Expenses</link:label>
    <link:label id="lab_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses_documentation_en-US" xlink:label="lab_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current accrued salary and salary related expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses" xlink:to="lab_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IntellectualPropertyRightsMember_d6b11bb4-0b4e-4a18-a755-c29887b9f1b0_terseLabel_en-US" xlink:label="lab_alvo_IntellectualPropertyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property rights</link:label>
    <link:label id="lab_alvo_IntellectualPropertyRightsMember_label_en-US" xlink:label="lab_alvo_IntellectualPropertyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Rights [Member]</link:label>
    <link:label id="lab_alvo_IntellectualPropertyRightsMember_documentation_en-US" xlink:label="lab_alvo_IntellectualPropertyRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntellectualPropertyRightsMember" xlink:href="alvo-20231231.xsd#alvo_IntellectualPropertyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IntellectualPropertyRightsMember" xlink:to="lab_alvo_IntellectualPropertyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RiskyYieldMember_64910fa9-7c8e-4bd9-b8ce-0cef001d1054_terseLabel_en-US" xlink:label="lab_alvo_RiskyYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risky yield</link:label>
    <link:label id="lab_alvo_RiskyYieldMember_label_en-US" xlink:label="lab_alvo_RiskyYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risky Yield [Member]</link:label>
    <link:label id="lab_alvo_RiskyYieldMember_documentation_en-US" xlink:label="lab_alvo_RiskyYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risky yield.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RiskyYieldMember" xlink:href="alvo-20231231.xsd#alvo_RiskyYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RiskyYieldMember" xlink:to="lab_alvo_RiskyYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherCurrentAsset_ec51b7aa-36a6-485d-bb92-98a4e20a899c_terseLabel_en-US" xlink:label="lab_alvo_OtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_alvo_OtherCurrentAsset_label_en-US" xlink:label="lab_alvo_OtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Asset</link:label>
    <link:label id="lab_alvo_OtherCurrentAsset_documentation_en-US" xlink:label="lab_alvo_OtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other current asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAsset" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherCurrentAsset" xlink:to="lab_alvo_OtherCurrentAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AgreementsTypeDomain_874b2787-3c12-4398-8f5e-039d1a738ebd_terseLabel_en-US" xlink:label="lab_alvo_AgreementsTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreements Type [Domain]</link:label>
    <link:label id="lab_alvo_AgreementsTypeDomain_label_en-US" xlink:label="lab_alvo_AgreementsTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements Type [Domain]</link:label>
    <link:label id="lab_alvo_AgreementsTypeDomain_documentation_en-US" xlink:label="lab_alvo_AgreementsTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreements Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementsTypeDomain" xlink:href="alvo-20231231.xsd#alvo_AgreementsTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AgreementsTypeDomain" xlink:to="lab_alvo_AgreementsTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesAuthorised_197d6a7c-c640-4a66-ae9c-6516c9e81abb_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesAuthorised_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares authorised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesAuthorised" xlink:to="lab_ifrs-full_NumberOfSharesAuthorised" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_9df8cb9a-31e7-46e2-b5bd-32994fc388ba_terseLabel_en-US" xlink:label="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Information About Board of Directors Remuneration [Table]</link:label>
    <link:label id="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_label_en-US" xlink:label="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Information About Board of Directors Remuneration [Table]</link:label>
    <link:label id="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_documentation_en-US" xlink:label="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of information about board of directors remuneration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable" xlink:to="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ScheduleOfOtherReservesTableTextBlock_ba292d1f-065d-4fac-8b2e-57b1d46e0cc4_terseLabel_en-US" xlink:label="lab_alvo_ScheduleOfOtherReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Reserves</link:label>
    <link:label id="lab_alvo_ScheduleOfOtherReservesTableTextBlock_label_en-US" xlink:label="lab_alvo_ScheduleOfOtherReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Reserves [Table Text Block]</link:label>
    <link:label id="lab_alvo_ScheduleOfOtherReservesTableTextBlock_documentation_en-US" xlink:label="lab_alvo_ScheduleOfOtherReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Other Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfOtherReservesTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfOtherReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ScheduleOfOtherReservesTableTextBlock" xlink:to="lab_alvo_ScheduleOfOtherReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory_b4c84798-daa9-4381-b6e0-45743ba6604c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Revenue From Transactions With Individual Customers</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_9cfd5895-3463-4eb6-a87b-0ddd1acb9f26_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConsentingFee_20e8b687-c366-4682-ac65-6aa647c5eaac_terseLabel_en-US" xlink:label="lab_alvo_ConsentingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consenting fee (see Note 21)</link:label>
    <link:label id="lab_alvo_ConsentingFee_label_en-US" xlink:label="lab_alvo_ConsentingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consenting Fee</link:label>
    <link:label id="lab_alvo_ConsentingFee_documentation_en-US" xlink:label="lab_alvo_ConsentingFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consenting fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConsentingFee" xlink:href="alvo-20231231.xsd#alvo_ConsentingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConsentingFee" xlink:to="lab_alvo_ConsentingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_EventDomain_54505723-e592-4071-b7b5-a9c7cdb4ef41_terseLabel_en-US" xlink:label="lab_alvo_EventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Event [Domain]</link:label>
    <link:label id="lab_alvo_EventDomain_label_en-US" xlink:label="lab_alvo_EventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Event [Domain]</link:label>
    <link:label id="lab_alvo_EventDomain_documentation_en-US" xlink:label="lab_alvo_EventDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EventDomain" xlink:href="alvo-20231231.xsd#alvo_EventDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_EventDomain" xlink:to="lab_alvo_EventDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfGoodwillLineItems_442357e2-d869-4573-a84a-bd5345123c98_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Goodwill [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfGoodwillLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Goodwill [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfGoodwillLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfGoodwillLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfGoodwillLineItems" xlink:to="lab_alvo_DisclosureOfGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_8f9c3d67-6dc3-4c8d-8df7-caad6061668c_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss on investment in joint venture</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_254c8307-073a-418b-a4f5-234736390a84_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss on investment in joint venture</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_b81442e8-4683-41d0-83ea-1f610eea5876_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of assets</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ThomasEkmanMember_9c652d65-ef39-4512-ab58-2ac08a9f0892_terseLabel_en-US" xlink:label="lab_alvo_ThomasEkmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tomas Ekman, Board Member*</link:label>
    <link:label id="lab_alvo_ThomasEkmanMember_label_en-US" xlink:label="lab_alvo_ThomasEkmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tomas Ekman [Member]</link:label>
    <link:label id="lab_alvo_ThomasEkmanMember_documentation_en-US" xlink:label="lab_alvo_ThomasEkmanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tomas Ekman.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThomasEkmanMember" xlink:href="alvo-20231231.xsd#alvo_ThomasEkmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ThomasEkmanMember" xlink:to="lab_alvo_ThomasEkmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember_67636725-294d-40af-9f8a-cfb4124b65b3_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goods or services transferred over time</link:label>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember_label_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goods or services transferred over time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenFinanceB.VMember_5fa5f686-98c1-4d6f-b51b-bcff5791313b_terseLabel_en-US" xlink:label="lab_alvo_AlvogenFinanceB.VMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Finance B.V. - Sister Company</link:label>
    <link:label id="lab_alvo_AlvogenFinanceB.VMember_label_en-US" xlink:label="lab_alvo_AlvogenFinanceB.VMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Finance B.V [Member]</link:label>
    <link:label id="lab_alvo_AlvogenFinanceB.VMember_documentation_en-US" xlink:label="lab_alvo_AlvogenFinanceB.VMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Finance B.V</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFinanceB.VMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenFinanceB.VMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenFinanceB.VMember" xlink:to="lab_alvo_AlvogenFinanceB.VMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_7f60f9b6-70cd-4c5c-ae72-25a5ceb39a7a_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable decrease</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible decrease in unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_cf8302cc-d90b-43e6-9187-98ebe0a9e0df_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_970b52c2-b695-4b6e-b9ad-74589af52cf5_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NonCashChangesInOtherChanges_8c09674c-a0e9-434a-9883-335acd7d816d_terseLabel_en-US" xlink:label="lab_alvo_NonCashChangesInOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other changes</link:label>
    <link:label id="lab_alvo_NonCashChangesInOtherChanges_label_en-US" xlink:label="lab_alvo_NonCashChangesInOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Changes in Other Changes</link:label>
    <link:label id="lab_alvo_NonCashChangesInOtherChanges_documentation_en-US" xlink:label="lab_alvo_NonCashChangesInOtherChanges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Changes in Other Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashChangesInOtherChanges" xlink:href="alvo-20231231.xsd#alvo_NonCashChangesInOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NonCashChangesInOtherChanges" xlink:to="lab_alvo_NonCashChangesInOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ShareAppreciationRightsMember_3c2a55c6-6e8c-473a-8215-350f2f394bfd_terseLabel_en-US" xlink:label="lab_alvo_ShareAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SARs</link:label>
    <link:label id="lab_alvo_ShareAppreciationRightsMember_label_en-US" xlink:label="lab_alvo_ShareAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share appreciation rights [Member]</link:label>
    <link:label id="lab_alvo_ShareAppreciationRightsMember_documentation_en-US" xlink:label="lab_alvo_ShareAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share appreciation rights mmeber</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ShareAppreciationRightsMember" xlink:to="lab_alvo_ShareAppreciationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RestrictedShareUnitsMember_9ba9a90b-cb29-44b7-b998-16105110b0a1_terseLabel_en-US" xlink:label="lab_ifrs-full_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_ifrs-full_RestrictedShareUnitsMember_label_en-US" xlink:label="lab_ifrs-full_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted share units [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestrictedShareUnitsMember" xlink:to="lab_ifrs-full_RestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NetCashProceedsFromTheTransaction_0a1b2340-db0b-4cc2-a889-06f955aa2f98_terseLabel_en-US" xlink:label="lab_alvo_NetCashProceedsFromTheTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash proceeds from the transaction</link:label>
    <link:label id="lab_alvo_NetCashProceedsFromTheTransaction_label_en-US" xlink:label="lab_alvo_NetCashProceedsFromTheTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Proceeds From The Transaction</link:label>
    <link:label id="lab_alvo_NetCashProceedsFromTheTransaction_documentation_en-US" xlink:label="lab_alvo_NetCashProceedsFromTheTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net cash proceeds from the transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NetCashProceedsFromTheTransaction" xlink:href="alvo-20231231.xsd#alvo_NetCashProceedsFromTheTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NetCashProceedsFromTheTransaction" xlink:to="lab_alvo_NetCashProceedsFromTheTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_5d704e86-603f-480a-8d89-684755e539ee_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Detailed Information About Inventories Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about inventories explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_ae29e04c-878a-45a8-9e2c-45c93d039453_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_b094ddb4-0156-4caa-b866-e522508c579c_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_2ad68310-8af3-498f-b38c-e1a4ca4e6dbf_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7f23a3bb-fea0-4eb5-909e-d94b591a5017_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdditionRestrictedCashAndCashEquivalents_8277bca4-ccb2-431f-a414-7c535be78266_terseLabel_en-US" xlink:label="lab_alvo_AdditionRestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions during the year</link:label>
    <link:label id="lab_alvo_AdditionRestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_alvo_AdditionRestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Addition Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_alvo_AdditionRestrictedCashAndCashEquivalents_documentation_en-US" xlink:label="lab_alvo_AdditionRestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Addition restricted cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionRestrictedCashAndCashEquivalents" xlink:href="alvo-20231231.xsd#alvo_AdditionRestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdditionRestrictedCashAndCashEquivalents" xlink:to="lab_alvo_AdditionRestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConvertibleOrdinarySharesMember_8c756e9a-5b3f-43bb-bc53-1405100f78e8_terseLabel_en-US" xlink:label="lab_alvo_ConvertibleOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Ordinary Shares</link:label>
    <link:label id="lab_alvo_ConvertibleOrdinarySharesMember_label_en-US" xlink:label="lab_alvo_ConvertibleOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Ordinary Shares [member]</link:label>
    <link:label id="lab_alvo_ConvertibleOrdinarySharesMember_documentation_en-US" xlink:label="lab_alvo_ConvertibleOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible ordinary shares [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleOrdinarySharesMember" xlink:href="alvo-20231231.xsd#alvo_ConvertibleOrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConvertibleOrdinarySharesMember" xlink:to="lab_alvo_ConvertibleOrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_INR_50610deb-e2aa-4408-9db2-a7a8fb217a61_terseLabel_en-US" xlink:label="lab_currency_INR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INR</link:label>
    <link:label id="lab_currency_INR_label_en-US" xlink:label="lab_currency_INR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">India, Rupees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_INR" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_INR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_INR" xlink:to="lab_currency_INR" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfInventoriesLineItems_5619fd2b-fcf7-499a-a799-2ccb91d9ea2d_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Inventories [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfInventoriesLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Inventories [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfInventoriesLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfInventoriesLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfInventoriesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfInventoriesLineItems" xlink:to="lab_alvo_DisclosureOfInventoriesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdalvoLimitedMember_0ba29ea6-f9a1-4e18-87c5-fdab0ea637dd_terseLabel_en-US" xlink:label="lab_alvo_AdalvoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adalvo Limited - Sister company</link:label>
    <link:label id="lab_alvo_AdalvoLimitedMember_label_en-US" xlink:label="lab_alvo_AdalvoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adalvo Limited [Member]</link:label>
    <link:label id="lab_alvo_AdalvoLimitedMember_documentation_en-US" xlink:label="lab_alvo_AdalvoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adalvo Limited member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdalvoLimitedMember" xlink:href="alvo-20231231.xsd#alvo_AdalvoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdalvoLimitedMember" xlink:to="lab_alvo_AdalvoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherBorrowingsFinancialInstitutionMember_15436cb5-ac96-477a-90f2-444d87ca5c85_terseLabel_en-US" xlink:label="lab_alvo_OtherBorrowingsFinancialInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Borrowings Financial Institution</link:label>
    <link:label id="lab_alvo_OtherBorrowingsFinancialInstitutionMember_label_en-US" xlink:label="lab_alvo_OtherBorrowingsFinancialInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Borrowings Financial Institution [member]</link:label>
    <link:label id="lab_alvo_OtherBorrowingsFinancialInstitutionMember_documentation_en-US" xlink:label="lab_alvo_OtherBorrowingsFinancialInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Borrowings Financial Institution [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherBorrowingsFinancialInstitutionMember" xlink:href="alvo-20231231.xsd#alvo_OtherBorrowingsFinancialInstitutionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherBorrowingsFinancialInstitutionMember" xlink:to="lab_alvo_OtherBorrowingsFinancialInstitutionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_01eefdbf-0352-4761-8ad5-041c2c0eccce_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsRedemptionConversionPrice_003a322e-6a47-4003-bcd2-7edfc9be0e01_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsRedemptionConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings redemption conversion price (in dollars per share)</link:label>
    <link:label id="lab_alvo_BorrowingsRedemptionConversionPrice_label_en-US" xlink:label="lab_alvo_BorrowingsRedemptionConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Redemption Conversion Price</link:label>
    <link:label id="lab_alvo_BorrowingsRedemptionConversionPrice_documentation_en-US" xlink:label="lab_alvo_BorrowingsRedemptionConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings redemption conversion price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRedemptionConversionPrice" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRedemptionConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsRedemptionConversionPrice" xlink:to="lab_alvo_BorrowingsRedemptionConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssuedToTheExistingAndANewBondHolderMember_359cc8ea-6b47-42a0-8b46-82c16e3df151_terseLabel_en-US" xlink:label="lab_alvo_IssuedToTheExistingAndANewBondHolderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued To The Existing And A New Bond Holder</link:label>
    <link:label id="lab_alvo_IssuedToTheExistingAndANewBondHolderMember_label_en-US" xlink:label="lab_alvo_IssuedToTheExistingAndANewBondHolderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued To The Existing And A New Bond Holder [member]</link:label>
    <link:label id="lab_alvo_IssuedToTheExistingAndANewBondHolderMember_documentation_en-US" xlink:label="lab_alvo_IssuedToTheExistingAndANewBondHolderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issued to the existing and a new bond holder [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToTheExistingAndANewBondHolderMember" xlink:href="alvo-20231231.xsd#alvo_IssuedToTheExistingAndANewBondHolderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssuedToTheExistingAndANewBondHolderMember" xlink:to="lab_alvo_IssuedToTheExistingAndANewBondHolderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_db1443e1-0f5b-4cd0-af07-0676dbd53b0e_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating cash flow before movement in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AfterTheTermsOfTheSecondAmendmentMember_5d23d2af-a20e-4329-8b5d-e80b81e5205a_terseLabel_en-US" xlink:label="lab_alvo_AfterTheTermsOfTheSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After The Terms Of The Second Amendment</link:label>
    <link:label id="lab_alvo_AfterTheTermsOfTheSecondAmendmentMember_label_en-US" xlink:label="lab_alvo_AfterTheTermsOfTheSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After The Terms Of The Second Amendment [member]</link:label>
    <link:label id="lab_alvo_AfterTheTermsOfTheSecondAmendmentMember_documentation_en-US" xlink:label="lab_alvo_AfterTheTermsOfTheSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After the terms of the second amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AfterTheTermsOfTheSecondAmendmentMember" xlink:href="alvo-20231231.xsd#alvo_AfterTheTermsOfTheSecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AfterTheTermsOfTheSecondAmendmentMember" xlink:to="lab_alvo_AfterTheTermsOfTheSecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContingentlyIssuablePennyWarrantsMember_b78cd17a-2b4a-4384-b320-6130f1878b6b_terseLabel_en-US" xlink:label="lab_alvo_ContingentlyIssuablePennyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingently Issuable Penny Warrants</link:label>
    <link:label id="lab_alvo_ContingentlyIssuablePennyWarrantsMember_label_en-US" xlink:label="lab_alvo_ContingentlyIssuablePennyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingently Issuable Penny Warrants [member]</link:label>
    <link:label id="lab_alvo_ContingentlyIssuablePennyWarrantsMember_documentation_en-US" xlink:label="lab_alvo_ContingentlyIssuablePennyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingently issuable penny warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContingentlyIssuablePennyWarrantsMember" xlink:href="alvo-20231231.xsd#alvo_ContingentlyIssuablePennyWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContingentlyIssuablePennyWarrantsMember" xlink:to="lab_alvo_ContingentlyIssuablePennyWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractualCapitalCommitmentContingentLiability_a0452d6e-66d2-4b6f-8234-30ffa703917a_terseLabel_en-US" xlink:label="lab_alvo_ContractualCapitalCommitmentContingentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment, contingent liability</link:label>
    <link:label id="lab_alvo_ContractualCapitalCommitmentContingentLiability_label_en-US" xlink:label="lab_alvo_ContractualCapitalCommitmentContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Capital Commitment, Contingent Liability</link:label>
    <link:label id="lab_alvo_ContractualCapitalCommitmentContingentLiability_documentation_en-US" xlink:label="lab_alvo_ContractualCapitalCommitmentContingentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Capital Commitment, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractualCapitalCommitmentContingentLiability" xlink:href="alvo-20231231.xsd#alvo_ContractualCapitalCommitmentContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractualCapitalCommitmentContingentLiability" xlink:to="lab_alvo_ContractualCapitalCommitmentContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_d8b1e45d-6749-401c-80c4-2debcc05a795_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock_b2fdaaab-b48b-44e9-8f8e-659d961725e3_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about noncurrent assets excluding financial instruments and deferred tax assets explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_d2e67b0d-7e49-4801-acfd-97772c258ffa_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of movements in exchange rates on cash held</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_5a7dd051-fd31-42b8-a9ab-5c2853e38df2_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables/ borrowings</link:label>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FixedInterestBearingBorrowingsMember_a47e67f6-bc0a-4f63-9278-67d0b9651b83_terseLabel_en-US" xlink:label="lab_alvo_FixedInterestBearingBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed-interest bearing - Borrowings</link:label>
    <link:label id="lab_alvo_FixedInterestBearingBorrowingsMember_label_en-US" xlink:label="lab_alvo_FixedInterestBearingBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed-Interest Bearing Borrowings [Member]</link:label>
    <link:label id="lab_alvo_FixedInterestBearingBorrowingsMember_documentation_en-US" xlink:label="lab_alvo_FixedInterestBearingBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed-Interest Bearing Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FixedInterestBearingBorrowingsMember" xlink:href="alvo-20231231.xsd#alvo_FixedInterestBearingBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FixedInterestBearingBorrowingsMember" xlink:to="lab_alvo_FixedInterestBearingBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherBorrowingsMember_24b27de4-3ea1-423f-9708-12f78beaa06f_terseLabel_en-US" xlink:label="lab_alvo_OtherBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:label id="lab_alvo_OtherBorrowingsMember_label_en-US" xlink:label="lab_alvo_OtherBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Borrowings [Member]</link:label>
    <link:label id="lab_alvo_OtherBorrowingsMember_documentation_en-US" xlink:label="lab_alvo_OtherBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherBorrowingsMember" xlink:href="alvo-20231231.xsd#alvo_OtherBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherBorrowingsMember" xlink:to="lab_alvo_OtherBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_a1d53216-9e88-43c0-8a3c-525445f651d7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssuedToTheExistingNoteholderMember_a0cc9414-7b28-4e4b-bc3a-21b2edd44ca3_terseLabel_en-US" xlink:label="lab_alvo_IssuedToTheExistingNoteholderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued To The Existing Noteholder</link:label>
    <link:label id="lab_alvo_IssuedToTheExistingNoteholderMember_label_en-US" xlink:label="lab_alvo_IssuedToTheExistingNoteholderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued To The Existing Noteholder [member]</link:label>
    <link:label id="lab_alvo_IssuedToTheExistingNoteholderMember_documentation_en-US" xlink:label="lab_alvo_IssuedToTheExistingNoteholderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issued to the existing noteholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToTheExistingNoteholderMember" xlink:href="alvo-20231231.xsd#alvo_IssuedToTheExistingNoteholderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssuedToTheExistingNoteholderMember" xlink:to="lab_alvo_IssuedToTheExistingNoteholderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheAConvertibleDebtMember_18c3bd6f-e07f-4a2a-96bc-5ad885fb97d6_terseLabel_en-US" xlink:label="lab_alvo_TrancheAConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche A Convertible Debt</link:label>
    <link:label id="lab_alvo_TrancheAConvertibleDebtMember_label_en-US" xlink:label="lab_alvo_TrancheAConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche A Convertible Debt [Member]</link:label>
    <link:label id="lab_alvo_TrancheAConvertibleDebtMember_documentation_en-US" xlink:label="lab_alvo_TrancheAConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche A Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConvertibleDebtMember" xlink:href="alvo-20231231.xsd#alvo_TrancheAConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheAConvertibleDebtMember" xlink:to="lab_alvo_TrancheAConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_99db30c5-ff7b-4593-a0f8-55e67741dbe7_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares_23990ceb-ed56-4820-bd9c-5e93b2848d5a_terseLabel_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of liability with shares</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares_label_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Settlement Of Liability With Shares</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares_documentation_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through settlement of liability with shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares" xlink:to="lab_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_864bfa8b-0369-4d9b-a06b-8aa1686e7ca7_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures_f520fdee-acda-4f72-b364-a37f68c6b47e_verboseLabel_en-US" xlink:label="lab_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments of joint venture partners in relation to joint ventures</link:label>
    <link:label id="lab_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures_label_en-US" xlink:label="lab_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Of Joint Venture Partners In Relation To Joint Ventures</link:label>
    <link:label id="lab_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures_documentation_en-US" xlink:label="lab_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments of joint venture partners in relation to joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures" xlink:href="alvo-20231231.xsd#alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures" xlink:to="lab_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ProceedsFromTheCapitalReorganization_1fa31e52-ae35-4c78-bdb6-bf6902f02c46_verboseLabel_en-US" xlink:label="lab_alvo_ProceedsFromTheCapitalReorganization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the Capital Reorganization</link:label>
    <link:label id="lab_alvo_ProceedsFromTheCapitalReorganization_e9aaba62-0376-4c47-ba9d-ad625787beb9_terseLabel_en-US" xlink:label="lab_alvo_ProceedsFromTheCapitalReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the capital reorganization</link:label>
    <link:label id="lab_alvo_ProceedsFromTheCapitalReorganization_label_en-US" xlink:label="lab_alvo_ProceedsFromTheCapitalReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From The Capital Reorganization</link:label>
    <link:label id="lab_alvo_ProceedsFromTheCapitalReorganization_documentation_en-US" xlink:label="lab_alvo_ProceedsFromTheCapitalReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from the capital reorganization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromTheCapitalReorganization" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromTheCapitalReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ProceedsFromTheCapitalReorganization" xlink:to="lab_alvo_ProceedsFromTheCapitalReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_762e8437-d8cb-4300-aa99-1e40ec90f7bc_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GBP</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AuditInformationAbstract_c441f793-238d-4695-8b26-da4d32ed1208_terseLabel_en-US" xlink:label="lab_alvo_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_alvo_AuditInformationAbstract_label_en-US" xlink:label="lab_alvo_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_alvo_AuditInformationAbstract_documentation_en-US" xlink:label="lab_alvo_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AuditInformationAbstract" xlink:href="alvo-20231231.xsd#alvo_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AuditInformationAbstract" xlink:to="lab_alvo_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPayable_3f019d13-f509-4b75-a484-a83fe23a74b4_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_ifrs-full_InterestPayable_label_en-US" xlink:label="lab_ifrs-full_InterestPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPayable" xlink:to="lab_ifrs-full_InterestPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SeniorBondWarrantsMember_869bf17a-1be2-4e3a-813c-a3af506e433b_terseLabel_en-US" xlink:label="lab_alvo_SeniorBondWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Bond Warrants</link:label>
    <link:label id="lab_alvo_SeniorBondWarrantsMember_label_en-US" xlink:label="lab_alvo_SeniorBondWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Bond Warrants [Member]</link:label>
    <link:label id="lab_alvo_SeniorBondWarrantsMember_documentation_en-US" xlink:label="lab_alvo_SeniorBondWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior bond warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SeniorBondWarrantsMember" xlink:to="lab_alvo_SeniorBondWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CommonStockSharesSubscribed_16162ac5-5ed6-4dbb-a3cb-0e5c47c6ff74_terseLabel_en-US" xlink:label="lab_alvo_CommonStockSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares subscribed (in shares)</link:label>
    <link:label id="lab_alvo_CommonStockSharesSubscribed_label_en-US" xlink:label="lab_alvo_CommonStockSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Subscribed</link:label>
    <link:label id="lab_alvo_CommonStockSharesSubscribed_documentation_en-US" xlink:label="lab_alvo_CommonStockSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock, shares subscribed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockSharesSubscribed" xlink:href="alvo-20231231.xsd#alvo_CommonStockSharesSubscribed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CommonStockSharesSubscribed" xlink:to="lab_alvo_CommonStockSharesSubscribed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_d0304ed0-eaa6-4adb-8767-4e29a125a1c0_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_99d89a64-5011-495a-9a25-2ae0d28aa9dc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfSharesCalledByEachWarrantOrRight_5dfecdfd-a9df-4b6d-8491-dd918d9007b5_terseLabel_en-US" xlink:label="lab_alvo_NumberOfSharesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by each warrant or right</link:label>
    <link:label id="lab_alvo_NumberOfSharesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_alvo_NumberOfSharesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Called By Each Warrant Or Right</link:label>
    <link:label id="lab_alvo_NumberOfSharesCalledByEachWarrantOrRight_documentation_en-US" xlink:label="lab_alvo_NumberOfSharesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares called by each warrant or right.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight" xlink:href="alvo-20231231.xsd#alvo_NumberOfSharesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight" xlink:to="lab_alvo_NumberOfSharesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_HRJAFEhfSisterCompanyMember_15f74f56-5625-450b-8091-b17caf0a6d47_terseLabel_en-US" xlink:label="lab_alvo_HRJAFEhfSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HRJ&#193;F ehf - Sister company</link:label>
    <link:label id="lab_alvo_HRJAFEhfSisterCompanyMember_label_en-US" xlink:label="lab_alvo_HRJAFEhfSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HRJ&#193;F ehf - Sister company [Member]</link:label>
    <link:label id="lab_alvo_HRJAFEhfSisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_HRJAFEhfSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HRJAF ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HRJAFEhfSisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_HRJAFEhfSisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_HRJAFEhfSisterCompanyMember" xlink:to="lab_alvo_HRJAFEhfSisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CapitalContributionSharesIssued_5641fa7c-3c92-4665-ac14-49525c427a2e_terseLabel_en-US" xlink:label="lab_alvo_CapitalContributionSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution (in shares)</link:label>
    <link:label id="lab_alvo_CapitalContributionSharesIssued_label_en-US" xlink:label="lab_alvo_CapitalContributionSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution Shares Issued</link:label>
    <link:label id="lab_alvo_CapitalContributionSharesIssued_documentation_en-US" xlink:label="lab_alvo_CapitalContributionSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalContributionSharesIssued" xlink:href="alvo-20231231.xsd#alvo_CapitalContributionSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CapitalContributionSharesIssued" xlink:to="lab_alvo_CapitalContributionSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDeferredTaxLiabilities_eed8e094-e1b0-4555-8f5a-0d1eeb9f28a5_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_NetDeferredTaxLiabilities_3d2e1992-e7c9-4a3d-aa89-0ab0e5f83c5c_negatedLabel_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax credited to profit or loss</link:label>
    <link:label id="lab_ifrs-full_NetDeferredTaxLiabilities_b61c4bc9-f57e-4cc6-8d95-dba5374dd2bd_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities attributable to other temporary differences</link:label>
    <link:label id="lab_ifrs-full_NetDeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDeferredTaxLiabilities" xlink:to="lab_ifrs-full_NetDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_73b29aca-6b6c-42a6-b8d5-0397351372e6_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_78f69586-75cd-42a9-ba89-8178442586f8_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BondsIssuedAtFairValue_ec07e6e8-7670-41f7-a575-52f042357dcb_terseLabel_en-US" xlink:label="lab_alvo_BondsIssuedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_alvo_BondsIssuedAtFairValue_label_en-US" xlink:label="lab_alvo_BondsIssuedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds Issued At Fair Value</link:label>
    <link:label id="lab_alvo_BondsIssuedAtFairValue_documentation_en-US" xlink:label="lab_alvo_BondsIssuedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bonds issued at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BondsIssuedAtFairValue" xlink:href="alvo-20231231.xsd#alvo_BondsIssuedAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BondsIssuedAtFairValue" xlink:to="lab_alvo_BondsIssuedAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e7b786f8-25fe-45c8-993a-26db2e68dc71_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExcerciseOfWarrantsMember_c75f9672-6e6c-4988-9660-dc543676ab3a_terseLabel_en-US" xlink:label="lab_alvo_ExcerciseOfWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Of Warrants</link:label>
    <link:label id="lab_alvo_ExcerciseOfWarrantsMember_label_en-US" xlink:label="lab_alvo_ExcerciseOfWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excercise Of Warrants [Member]</link:label>
    <link:label id="lab_alvo_ExcerciseOfWarrantsMember_documentation_en-US" xlink:label="lab_alvo_ExcerciseOfWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExcerciseOfWarrantsMember" xlink:href="alvo-20231231.xsd#alvo_ExcerciseOfWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExcerciseOfWarrantsMember" xlink:to="lab_alvo_ExcerciseOfWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_7470b22a-5bac-42ab-a5e7-e690052c8a4f_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, pledged as security</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, pledged as security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SaleOfStockAxis_e96b5d22-c0ae-4621-87a0-058fd0f5f26e_terseLabel_en-US" xlink:label="lab_alvo_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_alvo_SaleOfStockAxis_label_en-US" xlink:label="lab_alvo_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_alvo_SaleOfStockAxis_documentation_en-US" xlink:label="lab_alvo_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockAxis" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SaleOfStockAxis" xlink:to="lab_alvo_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_89d41404-da9f-4d77-81bb-783891706112_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_d7beb864-c8bc-4f76-ae04-5ab68c268a61_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goods or services transferred at point in time</link:label>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_label_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goods or services transferred at point in time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractualCapitalCommitmentsTerm_6d0f756e-df01-4936-b671-f1c1c63a36b4_terseLabel_en-US" xlink:label="lab_alvo_ContractualCapitalCommitmentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term</link:label>
    <link:label id="lab_alvo_ContractualCapitalCommitmentsTerm_label_en-US" xlink:label="lab_alvo_ContractualCapitalCommitmentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Capital Commitments, Term</link:label>
    <link:label id="lab_alvo_ContractualCapitalCommitmentsTerm_documentation_en-US" xlink:label="lab_alvo_ContractualCapitalCommitmentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Capital Commitments, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractualCapitalCommitmentsTerm" xlink:href="alvo-20231231.xsd#alvo_ContractualCapitalCommitmentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractualCapitalCommitmentsTerm" xlink:to="lab_alvo_ContractualCapitalCommitmentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IntangibleAssetsWithFiniteLivedMember_ae0765a4-0447-4057-a7f8-5dae2ba62a6d_terseLabel_en-US" xlink:label="lab_alvo_IntangibleAssetsWithFiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets with finite lived</link:label>
    <link:label id="lab_alvo_IntangibleAssetsWithFiniteLivedMember_label_en-US" xlink:label="lab_alvo_IntangibleAssetsWithFiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets With Finite Lived [Member]</link:label>
    <link:label id="lab_alvo_IntangibleAssetsWithFiniteLivedMember_documentation_en-US" xlink:label="lab_alvo_IntangibleAssetsWithFiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets with finite lived.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntangibleAssetsWithFiniteLivedMember" xlink:href="alvo-20231231.xsd#alvo_IntangibleAssetsWithFiniteLivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IntangibleAssetsWithFiniteLivedMember" xlink:to="lab_alvo_IntangibleAssetsWithFiniteLivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SaleOfStockIssuePricePerShare_4b825ef3-ac96-4a69-98e7-d08a4878b2b7_terseLabel_en-US" xlink:label="lab_alvo_SaleOfStockIssuePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock issue price (in dollars per share)</link:label>
    <link:label id="lab_alvo_SaleOfStockIssuePricePerShare_label_en-US" xlink:label="lab_alvo_SaleOfStockIssuePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock Issue Price Per Share</link:label>
    <link:label id="lab_alvo_SaleOfStockIssuePricePerShare_documentation_en-US" xlink:label="lab_alvo_SaleOfStockIssuePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of stock issue price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockIssuePricePerShare" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockIssuePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SaleOfStockIssuePricePerShare" xlink:to="lab_alvo_SaleOfStockIssuePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_d82ad5d9-db9b-4774-a2e7-a14d17c79681_totalLabel_en-US" xlink:label="lab_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax</link:label>
    <link:label id="lab_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_label_en-US" xlink:label="lab_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Expense Income and Adjustments For Deferred Tax Of Prior Periods</link:label>
    <link:label id="lab_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_documentation_en-US" xlink:label="lab_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax expense income and adjustments for deferred tax of prior periods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" xlink:href="alvo-20231231.xsd#alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" xlink:to="lab_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForTaxServices_7691742f-298b-4fcc-aec0-5cfd15aa9a1e_terseLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other fees, including tax services</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForTaxServices_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor's remuneration for tax services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForTaxServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FinalMaturityInDecember2027Member_51616cb3-8ecd-4d1f-9f3b-b1501786538a_terseLabel_en-US" xlink:label="lab_alvo_FinalMaturityInDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final Maturity in December 2027</link:label>
    <link:label id="lab_alvo_FinalMaturityInDecember2027Member_label_en-US" xlink:label="lab_alvo_FinalMaturityInDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Maturity in December 2027 [Member]</link:label>
    <link:label id="lab_alvo_FinalMaturityInDecember2027Member_documentation_en-US" xlink:label="lab_alvo_FinalMaturityInDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Maturity in December 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinalMaturityInDecember2027Member" xlink:href="alvo-20231231.xsd#alvo_FinalMaturityInDecember2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FinalMaturityInDecember2027Member" xlink:to="lab_alvo_FinalMaturityInDecember2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqMember_095a2b16-4272-4be7-8a18-96d5f3cffd64_terseLabel_en-US" xlink:label="lab_alvo_AztiqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq</link:label>
    <link:label id="lab_alvo_AztiqMember_label_en-US" xlink:label="lab_alvo_AztiqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq [Member]</link:label>
    <link:label id="lab_alvo_AztiqMember_documentation_en-US" xlink:label="lab_alvo_AztiqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqMember" xlink:href="alvo-20231231.xsd#alvo_AztiqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqMember" xlink:to="lab_alvo_AztiqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DerecognitionPrepaidDevelopmentCosts_3e71380a-ce95-4e42-a495-94c0798d3383_terseLabel_en-US" xlink:label="lab_alvo_DerecognitionPrepaidDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognition, prepaid development costs</link:label>
    <link:label id="lab_alvo_DerecognitionPrepaidDevelopmentCosts_label_en-US" xlink:label="lab_alvo_DerecognitionPrepaidDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognition, Prepaid Development Costs</link:label>
    <link:label id="lab_alvo_DerecognitionPrepaidDevelopmentCosts_documentation_en-US" xlink:label="lab_alvo_DerecognitionPrepaidDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derecognition, Prepaid Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionPrepaidDevelopmentCosts" xlink:href="alvo-20231231.xsd#alvo_DerecognitionPrepaidDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DerecognitionPrepaidDevelopmentCosts" xlink:to="lab_alvo_DerecognitionPrepaidDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_54a40bb9-0eec-44e3-9c12-eca6ee4d58a9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock_022ed95c-9487-4add-b788-b323f52bb6c3_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the reconciling items between the statutory rate and the effective tax rate</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Effective Tax Rate Reconciliation Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about effective tax rate reconciliation explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember_784b579f-8233-4c30-831b-537041f7be61_terseLabel_en-US" xlink:label="lab_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Embedded derivative liabilities associated with convertible bonds</link:label>
    <link:label id="lab_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember_label_en-US" xlink:label="lab_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative Liabilities Associated With Convertible Bonds [Member]</link:label>
    <link:label id="lab_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember_documentation_en-US" xlink:label="lab_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Embedded derivative liabilities associated with convertible bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember" xlink:href="alvo-20231231.xsd#alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember" xlink:to="lab_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_0d91579a-f3e1-4852-b41a-26effccc8786_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod_806d214e-82c0-485f-a229-65f37d0fbe65_terseLabel_en-US" xlink:label="lab_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of revenue recognition</link:label>
    <link:label id="lab_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod_label_en-US" xlink:label="lab_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Price Allocated To Remaining Performance Obligations, Period</link:label>
    <link:label id="lab_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod_documentation_en-US" xlink:label="lab_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Price Allocated To Remaining Performance Obligations, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" xlink:href="alvo-20231231.xsd#alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" xlink:to="lab_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LitigationAbstract_0a553ea7-4548-4aa4-819e-e1ed8d94cf66_terseLabel_en-US" xlink:label="lab_alvo_LitigationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation [Abstract]</link:label>
    <link:label id="lab_alvo_LitigationAbstract_label_en-US" xlink:label="lab_alvo_LitigationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation [Abstract]</link:label>
    <link:label id="lab_alvo_LitigationAbstract_documentation_en-US" xlink:label="lab_alvo_LitigationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LitigationAbstract" xlink:href="alvo-20231231.xsd#alvo_LitigationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LitigationAbstract" xlink:to="lab_alvo_LitigationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CompensationWaivedMember_4654bbd3-54b0-49df-b0ed-cbe57e7732ed_terseLabel_en-US" xlink:label="lab_alvo_CompensationWaivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Waived</link:label>
    <link:label id="lab_alvo_CompensationWaivedMember_label_en-US" xlink:label="lab_alvo_CompensationWaivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Waived [Member]</link:label>
    <link:label id="lab_alvo_CompensationWaivedMember_documentation_en-US" xlink:label="lab_alvo_CompensationWaivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationWaivedMember" xlink:href="alvo-20231231.xsd#alvo_CompensationWaivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CompensationWaivedMember" xlink:to="lab_alvo_CompensationWaivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_6e550116-a58c-4a77-968c-adf05fc162eb_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate difference</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_6fe44ca2-856c-435f-a572-6952b2a8b6d1_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Direct taxes &#8211; prior year</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for current tax of prior periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_07b9951a-3698-4325-bcc5-2fd54d69cc75_negatedLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested during the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_5d2a3d65-950b-4eee-bfb9-4d3d8ed06211_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfLitigations_1c2bd070-7b76-4513-b1b2-b92934f2d5a4_terseLabel_en-US" xlink:label="lab_alvo_NumberOfLitigations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of litigations</link:label>
    <link:label id="lab_alvo_NumberOfLitigations_label_en-US" xlink:label="lab_alvo_NumberOfLitigations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Litigations</link:label>
    <link:label id="lab_alvo_NumberOfLitigations_documentation_en-US" xlink:label="lab_alvo_NumberOfLitigations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Litigations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLitigations" xlink:href="alvo-20231231.xsd#alvo_NumberOfLitigations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfLitigations" xlink:to="lab_alvo_NumberOfLitigations" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss_a3b5696b-3c7e-4f0e-885c-2022ca97405a_totalLabel_en-US" xlink:label="lab_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities At Amortized Cost And Financial Liabilities At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortized cost and financial liabilities at fair value through profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="alvo-20231231.xsd#alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="lab_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInEquity_d2542ae5-37fa-4e6d-9b41-0f49fc1ff0d5_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">increase in equity</link:label>
    <link:label id="lab_ifrs-full_ChangesInEquity_label_en-US" xlink:label="lab_ifrs-full_ChangesInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInEquity" xlink:to="lab_ifrs-full_ChangesInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LoansFromRelatedPartyConvertedToEquity_da16977c-c89a-4acf-9d4f-0c07d9f91992_terseLabel_en-US" xlink:label="lab_alvo_LoansFromRelatedPartyConvertedToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans from related party converted to equity</link:label>
    <link:label id="lab_alvo_LoansFromRelatedPartyConvertedToEquity_label_en-US" xlink:label="lab_alvo_LoansFromRelatedPartyConvertedToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans From Related Party Converted To Equity</link:label>
    <link:label id="lab_alvo_LoansFromRelatedPartyConvertedToEquity_documentation_en-US" xlink:label="lab_alvo_LoansFromRelatedPartyConvertedToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans from related party converted to equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LoansFromRelatedPartyConvertedToEquity" xlink:href="alvo-20231231.xsd#alvo_LoansFromRelatedPartyConvertedToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LoansFromRelatedPartyConvertedToEquity" xlink:to="lab_alvo_LoansFromRelatedPartyConvertedToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_EarnoutSharesMember_0274a629-e490-44a8-8cdd-88834462a9b3_terseLabel_en-US" xlink:label="lab_alvo_EarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OACB Earn Out Shares</link:label>
    <link:label id="lab_alvo_EarnoutSharesMember_label_en-US" xlink:label="lab_alvo_EarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnout Shares [Member]</link:label>
    <link:label id="lab_alvo_EarnoutSharesMember_documentation_en-US" xlink:label="lab_alvo_EarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnout shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_EarnoutSharesMember" xlink:to="lab_alvo_EarnoutSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DirectorFees_b69f93f7-c46c-448f-87b5-c1f146822350_terseLabel_en-US" xlink:label="lab_alvo_DirectorFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board fees</link:label>
    <link:label id="lab_alvo_DirectorFees_label_en-US" xlink:label="lab_alvo_DirectorFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director Fees</link:label>
    <link:label id="lab_alvo_DirectorFees_documentation_en-US" xlink:label="lab_alvo_DirectorFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Director Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DirectorFees" xlink:href="alvo-20231231.xsd#alvo_DirectorFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DirectorFees" xlink:to="lab_alvo_DirectorFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_d2266d06-5803-4d2b-a24c-80ac8b7ce40b_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful lives of amortization</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_9f3f1e54-c08b-42e9-8e75-02ceae9a29e9_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement_d874b6f0-7bf2-49b4-8f80-f0ecc200ccc1_terseLabel_en-US" xlink:label="lab_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options after tax witholding in share based payment arrangement (in shares)</link:label>
    <link:label id="lab_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options After Tax Witholding In Share based Payment Arrangement</link:label>
    <link:label id="lab_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options After Tax Witholding In Share based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" xlink:href="alvo-20231231.xsd#alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" xlink:to="lab_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AggregatePeriodForDeterminingTheSharePrice_d49f4d3f-6c4e-4d24-80fb-92f5bcd6e070_terseLabel_en-US" xlink:label="lab_alvo_AggregatePeriodForDeterminingTheSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate period for determining the share price</link:label>
    <link:label id="lab_alvo_AggregatePeriodForDeterminingTheSharePrice_label_en-US" xlink:label="lab_alvo_AggregatePeriodForDeterminingTheSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Period For Determining The Share Price</link:label>
    <link:label id="lab_alvo_AggregatePeriodForDeterminingTheSharePrice_documentation_en-US" xlink:label="lab_alvo_AggregatePeriodForDeterminingTheSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate period for determining the share price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AggregatePeriodForDeterminingTheSharePrice" xlink:href="alvo-20231231.xsd#alvo_AggregatePeriodForDeterminingTheSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AggregatePeriodForDeterminingTheSharePrice" xlink:to="lab_alvo_AggregatePeriodForDeterminingTheSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_c9289448-531d-44f6-8f1b-930181f23228_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_dd8e4a8c-8517-4d97-b00c-96de8c39355a_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherCurrentAssetsLineItems_22e393ea-33ce-44d2-8a23-4db0fe7e790c_terseLabel_en-US" xlink:label="lab_alvo_OtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets [Line Items]</link:label>
    <link:label id="lab_alvo_OtherCurrentAssetsLineItems_label_en-US" xlink:label="lab_alvo_OtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Line Items]</link:label>
    <link:label id="lab_alvo_OtherCurrentAssetsLineItems_documentation_en-US" xlink:label="lab_alvo_OtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsLineItems" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherCurrentAssetsLineItems" xlink:to="lab_alvo_OtherCurrentAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_80ec3a31-2c9f-4689-b003-030ae6b4db25_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income / (loss)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_73ee55a1-c9d1-4752-94a4-7e6e8b9fbe18_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_f9f840d4-05cc-4a02-aa0e-9800821adcfc_terseLabel_en-US" xlink:label="lab_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Bond Agreement Two Thousand And Eighteen</link:label>
    <link:label id="lab_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_label_en-US" xlink:label="lab_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Bond Agreement Two Thousand And Eighteen [member]</link:label>
    <link:label id="lab_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_documentation_en-US" xlink:label="lab_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible bond agreement two thousand and eighteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember" xlink:to="lab_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CustomerrelatedIntangibleAssetsMember_54ef6362-f563-4b6a-9b78-18b952465d4b_terseLabel_en-US" xlink:label="lab_ifrs-full_CustomerrelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_ifrs-full_CustomerrelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_ifrs-full_CustomerrelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer-related intangible assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CustomerrelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember" xlink:to="lab_ifrs-full_CustomerrelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsTrancheOneMember_57c7e140-bb7d-4f96-89d3-b1106367280d_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings Tranche One</link:label>
    <link:label id="lab_alvo_BorrowingsTrancheOneMember_label_en-US" xlink:label="lab_alvo_BorrowingsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Tranche One [member]</link:label>
    <link:label id="lab_alvo_BorrowingsTrancheOneMember_documentation_en-US" xlink:label="lab_alvo_BorrowingsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings Tranche One [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheOneMember" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsTrancheOneMember" xlink:to="lab_alvo_BorrowingsTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DebtInstrumentIncreaseAccruedInterests_a150d2a2-8942-4c9f-87ed-7d1129fd3df4_terseLabel_en-US" xlink:label="lab_alvo_DebtInstrumentIncreaseAccruedInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_alvo_DebtInstrumentIncreaseAccruedInterests_label_en-US" xlink:label="lab_alvo_DebtInstrumentIncreaseAccruedInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Increase Accrued Interests</link:label>
    <link:label id="lab_alvo_DebtInstrumentIncreaseAccruedInterests_documentation_en-US" xlink:label="lab_alvo_DebtInstrumentIncreaseAccruedInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument increase accrued interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DebtInstrumentIncreaseAccruedInterests" xlink:href="alvo-20231231.xsd#alvo_DebtInstrumentIncreaseAccruedInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DebtInstrumentIncreaseAccruedInterests" xlink:to="lab_alvo_DebtInstrumentIncreaseAccruedInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock_b4a33821-2e9f-4d3c-9a03-01bc0ea8f863_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the movement in net deferred taxes</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Reconciliation Of Changes In Deferred Tax Liability Asset Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about reconciliation of changes in deferred tax liability asset explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SharesAuthorizedValue_1d9ac972-7e57-4df4-a300-da633c30c8b8_terseLabel_en-US" xlink:label="lab_alvo_SharesAuthorizedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized value</link:label>
    <link:label id="lab_alvo_SharesAuthorizedValue_label_en-US" xlink:label="lab_alvo_SharesAuthorizedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Authorized Value</link:label>
    <link:label id="lab_alvo_SharesAuthorizedValue_documentation_en-US" xlink:label="lab_alvo_SharesAuthorizedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares authorized value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SharesAuthorizedValue" xlink:href="alvo-20231231.xsd#alvo_SharesAuthorizedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SharesAuthorizedValue" xlink:to="lab_alvo_SharesAuthorizedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RestrictedCashMember_7660e943-407e-4d3f-b338-a6c91ec513ec_terseLabel_en-US" xlink:label="lab_alvo_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_alvo_RestrictedCashMember_label_en-US" xlink:label="lab_alvo_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_alvo_RestrictedCashMember_documentation_en-US" xlink:label="lab_alvo_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RestrictedCashMember" xlink:href="alvo-20231231.xsd#alvo_RestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RestrictedCashMember" xlink:to="lab_alvo_RestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LotusInternationalPteltdMember_bc53b346-9287-449b-841b-65b34659748f_terseLabel_en-US" xlink:label="lab_alvo_LotusInternationalPteltdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lotus International Pte. Ltd. - Sister company</link:label>
    <link:label id="lab_alvo_LotusInternationalPteltdMember_label_en-US" xlink:label="lab_alvo_LotusInternationalPteltdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lotus International PteLtd [Member]</link:label>
    <link:label id="lab_alvo_LotusInternationalPteltdMember_documentation_en-US" xlink:label="lab_alvo_LotusInternationalPteltdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lotus International Pte&#160;Ltd member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusInternationalPteltdMember" xlink:href="alvo-20231231.xsd#alvo_LotusInternationalPteltdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LotusInternationalPteltdMember" xlink:to="lab_alvo_LotusInternationalPteltdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_ISK_3c12bb90-c167-4b2d-b04a-612cb182fc1f_terseLabel_en-US" xlink:label="lab_currency_ISK" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ISK</link:label>
    <link:label id="lab_currency_ISK_label_en-US" xlink:label="lab_currency_ISK" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Iceland, Kronur</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_ISK" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ISK"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ISK" xlink:to="lab_currency_ISK" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssuanceOfOrdinaryShares_1f9167ba-02fb-4095-af5f-c5ca581b6f4d_terseLabel_en-US" xlink:label="lab_alvo_IssuanceOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Ordinary, (in shares)</link:label>
    <link:label id="lab_alvo_IssuanceOfOrdinaryShares_label_en-US" xlink:label="lab_alvo_IssuanceOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Ordinary Shares</link:label>
    <link:label id="lab_alvo_IssuanceOfOrdinaryShares_documentation_en-US" xlink:label="lab_alvo_IssuanceOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuanceOfOrdinaryShares" xlink:href="alvo-20231231.xsd#alvo_IssuanceOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssuanceOfOrdinaryShares" xlink:to="lab_alvo_IssuanceOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_35af0a61-04de-4c29-92ba-807d82a8fd6a_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation difference</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_70fcdb13-c821-4cb3-a17d-499a9e26dd90_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f98f99da-5379-419e-a19d-0dfb781fccf2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LeaseCostRecognizedInProfitAndLoss_7d0e6815-071d-4c42-a676-ba234b051e69_negatedTotalLabel_en-US" xlink:label="lab_alvo_LeaseCostRecognizedInProfitAndLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total amount recognized in profit and loss</link:label>
    <link:label id="lab_alvo_LeaseCostRecognizedInProfitAndLoss_label_en-US" xlink:label="lab_alvo_LeaseCostRecognizedInProfitAndLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Cost Recognized In Profit And Loss</link:label>
    <link:label id="lab_alvo_LeaseCostRecognizedInProfitAndLoss_documentation_en-US" xlink:label="lab_alvo_LeaseCostRecognizedInProfitAndLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease cost recognized in profit and loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseCostRecognizedInProfitAndLoss" xlink:href="alvo-20231231.xsd#alvo_LeaseCostRecognizedInProfitAndLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LeaseCostRecognizedInProfitAndLoss" xlink:to="lab_alvo_LeaseCostRecognizedInProfitAndLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions_37120f38-fc6f-4a34-94b7-d64121773969_terseLabel_en-US" xlink:label="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased service / interest</link:label>
    <link:label id="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Services received, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:to="lab_ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfLongtermIncentivePlansAbstract_075422fd-ceb8-4729-989e-f918561e6a16_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfLongtermIncentivePlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Longterm incentive plans [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfLongtermIncentivePlansAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfLongtermIncentivePlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Longterm incentive plans [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfLongtermIncentivePlansAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfLongtermIncentivePlansAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Longterm incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLongtermIncentivePlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract" xlink:to="lab_alvo_DisclosureOfLongtermIncentivePlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CompensationStatusAxis_c148e3d1-84d6-4532-9a31-0ea4429e2402_terseLabel_en-US" xlink:label="lab_alvo_CompensationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Status [Axis]</link:label>
    <link:label id="lab_alvo_CompensationStatusAxis_label_en-US" xlink:label="lab_alvo_CompensationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Status [Axis]</link:label>
    <link:label id="lab_alvo_CompensationStatusAxis_documentation_en-US" xlink:label="lab_alvo_CompensationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationStatusAxis" xlink:href="alvo-20231231.xsd#alvo_CompensationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CompensationStatusAxis" xlink:to="lab_alvo_CompensationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_6ab440ee-48ca-43e6-becd-576b12b2b819_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting standards</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsConversionFeatureFairValue_2679f8e0-fbe5-49df-b70a-deeaaf770f52_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsConversionFeatureFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings conversion feature fair value</link:label>
    <link:label id="lab_alvo_BorrowingsConversionFeatureFairValue_label_en-US" xlink:label="lab_alvo_BorrowingsConversionFeatureFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Conversion Feature Fair Value</link:label>
    <link:label id="lab_alvo_BorrowingsConversionFeatureFairValue_documentation_en-US" xlink:label="lab_alvo_BorrowingsConversionFeatureFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings conversion feature fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsConversionFeatureFairValue" xlink:href="alvo-20231231.xsd#alvo_BorrowingsConversionFeatureFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsConversionFeatureFairValue" xlink:to="lab_alvo_BorrowingsConversionFeatureFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_e7ac4796-e8a6-4182-a436-413fbad54a72_totalLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_135f6677-e77d-4bda-9c5b-77d4a6c1ac00_terseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total salary and other employee expenses</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VestedEarnOutSharesMember_de0e7910-7005-4ef9-ba1c-34216d20c8c8_terseLabel_en-US" xlink:label="lab_alvo_VestedEarnOutSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested Earn-Out Shares</link:label>
    <link:label id="lab_alvo_VestedEarnOutSharesMember_label_en-US" xlink:label="lab_alvo_VestedEarnOutSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested Earn-Out Shares [Member]</link:label>
    <link:label id="lab_alvo_VestedEarnOutSharesMember_documentation_en-US" xlink:label="lab_alvo_VestedEarnOutSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vested Earn-Out Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnOutSharesMember" xlink:href="alvo-20231231.xsd#alvo_VestedEarnOutSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VestedEarnOutSharesMember" xlink:to="lab_alvo_VestedEarnOutSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_893fc75c-90e8-49e3-be42-a2c898e7dd43_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_680f97fb-6c7e-49be-abc4-cb5bfeadf8c4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0710bc9b-4318-4c68-9f77-89f6a4353a4d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OrdinarySharesValueIssuedConversionOfBorrowings_a828e639-0da0-4510-b132-a5139ee4b995_terseLabel_en-US" xlink:label="lab_alvo_OrdinarySharesValueIssuedConversionOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity issued through conversion of borrowings</link:label>
    <link:label id="lab_alvo_OrdinarySharesValueIssuedConversionOfBorrowings_label_en-US" xlink:label="lab_alvo_OrdinarySharesValueIssuedConversionOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares Value Issued Conversion Of Borrowings</link:label>
    <link:label id="lab_alvo_OrdinarySharesValueIssuedConversionOfBorrowings_documentation_en-US" xlink:label="lab_alvo_OrdinarySharesValueIssuedConversionOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary shares value issued conversion of borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OrdinarySharesValueIssuedConversionOfBorrowings" xlink:href="alvo-20231231.xsd#alvo_OrdinarySharesValueIssuedConversionOfBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OrdinarySharesValueIssuedConversionOfBorrowings" xlink:to="lab_alvo_OrdinarySharesValueIssuedConversionOfBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_c1b57d81-bbcc-4c91-9834-5cca6b7f9534_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock_3b34bce3-587c-48a9-a2bb-8d65af2efc41_terseLabel_en-US" xlink:label="lab_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of maturities of outstanding borrowings</link:label>
    <link:label id="lab_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities Of Outstanding Borrowings Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of outstanding borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" xlink:to="lab_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LicenseRevenueMember_17ef211c-0426-4ce3-a067-523da6338a27_terseLabel_en-US" xlink:label="lab_alvo_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenue (point in time revenue recognition)</link:label>
    <link:label id="lab_alvo_LicenseRevenueMember_label_en-US" xlink:label="lab_alvo_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License revenue [Member]</link:label>
    <link:label id="lab_alvo_LicenseRevenueMember_documentation_en-US" xlink:label="lab_alvo_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LicenseRevenueMember" xlink:href="alvo-20231231.xsd#alvo_LicenseRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LicenseRevenueMember" xlink:to="lab_alvo_LicenseRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SaleOfStockDomain_a1f25686-a5d3-4a9e-bc4c-02cf8697f23e_terseLabel_en-US" xlink:label="lab_alvo_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_alvo_SaleOfStockDomain_label_en-US" xlink:label="lab_alvo_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_alvo_SaleOfStockDomain_documentation_en-US" xlink:label="lab_alvo_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockDomain" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SaleOfStockDomain" xlink:to="lab_alvo_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_934f8ee9-f965-4376-a883-8fa37d615733_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHF</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConversionPriceOfBondsMember_b988f22e-29bb-4cb0-806e-3b2f685ba876_terseLabel_en-US" xlink:label="lab_alvo_ConversionPriceOfBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price</link:label>
    <link:label id="lab_alvo_ConversionPriceOfBondsMember_label_en-US" xlink:label="lab_alvo_ConversionPriceOfBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Price Of Bonds [Member]</link:label>
    <link:label id="lab_alvo_ConversionPriceOfBondsMember_documentation_en-US" xlink:label="lab_alvo_ConversionPriceOfBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion price of bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConversionPriceOfBondsMember" xlink:href="alvo-20231231.xsd#alvo_ConversionPriceOfBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConversionPriceOfBondsMember" xlink:to="lab_alvo_ConversionPriceOfBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease_21df0227-84b3-40ea-a05d-e27688420beb_terseLabel_en-US" xlink:label="lab_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized loan cost changes</link:label>
    <link:label id="lab_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease_label_en-US" xlink:label="lab_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized, Period Increase (Decrease)</link:label>
    <link:label id="lab_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease" xlink:href="alvo-20231231.xsd#alvo_InterestCostsCapitalizedPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease" xlink:to="lab_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_081800c9-f923-4e1f-9d62-f6d22f9e566e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance liabilities</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_34d521c7-afd1-4da3-a33a-86731e49208d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance liabilities</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_37c3593b-8cbe-481a-b39d-2c6f46334561_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_8875637f-6842-48c2-ad3a-ae0405a20d07_terseLabel_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fair value of shares issued and noncash share listing expense [line items]</link:label>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_label_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Fair Value Of Shares Issued And NonCash Share Listing Expense [Line Items]</link:label>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_documentation_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of fair value of shares issued and non-cash share listing expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems" xlink:to="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_23b774b4-52a8-4ca7-a20c-356ca5975b37_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long- term benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, other long-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_7edc4774-0211-4e20-98ed-f25516970563_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassesOfCommonStockMember_c3c0976a-2212-4d2f-a89f-2e80d7f878a3_terseLabel_en-US" xlink:label="lab_alvo_ClassesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of Common Stock [member]</link:label>
    <link:label id="lab_alvo_ClassesOfCommonStockMember_label_en-US" xlink:label="lab_alvo_ClassesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of Common Stock [Member]</link:label>
    <link:label id="lab_alvo_ClassesOfCommonStockMember_documentation_en-US" xlink:label="lab_alvo_ClassesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Classes Of Common Stock Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassesOfCommonStockMember" xlink:href="alvo-20231231.xsd#alvo_ClassesOfCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassesOfCommonStockMember" xlink:to="lab_alvo_ClassesOfCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_28f8a123-1563-4871-b459-28bbb772115d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseDecreaseThroughCapitalReorganization_65eeeb8b-3a53-4100-b73e-c726d6d36992_terseLabel_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughCapitalReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Reorganization</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughCapitalReorganization_label_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughCapitalReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Capital Reorganization</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughCapitalReorganization_documentation_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughCapitalReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through capital reorganization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughCapitalReorganization" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughCapitalReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseDecreaseThroughCapitalReorganization" xlink:to="lab_alvo_IncreaseDecreaseThroughCapitalReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PublicWarrantsMember_74583444-728f-46f5-97d0-c8e59324e528_terseLabel_en-US" xlink:label="lab_alvo_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Warrants</link:label>
    <link:label id="lab_alvo_PublicWarrantsMember_label_en-US" xlink:label="lab_alvo_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Warrants [Member]</link:label>
    <link:label id="lab_alvo_PublicWarrantsMember_documentation_en-US" xlink:label="lab_alvo_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PublicWarrantsMember" xlink:href="alvo-20231231.xsd#alvo_PublicWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PublicWarrantsMember" xlink:to="lab_alvo_PublicWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0e6f5369-94c3-4423-bac1-2cfc4e65e0ac_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_3474d8ae-7129-4b38-a84b-acc18d58f388_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Share-based payment expense</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of effect of share-based payments on entity's profit or loss [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:to="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherCurrentAssetsAbstract_1245ad26-c679-42ef-a1dd-47ca9b2ffab8_terseLabel_en-US" xlink:label="lab_alvo_OtherCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets [Abstract]</link:label>
    <link:label id="lab_alvo_OtherCurrentAssetsAbstract_label_en-US" xlink:label="lab_alvo_OtherCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Abstract]</link:label>
    <link:label id="lab_alvo_OtherCurrentAssetsAbstract_documentation_en-US" xlink:label="lab_alvo_OtherCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsAbstract" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherCurrentAssetsAbstract" xlink:to="lab_alvo_OtherCurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_0c343c67-0606-4766-b9ef-5d380557b3df_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Useful Lives of Depreciation</link:label>
    <link:label id="lab_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of estimated useful lives of property plant and equipment explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_102c5709-0e14-4c70-8389-92bd0897e3be_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_571cb6cb-9c0e-496d-a923-d0ce746eef43_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_e544f565-05d7-44ed-bb20-9f9f820e3e73_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities_87f58871-ba3e-48aa-aa78-e93cd96e2e58_negatedLabel_en-US" xlink:label="lab_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of principal portion of lease liabilities</link:label>
    <link:label id="lab_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities_label_en-US" xlink:label="lab_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Principal Portion Of Lease Liabilities</link:label>
    <link:label id="lab_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities_documentation_en-US" xlink:label="lab_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments of principal portion of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities" xlink:href="alvo-20231231.xsd#alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities" xlink:to="lab_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_0d57761e-a2c1-4ed5-9b02-e0810f6abc86_negatedLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_db18249d-a7c9-4b66-a15f-5520c9f9a42f_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_0f3f39bc-978a-4f30-9ea7-dda49f1ed1ba_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DeferredTaxLiabilityAssetRollForward_41f2f8f7-e942-4e0c-bd40-e66a87f287d0_terseLabel_en-US" xlink:label="lab_alvo_DeferredTaxLiabilityAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset) [Roll Forward]</link:label>
    <link:label id="lab_alvo_DeferredTaxLiabilityAssetRollForward_label_en-US" xlink:label="lab_alvo_DeferredTaxLiabilityAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset) [Roll Forward]</link:label>
    <link:label id="lab_alvo_DeferredTaxLiabilityAssetRollForward_documentation_en-US" xlink:label="lab_alvo_DeferredTaxLiabilityAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DeferredTaxLiabilityAssetRollForward" xlink:href="alvo-20231231.xsd#alvo_DeferredTaxLiabilityAssetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DeferredTaxLiabilityAssetRollForward" xlink:to="lab_alvo_DeferredTaxLiabilityAssetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_6077004d-0c62-4845-8dc5-0bf019812199_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Within four years</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfFinanceIncomeAbstract_c7de8f94-ec0c-4d46-a911-b5b6777c90af_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfFinanceIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Finance Income [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfFinanceIncomeAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfFinanceIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Finance Income [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfFinanceIncomeAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfFinanceIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of finance income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfFinanceIncomeAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfFinanceIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract" xlink:to="lab_alvo_DisclosureOfFinanceIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock_016bc002-d3a9-470c-817f-ce1a7e2bdd8d_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Material Differences Between the Fair Value and Carrying Amount</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Carrying Amount And Financial Amount Of Certain Borrowings Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of carrying amount and financial amount of certain borrowings explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ComponentOfDebtConvertedIntoEquityAxis_312fd94a-97ed-4f9e-8212-73d4b0ff2b5d_terseLabel_en-US" xlink:label="lab_alvo_ComponentOfDebtConvertedIntoEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component Of Debt Converted Into Equity [Axis]</link:label>
    <link:label id="lab_alvo_ComponentOfDebtConvertedIntoEquityAxis_label_en-US" xlink:label="lab_alvo_ComponentOfDebtConvertedIntoEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Component Of Debt Converted Into Equity [Axis]</link:label>
    <link:label id="lab_alvo_ComponentOfDebtConvertedIntoEquityAxis_documentation_en-US" xlink:label="lab_alvo_ComponentOfDebtConvertedIntoEquityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Component of debt converted into equity [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis" xlink:href="alvo-20231231.xsd#alvo_ComponentOfDebtConvertedIntoEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis" xlink:to="lab_alvo_ComponentOfDebtConvertedIntoEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AgreementOneAxis_7c861dcf-c9c2-4998-8d37-b4efa17a7c10_terseLabel_en-US" xlink:label="lab_alvo_AgreementOneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement One [Axis]</link:label>
    <link:label id="lab_alvo_AgreementOneAxis_label_en-US" xlink:label="lab_alvo_AgreementOneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement One [Axis]</link:label>
    <link:label id="lab_alvo_AgreementOneAxis_documentation_en-US" xlink:label="lab_alvo_AgreementOneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneAxis" xlink:href="alvo-20231231.xsd#alvo_AgreementOneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AgreementOneAxis" xlink:to="lab_alvo_AgreementOneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_61e4358f-a28b-41aa-868e-34bade38617f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Fair Value Measurement of Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RichardDaviesMember_13d56b07-0c55-4092-9ed2-dc0ce044850e_terseLabel_en-US" xlink:label="lab_alvo_RichardDaviesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Richard Davies, Vice-Chairman</link:label>
    <link:label id="lab_alvo_RichardDaviesMember_label_en-US" xlink:label="lab_alvo_RichardDaviesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Richard Davies [Member]</link:label>
    <link:label id="lab_alvo_RichardDaviesMember_documentation_en-US" xlink:label="lab_alvo_RichardDaviesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Richard Davies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RichardDaviesMember" xlink:href="alvo-20231231.xsd#alvo_RichardDaviesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RichardDaviesMember" xlink:to="lab_alvo_RichardDaviesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember_f3ffaa81-d78b-43b5-848f-009d37215223_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares_42f3aff4-b453-4bfc-8f12-17c764a876e5_terseLabel_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SARs Settlement (in shares)</link:label>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares_label_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of Shares on Settlement of Share Appreciation Rights Shares</link:label>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares_documentation_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of shares on settlement of share appreciation rights shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares" xlink:to="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfFinancialLiabilitiesAxis_6e109e4d-1e4b-451a-b9ec-3ae165a4eb0a_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FinanceIncomeMember_4bbc9687-e1f7-4f29-a7eb-954b55bc759c_terseLabel_en-US" xlink:label="lab_alvo_FinanceIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Income</link:label>
    <link:label id="lab_alvo_FinanceIncomeMember_label_en-US" xlink:label="lab_alvo_FinanceIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Income [Member]</link:label>
    <link:label id="lab_alvo_FinanceIncomeMember_documentation_en-US" xlink:label="lab_alvo_FinanceIncomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance income [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinanceIncomeMember" xlink:href="alvo-20231231.xsd#alvo_FinanceIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FinanceIncomeMember" xlink:to="lab_alvo_FinanceIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FaysalKalmouaMember_4a008477-4af4-45c8-a471-511d83185c87_terseLabel_en-US" xlink:label="lab_alvo_FaysalKalmouaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Faysal Kalmoua, Board</link:label>
    <link:label id="lab_alvo_FaysalKalmouaMember_label_en-US" xlink:label="lab_alvo_FaysalKalmouaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Faysal Kalmoua [Member]</link:label>
    <link:label id="lab_alvo_FaysalKalmouaMember_documentation_en-US" xlink:label="lab_alvo_FaysalKalmouaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Faysal Kalmoua.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FaysalKalmouaMember" xlink:href="alvo-20231231.xsd#alvo_FaysalKalmouaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FaysalKalmouaMember" xlink:to="lab_alvo_FaysalKalmouaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_7f5d2994-1be7-4e89-9591-fe6752ed7783_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of assets and liabilities denominated in foreign currencies [line items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Assets And Liabilities Denominated In Foreign Currencies [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of assets and liabilities denominated in foreign currencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems" xlink:to="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_17dcd76d-053e-4ba6-bc9e-c07cf1c432e5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_L41EhfMember_8e140781-ef77-4a8d-bb2e-c57c164ec1bb_terseLabel_en-US" xlink:label="lab_alvo_L41EhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">L41 ehf.</link:label>
    <link:label id="lab_alvo_L41EhfMember_label_en-US" xlink:label="lab_alvo_L41EhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">L41 ehf [Member]</link:label>
    <link:label id="lab_alvo_L41EhfMember_documentation_en-US" xlink:label="lab_alvo_L41EhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">L41 ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_L41EhfMember" xlink:href="alvo-20231231.xsd#alvo_L41EhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_L41EhfMember" xlink:to="lab_alvo_L41EhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9906904e-13e2-46c5-8954-c4bc922cc77a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7a49f9cc-7abf-4908-8940-0915b6450e61_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_a345f18f-3824-48de-ac65-02b84a25cc84_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock_693bb49e-855e-4078-af29-89c239daeace_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of detailed information about classes of right of use assets</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Classes Of Right Of Use Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about classes of right of use assets explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_245d968e-831e-4905-8011-605761f032fe_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ReclassificationRightOfUseAssets_91457d21-1612-45d5-9577-bdf1c8be900e_negatedTerseLabel_en-US" xlink:label="lab_alvo_ReclassificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_alvo_ReclassificationRightOfUseAssets_label_en-US" xlink:label="lab_alvo_ReclassificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Right-of-Use Assets</link:label>
    <link:label id="lab_alvo_ReclassificationRightOfUseAssets_documentation_en-US" xlink:label="lab_alvo_ReclassificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReclassificationRightOfUseAssets" xlink:href="alvo-20231231.xsd#alvo_ReclassificationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ReclassificationRightOfUseAssets" xlink:to="lab_alvo_ReclassificationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ReorganizationShareListingExpense_8a8be7a8-ed07-429a-80b3-07e640f44fe3_terseLabel_en-US" xlink:label="lab_alvo_ReorganizationShareListingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reorganization, share listing expense</link:label>
    <link:label id="lab_alvo_ReorganizationShareListingExpense_6c021d12-14fc-42de-9315-733b7baece0b_verboseLabel_en-US" xlink:label="lab_alvo_ReorganizationShareListingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Difference &#8211; being the share listing expense</link:label>
    <link:label id="lab_alvo_ReorganizationShareListingExpense_label_en-US" xlink:label="lab_alvo_ReorganizationShareListingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reorganization, Share Listing Expense</link:label>
    <link:label id="lab_alvo_ReorganizationShareListingExpense_documentation_en-US" xlink:label="lab_alvo_ReorganizationShareListingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reorganization, share listing expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReorganizationShareListingExpense" xlink:href="alvo-20231231.xsd#alvo_ReorganizationShareListingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ReorganizationShareListingExpense" xlink:to="lab_alvo_ReorganizationShareListingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_cde6a747-0b07-4796-9898-195332026a66_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9a990cbf-a7cd-482e-a8c1-1d3c9ce38617_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_f7347a57-8ec6-4a35-a81b-661409c1affc_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets pledged as collateral for liabilities or contingent liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets pledged as collateral for liabilities or contingent liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:to="lab_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember_aca7ace6-810c-4e6d-917f-83902d56277a_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassified to other current liabilities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_4344f940-15d3-4ca0-82d2-4d5cb200ed6f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets_6dc4f411-8e1c-49f2-adcc-3b6178b2ebbb_terseLabel_en-US" xlink:label="lab_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of other intangible assets</link:label>
    <link:label id="lab_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets_label_en-US" xlink:label="lab_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Impairment Loss Reversal Of Impairment Loss Recognise In Profit Or Loss Intangible Assets</link:label>
    <link:label id="lab_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets_documentation_en-US" xlink:label="lab_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for impairment loss reversal of impairment loss recognise in profit or loss intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" xlink:to="lab_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_1185f570-340a-44b8-8c5c-27425f8b308f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_cc86db74-41da-4de7-b2f6-d9de7f690ef4_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherGainsLosses_ef536f61-1bdb-4bac-94b6-a23757d3d9f2_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-operating (loss) / profit</link:label>
    <link:label id="lab_ifrs-full_OtherGainsLosses_label_en-US" xlink:label="lab_ifrs-full_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other gains (losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherGainsLosses" xlink:to="lab_ifrs-full_OtherGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder_761a8a1d-f0cd-4cbf-9353-6a505f428452_terseLabel_en-US" xlink:label="lab_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of ownership interest held by each shareholder</link:label>
    <link:label id="lab_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder_label_en-US" xlink:label="lab_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Percentage Of Ownership Interest Held By Each Shareholder</link:label>
    <link:label id="lab_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder_documentation_en-US" xlink:label="lab_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum percentage of ownership interest held by each shareholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder" xlink:href="alvo-20231231.xsd#alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder" xlink:to="lab_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_05413f84-f804-4e39-80a8-78344b0c083b_terseLabel_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of related party loans with Ordinary Shares, (in shares)</link:label>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_label_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of Shares on Settlement of Related Party Loans Shares</link:label>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_documentation_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of shares on settlement of related party loans shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares" xlink:to="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FlokiArtEhfMember_78274067-dada-47ab-b450-ac206b90f3f5_terseLabel_en-US" xlink:label="lab_alvo_FlokiArtEhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fl&#243;ki-Art ehf. - Sister company</link:label>
    <link:label id="lab_alvo_FlokiArtEhfMember_label_en-US" xlink:label="lab_alvo_FlokiArtEhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Floki Art ehf [Member]</link:label>
    <link:label id="lab_alvo_FlokiArtEhfMember_documentation_en-US" xlink:label="lab_alvo_FlokiArtEhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Floki Art ehf</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiArtEhfMember" xlink:href="alvo-20231231.xsd#alvo_FlokiArtEhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FlokiArtEhfMember" xlink:to="lab_alvo_FlokiArtEhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_7eddddf7-8c9c-4d82-b44d-739fa2b2fde5_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities (see Note 13)</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_7df4d7f4-23f9-42b0-a938-8904e9eb84b1_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DerivaiveAssets_079ee801-5185-4f8d-ae65-30790fe3aa82_terseLabel_en-US" xlink:label="lab_alvo_DerivaiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_alvo_DerivaiveAssets_label_en-US" xlink:label="lab_alvo_DerivaiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivaive Assets</link:label>
    <link:label id="lab_alvo_DerivaiveAssets_documentation_en-US" xlink:label="lab_alvo_DerivaiveAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivaive assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerivaiveAssets" xlink:href="alvo-20231231.xsd#alvo_DerivaiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DerivaiveAssets" xlink:to="lab_alvo_DerivaiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinishedGoods_693ab25f-fa97-4166-88a2-3d91f434c740_terseLabel_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_ifrs-full_FinishedGoods_label_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current finished goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods" xlink:to="lab_ifrs-full_FinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CommitmentsInRelationToJointVentures_419f2e4d-a73d-4ce6-a756-0bd4ab191539_verboseLabel_en-US" xlink:label="lab_ifrs-full_CommitmentsInRelationToJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments in relation to joint ventures</link:label>
    <link:label id="lab_ifrs-full_CommitmentsInRelationToJointVentures_label_en-US" xlink:label="lab_ifrs-full_CommitmentsInRelationToJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments in relation to joint ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommitmentsInRelationToJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommitmentsInRelationToJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommitmentsInRelationToJointVentures" xlink:to="lab_ifrs-full_CommitmentsInRelationToJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VestingPercentageOfShares_100b9657-444a-48c7-bfbb-d45ffbffa177_terseLabel_en-US" xlink:label="lab_alvo_VestingPercentageOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage of shares</link:label>
    <link:label id="lab_alvo_VestingPercentageOfShares_label_en-US" xlink:label="lab_alvo_VestingPercentageOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Percentage Of Shares</link:label>
    <link:label id="lab_alvo_VestingPercentageOfShares_documentation_en-US" xlink:label="lab_alvo_VestingPercentageOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting percentage of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestingPercentageOfShares" xlink:href="alvo-20231231.xsd#alvo_VestingPercentageOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VestingPercentageOfShares" xlink:to="lab_alvo_VestingPercentageOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_5e881dd0-7ac8-476e-ad76-ad378c49a118_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Cash flows</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through financing cash flows, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue_3e578142-faec-4d1a-9027-5899b278a12b_terseLabel_en-US" xlink:label="lab_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on extinguishment of debt including change in fair value</link:label>
    <link:label id="lab_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue_label_en-US" xlink:label="lab_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Loss On Extinguishment Of Debt Including Change In Fair Value</link:label>
    <link:label id="lab_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue_documentation_en-US" xlink:label="lab_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain loss on extinguishment of debt including change in fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" xlink:href="alvo-20231231.xsd#alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" xlink:to="lab_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_da29d56f-c5c3-46d2-8679-ab6deae72da7_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Within two years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_b09e1682-aed4-4848-b04f-668ed3bf8cb3_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One to two years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_683c21a2-eb5a-4b50-bb54-fe414264e3ef_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock_5aaf3e0a-2a0d-48e4-85a3-e75bea42099e_terseLabel_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation and other contingencies</link:label>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for litigation and other contingencies explanatory [Policy Text Block]</link:label>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of accounting policy for litigation and other contingencies explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" xlink:href="alvo-20231231.xsd#alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" xlink:to="lab_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b99df142-1484-4fd4-8801-1aebf0688788_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RiskExposuresMember_046b4ec8-3ea3-4825-85a7-fabd647948e4_terseLabel_en-US" xlink:label="lab_ifrs-full_RiskExposuresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk variables [member]</link:label>
    <link:label id="lab_ifrs-full_RiskExposuresMember_label_en-US" xlink:label="lab_ifrs-full_RiskExposuresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk variables [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposuresMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposuresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RiskExposuresMember" xlink:to="lab_ifrs-full_RiskExposuresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares_5ee658ff-2eb9-4e64-adfa-465ea1e5998f_terseLabel_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of related party loans with Ordinary Shares</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares_label_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Settlement Of Related Party Loans With Ordinary Shares</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares_documentation_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through settlement of related party loans with ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" xlink:to="lab_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CashAndCashEquivalentsRollForward_54030573-675c-4f3d-ba96-8e409518f5b0_terseLabel_en-US" xlink:label="lab_alvo_CashAndCashEquivalentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents [Roll Forward]</link:label>
    <link:label id="lab_alvo_CashAndCashEquivalentsRollForward_label_en-US" xlink:label="lab_alvo_CashAndCashEquivalentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents [Roll Forward]</link:label>
    <link:label id="lab_alvo_CashAndCashEquivalentsRollForward_documentation_en-US" xlink:label="lab_alvo_CashAndCashEquivalentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CashAndCashEquivalentsRollForward" xlink:href="alvo-20231231.xsd#alvo_CashAndCashEquivalentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CashAndCashEquivalentsRollForward" xlink:to="lab_alvo_CashAndCashEquivalentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LandsbankinnHfMember_6eeddf6d-596a-4239-8256-6567bec58c3f_terseLabel_en-US" xlink:label="lab_alvo_LandsbankinnHfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Landsbankinn hf</link:label>
    <link:label id="lab_alvo_LandsbankinnHfMember_label_en-US" xlink:label="lab_alvo_LandsbankinnHfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Landsbankinn hf [member]</link:label>
    <link:label id="lab_alvo_LandsbankinnHfMember_documentation_en-US" xlink:label="lab_alvo_LandsbankinnHfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Landsbankinn hf.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LandsbankinnHfMember" xlink:href="alvo-20231231.xsd#alvo_LandsbankinnHfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LandsbankinnHfMember" xlink:to="lab_alvo_LandsbankinnHfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue_c959ed91-cfec-4ee2-9ddd-60f30ef21101_terseLabel_en-US" xlink:label="lab_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of cash option as a liability fairvalue</link:label>
    <link:label id="lab_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue_label_en-US" xlink:label="lab_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities From Share-Based Payment Transactions, Cash Settlement, Fair Value</link:label>
    <link:label id="lab_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue_documentation_en-US" xlink:label="lab_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities From Share-Based Payment Transactions, Cash Settlement, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:href="alvo-20231231.xsd#alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:to="lab_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_58419dd7-e0c2-4e2c-b03b-b45dce52feed_terseLabel_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_ea7d0471-5178-4d4d-a5c5-549a2f6b78fe_terseLabel_en-US" xlink:label="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclousre of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium [Table]</link:label>
    <link:label id="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_label_en-US" xlink:label="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclousre of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium [Table]</link:label>
    <link:label id="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_documentation_en-US" xlink:label="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclousre of detailed information about movements in ordinary shares, share capital and share premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable" xlink:to="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_be1d8bda-7f29-4805-8ad2-cb897957306b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForDebtIssueCosts_b1dfb4fb-148f-4ca6-878a-c18df0d7dff5_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForDebtIssueCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transaction cost from borrowings</link:label>
    <link:label id="lab_ifrs-full_PaymentsForDebtIssueCosts_ba5c47c2-a9ed-4c58-b540-e24477b875a4_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForDebtIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for debt issue costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForDebtIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForDebtIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for debt issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForDebtIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForDebtIssueCosts" xlink:to="lab_ifrs-full_PaymentsForDebtIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConvertibleLoanNotesMember_b9e8d0ea-89cd-44e8-9934-17b541891283_terseLabel_en-US" xlink:label="lab_alvo_ConvertibleLoanNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Convertible Bonds and Aztiq Convertible Bond</link:label>
    <link:label id="lab_alvo_ConvertibleLoanNotesMember_label_en-US" xlink:label="lab_alvo_ConvertibleLoanNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Loan Notes [Member]</link:label>
    <link:label id="lab_alvo_ConvertibleLoanNotesMember_documentation_en-US" xlink:label="lab_alvo_ConvertibleLoanNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Loan Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleLoanNotesMember" xlink:href="alvo-20231231.xsd#alvo_ConvertibleLoanNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConvertibleLoanNotesMember" xlink:to="lab_alvo_ConvertibleLoanNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_6b60cd31-beb6-4acd-ae74-ff53ae75267e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdjustmentsForSharelistingExpense_35281e8a-dbf7-4281-a423-83465aeb3f4a_terseLabel_en-US" xlink:label="lab_alvo_AdjustmentsForSharelistingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-listing expense</link:label>
    <link:label id="lab_alvo_AdjustmentsForSharelistingExpense_label_en-US" xlink:label="lab_alvo_AdjustmentsForSharelistingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Sharelisting Expense</link:label>
    <link:label id="lab_alvo_AdjustmentsForSharelistingExpense_documentation_en-US" xlink:label="lab_alvo_AdjustmentsForSharelistingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for share-listing expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForSharelistingExpense" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForSharelistingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdjustmentsForSharelistingExpense" xlink:to="lab_alvo_AdjustmentsForSharelistingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_0b22784c-59fd-4750-ba71-435fe2d69fae_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Assumptions and Inputs</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AggregateBorrowingsIndebtedness_19d338d2-75ff-4b57-8738-ef01e477bc61_terseLabel_en-US" xlink:label="lab_alvo_AggregateBorrowingsIndebtedness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate borrowings indebtedness</link:label>
    <link:label id="lab_alvo_AggregateBorrowingsIndebtedness_label_en-US" xlink:label="lab_alvo_AggregateBorrowingsIndebtedness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Borrowings Indebtedness</link:label>
    <link:label id="lab_alvo_AggregateBorrowingsIndebtedness_documentation_en-US" xlink:label="lab_alvo_AggregateBorrowingsIndebtedness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate borrowings indebtedness.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AggregateBorrowingsIndebtedness" xlink:href="alvo-20231231.xsd#alvo_AggregateBorrowingsIndebtedness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AggregateBorrowingsIndebtedness" xlink:to="lab_alvo_AggregateBorrowingsIndebtedness" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CapitalReorganizationSharesIssued_4b643bc0-b49f-4a2b-84ca-a1b85dca5c23_terseLabel_en-US" xlink:label="lab_alvo_CapitalReorganizationSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital reorganization shares issued (in shares)</link:label>
    <link:label id="lab_alvo_CapitalReorganizationSharesIssued_label_en-US" xlink:label="lab_alvo_CapitalReorganizationSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Reorganization Shares Issued</link:label>
    <link:label id="lab_alvo_CapitalReorganizationSharesIssued_documentation_en-US" xlink:label="lab_alvo_CapitalReorganizationSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital reorganization shares issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalReorganizationSharesIssued" xlink:href="alvo-20231231.xsd#alvo_CapitalReorganizationSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CapitalReorganizationSharesIssued" xlink:to="lab_alvo_CapitalReorganizationSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NatureOfFeesAxis_90304fae-0188-43f5-992c-52a0f6471018_terseLabel_en-US" xlink:label="lab_alvo_NatureOfFeesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature Of Fees [Axis]</link:label>
    <link:label id="lab_alvo_NatureOfFeesAxis_label_en-US" xlink:label="lab_alvo_NatureOfFeesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature Of Fees [Axis]</link:label>
    <link:label id="lab_alvo_NatureOfFeesAxis_documentation_en-US" xlink:label="lab_alvo_NatureOfFeesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nature of fees [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NatureOfFeesAxis" xlink:href="alvo-20231231.xsd#alvo_NatureOfFeesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NatureOfFeesAxis" xlink:to="lab_alvo_NatureOfFeesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FleetMember_71bce672-3751-4acc-a27c-a51783ab5338_terseLabel_en-US" xlink:label="lab_alvo_FleetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fleet</link:label>
    <link:label id="lab_alvo_FleetMember_label_en-US" xlink:label="lab_alvo_FleetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fleet [Member]</link:label>
    <link:label id="lab_alvo_FleetMember_documentation_en-US" xlink:label="lab_alvo_FleetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fleet member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FleetMember" xlink:href="alvo-20231231.xsd#alvo_FleetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FleetMember" xlink:to="lab_alvo_FleetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_dfbd3393-f46e-47c1-9e16-f8cee3c8dc5c_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_af7daa88-d949-450d-a7fb-d6a12121cc4d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AssetAcquisitionsDomain_4c2887dc-c710-4efc-9dcb-5570a8f91475_terseLabel_en-US" xlink:label="lab_alvo_AssetAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_alvo_AssetAcquisitionsDomain_label_en-US" xlink:label="lab_alvo_AssetAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisitions [Domain]</link:label>
    <link:label id="lab_alvo_AssetAcquisitionsDomain_documentation_en-US" xlink:label="lab_alvo_AssetAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionsDomain" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AssetAcquisitionsDomain" xlink:to="lab_alvo_AssetAcquisitionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_7e92d7c7-0ae0-4d6b-b927-f7f20c937265_verboseLabel_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax rate in foreign jurisdictions</link:label>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NoncurrentContractAssetsMaterializePeriod_ea8bd24c-1ecd-43a5-9a56-50f50ed52d7d_terseLabel_en-US" xlink:label="lab_alvo_NoncurrentContractAssetsMaterializePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current contract assets materialize period</link:label>
    <link:label id="lab_alvo_NoncurrentContractAssetsMaterializePeriod_label_en-US" xlink:label="lab_alvo_NoncurrentContractAssetsMaterializePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Contract Assets Materialize Period</link:label>
    <link:label id="lab_alvo_NoncurrentContractAssetsMaterializePeriod_documentation_en-US" xlink:label="lab_alvo_NoncurrentContractAssetsMaterializePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current contract assets materialize period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NoncurrentContractAssetsMaterializePeriod" xlink:href="alvo-20231231.xsd#alvo_NoncurrentContractAssetsMaterializePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NoncurrentContractAssetsMaterializePeriod" xlink:to="lab_alvo_NoncurrentContractAssetsMaterializePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_77cc6686-455e-4695-8578-c3df3a19eae4_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_38402b28-4f00-439a-a2c2-8e0e44a65d7f_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Detailed Information About Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_b70ba9ac-2b77-4cf9-b389-49a24a8bcf0a_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average rate</link:label>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_3649c2b1-1e9a-4075-856c-6ae0e747906e_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_11162262-f8aa-4ac8-bd62-66e940eeda36_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired_02f53ede-c67e-4f3e-b6e7-be5998f3431c_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
    <link:label id="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired_label_en-US" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PrincipalComponentMember_2592093b-21a5-4be6-974b-7afe2334ca7b_terseLabel_en-US" xlink:label="lab_alvo_PrincipalComponentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Component</link:label>
    <link:label id="lab_alvo_PrincipalComponentMember_label_en-US" xlink:label="lab_alvo_PrincipalComponentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Component [member]</link:label>
    <link:label id="lab_alvo_PrincipalComponentMember_documentation_en-US" xlink:label="lab_alvo_PrincipalComponentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal component [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrincipalComponentMember" xlink:href="alvo-20231231.xsd#alvo_PrincipalComponentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PrincipalComponentMember" xlink:to="lab_alvo_PrincipalComponentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_3aeb68e4-c48d-4879-9d8c-3cfabb4213c6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_498562a8-6935-4af7-910a-1a579579493a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of quantitative information about right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemuneration_b11ee4ed-6df0-46f1-93dc-8ff27264129a_totalLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total fees</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemuneration_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor's remuneration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemuneration" xlink:to="lab_ifrs-full_AuditorsRemuneration" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenLoanMember_36b4dd84-b239-410e-8a9f-ace75ae59ac8_terseLabel_en-US" xlink:label="lab_alvo_AlvogenLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Loan</link:label>
    <link:label id="lab_alvo_AlvogenLoanMember_label_en-US" xlink:label="lab_alvo_AlvogenLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Loan [member]</link:label>
    <link:label id="lab_alvo_AlvogenLoanMember_documentation_en-US" xlink:label="lab_alvo_AlvogenLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Loan [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLoanMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenLoanMember" xlink:to="lab_alvo_AlvogenLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_d9d0a4df-ba69-4f60-9fa8-8e0099523675_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities_72e945ef-4e18-4539-a12e-b789dd23426e_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain losses recognized in profit or loss excluding exchange differences fair value measurement liabilities</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in profit or loss excluding exchange differences, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SubscriptionAgreementsMember_05330c53-f17e-4024-bf90-16995f47cc97_terseLabel_en-US" xlink:label="lab_alvo_SubscriptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription Agreements</link:label>
    <link:label id="lab_alvo_SubscriptionAgreementsMember_label_en-US" xlink:label="lab_alvo_SubscriptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscription Agreements [Member]</link:label>
    <link:label id="lab_alvo_SubscriptionAgreementsMember_documentation_en-US" xlink:label="lab_alvo_SubscriptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscription agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SubscriptionAgreementsMember" xlink:href="alvo-20231231.xsd#alvo_SubscriptionAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SubscriptionAgreementsMember" xlink:to="lab_alvo_SubscriptionAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2_ae7fe9a6-64a1-4b79-a0cb-6321d033433d_terseLabel_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Alvotech Shares issued to OACB shareholders (in shares)</link:label>
    <link:label id="lab_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2_label_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Shares Issued Recognized Accordance With IFRS 2</link:label>
    <link:label id="lab_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2_documentation_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of shares issued recognized accordance with IFRS 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" xlink:to="lab_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock_41efb332-9d6e-4e90-9f34-e068a8866d3b_terseLabel_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Critical accounting judgments and key sources of estimation uncertainty</link:label>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for critical accounting judgments and key sources of estimation uncertainty explanatory [Policy Text Block]</link:label>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of accounting policy for critical accounting judgments and key sources of estimation uncertainty explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" xlink:href="alvo-20231231.xsd#alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" xlink:to="lab_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AgreementAxis_e9fc98fa-b913-4383-a3b6-e8aebc774985_terseLabel_en-US" xlink:label="lab_alvo_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_alvo_AgreementAxis_label_en-US" xlink:label="lab_alvo_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_alvo_AgreementAxis_documentation_en-US" xlink:label="lab_alvo_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementAxis" xlink:href="alvo-20231231.xsd#alvo_AgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AgreementAxis" xlink:to="lab_alvo_AgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfGoodwillTable_8111df48-a8e9-49da-ae17-dc043c14bd08_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Goodwill [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfGoodwillTable_label_en-US" xlink:label="lab_alvo_DisclosureOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Goodwill [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfGoodwillTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfGoodwillTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfGoodwillTable" xlink:to="lab_alvo_DisclosureOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LindaMcgoldrickMember_05a0ffe8-ce31-4850-a64d-5d9aea5ecc80_terseLabel_en-US" xlink:label="lab_alvo_LindaMcgoldrickMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Linda McGoldrick, Board Member</link:label>
    <link:label id="lab_alvo_LindaMcgoldrickMember_label_en-US" xlink:label="lab_alvo_LindaMcgoldrickMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Linda McGoldrick [Member]</link:label>
    <link:label id="lab_alvo_LindaMcgoldrickMember_documentation_en-US" xlink:label="lab_alvo_LindaMcgoldrickMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Linda McGoldrick.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LindaMcgoldrickMember" xlink:href="alvo-20231231.xsd#alvo_LindaMcgoldrickMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LindaMcgoldrickMember" xlink:to="lab_alvo_LindaMcgoldrickMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_27cbcd45-24f5-4c08-9e1f-883caa016b30_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenInc.SisterCompanyMember_c17c6121-cb95-4307-8d35-33fd5db4484c_terseLabel_en-US" xlink:label="lab_alvo_AlvogenInc.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Inc. - Sister company</link:label>
    <link:label id="lab_alvo_AlvogenInc.SisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenInc.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Inc. - Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenInc.SisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenInc.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Inc member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenInc.SisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenInc.SisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenInc.SisterCompanyMember" xlink:to="lab_alvo_AlvogenInc.SisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_3d15ffcd-3855-4688-9075-b22d67259ffb_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RevenueFromContractsWithCustomersAbstract_4f2d593e-5f76-432b-ad2d-aa9d4eff474a_terseLabel_en-US" xlink:label="lab_alvo_RevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Revenue and other Operating Income [Abstract]</link:label>
    <link:label id="lab_alvo_RevenueFromContractsWithCustomersAbstract_label_en-US" xlink:label="lab_alvo_RevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_alvo_RevenueFromContractsWithCustomersAbstract_documentation_en-US" xlink:label="lab_alvo_RevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of revenue and other operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RevenueFromContractsWithCustomersAbstract" xlink:href="alvo-20231231.xsd#alvo_RevenueFromContractsWithCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RevenueFromContractsWithCustomersAbstract" xlink:to="lab_alvo_RevenueFromContractsWithCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_f57a22d0-628c-46cc-9e89-6b10a7bf4f25_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_ifrs-full_Equity_861d19a5-1431-4ac0-9fec-f627cd6968e8_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_ifrs-full_Equity_a8ebaf71-a321-4f38-bcef-cd93fa1021c1_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ChangesInInventoryReserves_e5ceb8d3-a424-4379-af9b-52f706aa0a52_terseLabel_en-US" xlink:label="lab_alvo_ChangesInInventoryReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in inventory reserves</link:label>
    <link:label id="lab_alvo_ChangesInInventoryReserves_label_en-US" xlink:label="lab_alvo_ChangesInInventoryReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Inventory Reserves</link:label>
    <link:label id="lab_alvo_ChangesInInventoryReserves_documentation_en-US" xlink:label="lab_alvo_ChangesInInventoryReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Inventory Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ChangesInInventoryReserves" xlink:href="alvo-20231231.xsd#alvo_ChangesInInventoryReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ChangesInInventoryReserves" xlink:to="lab_alvo_ChangesInInventoryReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_30706f62-caee-4e76-82a1-f9019017de01_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives_39cc8d7d-5e07-4e01-98e0-0ab263770f68_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in the fair value of derivatives (see Note 28)</link:label>
    <link:label id="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_d2b53051-b138-407f-b478-e106c2af69f0_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Cost [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Cost [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about lease cost .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock_e0e2afdc-cd7e-4e3d-9466-e50cf02a1fee_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of taxation recognized in the consolidated statements of profit or loss and other comprehensive income or loss</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Detailed Information About Major Components Of Income Tax Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about major components of income tax explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DerivativeFinancialLiabilitiesRollForward_1d73a11a-3f02-42a0-a46b-4e8759a2f4cb_terseLabel_en-US" xlink:label="lab_alvo_DerivativeFinancialLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Liabilities [Roll Forward]</link:label>
    <link:label id="lab_alvo_DerivativeFinancialLiabilitiesRollForward_label_en-US" xlink:label="lab_alvo_DerivativeFinancialLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Financial Liabilities [Roll Forward]</link:label>
    <link:label id="lab_alvo_DerivativeFinancialLiabilitiesRollForward_documentation_en-US" xlink:label="lab_alvo_DerivativeFinancialLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerivativeFinancialLiabilitiesRollForward" xlink:href="alvo-20231231.xsd#alvo_DerivativeFinancialLiabilitiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward" xlink:to="lab_alvo_DerivativeFinancialLiabilitiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_db4b7e48-a5d7-4e42-96af-568e51996c73_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of detailed information about lease liabilities</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about lease liabilities explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherCurrentLiability_960a4829-40f3-443a-842b-a95933bf6de8_terseLabel_en-US" xlink:label="lab_alvo_OtherCurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_alvo_OtherCurrentLiability_label_en-US" xlink:label="lab_alvo_OtherCurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liability</link:label>
    <link:label id="lab_alvo_OtherCurrentLiability_documentation_en-US" xlink:label="lab_alvo_OtherCurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other current liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentLiability" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherCurrentLiability" xlink:to="lab_alvo_OtherCurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue_dd2560d6-a5d8-4c9d-ae91-efda76843d8e_terseLabel_en-US" xlink:label="lab_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in equity from share-based payment transactions, cash settlement, fair value</link:label>
    <link:label id="lab_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue_label_en-US" xlink:label="lab_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease In Equity From Share-Based Payment Transactions, Cash Settlement, Fair Value</link:label>
    <link:label id="lab_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue_documentation_en-US" xlink:label="lab_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease In Equity From Share-Based Payment Transactions, Cash Settlement, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:href="alvo-20231231.xsd#alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:to="lab_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PercentageChangeInForeignExchangeRate_80e8fc45-8cc2-4ae6-91cb-301631755bb9_terseLabel_en-US" xlink:label="lab_alvo_PercentageChangeInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change</link:label>
    <link:label id="lab_alvo_PercentageChangeInForeignExchangeRate_label_en-US" xlink:label="lab_alvo_PercentageChangeInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Change In Foreign Exchange Rate</link:label>
    <link:label id="lab_alvo_PercentageChangeInForeignExchangeRate_documentation_en-US" xlink:label="lab_alvo_PercentageChangeInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage change in foreign exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PercentageChangeInForeignExchangeRate" xlink:href="alvo-20231231.xsd#alvo_PercentageChangeInForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PercentageChangeInForeignExchangeRate" xlink:to="lab_alvo_PercentageChangeInForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareLineItems_6175e879-dc10-4a85-9a5a-e754946c57a2_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share [line items]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareLineItems" xlink:to="lab_ifrs-full_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_f26aab26-cb7e-4366-a9d7-8dd20bccb478_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AgreementsTypeAxis_ab2e4856-7f8c-489f-b6f8-2a7560d2c556_terseLabel_en-US" xlink:label="lab_alvo_AgreementsTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreements Type [Axis]</link:label>
    <link:label id="lab_alvo_AgreementsTypeAxis_label_en-US" xlink:label="lab_alvo_AgreementsTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements Type [Axis]</link:label>
    <link:label id="lab_alvo_AgreementsTypeAxis_documentation_en-US" xlink:label="lab_alvo_AgreementsTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreements type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementsTypeAxis" xlink:href="alvo-20231231.xsd#alvo_AgreementsTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AgreementsTypeAxis" xlink:to="lab_alvo_AgreementsTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock_9415bc55-0735-4305-b62c-df942e90c2f7_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of deferred tax recognized in the consolidated statements of financial position</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Detailed Information About Deferred Tax Recognized in the Consolidated Statements of Financial Position Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about deferred tax recognized in the consolidated statements of financial position explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfAuditFeesAbstract_a8081073-72eb-45bf-b15f-340b2809a6e1_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfAuditFeesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Audit Fees [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfAuditFeesAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfAuditFeesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Audit Fees [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfAuditFeesAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfAuditFeesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of audit fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfAuditFeesAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfAuditFeesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfAuditFeesAbstract" xlink:to="lab_alvo_DisclosureOfAuditFeesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_9180fb6a-0180-463b-8b58-eb5d9cac4928_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_f031f752-3ccd-498f-a2fb-c1f172c3b7bc_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_b50d1461-3f56-49c4-96a4-6663ef6e6785_terseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_label_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixtures and fittings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixturesAndFittingsMember" xlink:to="lab_ifrs-full_FixturesAndFittingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_86aad532-57cb-4c1e-ad5b-3ff0117fde92_terseLabel_en-US" xlink:label="lab_alvo_FasteignafelagiSmundurHf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company</link:label>
    <link:label id="lab_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_label_en-US" xlink:label="lab_alvo_FasteignafelagiSmundurHf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company [Member]</link:label>
    <link:label id="lab_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_FasteignafelagiSmundurHf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHf.SisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember" xlink:to="lab_alvo_FasteignafelagiSmundurHf.SisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherCurrentAssetsTable_aa0cb736-46d3-4879-8d1f-08f3b9492f00_terseLabel_en-US" xlink:label="lab_alvo_OtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets [Table]</link:label>
    <link:label id="lab_alvo_OtherCurrentAssetsTable_label_en-US" xlink:label="lab_alvo_OtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Table]</link:label>
    <link:label id="lab_alvo_OtherCurrentAssetsTable_documentation_en-US" xlink:label="lab_alvo_OtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsTable" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherCurrentAssetsTable" xlink:to="lab_alvo_OtherCurrentAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_0cf5a54d-4b3a-4227-bdae-3d6aeb99255c_terseLabel_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_1d7d60db-ae72-4e0e-ab9c-172eff24a03a_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">North America</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_37ed2f5a-6777-402f-95aa-01504bf877b9_negatedLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_7a27db93-7857-4c61-b00d-ce0f716b8917_terseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_2a3a3118-6ea9-468e-bcf8-35b6297d850f_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_cf511b9a-4b4f-42bf-98e9-075696c0249e_terseLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_923a84d7-eaf1-4280-a09e-d293030e22f6_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued and paid capital (presented in whole shares) (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock_9f48574e-4c4e-4279-8451-0d2d3bdb1aef_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash and Cash Equivalents</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Detailed Information About Cash and Cash Equivalents Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about cash and cash equivalents explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AmortizationMember_25750a6f-e666-4ee5-b25c-0c61ae0a3ccc_terseLabel_en-US" xlink:label="lab_alvo_AmortizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_alvo_AmortizationMember_label_en-US" xlink:label="lab_alvo_AmortizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization [member]</link:label>
    <link:label id="lab_alvo_AmortizationMember_documentation_en-US" xlink:label="lab_alvo_AmortizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationMember" xlink:href="alvo-20231231.xsd#alvo_AmortizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AmortizationMember" xlink:to="lab_alvo_AmortizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_b28f4b89-0bc9-47ec-939f-9856dc1c4f93_negatedLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenue</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_39db3827-cf21-42a2-9a6c-300b5fbd80c5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_fc62c1ad-5cd1-46c3-9cd5-f970717b0d71_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One to five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ProductRevenueMember_1b91176c-0e9a-4cc8-8fc5-6455a3b3a2e0_terseLabel_en-US" xlink:label="lab_alvo_ProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue (point in time revenue recognition)</link:label>
    <link:label id="lab_alvo_ProductRevenueMember_label_en-US" xlink:label="lab_alvo_ProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product revenue [Member]</link:label>
    <link:label id="lab_alvo_ProductRevenueMember_documentation_en-US" xlink:label="lab_alvo_ProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProductRevenueMember" xlink:href="alvo-20231231.xsd#alvo_ProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ProductRevenueMember" xlink:to="lab_alvo_ProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VariableRatesDomain_5f33314f-c0e7-40c2-9421-c71bda2d7a02_terseLabel_en-US" xlink:label="lab_alvo_VariableRatesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rates [Domain]</link:label>
    <link:label id="lab_alvo_VariableRatesDomain_label_en-US" xlink:label="lab_alvo_VariableRatesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rates [Domain]</link:label>
    <link:label id="lab_alvo_VariableRatesDomain_documentation_en-US" xlink:label="lab_alvo_VariableRatesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Rates [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableRatesDomain" xlink:href="alvo-20231231.xsd#alvo_VariableRatesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VariableRatesDomain" xlink:to="lab_alvo_VariableRatesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfLoans_b1584223-a88b-4c8f-990c-60401eefb88e_terseLabel_en-US" xlink:label="lab_alvo_NumberOfLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of loans</link:label>
    <link:label id="lab_alvo_NumberOfLoans_label_en-US" xlink:label="lab_alvo_NumberOfLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Loans</link:label>
    <link:label id="lab_alvo_NumberOfLoans_documentation_en-US" xlink:label="lab_alvo_NumberOfLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLoans" xlink:href="alvo-20231231.xsd#alvo_NumberOfLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfLoans" xlink:to="lab_alvo_NumberOfLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConversionPrice_834234d7-6415-4546-ad35-80e9840b64a7_terseLabel_en-US" xlink:label="lab_alvo_ConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_alvo_ConversionPrice_label_en-US" xlink:label="lab_alvo_ConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Price</link:label>
    <link:label id="lab_alvo_ConversionPrice_documentation_en-US" xlink:label="lab_alvo_ConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConversionPrice" xlink:href="alvo-20231231.xsd#alvo_ConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConversionPrice" xlink:to="lab_alvo_ConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_25ed97f5-b730-467b-b549-0f3340d07070_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_InterestIncomeOnCash_9864196d-0af8-41cb-b0f4-23ca971c7902_verboseLabel_en-US" xlink:label="lab_alvo_InterestIncomeOnCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_alvo_InterestIncomeOnCash_label_en-US" xlink:label="lab_alvo_InterestIncomeOnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income On Cash</link:label>
    <link:label id="lab_alvo_InterestIncomeOnCash_documentation_en-US" xlink:label="lab_alvo_InterestIncomeOnCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest income on cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InterestIncomeOnCash" xlink:href="alvo-20231231.xsd#alvo_InterestIncomeOnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_InterestIncomeOnCash" xlink:to="lab_alvo_InterestIncomeOnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_f7b38e66-bd18-4a45-97f4-29559bf468ba_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life of depreciation</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdditionalBondsIssuanceAxis_b5427f52-64d1-4778-a899-53aa1cdad633_terseLabel_en-US" xlink:label="lab_alvo_AdditionalBondsIssuanceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Bonds Issuance [Axis]</link:label>
    <link:label id="lab_alvo_AdditionalBondsIssuanceAxis_label_en-US" xlink:label="lab_alvo_AdditionalBondsIssuanceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Bonds Issuance [Axis]</link:label>
    <link:label id="lab_alvo_AdditionalBondsIssuanceAxis_documentation_en-US" xlink:label="lab_alvo_AdditionalBondsIssuanceAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional bonds issuance [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalBondsIssuanceAxis" xlink:href="alvo-20231231.xsd#alvo_AdditionalBondsIssuanceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdditionalBondsIssuanceAxis" xlink:to="lab_alvo_AdditionalBondsIssuanceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsAbstract_44efcf10-b62b-4db8-88e3-5c3e5c88f226_terseLabel_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General information about financial statements [Abstract]</link:label>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsAbstract_label_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General information about financial statements [Abstract]</link:label>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsAbstract_documentation_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General information about financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract" xlink:to="lab_alvo_GeneralInformationAboutFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture_efe94ffc-1c3d-4bef-acae-4febda5ea920_terseLabel_en-US" xlink:label="lab_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Place of business</link:label>
    <link:label id="lab_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture_label_en-US" xlink:label="lab_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal place of business of joint venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PrincipalPlaceOfBusinessOfJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture" xlink:to="lab_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenUKSisterCompanyMember_635e59cd-870c-466c-b5b3-01a0b0c94110_terseLabel_en-US" xlink:label="lab_alvo_AlvogenUKSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen UK - Sister company</link:label>
    <link:label id="lab_alvo_AlvogenUKSisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenUKSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen UK - Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenUKSisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenUKSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen UK member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenUKSisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenUKSisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenUKSisterCompanyMember" xlink:to="lab_alvo_AlvogenUKSisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_9a2bb474-8522-487b-a21f-7891eec2f9fb_terseLabel_en-US" xlink:label="lab_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two</link:label>
    <link:label id="lab_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_label_en-US" xlink:label="lab_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two [member]</link:label>
    <link:label id="lab_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_documentation_en-US" xlink:label="lab_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amendment to outstanding bonds november sixteenth two thousand and twenty two [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember" xlink:href="alvo-20231231.xsd#alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember" xlink:to="lab_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenEhf.SisterCompanyMember_6c538fe1-b18f-4435-881a-6097d1bdd91c_terseLabel_en-US" xlink:label="lab_alvo_AlvogenEhf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen ehf. - Sister company</link:label>
    <link:label id="lab_alvo_AlvogenEhf.SisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenEhf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen ehf. - Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenEhf.SisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenEhf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEhf.SisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenEhf.SisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenEhf.SisterCompanyMember" xlink:to="lab_alvo_AlvogenEhf.SisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExchangeOfClassAOacbOrdinarySharesMember_e34ede86-0016-42bc-ae82-533f5feaa2ea_terseLabel_en-US" xlink:label="lab_alvo_ExchangeOfClassAOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange of Class A OACB Ordinary Shares</link:label>
    <link:label id="lab_alvo_ExchangeOfClassAOacbOrdinarySharesMember_label_en-US" xlink:label="lab_alvo_ExchangeOfClassAOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange of Class A OACB Ordinary Shares [Member]</link:label>
    <link:label id="lab_alvo_ExchangeOfClassAOacbOrdinarySharesMember_documentation_en-US" xlink:label="lab_alvo_ExchangeOfClassAOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange of class A OACB ordinary dhares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExchangeOfClassAOacbOrdinarySharesMember" xlink:href="alvo-20231231.xsd#alvo_ExchangeOfClassAOacbOrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExchangeOfClassAOacbOrdinarySharesMember" xlink:to="lab_alvo_ExchangeOfClassAOacbOrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_e0c7f8a5-bb50-48ba-9fad-af85d95dbcb6_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash generated from financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_1bf9ce0e-4296-422a-bdac-ab2062580a5d_totalLabel_en-US" xlink:label="lab_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
    <link:label id="lab_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_e886d9fa-5aa3-4ffa-ad32-e1e19c0e2be3_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total depreciation, amortization and impairment expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_2877ec74-fa45-4d16-b25f-8579071ddc08_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Cost [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Cost [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about lease cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_2a2c5292-94d0-4c54-b78d-86d0076a3570_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Property Plant And Equipment [Abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_InventoryReserves_b1484582-a1a8-47ac-b1f0-aca12c3a3d1f_negatedLabel_en-US" xlink:label="lab_alvo_InventoryReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory reserves</link:label>
    <link:label id="lab_alvo_InventoryReserves_label_en-US" xlink:label="lab_alvo_InventoryReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Reserves</link:label>
    <link:label id="lab_alvo_InventoryReserves_documentation_en-US" xlink:label="lab_alvo_InventoryReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InventoryReserves" xlink:href="alvo-20231231.xsd#alvo_InventoryReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_InventoryReserves" xlink:to="lab_alvo_InventoryReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_a06ba945-a603-4e22-931e-d736a324050e_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on debt and borrowings</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_05314d07-d8e2-48f6-87b1-3f03362af47b_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of fair value of derivative financial instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems" xlink:to="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_4436cbd8-4e33-42f6-ae69-5ae403d15a96_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of consolidated statements of financial position</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination_5f4d5e79-5660-419f-be33-9c9443dbeb31_terseLabel_en-US" xlink:label="lab_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of year for issuing Shares after the closing of the Business Combination</link:label>
    <link:label id="lab_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination_label_en-US" xlink:label="lab_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of year for issuing Shares after the closing of the Business Combination</link:label>
    <link:label id="lab_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination_documentation_en-US" xlink:label="lab_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of year for issuing Shares after the closing of the Business Combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" xlink:href="alvo-20231231.xsd#alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" xlink:to="lab_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentPayablesToRelatedParties_331c4396-6e94-47cf-bfb2-dac91b1b649a_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentPayablesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liability to related party</link:label>
    <link:label id="lab_ifrs-full_NoncurrentPayablesToRelatedParties_fcda0d4d-4c19-4764-bb6b-336a7a81745b_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentPayablesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liability to related party (measured at amortized cost)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentPayablesToRelatedParties_label_en-US" xlink:label="lab_ifrs-full_NoncurrentPayablesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current payables to related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPayablesToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPayablesToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPayablesToRelatedParties" xlink:to="lab_ifrs-full_NoncurrentPayablesToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_d4b6010b-d48c-4f3f-b64e-1bc39a204964_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Reconciliation Of Contract Assets And Contract Liabilities</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheAxis_489540e3-be38-4dcf-bcf3-f62fcc0eee2e_terseLabel_en-US" xlink:label="lab_alvo_TrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche [axis]</link:label>
    <link:label id="lab_alvo_TrancheAxis_label_en-US" xlink:label="lab_alvo_TrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche [Axis]</link:label>
    <link:label id="lab_alvo_TrancheAxis_documentation_en-US" xlink:label="lab_alvo_TrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAxis" xlink:href="alvo-20231231.xsd#alvo_TrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheAxis" xlink:to="lab_alvo_TrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_952fce99-5892-4526-8a3f-c017d851ced1_verboseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of right of use assets (see Note 13)</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_5496d4a1-be1d-4119-983e-e6ed5b4933cc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_dbc10506-a020-4dd3-a753-d4bd448a2479_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Depreciation of right of use assets (see Note 13)</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IS_fd5ac93a-08ba-4090-8d27-2ea86c8160a4_terseLabel_en-US" xlink:label="lab_country_IS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICELAND</link:label>
    <link:label id="lab_country_IS_label_en-US" xlink:label="lab_country_IS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IS" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IS" xlink:to="lab_country_IS" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReservesMember_247f7d2b-9bb8-4808-99f8-87c196092233_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReservesMember_label_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember" xlink:to="lab_ifrs-full_OtherReservesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowings_bda978bd-4036-4a47-be86-10acf9282f06_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_9c7474a9-5e86-458e-81b7-ae5ef5bde74d_verboseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total non-current borrowings</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassOfStock1Domain_98d5aadb-41f6-46fa-a00a-e8f70cf2e147_terseLabel_en-US" xlink:label="lab_alvo_ClassOfStock1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Domain]</link:label>
    <link:label id="lab_alvo_ClassOfStock1Domain_label_en-US" xlink:label="lab_alvo_ClassOfStock1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Stock 1 [Domain]</link:label>
    <link:label id="lab_alvo_ClassOfStock1Domain_documentation_en-US" xlink:label="lab_alvo_ClassOfStock1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStock1Domain" xlink:href="alvo-20231231.xsd#alvo_ClassOfStock1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassOfStock1Domain" xlink:to="lab_alvo_ClassOfStock1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_c857ab94-39cd-4c91-8de4-83f9248d347d_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrants</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsRepurchaseAmount_34aa300c-9b62-4e27-bc79-95f805058c45_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings repurchase amount</link:label>
    <link:label id="lab_alvo_BorrowingsRepurchaseAmount_label_en-US" xlink:label="lab_alvo_BorrowingsRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Repurchase Amount</link:label>
    <link:label id="lab_alvo_BorrowingsRepurchaseAmount_documentation_en-US" xlink:label="lab_alvo_BorrowingsRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings repurchase amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRepurchaseAmount" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsRepurchaseAmount" xlink:to="lab_alvo_BorrowingsRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CurrentTaxAbstract_87d665cf-5f60-4dcc-9e38-6b00623ad508_terseLabel_en-US" xlink:label="lab_alvo_CurrentTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax</link:label>
    <link:label id="lab_alvo_CurrentTaxAbstract_label_en-US" xlink:label="lab_alvo_CurrentTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Tax [Abstract]</link:label>
    <link:label id="lab_alvo_CurrentTaxAbstract_documentation_en-US" xlink:label="lab_alvo_CurrentTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentTaxAbstract" xlink:href="alvo-20231231.xsd#alvo_CurrentTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CurrentTaxAbstract" xlink:to="lab_alvo_CurrentTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IntangibleAssetsOtherThanGoodwillRollForward_ad262e1a-2142-478c-bb47-98c5f3cd3019_terseLabel_en-US" xlink:label="lab_alvo_IntangibleAssetsOtherThanGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets Other Than Goodwill [Roll Forward]</link:label>
    <link:label id="lab_alvo_IntangibleAssetsOtherThanGoodwillRollForward_label_en-US" xlink:label="lab_alvo_IntangibleAssetsOtherThanGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Other Than Goodwill [Roll Forward]</link:label>
    <link:label id="lab_alvo_IntangibleAssetsOtherThanGoodwillRollForward_documentation_en-US" xlink:label="lab_alvo_IntangibleAssetsOtherThanGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward" xlink:href="alvo-20231231.xsd#alvo_IntangibleAssetsOtherThanGoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward" xlink:to="lab_alvo_IntangibleAssetsOtherThanGoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_aa7dfc45-e467-4bb5-87ed-8cd633debe24_terseLabel_en-US" xlink:label="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility rate</link:label>
    <link:label id="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Historical volatility for shares, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="lab_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsMember_544bc5fe-395c-4417-a5a0-df2ccb1be4eb_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable inputs [member]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsMember_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable inputs [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsMember" xlink:to="lab_ifrs-full_UnobservableInputsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock_06ea0714-7894-4f8b-b26a-794f9189d2e1_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities of Financial Assets and Liabilities</link:label>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of contractual maturities of financial assets and financial liabilities explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechUsaIncMember_efda9d01-aae5-429d-8924-80c28fc0f391_terseLabel_en-US" xlink:label="lab_alvo_AlvotechUsaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech USA Inc</link:label>
    <link:label id="lab_alvo_AlvotechUsaIncMember_label_en-US" xlink:label="lab_alvo_AlvotechUsaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech USA Inc [Member]</link:label>
    <link:label id="lab_alvo_AlvotechUsaIncMember_documentation_en-US" xlink:label="lab_alvo_AlvotechUsaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech USA Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechUsaIncMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechUsaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechUsaIncMember" xlink:to="lab_alvo_AlvotechUsaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LossOnExtinguishmentOfTheLeaseLiability_f3657187-db2c-451d-a24e-24849707653a_terseLabel_en-US" xlink:label="lab_alvo_LossOnExtinguishmentOfTheLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of the lease liability</link:label>
    <link:label id="lab_alvo_LossOnExtinguishmentOfTheLeaseLiability_label_en-US" xlink:label="lab_alvo_LossOnExtinguishmentOfTheLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Extinguishment of the lease liability</link:label>
    <link:label id="lab_alvo_LossOnExtinguishmentOfTheLeaseLiability_documentation_en-US" xlink:label="lab_alvo_LossOnExtinguishmentOfTheLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of the lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossOnExtinguishmentOfTheLeaseLiability" xlink:href="alvo-20231231.xsd#alvo_LossOnExtinguishmentOfTheLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LossOnExtinguishmentOfTheLeaseLiability" xlink:to="lab_alvo_LossOnExtinguishmentOfTheLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenLuxHoldingsSRLMember_67356cf1-2c43-4fb3-8aea-cfe751f4c910_terseLabel_en-US" xlink:label="lab_alvo_AlvogenLuxHoldingsSRLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company</link:label>
    <link:label id="lab_alvo_AlvogenLuxHoldingsSRLMember_label_en-US" xlink:label="lab_alvo_AlvogenLuxHoldingsSRLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Lux Holdings S r l [Member]</link:label>
    <link:label id="lab_alvo_AlvogenLuxHoldingsSRLMember_documentation_en-US" xlink:label="lab_alvo_AlvogenLuxHoldingsSRLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Lux Holdings S r l member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLuxHoldingsSRLMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenLuxHoldingsSRLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenLuxHoldingsSRLMember" xlink:to="lab_alvo_AlvogenLuxHoldingsSRLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_b6725452-d16b-4ec8-9967-b6d6901be09b_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_f7f8357b-53f3-4ffa-bd63-a170ebae5b55_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_HumiraMember_242a5f3d-e0c9-45f1-a3e4-180fab5ef9f8_terseLabel_en-US" xlink:label="lab_alvo_HumiraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Humira</link:label>
    <link:label id="lab_alvo_HumiraMember_label_en-US" xlink:label="lab_alvo_HumiraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Humira [Member]</link:label>
    <link:label id="lab_alvo_HumiraMember_documentation_en-US" xlink:label="lab_alvo_HumiraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Humira</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HumiraMember" xlink:href="alvo-20231231.xsd#alvo_HumiraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_HumiraMember" xlink:to="lab_alvo_HumiraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLoss_036163c6-1382-4c37-b23a-91267b20afaf_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLoss_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLoss" xlink:to="lab_ifrs-full_ImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_ebf2eed8-0762-4142-a634-3d5073167159_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_776ef8b3-8767-4d07-ac8c-f8e659f40638_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prior year</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_7dacbf4b-438d-4e33-8fe8-0f64af6a7eae_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior year deferred tax impact</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for deferred tax of prior periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:to="lab_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassOfStocksAxis_22fe44ef-ddba-415c-b517-4a9a5cc6b384_terseLabel_en-US" xlink:label="lab_alvo_ClassOfStocksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of stocks [axis]</link:label>
    <link:label id="lab_alvo_ClassOfStocksAxis_label_en-US" xlink:label="lab_alvo_ClassOfStocksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Stocks [Axis]</link:label>
    <link:label id="lab_alvo_ClassOfStocksAxis_documentation_en-US" xlink:label="lab_alvo_ClassOfStocksAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of stocks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStocksAxis" xlink:href="alvo-20231231.xsd#alvo_ClassOfStocksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassOfStocksAxis" xlink:to="lab_alvo_ClassOfStocksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FasteignaflagiEyjlfurhfMember_d2fe44b2-eac0-46ec-af22-b7aeb403592a_terseLabel_en-US" xlink:label="lab_alvo_FasteignaflagiEyjlfurhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company</link:label>
    <link:label id="lab_alvo_FasteignaflagiEyjlfurhfMember_label_en-US" xlink:label="lab_alvo_FasteignaflagiEyjlfurhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fasteignaflagi Eyjlfurhf [Member]</link:label>
    <link:label id="lab_alvo_FasteignaflagiEyjlfurhfMember_documentation_en-US" xlink:label="lab_alvo_FasteignaflagiEyjlfurhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fasteignaflagi Eyjlfurhf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignaflagiEyjlfurhfMember" xlink:href="alvo-20231231.xsd#alvo_FasteignaflagiEyjlfurhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FasteignaflagiEyjlfurhfMember" xlink:to="lab_alvo_FasteignaflagiEyjlfurhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_9db976b6-dce1-4ac3-9d2d-455d1f39c2d2_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_9fecf5e8-d3b3-4ee6-8f8b-120073b7758f_verboseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsRepurchasedFaceAmount_eef20e1f-e649-4770-87d0-f805f6d06266_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings repurchased face amount</link:label>
    <link:label id="lab_alvo_BorrowingsRepurchasedFaceAmount_label_en-US" xlink:label="lab_alvo_BorrowingsRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Repurchased Face Amount</link:label>
    <link:label id="lab_alvo_BorrowingsRepurchasedFaceAmount_documentation_en-US" xlink:label="lab_alvo_BorrowingsRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings repurchased face amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRepurchasedFaceAmount" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsRepurchasedFaceAmount" xlink:to="lab_alvo_BorrowingsRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassOfStocksDomain_f60eef4f-d684-4196-a813-49ebe364804e_terseLabel_en-US" xlink:label="lab_alvo_ClassOfStocksDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stocks [Domain]</link:label>
    <link:label id="lab_alvo_ClassOfStocksDomain_label_en-US" xlink:label="lab_alvo_ClassOfStocksDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Stocks [Domain]</link:label>
    <link:label id="lab_alvo_ClassOfStocksDomain_documentation_en-US" xlink:label="lab_alvo_ClassOfStocksDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Stocks [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStocksDomain" xlink:href="alvo-20231231.xsd#alvo_ClassOfStocksDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassOfStocksDomain" xlink:to="lab_alvo_ClassOfStocksDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateRiskMember_1bd03608-6c1e-4851-bd0c-3e84d9a47098_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate risk</link:label>
    <link:label id="lab_ifrs-full_InterestRateRiskMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest rate risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateRiskMember" xlink:to="lab_ifrs-full_InterestRateRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_571cb123-88b2-452c-9001-abaf35149ff0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs arising on share issue</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_8c4bab39-9543-46a4-a103-5fad8126dd8a_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about salaries and other emloyee expenses included in consolidated statements of profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_3aa9d5aa-c29d-4803-a196-f5d92843ff0d_terseLabel_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations satisfied over time</link:label>
    <link:label id="lab_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_label_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance obligations satisfied over time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:to="lab_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_901104a3-c669-412a-abe2-b637eee17ccc_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Current Assets</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Detailed Information About Other Current Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about other current assets explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRevenue_34c695e4-fa40-45e4-9bb7-704da921cac3_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_label_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_8de5a731-4012-4e46-a002-2b73736d1388_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_59af8a2d-79fd-4f66-bbbd-8e82c89c68ea_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d722d633-94b9-4b10-bed8-7abee2490174_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdalvoUKMember_042584aa-4f00-432c-9a6b-381386cb87f6_terseLabel_en-US" xlink:label="lab_alvo_AdalvoUKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adalvo UK - Sister company</link:label>
    <link:label id="lab_alvo_AdalvoUKMember_label_en-US" xlink:label="lab_alvo_AdalvoUKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adalvo UK [Member]</link:label>
    <link:label id="lab_alvo_AdalvoUKMember_documentation_en-US" xlink:label="lab_alvo_AdalvoUKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adalvo UK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdalvoUKMember" xlink:href="alvo-20231231.xsd#alvo_AdalvoUKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdalvoUKMember" xlink:to="lab_alvo_AdalvoUKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_8f180aa7-e5ad-40bc-a0ce-bc4bbdd4c4c3_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about salaries and other emloyee expenses included in consolidated statements of profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GrossPipeFinancingFeesPaid_03e21e5b-28ca-49da-b901-b770b5b86634_negatedLabel_en-US" xlink:label="lab_alvo_GrossPipeFinancingFeesPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross PIPE Financing fees paid</link:label>
    <link:label id="lab_alvo_GrossPipeFinancingFeesPaid_label_en-US" xlink:label="lab_alvo_GrossPipeFinancingFeesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Pipe Financing Fees Paid</link:label>
    <link:label id="lab_alvo_GrossPipeFinancingFeesPaid_documentation_en-US" xlink:label="lab_alvo_GrossPipeFinancingFeesPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross pipe financing fees paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GrossPipeFinancingFeesPaid" xlink:href="alvo-20231231.xsd#alvo_GrossPipeFinancingFeesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GrossPipeFinancingFeesPaid" xlink:to="lab_alvo_GrossPipeFinancingFeesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed_a009f419-4636-4abd-a1ab-3a4adbae62a7_terseLabel_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration transferred Loans Assumed</link:label>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed_label_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition Consideration Transferred Loans Assumed</link:label>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed_documentation_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration transferred Loans Assumed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredLoansAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed" xlink:to="lab_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ComponentOfBondsPayableDomain_ff5e1813-7e9c-45cb-8b05-65a49a430b88_terseLabel_en-US" xlink:label="lab_alvo_ComponentOfBondsPayableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component Of Bonds Payable [Domain]</link:label>
    <link:label id="lab_alvo_ComponentOfBondsPayableDomain_label_en-US" xlink:label="lab_alvo_ComponentOfBondsPayableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Component Of Bonds Payable [Domain]</link:label>
    <link:label id="lab_alvo_ComponentOfBondsPayableDomain_documentation_en-US" xlink:label="lab_alvo_ComponentOfBondsPayableDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Component of bonds payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfBondsPayableDomain" xlink:href="alvo-20231231.xsd#alvo_ComponentOfBondsPayableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ComponentOfBondsPayableDomain" xlink:to="lab_alvo_ComponentOfBondsPayableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdditionalExtensionPremiumToBondholders_810c28b1-c0b2-4b69-ab8f-c2bca000e6c8_terseLabel_en-US" xlink:label="lab_alvo_AdditionalExtensionPremiumToBondholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional extension premium to bondholders</link:label>
    <link:label id="lab_alvo_AdditionalExtensionPremiumToBondholders_label_en-US" xlink:label="lab_alvo_AdditionalExtensionPremiumToBondholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Extension Premium To Bondholders</link:label>
    <link:label id="lab_alvo_AdditionalExtensionPremiumToBondholders_documentation_en-US" xlink:label="lab_alvo_AdditionalExtensionPremiumToBondholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional extension premium to bondholders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalExtensionPremiumToBondholders" xlink:href="alvo-20231231.xsd#alvo_AdditionalExtensionPremiumToBondholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdditionalExtensionPremiumToBondholders" xlink:to="lab_alvo_AdditionalExtensionPremiumToBondholders" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_c0e426a5-1800-4d9c-9b55-170b5da90e5a_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_f9fd00cf-1116-45a6-b005-7d3b2cb2caa1_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses_fbf78c58-0296-4e90-a76f-1a3703471140_verboseLabel_en-US" xlink:label="lab_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-recognition of tax losses</link:label>
    <link:label id="lab_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses_label_en-US" xlink:label="lab_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Nonrecognition of Tax Losses</link:label>
    <link:label id="lab_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses_documentation_en-US" xlink:label="lab_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax rate effect of non-recognition&#160;of tax losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses" xlink:href="alvo-20231231.xsd#alvo_TaxRateEffectOfNonrecognitionOfTaxLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses" xlink:to="lab_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures_e0546272-d2ea-447c-a1c8-d0f43ab7e78f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in joint ventures</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for investments in joint ventures [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_8e43cae3-08f5-4160-82f5-41cd95e45cfa_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassOfWarrantsOrRightsOutstanding_4c53f1ef-b982-4ff6-b215-fab6dadee9a9_terseLabel_en-US" xlink:label="lab_alvo_ClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrants or rights outstanding (in shares)</link:label>
    <link:label id="lab_alvo_ClassOfWarrantsOrRightsOutstanding_label_en-US" xlink:label="lab_alvo_ClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Outstanding</link:label>
    <link:label id="lab_alvo_ClassOfWarrantsOrRightsOutstanding_documentation_en-US" xlink:label="lab_alvo_ClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsOutstanding" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassOfWarrantsOrRightsOutstanding" xlink:to="lab_alvo_ClassOfWarrantsOrRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_40806b0f-1320-4e19-a4e6-b6a4eb9027c4_terseLabel_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line items by function [member]</link:label>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_label_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line items by function [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LineItemsByFunctionMember" xlink:to="lab_ifrs-full_LineItemsByFunctionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_dad9db50-cfeb-4b6a-ab3a-e362412a54b8_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_Inventories_88ec89c7-a8fc-42ea-99a4-26c21db6ea83_totalLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Balance at 31 December</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_99b56b6b-4dd5-4895-a144-064197875668_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_84eff595-990d-448c-8a48-7287d8e34bf1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_1a49bdbb-ba3e-474a-8878-1af4eddef57c_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_3dcd03e4-ce2f-44b7-8462-9bf80a6493d2_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PrincipalAndAccruedInterestComponent.Member_4392d096-01fa-467e-a267-9442e03f1f57_terseLabel_en-US" xlink:label="lab_alvo_PrincipalAndAccruedInterestComponent.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal And Accrued Interest Component.</link:label>
    <link:label id="lab_alvo_PrincipalAndAccruedInterestComponent.Member_label_en-US" xlink:label="lab_alvo_PrincipalAndAccruedInterestComponent.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal And Accrued Interest Component. [member]</link:label>
    <link:label id="lab_alvo_PrincipalAndAccruedInterestComponent.Member_documentation_en-US" xlink:label="lab_alvo_PrincipalAndAccruedInterestComponent.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal and accrued interest component [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrincipalAndAccruedInterestComponent.Member" xlink:href="alvo-20231231.xsd#alvo_PrincipalAndAccruedInterestComponent.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PrincipalAndAccruedInterestComponent.Member" xlink:to="lab_alvo_PrincipalAndAccruedInterestComponent.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock_cf474a13-f246-49f6-aff3-3d2dfa54950d_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Impact on the Groups Operations</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Foreign Exchange Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of foreign exchange rate explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3eaabf01-20cd-4d4a-85e3-15c8d733d401_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConsentFeesToBondholdersMember_c1f12a46-1a14-4735-9218-628a9388f7f5_terseLabel_en-US" xlink:label="lab_alvo_ConsentFeesToBondholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consent Fees To Bondholders</link:label>
    <link:label id="lab_alvo_ConsentFeesToBondholdersMember_label_en-US" xlink:label="lab_alvo_ConsentFeesToBondholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consent Fees To Bondholders [member]</link:label>
    <link:label id="lab_alvo_ConsentFeesToBondholdersMember_documentation_en-US" xlink:label="lab_alvo_ConsentFeesToBondholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consent fees to bondholders [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConsentFeesToBondholdersMember" xlink:href="alvo-20231231.xsd#alvo_ConsentFeesToBondholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConsentFeesToBondholdersMember" xlink:to="lab_alvo_ConsentFeesToBondholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_15473f5a-6188-410f-8108-071e3d560a35_terseLabel_en-US" xlink:label="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech and CCHT Biopharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_a1d0737b-6fde-4e33-99ae-a69c054537a5_verboseLabel_en-US" xlink:label="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Alvotech &amp; CCHN Biopharmaceutical Co., Ltd</link:label>
    <link:label id="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech and CCHN Biopharmaceutical Co Ltd [Member]</link:label>
    <link:label id="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech and CCHN Biopharmaceutical Co Ltd member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember" xlink:to="lab_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_95ba3c90-747a-41f7-8359-bd0f5aba5160_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities to related parties</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current payables to related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_71e6537c-4ba9-4af6-85ea-1ab1e21aecbf_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPayments_b96c90b5-04ef-4459-833a-3b4cec9fbe41_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPayments" xlink:to="lab_ifrs-full_ReserveOfSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_6e8a5c4c-4f89-46d3-ba21-b31e5b3cf06c_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_EliminationOfPredecessorOrdinaryShares_4333260c-010d-4035-9a57-6a378092ad70_terseLabel_en-US" xlink:label="lab_alvo_EliminationOfPredecessorOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elimination of Predecessor Ordinary Shares (in shares)</link:label>
    <link:label id="lab_alvo_EliminationOfPredecessorOrdinaryShares_label_en-US" xlink:label="lab_alvo_EliminationOfPredecessorOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elimination of Predecessor Ordinary Shares</link:label>
    <link:label id="lab_alvo_EliminationOfPredecessorOrdinaryShares_documentation_en-US" xlink:label="lab_alvo_EliminationOfPredecessorOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elimination of predecessor ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EliminationOfPredecessorOrdinaryShares" xlink:href="alvo-20231231.xsd#alvo_EliminationOfPredecessorOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_EliminationOfPredecessorOrdinaryShares" xlink:to="lab_alvo_EliminationOfPredecessorOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenSpainSlMember_589cefbe-53cc-4afd-83c8-5afc06d16444_terseLabel_en-US" xlink:label="lab_alvo_AlvogenSpainSlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Spain SL - Sister company</link:label>
    <link:label id="lab_alvo_AlvogenSpainSlMember_label_en-US" xlink:label="lab_alvo_AlvogenSpainSlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Spain SL [Member]</link:label>
    <link:label id="lab_alvo_AlvogenSpainSlMember_documentation_en-US" xlink:label="lab_alvo_AlvogenSpainSlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Spain SL member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenSpainSlMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenSpainSlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenSpainSlMember" xlink:to="lab_alvo_AlvogenSpainSlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DetailsDomain_876a3520-99a3-4b96-8808-f21099d5ab0c_terseLabel_en-US" xlink:label="lab_alvo_DetailsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Details [Domain]</link:label>
    <link:label id="lab_alvo_DetailsDomain_label_en-US" xlink:label="lab_alvo_DetailsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Details [Domain]</link:label>
    <link:label id="lab_alvo_DetailsDomain_documentation_en-US" xlink:label="lab_alvo_DetailsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Details [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsDomain" xlink:href="alvo-20231231.xsd#alvo_DetailsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DetailsDomain" xlink:to="lab_alvo_DetailsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_1c4323d1-d6b7-4af3-8dab-5f2c3d75326b_terseLabel_en-US" xlink:label="lab_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lotus Pharmaceuticals Co. Ltd. - Sister company</link:label>
    <link:label id="lab_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_label_en-US" xlink:label="lab_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lotus Pharmaceuticals Co. Ltd. - Sister company [Member]</link:label>
    <link:label id="lab_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lotus Pharmaceuticals CoLtd member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember" xlink:to="lab_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingConversionPeriodPriorToExtinguishment_fee7b8ab-a068-4cdd-a73c-c70d572ea962_terseLabel_en-US" xlink:label="lab_alvo_BorrowingConversionPeriodPriorToExtinguishment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion period prior to extinguishment</link:label>
    <link:label id="lab_alvo_BorrowingConversionPeriodPriorToExtinguishment_label_en-US" xlink:label="lab_alvo_BorrowingConversionPeriodPriorToExtinguishment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Conversion Period Prior To Extinguishment</link:label>
    <link:label id="lab_alvo_BorrowingConversionPeriodPriorToExtinguishment_documentation_en-US" xlink:label="lab_alvo_BorrowingConversionPeriodPriorToExtinguishment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Conversion Period Prior To Extinguishment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingConversionPeriodPriorToExtinguishment" xlink:href="alvo-20231231.xsd#alvo_BorrowingConversionPeriodPriorToExtinguishment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingConversionPeriodPriorToExtinguishment" xlink:to="lab_alvo_BorrowingConversionPeriodPriorToExtinguishment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0065f610-97dd-46a7-badf-d9b694080d8b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables_5eaf0e98-4c67-45c5-8d1b-66a46aac249b_negatedLabel_en-US" xlink:label="lab_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts transferred to trade receivables</link:label>
    <link:label id="lab_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables_label_en-US" xlink:label="lab_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Assets Additions Amounts Transferred to Trade Receivables</link:label>
    <link:label id="lab_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables_documentation_en-US" xlink:label="lab_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract assets additions amounts transferred to trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables" xlink:to="lab_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassAOacbOrdinarySharesMember_92b5ffe8-62e3-410f-8def-2327bd0bf2eb_terseLabel_en-US" xlink:label="lab_alvo_ClassAOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A OACB Ordinary Shares</link:label>
    <link:label id="lab_alvo_ClassAOacbOrdinarySharesMember_label_en-US" xlink:label="lab_alvo_ClassAOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A OACB Ordinary Shares [Member]</link:label>
    <link:label id="lab_alvo_ClassAOacbOrdinarySharesMember_documentation_en-US" xlink:label="lab_alvo_ClassAOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class A OACB ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassAOacbOrdinarySharesMember" xlink:href="alvo-20231231.xsd#alvo_ClassAOacbOrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassAOacbOrdinarySharesMember" xlink:to="lab_alvo_ClassAOacbOrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqPharmaPartnersSarlMember_a5a52547-640c-4146-998b-d81f3cf320eb_terseLabel_en-US" xlink:label="lab_alvo_AztiqPharmaPartnersSarlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq Pharma Partners Sarl</link:label>
    <link:label id="lab_alvo_AztiqPharmaPartnersSarlMember_label_en-US" xlink:label="lab_alvo_AztiqPharmaPartnersSarlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq Pharma Partners Sarl [Member]</link:label>
    <link:label id="lab_alvo_AztiqPharmaPartnersSarlMember_documentation_en-US" xlink:label="lab_alvo_AztiqPharmaPartnersSarlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq Pharma Partners S.a r.l.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqPharmaPartnersSarlMember" xlink:href="alvo-20231231.xsd#alvo_AztiqPharmaPartnersSarlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqPharmaPartnersSarlMember" xlink:to="lab_alvo_AztiqPharmaPartnersSarlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_d4aba5ec-bfbe-4dcd-b9c5-20a3fdccde89_terseLabel_en-US" xlink:label="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclousre of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium [Line Items]</link:label>
    <link:label id="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_label_en-US" xlink:label="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclousre of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium [Line Items]</link:label>
    <link:label id="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_documentation_en-US" xlink:label="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclousre of detailed information about movements in ordinary shares, share capital and share premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems" xlink:to="lab_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_4a740516-918b-459f-8f92-e76bebb77fe2_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_73d60d28-30fc-4296-83ea-13876ff14f57_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities_89090abc-a627-4593-bd35-d79fb4fb4868_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through cumulative catch-up adjustments to revenue arising from change in measure of progress, contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_bd8a9ab6-1d62-4b77-a2a8-8ef11f62fe4f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncomeTaxExpense_2a8f28d7-8d4c-4bf5-a7b4-61a4086e9ed1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncomeTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for income tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock_dbdfa831-79f1-4555-a2ec-117b17d9ba5e_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of fair value of derivative financial instruments explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativesMember_e5ba536a-6b1c-45ff-ab39-ccae90362336_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_ifrs-full_DerivativesMember_label_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativesMember" xlink:to="lab_ifrs-full_DerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclousreOfGoodwillAbstract_8f0b8e1d-dcf5-421a-8221-12412a76bd2b_terseLabel_en-US" xlink:label="lab_alvo_DisclousreOfGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Goodwill [Abstract]</link:label>
    <link:label id="lab_alvo_DisclousreOfGoodwillAbstract_label_en-US" xlink:label="lab_alvo_DisclousreOfGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Goodwill [Abstract]</link:label>
    <link:label id="lab_alvo_DisclousreOfGoodwillAbstract_documentation_en-US" xlink:label="lab_alvo_DisclousreOfGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclousre of goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfGoodwillAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclousreOfGoodwillAbstract" xlink:to="lab_alvo_DisclousreOfGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxTable_f727059d-b954-4e39-91c1-7b685b569f27_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxTable_label_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable" xlink:to="lab_alvo_DisclosureOfIncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_b01fded0-f345-4481-aa01-6c13755fa863_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_207de298-9ff7-4dfa-840d-2ed1541ef3de_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AtpHoldingsEhfMember_3fd2d76b-f167-4819-b856-c14ceda97a53_terseLabel_en-US" xlink:label="lab_alvo_AtpHoldingsEhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATP Holdings ehf. - Sister company</link:label>
    <link:label id="lab_alvo_AtpHoldingsEhfMember_label_en-US" xlink:label="lab_alvo_AtpHoldingsEhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATP Holdings ehf [Member]</link:label>
    <link:label id="lab_alvo_AtpHoldingsEhfMember_documentation_en-US" xlink:label="lab_alvo_AtpHoldingsEhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ATP Holdings ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AtpHoldingsEhfMember" xlink:href="alvo-20231231.xsd#alvo_AtpHoldingsEhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AtpHoldingsEhfMember" xlink:to="lab_alvo_AtpHoldingsEhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FasteignafelagidEyjolfurHf.Member_5e75f8df-e710-4d75-bfa6-f089318642eb_terseLabel_en-US" xlink:label="lab_alvo_FasteignafelagidEyjolfurHf.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fasteignafelagid Eyjolfur hf.</link:label>
    <link:label id="lab_alvo_FasteignafelagidEyjolfurHf.Member_label_en-US" xlink:label="lab_alvo_FasteignafelagidEyjolfurHf.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fasteignafelagid Eyjolfur hf. [Member]</link:label>
    <link:label id="lab_alvo_FasteignafelagidEyjolfurHf.Member_documentation_en-US" xlink:label="lab_alvo_FasteignafelagidEyjolfurHf.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fasteignafelagid Eyjolfur hf.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagidEyjolfurHf.Member" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagidEyjolfurHf.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FasteignafelagidEyjolfurHf.Member" xlink:to="lab_alvo_FasteignafelagidEyjolfurHf.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue_c206e1d0-064b-4d7e-8c29-d8766d54ab36_terseLabel_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SARs Settlement (Note 22)</link:label>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue_label_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of Shares on Settlement of Share Appreciation Rights Value</link:label>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue_documentation_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of shares on settlement of share appreciation rights value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue" xlink:to="lab_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_4d3c3c8a-0cb3-403f-9763-5bbfdea644fc_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PrivatePlacementsMember_bca3778a-cea4-49cf-afbb-2128a8380568_terseLabel_en-US" xlink:label="lab_alvo_PrivatePlacementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_alvo_PrivatePlacementsMember_label_en-US" xlink:label="lab_alvo_PrivatePlacementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placements [Member]</link:label>
    <link:label id="lab_alvo_PrivatePlacementsMember_documentation_en-US" xlink:label="lab_alvo_PrivatePlacementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private placements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrivatePlacementsMember" xlink:href="alvo-20231231.xsd#alvo_PrivatePlacementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PrivatePlacementsMember" xlink:to="lab_alvo_PrivatePlacementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_6556afd2-8b81-4643-8230-78f3c0531829_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_649677e8-67e0-49b9-a1a2-ac0deb22148c_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_label_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_89e4e31d-c29a-41cb-9540-3f422795e73a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Revenue From Customers Based On Geographical Market</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_ce16d090-38f7-4d4a-bd70-f4218c6ce894_terseLabel_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_cf15cc1d-8b8c-4833-a991-7bfa8a99d5c2_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current accrued expenses and other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_283e203b-8c53-41c3-930c-fe2bc73d4e04_terseLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PremiumPaymentOnBonds_9b8ecefc-dab9-4de9-8668-501c071516e1_terseLabel_en-US" xlink:label="lab_alvo_PremiumPaymentOnBonds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium payment on bonds</link:label>
    <link:label id="lab_alvo_PremiumPaymentOnBonds_label_en-US" xlink:label="lab_alvo_PremiumPaymentOnBonds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium Payment On Bonds</link:label>
    <link:label id="lab_alvo_PremiumPaymentOnBonds_documentation_en-US" xlink:label="lab_alvo_PremiumPaymentOnBonds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium payment on bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PremiumPaymentOnBonds" xlink:href="alvo-20231231.xsd#alvo_PremiumPaymentOnBonds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PremiumPaymentOnBonds" xlink:to="lab_alvo_PremiumPaymentOnBonds" xlink:type="arc" order="1"/>
    <link:label id="lab_country_LU_9a8601da-4116-484f-9fa9-fd569a601592_terseLabel_en-US" xlink:label="lab_country_LU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LUXEMBOURG</link:label>
    <link:label id="lab_country_LU_label_en-US" xlink:label="lab_country_LU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LUXEMBOURG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_LU" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_LU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_LU" xlink:to="lab_country_LU" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_405fdd8b-7cce-4a20-bdf6-f2a429c5a308_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets, excluding financial instruments and deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:to="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock_f0d2e714-79cc-4355-b1cc-2963b5a46a49_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Information About Joint Venture</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Joint Venture Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about joint venture explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_6c06a85a-cdb3-4461-af8a-ab88998f203f_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Entirety of Supplemental Cash Flow Information [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_label_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Entirety of Supplemental Cash Flow Information [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure In Entirety of Supplemental Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems" xlink:to="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_505d7116-4f7f-4ac9-ac91-79338d7dfbb8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAssetsMember_61ad2ab2-578b-44d1-b82e-dd9586b35745_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_ifrs-full_OtherAssetsMember_label_en-US" xlink:label="lab_ifrs-full_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssetsMember" xlink:to="lab_ifrs-full_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_ef7480bf-d1f7-491b-83b9-16bc4dff251d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfer to Level 1</link:label>
    <link:label id="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_706fd047-904f-4b0c-a086-4867610bd933_terseLabel_en-US" xlink:label="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, liabilities</link:label>
    <link:label id="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_label_en-US" xlink:label="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:to="lab_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_314fc4e3-91e6-4b72-b4e3-8acdde60f3ee_terseLabel_en-US" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
    <link:label id="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_label_en-US" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_Lambhagavegur7EhfMember_19148579-8b5c-4f93-a558-eeff9ddeec67_terseLabel_en-US" xlink:label="lab_alvo_Lambhagavegur7EhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lambhagavegur 7 ehf.</link:label>
    <link:label id="lab_alvo_Lambhagavegur7EhfMember_label_en-US" xlink:label="lab_alvo_Lambhagavegur7EhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lambhagavegur 7 ehf [Member]</link:label>
    <link:label id="lab_alvo_Lambhagavegur7EhfMember_documentation_en-US" xlink:label="lab_alvo_Lambhagavegur7EhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lambhagavegur 7 ehf</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Lambhagavegur7EhfMember" xlink:href="alvo-20231231.xsd#alvo_Lambhagavegur7EhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_Lambhagavegur7EhfMember" xlink:to="lab_alvo_Lambhagavegur7EhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_423c1d51-2ee4-474a-9192-a9808f3e19a5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenLoanWarrantsMember_50e58034-b8f6-4dc4-af61-90dd19b2ffa6_terseLabel_en-US" xlink:label="lab_alvo_AlvogenLoanWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Loan Warrants</link:label>
    <link:label id="lab_alvo_AlvogenLoanWarrantsMember_label_en-US" xlink:label="lab_alvo_AlvogenLoanWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Loan Warrants [member]</link:label>
    <link:label id="lab_alvo_AlvogenLoanWarrantsMember_documentation_en-US" xlink:label="lab_alvo_AlvogenLoanWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Loan Warrants [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLoanWarrantsMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenLoanWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenLoanWarrantsMember" xlink:to="lab_alvo_AlvogenLoanWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NonCashChangesInOtherNonCashMovements_a609f3fe-2bac-477b-b76b-6999ee3f67bf_terseLabel_en-US" xlink:label="lab_alvo_NonCashChangesInOtherNonCashMovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash movements</link:label>
    <link:label id="lab_alvo_NonCashChangesInOtherNonCashMovements_label_en-US" xlink:label="lab_alvo_NonCashChangesInOtherNonCashMovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Changes in Other non-cash movements</link:label>
    <link:label id="lab_alvo_NonCashChangesInOtherNonCashMovements_documentation_en-US" xlink:label="lab_alvo_NonCashChangesInOtherNonCashMovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Changes in Other non-cash movements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashChangesInOtherNonCashMovements" xlink:href="alvo-20231231.xsd#alvo_NonCashChangesInOtherNonCashMovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NonCashChangesInOtherNonCashMovements" xlink:to="lab_alvo_NonCashChangesInOtherNonCashMovements" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_8b40332b-24b3-4a85-9f1d-e84baed7ba86_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_215c7155-4f8d-44c8-811c-ba1f1ab76005_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New grants during the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMajorCustomersLineItems_4c79b777-4bf6-48be-aa58-08878e51bfc5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMajorCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_4f9cbc54-6c86-479a-9d7b-4a4cf2a3f912_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_dd0e404b-03ef-4c89-993e-d602f47ae7d4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_0be4c638-4dde-4574-b75e-7e0936403edc_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ThereafterMember_9b8cd3fd-c224-48b6-a3fc-53f86b48e325_terseLabel_en-US" xlink:label="lab_alvo_ThereafterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_alvo_ThereafterMember_label_en-US" xlink:label="lab_alvo_ThereafterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereafter [Member]</link:label>
    <link:label id="lab_alvo_ThereafterMember_documentation_en-US" xlink:label="lab_alvo_ThereafterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Thereafter Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThereafterMember" xlink:href="alvo-20231231.xsd#alvo_ThereafterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ThereafterMember" xlink:to="lab_alvo_ThereafterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FairValueOfSharesIssuedMarketPricePerShare_b54c62d2-6c7f-4f79-86a3-9e60f999e9f8_terseLabel_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedMarketPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares issued, market price (in dollars per share)</link:label>
    <link:label id="lab_alvo_FairValueOfSharesIssuedMarketPricePerShare_label_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedMarketPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Shares Issued, Market Price Per Share</link:label>
    <link:label id="lab_alvo_FairValueOfSharesIssuedMarketPricePerShare_documentation_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedMarketPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of shares issued, market price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedMarketPricePerShare" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedMarketPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FairValueOfSharesIssuedMarketPricePerShare" xlink:to="lab_alvo_FairValueOfSharesIssuedMarketPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LaterPeriodMember_6ac8e407-5186-4eed-b162-7354c107cbf3_terseLabel_en-US" xlink:label="lab_alvo_LaterPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later</link:label>
    <link:label id="lab_alvo_LaterPeriodMember_label_en-US" xlink:label="lab_alvo_LaterPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later period [Member]</link:label>
    <link:label id="lab_alvo_LaterPeriodMember_documentation_en-US" xlink:label="lab_alvo_LaterPeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Later period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LaterPeriodMember" xlink:href="alvo-20231231.xsd#alvo_LaterPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LaterPeriodMember" xlink:to="lab_alvo_LaterPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_7e175e22-7314-45c6-985a-d21fbe7def7c_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Direct taxes - current</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AreaOfProperty_4f135b76-7904-46b5-9fea-11c75730b9e4_terseLabel_en-US" xlink:label="lab_alvo_AreaOfProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of property</link:label>
    <link:label id="lab_alvo_AreaOfProperty_label_en-US" xlink:label="lab_alvo_AreaOfProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Property</link:label>
    <link:label id="lab_alvo_AreaOfProperty_documentation_en-US" xlink:label="lab_alvo_AreaOfProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Area of Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AreaOfProperty" xlink:href="alvo-20231231.xsd#alvo_AreaOfProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AreaOfProperty" xlink:to="lab_alvo_AreaOfProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_4e392c57-b334-437e-85c3-88227de7bcde_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractAssetsRollForward_0e742a2e-a2ce-446e-a80f-a6b2fbfc53da_terseLabel_en-US" xlink:label="lab_alvo_ContractAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets</link:label>
    <link:label id="lab_alvo_ContractAssetsRollForward_label_en-US" xlink:label="lab_alvo_ContractAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Assets [Roll Forward]</link:label>
    <link:label id="lab_alvo_ContractAssetsRollForward_documentation_en-US" xlink:label="lab_alvo_ContractAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsRollForward" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractAssetsRollForward" xlink:to="lab_alvo_ContractAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_HirofumiImaiBoardMember_da7a26b8-4e4e-4881-93da-3aae8612d1ad_terseLabel_en-US" xlink:label="lab_alvo_HirofumiImaiBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hirofumi Imai, Board member</link:label>
    <link:label id="lab_alvo_HirofumiImaiBoardMember_label_en-US" xlink:label="lab_alvo_HirofumiImaiBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hirofumi Imai, Board [Member]</link:label>
    <link:label id="lab_alvo_HirofumiImaiBoardMember_documentation_en-US" xlink:label="lab_alvo_HirofumiImaiBoardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hirofumi Imai, Board</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HirofumiImaiBoardMember" xlink:href="alvo-20231231.xsd#alvo_HirofumiImaiBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_HirofumiImaiBoardMember" xlink:to="lab_alvo_HirofumiImaiBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PaymentsForDebtIssueCost_98ab1025-bbbb-4d32-a2b9-e5333668fe20_negatedLabel_en-US" xlink:label="lab_alvo_PaymentsForDebtIssueCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Recognition of deferred debt issue costs</link:label>
    <link:label id="lab_alvo_PaymentsForDebtIssueCost_label_en-US" xlink:label="lab_alvo_PaymentsForDebtIssueCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Debt Issue Cost</link:label>
    <link:label id="lab_alvo_PaymentsForDebtIssueCost_documentation_en-US" xlink:label="lab_alvo_PaymentsForDebtIssueCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for debt issue cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PaymentsForDebtIssueCost" xlink:href="alvo-20231231.xsd#alvo_PaymentsForDebtIssueCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PaymentsForDebtIssueCost" xlink:to="lab_alvo_PaymentsForDebtIssueCost" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid_f82b3692-03d1-4b20-a56e-8c0962956c90_terseLabel_en-US" xlink:label="lab_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property, plant and equipment in trade payables and other current liabilities</link:label>
    <link:label id="lab_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid_label_en-US" xlink:label="lab_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditure Tangible Assets Incurred But Not Paid</link:label>
    <link:label id="lab_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid_documentation_en-US" xlink:label="lab_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital expenditure tangible assets incurred but not paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid" xlink:href="alvo-20231231.xsd#alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid" xlink:to="lab_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables_7851d792-2b76-4730-8b73-d496694c88f1_negatedTerseLabel_en-US" xlink:label="lab_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amounts transferred to trade receivables</link:label>
    <link:label id="lab_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables_label_en-US" xlink:label="lab_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liabilities Additions Amounts Transferred to Trade Receivables</link:label>
    <link:label id="lab_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables_documentation_en-US" xlink:label="lab_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liabilities Additions Amounts Transferred to Trade Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" xlink:to="lab_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_95bc657e-f4b0-4d7e-ac0b-9e95edb90c97_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_d1e3b5c9-e964-4f97-b044-16ae4ae2110e_verboseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted loss per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_1aafbb1e-df87-4a7d-af96-cd75849f8677_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_898bb151-7e5a-427b-ae17-8a93a85d4270_terseLabel_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan expense</link:label>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_label_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NetCompensationExpenseMember_34363a33-74bc-4eab-b5ef-52d80c1fa63a_terseLabel_en-US" xlink:label="lab_alvo_NetCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Compensation Expense</link:label>
    <link:label id="lab_alvo_NetCompensationExpenseMember_label_en-US" xlink:label="lab_alvo_NetCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Compensation Expense [Member]</link:label>
    <link:label id="lab_alvo_NetCompensationExpenseMember_documentation_en-US" xlink:label="lab_alvo_NetCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NetCompensationExpenseMember" xlink:href="alvo-20231231.xsd#alvo_NetCompensationExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NetCompensationExpenseMember" xlink:to="lab_alvo_NetCompensationExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InventoryWritedown2011_9a96282f-d12c-4397-9312-11ac05191ddd_terseLabel_en-US" xlink:label="lab_ifrs-full_InventoryWritedown2011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_ifrs-full_InventoryWritedown2011_label_en-US" xlink:label="lab_ifrs-full_InventoryWritedown2011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoryWritedown2011" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InventoryWritedown2011" xlink:to="lab_ifrs-full_InventoryWritedown2011" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RightOfUsedAssetsRollForward_c9757bcc-9437-4649-bc13-c9bab07de5bc_terseLabel_en-US" xlink:label="lab_alvo_RightOfUsedAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right Of Used Assets [Roll Forward]</link:label>
    <link:label id="lab_alvo_RightOfUsedAssetsRollForward_label_en-US" xlink:label="lab_alvo_RightOfUsedAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right Of Used Assets [Roll Forward]</link:label>
    <link:label id="lab_alvo_RightOfUsedAssetsRollForward_documentation_en-US" xlink:label="lab_alvo_RightOfUsedAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right Of Used Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RightOfUsedAssetsRollForward" xlink:href="alvo-20231231.xsd#alvo_RightOfUsedAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RightOfUsedAssetsRollForward" xlink:to="lab_alvo_RightOfUsedAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfInventoriesAbstract_44b687d6-3547-4063-92b1-92059a62d2c6_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of current inventories [abstract]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfInventoriesAbstract_label_en-US" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of current inventories [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract" xlink:to="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsTrancheTwoMember_128c2bfd-33bd-42df-9e0e-80e32e6ccee8_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings Tranche Two</link:label>
    <link:label id="lab_alvo_BorrowingsTrancheTwoMember_label_en-US" xlink:label="lab_alvo_BorrowingsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Tranche Two [member]</link:label>
    <link:label id="lab_alvo_BorrowingsTrancheTwoMember_documentation_en-US" xlink:label="lab_alvo_BorrowingsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings Tranche Two [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheTwoMember" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsTrancheTwoMember" xlink:to="lab_alvo_BorrowingsTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_ba26ab51-81e3-4c10-aecd-318b93efe207_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Basic and Diluted Loss Per Share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PerformanceObligationsMember_28748254-5d1c-40d0-86e1-b6aa801ef67d_terseLabel_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations [member]</link:label>
    <link:label id="lab_ifrs-full_PerformanceObligationsMember_label_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance obligations [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PerformanceObligationsMember" xlink:to="lab_ifrs-full_PerformanceObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_98e1ee22-5c97-4050-87c2-9f03eec69846_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issue of bonds</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issue of bonds, notes and debentures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="lab_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FacilityLoansMember_9dd576a2-8e9d-4a9e-a3bb-0c71fcf404bc_terseLabel_en-US" xlink:label="lab_alvo_FacilityLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Loans</link:label>
    <link:label id="lab_alvo_FacilityLoansMember_label_en-US" xlink:label="lab_alvo_FacilityLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Loans [member]</link:label>
    <link:label id="lab_alvo_FacilityLoansMember_documentation_en-US" xlink:label="lab_alvo_FacilityLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Loans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityLoansMember" xlink:href="alvo-20231231.xsd#alvo_FacilityLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FacilityLoansMember" xlink:to="lab_alvo_FacilityLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_cd258474-17d5-4afc-a993-846f1cbab7de_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LeaseLiabilitiesRollForward_f111d330-81ed-4bee-9885-a237c54308b1_terseLabel_en-US" xlink:label="lab_alvo_LeaseLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Liabilities [Roll Forward]</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesRollForward_label_en-US" xlink:label="lab_alvo_LeaseLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liabilities [Roll Forward]</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesRollForward_documentation_en-US" xlink:label="lab_alvo_LeaseLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesRollForward" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LeaseLiabilitiesRollForward" xlink:to="lab_alvo_LeaseLiabilitiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock_8d4aa32d-4d3e-46c3-ba14-577089d4c8ca_terseLabel_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fair value of shares issued and non-cash share listing expense</link:label>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock_label_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of fair value of shares issued and noncash share listing expense [Table Text Block]</link:label>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock_documentation_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of fair value of shares issued and non-cash share listing expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" xlink:to="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GoodwillBalancesRollForward_58206ce4-8cc7-4550-8c3d-b35b6f6c9f99_terseLabel_en-US" xlink:label="lab_alvo_GoodwillBalancesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_alvo_GoodwillBalancesRollForward_label_en-US" xlink:label="lab_alvo_GoodwillBalancesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Balances [Roll Forward]</link:label>
    <link:label id="lab_alvo_GoodwillBalancesRollForward_documentation_en-US" xlink:label="lab_alvo_GoodwillBalancesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Balances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GoodwillBalancesRollForward" xlink:href="alvo-20231231.xsd#alvo_GoodwillBalancesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GoodwillBalancesRollForward" xlink:to="lab_alvo_GoodwillBalancesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AssetsAcquisitionAxis_5e70d4aa-ae4a-40fd-8f59-08f9cb1e1c4f_terseLabel_en-US" xlink:label="lab_alvo_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_alvo_AssetsAcquisitionAxis_label_en-US" xlink:label="lab_alvo_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Axis]</link:label>
    <link:label id="lab_alvo_AssetsAcquisitionAxis_documentation_en-US" xlink:label="lab_alvo_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetsAcquisitionAxis" xlink:href="alvo-20231231.xsd#alvo_AssetsAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AssetsAcquisitionAxis" xlink:to="lab_alvo_AssetsAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_952fb291-0029-467f-8038-dd1b4d41fa63_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment_d4f0662c-fd37-4822-8f46-1123c9b449f7_terseLabel_en-US" xlink:label="lab_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency adjustment</link:label>
    <link:label id="lab_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment_label_en-US" xlink:label="lab_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Assets Liabilities Foreign Currency Adjustment</link:label>
    <link:label id="lab_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment_documentation_en-US" xlink:label="lab_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract assets liabilities foreign currency adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment" xlink:to="lab_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_db7f4a20-7257-49a3-b69e-b63f944f709b_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncomeStatementsLocationDomain_003b3218-8c53-4b09-9cf5-85d93669ec2e_terseLabel_en-US" xlink:label="lab_alvo_IncomeStatementsLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statements Location [Domain]</link:label>
    <link:label id="lab_alvo_IncomeStatementsLocationDomain_label_en-US" xlink:label="lab_alvo_IncomeStatementsLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statements Location [Domain]</link:label>
    <link:label id="lab_alvo_IncomeStatementsLocationDomain_documentation_en-US" xlink:label="lab_alvo_IncomeStatementsLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statements Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncomeStatementsLocationDomain" xlink:to="lab_alvo_IncomeStatementsLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_408e4469-b0ee-4054-ae39-e628061b1667_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership and voting power held by Alvotech</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_00eba8bf-f17d-46a0-94a1-2158fe799d34_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in joint venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ComponentOfBondsPayableAxis_b52a71da-61b9-46d0-b1c6-7901067f8c51_terseLabel_en-US" xlink:label="lab_alvo_ComponentOfBondsPayableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component Of Bonds Payable [Axis]</link:label>
    <link:label id="lab_alvo_ComponentOfBondsPayableAxis_label_en-US" xlink:label="lab_alvo_ComponentOfBondsPayableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Component Of Bonds Payable [Axis]</link:label>
    <link:label id="lab_alvo_ComponentOfBondsPayableAxis_documentation_en-US" xlink:label="lab_alvo_ComponentOfBondsPayableAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Component of bonds payable [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfBondsPayableAxis" xlink:href="alvo-20231231.xsd#alvo_ComponentOfBondsPayableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ComponentOfBondsPayableAxis" xlink:to="lab_alvo_ComponentOfBondsPayableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersMember_89723bf3-4df2-4810-bc57-dbb3e5c6c04e_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customers [member]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersMember_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersMember" xlink:to="lab_ifrs-full_MajorCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_dac46e2e-054e-4799-962b-9e63cb21e76e_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation difference</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_964c05c7-a5f5-4865-bded-253ce5f69229_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c4829cec-8361-4c5f-9ead-f9ec71ae3b29_terseLabel_en-US" xlink:label="lab_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_label_en-US" xlink:label="lab_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Of Equity Instruments Outstanding [Abstract]</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_documentation_en-US" xlink:label="lab_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Of Equity Instruments Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract" xlink:to="lab_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesAxis_ddc0c835-44c7-40d9-9672-9f07beb17e39_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_7fe43a17-bb43-4482-a0c5-890c8631db7a_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in joint venture</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_67a3788c-a28f-46a7-a96e-822a1aa2ab3f_verboseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_b69bd27f-503d-4070-a1d7-9bf200795723_periodStartLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at 1 January</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_6c2535c8-952b-4fae-9338-9b3f95000fc4_periodEndLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at 31 December</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_649aa1c8-0a8a-4cbc-9805-0635833eb562_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_label_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of contractual maturities of financial assets and financial liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:to="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PredecessorEarnoutSharesMember_1c8de37f-84e2-4f34-a1c5-94152b7c2aad_terseLabel_en-US" xlink:label="lab_alvo_PredecessorEarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Predecessor Earn Out Shares</link:label>
    <link:label id="lab_alvo_PredecessorEarnoutSharesMember_label_en-US" xlink:label="lab_alvo_PredecessorEarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Predecessor Earnout Shares [member]</link:label>
    <link:label id="lab_alvo_PredecessorEarnoutSharesMember_documentation_en-US" xlink:label="lab_alvo_PredecessorEarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Predecessor earnout shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PredecessorEarnoutSharesMember" xlink:to="lab_alvo_PredecessorEarnoutSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OacbEarnoutSharesMember_b7e15c35-c3e4-4725-b322-17a97c015fdb_terseLabel_en-US" xlink:label="lab_alvo_OacbEarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OACB earnout shares</link:label>
    <link:label id="lab_alvo_OacbEarnoutSharesMember_label_en-US" xlink:label="lab_alvo_OacbEarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OACB earnout shares [member]</link:label>
    <link:label id="lab_alvo_OacbEarnoutSharesMember_documentation_en-US" xlink:label="lab_alvo_OacbEarnoutSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OACB earnout shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbEarnoutSharesMember" xlink:href="alvo-20231231.xsd#alvo_OacbEarnoutSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OacbEarnoutSharesMember" xlink:to="lab_alvo_OacbEarnoutSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock_050f75fe-3257-4bfc-b041-ef766a496875_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairment</link:label>
    <link:label id="lab_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Depreciation Amortization And Impairment Explanatory [Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of depreciation amortization and imapirment explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" xlink:to="lab_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LisaGraverMember_5b7ef20b-4f80-42f4-a919-db07f9064380_terseLabel_en-US" xlink:label="lab_alvo_LisaGraverMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lisa Graver, Board Member</link:label>
    <link:label id="lab_alvo_LisaGraverMember_label_en-US" xlink:label="lab_alvo_LisaGraverMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lisa Graver [Member]</link:label>
    <link:label id="lab_alvo_LisaGraverMember_documentation_en-US" xlink:label="lab_alvo_LisaGraverMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lisa Graver.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LisaGraverMember" xlink:href="alvo-20231231.xsd#alvo_LisaGraverMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LisaGraverMember" xlink:to="lab_alvo_LisaGraverMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheDomain_bfb44ad5-2f99-4d94-8a3f-4c5edac0d3d1_terseLabel_en-US" xlink:label="lab_alvo_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche [Domain]</link:label>
    <link:label id="lab_alvo_TrancheDomain_label_en-US" xlink:label="lab_alvo_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche [Domain]</link:label>
    <link:label id="lab_alvo_TrancheDomain_documentation_en-US" xlink:label="lab_alvo_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheDomain" xlink:to="lab_alvo_TrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_92e0c15b-9323-4e88-bee7-2e2d5f6d896a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare_dc5cd821-9a2b-481f-83e5-3a17e0daf3bd_terseLabel_en-US" xlink:label="lab_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percnetage of warrants issued representing fully diluted ordinary share</link:label>
    <link:label id="lab_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare_label_en-US" xlink:label="lab_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percnetage of Warrants Issued Representing Fully Diluted Ordinary Share</link:label>
    <link:label id="lab_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare_documentation_en-US" xlink:label="lab_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percnetage of warrants issued representing fully diluted ordinary share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" xlink:href="alvo-20231231.xsd#alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" xlink:to="lab_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_b3590964-603f-458e-807e-0b775d770997_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDeferredTaxAssets_486258c5-3146-4c4f-8aee-a2662b1d6211_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_NetDeferredTaxAssets_ace2a11c-27f0-47cd-a70b-a21ce1ade5f7_verboseLabel_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_NetDeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDeferredTaxAssets" xlink:to="lab_ifrs-full_NetDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_ee1bbcfb-79f3-4881-9fcb-b3cdeb2df4ee_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables from related parties</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current receivables due from related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_f20c12d1-cab1-4fa6-b1e7-e4bc13ee6690_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax losses expire</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_09895680-4f7f-47a2-80c3-dd107fa5293f_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_label_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:to="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_f5770db1-025c-46a9-9722-b1506553d148_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_a2972b2b-587b-48bf-ba93-0ecb2c5249d2_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock_d77d7bc4-b579-4e5a-97d6-c97a6c43e3c8_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Entirety Of Supplemental Cash Flow Information Explanatory [Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in entirety of supplemental cash flow information [Text block].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" xlink:to="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfCashAndCashEquivalentsTable_61f6a798-fa97-46b9-84b9-29616fa15e0c_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_alvo_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfCashAndCashEquivalentsTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of cash and cash Equivalents,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCashAndCashEquivalentsTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfCashAndCashEquivalentsTable" xlink:to="lab_alvo_DisclosureOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_29e6b99c-5a7a-4e26-a96c-512a4da0bbd2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance income and finance costs</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqFjrfestingarEhfMember_665390e2-76eb-44c4-bff5-7b6aaf5ef64f_terseLabel_en-US" xlink:label="lab_alvo_AztiqFjrfestingarEhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</link:label>
    <link:label id="lab_alvo_AztiqFjrfestingarEhfMember_label_en-US" xlink:label="lab_alvo_AztiqFjrfestingarEhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq Fjrfestingar ehf [Member]</link:label>
    <link:label id="lab_alvo_AztiqFjrfestingarEhfMember_documentation_en-US" xlink:label="lab_alvo_AztiqFjrfestingarEhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq Fjrfestingar ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFjrfestingarEhfMember" xlink:href="alvo-20231231.xsd#alvo_AztiqFjrfestingarEhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqFjrfestingarEhfMember" xlink:to="lab_alvo_AztiqFjrfestingarEhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_ade70f8b-4f15-45c9-a97a-207b6f7ad22e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceCostExplanatory_04ee7d9b-ee61-4aed-b40c-e6cd2ff00a4f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Finance Cost</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceCostExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance cost [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_d23974f6-1583-4402-b0d1-3a2309734d1e_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_5947be90-f1c8-471d-84b0-b20f33d153ef_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_dcf23748-a8d3-4945-bc35-3ef98e2c0e51_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VariableRatesAxis_8dec340a-292e-4570-a5d4-65fc8a808f87_terseLabel_en-US" xlink:label="lab_alvo_VariableRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_alvo_VariableRatesAxis_label_en-US" xlink:label="lab_alvo_VariableRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rates [Axis]</link:label>
    <link:label id="lab_alvo_VariableRatesAxis_documentation_en-US" xlink:label="lab_alvo_VariableRatesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable rate [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableRatesAxis" xlink:href="alvo-20231231.xsd#alvo_VariableRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VariableRatesAxis" xlink:to="lab_alvo_VariableRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_3bb13d6b-b418-426d-8208-7d6b7842cab1_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable increase</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible increase in unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_422269db-f843-49b3-b175-4d531db441a2_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase decrease in shares issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="lab_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LossFromExtinguishmentOfLeaseLiabilities_9ca54e12-6703-44cf-ad8b-28b01305e510_negatedTerseLabel_en-US" xlink:label="lab_alvo_LossFromExtinguishmentOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss from extinguishment of lease agreement (see Note 12)</link:label>
    <link:label id="lab_alvo_LossFromExtinguishmentOfLeaseLiabilities_label_en-US" xlink:label="lab_alvo_LossFromExtinguishmentOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss From Extinguishment Of Lease Liabilities</link:label>
    <link:label id="lab_alvo_LossFromExtinguishmentOfLeaseLiabilities_documentation_en-US" xlink:label="lab_alvo_LossFromExtinguishmentOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss from extinguishment of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossFromExtinguishmentOfLeaseLiabilities" xlink:href="alvo-20231231.xsd#alvo_LossFromExtinguishmentOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LossFromExtinguishmentOfLeaseLiabilities" xlink:to="lab_alvo_LossFromExtinguishmentOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_2fbe74f0-cf11-4ea0-9421-025c7f46e7b7_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase / (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_b58b2a96-f6e8-4a31-9a19-4761e4026d40_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Installment payments</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForSubsidiariesMember_57f0ffb9-6545-4585-bd4f-bfd345f874d8_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForSubsidiariesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_7f0869c1-b03f-4e7a-bc80-dc2e92ada5e9_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_cdef0148-f9cf-4620-9ee9-4f0f9d443ef2_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CommonStockHeldBySubsidiaries_5d92ed61-5c02-4962-8519-6f4fcf3d48eb_terseLabel_en-US" xlink:label="lab_alvo_CommonStockHeldBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock held by subsidiary (in shares)</link:label>
    <link:label id="lab_alvo_CommonStockHeldBySubsidiaries_label_en-US" xlink:label="lab_alvo_CommonStockHeldBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Held By Subsidiaries</link:label>
    <link:label id="lab_alvo_CommonStockHeldBySubsidiaries_documentation_en-US" xlink:label="lab_alvo_CommonStockHeldBySubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock held by subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockHeldBySubsidiaries" xlink:href="alvo-20231231.xsd#alvo_CommonStockHeldBySubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CommonStockHeldBySubsidiaries" xlink:to="lab_alvo_CommonStockHeldBySubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_35c33d46-bf23-40df-a027-ca6fb15b50d0_terseLabel_en-US" xlink:label="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction price allocated to remaining performance obligations</link:label>
    <link:label id="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_label_en-US" xlink:label="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction price allocated to remaining performance obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="lab_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_b13c46db-2877-412b-952d-50841a786748_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_732926b6-e9e1-4e93-8017-ec6063d853b4_verboseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfSharesCapitalRollForward_014d197d-8534-4ded-929b-d16c9d20e705_terseLabel_en-US" xlink:label="lab_alvo_IssueOfSharesCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of Shares Capital [Roll Forward]</link:label>
    <link:label id="lab_alvo_IssueOfSharesCapitalRollForward_label_en-US" xlink:label="lab_alvo_IssueOfSharesCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of Shares capital [Roll Forward]</link:label>
    <link:label id="lab_alvo_IssueOfSharesCapitalRollForward_documentation_en-US" xlink:label="lab_alvo_IssueOfSharesCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of Shares capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesCapitalRollForward" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesCapitalRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward" xlink:to="lab_alvo_IssueOfSharesCapitalRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheTwoMember_2f28a450-2483-4012-8766-8f35f0290a56_terseLabel_en-US" xlink:label="lab_alvo_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche two</link:label>
    <link:label id="lab_alvo_TrancheTwoMember_label_en-US" xlink:label="lab_alvo_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_alvo_TrancheTwoMember_documentation_en-US" xlink:label="lab_alvo_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheTwoMember" xlink:href="alvo-20231231.xsd#alvo_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheTwoMember" xlink:to="lab_alvo_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_4cec9f8b-9a13-44c3-9afc-c4a463339ddf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassBOacbOrdinarySharesMember_bd676810-94eb-4448-b483-b76bd9b3c5b3_terseLabel_en-US" xlink:label="lab_alvo_ClassBOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B OACB Ordinary Shares</link:label>
    <link:label id="lab_alvo_ClassBOacbOrdinarySharesMember_label_en-US" xlink:label="lab_alvo_ClassBOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class B OACB Ordinary Shares [Member]</link:label>
    <link:label id="lab_alvo_ClassBOacbOrdinarySharesMember_documentation_en-US" xlink:label="lab_alvo_ClassBOacbOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class B OACB ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassBOacbOrdinarySharesMember" xlink:href="alvo-20231231.xsd#alvo_ClassBOacbOrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassBOacbOrdinarySharesMember" xlink:to="lab_alvo_ClassBOacbOrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValue_751f79d4-728f-472b-a42c-c9a01e2977c7_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValue_434f76ec-acc5-42f4-945d-4bc105b4046e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balances</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValue_c9ae66ec-c12f-401e-a7dd-46c589c97985_periodEndLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balances</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfTranches_c4689ad4-6d36-4ad5-b061-62320db01c1e_terseLabel_en-US" xlink:label="lab_alvo_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_alvo_NumberOfTranches_label_en-US" xlink:label="lab_alvo_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:label id="lab_alvo_NumberOfTranches_documentation_en-US" xlink:label="lab_alvo_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfTranches" xlink:href="alvo-20231231.xsd#alvo_NumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfTranches" xlink:to="lab_alvo_NumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e58affc8-8bdd-4d4d-82d0-f39c3602073b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_4df7aabd-d052-4ef2-a2ed-32127eb07b9b_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_027b0f3a-46e9-4688-9012-7f1c3facb074_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CarryingValueOfDebtExtinguished_89624203-45a8-4d6d-9882-64327d29c9c9_terseLabel_en-US" xlink:label="lab_alvo_CarryingValueOfDebtExtinguished" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value of debt extinguished</link:label>
    <link:label id="lab_alvo_CarryingValueOfDebtExtinguished_label_en-US" xlink:label="lab_alvo_CarryingValueOfDebtExtinguished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying Value Of Debt Extinguished</link:label>
    <link:label id="lab_alvo_CarryingValueOfDebtExtinguished_documentation_en-US" xlink:label="lab_alvo_CarryingValueOfDebtExtinguished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value of debt extinguished.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CarryingValueOfDebtExtinguished" xlink:href="alvo-20231231.xsd#alvo_CarryingValueOfDebtExtinguished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CarryingValueOfDebtExtinguished" xlink:to="lab_alvo_CarryingValueOfDebtExtinguished" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_f3451e2b-cfb4-449e-b250-03167d7e66a3_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_000abbc4-8c45-43d8-8590-f77f79e54e62_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_b1dfb19e-09d8-4fe1-ad60-f7fec8faad07_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_7cbd0f98-a566-47ed-b0da-b2ed176abc1c_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_d2d396ab-c3e3-4958-84e6-66ef66416024_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the end of the year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_308ebad2-e129-48c9-95ae-f0abe828c165_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RestrictedCashInConnectionWithAmendedBondAgreement_333fa68f-752f-41bf-bb47-8cea47b6f2d3_negatedLabel_en-US" xlink:label="lab_alvo_RestrictedCashInConnectionWithAmendedBondAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted cash in connection with amended bond agreement</link:label>
    <link:label id="lab_alvo_RestrictedCashInConnectionWithAmendedBondAgreement_label_en-US" xlink:label="lab_alvo_RestrictedCashInConnectionWithAmendedBondAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash In Connection With Amended Bond Agreement</link:label>
    <link:label id="lab_alvo_RestrictedCashInConnectionWithAmendedBondAgreement_documentation_en-US" xlink:label="lab_alvo_RestrictedCashInConnectionWithAmendedBondAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash in connection with amended bond agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RestrictedCashInConnectionWithAmendedBondAgreement" xlink:href="alvo-20231231.xsd#alvo_RestrictedCashInConnectionWithAmendedBondAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RestrictedCashInConnectionWithAmendedBondAgreement" xlink:to="lab_alvo_RestrictedCashInConnectionWithAmendedBondAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheBConvertibleDebtMember_4d111b2c-55d4-42f8-9cf6-1b85848e6d58_terseLabel_en-US" xlink:label="lab_alvo_TrancheBConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B Convertible Debt</link:label>
    <link:label id="lab_alvo_TrancheBConvertibleDebtMember_label_en-US" xlink:label="lab_alvo_TrancheBConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B Convertible Debt [Member]</link:label>
    <link:label id="lab_alvo_TrancheBConvertibleDebtMember_documentation_en-US" xlink:label="lab_alvo_TrancheBConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche B Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheBConvertibleDebtMember" xlink:href="alvo-20231231.xsd#alvo_TrancheBConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheBConvertibleDebtMember" xlink:to="lab_alvo_TrancheBConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenFacilityMember_665526ea-2ae4-408b-a226-77d35669f66d_terseLabel_en-US" xlink:label="lab_alvo_AlvogenFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Facility</link:label>
    <link:label id="lab_alvo_AlvogenFacilityMember_label_en-US" xlink:label="lab_alvo_AlvogenFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Facility [Member]</link:label>
    <link:label id="lab_alvo_AlvogenFacilityMember_documentation_en-US" xlink:label="lab_alvo_AlvogenFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenFacilityMember" xlink:to="lab_alvo_AlvogenFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets_7c6e4e96-2909-44df-a4d0-f3632b185385_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) / decrease in contract assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_3ae64664-067c-406d-8963-e65989859718_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_7cef41c8-d4db-4a5f-b70d-14efcd20a36e_terseLabel_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing rate</link:label>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_0e9f3e32-dcee-4b02-bf4b-6eb14d316538_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in trade receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_bd47280b-4cd0-4649-a496-77fc83ec7398_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LoansToRelatedParties_ca97722e-9e97-46ce-aa0e-8095cb0c417c_terseLabel_en-US" xlink:label="lab_alvo_LoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans to related parties</link:label>
    <link:label id="lab_alvo_LoansToRelatedParties_label_en-US" xlink:label="lab_alvo_LoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans to related parties</link:label>
    <link:label id="lab_alvo_LoansToRelatedParties_documentation_en-US" xlink:label="lab_alvo_LoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans to related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LoansToRelatedParties" xlink:href="alvo-20231231.xsd#alvo_LoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LoansToRelatedParties" xlink:to="lab_alvo_LoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e4b5bb99-c371-4243-81ca-75fc33dd4217_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_b340ac89-7e10-4272-ae84-e657b44a79e4_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_dbf3f058-101f-48ab-9a2f-d8025651ba0b_terseLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a61aa29c-3118-48b5-989b-a04fe6463b68_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents denominated in US dollars</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_650d7ac8-3bc5-482a-bfe8-0e3597225e0e_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FurnitureFixturesAndLeaseholdImprovementsMember_95ca0011-91a9-4727-b2de-d202510035aa_terseLabel_en-US" xlink:label="lab_alvo_FurnitureFixturesAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and leasehold improvements</link:label>
    <link:label id="lab_alvo_FurnitureFixturesAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_alvo_FurnitureFixturesAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture, Fixtures and Leasehold Improvements [Member]</link:label>
    <link:label id="lab_alvo_FurnitureFixturesAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_alvo_FurnitureFixturesAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Furniture, Fixtures and Leasehold Improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FurnitureFixturesAndLeaseholdImprovementsMember" xlink:href="alvo-20231231.xsd#alvo_FurnitureFixturesAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FurnitureFixturesAndLeaseholdImprovementsMember" xlink:to="lab_alvo_FurnitureFixturesAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_0150a1f1-f644-4398-a821-ef3c299f1b83_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income) and adjustments for current tax of prior periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_8c98012b-713c-4297-ad9e-789c787fc241_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of exchange differences on translation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_ca1b3d70-340c-4727-8b65-23fd99c2d037_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument face value</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SeniorBondInterestRateFeatureMember_7134a300-c7f1-47ce-a830-d8103c80050e_terseLabel_en-US" xlink:label="lab_alvo_SeniorBondInterestRateFeatureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Bond Interest Rate Feature (included in other current assets)</link:label>
    <link:label id="lab_alvo_SeniorBondInterestRateFeatureMember_label_en-US" xlink:label="lab_alvo_SeniorBondInterestRateFeatureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Bond Interest Rate Feature [member]</link:label>
    <link:label id="lab_alvo_SeniorBondInterestRateFeatureMember_documentation_en-US" xlink:label="lab_alvo_SeniorBondInterestRateFeatureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior bond interest rate feature [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondInterestRateFeatureMember" xlink:href="alvo-20231231.xsd#alvo_SeniorBondInterestRateFeatureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SeniorBondInterestRateFeatureMember" xlink:to="lab_alvo_SeniorBondInterestRateFeatureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_ff3e4bf6-8f8b-405c-9a38-2bdb44dd496d_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassAAndClassBOrdinarySharesMember_c161750b-000b-4fe0-80ff-50cbd96be151_terseLabel_en-US" xlink:label="lab_alvo_ClassAAndClassBOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A and Class B Ordinary Shares</link:label>
    <link:label id="lab_alvo_ClassAAndClassBOrdinarySharesMember_label_en-US" xlink:label="lab_alvo_ClassAAndClassBOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A and Class B Ordinary Shares [Member]</link:label>
    <link:label id="lab_alvo_ClassAAndClassBOrdinarySharesMember_documentation_en-US" xlink:label="lab_alvo_ClassAAndClassBOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class A and class B ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassAAndClassBOrdinarySharesMember" xlink:href="alvo-20231231.xsd#alvo_ClassAAndClassBOrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassAAndClassBOrdinarySharesMember" xlink:to="lab_alvo_ClassAAndClassBOrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_2385ce51-232e-45ac-bbb3-fefe2c40df5b_verboseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_3b9fc852-3f8a-4aed-8536-770262dd20eb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CurrentEmployeeIncentivePlan_36d49d20-a3a4-4873-8692-f070e420fe66_verboseLabel_en-US" xlink:label="lab_alvo_CurrentEmployeeIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee incentive plan</link:label>
    <link:label id="lab_alvo_CurrentEmployeeIncentivePlan_label_en-US" xlink:label="lab_alvo_CurrentEmployeeIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Employee Incentive Plan</link:label>
    <link:label id="lab_alvo_CurrentEmployeeIncentivePlan_documentation_en-US" xlink:label="lab_alvo_CurrentEmployeeIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current employee incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentEmployeeIncentivePlan" xlink:href="alvo-20231231.xsd#alvo_CurrentEmployeeIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CurrentEmployeeIncentivePlan" xlink:to="lab_alvo_CurrentEmployeeIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock_a7839097-4e19-4394-9e5a-795850ad2b99_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Supplemental Cash Flow Information Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of supplemental cash flow information [Text block].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassACommonStockMember_6d475375-e687-47ed-b9a3-d86b2107f48a_terseLabel_en-US" xlink:label="lab_alvo_ClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A Shareholders</link:label>
    <link:label id="lab_alvo_ClassACommonStockMember_label_en-US" xlink:label="lab_alvo_ClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A Common Stock [Member]</link:label>
    <link:label id="lab_alvo_ClassACommonStockMember_documentation_en-US" xlink:label="lab_alvo_ClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class&#160;A common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassACommonStockMember" xlink:href="alvo-20231231.xsd#alvo_ClassACommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassACommonStockMember" xlink:to="lab_alvo_ClassACommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_StockExchangeDescriptionAxis_d092c00d-eb9f-4286-8773-830d9bcc476b_terseLabel_en-US" xlink:label="lab_alvo_StockExchangeDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Exchange Description [Axis]</link:label>
    <link:label id="lab_alvo_StockExchangeDescriptionAxis_label_en-US" xlink:label="lab_alvo_StockExchangeDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Exchange Description [Axis]</link:label>
    <link:label id="lab_alvo_StockExchangeDescriptionAxis_documentation_en-US" xlink:label="lab_alvo_StockExchangeDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock exchange description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockExchangeDescriptionAxis" xlink:href="alvo-20231231.xsd#alvo_StockExchangeDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_StockExchangeDescriptionAxis" xlink:to="lab_alvo_StockExchangeDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_a0ec5c32-1139-46dc-8336-0395efa6a969_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_1b1338b4-7ee3-4fd1-b437-ea2758a2ccd0_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Within three years</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechMaltaLtdMember_c7219828-6428-4613-a0b4-0bf4e7b8b24c_terseLabel_en-US" xlink:label="lab_alvo_AlvotechMaltaLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech Malta Ltd</link:label>
    <link:label id="lab_alvo_AlvotechMaltaLtdMember_label_en-US" xlink:label="lab_alvo_AlvotechMaltaLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech Malta Ltd [Member]</link:label>
    <link:label id="lab_alvo_AlvotechMaltaLtdMember_documentation_en-US" xlink:label="lab_alvo_AlvotechMaltaLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech Malta Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechMaltaLtdMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechMaltaLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechMaltaLtdMember" xlink:to="lab_alvo_AlvotechMaltaLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c716e47e-0967-4d5d-9884-f0ed5a128461_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FasteignafelagiSmundurHfMember_81e9acfd-d939-49d1-99d2-33825f16fbda_terseLabel_en-US" xlink:label="lab_alvo_FasteignafelagiSmundurHfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fasteignafelagi&#240; S&#230;mundur hf</link:label>
    <link:label id="lab_alvo_FasteignafelagiSmundurHfMember_label_en-US" xlink:label="lab_alvo_FasteignafelagiSmundurHfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fasteignafelagi Smundur hf [Member]</link:label>
    <link:label id="lab_alvo_FasteignafelagiSmundurHfMember_documentation_en-US" xlink:label="lab_alvo_FasteignafelagiSmundurHfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fasteignafelagi&#240; S&#230;mundur hf.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHfMember" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FasteignafelagiSmundurHfMember" xlink:to="lab_alvo_FasteignafelagiSmundurHfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_71bb04fc-1143-4ad6-894b-1ccb49df1b1f_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments granted in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NonCashIssuanceOfConvertibleBond_8c7103c5-e9a0-429a-a0bd-e495b690cd91_terseLabel_en-US" xlink:label="lab_alvo_NonCashIssuanceOfConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash issuance of Aztiq Convertible Bond</link:label>
    <link:label id="lab_alvo_NonCashIssuanceOfConvertibleBond_label_en-US" xlink:label="lab_alvo_NonCashIssuanceOfConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Issuance Of Convertible Bond</link:label>
    <link:label id="lab_alvo_NonCashIssuanceOfConvertibleBond_documentation_en-US" xlink:label="lab_alvo_NonCashIssuanceOfConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non cash issuance of convertible bond.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashIssuanceOfConvertibleBond" xlink:href="alvo-20231231.xsd#alvo_NonCashIssuanceOfConvertibleBond"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NonCashIssuanceOfConvertibleBond" xlink:to="lab_alvo_NonCashIssuanceOfConvertibleBond" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_b88c2d3a-fc5a-4344-b350-674497279a36_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Assets And Liabilities Denominated In Foreign Currencies [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Assets And Liabilities Denominated In Foreign Currencies [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of assets and liabilities denominated in foreign currencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable" xlink:to="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ForeignCountriesMember_661027d0-1d0a-4184-8c85-ddf00e6da719_terseLabel_en-US" xlink:label="lab_ifrs-full_ForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents denominated in other currencies</link:label>
    <link:label id="lab_ifrs-full_ForeignCountriesMember_label_en-US" xlink:label="lab_ifrs-full_ForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign countries [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignCountriesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ForeignCountriesMember" xlink:to="lab_ifrs-full_ForeignCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_be685898-fbef-4ac6-a873-af1781578a2d_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Recognition of equity component of convertible bonds</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through conversion of convertible instruments, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_16934d16-3b68-4a1e-be01-ddda59a0a458_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_64689764-df57-472b-8a71-bd119e84e137_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of consolidation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NonInterestBearingFinancialAssetsMember_379df963-6f52-4e60-9daa-4eb3e3cfc038_terseLabel_en-US" xlink:label="lab_alvo_NonInterestBearingFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-interest bearing</link:label>
    <link:label id="lab_alvo_NonInterestBearingFinancialAssetsMember_label_en-US" xlink:label="lab_alvo_NonInterestBearingFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Interest Bearing Financial Assets [Member]</link:label>
    <link:label id="lab_alvo_NonInterestBearingFinancialAssetsMember_documentation_en-US" xlink:label="lab_alvo_NonInterestBearingFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Interest Bearing Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonInterestBearingFinancialAssetsMember" xlink:href="alvo-20231231.xsd#alvo_NonInterestBearingFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NonInterestBearingFinancialAssetsMember" xlink:to="lab_alvo_NonInterestBearingFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_8bb67cfb-ee20-4d10-8541-e40f812002a4_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_d1967989-86fe-4ff3-b1f7-b783364c393b_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_5e46c3f0-29ee-4cf8-94cb-edba2f299473_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding basic (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_b0483b70-c6be-4851-b98e-7d3e070b9af0_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_4fca747d-1100-442e-ba2e-5e763f241cb2_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_b01c7713-f3ea-4c3c-b649-a7bd1d79e241_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities (measured at FVTPL)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_87da0444-f4ea-4c23-988d-6144a90e847f_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income from cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCost_206f7b40-92c6-4aad-b06c-8e255e471d89_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCost_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ProceedsReceivableFromConvertibleBonds_e74215b1-4833-490c-a55b-542d2571c9a1_terseLabel_en-US" xlink:label="lab_alvo_ProceedsReceivableFromConvertibleBonds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds receivable from Convertible Bonds (see Note 21)</link:label>
    <link:label id="lab_alvo_ProceedsReceivableFromConvertibleBonds_label_en-US" xlink:label="lab_alvo_ProceedsReceivableFromConvertibleBonds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds Receivable From Convertible Bonds</link:label>
    <link:label id="lab_alvo_ProceedsReceivableFromConvertibleBonds_documentation_en-US" xlink:label="lab_alvo_ProceedsReceivableFromConvertibleBonds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds receivable from convertible bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsReceivableFromConvertibleBonds" xlink:href="alvo-20231231.xsd#alvo_ProceedsReceivableFromConvertibleBonds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ProceedsReceivableFromConvertibleBonds" xlink:to="lab_alvo_ProceedsReceivableFromConvertibleBonds" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8e505963-9b05-4276-bccf-fb75f47f3de7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_abab4fcb-2dc7-4c48-8ebe-22d9d92bf903_terseLabel_en-US" xlink:label="lab_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_label_en-US" xlink:label="lab_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_documentation_en-US" xlink:label="lab_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:href="alvo-20231231.xsd#alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:to="lab_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_7955e4df-7521-4d85-b3f8-123ac0852cce_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_63b25c72-6a12-4902-b8ef-baabaa90412c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in trade and other payables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseDecreaseThroughPipeFinancing_a3cbf87c-83f8-4499-b178-811ac11042c2_terseLabel_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughPipeFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PIPE Financing</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughPipeFinancing_label_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughPipeFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through PIPE Financing</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughPipeFinancing_documentation_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughPipeFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through pipe financing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughPipeFinancing" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughPipeFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseDecreaseThroughPipeFinancing" xlink:to="lab_alvo_IncreaseDecreaseThroughPipeFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RecognitionOfDerivativeAsset_149738a5-ce4c-467d-ba7b-994956cd32de_terseLabel_en-US" xlink:label="lab_alvo_RecognitionOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of derivative asset</link:label>
    <link:label id="lab_alvo_RecognitionOfDerivativeAsset_label_en-US" xlink:label="lab_alvo_RecognitionOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognition Of Derivative Asset</link:label>
    <link:label id="lab_alvo_RecognitionOfDerivativeAsset_documentation_en-US" xlink:label="lab_alvo_RecognitionOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recognition of derivative asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RecognitionOfDerivativeAsset" xlink:href="alvo-20231231.xsd#alvo_RecognitionOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RecognitionOfDerivativeAsset" xlink:to="lab_alvo_RecognitionOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_15f9361f-95ac-40ed-a0f3-44ae99eff739_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about classes of right of use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_3b4d1f1c-5e71-4346-a898-dcde7c4bed9c_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_38423202-bfc6-42df-bb37-4a6c0a4b82a1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities_64506cee-eeaa-43a8-8d0d-ceed85664dde_negatedLabel_en-US" xlink:label="lab_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Borrowing, Classified As Financing Activities</link:label>
    <link:label id="lab_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities_documentation_en-US" xlink:label="lab_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments of borrowing, classified as financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities" xlink:href="alvo-20231231.xsd#alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities" xlink:to="lab_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9245ed67-093d-4be7-9bea-b9ae58bd9852_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_dd7dfd5a-fc76-4d43-8162-1a08f27ce035_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of material accounting policy information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_081388b2-4f9e-431c-a6cf-5c05944d0ffe_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenEmergingMarketsSisterCompanyMember_2a2a5e02-0ad6-4e1d-8c08-d1bf28b0af6e_terseLabel_en-US" xlink:label="lab_alvo_AlvogenEmergingMarketsSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Emerging Markets - Sister company</link:label>
    <link:label id="lab_alvo_AlvogenEmergingMarketsSisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenEmergingMarketsSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Emerging Markets - Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenEmergingMarketsSisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenEmergingMarketsSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Emerging Markets member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenEmergingMarketsSisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember" xlink:to="lab_alvo_AlvogenEmergingMarketsSisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock_77e1690c-365f-45db-a2db-0aa9dc6593ba_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Useful Lives of Amortization</link:label>
    <link:label id="lab_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Estimated Useful Lives Other Intangible Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of estimated useful lives other intangible assets explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_722183ca-f30b-4079-a62a-9380a484d1dc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other current liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract_e35375b6-8ac1-4ae6-a6b2-53094c66bdff_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseThroughPipeFinancingShares_299200c1-2b34-43e3-9070-541ec8dca80d_terseLabel_en-US" xlink:label="lab_alvo_IncreaseThroughPipeFinancingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PIPE Financing, (in shares)</link:label>
    <link:label id="lab_alvo_IncreaseThroughPipeFinancingShares_label_en-US" xlink:label="lab_alvo_IncreaseThroughPipeFinancingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Through PIPE Financing Shares</link:label>
    <link:label id="lab_alvo_IncreaseThroughPipeFinancingShares_documentation_en-US" xlink:label="lab_alvo_IncreaseThroughPipeFinancingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase through PIPE financing shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseThroughPipeFinancingShares" xlink:href="alvo-20231231.xsd#alvo_IncreaseThroughPipeFinancingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseThroughPipeFinancingShares" xlink:to="lab_alvo_IncreaseThroughPipeFinancingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_d6b40262-dd1f-46c9-906b-793438b828b9_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from private placement equity offering</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing other equity instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="lab_ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RawMaterialsAndConsumablesUsed_db68278d-453d-44b4-812c-13dc9c94adf7_terseLabel_en-US" xlink:label="lab_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_ifrs-full_RawMaterialsAndConsumablesUsed_label_en-US" xlink:label="lab_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw materials and consumables used</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:to="lab_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractAssets_1eba5446-f4a5-4485-99be-14518c69c437_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance asset</link:label>
    <link:label id="lab_ifrs-full_ContractAssets_5a0629c2-28e5-4e33-a3f8-6557b2c01d94_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance asset</link:label>
    <link:label id="lab_ifrs-full_ContractAssets_label_en-US" xlink:label="lab_ifrs-full_ContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractAssets" xlink:to="lab_ifrs-full_ContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_d753cee4-9e03-4629-a09d-ed0e6fe4a492_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock_640f252d-949b-47f6-8594-ba10d2d8652b_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about depreciation amortization and impairment expense included in consolidated statements profit or loss and other comprehensive income or loss explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_7d1c6506-f221-4a22-8a38-147910a26052_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfCreditRiskLineItems_bc0f4e62-f39c-49ec-80f5-970989495819_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Credit Risk [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfCreditRiskLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Credit Risk [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfCreditRiskLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCreditRiskLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfCreditRiskLineItems" xlink:to="lab_alvo_DisclosureOfCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_b6048ea1-0a2c-4c35-b470-8da90da3de77_negatedLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share of net loss of joint venture</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for undistributed profits of investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SeniorBondsMember_12ff804f-44f4-4b2e-95fb-474d43698a74_terseLabel_en-US" xlink:label="lab_alvo_SeniorBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Bonds</link:label>
    <link:label id="lab_alvo_SeniorBondsMember_label_en-US" xlink:label="lab_alvo_SeniorBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Bonds [Member]</link:label>
    <link:label id="lab_alvo_SeniorBondsMember_documentation_en-US" xlink:label="lab_alvo_SeniorBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SeniorBondsMember" xlink:to="lab_alvo_SeniorBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_2caa7be2-62a2-4dc1-b89b-e2bf69961b7d_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_089586c0-609d-4ca3-974f-dbd74ab72bc0_verboseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_cd26f715-de0a-4be8-9aac-35992a5568ef_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfFinancialAssetsAxis_a7fe2f30-01da-486a-b695-d41c1caa3187_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_TypesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenIcelandEhf.SisterCompanyMember_a7b8cc0f-001c-40b0-9c94-9385dce85443_terseLabel_en-US" xlink:label="lab_alvo_AlvogenIcelandEhf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Iceland ehf. - Sister company</link:label>
    <link:label id="lab_alvo_AlvogenIcelandEhf.SisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenIcelandEhf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Iceland ehf. - Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenIcelandEhf.SisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenIcelandEhf.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Iceland ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenIcelandEhf.SisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember" xlink:to="lab_alvo_AlvogenIcelandEhf.SisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities_fc6e3b9a-c205-4682-b0e7-54b440c138d7_terseLabel_en-US" xlink:label="lab_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock shares issued during the period conversion of convertible securities (in shares)</link:label>
    <link:label id="lab_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Shares Issued During The Period Conversion Of Convertible Securities</link:label>
    <link:label id="lab_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock shares issued during the period conversion of convertible securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" xlink:href="alvo-20231231.xsd#alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" xlink:to="lab_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherSubsidiariesMember_c4ca2df1-bf65-4707-8f56-192fcac5e5bd_terseLabel_en-US" xlink:label="lab_alvo_OtherSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Subsidiaries</link:label>
    <link:label id="lab_alvo_OtherSubsidiariesMember_label_en-US" xlink:label="lab_alvo_OtherSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Subsidiaries [Member]</link:label>
    <link:label id="lab_alvo_OtherSubsidiariesMember_documentation_en-US" xlink:label="lab_alvo_OtherSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherSubsidiariesMember" xlink:href="alvo-20231231.xsd#alvo_OtherSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherSubsidiariesMember" xlink:to="lab_alvo_OtherSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesTypeMember_51d4398b-68a7-426c-a208-2d9be2e328b9_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesTypeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, type [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesTypeMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesTypeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, type [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesTypeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsTable_97dae987-93e5-4305-aeef-077d4b1d0f9a_terseLabel_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General information about financial statements [Table]</link:label>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsTable_label_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General information about financial statements [Table]</link:label>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsTable_documentation_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General information about financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsTable" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable" xlink:to="lab_alvo_GeneralInformationAboutFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium_44e95733-4064-4155-8598-4e12ba938a2f_terseLabel_en-US" xlink:label="lab_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment period with additional premium</link:label>
    <link:label id="lab_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium_label_en-US" xlink:label="lab_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Prepayment Period With Additional Premium</link:label>
    <link:label id="lab_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium_documentation_en-US" xlink:label="lab_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Prepayment Period With Additional Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium" xlink:href="alvo-20231231.xsd#alvo_BorrowingPrepaymentPeriodWithAdditionalPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium" xlink:to="lab_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LossOnRemeasurementOfBonds_66e7df47-24b8-44a7-8581-569a87624514_terseLabel_en-US" xlink:label="lab_alvo_LossOnRemeasurementOfBonds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on remeasurement of bonds (see Note 21)</link:label>
    <link:label id="lab_alvo_LossOnRemeasurementOfBonds_label_en-US" xlink:label="lab_alvo_LossOnRemeasurementOfBonds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Remeasurement Of Bonds</link:label>
    <link:label id="lab_alvo_LossOnRemeasurementOfBonds_documentation_en-US" xlink:label="lab_alvo_LossOnRemeasurementOfBonds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss on remeasurement of bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossOnRemeasurementOfBonds" xlink:href="alvo-20231231.xsd#alvo_LossOnRemeasurementOfBonds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LossOnRemeasurementOfBonds" xlink:to="lab_alvo_LossOnRemeasurementOfBonds" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_dca20ff0-fca1-494a-ac33-dde2a05fecdb_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares at year-end (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_7f2b8ece-2e9d-4b86-ab9e-e8da30df5bbb_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_c3adf555-7151-41bb-9085-dde7c47286cc_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PaymentForContractualCommitment_c082686d-2d69-4d65-89a4-68c83034d5e6_terseLabel_en-US" xlink:label="lab_alvo_PaymentForContractualCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for contract commitment</link:label>
    <link:label id="lab_alvo_PaymentForContractualCommitment_label_en-US" xlink:label="lab_alvo_PaymentForContractualCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Contractual Commitment</link:label>
    <link:label id="lab_alvo_PaymentForContractualCommitment_documentation_en-US" xlink:label="lab_alvo_PaymentForContractualCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Contractual Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PaymentForContractualCommitment" xlink:href="alvo-20231231.xsd#alvo_PaymentForContractualCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PaymentForContractualCommitment" xlink:to="lab_alvo_PaymentForContractualCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_e62de44b-77ba-49f4-bce9-d81fd08ca842_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_531c8313-0ffe-4a75-bc83-1acba0398073_totalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax benefit</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ArniHararsonMember_0342e136-d556-45ff-9134-09b53b62ea85_terseLabel_en-US" xlink:label="lab_alvo_ArniHararsonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#193;rni Har&#240;arson, Board Member*</link:label>
    <link:label id="lab_alvo_ArniHararsonMember_label_en-US" xlink:label="lab_alvo_ArniHararsonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arni Hararson [Member]</link:label>
    <link:label id="lab_alvo_ArniHararsonMember_documentation_en-US" xlink:label="lab_alvo_ArniHararsonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">&#193;rni Har&#240;arson</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ArniHararsonMember" xlink:href="alvo-20231231.xsd#alvo_ArniHararsonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ArniHararsonMember" xlink:to="lab_alvo_ArniHararsonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesAbstract_fac8c7db-a3cd-4613-a80f-43cabe5d3269_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of joint ventures [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of joint ventures [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6d83fc97-eb47-4497-9d35-e59c9a1b103d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PreviouslyStatedMember_36e5edb2-27b0-4351-8e9e-d889f154d7cb_terseLabel_en-US" xlink:label="lab_ifrs-full_PreviouslyStatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior to reclassification</link:label>
    <link:label id="lab_ifrs-full_PreviouslyStatedMember_label_en-US" xlink:label="lab_ifrs-full_PreviouslyStatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously stated [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PreviouslyStatedMember" xlink:to="lab_ifrs-full_PreviouslyStatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability_5bfc83f8-d660-4f8e-bade-bf5edcaa1bc0_negatedTerseLabel_en-US" xlink:label="lab_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of contract liability</link:label>
    <link:label id="lab_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability_label_en-US" xlink:label="lab_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liabilities Additions Derecognition of contract liability</link:label>
    <link:label id="lab_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability_documentation_en-US" xlink:label="lab_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liabilities Additions Derecognition of contract liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability" xlink:to="lab_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RobertWessmanMember_a2ca74f0-27f4-44b8-a952-5fe7ca4be411_terseLabel_en-US" xlink:label="lab_alvo_RobertWessmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Robert Wessman, Chairman of the board</link:label>
    <link:label id="lab_alvo_RobertWessmanMember_label_en-US" xlink:label="lab_alvo_RobertWessmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Robert Wessman [Member]</link:label>
    <link:label id="lab_alvo_RobertWessmanMember_documentation_en-US" xlink:label="lab_alvo_RobertWessmanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Robert Wessman .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RobertWessmanMember" xlink:href="alvo-20231231.xsd#alvo_RobertWessmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RobertWessmanMember" xlink:to="lab_alvo_RobertWessmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2_3bf546c2-5488-4064-94a4-84e7f140a40a_terseLabel_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair market value</link:label>
    <link:label id="lab_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2_label_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Shares Issued Recognized amount in Accordance With IFRS 2</link:label>
    <link:label id="lab_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2_documentation_en-US" xlink:label="lab_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of shares issued recognized accordance with IFRS 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" xlink:to="lab_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock_15bef1c3-d3bf-4ec5-b51d-9c71ef9ab1a2_terseLabel_en-US" xlink:label="lab_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of movements in the group's outstanding borrowings</link:label>
    <link:label id="lab_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosureof Movements In Outstanding Borrowings Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure&#160;of movements in outstanding borrowings explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_8f87dc16-aff6-470f-b6d8-ebead68231c2_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheBMember_bec507c7-df98-4427-af1d-7f9d66c52aaf_terseLabel_en-US" xlink:label="lab_alvo_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B</link:label>
    <link:label id="lab_alvo_TrancheBMember_label_en-US" xlink:label="lab_alvo_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B [member]</link:label>
    <link:label id="lab_alvo_TrancheBMember_documentation_en-US" xlink:label="lab_alvo_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche B.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheBMember" xlink:href="alvo-20231231.xsd#alvo_TrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheBMember" xlink:to="lab_alvo_TrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExchangeOfPredecessorOrdinarySharesMember_502a4739-e62f-4c09-a652-d1c46402fc10_terseLabel_en-US" xlink:label="lab_alvo_ExchangeOfPredecessorOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange of Predecessor Ordinary Shares</link:label>
    <link:label id="lab_alvo_ExchangeOfPredecessorOrdinarySharesMember_label_en-US" xlink:label="lab_alvo_ExchangeOfPredecessorOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange of Predecessor Ordinary Shares [Member]</link:label>
    <link:label id="lab_alvo_ExchangeOfPredecessorOrdinarySharesMember_documentation_en-US" xlink:label="lab_alvo_ExchangeOfPredecessorOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange of predecessor ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExchangeOfPredecessorOrdinarySharesMember" xlink:href="alvo-20231231.xsd#alvo_ExchangeOfPredecessorOrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExchangeOfPredecessorOrdinarySharesMember" xlink:to="lab_alvo_ExchangeOfPredecessorOrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractualCapitalCommitments_fd625a4c-c88e-4fc1-8881-f95c897e259f_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractualCapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual capital commitments</link:label>
    <link:label id="lab_ifrs-full_ContractualCapitalCommitments_label_en-US" xlink:label="lab_ifrs-full_ContractualCapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual capital commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractualCapitalCommitments" xlink:to="lab_ifrs-full_ContractualCapitalCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExtinguishmentOfBorrowings_725c3650-4682-4c1a-bcd3-fa643324dc80_terseLabel_en-US" xlink:label="lab_alvo_ExtinguishmentOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of borrowings</link:label>
    <link:label id="lab_alvo_ExtinguishmentOfBorrowings_label_en-US" xlink:label="lab_alvo_ExtinguishmentOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment Of Borrowings</link:label>
    <link:label id="lab_alvo_ExtinguishmentOfBorrowings_documentation_en-US" xlink:label="lab_alvo_ExtinguishmentOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extinguishment of borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtinguishmentOfBorrowings" xlink:href="alvo-20231231.xsd#alvo_ExtinguishmentOfBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExtinguishmentOfBorrowings" xlink:to="lab_alvo_ExtinguishmentOfBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_7d7d0a09-78cb-4fe1-adad-a3d3378f0d64_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transactions with owners, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechBiosciencesIndiaPrivateLtdMember_af2d1e73-da7c-4966-841a-f41c14f57380_terseLabel_en-US" xlink:label="lab_alvo_AlvotechBiosciencesIndiaPrivateLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech Biosciences India Private Ltd</link:label>
    <link:label id="lab_alvo_AlvotechBiosciencesIndiaPrivateLtdMember_label_en-US" xlink:label="lab_alvo_AlvotechBiosciencesIndiaPrivateLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech Biosciences India Private Ltd [Member]</link:label>
    <link:label id="lab_alvo_AlvotechBiosciencesIndiaPrivateLtdMember_documentation_en-US" xlink:label="lab_alvo_AlvotechBiosciencesIndiaPrivateLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech Biosciences India Private Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechBiosciencesIndiaPrivateLtdMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechBiosciencesIndiaPrivateLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechBiosciencesIndiaPrivateLtdMember" xlink:to="lab_alvo_AlvotechBiosciencesIndiaPrivateLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechSwissAgMember_ff89c6f9-7380-40f1-8921-c1b3a4eaacb7_terseLabel_en-US" xlink:label="lab_alvo_AlvotechSwissAgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech Swiss AG</link:label>
    <link:label id="lab_alvo_AlvotechSwissAgMember_label_en-US" xlink:label="lab_alvo_AlvotechSwissAgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech Swiss AG [Member]</link:label>
    <link:label id="lab_alvo_AlvotechSwissAgMember_documentation_en-US" xlink:label="lab_alvo_AlvotechSwissAgMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech Swiss AG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechSwissAgMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechSwissAgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechSwissAgMember" xlink:to="lab_alvo_AlvotechSwissAgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember_fded6b65-7437-4b66-840f-7156533c63f0_terseLabel_en-US" xlink:label="lab_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Of In Kind Accrued Interest As A Result Of Warrant Exercise</link:label>
    <link:label id="lab_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember_label_en-US" xlink:label="lab_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of In Kind Accrued Interest As A Result Of Warrant Exercise [member]</link:label>
    <link:label id="lab_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember_documentation_en-US" xlink:label="lab_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of in kind accrued interest as a result of warrant exercise [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember" xlink:href="alvo-20231231.xsd#alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember" xlink:to="lab_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExtinguishmentOfBorrowingsAccruedInterest_15ab94d1-33a0-40a3-9a23-71799ef86488_terseLabel_en-US" xlink:label="lab_alvo_ExtinguishmentOfBorrowingsAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of borrowings accrued interest</link:label>
    <link:label id="lab_alvo_ExtinguishmentOfBorrowingsAccruedInterest_label_en-US" xlink:label="lab_alvo_ExtinguishmentOfBorrowingsAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment Of Borrowings Accrued Interest</link:label>
    <link:label id="lab_alvo_ExtinguishmentOfBorrowingsAccruedInterest_documentation_en-US" xlink:label="lab_alvo_ExtinguishmentOfBorrowingsAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extinguishment of borrowings accrued interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtinguishmentOfBorrowingsAccruedInterest" xlink:href="alvo-20231231.xsd#alvo_ExtinguishmentOfBorrowingsAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExtinguishmentOfBorrowingsAccruedInterest" xlink:to="lab_alvo_ExtinguishmentOfBorrowingsAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AsiaAndOtherMember_0e285097-a0a3-456a-a861-d86df0fe29c8_terseLabel_en-US" xlink:label="lab_alvo_AsiaAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia and Other</link:label>
    <link:label id="lab_alvo_AsiaAndOtherMember_label_en-US" xlink:label="lab_alvo_AsiaAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia And Other [Member]</link:label>
    <link:label id="lab_alvo_AsiaAndOtherMember_documentation_en-US" xlink:label="lab_alvo_AsiaAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asia and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AsiaAndOtherMember" xlink:href="alvo-20231231.xsd#alvo_AsiaAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AsiaAndOtherMember" xlink:to="lab_alvo_AsiaAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_e0b69d8c-c61d-4c22-aa89-b15f597c02df_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateTypesMember" xlink:to="lab_ifrs-full_InterestRateTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RecognitionOfNewBorrowingsDiscount_b10170d6-f7e5-49d1-b5e4-9393c53319f8_negatedLabel_en-US" xlink:label="lab_alvo_RecognitionOfNewBorrowingsDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Recognition of new borrowings discount</link:label>
    <link:label id="lab_alvo_RecognitionOfNewBorrowingsDiscount_label_en-US" xlink:label="lab_alvo_RecognitionOfNewBorrowingsDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognition Of New Borrowings Discount</link:label>
    <link:label id="lab_alvo_RecognitionOfNewBorrowingsDiscount_documentation_en-US" xlink:label="lab_alvo_RecognitionOfNewBorrowingsDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recognition of new borrowings discount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RecognitionOfNewBorrowingsDiscount" xlink:href="alvo-20231231.xsd#alvo_RecognitionOfNewBorrowingsDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RecognitionOfNewBorrowingsDiscount" xlink:to="lab_alvo_RecognitionOfNewBorrowingsDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock_05811b45-9934-4dfa-ac0d-50d61282a77e_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of detailed information about maturity analysis for lease liabilities</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about maturity analysis for lease liabilities explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FlokiFasteignirEhf.Member_0a37fb92-9373-435d-bd2f-ea0c4d627f0e_terseLabel_en-US" xlink:label="lab_alvo_FlokiFasteignirEhf.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fl&#243;ki Fasteignir ehf.</link:label>
    <link:label id="lab_alvo_FlokiFasteignirEhf.Member_label_en-US" xlink:label="lab_alvo_FlokiFasteignirEhf.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fl&#243;ki Fasteignir ehf. [Member]</link:label>
    <link:label id="lab_alvo_FlokiFasteignirEhf.Member_documentation_en-US" xlink:label="lab_alvo_FlokiFasteignirEhf.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fl&#243;ki Fasteignir ehf.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiFasteignirEhf.Member" xlink:href="alvo-20231231.xsd#alvo_FlokiFasteignirEhf.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FlokiFasteignirEhf.Member" xlink:to="lab_alvo_FlokiFasteignirEhf.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_8ea600fb-1797-42ff-8198-81d8f802f5df_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_0c913a5f-def4-4061-adcb-01bad1edb2f8_totalLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_label_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="lab_ifrs-full_AverageEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfAuditFeesExplanatoryTextBlock_65d5d801-af17-446d-9938-760af4ac6dd7_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfAuditFeesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Audit fees</link:label>
    <link:label id="lab_alvo_DisclosureOfAuditFeesExplanatoryTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfAuditFeesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Audit Fees Explanatory [Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfAuditFeesExplanatoryTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfAuditFeesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of audit fees explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfAuditFeesExplanatoryTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfAuditFeesExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfAuditFeesExplanatoryTextBlock" xlink:to="lab_alvo_DisclosureOfAuditFeesExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_56cd6e92-95e0-4be6-9da8-cb12f1415efb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_bac056ac-433a-499f-b087-8903daf8d3b3_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock_72f08c8a-5fff-4402-b136-023162f84987_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of detailed information about lease cost</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Detailed Information About Lease Cost Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about lease cost explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_880a04e6-ceea-4834-ad80-7733e86de383_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_553e7644-3fd4-4db2-946f-376520b21301_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMajorCustomersTable_1b7fb5ff-54a1-4621-a3b9-e686fcc1754a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMajorCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMajorCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMajorCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMajorCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMajorCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfMajorCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_635c9add-5f52-40a6-8a7b-77d8befabee4_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public warrants exercised</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_a5152d85-28a5-42df-bf0e-49279e765f7d_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Foreign Exchange Rate [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Foreign Exchange Rate [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of foreign exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfForeignExchangeRateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable" xlink:to="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_e025b342-3017-444e-84cd-9d2a8838f957_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment to employee</link:label>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_6aed3b2b-a1c6-46ed-aac3-a1eb1b52bc30_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_9a55b35b-1635-487b-b585-cc6aec646774_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock_0f14d35e-4bb5-4d3b-9892-d52bc66dff5f_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Restricted Cash</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Detailed Information about Restricted Cash and Cash Equivalents Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about restricted cash and cash equivalents explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RiskExposuresAxis_c7d28a2f-7a8c-4cdc-898f-e40992a3670c_terseLabel_en-US" xlink:label="lab_ifrs-full_RiskExposuresAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk variables [axis]</link:label>
    <link:label id="lab_ifrs-full_RiskExposuresAxis_label_en-US" xlink:label="lab_ifrs-full_RiskExposuresAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk variables [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposuresAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposuresAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RiskExposuresAxis" xlink:to="lab_ifrs-full_RiskExposuresAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ceca6883-2645-4ed3-9208-4191eca2ca1b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfOperatingSegments1_492eeb6d-ed33-4b54-9325-d2eb88944360_terseLabel_en-US" xlink:label="lab_alvo_NumberOfOperatingSegments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_alvo_NumberOfOperatingSegments1_label_en-US" xlink:label="lab_alvo_NumberOfOperatingSegments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Segments 1</link:label>
    <link:label id="lab_alvo_NumberOfOperatingSegments1_documentation_en-US" xlink:label="lab_alvo_NumberOfOperatingSegments1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Operating Segments 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfOperatingSegments1" xlink:href="alvo-20231231.xsd#alvo_NumberOfOperatingSegments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfOperatingSegments1" xlink:to="lab_alvo_NumberOfOperatingSegments1" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_58820823-884b-4d27-846f-966501b7d09d_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Depreciation Amortization And Imapirment [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Depreciation Amortization And Imapirment [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of depreciation amortization and imapirment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract" xlink:to="lab_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BeforeTheTermsOfTheSecondAmendmentMember_398bcb75-bcba-4f93-a800-93986441c1f2_terseLabel_en-US" xlink:label="lab_alvo_BeforeTheTermsOfTheSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Before The Terms Of The Second Amendment</link:label>
    <link:label id="lab_alvo_BeforeTheTermsOfTheSecondAmendmentMember_label_en-US" xlink:label="lab_alvo_BeforeTheTermsOfTheSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Before The Terms Of The Second Amendment [member]</link:label>
    <link:label id="lab_alvo_BeforeTheTermsOfTheSecondAmendmentMember_documentation_en-US" xlink:label="lab_alvo_BeforeTheTermsOfTheSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Before the terms of the second amendment [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BeforeTheTermsOfTheSecondAmendmentMember" xlink:href="alvo-20231231.xsd#alvo_BeforeTheTermsOfTheSecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BeforeTheTermsOfTheSecondAmendmentMember" xlink:to="lab_alvo_BeforeTheTermsOfTheSecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VestedEarnoutSharesIssued_63251715-940c-430e-b56b-3895883ccc35_terseLabel_en-US" xlink:label="lab_alvo_VestedEarnoutSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested earn-out shares (in shares)</link:label>
    <link:label id="lab_alvo_VestedEarnoutSharesIssued_label_en-US" xlink:label="lab_alvo_VestedEarnoutSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested Earnout Shares Issued</link:label>
    <link:label id="lab_alvo_VestedEarnoutSharesIssued_documentation_en-US" xlink:label="lab_alvo_VestedEarnoutSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vested Earnout Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnoutSharesIssued" xlink:href="alvo-20231231.xsd#alvo_VestedEarnoutSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VestedEarnoutSharesIssued" xlink:to="lab_alvo_VestedEarnoutSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_ab314cd9-1043-44a4-9386-89c76d02c18f_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TaxYearsDomain_5c40e137-c41c-400c-8167-21b74b7253be_terseLabel_en-US" xlink:label="lab_alvo_TaxYearsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax years [Domain]</link:label>
    <link:label id="lab_alvo_TaxYearsDomain_label_en-US" xlink:label="lab_alvo_TaxYearsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax years [Domain]</link:label>
    <link:label id="lab_alvo_TaxYearsDomain_documentation_en-US" xlink:label="lab_alvo_TaxYearsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxYearsDomain" xlink:href="alvo-20231231.xsd#alvo_TaxYearsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TaxYearsDomain" xlink:to="lab_alvo_TaxYearsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_23708d92-d5fe-4f51-b6c8-5d8c9cbee346_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_fefa96a1-1e32-424c-8678-86080c9eedba_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_f0b1146f-2991-4886-88b2-b5dde19b1c4b_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_87b55ca5-1539-4df0-8824-89cbde7dc545_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory_85c39b2f-502f-4b9a-8d87-5ecc3661e081_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting standards</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of first-time adoption [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractAssets_0c580908-7f02-45c1-ba5b-425072b1c10d_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_ifrs-full_CurrentContractAssets_dc09a92f-fb92-48cc-a810-82ced6c8d3e4_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contract assets</link:label>
    <link:label id="lab_ifrs-full_CurrentContractAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractAssets" xlink:to="lab_ifrs-full_CurrentContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsRollForward_3e863d2d-6bea-4a39-82f3-3c38e6ea829f_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings [Roll Forward]</link:label>
    <link:label id="lab_alvo_BorrowingsRollForward_label_en-US" xlink:label="lab_alvo_BorrowingsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings [Roll Forward]</link:label>
    <link:label id="lab_alvo_BorrowingsRollForward_documentation_en-US" xlink:label="lab_alvo_BorrowingsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRollForward" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsRollForward" xlink:to="lab_alvo_BorrowingsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2f54b1cd-4da0-4bdb-8113-3d10badb630b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Share Capital and Share Premium</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_7727abdb-ec2b-4f96-b8db-c9ecc5b1e635_terseLabel_en-US" xlink:label="lab_alvo_AlvogenPharmaPvtLtdSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Pharma Pvt Ltd - Sister Company</link:label>
    <link:label id="lab_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenPharmaPvtLtdSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Pharma Pvt Ltd - Sister Company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenPharmaPvtLtdSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Pharma Pvt Ltd member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenPharmaPvtLtdSisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember" xlink:to="lab_alvo_AlvogenPharmaPvtLtdSisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DerecognitionDueToAssetsAcquisition_1f42d76a-08a4-44f9-acdd-e3bbf5704ef7_negatedLabel_en-US" xlink:label="lab_alvo_DerecognitionDueToAssetsAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Derecognition due to acquisition of Alvotech Facility (see Note 12)</link:label>
    <link:label id="lab_alvo_DerecognitionDueToAssetsAcquisition_label_en-US" xlink:label="lab_alvo_DerecognitionDueToAssetsAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognition Due To Assets Acquisition</link:label>
    <link:label id="lab_alvo_DerecognitionDueToAssetsAcquisition_documentation_en-US" xlink:label="lab_alvo_DerecognitionDueToAssetsAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derecognition due to assets acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionDueToAssetsAcquisition" xlink:href="alvo-20231231.xsd#alvo_DerecognitionDueToAssetsAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DerecognitionDueToAssetsAcquisition" xlink:to="lab_alvo_DerecognitionDueToAssetsAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_9ff0c2ee-7967-469d-9824-0751a36981c0_verboseLabel_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_label_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of expense not deductible in determining taxable profit (tax loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="lab_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_2aca6bd4-e767-4d48-bf7e-07ca0c8957c9_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_7918883d-abcc-4ee4-9593-1af0a58960ed_verboseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic loss per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax_11a386e9-0ce1-4531-b6c5-3efd180db89e_terseLabel_en-US" xlink:label="lab_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation difference</link:label>
    <link:label id="lab_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax_label_en-US" xlink:label="lab_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Gains Losses Of Joint Ventures On Exchange Differences On Translation Net Of Tax</link:label>
    <link:label id="lab_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax_documentation_en-US" xlink:label="lab_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of gains losses of joint ventures on exchange differences on translation net of tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="alvo-20231231.xsd#alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="lab_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_2eeb0402-8533-499a-82a9-d0a8ed433efd_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value changes, including accretion</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_3e57902d-442a-404d-9135-d9af683651bc_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_1567caa5-ad56-4277-a028-95eac64d99e9_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate applied to cash flow projections</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate applied to cash flow projections</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:to="lab_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_f4d86cea-bc7c-4b36-9972-70397220c48c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Goodwill</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_42946ced-13d3-4907-846a-7f2f9bbcd1e7_terseLabel_en-US" xlink:label="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Information About Board of Directors Remuneration [Line Items]</link:label>
    <link:label id="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_label_en-US" xlink:label="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Information About Board of Directors Remuneration [Line Items]</link:label>
    <link:label id="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_documentation_en-US" xlink:label="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of information about board of directors remuneration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems" xlink:to="lab_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LeaseFacilityDomain_2135e92b-fec8-4424-ace7-49ba1a25b274_terseLabel_en-US" xlink:label="lab_alvo_LeaseFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Facility [Domain]</link:label>
    <link:label id="lab_alvo_LeaseFacilityDomain_label_en-US" xlink:label="lab_alvo_LeaseFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Facility [Domain]</link:label>
    <link:label id="lab_alvo_LeaseFacilityDomain_documentation_en-US" xlink:label="lab_alvo_LeaseFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseFacilityDomain" xlink:href="alvo-20231231.xsd#alvo_LeaseFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LeaseFacilityDomain" xlink:to="lab_alvo_LeaseFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AmortizationOfDeferredDebtIssuanceCosts_3e08e79b-18e0-4b91-adb2-5236dab06ac5_terseLabel_en-US" xlink:label="lab_alvo_AmortizationOfDeferredDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred debt issue costs</link:label>
    <link:label id="lab_alvo_AmortizationOfDeferredDebtIssuanceCosts_label_en-US" xlink:label="lab_alvo_AmortizationOfDeferredDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Deferred Debt Issuance Costs</link:label>
    <link:label id="lab_alvo_AmortizationOfDeferredDebtIssuanceCosts_documentation_en-US" xlink:label="lab_alvo_AmortizationOfDeferredDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of deferred debt issuancecCosts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationOfDeferredDebtIssuanceCosts" xlink:href="alvo-20231231.xsd#alvo_AmortizationOfDeferredDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AmortizationOfDeferredDebtIssuanceCosts" xlink:to="lab_alvo_AmortizationOfDeferredDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenMember_430ea685-4bd5-4506-a845-3be93eed3448_terseLabel_en-US" xlink:label="lab_alvo_AlvogenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen</link:label>
    <link:label id="lab_alvo_AlvogenMember_label_en-US" xlink:label="lab_alvo_AlvogenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen [Member]</link:label>
    <link:label id="lab_alvo_AlvogenMember_documentation_en-US" xlink:label="lab_alvo_AlvogenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenMember" xlink:to="lab_alvo_AlvogenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqFacilityLoansMember_d1bc4341-f1dd-43f2-b871-9074bd9ba4f1_terseLabel_en-US" xlink:label="lab_alvo_AztiqFacilityLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq Facility Loans</link:label>
    <link:label id="lab_alvo_AztiqFacilityLoansMember_label_en-US" xlink:label="lab_alvo_AztiqFacilityLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq Facility Loans [member]</link:label>
    <link:label id="lab_alvo_AztiqFacilityLoansMember_documentation_en-US" xlink:label="lab_alvo_AztiqFacilityLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq Facility Loans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFacilityLoansMember" xlink:href="alvo-20231231.xsd#alvo_AztiqFacilityLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqFacilityLoansMember" xlink:to="lab_alvo_AztiqFacilityLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_60b13093-b7be-40e6-ac52-69f2601fe2fd_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BcaFrameworkAgreementMember_c3ecf0ef-c5f6-4984-b544-764928afd042_terseLabel_en-US" xlink:label="lab_alvo_BcaFrameworkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCA Framework Agreement</link:label>
    <link:label id="lab_alvo_BcaFrameworkAgreementMember_label_en-US" xlink:label="lab_alvo_BcaFrameworkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCA Framework Agreement [member]</link:label>
    <link:label id="lab_alvo_BcaFrameworkAgreementMember_documentation_en-US" xlink:label="lab_alvo_BcaFrameworkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCA framework agreement [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BcaFrameworkAgreementMember" xlink:href="alvo-20231231.xsd#alvo_BcaFrameworkAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BcaFrameworkAgreementMember" xlink:to="lab_alvo_BcaFrameworkAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock_50da5a49-32a8-4a32-b1f4-0bc017ae2b2b_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Analysis Assumes that all Other Variables</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure in Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of currency risk sensitivity analysis on profit before tax explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_30688d93-fb91-4ea5-a9bd-e3bffdb9a31c_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_KashivMember_ab13941f-c477-4660-9f39-d00ee877f1cc_terseLabel_en-US" xlink:label="lab_alvo_KashivMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kashiv</link:label>
    <link:label id="lab_alvo_KashivMember_label_en-US" xlink:label="lab_alvo_KashivMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kashiv [Member]</link:label>
    <link:label id="lab_alvo_KashivMember_documentation_en-US" xlink:label="lab_alvo_KashivMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kashiv</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_KashivMember" xlink:href="alvo-20231231.xsd#alvo_KashivMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_KashivMember" xlink:to="lab_alvo_KashivMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_aed3de07-2812-4b77-9cbf-440175388b16_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherShareBasedPaymentsMember_ab842d7e-22d7-4a81-a50d-15886937cc60_terseLabel_en-US" xlink:label="lab_alvo_OtherShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Share Based Payments</link:label>
    <link:label id="lab_alvo_OtherShareBasedPaymentsMember_label_en-US" xlink:label="lab_alvo_OtherShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Share Based Payments [Member]</link:label>
    <link:label id="lab_alvo_OtherShareBasedPaymentsMember_documentation_en-US" xlink:label="lab_alvo_OtherShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Share Based Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherShareBasedPaymentsMember" xlink:href="alvo-20231231.xsd#alvo_OtherShareBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherShareBasedPaymentsMember" xlink:to="lab_alvo_OtherShareBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaximumExposureToCreditRisk_1bab68a4-6ce8-4f4b-bfce-14a4f167c762_terseLabel_en-US" xlink:label="lab_ifrs-full_MaximumExposureToCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum exposure to credit risk</link:label>
    <link:label id="lab_ifrs-full_MaximumExposureToCreditRisk_label_en-US" xlink:label="lab_ifrs-full_MaximumExposureToCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum exposure to credit risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaximumExposureToCreditRisk" xlink:to="lab_ifrs-full_MaximumExposureToCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_3dcf6f25-0cae-4a2d-8957-95eec95e35f2_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_bb7d6d97-31fc-4c4d-b0a9-0fac293d3394_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments_55e57d46-b4a8-4d7f-be2b-93cf111572ab_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of convertible bonds</link:label>
    <link:label id="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments_label_en-US" xlink:label="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of equity component of convertible instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:to="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_ab44889f-49b2-4dca-af35-8ef540a58c76_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_7e2f19ec-da91-470f-9fa0-6e6f77506f4f_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenAztiqABSisterCompanyMember_3e21c9f2-ab34-4616-be19-f0353d914be6_terseLabel_en-US" xlink:label="lab_alvo_AlvogenAztiqABSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Aztiq AB &#8211; Sister company</link:label>
    <link:label id="lab_alvo_AlvogenAztiqABSisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenAztiqABSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Aztiq AB &#8211; Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenAztiqABSisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenAztiqABSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Aztiq AB member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenAztiqABSisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenAztiqABSisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenAztiqABSisterCompanyMember" xlink:to="lab_alvo_AlvogenAztiqABSisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_EventAxis_c15770ce-0f91-4fe9-be90-d5d82c782148_terseLabel_en-US" xlink:label="lab_alvo_EventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Event [Axis]</link:label>
    <link:label id="lab_alvo_EventAxis_label_en-US" xlink:label="lab_alvo_EventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Event [Axis]</link:label>
    <link:label id="lab_alvo_EventAxis_documentation_en-US" xlink:label="lab_alvo_EventAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Event [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EventAxis" xlink:href="alvo-20231231.xsd#alvo_EventAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_EventAxis" xlink:to="lab_alvo_EventAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_4843e595-c679-4bff-af6a-ee2550d977d2_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_fa04c53a-da6f-4e01-a3f9-44aea05d275c_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of fair value of derivative financial instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable" xlink:to="lab_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_EarnoutWarrantsMember_2077bbf3-5886-4fa8-9fd1-dbc666fb2fa1_terseLabel_en-US" xlink:label="lab_alvo_EarnoutWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OACB Warrants</link:label>
    <link:label id="lab_alvo_EarnoutWarrantsMember_label_en-US" xlink:label="lab_alvo_EarnoutWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnout Warrants [Member]</link:label>
    <link:label id="lab_alvo_EarnoutWarrantsMember_documentation_en-US" xlink:label="lab_alvo_EarnoutWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnout warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_EarnoutWarrantsMember" xlink:to="lab_alvo_EarnoutWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GeneralAndAdministrativeMember_6f753ebf-54e9-46fd-9b4f-c573c0eebe93_terseLabel_en-US" xlink:label="lab_alvo_GeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_alvo_GeneralAndAdministrativeMember_label_en-US" xlink:label="lab_alvo_GeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative [Member]</link:label>
    <link:label id="lab_alvo_GeneralAndAdministrativeMember_documentation_en-US" xlink:label="lab_alvo_GeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General and administrative.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeMember" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GeneralAndAdministrativeMember" xlink:to="lab_alvo_GeneralAndAdministrativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ResearchAndDevelopmentMember_82b9e165-758c-468e-abbd-e64e142874ec_terseLabel_en-US" xlink:label="lab_alvo_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_alvo_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_alvo_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_alvo_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_alvo_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentMember" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ResearchAndDevelopmentMember" xlink:to="lab_alvo_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_c385de8f-38da-4079-be52-589d6bb5c407_terseLabel_en-US" xlink:label="lab_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Asset Of Defined Benefit Plans [Roll Forward]</link:label>
    <link:label id="lab_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_label_en-US" xlink:label="lab_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Asset Of Defined Benefit Plans [Roll Forward]</link:label>
    <link:label id="lab_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_documentation_en-US" xlink:label="lab_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Asset Of Defined Benefit Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward" xlink:href="alvo-20231231.xsd#alvo_LiabilityAssetOfDefinedBenefitPlansRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward" xlink:to="lab_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements_a67a3c76-4174-49cd-8707-996e4017494e_terseLabel_en-US" xlink:label="lab_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of other intangible assets through financing agreements</link:label>
    <link:label id="lab_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements_label_en-US" xlink:label="lab_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquistion Of Other Intangible Assets Through Financing Agreements</link:label>
    <link:label id="lab_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements_documentation_en-US" xlink:label="lab_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquistion Of Other Intangible Assets Through Financing Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" xlink:href="alvo-20231231.xsd#alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" xlink:to="lab_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_b1470d47-792f-4a69-9a7c-415f33735475_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate differences</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherBorrowings_421f2308-8ae6-4333-a438-d6d0d5f3398d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:label id="lab_ifrs-full_OtherBorrowings_label_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherBorrowings" xlink:to="lab_ifrs-full_OtherBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_0b6c3406-f4f5-4862-a370-7f1aa5f73f54_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharePrice2019_fdedff7b-cf2b-4c6e-a91f-3028fd22af9e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average share price (in dollar per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharePrice2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average share price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePrice2019" xlink:to="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_April2023LeaseFacilityMember_d52628c1-1594-4bfa-befa-72898dd1a756_terseLabel_en-US" xlink:label="lab_alvo_April2023LeaseFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2023 Lease Facility</link:label>
    <link:label id="lab_alvo_April2023LeaseFacilityMember_label_en-US" xlink:label="lab_alvo_April2023LeaseFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2023 Lease Facility [Member]</link:label>
    <link:label id="lab_alvo_April2023LeaseFacilityMember_documentation_en-US" xlink:label="lab_alvo_April2023LeaseFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2023 Lease Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_April2023LeaseFacilityMember" xlink:href="alvo-20231231.xsd#alvo_April2023LeaseFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_April2023LeaseFacilityMember" xlink:to="lab_alvo_April2023LeaseFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_143412cb-ee2b-4052-b501-b640cb422027_terseLabel_en-US" xlink:label="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss) / gain on extinguishment of financial liabilities</link:label>
    <link:label id="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_c352b34b-8d95-4190-9a3a-29c6ba63832c_negatedLabel_en-US" xlink:label="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss/(Gain) on extinguishment of financial liabilities</link:label>
    <link:label id="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_label_en-US" xlink:label="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) arising from difference between carrying amount of financial liability extinguished and consideration paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:to="lab_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ca226334-efd7-419c-a543-fac287af4160_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesLineItems_59c0da3b-0a2a-468e-9831-45eea6fd3543_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of joint ventures [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of joint ventures [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MaturityMonthAndYearAxis_3dd41280-9d95-4dbf-a46b-0c6a3d34cd19_terseLabel_en-US" xlink:label="lab_alvo_MaturityMonthAndYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Month and Year [Axis]</link:label>
    <link:label id="lab_alvo_MaturityMonthAndYearAxis_label_en-US" xlink:label="lab_alvo_MaturityMonthAndYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Month and Year [Axis]</link:label>
    <link:label id="lab_alvo_MaturityMonthAndYearAxis_documentation_en-US" xlink:label="lab_alvo_MaturityMonthAndYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity month and year [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturityMonthAndYearAxis" xlink:href="alvo-20231231.xsd#alvo_MaturityMonthAndYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MaturityMonthAndYearAxis" xlink:to="lab_alvo_MaturityMonthAndYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities_420af36a-36b4-4483-a688-5bea339ec08c_terseLabel_en-US" xlink:label="lab_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained through new operating leases</link:label>
    <link:label id="lab_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities_label_en-US" xlink:label="lab_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right Of Use Assets Obtained Through New Operating Lease Liabilities</link:label>
    <link:label id="lab_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right of use assets obained through new operating lease liabilites.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" xlink:href="alvo-20231231.xsd#alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" xlink:to="lab_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_b47b22eb-81f6-4cc4-9315-71b695336e29_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments (see Note 23)</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_98a3e7a0-5931-4e15-aecc-58280e95c350_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_8063f12d-0f45-4e86-b1c0-df132f50a203_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_ed94cc90-2222-4e83-99f1-469e9631d4ce_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareTable_70079f4a-b45f-4bcc-92da-a73ff5952f07_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share [table]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareTable_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareTable" xlink:to="lab_ifrs-full_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqConversionFeatureMember_00bf6a76-63b6-46cd-9b50-ad44229bcc34_terseLabel_en-US" xlink:label="lab_alvo_AztiqConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq Conversion Feature</link:label>
    <link:label id="lab_alvo_AztiqConversionFeatureMember_label_en-US" xlink:label="lab_alvo_AztiqConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq Conversion Feature [member]</link:label>
    <link:label id="lab_alvo_AztiqConversionFeatureMember_documentation_en-US" xlink:label="lab_alvo_AztiqConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq Conversion Feature [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConversionFeatureMember" xlink:href="alvo-20231231.xsd#alvo_AztiqConversionFeatureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqConversionFeatureMember" xlink:to="lab_alvo_AztiqConversionFeatureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_88075096-3109-4b2c-961b-5401ec469658_terseLabel_en-US" xlink:label="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Line Items]</link:label>
    <link:label id="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_label_en-US" xlink:label="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Line Items]</link:label>
    <link:label id="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_documentation_en-US" xlink:label="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detailed information about depreciation amortization and impairment expense included in consolidated statements profit or loss and other comprehensive income or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems" xlink:href="alvo-20231231.xsd#alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems" xlink:to="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock_070098da-84b7-4c6d-9754-fedb6db96f0b_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Interest Rate Sensitivity Analysis</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Interest Rate Sensitivity Analysis Impact On Profit Before Tax Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheOfSeniorBondWarrantsPercentage_07389f93-388c-46b2-8b6b-6f217cc853d2_terseLabel_en-US" xlink:label="lab_alvo_TrancheOfSeniorBondWarrantsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche of senior bond warrants percentage</link:label>
    <link:label id="lab_alvo_TrancheOfSeniorBondWarrantsPercentage_label_en-US" xlink:label="lab_alvo_TrancheOfSeniorBondWarrantsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche of Senior Bond Warrants, Percentage</link:label>
    <link:label id="lab_alvo_TrancheOfSeniorBondWarrantsPercentage_documentation_en-US" xlink:label="lab_alvo_TrancheOfSeniorBondWarrantsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche of Senior Bond Warrants, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheOfSeniorBondWarrantsPercentage" xlink:href="alvo-20231231.xsd#alvo_TrancheOfSeniorBondWarrantsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheOfSeniorBondWarrantsPercentage" xlink:to="lab_alvo_TrancheOfSeniorBondWarrantsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_3b898cc6-9c1e-45f8-b507-f182c1225ec1_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock_cb64dc18-c5e3-411f-961f-656d68d43fe6_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Groups Investment in a Joint Venture</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Changes In Investment In Joint Venture Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about changes in investment in joint venture explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory_e969141f-9634-4d39-b3d1-ea6f23e5d94b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Impairment Loss and Reversal of Impairment Loss</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_0b8127e8-1d59-4c14-8c62-9f8cf211f716_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_c805651f-9904-49c0-84b1-5cfeb37821a8_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of movements in the group's employee incentive plan liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock_7b063b7b-bba3-4e85-a23a-6f22a272a3f9_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of information about Board of Directors remuneration</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Board Of Directors And Key Managerial Personnel Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about board of directors and key managerial personnel explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b2f589ac-d401-4809-9da5-bda39725a4cc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MaturedOnAugust2030Member_38782db5-1b69-4766-8419-86ecd1dec078_terseLabel_en-US" xlink:label="lab_alvo_MaturedOnAugust2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matured on august 2030</link:label>
    <link:label id="lab_alvo_MaturedOnAugust2030Member_label_en-US" xlink:label="lab_alvo_MaturedOnAugust2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Matured On August 2030 [Member]</link:label>
    <link:label id="lab_alvo_MaturedOnAugust2030Member_documentation_en-US" xlink:label="lab_alvo_MaturedOnAugust2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Matured On August 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnAugust2030Member" xlink:href="alvo-20231231.xsd#alvo_MaturedOnAugust2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MaturedOnAugust2030Member" xlink:to="lab_alvo_MaturedOnAugust2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains_98be7f1d-3103-48bc-aa1d-412054a35f95_terseLabel_en-US" xlink:label="lab_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of SARs liability</link:label>
    <link:label id="lab_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains_label_en-US" xlink:label="lab_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Extinguishment Of Liability Losses Gains</link:label>
    <link:label id="lab_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains_documentation_en-US" xlink:label="lab_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for extinguishment of liability losses gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains" xlink:to="lab_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CapitalReorganizationEventSharesIssued_a40413f4-433e-4573-993d-4720bff17e57_terseLabel_en-US" xlink:label="lab_alvo_CapitalReorganizationEventSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital reorganization event shares issued (in shares)</link:label>
    <link:label id="lab_alvo_CapitalReorganizationEventSharesIssued_label_en-US" xlink:label="lab_alvo_CapitalReorganizationEventSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Reorganization Event Shares Issued</link:label>
    <link:label id="lab_alvo_CapitalReorganizationEventSharesIssued_documentation_en-US" xlink:label="lab_alvo_CapitalReorganizationEventSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital reorganization event shares issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalReorganizationEventSharesIssued" xlink:href="alvo-20231231.xsd#alvo_CapitalReorganizationEventSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CapitalReorganizationEventSharesIssued" xlink:to="lab_alvo_CapitalReorganizationEventSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_ebbc50d1-3572-40b2-a325-61d03f722c93_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_d8869fd8-7317-4d10-8e2e-2964ea4046d9_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_0e7c1bcb-5e8a-4d8d-b9d0-640199e13e9d_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_21391c65-0481-4d82-8a97-603a7c591ace_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_f8aacf2c-2b8f-4663-8aa9-760fb4b2ed0b_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock par or stated value per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_47fc40f8-7d62-426f-bafd-c2aa50b53434_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_7e526a60-d11d-4004-bef2-3f4936ef18f7_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operations</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_afc31443-5a2f-4505-ad6d-5fe169221888_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ResearchAndDevelopmentExpensesMember_ecea9348-7374-42a1-b9b7-1cdf9ef1a01d_terseLabel_en-US" xlink:label="lab_alvo_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_alvo_ResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_alvo_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expenses [Member]</link:label>
    <link:label id="lab_alvo_ResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_alvo_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentExpensesMember" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ResearchAndDevelopmentExpensesMember" xlink:to="lab_alvo_ResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock_05b5d9c0-49ea-4aff-96de-95a8a7e52ba4_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about salaries and other employee expenses included in consolidated statements of profit or loss explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_df82d07f-94ef-474c-9221-b9f861433253_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of assets</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e7652213-6968-4f41-8234-80a2e9dc44a6_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in contract liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DevelopmentAndOtherServiceRevenueMember_d6acad5e-6c27-48e5-808c-2cc4b955a028_terseLabel_en-US" xlink:label="lab_alvo_DevelopmentAndOtherServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and other service revenue (over time revenue recognition)</link:label>
    <link:label id="lab_alvo_DevelopmentAndOtherServiceRevenueMember_label_en-US" xlink:label="lab_alvo_DevelopmentAndOtherServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development and Other Service Revenue [Member]</link:label>
    <link:label id="lab_alvo_DevelopmentAndOtherServiceRevenueMember_documentation_en-US" xlink:label="lab_alvo_DevelopmentAndOtherServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development and other service revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DevelopmentAndOtherServiceRevenueMember" xlink:href="alvo-20231231.xsd#alvo_DevelopmentAndOtherServiceRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DevelopmentAndOtherServiceRevenueMember" xlink:to="lab_alvo_DevelopmentAndOtherServiceRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PennyWarrantsMember_0da336b4-f259-4849-8d53-aa0c231a791f_terseLabel_en-US" xlink:label="lab_alvo_PennyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penny Warrants</link:label>
    <link:label id="lab_alvo_PennyWarrantsMember_label_en-US" xlink:label="lab_alvo_PennyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Penny Warrants [Member]</link:label>
    <link:label id="lab_alvo_PennyWarrantsMember_documentation_en-US" xlink:label="lab_alvo_PennyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Penny Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PennyWarrantsMember" xlink:href="alvo-20231231.xsd#alvo_PennyWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PennyWarrantsMember" xlink:to="lab_alvo_PennyWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_a8235924-4fac-43fd-b325-ce12c61cd0f0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_2a82db23-9a09-416c-b424-2ea40a7ffccb_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive plan expense</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_c37c73f9-eee5-4d36-9e18-a328a07b4d61_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of exchange differences on translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock_4b6c761d-c693-4930-83ba-6eddef4df37a_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Depreciation Amortization And Impairment</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Depreciation Amortization And Impairment Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about depreciation amortization and impairment explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock_2188cfe6-a665-4caf-90ab-161303c53115_terseLabel_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenue</link:label>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for cost of product revenue explanatory [Policy Text Block]</link:label>
    <link:label id="lab_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of accounting policy for cost of product revenue explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" xlink:href="alvo-20231231.xsd#alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" xlink:to="lab_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DecreaseThroughDerecognitionRightOfUseAssets_cb0983f4-a39f-450c-8eb3-875975f67325_negatedTerseLabel_en-US" xlink:label="lab_alvo_DecreaseThroughDerecognitionRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Derecognition due to acquisition of Alvotech Facility (see Note 12)</link:label>
    <link:label id="lab_alvo_DecreaseThroughDerecognitionRightOfUseAssets_label_en-US" xlink:label="lab_alvo_DecreaseThroughDerecognitionRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease Through Derecognition, Right Of Use Assets</link:label>
    <link:label id="lab_alvo_DecreaseThroughDerecognitionRightOfUseAssets_documentation_en-US" xlink:label="lab_alvo_DecreaseThroughDerecognitionRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease Through Derecognition, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DecreaseThroughDerecognitionRightOfUseAssets" xlink:href="alvo-20231231.xsd#alvo_DecreaseThroughDerecognitionRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DecreaseThroughDerecognitionRightOfUseAssets" xlink:to="lab_alvo_DecreaseThroughDerecognitionRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FlokiInvestEhfMember_17684ed3-8159-4295-a785-2b1b01ba94c7_terseLabel_en-US" xlink:label="lab_alvo_FlokiInvestEhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fl&#243;ki Invest ehf - Sister company</link:label>
    <link:label id="lab_alvo_FlokiInvestEhfMember_label_en-US" xlink:label="lab_alvo_FlokiInvestEhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Floki Invest ehf [Member]</link:label>
    <link:label id="lab_alvo_FlokiInvestEhfMember_documentation_en-US" xlink:label="lab_alvo_FlokiInvestEhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Floki Invest ehf</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiInvestEhfMember" xlink:href="alvo-20231231.xsd#alvo_FlokiInvestEhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FlokiInvestEhfMember" xlink:to="lab_alvo_FlokiInvestEhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WorkInProgress_a2662a71-ecff-45ad-8902-d7ac7ed9f98a_terseLabel_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_ifrs-full_WorkInProgress_label_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current work in progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress" xlink:to="lab_ifrs-full_WorkInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExpenseCapitalized_ebc5a944-d07a-4460-8eb5-33a2e58821ad_terseLabel_en-US" xlink:label="lab_alvo_ExpenseCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense capitalized</link:label>
    <link:label id="lab_alvo_ExpenseCapitalized_label_en-US" xlink:label="lab_alvo_ExpenseCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Capitalized</link:label>
    <link:label id="lab_alvo_ExpenseCapitalized_documentation_en-US" xlink:label="lab_alvo_ExpenseCapitalized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense capitalized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExpenseCapitalized" xlink:href="alvo-20231231.xsd#alvo_ExpenseCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExpenseCapitalized" xlink:to="lab_alvo_ExpenseCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember_4ede002e-bd28-4fa0-bb02-dced0a4e00af_terseLabel_en-US" xlink:label="lab_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq Pharma Partners S.&#224; r.l. &#8211; Sister company</link:label>
    <link:label id="lab_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember_label_en-US" xlink:label="lab_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq Pharma Partners S.&#224; r.l. &#8211; Sister company [Member]</link:label>
    <link:label id="lab_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq Pharma Partners S.&#224; r.l. member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember" xlink:to="lab_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VestedEarnoutSharesValue_5ed99974-9977-4f8e-9b73-de40edb8b03f_terseLabel_en-US" xlink:label="lab_alvo_VestedEarnoutSharesValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested earn-out shares</link:label>
    <link:label id="lab_alvo_VestedEarnoutSharesValue_label_en-US" xlink:label="lab_alvo_VestedEarnoutSharesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested Earnout Shares Value</link:label>
    <link:label id="lab_alvo_VestedEarnoutSharesValue_documentation_en-US" xlink:label="lab_alvo_VestedEarnoutSharesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vested Earnout Shares Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnoutSharesValue" xlink:href="alvo-20231231.xsd#alvo_VestedEarnoutSharesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VestedEarnoutSharesValue" xlink:to="lab_alvo_VestedEarnoutSharesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_bd344884-e22b-4bb9-9b92-f122f599d0d5_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of composition of other current liabilities</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Current Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about other current liabilities explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_c6fbf441-fa63-4310-9ad2-eb4635ffa62c_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember_5daca1f3-6eb0-4d03-a643-ade40e6b035a_terseLabel_en-US" xlink:label="lab_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024-2026</link:label>
    <link:label id="lab_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember_label_en-US" xlink:label="lab_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Four to Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Four to Two Thousand Twenty Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember" xlink:href="alvo-20231231.xsd#alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember" xlink:to="lab_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingSharesIssuancePeriodForInterestDecrease_3d337f08-0025-43d2-a275-63648966c395_terseLabel_en-US" xlink:label="lab_alvo_BorrowingSharesIssuancePeriodForInterestDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuance period for interest decrease</link:label>
    <link:label id="lab_alvo_BorrowingSharesIssuancePeriodForInterestDecrease_label_en-US" xlink:label="lab_alvo_BorrowingSharesIssuancePeriodForInterestDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Shares Issuance Period For Interest Decrease</link:label>
    <link:label id="lab_alvo_BorrowingSharesIssuancePeriodForInterestDecrease_documentation_en-US" xlink:label="lab_alvo_BorrowingSharesIssuancePeriodForInterestDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Shares Issuance Period For Interest Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingSharesIssuancePeriodForInterestDecrease" xlink:href="alvo-20231231.xsd#alvo_BorrowingSharesIssuancePeriodForInterestDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingSharesIssuancePeriodForInterestDecrease" xlink:to="lab_alvo_BorrowingSharesIssuancePeriodForInterestDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsTrancheDomain_ffc3d4e7-a206-4aaa-8896-9735cd10945e_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings Tranche [Domain]</link:label>
    <link:label id="lab_alvo_BorrowingsTrancheDomain_label_en-US" xlink:label="lab_alvo_BorrowingsTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Tranche [Domain]</link:label>
    <link:label id="lab_alvo_BorrowingsTrancheDomain_documentation_en-US" xlink:label="lab_alvo_BorrowingsTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings Tranche [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheDomain" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsTrancheDomain" xlink:to="lab_alvo_BorrowingsTrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_a5ab623d-1314-49e5-8912-98d195bea3f9_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Interest Rate Sensitivity Analysis Impact On Profit Before Tax [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Interest Rate Sensitivity Analysis Impact On Profit Before Tax [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable" xlink:to="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_b3c858d5-324f-4817-8305-ae7a9421cd84_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of contractual maturities of financial assets and financial liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:to="lab_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_4d130c7b-4eaf-42ed-8b52-35ecb248de09_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross private placement equity offering fee</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_20963a9a-9658-4015-b7d3-345aa21d60ea_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross private placement equity offering fee</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_684f967c-cfb2-4fc3-b265-fedab31104ff_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsLiabilities_6f2e806c-3a55-4953-9ec9-ceae13bcb52c_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets less current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets (liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsLiabilities" xlink:to="lab_ifrs-full_CurrentAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NorwichClinicalServicesLtdMember_90830e1e-f5da-4b10-a705-ea51649caf3b_terseLabel_en-US" xlink:label="lab_alvo_NorwichClinicalServicesLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Norwich Clinical Services Ltd - Sister company</link:label>
    <link:label id="lab_alvo_NorwichClinicalServicesLtdMember_label_en-US" xlink:label="lab_alvo_NorwichClinicalServicesLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Norwich Clinical Services Ltd [Member]</link:label>
    <link:label id="lab_alvo_NorwichClinicalServicesLtdMember_documentation_en-US" xlink:label="lab_alvo_NorwichClinicalServicesLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Norwich Clinical Services Ltd member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NorwichClinicalServicesLtdMember" xlink:href="alvo-20231231.xsd#alvo_NorwichClinicalServicesLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NorwichClinicalServicesLtdMember" xlink:to="lab_alvo_NorwichClinicalServicesLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_34e614bb-a7bc-4d28-9077-68b0784fefc0_verboseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_c0a5aa4e-0e49-4a64-b435-49bbc209a971_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_14786d5b-e6dd-47c2-885b-b5a7454827a7_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6c69091c-e42d-4c01-a743-e07dd68e0d84_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b3ae5897-a1fb-467e-9390-695eb4cfb408_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForAuditServices_415f40c0-1d57-4778-83ff-7b62e0b9f428_terseLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement audit fees</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForAuditServices_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor's remuneration for audit services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_7b33175f-ce22-49ba-85df-6c617e25bc65_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure in Entirety of Supplemental Cash Flow Information [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_label_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure in Entirety of Supplemental Cash Flow Information [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_documentation_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in Entirety of Supplemental Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable" xlink:to="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember_4deb3b77-074a-4005-be0e-09dae1af146b_terseLabel_en-US" xlink:label="lab_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Substantial Modification Of Convertible Bonds And Derivative Liabilities</link:label>
    <link:label id="lab_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember_label_en-US" xlink:label="lab_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Modification Of Convertible Bonds And Derivative Liabilities [member]</link:label>
    <link:label id="lab_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember_documentation_en-US" xlink:label="lab_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Substantial modification of convertible bonds and derivative liabilities [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember" xlink:href="alvo-20231231.xsd#alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember" xlink:to="lab_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenSubordinatedLoanMember_4bfa86fb-3037-4b38-9e77-81683b1b9b5d_terseLabel_en-US" xlink:label="lab_alvo_AlvogenSubordinatedLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Subordinated Loan</link:label>
    <link:label id="lab_alvo_AlvogenSubordinatedLoanMember_label_en-US" xlink:label="lab_alvo_AlvogenSubordinatedLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Subordinated Loan [member]</link:label>
    <link:label id="lab_alvo_AlvogenSubordinatedLoanMember_documentation_en-US" xlink:label="lab_alvo_AlvogenSubordinatedLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Subordinated Loan [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenSubordinatedLoanMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenSubordinatedLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenSubordinatedLoanMember" xlink:to="lab_alvo_AlvogenSubordinatedLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_91bfc6f1-068c-4403-9017-a0f718f6d311_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_33599df5-e884-4d82-8737-cd5d1b798afc_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_69599a5e-ea54-4fb0-bb36-ff8726a1dd5a_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Maturity Analysis For Lease liabilities [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Maturity Analysis For Lease liabilities [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about maturity analysis for lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_e82315b5-e21c-4d7c-9958-7bf9c4e3295e_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_bf8f9cd6-9d18-4c01-bc36-aa14be8a00d1_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_b48bbf6b-2874-4370-aaf6-366243dbc490_negatedLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechGermanyGmbhMember_18f7e96e-5e0f-4005-96f5-546a15ccd9be_terseLabel_en-US" xlink:label="lab_alvo_AlvotechGermanyGmbhMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech Germany GmbH</link:label>
    <link:label id="lab_alvo_AlvotechGermanyGmbhMember_label_en-US" xlink:label="lab_alvo_AlvotechGermanyGmbhMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech Germany GmbH [Member]</link:label>
    <link:label id="lab_alvo_AlvotechGermanyGmbhMember_documentation_en-US" xlink:label="lab_alvo_AlvotechGermanyGmbhMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech Germany GmbH.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechGermanyGmbhMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechGermanyGmbhMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechGermanyGmbhMember" xlink:to="lab_alvo_AlvotechGermanyGmbhMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AmortizationAndImpairmentOfIntangibleAssets_7f9bf3d6-3f6a-449c-95c9-0d1a12e8e0fe_terseLabel_en-US" xlink:label="lab_alvo_AmortizationAndImpairmentOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of intangible assets (see Note 15)</link:label>
    <link:label id="lab_alvo_AmortizationAndImpairmentOfIntangibleAssets_label_en-US" xlink:label="lab_alvo_AmortizationAndImpairmentOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization And Impairment Of Intangible Assets</link:label>
    <link:label id="lab_alvo_AmortizationAndImpairmentOfIntangibleAssets_documentation_en-US" xlink:label="lab_alvo_AmortizationAndImpairmentOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization And Impairment Of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationAndImpairmentOfIntangibleAssets" xlink:href="alvo-20231231.xsd#alvo_AmortizationAndImpairmentOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AmortizationAndImpairmentOfIntangibleAssets" xlink:to="lab_alvo_AmortizationAndImpairmentOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_7e0aec37-da6f-4691-98e6-9b3d4d1d3a90_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of share-based payments</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_5a5ae626-f7e5-4313-9535-07cfe1618089_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_b831a913-b366-440d-9329-abfc205afea8_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsAxis" xlink:to="lab_ifrs-full_UnobservableInputsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_InterestComponentMember_ef2fbbc7-fcd6-430c-88da-466327e9c0b7_terseLabel_en-US" xlink:label="lab_alvo_InterestComponentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Component</link:label>
    <link:label id="lab_alvo_InterestComponentMember_label_en-US" xlink:label="lab_alvo_InterestComponentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Component [member]</link:label>
    <link:label id="lab_alvo_InterestComponentMember_documentation_en-US" xlink:label="lab_alvo_InterestComponentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest component [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InterestComponentMember" xlink:href="alvo-20231231.xsd#alvo_InterestComponentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_InterestComponentMember" xlink:to="lab_alvo_InterestComponentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxAbstract_bbbd4dbe-7b0c-4ab8-b8ff-19c540e16b39_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Income Tax [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Income Tax [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract" xlink:to="lab_alvo_DisclosureOfIncomeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LeaseLiabilitiesForeignCurrencyAdjustment_132080e9-1b1f-4002-8708-cef580b34b42_terseLabel_en-US" xlink:label="lab_alvo_LeaseLiabilitiesForeignCurrencyAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency adjustment</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesForeignCurrencyAdjustment_label_en-US" xlink:label="lab_alvo_LeaseLiabilitiesForeignCurrencyAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liabilities Foreign Currency Adjustment</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesForeignCurrencyAdjustment_documentation_en-US" xlink:label="lab_alvo_LeaseLiabilitiesForeignCurrencyAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease liabilities foreign currency adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesForeignCurrencyAdjustment" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesForeignCurrencyAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LeaseLiabilitiesForeignCurrencyAdjustment" xlink:to="lab_alvo_LeaseLiabilitiesForeignCurrencyAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassBCommonStockMember_214b6b16-7fb7-4eb8-833b-b71befa856d0_terseLabel_en-US" xlink:label="lab_alvo_ClassBCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B Shareholders</link:label>
    <link:label id="lab_alvo_ClassBCommonStockMember_label_en-US" xlink:label="lab_alvo_ClassBCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class B Common Stock [Member]</link:label>
    <link:label id="lab_alvo_ClassBCommonStockMember_documentation_en-US" xlink:label="lab_alvo_ClassBCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class&#160;B common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassBCommonStockMember" xlink:href="alvo-20231231.xsd#alvo_ClassBCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassBCommonStockMember" xlink:to="lab_alvo_ClassBCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfNewAccountingStandardsAbstract_5c937661-3452-485f-9460-cac0a4a560e6_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfNewAccountingStandardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of New Accounting Standards [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfNewAccountingStandardsAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfNewAccountingStandardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of New Accounting Standards [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfNewAccountingStandardsAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfNewAccountingStandardsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of new accounting standards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfNewAccountingStandardsAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfNewAccountingStandardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfNewAccountingStandardsAbstract" xlink:to="lab_alvo_DisclosureOfNewAccountingStandardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_3210ec0e-d38b-49e9-b6db-ed57a2efdb59_terseLabel_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fair value of shares issued and noncash share listing expense [table]</link:label>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_label_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Fair Value Of Shares Issued And NonCash Share Listing Expense [Table]</link:label>
    <link:label id="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_documentation_en-US" xlink:label="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of fair value of shares issued and non-cash share listing expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable" xlink:to="lab_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationLoansAssumed_874d9270-906a-40b8-8335-f68452c33b77_terseLabel_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationLoansAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration loans assumed</link:label>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationLoansAssumed_label_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationLoansAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition Consideration Loans Assumed</link:label>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationLoansAssumed_documentation_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationLoansAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration loans assumed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationLoansAssumed" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationLoansAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AssetAcquisitionConsiderationLoansAssumed" xlink:to="lab_alvo_AssetAcquisitionConsiderationLoansAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f8e1c972-1ced-489b-939d-1e5dd2493bd6_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_64796e12-fd29-4f72-946e-4cba1df8e707_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_49e2ad83-cb9c-42c0-b5b6-af5ccd0e6228_verboseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_a6eff2c1-9b30-4fef-bfc4-9ac99dd10cef_terseLabel_en-US" xlink:label="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Table]</link:label>
    <link:label id="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_label_en-US" xlink:label="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Table]</link:label>
    <link:label id="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_documentation_en-US" xlink:label="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detailed information about depreciation amortization and impairment expense included in consolidated statements profit or loss and other comprehensive income or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable" xlink:href="alvo-20231231.xsd#alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable" xlink:to="lab_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement_cedaae44-fd9d-469b-b916-ff14ddb4d71a_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value changes, including accretion</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in profit or loss attributable to change in unrealised gains or losses for liabilities held at end of period, fair value measurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_48cbade9-1082-4ed8-b6bc-76ca64f9124f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AccretionderecognitionOfBorrowingsDiscount_aa6d7b09-4e95-414e-a9a1-f895f627ca73_terseLabel_en-US" xlink:label="lab_alvo_AccretionderecognitionOfBorrowingsDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion/derecognition of borrowings discount</link:label>
    <link:label id="lab_alvo_AccretionderecognitionOfBorrowingsDiscount_label_en-US" xlink:label="lab_alvo_AccretionderecognitionOfBorrowingsDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AccretionDerecognition Of Borrowings Discount</link:label>
    <link:label id="lab_alvo_AccretionderecognitionOfBorrowingsDiscount_documentation_en-US" xlink:label="lab_alvo_AccretionderecognitionOfBorrowingsDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accretion/derecognition of borrowings discount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AccretionderecognitionOfBorrowingsDiscount" xlink:href="alvo-20231231.xsd#alvo_AccretionderecognitionOfBorrowingsDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AccretionderecognitionOfBorrowingsDiscount" xlink:to="lab_alvo_AccretionderecognitionOfBorrowingsDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DebtSecurities_e9f04b43-710f-4daa-917e-56bfabb330f6_terseLabel_en-US" xlink:label="lab_ifrs-full_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments issued</link:label>
    <link:label id="lab_ifrs-full_DebtSecurities_label_en-US" xlink:label="lab_ifrs-full_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instruments issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecurities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DebtSecurities" xlink:to="lab_ifrs-full_DebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AmortizationOfDeferredDebtIssueCosts_c6ff185b-c2eb-417d-b6a6-1f3894bbc9cb_terseLabel_en-US" xlink:label="lab_alvo_AmortizationOfDeferredDebtIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred debt issue costs</link:label>
    <link:label id="lab_alvo_AmortizationOfDeferredDebtIssueCosts_label_en-US" xlink:label="lab_alvo_AmortizationOfDeferredDebtIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Deferred Debt Issue Costs</link:label>
    <link:label id="lab_alvo_AmortizationOfDeferredDebtIssueCosts_documentation_en-US" xlink:label="lab_alvo_AmortizationOfDeferredDebtIssueCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of deferred debt issue costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationOfDeferredDebtIssueCosts" xlink:href="alvo-20231231.xsd#alvo_AmortizationOfDeferredDebtIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AmortizationOfDeferredDebtIssueCosts" xlink:to="lab_alvo_AmortizationOfDeferredDebtIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_f45df04b-45a4-4646-986b-8b7d207266e2_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_ede50987-aaeb-44af-bf0a-65e4cf146af4_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Item that will be reclassified to profit or loss in subsequent periods:</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod_7c2a40c6-74b4-4ad2-bb36-a72b08642bcd_terseLabel_en-US" xlink:label="lab_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent contract liabilities revenue recognition period</link:label>
    <link:label id="lab_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod_label_en-US" xlink:label="lab_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Contract Liabilities Revenue Recognition Period</link:label>
    <link:label id="lab_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod_documentation_en-US" xlink:label="lab_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities revenue recognition period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod" xlink:href="alvo-20231231.xsd#alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod" xlink:to="lab_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_StockExchangeDescriptionDomain_87422d87-5bbc-4f94-9c4a-1d051009a075_terseLabel_en-US" xlink:label="lab_alvo_StockExchangeDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Exchange Description [Domain]</link:label>
    <link:label id="lab_alvo_StockExchangeDescriptionDomain_label_en-US" xlink:label="lab_alvo_StockExchangeDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Exchange Description [Domain]</link:label>
    <link:label id="lab_alvo_StockExchangeDescriptionDomain_documentation_en-US" xlink:label="lab_alvo_StockExchangeDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Exchange Description [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockExchangeDescriptionDomain" xlink:href="alvo-20231231.xsd#alvo_StockExchangeDescriptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_StockExchangeDescriptionDomain" xlink:to="lab_alvo_StockExchangeDescriptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPortionOfLongtermBorrowings_a419397c-11a7-4ffe-b608-220de69804d2_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current maturities of borrowings</link:label>
    <link:label id="lab_ifrs-full_CurrentPortionOfLongtermBorrowings_71a31a02-45dd-44db-92d6-fe761a19e6a0_negatedLabel_en-US" xlink:label="lab_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of borrowings</link:label>
    <link:label id="lab_ifrs-full_CurrentPortionOfLongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:to="lab_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_5b353b50-db12-431a-9226-576d14edaa29_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other related parties</link:label>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRelatedPartiesMember" xlink:to="lab_ifrs-full_OtherRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DetailsAxis_953f3c9e-8352-442d-bb16-5c9660f71911_terseLabel_en-US" xlink:label="lab_alvo_DetailsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Details [Axis]</link:label>
    <link:label id="lab_alvo_DetailsAxis_label_en-US" xlink:label="lab_alvo_DetailsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Details [Axis]</link:label>
    <link:label id="lab_alvo_DetailsAxis_documentation_en-US" xlink:label="lab_alvo_DetailsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Details [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsAxis" xlink:href="alvo-20231231.xsd#alvo_DetailsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DetailsAxis" xlink:to="lab_alvo_DetailsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_d639e6af-b837-4c84-af6f-5ec34a62867f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfLeaseAgreements_34a9499b-99f2-4292-b1f3-c44622957453_terseLabel_en-US" xlink:label="lab_alvo_NumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lease agreements</link:label>
    <link:label id="lab_alvo_NumberOfLeaseAgreements_label_en-US" xlink:label="lab_alvo_NumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Lease Agreements</link:label>
    <link:label id="lab_alvo_NumberOfLeaseAgreements_documentation_en-US" xlink:label="lab_alvo_NumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Lease Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeaseAgreements" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfLeaseAgreements" xlink:to="lab_alvo_NumberOfLeaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember_911246b1-e2e3-4a91-ab18-2aa8756a425f_terseLabel_en-US" xlink:label="lab_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two</link:label>
    <link:label id="lab_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember_label_en-US" xlink:label="lab_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two [member]</link:label>
    <link:label id="lab_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember_documentation_en-US" xlink:label="lab_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amendment to outstanding bonds january to june two thousand and twenty two [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember" xlink:href="alvo-20231231.xsd#alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember" xlink:to="lab_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_28d43668-240a-4c3f-be30-832da02ecd9a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_6f8c56e5-0db4-4cc3-ac12-407f41d14a8f_terseLabel_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of related party loans with Ordinary Shares</link:label>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_label_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of Shares on Settlement of Related Party Loans Value</link:label>
    <link:label id="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_documentation_en-US" xlink:label="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of shares on settlement of related party loans value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue" xlink:to="lab_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_8b487248-b37e-4d9c-ad38-2ff72ded8ef4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FacilitiesMember_b8c8d8c3-8235-4600-ac3d-d65bd294bbbb_terseLabel_en-US" xlink:label="lab_alvo_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_alvo_FacilitiesMember_label_en-US" xlink:label="lab_alvo_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_alvo_FacilitiesMember_documentation_en-US" xlink:label="lab_alvo_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facilities member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilitiesMember" xlink:href="alvo-20231231.xsd#alvo_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FacilitiesMember" xlink:to="lab_alvo_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1d7ffda6-4d90-4859-b48e-ee7ca1ae024f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CurrentAccruedVacation_7444c435-d5dc-473a-b639-d9b0b9f4376e_verboseLabel_en-US" xlink:label="lab_alvo_CurrentAccruedVacation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued vacation leave</link:label>
    <link:label id="lab_alvo_CurrentAccruedVacation_label_en-US" xlink:label="lab_alvo_CurrentAccruedVacation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Accrued Vacation</link:label>
    <link:label id="lab_alvo_CurrentAccruedVacation_documentation_en-US" xlink:label="lab_alvo_CurrentAccruedVacation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current accrued vacation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedVacation" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedVacation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CurrentAccruedVacation" xlink:to="lab_alvo_CurrentAccruedVacation" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FlokiHoldingsS.aR.lMember_11859966-cce3-4d3f-b2c7-a2616db828ec_terseLabel_en-US" xlink:label="lab_alvo_FlokiHoldingsS.aR.lMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Floki Holdings S.&#224; r.l. - Sister company</link:label>
    <link:label id="lab_alvo_FlokiHoldingsS.aR.lMember_label_en-US" xlink:label="lab_alvo_FlokiHoldingsS.aR.lMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Floki Holdings S.&#224; r.l [Member]</link:label>
    <link:label id="lab_alvo_FlokiHoldingsS.aR.lMember_documentation_en-US" xlink:label="lab_alvo_FlokiHoldingsS.aR.lMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Floki Holdings S.&#224; r.l</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiHoldingsS.aR.lMember" xlink:href="alvo-20231231.xsd#alvo_FlokiHoldingsS.aR.lMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FlokiHoldingsS.aR.lMember" xlink:to="lab_alvo_FlokiHoldingsS.aR.lMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesAxis_0f5ba223-50ed-4874-87d4-98f9bb6ef90c_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:label id="lab_ifrs-full_JointVenturesAxis_label_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis" xlink:to="lab_ifrs-full_JointVenturesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LenderNameDomain_d7054ead-018b-481c-8893-93e011fc1284_terseLabel_en-US" xlink:label="lab_alvo_LenderNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Domain]</link:label>
    <link:label id="lab_alvo_LenderNameDomain_label_en-US" xlink:label="lab_alvo_LenderNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Domain]</link:label>
    <link:label id="lab_alvo_LenderNameDomain_documentation_en-US" xlink:label="lab_alvo_LenderNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lender name.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LenderNameDomain" xlink:href="alvo-20231231.xsd#alvo_LenderNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LenderNameDomain" xlink:to="lab_alvo_LenderNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantsMember_83b17f9c-8beb-4ed3-9e60-c804763b2a3c_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantsMember_label_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantsMember" xlink:to="lab_ifrs-full_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TranslationDifferenceRightOfUseAssets_38615f14-3193-457f-9c6b-ec69318ef759_terseLabel_en-US" xlink:label="lab_alvo_TranslationDifferenceRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation difference</link:label>
    <link:label id="lab_alvo_TranslationDifferenceRightOfUseAssets_label_en-US" xlink:label="lab_alvo_TranslationDifferenceRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Translation Difference Right Of Use Assets</link:label>
    <link:label id="lab_alvo_TranslationDifferenceRightOfUseAssets_documentation_en-US" xlink:label="lab_alvo_TranslationDifferenceRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Translation difference right of use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TranslationDifferenceRightOfUseAssets" xlink:href="alvo-20231231.xsd#alvo_TranslationDifferenceRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TranslationDifferenceRightOfUseAssets" xlink:to="lab_alvo_TranslationDifferenceRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MaturityMonthAndYearDomain_3d190eb7-e9b8-4d7e-8096-a08c8f2ee2dc_terseLabel_en-US" xlink:label="lab_alvo_MaturityMonthAndYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Month and Year [Domain]</link:label>
    <link:label id="lab_alvo_MaturityMonthAndYearDomain_label_en-US" xlink:label="lab_alvo_MaturityMonthAndYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Month and Year [Domain]</link:label>
    <link:label id="lab_alvo_MaturityMonthAndYearDomain_documentation_en-US" xlink:label="lab_alvo_MaturityMonthAndYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity Month and year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturityMonthAndYearDomain" xlink:href="alvo-20231231.xsd#alvo_MaturityMonthAndYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MaturityMonthAndYearDomain" xlink:to="lab_alvo_MaturityMonthAndYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_StockPriceMember_5a91b7af-c7b1-48d0-b89d-52e1bb8cfc12_terseLabel_en-US" xlink:label="lab_alvo_StockPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price</link:label>
    <link:label id="lab_alvo_StockPriceMember_label_en-US" xlink:label="lab_alvo_StockPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price [Member]</link:label>
    <link:label id="lab_alvo_StockPriceMember_documentation_en-US" xlink:label="lab_alvo_StockPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockPriceMember" xlink:href="alvo-20231231.xsd#alvo_StockPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_StockPriceMember" xlink:to="lab_alvo_StockPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_4bc09954-ce4c-42fe-b43d-d33b8ad14384_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Carrying Amount And Financial Amount Of Certain Borrowings [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Carrying Amount And Financial Amount Of Certain Borrowings [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of carrying amount and financial amount of certain borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable" xlink:to="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock_0e310830-2d3f-4c2c-a8b3-90318bf87c5d_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of expiration of unused tax losses</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Expiration Of Unused Tax Losses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about expiration of unused tax losses explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock_8022d00d-d6d1-47dc-bc81-92d771656f7c_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Groups Assets and Liabilities</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Assets And Liabilities Denominated In Foreign Currencies Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of assets and liabilities denominated in foreign currencies explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_e90dbb9c-fd2a-44fa-b027-c0b9d6a07331_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_4d0f02ba-53c1-42cf-81ba-15ca5bfcb8f5_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Table]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of currency risk sensitivity analysis on profit before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable" xlink:to="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechHfMember_211074ba-2da6-4bd9-9d53-9921623d0435_terseLabel_en-US" xlink:label="lab_alvo_AlvotechHfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech hf</link:label>
    <link:label id="lab_alvo_AlvotechHfMember_label_en-US" xlink:label="lab_alvo_AlvotechHfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech Hf [Member]</link:label>
    <link:label id="lab_alvo_AlvotechHfMember_documentation_en-US" xlink:label="lab_alvo_AlvotechHfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech hf.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechHfMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechHfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechHfMember" xlink:to="lab_alvo_AlvotechHfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FacilityMember_ca94218b-2e81-4a29-ae14-1826b3c530f3_verboseLabel_en-US" xlink:label="lab_alvo_FacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Facility</link:label>
    <link:label id="lab_alvo_FacilityMember_77e0ed48-c9db-46e9-aed5-8f1fdbe49032_terseLabel_en-US" xlink:label="lab_alvo_FacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility</link:label>
    <link:label id="lab_alvo_FacilityMember_label_en-US" xlink:label="lab_alvo_FacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility [Member]</link:label>
    <link:label id="lab_alvo_FacilityMember_documentation_en-US" xlink:label="lab_alvo_FacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityMember" xlink:href="alvo-20231231.xsd#alvo_FacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FacilityMember" xlink:to="lab_alvo_FacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_3ad7d4f1-baf9-451d-a6cc-14359b6bcd11_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect on financial statement</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_30c3026b-9281-4925-914b-2ecc6dfbcef7_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond_7c33e1fb-458d-4fca-8a41-cbf2b192a36a_terseLabel_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration transferred Convertible Bond</link:label>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond_label_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition Consideration Transferred Convertible Bond</link:label>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond_documentation_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration transferred Convertible Bond.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredConvertibleBond"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond" xlink:to="lab_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_ef40fa8a-25e1-4be6-a0cb-50ded5ffe1b4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CashEquivalentsAndCashMember_6c69347a-f9de-48ce-a996-3dc1860d41f7_terseLabel_en-US" xlink:label="lab_alvo_CashEquivalentsAndCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_alvo_CashEquivalentsAndCashMember_label_en-US" xlink:label="lab_alvo_CashEquivalentsAndCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Cash [Member]</link:label>
    <link:label id="lab_alvo_CashEquivalentsAndCashMember_documentation_en-US" xlink:label="lab_alvo_CashEquivalentsAndCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CashEquivalentsAndCashMember" xlink:href="alvo-20231231.xsd#alvo_CashEquivalentsAndCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CashEquivalentsAndCashMember" xlink:to="lab_alvo_CashEquivalentsAndCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_d03f2067-7913-4f11-b69d-033f9ff1b870_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_label_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivablesMember" xlink:to="lab_ifrs-full_TradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GainLossOnExtinguishmentOfDebt_1023ecd6-7902-463b-aa84-67366240842c_terseLabel_en-US" xlink:label="lab_alvo_GainLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain loss on extinguishment of debt</link:label>
    <link:label id="lab_alvo_GainLossOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_alvo_GainLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Loss On Extinguishment Of Debt</link:label>
    <link:label id="lab_alvo_GainLossOnExtinguishmentOfDebt_documentation_en-US" xlink:label="lab_alvo_GainLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain loss on extinguishment of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GainLossOnExtinguishmentOfDebt" xlink:href="alvo-20231231.xsd#alvo_GainLossOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GainLossOnExtinguishmentOfDebt" xlink:to="lab_alvo_GainLossOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuesFairValueMeasurementLiabilities_43bbef7a-4186-4b8f-b94e-eb17e746dc08_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issues fair value measurement liabilities</link:label>
    <link:label id="lab_ifrs-full_IssuesFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issues, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuesFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenFacilityAndAztiqFacilityMember_1c773f40-e2be-47a2-bfa8-a610f553d0f3_terseLabel_en-US" xlink:label="lab_alvo_AlvogenFacilityAndAztiqFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Facility and Aztiq Facility</link:label>
    <link:label id="lab_alvo_AlvogenFacilityAndAztiqFacilityMember_label_en-US" xlink:label="lab_alvo_AlvogenFacilityAndAztiqFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Facility and Aztiq Facility [member]</link:label>
    <link:label id="lab_alvo_AlvogenFacilityAndAztiqFacilityMember_documentation_en-US" xlink:label="lab_alvo_AlvogenFacilityAndAztiqFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Facility and Aztiq Facility [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityAndAztiqFacilityMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityAndAztiqFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenFacilityAndAztiqFacilityMember" xlink:to="lab_alvo_AlvogenFacilityAndAztiqFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesMember_25c3236a-53de-434a-baf3-961664c583b2_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities [member]</link:label>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_95533725-5a45-4c70-bc32-2cd6d89bfb33_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general and administrative expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_83ebf46b-8ed9-4d15-b63c-7f51d80e902e_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_3bd7c460-2571-44de-9091-7072d2ebc7a2_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in share capital</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_86ab1d91-b862-4a47-bee2-5a78e64eb868_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_7793ddbe-463e-4e34-ae21-d494ed10db4e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at 1 January</link:label>
    <link:label id="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_7ab0fd37-ab21-4e08-87b2-9253f12564c1_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at 31 December</link:label>
    <link:label id="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current restricted cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:to="lab_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted_7485fe37-63c8-49f8-947d-63090cec7d4b_terseLabel_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Per Share Other Equity Instruments Granted</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average fair value per share other equity instruments granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" xlink:to="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractAssets_69c469bd-fe93-4710-a93a-48f7c7e2542b_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractAssets_fca86599-7f9f-488f-b76d-c276507877cf_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current contract assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractAssets" xlink:to="lab_ifrs-full_NoncurrentContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReversalOfInventoryWritedown_441cb571-2a94-4276-a9c6-7f69bf85d2a8_terseLabel_en-US" xlink:label="lab_ifrs-full_ReversalOfInventoryWritedown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of inventory write-down</link:label>
    <link:label id="lab_ifrs-full_ReversalOfInventoryWritedown_label_en-US" xlink:label="lab_ifrs-full_ReversalOfInventoryWritedown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of inventory write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfInventoryWritedown" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfInventoryWritedown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfInventoryWritedown" xlink:to="lab_ifrs-full_ReversalOfInventoryWritedown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_1438a5b4-922d-4d6d-9005-b01b8fbcb948_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_4b605a21-1823-43ef-b6e2-913bbc59803e_verboseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesTable_48db9aa3-e2b8-4cb6-94df-b51e87e68499_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of joint ventures [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of joint ventures [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_4134d553-499f-4b70-b7ce-2a15a2dd6393_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseInTheFaceValueOfTheBondsMember_f17b8289-874a-4b84-bbac-de8b352d8dcb_terseLabel_en-US" xlink:label="lab_alvo_IncreaseInTheFaceValueOfTheBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase In The Face Value Of The Bonds</link:label>
    <link:label id="lab_alvo_IncreaseInTheFaceValueOfTheBondsMember_label_en-US" xlink:label="lab_alvo_IncreaseInTheFaceValueOfTheBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In The Face Value Of The Bonds [member]</link:label>
    <link:label id="lab_alvo_IncreaseInTheFaceValueOfTheBondsMember_documentation_en-US" xlink:label="lab_alvo_IncreaseInTheFaceValueOfTheBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase In the face value Of the bonds [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseInTheFaceValueOfTheBondsMember" xlink:href="alvo-20231231.xsd#alvo_IncreaseInTheFaceValueOfTheBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseInTheFaceValueOfTheBondsMember" xlink:to="lab_alvo_IncreaseInTheFaceValueOfTheBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FasteignafelagiEyjolfurEhfMember_5682fab5-b5a3-437e-aecd-094259d456a2_terseLabel_en-US" xlink:label="lab_alvo_FasteignafelagiEyjolfurEhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company</link:label>
    <link:label id="lab_alvo_FasteignafelagiEyjolfurEhfMember_label_en-US" xlink:label="lab_alvo_FasteignafelagiEyjolfurEhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf [Member]</link:label>
    <link:label id="lab_alvo_FasteignafelagiEyjolfurEhfMember_documentation_en-US" xlink:label="lab_alvo_FasteignafelagiEyjolfurEhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiEyjolfurEhfMember" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiEyjolfurEhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FasteignafelagiEyjolfurEhfMember" xlink:to="lab_alvo_FasteignafelagiEyjolfurEhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LeaseLiabilitiesTranslationDifference_3cafc345-a113-4cb6-ba07-58d932ab0d4f_terseLabel_en-US" xlink:label="lab_alvo_LeaseLiabilitiesTranslationDifference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation difference</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesTranslationDifference_label_en-US" xlink:label="lab_alvo_LeaseLiabilitiesTranslationDifference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liabilities Translation Difference</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesTranslationDifference_documentation_en-US" xlink:label="lab_alvo_LeaseLiabilitiesTranslationDifference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease liabilities translation difference.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesTranslationDifference" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesTranslationDifference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LeaseLiabilitiesTranslationDifference" xlink:to="lab_alvo_LeaseLiabilitiesTranslationDifference" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_c8fe23f4-568c-4184-bed3-f9c779fd642e_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_Lambahagavegur7EhfMember_9ea45a08-5be2-4527-8ce9-4a535bd9d457_terseLabel_en-US" xlink:label="lab_alvo_Lambahagavegur7EhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lambahagavegur 7 ehf</link:label>
    <link:label id="lab_alvo_Lambahagavegur7EhfMember_label_en-US" xlink:label="lab_alvo_Lambahagavegur7EhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lambahagavegur 7 ehf [Member]</link:label>
    <link:label id="lab_alvo_Lambahagavegur7EhfMember_documentation_en-US" xlink:label="lab_alvo_Lambahagavegur7EhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lambahagavegur 7 ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Lambahagavegur7EhfMember" xlink:href="alvo-20231231.xsd#alvo_Lambahagavegur7EhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_Lambahagavegur7EhfMember" xlink:to="lab_alvo_Lambahagavegur7EhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_51874723-8043-4909-9d54-0b6a7b80808e_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from new borrowings</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LaterThanTwoYearsMember_8f60bccc-c86b-4060-87d5-2ee7f13670d2_terseLabel_en-US" xlink:label="lab_alvo_LaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_alvo_LaterThanTwoYearsMember_label_en-US" xlink:label="lab_alvo_LaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later Than Two Years [Member]</link:label>
    <link:label id="lab_alvo_LaterThanTwoYearsMember_documentation_en-US" xlink:label="lab_alvo_LaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Later than two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LaterThanTwoYearsMember" xlink:href="alvo-20231231.xsd#alvo_LaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LaterThanTwoYearsMember" xlink:to="lab_alvo_LaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_abf1f761-95e2-4902-8578-ee4f5dfebde5_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of carrying amount and financial amount of certain borrowings [line items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Carrying Amount And Financial Amount Of Certain Borrowings [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of carrying amount and financial amount of certain borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems" xlink:to="lab_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_83000d2e-36bc-4840-9a26-c13d519d037c_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b94b60f3-e0a3-4add-aea7-bd221d2b35d9_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_41971990-9a8a-4cb4-817c-3832912843a9_verboseLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_b72c5353-701b-4c31-81e6-892ee8158639_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bottom of range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BorrowingsTrancheAxis_b45da7b6-3918-4e2b-baae-5d07dfe2dd1a_terseLabel_en-US" xlink:label="lab_alvo_BorrowingsTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings Tranche [Axis]</link:label>
    <link:label id="lab_alvo_BorrowingsTrancheAxis_label_en-US" xlink:label="lab_alvo_BorrowingsTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings Tranche [Axis]</link:label>
    <link:label id="lab_alvo_BorrowingsTrancheAxis_documentation_en-US" xlink:label="lab_alvo_BorrowingsTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings Tranche [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheAxis" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BorrowingsTrancheAxis" xlink:to="lab_alvo_BorrowingsTrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_Remaining15LeaseFacilitiesMember_bceab4d0-fe2f-4d7e-b856-58836c62292b_terseLabel_en-US" xlink:label="lab_alvo_Remaining15LeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining 15 Lease Facilities</link:label>
    <link:label id="lab_alvo_Remaining15LeaseFacilitiesMember_label_en-US" xlink:label="lab_alvo_Remaining15LeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining 15 Lease Facilities [Member]</link:label>
    <link:label id="lab_alvo_Remaining15LeaseFacilitiesMember_documentation_en-US" xlink:label="lab_alvo_Remaining15LeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining 15 Lease Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Remaining15LeaseFacilitiesMember" xlink:href="alvo-20231231.xsd#alvo_Remaining15LeaseFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_Remaining15LeaseFacilitiesMember" xlink:to="lab_alvo_Remaining15LeaseFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested_0466ef45-ac0f-4dc8-adef-6cc5a77f8b33_terseLabel_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested_label_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Per Share Other Equity Instruments Vested</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested_documentation_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average fair value per share other equity instruments vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" xlink:to="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassOfStockAxis_390c750f-62fd-4439-bdd3-d4293d30e679_terseLabel_en-US" xlink:label="lab_alvo_ClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Axis]</link:label>
    <link:label id="lab_alvo_ClassOfStockAxis_label_en-US" xlink:label="lab_alvo_ClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Stock [Axis]</link:label>
    <link:label id="lab_alvo_ClassOfStockAxis_documentation_en-US" xlink:label="lab_alvo_ClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of stock [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStockAxis" xlink:href="alvo-20231231.xsd#alvo_ClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassOfStockAxis" xlink:to="lab_alvo_ClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_71c03b8a-c15e-4b5e-a712-2bedb5e9e5f3_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New leases</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSalesMember_cdd4d6d0-b3ab-497a-b8f9-a177184b1f2f_terseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenue</link:label>
    <link:label id="lab_ifrs-full_CostOfSalesMember_label_en-US" xlink:label="lab_ifrs-full_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSalesMember" xlink:to="lab_ifrs-full_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_a3a0b0a4-0ff5-40f6-bc40-191764cda15b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange difference</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_afd27b8e-8d57-4a36-991d-3a0d58e7311e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AgreementOneDomain_3739fecb-01e2-4f61-b10a-6cdcce77354f_terseLabel_en-US" xlink:label="lab_alvo_AgreementOneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement One [Domain]</link:label>
    <link:label id="lab_alvo_AgreementOneDomain_label_en-US" xlink:label="lab_alvo_AgreementOneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement One [Domain]</link:label>
    <link:label id="lab_alvo_AgreementOneDomain_documentation_en-US" xlink:label="lab_alvo_AgreementOneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneDomain" xlink:href="alvo-20231231.xsd#alvo_AgreementOneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AgreementOneDomain" xlink:to="lab_alvo_AgreementOneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LicenceFeeIncome_d1a099dc-e530-4f39-a5d2-da70d589a71f_terseLabel_en-US" xlink:label="lab_ifrs-full_LicenceFeeIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and other revenue</link:label>
    <link:label id="lab_ifrs-full_LicenceFeeIncome_label_en-US" xlink:label="lab_ifrs-full_LicenceFeeIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licence fee income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicenceFeeIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicenceFeeIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicenceFeeIncome" xlink:to="lab_ifrs-full_LicenceFeeIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CommonStockSubscriptionPricePerShare_135d779d-5dbc-46d1-be55-faf5f137f691_terseLabel_en-US" xlink:label="lab_alvo_CommonStockSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, subscription (in dollars per share)</link:label>
    <link:label id="lab_alvo_CommonStockSubscriptionPricePerShare_label_en-US" xlink:label="lab_alvo_CommonStockSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Subscription Price Per Share</link:label>
    <link:label id="lab_alvo_CommonStockSubscriptionPricePerShare_documentation_en-US" xlink:label="lab_alvo_CommonStockSubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock, subscription price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockSubscriptionPricePerShare" xlink:href="alvo-20231231.xsd#alvo_CommonStockSubscriptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CommonStockSubscriptionPricePerShare" xlink:to="lab_alvo_CommonStockSubscriptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_147b2823-eb56-4f7e-94a4-28a721eac537_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_d7c8e68a-1911-41b7-b3af-fe7f0a6b4fc7_terseLabel_en-US" xlink:label="lab_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate</link:label>
    <link:label id="lab_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_label_en-US" xlink:label="lab_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate. [member]</link:label>
    <link:label id="lab_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_documentation_en-US" xlink:label="lab_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured overnight financing rate (SOFR) overnight index swap rate [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member" xlink:href="alvo-20231231.xsd#alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member" xlink:to="lab_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement_ec24ca82-585a-45c8-8d8a-6f8481a488f7_terseLabel_en-US" xlink:label="lab_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement_label_en-US" xlink:label="lab_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period of Requirements for Share-Based Payment Arrangement</link:label>
    <link:label id="lab_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period of Requirements for Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement" xlink:href="alvo-20231231.xsd#alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement" xlink:to="lab_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember_a5b7f466-8d9d-4402-bdc7-3ceeedf3a9c2_terseLabel_en-US" xlink:label="lab_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech &amp; CCHN Biopharmaceutical Co. Ltd</link:label>
    <link:label id="lab_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember_label_en-US" xlink:label="lab_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech CCHN Biopharmaceutical Co. Ltd [Member]</link:label>
    <link:label id="lab_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember_documentation_en-US" xlink:label="lab_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech &amp; CCHN Biopharmaceutical Co. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember" xlink:to="lab_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7210b8c9-b1e0-4249-b8a6-b2377d088457_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfOacbEarnOutShares_9552a056-9601-4ca7-828f-2364b6126fac_terseLabel_en-US" xlink:label="lab_alvo_IssueOfOacbEarnOutShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OACB Earn Out Shares (in shares)</link:label>
    <link:label id="lab_alvo_IssueOfOacbEarnOutShares_label_en-US" xlink:label="lab_alvo_IssueOfOacbEarnOutShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of OACB Earn Out Shares, Shares</link:label>
    <link:label id="lab_alvo_IssueOfOacbEarnOutShares_documentation_en-US" xlink:label="lab_alvo_IssueOfOacbEarnOutShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of OACB earn out shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfOacbEarnOutShares" xlink:href="alvo-20231231.xsd#alvo_IssueOfOacbEarnOutShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfOacbEarnOutShares" xlink:to="lab_alvo_IssueOfOacbEarnOutShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid_6ac58474-1d54-4eed-897b-2329737c552d_terseLabel_en-US" xlink:label="lab_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of intangibles in trade payables and other current liabilities</link:label>
    <link:label id="lab_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid_label_en-US" xlink:label="lab_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditure Intangible Assets Incurred But Not Paid</link:label>
    <link:label id="lab_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid_documentation_en-US" xlink:label="lab_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital expenditure intangible assets incurred but not paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid" xlink:href="alvo-20231231.xsd#alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid" xlink:to="lab_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LoansReceived_e7c03162-ea1a-4171-8b59-f13a3ea76ecf_terseLabel_en-US" xlink:label="lab_ifrs-full_LoansReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans received</link:label>
    <link:label id="lab_ifrs-full_LoansReceived_label_en-US" xlink:label="lab_ifrs-full_LoansReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LoansReceived" xlink:to="lab_ifrs-full_LoansReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_5ef2bd26-0ae6-4603-8fe4-7636c3b74ee8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement</link:label>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SettlementsFairValueMeasurementLiabilities_8d0326ad-0bba-453e-b04b-8d821853466f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment</link:label>
    <link:label id="lab_ifrs-full_SettlementsFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlements, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettlementsFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AccruedInterestOnDebtExtinguished_fa54907b-dc2d-45b2-a108-79ef5923c32b_terseLabel_en-US" xlink:label="lab_alvo_AccruedInterestOnDebtExtinguished" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on debt extiguished</link:label>
    <link:label id="lab_alvo_AccruedInterestOnDebtExtinguished_label_en-US" xlink:label="lab_alvo_AccruedInterestOnDebtExtinguished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest On Debt Extinguished</link:label>
    <link:label id="lab_alvo_AccruedInterestOnDebtExtinguished_documentation_en-US" xlink:label="lab_alvo_AccruedInterestOnDebtExtinguished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued interest on debt extinguished.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AccruedInterestOnDebtExtinguished" xlink:href="alvo-20231231.xsd#alvo_AccruedInterestOnDebtExtinguished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AccruedInterestOnDebtExtinguished" xlink:to="lab_alvo_AccruedInterestOnDebtExtinguished" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_367d4ffc-a9bd-4060-b026-031afabad551_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset_47ad5799-c826-4150-ad5d-75b7820b12c4_terseLabel_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase decrease through other current liabilities and income net defined benefit liability asset</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease Through Other Current Liabilities and Income Net Defined Benefit Liability Asset</link:label>
    <link:label id="lab_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset_documentation_en-US" xlink:label="lab_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease through other current liabilities and income net defined benefit liability asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lab_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_f2e3b135-e2be-428e-8eec-0afa780fb55d_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremium_caab76c3-fea5-43d8-8227-ee0d18e864aa_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:label id="lab_ifrs-full_SharePremium_label_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AnnMerchantMember_aa3c7487-22e4-4da9-bdb6-d9574671f499_terseLabel_en-US" xlink:label="lab_alvo_AnnMerchantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ann Merchant, Board Member</link:label>
    <link:label id="lab_alvo_AnnMerchantMember_label_en-US" xlink:label="lab_alvo_AnnMerchantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ann Merchant [Member]</link:label>
    <link:label id="lab_alvo_AnnMerchantMember_documentation_en-US" xlink:label="lab_alvo_AnnMerchantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ann Merchant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AnnMerchantMember" xlink:href="alvo-20231231.xsd#alvo_AnnMerchantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AnnMerchantMember" xlink:to="lab_alvo_AnnMerchantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_StockIssuedUnderPipeFinancingShares_7cb28e54-cc88-4def-9049-fa9f4f23a926_terseLabel_en-US" xlink:label="lab_alvo_StockIssuedUnderPipeFinancingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued under PIPE financing shares (in shares)</link:label>
    <link:label id="lab_alvo_StockIssuedUnderPipeFinancingShares_label_en-US" xlink:label="lab_alvo_StockIssuedUnderPipeFinancingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued Under PIPE Financing Shares</link:label>
    <link:label id="lab_alvo_StockIssuedUnderPipeFinancingShares_documentation_en-US" xlink:label="lab_alvo_StockIssuedUnderPipeFinancingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued under PIPE financing shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockIssuedUnderPipeFinancingShares" xlink:href="alvo-20231231.xsd#alvo_StockIssuedUnderPipeFinancingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_StockIssuedUnderPipeFinancingShares" xlink:to="lab_alvo_StockIssuedUnderPipeFinancingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_77be3500-0dd2-4134-9af4-2dc6414755d3_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1c367cf7-5274-46e0-8348-48c99e724726_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_70ace26f-3b7c-4a87-9d31-f1222fa9140c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheAConversionFeatureMember_764c9611-935a-4a3b-a60e-718f3bd74ef2_terseLabel_en-US" xlink:label="lab_alvo_TrancheAConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche A Conversion Feature</link:label>
    <link:label id="lab_alvo_TrancheAConversionFeatureMember_label_en-US" xlink:label="lab_alvo_TrancheAConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche A Conversion Feature [Member]</link:label>
    <link:label id="lab_alvo_TrancheAConversionFeatureMember_documentation_en-US" xlink:label="lab_alvo_TrancheAConversionFeatureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche A conversion feature.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConversionFeatureMember" xlink:href="alvo-20231231.xsd#alvo_TrancheAConversionFeatureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheAConversionFeatureMember" xlink:to="lab_alvo_TrancheAConversionFeatureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheAMember_861d4c45-f0d1-4680-ab4e-62fd2322a6cf_terseLabel_en-US" xlink:label="lab_alvo_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche A</link:label>
    <link:label id="lab_alvo_TrancheAMember_label_en-US" xlink:label="lab_alvo_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche A [member]</link:label>
    <link:label id="lab_alvo_TrancheAMember_documentation_en-US" xlink:label="lab_alvo_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche A [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAMember" xlink:href="alvo-20231231.xsd#alvo_TrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheAMember" xlink:to="lab_alvo_TrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_a03cdba0-61c1-4671-9019-9a740017f2a9_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities from share-based payment transactions</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities from share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:to="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LeaseLiabilitiesCancelledLease_6eb81a49-a321-41da-a6dc-0b5adcfc75ff_negatedTerseLabel_en-US" xlink:label="lab_alvo_LeaseLiabilitiesCancelledLease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled leases</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesCancelledLease_label_en-US" xlink:label="lab_alvo_LeaseLiabilitiesCancelledLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liabilities, Cancelled Lease</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesCancelledLease_documentation_en-US" xlink:label="lab_alvo_LeaseLiabilitiesCancelledLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Liabilities, Cancelled Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesCancelledLease" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesCancelledLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LeaseLiabilitiesCancelledLease" xlink:to="lab_alvo_LeaseLiabilitiesCancelledLease" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NotLaterThanFiveYearsMember_dffe336a-e552-4290-a8dd-0bec6edfc9a7_terseLabel_en-US" xlink:label="lab_alvo_NotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not later than five years</link:label>
    <link:label id="lab_alvo_NotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_alvo_NotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Later Than Five Years [Member]</link:label>
    <link:label id="lab_alvo_NotLaterThanFiveYearsMember_documentation_en-US" xlink:label="lab_alvo_NotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Not later than five years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NotLaterThanFiveYearsMember" xlink:href="alvo-20231231.xsd#alvo_NotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NotLaterThanFiveYearsMember" xlink:to="lab_alvo_NotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PremiumComponentMember_59bb6ebb-fa34-4e22-adb3-f3f1288d65a8_terseLabel_en-US" xlink:label="lab_alvo_PremiumComponentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium Component</link:label>
    <link:label id="lab_alvo_PremiumComponentMember_label_en-US" xlink:label="lab_alvo_PremiumComponentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium Component [member]</link:label>
    <link:label id="lab_alvo_PremiumComponentMember_documentation_en-US" xlink:label="lab_alvo_PremiumComponentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium component [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PremiumComponentMember" xlink:href="alvo-20231231.xsd#alvo_PremiumComponentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PremiumComponentMember" xlink:to="lab_alvo_PremiumComponentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2_0b8e899d-8352-4be4-81ee-df6b59c7427d_terseLabel_en-US" xlink:label="lab_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted net liabilities of OACB as of 15 June 2022</link:label>
    <link:label id="lab_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2_label_en-US" xlink:label="lab_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted Net Liabilities Recognized Amount In Accordance With Ifrs 2</link:label>
    <link:label id="lab_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2_documentation_en-US" xlink:label="lab_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjusted net liabilities recognized amount in accordance with IFRS 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" xlink:href="alvo-20231231.xsd#alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" xlink:to="lab_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives_eadbfbc3-0ee5-4c5e-9bbb-4c330f075326_terseLabel_en-US" xlink:label="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in the fair value of derivatives (see Note 28)</link:label>
    <link:label id="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Losses on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsLineItems_68f7454c-d928-46c0-9a8e-be1d75a5d1a6_terseLabel_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Line Items]</link:label>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsLineItems_label_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Line Items]</link:label>
    <link:label id="lab_alvo_GeneralInformationAboutFinancialStatementsLineItems_documentation_en-US" xlink:label="lab_alvo_GeneralInformationAboutFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General information about financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems" xlink:to="lab_alvo_GeneralInformationAboutFinancialStatementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GeneralAndAdministrativeExpensesMember_a6ea096a-df89-4ec9-99f8-8a08a97fdcc4_terseLabel_en-US" xlink:label="lab_alvo_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_alvo_GeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_alvo_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expenses [Member]</link:label>
    <link:label id="lab_alvo_GeneralAndAdministrativeExpensesMember_documentation_en-US" xlink:label="lab_alvo_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General and administrative expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GeneralAndAdministrativeExpensesMember" xlink:to="lab_alvo_GeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_d0270149-b009-492e-8be9-a162891ba675_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in allowance for receivables</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in allowance account for credit losses of financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfConsecutiveTradingDays_ad2e538a-3e35-49e2-a75e-be05c57b24d7_terseLabel_en-US" xlink:label="lab_alvo_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of consecutive trading days for determining the share</link:label>
    <link:label id="lab_alvo_NumberOfConsecutiveTradingDays_label_en-US" xlink:label="lab_alvo_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Consecutive Trading Days</link:label>
    <link:label id="lab_alvo_NumberOfConsecutiveTradingDays_documentation_en-US" xlink:label="lab_alvo_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of consecutive trading days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfConsecutiveTradingDays" xlink:href="alvo-20231231.xsd#alvo_NumberOfConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfConsecutiveTradingDays" xlink:to="lab_alvo_NumberOfConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CancellationsRightOfUseAssets_514a24ba-bd14-43a9-94a4-d84214901507_negatedTerseLabel_en-US" xlink:label="lab_alvo_CancellationsRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled leases</link:label>
    <link:label id="lab_alvo_CancellationsRightOfUseAssets_label_en-US" xlink:label="lab_alvo_CancellationsRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cancellations, Right Of Use Assets</link:label>
    <link:label id="lab_alvo_CancellationsRightOfUseAssets_documentation_en-US" xlink:label="lab_alvo_CancellationsRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cancellations, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CancellationsRightOfUseAssets" xlink:href="alvo-20231231.xsd#alvo_CancellationsRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CancellationsRightOfUseAssets" xlink:to="lab_alvo_CancellationsRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractAssetMember_cd25f72b-1f15-49f4-9d1c-43537b93814c_terseLabel_en-US" xlink:label="lab_alvo_ContractAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets</link:label>
    <link:label id="lab_alvo_ContractAssetMember_label_en-US" xlink:label="lab_alvo_ContractAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Asset [Member]</link:label>
    <link:label id="lab_alvo_ContractAssetMember_documentation_en-US" xlink:label="lab_alvo_ContractAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetMember" xlink:href="alvo-20231231.xsd#alvo_ContractAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractAssetMember" xlink:to="lab_alvo_ContractAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_UpfrontPayment_087b9f3c-92d5-4dec-84a2-ec2a8b3617bd_terseLabel_en-US" xlink:label="lab_alvo_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_alvo_UpfrontPayment_label_en-US" xlink:label="lab_alvo_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_alvo_UpfrontPayment_documentation_en-US" xlink:label="lab_alvo_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_UpfrontPayment" xlink:href="alvo-20231231.xsd#alvo_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_UpfrontPayment" xlink:to="lab_alvo_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DividendYieldMember_c7bf60a6-68c8-4810-b9e8-59f7bc181fa2_terseLabel_en-US" xlink:label="lab_alvo_DividendYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_alvo_DividendYieldMember_label_en-US" xlink:label="lab_alvo_DividendYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend Yield [Member]</link:label>
    <link:label id="lab_alvo_DividendYieldMember_documentation_en-US" xlink:label="lab_alvo_DividendYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend yield.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DividendYieldMember" xlink:href="alvo-20231231.xsd#alvo_DividendYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DividendYieldMember" xlink:to="lab_alvo_DividendYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CustomerAMember_25d56bb8-9a46-4014-bbf9-b834ffe687bf_terseLabel_en-US" xlink:label="lab_alvo_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_alvo_CustomerAMember_label_en-US" xlink:label="lab_alvo_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_alvo_CustomerAMember_documentation_en-US" xlink:label="lab_alvo_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerAMember" xlink:href="alvo-20231231.xsd#alvo_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CustomerAMember" xlink:to="lab_alvo_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_0878b81e-2fdb-4fd8-804d-d258dff1e99f_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EUR</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_f67b28f7-e942-49f5-bdc0-d1bdbb3e3d20_terseLabel_en-US" xlink:label="lab_alvo_InvestmentsAccountedForUsingEquityMethodRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Accounted For Using Equity Method [Roll Forward]</link:label>
    <link:label id="lab_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_label_en-US" xlink:label="lab_alvo_InvestmentsAccountedForUsingEquityMethodRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Accounted For Using Equity Method [Roll Forward]</link:label>
    <link:label id="lab_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_documentation_en-US" xlink:label="lab_alvo_InvestmentsAccountedForUsingEquityMethodRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments Accounted For Using Equity Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward" xlink:href="alvo-20231231.xsd#alvo_InvestmentsAccountedForUsingEquityMethodRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward" xlink:to="lab_alvo_InvestmentsAccountedForUsingEquityMethodRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PrepaymentPenaltyPercentageOnBonds_98fbf648-95ef-4d7f-8a8d-86fddbfa6d0d_terseLabel_en-US" xlink:label="lab_alvo_PrepaymentPenaltyPercentageOnBonds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment penalty percentage on bonds</link:label>
    <link:label id="lab_alvo_PrepaymentPenaltyPercentageOnBonds_label_en-US" xlink:label="lab_alvo_PrepaymentPenaltyPercentageOnBonds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment Penalty Percentage On Bonds</link:label>
    <link:label id="lab_alvo_PrepaymentPenaltyPercentageOnBonds_documentation_en-US" xlink:label="lab_alvo_PrepaymentPenaltyPercentageOnBonds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayment penalty percentage on bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrepaymentPenaltyPercentageOnBonds" xlink:href="alvo-20231231.xsd#alvo_PrepaymentPenaltyPercentageOnBonds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PrepaymentPenaltyPercentageOnBonds" xlink:to="lab_alvo_PrepaymentPenaltyPercentageOnBonds" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputLiabilities_b9fde7d6-66ee-480c-8f3f-765ed1186557_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable input, liabilities</link:label>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:to="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_61480b37-af18-4230-96d9-1e895b4c5931_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LoanAgreementMember_5df3bd44-87fc-4ec3-b45d-af5dbea711bf_terseLabel_en-US" xlink:label="lab_alvo_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan agreement</link:label>
    <link:label id="lab_alvo_LoanAgreementMember_label_en-US" xlink:label="lab_alvo_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan agreement [Member]</link:label>
    <link:label id="lab_alvo_LoanAgreementMember_documentation_en-US" xlink:label="lab_alvo_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LoanAgreementMember" xlink:href="alvo-20231231.xsd#alvo_LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LoanAgreementMember" xlink:to="lab_alvo_LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory_074a2fa0-af15-442d-ab56-f7355596c310_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of credit risk exposure [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExposureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExposureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember_0451c071-1bbf-4ee6-8169-f06c1e0285f2_terseLabel_en-US" xlink:label="lab_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027-2029</link:label>
    <link:label id="lab_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember_label_en-US" xlink:label="lab_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Seven to Two Thousand Twenty Nine [Member]</link:label>
    <link:label id="lab_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember_documentation_en-US" xlink:label="lab_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand twenty six to two thousand twenty eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember" xlink:href="alvo-20231231.xsd#alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember" xlink:to="lab_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromCurrentBorrowings_89a13fc2-4988-4d3d-8b8a-f3d93581e475_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from current borrowings</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromCurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromCurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromCurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechMancoEhfMember_af524592-1951-4fcc-bdc0-fbc75832c3c5_terseLabel_en-US" xlink:label="lab_alvo_AlvotechMancoEhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech Manco ehf</link:label>
    <link:label id="lab_alvo_AlvotechMancoEhfMember_label_en-US" xlink:label="lab_alvo_AlvotechMancoEhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech Manco ehf [Member]</link:label>
    <link:label id="lab_alvo_AlvotechMancoEhfMember_documentation_en-US" xlink:label="lab_alvo_AlvotechMancoEhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech Manco ehf.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechMancoEhfMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechMancoEhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechMancoEhfMember" xlink:to="lab_alvo_AlvotechMancoEhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfCashAndCashEquivalentsLineItems_cc862596-a956-4722-abdf-3f834512c2e5_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfCashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfCashAndCashEquivalentsLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCashAndCashEquivalentsLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfCashAndCashEquivalentsLineItems" xlink:to="lab_alvo_DisclosureOfCashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ea20a291-10b7-46f2-9f38-55f5d356547e_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_e227334b-e56f-49bd-b987-f6dd22097092_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ProceedsFromBorrowingsNetOfTransactionCosts_8f877d4d-dcdd-4fdb-8a44-51047d40c0e5_terseLabel_en-US" xlink:label="lab_alvo_ProceedsFromBorrowingsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings net of transaction costs</link:label>
    <link:label id="lab_alvo_ProceedsFromBorrowingsNetOfTransactionCosts_label_en-US" xlink:label="lab_alvo_ProceedsFromBorrowingsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Borrowings Net of Transaction Costs</link:label>
    <link:label id="lab_alvo_ProceedsFromBorrowingsNetOfTransactionCosts_documentation_en-US" xlink:label="lab_alvo_ProceedsFromBorrowingsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings net of transaction costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromBorrowingsNetOfTransactionCosts" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromBorrowingsNetOfTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ProceedsFromBorrowingsNetOfTransactionCosts" xlink:to="lab_alvo_ProceedsFromBorrowingsNetOfTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TransactionCosts_b7dd1c72-fec8-4b26-835a-a466fce10fd6_terseLabel_en-US" xlink:label="lab_alvo_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_alvo_TransactionCosts_label_en-US" xlink:label="lab_alvo_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_alvo_TransactionCosts_documentation_en-US" xlink:label="lab_alvo_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TransactionCosts" xlink:href="alvo-20231231.xsd#alvo_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TransactionCosts" xlink:to="lab_alvo_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures_6d3f7c5e-35cd-4495-b28e-8b93cf1130ed_terseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of bonds</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of bonds, notes and debentures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:to="lab_ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_438415c4-8f3c-4df9-8125-aa042bdc1d5e_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherLongtermBenefits_e695d27d-ec58-4523-a406-84c0f51c4449_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherLongtermBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive plan expense</link:label>
    <link:label id="lab_ifrs-full_OtherLongtermBenefits_label_en-US" xlink:label="lab_ifrs-full_OtherLongtermBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherLongtermBenefits" xlink:to="lab_ifrs-full_OtherLongtermBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_c93a6a54-edab-4678-888a-594d1cf48bfb_terseLabel_en-US" xlink:label="lab_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issuable as a percentage of fully diluted ordinary shares</link:label>
    <link:label id="lab_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_label_en-US" xlink:label="lab_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issuable As A Percentage Of Fully Diluted Ordinary Shares</link:label>
    <link:label id="lab_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_documentation_en-US" xlink:label="lab_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants issuable as a percentage of fully diluted ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" xlink:href="alvo-20231231.xsd#alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" xlink:to="lab_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_e36beb41-2303-48bf-8071-93dfc4e180c1_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_a6b63974-4f8f-4bbb-9571-6f681b1f196e_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other short-term receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39f5527f-f58c-49b4-b982-896d485b082a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_b8533772-69e9-46d8-915e-b76739d04ab0_negatedLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax credited to profit or loss</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ComponentOfDebtConvertedIntoEquityDomain_8688244d-486b-4919-ae1f-f93018379c2d_terseLabel_en-US" xlink:label="lab_alvo_ComponentOfDebtConvertedIntoEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component Of Debt Converted Into Equity [Domain]</link:label>
    <link:label id="lab_alvo_ComponentOfDebtConvertedIntoEquityDomain_label_en-US" xlink:label="lab_alvo_ComponentOfDebtConvertedIntoEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Component Of Debt Converted Into Equity [Domain]</link:label>
    <link:label id="lab_alvo_ComponentOfDebtConvertedIntoEquityDomain_documentation_en-US" xlink:label="lab_alvo_ComponentOfDebtConvertedIntoEquityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Component of debt converted into equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain" xlink:href="alvo-20231231.xsd#alvo_ComponentOfDebtConvertedIntoEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain" xlink:to="lab_alvo_ComponentOfDebtConvertedIntoEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_e936a721-b32f-4fa8-8cd3-72a10370572d_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillMember_f1f966b3-84fb-4f9f-92f2-d9039d19dac8_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_GoodwillMember_label_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillMember" xlink:to="lab_ifrs-full_GoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_311d7ab0-5d59-4c5b-b8fb-aea115864b8c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds on issue of equity shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MaturedOnApril2024Member_cf279b7f-7850-45f8-a6c0-11a2e9de60c2_terseLabel_en-US" xlink:label="lab_alvo_MaturedOnApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matured on March 2024</link:label>
    <link:label id="lab_alvo_MaturedOnApril2024Member_label_en-US" xlink:label="lab_alvo_MaturedOnApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Matured On April 2024 [Member]</link:label>
    <link:label id="lab_alvo_MaturedOnApril2024Member_documentation_en-US" xlink:label="lab_alvo_MaturedOnApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Matured On April 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnApril2024Member" xlink:href="alvo-20231231.xsd#alvo_MaturedOnApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MaturedOnApril2024Member" xlink:to="lab_alvo_MaturedOnApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_6033edc6-4a57-4ae6-b0d8-73006ab404a4_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfPredecessorEarnOutSharesValue_73107af1-6fe7-4109-886a-aad332b541cb_terseLabel_en-US" xlink:label="lab_alvo_IssueOfPredecessorEarnOutSharesValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Predecessor Earn Out Shares (Note 1.1)</link:label>
    <link:label id="lab_alvo_IssueOfPredecessorEarnOutSharesValue_label_en-US" xlink:label="lab_alvo_IssueOfPredecessorEarnOutSharesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of Predecessor Earn Out Shares Value</link:label>
    <link:label id="lab_alvo_IssueOfPredecessorEarnOutSharesValue_documentation_en-US" xlink:label="lab_alvo_IssueOfPredecessorEarnOutSharesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of predecessor earn out shares value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfPredecessorEarnOutSharesValue" xlink:href="alvo-20231231.xsd#alvo_IssueOfPredecessorEarnOutSharesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfPredecessorEarnOutSharesValue" xlink:to="lab_alvo_IssueOfPredecessorEarnOutSharesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock_9d50805a-2df8-4e9a-a777-a29fe640decd_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Litigation Settlements Explanatory [Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of litigation settlements explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock" xlink:to="lab_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity_d9c37851-dc27-4cdb-944b-ffb4385e2261_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion to Equity</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities reclassified into equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity" xlink:to="lab_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_c9ea16d3-61bb-4361-8b23-cee8a992e2df_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_60352b4f-70fb-44e3-88fa-c750c75a6320_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_2c57b124-8f8a-48e2-9186-a7bbbba52436_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in other assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases_d19b6a4d-d023-47f4-8b18-b08c77efbf4e_terseLabel_en-US" xlink:label="lab_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for indexed leases</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases_label_en-US" xlink:label="lab_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liabilities Adjustments For Indexed Leases</link:label>
    <link:label id="lab_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases_documentation_en-US" xlink:label="lab_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease liabilities adjustments for indexed leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases" xlink:to="lab_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_b38f91c2-068d-4ddb-8b93-063f6ee87b39_terseLabel_en-US" xlink:label="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Losses on disposals of property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_f8e936ae-358e-47ea-8dfa-e9fcbaf74490_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfOacbEarnOutSharesValue_d395be81-6dd8-4be4-b94a-6f5de533bbb9_terseLabel_en-US" xlink:label="lab_alvo_IssueOfOacbEarnOutSharesValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OACB Earn Out Shares (Note 1.1)</link:label>
    <link:label id="lab_alvo_IssueOfOacbEarnOutSharesValue_label_en-US" xlink:label="lab_alvo_IssueOfOacbEarnOutSharesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of OACB Earn Out Shares Value</link:label>
    <link:label id="lab_alvo_IssueOfOacbEarnOutSharesValue_documentation_en-US" xlink:label="lab_alvo_IssueOfOacbEarnOutSharesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of OACB earn out shares value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfOacbEarnOutSharesValue" xlink:href="alvo-20231231.xsd#alvo_IssueOfOacbEarnOutSharesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfOacbEarnOutSharesValue" xlink:to="lab_alvo_IssueOfOacbEarnOutSharesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6a2f1c75-5561-47ba-b2f6-5bf4b8d5fbe7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_72e90ea2-f3d0-4ee5-bf0b-98d75252dcee_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsAbstract_58b1d2dd-bf24-4991-ba28-315377fbce0a_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings [abstract]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsAbstract_label_en-US" xlink:label="lab_ifrs-full_BorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsAbstract" xlink:to="lab_ifrs-full_BorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfEquities_5268437b-b5e4-46e7-a22b-81199416a44e_verboseLabel_en-US" xlink:label="lab_alvo_IssueOfEquities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share issue</link:label>
    <link:label id="lab_alvo_IssueOfEquities_label_en-US" xlink:label="lab_alvo_IssueOfEquities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equities</link:label>
    <link:label id="lab_alvo_IssueOfEquities_documentation_en-US" xlink:label="lab_alvo_IssueOfEquities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of equities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfEquities" xlink:href="alvo-20231231.xsd#alvo_IssueOfEquities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfEquities" xlink:to="lab_alvo_IssueOfEquities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_UsdSofrMember_88e9269b-d95b-4740-8d13-624ff97e2eb2_terseLabel_en-US" xlink:label="lab_alvo_UsdSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USD SOFR</link:label>
    <link:label id="lab_alvo_UsdSofrMember_label_en-US" xlink:label="lab_alvo_UsdSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">USD SOFR [member]</link:label>
    <link:label id="lab_alvo_UsdSofrMember_documentation_en-US" xlink:label="lab_alvo_UsdSofrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">USD SOFR [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_UsdSofrMember" xlink:href="alvo-20231231.xsd#alvo_UsdSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_UsdSofrMember" xlink:to="lab_alvo_UsdSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssuedToANewBondHolderMember_5b498e5e-9af2-4a0b-8433-3af79a85e072_terseLabel_en-US" xlink:label="lab_alvo_IssuedToANewBondHolderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued To A New Bond Holder</link:label>
    <link:label id="lab_alvo_IssuedToANewBondHolderMember_label_en-US" xlink:label="lab_alvo_IssuedToANewBondHolderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued To A New Bond Holder [member]</link:label>
    <link:label id="lab_alvo_IssuedToANewBondHolderMember_documentation_en-US" xlink:label="lab_alvo_IssuedToANewBondHolderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issued to a new bond holder [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToANewBondHolderMember" xlink:href="alvo-20231231.xsd#alvo_IssuedToANewBondHolderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssuedToANewBondHolderMember" xlink:to="lab_alvo_IssuedToANewBondHolderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_cab01973-4a58-4004-be63-d8c07d9aea22_negatedPeriodStartLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_dbb46dbd-9266-41b8-b176-922a2dc7d5d8_negatedPeriodEndLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_86dc78e0-18a0-45fd-978b-e7061e91748d_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock_97903d1c-dc21-4df2-96eb-d4053d5dc6b0_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive plans</link:label>
    <link:label id="lab_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Long Term Incentive Plans Explanatory [Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of long-term incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" xlink:to="lab_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_6a86611b-2e9c-470f-ae49-e8e59e2d6b1d_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, variable interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, adjustment to interest rate basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:to="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AVT23Member_8a05f248-43ac-40c8-b4d8-f0160942968b_terseLabel_en-US" xlink:label="lab_alvo_AVT23Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVT23</link:label>
    <link:label id="lab_alvo_AVT23Member_label_en-US" xlink:label="lab_alvo_AVT23Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVT23 [Member]</link:label>
    <link:label id="lab_alvo_AVT23Member_documentation_en-US" xlink:label="lab_alvo_AVT23Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVT23</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AVT23Member" xlink:href="alvo-20231231.xsd#alvo_AVT23Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AVT23Member" xlink:to="lab_alvo_AVT23Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_a8278a67-41be-4a83-a6d9-3ea0684be978_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of The Groups' Revenue From Contracts With Customers</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_54d99ec7-b0af-4d1e-8274-7c1fff281816_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c0742cb8-798e-4064-baa7-9012602a5b8f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets_f7a406ae-4c50-4a74-8259-9abefc9c8841_terseLabel_en-US" xlink:label="lab_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for indexed leases</link:label>
    <link:label id="lab_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets_label_en-US" xlink:label="lab_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Indexed Leases Right Of Use Assets</link:label>
    <link:label id="lab_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets_documentation_en-US" xlink:label="lab_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for indexed leases right of use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForIndexedLeasesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets" xlink:to="lab_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_9651e3b0-d615-42fe-9aa7-892b18d72f6c_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_74d5f587-08a0-41f7-93de-6b383f3e565d_terseLabel_en-US" xlink:label="lab_alvo_AlvogenKoreaCo.LtdSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Korea co. Ltd - Sister company</link:label>
    <link:label id="lab_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenKoreaCo.LtdSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Korea co. Ltd - Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenKoreaCo.LtdSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Korea co .Ltd member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenKoreaCo.LtdSisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember" xlink:to="lab_alvo_AlvogenKoreaCo.LtdSisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_db1e99ad-a0ae-467d-aa4b-5c2b65fd753f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory_2a7bfc72-c345-456f-a6ab-6996c6c7f851_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of issued capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssuedCapitalAndSharePremiumMember_99b89e07-99d1-44ee-8058-afa4f406815a_terseLabel_en-US" xlink:label="lab_alvo_IssuedCapitalAndSharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued capital and share premium</link:label>
    <link:label id="lab_alvo_IssuedCapitalAndSharePremiumMember_label_en-US" xlink:label="lab_alvo_IssuedCapitalAndSharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued Capital and Share Premium [Member]</link:label>
    <link:label id="lab_alvo_IssuedCapitalAndSharePremiumMember_documentation_en-US" xlink:label="lab_alvo_IssuedCapitalAndSharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issued capital and share premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedCapitalAndSharePremiumMember" xlink:href="alvo-20231231.xsd#alvo_IssuedCapitalAndSharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssuedCapitalAndSharePremiumMember" xlink:to="lab_alvo_IssuedCapitalAndSharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaid_1daadfe1-7f01-44af-824c-a3168ee37db9_terseLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_ifrs-full_DividendsPaid_label_en-US" xlink:label="lab_ifrs-full_DividendsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaid" xlink:to="lab_ifrs-full_DividendsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncomeStatementsLocationAxis_2c8445a1-bed7-435e-b149-b839bd42926a_terseLabel_en-US" xlink:label="lab_alvo_IncomeStatementsLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income statement location [axis]</link:label>
    <link:label id="lab_alvo_IncomeStatementsLocationAxis_label_en-US" xlink:label="lab_alvo_IncomeStatementsLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statements Location [Axis]</link:label>
    <link:label id="lab_alvo_IncomeStatementsLocationAxis_documentation_en-US" xlink:label="lab_alvo_IncomeStatementsLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income statement location.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationAxis" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncomeStatementsLocationAxis" xlink:to="lab_alvo_IncomeStatementsLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TemporaryLabourExpense_54875dbe-1e1c-4fd8-b919-3ef716e62091_terseLabel_en-US" xlink:label="lab_alvo_TemporaryLabourExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary labor</link:label>
    <link:label id="lab_alvo_TemporaryLabourExpense_label_en-US" xlink:label="lab_alvo_TemporaryLabourExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Labour Expense</link:label>
    <link:label id="lab_alvo_TemporaryLabourExpense_documentation_en-US" xlink:label="lab_alvo_TemporaryLabourExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary labour expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TemporaryLabourExpense" xlink:href="alvo-20231231.xsd#alvo_TemporaryLabourExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TemporaryLabourExpense" xlink:to="lab_alvo_TemporaryLabourExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock_dcbfcd43-988a-4cd4-a44f-811a061451c1_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Revenue and other operating income Explanatory [Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of revenue and other operating income explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" xlink:to="lab_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_8696d16e-6f70-4162-a37d-264c7b9afa5d_negatedLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FeeAndCommissionExpense_8f9c8157-9504-42fe-a940-1ae36a08b739_terseLabel_en-US" xlink:label="lab_ifrs-full_FeeAndCommissionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consent fees to bond holders</link:label>
    <link:label id="lab_ifrs-full_FeeAndCommissionExpense_label_en-US" xlink:label="lab_ifrs-full_FeeAndCommissionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fee and commission expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FeeAndCommissionExpense" xlink:to="lab_ifrs-full_FeeAndCommissionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfInventoriesTable_5f396845-5bb8-4c37-87a0-44a3b3dc6c5e_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfInventoriesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Inventories [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfInventoriesTable_label_en-US" xlink:label="lab_alvo_DisclosureOfInventoriesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Inventories [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfInventoriesTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfInventoriesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfInventoriesTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfInventoriesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfInventoriesTable" xlink:to="lab_alvo_DisclosureOfInventoriesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_d063ab31-3b8a-4c78-8098-dc712aab354a_terseLabel_en-US" xlink:label="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of inventories recognised as expense</link:label>
    <link:label id="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_label_en-US" xlink:label="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of inventories recognised as expense during period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxLineItems_33d0f098-9222-48b7-a448-671160f96a14_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfIncomeTaxLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of income tax .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems" xlink:to="lab_alvo_DisclosureOfIncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_f744f347-9640-407a-a28c-3a9851482343_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue_3f339fdd-4e69-4e2b-9ce4-c5aba865f7e0_terseLabel_en-US" xlink:label="lab_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of derivative liabilities at fair value</link:label>
    <link:label id="lab_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue_label_en-US" xlink:label="lab_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognition Of Derivative Liabilities At Fair Value</link:label>
    <link:label id="lab_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue_documentation_en-US" xlink:label="lab_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recognition of derivative liabilities at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue" xlink:href="alvo-20231231.xsd#alvo_RecognitionOfDerivativeLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue" xlink:to="lab_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CurrentAccruedInterest_f7a44599-5cd6-4107-a3cc-a7cd397709f3_verboseLabel_en-US" xlink:label="lab_alvo_CurrentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_alvo_CurrentAccruedInterest_label_en-US" xlink:label="lab_alvo_CurrentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Accrued Interest</link:label>
    <link:label id="lab_alvo_CurrentAccruedInterest_documentation_en-US" xlink:label="lab_alvo_CurrentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current accrued interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedInterest" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CurrentAccruedInterest" xlink:to="lab_alvo_CurrentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CapitalContributionValue_4b756ef7-de44-42dd-99b9-b040297c2176_terseLabel_en-US" xlink:label="lab_alvo_CapitalContributionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution</link:label>
    <link:label id="lab_alvo_CapitalContributionValue_label_en-US" xlink:label="lab_alvo_CapitalContributionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution Value</link:label>
    <link:label id="lab_alvo_CapitalContributionValue_documentation_en-US" xlink:label="lab_alvo_CapitalContributionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalContributionValue" xlink:href="alvo-20231231.xsd#alvo_CapitalContributionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CapitalContributionValue" xlink:to="lab_alvo_CapitalContributionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CommonStockValueSubscriptions_7633a31c-607b-49d7-8bb1-60b57f83efe6_terseLabel_en-US" xlink:label="lab_alvo_CommonStockValueSubscriptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, value, subscriptions</link:label>
    <link:label id="lab_alvo_CommonStockValueSubscriptions_label_en-US" xlink:label="lab_alvo_CommonStockValueSubscriptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Subscriptions</link:label>
    <link:label id="lab_alvo_CommonStockValueSubscriptions_documentation_en-US" xlink:label="lab_alvo_CommonStockValueSubscriptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock, value, subscriptions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockValueSubscriptions" xlink:href="alvo-20231231.xsd#alvo_CommonStockValueSubscriptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CommonStockValueSubscriptions" xlink:to="lab_alvo_CommonStockValueSubscriptions" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember_8aca0ee6-5cce-4820-9a7e-489d44a2a2ba_terseLabel_en-US" xlink:label="lab_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction In Interest Rate If Additional Shares Are Issued Within Six Months</link:label>
    <link:label id="lab_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember_label_en-US" xlink:label="lab_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction In Interest Rate If Additional Shares Are Issued Within Six Months [member]</link:label>
    <link:label id="lab_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember_documentation_en-US" xlink:label="lab_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction In Interest Rate If Additional Shares Are Issued Within Six Months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember" xlink:href="alvo-20231231.xsd#alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember" xlink:to="lab_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities_a6e57319-28ae-41a8-8594-db22cd7c33b4_verboseLabel_en-US" xlink:label="lab_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividends received from joint ventures</link:label>
    <link:label id="lab_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received from joint ventures, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExistingEmployeesMember_61c2c3a4-c57c-4aef-89a4-2db0009e8e41_terseLabel_en-US" xlink:label="lab_alvo_ExistingEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Existing Employees</link:label>
    <link:label id="lab_alvo_ExistingEmployeesMember_label_en-US" xlink:label="lab_alvo_ExistingEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Existing Employees [Member]</link:label>
    <link:label id="lab_alvo_ExistingEmployeesMember_documentation_en-US" xlink:label="lab_alvo_ExistingEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Existing employees member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExistingEmployeesMember" xlink:href="alvo-20231231.xsd#alvo_ExistingEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExistingEmployeesMember" xlink:to="lab_alvo_ExistingEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_355eeeb4-b37d-4ad9-9481-3c5cf7db5533_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Financial Assets Measured at Cost</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqConsultingEhfMember_44c9c6ee-0e03-4398-9654-3c0ae6d3b586_terseLabel_en-US" xlink:label="lab_alvo_AztiqConsultingEhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq Consulting ehf. &#8211; Sister company</link:label>
    <link:label id="lab_alvo_AztiqConsultingEhfMember_label_en-US" xlink:label="lab_alvo_AztiqConsultingEhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq Consulting ehf [Member]</link:label>
    <link:label id="lab_alvo_AztiqConsultingEhfMember_documentation_en-US" xlink:label="lab_alvo_AztiqConsultingEhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq Consulting ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConsultingEhfMember" xlink:href="alvo-20231231.xsd#alvo_AztiqConsultingEhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqConsultingEhfMember" xlink:to="lab_alvo_AztiqConsultingEhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_7d61f7e9-662f-4218-856a-ccbfd00ccc25_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameMember" xlink:to="lab_ifrs-full_BorrowingsByNameMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_789630f5-2d18-404e-a731-66f6b71017d8_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate differences on translation of foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a5b60d90-cbf8-4436-9fc4-1d14c8818d73_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation differences</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_3f9f188b-4bd9-4aca-823b-c02a80ee0f02_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MinimumAmountOfRestrictedCashToBeMaintained_1210b1f0-f2c9-41af-bb17-d4292335a200_terseLabel_en-US" xlink:label="lab_alvo_MinimumAmountOfRestrictedCashToBeMaintained" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum amount of restricted cash to be maintained</link:label>
    <link:label id="lab_alvo_MinimumAmountOfRestrictedCashToBeMaintained_label_en-US" xlink:label="lab_alvo_MinimumAmountOfRestrictedCashToBeMaintained" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Amount Of Restricted Cash To Be Maintained</link:label>
    <link:label id="lab_alvo_MinimumAmountOfRestrictedCashToBeMaintained_documentation_en-US" xlink:label="lab_alvo_MinimumAmountOfRestrictedCashToBeMaintained" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum amount of restricted cash to be maintained.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MinimumAmountOfRestrictedCashToBeMaintained" xlink:href="alvo-20231231.xsd#alvo_MinimumAmountOfRestrictedCashToBeMaintained"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MinimumAmountOfRestrictedCashToBeMaintained" xlink:to="lab_alvo_MinimumAmountOfRestrictedCashToBeMaintained" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_A2022ConvertibleBondsMember_ea6b6a94-059c-499e-b472-8fc5c8914f82_terseLabel_en-US" xlink:label="lab_alvo_A2022ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Convertible Bonds</link:label>
    <link:label id="lab_alvo_A2022ConvertibleBondsMember_label_en-US" xlink:label="lab_alvo_A2022ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Convertible Bonds [Member]</link:label>
    <link:label id="lab_alvo_A2022ConvertibleBondsMember_documentation_en-US" xlink:label="lab_alvo_A2022ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Convertible Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_A2022ConvertibleBondsMember" xlink:href="alvo-20231231.xsd#alvo_A2022ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_A2022ConvertibleBondsMember" xlink:to="lab_alvo_A2022ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember_508492d1-1cf9-44f1-8145-9c418bfc9a44_terseLabel_en-US" xlink:label="lab_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company</link:label>
    <link:label id="lab_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Lux Holdings S.&#224; r.l &#8211; Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Lux Holdings S.&#224; r.l.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember" xlink:to="lab_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExtensionPremiumToBondHolders_ecfd9c5a-e204-4780-aa7a-20a89e69336d_terseLabel_en-US" xlink:label="lab_alvo_ExtensionPremiumToBondHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension premium to bond holders</link:label>
    <link:label id="lab_alvo_ExtensionPremiumToBondHolders_label_en-US" xlink:label="lab_alvo_ExtensionPremiumToBondHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extension Premium To Bond Holders</link:label>
    <link:label id="lab_alvo_ExtensionPremiumToBondHolders_documentation_en-US" xlink:label="lab_alvo_ExtensionPremiumToBondHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extension premium to bond holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtensionPremiumToBondHolders" xlink:href="alvo-20231231.xsd#alvo_ExtensionPremiumToBondHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExtensionPremiumToBondHolders" xlink:to="lab_alvo_ExtensionPremiumToBondHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_94601d27-4ec1-4755-9e89-8012635021f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AgreementDomain_7874829e-ae5b-4f92-96ef-0a5b7a80de4e_terseLabel_en-US" xlink:label="lab_alvo_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_alvo_AgreementDomain_label_en-US" xlink:label="lab_alvo_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_alvo_AgreementDomain_documentation_en-US" xlink:label="lab_alvo_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementDomain" xlink:href="alvo-20231231.xsd#alvo_AgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AgreementDomain" xlink:to="lab_alvo_AgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RestatedMember_89479074-3389-4917-ae51-5e1eb0e9a003_terseLabel_en-US" xlink:label="lab_ifrs-full_RestatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently stated [member]</link:label>
    <link:label id="lab_ifrs-full_RestatedMember_label_en-US" xlink:label="lab_ifrs-full_RestatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently stated [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestatedMember" xlink:to="lab_ifrs-full_RestatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_12c916d8-eb8c-4c9a-99c1-cfb83be174bb_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_d70778bb-8e20-4545-b64f-8ebc1e8a2f5f_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_46103014-e20e-448e-9cbc-7bbd62f4352a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_63d65b81-b908-412a-a363-c5a9d9a40c73_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_f10b0d63-cb33-4141-8302-b398c758d1b5_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at 1 January</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_6bd665a8-c2ad-4a4f-98a3-152932307ee5_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at 31 December</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_302d9672-8ccc-4c5d-b6b5-f583f124dd19_verboseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities (measured at amortized cost)</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_62978d4c-60c2-4ddd-90b5-2eca557b828a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_BusinessCombinationAndPipeFinancingMember_9cffc505-aa06-4bc2-8620-9ff4e417dc58_terseLabel_en-US" xlink:label="lab_alvo_BusinessCombinationAndPipeFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination and PIPE Financing</link:label>
    <link:label id="lab_alvo_BusinessCombinationAndPipeFinancingMember_label_en-US" xlink:label="lab_alvo_BusinessCombinationAndPipeFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination and PIPE Financing [Member]</link:label>
    <link:label id="lab_alvo_BusinessCombinationAndPipeFinancingMember_documentation_en-US" xlink:label="lab_alvo_BusinessCombinationAndPipeFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination and pipe financing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BusinessCombinationAndPipeFinancingMember" xlink:href="alvo-20231231.xsd#alvo_BusinessCombinationAndPipeFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_BusinessCombinationAndPipeFinancingMember" xlink:to="lab_alvo_BusinessCombinationAndPipeFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_cb4791e0-c12f-43de-8d01-3d7ab9d6fa1c_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TwoLeaseFacilitiesMember_fd22e0a0-af0a-471e-9091-952f72d50214_terseLabel_en-US" xlink:label="lab_alvo_TwoLeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Lease Facilities</link:label>
    <link:label id="lab_alvo_TwoLeaseFacilitiesMember_label_en-US" xlink:label="lab_alvo_TwoLeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Lease Facilities [Member]</link:label>
    <link:label id="lab_alvo_TwoLeaseFacilitiesMember_documentation_en-US" xlink:label="lab_alvo_TwoLeaseFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Lease Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoLeaseFacilitiesMember" xlink:href="alvo-20231231.xsd#alvo_TwoLeaseFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TwoLeaseFacilitiesMember" xlink:to="lab_alvo_TwoLeaseFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractLiabilitiesRollForward_538a91a1-c5d9-45c8-9bad-d59fd02db053_terseLabel_en-US" xlink:label="lab_alvo_ContractLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities</link:label>
    <link:label id="lab_alvo_ContractLiabilitiesRollForward_label_en-US" xlink:label="lab_alvo_ContractLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liabilities [Roll Forward]</link:label>
    <link:label id="lab_alvo_ContractLiabilitiesRollForward_documentation_en-US" xlink:label="lab_alvo_ContractLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesRollForward" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractLiabilitiesRollForward" xlink:to="lab_alvo_ContractLiabilitiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock_30a7424d-b39f-4200-a7fa-fa3bc46d1014_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in Ordinary Shares, Share Capital and Share Premium</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about movements in ordinary shares, share capital and share premium explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IncreaseThroughPipeFinancingValue_eaa0fb57-cbce-4865-b340-073ea55dcfae_terseLabel_en-US" xlink:label="lab_alvo_IncreaseThroughPipeFinancingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PIPE Financing (Note 1.1)</link:label>
    <link:label id="lab_alvo_IncreaseThroughPipeFinancingValue_label_en-US" xlink:label="lab_alvo_IncreaseThroughPipeFinancingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Through PIPE Financing Value</link:label>
    <link:label id="lab_alvo_IncreaseThroughPipeFinancingValue_documentation_en-US" xlink:label="lab_alvo_IncreaseThroughPipeFinancingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase through PIPE financing value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseThroughPipeFinancingValue" xlink:href="alvo-20231231.xsd#alvo_IncreaseThroughPipeFinancingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IncreaseThroughPipeFinancingValue" xlink:to="lab_alvo_IncreaseThroughPipeFinancingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_7bda26db-7c8f-4714-951d-a09d360d54eb_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageNumberOfEmployees_e3e7c343-a35d-4e9b-8d5b-1f6121015a6f_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average number of individuals employed</link:label>
    <link:label id="lab_ifrs-full_AverageNumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageNumberOfEmployees" xlink:to="lab_ifrs-full_AverageNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_95d7be43-0b07-4ab2-bd73-c52fffa17701_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of currency risk sensitivity analysis on profit before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems" xlink:to="lab_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConvertibleShareholderLoanMember_d2f5d375-deed-43d3-b67a-364726227e70_terseLabel_en-US" xlink:label="lab_alvo_ConvertibleShareholderLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Shareholder Loan</link:label>
    <link:label id="lab_alvo_ConvertibleShareholderLoanMember_label_en-US" xlink:label="lab_alvo_ConvertibleShareholderLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Shareholder Loan [member]</link:label>
    <link:label id="lab_alvo_ConvertibleShareholderLoanMember_documentation_en-US" xlink:label="lab_alvo_ConvertibleShareholderLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible shareholder loan [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleShareholderLoanMember" xlink:href="alvo-20231231.xsd#alvo_ConvertibleShareholderLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConvertibleShareholderLoanMember" xlink:to="lab_alvo_ConvertibleShareholderLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfEquityShares_e46ec8ee-0e89-46ca-9daf-ddf4e18d2de0_terseLabel_en-US" xlink:label="lab_alvo_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue (in shares)</link:label>
    <link:label id="lab_alvo_IssueOfEquityShares_label_en-US" xlink:label="lab_alvo_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of Equity Shares</link:label>
    <link:label id="lab_alvo_IssueOfEquityShares_documentation_en-US" xlink:label="lab_alvo_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of equity shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfEquityShares" xlink:href="alvo-20231231.xsd#alvo_IssueOfEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfEquityShares" xlink:to="lab_alvo_IssueOfEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OacbWarrantsMember_3521d4b4-c662-487b-bb0d-227c51738cf3_terseLabel_en-US" xlink:label="lab_alvo_OacbWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OACB Warrants</link:label>
    <link:label id="lab_alvo_OacbWarrantsMember_label_en-US" xlink:label="lab_alvo_OacbWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OACB Warrants [Member]</link:label>
    <link:label id="lab_alvo_OacbWarrantsMember_documentation_en-US" xlink:label="lab_alvo_OacbWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OACB warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbWarrantsMember" xlink:href="alvo-20231231.xsd#alvo_OacbWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OacbWarrantsMember" xlink:to="lab_alvo_OacbWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredSettlements_3c11a2b6-aec0-4c1c-acdb-b7fd2326fbab_terseLabel_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration transferred Settlements</link:label>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredSettlements_label_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition Consideration Transferred Settlements</link:label>
    <link:label id="lab_alvo_AssetAcquisitionConsiderationTransferredSettlements_documentation_en-US" xlink:label="lab_alvo_AssetAcquisitionConsiderationTransferredSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset acquisition consideration transferred Settlements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredSettlements" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AssetAcquisitionConsiderationTransferredSettlements" xlink:to="lab_alvo_AssetAcquisitionConsiderationTransferredSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LeaseFacilityAxis_d0f7bc99-3acd-430d-ad54-9763b810fa8e_terseLabel_en-US" xlink:label="lab_alvo_LeaseFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Facility [Axis]</link:label>
    <link:label id="lab_alvo_LeaseFacilityAxis_label_en-US" xlink:label="lab_alvo_LeaseFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Facility [Axis]</link:label>
    <link:label id="lab_alvo_LeaseFacilityAxis_documentation_en-US" xlink:label="lab_alvo_LeaseFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseFacilityAxis" xlink:href="alvo-20231231.xsd#alvo_LeaseFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LeaseFacilityAxis" xlink:to="lab_alvo_LeaseFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqConvertibleBondMember_eab28d29-b718-4996-9b84-ec1b296b2a2f_terseLabel_en-US" xlink:label="lab_alvo_AztiqConvertibleBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq Convertible Bond</link:label>
    <link:label id="lab_alvo_AztiqConvertibleBondMember_label_en-US" xlink:label="lab_alvo_AztiqConvertibleBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq Convertible Bond [member]</link:label>
    <link:label id="lab_alvo_AztiqConvertibleBondMember_documentation_en-US" xlink:label="lab_alvo_AztiqConvertibleBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq Convertible Bond[Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConvertibleBondMember" xlink:href="alvo-20231231.xsd#alvo_AztiqConvertibleBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqConvertibleBondMember" xlink:to="lab_alvo_AztiqConvertibleBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_fabab2a8-4272-4f8c-88a2-bd73bf14bacc_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_27f09440-a065-4e8c-908a-d314cfe61318_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ATPHoldingEhf.Member_a2b4bacf-5672-49fb-aac0-85e06a8751c1_terseLabel_en-US" xlink:label="lab_alvo_ATPHoldingEhf.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATP Holding ehf.</link:label>
    <link:label id="lab_alvo_ATPHoldingEhf.Member_label_en-US" xlink:label="lab_alvo_ATPHoldingEhf.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATP Holding ehf. [Member]</link:label>
    <link:label id="lab_alvo_ATPHoldingEhf.Member_documentation_en-US" xlink:label="lab_alvo_ATPHoldingEhf.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ATP Holding ehf.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ATPHoldingEhf.Member" xlink:href="alvo-20231231.xsd#alvo_ATPHoldingEhf.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ATPHoldingEhf.Member" xlink:to="lab_alvo_ATPHoldingEhf.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_c00d36a2-3f1d-4e6d-9b4c-f1a72c3f3731_terseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General And Administrative Expense</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MaturedOnMarch2029Member_f801c747-b771-48e3-b5fe-4618663becec_terseLabel_en-US" xlink:label="lab_alvo_MaturedOnMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matured On March 2029</link:label>
    <link:label id="lab_alvo_MaturedOnMarch2029Member_label_en-US" xlink:label="lab_alvo_MaturedOnMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Matured On March 2029 [Member]</link:label>
    <link:label id="lab_alvo_MaturedOnMarch2029Member_documentation_en-US" xlink:label="lab_alvo_MaturedOnMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Matured On March 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnMarch2029Member" xlink:href="alvo-20231231.xsd#alvo_MaturedOnMarch2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MaturedOnMarch2029Member" xlink:to="lab_alvo_MaturedOnMarch2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_d5292e05-ea11-4d57-802f-0a4bbfb10d4c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_870dcdd9-7a07-467a-a44d-ef378403de93_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_7fbdac40-d1b8-4e05-9799-dbb61cdeeee1_periodStartLabel_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Outstanding (in dollars per share)</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_16898925-a61a-4bf0-8639-178a7c8eed20_periodEndLabel_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Outstanding (in dollars per share)</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_label_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Per Share Other Equity Instruments Outstanding</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_documentation_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average fair value per share other equity instruments outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" xlink:to="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ThresholdDaysForDeterminingTheSharePrice_b5d33d2e-dd9f-4952-acbd-86efc5072e35_terseLabel_en-US" xlink:label="lab_alvo_ThresholdDaysForDeterminingTheSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of threshold days for determining the share price</link:label>
    <link:label id="lab_alvo_ThresholdDaysForDeterminingTheSharePrice_label_en-US" xlink:label="lab_alvo_ThresholdDaysForDeterminingTheSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Days For Determining The Share Price</link:label>
    <link:label id="lab_alvo_ThresholdDaysForDeterminingTheSharePrice_documentation_en-US" xlink:label="lab_alvo_ThresholdDaysForDeterminingTheSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold days for determining the share price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThresholdDaysForDeterminingTheSharePrice" xlink:href="alvo-20231231.xsd#alvo_ThresholdDaysForDeterminingTheSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ThresholdDaysForDeterminingTheSharePrice" xlink:to="lab_alvo_ThresholdDaysForDeterminingTheSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FlokiArtEhf.Member_95adabd1-0e0c-43d3-896d-c5b6af008756_terseLabel_en-US" xlink:label="lab_alvo_FlokiArtEhf.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fl&#243;ki-Art ehf.</link:label>
    <link:label id="lab_alvo_FlokiArtEhf.Member_label_en-US" xlink:label="lab_alvo_FlokiArtEhf.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fl&#243;ki-Art ehf. [Member]</link:label>
    <link:label id="lab_alvo_FlokiArtEhf.Member_documentation_en-US" xlink:label="lab_alvo_FlokiArtEhf.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fl&#243;ki-Art ehf.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiArtEhf.Member" xlink:href="alvo-20231231.xsd#alvo_FlokiArtEhf.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FlokiArtEhf.Member" xlink:to="lab_alvo_FlokiArtEhf.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_d334d562-6e00-432d-ac99-0622a56f3b33_terseLabel_en-US" xlink:label="lab_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvogen Malta Sh. Services - Sister company</link:label>
    <link:label id="lab_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_label_en-US" xlink:label="lab_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvogen Malta Sh. Services - Sister company [Member]</link:label>
    <link:label id="lab_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_documentation_en-US" xlink:label="lab_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvogen Malta Sh Services member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember" xlink:href="alvo-20231231.xsd#alvo_AlvogenMaltaSh.ServicesSisterCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember" xlink:to="lab_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_c646abb4-bccf-41d1-b07c-1cb427fa87a0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_4341e178-4971-4d5e-a55b-a1cc9a6894ac_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5253e546-bce9-41ca-bd15-b9c7e17ffbdb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_21f6da7e-b6be-48a0-93d4-403d0409f47d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfLeasesTerminated_e6231973-bd7b-409e-8d0d-4a2345fda9b9_terseLabel_en-US" xlink:label="lab_alvo_NumberOfLeasesTerminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leases terminated</link:label>
    <link:label id="lab_alvo_NumberOfLeasesTerminated_label_en-US" xlink:label="lab_alvo_NumberOfLeasesTerminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Leases Terminated</link:label>
    <link:label id="lab_alvo_NumberOfLeasesTerminated_documentation_en-US" xlink:label="lab_alvo_NumberOfLeasesTerminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Leases Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeasesTerminated" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeasesTerminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfLeasesTerminated" xlink:to="lab_alvo_NumberOfLeasesTerminated" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ContractLiabilitiesMember_67a3c04a-cbb9-4c91-8ab1-a2757451bf3b_terseLabel_en-US" xlink:label="lab_alvo_ContractLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities</link:label>
    <link:label id="lab_alvo_ContractLiabilitiesMember_label_en-US" xlink:label="lab_alvo_ContractLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liabilities [Member]</link:label>
    <link:label id="lab_alvo_ContractLiabilitiesMember_documentation_en-US" xlink:label="lab_alvo_ContractLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesMember" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ContractLiabilitiesMember" xlink:to="lab_alvo_ContractLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_120272d3-4a7f-409a-8975-706898b28cc6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in RSUs</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VariableInterestBearingBorrowingsMember_cd0c37c9-a2ec-4406-9fef-69daca1c6d74_terseLabel_en-US" xlink:label="lab_alvo_VariableInterestBearingBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable-interest bearing - Borrowings</link:label>
    <link:label id="lab_alvo_VariableInterestBearingBorrowingsMember_label_en-US" xlink:label="lab_alvo_VariableInterestBearingBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Bearing Borrowings [Member]</link:label>
    <link:label id="lab_alvo_VariableInterestBearingBorrowingsMember_documentation_en-US" xlink:label="lab_alvo_VariableInterestBearingBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Interest Bearing Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestBearingBorrowingsMember" xlink:href="alvo-20231231.xsd#alvo_VariableInterestBearingBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VariableInterestBearingBorrowingsMember" xlink:to="lab_alvo_VariableInterestBearingBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_f56e08e5-38e1-417c-b342-ca715db89b6a_terseLabel_en-US" xlink:label="lab_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_label_en-US" xlink:label="lab_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used</link:label>
    <link:label id="lab_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_documentation_en-US" xlink:label="lab_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense relating to short-term leases and low value leases for which recognition exemption has been used.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="alvo-20231231.xsd#alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lab_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_ad2900f2-c431-4eb7-aaad-1512eff008f0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SharesPrice_ce1b692e-b81a-4689-b1d9-20e453e1b3b1_terseLabel_en-US" xlink:label="lab_alvo_SharesPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares price (in dollars per share)</link:label>
    <link:label id="lab_alvo_SharesPrice_label_en-US" xlink:label="lab_alvo_SharesPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Price</link:label>
    <link:label id="lab_alvo_SharesPrice_documentation_en-US" xlink:label="lab_alvo_SharesPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SharesPrice" xlink:href="alvo-20231231.xsd#alvo_SharesPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SharesPrice" xlink:to="lab_alvo_SharesPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_d5ee5744-94de-4624-adfd-68e90d931480_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, goodwill</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LegalCost_c35c7f85-91f8-4c02-8002-19dcbdd772dc_terseLabel_en-US" xlink:label="lab_alvo_LegalCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal expenses</link:label>
    <link:label id="lab_alvo_LegalCost_label_en-US" xlink:label="lab_alvo_LegalCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal cost</link:label>
    <link:label id="lab_alvo_LegalCost_documentation_en-US" xlink:label="lab_alvo_LegalCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LegalCost" xlink:href="alvo-20231231.xsd#alvo_LegalCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LegalCost" xlink:to="lab_alvo_LegalCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_69de805b-7b9d-4159-ad46-e59c25a51b02_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_f5eb8935-7eee-4334-b988-56c3b8bb675c_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect on financial statement</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_5b409135-95d2-4167-8618-5e17ae8c084c_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:to="lab_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MarkLevickCeoMember_a8b8abc9-176a-4886-b0df-7f1b904b3e26_terseLabel_en-US" xlink:label="lab_alvo_MarkLevickCeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mark Levick CEO</link:label>
    <link:label id="lab_alvo_MarkLevickCeoMember_label_en-US" xlink:label="lab_alvo_MarkLevickCeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mark Levick CEO [Member]</link:label>
    <link:label id="lab_alvo_MarkLevickCeoMember_documentation_en-US" xlink:label="lab_alvo_MarkLevickCeoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mark Levick CEO .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MarkLevickCeoMember" xlink:href="alvo-20231231.xsd#alvo_MarkLevickCeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MarkLevickCeoMember" xlink:to="lab_alvo_MarkLevickCeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_b753f334-4c64-4431-bd93-2a1f4864ac37_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ownership interest in subsidiary</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_0ce70ed9-356a-412d-8c9d-9b4d93ad9b10_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership and voting power held by Alvotech</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesExplanatory_292d6944-3d8f-48cc-bb99-753ecfedcff2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interests in joint ventures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of joint ventures [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock_0231f71f-b601-4a8b-bbfd-a48c54ae72b5_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Aggregate Salary And Other Employee Expenses [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about aggregate salary and other employee expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CompensationStatusDomain_48392819-f8b4-41d5-be23-9d1485f218dc_terseLabel_en-US" xlink:label="lab_alvo_CompensationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Status [Domain]</link:label>
    <link:label id="lab_alvo_CompensationStatusDomain_label_en-US" xlink:label="lab_alvo_CompensationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Status [Domain]</link:label>
    <link:label id="lab_alvo_CompensationStatusDomain_documentation_en-US" xlink:label="lab_alvo_CompensationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationStatusDomain" xlink:href="alvo-20231231.xsd#alvo_CompensationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CompensationStatusDomain" xlink:to="lab_alvo_CompensationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_5f0fab62-caa2-4b3e-8bcf-77b76be0f563_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New leases</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9dd060b3-c28b-4f69-897e-22f4f93a8a93_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_ce87a2dd-8e05-443a-97d5-6f892f1d17e3_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercisable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_1ed6bbfb-05b6-4b55-8980-fd131c326320_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension contribution</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Goodwill_baeaf82e-d88d-4b5d-b8e6-51ed94732cd8_terseLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_Goodwill_fe735701-7b55-4355-ac49-8264744100cc_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of 1 January</link:label>
    <link:label id="lab_ifrs-full_Goodwill_d0995c99-7a15-4472-a027-8b69b46cb314_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of 31 December</link:label>
    <link:label id="lab_ifrs-full_Goodwill_label_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e7e37d0c-5ef1-42ac-ae33-52e547533b45_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssueOfPredecessorEarnOutShares_44d2eafe-a77f-4f87-a640-0e560ba7fe23_terseLabel_en-US" xlink:label="lab_alvo_IssueOfPredecessorEarnOutShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Predecessor Earn Out Shares, (in shares)</link:label>
    <link:label id="lab_alvo_IssueOfPredecessorEarnOutShares_label_en-US" xlink:label="lab_alvo_IssueOfPredecessorEarnOutShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of Predecessor Earn Out Shares</link:label>
    <link:label id="lab_alvo_IssueOfPredecessorEarnOutShares_documentation_en-US" xlink:label="lab_alvo_IssueOfPredecessorEarnOutShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue of predecessor earn out shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfPredecessorEarnOutShares" xlink:href="alvo-20231231.xsd#alvo_IssueOfPredecessorEarnOutShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssueOfPredecessorEarnOutShares" xlink:to="lab_alvo_IssueOfPredecessorEarnOutShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CustomerCMember_0e1ff65d-3390-40ac-8cc5-9ee63b4a4650_terseLabel_en-US" xlink:label="lab_alvo_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_alvo_CustomerCMember_label_en-US" xlink:label="lab_alvo_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_alvo_CustomerCMember_documentation_en-US" xlink:label="lab_alvo_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerCMember" xlink:href="alvo-20231231.xsd#alvo_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CustomerCMember" xlink:to="lab_alvo_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DeferredTaxAbstract_17c7c8e5-ece7-4c36-bf3e-653c0e4ab44f_terseLabel_en-US" xlink:label="lab_alvo_DeferredTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_alvo_DeferredTaxAbstract_label_en-US" xlink:label="lab_alvo_DeferredTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax [Abstract]</link:label>
    <link:label id="lab_alvo_DeferredTaxAbstract_documentation_en-US" xlink:label="lab_alvo_DeferredTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DeferredTaxAbstract" xlink:href="alvo-20231231.xsd#alvo_DeferredTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DeferredTaxAbstract" xlink:to="lab_alvo_DeferredTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b0506d56-124e-49ba-8187-915c36bf618d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_6d1a71fc-fa8b-4eed-b3b0-5589e111a512_verboseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities incurred in relation to interests in joint ventures</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities incurred in relation to interests in joint ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:to="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LenderNameAxis_d020f1e6-c89e-4b99-9801-005fae6ce0b1_terseLabel_en-US" xlink:label="lab_alvo_LenderNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_alvo_LenderNameAxis_label_en-US" xlink:label="lab_alvo_LenderNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_alvo_LenderNameAxis_documentation_en-US" xlink:label="lab_alvo_LenderNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lender name [Axis].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LenderNameAxis" xlink:href="alvo-20231231.xsd#alvo_LenderNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LenderNameAxis" xlink:to="lab_alvo_LenderNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesAbstract_94b3c6ad-f22f-4472-8442-370fe5dd81e9_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesAbstract" xlink:to="lab_ifrs-full_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_11f007fe-7f57-475e-b5aa-34e1ace9d7eb_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_IssuanceOfOrdinaryValue_c6c27478-bd0e-45b3-9628-ce0ab4a54e17_terseLabel_en-US" xlink:label="lab_alvo_IssuanceOfOrdinaryValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Ordinary Shares (Note 1.1)</link:label>
    <link:label id="lab_alvo_IssuanceOfOrdinaryValue_label_en-US" xlink:label="lab_alvo_IssuanceOfOrdinaryValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Ordinary Value</link:label>
    <link:label id="lab_alvo_IssuanceOfOrdinaryValue_documentation_en-US" xlink:label="lab_alvo_IssuanceOfOrdinaryValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of ordinary value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuanceOfOrdinaryValue" xlink:href="alvo-20231231.xsd#alvo_IssuanceOfOrdinaryValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_IssuanceOfOrdinaryValue" xlink:to="lab_alvo_IssuanceOfOrdinaryValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_12f0dda2-1695-4797-8321-77dc638ab8d2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfCreditRiskTable_57939998-a220-4a49-acae-ec872f1ced0c_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Credit Risk [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfCreditRiskTable_label_en-US" xlink:label="lab_alvo_DisclosureOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Credit Risk [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfCreditRiskTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCreditRiskTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfCreditRiskTable" xlink:to="lab_alvo_DisclosureOfCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_b1c29152-6f80-4dab-a268-009620e14fd9_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_28ec61b3-e5fb-4885-992a-8ecc85401d18_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ArionBankiHfMember_20158292-5b73-4ec2-a41b-036dc0d3ceb1_terseLabel_en-US" xlink:label="lab_alvo_ArionBankiHfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arion banki hf</link:label>
    <link:label id="lab_alvo_ArionBankiHfMember_label_en-US" xlink:label="lab_alvo_ArionBankiHfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arion banki hf [member]</link:label>
    <link:label id="lab_alvo_ArionBankiHfMember_documentation_en-US" xlink:label="lab_alvo_ArionBankiHfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arion banki hf [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ArionBankiHfMember" xlink:href="alvo-20231231.xsd#alvo_ArionBankiHfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ArionBankiHfMember" xlink:to="lab_alvo_ArionBankiHfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_f617c97a-406d-4e6a-89ba-6c1a93e931aa_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax [line items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Interest Rate Sensitivity Analysis Impact On Profit Before Tax [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems" xlink:to="lab_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdditionalBondsIssuanceDomain_016a5955-8c3b-458b-a336-d8199790fd6f_terseLabel_en-US" xlink:label="lab_alvo_AdditionalBondsIssuanceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Bonds Issuance [Domain]</link:label>
    <link:label id="lab_alvo_AdditionalBondsIssuanceDomain_label_en-US" xlink:label="lab_alvo_AdditionalBondsIssuanceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Bonds Issuance [Domain]</link:label>
    <link:label id="lab_alvo_AdditionalBondsIssuanceDomain_documentation_en-US" xlink:label="lab_alvo_AdditionalBondsIssuanceDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional bonds issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalBondsIssuanceDomain" xlink:href="alvo-20231231.xsd#alvo_AdditionalBondsIssuanceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdditionalBondsIssuanceDomain" xlink:to="lab_alvo_AdditionalBondsIssuanceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_91b84675-5fc6-420a-b846-ce9a46e0676c_terseLabel_en-US" xlink:label="lab_alvo_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrants or rights exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_label_en-US" xlink:label="lab_alvo_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Exercise Price Per Share</link:label>
    <link:label id="lab_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_documentation_en-US" xlink:label="lab_alvo_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights exercise price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:to="lab_alvo_ClassOfWarrantsOrRightsExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_902f0eef-4620-4ced-9a8c-37ee4d38b14a_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_8bc4c6a8-f98b-47e1-b720-0b99019155e0_verboseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables (measured at amortized cost)</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ddb25bf4-6c1f-4250-b244-f956e6f30074_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets_8c8ed575-9e35-45de-9673-d78ff438735c_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract asset additions</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through cumulative catch-up adjustments to revenue, contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_3422e1d1-8550-4a07-abe1-d9b1e82a03ac_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of loans from related parties</link:label>
    <link:label id="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_label_en-US" xlink:label="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash repayments of advances and loans from related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:to="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_65c9869e-ad9f-4855-a09c-2a0a6fcad2a5_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_MaturedOnAugust2029Member_132342c3-9a28-4fb4-a5d9-f59330510be7_terseLabel_en-US" xlink:label="lab_alvo_MaturedOnAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matured on August 2029</link:label>
    <link:label id="lab_alvo_MaturedOnAugust2029Member_label_en-US" xlink:label="lab_alvo_MaturedOnAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Matured On August 2029 [Member]</link:label>
    <link:label id="lab_alvo_MaturedOnAugust2029Member_documentation_en-US" xlink:label="lab_alvo_MaturedOnAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Matured on august 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnAugust2029Member" xlink:href="alvo-20231231.xsd#alvo_MaturedOnAugust2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_MaturedOnAugust2029Member" xlink:to="lab_alvo_MaturedOnAugust2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b7d5941a-fcf0-41c8-a11d-adad225e2666_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_7c1cfdeb-e8d7-4223-af4e-3ef0c0b4b465_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_4affde4b-1d2d-4e7f-9e17-71c676543461_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive plan</link:label>
    <link:label id="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_9392a934-2670-4d8a-9ab7-8a6c87f44afd_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive plan (measured at FVTPL)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_label_en-US" xlink:label="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current net defined benefit liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_2d1c9f0a-d8da-4cad-9d9a-6b8c52040deb_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about maturity analysis for lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_b99cde0d-0b69-4d8e-b888-8ecf115a4872_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance income and finance cost</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateMeasurementInputMember_54534ae7-73bf-4fab-ba8d-dd95fa4b0bea_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_InterestRateMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest rate, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateMeasurementInputMember" xlink:to="lab_ifrs-full_InterestRateMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_PredecessorOrdinarySharesMember_420f4b71-4c33-438e-9253-86299c1a0034_terseLabel_en-US" xlink:label="lab_alvo_PredecessorOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Predecessor Ordinary Shares</link:label>
    <link:label id="lab_alvo_PredecessorOrdinarySharesMember_label_en-US" xlink:label="lab_alvo_PredecessorOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Predecessor Ordinary Shares [Member]</link:label>
    <link:label id="lab_alvo_PredecessorOrdinarySharesMember_documentation_en-US" xlink:label="lab_alvo_PredecessorOrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Predecessor ordinary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorOrdinarySharesMember" xlink:href="alvo-20231231.xsd#alvo_PredecessorOrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_PredecessorOrdinarySharesMember" xlink:to="lab_alvo_PredecessorOrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_0bfa4c41-994f-4697-af19-29c17b45bc4f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other employee expense</link:label>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other employee expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEmployeeExpense" xlink:to="lab_ifrs-full_OtherEmployeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities_aae7bd08-12f9-4da1-b197-7f6e9c9c9927_terseLabel_en-US" xlink:label="lab_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from new borrowings</link:label>
    <link:label id="lab_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Borrowing Classified As Financing Activities</link:label>
    <link:label id="lab_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities_documentation_en-US" xlink:label="lab_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from borrowing, classified as financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities" xlink:to="lab_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechHannoverGmbhMember_65232dc9-1e41-40e2-b054-efb979f61af4_terseLabel_en-US" xlink:label="lab_alvo_AlvotechHannoverGmbhMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech Hannover GmbH</link:label>
    <link:label id="lab_alvo_AlvotechHannoverGmbhMember_label_en-US" xlink:label="lab_alvo_AlvotechHannoverGmbhMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech Hannover GmbH [Member]</link:label>
    <link:label id="lab_alvo_AlvotechHannoverGmbhMember_documentation_en-US" xlink:label="lab_alvo_AlvotechHannoverGmbhMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech Hannover GmbH.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechHannoverGmbhMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechHannoverGmbhMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechHannoverGmbhMember" xlink:to="lab_alvo_AlvotechHannoverGmbhMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_87eb73d8-69f4-44c3-b4a1-9dca78638958_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceMember_d3196347-27d4-4d7d-abde-9c46596529c0_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary differences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceMember" xlink:to="lab_ifrs-full_TemporaryDifferenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FinalMaturityInDecember2029Member_79a8bc06-0b5d-4918-b758-f9d1b16e408e_terseLabel_en-US" xlink:label="lab_alvo_FinalMaturityInDecember2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final Maturity in December 2029</link:label>
    <link:label id="lab_alvo_FinalMaturityInDecember2029Member_label_en-US" xlink:label="lab_alvo_FinalMaturityInDecember2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Maturity in December 2029 [Member]</link:label>
    <link:label id="lab_alvo_FinalMaturityInDecember2029Member_documentation_en-US" xlink:label="lab_alvo_FinalMaturityInDecember2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Maturity in December 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinalMaturityInDecember2029Member" xlink:href="alvo-20231231.xsd#alvo_FinalMaturityInDecember2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FinalMaturityInDecember2029Member" xlink:to="lab_alvo_FinalMaturityInDecember2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_a3b082a1-e9fe-4d9a-b82e-00ad646a019f_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [member]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasMember_42515610-679b-491e-90fa-74f0a1cf1903_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [member]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasMember_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasMember" xlink:to="lab_ifrs-full_GeographicalAreasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_0b21b35f-ff1e-4078-978b-357553813747_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_e265b249-1f24-42d5-b41b-d2b266580863_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_5a16e1dd-409a-43ee-9d4d-17d0bc401cce_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_e8cd2fc9-1646-40d4-94b6-6b1fb2413190_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of summary of significant accounting policies [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of summary of significant accounting policies [Table]</link:label>
    <link:label id="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_f93e7ec2-96cb-4c13-bafc-a7e788f6d62a_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0620b011-6268-454e-adcd-05baa2ebc421_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_25d98722-3184-4144-b4c4-0eabf6b99609_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of foreign exchange rate [line items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_label_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Tabular Form Of Foreign Exchange Rate [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in tabular form of foreign exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems" xlink:to="lab_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock_fd78781c-0728-445e-ba2b-90469c538ac0_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries and other employee expenses</link:label>
    <link:label id="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Salaries And Other Employee Expenses Explanatory [Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of salaries and other employee expenses explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" xlink:to="lab_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_5c0bf273-712a-4d12-afe8-8ea399ff0e4d_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AztiqFacilityMember_f498c481-91af-4eab-82c4-82b9f2fb3ba2_terseLabel_en-US" xlink:label="lab_alvo_AztiqFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aztiq Facility</link:label>
    <link:label id="lab_alvo_AztiqFacilityMember_label_en-US" xlink:label="lab_alvo_AztiqFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aztiq Facility [member]</link:label>
    <link:label id="lab_alvo_AztiqFacilityMember_documentation_en-US" xlink:label="lab_alvo_AztiqFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aztiq Facility [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFacilityMember" xlink:href="alvo-20231231.xsd#alvo_AztiqFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AztiqFacilityMember" xlink:to="lab_alvo_AztiqFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_953f8494-4170-4cf4-be1e-17fcd4b41a8f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ConvertibleBondMember_fbefbe34-7b0e-4443-8f5d-6ab2207bb7cd_terseLabel_en-US" xlink:label="lab_alvo_ConvertibleBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Bond</link:label>
    <link:label id="lab_alvo_ConvertibleBondMember_label_en-US" xlink:label="lab_alvo_ConvertibleBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Bond [member]</link:label>
    <link:label id="lab_alvo_ConvertibleBondMember_documentation_en-US" xlink:label="lab_alvo_ConvertibleBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible bond [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondMember" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ConvertibleBondMember" xlink:to="lab_alvo_ConvertibleBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_ebbb1a20-e46a-472c-9830-cb3ff65ccafe_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_3d58b6f8-7d8c-48c5-b179-49afcd2ae3bd_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of potential ordinary shares that are antidilutive in period presented</link:label>
    <link:label id="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_label_en-US" xlink:label="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of potential ordinary shares that are antidilutive in period presented</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:to="lab_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_SaemundurMember_f0178412-00c0-4d6a-9728-91aa14e4d55f_terseLabel_en-US" xlink:label="lab_alvo_SaemundurMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Saemundur</link:label>
    <link:label id="lab_alvo_SaemundurMember_label_en-US" xlink:label="lab_alvo_SaemundurMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Saemundur [Member]</link:label>
    <link:label id="lab_alvo_SaemundurMember_documentation_en-US" xlink:label="lab_alvo_SaemundurMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Saemundur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaemundurMember" xlink:href="alvo-20231231.xsd#alvo_SaemundurMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_SaemundurMember" xlink:to="lab_alvo_SaemundurMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CostOfProductRevenueMember_5b9e0c99-9844-4995-a0cf-1f892488d873_terseLabel_en-US" xlink:label="lab_alvo_CostOfProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenue</link:label>
    <link:label id="lab_alvo_CostOfProductRevenueMember_label_en-US" xlink:label="lab_alvo_CostOfProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of Product Revenue [Member]</link:label>
    <link:label id="lab_alvo_CostOfProductRevenueMember_documentation_en-US" xlink:label="lab_alvo_CostOfProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of product revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CostOfProductRevenueMember" xlink:href="alvo-20231231.xsd#alvo_CostOfProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CostOfProductRevenueMember" xlink:to="lab_alvo_CostOfProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ShareCapitalAndSharePremium_7e5c49ea-e381-4ffc-b705-a125bad086a3_terseLabel_en-US" xlink:label="lab_alvo_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital and share premium</link:label>
    <link:label id="lab_alvo_ShareCapitalAndSharePremium_label_en-US" xlink:label="lab_alvo_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital and Share Premium</link:label>
    <link:label id="lab_alvo_ShareCapitalAndSharePremium_documentation_en-US" xlink:label="lab_alvo_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share capital and share premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareCapitalAndSharePremium" xlink:href="alvo-20231231.xsd#alvo_ShareCapitalAndSharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ShareCapitalAndSharePremium" xlink:to="lab_alvo_ShareCapitalAndSharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_5d22e94c-7807-4ca5-b0ae-d9fb6abbe567_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Decrease) / increase in other liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_EliminationOfPredecessorOrdinaryValue_63efdeb9-165b-4cf3-9c66-6ac0745e82d5_terseLabel_en-US" xlink:label="lab_alvo_EliminationOfPredecessorOrdinaryValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elimination of Predecessor Ordinary Shares</link:label>
    <link:label id="lab_alvo_EliminationOfPredecessorOrdinaryValue_label_en-US" xlink:label="lab_alvo_EliminationOfPredecessorOrdinaryValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elimination of Predecessor Ordinary Value</link:label>
    <link:label id="lab_alvo_EliminationOfPredecessorOrdinaryValue_documentation_en-US" xlink:label="lab_alvo_EliminationOfPredecessorOrdinaryValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elimination of predecessor ordinary value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EliminationOfPredecessorOrdinaryValue" xlink:href="alvo-20231231.xsd#alvo_EliminationOfPredecessorOrdinaryValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_EliminationOfPredecessorOrdinaryValue" xlink:to="lab_alvo_EliminationOfPredecessorOrdinaryValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_VariableInterestBearingFinancialAssetsMember_d08eed68-691d-42db-850c-02857b8b42ab_terseLabel_en-US" xlink:label="lab_alvo_VariableInterestBearingFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable-interest bearing</link:label>
    <link:label id="lab_alvo_VariableInterestBearingFinancialAssetsMember_label_en-US" xlink:label="lab_alvo_VariableInterestBearingFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable-Interest Bearing Financial Assets [Member]</link:label>
    <link:label id="lab_alvo_VariableInterestBearingFinancialAssetsMember_documentation_en-US" xlink:label="lab_alvo_VariableInterestBearingFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable-Interest Bearing Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestBearingFinancialAssetsMember" xlink:href="alvo-20231231.xsd#alvo_VariableInterestBearingFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_VariableInterestBearingFinancialAssetsMember" xlink:to="lab_alvo_VariableInterestBearingFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGoodwillExplanatory_b25b4cfc-8556-4550-902b-b254e44315a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties_e1aa78d0-6ece-4e4b-ba2b-906b57dbb0e8_verboseLabel_en-US" xlink:label="lab_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase / (decrease) in liabilities with related parties</link:label>
    <link:label id="lab_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties_label_en-US" xlink:label="lab_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase Decrease In Liabilities To Related Parties</link:label>
    <link:label id="lab_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties_documentation_en-US" xlink:label="lab_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for increase decrease in liabilities to related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" xlink:to="lab_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetAssetsLiabilities_fa16d58e-a0fb-4ea6-8c41-a839475a3350_terseLabel_en-US" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net assets</link:label>
    <link:label id="lab_ifrs-full_NetAssetsLiabilities_label_en-US" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets (liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="lab_ifrs-full_NetAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment_f04bcb78-1b2a-4ed1-a642-0afabb117b1e_terseLabel_en-US" xlink:label="lab_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and impairment of property, plant and equipment (see Note 12)</link:label>
    <link:label id="lab_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation And Impairment Of Property Plant And Equipment</link:label>
    <link:label id="lab_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation And Impairment Of Property Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment" xlink:href="alvo-20231231.xsd#alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment" xlink:to="lab_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherExecutiveTeamMember_749f8a4a-c3b4-4a07-a442-a37c37533e0a_terseLabel_en-US" xlink:label="lab_alvo_OtherExecutiveTeamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Executive Team Members</link:label>
    <link:label id="lab_alvo_OtherExecutiveTeamMember_label_en-US" xlink:label="lab_alvo_OtherExecutiveTeamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Executive Team [Member]</link:label>
    <link:label id="lab_alvo_OtherExecutiveTeamMember_documentation_en-US" xlink:label="lab_alvo_OtherExecutiveTeamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Executive Team.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherExecutiveTeamMember" xlink:href="alvo-20231231.xsd#alvo_OtherExecutiveTeamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherExecutiveTeamMember" xlink:to="lab_alvo_OtherExecutiveTeamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DetailsOfFinanceIncomeAbstract_28d0d531-366c-45f0-9426-0d4c4027434d_terseLabel_en-US" xlink:label="lab_alvo_DetailsOfFinanceIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Details Of Finance Income [Abstract]</link:label>
    <link:label id="lab_alvo_DetailsOfFinanceIncomeAbstract_label_en-US" xlink:label="lab_alvo_DetailsOfFinanceIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Details Of Finance Income [Abstract]</link:label>
    <link:label id="lab_alvo_DetailsOfFinanceIncomeAbstract_documentation_en-US" xlink:label="lab_alvo_DetailsOfFinanceIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Details of finance income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsOfFinanceIncomeAbstract" xlink:href="alvo-20231231.xsd#alvo_DetailsOfFinanceIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DetailsOfFinanceIncomeAbstract" xlink:to="lab_alvo_DetailsOfFinanceIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfConvertibleInstruments_745cc0a2-deea-478b-b56d-6a46e09cce32_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of convertible instruments</link:label>
    <link:label id="lab_ifrs-full_IssueOfConvertibleInstruments_label_en-US" xlink:label="lab_ifrs-full_IssueOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of convertible instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfConvertibleInstruments" xlink:to="lab_ifrs-full_IssueOfConvertibleInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_df06adb1-4968-4e4c-a05c-84fdc186d126_terseLabel_en-US" xlink:label="lab_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of intangible asset</link:label>
    <link:label id="lab_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognition, Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derecognition, Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill" xlink:href="alvo-20231231.xsd#alvo_DerecognitionIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill" xlink:to="lab_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_55af27b9-e164-45bd-aba1-8c81dd33d8e7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_d4b5e355-1a57-4b81-8307-b0b9061c3cfd_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CustomerBMember_c2c8e197-3b6f-42ce-843e-59bc82971aa2_terseLabel_en-US" xlink:label="lab_alvo_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_alvo_CustomerBMember_label_en-US" xlink:label="lab_alvo_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_alvo_CustomerBMember_documentation_en-US" xlink:label="lab_alvo_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer B.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerBMember" xlink:href="alvo-20231231.xsd#alvo_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CustomerBMember" xlink:to="lab_alvo_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnOtherFinancialAssets_cdcb3f2d-7ba0-474c-973a-24b2862833b9_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other interest income</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnOtherFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on other financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnOtherFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:to="lab_ifrs-full_InterestIncomeOnOtherFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_LotusPharmaceuticalCo.LtdMember_015e6b61-768f-407f-8de0-dc8f80e6b809_terseLabel_en-US" xlink:label="lab_alvo_LotusPharmaceuticalCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lotus pharmaceutical co. ltd</link:label>
    <link:label id="lab_alvo_LotusPharmaceuticalCo.LtdMember_label_en-US" xlink:label="lab_alvo_LotusPharmaceuticalCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lotus pharmaceutical co. ltd [Member]</link:label>
    <link:label id="lab_alvo_LotusPharmaceuticalCo.LtdMember_documentation_en-US" xlink:label="lab_alvo_LotusPharmaceuticalCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lotus pharmaceutical co. ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusPharmaceuticalCo.LtdMember" xlink:href="alvo-20231231.xsd#alvo_LotusPharmaceuticalCo.LtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_LotusPharmaceuticalCo.LtdMember" xlink:to="lab_alvo_LotusPharmaceuticalCo.LtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FormerEmployeesMember_773c5124-07c0-4b13-a269-b79498d6831a_terseLabel_en-US" xlink:label="lab_alvo_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Employees</link:label>
    <link:label id="lab_alvo_FormerEmployeesMember_label_en-US" xlink:label="lab_alvo_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Employees [Member]</link:label>
    <link:label id="lab_alvo_FormerEmployeesMember_documentation_en-US" xlink:label="lab_alvo_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FormerEmployeesMember" xlink:href="alvo-20231231.xsd#alvo_FormerEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FormerEmployeesMember" xlink:to="lab_alvo_FormerEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfLeaseAgreementsEnteredInto_f6221662-ec03-47ee-86e9-30e477b72600_terseLabel_en-US" xlink:label="lab_alvo_NumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lease agreements entered into</link:label>
    <link:label id="lab_alvo_NumberOfLeaseAgreementsEnteredInto_label_en-US" xlink:label="lab_alvo_NumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Lease Agreements Entered Into</link:label>
    <link:label id="lab_alvo_NumberOfLeaseAgreementsEnteredInto_documentation_en-US" xlink:label="lab_alvo_NumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Lease Agreements Entered Into</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeaseAgreementsEnteredInto" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeaseAgreementsEnteredInto"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfLeaseAgreementsEnteredInto" xlink:to="lab_alvo_NumberOfLeaseAgreementsEnteredInto" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c813a97f-0555-47a3-89fb-34978d1b5c80_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1a2c9fa8-18ff-4980-b8d8-480915901224_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_4dc5a9d9-bc4e-4564-9db6-eb851a3a1989_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_57eecc1e-4288-4832-8b68-4e8484ac5ada_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_7e3a6885-da6a-49bf-9d39-4a399a934e56_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sold service</link:label>
    <link:label id="lab_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from rendering of services, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions" xlink:to="lab_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_3b023103-a5d0-46fe-a6b9-f26a153a333a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of subsidiaries and joint ventures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AlvotechUkLtdMember_544e7bd7-9164-4f50-9637-709d33f0921b_terseLabel_en-US" xlink:label="lab_alvo_AlvotechUkLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alvotech UK Ltd</link:label>
    <link:label id="lab_alvo_AlvotechUkLtdMember_label_en-US" xlink:label="lab_alvo_AlvotechUkLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alvotech UK Ltd [Member]</link:label>
    <link:label id="lab_alvo_AlvotechUkLtdMember_documentation_en-US" xlink:label="lab_alvo_AlvotechUkLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alvotech UK Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechUkLtdMember" xlink:href="alvo-20231231.xsd#alvo_AlvotechUkLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AlvotechUkLtdMember" xlink:to="lab_alvo_AlvotechUkLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond_40dbb27a-eb6e-423c-81ad-11ec8fc2ad13_terseLabel_en-US" xlink:label="lab_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of Facility through Aztiq Convertible Bond</link:label>
    <link:label id="lab_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond_label_en-US" xlink:label="lab_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Addition Of The Loan Facilities Through Convertible Bond</link:label>
    <link:label id="lab_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond_documentation_en-US" xlink:label="lab_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Addition of the loan facilities through convertible bond.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond" xlink:href="alvo-20231231.xsd#alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond" xlink:to="lab_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_349a11e7-7b47-480a-bbfc-07995dfafdd5_negatedLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_3185fd23-dabb-462a-bf5d-63d0d2f14f22_totalLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total outstanding borrowings, net of debt issue costs</link:label>
    <link:label id="lab_ifrs-full_Borrowings_9ed2e6f9-2f58-45b7-9607-30311191f8c8_terseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings (measured at amortized cost)</link:label>
    <link:label id="lab_ifrs-full_Borrowings_3aa9ad8e-399c-47e3-b34f-c253857aefc6_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_40c54d36-3949-45d9-816d-74f84e5586b5_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ForeignCurrencyDifferenceOnLeaseLiability_c963f174-d2ce-474e-824b-1926b56bfbb4_terseLabel_en-US" xlink:label="lab_alvo_ForeignCurrencyDifferenceOnLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency difference on lease liability</link:label>
    <link:label id="lab_alvo_ForeignCurrencyDifferenceOnLeaseLiability_label_en-US" xlink:label="lab_alvo_ForeignCurrencyDifferenceOnLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Difference On Lease Liability</link:label>
    <link:label id="lab_alvo_ForeignCurrencyDifferenceOnLeaseLiability_documentation_en-US" xlink:label="lab_alvo_ForeignCurrencyDifferenceOnLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign currency difference on lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ForeignCurrencyDifferenceOnLeaseLiability" xlink:href="alvo-20231231.xsd#alvo_ForeignCurrencyDifferenceOnLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ForeignCurrencyDifferenceOnLeaseLiability" xlink:to="lab_alvo_ForeignCurrencyDifferenceOnLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_TrancheOneMember_be24510e-8923-47d9-b4fd-92fa66ac1710_terseLabel_en-US" xlink:label="lab_alvo_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche one</link:label>
    <link:label id="lab_alvo_TrancheOneMember_label_en-US" xlink:label="lab_alvo_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_alvo_TrancheOneMember_documentation_en-US" xlink:label="lab_alvo_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheOneMember" xlink:href="alvo-20231231.xsd#alvo_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_TrancheOneMember" xlink:to="lab_alvo_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_14488120-01f6-4e55-ae9e-304f806fbc1e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other current assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_ClassesOfCommonStockAxis_4b4376e7-94e7-40c3-9e44-c7a2ffd58a00_terseLabel_en-US" xlink:label="lab_alvo_ClassesOfCommonStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of common stock [axis]</link:label>
    <link:label id="lab_alvo_ClassesOfCommonStockAxis_label_en-US" xlink:label="lab_alvo_ClassesOfCommonStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of common stock [Axis]</link:label>
    <link:label id="lab_alvo_ClassesOfCommonStockAxis_documentation_en-US" xlink:label="lab_alvo_ClassesOfCommonStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Classes of common stock axis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassesOfCommonStockAxis" xlink:href="alvo-20231231.xsd#alvo_ClassesOfCommonStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_ClassesOfCommonStockAxis" xlink:to="lab_alvo_ClassesOfCommonStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExplanatory_fca0409b-a6b0-4e92-bd12-f0fc0c487e5d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Finance Income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_51a393c4-ec5b-42fd-828f-b38c6eddc583_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NonInterestBearingFinancialLiabilitiesMember_a38199f1-29a0-4e38-9d52-16bde6f020d0_terseLabel_en-US" xlink:label="lab_alvo_NonInterestBearingFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-interest bearing</link:label>
    <link:label id="lab_alvo_NonInterestBearingFinancialLiabilitiesMember_label_en-US" xlink:label="lab_alvo_NonInterestBearingFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Interest Bearing Financial Liabilities [Member]</link:label>
    <link:label id="lab_alvo_NonInterestBearingFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_alvo_NonInterestBearingFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Interest Bearing Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonInterestBearingFinancialLiabilitiesMember" xlink:href="alvo-20231231.xsd#alvo_NonInterestBearingFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NonInterestBearingFinancialLiabilitiesMember" xlink:to="lab_alvo_NonInterestBearingFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_0a600e4f-b4e0-4989-979a-2b04ec2901f3_terseLabel_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property rights</link:label>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_label_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Copyrights, patents and other industrial property rights, service and operating rights [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:to="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageMember_c642b9fc-df0a-42f8-9112-76f4a8756a14_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageMember_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageMember" xlink:to="lab_ifrs-full_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ef337e94-db01-476f-8a83-e2d98426c9b6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_fd077a82-f0a4-45c1-9e65-19d12e1e06c0_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29136805-ceb0-4593-8f4e-790b80ead60b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_eb1dc2a2-ea39-4cee-9cd7-a0b8c57b3499_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Line Items]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about classes of right of use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_0d048265-b490-4e06-b173-d8d7a9bd027e_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_85fdcd05-9215-4a6a-9eab-660364b61402_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_61c9d181-3fab-436e-8c72-74c55d8425fe_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_GrossProceedsFromThePipeFinancing_18ec2d12-e2ab-4b89-b85b-de12fe146806_negatedLabel_en-US" xlink:label="lab_alvo_GrossProceedsFromThePipeFinancing" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from the PIPE Financing</link:label>
    <link:label id="lab_alvo_GrossProceedsFromThePipeFinancing_label_en-US" xlink:label="lab_alvo_GrossProceedsFromThePipeFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From The Pipe Financing</link:label>
    <link:label id="lab_alvo_GrossProceedsFromThePipeFinancing_documentation_en-US" xlink:label="lab_alvo_GrossProceedsFromThePipeFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross proceeds from the pipe financing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GrossProceedsFromThePipeFinancing" xlink:href="alvo-20231231.xsd#alvo_GrossProceedsFromThePipeFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_GrossProceedsFromThePipeFinancing" xlink:to="lab_alvo_GrossProceedsFromThePipeFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_4a1943f2-0cb5-4e7f-bc6e-f81a97f1726b_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of net loss of joint venture</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_69d6baa7-5553-4559-a214-f62580cd9774_verboseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share in losses</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberOfSeparateInstallments_46f90028-5bd4-443a-b26c-91e8c4542a8c_terseLabel_en-US" xlink:label="lab_alvo_NumberOfSeparateInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of separate installments</link:label>
    <link:label id="lab_alvo_NumberOfSeparateInstallments_label_en-US" xlink:label="lab_alvo_NumberOfSeparateInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Separate Installments</link:label>
    <link:label id="lab_alvo_NumberOfSeparateInstallments_documentation_en-US" xlink:label="lab_alvo_NumberOfSeparateInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Separate Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSeparateInstallments" xlink:href="alvo-20231231.xsd#alvo_NumberOfSeparateInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberOfSeparateInstallments" xlink:to="lab_alvo_NumberOfSeparateInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_CustomerDMember_e60ff3ab-3b20-497c-91a9-aefb24908d55_terseLabel_en-US" xlink:label="lab_alvo_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_alvo_CustomerDMember_label_en-US" xlink:label="lab_alvo_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_alvo_CustomerDMember_documentation_en-US" xlink:label="lab_alvo_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerDMember" xlink:href="alvo-20231231.xsd#alvo_CustomerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_CustomerDMember" xlink:to="lab_alvo_CustomerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock_4563e2d3-20d2-4150-9e41-0f64344bdcc1_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Detailed Information About Audit Fees</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Audit Fees Explanatory [Table Text Block]</link:label>
    <link:label id="lab_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about audit fees explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" xlink:to="lab_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_424a53fe-e5d8-4f43-b0fa-580fa763e669_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_f3a72538-34dd-404f-bf06-d67f0dd0636c_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_110c968f-aa94-4ce6-bb4b-66566d35ebb1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_906d3d38-18e2-4866-9d0a-8d8bdaf90128_terseLabel_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure In Entirety Of Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure In Entirety Of Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure in entirety of supplemental cash flow information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract" xlink:to="lab_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_3286ebb1-625f-4f2b-ab2e-ee76ee41b0c1_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_OtherNoncurrentAsset_9bf55588-b562-4858-b2f5-d533f3bc0485_terseLabel_en-US" xlink:label="lab_alvo_OtherNoncurrentAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_alvo_OtherNoncurrentAsset_label_en-US" xlink:label="lab_alvo_OtherNoncurrentAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Asset</link:label>
    <link:label id="lab_alvo_OtherNoncurrentAsset_documentation_en-US" xlink:label="lab_alvo_OtherNoncurrentAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other non-current asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherNoncurrentAsset" xlink:href="alvo-20231231.xsd#alvo_OtherNoncurrentAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_OtherNoncurrentAsset" xlink:to="lab_alvo_OtherNoncurrentAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited_09ad4fec-f534-4390-ad61-fa8d56971299_terseLabel_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited_label_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Per Share Other Equity Instruments Forfeited</link:label>
    <link:label id="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited_documentation_en-US" xlink:label="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Per Share Other Equity Instruments Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" xlink:to="lab_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_20a12ae9-955e-49da-90dc-d624b4c43c7c_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_df231357-c259-46f9-9822-3c15d083ef41_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_1b26693c-2ff9-4b3d-be3e-a98ed0878af2_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_6b937ef7-e1be-4d7a-b351-f664b3e5ff9f_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_fc9b9a47-b4ff-4f61-a28b-caaabb54d15f_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation difference</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember_d42720e3-1ec3-483a-9ded-9cb0dcbe215d_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_cf1c0d0c-a73e-49a0-8fad-548addec0329_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_e2ddbe2c-813c-42af-8084-b45f408d2d48_terseLabel_en-US" xlink:label="lab_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Share Based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Share Based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of share based payment arrangements abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:to="lab_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_FlokiFasteignirEhfMember_929edcf6-a221-48a8-a92d-e5eb98998374_terseLabel_en-US" xlink:label="lab_alvo_FlokiFasteignirEhfMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fl&#243;ki fasteignir ehf. - Sister company</link:label>
    <link:label id="lab_alvo_FlokiFasteignirEhfMember_label_en-US" xlink:label="lab_alvo_FlokiFasteignirEhfMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Floki Fasteignir ehf [Member]</link:label>
    <link:label id="lab_alvo_FlokiFasteignirEhfMember_documentation_en-US" xlink:label="lab_alvo_FlokiFasteignirEhfMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Floki Fasteignir ehf member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiFasteignirEhfMember" xlink:href="alvo-20231231.xsd#alvo_FlokiFasteignirEhfMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_FlokiFasteignirEhfMember" xlink:to="lab_alvo_FlokiFasteignirEhfMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fe69f0b1-f330-408a-b414-b8fa3cff4269_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_dbd202ee-2eb7-4f35-8871-8b1540f525cd_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersAxis" xlink:to="lab_ifrs-full_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssets_7eb0cfa2-ab32-41ae-b032-b0c3b0c84ee5_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_dce5e0f2-c6bc-48d5-8358-78409f695fc9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsTypeMember_a49f9e8c-0128-4977-a88a-32c2dfbd7acf_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsTypeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, type [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsTypeMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsTypeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, type [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsTypeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsTypeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsTypeMember" xlink:to="lab_ifrs-full_FinancialAssetsTypeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_8f3bd79a-b13b-48d4-82fc-9e8f0dee4447_terseLabel_en-US" xlink:label="lab_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_label_en-US" xlink:label="lab_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number And Weighted Average Fair Value Of Other Equity Instruments [Roll Forward]</link:label>
    <link:label id="lab_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_documentation_en-US" xlink:label="lab_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number And Weighted Average Fair Value Of Other Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward" xlink:href="alvo-20231231.xsd#alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward" xlink:to="lab_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_fd896f43-a7cc-437d-9c14-7c5d2e5532a1_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_9133c69d-db96-412f-b472-3e36a4868710_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding diluted (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTemporaryDifferencesMember_17940c6a-956d-4c8b-9303-7a7bbe873bad_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other temporary differences</link:label>
    <link:label id="lab_ifrs-full_OtherTemporaryDifferencesMember_label_en-US" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other temporary differences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:to="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>alvo-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0f568319-c84c-47ce-b7c2-396cc2b09ac1,g:54c4089e-eaa8-4b46-9747-283b5fa757be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alvotech.com/role/CoverPage" xlink:type="simple" xlink:href="alvo-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3088774b-d0d4-4d35-abae-36b16c0b7383" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3088774b-d0d4-4d35-abae-36b16c0b7383" xlink:to="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_7368cf59-3fa8-4e93-a1fe-7eba56b137e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_7368cf59-3fa8-4e93-a1fe-7eba56b137e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_b43335de-6957-4972-8c3c-9cd04a666de2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_7368cf59-3fa8-4e93-a1fe-7eba56b137e2" xlink:to="loc_dei_AddressTypeDomain_b43335de-6957-4972-8c3c-9cd04a666de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_1528f110-4f23-43e7-9fe6-1e9102e98387" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_b43335de-6957-4972-8c3c-9cd04a666de2" xlink:to="loc_dei_BusinessContactMember_1528f110-4f23-43e7-9fe6-1e9102e98387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStocksAxis_5481295b-04a6-4f5e-8566-2cc2d8f9ae10" xlink:href="alvo-20231231.xsd#alvo_ClassOfStocksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:to="loc_alvo_ClassOfStocksAxis_5481295b-04a6-4f5e-8566-2cc2d8f9ae10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStocksDomain_ab0d9b79-4afd-4fe0-9f8d-5212643c9dad" xlink:href="alvo-20231231.xsd#alvo_ClassOfStocksDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ClassOfStocksAxis_5481295b-04a6-4f5e-8566-2cc2d8f9ae10" xlink:to="loc_alvo_ClassOfStocksDomain_ab0d9b79-4afd-4fe0-9f8d-5212643c9dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_3729d015-b2c5-4a89-bf65-3206ff1688c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ClassOfStocksDomain_ab0d9b79-4afd-4fe0-9f8d-5212643c9dad" xlink:to="loc_ifrs-full_OrdinarySharesMember_3729d015-b2c5-4a89-bf65-3206ff1688c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_98d1a515-c32b-4c40-a97f-10d671e2f900" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ClassOfStocksDomain_ab0d9b79-4afd-4fe0-9f8d-5212643c9dad" xlink:to="loc_ifrs-full_WarrantsMember_98d1a515-c32b-4c40-a97f-10d671e2f900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_32069a00-176a-4a36-a7a1-5243b7291cb1" xlink:to="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_055c7176-cfde-47cb-8132-eb2ef32c862a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentType_055c7176-cfde-47cb-8132-eb2ef32c862a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_da473fa2-5a88-4506-8538-e8caa4155d4f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentRegistrationStatement_da473fa2-5a88-4506-8538-e8caa4155d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7de0f182-d5b5-4b07-b7c3-c7310f2c5760" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentAnnualReport_7de0f182-d5b5-4b07-b7c3-c7310f2c5760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f58bf877-fc9f-43ca-9797-97165e5bce27" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_CurrentFiscalYearEndDate_f58bf877-fc9f-43ca-9797-97165e5bce27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d84bb72a-23d0-45e6-b8dd-99076231ce7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentPeriodEndDate_d84bb72a-23d0-45e6-b8dd-99076231ce7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_092efdca-07e0-46f9-8117-7308b8f59782" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentTransitionReport_092efdca-07e0-46f9-8117-7308b8f59782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_931f71ad-f9ed-49c2-99d6-6787e413bf5d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentShellCompanyReport_931f71ad-f9ed-49c2-99d6-6787e413bf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f6b04066-84b3-459b-b0f0-1299ef54c7d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityFileNumber_f6b04066-84b3-459b-b0f0-1299ef54c7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a6b4973c-0ed1-478f-9a49-eb5af4418d3b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityRegistrantName_a6b4973c-0ed1-478f-9a49-eb5af4418d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0db558e9-8c5f-41f3-83d5-e6d145298afb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0db558e9-8c5f-41f3-83d5-e6d145298afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_db6b3c8e-4196-4024-b7cb-f143b6334566" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressAddressLine1_db6b3c8e-4196-4024-b7cb-f143b6334566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f21ff1b7-90f9-41e4-b174-42e0fca113ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressAddressLine2_f21ff1b7-90f9-41e4-b174-42e0fca113ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9dacfd2d-7058-4098-8325-430ab5614043" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressPostalZipCode_9dacfd2d-7058-4098-8325-430ab5614043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6428a717-9a70-4f53-8fcb-a5e289763484" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressCityOrTown_6428a717-9a70-4f53-8fcb-a5e289763484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_e118383f-0ec9-454c-9582-82aed6176cf1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityAddressCountry_e118383f-0ec9-454c-9582-82aed6176cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_aa377f6f-6e52-4634-a530-bac33cbe7cb7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_ContactPersonnelName_aa377f6f-6e52-4634-a530-bac33cbe7cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_06e11079-664e-4b07-b706-a0a81af2edc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_CityAreaCode_06e11079-664e-4b07-b706-a0a81af2edc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_678b8124-0f2e-432a-9656-d5c1bb0c91b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_LocalPhoneNumber_678b8124-0f2e-432a-9656-d5c1bb0c91b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6d7b5c8b-8ce5-41f2-8d0e-be819910a9ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_Security12bTitle_6d7b5c8b-8ce5-41f2-8d0e-be819910a9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_764adabc-58a2-4ed9-8694-06b4ba29d592" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_TradingSymbol_764adabc-58a2-4ed9-8694-06b4ba29d592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_288988c7-d4e6-483b-88a9-ff2134c9c6ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_SecurityExchangeName_288988c7-d4e6-483b-88a9-ff2134c9c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f6d34484-3c86-4a6b-aaa3-cd455c573eb2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f6d34484-3c86-4a6b-aaa3-cd455c573eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsOutstanding_d2de7d24-895a-4627-b56c-74932b31563c" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_alvo_ClassOfWarrantsOrRightsOutstanding_d2de7d24-895a-4627-b56c-74932b31563c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_d88db6bf-07b1-4d9c-ac5e-dc438bb69403" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_d88db6bf-07b1-4d9c-ac5e-dc438bb69403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_6dce1658-6f0a-49d8-b2ee-8f8ec4589e35" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityVoluntaryFilers_6dce1658-6f0a-49d8-b2ee-8f8ec4589e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c28b1f48-2a58-4966-b1b9-d385e0d35a16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityCurrentReportingStatus_c28b1f48-2a58-4966-b1b9-d385e0d35a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cf1c3eef-4730-4f6b-93eb-6f404881d7b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityInteractiveDataCurrent_cf1c3eef-4730-4f6b-93eb-6f404881d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_dd5a38fa-1ea9-42b7-833c-28303af60f00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityFilerCategory_dd5a38fa-1ea9-42b7-833c-28303af60f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_73e8f6ea-d1b1-462b-837c-d3e58f3accc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityEmergingGrowthCompany_73e8f6ea-d1b1-462b-837c-d3e58f3accc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_28577fb7-3f8d-4b52-af88-58f4f46691a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityExTransitionPeriod_28577fb7-3f8d-4b52-af88-58f4f46691a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9c02cc4d-9f40-4845-a25d-bad2a87f55fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9c02cc4d-9f40-4845-a25d-bad2a87f55fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_657d60e0-e0a2-42f5-82ad-9211e667e2c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_657d60e0-e0a2-42f5-82ad-9211e667e2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_78ba7abf-7e55-43fc-b3f8-e16e3407ca89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentAccountingStandard_78ba7abf-7e55-43fc-b3f8-e16e3407ca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ce9b955e-566a-44eb-a2de-df4c900c31f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityShellCompany_ce9b955e-566a-44eb-a2de-df4c900c31f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_02b5260f-3cad-4693-9b92-8a92963793a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_EntityCentralIndexKey_02b5260f-3cad-4693-9b92-8a92963793a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2c9b5fe0-0209-4791-8a3e-81f0741612a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2c9b5fe0-0209-4791-8a3e-81f0741612a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_84e8b036-6f2a-4116-88ab-d21a2dc64eb4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_AmendmentFlag_84e8b036-6f2a-4116-88ab-d21a2dc64eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_74ee989e-2ee9-4ea7-b965-b4f8ba4d39ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7ae95206-a4d9-4fae-b44b-36e00923968f" xlink:to="loc_dei_DocumentFiscalYearFocus_74ee989e-2ee9-4ea7-b965-b4f8ba4d39ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/AuditInformation" xlink:type="simple" xlink:href="alvo-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AuditInformationAbstract_ce08c5e1-0536-4961-a4b2-442e2029980e" xlink:href="alvo-20231231.xsd#alvo_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_64c5108e-f173-4a7f-bf77-d97efcdbe792" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AuditInformationAbstract_ce08c5e1-0536-4961-a4b2-442e2029980e" xlink:to="loc_dei_AuditorName_64c5108e-f173-4a7f-bf77-d97efcdbe792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_ef6e05e5-065d-40c5-8349-6bd83c136301" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AuditInformationAbstract_ce08c5e1-0536-4961-a4b2-442e2029980e" xlink:to="loc_dei_AuditorFirmId_ef6e05e5-065d-40c5-8349-6bd83c136301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_060c4238-a427-4481-a43a-69d25f3cafb8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AuditInformationAbstract_ce08c5e1-0536-4961-a4b2-442e2029980e" xlink:to="loc_dei_AuditorLocation_060c4238-a427-4481-a43a-69d25f3cafb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_3ede30d3-31ab-43c2-b930-3d1d103d3776" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_3ede30d3-31ab-43c2-b930-3d1d103d3776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicenceFeeIncome_a3437cef-3fe1-46cc-a7ac-a36a8bbfe00a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicenceFeeIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_LicenceFeeIncome_a3437cef-3fe1-46cc-a7ac-a36a8bbfe00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_549f1620-d080-49fc-98f3-51c0026df5d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_OtherRevenue_549f1620-d080-49fc-98f3-51c0026df5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_208eb94a-5ffb-4ba9-96e8-3c9352b6cdab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_CostOfSales_208eb94a-5ffb-4ba9-96e8-3c9352b6cdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_a50f04f3-bfb5-4e43-be96-20061cb5df02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_a50f04f3-bfb5-4e43-be96-20061cb5df02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_0545f3ab-d8c0-4d03-a69e-ee25420c0428" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_0545f3ab-d8c0-4d03-a69e-ee25420c0428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_7269c910-8ecb-4721-adee-d52acf29a88b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_7269c910-8ecb-4721-adee-d52acf29a88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_ff70fd42-6dcb-425c-953c-9ab955ad3061" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_ff70fd42-6dcb-425c-953c-9ab955ad3061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_63ff4219-f346-4bd3-8ac3-fe4e608320ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_63ff4219-f346-4bd3-8ac3-fe4e608320ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_4ed5297f-47a1-492b-ab16-5b9448306878" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_FinanceIncome_4ed5297f-47a1-492b-ab16-5b9448306878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_72d9be22-6353-4b0c-a653-d2e1430acae0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_FinanceCosts_72d9be22-6353-4b0c-a653-d2e1430acae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_7bca5e23-d1d3-476a-a3e5-7432b421b591" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_7bca5e23-d1d3-476a-a3e5-7432b421b591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_8a8ea9c4-de78-4629-88b5-13aa04861aba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_8a8ea9c4-de78-4629-88b5-13aa04861aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_70a79bb7-bdbd-4c8d-9f20-ed88b59c1168" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherGainsLosses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_OtherGainsLosses_70a79bb7-bdbd-4c8d-9f20-ed88b59c1168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_d6996fa8-bc03-4f5f-bd6b-6660252146fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_d6996fa8-bc03-4f5f-bd6b-6660252146fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_7c5864af-a7aa-4113-8c4c-bce2df5f6091" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_7c5864af-a7aa-4113-8c4c-bce2df5f6091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_1dc1fa61-8ef8-49eb-a4a6-fde42b254bb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_ProfitLoss_1dc1fa61-8ef8-49eb-a4a6-fde42b254bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_1e44bc57-e020-4523-ab52-20304351a0fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_1e44bc57-e020-4523-ab52-20304351a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_28e0d017-ae8d-4306-b367-47ca7686dbed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_1e44bc57-e020-4523-ab52-20304351a0fb" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_28e0d017-ae8d-4306-b367-47ca7686dbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d16c5bb8-9779-4542-8132-90d0cea091b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_28e0d017-ae8d-4306-b367-47ca7686dbed" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d16c5bb8-9779-4542-8132-90d0cea091b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_e9f61dc6-0e7d-4ef1-bde8-29252239eea8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_28e0d017-ae8d-4306-b367-47ca7686dbed" xlink:to="loc_ifrs-full_ComprehensiveIncome_e9f61dc6-0e7d-4ef1-bde8-29252239eea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_dc7cf068-abe4-401d-99dd-e0b5279000ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c434dedc-1e52-416c-bc09-d9a393890cca" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_dc7cf068-abe4-401d-99dd-e0b5279000ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_9f964e97-c50c-476d-98d1-a8232c59e958" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_dc7cf068-abe4-401d-99dd-e0b5279000ba" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_9f964e97-c50c-476d-98d1-a8232c59e958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_d79097de-0d9a-425c-aab3-6080ddb0191b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_dc7cf068-abe4-401d-99dd-e0b5279000ba" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_d79097de-0d9a-425c-aab3-6080ddb0191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofFinancialPosition"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_631bf838-9916-4e26-959f-67ddbaf2e225" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_21f49950-8810-4b18-bd3a-32eb15de3368" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_631bf838-9916-4e26-959f-67ddbaf2e225" xlink:to="loc_ifrs-full_AssetsAbstract_21f49950-8810-4b18-bd3a-32eb15de3368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_21f49950-8810-4b18-bd3a-32eb15de3368" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_6643db76-c45b-4ce2-a428-479e920b80fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_6643db76-c45b-4ce2-a428-479e920b80fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_c7e7c695-9c90-4166-9268-020383461789" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_RightofuseAssets_c7e7c695-9c90-4166-9268-020383461789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_3a62cf6e-b8ee-4a82-ae96-8bf33a3ebd17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_Goodwill_3a62cf6e-b8ee-4a82-ae96-8bf33a3ebd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_7118a212-bfdf-40f1-9f42-4e8b4f534980" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_7118a212-bfdf-40f1-9f42-4e8b4f534980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractAssets_837c910c-b4fa-4791-838e-6bf80b292164" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_NoncurrentContractAssets_837c910c-b4fa-4791-838e-6bf80b292164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_5c0e7ce0-ae82-4fb1-90b9-2eb90f5348de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_5c0e7ce0-ae82-4fb1-90b9-2eb90f5348de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_3f672445-7520-4bf2-8c73-41b9d4f1bf5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_3f672445-7520-4bf2-8c73-41b9d4f1bf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_9317db2b-3747-40c6-be87-e4015f8623df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_9317db2b-3747-40c6-be87-e4015f8623df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_6466f0a3-e2fe-4b4c-83f1-54090d2c74be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_DeferredTaxAssets_6466f0a3-e2fe-4b4c-83f1-54090d2c74be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_8ad1c639-d3d9-4a43-8bc9-f4ee33422b28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_256efa81-9977-469c-89fb-abf5624674c6" xlink:to="loc_ifrs-full_NoncurrentAssets_8ad1c639-d3d9-4a43-8bc9-f4ee33422b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_21f49950-8810-4b18-bd3a-32eb15de3368" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_ba65bb4b-055b-42ef-a0a1-038cc258174a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:to="loc_ifrs-full_Inventories_ba65bb4b-055b-42ef-a0a1-038cc258174a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_8d49b6b0-53e3-4e26-803f-9e1bd325f37f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:to="loc_ifrs-full_CurrentTradeReceivables_8d49b6b0-53e3-4e26-803f-9e1bd325f37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractAssets_d421a16f-43ab-4985-901d-eaf96d5a8740" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:to="loc_ifrs-full_CurrentContractAssets_d421a16f-43ab-4985-901d-eaf96d5a8740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_e199963f-b50e-479a-b5c2-4fad3022f5cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:to="loc_ifrs-full_OtherCurrentAssets_e199963f-b50e-479a-b5c2-4fad3022f5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_c7875604-7843-40f5-899b-29ac4ba393f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_c7875604-7843-40f5-899b-29ac4ba393f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_5fcd5eb9-58c1-4d65-89a4-4bada821eace" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:to="loc_ifrs-full_CashAndCashEquivalents_5fcd5eb9-58c1-4d65-89a4-4bada821eace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_9fdd1681-fd87-4a76-8c0d-840c89c10a47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5bff6b4-bff6-4d54-9caf-fd40c153515e" xlink:to="loc_ifrs-full_CurrentAssets_9fdd1681-fd87-4a76-8c0d-840c89c10a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_e7c48abe-c67f-411a-b3d1-4b525bff50c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_21f49950-8810-4b18-bd3a-32eb15de3368" xlink:to="loc_ifrs-full_Assets_e7c48abe-c67f-411a-b3d1-4b525bff50c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_af00a732-77c2-4251-b8f5-314da187de4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_631bf838-9916-4e26-959f-67ddbaf2e225" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_af00a732-77c2-4251-b8f5-314da187de4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_27181790-17ed-42ef-bc37-3ea420052b79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_af00a732-77c2-4251-b8f5-314da187de4e" xlink:to="loc_ifrs-full_EquityAbstract_27181790-17ed-42ef-bc37-3ea420052b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_e68d73ec-cc64-44c4-9e30-1435fd1cb024" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_27181790-17ed-42ef-bc37-3ea420052b79" xlink:to="loc_ifrs-full_IssuedCapital_e68d73ec-cc64-44c4-9e30-1435fd1cb024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_d6a7da7a-844c-4dab-a431-4c29517097c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_27181790-17ed-42ef-bc37-3ea420052b79" xlink:to="loc_ifrs-full_SharePremium_d6a7da7a-844c-4dab-a431-4c29517097c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_d98352f7-1cd6-4001-a5c1-7a2f83bd16e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_27181790-17ed-42ef-bc37-3ea420052b79" xlink:to="loc_ifrs-full_OtherReserves_d98352f7-1cd6-4001-a5c1-7a2f83bd16e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_14f29758-4bf9-4971-af0b-c92c9d2d0979" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_27181790-17ed-42ef-bc37-3ea420052b79" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_14f29758-4bf9-4971-af0b-c92c9d2d0979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_65ba36aa-d031-48db-b384-e02323b48a45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_27181790-17ed-42ef-bc37-3ea420052b79" xlink:to="loc_ifrs-full_RetainedEarnings_65ba36aa-d031-48db-b384-e02323b48a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_cbc9d69d-2f9b-4822-bbb0-ce45b04e05e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_27181790-17ed-42ef-bc37-3ea420052b79" xlink:to="loc_ifrs-full_Equity_cbc9d69d-2f9b-4822-bbb0-ce45b04e05e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract_39e20ba3-efc8-4054-82fe-1e60e54b28eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_af00a732-77c2-4251-b8f5-314da187de4e" xlink:to="loc_ifrs-full_LiabilitiesAbstract_39e20ba3-efc8-4054-82fe-1e60e54b28eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_39e20ba3-efc8-4054-82fe-1e60e54b28eb" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_50adfa52-7214-4bfa-8f2e-5c44d293ee76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:to="loc_ifrs-full_LongtermBorrowings_50adfa52-7214-4bfa-8f2e-5c44d293ee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_f47c6c11-2d0a-4abe-890c-8fc3a6fc656c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_f47c6c11-2d0a-4abe-890c-8fc3a6fc656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPayablesToRelatedParties_425c3c9b-d98f-4103-89b8-d2e7dd672dbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPayablesToRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:to="loc_ifrs-full_NoncurrentPayablesToRelatedParties_425c3c9b-d98f-4103-89b8-d2e7dd672dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_4ad3cd51-3f46-4b64-aff6-4df3557d4b15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_4ad3cd51-3f46-4b64-aff6-4df3557d4b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_996478d1-5fbe-4b37-8739-1e9bbf7bdd5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:to="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_996478d1-5fbe-4b37-8739-1e9bbf7bdd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_7bf614db-7da3-4658-8825-c0e904082532" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_7bf614db-7da3-4658-8825-c0e904082532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_4a39d1c2-7805-411a-abad-270dc82fb975" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_4a39d1c2-7805-411a-abad-270dc82fb975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_29d8b456-166d-4bff-aab1-ec41e7e8fbf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_35abbc8f-9a87-4f20-8f75-eb528fe83b1f" xlink:to="loc_ifrs-full_NoncurrentLiabilities_29d8b456-166d-4bff-aab1-ec41e7e8fbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_39e20ba3-efc8-4054-82fe-1e60e54b28eb" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_382412c8-54e8-4534-963f-78c5abcc9dd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_382412c8-54e8-4534-963f-78c5abcc9dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_43cc00f9-22d1-4ec1-8b8c-95743e9c6f0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_43cc00f9-22d1-4ec1-8b8c-95743e9c6f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_fe03884a-f9cf-4d3b-8fb5-14edbd34e185" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:to="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_fe03884a-f9cf-4d3b-8fb5-14edbd34e185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_2817c955-dc80-48b1-a087-61f718be2106" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_2817c955-dc80-48b1-a087-61f718be2106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_e09cde65-05a4-483f-8cdd-02d723ccc55a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:to="loc_ifrs-full_CurrentContractLiabilities_e09cde65-05a4-483f-8cdd-02d723ccc55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_fb6f9fd6-fdf5-4daa-97bf-6204cfd06a83" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_fb6f9fd6-fdf5-4daa-97bf-6204cfd06a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_6e1cbbea-c683-44bf-9a43-569187af3699" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_6e1cbbea-c683-44bf-9a43-569187af3699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_ee2207f1-502d-4810-ae83-8b8dabcc0af4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_c3cb3c89-31d4-45cb-a220-5f47cd98c758" xlink:to="loc_ifrs-full_CurrentLiabilities_ee2207f1-502d-4810-ae83-8b8dabcc0af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_4f99d9f2-4c72-47cc-a793-6ff7949bc16a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_39e20ba3-efc8-4054-82fe-1e60e54b28eb" xlink:to="loc_ifrs-full_Liabilities_4f99d9f2-4c72-47cc-a793-6ff7949bc16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_7def7233-0ec0-4fb1-bbbc-6b284de738b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_af00a732-77c2-4251-b8f5-314da187de4e" xlink:to="loc_ifrs-full_EquityAndLiabilities_7def7233-0ec0-4fb1-bbbc-6b284de738b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_107b08fd-156c-4309-a435-b1d6c20e8b9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f12e8c4b-b10d-40d9-a18a-72277fc7ca0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_107b08fd-156c-4309-a435-b1d6c20e8b9c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f12e8c4b-b10d-40d9-a18a-72277fc7ca0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_6c6f9ec0-237f-4687-9294-11f7af6c004e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f12e8c4b-b10d-40d9-a18a-72277fc7ca0c" xlink:to="loc_ifrs-full_ProfitLoss_6c6f9ec0-237f-4687-9294-11f7af6c004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f12e8c4b-b10d-40d9-a18a-72277fc7ca0c" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains_277b2034-ea79-4cbe-8533-696e0c8e2d2c" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains_277b2034-ea79-4cbe-8533-696e0c8e2d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForSharelistingExpense_bce3221b-5c38-408e-a946-34446e873f25" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForSharelistingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_alvo_AdjustmentsForSharelistingExpense_bce3221b-5c38-408e-a946-34446e873f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_0d217922-4573-4167-b71b-0cbb235f05c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_0d217922-4573-4167-b71b-0cbb235f05c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_88b4e28e-34ee-4665-b5c2-a3e44302bd5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_88b4e28e-34ee-4665-b5c2-a3e44302bd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_b28c81be-afab-4600-9e12-c93694a54260" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_b28c81be-afab-4600-9e12-c93694a54260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets_36e4b979-3e6d-4869-967c-f19f25968e5b" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets_36e4b979-3e6d-4869-967c-f19f25968e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_f903726d-e878-4d68-92a6-364d80720800" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_f903726d-e878-4d68-92a6-364d80720800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ChangesInInventoryReserves_6ee4a62a-6179-4bd2-a494-06603292f78c" xlink:href="alvo-20231231.xsd#alvo_ChangesInInventoryReserves"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_alvo_ChangesInInventoryReserves_6ee4a62a-6179-4bd2-a494-06603292f78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_54959dd7-019f-412c-ada8-411de47023bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_54959dd7-019f-412c-ada8-411de47023bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_2a372da1-3ac3-4673-aaf7-8913670bca3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_2a372da1-3ac3-4673-aaf7-8913670bca3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_f4a7cd26-cec7-4bb6-abae-287887dba423" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_f4a7cd26-cec7-4bb6-abae-287887dba423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_ae1ff477-b395-4941-b01a-d0fe749afad2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_ae1ff477-b395-4941-b01a-d0fe749afad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_b5d015ec-90c9-4025-85b4-262e16c3acf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_b5d015ec-90c9-4025-85b4-262e16c3acf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_056f6665-c63c-45ec-aa48-28f277397157" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_056f6665-c63c-45ec-aa48-28f277397157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_7e1dcf62-cd82-466f-bf07-3413bba6bff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_7e1dcf62-cd82-466f-bf07-3413bba6bff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7816d6be-2341-4e2b-9aac-01bee1d3cb38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7816d6be-2341-4e2b-9aac-01bee1d3cb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_ce92b5c3-63ca-4c00-82fb-836923804cbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_ce92b5c3-63ca-4c00-82fb-836923804cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_0a3ab441-72f1-44cf-acc2-c53138458904" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_0a3ab441-72f1-44cf-acc2-c53138458904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_efcc420a-5934-4536-912d-6fd31029a6eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_efcc420a-5934-4536-912d-6fd31029a6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_b3114ac3-f3b3-4460-ac05-85424e960c6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_b3114ac3-f3b3-4460-ac05-85424e960c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties_887812a8-1a22-4ed5-a19c-23abf9c39ee7" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties_887812a8-1a22-4ed5-a19c-23abf9c39ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets_6b7d7f09-7147-4bed-a7f7-d409557b5ce7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets_6b7d7f09-7147-4bed-a7f7-d409557b5ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_6865b499-2b20-4384-b5a4-9300405a79e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_6865b499-2b20-4384-b5a4-9300405a79e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_0ffe197e-8bd5-4527-9567-29c1db4db187" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_0ffe197e-8bd5-4527-9567-29c1db4db187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e8a61013-e4f1-44c1-a5c3-31c063ba7440" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities_e8a61013-e4f1-44c1-a5c3-31c063ba7440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_9ef3c883-348d-41be-8267-d9f4a2f1c9d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_9ef3c883-348d-41be-8267-d9f4a2f1c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_11d3b354-f3c7-42ba-a97b-4c8893a40a63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_d1c4444d-2512-4b01-a5fc-b8b74b5b023c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_11d3b354-f3c7-42ba-a97b-4c8893a40a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_b6962718-f3f1-43bc-a324-34ae3df06882" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f12e8c4b-b10d-40d9-a18a-72277fc7ca0c" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_b6962718-f3f1-43bc-a324-34ae3df06882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_688ae54e-1729-416e-99c6-dcc0acaa9005" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f12e8c4b-b10d-40d9-a18a-72277fc7ca0c" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_688ae54e-1729-416e-99c6-dcc0acaa9005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_6b5357f8-9b11-4cbf-91a5-1b8a1fe8331f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f12e8c4b-b10d-40d9-a18a-72277fc7ca0c" xlink:to="loc_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_6b5357f8-9b11-4cbf-91a5-1b8a1fe8331f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_318674d5-1e01-4c65-8b85-fe00661ea7ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f12e8c4b-b10d-40d9-a18a-72277fc7ca0c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_318674d5-1e01-4c65-8b85-fe00661ea7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8b9dbd74-1e82-45ce-b503-ea84382652a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_107b08fd-156c-4309-a435-b1d6c20e8b9c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8b9dbd74-1e82-45ce-b503-ea84382652a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_d1e05ea8-bbad-4810-b893-43c028680ee2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8b9dbd74-1e82-45ce-b503-ea84382652a4" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_d1e05ea8-bbad-4810-b893-43c028680ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_e4b7e776-ed01-432c-8f86-64facc9149c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8b9dbd74-1e82-45ce-b503-ea84382652a4" xlink:to="loc_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_e4b7e776-ed01-432c-8f86-64facc9149c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_76d08ec4-337a-4446-90fb-cd4e3a560384" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8b9dbd74-1e82-45ce-b503-ea84382652a4" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_76d08ec4-337a-4446-90fb-cd4e3a560384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RestrictedCashInConnectionWithAmendedBondAgreement_f4322ec2-4500-41d5-88e9-3f9cbc5cc656" xlink:href="alvo-20231231.xsd#alvo_RestrictedCashInConnectionWithAmendedBondAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8b9dbd74-1e82-45ce-b503-ea84382652a4" xlink:to="loc_alvo_RestrictedCashInConnectionWithAmendedBondAgreement_f4322ec2-4500-41d5-88e9-3f9cbc5cc656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c90f72ac-887e-43d5-8f38-1555f69a29ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8b9dbd74-1e82-45ce-b503-ea84382652a4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c90f72ac-887e-43d5-8f38-1555f69a29ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_107b08fd-156c-4309-a435-b1d6c20e8b9c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_d85b9972-5374-43c4-b58f-682eaaca791c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_d85b9972-5374-43c4-b58f-682eaaca791c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities_a4c5195f-446d-4228-9108-f980552a9f5a" xlink:href="alvo-20231231.xsd#alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities_a4c5195f-446d-4228-9108-f980552a9f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_5b8a5806-a0b7-482b-9697-db38387fd3db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_5b8a5806-a0b7-482b-9697-db38387fd3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_a4b1a31f-8a46-40ee-9cda-13daea0ca63f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_ProceedsFromIssuingOtherEquityInstruments_a4b1a31f-8a46-40ee-9cda-13daea0ca63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_d561de56-d458-4e5d-a32a-39e7e555cbe9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_d561de56-d458-4e5d-a32a-39e7e555cbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_08082d5d-6a04-4366-b21b-845b3e8bfb6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_08082d5d-6a04-4366-b21b-845b3e8bfb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_fe5ccdf3-6b16-44c9-b767-64f754b01ce7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_fe5ccdf3-6b16-44c9-b767-64f754b01ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts_75c32531-b261-499a-80db-79bb3c395c3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForDebtIssueCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_PaymentsForDebtIssueCosts_75c32531-b261-499a-80db-79bb3c395c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GrossProceedsFromThePipeFinancing_b50ecc47-d605-4835-adab-dd11031b24aa" xlink:href="alvo-20231231.xsd#alvo_GrossProceedsFromThePipeFinancing"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_alvo_GrossProceedsFromThePipeFinancing_b50ecc47-d605-4835-adab-dd11031b24aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GrossPipeFinancingFeesPaid_3efcb063-a7bf-43a1-8794-c98ba40156de" xlink:href="alvo-20231231.xsd#alvo_GrossPipeFinancingFeesPaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_alvo_GrossPipeFinancingFeesPaid_3efcb063-a7bf-43a1-8794-c98ba40156de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromTheCapitalReorganization_e21fbcb2-cf3e-4335-9671-502073168c8a" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromTheCapitalReorganization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_alvo_ProceedsFromTheCapitalReorganization_e21fbcb2-cf3e-4335-9671-502073168c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties_9d917ccf-7830-4a76-9559-5e6caf1a3df1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties_9d917ccf-7830-4a76-9559-5e6caf1a3df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_fef7dbf9-39a7-479f-92b1-6dcc5039ce23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_fef7dbf9-39a7-479f-92b1-6dcc5039ce23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_69cac5a6-1692-4646-b198-a6d6c5b85c85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_42024560-3b86-47fa-8907-1fc4eae225af" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_69cac5a6-1692-4646-b198-a6d6c5b85c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_7436bb33-ed26-4c5a-b3e7-07a855f86100" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_107b08fd-156c-4309-a435-b1d6c20e8b9c" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_7436bb33-ed26-4c5a-b3e7-07a855f86100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_0a5c5c29-791d-4e6f-9ad6-a779ea7c8244" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_107b08fd-156c-4309-a435-b1d6c20e8b9c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_0a5c5c29-791d-4e6f-9ad6-a779ea7c8244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_79115963-f793-4eff-9b7c-0b88836d5fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_107b08fd-156c-4309-a435-b1d6c20e8b9c" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_79115963-f793-4eff-9b7c-0b88836d5fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_b6d11d46-7d60-4d5c-be2b-8526ce22728a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_107b08fd-156c-4309-a435-b1d6c20e8b9c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_b6d11d46-7d60-4d5c-be2b-8526ce22728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="alvo-20231231.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_fefa12f1-3475-4ff1-95c5-ce7d6b07572f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fefa12f1-3475-4ff1-95c5-ce7d6b07572f" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_32163db0-35b0-4c2e-a191-fd25095b9a00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_32163db0-35b0-4c2e-a191-fd25095b9a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_32163db0-35b0-4c2e-a191-fd25095b9a00" xlink:to="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_e6ec63cc-bb47-431d-81cf-656bcd22bd99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_IssuedCapitalMember_e6ec63cc-bb47-431d-81cf-656bcd22bd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_eaa7c3d0-f9b7-487b-b5ee-29d5d214b050" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_SharePremiumMember_eaa7c3d0-f9b7-487b-b5ee-29d5d214b050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_83789010-aecb-4356-883e-3d9e1d7dfa97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_OtherReservesMember_83789010-aecb-4356-883e-3d9e1d7dfa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ce9a189c-ec50-42c7-8f04-636881692f56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ce9a189c-ec50-42c7-8f04-636881692f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_3bbd671c-acd0-4f7c-ad9a-c98281e58bc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_c775fc11-bb88-48af-b54e-c89e746616be" xlink:to="loc_ifrs-full_RetainedEarningsMember_3bbd671c-acd0-4f7c-ad9a-c98281e58bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_229a88f0-58a7-42be-859a-a10643087674" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_229a88f0-58a7-42be-859a-a10643087674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_229a88f0-58a7-42be-859a-a10643087674" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PennyWarrantsMember_6c1ce34d-5cb1-4e2f-8b13-3d688edb347c" xlink:href="alvo-20231231.xsd#alvo_PennyWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_PennyWarrantsMember_6c1ce34d-5cb1-4e2f-8b13-3d688edb347c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PublicWarrantsMember_d5665955-d5f7-498f-ad08-fa60facf1e91" xlink:href="alvo-20231231.xsd#alvo_PublicWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_PublicWarrantsMember_d5665955-d5f7-498f-ad08-fa60facf1e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_711a4aae-8f61-43dc-adeb-9773759cc133" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_711a4aae-8f61-43dc-adeb-9773759cc133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember_cb2a8cb0-8cda-4940-9039-c5bc52ef6bb9" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_ShareAppreciationRightsMember_cb2a8cb0-8cda-4940-9039-c5bc52ef6bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnOutSharesMember_bc6031b9-aba7-4870-9ebb-f09f160ddc40" xlink:href="alvo-20231231.xsd#alvo_VestedEarnOutSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_VestedEarnOutSharesMember_bc6031b9-aba7-4870-9ebb-f09f160ddc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherShareBasedPaymentsMember_eaff886a-82d3-48f7-9c97-fa29aa79a5c8" xlink:href="alvo-20231231.xsd#alvo_OtherShareBasedPaymentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_9f1bba2f-82ed-4b97-9bdb-9da9822d29e1" xlink:to="loc_alvo_OtherShareBasedPaymentsMember_eaff886a-82d3-48f7-9c97-fa29aa79a5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_87811086-a312-46a8-aa1f-7ba0b69b3542" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_1d207a29-06fc-48ae-943a-6df7306290c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_Equity_1d207a29-06fc-48ae-943a-6df7306290c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9cf60d14-cead-414b-b28b-e391b9246c21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_ProfitLoss_9cf60d14-cead-414b-b28b-e391b9246c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47942090-eec6-4915-a979-44a3e80ed303" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47942090-eec6-4915-a979-44a3e80ed303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_f62e5f91-b334-4ae3-bfea-b70a8a8c87cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_ComprehensiveIncome_f62e5f91-b334-4ae3-bfea-b70a8a8c87cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_10ec41ca-8e7c-42e2-b550-73be2ddaa620" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IssueOfEquity_10ec41ca-8e7c-42e2-b550-73be2ddaa620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughPipeFinancing_1962cfdf-708b-4b8d-aa0b-e00ef3865fbf" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughPipeFinancing"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_alvo_IncreaseDecreaseThroughPipeFinancing_1962cfdf-708b-4b8d-aa0b-e00ef3865fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughCapitalReorganization_142bac18-da67-43de-9c31-a89fecf52611" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughCapitalReorganization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_alvo_IncreaseDecreaseThroughCapitalReorganization_142bac18-da67-43de-9c31-a89fecf52611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares_eaca617b-8017-4b8f-af51-4d75e474bab6" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares_eaca617b-8017-4b8f-af51-4d75e474bab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_859894a2-bb4b-4283-bd4e-3408e780cd4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_859894a2-bb4b-4283-bd4e-3408e780cd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_af42ab98-3515-438f-9f05-76f59ee794d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_af42ab98-3515-438f-9f05-76f59ee794d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_e6beaf07-b3ae-471e-b991-6fc3060b616d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_e6beaf07-b3ae-471e-b991-6fc3060b616d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_d457e1f0-1d32-484a-b4b9-6433ef65a1b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_d457e1f0-1d32-484a-b4b9-6433ef65a1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e9a7d081-1dc4-45d9-a813-2a84813acf1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e0c9bc52-237b-4cab-96e8-dcf96df1ee13" xlink:to="loc_ifrs-full_Equity_e9a7d081-1dc4-45d9-a813-2a84813acf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/Generalinformation" xlink:type="simple" xlink:href="alvo-20231231.xsd#Generalinformation"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/Generalinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_0da18e6d-1a5d-4508-84a5-d8842c53b449" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_c9600eb2-a794-4d6b-9b2b-a5775aaed93d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_0da18e6d-1a5d-4508-84a5-d8842c53b449" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_c9600eb2-a794-4d6b-9b2b-a5775aaed93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryOfSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_1a797b45-196d-497e-8cb0-ce3d3440bda4" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_319d8a5a-891a-44d8-b76f-be287b6d133f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_1a797b45-196d-497e-8cb0-ce3d3440bda4" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_319d8a5a-891a-44d8-b76f-be287b6d133f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/NewAccountingStandards" xlink:type="simple" xlink:href="alvo-20231231.xsd#NewAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/NewAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfNewAccountingStandardsAbstract_2484102f-3b76-4a3c-ad30-6cc506c18195" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfNewAccountingStandardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory_11b8acc6-6a7d-40e2-8d29-949a08156f79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfNewAccountingStandardsAbstract_2484102f-3b76-4a3c-ad30-6cc506c18195" xlink:to="loc_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory_11b8acc6-6a7d-40e2-8d29-949a08156f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SegmentReporting" xlink:type="simple" xlink:href="alvo-20231231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_66446b08-1480-46f3-b606-12797217d777" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_705929ef-10c0-4bdf-ac8a-bb0f70cbf412" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_66446b08-1480-46f3-b606-12797217d777" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_705929ef-10c0-4bdf-ac8a-bb0f70cbf412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/Revenue" xlink:type="simple" xlink:href="alvo-20231231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RevenueFromContractsWithCustomersAbstract_4c54ed6b-3472-4e38-9b9f-bac28c7452ef" xlink:href="alvo-20231231.xsd#alvo_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock_8d76f0d7-f2b5-4eed-a6d3-09a6c018c6a1" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RevenueFromContractsWithCustomersAbstract_4c54ed6b-3472-4e38-9b9f-bac28c7452ef" xlink:to="loc_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock_8d76f0d7-f2b5-4eed-a6d3-09a6c018c6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpenses" xlink:type="simple" xlink:href="alvo-20231231.xsd#SalariesAndOtherEmployeeExpenses"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_a450a68f-b983-4bd3-a9b1-32422d712a84" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock_fd51c37b-8f52-4488-b962-cde89ac97081" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_a450a68f-b983-4bd3-a9b1-32422d712a84" xlink:to="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock_fd51c37b-8f52-4488-b962-cde89ac97081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCosts" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinanceIncomeAndFinanceCosts"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinanceIncomeAndFinanceCosts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfFinanceIncomeAbstract_b94dba64-848f-41d5-9e4f-84eb439d85b0" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfFinanceIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_d0aa9773-9aea-4447-a979-eb641750f030" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_b94dba64-848f-41d5-9e4f-84eb439d85b0" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_d0aa9773-9aea-4447-a979-eb641750f030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairment" xlink:type="simple" xlink:href="alvo-20231231.xsd#DepreciationAmortizationAndImpairment"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/DepreciationAmortizationAndImpairment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_006bad91-c092-4888-9bf3-3a453cc371ab" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock_66f71b59-1ad4-45b6-a708-ab52a66f908d" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_006bad91-c092-4888-9bf3-3a453cc371ab" xlink:to="loc_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock_66f71b59-1ad4-45b6-a708-ab52a66f908d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/AuditFees" xlink:type="simple" xlink:href="alvo-20231231.xsd#AuditFees"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/AuditFees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfAuditFeesAbstract_e079b8a8-f6d5-45e8-8a6a-23b9f8305d35" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfAuditFeesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfAuditFeesExplanatoryTextBlock_d12f4a51-f821-4034-99ae-ac8bf4d1ab47" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfAuditFeesExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfAuditFeesAbstract_e079b8a8-f6d5-45e8-8a6a-23b9f8305d35" xlink:to="loc_alvo_DisclosureOfAuditFeesExplanatoryTextBlock_d12f4a51-f821-4034-99ae-ac8bf4d1ab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTax" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTax"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/IncomeTax" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract_544d0d21-deb6-42ef-8cb7-71c3b5ee85cf" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_404ffb21-4b2f-4b42-af63-67eb7771548a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_544d0d21-deb6-42ef-8cb7-71c3b5ee85cf" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_404ffb21-4b2f-4b42-af63-67eb7771548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LossPerShare" xlink:type="simple" xlink:href="alvo-20231231.xsd#LossPerShare"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_9c99aea1-9152-4864-95b8-7301822331e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_23eb60e1-e848-4983-83c7-1ffd8b7f6e63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_9c99aea1-9152-4864-95b8-7301822331e4" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_23eb60e1-e848-4983-83c7-1ffd8b7f6e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipment" xlink:type="simple" xlink:href="alvo-20231231.xsd#PropertyPlantAndEquipment"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0782ca5f-d238-4e37-998b-5ed95b2f066a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_ca2ca828-b393-472d-8870-450534fe68bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0782ca5f-d238-4e37-998b-5ed95b2f066a" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_ca2ca828-b393-472d-8870-450534fe68bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/Leases" xlink:type="simple" xlink:href="alvo-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2086ffe7-afc9-4175-a5c6-524880c7a429" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_29ff9c9f-da74-4523-be75-5255faf88fb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2086ffe7-afc9-4175-a5c6-524880c7a429" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_29ff9c9f-da74-4523-be75-5255faf88fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/Goodwill" xlink:type="simple" xlink:href="alvo-20231231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfGoodwillAbstract_96ff9a7d-89d2-49a4-a927-bee8e1b46451" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGoodwillExplanatory_6833a322-9943-4316-b704-8fe5e743e867" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfGoodwillAbstract_96ff9a7d-89d2-49a4-a927-bee8e1b46451" xlink:to="loc_ifrs-full_DisclosureOfGoodwillExplanatory_6833a322-9943-4316-b704-8fe5e743e867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherIntangibleassets" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherIntangibleassets"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherIntangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_91e0f30d-aba9-450e-a713-cc73a094d9b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_2647a843-0e37-453e-b17d-fd84b5fd3c29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_91e0f30d-aba9-450e-a713-cc73a094d9b6" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_2647a843-0e37-453e-b17d-fd84b5fd3c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/CashAndCashEquivalents" xlink:type="simple" xlink:href="alvo-20231231.xsd#CashAndCashEquivalents"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/CashAndCashEquivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_7983a2dc-c565-4c52-857b-e14592569bf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_08c08272-92e2-4a59-a062-fde298052ca0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_7983a2dc-c565-4c52-857b-e14592569bf1" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_08c08272-92e2-4a59-a062-fde298052ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/Inventories" xlink:type="simple" xlink:href="alvo-20231231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_15df191b-0ebb-4c28-b4d2-5d9778b1e005" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_c41b6cef-381d-490f-87b9-e9498cdd9ce8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_15df191b-0ebb-4c28-b4d2-5d9778b1e005" xlink:to="loc_ifrs-full_DisclosureOfInventoriesExplanatory_c41b6cef-381d-490f-87b9-e9498cdd9ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentAssets" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsAbstract_a055f1db-9eaf-4025-aa7f-3b6cd061a0d4" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_04c10a8c-b3cb-4ddb-8fdf-19490bccde0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_a055f1db-9eaf-4025-aa7f-3b6cd061a0d4" xlink:to="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_04c10a8c-b3cb-4ddb-8fdf-19490bccde0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareCapital" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareCapital"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_057a1a82-3873-405b-bafd-4df94892a856" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_c02c2f26-5e58-4078-a858-683f2261b56b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_057a1a82-3873-405b-bafd-4df94892a856" xlink:to="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_c02c2f26-5e58-4078-a858-683f2261b56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/Otherreserves" xlink:type="simple" xlink:href="alvo-20231231.xsd#Otherreserves"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/Otherreserves" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f39263c7-e102-4402-b42a-73457eb9a6c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_35fde359-12dc-462f-961c-8039f4dc956c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f39263c7-e102-4402-b42a-73457eb9a6c3" xlink:to="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_35fde359-12dc-462f-961c-8039f4dc956c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/Borrowings" xlink:type="simple" xlink:href="alvo-20231231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_8c0c16da-2051-4f4d-be63-8ea4b27d9eab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_698d56ac-82ff-474f-bc9b-7a53d3588770" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_8c0c16da-2051-4f4d-be63-8ea4b27d9eab" xlink:to="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_698d56ac-82ff-474f-bc9b-7a53d3588770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LongTermIncentivePlans" xlink:type="simple" xlink:href="alvo-20231231.xsd#LongTermIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LongTermIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract_d85c05d1-36c3-4467-ac0a-72978a6aaa1e" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLongtermIncentivePlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock_f684cf98-1cff-4fb9-9a76-2125fa058513" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract_d85c05d1-36c3-4467-ac0a-72978a6aaa1e" xlink:to="loc_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock_f684cf98-1cff-4fb9-9a76-2125fa058513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_22c5867b-7fda-42b0-ae7b-02690675cd1f" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_fd002559-201a-466c-9d1b-ed9cc077b528" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_22c5867b-7fda-42b0-ae7b-02690675cd1f" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_fd002559-201a-466c-9d1b-ed9cc077b528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/Litigation" xlink:type="simple" xlink:href="alvo-20231231.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LitigationAbstract_209a897b-b214-4136-9e62-63d2d45ffce8" xlink:href="alvo-20231231.xsd#alvo_LitigationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock_6ff9ef8d-b8f7-4df9-a414-5bb2bf618bc1" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LitigationAbstract_209a897b-b214-4136-9e62-63d2d45ffce8" xlink:to="loc_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock_6ff9ef8d-b8f7-4df9-a414-5bb2bf618bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedParties" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_7584ed0c-1a23-47c6-aaab-e44c704fc1df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_89a41a63-9924-4758-a82d-ecf62f1b30db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_7584ed0c-1a23-47c6-aaab-e44c704fc1df" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_89a41a63-9924-4758-a82d-ecf62f1b30db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentLiabilities" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentLiabilitiesAbstract_ba19ee5e-e23b-44ab-910c-a65294683770" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_bba6da54-47a7-47ef-8999-9f11f24a02f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract_ba19ee5e-e23b-44ab-910c-a65294683770" xlink:to="loc_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_bba6da54-47a7-47ef-8999-9f11f24a02f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InterestsInJointVentures" xlink:type="simple" xlink:href="alvo-20231231.xsd#InterestsInJointVentures"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/InterestsInJointVentures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesAbstract_e9d4df14-04e8-4712-9ab3-185c8de040da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesExplanatory_46b80fef-428a-4f73-a567-49d8c2148920" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_e9d4df14-04e8-4712-9ab3-185c8de040da" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesExplanatory_46b80fef-428a-4f73-a567-49d8c2148920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstruments" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_130b66aa-cc28-4229-9923-1be96fde50c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_e10bccfa-032e-46ec-9a2e-dc46df75c878" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_130b66aa-cc28-4229-9923-1be96fde50c0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_e10bccfa-032e-46ec-9a2e-dc46df75c878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="alvo-20231231.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_63b92625-98af-4e05-863f-7741c4ef406a" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock_dbfe5513-50bc-4cf2-ac68-c5b543d829ad" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_63b92625-98af-4e05-863f-7741c4ef406a" xlink:to="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock_dbfe5513-50bc-4cf2-ac68-c5b543d829ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="alvo-20231231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_3371e955-8990-4a60-92d9-c956459f721a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_ad39f144-524e-47b7-a111-aa5bc355fb88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_3371e955-8990-4a60-92d9-c956459f721a" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_ad39f144-524e-47b7-a111-aa5bc355fb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_b9a5c01c-e823-4409-b49d-9d4ad716189c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_b9a5c01c-e823-4409-b49d-9d4ad716189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_d8867870-4bd0-4109-8dd1-bb305f5241b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_d8867870-4bd0-4109-8dd1-bb305f5241b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures_8db6b9eb-c08d-4e92-a702-abe688c55ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures_8db6b9eb-c08d-4e92-a702-abe688c55ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock_ea545eb2-09fe-41ce-a513-88eeaccfc52e" xlink:href="alvo-20231231.xsd#alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock_ea545eb2-09fe-41ce-a513-88eeaccfc52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_bc978604-e56d-48f3-8495-fda848ff8f3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_bc978604-e56d-48f3-8495-fda848ff8f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_5cef7147-4416-4f6e-92ef-8cd5012a1ffb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_5cef7147-4416-4f6e-92ef-8cd5012a1ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock_2a980ea5-d41b-4f8d-a128-01c40bfc3497" xlink:href="alvo-20231231.xsd#alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock_2a980ea5-d41b-4f8d-a128-01c40bfc3497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_b6b56870-c082-43f1-a375-eb1a2b7a63ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_b6b56870-c082-43f1-a375-eb1a2b7a63ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_a6778f63-3929-4ab7-a9a2-183c26d02882" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_a6778f63-3929-4ab7-a9a2-183c26d02882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_bc15b6a9-867e-40e7-8422-2b93290620ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_bc15b6a9-867e-40e7-8422-2b93290620ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_094b97de-c9b1-47ec-9500-a46d9d9ec3ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_094b97de-c9b1-47ec-9500-a46d9d9ec3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_fab78279-90d6-4a02-8402-7e2585a10a0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_fab78279-90d6-4a02-8402-7e2585a10a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_284baee9-8df4-4a68-852c-e0496305cfcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_284baee9-8df4-4a68-852c-e0496305cfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_e2c24aad-6762-4e84-8eb3-8b43ff08b5e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_e2c24aad-6762-4e84-8eb3-8b43ff08b5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_9d561b5d-533d-42f1-8c76-36c2afc92045" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_9d561b5d-533d-42f1-8c76-36c2afc92045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_dbceaa0a-f426-4e7b-83ac-1c3332897aec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_dbceaa0a-f426-4e7b-83ac-1c3332897aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_c62d2f6b-fc39-4f5b-ba24-f56360598fb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_c62d2f6b-fc39-4f5b-ba24-f56360598fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_47ea58a9-b8a3-466c-b82b-1079f941f57a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_47ea58a9-b8a3-466c-b82b-1079f941f57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock_af10a905-22d8-4e37-a622-62a5a275b81a" xlink:href="alvo-20231231.xsd#alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock_af10a905-22d8-4e37-a622-62a5a275b81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_5011406b-2c5a-4db5-97f4-5dcf357c712d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_5011406b-2c5a-4db5-97f4-5dcf357c712d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_71d90508-a68d-4993-a436-d0e3a2695aa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_71d90508-a68d-4993-a436-d0e3a2695aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_d27bfb97-d9ab-4846-83f2-384430c1ba49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_eb4ab136-fbda-42a3-b5e3-44865e148f4a" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_d27bfb97-d9ab-4846-83f2-384430c1ba49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GeneralinformationTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#GeneralinformationTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/GeneralinformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_7a9f8bdc-4b4a-4056-b1fa-2c9bb24467bd" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock_d6a93766-8965-4974-8149-e7d5377750df" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_7a9f8bdc-4b4a-4056-b1fa-2c9bb24467bd" xlink:to="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock_d6a93766-8965-4974-8149-e7d5377750df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_6c66232a-b9b8-4630-b2f0-017a62804c9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_7a9f8bdc-4b4a-4056-b1fa-2c9bb24467bd" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_6c66232a-b9b8-4630-b2f0-017a62804c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesTable" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryOfSignificantAccountingPoliciesTable"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesTable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_869f70b4-826a-4fa8-bdae-bce1ec8af16f" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock_8b36eebb-4ce1-4029-a9b3-f72e48c39370" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_869f70b4-826a-4fa8-bdae-bce1ec8af16f" xlink:to="loc_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock_8b36eebb-4ce1-4029-a9b3-f72e48c39370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_048f7d10-f548-4e9a-8e3e-f3c528db1b25" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_869f70b4-826a-4fa8-bdae-bce1ec8af16f" xlink:to="loc_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_048f7d10-f548-4e9a-8e3e-f3c528db1b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_8fbb7276-1104-4796-b14c-da2c03160c10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_4d11df76-8ff2-48ed-a6ee-615a5560c4a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_8fbb7276-1104-4796-b14c-da2c03160c10" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_4d11df76-8ff2-48ed-a6ee-615a5560c4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock_7f249a3e-cdda-4ca2-8be7-2707fa56ab8e" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_8fbb7276-1104-4796-b14c-da2c03160c10" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock_7f249a3e-cdda-4ca2-8be7-2707fa56ab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory_2ecb323c-4a86-41c9-aa82-a63868ac826a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_8fbb7276-1104-4796-b14c-da2c03160c10" xlink:to="loc_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory_2ecb323c-4a86-41c9-aa82-a63868ac826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RevenueTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RevenueFromContractsWithCustomersAbstract_d64c75f2-4ee1-47ea-9ed3-a49c16ae6837" xlink:href="alvo-20231231.xsd#alvo_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_5708e477-7f3c-4b42-8ff9-ee01c813890c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RevenueFromContractsWithCustomersAbstract_d64c75f2-4ee1-47ea-9ed3-a49c16ae6837" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_5708e477-7f3c-4b42-8ff9-ee01c813890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_fb162c52-1d18-42f4-baff-c8da8e7fed2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RevenueFromContractsWithCustomersAbstract_d64c75f2-4ee1-47ea-9ed3-a49c16ae6837" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_fb162c52-1d18-42f4-baff-c8da8e7fed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#SalariesAndOtherEmployeeExpensesTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_555d5c46-76e7-4165-a664-0d8cca100eaa" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock_d0d89fb7-45af-425c-a879-2ac4f9eafe0c" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_555d5c46-76e7-4165-a664-0d8cca100eaa" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock_d0d89fb7-45af-425c-a879-2ac4f9eafe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock_9f249fcb-f155-4907-82d9-06048ff8204c" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_555d5c46-76e7-4165-a664-0d8cca100eaa" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock_9f249fcb-f155-4907-82d9-06048ff8204c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinanceIncomeAndFinanceCostsTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfFinanceIncomeAbstract_f5c768cd-fdbc-4f0b-9404-67ac14d507ec" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfFinanceIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExplanatory_a73a8ab7-c052-42d3-98c8-e9cf92f79d4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_f5c768cd-fdbc-4f0b-9404-67ac14d507ec" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExplanatory_a73a8ab7-c052-42d3-98c8-e9cf92f79d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceCostExplanatory_0435db70-e6d5-465b-b480-cc6fc7ec7f60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_f5c768cd-fdbc-4f0b-9404-67ac14d507ec" xlink:to="loc_ifrs-full_DisclosureOfFinanceCostExplanatory_0435db70-e6d5-465b-b480-cc6fc7ec7f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#DepreciationAmortizationAndImpairmentTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_c1726d72-1884-4f70-8d3c-0e1819b18c43" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock_3772cd08-0c4b-4304-92fc-25b91932ecc1" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_c1726d72-1884-4f70-8d3c-0e1819b18c43" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock_3772cd08-0c4b-4304-92fc-25b91932ecc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock_5bb44023-2721-4c07-893b-a75f7395e3ca" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_c1726d72-1884-4f70-8d3c-0e1819b18c43" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock_5bb44023-2721-4c07-893b-a75f7395e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/AuditFeesTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#AuditFeesTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/AuditFeesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfAuditFeesAbstract_464049db-edcc-4b6a-ab1e-265ac42331e6" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfAuditFeesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock_f2598c70-0e64-42ff-8f91-bf3a9a77c6e8" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfAuditFeesAbstract_464049db-edcc-4b6a-ab1e-265ac42331e6" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock_f2598c70-0e64-42ff-8f91-bf3a9a77c6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/IncomeTaxTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract_d5ca2062-0850-40c3-8861-7e467898dbfc" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock_eca856fb-fff7-4c8f-b051-6bb86d697730" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_d5ca2062-0850-40c3-8861-7e467898dbfc" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock_eca856fb-fff7-4c8f-b051-6bb86d697730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock_83f480b7-5758-4b0c-bc74-1828b59b3161" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_d5ca2062-0850-40c3-8861-7e467898dbfc" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock_83f480b7-5758-4b0c-bc74-1828b59b3161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock_74f4dbc4-9284-4d2c-a869-ce23cb75ed5b" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_d5ca2062-0850-40c3-8861-7e467898dbfc" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock_74f4dbc4-9284-4d2c-a869-ce23cb75ed5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock_02ae8855-9a2e-4a16-8917-d4f9d2caffc1" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_d5ca2062-0850-40c3-8861-7e467898dbfc" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock_02ae8855-9a2e-4a16-8917-d4f9d2caffc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock_a89edabe-6b64-4951-9404-1da103290dba" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_d5ca2062-0850-40c3-8861-7e467898dbfc" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock_a89edabe-6b64-4951-9404-1da103290dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LossPerShareTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#LossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_47840f65-6644-48ae-91ff-e71970964fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_9fb0197b-d9b9-46b6-96bc-0bae56f0a12e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_47840f65-6644-48ae-91ff-e71970964fc3" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_9fb0197b-d9b9-46b6-96bc-0bae56f0a12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipmentTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#PropertyPlantAndEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_eb50607b-1f0b-4410-a921-8aa9f7a563c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_6f0b55e5-8e1a-494c-8363-cf5a0537318e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_eb50607b-1f0b-4410-a921-8aa9f7a563c1" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_6f0b55e5-8e1a-494c-8363-cf5a0537318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_ab61d136-9101-4889-aec0-4bac42b5f37b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_c0991939-52a7-4e04-9c43-973351d17313" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_ab61d136-9101-4889-aec0-4bac42b5f37b" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_c0991939-52a7-4e04-9c43-973351d17313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock_1283f390-a270-4395-8106-c01bc4010b95" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_ab61d136-9101-4889-aec0-4bac42b5f37b" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock_1283f390-a270-4395-8106-c01bc4010b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_ef251932-8e9d-4638-9194-954893a7d28e" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_ab61d136-9101-4889-aec0-4bac42b5f37b" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_ef251932-8e9d-4638-9194-954893a7d28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock_e80fee76-ef95-4761-a098-84d99c376f64" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_ab61d136-9101-4889-aec0-4bac42b5f37b" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock_e80fee76-ef95-4761-a098-84d99c376f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock_da6bca8d-4b44-4909-a507-127473eca683" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_ab61d136-9101-4889-aec0-4bac42b5f37b" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock_da6bca8d-4b44-4909-a507-127473eca683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GoodwillTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/GoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfGoodwillAbstract_14e16d4c-27aa-4144-a617-a2d20596819c" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_4c93d461-268c-4006-90c6-a3d5f66f67e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfGoodwillAbstract_14e16d4c-27aa-4144-a617-a2d20596819c" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_4c93d461-268c-4006-90c6-a3d5f66f67e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherIntangibleassetsTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherIntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherIntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_f622435b-e07a-4d5b-8a60-a0e63aafb77b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_51406f36-5942-4816-a14a-8f3c0d68152a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_f622435b-e07a-4d5b-8a60-a0e63aafb77b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_51406f36-5942-4816-a14a-8f3c0d68152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory_d4e97389-e710-40cd-9500-5d7e6474ac3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_f622435b-e07a-4d5b-8a60-a0e63aafb77b" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory_d4e97389-e710-40cd-9500-5d7e6474ac3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/CashAndCashEquivalentsTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#CashAndCashEquivalentsTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/CashAndCashEquivalentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_ae521037-85b8-464e-b883-1f075359c42b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock_c2cd210e-ed73-4033-9eee-98c7c4558355" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_ae521037-85b8-464e-b883-1f075359c42b" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock_c2cd210e-ed73-4033-9eee-98c7c4558355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock_a1432ffb-8040-4465-b81a-8981c545c596" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_ae521037-85b8-464e-b883-1f075359c42b" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock_a1432ffb-8040-4465-b81a-8981c545c596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InventoriesTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_9e5e182e-91dd-4978-8175-25b1a79f401e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_a11732b0-4c12-47d8-8aa6-5f7af94679de" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_9e5e182e-91dd-4978-8175-25b1a79f401e" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_a11732b0-4c12-47d8-8aa6-5f7af94679de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentAssetsTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsAbstract_342aadb9-2681-4fbb-9079-d8dcc633b46a" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_bb14c461-7bc0-4b9c-8aa5-eee60b6d8b2f" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_342aadb9-2681-4fbb-9079-d8dcc633b46a" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_bb14c461-7bc0-4b9c-8aa5-eee60b6d8b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareCapitalTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_94d7e971-eb3e-4997-b728-44d6c927670b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_346e4b7e-02d6-4f20-8876-ef32f58bacb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_94d7e971-eb3e-4997-b728-44d6c927670b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_346e4b7e-02d6-4f20-8876-ef32f58bacb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock_934ec85d-2fcc-4ac5-ad21-503e827eca2b" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_94d7e971-eb3e-4997-b728-44d6c927670b" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock_934ec85d-2fcc-4ac5-ad21-503e827eca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherreservesTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherreservesTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherreservesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_42f47501-24bc-4f28-b36c-b36f8d877a36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfOtherReservesTableTextBlock_bc69e2c0-1b2b-4fbc-98e0-05ba881f850f" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfOtherReservesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_42f47501-24bc-4f28-b36c-b36f8d877a36" xlink:to="loc_alvo_ScheduleOfOtherReservesTableTextBlock_bc69e2c0-1b2b-4fbc-98e0-05ba881f850f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_3a077c1a-5958-4344-a580-d5d70be9204a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_26ef04bb-79d5-4287-9a87-7c513c2b544d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_3a077c1a-5958-4344-a580-d5d70be9204a" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_26ef04bb-79d5-4287-9a87-7c513c2b544d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock_efe95d70-6a49-48b4-a724-12701a20af57" xlink:href="alvo-20231231.xsd#alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_3a077c1a-5958-4344-a580-d5d70be9204a" xlink:to="loc_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock_efe95d70-6a49-48b4-a724-12701a20af57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock_87e261c7-fcf4-474d-b7c1-f25f28620edf" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_3a077c1a-5958-4344-a580-d5d70be9204a" xlink:to="loc_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock_87e261c7-fcf4-474d-b7c1-f25f28620edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LongTermIncentivePlansTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#LongTermIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LongTermIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract_d3feb555-c9c6-4079-a721-99bb40885b59" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLongtermIncentivePlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_6a1bffd2-676b-49f1-ab18-d26da88c6f62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract_d3feb555-c9c6-4079-a721-99bb40885b59" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_6a1bffd2-676b-49f1-ab18-d26da88c6f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_39502363-c3b0-4cca-9e16-0c89f00bf444" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_5d4ffe05-3c99-4084-9de5-05bf48444e43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_39502363-c3b0-4cca-9e16-0c89f00bf444" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_5d4ffe05-3c99-4084-9de5-05bf48444e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_af9802c6-d863-48f4-8d35-e34ae70df6b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_39502363-c3b0-4cca-9e16-0c89f00bf444" xlink:to="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_af9802c6-d863-48f4-8d35-e34ae70df6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_3d1a78b9-39c5-4002-ae6a-f76fd8648115" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_0bad27a8-bd25-4121-897b-96d4156ccb77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_3d1a78b9-39c5-4002-ae6a-f76fd8648115" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_0bad27a8-bd25-4121-897b-96d4156ccb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock_81a05efd-641f-4f2e-b894-888284466ef3" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_3d1a78b9-39c5-4002-ae6a-f76fd8648115" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock_81a05efd-641f-4f2e-b894-888284466ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentLiabilitiesAbstract_87a48b5c-c422-4618-b5f9-c5ca23694f55" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_cee3f52f-9d0c-4c48-83b3-135d0f0389db" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract_87a48b5c-c422-4618-b5f9-c5ca23694f55" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_cee3f52f-9d0c-4c48-83b3-135d0f0389db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InterestsInJointVenturesTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#InterestsInJointVenturesTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/InterestsInJointVenturesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesAbstract_606abe9f-3980-4256-aafc-80d06b24fedd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock_e3f59e7a-8f5e-4df4-b824-cc54849d1a1f" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_606abe9f-3980-4256-aafc-80d06b24fedd" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock_e3f59e7a-8f5e-4df4-b824-cc54849d1a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock_1daed164-96a3-49c7-8e13-e54ce39c86b8" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_606abe9f-3980-4256-aafc-80d06b24fedd" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock_1daed164-96a3-49c7-8e13-e54ce39c86b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_0e5527d6-d315-47a6-a671-dee326b2d12f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_0e5527d6-d315-47a6-a671-dee326b2d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_c3c556bc-0b8b-4e95-a931-2f431f1e7609" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_c3c556bc-0b8b-4e95-a931-2f431f1e7609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock_3700f395-ec25-4d98-9e2a-782b01f3cb6e" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock_3700f395-ec25-4d98-9e2a-782b01f3cb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock_5e910bb3-074e-47a6-90b1-bf44239eef04" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock_5e910bb3-074e-47a6-90b1-bf44239eef04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_97e790fd-fb49-4f45-b071-8dcd970db726" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_97e790fd-fb49-4f45-b071-8dcd970db726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_3e5ca4ad-0657-47f4-aa5f-0558407f268b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_3e5ca4ad-0657-47f4-aa5f-0558407f268b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock_a078c5b8-1d01-424c-9146-946cace0ca24" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock_a078c5b8-1d01-424c-9146-946cace0ca24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock_3470cbd3-9c68-419e-af1f-aabfd15fe702" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock_3470cbd3-9c68-419e-af1f-aabfd15fe702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock_6b9db37f-3410-4310-9425-c4f124a7b667" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock_6b9db37f-3410-4310-9425-c4f124a7b667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock_288b5b59-a765-492e-a825-93eb4187bead" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock_288b5b59-a765-492e-a825-93eb4187bead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureExplanatory_b5000b3e-43b6-4e28-8e1b-4fddde436a20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExposureExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureExplanatory_b5000b3e-43b6-4e28-8e1b-4fddde436a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock_02908ea4-1007-47ad-b339-72a3291fc306" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6322838e-143c-4cb2-bb2f-7be46e635a28" xlink:to="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock_02908ea4-1007-47ad-b339-72a3291fc306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="alvo-20231231.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_3fb2860e-ff65-4958-b84a-72a794db3705" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock_1153ee5c-0e06-4b87-8b63-a64095223e5c" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_3fb2860e-ff65-4958-b84a-72a794db3705" xlink:to="loc_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock_1153ee5c-0e06-4b87-8b63-a64095223e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GeneralinformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_c28864a6-33e8-4601-8159-b5ea3b2e6889" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_c28864a6-33e8-4601-8159-b5ea3b2e6889" xlink:to="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_4485781f-b0db-4eeb-8986-f690039770d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_76d839e3-ca86-4b7f-a318-6f2ac9f2b36f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_4485781f-b0db-4eeb-8986-f690039770d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_f59549bc-bcdb-4d83-a773-a613d0aa6ab3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_4485781f-b0db-4eeb-8986-f690039770d4" xlink:to="loc_ifrs-full_OrdinarySharesMember_f59549bc-bcdb-4d83-a773-a613d0aa6ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_9dbf14b0-3f06-46b4-935b-0b87efe9c374" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_9dbf14b0-3f06-46b4-935b-0b87efe9c374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_631cd352-fbf4-402d-820e-44e2404f0dc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_9dbf14b0-3f06-46b4-935b-0b87efe9c374" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_631cd352-fbf4-402d-820e-44e2404f0dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_00538a95-8876-472b-a521-e88536044269" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_631cd352-fbf4-402d-820e-44e2404f0dc3" xlink:to="loc_alvo_EarnoutWarrantsMember_00538a95-8876-472b-a521-e88536044269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementsTypeAxis_8094e302-a44b-4e24-9547-de178432fe8a" xlink:href="alvo-20231231.xsd#alvo_AgreementsTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_alvo_AgreementsTypeAxis_8094e302-a44b-4e24-9547-de178432fe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementsTypeDomain_70bfc345-4d6e-4e00-ba35-57201e61901d" xlink:href="alvo-20231231.xsd#alvo_AgreementsTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementsTypeAxis_8094e302-a44b-4e24-9547-de178432fe8a" xlink:to="loc_alvo_AgreementsTypeDomain_70bfc345-4d6e-4e00-ba35-57201e61901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SubscriptionAgreementsMember_b8987b3d-5c3b-4095-9244-72597e6e84f1" xlink:href="alvo-20231231.xsd#alvo_SubscriptionAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementsTypeDomain_70bfc345-4d6e-4e00-ba35-57201e61901d" xlink:to="loc_alvo_SubscriptionAgreementsMember_b8987b3d-5c3b-4095-9244-72597e6e84f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_db7432e5-d573-4607-94f2-90675062b92b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_db7432e5-d573-4607-94f2-90675062b92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_e7fd5ad3-e210-4c30-ae38-e6054835f14f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_db7432e5-d573-4607-94f2-90675062b92b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_e7fd5ad3-e210-4c30-ae38-e6054835f14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_2e212a31-b831-41b9-a935-4dbb84882fe6" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e7fd5ad3-e210-4c30-ae38-e6054835f14f" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_2e212a31-b831-41b9-a935-4dbb84882fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_7278304c-8ab8-4018-a84d-fbfae955e1b4" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_e7fd5ad3-e210-4c30-ae38-e6054835f14f" xlink:to="loc_alvo_EarnoutSharesMember_7278304c-8ab8-4018-a84d-fbfae955e1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c5652203-4bd8-4fb5-bf8c-13541854ad7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c5652203-4bd8-4fb5-bf8c-13541854ad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_55f0349a-6cef-463c-809e-5d5a52016182" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c5652203-4bd8-4fb5-bf8c-13541854ad7b" xlink:to="loc_ifrs-full_EquityMember_55f0349a-6cef-463c-809e-5d5a52016182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbWarrantsMember_9a55165d-f8c7-43cc-98e8-f86883806045" xlink:href="alvo-20231231.xsd#alvo_OacbWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_55f0349a-6cef-463c-809e-5d5a52016182" xlink:to="loc_alvo_OacbWarrantsMember_9a55165d-f8c7-43cc-98e8-f86883806045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_f2a65901-4e35-49dd-a9fd-77cb1b70fa92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_f2a65901-4e35-49dd-a9fd-77cb1b70fa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_b97ef570-b69c-45a3-8b4b-05c89b7792c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_f2a65901-4e35-49dd-a9fd-77cb1b70fa92" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_b97ef570-b69c-45a3-8b4b-05c89b7792c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BusinessCombinationAndPipeFinancingMember_81f83a27-a563-4f84-a3e3-e088df512c3e" xlink:href="alvo-20231231.xsd#alvo_BusinessCombinationAndPipeFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_b97ef570-b69c-45a3-8b4b-05c89b7792c7" xlink:to="loc_alvo_BusinessCombinationAndPipeFinancingMember_81f83a27-a563-4f84-a3e3-e088df512c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b04e650e-7c84-4494-a082-fc69c276e03d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b04e650e-7c84-4494-a082-fc69c276e03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b04e650e-7c84-4494-a082-fc69c276e03d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqPharmaPartnersSarlMember_6288f2ef-fea8-4313-aa65-dbc331733a6c" xlink:href="alvo-20231231.xsd#alvo_AztiqPharmaPartnersSarlMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:to="loc_alvo_AztiqPharmaPartnersSarlMember_6288f2ef-fea8-4313-aa65-dbc331733a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenMember_05b1adf0-bacc-4730-bd09-4437b4882968" xlink:href="alvo-20231231.xsd#alvo_AlvogenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:to="loc_alvo_AlvogenMember_05b1adf0-bacc-4730-bd09-4437b4882968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherSubsidiariesMember_07fa2cb7-d024-48b3-92bf-526ca3a0166a" xlink:href="alvo-20231231.xsd#alvo_OtherSubsidiariesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_78d70666-ba84-4d96-b11f-aa45ee6a5806" xlink:to="loc_alvo_OtherSubsidiariesMember_07fa2cb7-d024-48b3-92bf-526ca3a0166a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0b48a9f4-e14f-4c73-b344-83514f540ed5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0b48a9f4-e14f-4c73-b344-83514f540ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_6c5dde5e-b4be-467c-8dd5-895e6a497553" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0b48a9f4-e14f-4c73-b344-83514f540ed5" xlink:to="loc_ifrs-full_NonadjustingEventsMember_6c5dde5e-b4be-467c-8dd5-895e6a497553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_d30849db-3170-446e-8b6c-be534f235108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_6c5dde5e-b4be-467c-8dd5-895e6a497553" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_d30849db-3170-446e-8b6c-be534f235108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsTable_d9f4e303-bf6a-41b4-95b7-01c49ab8cd03" xlink:to="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_8e75de81-24b6-4902-a1a8-5087a0cf8513" xlink:href="alvo-20231231.xsd#alvo_NumberOfSharesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_8e75de81-24b6-4902-a1a8-5087a0cf8513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromTheCapitalReorganization_c6523d07-905e-47cf-bcc6-0e64e4df9c6d" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromTheCapitalReorganization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_ProceedsFromTheCapitalReorganization_c6523d07-905e-47cf-bcc6-0e64e4df9c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockSharesSubscribed_f665035b-ea4d-4544-ac35-a50e3d79ee95" xlink:href="alvo-20231231.xsd#alvo_CommonStockSharesSubscribed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_CommonStockSharesSubscribed_f665035b-ea4d-4544-ac35-a50e3d79ee95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockSubscriptionPricePerShare_bc736114-ba22-4440-8df1-ab5a0d8074f0" xlink:href="alvo-20231231.xsd#alvo_CommonStockSubscriptionPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_CommonStockSubscriptionPricePerShare_bc736114-ba22-4440-8df1-ab5a0d8074f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockValueSubscriptions_e14f1fe3-53dc-446e-82b9-9b222becd4c0" xlink:href="alvo-20231231.xsd#alvo_CommonStockValueSubscriptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_CommonStockValueSubscriptions_e14f1fe3-53dc-446e-82b9-9b222becd4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_19efb52a-ed48-4793-aa34-71e020ab7644" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_19efb52a-ed48-4793-aa34-71e020ab7644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_a2bf2eef-0129-4c92-a48f-dd6c206a8090" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_a2bf2eef-0129-4c92-a48f-dd6c206a8090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReorganizationShareListingExpense_dc79ab58-4d07-435e-9bbe-4a8c967a6e08" xlink:href="alvo-20231231.xsd#alvo_ReorganizationShareListingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_ReorganizationShareListingExpense_dc79ab58-4d07-435e-9bbe-4a8c967a6e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedMarketPricePerShare_f7474af6-d833-40bf-9d9b-0bf32438ea73" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedMarketPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_FairValueOfSharesIssuedMarketPricePerShare_f7474af6-d833-40bf-9d9b-0bf32438ea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_408b293a-a8ff-40c5-ae6f-11ac844d4cbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_408b293a-a8ff-40c5-ae6f-11ac844d4cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExpenseCapitalized_05de6b3a-312d-4ffc-9221-68b16fce45ae" xlink:href="alvo-20231231.xsd#alvo_ExpenseCapitalized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_ExpenseCapitalized_05de6b3a-312d-4ffc-9221-68b16fce45ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_a3477c90-62b9-48f1-affa-1068bf3e64b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_a3477c90-62b9-48f1-affa-1068bf3e64b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_241f9bd3-8675-4cc1-bd94-7046524d6332" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_241f9bd3-8675-4cc1-bd94-7046524d6332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder_245b247c-9c27-4768-80fd-852681cb6c60" xlink:href="alvo-20231231.xsd#alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder_245b247c-9c27-4768-80fd-852681cb6c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_d601dd8a-032d-4005-939f-0f3138db6b60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_ProfitLoss_d601dd8a-032d-4005-939f-0f3138db6b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_697cc6f7-ef67-434d-967e-918f05d3355d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_RetainedEarnings_697cc6f7-ef67-434d-967e-918f05d3355d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_65baee6a-05fe-41bb-820d-0a599269819c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_CashAndCashEquivalents_65baee6a-05fe-41bb-820d-0a599269819c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsLiabilities_d2ccb0ed-26bc-4b50-b873-c85ff78ffe17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_CurrentAssetsLiabilities_d2ccb0ed-26bc-4b50-b873-c85ff78ffe17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_ca8ec701-1898-4a2f-b3a7-002cf7f9801a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_IssueOfEquity_ca8ec701-1898-4a2f-b3a7-002cf7f9801a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_1c3f4894-0427-4684-b8b8-201730842167" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_1c3f4894-0427-4684-b8b8-201730842167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_e023d582-91f0-49ea-b26c-23f1383f2924" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_e023d582-91f0-49ea-b26c-23f1383f2924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_01645b5f-6bd8-4180-966a-a02ffce6c93a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_ParValuePerShare_01645b5f-6bd8-4180-966a-a02ffce6c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_901077e6-318c-43b5-83fe-0fbf4b80becc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsLineItems_e9193c2b-899f-4520-82df-8754500fa664" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_901077e6-318c-43b5-83fe-0fbf4b80becc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_9bf94917-f830-4e64-9328-526c0006c433" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_9bf94917-f830-4e64-9328-526c0006c433" xlink:to="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_448bb195-3bde-492c-8c14-35439dfdb98e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_448bb195-3bde-492c-8c14-35439dfdb98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_ebf72cda-4029-4bc9-ab02-1abc9b89948e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_448bb195-3bde-492c-8c14-35439dfdb98e" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_ebf72cda-4029-4bc9-ab02-1abc9b89948e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_2d1931ce-f7b1-4ed7-97d1-16b8ec13c92b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_ebf72cda-4029-4bc9-ab02-1abc9b89948e" xlink:to="loc_ifrs-full_OrdinarySharesMember_2d1931ce-f7b1-4ed7-97d1-16b8ec13c92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassesOfCommonStockAxis_e3e6c4a6-42c3-475b-b25d-58e91b02eba1" xlink:href="alvo-20231231.xsd#alvo_ClassesOfCommonStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:to="loc_alvo_ClassesOfCommonStockAxis_e3e6c4a6-42c3-475b-b25d-58e91b02eba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassesOfCommonStockMember_eea33a31-2645-4935-b6bd-c6534f138961" xlink:href="alvo-20231231.xsd#alvo_ClassesOfCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ClassesOfCommonStockAxis_e3e6c4a6-42c3-475b-b25d-58e91b02eba1" xlink:to="loc_alvo_ClassesOfCommonStockMember_eea33a31-2645-4935-b6bd-c6534f138961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassACommonStockMember_df3102cf-721e-44f9-919b-45c01c1da6a7" xlink:href="alvo-20231231.xsd#alvo_ClassACommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ClassesOfCommonStockMember_eea33a31-2645-4935-b6bd-c6534f138961" xlink:to="loc_alvo_ClassACommonStockMember_df3102cf-721e-44f9-919b-45c01c1da6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassBCommonStockMember_bd92fcba-3fbc-464e-bbd1-4a9d9f376e13" xlink:href="alvo-20231231.xsd#alvo_ClassBCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ClassesOfCommonStockMember_eea33a31-2645-4935-b6bd-c6534f138961" xlink:to="loc_alvo_ClassBCommonStockMember_bd92fcba-3fbc-464e-bbd1-4a9d9f376e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_aee08f6c-7f24-49dd-9154-aecbc494c24e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_aee08f6c-7f24-49dd-9154-aecbc494c24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_f7228cce-6399-429e-a0b5-e320325863e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_aee08f6c-7f24-49dd-9154-aecbc494c24e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_f7228cce-6399-429e-a0b5-e320325863e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_aadfdc23-2bac-4f81-b581-e66666eec023" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_f7228cce-6399-429e-a0b5-e320325863e3" xlink:to="loc_alvo_EarnoutSharesMember_aadfdc23-2bac-4f81-b581-e66666eec023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable_0f85c64c-a9c1-487c-8ff9-b22f87a8c003" xlink:to="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2_5f0fdde6-6d2d-4018-8225-a8c114b4838b" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2_5f0fdde6-6d2d-4018-8225-a8c114b4838b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2_1527b7b0-5d7f-44a0-9426-2b042693427e" xlink:href="alvo-20231231.xsd#alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2_1527b7b0-5d7f-44a0-9426-2b042693427e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2_b0bc4243-c3cb-4425-86f0-15de24b74e72" xlink:href="alvo-20231231.xsd#alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2_b0bc4243-c3cb-4425-86f0-15de24b74e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReorganizationShareListingExpense_34dc9731-b60c-4f10-a7c3-a81314c5a4b6" xlink:href="alvo-20231231.xsd#alvo_ReorganizationShareListingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems_17a7f28c-81c5-48af-8cdc-7ae4021add08" xlink:to="loc_alvo_ReorganizationShareListingExpense_34dc9731-b60c-4f10-a7c3-a81314c5a4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_ee8688a8-26bc-40da-abd3-0f4126de8e53" xlink:href="alvo-20231231.xsd#alvo_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GeneralInformationAboutFinancialStatementsAbstract_ee8688a8-26bc-40da-abd3-0f4126de8e53" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2af2d2a1-5397-4165-be6e-efffe8bee4f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2af2d2a1-5397-4165-be6e-efffe8bee4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2af2d2a1-5397-4165-be6e-efffe8bee4f4" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechHfMember_56920944-d2e6-4bad-9074-c33b5f7ba100" xlink:href="alvo-20231231.xsd#alvo_AlvotechHfMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechHfMember_56920944-d2e6-4bad-9074-c33b5f7ba100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechGermanyGmbhMember_cacccf5a-503a-4022-9de4-8c37c9b1ffef" xlink:href="alvo-20231231.xsd#alvo_AlvotechGermanyGmbhMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechGermanyGmbhMember_cacccf5a-503a-4022-9de4-8c37c9b1ffef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechSwissAgMember_27eec329-1ce2-4efc-a271-4bae663eccdb" xlink:href="alvo-20231231.xsd#alvo_AlvotechSwissAgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechSwissAgMember_27eec329-1ce2-4efc-a271-4bae663eccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechHannoverGmbhMember_77dfc2c8-e642-44f7-a272-f2ac8367774a" xlink:href="alvo-20231231.xsd#alvo_AlvotechHannoverGmbhMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechHannoverGmbhMember_77dfc2c8-e642-44f7-a272-f2ac8367774a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechMaltaLtdMember_762254ad-f881-4bcc-b117-075d4e0a9cef" xlink:href="alvo-20231231.xsd#alvo_AlvotechMaltaLtdMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechMaltaLtdMember_762254ad-f881-4bcc-b117-075d4e0a9cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechUsaIncMember_b1e38604-a98e-42fa-8fd7-2b41e3c7f64c" xlink:href="alvo-20231231.xsd#alvo_AlvotechUsaIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechUsaIncMember_b1e38604-a98e-42fa-8fd7-2b41e3c7f64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechUkLtdMember_0116f429-a59c-46a8-b156-fcb233a91bd9" xlink:href="alvo-20231231.xsd#alvo_AlvotechUkLtdMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechUkLtdMember_0116f429-a59c-46a8-b156-fcb233a91bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechMancoEhfMember_e2947693-9d0b-476f-9fe6-56155540578d" xlink:href="alvo-20231231.xsd#alvo_AlvotechMancoEhfMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechMancoEhfMember_e2947693-9d0b-476f-9fe6-56155540578d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechBiosciencesIndiaPrivateLtdMember_d04b3d2f-2b94-4f64-b435-328cccdd09a6" xlink:href="alvo-20231231.xsd#alvo_AlvotechBiosciencesIndiaPrivateLtdMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_AlvotechBiosciencesIndiaPrivateLtdMember_d04b3d2f-2b94-4f64-b435-328cccdd09a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHfMember_377a0700-2800-4b61-89d9-3561fe86efd9" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHfMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b8f32582-061b-45e9-8cfc-3e7b428447bc" xlink:to="loc_alvo_FasteignafelagiSmundurHfMember_377a0700-2800-4b61-89d9-3561fe86efd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_858ddc7d-f507-4a54-be51-4278c6c4340d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:to="loc_ifrs-full_JointVenturesAxis_858ddc7d-f507-4a54-be51-4278c6c4340d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_45bfe90a-8d31-4cad-be24-dd727f9a0966" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_858ddc7d-f507-4a54-be51-4278c6c4340d" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_45bfe90a-8d31-4cad-be24-dd727f9a0966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember_162ba2d6-995e-42d0-b323-6dd200bfd305" xlink:href="alvo-20231231.xsd#alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_45bfe90a-8d31-4cad-be24-dd727f9a0966" xlink:to="loc_alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember_162ba2d6-995e-42d0-b323-6dd200bfd305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_084367d1-6d6b-449b-8fbb-c2e82033ac30" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_e3a0147e-81fe-460f-9ab9-2c61d25bcc71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_e3a0147e-81fe-460f-9ab9-2c61d25bcc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_f028bb95-edae-48bd-a406-7111ed1ba595" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_f028bb95-edae-48bd-a406-7111ed1ba595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_2760b9f8-73db-4a06-ab4a-23ccc4726108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_669cbde7-15d7-40fd-b87e-3110374860df" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_2760b9f8-73db-4a06-ab4a-23ccc4726108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_990e7c76-fae4-4b9d-9896-8d3b61e092e8" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_af0d774e-0a56-475c-ad8c-409eb71df639" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_990e7c76-fae4-4b9d-9896-8d3b61e092e8" xlink:to="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_af0d774e-0a56-475c-ad8c-409eb71df639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_af0d774e-0a56-475c-ad8c-409eb71df639" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0a616be0-6b6a-4293-9c6d-a9bc0658e062" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_4ee8f95a-cc3b-4834-93de-2d3cc91e60b6" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0a616be0-6b6a-4293-9c6d-a9bc0658e062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusPharmaceuticalCo.LtdMember_50cc0113-f84d-4e00-96b3-d6cf69bf303d" xlink:href="alvo-20231231.xsd#alvo_LotusPharmaceuticalCo.LtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0a616be0-6b6a-4293-9c6d-a9bc0658e062" xlink:to="loc_alvo_LotusPharmaceuticalCo.LtdMember_50cc0113-f84d-4e00-96b3-d6cf69bf303d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_af0d774e-0a56-475c-ad8c-409eb71df639" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_f779f3b8-f48e-4a0e-b2f4-ea38c0698440" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_f779f3b8-f48e-4a0e-b2f4-ea38c0698440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfOperatingSegments1_8789a901-446e-48a4-9feb-55397c59c064" xlink:href="alvo-20231231.xsd#alvo_NumberOfOperatingSegments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_alvo_NumberOfOperatingSegments1_8789a901-446e-48a4-9feb-55397c59c064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_UpfrontPayment_5a6b4482-7608-4538-882c-7c72be104f0d" xlink:href="alvo-20231231.xsd#alvo_UpfrontPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_alvo_UpfrontPayment_5a6b4482-7608-4538-882c-7c72be104f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7be99bb0-e829-4495-9f24-9700484c4bfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3b571d70-dd1a-4911-ac7e-9ce0cab14022" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7be99bb0-e829-4495-9f24-9700484c4bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_008300f9-2c27-45c6-9e6e-f4977f8e134a" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_008300f9-2c27-45c6-9e6e-f4977f8e134a" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_61572556-dcca-4da7-ba55-b457fd26606c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_61572556-dcca-4da7-ba55-b457fd26606c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_61572556-dcca-4da7-ba55-b457fd26606c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_dfe39cc2-3658-4be6-bf45-a529d5283346" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:to="loc_ifrs-full_ComputerSoftwareMember_dfe39cc2-3658-4be6-bf45-a529d5283346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember_86910c83-4257-4884-826e-a8e60a0eff8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CustomerrelatedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:to="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember_86910c83-4257-4884-826e-a8e60a0eff8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntellectualPropertyRightsMember_cb35ce5c-f92d-4373-bc25-730c40314174" xlink:href="alvo-20231231.xsd#alvo_IntellectualPropertyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ce8806fa-db05-41a6-a504-2a6b93e0ebed" xlink:to="loc_alvo_IntellectualPropertyRightsMember_cb35ce5c-f92d-4373-bc25-730c40314174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_c93ba5c8-ce01-479d-87c0-84a7c1ae8254" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:to="loc_ifrs-full_RangeAxis_c93ba5c8-ce01-479d-87c0-84a7c1ae8254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_0dbe0af9-0072-4f66-9bdc-ce22b7ead306" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_c93ba5c8-ce01-479d-87c0-84a7c1ae8254" xlink:to="loc_ifrs-full_RangesMember_0dbe0af9-0072-4f66-9bdc-ce22b7ead306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_678319bb-47f2-4a54-a01b-709c79dd2a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_0dbe0af9-0072-4f66-9bdc-ce22b7ead306" xlink:to="loc_ifrs-full_BottomOfRangeMember_678319bb-47f2-4a54-a01b-709c79dd2a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_751975b4-9965-42bb-a505-8cf7de74462d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_0dbe0af9-0072-4f66-9bdc-ce22b7ead306" xlink:to="loc_ifrs-full_TopOfRangeMember_751975b4-9965-42bb-a505-8cf7de74462d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c25bbc7a-0830-4ca6-827e-a8921343c360" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_6386fb7f-d30d-4944-b2e8-bbf2b102d9d2" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c25bbc7a-0830-4ca6-827e-a8921343c360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_0732dad3-433a-4f2d-9a22-bf96e92dce69" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_c25bbc7a-0830-4ca6-827e-a8921343c360" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_0732dad3-433a-4f2d-9a22-bf96e92dce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_d968801c-de0f-415e-9f29-22f5671155b2" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_d968801c-de0f-415e-9f29-22f5671155b2" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5bf369d7-a4a7-4682-a117-5da00e3e650f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5bf369d7-a4a7-4682-a117-5da00e3e650f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5bf369d7-a4a7-4682-a117-5da00e3e650f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityMember_6d539d63-b90c-4b9e-8aad-bc9eac816797" xlink:href="alvo-20231231.xsd#alvo_FacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_alvo_FacilityMember_6d539d63-b90c-4b9e-8aad-bc9eac816797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityEquipmentMember_886175c2-3317-444a-8b4a-52b96e2d573b" xlink:href="alvo-20231231.xsd#alvo_FacilityEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_alvo_FacilityEquipmentMember_886175c2-3317-444a-8b4a-52b96e2d573b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_2f31efdf-9721-472e-ba2b-a29e53bd05ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_ifrs-full_ComputerEquipmentMember_2f31efdf-9721-472e-ba2b-a29e53bd05ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_2b34c2c6-0b04-4925-86a0-2360735f93ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_2b34c2c6-0b04-4925-86a0-2360735f93ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_0ad95a9e-5210-4058-839b-cc89004cc032" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_1c09a0d8-defd-4970-b630-55e42cd5ecd7" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_0ad95a9e-5210-4058-839b-cc89004cc032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_6e31c0dc-9ee4-45d2-a842-009c022733f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:to="loc_ifrs-full_RangeAxis_6e31c0dc-9ee4-45d2-a842-009c022733f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_62da08b5-ac4b-47dc-bb85-b021663b15bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_6e31c0dc-9ee4-45d2-a842-009c022733f0" xlink:to="loc_ifrs-full_RangesMember_62da08b5-ac4b-47dc-bb85-b021663b15bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_5e6b8d4b-8171-4183-8f68-67318f8108aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_62da08b5-ac4b-47dc-bb85-b021663b15bf" xlink:to="loc_ifrs-full_BottomOfRangeMember_5e6b8d4b-8171-4183-8f68-67318f8108aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_ae86b21e-5b0a-484b-b908-4714cec0aba3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_62da08b5-ac4b-47dc-bb85-b021663b15bf" xlink:to="loc_ifrs-full_TopOfRangeMember_ae86b21e-5b0a-484b-b908-4714cec0aba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_714421f2-127a-4691-91c1-63d136bdd78d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_e15ca693-e8ce-4236-9e32-825d78fdb592" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_714421f2-127a-4691-91c1-63d136bdd78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_562fecfb-0f39-4a89-aada-933c8e54f558" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_714421f2-127a-4691-91c1-63d136bdd78d" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_562fecfb-0f39-4a89-aada-933c8e54f558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_e13fb45d-4e0d-44db-a36d-61e87b75c677" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfOperatingSegments1_c99fe57a-1326-41c9-b903-b8a2b358094d" xlink:href="alvo-20231231.xsd#alvo_NumberOfOperatingSegments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_e13fb45d-4e0d-44db-a36d-61e87b75c677" xlink:to="loc_alvo_NumberOfOperatingSegments1_c99fe57a-1326-41c9-b903-b8a2b358094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_e38aa574-cc62-433b-a7e0-4cce40f1053b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_e13fb45d-4e0d-44db-a36d-61e87b75c677" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_e38aa574-cc62-433b-a7e0-4cce40f1053b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_5db8cce7-51d4-476d-8b93-11be908a58ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_e38aa574-cc62-433b-a7e0-4cce40f1053b" xlink:to="loc_ifrs-full_GeographicalAreasAxis_5db8cce7-51d4-476d-8b93-11be908a58ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_5db8cce7-51d4-476d-8b93-11be908a58ca" xlink:to="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2f1461d2-02db-4521-b4b6-ccae0aef2875" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:to="loc_srt_EuropeMember_2f1461d2-02db-4521-b4b6-ccae0aef2875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_885c0625-fd8d-4901-a23a-5f6da86c46fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:to="loc_srt_NorthAmericaMember_885c0625-fd8d-4901-a23a-5f6da86c46fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AsiaAndOtherMember_5b668966-8565-47e7-b96b-89ccf37ee95e" xlink:href="alvo-20231231.xsd#alvo_AsiaAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_5d9244ee-caee-4434-a0c2-b8a1b12210a8" xlink:to="loc_alvo_AsiaAndOtherMember_5b668966-8565-47e7-b96b-89ccf37ee95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_badf9f55-e474-4b55-bd65-518befd533a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_e38aa574-cc62-433b-a7e0-4cce40f1053b" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_badf9f55-e474-4b55-bd65-518befd533a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_363bde3f-c897-4709-9b61-9ea0a826e028" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_badf9f55-e474-4b55-bd65-518befd533a3" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_363bde3f-c897-4709-9b61-9ea0a826e028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_c26bfff6-ac67-491b-8789-46afb1aff50d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_18eb070a-b2c6-432b-96cb-8efaef2bb590" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_c26bfff6-ac67-491b-8789-46afb1aff50d" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_18eb070a-b2c6-432b-96cb-8efaef2bb590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_2f33eb93-edf5-4da4-91ca-d77c52c10e7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_18eb070a-b2c6-432b-96cb-8efaef2bb590" xlink:to="loc_ifrs-full_GeographicalAreasAxis_2f33eb93-edf5-4da4-91ca-d77c52c10e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_2f33eb93-edf5-4da4-91ca-d77c52c10e7b" xlink:to="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0c1425b8-6c4b-4fb9-9c75-c307f77f88a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:to="loc_srt_EuropeMember_0c1425b8-6c4b-4fb9-9c75-c307f77f88a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_fa80d91a-8049-4876-9660-9eb593946631" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:to="loc_srt_NorthAmericaMember_fa80d91a-8049-4876-9660-9eb593946631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AsiaAndOtherMember_754bfb61-5613-4c3a-8237-579ac9cc3ece" xlink:href="alvo-20231231.xsd#alvo_AsiaAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_59e4f6ad-6079-4f5f-b5cf-a5a978016800" xlink:to="loc_alvo_AsiaAndOtherMember_754bfb61-5613-4c3a-8237-579ac9cc3ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_4ef5f21b-5ebd-47e9-a0d1-78eab01fe116" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_18eb070a-b2c6-432b-96cb-8efaef2bb590" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_4ef5f21b-5ebd-47e9-a0d1-78eab01fe116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_968897f5-1c2e-4f0c-8c21-a7850422d68c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_4ef5f21b-5ebd-47e9-a0d1-78eab01fe116" xlink:to="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_968897f5-1c2e-4f0c-8c21-a7850422d68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_da50cd1c-6da0-4f37-810d-17fd6a14f238" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMajorCustomersTable_5da3c142-a194-4ec0-92c1-de9c46df1298" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMajorCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_da50cd1c-6da0-4f37-810d-17fd6a14f238" xlink:to="loc_ifrs-full_DisclosureOfMajorCustomersTable_5da3c142-a194-4ec0-92c1-de9c46df1298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_a4194d4f-da54-46bc-98a4-93d73b8f52ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersTable_5da3c142-a194-4ec0-92c1-de9c46df1298" xlink:to="loc_ifrs-full_MajorCustomersAxis_a4194d4f-da54-46bc-98a4-93d73b8f52ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersAxis_a4194d4f-da54-46bc-98a4-93d73b8f52ee" xlink:to="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerAMember_849f9ac0-cc5e-4e0c-991c-12b261bd337a" xlink:href="alvo-20231231.xsd#alvo_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:to="loc_alvo_CustomerAMember_849f9ac0-cc5e-4e0c-991c-12b261bd337a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerBMember_05224c4c-0257-41c7-bd42-fd95640db125" xlink:href="alvo-20231231.xsd#alvo_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:to="loc_alvo_CustomerBMember_05224c4c-0257-41c7-bd42-fd95640db125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerCMember_dcb443ce-9f62-4a3b-bcab-9d955df02ba9" xlink:href="alvo-20231231.xsd#alvo_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:to="loc_alvo_CustomerCMember_dcb443ce-9f62-4a3b-bcab-9d955df02ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CustomerDMember_44d7e200-7477-4303-b4ba-db581f4bd14b" xlink:href="alvo-20231231.xsd#alvo_CustomerDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_7d6ed0b6-f314-41df-9506-eda2cf0f28cb" xlink:to="loc_alvo_CustomerDMember_44d7e200-7477-4303-b4ba-db581f4bd14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMajorCustomersLineItems_93103b0f-2d13-45d4-af81-aab33b73feb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersTable_5da3c142-a194-4ec0-92c1-de9c46df1298" xlink:to="loc_ifrs-full_DisclosureOfMajorCustomersLineItems_93103b0f-2d13-45d4-af81-aab33b73feb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_e3a5bbcc-3b2c-4b72-b484-6893a1956a29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersLineItems_93103b0f-2d13-45d4-af81-aab33b73feb5" xlink:to="loc_ifrs-full_Revenue_e3a5bbcc-3b2c-4b72-b484-6893a1956a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_fff35f0e-f136-48c3-843a-853f34eb2d63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMajorCustomersLineItems_93103b0f-2d13-45d4-af81-aab33b73feb5" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_fff35f0e-f136-48c3-843a-853f34eb2d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RevenueFromContractsWithCustomersAbstract_6b494a1c-e947-40d3-8af7-b52bd8acb2bb" xlink:href="alvo-20231231.xsd#alvo_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RevenueFromContractsWithCustomersAbstract_6b494a1c-e947-40d3-8af7-b52bd8acb2bb" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_82fde80c-50df-462c-8e20-397474fb1d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_82fde80c-50df-462c-8e20-397474fb1d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_82fde80c-50df-462c-8e20-397474fb1d52" xlink:to="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProductRevenueMember_b734addb-935b-4af5-866a-d0a2bcd6180c" xlink:href="alvo-20231231.xsd#alvo_ProductRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:to="loc_alvo_ProductRevenueMember_b734addb-935b-4af5-866a-d0a2bcd6180c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LicenseRevenueMember_d1de40d2-9890-4ffa-bf03-1b70dc5b4904" xlink:href="alvo-20231231.xsd#alvo_LicenseRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:to="loc_alvo_LicenseRevenueMember_d1de40d2-9890-4ffa-bf03-1b70dc5b4904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DevelopmentAndOtherServiceRevenueMember_87b70524-0f77-4e80-970b-646f505b1bdd" xlink:href="alvo-20231231.xsd#alvo_DevelopmentAndOtherServiceRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_0b5e908b-855a-49a8-a021-855fecfb5f1b" xlink:to="loc_alvo_DevelopmentAndOtherServiceRevenueMember_87b70524-0f77-4e80-970b-646f505b1bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_54555790-bb6f-4fa4-bdb5-8929b2f63bcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_69de5035-7a9f-4ab4-b29f-aa1beba1c8f7" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_54555790-bb6f-4fa4-bdb5-8929b2f63bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_aba3da4b-5d28-401a-b3c3-e365d11a142a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_54555790-bb6f-4fa4-bdb5-8929b2f63bcc" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_aba3da4b-5d28-401a-b3c3-e365d11a142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_dba4a322-275f-4be1-a73b-b953130f2862" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_54555790-bb6f-4fa4-bdb5-8929b2f63bcc" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_dba4a322-275f-4be1-a73b-b953130f2862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d97ed54a-122b-41a3-a8cc-cf3db3d40fe3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_7127675f-09d6-48b6-9c88-ac66d76e9976" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d97ed54a-122b-41a3-a8cc-cf3db3d40fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_151d25b8-0f33-47c7-9931-26bcffb37e50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d97ed54a-122b-41a3-a8cc-cf3db3d40fe3" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_151d25b8-0f33-47c7-9931-26bcffb37e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RevenueFromContractsWithCustomersAbstract_094d54c4-0c92-416b-98f9-ce75e8f3746e" xlink:href="alvo-20231231.xsd#alvo_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_bda422a0-01a7-4ed8-976f-9ae3e9339205" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RevenueFromContractsWithCustomersAbstract_094d54c4-0c92-416b-98f9-ce75e8f3746e" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_bda422a0-01a7-4ed8-976f-9ae3e9339205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_f67ea609-7e86-4378-9972-61c62e3593b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_bda422a0-01a7-4ed8-976f-9ae3e9339205" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_f67ea609-7e86-4378-9972-61c62e3593b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_6acb6098-37ef-4ff2-b06e-c8635bcfeb6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_f67ea609-7e86-4378-9972-61c62e3593b3" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_6acb6098-37ef-4ff2-b06e-c8635bcfeb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetMember_8b9d2983-6968-4944-810c-30268929a42b" xlink:href="alvo-20231231.xsd#alvo_ContractAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_6acb6098-37ef-4ff2-b06e-c8635bcfeb6c" xlink:to="loc_alvo_ContractAssetMember_8b9d2983-6968-4944-810c-30268929a42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesMember_b1330e8e-43e0-4a5b-8d69-007235020441" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_6acb6098-37ef-4ff2-b06e-c8635bcfeb6c" xlink:to="loc_alvo_ContractLiabilitiesMember_b1330e8e-43e0-4a5b-8d69-007235020441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_818d3db5-835e-47f6-9512-65eee3495368" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_bda422a0-01a7-4ed8-976f-9ae3e9339205" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_818d3db5-835e-47f6-9512-65eee3495368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_818d3db5-835e-47f6-9512-65eee3495368" xlink:to="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractAssets_ae7a000e-d228-4e87-bf84-2b656154b6c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:to="loc_ifrs-full_ContractAssets_ae7a000e-d228-4e87-bf84-2b656154b6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets_399dfeb2-edab-4650-83f8-3aaf47edc5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets_399dfeb2-edab-4650-83f8-3aaf47edc5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables_1fee69a3-1211-41c6-a2eb-762d544678ba" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:to="loc_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables_1fee69a3-1211-41c6-a2eb-762d544678ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractAssets_3874261e-b879-49b0-b9ea-753fcfaf5578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractAssetsRollForward_eb61672a-3269-4468-8991-b6f4b80ef5c3" xlink:to="loc_ifrs-full_ContractAssets_3874261e-b879-49b0-b9ea-753fcfaf5578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_818d3db5-835e-47f6-9512-65eee3495368" xlink:to="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_a3300dba-4b0e-46c5-99d5-dfe11a7249d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_ifrs-full_ContractLiabilities_a3300dba-4b0e-46c5-99d5-dfe11a7249d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables_9c74e565-e639-4c79-82d9-8a4eec16e8c3" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables_9c74e565-e639-4c79-82d9-8a4eec16e8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability_bcf859ff-c0c2-46a4-ab17-c91e88d4eb72" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability_bcf859ff-c0c2-46a4-ab17-c91e88d4eb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractLiabilityCustomerPrepayments_047a265e-9836-4bd7-ad4c-3b26bd60e21f" xlink:href="alvo-20231231.xsd#alvo_ContractLiabilityCustomerPrepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_alvo_ContractLiabilityCustomerPrepayments_047a265e-9836-4bd7-ad4c-3b26bd60e21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities_8d8648d4-735a-4e5d-80ac-16fea41a375a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities_8d8648d4-735a-4e5d-80ac-16fea41a375a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment_b07fc157-30c6-40d7-9453-1ef54124e216" xlink:href="alvo-20231231.xsd#alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment_b07fc157-30c6-40d7-9453-1ef54124e216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_20a418d8-4ff3-42f3-87c6-b7eb23ea84c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ContractLiabilitiesRollForward_84a439a1-e26b-432c-89ba-e9215c6d5a55" xlink:to="loc_ifrs-full_ContractLiabilities_20a418d8-4ff3-42f3-87c6-b7eb23ea84c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RevenueAdditionalinformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RevenueAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RevenueAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RevenueFromContractsWithCustomersAbstract_4e96dbba-6b0a-4e9a-a490-e99424564966" xlink:href="alvo-20231231.xsd#alvo_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RevenueFromContractsWithCustomersAbstract_4e96dbba-6b0a-4e9a-a490-e99424564966" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_197c79a5-fe48-42fd-a10f-689cc88fc029" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:to="loc_ifrs-full_RangeAxis_197c79a5-fe48-42fd-a10f-689cc88fc029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_84e7d2e4-7ce4-470b-91a4-5722b51e4cae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_197c79a5-fe48-42fd-a10f-689cc88fc029" xlink:to="loc_ifrs-full_RangesMember_84e7d2e4-7ce4-470b-91a4-5722b51e4cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_a1c15705-e8c9-4138-a7a8-6727068ba8f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_84e7d2e4-7ce4-470b-91a4-5722b51e4cae" xlink:to="loc_ifrs-full_BottomOfRangeMember_a1c15705-e8c9-4138-a7a8-6727068ba8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_1d4c4552-62cd-4d51-957a-f910ad7f6710" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_84e7d2e4-7ce4-470b-91a4-5722b51e4cae" xlink:to="loc_ifrs-full_TopOfRangeMember_1d4c4552-62cd-4d51-957a-f910ad7f6710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_4145ef70-cfb8-4f81-9868-4455dda1f3f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:to="loc_ifrs-full_MaturityAxis_4145ef70-cfb8-4f81-9868-4455dda1f3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_91890b49-cf2d-404f-bf15-a59c7cd1bdcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_4145ef70-cfb8-4f81-9868-4455dda1f3f7" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_91890b49-cf2d-404f-bf15-a59c7cd1bdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NotLaterThanFiveYearsMember_a5e16ff0-d42f-47f8-9410-3bce207b9eca" xlink:href="alvo-20231231.xsd#alvo_NotLaterThanFiveYearsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_91890b49-cf2d-404f-bf15-a59c7cd1bdcb" xlink:to="loc_alvo_NotLaterThanFiveYearsMember_a5e16ff0-d42f-47f8-9410-3bce207b9eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsAxis_f15157bf-5222-4460-a149-e96efb4ec60e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:to="loc_ifrs-full_PerformanceObligationsAxis_f15157bf-5222-4460-a149-e96efb4ec60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsMember_00a9f2b8-273d-4291-80fd-2584033dafc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PerformanceObligationsAxis_f15157bf-5222-4460-a149-e96efb4ec60e" xlink:to="loc_ifrs-full_PerformanceObligationsMember_00a9f2b8-273d-4291-80fd-2584033dafc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_be22510d-df56-49ba-bdb3-e8596f8d584e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PerformanceObligationsMember_00a9f2b8-273d-4291-80fd-2584033dafc3" xlink:to="loc_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_be22510d-df56-49ba-bdb3-e8596f8d584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_14138daf-a171-4dad-a0e5-474182a1d663" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractAssets_5f3cf7a9-9e22-414b-b02c-ace0b77bf606" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_NoncurrentContractAssets_5f3cf7a9-9e22-414b-b02c-ace0b77bf606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractAssets_65ba858b-7dc4-4d5a-a9af-432e98f2b8e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_CurrentContractAssets_65ba858b-7dc4-4d5a-a9af-432e98f2b8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NoncurrentContractAssetsMaterializePeriod_eb64e60c-3b35-4537-b1c9-b2d755c76cbb" xlink:href="alvo-20231231.xsd#alvo_NoncurrentContractAssetsMaterializePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_alvo_NoncurrentContractAssetsMaterializePeriod_eb64e60c-3b35-4537-b1c9-b2d755c76cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_f6224a69-bd4e-486f-82e9-b2c6dbb365a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_f6224a69-bd4e-486f-82e9-b2c6dbb365a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_039853fb-f380-4305-be2b-0a4bb3476a82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_CurrentContractLiabilities_039853fb-f380-4305-be2b-0a4bb3476a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod_3f4e2fe3-e082-4cc8-beb6-6ffac512e26d" xlink:href="alvo-20231231.xsd#alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod_3f4e2fe3-e082-4cc8-beb6-6ffac512e26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_338152cf-5583-42dc-be72-e0198bc409d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_338152cf-5583-42dc-be72-e0198bc409d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod_acada7da-8c05-450c-8831-7821c0fcbe1e" xlink:href="alvo-20231231.xsd#alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e73c8dc9-1408-4db2-9314-01b7581fd677" xlink:to="loc_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod_acada7da-8c05-450c-8831-7821c0fcbe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SalariesAndOtherEmployeeExpensesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_3dc35eb3-7bbf-4354-af06-cd1aae025b3c" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees_0b4fc82c-38f1-426f-a7b6-cc606413dcbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_3dc35eb3-7bbf-4354-af06-cd1aae025b3c" xlink:to="loc_ifrs-full_AverageNumberOfEmployees_0b4fc82c-38f1-426f-a7b6-cc606413dcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_76f353ee-9e45-4cc3-afde-097c86b75896" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_78029af0-109d-4053-8334-7e52feb18569" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_76f353ee-9e45-4cc3-afde-097c86b75896" xlink:to="loc_ifrs-full_WagesAndSalaries_78029af0-109d-4053-8334-7e52feb18569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_e57f9256-a901-43e6-80d4-7faa498c01df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_76f353ee-9e45-4cc3-afde-097c86b75896" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_e57f9256-a901-43e6-80d4-7faa498c01df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermBenefits_64d8a74e-e2ce-467d-aaae-5c8d1c551f5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_76f353ee-9e45-4cc3-afde-097c86b75896" xlink:to="loc_ifrs-full_OtherLongtermBenefits_64d8a74e-e2ce-467d-aaae-5c8d1c551f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_3f674499-88ca-4f13-8606-36cf09334b6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_76f353ee-9e45-4cc3-afde-097c86b75896" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_3f674499-88ca-4f13-8606-36cf09334b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_7fc21fc1-c2c6-4b19-b794-ed62eb66f75c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_76f353ee-9e45-4cc3-afde-097c86b75896" xlink:to="loc_ifrs-full_OtherEmployeeExpense_7fc21fc1-c2c6-4b19-b794-ed62eb66f75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TemporaryLabourExpense_ae719f7a-09cb-4696-85d2-784c4fcfc581" xlink:href="alvo-20231231.xsd#alvo_TemporaryLabourExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_76f353ee-9e45-4cc3-afde-097c86b75896" xlink:to="loc_alvo_TemporaryLabourExpense_ae719f7a-09cb-4696-85d2-784c4fcfc581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_db6a4df7-3447-4bb2-a57c-4d1fec855b13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_76f353ee-9e45-4cc3-afde-097c86b75896" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_db6a4df7-3447-4bb2-a57c-4d1fec855b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_87f7cc35-ef79-4806-b299-98fcd5a08640" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_b5cbdc3c-c81a-43a3-9888-0f2d958ddf8e" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract_87f7cc35-ef79-4806-b299-98fcd5a08640" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_b5cbdc3c-c81a-43a3-9888-0f2d958ddf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_eb2f75cc-0006-427c-b94a-b20a155ff065" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_b5cbdc3c-c81a-43a3-9888-0f2d958ddf8e" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_eb2f75cc-0006-427c-b94a-b20a155ff065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_eb2f75cc-0006-427c-b94a-b20a155ff065" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CostOfProductRevenueMember_db618429-f1b5-40e4-8efb-c7bbcb09ff37" xlink:href="alvo-20231231.xsd#alvo_CostOfProductRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:to="loc_alvo_CostOfProductRevenueMember_db618429-f1b5-40e4-8efb-c7bbcb09ff37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentExpensesMember_69ad7a9c-7f1f-4ab2-8cce-31e9b4ea3253" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:to="loc_alvo_ResearchAndDevelopmentExpensesMember_69ad7a9c-7f1f-4ab2-8cce-31e9b4ea3253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember_0a42c758-127e-4c77-a5dc-85a93bc31ac4" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_68eedcff-a89d-4a1d-b41e-4d1164e27887" xlink:to="loc_alvo_GeneralAndAdministrativeExpensesMember_0a42c758-127e-4c77-a5dc-85a93bc31ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_cde9ce3a-7739-4279-8914-faf935a81fa8" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable_b5cbdc3c-c81a-43a3-9888-0f2d958ddf8e" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_cde9ce3a-7739-4279-8914-faf935a81fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_651b70ba-edc3-496b-a49d-b475c2a81e37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems_cde9ce3a-7739-4279-8914-faf935a81fa8" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_651b70ba-edc3-496b-a49d-b475c2a81e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsOfFinanceIncomeAbstract_01425bfa-62ca-44cb-acea-7a62607cfe3f" xlink:href="alvo-20231231.xsd#alvo_DetailsOfFinanceIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_e41fe1eb-adb5-45ca-a16a-d96e90c6343f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailsOfFinanceIncomeAbstract_01425bfa-62ca-44cb-acea-7a62607cfe3f" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_e41fe1eb-adb5-45ca-a16a-d96e90c6343f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_995cb230-9884-4f92-9e79-1f887675745b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailsOfFinanceIncomeAbstract_01425bfa-62ca-44cb-acea-7a62607cfe3f" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_995cb230-9884-4f92-9e79-1f887675745b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets_cc595895-8bae-42fd-ba97-8f8fb54d2173" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnOtherFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailsOfFinanceIncomeAbstract_01425bfa-62ca-44cb-acea-7a62607cfe3f" xlink:to="loc_ifrs-full_InterestIncomeOnOtherFinancialAssets_cc595895-8bae-42fd-ba97-8f8fb54d2173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_321417e3-a5a3-43be-a089-788a2fe37e6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailsOfFinanceIncomeAbstract_01425bfa-62ca-44cb-acea-7a62607cfe3f" xlink:to="loc_ifrs-full_FinanceIncome_321417e3-a5a3-43be-a089-788a2fe37e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfFinanceIncomeAbstract_3c6d0080-4569-4c23-a312-7a396159c1ad" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfFinanceIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_28800a01-b94f-43f0-9dcf-dc20de99ef3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_3c6d0080-4569-4c23-a312-7a396159c1ad" xlink:to="loc_ifrs-full_LossesOnChangeInFairValueOfDerivatives_28800a01-b94f-43f0-9dcf-dc20de99ef3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_379d14d1-0407-43a0-9696-958f3ac55516" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_3c6d0080-4569-4c23-a312-7a396159c1ad" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_379d14d1-0407-43a0-9696-958f3ac55516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConsentingFee_0c1e60ea-f96d-4b2c-aefd-7c8152c78793" xlink:href="alvo-20231231.xsd#alvo_ConsentingFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_3c6d0080-4569-4c23-a312-7a396159c1ad" xlink:to="loc_alvo_ConsentingFee_0c1e60ea-f96d-4b2c-aefd-7c8152c78793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossOnRemeasurementOfBonds_58e52152-798f-4905-8078-847937487f32" xlink:href="alvo-20231231.xsd#alvo_LossOnRemeasurementOfBonds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_3c6d0080-4569-4c23-a312-7a396159c1ad" xlink:to="loc_alvo_LossOnRemeasurementOfBonds_58e52152-798f-4905-8078-847937487f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_4ff214fe-6985-432b-857f-dbd2d65ea32e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_3c6d0080-4569-4c23-a312-7a396159c1ad" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_4ff214fe-6985-432b-857f-dbd2d65ea32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationOfDeferredDebtIssuanceCosts_68c1b1aa-78ec-4b0f-83aa-a48d9b2063e9" xlink:href="alvo-20231231.xsd#alvo_AmortizationOfDeferredDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_3c6d0080-4569-4c23-a312-7a396159c1ad" xlink:to="loc_alvo_AmortizationOfDeferredDebtIssuanceCosts_68c1b1aa-78ec-4b0f-83aa-a48d9b2063e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_e108d019-dfad-4b38-93da-02c955de04fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfFinanceIncomeAbstract_3c6d0080-4569-4c23-a312-7a396159c1ad" xlink:to="loc_ifrs-full_FinanceCosts_e108d019-dfad-4b38-93da-02c955de04fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_e69fcb28-631f-4ffd-89f6-69bfaa3c7e2a" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment_8858a1f3-c56b-423a-8aea-8f604ef5d672" xlink:href="alvo-20231231.xsd#alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_e69fcb28-631f-4ffd-89f6-69bfaa3c7e2a" xlink:to="loc_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment_8858a1f3-c56b-423a-8aea-8f604ef5d672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_3ce91694-790d-4851-b15f-585fd3026e8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_e69fcb28-631f-4ffd-89f6-69bfaa3c7e2a" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_3ce91694-790d-4851-b15f-585fd3026e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationAndImpairmentOfIntangibleAssets_9403410a-59cf-45c9-b033-baa43894337e" xlink:href="alvo-20231231.xsd#alvo_AmortizationAndImpairmentOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_e69fcb28-631f-4ffd-89f6-69bfaa3c7e2a" xlink:to="loc_alvo_AmortizationAndImpairmentOfIntangibleAssets_9403410a-59cf-45c9-b033-baa43894337e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_8595d32a-3006-45bb-828c-c0a606ce8a8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_e69fcb28-631f-4ffd-89f6-69bfaa3c7e2a" xlink:to="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_8595d32a-3006-45bb-828c-c0a606ce8a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_ccfba8a6-3ead-441e-afe8-fcc00c3eec03" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_2a3b9068-db86-400d-9f10-b914a390efa6" xlink:href="alvo-20231231.xsd#alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract_ccfba8a6-3ead-441e-afe8-fcc00c3eec03" xlink:to="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_2a3b9068-db86-400d-9f10-b914a390efa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_26466cbe-4457-4225-be41-17ce5123a835" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_2a3b9068-db86-400d-9f10-b914a390efa6" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_26466cbe-4457-4225-be41-17ce5123a835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_26466cbe-4457-4225-be41-17ce5123a835" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CostOfProductRevenueMember_8e569007-ec3a-4b3a-9fb1-f09cf6f12a7e" xlink:href="alvo-20231231.xsd#alvo_CostOfProductRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:to="loc_alvo_CostOfProductRevenueMember_8e569007-ec3a-4b3a-9fb1-f09cf6f12a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentExpensesMember_d5d6de87-7dd3-4153-8c2f-3dba4ba45289" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:to="loc_alvo_ResearchAndDevelopmentExpensesMember_d5d6de87-7dd3-4153-8c2f-3dba4ba45289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember_0b15ca43-51ce-4cd1-9183-190d24854db2" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_18e18d45-9abe-4a4e-8e23-799a2b830a2e" xlink:to="loc_alvo_GeneralAndAdministrativeExpensesMember_0b15ca43-51ce-4cd1-9183-190d24854db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_d3af45a4-ad19-4e73-aae1-5a6dc968fd29" xlink:href="alvo-20231231.xsd#alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable_2a3b9068-db86-400d-9f10-b914a390efa6" xlink:to="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_d3af45a4-ad19-4e73-aae1-5a6dc968fd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_ed9263d3-3e7c-4fb5-ae1e-3de85168cb63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems_d3af45a4-ad19-4e73-aae1-5a6dc968fd29" xlink:to="loc_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_ed9263d3-3e7c-4fb5-ae1e-3de85168cb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfAuditFeesAbstract_f2cb77e9-210e-412a-821a-800e17a680da" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfAuditFeesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_4c51b106-9441-4f59-96df-8560a1170bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfAuditFeesAbstract_f2cb77e9-210e-412a-821a-800e17a680da" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_4c51b106-9441-4f59-96df-8560a1170bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices_8f3d437e-c0f0-441f-aecf-617142791956" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfAuditFeesAbstract_f2cb77e9-210e-412a-821a-800e17a680da" xlink:to="loc_ifrs-full_AuditorsRemunerationForTaxServices_8f3d437e-c0f0-441f-aecf-617142791956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration_b5c33648-f8c1-4da1-bb30-9d1368113b88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfAuditFeesAbstract_f2cb77e9-210e-412a-821a-800e17a680da" xlink:to="loc_ifrs-full_AuditorsRemuneration_b5c33648-f8c1-4da1-bb30-9d1368113b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract_49866b0c-83c0-4460-8e6f-5293426ba118" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentTaxAbstract_3e6bb063-ae0a-45c6-a9a4-0686d06f5c44" xlink:href="alvo-20231231.xsd#alvo_CurrentTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_49866b0c-83c0-4460-8e6f-5293426ba118" xlink:to="loc_alvo_CurrentTaxAbstract_3e6bb063-ae0a-45c6-a9a4-0686d06f5c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_71c1407a-baf2-4cbb-8a2a-6736956e2913" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CurrentTaxAbstract_3e6bb063-ae0a-45c6-a9a4-0686d06f5c44" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_71c1407a-baf2-4cbb-8a2a-6736956e2913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_7f20ac42-23fd-41b8-a1f7-49daf1f09af5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CurrentTaxAbstract_3e6bb063-ae0a-45c6-a9a4-0686d06f5c44" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_7f20ac42-23fd-41b8-a1f7-49daf1f09af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_eb05afbd-84a6-485e-9619-a2841371218c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CurrentTaxAbstract_3e6bb063-ae0a-45c6-a9a4-0686d06f5c44" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_eb05afbd-84a6-485e-9619-a2841371218c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DeferredTaxAbstract_b39b6a7b-a714-41bc-8d7b-37f43d46b6bf" xlink:href="alvo-20231231.xsd#alvo_DeferredTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_49866b0c-83c0-4460-8e6f-5293426ba118" xlink:to="loc_alvo_DeferredTaxAbstract_b39b6a7b-a714-41bc-8d7b-37f43d46b6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_7da0dde7-f5ad-4b1e-85df-044ce097e0b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DeferredTaxAbstract_b39b6a7b-a714-41bc-8d7b-37f43d46b6bf" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_7da0dde7-f5ad-4b1e-85df-044ce097e0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_8ee08b3e-7dc0-439a-b0a2-0fee3a43b8e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DeferredTaxAbstract_b39b6a7b-a714-41bc-8d7b-37f43d46b6bf" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_8ee08b3e-7dc0-439a-b0a2-0fee3a43b8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_292c9bd5-a2fd-4f9b-b74c-2b183ac2970f" xlink:href="alvo-20231231.xsd#alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DeferredTaxAbstract_b39b6a7b-a714-41bc-8d7b-37f43d46b6bf" xlink:to="loc_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods_292c9bd5-a2fd-4f9b-b74c-2b183ac2970f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_feb33ab7-9040-409c-8c7b-527e36a064ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_49866b0c-83c0-4460-8e6f-5293426ba118" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_feb33ab7-9040-409c-8c7b-527e36a064ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract_c2f62f84-b3b5-4e1e-b912-6fed4ae2220b" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_c2f62f84-b3b5-4e1e-b912-6fed4ae2220b" xlink:to="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_81d2ec82-3c09-4654-a93e-09b70866bea4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_81d2ec82-3c09-4654-a93e-09b70866bea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_acc89e5e-07b9-4d28-86ef-170f35dcf512" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_81d2ec82-3c09-4654-a93e-09b70866bea4" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_acc89e5e-07b9-4d28-86ef-170f35dcf512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_b746588a-693a-40af-8067-899acd9c1b51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_acc89e5e-07b9-4d28-86ef-170f35dcf512" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_b746588a-693a-40af-8067-899acd9c1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceMember_6d316a69-3dc0-4dbc-83b5-1ce5aeb136e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_acc89e5e-07b9-4d28-86ef-170f35dcf512" xlink:to="loc_ifrs-full_TemporaryDifferenceMember_6d316a69-3dc0-4dbc-83b5-1ce5aeb136e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_43510af9-6dea-4288-a8c2-2d9c058a01e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:to="loc_srt_StatementGeographicalAxis_43510af9-6dea-4288-a8c2-2d9c058a01e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_79fff4fe-623c-4005-80f8-cfa70b2c606b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_43510af9-6dea-4288-a8c2-2d9c058a01e9" xlink:to="loc_srt_SegmentGeographicalDomain_79fff4fe-623c-4005-80f8-cfa70b2c606b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IS_1a96e06d-cb8b-4381-bd82-078217918f28" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_79fff4fe-623c-4005-80f8-cfa70b2c606b" xlink:to="loc_country_IS_1a96e06d-cb8b-4381-bd82-078217918f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_LU_42107cc4-1546-4700-9b6f-9f2f5d9d4295" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_LU"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_79fff4fe-623c-4005-80f8-cfa70b2c606b" xlink:to="loc_country_LU_42107cc4-1546-4700-9b6f-9f2f5d9d4295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable_644c565d-5d61-4db3-a0de-8ae19eb3f3f5" xlink:to="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_4b6a65c8-cc89-4b47-a170-1cb51f753885" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods_4b6a65c8-cc89-4b47-a170-1cb51f753885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_24fe7d2d-d813-4e6a-b743-999f5b840590" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_24fe7d2d-d813-4e6a-b743-999f5b840590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities_91c671f3-8cc7-4011-8c62-ca802c14143d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_NetDeferredTaxLiabilities_91c671f3-8cc7-4011-8c62-ca802c14143d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_f6062073-a1a5-4ceb-b009-89deeb7dc091" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_DeferredTaxAssets_f6062073-a1a5-4ceb-b009-89deeb7dc091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_7a17e7cb-ea68-4c2b-9118-dabd9b121445" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_6c6d588e-8103-4513-a94d-a68c15587c69" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_7a17e7cb-ea68-4c2b-9118-dabd9b121445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract_686f4d88-0c99-464f-9914-88e634bbb9dc" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_b9dbc7ff-bbd0-4855-878a-c7e8ec210287" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_686f4d88-0c99-464f-9914-88e634bbb9dc" xlink:to="loc_ifrs-full_ApplicableTaxRate_b9dbc7ff-bbd0-4855-878a-c7e8ec210287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_e580b0ac-e51a-4033-9c47-a0eb33707451" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_686f4d88-0c99-464f-9914-88e634bbb9dc" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_e580b0ac-e51a-4033-9c47-a0eb33707451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_396245cf-a740-4cce-9a3e-1158e1a39749" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_686f4d88-0c99-464f-9914-88e634bbb9dc" xlink:to="loc_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_396245cf-a740-4cce-9a3e-1158e1a39749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses_21609101-9628-4a8a-b436-6db3ff364d64" xlink:href="alvo-20231231.xsd#alvo_TaxRateEffectOfNonrecognitionOfTaxLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_686f4d88-0c99-464f-9914-88e634bbb9dc" xlink:to="loc_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses_21609101-9628-4a8a-b436-6db3ff364d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_7204310e-3542-4f04-91fe-6e383fc44642" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_686f4d88-0c99-464f-9914-88e634bbb9dc" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_7204310e-3542-4f04-91fe-6e383fc44642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_0a10af92-ad0f-47b4-8a98-d6bacb965fc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_686f4d88-0c99-464f-9914-88e634bbb9dc" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_0a10af92-ad0f-47b4-8a98-d6bacb965fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract_a830205e-5830-49d2-969d-42ed865d2d07" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DeferredTaxLiabilityAssetRollForward_cf5e3e3c-2672-473e-8a52-afcd654fbb36" xlink:href="alvo-20231231.xsd#alvo_DeferredTaxLiabilityAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_a830205e-5830-49d2-969d-42ed865d2d07" xlink:to="loc_alvo_DeferredTaxLiabilityAssetRollForward_cf5e3e3c-2672-473e-8a52-afcd654fbb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_f5724133-24ff-4308-8864-f8682cddc210" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DeferredTaxLiabilityAssetRollForward_cf5e3e3c-2672-473e-8a52-afcd654fbb36" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_f5724133-24ff-4308-8864-f8682cddc210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_efeb785c-048a-4e15-86f3-bdfdad43c2ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DeferredTaxLiabilityAssetRollForward_cf5e3e3c-2672-473e-8a52-afcd654fbb36" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_efeb785c-048a-4e15-86f3-bdfdad43c2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_7c82ef07-b1b0-4f0e-894d-e7f20aa98809" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DeferredTaxLiabilityAssetRollForward_cf5e3e3c-2672-473e-8a52-afcd654fbb36" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_7c82ef07-b1b0-4f0e-894d-e7f20aa98809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets_dea258f5-fae2-4735-8532-445247777250" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DeferredTaxLiabilityAssetRollForward_cf5e3e3c-2672-473e-8a52-afcd654fbb36" xlink:to="loc_ifrs-full_NetDeferredTaxAssets_dea258f5-fae2-4735-8532-445247777250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities_17d6dab8-4244-4ea8-913b-23c50cd2d97c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DeferredTaxLiabilityAssetRollForward_cf5e3e3c-2672-473e-8a52-afcd654fbb36" xlink:to="loc_ifrs-full_NetDeferredTaxLiabilities_17d6dab8-4244-4ea8-913b-23c50cd2d97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract_e4b58e53-925e-4670-9cf9-e3d180eafc0b" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_36fb06eb-74a4-4e95-95ae-80b516059528" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_e4b58e53-925e-4670-9cf9-e3d180eafc0b" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_36fb06eb-74a4-4e95-95ae-80b516059528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_36fb06eb-74a4-4e95-95ae-80b516059528" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2e9398f9-3bb8-4a8b-b1ad-c2994192e4ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_4a58c8a5-7b4d-4a7d-b4fd-fe866d32320b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2e9398f9-3bb8-4a8b-b1ad-c2994192e4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_b3417242-e715-463d-a80a-78ce57980889" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2e9398f9-3bb8-4a8b-b1ad-c2994192e4ba" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_b3417242-e715-463d-a80a-78ce57980889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_95a82f54-84e2-40c1-b506-53e725110c09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2e9398f9-3bb8-4a8b-b1ad-c2994192e4ba" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_95a82f54-84e2-40c1-b506-53e725110c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_36fb06eb-74a4-4e95-95ae-80b516059528" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets_5a873b88-367e-4d5f-a266-2507090b7626" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:to="loc_ifrs-full_NetDeferredTaxAssets_5a873b88-367e-4d5f-a266-2507090b7626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities_971acf0a-6c75-4d5f-8db1-40bca989b68e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:to="loc_ifrs-full_NetDeferredTaxLiabilities_971acf0a-6c75-4d5f-8db1-40bca989b68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_65361188-f5f9-4a56-8d1f-948844ac1608" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_05ddaa9f-607d-4bf9-bcce-8790a1432faa" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_65361188-f5f9-4a56-8d1f-948844ac1608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxAbstract_c193da1c-aeea-4963-9166-35ae0c54038c" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxTable_33f02ab2-79f7-4b45-bca4-f09325af89c4" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxAbstract_c193da1c-aeea-4963-9166-35ae0c54038c" xlink:to="loc_alvo_DisclosureOfIncomeTaxTable_33f02ab2-79f7-4b45-bca4-f09325af89c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxYearsAxis_9b1311e2-26de-4380-a53a-dbfa827c739c" xlink:href="alvo-20231231.xsd#alvo_TaxYearsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable_33f02ab2-79f7-4b45-bca4-f09325af89c4" xlink:to="loc_alvo_TaxYearsAxis_9b1311e2-26de-4380-a53a-dbfa827c739c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:href="alvo-20231231.xsd#alvo_TaxYearsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TaxYearsAxis_9b1311e2-26de-4380-a53a-dbfa827c739c" xlink:to="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember_7118d442-f833-4c7c-bb85-80319f34b675" xlink:href="alvo-20231231.xsd#alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:to="loc_alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember_7118d442-f833-4c7c-bb85-80319f34b675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember_a59fc00f-220c-42df-8d9d-c8ab3dbdb86f" xlink:href="alvo-20231231.xsd#alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:to="loc_alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember_a59fc00f-220c-42df-8d9d-c8ab3dbdb86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LaterPeriodMember_f998c8bb-b430-4b75-af21-f2312e2e6fe3" xlink:href="alvo-20231231.xsd#alvo_LaterPeriodMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TaxYearsDomain_731a84d7-d078-495d-b2f5-96fbfc21ef3b" xlink:to="loc_alvo_LaterPeriodMember_f998c8bb-b430-4b75-af21-f2312e2e6fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfIncomeTaxLineItems_fa4e34c1-9405-4b5a-b284-42cf5f8579b1" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfIncomeTaxLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxTable_33f02ab2-79f7-4b45-bca4-f09325af89c4" xlink:to="loc_alvo_DisclosureOfIncomeTaxLineItems_fa4e34c1-9405-4b5a-b284-42cf5f8579b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_8f3fc3ae-9206-4f62-8644-2737cfe93746" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfIncomeTaxLineItems_fa4e34c1-9405-4b5a-b284-42cf5f8579b1" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_8f3fc3ae-9206-4f62-8644-2737cfe93746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LossPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LossPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LossPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_844d0f0f-5b98-4e6a-8778-628cbafb5356" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_ff611c7e-99ee-49ca-8784-751778975408" xlink:href="alvo-20231231.xsd#alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_844d0f0f-5b98-4e6a-8778-628cbafb5356" xlink:to="loc_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_ff611c7e-99ee-49ca-8784-751778975408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_fa84f052-1b5d-4fd0-8566-206cf4dfe001" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_844d0f0f-5b98-4e6a-8778-628cbafb5356" xlink:to="loc_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented_fa84f052-1b5d-4fd0-8566-206cf4dfe001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LossPerShareSummaryofBasicandDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_4924bc58-60b3-4e1c-bfd8-b390849f39da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable_9e8ac3f8-e64d-4421-b4db-6e16e2d08223" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_4924bc58-60b3-4e1c-bfd8-b390849f39da" xlink:to="loc_ifrs-full_EarningsPerShareTable_9e8ac3f8-e64d-4421-b4db-6e16e2d08223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_9e8ac3f8-e64d-4421-b4db-6e16e2d08223" xlink:to="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_e3a15166-a717-426c-a2ff-5a91bfde27cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_ProfitLoss_e3a15166-a717-426c-a2ff-5a91bfde27cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_476ba450-cb45-4728-b81b-286c41c67951" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_WeightedAverageShares_476ba450-cb45-4728-b81b-286c41c67951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_d0aebb8a-92d7-4ca2-a271-e21c86653571" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_d0aebb8a-92d7-4ca2-a271-e21c86653571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_45ed73e2-e53f-46b8-80d1-7efac2708873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_45ed73e2-e53f-46b8-80d1-7efac2708873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_3dc71a15-7c64-49fd-8966-70c521a5a311" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_4f62221a-e784-4a9b-ad71-0fdc74b6fdd5" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_3dc71a15-7c64-49fd-8966-70c521a5a311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_7a81f9cb-558c-468e-99ad-2a87857d48c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_7a81f9cb-558c-468e-99ad-2a87857d48c5" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9037609e-4ca5-4f61-9e87-24e1ffd358cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9037609e-4ca5-4f61-9e87-24e1ffd358cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_bcbdc428-e325-44df-b629-a9133d0b9b1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9037609e-4ca5-4f61-9e87-24e1ffd358cb" xlink:to="loc_ifrs-full_CarryingAmountMember_bcbdc428-e325-44df-b629-a9133d0b9b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_a6670314-86ff-4cbc-8a4b-27b45b588d4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_bcbdc428-e325-44df-b629-a9133d0b9b1d" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_a6670314-86ff-4cbc-8a4b-27b45b588d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_db662e0e-a737-4637-ad74-26c037663fca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_bcbdc428-e325-44df-b629-a9133d0b9b1d" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_db662e0e-a737-4637-ad74-26c037663fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_a35da168-1ba1-435f-81a7-b30c725ea98a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_a35da168-1ba1-435f-81a7-b30c725ea98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_a35da168-1ba1-435f-81a7-b30c725ea98a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityMember_20235103-10a9-4ae2-a9d9-0627c7e8118e" xlink:href="alvo-20231231.xsd#alvo_FacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:to="loc_alvo_FacilityMember_20235103-10a9-4ae2-a9d9-0627c7e8118e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityEquipmentMember_871408f9-1ca1-4c13-8c93-2e31b13ba8be" xlink:href="alvo-20231231.xsd#alvo_FacilityEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:to="loc_alvo_FacilityEquipmentMember_871408f9-1ca1-4c13-8c93-2e31b13ba8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FurnitureFixturesAndLeaseholdImprovementsMember_f47750c8-caf1-45d9-b52f-60f09312d130" xlink:href="alvo-20231231.xsd#alvo_FurnitureFixturesAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:to="loc_alvo_FurnitureFixturesAndLeaseholdImprovementsMember_f47750c8-caf1-45d9-b52f-60f09312d130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_ccf4f53e-08d5-4677-a6f6-af36371b3189" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_312f768e-b779-4b10-b5bb-35fd02a2609f" xlink:to="loc_ifrs-full_ComputerEquipmentMember_ccf4f53e-08d5-4677-a6f6-af36371b3189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0b2c6804-329a-43a3-806d-4e2b1cfe1767" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5dec4a90-b996-405b-b968-16c084063653" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0b2c6804-329a-43a3-806d-4e2b1cfe1767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:href="alvo-20231231.xsd#alvo_PropertyPlantAndEquipmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0b2c6804-329a-43a3-806d-4e2b1cfe1767" xlink:to="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_d9f3360f-243d-42c3-ab70-879def06cb01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_d9f3360f-243d-42c3-ab70-879def06cb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_994fe3ca-4b03-4152-bbd0-4c9138fd42ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_994fe3ca-4b03-4152-bbd0-4c9138fd42ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f52328ca-bf00-4a0c-a569-f5f48d025c99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f52328ca-bf00-4a0c-a569-f5f48d025c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_fa0d5e4f-bee1-482d-89b2-08f4d88d5d27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_fa0d5e4f-bee1-482d-89b2-08f4d88d5d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_f1803eb0-4b54-486b-a246-38e5d08f9609" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_f1803eb0-4b54-486b-a246-38e5d08f9609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_e4dbca62-9c06-4155-b907-fbb995f0839e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_e4dbca62-9c06-4155-b907-fbb995f0839e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9cf2bb32-030d-4f0c-99ce-e35e69001cf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_PropertyPlantAndEquipmentRollForward_800be841-9117-4c38-b411-a320981c6302" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_9cf2bb32-030d-4f0c-99ce-e35e69001cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#PropertyPlantAndEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_91fa64d6-09a9-4be5-a238-389e4f15fa15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_91fa64d6-09a9-4be5-a238-389e4f15fa15" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetsAcquisitionAxis_9aa953b1-1cac-4eec-8fda-23100afab36f" xlink:href="alvo-20231231.xsd#alvo_AssetsAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:to="loc_alvo_AssetsAcquisitionAxis_9aa953b1-1cac-4eec-8fda-23100afab36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionsDomain_15261457-82a6-4605-9af5-6d2bc1bd7225" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AssetsAcquisitionAxis_9aa953b1-1cac-4eec-8fda-23100afab36f" xlink:to="loc_alvo_AssetAcquisitionsDomain_15261457-82a6-4605-9af5-6d2bc1bd7225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaemundurMember_39b7d770-5f73-4324-9153-557c93ce27c6" xlink:href="alvo-20231231.xsd#alvo_SaemundurMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AssetAcquisitionsDomain_15261457-82a6-4605-9af5-6d2bc1bd7225" xlink:to="loc_alvo_SaemundurMember_39b7d770-5f73-4324-9153-557c93ce27c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_9c77efd7-f5fd-43cf-b325-4264100e6b8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_9c77efd7-f5fd-43cf-b325-4264100e6b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_a9de1ee4-2d6c-4d6c-843b-effbd2f35171" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_9c77efd7-f5fd-43cf-b325-4264100e6b8e" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_a9de1ee4-2d6c-4d6c-843b-effbd2f35171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityMember_1f7f8f05-a188-4939-9c72-bf24a7a78e6d" xlink:href="alvo-20231231.xsd#alvo_FacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_a9de1ee4-2d6c-4d6c-843b-effbd2f35171" xlink:to="loc_alvo_FacilityMember_1f7f8f05-a188-4939-9c72-bf24a7a78e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_0b71047f-e0fa-44c0-baa6-cc87f626b5ef" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_c2f08ba6-0352-44ec-8bf6-68f5602d2614" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_c2f08ba6-0352-44ec-8bf6-68f5602d2614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionsConsiderationTransferred_c61f7e04-a1c6-4f0d-b687-01180230778e" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionsConsiderationTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_AssetAcquisitionsConsiderationTransferred_c61f7e04-a1c6-4f0d-b687-01180230778e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond_87fc2b2c-8e46-4578-96d5-c80212261e88" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredConvertibleBond"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond_87fc2b2c-8e46-4578-96d5-c80212261e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed_e8f4be7a-063c-4d3d-8d22-180a116551ea" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredLoansAssumed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed_e8f4be7a-063c-4d3d-8d22-180a116551ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationTransferredSettlements_f9510177-1a08-4154-acf2-c4fe0e0d867b" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationTransferredSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_AssetAcquisitionConsiderationTransferredSettlements_f9510177-1a08-4154-acf2-c4fe0e0d867b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossOnExtinguishmentOfTheLeaseLiability_38f5f7db-b97d-4739-bdfe-cd88cf2cf8d4" xlink:href="alvo-20231231.xsd#alvo_LossOnExtinguishmentOfTheLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_alvo_LossOnExtinguishmentOfTheLeaseLiability_38f5f7db-b97d-4739-bdfe-cd88cf2cf8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_66c10599-320b-438f-98f2-ee30b2a1cd72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b74883d9-d98e-4d75-b32d-2bfa04e6b29c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_66c10599-320b-438f-98f2-ee30b2a1cd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_709ace78-e647-4760-a0f4-2e494085ba49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:href="alvo-20231231.xsd#alvo_RightOfUsedAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_709ace78-e647-4760-a0f4-2e494085ba49" xlink:to="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_825ba7d8-4df3-4640-b81e-41364615f803" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_ifrs-full_RightofuseAssets_825ba7d8-4df3-4640-b81e-41364615f803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets_b5e7f1ac-3cfc-4430-8eff-da4e9a012d59" xlink:href="alvo-20231231.xsd#alvo_AdjustmentsForIndexedLeasesRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets_b5e7f1ac-3cfc-4430-8eff-da4e9a012d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_8b8de58f-4e99-4773-83a9-f3ba348d0e55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_8b8de58f-4e99-4773-83a9-f3ba348d0e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CancellationsRightOfUseAssets_89453bc6-f32c-4661-b560-2a5d61cccc1d" xlink:href="alvo-20231231.xsd#alvo_CancellationsRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_alvo_CancellationsRightOfUseAssets_89453bc6-f32c-4661-b560-2a5d61cccc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DecreaseThroughDerecognitionRightOfUseAssets_7f9f3db7-3d12-44db-a17b-64b4ecd89fea" xlink:href="alvo-20231231.xsd#alvo_DecreaseThroughDerecognitionRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_alvo_DecreaseThroughDerecognitionRightOfUseAssets_7f9f3db7-3d12-44db-a17b-64b4ecd89fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReclassificationRightOfUseAssets_10971d66-f01a-4044-ba63-caf15d75029c" xlink:href="alvo-20231231.xsd#alvo_ReclassificationRightOfUseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_alvo_ReclassificationRightOfUseAssets_10971d66-f01a-4044-ba63-caf15d75029c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_4486f919-30ec-4d89-b544-8ec11d10cd8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_4486f919-30ec-4d89-b544-8ec11d10cd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TranslationDifferenceRightOfUseAssets_a5218ef1-2019-41d8-9603-2dee26744015" xlink:href="alvo-20231231.xsd#alvo_TranslationDifferenceRightOfUseAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_alvo_TranslationDifferenceRightOfUseAssets_a5218ef1-2019-41d8-9603-2dee26744015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_7eff8bb5-e8e5-4638-9b26-85b9ab1523c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_RightOfUsedAssetsRollForward_5284637a-7b2e-4768-8709-b689b5cea373" xlink:to="loc_ifrs-full_RightofuseAssets_7eff8bb5-e8e5-4638-9b26-85b9ab1523c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_98b0577d-f293-4ccb-b5b5-8b0ce211b603" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_98b0577d-f293-4ccb-b5b5-8b0ce211b603" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:to="loc_srt_CounterpartyNameAxis_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acb4db7c-72ae-4026-bf5d-a588c534f8b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e1d5c6da-c65e-436a-9471-6c3ad3b46a0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acb4db7c-72ae-4026-bf5d-a588c534f8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagidEyjolfurHf.Member_240c72e9-3c64-4cd9-9c8b-92599f8bf13c" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagidEyjolfurHf.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_acb4db7c-72ae-4026-bf5d-a588c534f8b0" xlink:to="loc_alvo_FasteignafelagidEyjolfurHf.Member_240c72e9-3c64-4cd9-9c8b-92599f8bf13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_67a52cae-9351-4515-ab48-13cd1763b2a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:to="loc_srt_StatementGeographicalAxis_67a52cae-9351-4515-ab48-13cd1763b2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0e9ed4ae-7bd3-4042-9c97-3d8dfbf99aa5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_67a52cae-9351-4515-ab48-13cd1763b2a3" xlink:to="loc_srt_SegmentGeographicalDomain_0e9ed4ae-7bd3-4042-9c97-3d8dfbf99aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IS_ac36bb05-4b7a-447b-9fa2-32b033f14795" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0e9ed4ae-7bd3-4042-9c97-3d8dfbf99aa5" xlink:to="loc_country_IS_ac36bb05-4b7a-447b-9fa2-32b033f14795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_111bf70f-0c81-4e5c-bb03-1e64718e5fdf" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageRemainingLeaseTerm_afff09c9-0104-4f6b-bd86-021208aee59b" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_alvo_WeightedAverageRemainingLeaseTerm_afff09c9-0104-4f6b-bd86-021208aee59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AreaOfProperty_0d3b40c6-9626-462c-84e0-0b71b384f89b" xlink:href="alvo-20231231.xsd#alvo_AreaOfProperty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_alvo_AreaOfProperty_0d3b40c6-9626-462c-84e0-0b71b384f89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_e96ca346-7dc0-45c8-9ade-dc0f9c279319" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_ifrs-full_RightofuseAssets_e96ca346-7dc0-45c8-9ade-dc0f9c279319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_2e7efd2b-6ae9-406f-83ef-836799c7d38b" xlink:href="alvo-20231231.xsd#alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_0de3b00c-8668-4ad0-9981-2430960d5ceb" xlink:to="loc_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_2e7efd2b-6ae9-406f-83ef-836799c7d38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryofClassesofRightOfUseAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_6fa5c803-9b0d-4693-8b42-36627f4164d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_51d81d0d-79a9-45ed-972b-770f9f0de1dd" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_6fa5c803-9b0d-4693-8b42-36627f4164d4" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_51d81d0d-79a9-45ed-972b-770f9f0de1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_165d396c-cfc5-484a-9bc6-2503ecc7f291" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_51d81d0d-79a9-45ed-972b-770f9f0de1dd" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_165d396c-cfc5-484a-9bc6-2503ecc7f291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_165d396c-cfc5-484a-9bc6-2503ecc7f291" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilitiesMember_7e505bdf-c8ab-44c7-9f91-78fd74516f11" xlink:href="alvo-20231231.xsd#alvo_FacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:to="loc_alvo_FacilitiesMember_7e505bdf-c8ab-44c7-9f91-78fd74516f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FleetMember_14120bc2-7bac-4971-9458-a6e7c21dbe67" xlink:href="alvo-20231231.xsd#alvo_FleetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:to="loc_alvo_FleetMember_14120bc2-7bac-4971-9458-a6e7c21dbe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_bb399644-e4d8-4c10-8209-3a1db443f2e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_035dcacb-3beb-40ac-acd9-82299b94cd30" xlink:to="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_bb399644-e4d8-4c10-8209-3a1db443f2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_f8d1ab1d-99f5-4c56-9574-4cdad6e0d2bd" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable_51d81d0d-79a9-45ed-972b-770f9f0de1dd" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_f8d1ab1d-99f5-4c56-9574-4cdad6e0d2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_3ee80f09-a965-42cb-8088-859895f12462" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems_f8d1ab1d-99f5-4c56-9574-4cdad6e0d2bd" xlink:to="loc_ifrs-full_RightofuseAssets_3ee80f09-a965-42cb-8088-859895f12462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_f363269f-6b2a-48f1-8321-cd3171bc1c0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_f363269f-6b2a-48f1-8321-cd3171bc1c0d" xlink:to="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_ebaa6c62-25a2-400d-80a4-b3c6a8a5cfb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_ifrs-full_LeaseLiabilities_ebaa6c62-25a2-400d-80a4-b3c6a8a5cfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases_a8af96e3-d51a-4eb9-867c-f90121bd6908" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases_a8af96e3-d51a-4eb9-867c-f90121bd6908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_bc33d7c7-9cd5-4907-8b71-3057f2593d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_bc33d7c7-9cd5-4907-8b71-3057f2593d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesCancelledLease_8e1906e7-ad68-4ccc-9292-40af885ddd7c" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesCancelledLease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_alvo_LeaseLiabilitiesCancelledLease_8e1906e7-ad68-4ccc-9292-40af885ddd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_83f91d7c-710a-4279-bbdc-a8e9e9931ccd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_ifrs-full_CashOutflowForLeases_83f91d7c-710a-4279-bbdc-a8e9e9931ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionDueToAssetsAcquisition_27b13200-e56e-498d-a32b-6cc965e59a7f" xlink:href="alvo-20231231.xsd#alvo_DerecognitionDueToAssetsAcquisition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_alvo_DerecognitionDueToAssetsAcquisition_27b13200-e56e-498d-a32b-6cc965e59a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesForeignCurrencyAdjustment_19028b47-9a5d-49d9-b90a-63ee0fbf203a" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesForeignCurrencyAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_alvo_LeaseLiabilitiesForeignCurrencyAdjustment_19028b47-9a5d-49d9-b90a-63ee0fbf203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseLiabilitiesTranslationDifference_090d9cdf-b5f6-4ad4-98dc-a2c50cbddfca" xlink:href="alvo-20231231.xsd#alvo_LeaseLiabilitiesTranslationDifference"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_alvo_LeaseLiabilitiesTranslationDifference_090d9cdf-b5f6-4ad4-98dc-a2c50cbddfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_4afa3eaa-9e15-4b2c-8de9-aba84393c96b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseLiabilitiesRollForward_34b26378-187d-42b6-ad52-ed6962e0f230" xlink:to="loc_ifrs-full_LeaseLiabilities_4afa3eaa-9e15-4b2c-8de9-aba84393c96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_924b838f-ca4d-46a5-9ed7-28386aa94777" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_f363269f-6b2a-48f1-8321-cd3171bc1c0d" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_924b838f-ca4d-46a5-9ed7-28386aa94777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_01cd4870-3da1-465a-891e-7355a758a95f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_f363269f-6b2a-48f1-8321-cd3171bc1c0d" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_01cd4870-3da1-465a-891e-7355a758a95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryOfLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_b3e8a234-ae18-4a63-a7b2-973e2dc6898d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_5219180b-479c-4c93-a614-2da47a82681e" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_b3e8a234-ae18-4a63-a7b2-973e2dc6898d" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_5219180b-479c-4c93-a614-2da47a82681e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_4c19fac2-3282-4cae-b88c-6610948cf9da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_5219180b-479c-4c93-a614-2da47a82681e" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_4c19fac2-3282-4cae-b88c-6610948cf9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_4c19fac2-3282-4cae-b88c-6610948cf9da" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilitiesMember_2ee4f4ee-7597-423e-b8e5-257ca9c6638a" xlink:href="alvo-20231231.xsd#alvo_FacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:to="loc_alvo_FacilitiesMember_2ee4f4ee-7597-423e-b8e5-257ca9c6638a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FleetMember_9b2da623-8f31-4525-900f-642c885fe9e2" xlink:href="alvo-20231231.xsd#alvo_FleetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:to="loc_alvo_FleetMember_9b2da623-8f31-4525-900f-642c885fe9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_b7a8c1e3-037c-44dc-a0ba-5102d99b26a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_6bf30d10-e3ea-4c10-a361-c61d1c538762" xlink:to="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_b7a8c1e3-037c-44dc-a0ba-5102d99b26a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostTable_5219180b-479c-4c93-a614-2da47a82681e" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_ccc34b1e-796d-4430-9b26-572bff045e33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_ccc34b1e-796d-4430-9b26-572bff045e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_08ed03ab-752f-44ef-9399-dfc2b12b14f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_08ed03ab-752f-44ef-9399-dfc2b12b14f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ForeignCurrencyDifferenceOnLeaseLiability_d8d77034-738a-49ba-b051-e3d917c942ef" xlink:href="alvo-20231231.xsd#alvo_ForeignCurrencyDifferenceOnLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_alvo_ForeignCurrencyDifferenceOnLeaseLiability_d8d77034-738a-49ba-b051-e3d917c942ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LossFromExtinguishmentOfLeaseLiabilities_6a6615f6-8cec-4a84-88c8-d859c8ad0bc3" xlink:href="alvo-20231231.xsd#alvo_LossFromExtinguishmentOfLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_alvo_LossFromExtinguishmentOfLeaseLiabilities_6a6615f6-8cec-4a84-88c8-d859c8ad0bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseCostRecognizedInProfitAndLoss_8f2227d5-3349-4de7-b238-87e9e83b3cdd" xlink:href="alvo-20231231.xsd#alvo_LeaseCostRecognizedInProfitAndLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_alvo_LeaseCostRecognizedInProfitAndLoss_8f2227d5-3349-4de7-b238-87e9e83b3cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_f118824b-7d1e-4b34-829d-2f3cb85ab133" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems_cd288bea-c27e-41bf-88e7-057d8f814389" xlink:to="loc_ifrs-full_RightofuseAssets_f118824b-7d1e-4b34-829d-2f3cb85ab133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1820aa9b-5371-4862-89b7-7d5363e3ebf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_8afe0404-758f-4f8c-925e-f7b1b0ea4f9f" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1820aa9b-5371-4862-89b7-7d5363e3ebf8" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_8afe0404-758f-4f8c-925e-f7b1b0ea4f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_c1b147d0-0c9a-4b6e-8b72-089ad5313776" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_8afe0404-758f-4f8c-925e-f7b1b0ea4f9f" xlink:to="loc_ifrs-full_MaturityAxis_c1b147d0-0c9a-4b6e-8b72-089ad5313776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_c1b147d0-0c9a-4b6e-8b72-089ad5313776" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_811e498c-2640-4152-bef1-f75c50c6b20b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_811e498c-2640-4152-bef1-f75c50c6b20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_d98d1b91-4df4-4b18-a324-abe3fd62fc9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_d98d1b91-4df4-4b18-a324-abe3fd62fc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_4764b751-2aa0-41a7-a784-54bb1300f81c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2ba00e2f-5887-459f-b10d-1f4e7b80245b" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_4764b751-2aa0-41a7-a784-54bb1300f81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_d6a48431-24f3-4f29-b576-e017fec1913a" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable_8afe0404-758f-4f8c-925e-f7b1b0ea4f9f" xlink:to="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_d6a48431-24f3-4f29-b576-e017fec1913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_1e485b82-34dc-4afa-8929-e009cdd3d4bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems_d6a48431-24f3-4f29-b576-e017fec1913a" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_1e485b82-34dc-4afa-8929-e009cdd3d4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GoodwillSummaryofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/GoodwillSummaryofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfGoodwillAbstract_eff76b6e-18c8-4a8c-a3aa-7e63f8fbd4c0" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GoodwillBalancesRollForward_e1f3f04d-c4fc-4522-bdb1-02b2146759e0" xlink:href="alvo-20231231.xsd#alvo_GoodwillBalancesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfGoodwillAbstract_eff76b6e-18c8-4a8c-a3aa-7e63f8fbd4c0" xlink:to="loc_alvo_GoodwillBalancesRollForward_e1f3f04d-c4fc-4522-bdb1-02b2146759e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_44eca41f-5e81-417c-913e-225ec9c0aa8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GoodwillBalancesRollForward_e1f3f04d-c4fc-4522-bdb1-02b2146759e0" xlink:to="loc_ifrs-full_Goodwill_44eca41f-5e81-417c-913e-225ec9c0aa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_863dda3d-ebfe-4b41-8df8-9a8772c0166a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GoodwillBalancesRollForward_e1f3f04d-c4fc-4522-bdb1-02b2146759e0" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill_863dda3d-ebfe-4b41-8df8-9a8772c0166a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_9d089e85-081e-493e-979b-9ed5b4aa6c9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_GoodwillBalancesRollForward_e1f3f04d-c4fc-4522-bdb1-02b2146759e0" xlink:to="loc_ifrs-full_Goodwill_9d089e85-081e-493e-979b-9ed5b4aa6c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/GoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#GoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/GoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfGoodwillAbstract_e3e3c7d3-73b9-4bdd-850e-6f5672d0b0e0" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfGoodwillTable_425ee260-4624-42cf-927a-c285171605e2" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfGoodwillAbstract_e3e3c7d3-73b9-4bdd-850e-6f5672d0b0e0" xlink:to="loc_alvo_DisclosureOfGoodwillTable_425ee260-4624-42cf-927a-c285171605e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfGoodwillTable_425ee260-4624-42cf-927a-c285171605e2" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_7020c94d-a070-4a14-bad2-a3a55553a823" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_84ab8dca-0614-4b08-9e0c-9c6bf1b491a7" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_7020c94d-a070-4a14-bad2-a3a55553a823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_937158f8-d23e-47ae-a59d-14841b8bc4a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_7020c94d-a070-4a14-bad2-a3a55553a823" xlink:to="loc_ifrs-full_GoodwillMember_937158f8-d23e-47ae-a59d-14841b8bc4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfGoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfGoodwillTable_425ee260-4624-42cf-927a-c285171605e2" xlink:to="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_32e9d0e8-3e3f-4587-8ab1-8c737e0bb2df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:to="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_32e9d0e8-3e3f-4587-8ab1-8c737e0bb2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_781a0132-ca2e-423c-a6cb-723a8fb3d1c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:to="loc_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_781a0132-ca2e-423c-a6cb-723a8fb3d1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_49768db5-ae73-4632-84ad-0692b3db6770" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfGoodwillLineItems_ca8e131b-3620-49b7-bc80-c5367a1acd26" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_49768db5-ae73-4632-84ad-0692b3db6770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_9cb7ea66-39d5-45c9-9714-5de13851e77b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_9cb7ea66-39d5-45c9-9714-5de13851e77b" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc169c4c-fcec-4ec8-a516-a9419f1a0e36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc169c4c-fcec-4ec8-a516-a9419f1a0e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_2216fdbb-ccbc-436e-8ec2-08e714737c74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fc169c4c-fcec-4ec8-a516-a9419f1a0e36" xlink:to="loc_ifrs-full_CarryingAmountMember_2216fdbb-ccbc-436e-8ec2-08e714737c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_f4b936f0-40c4-4e8d-affc-da5e050b389c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_2216fdbb-ccbc-436e-8ec2-08e714737c74" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_f4b936f0-40c4-4e8d-affc-da5e050b389c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationMember_1b13bd15-f0c8-4e2c-914c-f54870d91610" xlink:href="alvo-20231231.xsd#alvo_AmortizationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_2216fdbb-ccbc-436e-8ec2-08e714737c74" xlink:to="loc_alvo_AmortizationMember_1b13bd15-f0c8-4e2c-914c-f54870d91610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_062322e5-be33-44c0-92f9-c01d58cd93d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_062322e5-be33-44c0-92f9-c01d58cd93d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_062322e5-be33-44c0-92f9-c01d58cd93d1" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_b7b8a1b9-e8a7-4409-9c35-9554550bd61d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:to="loc_ifrs-full_ComputerSoftwareMember_b7b8a1b9-e8a7-4409-9c35-9554550bd61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember_9ba07377-51ce-422e-817f-762784a09ad1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CustomerrelatedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:to="loc_ifrs-full_CustomerrelatedIntangibleAssetsMember_9ba07377-51ce-422e-817f-762784a09ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_84731698-1dc8-4a99-a800-34c9f228bd65" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_9175696b-1f30-4cf1-a01a-7a82190a00fe" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_84731698-1dc8-4a99-a800-34c9f228bd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_a792ceae-c8ea-4c4c-ba29-5df667fc8b21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_cb744d7e-2ecb-485c-9786-8550907f4766" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_a792ceae-c8ea-4c4c-ba29-5df667fc8b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:href="alvo-20231231.xsd#alvo_IntangibleAssetsOtherThanGoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_a792ceae-c8ea-4c4c-ba29-5df667fc8b21" xlink:to="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1b88e66c-ff30-47bd-bf34-870a8ccd9219" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1b88e66c-ff30-47bd-bf34-870a8ccd9219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4a5572d3-30be-4afa-b59c-719c40607c98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4a5572d3-30be-4afa-b59c-719c40607c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ca0aa162-aab3-49f1-a94b-b43cd4b4a603" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ca0aa162-aab3-49f1-a94b-b43cd4b4a603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_c72494be-3103-4752-b8d9-56a00d3740e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_c72494be-3103-4752-b8d9-56a00d3740e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_660ef786-1aeb-4198-9cdd-7829b0da91fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_660ef786-1aeb-4198-9cdd-7829b0da91fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_9cd4035d-02ed-40c3-85cf-4d75ae9a1814" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_9cd4035d-02ed-40c3-85cf-4d75ae9a1814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_03756fd1-9675-4ae0-88b0-7abf4fd7de85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_03756fd1-9675-4ae0-88b0-7abf4fd7de85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_05cd0965-f168-4975-8093-a5b95ef872e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IntangibleAssetsOtherThanGoodwillRollForward_8642b0d2-b215-4d03-a2e0-5f8aff8b975d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_05cd0965-f168-4975-8093-a5b95ef872e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_47ec70e4-f371-436a-859a-3fc238b8df19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_936d3ab1-1642-4a92-9b3c-ae813c93d456" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_47ec70e4-f371-436a-859a-3fc238b8df19" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_936d3ab1-1642-4a92-9b3c-ae813c93d456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_18f5d644-f32f-4643-ad3e-e083e39fcff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_936d3ab1-1642-4a92-9b3c-ae813c93d456" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_18f5d644-f32f-4643-ad3e-e083e39fcff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_18f5d644-f32f-4643-ad3e-e083e39fcff0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_b0212c0f-45e8-425c-a73b-b9a49338f66e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:to="loc_ifrs-full_CostOfSalesMember_b0212c0f-45e8-425c-a73b-b9a49338f66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentMember_5caf101c-8d11-47f4-ad8e-9dd9850372bc" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:to="loc_alvo_ResearchAndDevelopmentMember_5caf101c-8d11-47f4-ad8e-9dd9850372bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeMember_3a6eea43-fa07-40d4-803a-a0a1331169e5" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_ddf66f74-f66c-46cb-afe8-6fed624b19b1" xlink:to="loc_alvo_GeneralAndAdministrativeMember_3a6eea43-fa07-40d4-803a-a0a1331169e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_d4103ba5-db92-419c-916a-c78e629dba2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_936d3ab1-1642-4a92-9b3c-ae813c93d456" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_d4103ba5-db92-419c-916a-c78e629dba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_334b4e0d-102e-4ed2-a065-258d3010d8fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_d4103ba5-db92-419c-916a-c78e629dba2f" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_334b4e0d-102e-4ed2-a065-258d3010d8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherIntangibleassetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_6fdf8b1a-e561-4254-86dd-eea5731f0c62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAbstract_6fdf8b1a-e561-4254-86dd-eea5731f0c62" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7f055ccb-fcb7-4fbf-9673-3b1b30e66480" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7f055ccb-fcb7-4fbf-9673-3b1b30e66480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_762d2eb7-7706-460d-a0c5-eeaac59c2010" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7f055ccb-fcb7-4fbf-9673-3b1b30e66480" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_762d2eb7-7706-460d-a0c5-eeaac59c2010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntangibleAssetsWithFiniteLivedMember_3dcfbaae-639d-438a-a32b-00cec39cb064" xlink:href="alvo-20231231.xsd#alvo_IntangibleAssetsWithFiniteLivedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_762d2eb7-7706-460d-a0c5-eeaac59c2010" xlink:to="loc_alvo_IntangibleAssetsWithFiniteLivedMember_3dcfbaae-639d-438a-a32b-00cec39cb064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntellectualPropertyRightsMember_de4d149d-e447-46de-8b2e-50af39110261" xlink:href="alvo-20231231.xsd#alvo_IntellectualPropertyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_762d2eb7-7706-460d-a0c5-eeaac59c2010" xlink:to="loc_alvo_IntellectualPropertyRightsMember_de4d149d-e447-46de-8b2e-50af39110261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationAxis_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_alvo_IncomeStatementsLocationAxis_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_f2a306c7-984f-448f-8115-cc4cec04f401" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationAxis_f7c25fd7-4ef7-41a7-85af-8fd5c03715b8" xlink:to="loc_alvo_IncomeStatementsLocationDomain_f2a306c7-984f-448f-8115-cc4cec04f401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_53fce948-9ba9-4f23-be19-4cef2ac6e141" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationDomain_f2a306c7-984f-448f-8115-cc4cec04f401" xlink:to="loc_ifrs-full_CostOfSalesMember_53fce948-9ba9-4f23-be19-4cef2ac6e141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember_a8f4f4a1-d8b2-4969-aec2-7a796c6acf21" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationDomain_f2a306c7-984f-448f-8115-cc4cec04f401" xlink:to="loc_alvo_GeneralAndAdministrativeExpensesMember_a8f4f4a1-d8b2-4969-aec2-7a796c6acf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ba2a0334-f758-4c75-b4ba-458a875d1213" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_srt_ProductOrServiceAxis_ba2a0334-f758-4c75-b4ba-458a875d1213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5118f31f-958e-47c5-9431-c3c812da2a31" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ba2a0334-f758-4c75-b4ba-458a875d1213" xlink:to="loc_srt_ProductsAndServicesDomain_5118f31f-958e-47c5-9431-c3c812da2a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AVT23Member_7f17c4af-3972-4426-8ca8-ede631319f02" xlink:href="alvo-20231231.xsd#alvo_AVT23Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5118f31f-958e-47c5-9431-c3c812da2a31" xlink:to="loc_alvo_AVT23Member_7f17c4af-3972-4426-8ca8-ede631319f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_898d0a7b-548e-488b-9296-14de2c4ac9c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_srt_CounterpartyNameAxis_898d0a7b-548e-488b-9296-14de2c4ac9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65de5cae-842f-4f2f-bf99-d47d382035b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_898d0a7b-548e-488b-9296-14de2c4ac9c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65de5cae-842f-4f2f-bf99-d47d382035b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_KashivMember_fb1e1d6f-95d0-4e51-86f5-ac5f1704e42a" xlink:href="alvo-20231231.xsd#alvo_KashivMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65de5cae-842f-4f2f-bf99-d47d382035b0" xlink:to="loc_alvo_KashivMember_fb1e1d6f-95d0-4e51-86f5-ac5f1704e42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_srt_StatementScenarioAxis_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_565d112b-0a55-46a7-a5e9-13d6c7b17825" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8418ca52-12ec-4b1e-8a94-c0f8998f9b2e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_565d112b-0a55-46a7-a5e9-13d6c7b17825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ba472a4c-24ac-438e-a8d2-97da8ed06c16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_565d112b-0a55-46a7-a5e9-13d6c7b17825" xlink:to="loc_srt_ScenarioForecastMember_ba472a4c-24ac-438e-a8d2-97da8ed06c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_a27530fb-4894-46f1-8bab-22d0bfb676f2" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLoss_c04d89be-50cd-49e3-91c4-d8ac0fd155df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_ifrs-full_ImpairmentLoss_c04d89be-50cd-49e3-91c4-d8ac0fd155df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_a7e6fbd1-2735-47cb-a3af-0d8c7d571031" xlink:href="alvo-20231231.xsd#alvo_DerecognitionIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_a7e6fbd1-2735-47cb-a3af-0d8c7d571031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PaymentForContractualCommitment_70fd83c3-316d-48d6-a5c7-f5ed52d9f065" xlink:href="alvo-20231231.xsd#alvo_PaymentForContractualCommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_alvo_PaymentForContractualCommitment_70fd83c3-316d-48d6-a5c7-f5ed52d9f065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_f12f2a73-1f69-47e7-82ad-6b5026c43a61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_f12f2a73-1f69-47e7-82ad-6b5026c43a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractualCapitalCommitmentContingentLiability_028dd2ea-c0df-4e22-bcf3-f00bdadd22af" xlink:href="alvo-20231231.xsd#alvo_ContractualCapitalCommitmentContingentLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_alvo_ContractualCapitalCommitmentContingentLiability_028dd2ea-c0df-4e22-bcf3-f00bdadd22af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContractualCapitalCommitmentsTerm_a4475642-220b-4f05-a9ca-ee0ade9b13c3" xlink:href="alvo-20231231.xsd#alvo_ContractualCapitalCommitmentsTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_50659f57-7ef3-42e8-9266-b179d2e57584" xlink:to="loc_alvo_ContractualCapitalCommitmentsTerm_a4475642-220b-4f05-a9ca-ee0ade9b13c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_9f4b8e09-5782-4a7c-a94f-6f1194f95c98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCashAndCashEquivalentsTable_2c173d8d-b987-45e2-a8fa-afd9d01595f4" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_9f4b8e09-5782-4a7c-a94f-6f1194f95c98" xlink:to="loc_alvo_DisclosureOfCashAndCashEquivalentsTable_2c173d8d-b987-45e2-a8fa-afd9d01595f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a44e02c1-ed6d-453c-ac99-9b2037655ced" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfCashAndCashEquivalentsTable_2c173d8d-b987-45e2-a8fa-afd9d01595f4" xlink:to="loc_srt_StatementGeographicalAxis_a44e02c1-ed6d-453c-ac99-9b2037655ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c5cf91e8-b628-430b-966f-f946b3b55d3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a44e02c1-ed6d-453c-ac99-9b2037655ced" xlink:to="loc_srt_SegmentGeographicalDomain_c5cf91e8-b628-430b-966f-f946b3b55d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b9d99750-824b-40ee-abd2-9d5c442f51e0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5cf91e8-b628-430b-966f-f946b3b55d3c" xlink:to="loc_country_US_b9d99750-824b-40ee-abd2-9d5c442f51e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignCountriesMember_d1efafb7-71f0-4757-831d-be950c341d93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignCountriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5cf91e8-b628-430b-966f-f946b3b55d3c" xlink:to="loc_ifrs-full_ForeignCountriesMember_d1efafb7-71f0-4757-831d-be950c341d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCashAndCashEquivalentsLineItems_6d924f31-e6a3-49dc-a01f-2ddbc06608a3" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfCashAndCashEquivalentsTable_2c173d8d-b987-45e2-a8fa-afd9d01595f4" xlink:to="loc_alvo_DisclosureOfCashAndCashEquivalentsLineItems_6d924f31-e6a3-49dc-a01f-2ddbc06608a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_821a9107-b6c7-4bfb-8660-145199ff42ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfCashAndCashEquivalentsLineItems_6d924f31-e6a3-49dc-a01f-2ddbc06608a3" xlink:to="loc_ifrs-full_CashAndCashEquivalents_821a9107-b6c7-4bfb-8660-145199ff42ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#CashAndCashEquivalentsSummaryofRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_1c31cc0d-4cd6-4463-826e-f5da3fff040e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CashAndCashEquivalentsRollForward_116bfeed-ae86-4953-9b7b-f70afcdbe8cc" xlink:href="alvo-20231231.xsd#alvo_CashAndCashEquivalentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_1c31cc0d-4cd6-4463-826e-f5da3fff040e" xlink:to="loc_alvo_CashAndCashEquivalentsRollForward_116bfeed-ae86-4953-9b7b-f70afcdbe8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_61c30c41-ee8f-4322-aaae-479df0586d5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CashAndCashEquivalentsRollForward_116bfeed-ae86-4953-9b7b-f70afcdbe8cc" xlink:to="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_61c30c41-ee8f-4322-aaae-479df0586d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionRestrictedCashAndCashEquivalents_7df2cbaf-9b83-4eb7-b954-32dd7ae147aa" xlink:href="alvo-20231231.xsd#alvo_AdditionRestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CashAndCashEquivalentsRollForward_116bfeed-ae86-4953-9b7b-f70afcdbe8cc" xlink:to="loc_alvo_AdditionRestrictedCashAndCashEquivalents_7df2cbaf-9b83-4eb7-b954-32dd7ae147aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InterestIncomeOnCash_5b27c7d7-4ed7-4ae3-b008-ec4c54341a55" xlink:href="alvo-20231231.xsd#alvo_InterestIncomeOnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CashAndCashEquivalentsRollForward_116bfeed-ae86-4953-9b7b-f70afcdbe8cc" xlink:to="loc_alvo_InterestIncomeOnCash_5b27c7d7-4ed7-4ae3-b008-ec4c54341a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_e3c7d8b3-30c9-4cfd-988b-52744825573d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CashAndCashEquivalentsRollForward_116bfeed-ae86-4953-9b7b-f70afcdbe8cc" xlink:to="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_e3c7d8b3-30c9-4cfd-988b-52744825573d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#InventoriesSummaryofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_74a570af-9bdc-43c1-ad9d-b2d555850520" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterialsAndConsumablesUsed_3834d75b-d343-472b-9f0c-8d2e37bf1cc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterialsAndConsumablesUsed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_74a570af-9bdc-43c1-ad9d-b2d555850520" xlink:to="loc_ifrs-full_RawMaterialsAndConsumablesUsed_3834d75b-d343-472b-9f0c-8d2e37bf1cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_c50765b9-297d-4138-b158-41abaf8b9ac3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_74a570af-9bdc-43c1-ad9d-b2d555850520" xlink:to="loc_ifrs-full_WorkInProgress_c50765b9-297d-4138-b158-41abaf8b9ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_98c33df2-216d-4662-a857-8714c893c577" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_74a570af-9bdc-43c1-ad9d-b2d555850520" xlink:to="loc_ifrs-full_FinishedGoods_98c33df2-216d-4662-a857-8714c893c577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InventoryReserves_55950d53-7578-4e7e-a9ed-21f0e42aa7d7" xlink:href="alvo-20231231.xsd#alvo_InventoryReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_74a570af-9bdc-43c1-ad9d-b2d555850520" xlink:to="loc_alvo_InventoryReserves_55950d53-7578-4e7e-a9ed-21f0e42aa7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_784ec061-f420-4357-bf1f-53ef8fef14d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_74a570af-9bdc-43c1-ad9d-b2d555850520" xlink:to="loc_ifrs-full_Inventories_784ec061-f420-4357-bf1f-53ef8fef14d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InventoriesAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#InventoriesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/InventoriesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_ab17446d-7237-4bf9-9c9d-f80082ccfd28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfInventoriesTable_44dca31d-148d-44a8-94be-4974222ade03" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfInventoriesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_ab17446d-7237-4bf9-9c9d-f80082ccfd28" xlink:to="loc_alvo_DisclosureOfInventoriesTable_44dca31d-148d-44a8-94be-4974222ade03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_3d8d1b50-5dc4-4243-b458-665836c930f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfInventoriesTable_44dca31d-148d-44a8-94be-4974222ade03" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_3d8d1b50-5dc4-4243-b458-665836c930f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_9aed1e9f-b326-42c5-8146-b4d2041e56ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_3d8d1b50-5dc4-4243-b458-665836c930f7" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_9aed1e9f-b326-42c5-8146-b4d2041e56ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_5188c723-a8cb-40d3-b83b-f7c991f43213" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_9aed1e9f-b326-42c5-8146-b4d2041e56ac" xlink:to="loc_ifrs-full_CostOfSalesMember_5188c723-a8cb-40d3-b83b-f7c991f43213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfInventoriesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfInventoriesTable_44dca31d-148d-44a8-94be-4974222ade03" xlink:to="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_ac1cc0a0-a8eb-4c6a-815d-7f2e48c101d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:to="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_ac1cc0a0-a8eb-4c6a-815d-7f2e48c101d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoryWritedown2011_46f013f3-9c49-4383-bd95-55607f6b4b85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:to="loc_ifrs-full_InventoryWritedown2011_46f013f3-9c49-4383-bd95-55607f6b4b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfInventoryWritedown_27464887-4483-4b0c-ab53-8a8b3a0077ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfInventoryWritedown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfInventoriesLineItems_f1b447e1-8fa9-4150-8b07-b711281a7cd2" xlink:to="loc_ifrs-full_ReversalOfInventoryWritedown_27464887-4483-4b0c-ab53-8a8b3a0077ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsAbstract_591fe8e9-dc15-4c8a-bc03-f4949b8649e4" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_555b45c9-da00-4dd2-bc33-54627bbeb97d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_591fe8e9-dc15-4c8a-bc03-f4949b8649e4" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_555b45c9-da00-4dd2-bc33-54627bbeb97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_3ccca18e-ecf9-4e9e-9f89-8bd2ddff92bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_591fe8e9-dc15-4c8a-bc03-f4949b8649e4" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_3ccca18e-ecf9-4e9e-9f89-8bd2ddff92bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsReceivableFromConvertibleBonds_16db8aa7-924a-4583-9ec5-9be82fbd967b" xlink:href="alvo-20231231.xsd#alvo_ProceedsReceivableFromConvertibleBonds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_591fe8e9-dc15-4c8a-bc03-f4949b8649e4" xlink:to="loc_alvo_ProceedsReceivableFromConvertibleBonds_16db8aa7-924a-4583-9ec5-9be82fbd967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerivaiveAssets_ce7ac977-e509-4dc4-b0a3-22d4f2c5e088" xlink:href="alvo-20231231.xsd#alvo_DerivaiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_591fe8e9-dc15-4c8a-bc03-f4949b8649e4" xlink:to="loc_alvo_DerivaiveAssets_ce7ac977-e509-4dc4-b0a3-22d4f2c5e088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_254d6e2a-e8dd-435b-8df1-02d6ee19f4bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_591fe8e9-dc15-4c8a-bc03-f4949b8649e4" xlink:to="loc_ifrs-full_OtherCurrentReceivables_254d6e2a-e8dd-435b-8df1-02d6ee19f4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_dbbae012-34ed-4aaa-9873-972098ee4795" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_591fe8e9-dc15-4c8a-bc03-f4949b8649e4" xlink:to="loc_ifrs-full_OtherCurrentAssets_dbbae012-34ed-4aaa-9873-972098ee4795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsAbstract_285f478f-23a0-4a20-aba0-ec629a773a41" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsAbstract_285f478f-23a0-4a20-aba0-ec629a773a41" xlink:to="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_968f78e1-a849-46f0-8937-a66ea08c12d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:to="loc_srt_ProductOrServiceAxis_968f78e1-a849-46f0-8937-a66ea08c12d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a39b5cb1-832d-49ea-916d-5f55d484739e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_968f78e1-a849-46f0-8937-a66ea08c12d3" xlink:to="loc_srt_ProductsAndServicesDomain_a39b5cb1-832d-49ea-916d-5f55d484739e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AVT23Member_c3007138-90be-4a33-94f7-8beca9d37ade" xlink:href="alvo-20231231.xsd#alvo_AVT23Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a39b5cb1-832d-49ea-916d-5f55d484739e" xlink:to="loc_alvo_AVT23Member_c3007138-90be-4a33-94f7-8beca9d37ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7ca12449-83d4-4c2b-bec0-e063af60d150" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_8417a103-6f0f-4abd-9fe6-5bdebce0eb4c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7ca12449-83d4-4c2b-bec0-e063af60d150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IntellectualPropertyRightsMember_f5ff62f5-3b92-41d1-8a03-f8e61d5a958a" xlink:href="alvo-20231231.xsd#alvo_IntellectualPropertyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7ca12449-83d4-4c2b-bec0-e063af60d150" xlink:to="loc_alvo_IntellectualPropertyRightsMember_f5ff62f5-3b92-41d1-8a03-f8e61d5a958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsTable_6b0412a7-a2a3-4cc8-91b6-f3db3ed6d978" xlink:to="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_3681efc2-5b24-4ab6-b8a9-f2612afb9350" xlink:href="alvo-20231231.xsd#alvo_DerecognitionIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:to="loc_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill_3681efc2-5b24-4ab6-b8a9-f2612afb9350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerecognitionPrepaidDevelopmentCosts_362411de-acf9-4d77-9dcf-3ff3e35c5a2a" xlink:href="alvo-20231231.xsd#alvo_DerecognitionPrepaidDevelopmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:to="loc_alvo_DerecognitionPrepaidDevelopmentCosts_362411de-acf9-4d77-9dcf-3ff3e35c5a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_e7f0e4cc-9247-4881-880a-bd7ab56f7e2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentAssetsLineItems_b6d47a44-1ffe-44b2-8408-1ee655880f8d" xlink:to="loc_ifrs-full_OtherCurrentAssets_e7f0e4cc-9247-4881-880a-bd7ab56f7e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareCapitalAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_e6f97502-433a-4ad7-bf1d-21f33bc305ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_e6f97502-433a-4ad7-bf1d-21f33bc305ff" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_842b606e-ff17-408e-bbe4-eeb2a9cceb64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_842b606e-ff17-408e-bbe4-eeb2a9cceb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_842b606e-ff17-408e-bbe4-eeb2a9cceb64" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassAAndClassBOrdinarySharesMember_d350cd36-e9b6-4f86-878c-6160b021e74a" xlink:href="alvo-20231231.xsd#alvo_ClassAAndClassBOrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_ClassAAndClassBOrdinarySharesMember_d350cd36-e9b6-4f86-878c-6160b021e74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_f8218550-f357-4ef4-be16-0b5513c4fb1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_ifrs-full_OrdinarySharesMember_f8218550-f357-4ef4-be16-0b5513c4fb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_2dd6049b-3ce7-4711-9cde-5560992671e8" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_2dd6049b-3ce7-4711-9cde-5560992671e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassAOacbOrdinarySharesMember_336bf40c-f953-4876-98ae-a68d765018ff" xlink:href="alvo-20231231.xsd#alvo_ClassAOacbOrdinarySharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_ClassAOacbOrdinarySharesMember_336bf40c-f953-4876-98ae-a68d765018ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassBOacbOrdinarySharesMember_ba446065-fd9f-401b-be58-ba8f32095167" xlink:href="alvo-20231231.xsd#alvo_ClassBOacbOrdinarySharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_ClassBOacbOrdinarySharesMember_ba446065-fd9f-401b-be58-ba8f32095167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_e4ecd157-3e23-49fe-b35c-245bab11f18c" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9a6b24f1-c81d-4c74-bde7-bb254ebb3a0b" xlink:to="loc_alvo_EarnoutSharesMember_e4ecd157-3e23-49fe-b35c-245bab11f18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockExchangeDescriptionAxis_05770a67-8646-4398-889e-50f862090110" xlink:href="alvo-20231231.xsd#alvo_StockExchangeDescriptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_alvo_StockExchangeDescriptionAxis_05770a67-8646-4398-889e-50f862090110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockExchangeDescriptionDomain_dbbfc157-5b9b-4995-bf1a-3eb682aae535" xlink:href="alvo-20231231.xsd#alvo_StockExchangeDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_StockExchangeDescriptionAxis_05770a67-8646-4398-889e-50f862090110" xlink:to="loc_alvo_StockExchangeDescriptionDomain_dbbfc157-5b9b-4995-bf1a-3eb682aae535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExchangeOfPredecessorOrdinarySharesMember_b153e043-92d6-47a6-8489-12ad0ff10eb2" xlink:href="alvo-20231231.xsd#alvo_ExchangeOfPredecessorOrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_StockExchangeDescriptionDomain_dbbfc157-5b9b-4995-bf1a-3eb682aae535" xlink:to="loc_alvo_ExchangeOfPredecessorOrdinarySharesMember_b153e043-92d6-47a6-8489-12ad0ff10eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExchangeOfClassAOacbOrdinarySharesMember_a19657f4-2a11-4d45-9d32-8b423dd38041" xlink:href="alvo-20231231.xsd#alvo_ExchangeOfClassAOacbOrdinarySharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_StockExchangeDescriptionDomain_dbbfc157-5b9b-4995-bf1a-3eb682aae535" xlink:to="loc_alvo_ExchangeOfClassAOacbOrdinarySharesMember_a19657f4-2a11-4d45-9d32-8b423dd38041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockAxis_379edf4b-f1a2-40ab-8f74-361edfc03f4f" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_alvo_SaleOfStockAxis_379edf4b-f1a2-40ab-8f74-361edfc03f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockDomain_207e4c30-9dcf-4ebe-99bd-d2126a67acd3" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_SaleOfStockAxis_379edf4b-f1a2-40ab-8f74-361edfc03f4f" xlink:to="loc_alvo_SaleOfStockDomain_207e4c30-9dcf-4ebe-99bd-d2126a67acd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrivatePlacementsMember_eef418b1-0dfa-4c33-a6bf-177597c565f6" xlink:href="alvo-20231231.xsd#alvo_PrivatePlacementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_SaleOfStockDomain_207e4c30-9dcf-4ebe-99bd-d2126a67acd3" xlink:to="loc_alvo_PrivatePlacementsMember_eef418b1-0dfa-4c33-a6bf-177597c565f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_0cdb01af-6d7d-4f68-9ba1-561841a11259" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_0cdb01af-6d7d-4f68-9ba1-561841a11259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_56daa20d-00ab-4dbe-ade7-2bb678348e4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_0cdb01af-6d7d-4f68-9ba1-561841a11259" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_56daa20d-00ab-4dbe-ade7-2bb678348e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_f69bc88c-99bc-40d1-b8ff-c7e902a2375b" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_56daa20d-00ab-4dbe-ade7-2bb678348e4d" xlink:to="loc_alvo_SeniorBondWarrantsMember_f69bc88c-99bc-40d1-b8ff-c7e902a2375b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2b0a62e6-2937-4f32-bb8d-285a5d1b370a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_srt_StatementGeographicalAxis_2b0a62e6-2937-4f32-bb8d-285a5d1b370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2247f900-d3cf-4872-b758-dc3ebe9c1bd7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2b0a62e6-2937-4f32-bb8d-285a5d1b370a" xlink:to="loc_srt_SegmentGeographicalDomain_2247f900-d3cf-4872-b758-dc3ebe9c1bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ForeignCountriesMember_b268f0c6-9c3a-4c84-9a64-375ececa8576" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignCountriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2247f900-d3cf-4872-b758-dc3ebe9c1bd7" xlink:to="loc_ifrs-full_ForeignCountriesMember_b268f0c6-9c3a-4c84-9a64-375ececa8576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ce6fffa3-28d0-4ee1-8ebc-297a6af9ac53" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SharesAuthorizedValue_cde68196-ec11-4273-8cb6-3765c038dc8c" xlink:href="alvo-20231231.xsd#alvo_SharesAuthorizedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_SharesAuthorizedValue_cde68196-ec11-4273-8cb6-3765c038dc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_39c187b2-c0f5-4069-8e17-05d9a6ce537a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_39c187b2-c0f5-4069-8e17-05d9a6ce537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_47286a52-6455-42e7-9723-95292c6f2d12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_47286a52-6455-42e7-9723-95292c6f2d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_6488f9d8-9f20-4d7b-a496-8d8f2350cb45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_ParValuePerShare_6488f9d8-9f20-4d7b-a496-8d8f2350cb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalReorganizationEventSharesIssued_f919722b-1918-4164-b2d0-be54b1e93eb7" xlink:href="alvo-20231231.xsd#alvo_CapitalReorganizationEventSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_CapitalReorganizationEventSharesIssued_f919722b-1918-4164-b2d0-be54b1e93eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1d7eda76-99c6-4353-8071-732bd3e044bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_1d7eda76-99c6-4353-8071-732bd3e044bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalReorganizationSharesIssued_e0857732-77e9-4545-9a2b-7a8cef2c5c17" xlink:href="alvo-20231231.xsd#alvo_CapitalReorganizationSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_CapitalReorganizationSharesIssued_e0857732-77e9-4545-9a2b-7a8cef2c5c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockIssuedUnderPipeFinancingShares_ab29698e-3c46-4c69-ac68-6654c9e07f19" xlink:href="alvo-20231231.xsd#alvo_StockIssuedUnderPipeFinancingShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_StockIssuedUnderPipeFinancingShares_ab29698e-3c46-4c69-ac68-6654c9e07f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaid_ccbd2501-535d-4ff7-b969-5c2f16e63ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_DividendsPaid_ccbd2501-535d-4ff7-b969-5c2f16e63ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_17aa09df-2904-49b9-b0fb-8fc8ece2a09c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_17aa09df-2904-49b9-b0fb-8fc8ece2a09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockIssuePricePerShare_150592bd-b6cd-4260-87c7-b97a25dcb409" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockIssuePricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_SaleOfStockIssuePricePerShare_150592bd-b6cd-4260-87c7-b97a25dcb409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_a8a4a6fc-a992-49ec-96e2-d3723c183482" xlink:href="alvo-20231231.xsd#alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_a8a4a6fc-a992-49ec-96e2-d3723c183482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommonStockHeldBySubsidiaries_f4250bf4-e23e-4f5c-bdbd-eba58dc0a887" xlink:href="alvo-20231231.xsd#alvo_CommonStockHeldBySubsidiaries"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_alvo_CommonStockHeldBySubsidiaries_f4250bf4-e23e-4f5c-bdbd-eba58dc0a887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d86e901e-60e7-413c-b4cf-ebbd5236d845" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2b23b568-436c-4c15-9b59-bd88fc450d5c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d86e901e-60e7-413c-b4cf-ebbd5236d845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareCapitalSummaryofShareCapitalandSharePremiumDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1fc243d8-322c-4a51-b3f0-9d705af5e2a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7574a384-ddfa-4903-90f2-4dff83649868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1fc243d8-322c-4a51-b3f0-9d705af5e2a6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7574a384-ddfa-4903-90f2-4dff83649868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_61bc2f74-2a20-4325-894a-6894556b4e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7574a384-ddfa-4903-90f2-4dff83649868" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_61bc2f74-2a20-4325-894a-6894556b4e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_5c42d62f-c0cb-4783-a765-6f2db0851e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_61bc2f74-2a20-4325-894a-6894556b4e22" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_5c42d62f-c0cb-4783-a765-6f2db0851e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_63282242-0d78-4601-b496-29154b2bb30f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_5c42d62f-c0cb-4783-a765-6f2db0851e6e" xlink:to="loc_ifrs-full_OrdinarySharesMember_63282242-0d78-4601-b496-29154b2bb30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_009b3598-f4d4-411e-988b-d229d55a55f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7574a384-ddfa-4903-90f2-4dff83649868" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_009b3598-f4d4-411e-988b-d229d55a55f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_8c986114-e73d-472c-8211-1cdc5f26e1e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_009b3598-f4d4-411e-988b-d229d55a55f3" xlink:to="loc_ifrs-full_NumberOfSharesIssued_8c986114-e73d-472c-8211-1cdc5f26e1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareCapitalAndSharePremium_eced371d-d013-4ac9-8773-d79b680d2c3a" xlink:href="alvo-20231231.xsd#alvo_ShareCapitalAndSharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_009b3598-f4d4-411e-988b-d229d55a55f3" xlink:to="loc_alvo_ShareCapitalAndSharePremium_eced371d-d013-4ac9-8773-d79b680d2c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_a94d6f1e-8748-46de-b786-995d9cbecd22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_a94d6f1e-8748-46de-b786-995d9cbecd22" xlink:to="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_972b8cbd-de9b-4248-830f-4baa9cb495fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_972b8cbd-de9b-4248-830f-4baa9cb495fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_972b8cbd-de9b-4248-830f-4baa9cb495fb" xlink:to="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_b2234379-6945-4c89-bd1d-42dbfc3913c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:to="loc_ifrs-full_IssuedCapitalMember_b2234379-6945-4c89-bd1d-42dbfc3913c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_e640f52f-cbdb-4a3f-b81f-74670d0e0dea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:to="loc_ifrs-full_SharePremiumMember_e640f52f-cbdb-4a3f-b81f-74670d0e0dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedCapitalAndSharePremiumMember_cfdcda6f-ad23-48d9-93d2-b1292c844079" xlink:href="alvo-20231231.xsd#alvo_IssuedCapitalAndSharePremiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_2b7f2b94-cec2-4508-8914-b53d5f326e29" xlink:to="loc_alvo_IssuedCapitalAndSharePremiumMember_cfdcda6f-ad23-48d9-93d2-b1292c844079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f2abda2d-f33e-4ee2-a31d-767a4ae481d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f2abda2d-f33e-4ee2-a31d-767a4ae481d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f2abda2d-f33e-4ee2-a31d-767a4ae481d5" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PennyWarrantsMember_5b300385-16ef-4e46-b02f-13f69a0156de" xlink:href="alvo-20231231.xsd#alvo_PennyWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:to="loc_alvo_PennyWarrantsMember_5b300385-16ef-4e46-b02f-13f69a0156de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PublicWarrantsMember_efd0ef2a-e8e1-4eca-a774-271429d776aa" xlink:href="alvo-20231231.xsd#alvo_PublicWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:to="loc_alvo_PublicWarrantsMember_efd0ef2a-e8e1-4eca-a774-271429d776aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_d88b41a4-1bfb-496c-9304-808184edb6d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_d88b41a4-1bfb-496c-9304-808184edb6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember_efa1703f-b22d-4197-900b-fc28bc5b84d4" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_87d72be7-68a2-464f-b818-a52bb71d0478" xlink:to="loc_alvo_ShareAppreciationRightsMember_efa1703f-b22d-4197-900b-fc28bc5b84d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_45279e54-69b4-4824-8d85-506eefcfb2ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_45279e54-69b4-4824-8d85-506eefcfb2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_49649ccc-d243-436d-a77a-2611a26e5655" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_45279e54-69b4-4824-8d85-506eefcfb2ed" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_49649ccc-d243-436d-a77a-2611a26e5655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorOrdinarySharesMember_5d4f7e2c-0b32-4197-8644-a0bee93390c6" xlink:href="alvo-20231231.xsd#alvo_PredecessorOrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_49649ccc-d243-436d-a77a-2611a26e5655" xlink:to="loc_alvo_PredecessorOrdinarySharesMember_5d4f7e2c-0b32-4197-8644-a0bee93390c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_28bf7754-c93d-4150-b384-1a9a79717cc2" xlink:href="alvo-20231231.xsd#alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable_f4deb587-c315-44e9-a489-a40569cfddc3" xlink:to="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_28bf7754-c93d-4150-b384-1a9a79717cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesCapitalRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems_28bf7754-c93d-4150-b384-1a9a79717cc2" xlink:to="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_650d8a4d-152d-4788-908d-eac1346d54fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_650d8a4d-152d-4788-908d-eac1346d54fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f4c1da32-ed71-4356-8c3d-aec2fd10b555" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_Equity_f4c1da32-ed71-4356-8c3d-aec2fd10b555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfEquityShares_da464d23-f0b8-41a0-8f6b-a0ab028335aa" xlink:href="alvo-20231231.xsd#alvo_IssueOfEquityShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfEquityShares_da464d23-f0b8-41a0-8f6b-a0ab028335aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfEquities_59e89fc1-07e9-495b-9b8b-efda0ecc0b24" xlink:href="alvo-20231231.xsd#alvo_IssueOfEquities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfEquities_59e89fc1-07e9-495b-9b8b-efda0ecc0b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EliminationOfPredecessorOrdinaryShares_7c7fcc04-0b1e-41b3-abd5-d7bee801c89a" xlink:href="alvo-20231231.xsd#alvo_EliminationOfPredecessorOrdinaryShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_EliminationOfPredecessorOrdinaryShares_7c7fcc04-0b1e-41b3-abd5-d7bee801c89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EliminationOfPredecessorOrdinaryValue_0eeb3f14-381a-40d1-8dc2-70aec416952b" xlink:href="alvo-20231231.xsd#alvo_EliminationOfPredecessorOrdinaryValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_EliminationOfPredecessorOrdinaryValue_0eeb3f14-381a-40d1-8dc2-70aec416952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuanceOfOrdinaryShares_b98a2000-e369-4178-9fa7-5ecc5d152646" xlink:href="alvo-20231231.xsd#alvo_IssuanceOfOrdinaryShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssuanceOfOrdinaryShares_b98a2000-e369-4178-9fa7-5ecc5d152646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuanceOfOrdinaryValue_430b76e9-90d2-4a1b-ad41-6c23b22a807b" xlink:href="alvo-20231231.xsd#alvo_IssuanceOfOrdinaryValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssuanceOfOrdinaryValue_430b76e9-90d2-4a1b-ad41-6c23b22a807b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseThroughPipeFinancingShares_7bae9be6-0dbb-4d3d-bb25-78a4249eff91" xlink:href="alvo-20231231.xsd#alvo_IncreaseThroughPipeFinancingShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IncreaseThroughPipeFinancingShares_7bae9be6-0dbb-4d3d-bb25-78a4249eff91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseThroughPipeFinancingValue_95c33891-de89-4608-8b31-92caeac7c6e2" xlink:href="alvo-20231231.xsd#alvo_IncreaseThroughPipeFinancingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IncreaseThroughPipeFinancingValue_95c33891-de89-4608-8b31-92caeac7c6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_79b71d3f-09ad-4645-81b7-3c5bfc7b6724" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_79b71d3f-09ad-4645-81b7-3c5bfc7b6724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfPredecessorEarnOutShares_876ed378-d991-4714-a851-c2c4b4f78b0c" xlink:href="alvo-20231231.xsd#alvo_IssueOfPredecessorEarnOutShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfPredecessorEarnOutShares_876ed378-d991-4714-a851-c2c4b4f78b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfPredecessorEarnOutSharesValue_f57d8b7f-d97a-427f-b466-e906275622fe" xlink:href="alvo-20231231.xsd#alvo_IssueOfPredecessorEarnOutSharesValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfPredecessorEarnOutSharesValue_f57d8b7f-d97a-427f-b466-e906275622fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfOacbEarnOutShares_240d8d7a-d549-4604-8e5a-d7a4c948582d" xlink:href="alvo-20231231.xsd#alvo_IssueOfOacbEarnOutShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfOacbEarnOutShares_240d8d7a-d549-4604-8e5a-d7a4c948582d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfOacbEarnOutSharesValue_df2a6d1f-27ae-40f4-8196-c2b2e2b5a652" xlink:href="alvo-20231231.xsd#alvo_IssueOfOacbEarnOutSharesValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfOacbEarnOutSharesValue_df2a6d1f-27ae-40f4-8196-c2b2e2b5a652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares_2ed183f4-ddf1-4ec8-bed3-3f1b1a5e19f8" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares_2ed183f4-ddf1-4ec8-bed3-3f1b1a5e19f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue_13d8d7da-7fc7-4999-8f7b-f99be1f6373c" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue_13d8d7da-7fc7-4999-8f7b-f99be1f6373c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_14e602bc-0672-40df-b492-8104f203287e" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_14e602bc-0672-40df-b492-8104f203287e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_5b987f1c-97c3-4ad8-b1fb-c74407dc37a8" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_5b987f1c-97c3-4ad8-b1fb-c74407dc37a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalContributionSharesIssued_8be5eb93-818f-4aa6-9e05-bd1eea2ac457" xlink:href="alvo-20231231.xsd#alvo_CapitalContributionSharesIssued"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_CapitalContributionSharesIssued_8be5eb93-818f-4aa6-9e05-bd1eea2ac457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalContributionValue_15cb4a42-8721-4338-a7df-296f97172a08" xlink:href="alvo-20231231.xsd#alvo_CapitalContributionValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_CapitalContributionValue_15cb4a42-8721-4338-a7df-296f97172a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnoutSharesIssued_98ddc9c1-956f-4606-970f-5bc838a8cd09" xlink:href="alvo-20231231.xsd#alvo_VestedEarnoutSharesIssued"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_VestedEarnoutSharesIssued_98ddc9c1-956f-4606-970f-5bc838a8cd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestedEarnoutSharesValue_598c9114-ca7c-40b7-97d9-96560480645d" xlink:href="alvo-20231231.xsd#alvo_VestedEarnoutSharesValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_alvo_VestedEarnoutSharesValue_598c9114-ca7c-40b7-97d9-96560480645d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_87c01efe-d902-4dca-8569-96ff6fc4dc6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_87c01efe-d902-4dca-8569-96ff6fc4dc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_4a7d0c6b-852a-4d5c-970f-2b71c5ea4c33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_IssueOfEquity_4a7d0c6b-852a-4d5c-970f-2b71c5ea4c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_65e9245e-cce0-484b-83eb-46331c3d3499" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_65e9245e-cce0-484b-83eb-46331c3d3499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_9eb89b2e-21ef-42c6-8cd2-fe7ef49c0e87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IssueOfSharesCapitalRollForward_43e0280f-09c5-4c59-a8d5-c82601f987a4" xlink:to="loc_ifrs-full_Equity_9eb89b2e-21ef-42c6-8cd2-fe7ef49c0e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherreservesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherreservesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherreservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dd3143cc-c8cf-4a03-919d-8ce471926ef8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments_c23f1587-da27-4ae3-9f4f-aba5d9b9629c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dd3143cc-c8cf-4a03-919d-8ce471926ef8" xlink:to="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments_c23f1587-da27-4ae3-9f4f-aba5d9b9629c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPayments_42d8319b-805b-4562-9b16-b9c1e314445c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dd3143cc-c8cf-4a03-919d-8ce471926ef8" xlink:to="loc_ifrs-full_ReserveOfSharebasedPayments_42d8319b-805b-4562-9b16-b9c1e314445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_e59e0bc8-58e3-4e4d-b274-703f635d9230" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dd3143cc-c8cf-4a03-919d-8ce471926ef8" xlink:to="loc_ifrs-full_OtherReserves_e59e0bc8-58e3-4e4d-b274-703f635d9230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_070dc50c-1828-414a-bad7-26c8e1669375" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_dd38fd29-eac5-42a2-9403-19fa5804a422" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_070dc50c-1828-414a-bad7-26c8e1669375" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_dd38fd29-eac5-42a2-9403-19fa5804a422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_8215ba89-6aef-4077-9500-93278efc583a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_dd38fd29-eac5-42a2-9403-19fa5804a422" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_8215ba89-6aef-4077-9500-93278efc583a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_8215ba89-6aef-4077-9500-93278efc583a" xlink:to="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_474a400e-648a-4b29-8878-5cb0bfa545f3" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:to="loc_alvo_SeniorBondsMember_474a400e-648a-4b29-8878-5cb0bfa545f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_A2022ConvertibleBondsMember_bc39aaba-0c83-49e6-b35e-da72cdebb5bd" xlink:href="alvo-20231231.xsd#alvo_A2022ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:to="loc_alvo_A2022ConvertibleBondsMember_bc39aaba-0c83-49e6-b35e-da72cdebb5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConvertibleBondMember_8d741c24-8d12-4ee8-88b0-d8ea57724e42" xlink:href="alvo-20231231.xsd#alvo_AztiqConvertibleBondMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:to="loc_alvo_AztiqConvertibleBondMember_8d741c24-8d12-4ee8-88b0-d8ea57724e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember_62ce8e8b-597a-4e0a-8984-bd7b1d96af3b" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_220671fe-fa22-49cf-8b8b-9cf344e83c9f" xlink:to="loc_alvo_AlvogenFacilityMember_62ce8e8b-597a-4e0a-8984-bd7b1d96af3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_dd38fd29-eac5-42a2-9403-19fa5804a422" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_b6e2e4bc-6336-425f-aa6a-d4555f8339cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_BondsIssued_b6e2e4bc-6336-425f-aa6a-d4555f8339cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_e3428838-0469-4169-8857-b739d0ede92d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_LoansReceived_e3428838-0469-4169-8857-b739d0ede92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_6d933bd9-f42b-4972-9c84-48b5ce92fffd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_OtherBorrowings_6d933bd9-f42b-4972-9c84-48b5ce92fffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_4d0e413d-6501-4513-9214-8d1de031531e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_Borrowings_4d0e413d-6501-4513-9214-8d1de031531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_1617edf3-659a-4b87-8a9e-6e2ff686995e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_1617edf3-659a-4b87-8a9e-6e2ff686995e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_1f139e4c-0062-4a1c-9eb5-04ff5d230f59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_eae991ae-32f9-4847-b891-722f0c4e1ceb" xlink:to="loc_ifrs-full_LongtermBorrowings_1f139e4c-0062-4a1c-9eb5-04ff5d230f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_85d572cb-25d3-43a1-85d0-5f8abc643c82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_85d572cb-25d3-43a1-85d0-5f8abc643c82" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStockAxis_0c47441c-7737-4fd1-8772-786352beb64f" xlink:href="alvo-20231231.xsd#alvo_ClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_ClassOfStockAxis_0c47441c-7737-4fd1-8772-786352beb64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfStock1Domain_ba569623-fa73-4591-bf39-bdcfd6dd0795" xlink:href="alvo-20231231.xsd#alvo_ClassOfStock1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ClassOfStockAxis_0c47441c-7737-4fd1-8772-786352beb64f" xlink:to="loc_alvo_ClassOfStock1Domain_ba569623-fa73-4591-bf39-bdcfd6dd0795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassACommonStockMember_1ce9ebd4-31a2-4e13-b2d4-b0637e3dfb2a" xlink:href="alvo-20231231.xsd#alvo_ClassACommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ClassOfStock1Domain_ba569623-fa73-4591-bf39-bdcfd6dd0795" xlink:to="loc_alvo_ClassACommonStockMember_1ce9ebd4-31a2-4e13-b2d4-b0637e3dfb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementAxis_fd7a77c7-d604-4e15-96d0-c8270af290c5" xlink:href="alvo-20231231.xsd#alvo_AgreementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_AgreementAxis_fd7a77c7-d604-4e15-96d0-c8270af290c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementDomain_9424ae03-ba98-42b7-a810-ffb463952e8a" xlink:href="alvo-20231231.xsd#alvo_AgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementAxis_fd7a77c7-d604-4e15-96d0-c8270af290c5" xlink:to="loc_alvo_AgreementDomain_9424ae03-ba98-42b7-a810-ffb463952e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BcaFrameworkAgreementMember_cd1fc3db-238a-415a-927f-169935f32acc" xlink:href="alvo-20231231.xsd#alvo_BcaFrameworkAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementDomain_9424ae03-ba98-42b7-a810-ffb463952e8a" xlink:to="loc_alvo_BcaFrameworkAgreementMember_cd1fc3db-238a-415a-927f-169935f32acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_74d45f5e-804d-4e6b-befe-09b0981368a9" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementDomain_9424ae03-ba98-42b7-a810-ffb463952e8a" xlink:to="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_74d45f5e-804d-4e6b-befe-09b0981368a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_61f85c27-3743-483a-8851-162e74c4219c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_61f85c27-3743-483a-8851-162e74c4219c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_61f85c27-3743-483a-8851-162e74c4219c" xlink:to="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleOrdinarySharesMember_bfe8d500-bc4e-4699-8072-50c18493bfcc" xlink:href="alvo-20231231.xsd#alvo_ConvertibleOrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_ConvertibleOrdinarySharesMember_bfe8d500-bc4e-4699-8072-50c18493bfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleShareholderLoanMember_a1e5453a-bf0c-44f6-8090-f448565948aa" xlink:href="alvo-20231231.xsd#alvo_ConvertibleShareholderLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_ConvertibleShareholderLoanMember_a1e5453a-bf0c-44f6-8090-f448565948aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondMember_5da35493-e8a3-46d0-889b-a7d064d78111" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_ConvertibleBondMember_5da35493-e8a3-46d0-889b-a7d064d78111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_19860c35-d9e7-4b3b-9e92-8b16b431829c" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_SeniorBondsMember_19860c35-d9e7-4b3b-9e92-8b16b431829c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConvertibleDebtMember_d4ef8116-ca7f-45b6-92ac-d71835632962" xlink:href="alvo-20231231.xsd#alvo_TrancheAConvertibleDebtMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_TrancheAConvertibleDebtMember_d4ef8116-ca7f-45b6-92ac-d71835632962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheBConvertibleDebtMember_8eba8f00-4305-4c0f-af0e-6528552e29a3" xlink:href="alvo-20231231.xsd#alvo_TrancheBConvertibleDebtMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_TrancheBConvertibleDebtMember_8eba8f00-4305-4c0f-af0e-6528552e29a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConvertibleBondMember_ac3d404f-382c-434e-a367-38b27ac25ecf" xlink:href="alvo-20231231.xsd#alvo_AztiqConvertibleBondMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AztiqConvertibleBondMember_ac3d404f-382c-434e-a367-38b27ac25ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFacilityLoansMember_cd5c2a93-884e-4ef2-8cbf-6275e6ba1a78" xlink:href="alvo-20231231.xsd#alvo_AztiqFacilityLoansMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AztiqFacilityLoansMember_cd5c2a93-884e-4ef2-8cbf-6275e6ba1a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember_7b40b32a-6451-4b0c-a6cc-9cecf8670d16" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenFacilityMember_7b40b32a-6451-4b0c-a6cc-9cecf8670d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFacilityMember_740146e5-699b-49dd-92b3-cabc86de749b" xlink:href="alvo-20231231.xsd#alvo_AztiqFacilityMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AztiqFacilityMember_740146e5-699b-49dd-92b3-cabc86de749b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityAndAztiqFacilityMember_27e4ac6e-86f3-4da0-b1c7-4c325fc3cf6d" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityAndAztiqFacilityMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenFacilityAndAztiqFacilityMember_27e4ac6e-86f3-4da0-b1c7-4c325fc3cf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLoanMember_3bab6ec1-1993-4482-b39f-21fdf8eabfa0" xlink:href="alvo-20231231.xsd#alvo_AlvogenLoanMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenLoanMember_3bab6ec1-1993-4482-b39f-21fdf8eabfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LoanAgreementMember_d58595a6-bc9d-46c1-baa8-ad45505b0e01" xlink:href="alvo-20231231.xsd#alvo_LoanAgreementMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_LoanAgreementMember_d58595a6-bc9d-46c1-baa8-ad45505b0e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenSubordinatedLoanMember_1bef3ab5-7936-4c21-b2ab-cbc96627b3ba" xlink:href="alvo-20231231.xsd#alvo_AlvogenSubordinatedLoanMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenSubordinatedLoanMember_1bef3ab5-7936-4c21-b2ab-cbc96627b3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLoanWarrantsMember_af1342ae-98f5-4b79-a0b3-be4400f0de75" xlink:href="alvo-20231231.xsd#alvo_AlvogenLoanWarrantsMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_AlvogenLoanWarrantsMember_af1342ae-98f5-4b79-a0b3-be4400f0de75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FacilityLoansMember_423f832b-c1ed-4dd6-b769-8747de296577" xlink:href="alvo-20231231.xsd#alvo_FacilityLoansMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_FacilityLoansMember_423f832b-c1ed-4dd6-b769-8747de296577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherBorrowingsFinancialInstitutionMember_ddfed47a-0654-4353-b119-6b438cf5cbfb" xlink:href="alvo-20231231.xsd#alvo_OtherBorrowingsFinancialInstitutionMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_581924da-763d-47c0-961b-a1cc91e65a9e" xlink:to="loc_alvo_OtherBorrowingsFinancialInstitutionMember_ddfed47a-0654-4353-b119-6b438cf5cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_4d4a1fc0-3d8b-4a3c-b647-7a646b4e0700" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_a7fc8bb8-6b92-49ad-9d9b-c9edb32a6560" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_4d4a1fc0-3d8b-4a3c-b647-7a646b4e0700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_ab15a8dd-f519-41b4-803a-841fe6057663" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_4d4a1fc0-3d8b-4a3c-b647-7a646b4e0700" xlink:to="loc_ifrs-full_OrdinarySharesMember_ab15a8dd-f519-41b4-803a-841fe6057663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EventAxis_2710bdf3-0485-4217-8818-094b602736bd" xlink:href="alvo-20231231.xsd#alvo_EventAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_EventAxis_2710bdf3-0485-4217-8818-094b602736bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:href="alvo-20231231.xsd#alvo_EventDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_EventAxis_2710bdf3-0485-4217-8818-094b602736bd" xlink:to="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember_256a4b56-a244-400c-b763-84c92f85b461" xlink:href="alvo-20231231.xsd#alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:to="loc_alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember_256a4b56-a244-400c-b763-84c92f85b461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember_e2e276cf-f0e0-45a5-9d0c-8313046c57f2" xlink:href="alvo-20231231.xsd#alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:to="loc_alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember_e2e276cf-f0e0-45a5-9d0c-8313046c57f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember_2a351995-ca0d-46b9-855b-085cc7a925a5" xlink:href="alvo-20231231.xsd#alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:to="loc_alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember_2a351995-ca0d-46b9-855b-085cc7a925a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseInTheFaceValueOfTheBondsMember_4a10416b-6a37-4e32-93b5-f4f4475fa0fb" xlink:href="alvo-20231231.xsd#alvo_IncreaseInTheFaceValueOfTheBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_EventDomain_b78001bf-c335-449e-80d2-729259dd964b" xlink:to="loc_alvo_IncreaseInTheFaceValueOfTheBondsMember_4a10416b-6a37-4e32-93b5-f4f4475fa0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationAxis_1683582a-36bc-4bc5-aaed-3d18e9ce5c75" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_IncomeStatementsLocationAxis_1683582a-36bc-4bc5-aaed-3d18e9ce5c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_9003bf9e-0732-4eca-88fb-ac9f3294a733" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationAxis_1683582a-36bc-4bc5-aaed-3d18e9ce5c75" xlink:to="loc_alvo_IncomeStatementsLocationDomain_9003bf9e-0732-4eca-88fb-ac9f3294a733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinanceIncomeMember_c32b7941-6917-48f9-bc21-17f2e4f9bd49" xlink:href="alvo-20231231.xsd#alvo_FinanceIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationDomain_9003bf9e-0732-4eca-88fb-ac9f3294a733" xlink:to="loc_alvo_FinanceIncomeMember_c32b7941-6917-48f9-bc21-17f2e4f9bd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0" xlink:href="alvo-20231231.xsd#alvo_ComponentOfDebtConvertedIntoEquityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_2bcbfdff-3f2d-453f-9338-c150515f1ece" xlink:href="alvo-20231231.xsd#alvo_ComponentOfDebtConvertedIntoEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityAxis_3deb2d74-3bd2-4a00-bfa1-ca56f235dfc0" xlink:to="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_2bcbfdff-3f2d-453f-9338-c150515f1ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrincipalAndAccruedInterestComponent.Member_12f125dc-5380-444c-b535-91c80a5997ec" xlink:href="alvo-20231231.xsd#alvo_PrincipalAndAccruedInterestComponent.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_2bcbfdff-3f2d-453f-9338-c150515f1ece" xlink:to="loc_alvo_PrincipalAndAccruedInterestComponent.Member_12f125dc-5380-444c-b535-91c80a5997ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PremiumComponentMember_652cfcb9-ce99-4681-a04a-cc1d6879420e" xlink:href="alvo-20231231.xsd#alvo_PremiumComponentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ComponentOfDebtConvertedIntoEquityDomain_2bcbfdff-3f2d-453f-9338-c150515f1ece" xlink:to="loc_alvo_PremiumComponentMember_652cfcb9-ce99-4681-a04a-cc1d6879420e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalBondsIssuanceAxis_77b97080-65e6-40eb-8634-11468b74137e" xlink:href="alvo-20231231.xsd#alvo_AdditionalBondsIssuanceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_AdditionalBondsIssuanceAxis_77b97080-65e6-40eb-8634-11468b74137e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:href="alvo-20231231.xsd#alvo_AdditionalBondsIssuanceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AdditionalBondsIssuanceAxis_77b97080-65e6-40eb-8634-11468b74137e" xlink:to="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToANewBondHolderMember_12d789b3-7a37-4af2-a1e6-2c83d3223063" xlink:href="alvo-20231231.xsd#alvo_IssuedToANewBondHolderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:to="loc_alvo_IssuedToANewBondHolderMember_12d789b3-7a37-4af2-a1e6-2c83d3223063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToTheExistingNoteholderMember_45883b07-08cd-4989-bd5f-6fa9dcdab798" xlink:href="alvo-20231231.xsd#alvo_IssuedToTheExistingNoteholderMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:to="loc_alvo_IssuedToTheExistingNoteholderMember_45883b07-08cd-4989-bd5f-6fa9dcdab798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssuedToTheExistingAndANewBondHolderMember_0693bdbf-31c7-4cc5-bc14-f6bfede7e10c" xlink:href="alvo-20231231.xsd#alvo_IssuedToTheExistingAndANewBondHolderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AdditionalBondsIssuanceDomain_4070bf4c-3463-4b44-993f-da863ab15fad" xlink:to="loc_alvo_IssuedToTheExistingAndANewBondHolderMember_0693bdbf-31c7-4cc5-bc14-f6bfede7e10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfBondsPayableAxis_68af5291-3a3c-4e39-a520-337c02921e59" xlink:href="alvo-20231231.xsd#alvo_ComponentOfBondsPayableAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_ComponentOfBondsPayableAxis_68af5291-3a3c-4e39-a520-337c02921e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ComponentOfBondsPayableDomain_4bdcb192-4e33-4e0f-b7eb-83855fb93cf5" xlink:href="alvo-20231231.xsd#alvo_ComponentOfBondsPayableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ComponentOfBondsPayableAxis_68af5291-3a3c-4e39-a520-337c02921e59" xlink:to="loc_alvo_ComponentOfBondsPayableDomain_4bdcb192-4e33-4e0f-b7eb-83855fb93cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrincipalComponentMember_b997e2c2-7911-4794-926a-c644102ef65e" xlink:href="alvo-20231231.xsd#alvo_PrincipalComponentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ComponentOfBondsPayableDomain_4bdcb192-4e33-4e0f-b7eb-83855fb93cf5" xlink:to="loc_alvo_PrincipalComponentMember_b997e2c2-7911-4794-926a-c644102ef65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InterestComponentMember_cd57e5ce-ea0f-4778-a4a4-49dfa0333195" xlink:href="alvo-20231231.xsd#alvo_InterestComponentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ComponentOfBondsPayableDomain_4bdcb192-4e33-4e0f-b7eb-83855fb93cf5" xlink:to="loc_alvo_InterestComponentMember_cd57e5ce-ea0f-4778-a4a4-49dfa0333195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneAxis_fc0adda3-304f-4e7f-8bcb-426965ee39c1" xlink:href="alvo-20231231.xsd#alvo_AgreementOneAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_AgreementOneAxis_fc0adda3-304f-4e7f-8bcb-426965ee39c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneDomain_d7ef03dc-3147-4e10-81e4-e6142d4410d0" xlink:href="alvo-20231231.xsd#alvo_AgreementOneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementOneAxis_fc0adda3-304f-4e7f-8bcb-426965ee39c1" xlink:to="loc_alvo_AgreementOneDomain_d7ef03dc-3147-4e10-81e4-e6142d4410d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember_2bd04bb1-6d6e-4bf4-90a6-933af798d96b" xlink:href="alvo-20231231.xsd#alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementOneDomain_d7ef03dc-3147-4e10-81e4-e6142d4410d0" xlink:to="loc_alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember_2bd04bb1-6d6e-4bf4-90a6-933af798d96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_3fd5847b-9c98-4543-934e-d615663ffb8a" xlink:href="alvo-20231231.xsd#alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementOneDomain_d7ef03dc-3147-4e10-81e4-e6142d4410d0" xlink:to="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_3fd5847b-9c98-4543-934e-d615663ffb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_d3e80adc-0ccd-483b-b4bf-aef0577fe940" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_RangeAxis_d3e80adc-0ccd-483b-b4bf-aef0577fe940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_d3e80adc-0ccd-483b-b4bf-aef0577fe940" xlink:to="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c7b11ade-06b7-4ac5-80f8-8a9001d63eb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:to="loc_ifrs-full_BottomOfRangeMember_c7b11ade-06b7-4ac5-80f8-8a9001d63eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_b71a7efe-3817-4d5b-94b8-94c92f721f60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:to="loc_ifrs-full_TopOfRangeMember_b71a7efe-3817-4d5b-94b8-94c92f721f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageMember_c7edaa61-da6b-468b-ae0c-dcedaba45421" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_721a0fa3-056d-4fa5-9188-2b9c5c5899ab" xlink:to="loc_ifrs-full_WeightedAverageMember_c7edaa61-da6b-468b-ae0c-dcedaba45421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NatureOfFeesAxis_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b" xlink:href="alvo-20231231.xsd#alvo_NatureOfFeesAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_NatureOfFeesAxis_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NatureOfFeesDomain_a87c66fa-8b4c-41cf-be23-bee4a7d7bde7" xlink:href="alvo-20231231.xsd#alvo_NatureOfFeesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_NatureOfFeesAxis_e4650e7d-2a4b-4ea0-bf91-4010a21c0f9b" xlink:to="loc_alvo_NatureOfFeesDomain_a87c66fa-8b4c-41cf-be23-bee4a7d7bde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConsentFeesToBondholdersMember_a2cbc651-64a2-4936-9abd-db27de5518fc" xlink:href="alvo-20231231.xsd#alvo_ConsentFeesToBondholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_NatureOfFeesDomain_a87c66fa-8b4c-41cf-be23-bee4a7d7bde7" xlink:to="loc_alvo_ConsentFeesToBondholdersMember_a2cbc651-64a2-4936-9abd-db27de5518fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsAxis_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc" xlink:href="alvo-20231231.xsd#alvo_DetailsAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_DetailsAxis_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DetailsDomain_40ea0c80-1378-4dae-a7df-845caadac704" xlink:href="alvo-20231231.xsd#alvo_DetailsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailsAxis_3a24b9a5-9f9e-434d-aca8-c085bb6b54bc" xlink:to="loc_alvo_DetailsDomain_40ea0c80-1378-4dae-a7df-845caadac704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BeforeTheTermsOfTheSecondAmendmentMember_cfb6a747-eaa9-4dbd-8fea-bd3bed01e866" xlink:href="alvo-20231231.xsd#alvo_BeforeTheTermsOfTheSecondAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailsDomain_40ea0c80-1378-4dae-a7df-845caadac704" xlink:to="loc_alvo_BeforeTheTermsOfTheSecondAmendmentMember_cfb6a747-eaa9-4dbd-8fea-bd3bed01e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AfterTheTermsOfTheSecondAmendmentMember_a1366c99-c591-4b54-aad3-f07ff14d8634" xlink:href="alvo-20231231.xsd#alvo_AfterTheTermsOfTheSecondAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DetailsDomain_40ea0c80-1378-4dae-a7df-845caadac704" xlink:to="loc_alvo_AfterTheTermsOfTheSecondAmendmentMember_a1366c99-c591-4b54-aad3-f07ff14d8634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_f3f6ffc1-d689-4fc7-bc2a-ad422da41bdd" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContingentlyIssuablePennyWarrantsMember_681d34bb-4ee2-4bff-8ab4-da350bd237c8" xlink:href="alvo-20231231.xsd#alvo_ContingentlyIssuablePennyWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:to="loc_alvo_ContingentlyIssuablePennyWarrantsMember_681d34bb-4ee2-4bff-8ab4-da350bd237c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondInterestRateFeatureMember_2a5e8b71-1c83-4e0b-9aa3-7e711c0a700e" xlink:href="alvo-20231231.xsd#alvo_SeniorBondInterestRateFeatureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:to="loc_alvo_SeniorBondInterestRateFeatureMember_2a5e8b71-1c83-4e0b-9aa3-7e711c0a700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_66dddf52-3210-46a5-954c-07bebf0a6de0" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:to="loc_alvo_SeniorBondWarrantsMember_66dddf52-3210-46a5-954c-07bebf0a6de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConversionFeatureMember_1654f8a6-101d-4ff2-bedf-ef4b69f4dddf" xlink:href="alvo-20231231.xsd#alvo_AztiqConversionFeatureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_541693fc-e1c1-4395-8ff7-5bb0de2362a9" xlink:to="loc_alvo_AztiqConversionFeatureMember_1654f8a6-101d-4ff2-bedf-ef4b69f4dddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAxis_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506" xlink:href="alvo-20231231.xsd#alvo_TrancheAxis"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_TrancheAxis_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_71938d88-63b7-4229-aca5-00f77ed30ce8" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheAxis_2e6fb1e2-0c4c-4b20-9bb3-bce3c68e6506" xlink:to="loc_alvo_TrancheDomain_71938d88-63b7-4229-aca5-00f77ed30ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAMember_253a079e-0e69-41da-b3c1-dd9889eb4dd4" xlink:href="alvo-20231231.xsd#alvo_TrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheDomain_71938d88-63b7-4229-aca5-00f77ed30ce8" xlink:to="loc_alvo_TrancheAMember_253a079e-0e69-41da-b3c1-dd9889eb4dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheBMember_23ef9d7d-19f3-4d45-8c74-87de4f0f5189" xlink:href="alvo-20231231.xsd#alvo_TrancheBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheDomain_71938d88-63b7-4229-aca5-00f77ed30ce8" xlink:to="loc_alvo_TrancheBMember_23ef9d7d-19f3-4d45-8c74-87de4f0f5189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_dba10c8b-9469-4136-a073-7820e61c28fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_dba10c8b-9469-4136-a073-7820e61c28fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_1c843362-618d-49b7-8774-52c46afe7f39" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_dba10c8b-9469-4136-a073-7820e61c28fd" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_1c843362-618d-49b7-8774-52c46afe7f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_ccbc5ca8-d5cc-4d2e-a61a-854355993cc4" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_1c843362-618d-49b7-8774-52c46afe7f39" xlink:to="loc_alvo_SeniorBondWarrantsMember_ccbc5ca8-d5cc-4d2e-a61a-854355993cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_40c9c3fc-ccd6-4223-9d39-f3b6bec48135" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_1c843362-618d-49b7-8774-52c46afe7f39" xlink:to="loc_alvo_SeniorBondsMember_40c9c3fc-ccd6-4223-9d39-f3b6bec48135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_a9d19bff-843d-4027-8c52-5553f4668292" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_a9d19bff-843d-4027-8c52-5553f4668292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_3c093a7d-3727-4dea-b3c7-c200da5ee393" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_a9d19bff-843d-4027-8c52-5553f4668292" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_3c093a7d-3727-4dea-b3c7-c200da5ee393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_4ec3e19d-d6ee-4f9d-b2b5-6d8415f50975" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_3c093a7d-3727-4dea-b3c7-c200da5ee393" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_4ec3e19d-d6ee-4f9d-b2b5-6d8415f50975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ccba0edd-8822-4e56-a784-5090957a8763" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ccba0edd-8822-4e56-a784-5090957a8763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_e39a004c-e2a3-4e8f-9fe9-7f90755de476" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ccba0edd-8822-4e56-a784-5090957a8763" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_e39a004c-e2a3-4e8f-9fe9-7f90755de476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_0eaa5165-3f45-460c-9528-48f0074c1ab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_e39a004c-e2a3-4e8f-9fe9-7f90755de476" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_0eaa5165-3f45-460c-9528-48f0074c1ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5cfdf885-d37d-4aa3-94fa-ec747aa6a358" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_dei_LegalEntityAxis_5cfdf885-d37d-4aa3-94fa-ec747aa6a358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e35efc4d-a991-414e-8f85-f0b7763c2ad2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5cfdf885-d37d-4aa3-94fa-ec747aa6a358" xlink:to="loc_dei_EntityDomain_e35efc4d-a991-414e-8f85-f0b7763c2ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqMember_2ec048ba-ebc8-4766-bb8e-06582deb4de4" xlink:href="alvo-20231231.xsd#alvo_AztiqMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e35efc4d-a991-414e-8f85-f0b7763c2ad2" xlink:to="loc_alvo_AztiqMember_2ec048ba-ebc8-4766-bb8e-06582deb4de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ATPHoldingEhf.Member_4822ea63-a9cf-446e-924b-6cdb89c45e30" xlink:href="alvo-20231231.xsd#alvo_ATPHoldingEhf.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e35efc4d-a991-414e-8f85-f0b7763c2ad2" xlink:to="loc_alvo_ATPHoldingEhf.Member_4822ea63-a9cf-446e-924b-6cdb89c45e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheAxis_4884beef-0583-4437-a957-9c0ff9a7a855" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheAxis"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_BorrowingsTrancheAxis_4884beef-0583-4437-a957-9c0ff9a7a855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheDomain_fbff7610-f482-4f73-9d68-b0815c1fd72f" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsTrancheAxis_4884beef-0583-4437-a957-9c0ff9a7a855" xlink:to="loc_alvo_BorrowingsTrancheDomain_fbff7610-f482-4f73-9d68-b0815c1fd72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheOneMember_a85147d4-86f7-4ae2-811c-bd276746d0b3" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsTrancheDomain_fbff7610-f482-4f73-9d68-b0815c1fd72f" xlink:to="loc_alvo_BorrowingsTrancheOneMember_a85147d4-86f7-4ae2-811c-bd276746d0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsTrancheTwoMember_a045b2f8-0cb9-4bb0-8940-ab83739574f4" xlink:href="alvo-20231231.xsd#alvo_BorrowingsTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsTrancheDomain_fbff7610-f482-4f73-9d68-b0815c1fd72f" xlink:to="loc_alvo_BorrowingsTrancheTwoMember_a045b2f8-0cb9-4bb0-8940-ab83739574f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LenderNameAxis_136ffd55-6102-48b9-8f70-dd60c96315be" xlink:href="alvo-20231231.xsd#alvo_LenderNameAxis"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_LenderNameAxis_136ffd55-6102-48b9-8f70-dd60c96315be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LenderNameDomain_6c164edb-c91c-45eb-91b4-6705c7001416" xlink:href="alvo-20231231.xsd#alvo_LenderNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LenderNameAxis_136ffd55-6102-48b9-8f70-dd60c96315be" xlink:to="loc_alvo_LenderNameDomain_6c164edb-c91c-45eb-91b4-6705c7001416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ArionBankiHfMember_8e33b832-a3cd-4690-9194-b1e3dc757058" xlink:href="alvo-20231231.xsd#alvo_ArionBankiHfMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LenderNameDomain_6c164edb-c91c-45eb-91b4-6705c7001416" xlink:to="loc_alvo_ArionBankiHfMember_8e33b832-a3cd-4690-9194-b1e3dc757058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LandsbankinnHfMember_b288361c-e6d2-47f4-840d-f6037fecadf9" xlink:href="alvo-20231231.xsd#alvo_LandsbankinnHfMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LenderNameDomain_6c164edb-c91c-45eb-91b4-6705c7001416" xlink:to="loc_alvo_LandsbankinnHfMember_b288361c-e6d2-47f4-840d-f6037fecadf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_44a1598b-79d1-480e-a6a1-a465b320bcb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_MaturityAxis_44a1598b-79d1-480e-a6a1-a465b320bcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_db516481-874f-477a-b925-d03b74c2ed96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_44a1598b-79d1-480e-a6a1-a465b320bcb5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_db516481-874f-477a-b925-d03b74c2ed96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinalMaturityInDecember2029Member_00d99b96-1c99-4482-91c3-d7375391b10d" xlink:href="alvo-20231231.xsd#alvo_FinalMaturityInDecember2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_db516481-874f-477a-b925-d03b74c2ed96" xlink:to="loc_alvo_FinalMaturityInDecember2029Member_00d99b96-1c99-4482-91c3-d7375391b10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinalMaturityInDecember2027Member_ece9918a-30c1-4059-aacd-691d32fca87f" xlink:href="alvo-20231231.xsd#alvo_FinalMaturityInDecember2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_db516481-874f-477a-b925-d03b74c2ed96" xlink:to="loc_alvo_FinalMaturityInDecember2027Member_ece9918a-30c1-4059-aacd-691d32fca87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposuresAxis_99db7f43-8849-468a-a06e-fb663c7ed3d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposuresAxis"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_RiskExposuresAxis_99db7f43-8849-468a-a06e-fb663c7ed3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposuresMember_d3a28093-8640-46a5-bf79-24bec48f20a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RiskExposuresMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RiskExposuresAxis_99db7f43-8849-468a-a06e-fb663c7ed3d1" xlink:to="loc_ifrs-full_RiskExposuresMember_d3a28093-8640-46a5-bf79-24bec48f20a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_df28740e-2af0-4485-bf99-1fa1087bf20d" xlink:href="alvo-20231231.xsd#alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RiskExposuresMember_d3a28093-8640-46a5-bf79-24bec48f20a2" xlink:to="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_df28740e-2af0-4485-bf99-1fa1087bf20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_39ef2a81-d826-4b0a-8858-cc2bbb730a6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_39ef2a81-d826-4b0a-8858-cc2bbb730a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_ecd90ea1-d9f4-4264-a7ac-ba4c64a02f75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_39ef2a81-d826-4b0a-8858-cc2bbb730a6b" xlink:to="loc_ifrs-full_InterestRateTypesMember_ecd90ea1-d9f4-4264-a7ac-ba4c64a02f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_UsdSofrMember_459c4193-121b-4647-8926-85c6e1912f1f" xlink:href="alvo-20231231.xsd#alvo_UsdSofrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_ecd90ea1-d9f4-4264-a7ac-ba4c64a02f75" xlink:to="loc_alvo_UsdSofrMember_459c4193-121b-4647-8926-85c6e1912f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableRatesAxis_f43ed206-657c-41fe-bd97-d28500c5799e" xlink:href="alvo-20231231.xsd#alvo_VariableRatesAxis"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_VariableRatesAxis_f43ed206-657c-41fe-bd97-d28500c5799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableRatesDomain_461deff6-ae10-4a6f-9236-025a94ffc231" xlink:href="alvo-20231231.xsd#alvo_VariableRatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_VariableRatesAxis_f43ed206-657c-41fe-bd97-d28500c5799e" xlink:to="loc_alvo_VariableRatesDomain_461deff6-ae10-4a6f-9236-025a94ffc231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_659829ac-d6a9-49b9-9993-adbf631a938d" xlink:href="alvo-20231231.xsd#alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_VariableRatesDomain_461deff6-ae10-4a6f-9236-025a94ffc231" xlink:to="loc_alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member_659829ac-d6a9-49b9-9993-adbf631a938d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturityMonthAndYearAxis_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b" xlink:href="alvo-20231231.xsd#alvo_MaturityMonthAndYearAxis"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_alvo_MaturityMonthAndYearAxis_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:href="alvo-20231231.xsd#alvo_MaturityMonthAndYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_MaturityMonthAndYearAxis_d8eaa9a6-87f7-4f6d-b4cf-9f0d550b035b" xlink:to="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnMarch2029Member_d96a3230-a507-4e58-bc65-a0fd88ff434c" xlink:href="alvo-20231231.xsd#alvo_MaturedOnMarch2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:to="loc_alvo_MaturedOnMarch2029Member_d96a3230-a507-4e58-bc65-a0fd88ff434c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnAugust2029Member_91ffa96a-e8ba-4691-af05-806b50a45c78" xlink:href="alvo-20231231.xsd#alvo_MaturedOnAugust2029Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:to="loc_alvo_MaturedOnAugust2029Member_91ffa96a-e8ba-4691-af05-806b50a45c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnAugust2030Member_9f9cab8c-9f19-4d71-99a6-33d5a4cf7416" xlink:href="alvo-20231231.xsd#alvo_MaturedOnAugust2030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:to="loc_alvo_MaturedOnAugust2030Member_9f9cab8c-9f19-4d71-99a6-33d5a4cf7416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MaturedOnApril2024Member_321d8c48-7a95-4697-8e60-fd1f323168a7" xlink:href="alvo-20231231.xsd#alvo_MaturedOnApril2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_MaturityMonthAndYearDomain_85dd76d7-b341-4988-b2b1-d25f5bd4d3ff" xlink:to="loc_alvo_MaturedOnApril2024Member_321d8c48-7a95-4697-8e60-fd1f323168a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis_3cafa7b6-da0f-4831-a633-f0bf24c69c35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialAssetsAxis"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsAxis_3cafa7b6-da0f-4831-a633-f0bf24c69c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsTypeMember_d2e7f6be-d19e-4e5e-b129-b1d7d8e1244c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_3cafa7b6-da0f-4831-a633-f0bf24c69c35" xlink:to="loc_ifrs-full_FinancialAssetsTypeMember_d2e7f6be-d19e-4e5e-b129-b1d7d8e1244c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_dead2cfe-9b3b-451c-8ec6-e8ffb3da4f55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsTypeMember_d2e7f6be-d19e-4e5e-b129-b1d7d8e1244c" xlink:to="loc_ifrs-full_TradeReceivablesMember_dead2cfe-9b3b-451c-8ec6-e8ffb3da4f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_39d46355-9cda-4a29-a22d-6853ee830a74" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants_0ad11ce4-7dba-44e2-8868-b8590a295205" xlink:href="alvo-20231231.xsd#alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants_0ad11ce4-7dba-44e2-8868-b8590a295205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_90cf85be-0460-4c45-adb1-d8b41383a531" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_90cf85be-0460-4c45-adb1-d8b41383a531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities_04f0d629-2081-4c95-b084-d119370ce5b6" xlink:href="alvo-20231231.xsd#alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities_04f0d629-2081-4c95-b084-d119370ce5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfConvertibleInstruments_da9228d2-07bd-43fe-99cf-b74384da4c85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfConvertibleInstruments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_IssueOfConvertibleInstruments_da9228d2-07bd-43fe-99cf-b74384da4c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_722911bc-fb08-48f2-845c-7b97c85fd0bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_722911bc-fb08-48f2-845c-7b97c85fd0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GainLossOnExtinguishmentOfDebt_cc3d683a-f564-4def-a2a0-b332d89620f8" xlink:href="alvo-20231231.xsd#alvo_GainLossOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_GainLossOnExtinguishmentOfDebt_cc3d683a-f564-4def-a2a0-b332d89620f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_f47452a8-f37e-4111-8a8b-cdd2a5a34f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_RepaymentsOfBondsNotesAndDebentures_f47452a8-f37e-4111-8a8b-cdd2a5a34f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PremiumPaymentOnBonds_61c140d9-b252-496d-b267-0caa51bd38ed" xlink:href="alvo-20231231.xsd#alvo_PremiumPaymentOnBonds"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_PremiumPaymentOnBonds_61c140d9-b252-496d-b267-0caa51bd38ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtensionPremiumToBondHolders_bd007f42-9a98-4d7c-9ca9-a76d639a1ea5" xlink:href="alvo-20231231.xsd#alvo_ExtensionPremiumToBondHolders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ExtensionPremiumToBondHolders_bd007f42-9a98-4d7c-9ca9-a76d639a1ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionalExtensionPremiumToBondholders_d19667db-ea6f-49dc-9158-dafff0ff9ee2" xlink:href="alvo-20231231.xsd#alvo_AdditionalExtensionPremiumToBondholders"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_AdditionalExtensionPremiumToBondholders_d19667db-ea6f-49dc-9158-dafff0ff9ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_a57abea6-a92b-4030-b379-66c684d29b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_a57abea6-a92b-4030-b379-66c684d29b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuesFairValueMeasurementLiabilities_f3efa5de-4b7c-4e24-b23d-54105ed5c194" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuesFairValueMeasurementLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_IssuesFairValueMeasurementLiabilities_f3efa5de-4b7c-4e24-b23d-54105ed5c194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_87f4dead-bc39-42b0-b478-01f38f5c1270" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_NotionalAmount_87f4dead-bc39-42b0-b478-01f38f5c1270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities_9a2ef073-4fc8-41ab-bee0-bf1afb833257" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities_9a2ef073-4fc8-41ab-bee0-bf1afb833257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingConversionPeriodPriorToExtinguishment_e41f1468-fbc4-4ed3-a79e-fad57ce3049e" xlink:href="alvo-20231231.xsd#alvo_BorrowingConversionPeriodPriorToExtinguishment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingConversionPeriodPriorToExtinguishment_e41f1468-fbc4-4ed3-a79e-fad57ce3049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_8e5b0e8b-ef52-44e2-af2e-be52fe068373" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_BondsIssued_8e5b0e8b-ef52-44e2-af2e-be52fe068373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium_db60e5a0-c3dd-4da2-824f-eb3571c33fd9" xlink:href="alvo-20231231.xsd#alvo_BorrowingPrepaymentPeriodWithAdditionalPremium"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium_db60e5a0-c3dd-4da2-824f-eb3571c33fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PrepaymentPenaltyPercentageOnBonds_121bae40-0813-4b25-b1b9-20998ed2acea" xlink:href="alvo-20231231.xsd#alvo_PrepaymentPenaltyPercentageOnBonds"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_PrepaymentPenaltyPercentageOnBonds_121bae40-0813-4b25-b1b9-20998ed2acea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_66c4dd90-8063-45aa-b7c0-973c7b2d0aa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_BorrowingsInterestRate_66c4dd90-8063-45aa-b7c0-973c7b2d0aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FeeAndCommissionExpense_82f9c3da-357e-441b-8048-de88d6db4433" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_FeeAndCommissionExpense_82f9c3da-357e-441b-8048-de88d6db4433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MinimumAmountOfRestrictedCashToBeMaintained_9bf491af-e9dc-4e2e-9907-8afff592b210" xlink:href="alvo-20231231.xsd#alvo_MinimumAmountOfRestrictedCashToBeMaintained"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_MinimumAmountOfRestrictedCashToBeMaintained_9bf491af-e9dc-4e2e-9907-8afff592b210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingSharesIssuancePeriodForInterestDecrease_35bc76be-b292-4e5d-aaa2-1b19e383ace8" xlink:href="alvo-20231231.xsd#alvo_BorrowingSharesIssuancePeriodForInterestDecrease"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingSharesIssuancePeriodForInterestDecrease_35bc76be-b292-4e5d-aaa2-1b19e383ace8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_27780319-69b6-49e5-af9c-6c070b45595a" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsExercisePricePerShare"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_27780319-69b6-49e5-af9c-6c070b45595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_b6d6242d-3def-418d-934e-8198153effcf" xlink:href="alvo-20231231.xsd#alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_b6d6242d-3def-418d-934e-8198153effcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue_75379e23-c5d8-4b07-918d-76322a8126d2" xlink:href="alvo-20231231.xsd#alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue_75379e23-c5d8-4b07-918d-76322a8126d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TransactionCosts_06065397-b3c9-4ef2-b6eb-18b496dd3108" xlink:href="alvo-20231231.xsd#alvo_TransactionCosts"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_TransactionCosts_06065397-b3c9-4ef2-b6eb-18b496dd3108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CarryingValueOfDebtExtinguished_efcfe2ef-fba2-4692-bdfd-05cb5f7c1e11" xlink:href="alvo-20231231.xsd#alvo_CarryingValueOfDebtExtinguished"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_CarryingValueOfDebtExtinguished_efcfe2ef-fba2-4692-bdfd-05cb5f7c1e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AccruedInterestOnDebtExtinguished_3176a0af-4760-494e-b2e6-0b56573a5e9d" xlink:href="alvo-20231231.xsd#alvo_AccruedInterestOnDebtExtinguished"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_AccruedInterestOnDebtExtinguished_3176a0af-4760-494e-b2e6-0b56573a5e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NetCashProceedsFromTheTransaction_9cd182d4-da55-4d18-88fe-13fa9da2bfd1" xlink:href="alvo-20231231.xsd#alvo_NetCashProceedsFromTheTransaction"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_NetCashProceedsFromTheTransaction_9cd182d4-da55-4d18-88fe-13fa9da2bfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RecognitionOfDerivativeAsset_34d9af03-9f48-4fb7-9e11-1d282c4977ee" xlink:href="alvo-20231231.xsd#alvo_RecognitionOfDerivativeAsset"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_RecognitionOfDerivativeAsset_34d9af03-9f48-4fb7-9e11-1d282c4977ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue_7a11815a-f9c3-4946-8c9b-457e8ead2e8f" xlink:href="alvo-20231231.xsd#alvo_RecognitionOfDerivativeLiabilitiesAtFairValue"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue_7a11815a-f9c3-4946-8c9b-457e8ead2e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_dfa3b757-dba2-47c0-94de-7f820a3e7b1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_dfa3b757-dba2-47c0-94de-7f820a3e7b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfTranches_5b3811a6-2b68-4947-8ef0-7fa4571f6e5a" xlink:href="alvo-20231231.xsd#alvo_NumberOfTranches"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_NumberOfTranches_5b3811a6-2b68-4947-8ef0-7fa4571f6e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_220ac598-adca-41ba-a771-7d4719d1b178" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_220ac598-adca-41ba-a771-7d4719d1b178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRedemptionConversionPrice_e7e58aba-3d8e-4216-96d9-55d38bc85371" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRedemptionConversionPrice"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingsRedemptionConversionPrice_e7e58aba-3d8e-4216-96d9-55d38bc85371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsConversionFeatureFairValue_816f1e45-26af-476c-bbee-6c9f9fc388b1" xlink:href="alvo-20231231.xsd#alvo_BorrowingsConversionFeatureFairValue"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingsConversionFeatureFairValue_816f1e45-26af-476c-bbee-6c9f9fc388b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecurities_5a711ef7-4801-4ae5-92ac-7b21934baeae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecurities"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_DebtSecurities_5a711ef7-4801-4ae5-92ac-7b21934baeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_0d2c5e86-e03d-4a5c-a62d-ec7ff613f341" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_0d2c5e86-e03d-4a5c-a62d-ec7ff613f341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AssetAcquisitionConsiderationLoansAssumed_100d03fe-a44e-4e4c-8c3c-03e208e6caf8" xlink:href="alvo-20231231.xsd#alvo_AssetAcquisitionConsiderationLoansAssumed"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_AssetAcquisitionConsiderationLoansAssumed_100d03fe-a44e-4e4c-8c3c-03e208e6caf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRepurchasedFaceAmount_5e3aa53c-3db9-4604-811c-71653f56ad3b" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRepurchasedFaceAmount"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingsRepurchasedFaceAmount_5e3aa53c-3db9-4604-811c-71653f56ad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_08f2143d-f690-4579-ba36-80621debcc73" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares_08f2143d-f690-4579-ba36-80621debcc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_87f96372-27b6-4416-b4d5-ecea304bc146" xlink:href="alvo-20231231.xsd#alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue_87f96372-27b6-4416-b4d5-ecea304bc146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSeparateInstallments_abfdfdb3-921c-41fd-9bb5-5e406faa94b8" xlink:href="alvo-20231231.xsd#alvo_NumberOfSeparateInstallments"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_NumberOfSeparateInstallments_abfdfdb3-921c-41fd-9bb5-5e406faa94b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AggregateBorrowingsIndebtedness_e3c7172d-d9f4-4503-8ea6-18e7be8a8c6a" xlink:href="alvo-20231231.xsd#alvo_AggregateBorrowingsIndebtedness"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_AggregateBorrowingsIndebtedness_e3c7172d-d9f4-4503-8ea6-18e7be8a8c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPayable_da67b624-621d-44a4-8a90-1e50400db6ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPayable"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_InterestPayable_da67b624-621d-44a4-8a90-1e50400db6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare_2629bb54-a1cf-47f8-82ad-a70b8d2bccb6" xlink:href="alvo-20231231.xsd#alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare_2629bb54-a1cf-47f8-82ad-a70b8d2bccb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtinguishmentOfBorrowings_bce3b2e8-0114-4266-ab50-955ca5d11c90" xlink:href="alvo-20231231.xsd#alvo_ExtinguishmentOfBorrowings"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ExtinguishmentOfBorrowings_bce3b2e8-0114-4266-ab50-955ca5d11c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExtinguishmentOfBorrowingsAccruedInterest_ac879f86-c36c-4af8-a64d-7ded71af2f6f" xlink:href="alvo-20231231.xsd#alvo_ExtinguishmentOfBorrowingsAccruedInterest"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ExtinguishmentOfBorrowingsAccruedInterest_ac879f86-c36c-4af8-a64d-7ded71af2f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_732faf58-b23f-427f-8c5e-6beb460859e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_Borrowings_732faf58-b23f-427f-8c5e-6beb460859e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_da848cf3-6f09-41db-84e5-f666c8d8c124" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_da848cf3-6f09-41db-84e5-f666c8d8c124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_c91d6587-9fda-4830-a090-b103ccf2ce4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_LoansReceived_c91d6587-9fda-4830-a090-b103ccf2ce4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRepurchaseAmount_2b2d2fb8-a340-4eb8-abaf-6c7296aca735" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRepurchaseAmount"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_BorrowingsRepurchaseAmount_2b2d2fb8-a340-4eb8-abaf-6c7296aca735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLoans_7857c547-2cf1-4ed8-b96c-8b8d5f8edc7a" xlink:href="alvo-20231231.xsd#alvo_NumberOfLoans"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_NumberOfLoans_7857c547-2cf1-4ed8-b96c-8b8d5f8edc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromBorrowingsNetOfTransactionCosts_bc01f004-4c21-468a-85ad-5dc21543da86" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromBorrowingsNetOfTransactionCosts"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_alvo_ProceedsFromBorrowingsNetOfTransactionCosts_bc01f004-4c21-468a-85ad-5dc21543da86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_313ccd6c-9eb7-48d3-8e40-9d07cb9fc77f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_313ccd6c-9eb7-48d3-8e40-9d07cb9fc77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_fb899a53-81fd-46f3-b0d6-488295bf2300" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_a261989f-4c37-4fde-8ae6-1dd6b31dc150" xlink:to="loc_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_fb899a53-81fd-46f3-b0d6-488295bf2300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_4e4a6364-7ebf-4027-aabe-becf26333276" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_4e4a6364-7ebf-4027-aabe-becf26333276" xlink:to="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_4f85e16e-dd01-4173-a46a-f79182090326" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_ifrs-full_Borrowings_4f85e16e-dd01-4173-a46a-f79182090326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PaymentsForDebtIssueCost_8b217df3-f4a3-40ee-a461-7b0e04beb0ff" xlink:href="alvo-20231231.xsd#alvo_PaymentsForDebtIssueCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_alvo_PaymentsForDebtIssueCost_8b217df3-f4a3-40ee-a461-7b0e04beb0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AccretionderecognitionOfBorrowingsDiscount_4122a844-9f21-4815-b2e3-17e6652fc194" xlink:href="alvo-20231231.xsd#alvo_AccretionderecognitionOfBorrowingsDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_alvo_AccretionderecognitionOfBorrowingsDiscount_4122a844-9f21-4815-b2e3-17e6652fc194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RecognitionOfNewBorrowingsDiscount_63ebaf70-58e2-4d20-90d2-ee4e9a4c51f7" xlink:href="alvo-20231231.xsd#alvo_RecognitionOfNewBorrowingsDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_alvo_RecognitionOfNewBorrowingsDiscount_63ebaf70-58e2-4d20-90d2-ee4e9a4c51f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities_4478ca30-e8d1-40b6-bf30-66b408adf486" xlink:href="alvo-20231231.xsd#alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities_4478ca30-e8d1-40b6-bf30-66b408adf486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LoansFromRelatedPartyConvertedToEquity_e9382cf4-60ef-4a1b-8b8a-2ca1c2036421" xlink:href="alvo-20231231.xsd#alvo_LoansFromRelatedPartyConvertedToEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_alvo_LoansFromRelatedPartyConvertedToEquity_e9382cf4-60ef-4a1b-8b8a-2ca1c2036421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities_abb57afa-b8b3-4c4f-9b0d-8fae56c66cab" xlink:href="alvo-20231231.xsd#alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities_abb57afa-b8b3-4c4f-9b0d-8fae56c66cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DebtInstrumentIncreaseAccruedInterests_a5d192e6-e28d-4a24-a8ef-9cdc1ba0c751" xlink:href="alvo-20231231.xsd#alvo_DebtInstrumentIncreaseAccruedInterests"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_alvo_DebtInstrumentIncreaseAccruedInterests_a5d192e6-e28d-4a24-a8ef-9cdc1ba0c751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmortizationOfDeferredDebtIssueCosts_f2225ecb-c19b-4ecb-b7d7-f6ede8449137" xlink:href="alvo-20231231.xsd#alvo_AmortizationOfDeferredDebtIssueCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_alvo_AmortizationOfDeferredDebtIssueCosts_f2225ecb-c19b-4ecb-b7d7-f6ede8449137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_01848aae-5c8a-4d68-a8ff-11a4a7c674ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_01848aae-5c8a-4d68-a8ff-11a4a7c674ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_9e79e602-c4d7-4211-bd0d-1d492bd926ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_81dd1904-56b7-4931-8b91-0167dfefbe9d" xlink:to="loc_ifrs-full_Borrowings_9e79e602-c4d7-4211-bd0d-1d492bd926ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_97b0d66d-b2a5-47ec-97c9-b82d9a08f293" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1f82928d-f299-4608-9a42-c94472c1ddac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_97b0d66d-b2a5-47ec-97c9-b82d9a08f293" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1f82928d-f299-4608-9a42-c94472c1ddac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_a4146015-7a81-4e65-bcb0-ee6005956f24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1f82928d-f299-4608-9a42-c94472c1ddac" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_a4146015-7a81-4e65-bcb0-ee6005956f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a4146015-7a81-4e65-bcb0-ee6005956f24" xlink:to="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleLoanNotesMember_9f64d526-4329-4a63-9892-67816832f3fe" xlink:href="alvo-20231231.xsd#alvo_ConvertibleLoanNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:to="loc_alvo_ConvertibleLoanNotesMember_9f64d526-4329-4a63-9892-67816832f3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_a454db1d-e5ef-4abb-87c9-210d3dc89862" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:to="loc_alvo_SeniorBondsMember_a454db1d-e5ef-4abb-87c9-210d3dc89862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherBorrowingsMember_42b02ebe-8f99-49d9-953e-b3ce2c3dbca7" xlink:href="alvo-20231231.xsd#alvo_OtherBorrowingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:to="loc_alvo_OtherBorrowingsMember_42b02ebe-8f99-49d9-953e-b3ce2c3dbca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember_07723a56-b7c2-4f09-8736-67faa0ae68a7" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_5145b2c9-2bac-4360-811e-93d3b0ac95c5" xlink:to="loc_alvo_AlvogenFacilityMember_07723a56-b7c2-4f09-8736-67faa0ae68a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_14258eef-b831-45a1-9ec3-7d81dedc4456" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1f82928d-f299-4608-9a42-c94472c1ddac" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_14258eef-b831-45a1-9ec3-7d81dedc4456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:href="alvo-20231231.xsd#alvo_BorrowingsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_14258eef-b831-45a1-9ec3-7d81dedc4456" xlink:to="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_e203ab54-1c55-4a88-8499-9cd969fac7fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_Borrowings_e203ab54-1c55-4a88-8499-9cd969fac7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_0c532775-7522-4999-bb2a-fe5d9cdc9c68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_0c532775-7522-4999-bb2a-fe5d9cdc9c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease_3ba8fb5a-a33f-44aa-af8f-46a79a0ee7a4" xlink:href="alvo-20231231.xsd#alvo_InterestCostsCapitalizedPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease_3ba8fb5a-a33f-44aa-af8f-46a79a0ee7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement_8870f893-dabc-4636-8274-079cb9444a24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement_8870f893-dabc-4636-8274-079cb9444a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashChangesInOtherChanges_4fece731-fbc3-43f8-9d67-8551086a02f0" xlink:href="alvo-20231231.xsd#alvo_NonCashChangesInOtherChanges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_alvo_NonCashChangesInOtherChanges_4fece731-fbc3-43f8-9d67-8551086a02f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_a882e5a9-e738-4325-8599-e71df412118e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_a882e5a9-e738-4325-8599-e71df412118e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity_98e40728-e307-4f8d-b793-1a0bfa8b2cb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity_98e40728-e307-4f8d-b793-1a0bfa8b2cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashChangesInOtherNonCashMovements_ac7f18bd-c6d3-4fc1-b6c1-189ed541d1b1" xlink:href="alvo-20231231.xsd#alvo_NonCashChangesInOtherNonCashMovements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_alvo_NonCashChangesInOtherNonCashMovements_ac7f18bd-c6d3-4fc1-b6c1-189ed541d1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_63eeb9c8-1943-4b00-9f49-8aceadfee04f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_Borrowings_63eeb9c8-1943-4b00-9f49-8aceadfee04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings_1379be72-0976-4000-8490-a944590f8492" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_ProceedsFromCurrentBorrowings_1379be72-0976-4000-8490-a944590f8492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_655d8dcc-55d7-4f33-9b6c-acb279480229" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_BorrowingsRollForward_16eb0cb0-c8c8-4088-823e-e052451caf96" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_655d8dcc-55d7-4f33-9b6c-acb279480229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForDebtIssueCosts_07099426-81b7-4e84-975a-2d14faa5a5ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForDebtIssueCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_14258eef-b831-45a1-9ec3-7d81dedc4456" xlink:to="loc_ifrs-full_PaymentsForDebtIssueCosts_07099426-81b7-4e84-975a-2d14faa5a5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_7aa8a4e7-bea4-454a-ace0-7084277e843a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0ee4b454-d596-4fd1-b736-9da0b78095df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_7aa8a4e7-bea4-454a-ace0-7084277e843a" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0ee4b454-d596-4fd1-b736-9da0b78095df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_c9efdacf-091d-45d5-8005-ffe36f8e8e6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0ee4b454-d596-4fd1-b736-9da0b78095df" xlink:to="loc_ifrs-full_MaturityAxis_c9efdacf-091d-45d5-8005-ffe36f8e8e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_c9efdacf-091d-45d5-8005-ffe36f8e8e6c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_afe6efba-1cad-44e5-953c-4dd04985fbfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_afe6efba-1cad-44e5-953c-4dd04985fbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1b9b1070-111c-4db5-a753-7e7221a7455f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_1b9b1070-111c-4db5-a753-7e7221a7455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_094d74e6-5088-4f5f-9dcf-ec92b117f354" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_094d74e6-5088-4f5f-9dcf-ec92b117f354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_89d96fa9-a17b-4c44-9acd-af539fae0827" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_89d96fa9-a17b-4c44-9acd-af539fae0827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThereafterMember_a70df2f0-4715-4d78-a1a4-f32431b9fa53" xlink:href="alvo-20231231.xsd#alvo_ThereafterMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_595643e0-8f81-48f7-9135-184f295b4ca1" xlink:to="loc_alvo_ThereafterMember_a70df2f0-4715-4d78-a1a4-f32431b9fa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_aa47283b-f677-4fc8-aeed-9284c568294b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0ee4b454-d596-4fd1-b736-9da0b78095df" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_aa47283b-f677-4fc8-aeed-9284c568294b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_ad263c91-8c55-4a0f-b75a-b6ba9bd1374c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_aa47283b-f677-4fc8-aeed-9284c568294b" xlink:to="loc_ifrs-full_Borrowings_ad263c91-8c55-4a0f-b75a-b6ba9bd1374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LongTermIncentivePlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract_730f8af0-0c52-4df7-8f31-40f9a2c0fc86" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLongtermIncentivePlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract_730f8af0-0c52-4df7-8f31-40f9a2c0fc86" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_31138ca0-fef8-4c12-ace9-cdf124c43a61" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_srt_TitleOfIndividualAxis_31138ca0-fef8-4c12-ace9-cdf124c43a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5b8619af-5e16-4375-ad96-07fca409cc8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_31138ca0-fef8-4c12-ace9-cdf124c43a61" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5b8619af-5e16-4375-ad96-07fca409cc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FormerEmployeesMember_c20accbb-4cde-4c9c-bd94-baa36245fbb4" xlink:href="alvo-20231231.xsd#alvo_FormerEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5b8619af-5e16-4375-ad96-07fca409cc8e" xlink:to="loc_alvo_FormerEmployeesMember_c20accbb-4cde-4c9c-bd94-baa36245fbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExistingEmployeesMember_c0a0ef46-c8b5-4620-8642-2faa587cc654" xlink:href="alvo-20231231.xsd#alvo_ExistingEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5b8619af-5e16-4375-ad96-07fca409cc8e" xlink:to="loc_alvo_ExistingEmployeesMember_c0a0ef46-c8b5-4620-8642-2faa587cc654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_d011bfd9-abfd-4b8b-9528-a47ccfe57324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b7c7b70e-7915-4e0c-b1f4-56ae36b3de7c" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_d011bfd9-abfd-4b8b-9528-a47ccfe57324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_2ce7c5f8-3123-41c1-a950-36d7a70adcb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_d011bfd9-abfd-4b8b-9528-a47ccfe57324" xlink:to="loc_ifrs-full_OrdinarySharesMember_2ce7c5f8-3123-41c1-a950-36d7a70adcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_623425e8-e133-4069-a696-b19c0ed9b73c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3eff68c2-5cc3-4dfb-ac26-7d8a7160e95f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_623425e8-e133-4069-a696-b19c0ed9b73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember_85e40fde-9548-4412-ba8e-92fbf2ca2366" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_623425e8-e133-4069-a696-b19c0ed9b73c" xlink:to="loc_alvo_ShareAppreciationRightsMember_85e40fde-9548-4412-ba8e-92fbf2ca2366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_18f26ac2-e7a6-4771-83d0-20c5969cbeb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_18f26ac2-e7a6-4771-83d0-20c5969cbeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_509e945b-d333-4d50-a4e1-180d79744341" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_18f26ac2-e7a6-4771-83d0-20c5969cbeb4" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_509e945b-d333-4d50-a4e1-180d79744341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_46169514-d868-4039-8862-9863501c9dcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_509e945b-d333-4d50-a4e1-180d79744341" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_46169514-d868-4039-8862-9863501c9dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f6b54d10-f1e8-4ab0-8e85-66d52a2948a3" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_06bb608c-2f3a-47c8-ad68-bb6cb7828f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_06bb608c-2f3a-47c8-ad68-bb6cb7828f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_6a6c08f6-99c2-40f3-8adc-a43f76e4ff59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_NumberOfEmployees_6a6c08f6-99c2-40f3-8adc-a43f76e4ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_405302e8-f5df-4242-8588-a0ee11925366" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_405302e8-f5df-4242-8588-a0ee11925366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination_77b3f35e-90a5-4a76-b235-d216915e2774" xlink:href="alvo-20231231.xsd#alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination_77b3f35e-90a5-4a76-b235-d216915e2774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_7c132a45-2bd6-4575-a99a-28a768221e9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_7c132a45-2bd6-4575-a99a-28a768221e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue_52544203-725a-4a21-823e-871fb276e94f" xlink:href="alvo-20231231.xsd#alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue_52544203-725a-4a21-823e-871fb276e94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue_9cdece47-d30a-4fb9-825a-0f589260fe8d" xlink:href="alvo-20231231.xsd#alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue_9cdece47-d30a-4fb9-825a-0f589260fe8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_172bb982-665d-4b7d-b996-83bf1cd96fc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_172bb982-665d-4b7d-b996-83bf1cd96fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity_2a1dd53f-7cab-4726-a5eb-af65f1072dcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_ChangesInEquity_2a1dd53f-7cab-4726-a5eb-af65f1072dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset_332e9b2f-81a7-41cd-870d-6d5d92e72f29" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset_332e9b2f-81a7-41cd-870d-6d5d92e72f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_cc17af30-170f-4c80-9180-87ebc04e37bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_cc17af30-170f-4c80-9180-87ebc04e37bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_cadcdbfa-9e57-447e-8a6a-0c14b7d608fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_cadcdbfa-9e57-447e-8a6a-0c14b7d608fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement_f510ecca-bde2-4189-80cb-7af7bf169e29" xlink:href="alvo-20231231.xsd#alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_0b4e6f0e-5e04-455e-99fb-0f3c0e4f6a5f" xlink:to="loc_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement_f510ecca-bde2-4189-80cb-7af7bf169e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract_f891ff16-8a00-4905-a4bc-0b3290205ad6" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfLongtermIncentivePlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_bb5f0884-58d7-41de-aad1-71ef453599f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfLongtermIncentivePlansAbstract_f891ff16-8a00-4905-a4bc-0b3290205ad6" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_bb5f0884-58d7-41de-aad1-71ef453599f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_dacc618b-6b39-4a40-bb02-d24684535934" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_bb5f0884-58d7-41de-aad1-71ef453599f3" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_dacc618b-6b39-4a40-bb02-d24684535934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_d2dfcd9f-4297-4811-a4c9-c854d4fddac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_dacc618b-6b39-4a40-bb02-d24684535934" xlink:to="loc_ifrs-full_RestatedMember_d2dfcd9f-4297-4811-a4c9-c854d4fddac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreviouslyStatedMember_3f219747-7498-4c11-9a78-4cac9ba90a98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestatedMember_d2dfcd9f-4297-4811-a4c9-c854d4fddac9" xlink:to="loc_ifrs-full_PreviouslyStatedMember_3f219747-7498-4c11-9a78-4cac9ba90a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember_286e0346-a9e0-4829-92cc-9ec0e03455b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestatedMember_d2dfcd9f-4297-4811-a4c9-c854d4fddac9" xlink:to="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember_286e0346-a9e0-4829-92cc-9ec0e03455b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_f0bc3169-8618-446a-930c-b233875a21d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_bb5f0884-58d7-41de-aad1-71ef453599f3" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_f0bc3169-8618-446a-930c-b233875a21d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:href="alvo-20231231.xsd#alvo_LiabilityAssetOfDefinedBenefitPlansRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_f0bc3169-8618-446a-930c-b233875a21d0" xlink:to="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_3ca580fc-ad0c-4cd5-bc44-6e43d40ed7f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_3ca580fc-ad0c-4cd5-bc44-6e43d40ed7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_36175c65-4401-423d-a04a-181637ffb675" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:to="loc_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset_36175c65-4401-423d-a04a-181637ffb675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d8da3ad5-73d4-40ed-8249-880440175351" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_d8da3ad5-73d4-40ed-8249-880440175351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_5bf9775e-9f87-4bcc-b63d-0d6114c41fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward_cb10091f-4d8f-45b3-8700-8d02200ec2af" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_5bf9775e-9f87-4bcc-b63d-0d6114c41fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareBasedPaymentsSummaryofMovementsinRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_7b53e944-2b9a-47e2-82f8-d3c5bcb39228" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_531b566b-7de6-44fc-9440-9668eaf448da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_7b53e944-2b9a-47e2-82f8-d3c5bcb39228" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_531b566b-7de6-44fc-9440-9668eaf448da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fb2fc671-745d-4aff-9076-98c9cfaa65b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_531b566b-7de6-44fc-9440-9668eaf448da" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fb2fc671-745d-4aff-9076-98c9cfaa65b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2a94830c-7e1f-4a36-adbd-2150b33eeda1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fb2fc671-745d-4aff-9076-98c9cfaa65b2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2a94830c-7e1f-4a36-adbd-2150b33eeda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_f0bb8e4c-3be9-4b27-913a-bc62f4845b68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2a94830c-7e1f-4a36-adbd-2150b33eeda1" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_f0bb8e4c-3be9-4b27-913a-bc62f4845b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_47d5522d-8407-4366-a493-b4263337d0cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_531b566b-7de6-44fc-9440-9668eaf448da" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_47d5522d-8407-4366-a493-b4263337d0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:href="alvo-20231231.xsd#alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_47d5522d-8407-4366-a493-b4263337d0cd" xlink:to="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b2325121-0d39-48db-b4d5-2ed1de8eaf2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b2325121-0d39-48db-b4d5-2ed1de8eaf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_92036a4a-18f7-4cfa-b35d-83d6625246f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_92036a4a-18f7-4cfa-b35d-83d6625246f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e319a152-bfd2-4d99-89da-2aa1b3ce8f8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e319a152-bfd2-4d99-89da-2aa1b3ce8f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_d6ce9fa7-e22f-4eb1-83d1-4629d2a62214" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_d6ce9fa7-e22f-4eb1-83d1-4629d2a62214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_fecdb804-2a93-4cae-8f27-69d77b12b664" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward_39d27f38-5ebd-4b3d-a900-82560c5a6e20" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_fecdb804-2a93-4cae-8f27-69d77b12b664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_47d5522d-8407-4366-a493-b4263337d0cd" xlink:to="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_a38d0108-ed24-4938-87d1-8dccce3c5a29" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_a38d0108-ed24-4938-87d1-8dccce3c5a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted_07aaf5dd-e3b6-4031-8781-1c3e62237ed7" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted_07aaf5dd-e3b6-4031-8781-1c3e62237ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited_cd1d8132-4130-4f0e-b3b7-d56ef26c379a" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited_cd1d8132-4130-4f0e-b3b7-d56ef26c379a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested_8cb449b9-4818-42b5-a63e-e1ad7846d207" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested_8cb449b9-4818-42b5-a63e-e1ad7846d207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_ab0b50be-3913-4696-b4bc-0eaeec47fee6" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract_c72e94c2-e4c5-4fd3-879f-24360091c921" xlink:to="loc_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding_ab0b50be-3913-4696-b4bc-0eaeec47fee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_fa9034d0-4b5b-4c9d-bf43-dc641756245b" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c81360c8-3d75-4e22-8999-fd4390bb8402" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_fa9034d0-4b5b-4c9d-bf43-dc641756245b" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c81360c8-3d75-4e22-8999-fd4390bb8402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77e082e8-62ce-4211-803b-b240ad3313b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c81360c8-3d75-4e22-8999-fd4390bb8402" xlink:to="loc_srt_RangeAxis_77e082e8-62ce-4211-803b-b240ad3313b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83ba829e-67ab-4364-89dd-6b3172fcb000" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_77e082e8-62ce-4211-803b-b240ad3313b6" xlink:to="loc_srt_RangeMember_83ba829e-67ab-4364-89dd-6b3172fcb000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5ed55fba-411e-477a-a156-160e643e7e3d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_83ba829e-67ab-4364-89dd-6b3172fcb000" xlink:to="loc_srt_MinimumMember_5ed55fba-411e-477a-a156-160e643e7e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b0b66b90-6d8f-4a68-8d99-033f552b6478" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_83ba829e-67ab-4364-89dd-6b3172fcb000" xlink:to="loc_srt_MaximumMember_b0b66b90-6d8f-4a68-8d99-033f552b6478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_92952b5d-caae-46f3-aaf9-a41cb9bb507f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c81360c8-3d75-4e22-8999-fd4390bb8402" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_92952b5d-caae-46f3-aaf9-a41cb9bb507f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement_2be87731-f550-4207-a503-25fcb51699a9" xlink:href="alvo-20231231.xsd#alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_92952b5d-caae-46f3-aaf9-a41cb9bb507f" xlink:to="loc_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement_2be87731-f550-4207-a503-25fcb51699a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8657e07d-1732-4d16-ae70-b7261719ebe2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_92952b5d-caae-46f3-aaf9-a41cb9bb507f" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_8657e07d-1732-4d16-ae70-b7261719ebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_9c611d6a-9fb8-46a5-86c2-df6df6635165" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_73ed8fc6-7035-4bd1-b36a-c37fe96a4a4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract_9c611d6a-9fb8-46a5-86c2-df6df6635165" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_73ed8fc6-7035-4bd1-b36a-c37fe96a4a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationAxis_3cb3f1bd-c4e9-4eff-b021-859846914d7c" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_73ed8fc6-7035-4bd1-b36a-c37fe96a4a4e" xlink:to="loc_alvo_IncomeStatementsLocationAxis_3cb3f1bd-c4e9-4eff-b021-859846914d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:href="alvo-20231231.xsd#alvo_IncomeStatementsLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationAxis_3cb3f1bd-c4e9-4eff-b021-859846914d7c" xlink:to="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_6db0d1eb-fa5b-45ea-8f48-bfb950ac585b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:to="loc_ifrs-full_CostOfSalesMember_6db0d1eb-fa5b-45ea-8f48-bfb950ac585b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ResearchAndDevelopmentExpensesMember_891ead7d-2a16-4e5c-957f-129e6f2a615c" xlink:href="alvo-20231231.xsd#alvo_ResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:to="loc_alvo_ResearchAndDevelopmentExpensesMember_891ead7d-2a16-4e5c-957f-129e6f2a615c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_GeneralAndAdministrativeExpensesMember_6360c1e5-d364-44ce-9b12-92b3c05c11ec" xlink:href="alvo-20231231.xsd#alvo_GeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_IncomeStatementsLocationDomain_420dec1a-a310-4fa6-a9c9-436ea3157741" xlink:to="loc_alvo_GeneralAndAdministrativeExpensesMember_6360c1e5-d364-44ce-9b12-92b3c05c11ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aba806e3-a0e9-41c3-9b95-76c2bde821e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_73ed8fc6-7035-4bd1-b36a-c37fe96a4a4e" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aba806e3-a0e9-41c3-9b95-76c2bde821e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_579de708-06f5-4aa0-99cb-74a0576843b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aba806e3-a0e9-41c3-9b95-76c2bde821e8" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_579de708-06f5-4aa0-99cb-74a0576843b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/LitigationAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#LitigationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/LitigationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LitigationAbstract_69f8091f-a573-46e0-a3a1-063f1277c4ec" xlink:href="alvo-20231231.xsd#alvo_LitigationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLitigations_e06d7448-cc5c-44f1-a43d-24f7c0ff5f71" xlink:href="alvo-20231231.xsd#alvo_NumberOfLitigations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LitigationAbstract_69f8091f-a573-46e0-a3a1-063f1277c4ec" xlink:to="loc_alvo_NumberOfLitigations_e06d7448-cc5c-44f1-a43d-24f7c0ff5f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LegalCost_3148f73f-92bb-4608-83f0-b7a56425e495" xlink:href="alvo-20231231.xsd#alvo_LegalCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LitigationAbstract_69f8091f-a573-46e0-a3a1-063f1277c4ec" xlink:to="loc_alvo_LegalCost_3148f73f-92bb-4608-83f0-b7a56425e495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_43bc925a-350a-453d-b6fa-fce532e8a8a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_43bc925a-350a-453d-b6fa-fce532e8a8a2" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2f77fcc5-58c6-4d89-8741-1c98fb07806b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:to="loc_srt_CounterpartyNameAxis_2f77fcc5-58c6-4d89-8741-1c98fb07806b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2f77fcc5-58c6-4d89-8741-1c98fb07806b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_d17dbb01-6021-4f63-878d-306bdc191502" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHf.SisterCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:to="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_d17dbb01-6021-4f63-878d-306bdc191502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiFasteignirEhf.Member_721fa112-978f-49c7-9937-40bfd38add57" xlink:href="alvo-20231231.xsd#alvo_FlokiFasteignirEhf.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:to="loc_alvo_FlokiFasteignirEhf.Member_721fa112-978f-49c7-9937-40bfd38add57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiArtEhf.Member_863e8239-ae43-41c3-93aa-eb22fd802a31" xlink:href="alvo-20231231.xsd#alvo_FlokiArtEhf.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604db5bc-8c88-469a-93b0-18559e084c31" xlink:to="loc_alvo_FlokiArtEhf.Member_863e8239-ae43-41c3-93aa-eb22fd802a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseFacilityAxis_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d" xlink:href="alvo-20231231.xsd#alvo_LeaseFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:to="loc_alvo_LeaseFacilityAxis_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:href="alvo-20231231.xsd#alvo_LeaseFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseFacilityAxis_16a1b09e-1834-4ca4-979c-0a1fb5b4fe6d" xlink:to="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TwoLeaseFacilitiesMember_f73f3230-8b68-46b5-86c2-69cf49a39c3b" xlink:href="alvo-20231231.xsd#alvo_TwoLeaseFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:to="loc_alvo_TwoLeaseFacilitiesMember_f73f3230-8b68-46b5-86c2-69cf49a39c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_April2023LeaseFacilityMember_13fd71da-4bb0-46c9-ac49-1bcc0d602ad1" xlink:href="alvo-20231231.xsd#alvo_April2023LeaseFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:to="loc_alvo_April2023LeaseFacilityMember_13fd71da-4bb0-46c9-ac49-1bcc0d602ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Remaining15LeaseFacilitiesMember_5c6c2933-7594-468c-926b-d238f4e7796d" xlink:href="alvo-20231231.xsd#alvo_Remaining15LeaseFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_LeaseFacilityDomain_3e56b410-fc53-4128-bcb9-4180e043910b" xlink:to="loc_alvo_Remaining15LeaseFacilitiesMember_5c6c2933-7594-468c-926b-d238f4e7796d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_2b9bc984-3fed-4dc2-960d-85b9ca0a8b52" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeaseAgreementsEnteredInto_a8f70729-5139-4ff1-ac9b-9cf3cb13c93d" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeaseAgreementsEnteredInto"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_NumberOfLeaseAgreementsEnteredInto_a8f70729-5139-4ff1-ac9b-9cf3cb13c93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WeightedAverageRemainingLeaseTerm_6a30755b-9c8e-4055-9480-026fe56df90e" xlink:href="alvo-20231231.xsd#alvo_WeightedAverageRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_WeightedAverageRemainingLeaseTerm_6a30755b-9c8e-4055-9480-026fe56df90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeasesTerminated_403b44e0-1fc9-44be-a999-810504a53afd" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeasesTerminated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_NumberOfLeasesTerminated_403b44e0-1fc9-44be-a999-810504a53afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfLeaseAgreements_cf39ea6e-d955-473a-9388-4b327b061980" xlink:href="alvo-20231231.xsd#alvo_NumberOfLeaseAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_NumberOfLeaseAgreements_cf39ea6e-d955-473a-9388-4b327b061980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LoansToRelatedParties_8ef19f40-533e-4228-825e-59f33f8286ae" xlink:href="alvo-20231231.xsd#alvo_LoansToRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_96f8f1f7-8fb1-4068-9548-6cee5758c6e8" xlink:to="loc_alvo_LoansToRelatedParties_8ef19f40-533e-4228-825e-59f33f8286ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesSummaryofRelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_513eb4e7-f99e-403b-af7c-9ee2691b4171" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7c32c1e2-88e9-4675-b6c6-594091928ebf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_513eb4e7-f99e-403b-af7c-9ee2691b4171" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7c32c1e2-88e9-4675-b6c6-594091928ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9da972ca-fb84-4d1a-9e56-75c4df1b6747" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7c32c1e2-88e9-4675-b6c6-594091928ebf" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9da972ca-fb84-4d1a-9e56-75c4df1b6747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_9da972ca-fb84-4d1a-9e56-75c4df1b6747" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLuxHoldingsSRLMember_0b36d9c9-45d2-40c7-8920-4c7bfd7284cd" xlink:href="alvo-20231231.xsd#alvo_AlvogenLuxHoldingsSRLMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenLuxHoldingsSRLMember_0b36d9c9-45d2-40c7-8920-4c7bfd7284cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AtpHoldingsEhfMember_ffdc8581-e23b-47d4-b2f1-0d0ff843886c" xlink:href="alvo-20231231.xsd#alvo_AtpHoldingsEhfMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AtpHoldingsEhfMember_ffdc8581-e23b-47d4-b2f1-0d0ff843886c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFjrfestingarEhfMember_a1c19332-a7e4-4533-b43d-cd1857f6fa22" xlink:href="alvo-20231231.xsd#alvo_AztiqFjrfestingarEhfMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AztiqFjrfestingarEhfMember_a1c19332-a7e4-4533-b43d-cd1857f6fa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_8a4cadb2-e430-4f88-8afa-4e30c230b913" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHf.SisterCompanyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_8a4cadb2-e430-4f88-8afa-4e30c230b913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiEyjolfurEhfMember_60d03009-0fa9-4f02-a560-6c024da47df2" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiEyjolfurEhfMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FasteignafelagiEyjolfurEhfMember_60d03009-0fa9-4f02-a560-6c024da47df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConsultingEhfMember_c9862b00-bef2-41cf-8f10-4e829b9a753f" xlink:href="alvo-20231231.xsd#alvo_AztiqConsultingEhfMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AztiqConsultingEhfMember_c9862b00-bef2-41cf-8f10-4e829b9a753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiArtEhfMember_b7815af3-f47a-4c53-9322-ffeac8f6aa68" xlink:href="alvo-20231231.xsd#alvo_FlokiArtEhfMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FlokiArtEhfMember_b7815af3-f47a-4c53-9322-ffeac8f6aa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember_6315f512-2c3c-4952-a640-13d64fd4fea1" xlink:href="alvo-20231231.xsd#alvo_AlvogenIcelandEhf.SisterCompanyMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember_6315f512-2c3c-4952-a640-13d64fd4fea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEhf.SisterCompanyMember_89711954-d4ea-45bf-9ce3-18a693af222c" xlink:href="alvo-20231231.xsd#alvo_AlvogenEhf.SisterCompanyMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenEhf.SisterCompanyMember_89711954-d4ea-45bf-9ce3-18a693af222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenUKSisterCompanyMember_6ba7fd22-7808-4e10-8a78-e7faec788fe2" xlink:href="alvo-20231231.xsd#alvo_AlvogenUKSisterCompanyMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenUKSisterCompanyMember_6ba7fd22-7808-4e10-8a78-e7faec788fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFinanceB.VMember_270d97e8-4258-45b1-abe4-7b4ebba90e51" xlink:href="alvo-20231231.xsd#alvo_AlvogenFinanceB.VMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenFinanceB.VMember_270d97e8-4258-45b1-abe4-7b4ebba90e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_d9803858-726e-4e8e-893b-ad85bb69384b" xlink:href="alvo-20231231.xsd#alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_d9803858-726e-4e8e-893b-ad85bb69384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusInternationalPteltdMember_571a625a-3a1a-42d3-a63f-a3c53fc97767" xlink:href="alvo-20231231.xsd#alvo_LotusInternationalPteltdMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_LotusInternationalPteltdMember_571a625a-3a1a-42d3-a63f-a3c53fc97767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember_559f509b-c093-4a9f-a2c5-4aaf9409991b" xlink:href="alvo-20231231.xsd#alvo_AlvogenEmergingMarketsSisterCompanyMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember_559f509b-c093-4a9f-a2c5-4aaf9409991b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_63be4742-69ef-478c-90b7-b7301ec575a8" xlink:href="alvo-20231231.xsd#alvo_AlvogenKoreaCo.LtdSisterCompanyMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_63be4742-69ef-478c-90b7-b7301ec575a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenInc.SisterCompanyMember_3a0685c4-a084-451d-87bb-d354b1209def" xlink:href="alvo-20231231.xsd#alvo_AlvogenInc.SisterCompanyMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenInc.SisterCompanyMember_3a0685c4-a084-451d-87bb-d354b1209def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_e411ece4-fabc-48cf-b084-87966b33d969" xlink:href="alvo-20231231.xsd#alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_e411ece4-fabc-48cf-b084-87966b33d969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdalvoLimitedMember_56e73611-49d6-41a9-b02c-d2b747c1e7e6" xlink:href="alvo-20231231.xsd#alvo_AdalvoLimitedMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AdalvoLimitedMember_56e73611-49d6-41a9-b02c-d2b747c1e7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdalvoUKMember_c0488ec7-bfd7-419d-b43c-eddbbffcb1c6" xlink:href="alvo-20231231.xsd#alvo_AdalvoUKMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AdalvoUKMember_c0488ec7-bfd7-419d-b43c-eddbbffcb1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiInvestEhfMember_5a560699-8929-4722-b150-f2a85a1e930b" xlink:href="alvo-20231231.xsd#alvo_FlokiInvestEhfMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FlokiInvestEhfMember_5a560699-8929-4722-b150-f2a85a1e930b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiHoldingsS.aR.lMember_173f59ae-f142-4064-b92f-5c474ff918b6" xlink:href="alvo-20231231.xsd#alvo_FlokiHoldingsS.aR.lMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FlokiHoldingsS.aR.lMember_173f59ae-f142-4064-b92f-5c474ff918b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_L41EhfMember_68f5a6b4-9b5d-4b5e-a987-2b131a7ca77e" xlink:href="alvo-20231231.xsd#alvo_L41EhfMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_L41EhfMember_68f5a6b4-9b5d-4b5e-a987-2b131a7ca77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_df783559-1745-4fda-b4a9-473f5ed33128" xlink:href="alvo-20231231.xsd#alvo_AlvogenMaltaSh.ServicesSisterCompanyMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_df783559-1745-4fda-b4a9-473f5ed33128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenSpainSlMember_8f22e66b-5be8-4de0-b2b2-f81f34c93185" xlink:href="alvo-20231231.xsd#alvo_AlvogenSpainSlMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenSpainSlMember_8f22e66b-5be8-4de0-b2b2-f81f34c93185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NorwichClinicalServicesLtdMember_d3264a05-cda2-47aa-953f-1c2c7810e11a" xlink:href="alvo-20231231.xsd#alvo_NorwichClinicalServicesLtdMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_NorwichClinicalServicesLtdMember_d3264a05-cda2-47aa-953f-1c2c7810e11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignaflagiEyjlfurhfMember_64ece6f8-73d0-44c4-b816-ee4b2d09afb3" xlink:href="alvo-20231231.xsd#alvo_FasteignaflagiEyjlfurhfMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FasteignaflagiEyjlfurhfMember_64ece6f8-73d0-44c4-b816-ee4b2d09afb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FlokiFasteignirEhfMember_60b1320d-ff6e-4bbe-b5ce-8ad150597d1c" xlink:href="alvo-20231231.xsd#alvo_FlokiFasteignirEhfMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_FlokiFasteignirEhfMember_60b1320d-ff6e-4bbe-b5ce-8ad150597d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_8b0c8e17-750c-4b2a-8b51-a7d105aa7e65" xlink:href="alvo-20231231.xsd#alvo_AlvogenPharmaPvtLtdSisterCompanyMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_8b0c8e17-750c-4b2a-8b51-a7d105aa7e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Lambahagavegur7EhfMember_3c435b96-253b-473e-ad94-9d7a1f5755c5" xlink:href="alvo-20231231.xsd#alvo_Lambahagavegur7EhfMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_914b59b8-0d9c-4237-9298-addc88fa6eab" xlink:to="loc_alvo_Lambahagavegur7EhfMember_3c435b96-253b-473e-ad94-9d7a1f5755c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7c32c1e2-88e9-4675-b6c6-594091928ebf" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_0f043c7e-44c2-4751-bac1-9d59187a329c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_0f043c7e-44c2-4751-bac1-9d59187a329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_1a6d75d5-d0b5-49eb-9688-77f2cb3d455e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_1a6d75d5-d0b5-49eb-9688-77f2cb3d455e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_bd0fe2f0-4c0a-4cbe-bde6-69c7d9e946a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_bd0fe2f0-4c0a-4cbe-bde6-69c7d9e946a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_405eb4a8-9e2c-4b20-8403-3c25277cf9fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_405eb4a8-9e2c-4b20-8403-3c25277cf9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1ebd866c-0d46-471e-8fef-66444246e58a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_7537b8d0-73db-491a-834a-b550c098e6e4" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_1ebd866c-0d46-471e-8fef-66444246e58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesScheduleofRelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_226e4180-e946-4173-9092-e1aa962bcb59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_021e0c17-8a2e-481f-b0b1-9f53c77c4131" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_226e4180-e946-4173-9092-e1aa962bcb59" xlink:to="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_021e0c17-8a2e-481f-b0b1-9f53c77c4131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_6e1f19ee-5ed9-4f07-b00c-570de0b69963" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_021e0c17-8a2e-481f-b0b1-9f53c77c4131" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_6e1f19ee-5ed9-4f07-b00c-570de0b69963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_6e1f19ee-5ed9-4f07-b00c-570de0b69963" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember_81763b40-46be-4d08-8f6f-937c74843880" xlink:href="alvo-20231231.xsd#alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember_81763b40-46be-4d08-8f6f-937c74843880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember_aa018c2a-2118-40a9-8f42-94b4772f2bca" xlink:href="alvo-20231231.xsd#alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember_aa018c2a-2118-40a9-8f42-94b4772f2bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenAztiqABSisterCompanyMember_02340af5-d7ef-416c-a355-c7677f4b03c6" xlink:href="alvo-20231231.xsd#alvo_AlvogenAztiqABSisterCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenAztiqABSisterCompanyMember_02340af5-d7ef-416c-a355-c7677f4b03c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqFjrfestingarEhfMember_eb2020c9-6f9e-42c5-b46f-5a214e9c20fa" xlink:href="alvo-20231231.xsd#alvo_AztiqFjrfestingarEhfMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AztiqFjrfestingarEhfMember_eb2020c9-6f9e-42c5-b46f-5a214e9c20fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_799369df-d9ea-4ff2-8b61-536ec8ecd31a" xlink:href="alvo-20231231.xsd#alvo_FasteignafelagiSmundurHf.SisterCompanyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_FasteignafelagiSmundurHf.SisterCompanyMember_799369df-d9ea-4ff2-8b61-536ec8ecd31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember_add0306b-2abb-4306-b112-93645e3ea1d0" xlink:href="alvo-20231231.xsd#alvo_AlvogenIcelandEhf.SisterCompanyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenIcelandEhf.SisterCompanyMember_add0306b-2abb-4306-b112-93645e3ea1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEhf.SisterCompanyMember_c9cd6ee4-7922-4ffd-ad87-e6a78f9ec892" xlink:href="alvo-20231231.xsd#alvo_AlvogenEhf.SisterCompanyMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenEhf.SisterCompanyMember_c9cd6ee4-7922-4ffd-ad87-e6a78f9ec892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenUKSisterCompanyMember_e5086ad6-4574-43be-9c65-315474206f4b" xlink:href="alvo-20231231.xsd#alvo_AlvogenUKSisterCompanyMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenUKSisterCompanyMember_e5086ad6-4574-43be-9c65-315474206f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_88614146-ddce-41ad-8d9f-7195b3b2e8b1" xlink:href="alvo-20231231.xsd#alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember_88614146-ddce-41ad-8d9f-7195b3b2e8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember_4b77dca8-02c3-4555-99a6-dc200cf67070" xlink:href="alvo-20231231.xsd#alvo_AlvogenEmergingMarketsSisterCompanyMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenEmergingMarketsSisterCompanyMember_4b77dca8-02c3-4555-99a6-dc200cf67070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_13da9074-d8bb-4f62-8fd9-c013538da46f" xlink:href="alvo-20231231.xsd#alvo_AlvogenKoreaCo.LtdSisterCompanyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenKoreaCo.LtdSisterCompanyMember_13da9074-d8bb-4f62-8fd9-c013538da46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenInc.SisterCompanyMember_f84bfdf8-f00a-4451-a3bb-4b545d8ddca3" xlink:href="alvo-20231231.xsd#alvo_AlvogenInc.SisterCompanyMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenInc.SisterCompanyMember_f84bfdf8-f00a-4451-a3bb-4b545d8ddca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_2b1dbe6c-fecd-4c7b-b4a2-b982f03c75ef" xlink:href="alvo-20231231.xsd#alvo_AlvogenMaltaSh.ServicesSisterCompanyMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenMaltaSh.ServicesSisterCompanyMember_2b1dbe6c-fecd-4c7b-b4a2-b982f03c75ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_a3f8ce9a-6a5d-4533-86b6-3825ba3df806" xlink:href="alvo-20231231.xsd#alvo_AlvogenPharmaPvtLtdSisterCompanyMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_AlvogenPharmaPvtLtdSisterCompanyMember_a3f8ce9a-6a5d-4533-86b6-3825ba3df806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HRJAFEhfSisterCompanyMember_8c6f0376-89d2-4dde-ade2-eac8fd703351" xlink:href="alvo-20231231.xsd#alvo_HRJAFEhfSisterCompanyMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_HRJAFEhfSisterCompanyMember_8c6f0376-89d2-4dde-ade2-eac8fd703351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_L41EhfMember_e51b248c-0515-48db-9df3-12b3d88d38a4" xlink:href="alvo-20231231.xsd#alvo_L41EhfMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_L41EhfMember_e51b248c-0515-48db-9df3-12b3d88d38a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_Lambhagavegur7EhfMember_015be8e3-9cda-4038-9a8d-b9fa0805e20b" xlink:href="alvo-20231231.xsd#alvo_Lambhagavegur7EhfMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_41ef4d0a-7255-4492-940c-4a16c0701cad" xlink:to="loc_alvo_Lambhagavegur7EhfMember_015be8e3-9cda-4038-9a8d-b9fa0805e20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_193a4ec1-0be9-4295-bbd9-e07060e87ad6" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_021e0c17-8a2e-481f-b0b1-9f53c77c4131" xlink:to="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_193a4ec1-0be9-4295-bbd9-e07060e87ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_9d51f9e8-9bfb-4319-928f-306f982b4171" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_193a4ec1-0be9-4295-bbd9-e07060e87ad6" xlink:to="loc_ifrs-full_ServicesReceivedRelatedPartyTransactions_9d51f9e8-9bfb-4319-928f-306f982b4171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_2ac796a0-0211-47af-a52f-349c2570dad3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_193a4ec1-0be9-4295-bbd9-e07060e87ad6" xlink:to="loc_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions_2ac796a0-0211-47af-a52f-349c2570dad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_3f189280-6165-4794-a847-84a094b101f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_3f189280-6165-4794-a847-84a094b101f4" xlink:to="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_769842c9-e4a7-4ee3-ac32-0dc4b7260c7e" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RobertWessmanMember_d876e890-41bf-42e5-a6e9-8230d04f915f" xlink:href="alvo-20231231.xsd#alvo_RobertWessmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_RobertWessmanMember_d876e890-41bf-42e5-a6e9-8230d04f915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RichardDaviesMember_0f707890-1b8b-455d-ba91-7b12b54234d0" xlink:href="alvo-20231231.xsd#alvo_RichardDaviesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_RichardDaviesMember_0f707890-1b8b-455d-ba91-7b12b54234d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AnnMerchantMember_9e50adaa-8f15-4192-934f-8c45457b5d9f" xlink:href="alvo-20231231.xsd#alvo_AnnMerchantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_AnnMerchantMember_9e50adaa-8f15-4192-934f-8c45457b5d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ArniHararsonMember_3dc00d17-a0a9-4657-aba8-8b3c8b9f7197" xlink:href="alvo-20231231.xsd#alvo_ArniHararsonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_ArniHararsonMember_3dc00d17-a0a9-4657-aba8-8b3c8b9f7197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FaysalKalmouaMember_cdeb3a3f-c36a-4106-a1e9-e6e7367b49f4" xlink:href="alvo-20231231.xsd#alvo_FaysalKalmouaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_FaysalKalmouaMember_cdeb3a3f-c36a-4106-a1e9-e6e7367b49f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LindaMcgoldrickMember_65be12cf-8489-41d9-a2f2-a6621105786a" xlink:href="alvo-20231231.xsd#alvo_LindaMcgoldrickMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_LindaMcgoldrickMember_65be12cf-8489-41d9-a2f2-a6621105786a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LisaGraverMember_b7e3e513-cf91-40f9-80a5-60efd17b6c40" xlink:href="alvo-20231231.xsd#alvo_LisaGraverMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_LisaGraverMember_b7e3e513-cf91-40f9-80a5-60efd17b6c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThomasEkmanMember_302f44fc-cd26-43a7-8f69-f5872f49731b" xlink:href="alvo-20231231.xsd#alvo_ThomasEkmanMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_ThomasEkmanMember_302f44fc-cd26-43a7-8f69-f5872f49731b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_MarkLevickCeoMember_6ac587cb-ccce-4084-af4a-4217309d89b9" xlink:href="alvo-20231231.xsd#alvo_MarkLevickCeoMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_MarkLevickCeoMember_6ac587cb-ccce-4084-af4a-4217309d89b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherExecutiveTeamMember_99a7cfe9-d382-4cc0-92ef-b154e532cb03" xlink:href="alvo-20231231.xsd#alvo_OtherExecutiveTeamMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_OtherExecutiveTeamMember_99a7cfe9-d382-4cc0-92ef-b154e532cb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HirofumiImaiBoardMember_b510395c-50ba-4e97-8aab-bd70c358517d" xlink:href="alvo-20231231.xsd#alvo_HirofumiImaiBoardMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_37646c69-864b-41b2-ac50-4b56a4bad411" xlink:to="loc_alvo_HirofumiImaiBoardMember_b510395c-50ba-4e97-8aab-bd70c358517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationStatusAxis_cb04569a-3e9d-4f54-93f3-4603e3a911a2" xlink:href="alvo-20231231.xsd#alvo_CompensationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:to="loc_alvo_CompensationStatusAxis_cb04569a-3e9d-4f54-93f3-4603e3a911a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationStatusDomain_f571058c-ed31-49b0-9c83-91b95799754c" xlink:href="alvo-20231231.xsd#alvo_CompensationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CompensationStatusAxis_cb04569a-3e9d-4f54-93f3-4603e3a911a2" xlink:to="loc_alvo_CompensationStatusDomain_f571058c-ed31-49b0-9c83-91b95799754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CompensationWaivedMember_e5c2acdb-05f4-4db3-8eac-4d327cf09b1b" xlink:href="alvo-20231231.xsd#alvo_CompensationWaivedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CompensationStatusDomain_f571058c-ed31-49b0-9c83-91b95799754c" xlink:to="loc_alvo_CompensationWaivedMember_e5c2acdb-05f4-4db3-8eac-4d327cf09b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NetCompensationExpenseMember_134c1f16-8e5a-4291-b790-14530af6a0b2" xlink:href="alvo-20231231.xsd#alvo_NetCompensationExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_CompensationStatusDomain_f571058c-ed31-49b0-9c83-91b95799754c" xlink:to="loc_alvo_NetCompensationExpenseMember_134c1f16-8e5a-4291-b790-14530af6a0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:href="alvo-20231231.xsd#alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable_0581267c-d723-424c-9df5-d214bbca6e8c" xlink:to="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DirectorFees_acf991d5-26b0-42f1-95a0-6c4dd8dcb7a8" xlink:href="alvo-20231231.xsd#alvo_DirectorFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_alvo_DirectorFees_acf991d5-26b0-42f1-95a0-6c4dd8dcb7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_58f3160a-7396-4fd4-bae7-b2e422f5b524" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_58f3160a-7396-4fd4-bae7-b2e422f5b524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_f091675c-0705-48e1-9487-a97434bd886d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_f091675c-0705-48e1-9487-a97434bd886d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_3a570c4a-65bb-4c36-9cf4-755c51e49460" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_3a570c4a-65bb-4c36-9cf4-755c51e49460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_7a184c2c-e882-4d88-87b9-1edd53a17ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_7a184c2c-e882-4d88-87b9-1edd53a17ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_ab069e28-77ce-4161-a3ec-371f72972466" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems_0253ecac-e9bc-42f1-907f-47c22101eb1b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_ab069e28-77ce-4161-a3ec-371f72972466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentLiabilitiesAbstract_7db057c0-0f85-4975-bed2-2f6afcafcd5c" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses_c852015a-8348-451b-bd13-65aff3979614" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract_7db057c0-0f85-4975-bed2-2f6afcafcd5c" xlink:to="loc_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses_c852015a-8348-451b-bd13-65aff3979614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedInterest_9035ba5f-48fc-4ada-8094-815ebd3eeb73" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract_7db057c0-0f85-4975-bed2-2f6afcafcd5c" xlink:to="loc_alvo_CurrentAccruedInterest_9035ba5f-48fc-4ada-8094-815ebd3eeb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentAccruedVacation_9dde54b9-7759-4cea-a54c-df7d966164ca" xlink:href="alvo-20231231.xsd#alvo_CurrentAccruedVacation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract_7db057c0-0f85-4975-bed2-2f6afcafcd5c" xlink:to="loc_alvo_CurrentAccruedVacation_9dde54b9-7759-4cea-a54c-df7d966164ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CurrentEmployeeIncentivePlan_af72afbc-e0da-4edd-af4b-cc8e5b562bc2" xlink:href="alvo-20231231.xsd#alvo_CurrentEmployeeIncentivePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract_7db057c0-0f85-4975-bed2-2f6afcafcd5c" xlink:to="loc_alvo_CurrentEmployeeIncentivePlan_af72afbc-e0da-4edd-af4b-cc8e5b562bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_7ec9b7a9-7fad-4b14-957f-1bf388de9de8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract_7db057c0-0f85-4975-bed2-2f6afcafcd5c" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_7ec9b7a9-7fad-4b14-957f-1bf388de9de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_11c89f84-d549-4b00-9c05-6c52b283c7c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_OtherCurrentLiabilitiesAbstract_7db057c0-0f85-4975-bed2-2f6afcafcd5c" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_11c89f84-d549-4b00-9c05-6c52b283c7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesAbstract_63792c48-250b-4445-ac07-5141bebc99a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_c46a7554-b032-4496-923b-eb551eb51dc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_63792c48-250b-4445-ac07-5141bebc99a9" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesTable_c46a7554-b032-4496-923b-eb551eb51dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_6c8d1b08-de04-48b6-9a03-3a26b934e0db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_c46a7554-b032-4496-923b-eb551eb51dc4" xlink:to="loc_ifrs-full_JointVenturesAxis_6c8d1b08-de04-48b6-9a03-3a26b934e0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_b92fc86e-6b59-4754-a6a2-8f6bdb14a4b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_6c8d1b08-de04-48b6-9a03-3a26b934e0db" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_b92fc86e-6b59-4754-a6a2-8f6bdb14a4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_2eb9a0d1-9161-40b2-959a-59282018d351" xlink:href="alvo-20231231.xsd#alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_b92fc86e-6b59-4754-a6a2-8f6bdb14a4b0" xlink:to="loc_alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember_2eb9a0d1-9161-40b2-959a-59282018d351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_c46a7554-b032-4496-923b-eb551eb51dc4" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture_cc7d84a8-e84f-4617-a4ef-944648c72422" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PrincipalPlaceOfBusinessOfJointVenture"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:to="loc_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture_cc7d84a8-e84f-4617-a4ef-944648c72422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_54ea4d05-a9c7-40d7-aff9-4d069fb5cd87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_54ea4d05-a9c7-40d7-aff9-4d069fb5cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_21c1d617-af5a-4c9b-88cf-1dc6717ce450" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c7e514d1-126c-4bdb-a7a3-dc5d4587c442" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_21c1d617-af5a-4c9b-88cf-1dc6717ce450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesAbstract_fc6dfd58-b26c-47ec-938e-fe2785f237d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_ca19bfbd-0091-4c79-af37-073ac7096cb2" xlink:href="alvo-20231231.xsd#alvo_InvestmentsAccountedForUsingEquityMethodRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_fc6dfd58-b26c-47ec-938e-fe2785f237d0" xlink:to="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_ca19bfbd-0091-4c79-af37-073ac7096cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_90f2d95c-7b31-40df-ad6c-dc10269ab80e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_ca19bfbd-0091-4c79-af37-073ac7096cb2" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_90f2d95c-7b31-40df-ad6c-dc10269ab80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_b02419b1-f8c1-4c5c-b118-4d6a0ec5f6c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_ca19bfbd-0091-4c79-af37-073ac7096cb2" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_b02419b1-f8c1-4c5c-b118-4d6a0ec5f6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_ec241bca-6767-47e8-8616-10275e42392a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_ca19bfbd-0091-4c79-af37-073ac7096cb2" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_ec241bca-6767-47e8-8616-10275e42392a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax_9aa97a40-3ebc-4c50-ab8e-095fc38f685a" xlink:href="alvo-20231231.xsd#alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_ca19bfbd-0091-4c79-af37-073ac7096cb2" xlink:to="loc_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax_9aa97a40-3ebc-4c50-ab8e-095fc38f685a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_0235e708-84e3-4538-bf20-109a44ec69f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_InvestmentsAccountedForUsingEquityMethodRollForward_ca19bfbd-0091-4c79-af37-073ac7096cb2" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_0235e708-84e3-4538-bf20-109a44ec69f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#InterestsInJointVenturesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesAbstract_88dc3cd4-4b16-42d6-9162-b969fd2c42cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities_cb2ce9df-a685-4d17-be4c-bfeecb76092f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_88dc3cd4-4b16-42d6-9162-b969fd2c42cf" xlink:to="loc_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities_cb2ce9df-a685-4d17-be4c-bfeecb76092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommitmentsInRelationToJointVentures_c07dce45-afbd-4944-9894-178a5c2a713c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommitmentsInRelationToJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_88dc3cd4-4b16-42d6-9162-b969fd2c42cf" xlink:to="loc_ifrs-full_CommitmentsInRelationToJointVentures_c07dce45-afbd-4944-9894-178a5c2a713c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures_c9ee6248-e416-4e0a-9fce-94d9fbe97671" xlink:href="alvo-20231231.xsd#alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_88dc3cd4-4b16-42d6-9162-b969fd2c42cf" xlink:to="loc_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures_c9ee6248-e416-4e0a-9fce-94d9fbe97671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_7fc7953f-60df-43f5-80a5-b1fed7d640a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesAbstract_88dc3cd4-4b16-42d6-9162-b969fd2c42cf" xlink:to="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_7fc7953f-60df-43f5-80a5-b1fed7d640a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_abe017b7-2cf9-4c00-ada8-f9765f30d356" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_b143bbbb-d97b-49c3-af1a-929e69015f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_abe017b7-2cf9-4c00-ada8-f9765f30d356" xlink:to="loc_ifrs-full_CashAndCashEquivalents_b143bbbb-d97b-49c3-af1a-929e69015f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_659a0134-d73e-404e-b5c1-8a672da4946d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_abe017b7-2cf9-4c00-ada8-f9765f30d356" xlink:to="loc_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_659a0134-d73e-404e-b5c1-8a672da4946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_dd1e1694-4cc1-49e8-8fe3-48c796d008b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_abe017b7-2cf9-4c00-ada8-f9765f30d356" xlink:to="loc_ifrs-full_CurrentTradeReceivables_dd1e1694-4cc1-49e8-8fe3-48c796d008b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentAsset_884e849e-bc55-447b-9291-0f3efe615d4c" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_abe017b7-2cf9-4c00-ada8-f9765f30d356" xlink:to="loc_alvo_OtherCurrentAsset_884e849e-bc55-447b-9291-0f3efe615d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_18a55be2-303d-42f6-bf9e-817fd85f9e68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_abe017b7-2cf9-4c00-ada8-f9765f30d356" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_18a55be2-303d-42f6-bf9e-817fd85f9e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherNoncurrentAsset_7632b009-436f-4779-b0b7-990ab660f7c0" xlink:href="alvo-20231231.xsd#alvo_OtherNoncurrentAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_abe017b7-2cf9-4c00-ada8-f9765f30d356" xlink:to="loc_alvo_OtherNoncurrentAsset_7632b009-436f-4779-b0b7-990ab660f7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCost_67d5c100-a563-417f-ab9c-78b0227d055a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_abe017b7-2cf9-4c00-ada8-f9765f30d356" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCost_67d5c100-a563-417f-ab9c-78b0227d055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_f37477da-5173-4989-b529-1380349f5219" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_ifrs-full_Borrowings_f37477da-5173-4989-b529-1380349f5219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_30aba9e6-6dfc-499f-ab55-e77b5163b3c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_30aba9e6-6dfc-499f-ab55-e77b5163b3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPayablesToRelatedParties_004e978b-080f-413d-b052-0dc9bc73a43c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPayablesToRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_ifrs-full_NoncurrentPayablesToRelatedParties_004e978b-080f-413d-b052-0dc9bc73a43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_ec993077-f224-4a11-a524-5ce144df501c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_ec993077-f224-4a11-a524-5ce144df501c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_aff96644-710c-4272-9e01-737ca6e9cdb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_aff96644-710c-4272-9e01-737ca6e9cdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_970137dd-4f1c-41d5-b429-c7b38483298c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_ifrs-full_LeaseLiabilities_970137dd-4f1c-41d5-b429-c7b38483298c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_ccb4c483-effb-4b58-82c2-5918b2907a8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_ccb4c483-effb-4b58-82c2-5918b2907a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OtherCurrentLiability_0cc0bf11-9fd9-4ce4-9312-10da712fb561" xlink:href="alvo-20231231.xsd#alvo_OtherCurrentLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_alvo_OtherCurrentLiability_0cc0bf11-9fd9-4ce4-9312-10da712fb561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss_b5278ba0-bd4d-4df4-b7f5-6441a2ab604c" xlink:href="alvo-20231231.xsd#alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_fbb136bc-b264-4e19-99e0-820befa66437" xlink:to="loc_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss_b5278ba0-bd4d-4df4-b7f5-6441a2ab604c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1a3767bc-0c0c-4376-a33b-190e7fcd9f8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_e37ada93-0412-4fef-9781-73325212bd8c" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1a3767bc-0c0c-4376-a33b-190e7fcd9f8f" xlink:to="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_e37ada93-0412-4fef-9781-73325212bd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_e37ada93-0412-4fef-9781-73325212bd8c" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a2e5a6cd-a872-46d3-a5d3-0ddbd908184e" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondsMember_330c9f72-ed37-4c7c-9055-92cf6f3b9f8b" xlink:href="alvo-20231231.xsd#alvo_SeniorBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:to="loc_alvo_SeniorBondsMember_330c9f72-ed37-4c7c-9055-92cf6f3b9f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AztiqConvertibleBondMember_a79fa7e0-7903-452e-ad09-64651cd29228" xlink:href="alvo-20231231.xsd#alvo_AztiqConvertibleBondMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:to="loc_alvo_AztiqConvertibleBondMember_a79fa7e0-7903-452e-ad09-64651cd29228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_A2022ConvertibleBondsMember_24af089b-3c44-4f96-8819-12d7d72ae3ca" xlink:href="alvo-20231231.xsd#alvo_A2022ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:to="loc_alvo_A2022ConvertibleBondsMember_24af089b-3c44-4f96-8819-12d7d72ae3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AlvogenFacilityMember_fdca43c7-d3e5-48e2-b070-19e20e452922" xlink:href="alvo-20231231.xsd#alvo_AlvogenFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_32363602-d050-470e-a1fd-cfb7e158f4f8" xlink:to="loc_alvo_AlvogenFacilityMember_fdca43c7-d3e5-48e2-b070-19e20e452922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_df597256-a945-4a88-a598-51d97584ed05" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable_e37ada93-0412-4fef-9781-73325212bd8c" xlink:to="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_df597256-a945-4a88-a598-51d97584ed05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_d69703f2-505a-44ad-9594-97c8cd67a183" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_df597256-a945-4a88-a598-51d97584ed05" xlink:to="loc_ifrs-full_BondsIssued_d69703f2-505a-44ad-9594-97c8cd67a183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_BondsIssuedAtFairValue_78faa7b5-6b1f-4c57-89e9-b6b8e96397f7" xlink:href="alvo-20231231.xsd#alvo_BondsIssuedAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems_df597256-a945-4a88-a598-51d97584ed05" xlink:to="loc_alvo_BondsIssuedAtFairValue_78faa7b5-6b1f-4c57-89e9-b6b8e96397f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_a736108f-1943-4807-8f6c-aff3ab9a9385" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_a736108f-1943-4807-8f6c-aff3ab9a9385" xlink:to="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_3713722b-51d7-43df-98a8-89bfd93ac38d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_3713722b-51d7-43df-98a8-89bfd93ac38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_3713722b-51d7-43df-98a8-89bfd93ac38d" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_47e3e48c-7cb5-4f8a-a324-b22823c71742" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_SeniorBondWarrantsMember_47e3e48c-7cb5-4f8a-a324-b22823c71742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConversionFeatureMember_598599a5-1f3c-4acd-8a5b-d73c9fdfd266" xlink:href="alvo-20231231.xsd#alvo_TrancheAConversionFeatureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_TrancheAConversionFeatureMember_598599a5-1f3c-4acd-8a5b-d73c9fdfd266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondInterestRateFeatureMember_f01d456f-e551-4147-9d1b-3eaebe966b5b" xlink:href="alvo-20231231.xsd#alvo_SeniorBondInterestRateFeatureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_SeniorBondInterestRateFeatureMember_f01d456f-e551-4147-9d1b-3eaebe966b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_cac60ba6-46c4-41ac-a33d-2d684a1d300f" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_cac60ba6-46c4-41ac-a33d-2d684a1d300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_118a1fdd-734d-4b12-ad1d-7e3d3ba26076" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_EarnoutSharesMember_118a1fdd-734d-4b12-ad1d-7e3d3ba26076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_d638dbdb-b972-4c58-bb39-889d0facd9b0" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_99fd028c-1831-4cba-b5c9-a97dd9eecce9" xlink:to="loc_alvo_EarnoutWarrantsMember_d638dbdb-b972-4c58-bb39-889d0facd9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1cb557a3-e686-41fa-8404-adf659766647" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1cb557a3-e686-41fa-8404-adf659766647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_1cb557a3-e686-41fa-8404-adf659766647" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_7183e3ee-63a4-4813-8af8-1759a41fee15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_7183e3ee-63a4-4813-8af8-1759a41fee15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_b8d6be6a-679a-4874-96bc-b26d7de102ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_b8d6be6a-679a-4874-96bc-b26d7de102ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_9567e6b7-b542-414a-8574-64f7a69af25d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8640b141-6a70-45c5-a342-d9560ed9d976" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_9567e6b7-b542-414a-8574-64f7a69af25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_401c34bf-807f-4e78-8de4-2d199c52b6df" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_a0a882da-5af0-4961-92f6-81f2809f64b4" xlink:to="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_401c34bf-807f-4e78-8de4-2d199c52b6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_5bd4da80-b504-4b14-b08a-f7cd80b7072b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_401c34bf-807f-4e78-8de4-2d199c52b6df" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_5bd4da80-b504-4b14-b08a-f7cd80b7072b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_9ae3ede5-852e-4d47-9252-af8af3cb04f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_9ae3ede5-852e-4d47-9252-af8af3cb04f1" xlink:to="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_efb7c881-c1d4-4096-a35f-e2e0e1a04f3c" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_3295a0a4-b533-48a0-8d98-59e4e9235a01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_3295a0a4-b533-48a0-8d98-59e4e9235a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_c72cb07e-8cd7-465a-a232-6104456ac3ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_c72cb07e-8cd7-465a-a232-6104456ac3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_be9784ec-079f-4d36-be91-6a65c008489d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_81febe30-5f5a-4016-a2d9-178c0c9659d9" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_be9784ec-079f-4d36-be91-6a65c008489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4cf7f097-651e-4f0e-8ab5-b3d8152cc254" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4cf7f097-651e-4f0e-8ab5-b3d8152cc254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4cf7f097-651e-4f0e-8ab5-b3d8152cc254" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_264bd524-908f-4055-b768-a5fc296390ff" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_SeniorBondWarrantsMember_264bd524-908f-4055-b768-a5fc296390ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConversionFeatureMember_746bd69b-b4cf-45d5-8ba9-21fa8e63476b" xlink:href="alvo-20231231.xsd#alvo_TrancheAConversionFeatureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_TrancheAConversionFeatureMember_746bd69b-b4cf-45d5-8ba9-21fa8e63476b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondInterestRateFeatureMember_8a498e98-aa45-495e-8aa9-b480a1b13672" xlink:href="alvo-20231231.xsd#alvo_SeniorBondInterestRateFeatureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_SeniorBondInterestRateFeatureMember_8a498e98-aa45-495e-8aa9-b480a1b13672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_cb32fad9-56c4-46df-9a13-415a90b9d1e1" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_cb32fad9-56c4-46df-9a13-415a90b9d1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_b297d89a-4f42-4a61-ba53-87468d5425bf" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_EarnoutSharesMember_b297d89a-4f42-4a61-ba53-87468d5425bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_aeda224f-6947-42a9-a3e7-9ed41bfe11c9" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_703aa093-790e-42d3-a8df-6f9bfa12e023" xlink:to="loc_alvo_EarnoutWarrantsMember_aeda224f-6947-42a9-a3e7-9ed41bfe11c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_59317a24-1a43-4eba-bf28-d00accf1fb37" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable_7e56faa7-f274-40bb-a0b6-3764ab953a1a" xlink:to="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_59317a24-1a43-4eba-bf28-d00accf1fb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:href="alvo-20231231.xsd#alvo_DerivativeFinancialLiabilitiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems_59317a24-1a43-4eba-bf28-d00accf1fb37" xlink:to="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_35599bc6-364f-4901-8e23-9bcf53031698" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_35599bc6-364f-4901-8e23-9bcf53031698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuesFairValueMeasurementLiabilities_49fdcdcf-5d53-46bb-84d3-7a59de818e5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuesFairValueMeasurementLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_IssuesFairValueMeasurementLiabilities_49fdcdcf-5d53-46bb-84d3-7a59de818e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_964c039f-fac7-4399-8453-e297d9711633" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_964c039f-fac7-4399-8453-e297d9711633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_f6cad003-bc8f-42ab-b005-e2962fe32619" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_f6cad003-bc8f-42ab-b005-e2962fe32619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities_0262911f-0eea-4e54-b1bc-62720723f196" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettlementsFairValueMeasurementLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities_0262911f-0eea-4e54-b1bc-62720723f196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_4e9bccf0-4d44-41c0-a899-3f38b610a0eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DerivativeFinancialLiabilitiesRollForward_bf676de4-6fc8-4c1d-b047-086c966dcf04" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_4e9bccf0-4d44-41c0-a899-3f38b610a0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_8093d81d-0c38-4ad9-aa10-afb15bbc0188" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_8093d81d-0c38-4ad9-aa10-afb15bbc0188" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5463aa3f-30c2-4f44-84a7-a0d0f1b3ce12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_fff0bdc2-ffb1-469c-8ae5-abbc310bb5d5" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5463aa3f-30c2-4f44-84a7-a0d0f1b3ce12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_bc82100c-9f22-4334-ac4b-6e9d4cb99868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5463aa3f-30c2-4f44-84a7-a0d0f1b3ce12" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_bc82100c-9f22-4334-ac4b-6e9d4cb99868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_db941ce0-6788-4c7f-9a12-f13b48478e36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5463aa3f-30c2-4f44-84a7-a0d0f1b3ce12" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_db941ce0-6788-4c7f-9a12-f13b48478e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4db9fb30-5d5c-4c3e-90b6-213b93902222" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4db9fb30-5d5c-4c3e-90b6-213b93902222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4db9fb30-5d5c-4c3e-90b6-213b93902222" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_37425d73-b3c9-4e8f-b92c-98f221aebbbd" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_SeniorBondWarrantsMember_37425d73-b3c9-4e8f-b92c-98f221aebbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAConversionFeatureMember_840b65d6-fc55-4743-b18c-ecebeaece0d0" xlink:href="alvo-20231231.xsd#alvo_TrancheAConversionFeatureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_TrancheAConversionFeatureMember_840b65d6-fc55-4743-b18c-ecebeaece0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_dcb17c29-155a-4049-ad4d-ea4d27d1b145" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_dcb17c29-155a-4049-ad4d-ea4d27d1b145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbEarnoutSharesMember_c53f5c01-b8bc-4118-ae87-ad7b65966f64" xlink:href="alvo-20231231.xsd#alvo_OacbEarnoutSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_OacbEarnoutSharesMember_c53f5c01-b8bc-4118-ae87-ad7b65966f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_cb63e1e8-16fb-4723-a0f5-fae49c4bbd2c" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_EarnoutSharesMember_cb63e1e8-16fb-4723-a0f5-fae49c4bbd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbWarrantsMember_fb752a1a-4be6-4315-8272-b3624e7b265a" xlink:href="alvo-20231231.xsd#alvo_OacbWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_OacbWarrantsMember_fb752a1a-4be6-4315-8272-b3624e7b265a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_e6bfc5c0-07d8-4078-9a91-d42270b265f9" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_010ae6c9-7811-469b-93fc-671352f84edc" xlink:to="loc_alvo_EarnoutWarrantsMember_e6bfc5c0-07d8-4078-9a91-d42270b265f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_f80d1f7d-d66e-4b5b-956a-50b340735399" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_f80d1f7d-d66e-4b5b-956a-50b340735399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_b629136f-1810-4e8d-9504-7f05c2ed1c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_f80d1f7d-d66e-4b5b-956a-50b340735399" xlink:to="loc_ifrs-full_BorrowingsByNameMember_b629136f-1810-4e8d-9504-7f05c2ed1c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondMember_3268198b-f507-4beb-bd6a-8de6822177a8" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_b629136f-1810-4e8d-9504-7f05c2ed1c9f" xlink:to="loc_alvo_ConvertibleBondMember_3268198b-f507-4beb-bd6a-8de6822177a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_d63e5d49-e76c-4419-922a-16fdde20d301" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_RangeAxis_d63e5d49-e76c-4419-922a-16fdde20d301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_bd59f0dc-6981-455e-970b-3011e214c43a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_d63e5d49-e76c-4419-922a-16fdde20d301" xlink:to="loc_ifrs-full_RangesMember_bd59f0dc-6981-455e-970b-3011e214c43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_adc6fc80-c6e1-41e6-b3d8-8a643f5b767d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_bd59f0dc-6981-455e-970b-3011e214c43a" xlink:to="loc_srt_MinimumMember_adc6fc80-c6e1-41e6-b3d8-8a643f5b767d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56d6c85c-7367-4680-a7bb-1401db26e364" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_bd59f0dc-6981-455e-970b-3011e214c43a" xlink:to="loc_srt_MaximumMember_56d6c85c-7367-4680-a7bb-1401db26e364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneAxis_0ae79a0b-7986-4ee5-902a-4df312de64ba" xlink:href="alvo-20231231.xsd#alvo_AgreementOneAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_alvo_AgreementOneAxis_0ae79a0b-7986-4ee5-902a-4df312de64ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementOneDomain_dfd1583f-4f50-45fe-bd72-eb0bd7c956fc" xlink:href="alvo-20231231.xsd#alvo_AgreementOneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementOneAxis_0ae79a0b-7986-4ee5-902a-4df312de64ba" xlink:to="loc_alvo_AgreementOneDomain_dfd1583f-4f50-45fe-bd72-eb0bd7c956fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_a4e094d9-3046-427f-b065-896d47413c9b" xlink:href="alvo-20231231.xsd#alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementOneDomain_dfd1583f-4f50-45fe-bd72-eb0bd7c956fc" xlink:to="loc_alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember_a4e094d9-3046-427f-b065-896d47413c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAxis_8de97105-4e86-451f-9d6e-73ae12a6d1f2" xlink:href="alvo-20231231.xsd#alvo_TrancheAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_alvo_TrancheAxis_8de97105-4e86-451f-9d6e-73ae12a6d1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheAxis_8de97105-4e86-451f-9d6e-73ae12a6d1f2" xlink:to="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheBMember_d8c45b06-26c3-4d0c-8022-3782f4ca9fdd" xlink:href="alvo-20231231.xsd#alvo_TrancheBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:to="loc_alvo_TrancheBMember_d8c45b06-26c3-4d0c-8022-3782f4ca9fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheOneMember_021993de-bafd-4ab0-b0a2-aa5b2e6d3d1f" xlink:href="alvo-20231231.xsd#alvo_TrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:to="loc_alvo_TrancheOneMember_021993de-bafd-4ab0-b0a2-aa5b2e6d3d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheTwoMember_5b6a161f-bd8d-4d09-bb29-3ed5cf4ce70d" xlink:href="alvo-20231231.xsd#alvo_TrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheDomain_365aa54b-50c0-44c0-ac75-642e53c83070" xlink:to="loc_alvo_TrancheTwoMember_5b6a161f-bd8d-4d09-bb29-3ed5cf4ce70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementAxis_0c797132-7e10-4107-aa32-07cd639fc1da" xlink:href="alvo-20231231.xsd#alvo_AgreementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_alvo_AgreementAxis_0c797132-7e10-4107-aa32-07cd639fc1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AgreementDomain_e1ddc568-63ba-4027-84d0-e26af15e24b1" xlink:href="alvo-20231231.xsd#alvo_AgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementAxis_0c797132-7e10-4107-aa32-07cd639fc1da" xlink:to="loc_alvo_AgreementDomain_e1ddc568-63ba-4027-84d0-e26af15e24b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_b4b84b6c-0891-4919-a2c1-a04387b581dc" xlink:href="alvo-20231231.xsd#alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_AgreementDomain_e1ddc568-63ba-4027-84d0-e26af15e24b1" xlink:to="loc_alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember_b4b84b6c-0891-4919-a2c1-a04387b581dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_480e88e6-e54c-440c-ac8a-b874d3432335" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_480e88e6-e54c-440c-ac8a-b874d3432335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_c2e74485-7a24-442a-9859-ddbab9ebc74f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_480e88e6-e54c-440c-ac8a-b874d3432335" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_c2e74485-7a24-442a-9859-ddbab9ebc74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ContingentlyIssuablePennyWarrantsMember_8095d831-ff62-446e-97a3-4a4b7bd154e5" xlink:href="alvo-20231231.xsd#alvo_ContingentlyIssuablePennyWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_c2e74485-7a24-442a-9859-ddbab9ebc74f" xlink:to="loc_alvo_ContingentlyIssuablePennyWarrantsMember_8095d831-ff62-446e-97a3-4a4b7bd154e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PennyWarrantsMember_a902bd82-f347-4a58-aff5-708431488311" xlink:href="alvo-20231231.xsd#alvo_PennyWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_c2e74485-7a24-442a-9859-ddbab9ebc74f" xlink:to="loc_alvo_PennyWarrantsMember_a902bd82-f347-4a58-aff5-708431488311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_9d961e6b-5ad7-49ee-a950-e4aec92b48f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_0ed0b53e-06ff-4f2a-a636-4f7a76203c9b" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_9d961e6b-5ad7-49ee-a950-e4aec92b48f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_9e82900d-7e07-46fa-9f16-e124b044e449" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_9d961e6b-5ad7-49ee-a950-e4aec92b48f8" xlink:to="loc_ifrs-full_OrdinarySharesMember_9e82900d-7e07-46fa-9f16-e124b044e449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_8b48923e-fb32-49e4-842e-2a773c46ae51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_8b48923e-fb32-49e4-842e-2a773c46ae51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_8b339c1d-f599-45b3-97c6-64bb2421085a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_8b48923e-fb32-49e4-842e-2a773c46ae51" xlink:to="loc_ifrs-full_NonadjustingEventsMember_8b339c1d-f599-45b3-97c6-64bb2421085a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ExcerciseOfWarrantsMember_c9e2b95f-3cff-49d7-a478-97ac822c7a61" xlink:href="alvo-20231231.xsd#alvo_ExcerciseOfWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_8b339c1d-f599-45b3-97c6-64bb2421085a" xlink:to="loc_alvo_ExcerciseOfWarrantsMember_c9e2b95f-3cff-49d7-a478-97ac822c7a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_3c584002-c9e2-4d21-9def-878c0467c755" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_208de23d-b90b-4317-867f-69f1173542b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_208de23d-b90b-4317-867f-69f1173542b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_d73079a6-138b-490f-8fd0-04de8ab75fd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_d73079a6-138b-490f-8fd0-04de8ab75fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseInOutstandingBondsFairValue_e7f2774e-5d68-4fb7-b839-acdfb31eadeb" xlink:href="alvo-20231231.xsd#alvo_IncreaseInOutstandingBondsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_IncreaseInOutstandingBondsFairValue_e7f2774e-5d68-4fb7-b839-acdfb31eadeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_f9940f47-5ec5-4508-9b59-8139f728cc6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_BorrowingsInterestRate_f9940f47-5ec5-4508-9b59-8139f728cc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_0788d075-b5c6-4be4-9454-b5fc7635aa72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid_0788d075-b5c6-4be4-9454-b5fc7635aa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_21b8fddf-69db-4aa9-8f53-0f0bb970d845" xlink:href="alvo-20231231.xsd#alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares_21b8fddf-69db-4aa9-8f53-0f0bb970d845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities_694c22ec-fc31-414d-b76c-488c14f0da48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettlementsFairValueMeasurementLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_SettlementsFairValueMeasurementLiabilities_694c22ec-fc31-414d-b76c-488c14f0da48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_06c99425-fd81-4344-b50e-75a659a3f374" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_06c99425-fd81-4344-b50e-75a659a3f374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsOutstanding_0a3a0f63-93f9-4a67-b790-5c4fd1eea560" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_ClassOfWarrantsOrRightsOutstanding_0a3a0f63-93f9-4a67-b790-5c4fd1eea560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConversionPrice_7e2b1080-ce1d-463a-8520-3acb5ef9ff33" xlink:href="alvo-20231231.xsd#alvo_ConversionPrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_ConversionPrice_7e2b1080-ce1d-463a-8520-3acb5ef9ff33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheOfSeniorBondWarrantsPercentage_c3ea4840-cdeb-4e3f-839c-1f81f18c4d5f" xlink:href="alvo-20231231.xsd#alvo_TrancheOfSeniorBondWarrantsPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_TrancheOfSeniorBondWarrantsPercentage_c3ea4840-cdeb-4e3f-839c-1f81f18c4d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_3e59327c-578f-4e37-b051-0f1298d21578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_3e59327c-578f-4e37-b051-0f1298d21578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_72882718-8fc0-49f6-9a84-3be413b0ed67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_FinanceCosts_72882718-8fc0-49f6-9a84-3be413b0ed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AggregatePeriodForDeterminingTheSharePrice_323d41ee-fe1a-4a00-b7ce-ecea12c7e2e8" xlink:href="alvo-20231231.xsd#alvo_AggregatePeriodForDeterminingTheSharePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_AggregatePeriodForDeterminingTheSharePrice_323d41ee-fe1a-4a00-b7ce-ecea12c7e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SharesPrice_2ee9d85e-7764-4917-939c-35ef053f9933" xlink:href="alvo-20231231.xsd#alvo_SharesPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_SharesPrice_2ee9d85e-7764-4917-939c-35ef053f9933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ThresholdDaysForDeterminingTheSharePrice_90907751-a87e-4898-b27f-7605dba4f9c6" xlink:href="alvo-20231231.xsd#alvo_ThresholdDaysForDeterminingTheSharePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_ThresholdDaysForDeterminingTheSharePrice_90907751-a87e-4898-b27f-7605dba4f9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfConsecutiveTradingDays_067c1818-f0ea-4dc8-a52e-614d74865399" xlink:href="alvo-20231231.xsd#alvo_NumberOfConsecutiveTradingDays"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_NumberOfConsecutiveTradingDays_067c1818-f0ea-4dc8-a52e-614d74865399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_5a292c95-72bf-4104-bcbd-1a728c908934" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsExercisePricePerShare"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_5a292c95-72bf-4104-bcbd-1a728c908934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_89b7d992-de9e-444a-b0db-1db6e3e9ef50" xlink:href="alvo-20231231.xsd#alvo_NumberOfSharesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_89b7d992-de9e-444a-b0db-1db6e3e9ef50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_d387c650-87fc-42e5-927a-a472ffea836c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_d387c650-87fc-42e5-927a-a472ffea836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_4fae936b-fba4-4957-b4ac-c74ddf8078a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_Liabilities_4fae936b-fba4-4957-b4ac-c74ddf8078a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VestingPercentageOfShares_647e6514-7798-4ae8-959e-e8fa9837f08d" xlink:href="alvo-20231231.xsd#alvo_VestingPercentageOfShares"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_alvo_VestingPercentageOfShares_647e6514-7798-4ae8-959e-e8fa9837f08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_f039446c-46fa-47f4-a60f-57e9a35b6b8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_NumberOfSharesIssued_f039446c-46fa-47f4-a60f-57e9a35b6b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_f4eec38a-b5e8-4161-9ce0-49c5dec2cc2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_951e56d1-93e3-430f-8517-226572a164b3" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_f4eec38a-b5e8-4161-9ce0-49c5dec2cc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofAssumptionsandInputsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_49ebdeb5-7043-47b6-ae18-bae6b63142df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_49ebdeb5-7043-47b6-ae18-bae6b63142df" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:to="loc_ifrs-full_UnobservableInputsAxis_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_d5b6aaf3-3d1b-4c0b-80e2-222a4fc95d54" xlink:to="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_StockPriceMember_19712e27-d5cc-42f0-8d03-5969eb55e6d6" xlink:href="alvo-20231231.xsd#alvo_StockPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_alvo_StockPriceMember_19712e27-d5cc-42f0-8d03-5969eb55e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ConversionPriceOfBondsMember_26530166-314a-440c-bb38-36b52a870eeb" xlink:href="alvo-20231231.xsd#alvo_ConversionPriceOfBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_alvo_ConversionPriceOfBondsMember_26530166-314a-440c-bb38-36b52a870eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2bad5fc3-be1c-400f-a273-9bdecc51fd19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_2bad5fc3-be1c-400f-a273-9bdecc51fd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateMeasurementInputMember_8bc7b05b-733c-48fc-9b1b-fa6725f41409" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_ifrs-full_InterestRateMeasurementInputMember_8bc7b05b-733c-48fc-9b1b-fa6725f41409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DividendYieldMember_c5e14367-78d0-4413-956e-9a125121579c" xlink:href="alvo-20231231.xsd#alvo_DividendYieldMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_alvo_DividendYieldMember_c5e14367-78d0-4413-956e-9a125121579c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RiskyYieldMember_4873ec30-f5fa-4c65-80b8-ccef4c8384c3" xlink:href="alvo-20231231.xsd#alvo_RiskyYieldMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_370c3f4f-bc29-466d-81f1-45051c0fe755" xlink:to="loc_alvo_RiskyYieldMember_4873ec30-f5fa-4c65-80b8-ccef4c8384c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_af0f54ae-48de-405a-b062-01be73dc1e66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_af0f54ae-48de-405a-b062-01be73dc1e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_af0f54ae-48de-405a-b062-01be73dc1e66" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember_9479bff9-374e-424e-9725-5c700e34dff3" xlink:href="alvo-20231231.xsd#alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:to="loc_alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember_9479bff9-374e-424e-9725-5c700e34dff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PredecessorEarnoutSharesMember_ec226b04-2a5d-4880-abe5-9c942ea3070c" xlink:href="alvo-20231231.xsd#alvo_PredecessorEarnoutSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:to="loc_alvo_PredecessorEarnoutSharesMember_ec226b04-2a5d-4880-abe5-9c942ea3070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbEarnoutSharesMember_9a15a2d2-1e5b-44e2-8722-b6c612706ec6" xlink:href="alvo-20231231.xsd#alvo_OacbEarnoutSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_e53c0e07-23c6-4e4b-ae5d-a157f2f30e0b" xlink:to="loc_alvo_OacbEarnoutSharesMember_9a15a2d2-1e5b-44e2-8722-b6c612706ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_253b03d2-94db-48f0-85f8-b752bc3d1027" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_99055d1f-59a2-4b25-bffa-945b504bc6c7" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_253b03d2-94db-48f0-85f8-b752bc3d1027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_883a2341-98a5-4dae-8f37-063a02044b50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_253b03d2-94db-48f0-85f8-b752bc3d1027" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_883a2341-98a5-4dae-8f37-063a02044b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_294dd5f8-b0bb-43be-b688-1af4c63fb354" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_253b03d2-94db-48f0-85f8-b752bc3d1027" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_294dd5f8-b0bb-43be-b688-1af4c63fb354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e269fb75-e7d0-4435-8a06-f6c11fa08e66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e269fb75-e7d0-4435-8a06-f6c11fa08e66" xlink:to="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_a4ff7dc7-3f06-47bc-821e-a603a998382d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:to="loc_ifrs-full_TypesOfRisksAxis_a4ff7dc7-3f06-47bc-821e-a603a998382d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_18bb73bb-7465-4953-8b7e-71eba8316ef3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_a4ff7dc7-3f06-47bc-821e-a603a998382d" xlink:to="loc_ifrs-full_TypesOfRisksMember_18bb73bb-7465-4953-8b7e-71eba8316ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_b5756c8a-00db-4e5b-b3f6-bddf36bcedf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_18bb73bb-7465-4953-8b7e-71eba8316ef3" xlink:to="loc_ifrs-full_InterestRateRiskMember_b5756c8a-00db-4e5b-b3f6-bddf36bcedf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_f6aa6f69-b060-4c05-abf3-40e989c70b6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_f6aa6f69-b060-4c05-abf3-40e989c70b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_f5211e09-99eb-4708-ba0d-5c0fee6c6239" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_f6aa6f69-b060-4c05-abf3-40e989c70b6e" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_f5211e09-99eb-4708-ba0d-5c0fee6c6239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestRateFinancialLiabilitiesMember_2164b18b-26fb-4043-8793-e0d04b97d213" xlink:href="alvo-20231231.xsd#alvo_VariableInterestRateFinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_f5211e09-99eb-4708-ba0d-5c0fee6c6239" xlink:to="loc_alvo_VariableInterestRateFinancialLiabilitiesMember_2164b18b-26fb-4043-8793-e0d04b97d213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable_587343d0-c7d2-444d-9412-79b323d763d9" xlink:to="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_d063e82b-32f0-44ec-93bb-042963d6e7f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_d063e82b-32f0-44ec-93bb-042963d6e7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_1e9a29b5-636e-45e6-8809-0f0d82f209b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_1e9a29b5-636e-45e6-8809-0f0d82f209b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_be320a1d-63f4-4450-9889-90b5b99579c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_be320a1d-63f4-4450-9889-90b5b99579c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_47818a46-0de9-4d50-bb5c-7c0a857bc2d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems_bab6056a-cc1a-4f7a-b9c6-988950a77857" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_47818a46-0de9-4d50-bb5c-7c0a857bc2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_b9e2ff58-a21a-4c11-8efe-15f0b8bfe5d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_b2c06703-ddbe-4537-8ac3-55e4df942800" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfForeignExchangeRateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_b9e2ff58-a21a-4c11-8efe-15f0b8bfe5d8" xlink:to="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_b2c06703-ddbe-4537-8ac3-55e4df942800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_57205420-04f7-4a19-b678-8b08bf819f47" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_b2c06703-ddbe-4537-8ac3-55e4df942800" xlink:to="loc_srt_CurrencyAxis_57205420-04f7-4a19-b678-8b08bf819f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_57205420-04f7-4a19-b678-8b08bf819f47" xlink:to="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_edb60053-3fa4-4cb8-a548-eb13223cf5c0" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_EUR_edb60053-3fa4-4cb8-a548-eb13223cf5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_970bc941-1b79-47a4-b6a0-dfd4387e9eb7" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_GBP_970bc941-1b79-47a4-b6a0-dfd4387e9eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_ISK_a0fbf990-6671-4fe5-9f99-89ec22cad92a" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ISK"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_ISK_a0fbf990-6671-4fe5-9f99-89ec22cad92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_7d0bebe9-46f3-4f75-a70b-22008314c528" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_CHF_7d0bebe9-46f3-4f75-a70b-22008314c528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_INR_e7fe1e51-3468-481f-a0c0-b5e8c48edfc6" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_INR"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_e7912a40-1272-4b8e-bfe9-2548b29c55c4" xlink:to="loc_currency_INR_e7fe1e51-3468-481f-a0c0-b5e8c48edfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateTable_b2c06703-ddbe-4537-8ac3-55e4df942800" xlink:to="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_fb985f65-fe39-4ce8-b28e-680b0717e7d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_fb985f65-fe39-4ce8-b28e-680b0717e7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_6b595008-8503-483f-bb5f-7175044abf06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_6b595008-8503-483f-bb5f-7175044abf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_PercentageChangeInForeignExchangeRate_dacb58af-4bdb-48d7-8575-dbd40e2b0b0c" xlink:href="alvo-20231231.xsd#alvo_PercentageChangeInForeignExchangeRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems_da7d17f0-dbb9-4dd7-922d-61d22495568e" xlink:to="loc_alvo_PercentageChangeInForeignExchangeRate_dacb58af-4bdb-48d7-8575-dbd40e2b0b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_c2b268cc-9a72-4e9e-a598-8ac4616c0a93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_c2b268cc-9a72-4e9e-a598-8ac4616c0a93" xlink:to="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_c1c388af-42fd-4f1c-b24d-66606aef0aeb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:to="loc_srt_CurrencyAxis_c1c388af-42fd-4f1c-b24d-66606aef0aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_c1c388af-42fd-4f1c-b24d-66606aef0aeb" xlink:to="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_87939d0b-55c5-4707-840d-2dfdfbf8eb1e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_EUR_87939d0b-55c5-4707-840d-2dfdfbf8eb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_04434245-9033-464b-bdc6-511aa10919f2" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_GBP_04434245-9033-464b-bdc6-511aa10919f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_ISK_b27b969c-594b-4c52-9588-3d8b7fcda4d6" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ISK"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_ISK_b27b969c-594b-4c52-9588-3d8b7fcda4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_bae63013-3696-4189-8e61-b8b0d32e6d1f" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_CHF_bae63013-3696-4189-8e61-b8b0d32e6d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_INR_db807fc0-fc75-4e7e-818b-85296ccf91e8" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_INR"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_eff17bf1-f60f-407a-9212-9ad16ad912d5" xlink:to="loc_currency_INR_db807fc0-fc75-4e7e-818b-85296ccf91e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a4a46cc9-ab35-4cad-b5a0-7c35cb582423" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a4a46cc9-ab35-4cad-b5a0-7c35cb582423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_c1e7dc0f-1b69-4d8f-8000-342695eb6362" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_a4a46cc9-ab35-4cad-b5a0-7c35cb582423" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_c1e7dc0f-1b69-4d8f-8000-342695eb6362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OacbWarrantsMember_56a0135c-60d1-47fd-aaf0-9ee1af39369f" xlink:href="alvo-20231231.xsd#alvo_OacbWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_c1e7dc0f-1b69-4d8f-8000-342695eb6362" xlink:to="loc_alvo_OacbWarrantsMember_56a0135c-60d1-47fd-aaf0-9ee1af39369f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_626ddd8d-8065-4afc-964a-854baa4ea9a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_626ddd8d-8065-4afc-964a-854baa4ea9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9127d957-8f17-4af8-9e9d-c69de058e8fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_626ddd8d-8065-4afc-964a-854baa4ea9a1" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9127d957-8f17-4af8-9e9d-c69de058e8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_966bf59b-7411-48c5-9ddd-44b30d1acf4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9127d957-8f17-4af8-9e9d-c69de058e8fd" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_966bf59b-7411-48c5-9ddd-44b30d1acf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable_64a5d9d2-90cd-4aac-8f57-8be6cf260c2b" xlink:to="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_fdd3b2d9-dad7-4fba-816f-c1ddf38d77c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:to="loc_ifrs-full_Assets_fdd3b2d9-dad7-4fba-816f-c1ddf38d77c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_82113128-8aff-48e1-83a9-9bf8d70923e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:to="loc_ifrs-full_Liabilities_82113128-8aff-48e1-83a9-9bf8d70923e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_e86af3f3-2684-481f-8b14-dccc4cedbb59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems_2e22be48-c452-4368-91ea-557482cd7b99" xlink:to="loc_ifrs-full_NetAssetsLiabilities_e86af3f3-2684-481f-8b14-dccc4cedbb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_790aca12-4506-46ad-8483-dbb214bf1af1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_790aca12-4506-46ad-8483-dbb214bf1af1" xlink:to="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_9b04d982-f5bd-4a29-80fa-74a1c7cde37e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:to="loc_ifrs-full_TypesOfRisksAxis_9b04d982-f5bd-4a29-80fa-74a1c7cde37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_fc997d78-d49f-4c75-907e-e182b428d97b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_9b04d982-f5bd-4a29-80fa-74a1c7cde37e" xlink:to="loc_ifrs-full_TypesOfRisksMember_fc997d78-d49f-4c75-907e-e182b428d97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_51403a31-b30c-475d-bfac-0263a19b47a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_fc997d78-d49f-4c75-907e-e182b428d97b" xlink:to="loc_ifrs-full_CurrencyRiskMember_51403a31-b30c-475d-bfac-0263a19b47a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_06ef794d-337e-430f-a5a4-a5e153b6bebc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:to="loc_srt_CurrencyAxis_06ef794d-337e-430f-a5a4-a5e153b6bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_06ef794d-337e-430f-a5a4-a5e153b6bebc" xlink:to="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_cbbc0e7d-e0bd-4981-9ae4-4dc2ac8d79ef" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_EUR_cbbc0e7d-e0bd-4981-9ae4-4dc2ac8d79ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_306a2c3a-3282-4011-84ab-3bd9fb3c0aa7" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_GBP_306a2c3a-3282-4011-84ab-3bd9fb3c0aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_ISK_02f1dcaa-f6d9-42ab-8359-401e41246e49" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ISK"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_ISK_02f1dcaa-f6d9-42ab-8359-401e41246e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_35d87b0c-4c6a-44ff-8364-7d0f88304083" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_CHF_35d87b0c-4c6a-44ff-8364-7d0f88304083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_INR_040d6b3b-ae9f-4b50-8a03-ee4375d6e8f5" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_INR"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b19976b1-2214-4068-a4d3-7fcc364a8051" xlink:to="loc_currency_INR_040d6b3b-ae9f-4b50-8a03-ee4375d6e8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:href="alvo-20231231.xsd#alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable_63bc5ebf-2440-4a76-ba55-86cbebc213cf" xlink:to="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_93e3ffab-1186-4e92-984b-703da7897eee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_93e3ffab-1186-4e92-984b-703da7897eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_7e184d96-4f3a-44fc-8677-799ab020b86c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_7e184d96-4f3a-44fc-8677-799ab020b86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_44ee88ca-86ee-477b-ac8f-13bdfe3e3adf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_44ee88ca-86ee-477b-ac8f-13bdfe3e3adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_4ff29dc9-8339-4644-a832-bf14e842b23d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems_67aab45d-30ce-40f6-80f3-d0d1742fce32" xlink:to="loc_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities_4ff29dc9-8339-4644-a832-bf14e842b23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_d415a080-7334-42a4-91a8-ec87c691dc05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCreditRiskTable_efe99dca-b827-4bed-ac3e-738ff735b25a" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_d415a080-7334-42a4-91a8-ec87c691dc05" xlink:to="loc_alvo_DisclosureOfCreditRiskTable_efe99dca-b827-4bed-ac3e-738ff735b25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_67433c1d-dd43-44e5-a095-3f0e21001e42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfCreditRiskTable_efe99dca-b827-4bed-ac3e-738ff735b25a" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_67433c1d-dd43-44e5-a095-3f0e21001e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_67433c1d-dd43-44e5-a095-3f0e21001e42" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CashEquivalentsAndCashMember_1031492d-cc07-4697-b3b9-f26a8bdc9028" xlink:href="alvo-20231231.xsd#alvo_CashEquivalentsAndCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:to="loc_alvo_CashEquivalentsAndCashMember_1031492d-cc07-4697-b3b9-f26a8bdc9028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RestrictedCashMember_bc8cf14a-d41b-4771-b65e-aa72dca0069e" xlink:href="alvo-20231231.xsd#alvo_RestrictedCashMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:to="loc_alvo_RestrictedCashMember_bc8cf14a-d41b-4771-b65e-aa72dca0069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsMember_27bdcff0-6508-4a0d-9ae3-f6ba4c3dda05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f936472f-f14d-49c2-afb3-60bcd5349c5c" xlink:to="loc_ifrs-full_OtherAssetsMember_27bdcff0-6508-4a0d-9ae3-f6ba4c3dda05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfCreditRiskLineItems_ea6d4aa7-4bb9-456a-a526-04c865354d08" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfCreditRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfCreditRiskTable_efe99dca-b827-4bed-ac3e-738ff735b25a" xlink:to="loc_alvo_DisclosureOfCreditRiskLineItems_ea6d4aa7-4bb9-456a-a526-04c865354d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaximumExposureToCreditRisk_ee022395-1507-4c73-bf61-5fe8eee95e88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfCreditRiskLineItems_ea6d4aa7-4bb9-456a-a526-04c865354d08" xlink:to="loc_ifrs-full_MaximumExposureToCreditRisk_ee022395-1507-4c73-bf61-5fe8eee95e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_a107e926-f0e5-4290-be78-f7e8b96a9345" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_a107e926-f0e5-4290-be78-f7e8b96a9345" xlink:to="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:to="loc_ifrs-full_MaturityAxis_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_da48f6a3-249e-4ae8-8329-9e5eb6ac46b2" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_c231f3ee-0659-461a-b053-a2fa6155c8de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_c231f3ee-0659-461a-b053-a2fa6155c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_e8a11067-1519-4c26-b12f-7845307cf108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_e8a11067-1519-4c26-b12f-7845307cf108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_LaterThanTwoYearsMember_809e61bd-e928-4aa2-ab47-d5c8ca6f71d7" xlink:href="alvo-20231231.xsd#alvo_LaterThanTwoYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ab7a7fff-aab1-44f7-9281-80d11df11d3f" xlink:to="loc_alvo_LaterThanTwoYearsMember_809e61bd-e928-4aa2-ab47-d5c8ca6f71d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_f84c7efb-0de8-4bed-9e0f-070831dfba57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_cd7f93f5-bf18-4bed-8f99-9860b5bd91e0" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_f84c7efb-0de8-4bed-9e0f-070831dfba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonInterestBearingFinancialAssetsMember_f8ebff54-3e1b-4ae0-8ce6-9e00f96a909c" xlink:href="alvo-20231231.xsd#alvo_NonInterestBearingFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f84c7efb-0de8-4bed-9e0f-070831dfba57" xlink:to="loc_alvo_NonInterestBearingFinancialAssetsMember_f8ebff54-3e1b-4ae0-8ce6-9e00f96a909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestBearingFinancialAssetsMember_24d8f84b-8f61-46f2-b62d-8dafd8be0a71" xlink:href="alvo-20231231.xsd#alvo_VariableInterestBearingFinancialAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_f84c7efb-0de8-4bed-9e0f-070831dfba57" xlink:to="loc_alvo_VariableInterestBearingFinancialAssetsMember_24d8f84b-8f61-46f2-b62d-8dafd8be0a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_81586b2c-1d92-4c8c-afaf-cae07f7daabb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_81586b2c-1d92-4c8c-afaf-cae07f7daabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_81586b2c-1d92-4c8c-afaf-cae07f7daabb" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonInterestBearingFinancialLiabilitiesMember_99394ee9-0d58-4c43-891c-433e9b0d5727" xlink:href="alvo-20231231.xsd#alvo_NonInterestBearingFinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:to="loc_alvo_NonInterestBearingFinancialLiabilitiesMember_99394ee9-0d58-4c43-891c-433e9b0d5727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_FixedInterestBearingBorrowingsMember_3c288ad2-4051-4076-8e9b-6d8cfa0c2a0d" xlink:href="alvo-20231231.xsd#alvo_FixedInterestBearingBorrowingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:to="loc_alvo_FixedInterestBearingBorrowingsMember_3c288ad2-4051-4076-8e9b-6d8cfa0c2a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_eff1954d-6acf-46d7-a077-e9a2a69786f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:to="loc_ifrs-full_DerivativesMember_eff1954d-6acf-46d7-a077-e9a2a69786f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_VariableInterestBearingBorrowingsMember_f86c6b0c-8071-4163-bce9-677280542c33" xlink:href="alvo-20231231.xsd#alvo_VariableInterestBearingBorrowingsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_78b026fc-f854-4fd7-b1c9-878f8eb9bfaf" xlink:to="loc_alvo_VariableInterestBearingBorrowingsMember_f86c6b0c-8071-4163-bce9-677280542c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_fc1537f3-199c-4c07-a1b5-1164cfc23361" xlink:href="alvo-20231231.xsd#alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable_6e346ad2-c5af-4c60-bc00-92af261313ba" xlink:to="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_fc1537f3-199c-4c07-a1b5-1164cfc23361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_e4875ff3-a150-49b3-8515-dc2159aab362" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_fc1537f3-199c-4c07-a1b5-1164cfc23361" xlink:to="loc_ifrs-full_FinancialAssets_e4875ff3-a150-49b3-8515-dc2159aab362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_e509069c-6d3b-4434-bdae-66db498fc07f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems_fc1537f3-199c-4c07-a1b5-1164cfc23361" xlink:to="loc_ifrs-full_FinancialLiabilities_e509069c-6d3b-4434-bdae-66db498fc07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_466a0e5f-da7a-4634-9da5-4ffb2acf3e1c" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_09ef14ad-cfc8-4c13-87af-d9bc646b7f28" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract_466a0e5f-da7a-4634-9da5-4ffb2acf3e1c" xlink:to="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_09ef14ad-cfc8-4c13-87af-d9bc646b7f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d0026f68-1acf-4f90-a8d9-7d729f71cf8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_09ef14ad-cfc8-4c13-87af-d9bc646b7f28" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d0026f68-1acf-4f90-a8d9-7d729f71cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_0208a8b2-a715-4f2d-8f6c-60c80aa4e7f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d0026f68-1acf-4f90-a8d9-7d729f71cf8b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_0208a8b2-a715-4f2d-8f6c-60c80aa4e7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_eeec9b20-7456-43d9-a79d-f2e5cf9dcc71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0208a8b2-a715-4f2d-8f6c-60c80aa4e7f6" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_eeec9b20-7456-43d9-a79d-f2e5cf9dcc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ShareAppreciationRightsMember_4ae879df-8b73-4e55-a067-14abd6377521" xlink:href="alvo-20231231.xsd#alvo_ShareAppreciationRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_0208a8b2-a715-4f2d-8f6c-60c80aa4e7f6" xlink:to="loc_alvo_ShareAppreciationRightsMember_4ae879df-8b73-4e55-a067-14abd6377521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:href="alvo-20231231.xsd#alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable_09ef14ad-cfc8-4c13-87af-d9bc646b7f28" xlink:to="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid_b884e126-6812-4580-a286-27ffdf3133b1" xlink:href="alvo-20231231.xsd#alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid_b884e126-6812-4580-a286-27ffdf3133b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid_ff57657b-9bed-4746-8b94-cd67cf8111d0" xlink:href="alvo-20231231.xsd#alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid_ff57657b-9bed-4746-8b94-cd67cf8111d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities_26978cb7-3ea6-4ff6-8c08-2929b2454f09" xlink:href="alvo-20231231.xsd#alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities_26978cb7-3ea6-4ff6-8c08-2929b2454f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond_d7251b15-df26-4429-b5d5-66cfaea32d20" xlink:href="alvo-20231231.xsd#alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond_d7251b15-df26-4429-b5d5-66cfaea32d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NonCashIssuanceOfConvertibleBond_97271712-0bbe-4e12-9f10-a421717a37cd" xlink:href="alvo-20231231.xsd#alvo_NonCashIssuanceOfConvertibleBond"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_NonCashIssuanceOfConvertibleBond_97271712-0bbe-4e12-9f10-a421717a37cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_OrdinarySharesValueIssuedConversionOfBorrowings_dc9bb0fd-2847-48ff-8390-f419aab7e3c3" xlink:href="alvo-20231231.xsd#alvo_OrdinarySharesValueIssuedConversionOfBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_OrdinarySharesValueIssuedConversionOfBorrowings_dc9bb0fd-2847-48ff-8390-f419aab7e3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements_6a976b88-18f6-4b43-ba15-dbc386e16a6c" xlink:href="alvo-20231231.xsd#alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements_6a976b88-18f6-4b43-ba15-dbc386e16a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares_e4e73ca6-e8f2-4ea2-b4a9-8d676678cfe8" xlink:href="alvo-20231231.xsd#alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems_f1f1ecb1-e06f-494f-bea0-0e8da172c091" xlink:to="loc_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares_e4e73ca6-e8f2-4ea2-b4a9-8d676678cfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="alvo-20231231.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_06fbb3d4-52aa-407a-a3fe-fecff13c2ef2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_06fbb3d4-52aa-407a-a3fe-fecff13c2ef2" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da7d0530-8da3-4596-8f5b-15806d44e606" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_srt_ProductOrServiceAxis_da7d0530-8da3-4596-8f5b-15806d44e606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_49bc6a2f-6368-4bc1-a594-4ef87218007f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_da7d0530-8da3-4596-8f5b-15806d44e606" xlink:to="loc_srt_ProductsAndServicesDomain_49bc6a2f-6368-4bc1-a594-4ef87218007f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_HumiraMember_6b7028fc-b309-4ef6-adde-b4a5090f87ff" xlink:href="alvo-20231231.xsd#alvo_HumiraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49bc6a2f-6368-4bc1-a594-4ef87218007f" xlink:to="loc_alvo_HumiraMember_6b7028fc-b309-4ef6-adde-b4a5090f87ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_59e3eab2-0c0e-4040-910d-415bd976db6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_59e3eab2-0c0e-4040-910d-415bd976db6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_c99d81c1-199d-42d9-b572-f3a0235b5f18" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_59e3eab2-0c0e-4040-910d-415bd976db6a" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_c99d81c1-199d-42d9-b572-f3a0235b5f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_b3866e8f-872c-4bfd-8e87-1e0e1411771b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_c99d81c1-199d-42d9-b572-f3a0235b5f18" xlink:to="loc_ifrs-full_OrdinarySharesMember_b3866e8f-872c-4bfd-8e87-1e0e1411771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5198e1a6-f3c3-4174-ad13-05e8885cdeeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5198e1a6-f3c3-4174-ad13-05e8885cdeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_29e598a9-09a0-44d9-966a-39ba8af7b1c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5198e1a6-f3c3-4174-ad13-05e8885cdeeb" xlink:to="loc_ifrs-full_NonadjustingEventsMember_29e598a9-09a0-44d9-966a-39ba8af7b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_d1859032-8156-40ff-8771-00163a51e133" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_29e598a9-09a0-44d9-966a-39ba8af7b1c0" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_d1859032-8156-40ff-8771-00163a51e133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheAxis_c6752c28-d25c-4990-a405-ce156c77c102" xlink:href="alvo-20231231.xsd#alvo_TrancheAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_alvo_TrancheAxis_c6752c28-d25c-4990-a405-ce156c77c102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheDomain_aabef385-7737-4f46-9297-9f829c60821d" xlink:href="alvo-20231231.xsd#alvo_TrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheAxis_c6752c28-d25c-4990-a405-ce156c77c102" xlink:to="loc_alvo_TrancheDomain_aabef385-7737-4f46-9297-9f829c60821d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheTwoMember_7194adde-f256-45d9-b339-d9d8d05deaa2" xlink:href="alvo-20231231.xsd#alvo_TrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheDomain_aabef385-7737-4f46-9297-9f829c60821d" xlink:to="loc_alvo_TrancheTwoMember_7194adde-f256-45d9-b339-d9d8d05deaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_TrancheOneMember_2371b812-75b8-433c-940d-8b01e3c850f5" xlink:href="alvo-20231231.xsd#alvo_TrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alvo_TrancheDomain_aabef385-7737-4f46-9297-9f829c60821d" xlink:to="loc_alvo_TrancheOneMember_2371b812-75b8-433c-940d-8b01e3c850f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_62748741-2e07-4a96-983b-9613818a0670" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_af4b3e3b-b5bb-42a2-bd1d-f954a5444d38" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_62748741-2e07-4a96-983b-9613818a0670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutSharesMember_ee9dedc2-432a-427c-9fe2-cacf98fbd1fc" xlink:href="alvo-20231231.xsd#alvo_EarnoutSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_62748741-2e07-4a96-983b-9613818a0670" xlink:to="loc_alvo_EarnoutSharesMember_ee9dedc2-432a-427c-9fe2-cacf98fbd1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4ad6713a-0767-4773-ba10-3be12e216b7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4ad6713a-0767-4773-ba10-3be12e216b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesTypeMember_594a7fe7-5abd-42de-9367-630a35692452" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialLiabilitiesAxis_4ad6713a-0767-4773-ba10-3be12e216b7d" xlink:to="loc_ifrs-full_FinancialLiabilitiesTypeMember_594a7fe7-5abd-42de-9367-630a35692452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SeniorBondWarrantsMember_0ecf980b-41ea-405c-9376-c770fd9a9d91" xlink:href="alvo-20231231.xsd#alvo_SeniorBondWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_594a7fe7-5abd-42de-9367-630a35692452" xlink:to="loc_alvo_SeniorBondWarrantsMember_0ecf980b-41ea-405c-9376-c770fd9a9d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_EarnoutWarrantsMember_34192361-2908-4db1-8d27-b6badb8d9a02" xlink:href="alvo-20231231.xsd#alvo_EarnoutWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesTypeMember_594a7fe7-5abd-42de-9367-630a35692452" xlink:to="loc_alvo_EarnoutWarrantsMember_34192361-2908-4db1-8d27-b6badb8d9a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c4ea43dd-16bc-4cdd-b63c-2488927a9bff" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_c7c53123-7700-4fdd-86c3-dc6a52af9aa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_Revenue_c7c53123-7700-4fdd-86c3-dc6a52af9aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_cb5e2a96-4cb1-4113-bb92-be8092b485a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_cb5e2a96-4cb1-4113-bb92-be8092b485a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_626e5aca-3626-472b-a994-6bc367a4ad4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_IssueOfEquity_626e5aca-3626-472b-a994-6bc367a4ad4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_ae6e238c-0d06-4531-a63a-2791b5360fbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_ae6e238c-0d06-4531-a63a-2791b5360fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_e8f52c55-a2fb-46cd-91a1-7e47df835ab6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_ParValuePerShare_e8f52c55-a2fb-46cd-91a1-7e47df835ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_SaleOfStockIssuePricePerShare_d504a8a0-971a-4da9-8652-6339998b643b" xlink:href="alvo-20231231.xsd#alvo_SaleOfStockIssuePricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_alvo_SaleOfStockIssuePricePerShare_d504a8a0-971a-4da9-8652-6339998b643b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_4a133b52-080b-4a8a-9b2f-e116b0c10ecf" xlink:href="alvo-20231231.xsd#alvo_ClassOfWarrantsOrRightsExercisePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_alvo_ClassOfWarrantsOrRightsExercisePricePerShare_4a133b52-080b-4a8a-9b2f-e116b0c10ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_6c2d86a9-8128-4d97-a4bc-e49795c8ac71" xlink:href="alvo-20231231.xsd#alvo_NumberOfSharesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_alvo_NumberOfSharesCalledByEachWarrantOrRight_6c2d86a9-8128-4d97-a4bc-e49795c8ac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_5495bd0e-5f48-435d-9ad2-764ffa2435d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_3bbc0ed8-c041-4ee8-8454-1518c57f827a" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_5495bd0e-5f48-435d-9ad2-764ffa2435d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>alvo-20231231_g1.jpg
<TEXT>
begin 644 alvo-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %K KH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N#UCQMXF/C"^T/0/#>FZFEG#'
M+)<W^L/:'+C. JV\F?KFN\KAM!_Y*QXH_P"O6V_]!% #?[>^)'_0F>'?_"FF
M_P#D&C^WOB1_T)GAW_PIIO\ Y!KNZ* .$_M[XD?]"9X=_P#"FF_^0:/[>^)'
M_0F>'?\ PIIO_D&N[HH X3^WOB1_T)GAW_PIIO\ Y!H_M[XD?]"9X=_\*:;_
M .0:[NB@#A/[>^)'_0F>'?\ PIIO_D&C^WOB1_T)GAW_ ,*:;_Y!KNZ* .$_
MM[XD?]"9X=_\*:;_ .0:/[>^)'_0F>'?_"FF_P#D&N[HH X3^WOB1_T)GAW_
M ,*:;_Y!H_M[XD?]"9X=_P#"FF_^0:[NB@#A/[>^)'_0F>'?_"FF_P#D&C^W
MOB1_T)GAW_PIIO\ Y!KNZ* .$_M[XD?]"9X=_P#"FF_^0:/[>^)'_0F>'?\
MPIIO_D&N[HH X3^WOB1_T)GAW_PIIO\ Y!JMJ7BSXB:7I]Q=R^"_#[1P(9&"
M^)9<X SQ_H5>B5C^,/\ D5=6_P"O:3_T$T 3^'=6_M_P_IFI^5Y'VVVBN?*W
M;MF] VW.!G&>N*T:Y[X=_P#)/_#/_8,MO_12UT- !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.:5!&X5U:)D5@&1]W)/3KU ( /:H?$%A<:Q+I:7*-?11+,T6>=IZ&M&O'/\
MA4^KMXJTO68TMK V\EL[PPW,C;%64O)&I/4$'&.!QT XKV.@ HHHH **** "
ML?QA_P BKJW_ %[2?^@FMBL?QA_R*NK?]>TG_H)H K?#O_DG_AG_ +!EM_Z*
M6NAKGOAW_P D_P##/_8,MO\ T4M=#0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5PV@_\E8\4?\ 7K;?^@BNYKS:U\0:9HOQ
M:\2+J&H6]D7M;<J)Y0F[Y1TS0!Z316#_ ,)[X;_Z#NG_ /@2G^-'_">^&_\
MH.Z?_P"!*?XT ;U%8/\ PGOAO_H.Z?\ ^!*?XT?\)[X;_P"@[I__ ($I_C0!
MO45@_P#">^&_^@[I_P#X$I_C1_PGOAO_ *#NG_\ @2G^- &]16!_PGWAO_H/
M:=_X$I_C2_\ ">^&_P#H.Z?_ .!*?XT ;U%8/_">^&_^@[I__@2G^-'_  GO
MAO\ Z#NG_P#@2G^- &]16#_PGOAO_H.Z?_X$I_C1_P )[X;_ .@[I_\ X$I_
MC0!O45@_\)[X;_Z#NG_^!*?XT?\ "?>&_P#H/:?_ .!*?XT ;U%8/_">^&_^
M@[I__@2G^-'_  GOAO\ Z#NG_P#@2G^- &]6/XP_Y%75O^O:3_T$U#_PGOAO
M_H.Z?_X$I_C61XM\=>'9/#&J(FN:>S-;. HN$)/!]Z -3X=_\D_\,_\ 8,MO
M_12UT-<]\._^2?\ AG_L&6W_ **6NAH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BN7\;>,KCPK-HEK9:6VK7VK73VL,(F$0!6&28DL0?X
M8V[=2*S_ /A+O%__ $)*_P#@T'_QN@#N**X?_A+O%_\ T)*_^#0?_&Z/^$N\
M7_\ 0DK_ .#0?_&Z .XK,U+PSI&L3B:^TRTO)@-HDGA5SCTR17-?\)=XO_Z$
ME?\ P:#_ .-T?\)=XO\ ^A)7_P &@_\ C= &U_P@?AO_ * .G?\ @,G^%'_"
M!^&_^@#IW_@,G^%8O_"7>+_^A)7_ ,&@_P#C='_"7>+_ /H25_\ !H/_ (W0
M!M?\('X;_P"@#IW_ (#)_A1_P@?AO_H Z=_X#)_A6+_PEWB__H25_P#!H/\
MXW1_PEWB_P#Z$E?_  :#_P"-T ;7_"!^&_\ H Z=_P" R?X4?\('X;_Z .G?
M^ R?X5B_\)=XO_Z$E?\ P:#_ .-TVU^(&KP^)-%TK6/#)TQ-6FDMX+A+T3 .
MD,DV"-@X*Q-^.* ,7X5^"?#\]CXC,FB6#E?$&HH-ULAP!.P Z=*[;_A _#?_
M $ =._\  9/\*Y?X>ZO:Z#X=\6W][*(;6W\0:D\CGL!.U;5G\4/#U]>V]I%>
M'SY9C;E"O^KE$DD>QO0[XI!Z?+]* +W_  @?AO\ Z .G?^ R?X4?\('X;_Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCV/O0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .&\
M=_\ (]?#;_L+7/\ Z;KJNYKAO'?_ "/7PV_["US_ .FZZKN: "BBB@ HHHH
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M/JLD%U-<+?SB8I*<B/ QM7VKHZ* "BBB@ HHHH **** "BBB@ HHHH ****
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MKPW_ -#!I7_@;%_\51_PG7AO_H8-*_\  V+_ .*IO_"!>&?^A<TG_P  8O\
MXFC_ (0+PS_T+FD_^ ,7_P 30 [_ (3KPW_T,.E?^!L7_P 51_PG7AO_ *&'
M2O\ P-B_^*JCK7@3PTNCW[+X=TH$02$$647'RG_9K#^%_@CPY<> -$DET#2Y
M)&@R6>RC)/)ZG;0!<^!9#?!GP40<@Z1;$'_MF*[JHK6UALK>.WMXHX((U")%
M$H554=  . *EH *X;XZ?\D9\;?\ 8(NO_1;5W-<-\=/^2,^-O^P1=?\ HMJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
M-X[_ .1Z^&W_ &%KG_TW75=S7#>._P#D>OAM_P!A:Y_]-UU7<T %%%% !111
M0 4444 %%%% !7#>-?\ DH'P]_Z_[K_TBN*[FN&\:_\ )0/A[_U_W7_I%<4
M=S7#?%'_ (^/!?\ V,5M_P"BY:[FN1^(WAS5O$-GH[Z*UF+[3M3BOPM^[K$X
M17!4E5)!^;T[4 ==17#?:/B5_P ^'A3_ ,#;G_XS1]H^)?\ SX^%/_ VY_\
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M5=S0 4444 %%%% !1110 4444 %<-XU_Y*!\/?\ K_NO_2*XKN:X;QK_ ,E
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M*10(R_\ A8WB'_HF?B7_ ,"=._\ DJC_ (6-XA_Z)GXE_P# G3O_ )*KO:*
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M<_[08=J]#H \/\:_$#7I/&GP^=OAUXBB:/5+AEC:XT_,I-A<C"XNB,@$GG'
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M *)GXE_\"=._^2J/^%C>(?\ HF?B7_P)T[_Y*KO:* ."_P"%C>(?^B9^)?\
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MZ]_UZ2?RH P=)T_Q[J6E6=V?$M@AN(4E*BP'&Y0<=?>K7]A^//\ H9[#_P
M!_C72>%V"^%])). +.$DG_<%6FU6R7[*#=P_Z4YC@_>#]ZP!)"\\G"L>/0T
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MUDLC>+<PM:!2YN X\O:.IW=,#!J";Q!I=O"LTNI6D<3)YBR/.H4K_>!ST]Z
M.5_M?Q]_T+^E_P#@:?\ "J=]XV\6:#>:5_:VA6,=G>WB6C20719D+*Q!QCG[
MM=];WMO=/*D,\4SQ-MD6-PQ0]<''0UQGQ7_X]_#7_8:@_P#0)* %\=_\CU\-
MO^PM<_\ INNJ[2YD,-O+(.JH6'X"N+\=_P#(]?#;_L+7/_INNJ[*^_X\KC_K
MFW\C0!YKX0F\=^+O#EEK"^(+"U6\3S5A%B#L!)P,YYK8_L/QY_T,]A_X #_&
MIO@W_P DR\/_ /7L/YFNSH X;^P_'G_0SV'_ ( #_&C^P_'G_0SV'_@ /\:Q
M_C3XDU[2[.-_#D=S+/I.W5KN&W0'[3#$P9K?GH7 (R,_2LJ/QUK-AXE\0:CI
M]O-J.D3ZA9(L+Q2%DCEM8_GC!(PH<DMQZ]Z -;1/A[XST+4M<O8/%-FTNKWB
MWLX:Q& X@BA 7VVPK^.:U_[#\>?]#/8?^  _QKA?$OQ6\9V]I.EII\4-Q%))
M%/BTD=K<QSP(&^]\ZRI*SKC[H7')!PZ/XV>()51WLK:VAN+QK)96L[EC9.(Y
MV!F7 W*YCC *GCS.>U '<?V'X\_Z&>P_\ !_C1_87CS_ *&>P_\   ?XUS7P
MK\5:[+XRUC2M0_?:=+=WLT$CQ2!X]LH"J&8X*$$X&!]37KU 'F'BJ3QWX5T&
MXU1O$%A<K;M&6A^P@;@752,Y]#7I-G,;BS@E;[SQJQQ[C-<K\6_^2>ZM](O_
M $:E=-I?_(-M/^N*?^@B@"RQVJ3[5Y;X3O/'/C+3;C4HM=L+*$WUW;QP?8@V
MU(KB2-<G/)P@KU&3_5M]*X;X+_\ (D/_ -A34O\ TMFH =_8?CS_ *&>P_\
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M<^(KWQ/KVEZ+X=M[Z#2)XK>2XGOA$7=X(YN%VG@"4#\*E_X2#QW_ -"G8_\
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M;NYDABE>3:FV*62*8G ."K1-@=P1R#D  Z#=\1O7PY_WYG_^.4;OB-Z^'/\
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MX@:V;4;**[:U<R0-(N3&Q!!93V."1D>M4E^'_AU6#+H]JK J<K&!RJ[0?J
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M3GQ5_P!]:?\ _)5 '=5POQ7_ ./?PU_V&H/_ $"2C_A9&K_]$Y\5?]]:?_\
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M=&<H=@^7Z4DNFVLS(TEO&[1OYB%E!VMZCWJS10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7#:]X'URX\9S^(-#UZ'3'N+&&RFAN+/SP1&\CA@=ZX_P!:1^%=S10!P?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@##\6>,+#P98P75^EU*L\ZV\45G;O/*\C=
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ME+$4M98;1&WQF5-TY3 RP#8QTPN<=: /03\7=/49.@>*0/\ L W/_P 12_\
M"W+#_H7_ !3_ ."&Z_\ B*\Z\0>(/%_B#PMK&G7ZW"WD<(:/R;'RXYU)RDJG
M)*MG&5SBO5/ASJ6J:CH5Q_:Y9[FWO;BVCE>,(98DD*QR$  990#P.] %#_A;
MEA_T+_BG_P $%U_\15SP]\3-+\1>(%T6.SU:PU![62\2/4M.EM@\2/&CE2Z@
M'!E3@?WJZVN$U+_DNGAS_L7-4_\ 2K3Z!'=T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!PWQ._X^?"'_8=MOYFNYKAOB=_Q\^$/^P[;?S-=S0!Y=\1OC9_PKW7;NQD
MTE;J"VT_[>T_VED+#S%0H (V /S9!9@/4@<C8C^+WA^&"]EO;Z.!;5Y#+L5V
M\J-&PSO\O !X)&1Z$TNO?#_PWX^U'5)I[N2Z::T;2[ZWMKE=AB8@M&Z@'&<<
M]\5G:E\+_!%O=W,5Y<BVEO(Y!/!)=JOFPR-\R$'JA;]: -M?BIX;D:58KUKA
MXYI(&2")I&W1D!^%!/RDC/>J4?QB\.6]B\][J")L:7?Y,<C[%1I!EAMR/]4_
M;&5/M4<WP?\ #=GJG]N">[L;V&1YVNX[@1\,%#JW&-I"KGZ=:HZ?\*O!FL+/
M?:;J$MQ;RQS07+V=XKQS(Y9]KD _=,CLO3&[O0!MV7Q<\,ZDI-K>2SNIYB2V
MD,@7&=^S;G;COBD7XO>%I)(T74@QE8+$=C 2Y&05)&#P>@Y]JH:;\(O#37MK
MK&G7=X)EV[;FVN@1)&%*F,D#E".H]J='\$?#D>E_V<3>/8*Y:*W>8%81V1.,
MA1VYS[T >@5PFI?\ET\.?]BYJG_I5I]=W7":E_R73PY_V+FJ?^E6GT =W111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>alvo-20231231_g2.jpg
<TEXT>
begin 644 alvo-20231231_g2.jpg
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M       % P0&!P$"" D1$A,4  H5%A<C)?_$ !H! 0$! 0$! 0
M   ! @,'!0;_Q  Q$0 ! P("!P8& P         !  (1(3$#$@0%$T%1@? 4
M(F%QH;$&!S*1T?$6P>'_V@ , P$  A$#$0 _ -/\V'*U:43Y8>!J'C1VY)35
MUUMJ'(VH(MB^KBMDC,GLKZ0DL(E2Q"1V!-#T@9:FHJP8C'*(DB/;(X2V=LD6
MSY9PY5XN #A<S!\_VB:'NSP2<*S*#DFW/D3D_'-SCAZRE<WGSQ8%B0J3Q"2(
M([;B2),8PER(B5C=7NC?^LU)-TS+ACAPF&D($BJF40Z9!NH=QX(@(\$/E-Z&
ML^[[T\8O=QO$LZ7YR?SH?$[3=;I;&)TRJN5YA4^A\L>Z(--9#)(V\RW,QV6?
M6U)2V+:EW<AV5*!LE3<:XDD&XZ*)B6XNGN;N>-A&E]W]3%*JR!-RL!0M2S89
M 7!I!EC;9ZX$MI09%KD6S'33?=\X9IK(,T]-U'*B6FNVV-$@7,(K$P0A?45$
M&4:RNLRVA]@@]MXW<W.-DCFYA-)J[T7T)P:Q8TJ8'XSLY9;,7+I@JY35;[/&
M>V^FV^^=%Q?F"B75_4YGTVLKCWJF86++Y1/9D>Z^+%3\OFAXK*),=?N:<J9!
M1X7/G';XJ3=Y39I:;+O'2ROLT3USO[<:XQEECYHF"+.[8XXI26;0*XNKN<*K
MG":;99>'V)=E;PV3M$'GQ_3<O@4AD@\FQ:NOF1PV=/&R#=?*J>$E-L[Z^NI'
M$?=$0H60 9($'2:.FQ!^-F&"!43( I)D5"%!;E+"[8D.*L5EV#U@X0VPL@\;
M.%6ZJ6<*)J;:9QG\J*%?PZ<J<^\G23N6+TIW)(^R2IR[ 1>SFI<GH4&TX=58
M24L/ O3+,T?!R>Q330XZQ9,Q'/V+@N[CH8<8CH B"6:[Y: )@S)Z\-^Y$8U(
M>2'F/H?IOH'F:JYP#DI7G4=6",KGK*1Q]:$'YQ9+^8L]Z^AI!(AOF2'8G_EV
MJ$@6&9<M$C1C>/)[9*!R*6M!!) W=417;$\C?-->]DU!PXXF0@S=%F@I_*)&
M@-/@M1%/ 81$WDH9KV8[</D_XI29_358Q@#G&2JR:>Y5\@S&K#%B3,) \^4=
M%$6T^M:KJJA;NR+/LB!US7C%%JX>SN=R^/Q*'-$'OMRR5<28^08!D4WGOT^I
MMN]UPYSOKA#Y,[:XRD<0BUBG^B^?^A&1<C0UWU)=#*/.4F<@<598D2GN@!XO
M\N4&9W$7+%-@[M;""V46Q+5LLKA)3.FFV--LX @V1=E_*BK\(D7_ -B5RBGY
MN?%_C?=/7Z\?YL<K96WPDCHCMUO-?3=57.<833_Z%?DWSG7&FNN=O7'IGTYO
M^H<KVN;HGG]MM=-=M]]L:ZZXSMMMMG&NNNNN/7.VV<^F,8QC&<YSG.,8QCUS
M^=$2%?B)#ONI_P!D'KKJ6JT]R=+5U.^J)J_F8_&5(\5"3PE):PK[&C]+&6RC
MJ;Y++3 ,SSOE9X-!EWR>N^@UQOIR;5Y/B3U]T1 >$*PNENP>ZO*7>V+@HF,=
M%[S"-1EP.Z&Y^G%XR6,5#K++/&,H)5_^;Z3H56#P6++A@$;EP/+&1Z/UF,+6
M?N6#W"FQBMDDFD\8F+VK1%.3XQ_&;;7C[L#JXT=Z,A]BU;TM-W5H"Z2KRGSE
M35S3T]*&SI$TXK@$:M>T=PD;?"C+2/:@]"*J^!<9BZ+PH_\ X[?;\T&D$UH=
MW7/TY$OGX$;8GU">#CRJ7%5N-L6+6$GN.80UYHWT=9#GP?.<)=,9)EHKHJDY
M3C2B7^A4;+I[H+IC-DE\91VW_,M,,=YGV%>5T4I?ZS-=P:6^,$W8$O""9Y..
MB[HNLA>\DF31"5G;(<:&MHY@?.R1W1^\DC%8.CLY5'%U7;)5P=,/E$-G1DDL
MZK+'?)K_ +UO1!?^O2FPLB>^6+QX6+&!%O\ %E670XW@5;V&,;32#1EN]MFS
M@V(ZW%GTB+'(N0HP6/2IF/VUP@PD<6=R4>FD8(D7RT9O%QZ7YBM^2++_ %8Z
M\ATFJ'R<UM)8P)-US)+P&U^;A1AIH1 E8B]C4Y!E8T28.\*)O1;X(^V%O6SG
M&^KEIONDMC;&V?4RQZ'WW]<47-/UZN3>99]W)Y<W<RHFJY6IS5U96R_/JIV%
MA"BE.K"[@ZE6%+URJ[:*[Q79AM!XCLVR)RW]F8Z&SC/_ )[?VF $GP-/5%AO
MN/N697^T9,*+D5 U,=ILQ0[V?&ZP*PH(_A1.;&J=92<I*'T?<M5!ZQY_(B+@
M^Y)J(;.E2CA1[E3Y]\J?D@9X@1PW61;OV_-IQ.?V*>'^.6<EK.KJ8Y^KF/.N
M<H5:M:%[$H-I8[VH9N;C<D<5;'K*IY0U(DR@\% Z[=,YP+2C<CB482'M'F=2
M@HO3]8%@(\IN*2/!%+@U\7O3KCR8U?Y'3/6-*@I%&8<C6=KU_2/+\WJ4/>U?
M:IGTU&=A+R3IZW_Z\D2U,#=1QYXDNDPTAL*V1&_9CC)SKK*<TR.0OYUZY(IP
MOS2*OPB2PO;QBP_O>P!_0'4O4?6=B6F*%,HJ#/MS]$1)O'HZ"*DS0@3'@L0Y
M_!A@K9B6-%":>P]B@NH0?.'JZRKI397/$B:DFQ]&@^Y1%=BC+VZ!>AN2+.\C
M'>)6FY0W1B<B;C)=S['9P=CRVN&#P4>LL%SBPGL@:E&6RC0TF>/D]3;99P@7
MP]2<+:*: )H28S$<@";PBGNXVX@YJX(J1M3/,M>,X1%]G6I60E'#A8Q,)Q(<
MH:-UI)-I0^SL1/%E$M,)(:J;("Q#7VC0(T4+208I;  LB5Q\UG%L"XNZEB7=
M7(ECW7S;>][2"0N["<U+-V$>C!$P0=,EY.92#*QQ\Z^6;OEOZDQ#/BCZ)FRV
MG]-2.I/%G:SGFZCJ4FONBE;JR'3ZA."B?38GI'HNQNBK]&UKK*+=N:=B;(*1
M@/M(73!C&JYA1>*Z5+# 0G^R;?,TF%>*/W1$L[=&2!79-EJTTWZ9DR2)/.-_
M@B'+P[<M1/D.5ROF>!S2=3:B[K93"66%7EJM:TE LR:WAPV.NE-W@RN(Z9V8
M$ C5 :1#.23D,];:[ZKL-]EE]E#*%PX'\HAIZ+)S7PQ6N:Y4X0L25P2BNACJ
MEAZPN8MXC8.M*2J:(-0QE]29>119<R(;89BQFS,7/7]B"V[MBF]V9JNG#]5W
M#W+&\T->NI12U4UQW6GC7\?<K:\HG9K$[ L5] +#GMX2=:'SRVIA,9E(XNS(
MF#[^50TC#GV&(HP0%!1F\+P&&)/'Q-(=M(2A8R_H$-D7B9\81!CX>N<&'%M[
MR.N*NM*T)!!KU)2"=V-'K!Q61=,I+@L:*+,#;,K'ZTBY\8KINOOE5DR+I"UO
M37Y&.WIG.<L)DC=$\Z(LZG.#8=07F&O-A1]X=&U/#.@28/HZXZ[A4TAHZ*3J
M6"3ABRVL5(.5Z[=S ?7^TEDDD3<! <K%DW "0&8PJ=V /E1^:!WB)-QOX@G^
MO.)1>WY*.*HDT\D?+?7E7V[>-#7S;K52EYC,*E/P1MAQ&&H]**;$F@Z=5U.V
M:$B<Q>0; EGBJ;@<D@'!OV(IF;8[E7!]""+_ (_:+W_.1XU^>[AYJC71QTK:
MH/H#DR(1D#7-SQB<:M;&/!@Y-IN+9V#)2X@V]DSL<<5=2X?($=A<H82E^4)L
MCB&A8HV=UP$361%>-K^*+GW@]A-D]*AF71W2/5O65[26DS?\>N(//[A7Q5PH
MB1!DA*DO.12+!(RXGLN;AW)$8S(V$8E31LB4?.]!V2NR!! VM22:<:7(]AZE
M%-#WJ._H<O6'M]\DQ_G9!$?:.=?6U??";8H_1(X]F_V1RGV/E5;>NGO70;J>
M_'Q>FWDOSTT?M'RSU^=OI&!V<Z#I$:/B[(8V33<!FQQ^Z[::.[/F?A]V7LPW
M9AE@_"^)&9]3Z5WGMR[)W<=ES1BL&5U#+3,D<0#-$$$!I;^C!860_P"6KL8_
M?B<<>?2'3SZH]G]H.S7^JP;?RM_KLV_O^%JA[]_B0TT3]^WM]<^*ZB^#.T:D
MU-I'\K^-,#;ZJU=C;#1]>[+1\':Z)@OV6!A]E=L\'#S9,)F8Y&!K9,2OS>BZ
?OSZ-H[^W:P;GP,)V5FDPQN;#:<K1D,-$PT28$!?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@   NX   !]" 8   #]<.8.    "7!(67,  $SE
M  !,Y0%USO"5   ZO$E$051XG.V=^9=5Q=7W\\OS5[S)H\DR"2OJ2N+[FN<Q
MB;,BX 0291!1! V"@J(0400$145Q0D5%D::!A@::>6@F&VS&5J:&%F2>YTG&
M>^XY9[_W6UCMI>V&OE5UJLZYO3]KU>H,W'NKZM2I^M:NO7?]BIB?"7T*CU61
MOWH(><774^JK_T/>I!O)K_J2PK.'7->.81B&81B&:<#\RG4%XD1X8C.EYS]&
MJ8(KA&C/+OZ*OD3ILZZKR# ,PS ,PS106+A+SA\C_[LW*#6FT2]$NRACKZ9@
M^PS7M608AF$8AF$:*"S<09"F8-<\X193JVC_J7@SFU/XXP[7M648AF$8AF$:
M("S<,X1G#U)Z_J.UNLA<5 I_3_Z:=UU7EV$8AF$8AFF L'#/X%=^?&G!GFUU
M+[F%@KV+,FH_<%UMAF$8AF$8I@'!POW<$?*F-:VW<$\57D7I);TH/'/ =<T9
MAF$8AF&8!D3#%N[>:?+7?E!_T2ZM[N/^0L&.62)]),,P#,,P#,/8H$$+]_#
M"O)*;LY9N*.D2UNQU9UA&(9A&(:Q1L,5[JD?*;VHZ^4#4NLJF<\%6R:X;@7#
M, S#, S30&B8PAWI'S>/)V_<7]5$NW29*;X^LP$XZ;HU#,,P#,,P3 .@00IW
M<4/JG%9:HKWZ1M6*UXG\\ZZ;Q# ,PS ,P^0Y#4^XI\^27_F)R,EN0KA[XZ^C
M8-\WKEO%, S#, S#Y#D-3KB'1]:2-ZV)$=$N?=W395W$)4X,PS ,PS ,$Q4-
M3KC[JX>H!Z36974O^C,%FXM=-XUA&(9A&(;)8QJ4< ^/KC<JV"]*#[FP$X6G
M][AN(L,P#,,P#).G-!SAGCI!Z45=(A/NWJ0;15YXAF$8AF$8AHF"!B/<D?XQ
M-?::R(0[@EV#K25\FRK#, S#, P3"0U"N(<GME"ZM VE1OXF.N&>*?"?1]8:
MAF$8AF$8AC%-_@MWI']<_SFEBJZ-5+0+X?[MZT3>*=<M9AB&81B&8?*0/!?N
MX87TCS/OCURTBP#5Q=V(SA]SW6B&81B&81@F#\EOX>Z=(K_B-2NBG84[PS ,
MPS ,$R5Y+=QQHZE7_#=[PGW92T2IDZZ;S3 ,PS ,P^0A>2W<T_/:61/M[./.
M, S#, S#1$F>"G>?@IVS*55P)0MWAF$8AF$8)B_(2^&.](_>A!NLBG9O_'44
M;)U,%*1=-Y]A&(9A&(;)0_)/N(N U(&4*KS*KG"?U8+"8]^[;CW#, S#, R3
MI^2=< _V+"1OTC^MBO;4J-^RFPS#, S#, P3*?DEW%,GR%_>AU(%5]BUMD^Y
MG<(#RUVWGF$8AF$8ALEC\D>X!VD*ML^P[MN>&OU'\M>\G_E]SW4/, S#, S#
M,'E,G@CWD,+3^R@]_S&[HAW6]FE-B,X=<=T!#,,P#,,P3)Z3)\)]//E57UH7
M[:G1?Z!@TVC7C6>8R/ \CU*IU&5+&(:NJ\HP#,,T.,[6:XU"P7J6#^2%< ]/
M[2)OTHW6A7MZ_J-$J1]=-Y]AC'/JU&FJJ/B6QH\OIC%CQEZVE):6TI$C?/+$
M, S#V %B?.W:=?5:HU"PGF%=P_J69/)"N/L5 ^Q;V\=>0\'>,M=-9QCC'#UZ
ME(8/_X+:M'F8FC1I1G?>>1<U;MQ$_,TN^-_D_W[??<WIE5?ZT>;-6UQ7GV$8
MALES(-KGSY]/G3H]6>OZ5%O!>O;((^UIXL1)=.;,&==-4";APMVC8/]2\B;\
MKWUK^](7,R/GI.L.8!BC8#(L+BZFVV^_D_[YSYMR*C?==(L0[VQY9QB&8:($
MEG:(]AMOO#GGM:IY\Q:T<F6%ZR8HDVCA'IX]2.G%SU"JX$JKHMV;<2^%1]>[
M;C[#&":D??OV48<.'>D?_[A1E+___9_U+I@087F?.W>>ZX8P#,,P><JY<^?H
MPP^'7K1&W7##/RZY/LG_7_Y]_?5!=/)D,HVOR17N2/^X;2IY$_['KK5]3"/R
M*S\A\L^[[@&&,<QQVK!A [5L^2]EX8XCR\F3I[AN",,P#).GG#AQ0@CO^HKV
M["+7MO_\YT7A%II$$BO<PQ]WV$__6' %I><]0N')K:Z;SS 1H"_<X4?(PIUA
M&(:)"@CWUUX;E)-@KRGR6;C;QC]/?M4(8?VV*MS'7DW!QD*^;(G)4WX6[KE.
MABS<&89A&!O4M+CG6MCB[@"1_G'*;79%>Z:D2UL3>:=<-Y]A(H*%.\,P#!-O
M6+@GC2!-Z26]K(OVU.@_4GAXM6;=/0J/50D?^?3")RB]N!N%!RLRFP'.!<_$
M 1;N#,,P3+QAX9XP@GWEY(W[BW7A[J_HJUEQCX*=L\F;<L?%WUUT+?EKWB<Z
M?]Q,!S&,,BS<&29J?-^G4Z=."?%QN9(O-STRC$E8N"<)[[3]@-1,@=B&I5R'
M$/GF:XIV^?V9C0A\]BE]UE!',8P*+-P9)BJ"(*!=NW:+RU^&#OV(WGWWO<N6
M29-*:.?.G:ZKSC"Q@H5[@@@V%5)JS)\LN\@@_>/'&5&M=\M6>EZ[2V\.IC6A
M\,A:0SW%,"JP<&>8:&A%Z]954N_>+XO;&V^YY;9ZE6;-[J$>/9X7]RLP#',!
M%NX) 0&IZ=(V&9'[:[O6]ED/_'394JA<=[C(7/:2J((KR%\]Q%R',4S.L'!G
MF*CHTZ<OW7SSK?6^W1'B G]Q,^3@P6]GOB'MN@D,$PM8N">!P"-_W4>4&OT'
MNZ*]Z,\4;"[6JGIX8@MYLUO6^S?Y1E;&'2S<&28*-F[<5/V.J+Q7]]Y[/ZU<
MN=)U,Q@F%K!PCSMA0.&!Y77ZAT=6<-E261<*SQY4KSLV'-^]0:G"J^K]N^E%
M78A2)\SU'\/4&Q;N#!,%+-P9QAPLW.-.1L2FE_['KFB'M7W\=13L^T:KZN&1
M=>1-:YK;;X^]AH+-XPUU'L/D @MWAHD"%NX,8PX6[K%F_P7_\*)KK0MWO^)U
M<4.K,ID-AU_Q6D[6=E%&_D;X\L/%AF'LPL*=8:* A3O#F(.%>\SQ9MQMW]I>
M?'U&>)_4JK=(_SCA!K4Z(+?[^L\Y/21C&1;N#!,%JL)=!JJR<&>8GV'A'E>"
M-/D;OK NVN';'FR9H%7U\/0^[7SSWJ0;*=B[6/CX,XP=6+@S3!2PQ9UAS,'"
M/::$QS>1-^,>Z\(]7=J*PC,'M.KN5WUIIBY+7N ;51F+L'!GF"A0%>XR)20+
M=X;Y&1;N<<0_1_ZJM^VG?QSW%PIVS,KL&GSEJB/?/*SE1NI3_+=,?68:[%B&
MN10LW!DF"EBX,XPY6+C'D OI'V^S:VTOO(K22WKI6]LK!IC=3,QN273NB*&>
M99A+P<*=8:* A3O#F(.%>]S(B%21_K'@"KO6]I);*-B[2,NG/! !J?]KMFX%
M5U*P?9K!#F:8NMC#PIUA(H"#4QG&'"S<XT3H"Y&:&GNU96O[[\E?\ZY>U<\>
MI/3B9X30-KZIF' #IX=D+,#"G6&B@(-3&<8<+-QC1/CC#DK/;6M7M$,8SVPN
M?EN9($W!MJD9@?T_$6TLKB*_8B"1=\I<9S/,+V#ASC!1P*XR#&,.'>&.=XJ%
MNT&"C864&MW(NG /ML_0JK?8<&BF?[SLYF+2/RG8L]!03S-,;;!P9Y@H8.'.
M,.9@X1X7SATAK^0FZZ(=@EOKHB/_//E5(R@U)N(-1\$5E/[F.>W@628W=NS8
M(0H$+19.G;)ERU;Q78<.'7+=K#I(EG!'/ZY:M:K>_8]_NV_??DJE4E;J9XHS
M9\XHC3]7!$% 1XX<%6-][=JUVN]-;07?'==GN6_?OE_4=_+DR5K"_:Z[FM+(
MD05&^Q#/!@(H;J#_\'RQV3$];O >R3D=[U6^<>[<.=J]>[=8:TSW'<:+[#O7
MXT;750:E:]>G:>'"KR.9G[(+G@6>"9Z-*6(CW/UU'UD7[2+]XZY2K7J+](^6
M,N"(]) (5 W2AGJ=D?SXXX^T?OUZFCES%GWPP8?4O?MS].BC'>C!!UN)TJ)%
M2V'U4BWWW'-?1A _*+ZK5:LVU+'C$S1PX.M46#B:RLN7B(G(Y(NM1G*$>V5E
M9>89/4O-F[>H]S.X__X6]/##C]"@06_2KEV[(J^C/F_3BA4KZ)EGNF7:^4#.
M8V[(D/<B%R<0Z0<.',@L4!7TU5<CZ957^M&__]V96K=N*\9Z+L^GON\1_EYX
MCUI3APX=J6?/7IFVOBO&'42%J_?HR)$C]-EGGU/;M@^+L99=[V;-[J$;;OB'
MLLC N]6D23.C_8AG\]9;@^G@P8-.^@MC$_/>FC5KJL<.GB>>*YXOYB&38P<%
M\[B<T]NU:R_F><SWF/<Q_V,=2 KH/XA"K"%XCCUZ/"_6K(<>:BW6&M/O'<:+
M[+LV;1ZF9Y_M0<.&?4;3IDVC[=NW6Q7S)H3[+;?<5CV?1%GP+/!,\&SPC(8-
M^Y1*2TM%&U3GYU@(]V!?.7GCK[,KW NN(']Y'Z+428V*IR]DP+%8;YP0X&96
M1@\(#AR3K5JU.O,B#<LL&(]7'Z&AX,7&0JNSV-96ZOH^"%XL(D5%XVCKUJUT
M^O1I![V2#.%N8M*&&-Z[=V^D]=0%HKUQXR;*8Q!";]:L64;K%(:A6&PV;]Y,
M8\:,I:>>ZDIWW-&XSG%N^OVIS[N%11)"'FT_?/@P>9YGM ]JX^#!0V(C?O/-
MMUIKKV[!^]JV;3NQ";;#*O'NPI(.H=ZY\U/5_94]3N2\&]78N=3W8AW >K!L
MV3*Q(<4Z$1=PNK1SYTZ:,F6JF/\PSF^\\>9:^\_%>() ???=]VCY\A7B.4?9
M=R;6 )<%SPAC'^_ B!%?B7<BEXV/>^%^_ABE%SUM/_WCE-LH//2=5M7#PVN$
MU=[JAB-3<#,KHPZL*E]_74:]>KTHCJ"S%S)9I'B/NM3VF[#6#1WZ$55555FV
M'B9'N+_QQEMBT<KU.4G7 _R%>(@KV%3B*#=[(YGKLX!PGS9MNK$Z03BL7KU&
M6(P@&K(WNG(,NUH(Y6_+OL)?;"AP*C-]^@SA5A65D,#W+EBPD)HVO?N2?: J
MJ*(08O*98>,%JVW48+,'R_K @:^)$\?L<5USOK4I/+/';O:SPX89ZP/6"5<G
M$A+?]X7[T/CQQ?388QWHMMONN*CO;*Y7M;UWV75 P7LP8,! 6K1H,9TZ%4U"
MC:0+]^SQAC[#*1/Z#.](?:SP;H5[X%&P=9)P ;$J?L<T(G_-^WI96KS3E"[O
M85VTBTW'I!N%BPZ3.YLW;Q%'HW*1=2TX:BXB\B]$*2;I<>/&6PR@289PQV9F
MXL1)XIA3Y=G)?O[7OQX2[@UQ9,Z<4B&\5=N' K>#;=NV&:D/^@E'\K#0PE)4
M\W0J3B6[;BAP4X%[U+IUE91.FW<SQ'C$Z0,$55SFDOJ\JY@#,;]$;1S J<>H
M4:-^L=F+^]C!?T<?]>\_0 @J&R<W-<&S6;SX&^K=^^5JP9Z$OD.!:PW6VBCF
MV*0+]]KZ#?\9 A[O"MZ92^%4N(<G?J#TO';VK>U(_WABLU;=@YVSR"OZLQ/A
M+JSN%0,,/86& 1;L\O)RZMKU&2$\LBT$KE_<VEYD_)6+*X[]$8@7/<D0[F#_
M_OWTP@L]E3=>LH\A7.(&%J7^_5^M%L@JSP&?@Y@T(51AK1X\^&WQ;./\WM2U
M(*+.M]YZNW"#F#MWGH$G=#'9PCT)_2+'"-X?O$=1@9.(39M^$"Y$V2>;2>DC
MV4\WW70+=>KT),V>/<=J0.O9LV>IN'A"M4M,4MZ][/<.<]BKKPXPGI AGX1[
MS?&&=P7OS*7BL-P)=^0^WS2&4J-^9U?TCKV&@LW%XK(G56#M3L][A%(C_]N9
M<,<-K;BIE;D\6$"6+5LN A.E3V#<BSPNQ@0(08 C_^@#IY(CW/%,\3N8Y%2M
MG.CC+EVZBF/H.($-)DX#=*SM\#<U(<I@L4?:- 1R)<6:7%>_X"\VPJ;]_I-F
M<4<=[[[[7N'>$YT?\GS:OGV'"!S&V''=9MV"=0.!K5.G3K.6R>C33S\3+CLU
MXZY<]T6N8TV*=Y.6]WP4[MEK/MX9S+O(SE4;SH0[+-[>M*;6!6^ZK+-(/:E,
MX%W(@#/Z#\Y$NR@%5U)Z45<*3\<[P"X.0(S";SS;%S!)$Z"L=[=NW45:J>A(
MCG 'L'Y!&.CT*X1_24E))"X4*N"(M%^__LI6-7P."R6$I X0= B8P@F5M)ZY
M?@],O4<8H\7%Q73^_'DCS^QGX7Y[[/L)]</<AQ.4*(%H1W8A*3J3--_65K*M
MR'C6409>PM(.T9[T/LL><YB3!@UZX[(N(/4E'X5[;>,-[U!MXMV9</=7]+4O
M=C-B6\M*'084'JP@;_K=;D6[+$77BDNK.#UDW<!*C0PB23ABK,_D!W_+Z'S>
MDR7< 7*S2]<GE?K*#9$I7W =( 9@;7_@@7]I"4 <ZR,]FSHI81W#0BO%2CZ)
M"+0))QKSY\\WXK><%.$NYT#$AD1YRH3YZ:677LX;T5ZS_Q#T#)_W*,!8FC!A
MXB\L[4DOTN>]M'2ND7<NWX5[]GC#NU1SS7<BW,.CZRDU]FK[UO;%W?0JGCI!
M_O)7*%7X>_>B7;8)Z2%/[33S8/(01.++E\#UBVCB14:@770!9<D3[N@'Y,;5
MR;X"(8/,([ZO[CYG F1@0.YU5=]V%'P6V7)TQ\>D2275XL'UN(_B/4*!FQ12
MK^J2).&.(_B//_Y$N\UU<>K4:1H^_ LA;O-U[. 9PW5QSYX]QONOHN);<0]
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M_>L(=]3IC3?>C/2"'PD$0%E9677*5]4QB[^PD$$,1 4V&SIC\MY[[Q?B/Z[
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M<.L68_3IO?>J6T!EP.#77Y<IUZ&XN%A;N,--)LH3H[B15.&^=^]>,4_J)"-
M]J9HA'M&.$- VQ6JOQ8;!6P8=, E1M[XZYR+;E/%W_ %WZ@:4Y#"3S4P47X&
M5EL6[K\$&2E@39-YM54G=UC=3=R,F U<F[(S6JCT\U-/==6^)34;I-R3"TJN
MV0]D.Y *33?-FRIE98NTA(^I"ZSJ(M^#4V&U5LV:(2^7P6;6U$:TOB!%+^[7
MT!'NC1O?)4[X5)&7K^F,7YR\'CB@D8PC8215N&,M@7NKO)Q1I40CW#,B$:XJ
M<%FQ*E)'_U&XYL!%1QEL.!8]G:#TCY<OWHQ[*#QN+^"'J3\ZPEU./G!/,&?E
MS!_A#C I0TRJ^+#*11D!<[MW[S9:+RDR581[5"(3:=%P08U.&DV7PAW"6-Z2
M&9<^K5D_%7&6%%<9"'=5(2*%NXMY WG=<2E3TH4[XJ58N.?V[%P)=Z3JU+EA
M&!M-X\(=0:$(#K4N4*<U%<&PR@0>!5LGV=]P1%V0'G+5V^(&6"9>Z IW? XB
MVYQ?<7X)=X"4;["ZZ_@43I@PP5A]L.#TZ/%"]?>KU <7$>G>DEH3^,HCH#?)
MPEV*1Q;N]F'A[DZXHPYL<<^]SY(JW%&,"W>D840Z1ML"%6DG=0A/[Z'THJYY
M96V7Q9MRVX7TD$RL,"'<$93$PKUN("3ET:3J43XRS)@*4EVZ=*D082H"3HHX
M6.Q-DR_"G2WN;L@'X:[J(N9:N.-S+[WTLKALJZ' PMT@N/ (%Q]9%Z:S6XJ+
MGI2!>\\/1<(Z[5ID1U(RFQ&1'O+<$7,/F]$"05BC1HUBX6X!"%V=VU11D,9+
M%SQS7+&M<O&6% GPC8_B@AH6[O$4[DD)3C4AW.'C#D%FJV"L2N&N*O[B(-PQ
MG[SZZ@#CL3AQAH6[*3+B-[WL1?NB=$PC"O8OU:IZ>&*SDWSS5LO8J\5-L+@1
MMJ&!EWS3IA]$Y@FDC7O^^9XB[[#K\M!#K;5>7A;N]4=.\BK""9,\GI?.14=(
M/3=[]AR1P4+U>2-%9136=J CW.,0G)JOPEU^)I^%.RS=>&88W_@>6P69<. O
MK)I[/@["'9]AX:[V[%BX9X!X]L;_7[MB=-1OR5\Y@"BEMUCX*_JZ$=,C?T/>
MN+^2-[T9I4M;DS?K ?)*;HG,U0@WP>)&V(8"7LI5JU8+*V?;MNU^$;PF_[.K
MHOK29D_:+-SKQZI5J[0R^, BB+1MOJ^V\<4MC;C@2"7]IQPO+[[8FXX=TTMU
M6Q=L<8^G<&\(KC*UC76;\S-^2\6-CH6[.UBXFP#96,J>LNX?+M(_'EBA944.
MCZX7UFCKHCWSF^F%3U"PM434 4&]$-5(1XD\\NG9#XJ-B='?'-V(_+4?&'GD
M<0;B"A9V7,.-P,3L258>/4=96+C'3[C#305^H"I]CW\/'WD(9^0[SY4@"&C%
MBA7TX(.ME"=KY!G'B1$N&XH"%NXLW'4P(=R39D!AX>X.%NX&"';,(*_X>KO"
MM_ J\M>\FU%I&M=]ITY2>DE/ZZ+=*[F9_ V?4WAJ5QT=FJ;PQ ^9NO4R;GV'
MA3^??=V1!QCN!)T[=Z%;;[V]^N4P(93C5EBXY\(J^O;;[X2ONZJXP['Z@@4+
M<OYEB%E<M@7QKS(.\=M89%0V#?6%A3L+=QU,6=R35%BXNX.%NR80G[ <P^W#
MJOB=W3+SVSNUZA[L743>A/^Q*]S'7BU$>[W<>\X?CV1CD5[:2ZO?XDQY^9)J
MWW&=8] D%!;NN8')'K>IJK1-WFS8MV^_''W=#U%5517==U]SY3[%9@/!L;#<
M1P4+]W@*]X80G)K4PL+='2S<=4B?)7_-^_8MUN/^2L'F8JVJAZ?W4GK.0W;K
MKIC=Q9MQM]G^&W^=<,G)-[9LV2I\D4VYHL2]L'#/'<0\2/<IE0T=! JN-\]%
M1 \9\E[.OR/K)JWM1XY$>TK&P:GQ%.[R,RS<XU=8N+N#A;L&X>'5PNW#MG"'
M%1IN+LKXY\FO^H)21=?:JS<"4:??K91/'3?1&G69P09BT=,B-B%?P.437;IT
M;3"B74[:+-QS Q,U8A^0P4)EG. S??KT%<&F]0'6^3ON:*S<GQ!$I:5S(^X5
MMKC'5;BSJTQ\"PMW=[!PUR"]N)MUT2[2&NJF?SRZ7@2V6JWWF$;DK_]4Z0;3
M\-1N<8F2R?K@AEC<%(L;8Y,._-J__'($W7[[G0U&M,M)FX5[[JQ;5RDN55*U
M+C=OWH+6K%E3K]\:/OR+ZL_E^COXVZ/'\V*1BAH6[BS<=6#ASL+=)BS<%8%X
M=G%AT87+EC0&J'>*_._>,I^QY7+UGM5<7%"E0GAF?^;S+<S6"5;W>>U$$&S2
MP:+XY).=M5Z$)!86[FH@P\S0H1\)J[MJ:L8WWGCSLK\#,?SPPX]4?R[7OL3?
MJ/*VUU97%NXLW%5AX<["W28LW%4X=X3299VMBW84O_)CK8X3&XXQC:S7&^XN
MJD0BW%%&_8Z"36-%%IND FO[Q(D3Q<+!PEV7AB'<07EYN;B 1;6=.-W9OGW[
M)7\#IT!R<Y"+/[T4!%'=DEH;+-SC*=PY.#7^A86[?5BXYTKHB\#0U-AKG CW
M8-,8]5[+"%18[&W7&3GN=4 @K>D 55F\<7\1L0I)9=>NW<*=(#N+C&YQE1=8
M9=)FX:[.X,%O*P6HR@EWT* WQ<:Q-G;NW*D5[(E4IF5E9=;Z@H-3XRG<Y6=8
MN,>OL,7='2S<<R0\L9F\F<V=B'8AW+?/4.ZT8.<<^W4NNC;SN[.5ZRSZ_.#*
M2#=*Z45=]=R/'((%L6/')XP(=SD1F[J(Z7)%M[XLW/78MV^?<N H"GS=O_ON
MNU]\+\1\<?$$I5,@C GD>\=E45'=DEH;;'&/IW!O2*XR-N=>DW-X\^8/:#T;
M%NZYP\(]%^ ?CO2/#EQ-9/%7]E/JL/#$%O*F-;5;W\+?D__=FYE^TUO,T.9(
MZVD@X-<%2,FW?/D*D=Y/5PC+10.B"6X0.@7N$?4I^"V=A8Z%NSX0FZIB#U;Q
M]]Y[GTZ=.GW1=\+:WKW[<\H3,W*^SY\_/[);4FN#A3L+=QUTA3O$9Y,FS3+M
MO"]1I6W;A^GSSX=GYH!3RGW'PCUW6+CG0'CH.^/937(MWM3&N?>6=YK\U>]0
M:O0?[=85Z1^/5N9>W^P^/[Y)Y*V/NJ[I^8_II=AT@._[XAIXF;M=YR5&>?31
M#E10,(K&C!EKI<"JFGV[J\JDS<)=A\-"4+5JU3IGP2<%%4Y[UJ]?7_V-L+9/
MF3)5')^KIIO$(GSDB-T%A84["W<==(0[VH>3K[???H>6+ETJVIF44EE9*5+#
MAF&HW'<LW'.'A7M]R8@Z?WD?D8W$I7!/%5R9L^M)>&3M3^D??VVOGJ/_0/ZZ
MC[33+:;+G[-3W['7:%]J91O?]VGV[#G"RJWZ$F0' B(7/#*.V"JC1X\1@H&%
MNSO.G#E#'W_\B;+@@^#X]-//J@7KX<.'J7OW9Y6_#P&SLV;-TA("*D"XXQU@
MX1Y=_53$F73)R'?A#N-+2<EDZ^,^#N@(=_DY%NZYK_L-0K@'NTI%(*-3T?Y3
M$3=_[BV[O"@. PJ/?4_I>>WMUG'D?V=^\Q$*3^U2?\(.@H"]Z4VU3PALXOL7
M"W=5JSM<5A8L6&"]_A *^2;<L0 G2;B##1NJZ)%'<L_KCL!6?*9#AXZBWR Z
MIDV;KNPW#\L93F&BOB6U-O(E.%76)]=Q&U?A+C_3$(1[TN8-4^@*=XSW;MVZ
M"\-30X&%>WU(GQ6N%*X%>W4IN(*\F?=3L&VJ2$T)@5Y;G<-#JRB]H*/]C471
MGRG8.4OK 3L) BZ\ZB>??'5_/9OXOIYPE\?0$*H0;[;)5^$^<>(D$7^0%#!Y
M0W1".*NT&9-P4=$XX>O^S#/=E-UN6K1H*5P%7(#4EEV[/I-HBSO>)9V3DS@*
M]X;B*H//3Y^NGG@BR9BPN#_]=#<6[CF^5WDOW)')Q;E8KTT@3_P[^<M?H6#K
M9.$.$YX]*&Y%#78O(+_R$R'N7=0K7=Y#^-4KXS (V)MR!P7[OA$6_[CC^RS<
MHQ+NJO[9>!8(UCI]6F/\.Z"BXEMJT^9A98LSW$S@XJ*2%E3^9N_>+UNY);4V
M]NS90R^\T#.Q%O>5*RN43]SB;'&7<Q1<J/)9N-]]][TT=>HT,:<W-"#<Y>F=
M:O]AT\W"/;?W*J^%>_CC#J?I'R];"J\BK_C_B8PQZ=+6Y$UO1MZD?V1$[Y_<
M;":0%UW'188<!P&/^BWY*P<0I=PLP+F 27[>O/G5:?=4A#M*LV;WB" CV\1/
MN*=H^_8=U<)=10AA0L+$Y$J JH*8 ]R&>O/-MRH]#[A;_>M?#U6/*Q5Q9NN6
MU-HP(=S[].DK O5<@"P\*GTOWR-D-)D^?7ID]=,5[IBC%BY<&%G]=-$5[LBR
M]=57(ZU=.!8GT&Z5L9'=?YTZ/4E;MFQUW11KL'"_#/Z:=T5:0^<"/2'%7_.>
MWI.-0Q#PF$:)2 _I^SXM6+!0I.52]7&7EH[5J]=8KW_\A#L)JPU\ME6$N^S+
MWKU?HGW[]ANKDRV0'0:YV56?A\IE3BYN2:T-$\(=/O('#QYR4O_BXF)E\7/!
M%>4^6K9L663U@W"'&YGJ>XXL1>/'QS=Y@$IFINSV0<C \GSR9+(RFYD F=%4
MQZ[\'-)2?OOMMZZ;8@T6[G41!A3L741>R2W.Q7!2"JSDNM;V8/OT6 0!XX99
M2I_1:DO4P(]ZT:+%=/_]+;3SN$=I;:N+. IW""\(,)U%^/''.]'WWW^?R P1
M7WSQ9;654W4LY5H@RN"BY!(LA'!UD5E,5-H!/_$5*U8XJ?MSS_50<C>0GT'N
M_%6K5D561UA#X>ZB^I[#!6WDR(+8QHX\_WS/:D&DVL:>/7N)#61# R=ML@]4
MYQ"\>^/&C8_M^# -"_<Z",\<H/227L(5Q;6(3$09TXC\JA%$_GGUIYH^:_^2
MJ$N48--H];98HJJJBMJW?TP['>20(>]:KWL<A3M<'>#RH"/<85E$V^!^DC1P
MFRH" 57;KS+V7GOM=>>N1;A YI-/A@F7!1VK.Q93Y+*W"6ZOE<],]3V">YC)
M]Z@F2#O:H</CRL&S*,@X%%>+]*!!@ZK'@>HS@)\V@J0;&CH9A[+?OQ=?[)W(
MDTX56+C7!E(1[I@5"\MO(LJHWU*Z["D*3^W4>JAQ"P+&)@(WSL89++;=NG53
MMKC+A?2AAUI;3\,71^&.H-*A0S_2$J[X' (]R\N7&*N733[ZZ&-KPAV^RS@J
MMWE+:FW 30>7@F'3I;,)EME!;+G][-V[E_KUZZ]\"[%\SH\\TCYR-Q_<IJLZ
MKO 9N$/ G<?WXQ? ^<$''VC/&7%Y%VR#4P9LF'7G'/0?WN$D&DQRA85[+0AK
M>VDKY\(Q*07!L.)2J$!]PHEE$/#H/XH;9[4RY$2,],TU<7/J9Y]];K7N<13N
MF/1'C2JLGEA4_+9_%AKMQ"VBAPZY\7M60]ZFVB92\8Z^12#L*Z_TBX65#$?L
M,V?.JHX747WF<DQB#&W;MBTB$;9!;++GS"FE7KU>%&XD^'V5L2K;VJ/'\UK7
MUM<';#!TQA3&2]>N3XOL17&[; >Q1B;>%Z0UC/+D(XY A+9L^:#VQ@<%+E^#
M![]#:]>NS6L!S\*]%H(M$]S?D)J44G"E<"F"FXL.\0P"_C5YDV^E8,_76FV+
MDF/'CF4FJK>5+6[9"WC3ILV$>+=E>1\V[#.Z]=;;8R7<(;1*2^>*]&RZ?MX0
M4G?=U93:M6LOA-%;;PVFPL+15%145.]24E(BW*%LNE_HW*::2]\@"PW\6^/B
ME[IN766UVYGJADV.2VQ(82&&[S/<T')YYI<J>&>PV4$<!:S[>.]UGI$\J1LQ
MXJO(GP/JKCMNT%ZT^XDG_BU.AE3[$<&\\.DW(^X^RPC%=<+/6E=\HGVX3*@A
MN<Q@W,%-2/:![CJ&#1[6!=PI 7&+K#6FWC_= N. B53!+-QK$![?1%[Q]3$0
MC<DHWI3;19\IDX @X/3B[A2>.ZPS7B,%1_,R):0)4?7@@ZV$V$# *HYNR\O+
M19[W^I<-ERVP%L(B+46<ZB1M6KB#K5NW4I<N7;7[LV:@HVH[<8S<O_^K(E6E
M+39NW"BRZ^B*V)I%?A<$"BQC<;**8</Z\LM]E"ZBJMG&FL]=MP_K^KP)H6,K
M%2<"Z9%V4E7<H@],;B8Q!GOT>"&S85NG[7Z#4S6<!NC63XX;G*+T[=M/9-*!
M(6'NW'GUFE?ME"HZ?/BP46-"0<$H8\^VMCG+Y!RF6W"ZL'^_WBDC"_=L_//D
M5[SN7"@FJ>@&<"8B"'AT(PJV3-1R!8H2I/%[]-$.1H1[]@4Z*! Q\!U$\)K)
MHIH:KN8$'85PQZ+TZJL#M#/UU-:W4BC5MV0O9K @V;K@!U9W6$@QP4;1!Q@#
M<4S?IGL*5%M[L\>K;HDBXP_<"Q"4'#40*YBG3(IOU7Z4GT4].G;L1+MW[]9J
M&VX-1CI'W1,0%"DR93]AXX[,2Z;G8)W2O?NS8C-A:N.]?/D*L<Z8'!LJ\VV4
M)?O=A>5=!Q;N6>#&3&_\=>Z%8D**-^E&O8N* H^"S<6)" ).SVL7VT!5+!H0
MFKJ60E,37DWQ7U<QL6A'(=Q]WZ>)$R=56P=-]*GN\Y#/!#=DVD*ZCICL SE9
M#QKT9BPOF\%F D+6]3.W-:[P%]E:;(#-H Q\=MWV[/&(^N@**;C8X1(LC!V3
MFS[95_6=4VT6&!),W58*8PF^+TYC(ZKQAK_3IDW3ZB\6[C\1GCU(Z;(N[-M>
MWS+V&@HVCM)ZB' _22]XW'U;ZE,*KR)__:?: S<JX'H"H6G:&A?5I&]J$HQ"
MN(--FWZ@3IV>B,T1JQ08\'FW!:QI$%JF+-#RV<,7&*XX<03B$@)"UM?U<X^Z
MP)I;5E9FI6]QK\&R9<O%)5]QZ5LY)DVDPX5?NG27B:J><2F8#Q!(:TJX8Q-?
M5#1."#K78R+JL89[5W1C&%BX_X2P_!;]V;U 3$A)+^Q$X1D]/RT1!!QG%YF:
M);-9@6M/'(%_+@+6Y*3J>I*R4:3+113"'1:T+[\<H9S7V_2$+X4[ IQL@HND
ML#DRU0Z4/GWZQ"8@M39PB9(<7_@;E\V;Z3%UX5GTS<P=]A9O6%:174;6PW7?
M2I&-/.RZP.<;6:1PT93K.2/*@K;!)6C(D/>,94W"I@[^\S*N)@YC(XJQAM*O
M7S_M^8^%.X44'EU/WJP'W O#A!1OP@T4[E^J]P13)Q,9!)Q>^A^]2Z8B!-8L
M!#7EZ\17LT0IW '\?I]\LK/S=LJVNA#N +>IFFH'7 F0)2?N(!A8]GF^O4=R
M(XB[&Y8N76I]$X4,+-D"+0[%A' ',*#T[OV2:)N)H.2X%MQ3 5<ZDV#C,W7J
MM(M2LN9;_YF:_UBXI\^07_FQ"$!T+0H34> R4O%:1GAKW'28X"!@G,H$._7\
M(:,$ 5)(AR47#M<3551%B@\L(%'F <?B9"(UI&YQ*=RQ@4$F!-T^0 S&.^\,
ML19@J\X)VK)EJTCC*<>:Z_%N^KU!FE)D\H!KD&W@%H%L*:B#'->N^\64< =K
MUJP1J4#CTC:3!6W"^H*3A2B (!TTZ UAT7<]YYHL& =P.?SPPZ%&[DMH\,(]
M/%9%WI0[G O"I!1O>E,*CZS3>GB)#@(NN$+<$DOGCQD:RF;!38H]>_ZG6KR[
MGK"B*K)MR&X0]<4QN$P'67!<+L(NA3L8.;) *\,,/H<THRM7KHRUFXSD_/GS
MXJ(?>1&5Z_%NHDC1CKEAX,#7A=N**R \<*^!K)?K/C8IW &"79&B-PYM,SE^
M\+=__P&1IG'=O'G+17$F2>\_V0:D&$:J81,T>.'N5W[B7@PFI8QI1/Z&X2(;
MC#+>:4J7]TAT$+!7<K/8?,01B"+X)>>[>)?M&C9L6,17A*?H^/'C]/GGPX5X
M=]6?;H7[86&!_O>_.U<O0KF<YDBQB+SMZ,ND@$4&XAT7166/N226[,!"+-B[
M=NURW;UT\.!!D3<_NWZN^L>T<(?;Q\2)$\5I77;<4=).0:6[CZR_K<NA?OCA
M!VK?_E'C"0UL%SEOX\0268=,Y;YO\,(]O? )YT(P*<5?]W%F1M*S;H9'UI(W
MK:GSMFB5,7\B;/AT;XN-"HAW9$6!-1KN"4D6')>;%'$L'34(G(+@A.5=NLW8
M[E/7%G=,N*K!NOCW$+_??/.-Z,LD <L[,C9)ZVE2WR6YV8+_M<U@U$NS2N1/
M[]/GE>J^E<+6EL"5HM"T<,>&'^\,Q+N\'"^I8T?6&[>;(H#4SHG9';1QXZ9J
MRWL273_EG(W\])A#,)>80D>X9V_@$RO<O4E_=R\$XUP*KA!^W8@#,$&PJU0$
MMSIOETX9W8C\->^+TX,X _]5N#A(L9E4JX4LV1>3P(([=.A0ZWU:7KY$!-;9
M/LV0SP]7M;MBY\Z=8C.82[NSK>UQNB4U5V!E[-[].1'\+<=@S7$9UX+^A\5O
MQ(BOC%RW;AK$/.!:>J2)A*'!17\.'CPXLO955E:*-)%QR%"5ZYR#O_?>>[](
MEXG 6]O@5.:]]]X709VF[BF)LF2O4?#31T8N)(TP35*%.]8 /$\=X8Y8@5]Y
MLUNZ%X)Q+85747K.@Q1LGVXLDTIX['OR9MSCOFTZI>A:\JN^B&UVF9HL6+"0
M>O5Z,;,P/G#114G9+W'<CR.S\P?CQ45[7!WW(U@309:M6[>M]ONNZ_(I4VV7
MWXTL(*Z 2]+8L45TYYUWY53ON-Z2FALGA(B P,2E5#*W?93//==W(_L=D75"
MA@YDR"DO+W<2B%I?$+"*?/+(#8X\_]G]&&6_RN_%A6M1 K_M3S_]3 0\0\#7
M?$[9=8G+V,%)0>?.3]'BQ8N=;KHA4DM+YXHY7XX-U^]=;;^;/1]@K44<"6XU
MCP*\RPATQ:8\5]=%6>?77GM=]*UM$!2?G?TNUX(Q^:M@VU3.*%-+\:8W$]EC
M1""JCD][3?QSY*]Z.]/G?W#>1J6"X-3,9D8W0-<F.-J$M63APJ_%+AW"(_OX
MUG2I.:F9+!"-"(["0N@RR!''G@BT1!:?CAV?$)=J1-EN3%@=.CSNQ.J5#5)O
MXOBZOL\9]48?Q?&65!4@8)!I""(,_8#3++EYBTN!N$&J1^1++RTM=;(XJ[)M
MVS8:,V:L<,N E156RZC["QMP_&[48.S M6_X\"]$FEFX4&2_1[4)0ML%\RO&
M#JRQ$R9,%*=L<0%SW[AQX\7= \C:@\US7/H-!6LJUE9DQ<%:&W7V++@>XB0M
MESZ0_ZY%BY;"H!=M?%CMP-T*[YS*N,=<"_>S7R&?N+_Z'?*FW):LRX"B*)D-
M3'IN6_)7#K@@3'52/EX"7&+DK^Q/WKB_N&]SCB4]M]V%$PB3FQF+X&ALPX8J
MD?5@X,#71+ 14BK*6U==3WYU%=0-Q\W8K</B'03QR$R"R1F^F(L6+19B[KGG
M>@BK&A9E>;1KHOW8'%14N+=:^[Y/966+Q";B<FV#91&++"S5^08L7G"?@24;
M0JQ___YB?$+T9%N,HRY8R!HWOHL>>ZR#\%]___T/:/+DR6*LN,P:HP,"^-"W
M".;#IJ]W[Y=%^Z2E.M?%_E(%<]_<N?.L;BSAYPO# ]ZCPL+1-&# 0'KTT0[B
M=$1:4&V)4<Q3F*\P;\&H [&.S07F6%.!E";!O(_Y!.Y'DR:5B)//%U[H>5'_
MV>@[K$=8,S%^L(9B+<6:BK75EOL)UA[<-@L17I\ZRW[!AACI6*/.QE87V"Q,
MGS[]%\''ERM(#H%,5)C7Q 5,"+@,CVX0-WGZW[U!?L7 AE4R;<;-L<'>,@I_
MW)'I#PMYEC,;IF#/ A'DZ;S]]2F9>@8[YU!X]F!B7&0N!29E6.+P$F 1@141
M 30H>*DA1N)22DHFBWH=.G1(+'IQ! L*Z@:K$$0'%I8%"Q;0[-ES1/UUVH_G
M@6<$T1P','9PU3DFWTO5&ZX/\0F$C ;YW/$NX30""S>$()X["JS'4;P3B%W!
M]\.BCI,?;!Z/'3N668Q/B^>3M"#@VL "C_:@74ASBQMM,0^@W6B_;A_BV> ]
M=74:A+&#DSN,G5V[=HNZ0,RCC9=[MW3G4_0A?@<;3\Q7F+=.GCR9J),QC'.(
M3ZP+&S=N%+[D>!_0MJCZ#W.Q[#NLF9B7L8;B&;K8Z&#N01:Y7.8-S!>NXXTP
GSG":4]^U$>_JJE6KQ1C%>_/_ 9WZ,Q0XI+T:     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@   X0   "6" ,   "Q9K8$    ,U!,5$5,:7$Z
M.CPZ.CSYGQLZ.CPZ.CPZ.CLZ.CPZ.CPZ.CSYGQKYGQKYGQKYGQHZ.CSYGQLY
M.3O]!27,    #G123E, Z*QTSQB)_&@\U"6D3+ZTYZ$    )<$A9<P  +B,
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MO0(QZ?#1Z7^CA-T[K)=]#R$)NG5'/\!IDG.+"MCJ_(ATP&LB P"**I6?)RR
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MY\%W*_7Q<PAMB1?%7F.*S9/Q?=W0P\Q04$9B9'[BR^O]8_\ CZD[8=<R4!D
+    245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430473745664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALVOTECH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">N4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Rue de Bitbourg<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">1273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Luxembourg<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">LU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">266,821,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsOutstanding', window );">Class of warrants or rights outstanding (in shares)</a></td>
<td class="nump">10,363,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001898416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStocksAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALVO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStocksAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALVOW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">S&#230;mundargata 15-19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Reykjav&#237;k<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Robert Wessman<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">422 4500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassOfWarrantsOrRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassOfWarrantsOrRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassOfStocksAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassOfStocksAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassOfStocksAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassOfStocksAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414085040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte ehf.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">K&#243;pavogur, Iceland<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417139376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Product revenue</a></td>
<td class="nump">$ 48,699<span></span>
</td>
<td class="nump">$ 24,836<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">License and other revenue</a></td>
<td class="nump">42,735<span></span>
</td>
<td class="nump">58,193<span></span>
</td>
<td class="nump">36,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other income</a></td>
<td class="nump">1,948<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">2,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of product revenue</a></td>
<td class="num">(160,856)<span></span>
</td>
<td class="num">(64,095)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(210,827)<span></span>
</td>
<td class="num">(180,622)<span></span>
</td>
<td class="num">(191,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(76,559)<span></span>
</td>
<td class="num">(186,742)<span></span>
</td>
<td class="num">(84,134)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(354,860)<span></span>
</td>
<td class="num">(346,442)<span></span>
</td>
<td class="num">(235,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod', window );">Share of net loss of joint venture</a></td>
<td class="num">(7,153)<span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
<td class="num">(2,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss on investment in joint venture</a></td>
<td class="nump">21,519<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">4,823<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
<td class="nump">51,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="num">(267,157)<span></span>
</td>
<td class="num">(188,419)<span></span>
</td>
<td class="num">(117,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Exchange rate differences</a></td>
<td class="num">(5,183)<span></span>
</td>
<td class="nump">10,566<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid', window );">(Loss) / gain on extinguishment of financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,311)<span></span>
</td>
<td class="nump">151,788<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Non-operating (loss) / profit</a></td>
<td class="num">(296,189)<span></span>
</td>
<td class="num">(205,205)<span></span>
</td>
<td class="nump">86,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before taxes</a></td>
<td class="num">(651,049)<span></span>
</td>
<td class="num">(551,647)<span></span>
</td>
<td class="num">(149,198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit</a></td>
<td class="nump">99,318<span></span>
</td>
<td class="nump">38,067<span></span>
</td>
<td class="nump">47,694<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">(551,731)<span></span>
</td>
<td class="num">(513,580)<span></span>
</td>
<td class="num">(101,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Item that will be reclassified to profit or loss in subsequent periods:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange rate differences on translation of foreign operations</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(6,111)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">$ (551,817)<span></span>
</td>
<td class="num">$ (519,691)<span></span>
</td>
<td class="num">$ (101,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (2.60)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (2.60)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_11&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from licence fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417794032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 236,779<span></span>
</td>
<td class="nump">$ 220,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">119,802<span></span>
</td>
<td class="nump">47,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,058<span></span>
</td>
<td class="nump">11,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">19,076<span></span>
</td>
<td class="nump">25,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractAssets', window );">Contract assets</a></td>
<td class="nump">10,856<span></span>
</td>
<td class="nump">3,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investment in joint venture</a></td>
<td class="nump">18,494<span></span>
</td>
<td class="nump">48,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">5,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">26,132<span></span>
</td>
<td class="nump">25,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">309,807<span></span>
</td>
<td class="nump">209,496<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">755,248<span></span>
</td>
<td class="nump">597,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">74,433<span></span>
</td>
<td class="nump">71,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">41,292<span></span>
</td>
<td class="nump">32,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Contract assets</a></td>
<td class="nump">35,193<span></span>
</td>
<td class="nump">25,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">31,871<span></span>
</td>
<td class="nump">32,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties', window );">Receivables from related parties</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">11,157<span></span>
</td>
<td class="nump">66,427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">194,842<span></span>
</td>
<td class="nump">230,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">950,090<span></span>
</td>
<td class="nump">828,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">2,279<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">1,229,690<span></span>
</td>
<td class="nump">1,058,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="nump">42,911<span></span>
</td>
<td class="nump">30,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Translation reserve</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(2,205,845)<span></span>
</td>
<td class="num">(1,654,114)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="num">(932,493)<span></span>
</td>
<td class="num">(564,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Borrowings</a></td>
<td class="nump">922,134<span></span>
</td>
<td class="nump">744,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">520,553<span></span>
</td>
<td class="nump">380,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPayablesToRelatedParties', window );">Other long-term liability to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">105,632<span></span>
</td>
<td class="nump">35,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan', window );">Long-term incentive plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">73,261<span></span>
</td>
<td class="nump">57,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">1,621,633<span></span>
</td>
<td class="nump">1,225,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">80,563<span></span>
</td>
<td class="nump">49,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">9,683<span></span>
</td>
<td class="nump">5,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Current maturities of borrowings</a></td>
<td class="nump">38,025<span></span>
</td>
<td class="nump">19,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Liabilities to related parties</a></td>
<td class="nump">9,851<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">59,183<span></span>
</td>
<td class="nump">36,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Taxes payable</a></td>
<td class="nump">925<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">62,720<span></span>
</td>
<td class="nump">54,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">260,950<span></span>
</td>
<td class="nump">167,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,882,583<span></span>
</td>
<td class="nump">1,392,859<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">$ 950,090<span></span>
</td>
<td class="nump">$ 828,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables due from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414927008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">$ (551,731)<span></span>
</td>
<td class="num">$ (513,580)<span></span>
</td>
<td class="num">$ (101,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains', window );">Gain on extinguishment of SARs liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,803)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdjustmentsForSharelistingExpense', window );">Share-listing expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,411<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Long-term incentive plan expense</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">5,492<span></span>
</td>
<td class="nump">17,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">24,210<span></span>
</td>
<td class="nump">20,409<span></span>
</td>
<td class="nump">18,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment of property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets', window );">Impairment of other intangible assets</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">3,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets', window );">Change in allowance for receivables</a></td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ChangesInInventoryReserves', window );">Change in inventory reserves</a></td>
<td class="nump">8,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss on investment in joint venture</a></td>
<td class="nump">21,519<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod', window );">Share of net loss of joint venture</a></td>
<td class="nump">7,153<span></span>
</td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="num">(4,823)<span></span>
</td>
<td class="num">(2,549)<span></span>
</td>
<td class="num">(51,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance costs</a></td>
<td class="nump">267,157<span></span>
</td>
<td class="nump">188,419<span></span>
</td>
<td class="nump">117,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid', window );">Loss/(Gain) on extinguishment of financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,311<span></span>
</td>
<td class="num">(151,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payments</a></td>
<td class="nump">18,033<span></span>
</td>
<td class="nump">10,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Exchange rate difference</a></td>
<td class="nump">5,183<span></span>
</td>
<td class="num">(10,566)<span></span>
</td>
<td class="num">(2,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Income tax benefit</a></td>
<td class="num">(99,318)<span></span>
</td>
<td class="num">(38,067)<span></span>
</td>
<td class="num">(47,694)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Operating cash flow before movement in working capital</a></td>
<td class="num">(283,554)<span></span>
</td>
<td class="num">(228,861)<span></span>
</td>
<td class="num">(193,220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(11,304)<span></span>
</td>
<td class="num">(32,412)<span></span>
</td>
<td class="num">(29,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Increase in trade receivables</a></td>
<td class="num">(8,320)<span></span>
</td>
<td class="num">(3,576)<span></span>
</td>
<td class="num">(28,813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties', window );">Increase / (decrease) in liabilities with related parties</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets', window );">(Increase) / decrease in contract assets</a></td>
<td class="num">(17,393)<span></span>
</td>
<td class="num">(9,218)<span></span>
</td>
<td class="nump">15,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Increase in other assets</a></td>
<td class="num">(802)<span></span>
</td>
<td class="num">(17,194)<span></span>
</td>
<td class="num">(4,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase in trade and other payables</a></td>
<td class="nump">31,772<span></span>
</td>
<td class="nump">16,442<span></span>
</td>
<td class="nump">14,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities', window );">Increase in contract liabilities</a></td>
<td class="nump">35,396<span></span>
</td>
<td class="nump">19,396<span></span>
</td>
<td class="nump">21,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">(Decrease) / increase in other liabilities</a></td>
<td class="num">(5,182)<span></span>
</td>
<td class="num">(21,384)<span></span>
</td>
<td class="nump">5,160<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operations</a></td>
<td class="num">(257,226)<span></span>
</td>
<td class="num">(276,751)<span></span>
</td>
<td class="num">(200,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(57,254)<span></span>
</td>
<td class="num">(35,372)<span></span>
</td>
<td class="num">(28,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities', window );">Income tax paid</a></td>
<td class="num">(1,354)<span></span>
</td>
<td class="num">(834)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(312,185)<span></span>
</td>
<td class="num">(312,389)<span></span>
</td>
<td class="num">(228,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property, plant and equipment</a></td>
<td class="num">(33,234)<span></span>
</td>
<td class="num">(37,880)<span></span>
</td>
<td class="num">(20,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Disposal of property, plant and equipment</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisition of intangible assets</a></td>
<td class="num">(13,239)<span></span>
</td>
<td class="num">(11,122)<span></span>
</td>
<td class="num">(20,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RestrictedCashInConnectionWithAmendedBondAgreement', window );">Restricted cash in connection with amended bond agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,914)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(46,340)<span></span>
</td>
<td class="num">(63,537)<span></span>
</td>
<td class="num">(40,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings</a></td>
<td class="num">(99,367)<span></span>
</td>
<td class="num">(34,714)<span></span>
</td>
<td class="num">(37,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities', window );">Repayments of principal portion of lease liabilities</a></td>
<td class="num">(8,269)<span></span>
</td>
<td class="num">(11,147)<span></span>
</td>
<td class="num">(7,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="nump">278,831<span></span>
</td>
<td class="nump">193,678<span></span>
</td>
<td class="nump">113,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments', window );">Gross proceeds from private placement equity offering</a></td>
<td class="nump">136,879<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Gross private placement equity offering fee</a></td>
<td class="num">(4,141)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from warrants</a></td>
<td class="nump">6,390<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds on issue of equity shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">185,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Transaction cost from borrowings</a></td>
<td class="num">(9,004)<span></span>
</td>
<td class="num">(12,102)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GrossProceedsFromThePipeFinancing', window );">Gross proceeds from the PIPE Financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">174,930<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GrossPipeFinancingFeesPaid', window );">Gross PIPE Financing fees paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,562)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ProceedsFromTheCapitalReorganization', window );">Proceeds from the Capital Reorganization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansFromRelatedParties', window );">Proceeds from loans from related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties', window );">Repayment of loans from related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash generated from financing activities</a></td>
<td class="nump">301,319<span></span>
</td>
<td class="nump">424,910<span></span>
</td>
<td class="nump">254,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Increase / (decrease) in cash and cash equivalents</a></td>
<td class="num">(57,206)<span></span>
</td>
<td class="nump">48,984<span></span>
</td>
<td class="num">(13,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">66,427<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">31,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of movements in exchange rates on cash held</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the year</a></td>
<td class="nump">$ 11,157<span></span>
</td>
<td class="nump">$ 66,427<span></span>
</td>
<td class="nump">$ 17,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for extinguishment of liability losses gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss reversal of impairment loss recognise in profit or loss intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase decrease in liabilities to related parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdjustmentsForSharelistingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdjustmentsForSharelistingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ChangesInInventoryReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Inventory Reserves</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ChangesInInventoryReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_GrossPipeFinancingFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross pipe financing fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_GrossPipeFinancingFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_GrossProceedsFromThePipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from the pipe financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_GrossProceedsFromThePipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ProceedsFromTheCapitalReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the capital reorganization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ProceedsFromTheCapitalReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of principal portion of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RestrictedCashInConnectionWithAmendedBondAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash in connection with amended bond agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RestrictedCashInConnectionWithAmendedBondAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in contract assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for undistributed profits of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from advances and loans from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of advances and loans from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_11&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for income taxes paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the allowance account used to record the impairment of financial assets due to credit losses. [Refer: Financial assets; Allowance account for credit losses of financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_16&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The losses on the disposal of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430474214176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Penny Warrants</div></th>
<th class="th"><div>Public Warrants</div></th>
<th class="th"><div>RSUs</div></th>
<th class="th"><div>SARs</div></th>
<th class="th"><div>Vested Earn-Out Shares</div></th>
<th class="th"><div>Other Share Based Payments</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th">
<div>Share capital </div>
<div>Penny Warrants</div>
</th>
<th class="th">
<div>Share capital </div>
<div>Public Warrants</div>
</th>
<th class="th">
<div>Share capital </div>
<div>RSUs</div>
</th>
<th class="th">
<div>Share capital </div>
<div>SARs</div>
</th>
<th class="th">
<div>Share capital </div>
<div>Vested Earn-Out Shares</div>
</th>
<th class="th"><div>Share premium</div></th>
<th class="th">
<div>Share premium </div>
<div>Penny Warrants</div>
</th>
<th class="th">
<div>Share premium </div>
<div>Public Warrants</div>
</th>
<th class="th">
<div>Share premium </div>
<div>RSUs</div>
</th>
<th class="th">
<div>Share premium </div>
<div>SARs</div>
</th>
<th class="th">
<div>Share premium </div>
<div>Vested Earn-Out Shares</div>
</th>
<th class="th"><div>Other reserves</div></th>
<th class="th">
<div>Other reserves </div>
<div>RSUs</div>
</th>
<th class="th">
<div>Other reserves </div>
<div>SARs</div>
</th>
<th class="th">
<div>Other reserves </div>
<div>Other Share Based Payments</div>
</th>
<th class="th"><div>Translation reserve</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">$ (867,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,974<span></span>
</td>
<td class="num">$ (1,039,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">(101,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation differences</a></td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">(101,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="num">(101,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">833,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="num">(135,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,669<span></span>
</td>
<td class="num">(1,140,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">(513,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(513,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation differences</a></td>
<td class="num">(6,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">(519,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,111)<span></span>
</td>
<td class="num">(513,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseDecreaseThroughPipeFinancing', window );">PIPE Financing</a></td>
<td class="nump">169,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseDecreaseThroughCapitalReorganization', window );">Capital Reorganization</a></td>
<td class="num">(171,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares', window );">Settlement of related party loans with Ordinary Shares</a></td>
<td class="nump">32,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Recognition of share-based payments</a></td>
<td class="nump">14,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Recognition of equity component of convertible bonds</a></td>
<td class="nump">16,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="num">(564,416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
<td class="num">(1,654,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">(551,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(551,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation differences</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">(551,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="num">(551,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,159<span></span>
</td>
<td class="nump">$ 7,612<span></span>
</td>
<td class="nump">$ 5,095<span></span>
</td>
<td class="num">(9,526)<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Recognition of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (678)<span></span>
</td>
<td class="num">$ (13,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,095<span></span>
</td>
<td class="num">$ (9,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,781)<span></span>
</td>
<td class="num">$ (4,231)<span></span>
</td>
<td class="nump">$ 16,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Capital contribution</a></td>
<td class="nump">132,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Public warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,184<span></span>
</td>
<td class="nump">$ 7,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,159<span></span>
</td>
<td class="nump">$ 7,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Recognition of equity component of convertible bonds</a></td>
<td class="nump">5,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="num">$ (932,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,229,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,528)<span></span>
</td>
<td class="num">$ (2,205,845)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncreaseDecreaseThroughCapitalReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through capital reorganization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncreaseDecreaseThroughCapitalReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncreaseDecreaseThroughPipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through pipe financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncreaseDecreaseThroughPipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through settlement of related party loans with ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411287104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsAbstract', window );"><strong>General information about financial statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General information</a></td>
<td class="text">General information <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech (the &#8220;Parent&#8221; or the &#8220;Company&#8221; or &#8220;Alvotech&#8221;), previously known as Alvotech Lux Holdings S.A.S., the surviving company after the Business Combination (as defined below) with, among other parties, Alvotech Holdings S.A. (the &#8220;Predecessor&#8221;), is a Luxembourg public limited company (soci&#233;t&#233; anonyme) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg and is registered with the Luxembourg Trade and Companies&#8217; Register under number B 258884. The Company was incorporated on 23 August 2021. These consolidated financial statements were approved by the Group&#8217;s Board of Directors, and authorized for issue, on 20 March 2024. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company and its subsidiaries (collectively referred to as the &#8220;Group&#8221;) are a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide. The Group has commercialized a certain biosimilar product and has multiple biosimilar molecules. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1 Capital Reorganization </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 15 June 2022 (the &#8220;Closing Date&#8221;), the Company consummated the capital reorganization with Alvotech Holdings S.A. and OACB (the &#8220;Business Combination&#8221; or &#8220;Capital Reorganization&#8221;) pursuant to the business combination agreement, dated as of 7 December 2021, as amended by an amendment agreement dated 18 April 2022 and 7 June 2022 (the &#8220;Business Combination Agreement&#8221;), by and among the Company, Oaktree Acquisition Corp. II (&#8220;OACB&#8221;) and the Predecessor. The closing of the Business Combination resulted in the following transactions: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">OACB merged with and into the Company, whereby (i) all of the outstanding ordinary shares of OACB (&#8220;OACB Ordinary Shares&#8221;) were exchanged for ordinary shares of Alvotech (&#8220;Ordinary Shares&#8221;) on a one-for-one basis, pursuant to a share capital increase of Alvotech and (ii) all of the outstanding warrants of OACB ceased to represent a right to acquire OACB Ordinary Shares and now represent a right to be issued one Ordinary Share, with Alvotech as the surviving company in the merger. Prior to the merger OACB shares were redeemed, resulting in $9.8 million of cash proceeds from the OACB trust account; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Alvotech redeemed and canceled the initial shares held by the initial sole shareholder of Alvotech pursuant to a share capital reduction of Alvotech; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The legal form of Alvotech changed from a simplified joint stock company (soci&#233;t&#233; par actions simplifi&#233;e) to a public limited liability company (soci&#233;t&#233; anonyme) under Luxembourg law; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Predecessor merged with and into the Parent, whereby all outstanding ordinary shares of the Predecessor (&#8220;Predecessor Ordinary Shares&#8221;) were exchanged for Ordinary Shares, pursuant to a share capital increase of Alvotech, with Alvotech as the surviving company in the merger. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrently with the execution of the Business Combination Agreement, OACB and Alvotech entered into subscription agreements (&#8220;Subscription Agreements&#8221;) with certain investors (the &#8220;PIPE Financing&#8221;). On 15&#160;June 2022, immediately prior to the closing of the Business Combination, the PIPE Financing was closed, pursuant to the Subscription Agreements, in which subscribers collectively subscribed for 17,493,000 Ordinary Shares at $10.00 per share for an aggregate subscription price equal to $174.9 million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Business Combination, Predecessor shareholders were granted a total of 38,330,000 Ordinary Shares subject to certain vesting conditions (&#8220;Predecessor Earn Out Shares&#8221;). Former OACB shareholders were granted a total of 1,250,000 Ordinary Shares subject to certain vesting conditions (&#8220;OACB Earn Out Shares&#8221;). Additionally, as part of the Business Combination the Company assumed the 10,916,647 outstanding warrants (&#8220;OACB Warrants&#8221;), on substantially the same contractual terms and conditions as were in effect immediately prior to the Business Combination. See Note 28 for further details. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Business Combination was accounted for as a capital reorganization. Under this method of accounting, OACB was treated as the &#8220;acquired&#8221; company for financial reporting purposes, with Alvotech Holdings S.A. being the accounting acquirer and accounting predecessor. Accordingly, the capital reorganization was treated as the equivalent of Alvotech issuing shares at the closing of the Business Combination for the net assets of OACB as of the Closing Date, accompanied by a recapitalization. The capital reorganization, which was not within the scope of IFRS 3 since OACB did not meet the definition of a business in accordance with that guidance, was accounted for within the scope of IFRS 2. In accordance with IFRS 2, Alvotech recorded a one-time non-cash share listing expense of $83.4 million, recognized as a general and administrative expense, based on the excess of the fair value of </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech shares issued, at the Closing Date, over the fair value of OACB&#8217;s identifiable net assets acquired. The fair value of shares issued was estimated based on a market price of $9.38 per share as of 15&#160;June 2022. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(in 000s) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class A Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">976,505</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class B Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,250,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Alvotech Shares issued to OACB shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,226,505</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of Shares issued to OACB as of 15 June 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$56,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of OACB Earn Out Shares issued to OACB as of 15 June 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Estimated fair market value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,160&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjusted net liabilities of OACB as of 15 June 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18,251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Difference &#8211; being the share listing expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,411&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Business Combination and PIPE Financing, the Company incurred $28.5 million of transaction costs, which represent legal, financial advisory, and other professional fees in connection with the Business Combination and PIPE Financing, during the year ended December&#160;31, 2022. Of this amount, $5.6 million represented equity issuance costs related to PIPE Financing that were capitalized in share premium. The remaining $22.9 million was recognized as general and administrative expense. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2 Information about subsidiaries and joint ventures </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:37.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Entity name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Principal </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">activity</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issued and </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">paid capital </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(presented in </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">whole shares)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Place of </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">establishment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proportion of ownership </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">and voting power held by </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Alvotech </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31.12.2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31.12.2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech hf</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,893,650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Germany GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,182</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Germany</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Swiss AG</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153,930</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Switzerland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Hannover GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,983</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Germany</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Malta Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,450</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Malta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech USA Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">USA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech UK Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">UK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Manco ehf</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">215,390</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Biosciences India Private Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignafelagi&#240; S&#230;mundur hf</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Real estate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,965,337</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech &amp; CCHN Biopharmaceutical Co. Ltd*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,000,021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Alvotech &amp; CCHN Biopharmaceutical Co. Ltd. is an unconsolidated joint venture (see Note 27). </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.3 Information about shareholders </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant shareholders of the Company are Aztiq Pharma Partners S.&#224; r.l. (Aztiq) and Alvogen Lux Holdings S.&#224; r.l. (Alvogen), with 37.9% and 33.7% ownership interest as of 31&#160;December 2023, and  40.7% and 35.8% ownership interest as of 31&#160;December 2022, respectively. The remaining 28.4% ownership interest is held by various entities, with no single shareholder holding more than 2.4% ownership interest as of 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The remaining 23.5% ownership interest was held by various entities, with no single shareholder holding more than 2.4% ownership interest as of 31&#160;December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.4 Going concern </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group has primarily funded its operations with proceeds from the issuance of ordinary shares and the issuance of loans and borrowings to both related parties and third parties. The Group has also incurred recurring losses since its inception, including net losses of $551.7&#160;million, $513.6 million, and $101.5 million for the years ended 31&#160;December 2023, 2022, and 2021, respectively, and had an accumulated deficit of $2,205.8&#160;million as of 31&#160;December 2023. The Group has not generated positive operational cash flow, largely due to the continued focus on biosimilar product development and expansion efforts. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the Group had cash and cash equivalents, excluding restricted cash, of $11.2&#160;million and current assets less current liabilities of ($66.1) million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, the development of and regulatory approval of commercially viable biosimilar products, the need to raise adequate additional financing necessary to fund the development and commercialization of its biosimilar products.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company announced in February 2024 that the U.S. Food and Drug Administration ("FDA") has approved SIMLANDI (adalimumab) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn&#8217;s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. Teva is Alvotech&#8217;s strategic partner for the exclusive commercialization of SIMLANDI in the United States. SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA, and will qualify for interchangeable exclusivity for the 40mg/0.4ml injection. This approval is an important milestone for the Company to access the U.S. market with a unique positioning. The Company expects to launch AVT02 with its partner Teva in the United States during the first half of 2024. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, in February 2024, the Company announced it has reached settlement agreements with Johnson &amp; Johnson in Japan, Canada and in the European Economic Area (EEA) for AVT04, a biosimilar to Stelara (ustekinumab). Regulatory approval for AVT04 in these markets has already been granted. Market applications for AVT04 are currently pending in additional global markets, including in the U.S. Market entry of AVT04 in Canada started in March 2024. Launch of AVT04 in Japan is anticipated after the upcoming round of National Health Insurance reimbursement price listings, in May 2024. Entry to the first European markets is expected as soon as possible after the expiration date of the European Supplementary Protection Certificate for Stelara, which is in late July 2024. These approvals represent another significant milestone for the Company to tap into the Stelara market.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The closing of the private placement equity offering in February 2024 provided the Group with gross proceeds of $166&#160;million (net proceeds of $160&#160;million) that is expected to be used to finance general corporate purposes and working capital, to strengthen its production capacity, and to support expected biosimilars launches. As part of the transaction, the Group sold 10,127,132 Ordinary Shares, par value USD 0.01 per share, at a purchase price of $16.41 per share, or ISK 2,250 per share, at foreign exchange rates on 23 February 2024.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Group expects to continue to source its financing during the development of its biosimilar products from existing out-license contracts with commercial partners. In light of these conditions and events management evaluated whether there is substantial doubt about the Group&#8217;s ability to continue as a going concern for at least one year after the date that the consolidated financial statements are issued. Based on the cash on hand, funding received, and projected future cash flows, management concluded that the Group has the ability to continue as a going concern for at least one year after the date that the consolidated financial statements are issued. As such, the consolidated financial statements have been prepared on a going concern basis</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, although management continues to pursue these plans, there is no assurance that the Group will be successful in obtaining sufficient funding on terms acceptable to the Group to fund continuing operations, if at all. If financing is obtained, the terms of such financing may adversely affect the holdings or the rights of the Group&#8217;s shareholders. The ability to obtain funding, therefore, is outside of management&#8217;s control and is a material uncertainty that may cast significant doubt upon the Group&#8217;s ability to continue as a going concern. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_GeneralInformationAboutFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_GeneralInformationAboutFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411631952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1 Basis of preparation </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements of the Group have been prepared in accordance and in compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), which comprise all standards and interpretations approved by the IASB, and as adopted by the European Union ("EU"). </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All amendments to IFRSs issued by the IASB that are effective for annual periods that begin on or after 1 January 2023 have been adopted as further described within the footnotes to the consolidated financial statements. The Group has not adopted any standards or amendments to standards in issue that are available for early adoption. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and financial liabilities which have been measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The consolidated financial statements are presented in U.S. Dollar ("USD") and all values are rounded to the nearest thousand unless otherwise indicated. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.2 Basis of consolidation </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">has power over the investee; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">is exposed, or has rights, to variable returns from its involvement with the investee; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">has the ability to use its power to affect its returns. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company&#8217;s voting rights in an investee are sufficient to give it power, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the size of the Company&#8217;s holding of voting rights relative to the size and dispersion of holdings of the other vote holders; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">potential voting rights held by the Company, other vote holders or other parties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">rights arising from other contractual arrangements; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders&#8217; meetings. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income or loss from the date the Company gains control until the date when the Company ceases to control the subsidiary. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All intra-group transactions, balances, income and expenses are eliminated in full in consolidation. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3 Investments in joint ventures </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent the Group concludes that it does not control, and thus consolidate, a joint venture, the Group accounts for its interest in joint ventures using the equity method of accounting. As such, investments in a joint venture are initially recognized at cost and the carrying amount is subsequently adjusted for the Group&#8217;s share of the profit or loss of the joint venture, as well as any distributions received from the joint venture. The Group carries its ownership interest in a joint venture as &#8220;Investment in joint venture&#8221; on the consolidated statements of financial position. The Group&#8217;s profit or loss includes its share of the profit or loss of the joint venture and, to the extent applicable, other comprehensive income or loss for the Group includes its share of other comprehensive income or loss of the joint venture. The Group&#8217;s share of a joint venture&#8217;s profit or loss in a particular year is presented as &#8220;Share of net loss of joint venture&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amount of equity-accounted investments is assessed for impairment as a single asset. Impairment losses are incurred only if there is objective evidence of impairment as a result of loss events that have an impact on estimated future cash flows and that can be reliably estimated. Losses expected as a result of future events are not recognized. The Group  recognized an impairment loss of $21.5&#160;million related to its investment in the joint venture for the year ended 31&#160;December 2023. No impairment losses were recognized in 2022 or 2021. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4 Critical accounting judgments and key sources of estimation uncertainty </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the consolidated financial statements in conformity with IFRS requires Group management to make judgments, estimates and assumptions about the reported amounts of assets, liabilities, income and expenses that are not readily apparent from other sources. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and other factors that are considered to be relevant. Judgments and assumptions involving key estimates are primarily made in relation to the measurement and recognition of revenue, the impairment of the investment in the joint venture, the valuation of derivative financial liabilities, the valuation of restricted share units (&#8220;RSUs&#8221;), and the valuation of deferred tax assets. Apart from those involving estimations, critical accounting judgments include the Group&#8217;s evaluation as to whether it controls its joint venture in China  and material uncertainties with respect to the Group&#8217;s going concern assessment. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Existing circumstances and assumptions may change due to events arising that are beyond the Group&#8217;s control. Therefore, actual results may differ from these estimates. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.5 Segment reporting </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group operates and manages its business as one operating segment based on the manner in which the Chief Executive Officer, the Group&#8217;s chief operating decision maker, assesses performance and allocates resources across the Group. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.6 Revenue recognition </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Product revenue</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue from the sale of its biosimilar product to commercial partners, identified as the customer, when control is transferred, and the performance obligations have been satisfied. This is when the title passes to the customer, which is upon shipment of the product. At that point, the commercial partner has full discretion over the channel and price to sell the products. Revenue is recognized based on the net selling price from the commercial partners, which is considered to be the transaction price and includes estimated rebates, returns and chargebacks, and other forms of variable consideration recognized by the customer. Variable consideration is accounted for by the Company only to the extent that it is highly probable that a significant reversal in the revenue recognized will not occur. Variable consideration, which includes any adjustments to the net selling price, is estimated based on the most likely amount method on a contract-by-contract basis. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Out-licensing revenue</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant part of the Group&#8217;s revenue is generated from long-term out-license contracts which provide the customer with an exclusive right to market and sell products in a particular territory once such products are approved for commercialization. These contracts typically include the Group&#8217;s promises to continue development of the underlying compound and to provide supply of the product to the customer upon commercialization. The Group concludes that the license, development services and commercial supply are separate performance obligations. This is because customers generally have the capabilities to perform the necessary development, manufacturing and commercialization activities on their own or with readily available resources and have the requisite expertise in the industry and the territory for which the license has been granted. Further, the intellectual property is generally in a later phase of development at the time the license is granted such that any subsequent development activities performed by the Group are not expected to significantly modify or transform the intellectual property. The fact that the Group is contractually obligated to perform development activities for and provide commercial supply to the </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">customer does not impact this conclusion. The Group&#8217;s promise to provide commercial supply to its customers is contingent upon the achievement of regulatory approval in the particular territory for which the license has been granted. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consideration to which the Group is entitled pursuant to these contracts generally includes upfront payments and payments based upon the achievement of development and regulatory milestones. All contracts include a potential refund obligation whereby the Group must refund the consideration paid by the customer in the event of a technical failure or the occurrence of certain other matters that result in partial or full cancellation of the contract. As such, the entire transaction price is comprised of variable consideration, which is estimated using the most likely amount method due to the binary nature of the outcomes under these contracts. Such variable consideration is included in the transaction price only when it is highly probable that doing so will not result in a significant reversal of cumulative revenue recognized when the underlying uncertainty associated with the variable consideration is subsequently resolved. The Group does not account for a significant financing component since a substantial amount of consideration promised by the customer is variable and the amount or timing of that consideration varies on the basis of a future event that is not substantially within the control of either party. Certain contracts also include commercialization milestones upon the first commercial sale of a product in a particular territory, as well as royalties. Commercialization milestones and royalties are accounted for as sales-based royalties; therefore, such amounts are not included in the transaction price and recognized as revenue until the underlying sale that triggers the milestone or royalty occurs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upfront payments, when applicable, are received in advance of transferring control of all goods and services. Therefore, a portion of upfront payments is recorded as a contract liability upon receipt. Due to the existence of refund provisions, upfront payments and certain development milestone payments are generally included in the transaction price upon submission of the first clinical trial application to the respective regulatory agency, since it is at this point in time that a significant reversal of cumulative revenue recognized related to such payments is no longer highly probable. Other development and regulatory milestones may not be included in the transaction price until such milestones are achieved due to the degree of uncertainty associated with achieving these milestones. Contract liabilities are presented on the consolidated statements of financial position as either current or non-current based upon forecasted performance. In certain contracts, the Group may transfer control of goods and services, and thus recognize revenue, prior to having the right to invoice the customer. In these circumstances, the Group recognizes contract assets for revenue recognized, and subsequently reclasses the contract asset to trade receivables upon issuing an invoice and the right to consideration is only conditional on the passage of time. Contract assets are presented on the consolidated statements of financial position as either current or non-current based upon the expected timing of settlement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standalone selling prices of the development services and the license to intellectual property are not directly observable and, therefore, are estimated. The standalone selling price of the development services is estimated based on the expected costs to be incurred during the development period, using various data points such as the underlying development budget, contractual milestones and performance completed at the time of entering into the contract with a customer. The standalone selling price of the license is estimated using the residual approach on the basis that the Group licenses intellectual property for a broad range of amounts and has not previously licensed intellectual property on a standalone basis. Therefore, the Group first allocates the transaction price to the development services and subsequently allocates the remainder of the transaction price to the license. If the product is still in early phase of development and the constraint on variable consideration has not been resolved, all the transaction price is allocated to the development service. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standalone selling price of the commercial supply is directly observable and the stated prices in the Group&#8217;s supply contracts reflect the standalone selling price of such goods. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The licenses to intellectual property are right of use licenses on the basis that the ongoing development work performed by the Group does not significantly affect the intellectual property to which the customer has rights. Therefore, control of the license transfers to the customer at the point in time when the right to use the license is granted to the customer. The license is generally granted to the customer at the time the contract is executed with the customer. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group satisfies its performance obligation related to the development services over time as the Group&#8217;s performance enhances the value of the licensed intellectual property controlled by the customer throughout the performance period. The Group recognizes revenue using a cost-based input measure since this measure best reflects the progress of the development services and, therefore, the pattern of transfer of control of the services to the customer. In certain instances, the Group may subcontract services to other parties for which the Group is ultimately responsible. Costs incurred for such subcontracted services are included in the Group&#8217;s measure of progress for </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">satisfying its performance obligation. Changes in the total estimated costs to be incurred in measuring the Group&#8217;s progress toward satisfying its performance obligation may result in adjustments to cumulative revenue recognized at the time the change in estimate occurs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the achievement of regulatory approval and the commencement of commercial sale of its products, the Group will satisfy its performance obligation related to commercial supply at the point in time when control of the manufactured product is transferred to the customer. Transfer of control for such goods will occur in accordance with the stated shipping terms. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group does not incur incremental costs of obtaining a contract with a customer that would require capitalization. Costs to fulfill performance obligations are not incurred in advance of performance and, as such, are expensed when incurred. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other revenue</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other revenue primarily consists of clinical trial support services rendered by the Group for its customers, which is recognized as the service is provided. Revenue for such services is presented in the consolidated statements of profit or loss and other comprehensive income or loss net of any discounts. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.7 Cost of product revenue </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product revenue includes the cost of inventory sold, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as shipping and freight costs and royalty costs related to in-license agreements. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.8 Research and development expenses </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses primarily consist of personnel costs, material and other lab supply costs, facility costs and internal and external costs related to the execution of studies and other development program advancement initiatives. Such expenses also include costs incurred in preparation for commercial launch, such as designing and developing commercial-scale manufacturing capabilities and processes, quality control processes, production asset validation and other related activities. The costs also include amortization, depreciation and impairment losses related to software, property, plant and equipment, and right-of-use assets used in research and development activities and pre-commercial manufacturing and quality control activities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An internally generated intangible asset arising from the Group&#8217;s development is recognized only if the Group can demonstrate: the technical feasibility of completing the intangible asset so that it will be available for use or sale; the intent to complete the intangible asset and use or sell it; how the intangible asset will generate probable future economic benefits; the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and the ability to measure reliably the expenditure attributable to the intangible asset during its development. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount initially recognized for internally-generated intangible assets is the sum of the expenditures incurred from the date when the intangible asset first meets the aforementioned recognition criteria. If an internally-generated intangible asset cannot be recognized, the related development expenditure is charged to profit or loss in the period in which it is incurred. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenditures related to research and development activities are generally recognized as an expense in the period in which they are incurred. The Company did not capitalize any development expenses as intangible assets during the years ended 31&#160;December 2023, 2022, and 2021 as not all the criteria in paragraph 57 of IAS 38 have been met.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.9 General and administrative expenses </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administration expenses primarily consist of personnel-related costs, including salaries and other related compensation expense, for corporate and other administrative and operational functions including finance, human resources, information technology and legal, as well as facility-related costs. These costs relate to the operation of the business and are not related to research and development initiatives. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenditures related to general and administration activities are recognized as an expense in the period in which they are incurred. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.10 Finance income and finance cost </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income consists of changes in the fair value of derivative financial liabilities and interest income. Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset&#8217;s net carrying amount on initial recognition. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance cost consists of changes in the fair value of derivative financial liabilities, interest expense related to lease liabilities and borrowings, accretion of borrowings and amortization of deferred debt issue costs. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.11 Foreign currency translation </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements are presented in U.S. Dollars, which is the Group&#8217;s presentation currency. The Group maintains the financial statements of each entity within the Group in its respective functional currency. The majority of the Group&#8217;s expenses are incurred in U.S. Dollars and Icelandic Krona, and the majority of the Company&#8217;s cash and cash equivalents are held in a combination of Icelandic Krona, Euros and U.S. Dollars. Transactions in currencies other than the Group&#8217;s presentation currency (foreign currencies) are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non- monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognized in profit or loss in the period in which they arise. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exchange differences arising on translation of a foreign controlled subsidiary are recognized in other comprehensive income or loss and accumulated in a translation reserve within equity. The cumulative translation amount is reclassified to profit or loss if and when the net investment in the foreign controlled subsidiary is disposed. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.12 Fair value measurements </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group measures certain financial liabilities at fair value through profit or loss (FVTPL) at each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure the fair values of such financial liabilities, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques, as follows: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 1: quoted prices in active markets for identical assets and liabilities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (e.g., prices) or indirectly (e.g., derived from prices); and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 3: inputs for the asset or liability that are unobservable. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amounts of cash and cash equivalents, restricted cash, trade receivables, other current assets, contract assets, trade and other payables and other current liabilities in the Group&#8217;s consolidated statements of financial position approximate their fair value because of the short maturities and nature of these instruments. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For liabilities that are measured at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by reassessing the inputs used in determining fair value at the end of each reporting period. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.13 Goodwill and other intangible assets </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Goodwill and business combinations</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisitions are first reviewed to determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not meet the definition of a business, the Group will account for the transaction as an asset acquisition. If the definition of a business combination is met, the Group will account for the transaction using the acquisition method of accounting. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange fo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">r control of the acquiree. Acquisition-related costs are recognized in the consolidated statements of profit or loss and other comprehensive income or loss as incurred.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of the purchase price of the business combination over the Group&#8217;s interest in the net fair value of the identifiable assets, liabilities, contingent liabilities, the amount of any noncontrolling interests in the acquiree and the fair value of the acquirer&#8217;s previously held equity interest in the acquiree. Goodwill is reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the initial accounting for a business combination is incomplete by the end of the reporting period in which the business combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period, or as additional assets or liabilities are recognized, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group did not complete any business combinations during the years ended 31&#160;December 2023. Refer to Note 1.1 for the Business Combination completed during the year ended 31&#160;December 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other intangible assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other intangible assets consist of software, customer relationships, and intellectual property rights. Intangible assets acquired in a business combination are identified and recognized separately from goodwill if they satisfy the definition of an intangible asset and their fair values can be reliably measured. The cost of intangible assets is their fair value at the acquisition date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with finite useful lives are reported at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over an asset&#8217;s estimated useful life. The estimated useful life and amortization method are reviewed at each balance sheet date, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The following useful lives are used in the calculation of amortization: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"></td><td style="width:78.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intellectual property rights*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10 years</span></td></tr></table></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">From launch date</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with indefinite useful lives are reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.14 Income tax </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax includes the current tax and deferred tax charge recorded in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Current tax</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current tax expense is based on taxable profit for the year. Taxable profit differs from &#8216;profit before tax&#8217; as reported in the consolidated statements of profit or loss and other comprehensive income or loss because it excludes items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group&#8217;s current tax expense is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accruals for tax contingencies are made when it is not probable that a tax authority will accept the tax position, based upon management&#8217;s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Accruals for tax contingencies are measured using either the most likely amount or the expected value amount depending on which method the entity expects to better predict the resolution of the uncertainty. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Deferred tax</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax is provided in full for all temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit, except to the extent the temporary difference arises from: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The initial recognition of an asset or a liability in a transaction that is not a business combination and that affects neither the taxable profit nor accounting profit; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The initial recognition of residual goodwill (for deferred tax liabilities only); or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Investments in subsidiaries, branches, associates and joint ventures, where the Group is able to control the timing of the reversal of the temporary difference and it is not probable that it will reverse in the foreseeable future. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and deferred tax assets reflects the tax consequences that would follow from the manner in which the Group expects, at the balance sheet date, to recover or settle the carrying amount of the assets and liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax is charged or credited to the consolidated statements of profit or loss and other comprehensive income or loss, except when the tax arises from a business combination or it relates to items charged or credited directly to equity, in which case the deferred tax is also taken directly to equity. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis in that taxation authority. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.15 Property, plant and equipment </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment is recognized as an asset when it is probable that future economic benefits associated with the asset will flow to the Group and the cost of the asset can be measured in a reliable manner. Property, plant and equipment which qualifies for recognition as an asset are initially measured at cost. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cost of property, plant and equipment includes an asset&#8217;s purchase price and any directly attributable costs of bringing the asset to working condition for its intended use. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation is calculated and recognized as an expense on a straight-line basis over an asset&#8217;s estimated useful life. The estimated useful lives, residual values and depreciation method are reviewed at each balance sheet date, with the effect of any changes in estimate accounted for on a prospective basis. The following useful lives are used in the calculation of depreciation: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"></td><td style="width:78.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5-20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3-15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5 years</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of the Group&#8217;s property, plant and equipment assets have been pledged to secure borrowings as further described in Note 21. Significant disposals of pledged assets are subject to lender approval. Upon disposal or retirement of an asset, the difference between the sales proceeds, if applicable, and the carrying amount of the asset is recognized in the consolidated statements of profit or loss and other comprehensive income or loss at the time of disposal or retirement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the end of each reporting period, or sooner if events triggering an interim impairment assessment occur, the Group reviews the carrying amounts of its property, plant and equipment to determine whether there is any indication that the value of such assets are impaired. Triggering events that warrant an interim impairment assessment include, but are not limited to, the technical obsolescence of equipment or failure of such equipment to meet regulatory requirements. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss and the carrying amount of the asset is reduced to its recoverable amount, which is the higher of fair value less costs of disposal and value in use. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.16 Inventories </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories, which consist of raw materials and supplies, work in progress and finished goods are stated at the lower of cost or net realizable value. Net realizable value is the expected sales price less completion costs and costs to be incurred in marketing, selling and distributing the inventory. Cost is calculated using the weighted average cost method or the first-in,first-out method, depending on the nature of the inventory. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories include direct costs for raw materials and supplies and, as applicable, direct and indirect labor and overhead expenses that have been incurred to bring inventories to their present location and condition.  </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the net realizable value is lower than the carrying amount, a write-down of inventory is recognized for the amount by which the carrying amount exceeds net realizable value.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group does not pledge inventories as collateral to secure its liabilities. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.17 Financial assets </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Recognition of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets are recognized when the Group becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets, other than financial assets measured at FVTPL, are added to or deducted from the fair value of the financial assets, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets at FVTPL are recognized immediately in profit or loss. There were no transaction costs related to the acquisition of financials assets in 2023, 2022, or 2021. All of the Group&#8217;s financial assets are measured at amortized cost as of 31&#160;December 2023 and 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial assets measured at amortized cost</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets measured at amortized cost are debt instruments that give rise to contractual cash flows that are solely payments of principal and interest on the principal amount outstanding. The Group&#8217;s financial assets measured at amortized cost are trade receivables, certain other current assets, receivables from related parties, restricted cash and cash and cash equivalents. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income is recognized by applying the effective interest rate, except for short-term receivables when the effect of discounting is immaterial. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Impairment of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognizes a loss allowance for expected credit losses ("ECL") on its trade receivables and other debt instruments that are measured at amortized cost. In addition, although contract assets are not financial assets, a loss allowance for ECL are also recognized for such assets. ECL is based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group always recognizes lifetime ECL for trade receivables and contract assets. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group&#8217;s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecasted direction of conditions at the reporting date, including time value of money where appropriate. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group writes off a financial asset when there is no reasonable expectation of recovery, such as information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. A trade receivable or contract asset that is considered uncollectible is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognized in profit or loss. The Group did not write off any trade receivables or contract assets during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group estimates impairment for related party receivables on an individual basis. No impairment is recognized for restricted cash or cash and cash equivalents as management has estimated that the effects of any calculated ECL would be immaterial. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derecognition of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Group neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Group recognizes its retained interest in the asset as well as an associated liability. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On derecognition of a financial asset, the difference between the asset&#8217;s carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognized in other comprehensive income or loss and accumulated in equity is recognized in profit or loss. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.18 Financial liabilities </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s financial liabilities consist of trade and other payables, certain other current liabilities loans and borrowings, lease liabilities, derivative financial instruments, long-term incentive plans, share appreciation right plans and other long-term liability to a related party. All financial liabilities are initially measured at fair value. Loans and borrowings are recorded net of directly attributable transaction costs and less the value attributable to any embedded derivative financial instruments, if applicable. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group derecognizes financial liabilities when, and only when, the Group&#8217;s obligations are discharged, cancelled, substantially modified or have expired. Additionally, management elected, as part of its accounting policy, to recognize the difference between the carrying amount of the financial liabilities and the fair value of the consideration paid for the extinguishment in the consolidated statement of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities subsequently measured at amortized cost</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After initial recognition, financial liabilities other than derivative financial instruments and awards issued pursuant to long-term incentive plans are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that discounts all estimated future cash payments through the expected life of the financial liability, or a shorter period if appropriate, to the amortized cost of a financial liability. The effective interest rate includes the effects of any discount or premium on acquisition of the financial liability, as well as any fees or costs incurred upon acquisition. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities subsequently measured at FVTPL</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivative financial instruments </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain rights and features pursuant to borrowing arrangements and other contracts may provide the counterparty with one or more financial instruments that need to be evaluated and potentially accounted for separately by the Group. These financial instruments are either embedded in a host instrument or are treated as a separate financial instrument if they are contractually transferable independent from the host instrument. Such rights and features pursuant to the Group&#8217;s contracts with both third parties and related parties include earn out rights, conversion rights and warrant rights. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity conversion features within host debt instruments that meet the definition of a derivative and have economic and risk characteristics that are not closely related to the host instrument are embedded derivatives that are separated from the host instrument and accounted for separately. As part of the accounting for embedded derivatives or separate financial instruments, management considers the appropriate accounting classification under IAS 32. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Embedded derivatives and separate financial instruments that meet the fixed-for-fixed criteria are classified as equity and initially measured at fair value. Warrant rights that provide the holder with an option to purchase ordinary shares at a specified price or pursuant to a specified formula are generally separate derivative financial instruments that are accounted for as derivative liabilities. Earn Out Shares grant the holder with a variable number of Ordinary Shares based on certain vesting conditions tied to the stock price and are accounted for as derivative liabilities. In the event that the fair value of any derivative liabilities, determined using unobservable inputs, exceeds the transaction price of a borrowing arrangement, the Group records a deferred loss at the inception of the borrowing arrangement for the difference between the fair value of the derivative liabilities and the transaction price of the borrowing arrangement. Such deferred losses are recognized over the term of the related borrowing arrangement using the straight-line method of amortization. The deferred loss is netted against derivative financial liabilities on the consolidated statements of financial position. Amortization of the deferred loss is recognized as a component of &#8220;Finance costs&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognized derivative liabilities related to the Predecessor Earn Out Shares, OACB Earn Out Shares and assumed OACB warrants. Additionally, the Group recognized an embedded derivative for the conversion feature associated with the Tranche A Convertible Bonds, as further described in Note 21. These features are liability-classified, rather than equity-classified, because the Group is obligated to issue a variable number of ordinary shares to the holder upon conversion or exercise of the feature. Therefore, these derivative liabilities were initially recorded at fair value and remeasured to fair value at each reporting period with gains and losses arising from changes in the fair value recognized in finance income or finance costs, as appropriate. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of the derivative liabilities were determined using a valuation approach that incorporated a range of inputs that are both observable and unobservable in nature. The inputs used in the initial and subsequent fair value measurements predominantly relate to (i) the price of the Group&#8217;s Ordinary Shares (ii) the volatility of the Group&#8217;s Ordinary Shares, (ii) a risky discount rate corresponding to the credit risk associated with the repayment of the host debt instruments, and (iii) the probabilities of each derivative being exercised by the holder and the timing of such exercises. The probabilities are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group will derecognize any derivative liabilities if and when the rights are exercised by the holders or the time period during which the rights can be exercised expires. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Liabilities to related parties </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Group&#8217;s liabilities to related parties arose from its acquisition of rights for the commercialization of the Group&#8217;s biosimilar Adalimumab product in certain territories in Asia from Lotus Pharmaceutical Co. Ltd., a </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related party, during the year ended 31&#160;December 2021. Pursuant to the terms of the asset acquisition, the Group made an upfront payment of $1.9 million and is required to pay $7.4 million upon the commercial launch of Adalimumab in China which became due on 31 December 2023. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Long-term incentive plans </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Share appreciation rights</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group issued to certain current and former employees share appreciation rights ("SARs") that require settlement in connection with the occurrence of specified, future triggering events. Grants occurred from 2015 through 2020. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. The individuals retain their vested awards upon termination of employment with the Group. Settlement amounts are determined by the change in the Group&#8217;s market value from the grant date of the SAR until the triggering events occur. The SARs do not expire at a specific date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the terms of the SAR agreements, management determined that the Group cannot avoid paying cash to settle the awards and, therefore, SARs are liability-classified in the consolidated statements of financial position. Accordingly, SARs were recorded at fair value and were subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. The fair value of the SARs was determined using the Black-Scholes-Merton pricing model. In connection with the closing of the Business Combination, the Company reached a settlement agreement for share appreciation rights previously awarded to certain current and former employees. The remaining share appreciation rights were settled through the issuance of fully vested RSUs under the Management Incentive Plan on 1 December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Employee incentive plan</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group also sponsors an employee incentive plan for certain qualifying employees. Under the plans, such employees are entitled to cash payments upon achievement of key milestones, such as a research and development milestone or the occurrence of an exit event. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. Since the Group cannot avoid paying cash to settle the awards, the employee incentive plan is liability-classified in the consolidated statements of financial position. Accordingly, awards issued pursuant to the employee incentive plan are recorded at fair value and are subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. Employee incentive plan liabilities are presented as either current or non-current on the consolidated statements of financial position based on the anticipated timing of settlement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the employee incentive plan awards is determined by estimating the probability of success in reaching the specified milestones and other levers, such as the anticipated timing of potential milestone achievement. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Management Incentive Plan</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group can issue share options, restricted share units (&#8220;RSUs&#8221;), and other share-based awards under the Company&#8217;s new incentive plan (the &#8220;Management Incentive Plan&#8221;) which was approved by the Board in June 2022. Awards issued under the Management Incentive Plan are accounted for in accordance with IFRS 2. Share-based payments are classified as equity-settled share-based payments as the Company intends to settle the awards with equity and has the commercial substance to do so. Share-based payments are measured at the grant date fair value of the instruments issued and recognized over the expected vesting periods. The number of shares expected to vest are reviewed and adjusted at the end of each reporting period such that the amount of expense recognized shall be based on the number of equity instruments that will eventually vest. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.19 Litigation and other contingencies </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group may, from time to time, become involved in legal proceedings arising out of the normal course of its operations. For instance, as a developer and manufacturer of biosimilars, the Group may be subject to lawsuits alleging patent infringement or other similar claims filed by the reference product sponsor. Similarly, the Group may utilize patent challenge procedures to challenge the validity, enforceability or infringement of the reference product </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sponsor&#8217;s patents. Other parties may also file patent infringement claims against the Group alleging that the Group&#8217;s products or manufacturing process techniques infringe their patents. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group establishes reserves for specific legal matters when it determines that the likelihood of an unfavorable outcome is probable and the loss is reasonably estimable. When such conditions are not met for a specific legal matter, no reserve is established. Although management currently believes that resolving claims against the Group, including claims where an unfavorable outcome is reasonably possible, will not have a material impact on the liquidity, results of operations, or financial condition of the Group, these matters are subject to inherent uncertainties and management&#8217;s view of these matters may change in the future. It is possible that an unfavorable outcome of a lawsuit or other contingency could have a material impact on the liquidity, results of operations, or financial condition of the Group. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount of loss can be reasonably estimated. Accruals are based only on information available at the time of the assessment, due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Group&#8217;s results of operations in a given period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group maintains liability insurance coverages for various claims and exposures. The Group&#8217;s insurance coverage limits its maximum exposure on claims; however, the Group is responsible for any uninsured portion of losses. Management believes that present insurance coverage is sufficient to cover potential exposures. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.20 Leases </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for those with a lease term of twelve months or less and leases of low value assets. For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The Group&#8217;s leased assets consist of various real estate, fleet and equipment leases. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets reflect the initial measurement of the lease liability, lease payments made at or before the lease commencement date and any initial direct costs less lease incentives that may have been received by the Group. These assets are subsequently measured at cost less accumulated depreciation, impairment losses and remeasurements of the underlying lease liability. Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the underlying asset. If a lease transfers ownership of the underlying asset to the Group or the lease includes a purchase option that the Group is reasonably certain to exercise, the related right-of-use asset is depreciated over the useful life of the underlying asset. Depreciation starts at the commencement date of the lease. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate, which is the rate of interest that the Group would need to pay to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term in a similar economic environment based on information available at the commencement date of the lease. The lease payments included in the measurement of the lease liability comprise fixed payments (including in-substance fixed payments) less any incentives, variable lease payments that depend on an index or rate, expected residual guarantees and the exercise price of purchase options reasonably certain to be exercised by the Group. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability, using the effective interest method, and by reducing the carrying amount to reflect payments made during the lease term. The Group remeasures the lease liability if the lease term has changed, when lease payments based on an index or rate change or when a lease contract is modified and the modification is not accounted for as a separate lease. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable payments that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a practical expedient, lessees are not required to separate non-lease components from lease components, and instead account for any lease and associated non-lease components as a single lease component. The Group has used this practical expedient. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.21 Loss per share </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of the Predecessor Earn Out Shares and OACB Earn Out Shares have equal dividend and participation rights to the ordinary shareholders. However, these participating securities are classified as liabilities and as such, the shares held are not included in the weighted average number of ordinary shares outstanding in the basic loss per share calculation. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The calculation of basic loss per share is based on the loss for the year attributable to ordinary shareholders of the Group and the weighted average number of ordinary shares outstanding during the period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted loss per share is computed by dividing the loss for the year attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding in the basic loss per share calculation, both of which are adjusted for the effects of all dilutive potential ordinary shares. Antidilutive effects of potential ordinary shares, which result in an increase in earnings per share or a reduction in loss per share, are not recognized in the computation of diluted loss per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413541584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfNewAccountingStandardsAbstract', window );"><strong>Disclosure Of New Accounting Standards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory', window );">New accounting standards</a></td>
<td class="text">New accounting standards <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">New standards and interpretations adopted and effective during the periods</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following new IFRS standards have been adopted by the Group effective 1 January 2023: </span></div><div style="margin-top:5.1pt;padding-left:27.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IFRS 17 - Insurance Contracts</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2017, the IASB issued IFRS 17, Insurance Contracts, which replaces IFRS 4, Insurance Contracts. This standard sets out principles for the recognition, measurement, presentation and disclosure of insurance contracts that are within the scope of IFRS 17. In June 2020, the IASB issued Amendments to IFRS 17, which addresses concerns and implementation challenges that were identified after IFRS 17, Insurance Contracts, was published in 2017. The amendments are effective for annual periods beginning on or after 1 January 2023. IFRS 17 requires fundamental accounting changes to how insurance contracts are measured and accounted for. It introduces the general measurement model, based on a risk-adjusted present value of future cash flows that will arise as the insurance contract is fulfilled. This new measurement model aims to provide relevant information of the future cash flows. The general measurement model is modified for the measurement of reinsurance contracts held, direct participating contracts, and investment contracts with discretionary participation features. Also, while the general measurement model applies to all groups of insurance contracts in scope of IFRS 17, a simplified approach (a premium allocation approach) may be used to measure contracts that meet certain criteria. IFRS 17 also includes new disclosure requirements, providing more clarity and transparency for users of financial statements. The adoption of the standard did not have a material impact on the consolidated financial statements of the Group.</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:27.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 1 (Amendment) - Disclosure of Accounting Policies</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued Disclosure of Accounting Policies (Amendments to IAS 1) and IFRS Practice Statement 2 Making Materiality Judgements. The amendments replace the requirement for entities to disclose their significant accounting policies with the requirement to disclose their material accounting policy information. The amendments also include guidance to help entities apply the definition of material in making decisions about accounting policy disclosures.  The adoption of these amendments did not have a material impact on the consolidated financial statements of the Group.</span></div><div><span><br/></span></div><div style="padding-left:27.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 8 (Amendments) - Definition of Accounting Estimates</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments on IAS 8 to help entities to distinguish between accounting policies and accounting estimates. The amendments clarify how companies distinguish changes in accounting policies from changes in accounting estimates, with a primary focus on the definition of and clarifications on accounting estimates. The distinction between the two is important because changes in accounting policies are applied retrospectively, while changes in accounting estimates are applied prospectively. The amendments further clarify that accounting estimates are monetary amounts in the financial statements and are subject to measurement uncertainty. The amendments also clarify the relationship between accounting policies and accounting estimates by specifying that a company develops accounting estimates to achieve the objective set out by an accounting policy. The amendments are reflected in all financial statements and disclosures of the Group. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.</span></div><div style="margin-top:7.95pt;padding-left:27.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 12 (Amendments) - Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments on IAS 12, which clarifies how companies shall account for deferred tax on transactions such as leases and decommissioning obligations, with a focus on reducing diversity in practice. The amendments narrow the scope of the initial recognition exemption in paragraphs 15 and 24 of IAS 12 so that it does not apply to transactions that give rise to equal and offsetting temporary differences. As a result, companies will need to recognize deferred tax assets and a deferred tax liability for temporary differences arising on initial recognition of a lease and a decommissioning provision. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.</span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 12 (Amendments) - International Tax Reform&#8212;Pillar Two Model Rules</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, the OECD released technical guidance on its 15% global minimum tax agreed as the second &#8216;pillar&#8217; of a project to address the tax challenges arising from digitalisation of the economy. This guidance elaborates on the application and operation of the Global Anti-Base Erosion (GloBE) Rules agreed and released in December 2021 which lay out a co-ordinated system to ensure that multinational enterprises with revenues above &#8364;750 million pay tax of at least 15% on the income arising in each of the jurisdictions in which they operate. In May 2023, the IASB issued amendments to IAS12 Income Taxes to introduce a temporary exception to the requirements to recognise and disclose information about deferred tax assets and liabilities related to Pillar Two income taxes. As the Company does not meet the revenue thresholds, this guidance had no impact on the Group's consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">New and revised IFRS standards in issue but not yet effective</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following new standards are not yet adopted by or effective for the Group and have not been applied in preparing these consolidated financial statements. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 1 (Amendments) &#8211; Classification of Liabilities as Current or Non-Current </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments to IAS 1, which affect the presentation of liabilities as current or non-current in the statement of financial position. The amendment does not impact the amount or timing of recognition of any asset, liability, income or expenses, or the information disclosed about those items. The amendments clarify that the classification of liabilities as current or non-current is based on rights that are in existence at the end of the reporting period, specify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, explain that rights are in existence if covenants are complied with at the end of the reporting period, and introduce a definition of &#8216;settlement&#8217; to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. The Group currently evaluates the impact of these amendments on the consolidated financial statements. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 1 (Amendments) &#8211; Non-current Liabilities with Covenants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These amendments clarify how conditions with which an entity must comply within twelve months after the reporting period affect the classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these conditions. The amendments also respond to stakeholders&#8217; concerns about the classification of such a liability as current or non-current. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group currently evaluates the impact of these amendments on the consolidated financial statements.</span></div><div style="margin-top:1pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IFRS 16 (Amendment) - Lease Liability in a Sale and Leaseback</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This amendment adds subsequent measurement requirements for sale and leaseback transactions. This amendment includes requirements for sale and leaseback transactions in IFRS 16 to explain how an entity accounts for a sale and leaseback after the date of the transaction. Sale and leaseback transactions where some or all the lease payments are variable lease payments that do not depend on an index or rate are most likely to be impacted. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group anticipates that the application of this amendment will not have a material impact on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfNewAccountingStandardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of new accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfNewAccountingStandardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the entity's first-time adoption of International Financial Reporting Standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Section Presentation and disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS01_g20-33_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411582704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment reporting</a></td>
<td class="text">Segment reporting <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As disclosed in Note 2, the Group operates and manages its business as one operating segment. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant portion of the Group&#8217;s revenue is generated from long-term out-license contracts which provide the customer with exclusive rights to a particular territory, which generally span multiple countries or a particular continent, as well as the Group&#8217;s promises to continue development of the underlying compound and to provide supply of the product to the customer upon commercialization. Therefore, based on the nature of the customer agreements, revenue information is not currently available on a country-by-country basis. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from customers based on the geographic market in which the revenue is earned, which predominantly aligns with the rights conveyed to the Group&#8217;s customers pursuant to its out-license contracts, is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Europe</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Asia and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">91,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,029&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current assets, excluding financial instruments and deferred tax assets, based on the location of the asset is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.272%"><tr><td style="width:1.0%"></td><td style="width:63.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Europe</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">415,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">334,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Asia and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">426,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">338,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from transactions with individual customers that exceeds ten percent or more of the Group&#8217;s total revenue is as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"><tr><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412443264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock', window );">Revenue</a></td>
<td class="text">Revenue <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Disaggregated revenue </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Groups&#8217; revenue from contracts with customers, disaggregated by the type of good or service and timing of transfer of control of such goods and services to customers: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue (point in time revenue recognition)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License revenue (point in time revenue recognition)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Development and other service revenue (over time revenue recognition)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">91,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,029&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reassessment of variable consideration </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to revenue in the period of change. The Group updates variable consideration estimates on a quarterly basis. The quarterly changes in estimates did not result in material adjustments to the Group&#8217;s previously reported revenue or trade receivables during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contract assets and liabilities </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Contract </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Assets </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Contract </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liabilities </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract asset additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts transferred to trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer prepayments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December  2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">93,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract asset additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,634&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts transferred to trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition of contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(42,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,101)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December 2023</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,049&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132,444&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The net increase in contract assets as of 31&#160;December 2023 is due to revenue recognized when the performance obligation has been met which is offset by the transfer of such amounts to trade receivables on the basis that the Group&#8217;s right to that consideration is no longer contingent on its performance. The net increase in contract liabilities as of 31&#160;December 2023 is due to customer prepayments in advance of the Group&#8217;s performance. As of 31&#160;December 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, $10.9 million and $35.2 million are recorded as non-current contract assets and current contract assets, respectively. Non-current contract assets will materialize over the next 2 to 3 years. As of 31&#160;December 2023, $73.3 million and $59.2 million are recorded as non-current contract liabilities and current contract liabilities, respectively. Non-current contract liabilities will</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> be recognized as revenue over the next 2 to 6 years as either services are rendered or contractual milestones are achieved, depending on the performance obligation to which the payment relates. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Remaining performance obligations </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the long-term nature of the Group&#8217;s out-license contracts, the Group&#8217;s obligations pursuant to such contracts represent partially unsatisfied performance obligations at year-end. The revenues under existing out-license contracts with original expected durations of more than one year are estimated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to be $383.0 million. The</span> Group expects to recognize the majority of these revenues over the next 5 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue and other operating income explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue and other operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430415539088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Salaries And Other Employee Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract', window );"><strong>Disclosure Of Salaries And Other Employee Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock', window );">Salaries and other employee expenses</a></td>
<td class="text">Salaries and other employee expenses <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The average number of individuals employed by the Group during the years ended 31&#160;December 2023, 2022, and 2021 was 999, 858, and 645, respectively. The aggregate salary and other employee expenses incurred by the Group for these employees were as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salary expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">92,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Defined contribution plan expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term incentive plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share-based payments (see Note 23)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other employee expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Temporary labor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">164,909&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.43pt">Defined contribution plan expense consists of costs incurred by the Group for employees of certain subsidiaries that are required by local laws to participate in pension schemes. These pension schemes are not sponsored or administered by the Group. Pursuant to the requirements of the schemes, the Group is required to contribute a certain percentage of its payroll costs to the pension schemes. Such contributions are charged to the consolidated statements of profit or loss and other comprehensive income or loss as they are incurred in accordance with the rules of the pension schemes. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salaries and other employee expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total salary and other employee expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">164,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109,520&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of salaries and other employee expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of salaries and other employee expenses explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414838160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income And Finance Costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfFinanceIncomeAbstract', window );"><strong>Disclosure Of Finance Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Finance income and finance costs</a></td>
<td class="text">Finance income and finance costs <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income earned during the years ended 31&#160;December 2023, 2022 and 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in the fair value of derivatives (see Note 28)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income from cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">556&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,823&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,549&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,568&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance costs incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in the fair value of derivatives (see Note 28)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on debt and borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">129,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">106,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consenting fee (see Note 21)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss on remeasurement of bonds (see Note 21)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities (see Note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of deferred debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">267,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">188,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of finance income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414784656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Depreciation, Amortization And Impairment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract', window );"><strong>Disclosure Of Depreciation Amortization And Imapirment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock', window );">Depreciation, amortization and impairment</a></td>
<td class="text">Depreciation, amortization and impairment <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation, amortization and impairment expenses incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and impairment of property, plant and equipment (see Note 12)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation of right of use assets (see Note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization and impairment of intangible assets (see Note 15)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation, amortization and impairment expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total depreciation, amortization and impairment expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of depreciation amortization and imapirment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of depreciation amortization and imapirment explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412458848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Fees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfAuditFeesAbstract', window );"><strong>Disclosure Of Audit Fees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfAuditFeesExplanatoryTextBlock', window );">Audit fees</a></td>
<td class="text">Audit fees <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financial Statement audit fees</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other fees, including tax services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total fees</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial Statements audit fees consist of fees for the audit of our annual financial statements and other professional services provided in connection with the statutory and regulatory filings or engagements, including fees for the review of our interim financial information. </span></div><div style="margin-top:12pt;padding-left:28.34pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other fees, including tax services, include fees for review of our current and historical financial information included in our SEC registration statements, fees for tax compliance, tax advice, and tax planning. </span></div>Audit fees for 2021 included fees for the audit of the consolidated financial statements for 2019 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfAuditFeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of audit fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfAuditFeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfAuditFeesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of audit fees explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfAuditFeesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411107696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure Of Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Tax</a></td>
<td class="text">Income tax <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxation recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct taxes - current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct taxes &#8211; prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total current tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(89,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(54,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(48,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(100,565)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,967)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(48,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(99,318)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,067)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(47,694)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The prior year deferred tax impact of $10.7 million mainly relates to foreign currency impact on losses denominated in Icelandic krona. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The factors affecting the tax benefit during the years ended 31&#160;December 2023 and 2022 relate to the recognition of a deferred tax asset on accumulated tax losses, as management assessed that it was probable that the accumulated tax losses would be fully utilized in the coming years, as further described below. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no accruals for tax contingencies during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate for the year of 15.3% (2022: 6.9%, 2021: 32.0%) is lower than the applicable Luxembourgish statutory rate of corporation tax. The reconciling items between the statutory rate and the effective tax rate are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effect of tax rate in foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-recognition of tax losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The movement in net deferred taxes during the years ended 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">170,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax credited to profit or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">309,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">309,807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(53)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(309)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Where there is a right of offset of deferred tax balances within the same tax jurisdiction, IAS 12 requires these to be presented after such offset in the consolidated statements of financial position. The closing deferred tax balances included above are after offset; however, the disclosure of deferred tax assets by category below are presented before such offset. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount of deferred tax recognized in the consolidated statements of financial position as of 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets attributable to temporary differences in respect of tax losses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">301,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">205,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets attributable to other temporary differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities attributable to other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">309,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,187&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A deferred tax liability has been recognized in relation to ordinary timing differences arising from depreciation, amortization, other provisions and difference in measurement basis of customer relationships. A deferred tax liability of $3.6&#160;million and $2.9 million has been recognized as of 31&#160;December 2023 and 2022, respectively. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A deferred tax asset has been recognized in relation to ordinary timing differences arising from various provisions, reserves, employee benefits and tax losses carried forward in the Group. The deferred tax asset on tax losses relates to tax losses arising in Iceland, and management considers probable that future forecasted profit associated with product and out-licensing revenue will be available to offset the cumulative tax losses as of 31&#160;December 2023. No deferred tax asset is recognized on tax losses arising in Luxembourg as their recoverability is unlikely to be realized. A deferred tax asset of $309.8&#160;million and $209.5 million is recognized as of 31&#160;December 2023 and 2022, respectively. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These tax losses expire as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"></td><td style="width:78.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024-2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027-2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">289,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Later</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,155,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,513,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 2023, the Group has total unused tax losses of $1,514 million which is comprised of $1,501 million of accumulated tax losses in Iceland and $13 million accumulated tax losses in Luxembourg.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411139568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text">Loss per share <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic loss per share is computed by dividing loss for the year by the weighted average number of ordinary shares outstanding during the period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted loss per share is computed by adjusting the calculation of basic loss per share for the effects of dilutive potential ordinary shares from financial instruments that may be converted or exercised into ordinary shares of the Group. For the years ended 31&#160;December 2023 and 2022, 86,745,377 and 148,857,998, respectively, potential ordinary shares pursuant to the RSUs, Senior Bond Warrants, Aztiq Convertible Bond, 2022 Convertible Bonds, OACB Warrants, Predecessor Earn Out Shares, and OACB Earn Out Shares (as defined and discussed in Notes 21 and 28) were excluded in the calculation of diluted loss per share, since the effect of doing so would result in a reduction of loss per share and thus be antidilutive. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> For the year ended 31&#160;December 2021, there were no potential ordinary shares pursuant to such agreements as all conversion, warrant and funding rights associated with these agreements had been exercised or otherwise expired (refer to Note 22 for further details). Therefore, the calculation of diluted loss per share did not differ from the calculation of basic loss per share. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The calculation of basic and diluted loss per share for the years ended 31&#160;December 2023, 2022, and 2021 is as follows (in thousands, except for share and per share amounts):</span></div><div style="margin-top:12pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss for the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(551,731)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(513,580)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(101,504)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of ordinary shares outstanding</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">227,256,469&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">197,721,710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,673,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.43)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.60)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.92)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413540128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant And Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment consists of facility and computer equipment, furniture, fixtures and leasehold improvements. Movements within property, plant and equipment during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"><tr><td style="width:1.0%"></td><td style="width:28.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Facility</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;Equipment </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Furniture, <br/>fixtures and <br/>leasehold <br/>improvements </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Computer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">equipment </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">271,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">176,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">304,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,583&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,063&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">729&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">236,779&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"><tr><td style="width:1.0%"></td><td style="width:28.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Facility</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;Equipment </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Furniture, <br/>fixtures and <br/>leasehold <br/>improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Computer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">equipment </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">88,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">271,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,002&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">114,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,365&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">440&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">220,594&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, the Group entered into a share purchase agreement (the &#8220;Share Purchase Agreement&#8221;) relating to shares in Fasteignaf&#233;lagi&#240; S&#230;mundur hf. (&#8220;Saemundur&#8221;) with ATP Holdings ehf., an affiliate of Aztiq. Pursuant to the Share Purchase Agreement, Alvotech purchased 99.99% of the shares in Saemundur through the issuance the Aztiq Convertible Bond, as defined and discussed in Note 21, and the assumption of debt. At the time of closing, Saemundur&#8217;s only asset was the property where Alvotech&#8217;s Reykjavik manufacturing and research facility (the &#8220;Facility&#8221;) are located. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Share Purchase Agreement was accounted for as an asset acquisition under IFRS 3 as all of the fair value of the gross assets acquired from Saemundur were concentrated in the Alvotech Facility. As a result, the purchase price was determined to be $115.0 million, which consists of $80.0 million related to the fair value of the Aztiq Convertible Bond, $30.0 million in loans assumed by the Company, and $5.0 million associated with the settlement of the pre-existing relationship with Saemundur. The entire purchase price was allocated to the Facility as it was the only asset acquired. Additionally, the Company recognized a $3.9 million loss on the extinguishment of the lease liability related to the Facility. See Note 21 for further details. </span></div>The Group pledged $127.4 million and $122.4 million of property, plant and equipment as collateral to secure bank loans with third parties as of 31&#160;December 2023 and 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430493633792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s leased assets consist of facilities, fleet and equipment pursuant to both arrangements with third parties and related parties. The carrying amounts of the Group&#8217;s right-of-use assets and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjustments for indexed leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition due to acquisition of Alvotech Facility (see Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(88,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">119,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group entered into lease agreement with Fasteignafelagid Eyjolfur hf. in April 2023 for a facility expansion in Iceland with remaining lease terms of approximately 15 years as of 31 December 2023. The building is 140,000 square feet and is currently in construction. The expansion is close to being finalized and is expected to be completed in 2024. The lease amount is in substance fixed and is based on construction cost, adjusted monthly. Righ-of-use asset as of 31&#160;December 2023 amounts to $68.5&#160;million.</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s right-of-use assets as of 31&#160;December 2023 and 2022 are comprised of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fleet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">119,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The Group&#8217;s lease liabilities and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"></td><td style="width:64.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjustments for indexed leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Installment payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition due to acquisition of Alvotech Facility (see Note 12)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(80,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,632&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,369&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amounts recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 in relation to the Group&#8217;s lease arrangements are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation expense from right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fleet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total depreciation expense from right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,869)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,699)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,840)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,022)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency difference on lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from extinguishment of lease agreement (see Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total amount recognized in profit and loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,713)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,068)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,378)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The maturity analysis of undiscounted lease payments as of 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less than one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">89,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">155,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div>The Group&#8217;s lease liabilities as of 31&#160;December 2023 and 2022 do not include $0.7 million and  $0.1 million, respectively, of costs for short-term leases and low value leases.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412003232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclousreOfGoodwillAbstract', window );"><strong>Disclosure of Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoodwillExplanatory', window );">Goodwill</a></td>
<td class="text">Goodwill <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s goodwill balances as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(724)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill is recognized at the Group level, which is determined to be the smallest cash-generating unit. The recoverable amount of the cash-generating unit is determined based on a value in use calculation which uses cash flow projections based on the financial forecast for the period 2024-2030 which reflect the recent business developments of the Group and has been approved by management and the Board of Directors. The Group determined that the terminal growth rate and the discount rate are the key assumptions used in determining the current estimate of value in use. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash flows beyond 2030 have been extrapolated using a negative 5% terminal rate in both the 2023 and 2022 value in use calculations, respectively. A discount rate of 25.0% (2022: 27.6%) per annum was used in determining the current estimate of value in use. Since the recoverable amount of the cash-generating unit was substantially in excess of its carrying amount as of 31&#160;December 2023 and 2022, management believes that any reasonably possible change in the key assumptions on which the recoverable amount of the cash-generating unit is based would not cause the carrying amount of the cash-generating unit to exceed its recoverable amount. </span></div>There were no goodwill impairment charges recognized in the consolidated statements of profit or loss and other comprehensive income or loss in any prior periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclousreOfGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclousre of goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclousreOfGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414842176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Other Intangible assets</a></td>
<td class="text">Other Intangible assets <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other intangible assets consist of software, customer relationships, and licensed intellectual property rights. Movements in intangible assets during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Software </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Customer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">relationships </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Intellectual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">property </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Retirement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Software </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Customer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">relationships </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Intellectual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">property </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,684&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,341&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">311&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions during the year ended 31&#160;December 2023 were primarily comprised of licensed intellectual property rights from Kashiv as detailed below. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense for amortization of the Group&#8217;s intangible assets is included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">324&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">944&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">733&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">923&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At 31&#160;December 2023 and 2022, the Group performed a review of its intangible assets and determined certain software development had been abandoned. In assessing recoverable amount, the Group determined the market for resale was non-existent. Management therefore determined to fully impair the assets, resulting in an impairment charge of $1.8 million and $2.8 million during the years ended 31&#160;December 2023 and 2022, respectively. The impairment charge was recognized as an expense within &#8220;General and administrative expense&#8221;. For the year ended 31&#160;December 2022, the impairment was recognized as an expense as follows: $2.1 million in "Cost of product revenue" and $0.7 million in "General and administrative expense".</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At 31&#160;December 2023, following the termination of the agreement with Biosana, the Group derecognized $15.0&#160;million of other intangible assets relating to intellectual property rights for the co-development and commercialization of AVT23. A corresponding receivable was recognized to reflect the claim against Biosana for full reimbursement. See further information on the receivable in Note 18.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech entered into an exclusive product licensing and supply agreement with Kashiv for the development and commercialization of AVT23 in September 2023. Under the terms of the agreement, Kashiv granted Alvotech an exclusive right for AVT23 which will be produced using Kashiv&#8217;s proprietary process technology and commercialized by Alvotech in specific territories. In exchange, Alvotech made an upfront payment of $3.0&#160;million upon the signing of the agreement, with an additional $3.0&#160;million due upon the beginning of Phase 3 which coincides with the clinical trial application ("CTA") submission.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, Alvotech may be obligated to pay Kashiv up to an aggregate of $25&#160;million (including the $6&#160;million upfront payments mentioned above), payable upon the achievement of various development and regulatory milestones, as well as certain tiered royalty payments up to an aggregate of $15&#160;million based on commercial sales of AVT23. The agreement terminates 10 years after the launch of AVT23 and is subject to certain customary termination rights.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412474208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash And Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash And Cash Equivalents</a></td>
<td class="text">Cash and cash equivalents <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Cash and cash equivalents</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents include both cash in banks and on hand. Cash and cash equivalents as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents denominated in US dollars</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents denominated in other currencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Restricted cash</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Restricted cash relates to cash that may only be used pursuant to certain of the Group&#8217;s borrowing arrangements. Therefore, these deposits are not available for general use by the Group. Movements in restricted cash balances during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,187&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s restricted cash is available for use after one year or later.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411582704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text">Inventories <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s inventory balances as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The increase in inventory from 31&#160;December 2022 to 31&#160;December 2023 is due to the expansion of the commercial launch of certain of the Group&#8217;s biosimilar products.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognised $42.8 million and $20.9 million within cost of goods sold during the years ended 31&#160;December 2023 and 2022, respectively.</span></div>During the years ended 31&#160;December 2023, 2022, and 2021, write-down of inventories amounted to $10.4&#160;million, $2.1 million and $1.2 million, respectively, due to product expiration and results from quality control inspections. There were no reversals of inventory write-downs during the years ended 31&#160;December 2023, 2022, and 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412459376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Other Current Assets</a></td>
<td class="text">Other current assets <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other current assets as of 31&#160;December 2023 and 2022 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value-added tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,035&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds receivable from Convertible Bonds (see Note 21)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">851&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other short-term receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,871&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,949&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year, the Group terminated the co-development agreement with Biosana for AVT23 and derecognized $15.0&#160;million of other intangible assets and $3.5&#160;million of prepaid development costs. A receivable of $18.5&#160;million was recognized under other current assets which was fully reserved due to the uncertainty that it would be collected.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413532208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory', window );">Share Capital</a></td>
<td class="text">Share capital <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all liabilities. Equity instruments issued by a Group entity are recognized in the amount of the proceeds received, net of direct issue costs.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the Capital Reorganization the Group&#8217;s equity consisted of Class A and Class B ordinary shares (together the &#8220;Predecessor Ordinary Shares&#8221;). The Group&#8217;s authorized share capital was $99.7 million, consisting of the equivalent of 99,961,829 Class A or Class B ordinary shares with a par value of $0.01 per share. All share capital issued as of 31&#160;December 2023 and 2022 was fully paid.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Capital Reorganization resulted in the following share capital activity: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">All of the outstanding Predecessor Ordinary Shares were exchanged for 180,600,000 Ordinary Shares and 38,330,000 Predecessor Earn Out Shares; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">976,505 of Class A OACB Ordinary Shares were exchanged for Ordinary Shares; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">6,250,000 of Class B OACB Ordinary Shares were exchanged for 5,000,000 Ordinary Shares and 1,250,000 OACB Earn Out Shares; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">17,493,000 Ordinary Shares were issued in the PIPE Financing. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No dividends were paid or declared during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share capital and share premium of the Group&#8217;s Ordinary Shares issued as of 31&#160;December 2023, and 2022 are as follows (in thousands, except for share amounts): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266,821,844</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,231,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252,160,087</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,060,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total share capital and share premium</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266,821,844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,231,969&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252,160,087</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,060,558&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 10 February 2023, the Company completed a private placement equity offering for gross proceeds of $137.0&#160;million, and transaction costs of $4.1&#160;million, of its ordinary shares, par value $0.01 per share, at a purchase price of $11.57 per share. The shares were delivered from previously issued ordinary shares held by Alvotech&#8217;s subsidiary, Alvotech Manco ehf. As a result of proceeds raised from the private placement offering, the Company extinguished the derivative financial liability related to the Senior Bond Warrants since the Company has not anymore the obligation to issue the penny warrants representing 1.0% of the fully diluted ordinary share capital. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This was accounted for as an extinguishment of a derivative financial liability in the consolidated statements of profit or loss and other comprehensive income or loss. See Notes 21 and 28 for further information.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s Class A and Class B ordinary shares, share capital and share premium during the years ended 31&#160;December 2023, 2022, and 2021 are as follows (in thousands, except for share amounts): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ordinary </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Predecessor </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ordinary </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,259,139</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">166,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">166,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share issue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,222,660</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">833,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">833,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,481,799</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,000,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,000,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Elimination of Predecessor Ordinary Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13,481,799)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(135)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of Ordinary Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186,576,505</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">PIPE Financing (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,493,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">174,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">174,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Transaction costs arising on share issue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,330,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(227,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(227,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">SARs Settlement (Note 22)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,510,582</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of related party loans with Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252,160,087</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,058,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,060,558&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capital contribution</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,834,061</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested earn-out shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Penny warrants (Note 28)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,479,962</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Public warrants (Note 28)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">553,552</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of RSUs with shares (Note 23)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">838,919</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of SARs with shares (Note 22)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,044,737)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266,821,844</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,229,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,231,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>Alvotech Manco ehf., a subsidiary of Alvotech hf., owns 22,905,618 Ordinary Shares in Alvotech. Such shares are intended for the future issuance of Ordinary Shares under the Management Incentive Plan and other equity offerings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411729216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory', window );">Other reserves</a></td>
<td class="text">Other reserves <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other reserves as of 31&#160;December 2023 and 2022 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity component of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other liabilities. [Refer: Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411368288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">Borrowings</a></td>
<td class="text">Borrowings <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s debt consists of interest-bearing borrowings from financial institutions, related parties and third parties. Outstanding borrowings, net of transaction costs, presented on the consolidated statements of financial position as current and non-current as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">530,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">155,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total outstanding borrowings, net of debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current portion of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total non-current borrowings</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">922,134&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">744,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Convertible shareholder loans </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Business Combination Agreement (see Note 1.1), on 7&#160;December 2021, the Group&#8217;s shareholders entered into the BCA Framework Agreement resulting in the exercise of the conversion, warrant, and funding rights associated with the convertible shareholder loans. As a result, the following issuances of Class A ordinary shares occurred: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">1,522,103 shares from the exercise of warrant and funding rights in exchange for $101.3 million of cash;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">1,137,248 shares from the exercise of warrant rights in exchange for the settlement of $73.7 million of accrued payment-in-kind interest; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">2,306,555 shares resulting from the conversion of $166.8 million of outstanding principal and accrued payment-in-kind interest.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with these exercises, for the year ended 31 December 2021, the Group recognized finance income of $48.7 million resulting from the remeasurement of the derivative liabilities at the date of extinguishment and a $149.2 million gain on extinguishment of financial liabilities, which primarily reflects the difference between the carrying amount of the pre-transaction convertible shareholder loans and the related derivative financial liabilities and the fair value of the ordinary shares issued. In addition, the gain on extinguishment of financial liabilities includes transaction costs incurred as part of the extinguishment, the acceleration of previously deferred debt issue costs incurred in connection with the issuance of the convertible shareholder loans and the acceleration of previously unamortized accretion of the convertible shareholder loans. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Bonds </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 24&#160;June 2021, holders of the Group&#8217;s convertible bonds converted $100.7 million of principal and accrued interest and $4.8 million of additional premium offered by the Group to the bondholders into 455,687 Class A ordinary shares. Following the conversion, certain bondholders elected to redeem their remaining bonds for cash, resulting in the payment of $55.3 million in outstanding principal and accrued interest plus an additional $6.1 million of premium that the bondholders elected to be paid in cash. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The remaining unconverted and unredeemed bonds were replaced with new bonds with an extended maturity of June 2025 and the elimination of conversion rights, among other amendments to the terms and conditions. The Group offered the holders of the replaced bonds an extension premium of $8.1 million for their agreement to extend the maturity of the replaced bonds to June 2025, as well as an additional premium of $2.6 million, both of which were granted to the bondholders in the form of additional bonds. The Group also issued an additional $113.8 million of bonds to one previous bondholder and one new bondholder. On the date of issuance, the fair value and the nominal value of the bonds was $358.8 million and $397.4 million, respectively. The difference between the nominal value and fair value was recognized as a discount that will be amortized over the term of the bonds. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group determined that the 24 June 2021 transaction was a substantial modification to its convertible bonds and the associated derivative financial liability and accounted for the transaction as an extinguishment. As a result, the </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Group recognized a gain on extinguishment of financial liabilities of $2.6 million during the year ended 31 December 2021, primarily driven by the difference between the fair value of the post-transaction bonds and the carrying amount of the pre-transaction bonds. The gain on extinguishment of financial liabilities also includes the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Transaction costs and fees incurred as part of the extinguishment; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The acceleration of previously deferred debt issue costs incurred in connection with the issuance of the pre-transaction bonds; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The acceleration of previously unamortized accretion of the pre-transaction bonds. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the extinguishment of the convertible bonds and as noted above, the bondholders had the option to convert the bonds into Class A ordinary shares up to fourteen days prior to maturity. This conversion right was separately accounted for as a derivative financial liability. During the period from 1 January 2021 to 24 June 2021, there was no change in fair value of the derivative financial liability. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31 December 2021, the carrying amount of the bonds was $363.1 million. Accrued interest on the bonds as of 31 December 2021 is $31.0 million. The Group has the option, at any time, to prepay all or any part of the outstanding bonds. If the Group elects to prepay the bonds within the first three years of the bond agreement, the bondholders are entitled to be paid an additional premium of at least 2.0% of the outstanding principal at the time of such prepayment.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January and June of 2022, the Group amended the terms of the outstanding bonds. The amendments resulted in the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Following the close of the Business Combination, the interest rate will range from 7.5% to 10.0% depending on the amount of aggregate net proceeds, as defined by the terms of the amended bond agreement; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A $7.4&#160;million consent fee, recognized as finance costs, paid to the bondholders who did not vote against the Business Combination Agreement; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The requirement for Alvotech to maintain a minimum of $25.0 million of restricted cash in a separate liquidity account; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A decrease in the interest rate to 7.5%, following the closing of the Business Combination, if the Company issues additional shares within six months of the Closing Date, resulting in the Company exceeding the amount of aggregate net proceeds, as defined in the bond agreement.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the closing of the Business Combination, there was a change in future cash flows on the bonds related to the increase in interest rate from 7.5% to 10.0%. The Company remeasured the carrying value in accordance with IFRS 9 to the present value of the revised cash flows and recognized a $6.5 million loss on the remeasurement of the bonds. The outstanding bonds were subsequently amended as described below.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Senior Bonds </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16&#160;November 2022, the Group amended and upsized the outstanding bonds by $70.0 million. The amended bond agreement (the &#8220;Senior Bonds&#8221;) resulted in the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">An increase in principal from $455.7&#160;million at the time of the amendment, to $525.7 million;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">An increase in the interest rate, resulting in a range from 10.75% to 12.0% depending on the occurrence of certain events, as defined by the terms of the agreement. The Group accounted for this interest rate feature (the &#8220;Senior Bond Interest Rate Feature&#8221;) as an embedded derivative, classified as an other current asset in the consolidated statement of financial position as of 31 December 2022; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Amended the terms of the related party loans from Alvogen, setting forth subordination conditions; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Contingently issuable penny warrants (exercise price of $0.01) to the bondholders (the &#8220;Senior Bond Warrants&#8221;) if certain events occur, issuable in two tranches representing 1.5% and 1.0% of the fully diluted ordinary share capital, as defined in the Senior Bonds agreement (see Note 28). </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group determined that the 16 November 2022 transaction was a substantial modification to its bonds and accounted for the transaction as an extinguishment. As a result, the Group recognized a loss on extinguishment of financial liabilities of $40.9 million, including $12.1 million of transaction costs, during the year ended 31 </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 2022, primarily driven by the difference between the fair value of the post-transaction Senior Bonds and the Senior Bond Warrants and the carrying amount of the pre-transaction bonds. The loss on extinguishment of financial liabilities includes the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Extinguishment of bonds with a carrying value of $440.1&#160;million, including $4.8 million of accrued interest;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Net cash proceeds of $57.9&#160;million, including transaction costs paid of $12.1 million;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Recognition of a $4.6&#160;million derivative asset for the Senior Bond Interest Rate Feature;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Recognition of $528.2&#160;million and $15.4 million representing the fair value of the new Senior Bonds and Senior Bond Warrants (see Note 28), respectively.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of proceeds raised from the private placement offering executed in February 2023, the Company extinguished the liability related to the senior bond warrants since the Company has not anymore the obligation to issue the penny warrants representing the 1.0% Senior Bond Warrants (see Note 28 for further information).</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Senior Bonds is $549.4&#160;million, compared to $530.5&#160;million as of 31&#160;December 2022. The Group has the option, at any time, to prepay all or any part of the outstanding bonds in exchange for the payment of the redemption premium pursuant to the terms of the agreement.</span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group has pledged its intellectual property as collateral for the Senior Bonds. Additionally, the Group has pledged the Facility of up to $600&#160;million over the Facility as collateral for the Senior Bonds (2nd lien pledge), as further described in Note 12.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">2022 Convertible Bonds </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 20&#160;December 2022, the Group issued two tranches of convertible bonds (the &#8220;2022 Convertible Bonds&#8221;). Tranche A is ISK denominated with a principal balance of $59.1 million, of which $3.5 million in cash proceeds were received in February 2023, and carries an annual payment-in-kind interest rate of 15% per year, while Tranche B is USD denominated with a principal balance of $0.6 million and carries an annual payment-in-kind interest rate of 12.5% per year. The maturity date of the Convertible Bonds is the later of the (i) 20 December 2025 or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Holders of both the Tranche A and Tranche B of the 2022 Convertible Bonds, may elect, at their sole discretion, to convert all or part of the principal amount and accrued interest into Alvotech Ordinary Shares at a conversion price of $10.00 per share on 31 December 2023, 30 June 2024, or upon mandatory or optional redemption of the bonds. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conversion features (the &#8220;Tranche A Conversion Feature&#8221; and &#8220;Tranche B Conversion Feature&#8221;) for both the Tranche A and Tranche B of the 2022 Convertible Bonds were determined to be embedded derivatives as the economic characteristics and risks are not closely related to the debt host. The Group classified the Tranche A Conversion Feature as a liability due to the variability created by conversion rates resulting from the tranche being denominated in ISK and was determined to have a fair value of $24.9 million at issuance date (see Note 28 for further details). The Group classified the Tranche B Conversion Feature as equity due to the conversion price having preservation and passage of time adjustments that meet the fixed-for-fixed criteria.</span></div><div style="margin-top:8.4pt;padding-left:27.5pt;padding-right:7.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">On 25 January 2023, the Company issued an additional $10.0&#160;million of Tranche B Convertible Bonds. The Tranche B Conversion Feature associated with this additional issuance was determined to have a fair value of $1.4&#160;million at issuance date.</span></div><div style="margin-top:8.4pt;padding-left:27.5pt;padding-right:7.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">On 24 July 2023, Alvotech announced that Teva and Alvotech have agreed to expand their existing partnership agreement. As part of the agreement, Teva acquired Tranche B Convertible Bonds in principal amount of $40&#160;million. The Tranche B Conversion Feature associated with this additional issuance was determined to have a fair value of $3.9&#160;million at issuance date.</span></div><div style="padding-right:7.75pt;text-align:justify"><span><br/></span></div><div style="padding-left:28.34pt;padding-right:7.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 31 July 2023, Alvotech completed a private placement of Tranche A Convertible Bonds for a total principal amount of $100&#160;million, or approximately ISK 13&#160;billion at current exchange rates. As part of this private placement, ATP Holdings ehf., an affiliated of Aztiq, acquired Tranche A Convertible Bonds in principal amount of $30&#160;million. The Tranche A Conversion Feature associated with these additional issuances was determined to have a fair value of $45.6&#160;million at issuance date (see Note 28 for further details). </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of 31&#160;December 2023, the carrying amount of the Tranche A and Tranche B of the 2022 Convertible Bonds is $107.1 million and $48.8 million, respectively.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Aztiq Convertible Bond </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, the Group issued a convertible bond (also known as the &#8220;Aztiq Convertible Bond&#8221;) to ATP Holdings ehf, an affiliate of Aztiq, for the Share Purchase Agreement and the acquisition of the Alvotech Facility (See Note 12). The Aztiq Convertible Bond has a principal amount of $80.0 million and carries an interest rate of 12.50% per annum. Interest is payable in six-month intervals and is capitalized and added to the outstanding principal amount of the bonds. The maturity date of the convertible bond is the later of the (i) 16 November 2025 or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Bondholders have the right to convert their outstanding bonds into ordinary shares of Alvotech on 30 December 2023, 30 June 2024, or when the bond has been called or put up for mandatory or optional redemption, for a conversion price is $10.00 per share. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conversion feature (the &#8220;Aztiq Conversion Feature&#8221;) was determined to be an embedded derivative as the economic characteristics and risks are not closely related to the debt host. The Group classified the Aztiq Conversion Feature as equity due to the conversion price having preservation and passage of time adjustments that meet fixed-for-fixed criteria. As a result, the Group recognized the following related to the Aztiq Convertible Bond: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$64.0&#160;million related to the debt host;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$16.0&#160;million related to the Aztiq Conversion Feature; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$30.0&#160;million related to the loans (the &#8220;Facility Loans&#8221;) on the building, which were assumed by the Group as part of the asset acquisition.</span></div><div style="margin-top:0.35pt;padding-left:28.34pt;padding-right:7.9pt;text-align:justify;text-indent:-0.05pt"><span><br/></span></div><div style="margin-top:0.35pt;padding-left:28.34pt;padding-right:7.9pt;text-indent:-0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">In April 2023, we were communicated that ATP Holdings ehf. sold a portion of the Aztiq Convertible Bond to Mitsui &amp; Co., Ltd. ("Mitsui"), a global trading and investment company headquartered in Japan, and Shinhan Healthcare fund 5 ("Shinhan"), a fund established under the laws of the Republic of Korea.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Aztiq Convertible Bond was  $80.7&#160;million and includes $15.1 million held by ATP Holdings ehf. The carrying amount of the Aztiq Convertible Bond was $65.8&#160;million as of 31&#160;December 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Alvogen Facility</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with an undertaking by Alvotech shareholders to ensure that Alvotech was sufficiently funded through the closing of the Business Combination by providing at least $50.0 million for the operations of the Group, Alvogen and Aztiq provided interest free loan advances to Alvotech. On 22&#160;February 2022, Alvotech borrowed $15.0 million under the facility from Alvogen, as lender. On 29&#160;March 2022, Alvotech withdrew an additional amount of $10.0 million under the facility, for aggregate indebtedness of $25.0 million. On 11&#160;March 2022, Alvotech borrowed $15.0 million under the facility from Aztiq, as lender. On 31&#160;March 2022, Alvotech withdrew an additional amount of $10.0 million under the facility, for aggregate indebtedness of $25.0 million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 12 July 2022, the Company entered into settlement agreements with both Aztiq and Alvogen for the $25.0 million in related party loans provided by each party. As a result of the settlement agreements, Aztiq and Alvogen each received 2,500,000 Ordinary Shares. The settlement was accounted for as an extinguishment of financial liabilities. In accordance with IFRS 9, the difference between the fair value of the consideration paid for the settlement, which was determined to be $32.2 million, and the extinguished financial liabilities of $50.0 million was recognized as a gain on the extinguishment of financial liabilities in the consolidated statement of profit or loss and other comprehensive income or loss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 11&#160;April 2022, Alvotech entered into a loan agreement with Alvogen, as lender, for a loan of up to $40.0 million bearing an interest rate of 10% per annum. The loan was drawable in two separate installments of $20.0 million each. On 12&#160;April 2022, Alvotech withdrew the first installment of $20.0 million. Alvotech withdrew a second installment of $20.0 million on 9&#160;May 2022 for aggregate indebtedness of $40.0 million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 1&#160;June 2022, Alvotech also entered into a loan agreement with Alvogen, as lender, for a loan of $20.0 million bearing an interest rate of 10% per annum. Alvotech withdrew the entire loan amount of $20.0 million on 1&#160;June 2022. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the 16 November 2022 Senior Bonds amendment, Alvotech entered into a subordinated loan agreement with Alvogen (the &#8220;Alvogen Facility&#8221;). As part of the subordinated loan agreement, the Group agreed to the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Rollover the $63.3&#160;million outstanding, which includes $3.3 million of accrued interest, under the Alvogen loans, into the new subordinated loan agreement, and withdraw an additional $50.0 million in loans;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The interest rate was increased from 10% per annum to 17.5% per annum on the outstanding amounts under the loan facility;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A repayment date of 91 days after the full redemption or the final maturity date of the Senior Bonds; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Contingently issuable penny warrants to the bondholders (the &#8220;Alvogen Facility Warrants&#8221;) if certain events occur, representing 4.0% of the fully diluted ordinary share capital, as defined in the Alvogen Facility agreement.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group determined that the 16 November 2022 transaction was a substantial modification to its related party loans and accounted for the transaction as an extinguishment. As a result, the Group recognized the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Extinguishment of bonds with a carrying value of $63.2&#160;million, including $3.2 million of accrued interest;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Net cash proceeds of $50.0&#160;million; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Recognition of $113.2&#160;million and $1.3 million representing the fair value of the new Alvogen Facility and Alvogen Facility Warrants, respectively.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 20&#160;December 2022, the Company repaid $50.0 million under the Alvogen Facility, with proceeds from the 2022 Convertible Bonds. As a result, Alvotech extinguished the liability to issue the Alvogen Facility Warrants. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Alvogen Facility is $76.6&#160;million, compared to $64.6&#160;million as of 31&#160;December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Facility Loans </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted above, the Group assumed the Facility Loans as part of the asset acquisition for the Facility. On 9&#160;December 2022, the Group extinguished the assumed loans from Arion banki hf., with an outstanding balance of $30.9 million, with two new loans from Landsbankinn hf. for $48.8 million, with variable interest rate, currently 8.3% and 9.3% per annum. The refinancing resulted in net cash proceeds of $17.2 million after transaction costs paid. The Group has pledged the facility as collateral to secure these loans (1st lien pledge), as further described in Note 12.</span></div><div style="margin-top:0.35pt;padding-left:27.5pt;padding-right:7.9pt"><span><br/></span></div><div style="margin-top:0.35pt;padding-left:27.5pt;padding-right:7.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">These two loans were denominated in Icelandic Krona and included a conversion clause to convert them into USD. The conversion of these two loans took place in March 2023.</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="padding-left:27.5pt;padding-right:7.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">Under the terms of the loan agreements after conversion, the first loan includes annuity payments that are due monthly with a final maturity in December 2029 and a variable interest rate of USD </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">Secured Overnight Funding Rate ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">SOFR") plus a margin of 4.75%. The second loan is a bullet loan with a final maturity in December 2027 and a variable interest rate of USD SOFR plus a margin of 3.75%</span></div><div style="margin-top:0.55pt"><span><br/></span></div><div style="padding-left:27.5pt;padding-right:7.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%">The Group determined that conversion to USD of the two loans was a substantial modification to loan agreements and accounted for the transaction as an extinguishment. No gain or loss was recognized as part of the extinguishment.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of 31&#160;December 2023, the carrying amount of the Facility Loans is $48.5&#160;million.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Other borrowings </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2015 and 2016, the Group entered into several term loan agreements with a financial institution for a total principal amount of $25.9 million. The loan agreements set forth terms and conditions between the Group and the financial institution, inclusive of certain representations and non-financial covenants. Per the terms of the loan </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">agreements, the loans mature throughout 2024, depending on the issuance date of each loan. Interest on the loans is based on variable interest rate of USD SOFR plus a margin of 4.95%, payable on a monthly basis. Interest accrued and unpaid at the end of each interest period increases the principal obligations owed by the Group to the financial institution. As of 31&#160;December 2023, the outstanding balance on the loans is $0.5&#160;million, compared to a balance of $3.2&#160;million as of 31&#160;December 2022. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 22 February 2022, the Group entered into a credit facility agreement with Landsbankinn hf. with the ability to draw down an amount up to $8&#160;million. The credit facility is in place to help finance equipment purchases in the future. Per the terms of the credit facility, any borrowings are required to be paid by 1 August 2024 and have a variable interest rate of USD SOFR plus a margin of 4.95%. As of 31&#160;December 2023, the outstanding balance on the credit facility was $7.8&#160;million, compared to $13.9&#160;million as of 31&#160;December 2022. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 22 February 2022, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $3.2 million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in March 2029. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $2.5&#160;million, compared to $2.9&#160;million as of 31&#160;December 2022.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 5 August 2022, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $1.8 million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in August 2029. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $1.6&#160;million, compared to $1.8&#160;million as of 31&#160;December 2022. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 4 August 2023, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $11.5&#160;million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in August 2030. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $11.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group is in compliance with all representations and non-financial covenants required by these agreements. In addition, the Group has pledged equipment as collateral to secure these borrowings, as further described in Note 12. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 14 December 2023, the Group entered into a qualified receivable financing agreement with Landsbankinn hf. for a principal amount of $25.0&#160;million. The qualified receivable financing arrangement has a variable interest rate of USD SOFR plus a margin of 3.50% and a maturity of April 2024. As of 31&#160;December 2023, the outstanding balance on the loan was $25.0&#160;million. The Group has pledged $25&#160;million of its trade receivables to secure this financing.</span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s outstanding borrowings during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">400,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of deferred debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accretion/derecognition of borrowings discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of new borrowings discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(43,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds from new borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">275,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">467,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loans from related party converted to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Repayments of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(99,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(83,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of deferred debt issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency exchange difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average interest rates of outstanding borrowings for the years ended 31&#160;December 2023, 2022, and 2021 are 12.73%, 12.41%, and 14.83%, respectively.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below details the changes in the Group&#8217;s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group&#8217;s consolidated cash flow statement as cash flows from financing activities.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1 January <br/>2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Financing Cash flows (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Capitalized loan cost changes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair value changes, including accretion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other changes (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign exchange impact</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds and Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(36,071)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">236,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds (including related party)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">530,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,968&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,556&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">170,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(35,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Other changes include interest accruals and effects of payments including $3.5&#160;million in cash received from borrowings from the 2022 Convertible Bonds and transaction cost of $9&#160;million paid in 2023.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.242%"><tr><td style="width:1.0%"></td><td style="width:19.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 January <br/>2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing Cash flows (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized loan cost changes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value changes, including accretion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other changes (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion to Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-cash movements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds and Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(40,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds (including related party)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">394,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">70,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,069&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34,308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">530,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">400,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">268,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Other changes include interest accruals and payments.</span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of principal amounts on the Group&#8217;s outstanding borrowings as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within two years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">867,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">696,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within four years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,857&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411138880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfLongtermIncentivePlansAbstract', window );"><strong>Disclosure Of Longterm incentive plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock', window );">Long-term incentive plans</a></td>
<td class="text">Long-term incentive plans <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Share appreciation rights</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to 2020, the Group granted SARs to three former employees. During the year ended 31&#160;December 2021 and 2020, the Group granted SARs to one and two current employees, respectively. There were no new granted SARs in the years ended 31&#160;December 2023 and 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Settlement of SARs </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the closing of the Business Combination, the Company reached a settlement agreement for share appreciation rights previously awarded to certain current and former employees. The rights were settled as follows: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">two former employees will each receive 1,755,291 Ordinary Shares to be issued one year after the Closing Date. In accordance with IFRS 2, the settlements were accounted for as a modification of a share-based payment transaction that changes the awards classification from cash-settled to equity-settled; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">one former employee will receive a $1.5 million cash payment in July 2022; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">one current employee can elect to receive a cash payment of $1.5 million or 150,000 Ordinary Shares to be issued one year after the Closing Date. The Company recognized the cash settlement option as a liability with a fair value of $0.8 million and the share settlement option as equity with a fair value of $0.7 million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The settlement agreements resulted in a net $36.8 million decrease in the SARs liability, a $31.0 million increase in equity equal to the fair value of the Ordinary Shares issued to the two former employees, a $1.5 million increase in other current liabilities, and income of $4.3 million in "General and administrative expense" recognized for the difference between the extinguished liabilities and the fair value of consideration paid to the current and former employees. As of 31&#160;December 2022, the Company recognized $0.7 million as an other current liability related to the remaining SARs liability. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All liabilities described above have been fully settled in 2023 as follows:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Shares were delivered to the two former employees, on a net basis after tax withholding, resulting in a total of 2,465,845 shares which has been reflected accordingly in Note 19.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The employee who could choose between receiving $1.5&#160;million or 150,000 Ordinary Shares elected to receive the cash payment. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Employee incentive plan</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s employee incentive plan liabilities during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December prior to reclassification</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">659&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassified to other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(659)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">544&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of long-term incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfLongtermIncentivePlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Longterm incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfLongtermIncentivePlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411631952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share Based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text">Share-based payments <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 1 December 2022, the Renumeration Committee authorized and the Group granted RSUs to employees, executives, and directors granting rights to Ordinary Shares once vesting conditions are met. Compensation expense for RSUs is determined based upon the market price of the Ordinary Shares underlying the awards on the date of grant and expensed over the vesting period, which is generally a 1 to 4-year period, with a 1-year cliff vesting period </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and subsequent monthly vesting, resulting from participants completing a service condition. Movements in RSUs during the year ended 31&#160;December 2023 are as follows:</span></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.030%"><tr><td style="width:1.0%"></td><td style="width:41.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">RSUs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,979,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New grants during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">820,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$8.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,659,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,587,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$7.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,466,374)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(679,562)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,745,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$7.04&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,979,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recogniz</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ed $18.0 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.3&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of shar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e-based payment expense during the years ended 31&#160;December 2023 and 2022, respectively, as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"></td><td style="width:64.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,991&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,033&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,317&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share based payment arrangements abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411370000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LitigationAbstract', window );"><strong>Litigation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock', window );">Litigation</a></td>
<td class="text">Litigation <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group was involved in four litigations (all now dismissed) in the United States adverse to AbbVie arising out of the development of Alvotech&#8217;s AVT02 product, and the filing of a biologics license application with the U.S. Food and Drug Administration seeking regulatory approval (the &#8220;AbbVie Litigations&#8221;).</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alvotech entered into the AbbVie U.S. Agreement with AbbVie Inc. and AbbVie Biotechnology Ltd with respect to AVT02 for the U.S. market. Pursuant to the settlement component of the AbbVie U.S. Agreement, the parties agreed to stipulate to the dismissal of all claims, counterclaims and potential claims in the four U.S. litigations, with each party to bear its own fees and costs. The parties further agreed to release each other from certain claims and demands. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group incurred approximately $0.0 million, $8.7 million and $13.5 million in legal expenses during the years ended 31&#160;December 2023, 2022, and 2021, respectively, in preparation for, and/or in relation to, these litigations. Aside from this matter, the Group is not currently a party to any material litigation or similar matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of litigation settlements explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LitigationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LitigationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412459376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related parties</a></td>
<td class="text">Related parties <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related parties are those parties which have considerable influence over the Group, directly or indirectly, including a parent company, owners or their families, large investors, key management personnel and their families and parties that are controlled by or dependent on the Group, such as affiliates and joint ventures. Key management personnel include the Group&#8217;s executive officers and directors, since these individuals have the authority and responsibility for planning, directing and controlling the activities of the Group. Interests in subsidiaries are set out in Note 1. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Transactions with related parties</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A related party transaction is a transfer of resources, services or obligations between the Group and a related party, regardless of whether a price is charged. The Group engages with related parties for both purchased and sold services, loans and other borrowings and other activities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group entered into lease agreement with Fasteignaf&#233;lagi&#240; Eyj&#243;lfur hf. in April 2023 for a new facility in Iceland with remaining lease terms of approximately 15 years as of 31 December 2023 (see Note 13). The Group also entered into seventeen separate lease agreements with Fl&#243;ki Fasteignir ehf. (HRJAF ehf.) throughout 2020, 2021 and 2023 for a group of apartment buildings in Iceland used for temporary housing of employees and third party </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contractors. Two of the leases were terminated during the year ended 31&#160;December 2021. The remaining lease terms for the other fifteen leases approximate 7 years, on average, as of 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group entered into office sublease sharing agreement with Alvogen UK Ltd. in August 2023. The agreement was effective from 1 January 2023 and shall terminate upon the expiration or termination of the Lease.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group entered into art lease agreement with Fl&#243;ki-Art ehf. in January 2023, as a result of the Share Purchase Agreement (see Note 12). The leased asset is located in S&#230;mundargata 15-19, Reykjavik. The remaining lease term for the leased asset is 15 years, as of 31 December 2023.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group provides and receives certain support services through arrangements with Aztiq, Alvogen, and Alvogen Malta (Outlicensing) Ltd. (Adalvo). Services provided to Alvogen consist of finance, administrative, legal and human resource services. Services received from Alvogen primarily consist of marketing, salary processing, and information technology support services. Services received from Adalvo primarily consist of legal, regulatory, supply chain management, and portfolio and market intelligence services. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchased service includes rental fees and service expenses, as described above. Rental fees and service expenses with related parties are presented as &#8220;General and administrative expenses&#8221; or &#8220;Research and development expenses&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss, depending on the nature of the service performed and expense incurred by the Group. Rental liabilities from lease arrangements with related parties are presented as a component of &#8220;Lease liabilities&#8221; on the consolidated statements of financial position. Service payables are presented as &#8220;Liabilities to related parties&#8221; on the consolidated statements of financial position. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest includes interest expense on borrowings. Interest expenses on loans from related parties are presented as &#8220;Finance costs&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. Borrowings are presented as &#8220;Borrowings&#8221; and &#8220;Current maturities of borrowings&#8221; on the consolidated statements of financial position. See Note 21 for further details on the borrowing arrangements with related parties. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sold service includes services provided to related parties, as described above. Income from related parties for such services are presented as &#8220;Other income&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. Amounts receivable for such activities are presented as &#8220;Receivables from related parties&#8221; on the consolidated statements of financial position. The Group has not recorded bad debt provisions for its receivables from related parties. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions as of and for the year ended 31&#160;December 2023 are as follows:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"></td><td style="width:39.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Purchased service /</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Sold service</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Receivables</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Payables/ </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">borrowings</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ATP Holdings ehf. - Sister company (a)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Consulting ehf. &#8211; Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki-Art ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen UK - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">581&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Finance B.V. - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus International Pte. Ltd. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">539&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo Limited - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo UK - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki Invest ehf - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Floki Holdings S.&#224; r.l. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Spain SL - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Norwich Clinical Services Ltd - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company (d)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,732&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki fasteignir ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,781&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">597&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">896&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,956&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). In relation to the private placement of Tranche A Convertible Bonds in July, the Company paid underwriters fee to APT Holding amounting to $3.3&#160;million. The underwriter&#8217;s fee is accounted for as a transaction cost that is amortized through profit and loss over the life of the instrument.  </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Payables to Lotus Pharmaceuticals Co. Ltd. consists of the other current liability as further described in Note 2. This other current liability is presented as &#8220;Liabilities to related party&#8221; on the consolidated statements of financial position. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The amount receivable from Alvotech &amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Refer to Note 13 for the details of the new lease. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions as of and for the year ended 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"></td><td style="width:39.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchased service / <br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sold service</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Receivables</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payables/ <br/>borrowings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Consulting ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ATP Holdings ehf. - Sister company (a)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">765&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company (e)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus International Pte. Ltd. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Korea co. Ltd - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo Limited - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">603&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Spain SL - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Norwich Clinical Services Ltd - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Pharma Pvt Ltd - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki fasteignir ehf. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">L41 ehf.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lambhagavegur 7 ehf. (d)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">818&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">163,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities including discount and accretion (see Note 21). </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#8220;Other long-term liability to related party&#8221; on the consolidated statements of financial position. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The amount receivable from Alvotech &amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Lambahagavegur is no longer a related party as it was sold during the year ended 31&#160;December 2023. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. was acquired as part of the Share Purchase Agreement, with ATP Holdings ehf., on 16 November 2022. The related party transactions reflect activity until the acquisition date. See Note 12 and Note 21 for further details.  </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions for the year ended 31&#160;December 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"><tr><td style="width:1.0%"></td><td style="width:59.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchased service / <br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sold <br/>service</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Pharma Partners S.&#224; r.l. &#8211; Sister company (a) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Aztiq AB &#8211; Sister company (a) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. (a) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company  </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,762&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company  </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen UK - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Korea co. Ltd - Sister company </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Pharma Pvt Ltd - Sister Company </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">HRJ&#193;F ehf - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">L41 ehf. </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lambhagavegur 7 ehf. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,940&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,715&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#8220;Other long-term liability to related party&#8221; on the consolidated statements of financial position. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Commitments and guarantees</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group does not have any contractual commitments with its related parties other than the receivables, loans and payables previously disclosed. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Key management personnel</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At 31&#160;December 2023 and 2022 there are no loans to the members of the Board of Directors and the CEO. In addition, there were no transactions carried out between the Group and members of the Board of Directors nor the CEO in the years ended 31&#160;December 2023 and 2022. The Board of Directors&#8217; remuneration is shown in the table below. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"><tr><td style="width:1.0%"></td><td style="width:45.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors&#8217; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Board fees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension <br/>contribution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">year-end**</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman, Chairman of the board*</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies, Vice-Chairman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,143,713</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant, Board Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#193;rni Har&#240;arson, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua, Board Member*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick, Board Member</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver, Board Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">421&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">416&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,175,459</span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Waived their board compensation (both cash and equity)</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Direct share ownership </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Key employees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Salaries and benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Termination benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long- term benefits</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman CEO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Executive Team Members (9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">372&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"><tr><td style="width:1.0%"></td><td style="width:45.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors&#8217; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Board fees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long-term benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">year-end**</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman, Chairman of the board</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies, Vice-Chairman</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,133,131</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#193;rni Har&#240;arson, Board Member (from 16.6.2022)*</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua, Board Member*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick, Board Member (from 16.6.2022)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman, Board Member*</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Hirofumi Imai, Board member (until 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">927&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,133,131</span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Waived their board compensation (both cash and equity)</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Direct share ownership </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Key employees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Salaries and benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Termination benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long- term benefits</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mark Levick CEO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Executive Team Members (9)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">820&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">608&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411138880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentLiabilitiesAbstract', window );"><strong>Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory', window );">Other current liabilities</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other current liabilities </span><div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other current liabilities as of 31&#160;December 2023 and 2022 is as follows: </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unpaid salary and salary related expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued vacation leave</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee incentive plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62,720&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current liabilities. [Refer: Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414819456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interests In Joint Ventures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesAbstract', window );"><strong>Disclosure of joint ventures [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesExplanatory', window );">Interests in joint ventures</a></td>
<td class="text">Interests in joint ventures <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2018, Alvotech hf., a subsidiary of the Group, entered into a joint venture agreement with Changchun High &amp; New Technology Industries (Group) Inc. (the &#8220;joint venture partner&#8221;, "CCHN") to form a newly created joint venture entity, Alvotech &amp; CCHN Biopharmaceutical Co., Ltd. (the &#8220;joint venture&#8221; or &#8220;JVCO&#8221;). The purpose of the JVCO is to develop, manufacture and sell biosimilar products in the Chinese market. The JVCO&#8217;s place of business is also the country of incorporation. </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"><tr><td style="width:1.0%"></td><td style="width:33.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%;text-decoration:underline">Name of entity</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Place of business</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Ownership interest </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech &amp; CCHN Biopharmaceutical Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The proportion of ownership interest is the same as the proportion of voting rights held by the Group. Management evaluated whether the Group&#8217;s voting rights are sufficient for providing a practical ability to direct the relevant activities and strategic objectives of JVCO unilaterally. As the Group does not hold a majority of the voting rights, the Group does not control JVCO. As a result, the Group&#8217;s investment in JVCO is accounted for using the equity method. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the change in the Group&#8217;s investment in a joint venture during the years ended 31&#160;December 2023 and 2022: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share in losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment loss on investment in joint venture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Group did not receive any dividends from JVCO during the years ended 31&#160;December 2023, 2022, and 2021. The Group had a $5.0 million commitment to provide a cash contribution to JVCO as of 31&#160;December 2020, which was paid during the year ended 31&#160;December 2021. Similarly, the joint venture partner had a $50.0 million commitment to provide a cash contribution to JVCO as of 31&#160;December 2020, which was also paid during the year ended 31&#160;December 2021. The Group does not have any remaining commitments to JVCO as of 31&#160;December 2023 and 2022. Furthermore, the Group does not have any contingent liabilities relating to its interests in JVCO as of 31&#160;December 2023 or 2022. While there are no significant restrictions resulting from contractual arrangements with JVCO, entities in China are subject to local exchange control regulations. These regulations provide for restrictions on exporting capital from those countries, other than dividends</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. As of 31 December 2023, it had become clear that there were uncertainties around the economic conditions in China. Accordingly, the Group recorded an impairment loss on its investment in JVCO based on discussions between Alvotech and CCHN to buy back Alvotech&#180;s interest in the joint venture. The Group estimated the recoverable amount using value in use where the recoverable amount is estimated as the future cash flows expected to arise from dividends to be received from the investment and from its ultimate disposal.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of joint ventures. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B4<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B4_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412480720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text">Financial instruments <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Accounting classification and carrying amounts</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets as of 31&#160;December 2023 and 2022, all of which are measured at amortized cost, are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,035&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Receivables from related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other long-term assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,484</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial liabilities as of 31&#160;December 2023 and 2022 are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial liabilities (measured at FVTPL)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">380,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other long-term liability to related party (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term incentive plan (measured at FVTPL)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade and other payables (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities (measured at amortized cost)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Liabilities to related parties (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,748,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,297,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is management&#8217;s estimate that the carrying amounts of financial assets and financial liabilities carried at amortized cost approximate their fair value, with the exception of the Senior Bonds, Aztiq Convertible Bond, 2022 Convertible Bonds, and Alvogen Facility, since any applicable interest receivable or payable is either close to current market rates or the instruments are short-term in nature. Material differences between the fair values and carrying amounts of these borrowings are identified as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">559,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">155,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">82,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">862,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">944,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">530,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">535,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">693,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">720,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Fair value measurements</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables illustrate the fair value measurement hierarchy of the Group&#8217;s financial instruments measured at fair value on a recurring basis as of 31&#160;December 2023 and 2022: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Bond Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">349,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">349,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">356,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bond Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bond Interest Rate Feature (included in other current assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">276,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">276,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">286,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">381,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of Level 3 financial instruments:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.818%"><tr><td style="width:1.0%"></td><td style="width:49.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Senior Bond Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Senior Bond Interest Rate Feature</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 January  2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer to Level 1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(45,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognized the transfer of the Senior Bond Warrants from Level 3 to Level 1 for $19.7&#160;million (2022: $45.3 million) during the year ended 31&#160;December 2023 due to the lift of the lock-up period for the un-exercised Senior Bond Warrants. The Group did not recognize any transfer of assets or liabilities between levels of the fair value hierarchy during the years ended 31&#160;December 2022 and 2021. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 16 November 2022, the Group amended and upsized the outstanding bonds by $70.0&#160;million. The amended bond agreement of the Senior Bonds resulted in, among other things, an increase in the interest rate, resulting in a range from 10.75% to 12.0% depending on the occurrence of certain events, as defined by the terms of the agreement (see Note 21). The Group accounted for this interest rate feature (the &#8220;Senior Bond Interest Rate Feature&#8221;) as an embedded derivative, classified as an "Other current assets" in the consolidated statement of financial position as of 31 December 2022. Since the conditions to adjust the coupon rate have not been met as of 31 March 2023 per the terms of the agreement, the interest rate on the Senior Bonds is now fixed and the embedded derivative previously recorded has been extinguished during the year ended 31&#160;December 2023, resulting in a loss on extinguishment of $0.9&#160;million recorded in finance costs.</span></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Senior Bond Warrants</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted in Note 21, as a result of proceeds raised from the private placement offering executed in February 2023, the Company extinguished the derivative financial liability related to the senior bond warrants since the Company has not anymore the obligation to issue the 1.0% Senior Bond Warrants, resulting in a gain on extinguishment of $6.5 million. In January and February 2023, the Senior Bond Warrant holders (also known as penny warrant holders) elected to exercise their warrants. As a result, 2,479,962 ordinary shares were issued in exchange for the exercising of the penny warrants. The Company received an immaterial amount of cash and recognized the transaction as an extinguishment of the derivative financial liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Senior Bond Warrants was derived from the publicly quoted trading price of the Ordinary Shares at the valuation date. As of 31&#160;December 2023, the Company had 1,718,845 warrants with an exercise price of $0.01, representing the 1.5% tranche of Senior Bond Warrants. The Senior Bond Warrants had a fair value of $19.7&#160;million as of 31&#160;December 2023. The change in fair resulted in $8.1 million of finance costs for the year ended 31&#160;December 2023.  </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Tranche A Conversion Feature </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted in Note 21, in connection with the Convertible Bonds the Group classified the Tranche A Conversion Feature as an embedded derivative liability due to the variability created by conversion rates resulting from the tranche being denominated in ISK. The conversion feature had a fair value of $118.8&#160;million as of 31&#160;December 2023. The change in fair resulted in $35.2&#160;million of finance costs for the year ended 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Tranche A Conversion Feature was determined using a lattice model that incorporated inputs and assumptions as further described below. The inputs and assumptions associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the Tranche A Conversion Feature: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.787%"><tr><td style="width:1.0%"></td><td style="width:55.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$11.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Conversion price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risky yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Predecessor Earn Out Shares </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Business Combination, Predecessor shareholders were granted a total of 38,330,000 Ordinary Shares subject to certain vesting conditions (&#8220;Predecessor Earn Out Shares&#8221;). One half of the Predecessor Earn Out Shares will vest if, at any time during the five years following the closing of the Business Combination, the Alvotech ordinary share price is at or above a volume weighted average price (&#8220;VWAP&#8221;) of $15.00 per share for any <span style="-sec-ix-hidden:f-2302">ten</span> trading days within any <span style="-sec-ix-hidden:f-2303">twenty</span>-trading day period, with the other half vesting at a VWAP of $20.00 per share for any <span style="-sec-ix-hidden:f-2305">ten</span> trading days within any <span style="-sec-ix-hidden:f-2306">twenty</span>-trading day period. The Predecessor Earn Out Shares are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The Predecessor Earn Out Shares had a fair value of $349.9 million as of 31&#160;December 2023, resulting in $73.7&#160;million of finance costs during the year ended 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Predecessor Earn Out Shares was determined using Monte Carlo analysis that incorporated inputs and assumptions as further described below. The inputs and assumptions associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the Predecessor Earn Out Shares: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,330,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,330,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$11.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">OACB Earn Out Shares </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Former OACB shareholders were granted a total of 1,250,000 Ordinary Shares subject to certain vesting conditions (&#8220;OACB Earn Out Shares&#8221;). One half of the OACB Earn Out Shares will vest if, at any time during the five years following the closing of the Business Combination, the Alvotech ordinary share price is at or above a VWAP of $12.50 per share for any <span style="-sec-ix-hidden:f-2320">ten</span> trading days within any <span style="-sec-ix-hidden:f-2321">twenty</span>-trading day period, with the other half vesting at a VWAP of $15.00 per share.  On 17 February 2023, the first half of OACB Earn Out Shares vested resulting in the issuance of 625,000 ordinary shares by the Group. The OACB Earn Out Shares are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The OACB Earn Out Shares had a fair value of $6.2 million as of 31&#160;December 2023, resulting in $4.0&#160;million of finance costs during the year ended 31&#160;December 2023. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the OACB Earn Out Shares was determined using a Monte Carlo analysis that incorporated inputs and assumptions as further described below. Assumptions and inputs associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the OACB Earn Out Shares: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">625,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,250,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$11.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Volatility rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">OACB Warrants </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, as part of the Business Combination the Company assumed the 10,916,647 outstanding OACB Warrants, on substantially the same contractual terms and conditions as were in effect immediately prior to the Business Combination, including an exercise price of $11.50. Each warrant entitles the holder to purchase one Alvotech ordinary share.  During 2023, holders of the OACB warrants exercised their warrant rights for an exercise price of $11.50 for the rights to one ordinary share per warrant. The exercises resulted in the issuance of 553.552 ordinary shares and cash proceeds of approximately $6.3&#160;million. The OACB warrants are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The OACB warrants had a fair value of $25.9&#160;million as of 31&#160;December 2023. The fair value of the warrants was derived from the publicly quoted trading price at the valuation date. The change in fair value of the OACB Warrants resulted in $17.0&#160;million of finance costs during the year ended 31&#160;December 2023. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Capital management</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The capital structure of the Group consists of equity, debt and cash. For the foreseeable future, the Board of Directors will maintain a capital structure that supports the Group&#8217;s strategic objectives through managing the budgeting process, maintaining strong investor relations and managing the financial risks of the Group, as further described below. No changes were made in the objectives, policies or processes for managing capital during the years ended 31&#160;December 2023 and 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial risk management</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s corporate treasury function provides services across the organization, coordinates access to domestic and international financial markets, monitors and manages the financial risks relating to the Group&#8217;s operations through internal risk reports which analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Interest rate risk</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group&#8217;s exposure to the risk of fluctuations in market interest rates primarily relates to the cash in bank and borrowings that are subject to floating interest rates. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides an interest rate sensitivity analysis for the effect on loss before tax: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-rate financial instruments +100</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(89)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-rate financial instruments -100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Foreign currency risk</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group uses the US dollar as its reporting currency and conducts business on a global basis in various currencies. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Icelandic and UK market currencies, as well as in the Swiss franc. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below are the foreign currencies that have the most significant impact on the Group&#8217;s operations. </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"></td><td style="width:23.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.455%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Closing rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Average rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2023 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>assets </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,735)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">144,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(141,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net <br/>assets </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reasonable possible strengthening or weakening of the Group&#8217;s significant foreign currencies against the USD would affect the measurement of financial instruments denominated in a foreign currency and affect profit or loss and equity by the amount shown in the sensitivity analysis table below. The analysis assumes that all other variables, such as interest rates, remain constant. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">EUR </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">GBP </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">ISK </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">CHF </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">INR </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Year ended 31 December 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">-10% weakening</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">+10% strengthening</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Year ended 31 December 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">-10% weakening</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">+10% strengthening</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Credit risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Credit risk it the risk that a counterparty will not fulfill its contractual obligations under a financial instrument contract, leading to a financial loss for the Group. The maximum credit risk exposure for the Group&#8217;s financial assets as of 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,848&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,498&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s cash and cash equivalents and restricted cash are deposited with high-quality financial institutions. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Group has not experienced any losses on its deposits of cash and cash equivalents and restricted cash yet monitors the credit rating of these financial institutions on a periodic basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets primarily consist of other current assets, as described in Note 18, and trade receivables and contract assets recognized in connection with the Group&#8217;s performance pursuant to its contracts with customers, all of which are large multinational pharmaceutical companies. In 2023, the Group recognized a receivable of $18.5&#160;million in other current assets following the termination of the co-development agreement with Biosana which was fully reserved as of 31&#160;December 2023 due to the uncertainty of its collection (see Note 18). There are no other significant amounts past due as of 31&#160;December 2023 and 2022 and the Group concludes that any expected credit losses with respect to these assets, except as described above, is immaterial. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Liquidity risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of financial assets and liabilities as of 31&#160;December 2023 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one<br/>year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">One to two<br/>years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,468&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">142,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">142,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,101,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,167,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">121,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">253,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,631,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,951,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of financial assets and liabilities as of 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one<br/>year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">One to two<br/>years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">106,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,671&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">112,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">896,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,008,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">380,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">380,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">92,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">175,382&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,344,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,593,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div>Refer to Note 13 for the maturity analysis of the Group&#8217;s undiscounted lease payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411137184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract', window );"><strong>Disclosure In Entirety Of Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock', window );">Supplemental cash flow information</a></td>
<td class="text">Supplemental cash flow information <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplement cash flow information for the years ended 31&#160;December 2023, 2022, and 2021 is included below (see Note 21 for non-cash movements in borrowings).</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"><tr><td style="width:1.0%"></td><td style="width:50.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of property, plant and equipment in trade payables and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,812&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of intangibles in trade payables and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets obtained through new operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Purchase of Facility through Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-cash issuance of Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity issued through conversion of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">346,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of other intangible assets through financing agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of RSUs with shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of SARs with shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in entirety of supplemental cash flow information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in entirety of supplemental cash flow information [Text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430415748496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text">Subsequent events <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group evaluated subsequent events through 20 March 2024, the date the consolidated financial statements were available to be issued. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 15 February 2024, the Company announced it has reached settlement agreements with Johnson &amp; Johnson in Japan, Canada and in the EEA for AVT04, a biosimilar to Stelara (ustekinumab). Regulatory approval for AVT04 in these markets has already been granted. Market applications for AVT04 are currently pending in additional global markets, including in the U.S. Alvotech's commercialization partner in Canada, JAMP Pharma, launched AVT04 in Canada on March 1, 2024. Launch of AVT04 in Japan is anticipated after the upcoming round of National Health Insurance reimbursement price listings, in May 2024. Entry to the first European markets is expected as soon as possible after the expiration date of the European Supplementary Protection Certificate (SPC) for Stelara, which is in late July 2024.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 23 February 2024, the Company announced that the FDA has approved SIMLANDI (adalimumab) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn&#8217;s disease, adult ulcerative colitis, adult plaque psoriasis, </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest-grossing pharmaceutical products in the world, with sales in the U.S. of nearly $12.2&#160;billion. Teva is Alvotech&#8217;s strategic partner for the exclusive commercialization of SIMLANDI in the United States.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 26 February 2024, the Company announced the sale of 10,127,132 Ordinary Shares for an approximate value of $166&#160;million (net proceeds of $160&#160;million), par value USD 0.01 per share, at a purchase price of $16.41 per share, or ISK 2,250 per share at the foreign exchange rates on 23 February 2024. The Shares will be delivered to the Investors from previously issued treasury shares held by Alvotech&#8217;s subsidiary, Alvotech Manco ehf. The Transaction took place on the Nasdaq Iceland Exchange.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 12 February 2024, the second tranche of OACB Earn Out Shares vested resulting in the issuance of 625,000 Ordinary Shares. The issuance of Ordinary Shares for the second tranche will be accounted for as an extinguishment of a financial liability in the consolidated statements of profit or loss and other comprehensive income or loss.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On 12 February 2024, the first tranche of Predecessor Earn Out Shares vested resulting in the issuance of 19,165,000 Ordinary Shares. The issuance of Ordinary Shares for the first tranche will be accounted for as an extinguishment of a financial liability in the consolidated statements of profit or loss and other comprehensive income or loss.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent to 31&#160;December 2023, Senior Bond Warrant holders elected to exercise their warrants. As a result,  1,501,599 Ordinary Shares were issued in exchange for the exercising of the penny warrants. The Company received an immaterial amount of cash and will recognize the transaction as an extinguishment of the derivative financial liabilities. The difference between the equity issued and carrying value of the derivative financial liabilities will be recognized in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent to 31&#160;December 2023, holders of the OACB Warrants exercised their warrant rights for an exercise price of $11.50 for the rights to one Ordinary Share per warrant. The exercises result in the issuance of 419,660 Ordinary Shares and cash proceeds of $4.8&#160;million. The Company will recognize the transaction as an extinguishment of the derivative financial liabilities. The difference between the equity issued and carrying value of the derivative financial liabilities will be recognized in the consolidated statements of profit or loss and other comprehensive income or loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430420497056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text">Basis of preparation <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements of the Group have been prepared in accordance and in compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), which comprise all standards and interpretations approved by the IASB, and as adopted by the European Union ("EU"). </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All amendments to IFRSs issued by the IASB that are effective for annual periods that begin on or after 1 January 2023 have been adopted as further described within the footnotes to the consolidated financial statements. The Group has not adopted any standards or amendments to standards in issue that are available for early adoption. </span></div>The consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and financial liabilities which have been measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The consolidated financial statements are presented in U.S. Dollar ("USD") and all values are rounded to the nearest thousand unless otherwise indicated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">Basis of consolidation</a></td>
<td class="text">Basis of consolidation <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">has power over the investee; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">is exposed, or has rights, to variable returns from its involvement with the investee; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">has the ability to use its power to affect its returns. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company&#8217;s voting rights in an investee are sufficient to give it power, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the size of the Company&#8217;s holding of voting rights relative to the size and dispersion of holdings of the other vote holders; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">potential voting rights held by the Company, other vote holders or other parties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">rights arising from other contractual arrangements; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders&#8217; meetings. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income or loss from the date the Company gains control until the date when the Company ceases to control the subsidiary. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. </span></div>All intra-group transactions, balances, income and expenses are eliminated in full in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures', window );">Investments in joint ventures</a></td>
<td class="text">Investments in joint ventures <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent the Group concludes that it does not control, and thus consolidate, a joint venture, the Group accounts for its interest in joint ventures using the equity method of accounting. As such, investments in a joint venture are initially recognized at cost and the carrying amount is subsequently adjusted for the Group&#8217;s share of the profit or loss of the joint venture, as well as any distributions received from the joint venture. The Group carries its ownership interest in a joint venture as &#8220;Investment in joint venture&#8221; on the consolidated statements of financial position. The Group&#8217;s profit or loss includes its share of the profit or loss of the joint venture and, to the extent applicable, other comprehensive income or loss for the Group includes its share of other comprehensive income or loss of the joint venture. The Group&#8217;s share of a joint venture&#8217;s profit or loss in a particular year is presented as &#8220;Share of net loss of joint venture&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div>The carrying amount of equity-accounted investments is assessed for impairment as a single asset. Impairment losses are incurred only if there is objective evidence of impairment as a result of loss events that have an impact on estimated future cash flows and that can be reliably estimated. Losses expected as a result of future events are not recognized. The Group  recognized an impairment loss of $21.5&#160;million related to its investment in the joint venture for the year ended 31&#160;December 2023. No impairment losses were recognized in 2022 or 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock', window );">Critical accounting judgments and key sources of estimation uncertainty</a></td>
<td class="text">Critical accounting judgments and key sources of estimation uncertainty <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the consolidated financial statements in conformity with IFRS requires Group management to make judgments, estimates and assumptions about the reported amounts of assets, liabilities, income and expenses that are not readily apparent from other sources. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and other factors that are considered to be relevant. Judgments and assumptions involving key estimates are primarily made in relation to the measurement and recognition of revenue, the impairment of the investment in the joint venture, the valuation of derivative financial liabilities, the valuation of restricted share units (&#8220;RSUs&#8221;), and the valuation of deferred tax assets. Apart from those involving estimations, critical accounting judgments include the Group&#8217;s evaluation as to whether it controls its joint venture in China  and material uncertainties with respect to the Group&#8217;s going concern assessment. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Existing circumstances and assumptions may change due to events arising that are beyond the Group&#8217;s control. Therefore, actual results may differ from these estimates. </span></div>The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text">Segment reporting The Group operates and manages its business as one operating segment based on the manner in which the Chief Executive Officer, the Group&#8217;s chief operating decision maker, assesses performance and allocates resources across the Group.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Product revenue</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue from the sale of its biosimilar product to commercial partners, identified as the customer, when control is transferred, and the performance obligations have been satisfied. This is when the title passes to the customer, which is upon shipment of the product. At that point, the commercial partner has full discretion over the channel and price to sell the products. Revenue is recognized based on the net selling price from the commercial partners, which is considered to be the transaction price and includes estimated rebates, returns and chargebacks, and other forms of variable consideration recognized by the customer. Variable consideration is accounted for by the Company only to the extent that it is highly probable that a significant reversal in the revenue recognized will not occur. Variable consideration, which includes any adjustments to the net selling price, is estimated based on the most likely amount method on a contract-by-contract basis. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Out-licensing revenue</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant part of the Group&#8217;s revenue is generated from long-term out-license contracts which provide the customer with an exclusive right to market and sell products in a particular territory once such products are approved for commercialization. These contracts typically include the Group&#8217;s promises to continue development of the underlying compound and to provide supply of the product to the customer upon commercialization. The Group concludes that the license, development services and commercial supply are separate performance obligations. This is because customers generally have the capabilities to perform the necessary development, manufacturing and commercialization activities on their own or with readily available resources and have the requisite expertise in the industry and the territory for which the license has been granted. Further, the intellectual property is generally in a later phase of development at the time the license is granted such that any subsequent development activities performed by the Group are not expected to significantly modify or transform the intellectual property. The fact that the Group is contractually obligated to perform development activities for and provide commercial supply to the </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">customer does not impact this conclusion. The Group&#8217;s promise to provide commercial supply to its customers is contingent upon the achievement of regulatory approval in the particular territory for which the license has been granted. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consideration to which the Group is entitled pursuant to these contracts generally includes upfront payments and payments based upon the achievement of development and regulatory milestones. All contracts include a potential refund obligation whereby the Group must refund the consideration paid by the customer in the event of a technical failure or the occurrence of certain other matters that result in partial or full cancellation of the contract. As such, the entire transaction price is comprised of variable consideration, which is estimated using the most likely amount method due to the binary nature of the outcomes under these contracts. Such variable consideration is included in the transaction price only when it is highly probable that doing so will not result in a significant reversal of cumulative revenue recognized when the underlying uncertainty associated with the variable consideration is subsequently resolved. The Group does not account for a significant financing component since a substantial amount of consideration promised by the customer is variable and the amount or timing of that consideration varies on the basis of a future event that is not substantially within the control of either party. Certain contracts also include commercialization milestones upon the first commercial sale of a product in a particular territory, as well as royalties. Commercialization milestones and royalties are accounted for as sales-based royalties; therefore, such amounts are not included in the transaction price and recognized as revenue until the underlying sale that triggers the milestone or royalty occurs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upfront payments, when applicable, are received in advance of transferring control of all goods and services. Therefore, a portion of upfront payments is recorded as a contract liability upon receipt. Due to the existence of refund provisions, upfront payments and certain development milestone payments are generally included in the transaction price upon submission of the first clinical trial application to the respective regulatory agency, since it is at this point in time that a significant reversal of cumulative revenue recognized related to such payments is no longer highly probable. Other development and regulatory milestones may not be included in the transaction price until such milestones are achieved due to the degree of uncertainty associated with achieving these milestones. Contract liabilities are presented on the consolidated statements of financial position as either current or non-current based upon forecasted performance. In certain contracts, the Group may transfer control of goods and services, and thus recognize revenue, prior to having the right to invoice the customer. In these circumstances, the Group recognizes contract assets for revenue recognized, and subsequently reclasses the contract asset to trade receivables upon issuing an invoice and the right to consideration is only conditional on the passage of time. Contract assets are presented on the consolidated statements of financial position as either current or non-current based upon the expected timing of settlement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standalone selling prices of the development services and the license to intellectual property are not directly observable and, therefore, are estimated. The standalone selling price of the development services is estimated based on the expected costs to be incurred during the development period, using various data points such as the underlying development budget, contractual milestones and performance completed at the time of entering into the contract with a customer. The standalone selling price of the license is estimated using the residual approach on the basis that the Group licenses intellectual property for a broad range of amounts and has not previously licensed intellectual property on a standalone basis. Therefore, the Group first allocates the transaction price to the development services and subsequently allocates the remainder of the transaction price to the license. If the product is still in early phase of development and the constraint on variable consideration has not been resolved, all the transaction price is allocated to the development service. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standalone selling price of the commercial supply is directly observable and the stated prices in the Group&#8217;s supply contracts reflect the standalone selling price of such goods. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The licenses to intellectual property are right of use licenses on the basis that the ongoing development work performed by the Group does not significantly affect the intellectual property to which the customer has rights. Therefore, control of the license transfers to the customer at the point in time when the right to use the license is granted to the customer. The license is generally granted to the customer at the time the contract is executed with the customer. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group satisfies its performance obligation related to the development services over time as the Group&#8217;s performance enhances the value of the licensed intellectual property controlled by the customer throughout the performance period. The Group recognizes revenue using a cost-based input measure since this measure best reflects the progress of the development services and, therefore, the pattern of transfer of control of the services to the customer. In certain instances, the Group may subcontract services to other parties for which the Group is ultimately responsible. Costs incurred for such subcontracted services are included in the Group&#8217;s measure of progress for </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">satisfying its performance obligation. Changes in the total estimated costs to be incurred in measuring the Group&#8217;s progress toward satisfying its performance obligation may result in adjustments to cumulative revenue recognized at the time the change in estimate occurs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the achievement of regulatory approval and the commencement of commercial sale of its products, the Group will satisfy its performance obligation related to commercial supply at the point in time when control of the manufactured product is transferred to the customer. Transfer of control for such goods will occur in accordance with the stated shipping terms. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group does not incur incremental costs of obtaining a contract with a customer that would require capitalization. Costs to fulfill performance obligations are not incurred in advance of performance and, as such, are expensed when incurred. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other revenue</span></div>Other revenue primarily consists of clinical trial support services rendered by the Group for its customers, which is recognized as the service is provided. Revenue for such services is presented in the consolidated statements of profit or loss and other comprehensive income or loss net of any discounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock', window );">Cost of product revenue</a></td>
<td class="text">Cost of product revenue Cost of product revenue includes the cost of inventory sold, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as shipping and freight costs and royalty costs related to in-license agreements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenses</a></td>
<td class="text">Research and development expenses <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses primarily consist of personnel costs, material and other lab supply costs, facility costs and internal and external costs related to the execution of studies and other development program advancement initiatives. Such expenses also include costs incurred in preparation for commercial launch, such as designing and developing commercial-scale manufacturing capabilities and processes, quality control processes, production asset validation and other related activities. The costs also include amortization, depreciation and impairment losses related to software, property, plant and equipment, and right-of-use assets used in research and development activities and pre-commercial manufacturing and quality control activities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An internally generated intangible asset arising from the Group&#8217;s development is recognized only if the Group can demonstrate: the technical feasibility of completing the intangible asset so that it will be available for use or sale; the intent to complete the intangible asset and use or sell it; how the intangible asset will generate probable future economic benefits; the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and the ability to measure reliably the expenditure attributable to the intangible asset during its development. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount initially recognized for internally-generated intangible assets is the sum of the expenditures incurred from the date when the intangible asset first meets the aforementioned recognition criteria. If an internally-generated intangible asset cannot be recognized, the related development expenditure is charged to profit or loss in the period in which it is incurred. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenditures related to research and development activities are generally recognized as an expense in the period in which they are incurred. The Company did not capitalize any development expenses as intangible assets during the years ended 31&#160;December 2023, 2022, and 2021 as not all the criteria in paragraph 57 of IAS 38 have been met.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">General and administrative expenses</a></td>
<td class="text">General and administrative expenses <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administration expenses primarily consist of personnel-related costs, including salaries and other related compensation expense, for corporate and other administrative and operational functions including finance, human resources, information technology and legal, as well as facility-related costs. These costs relate to the operation of the business and are not related to research and development initiatives. </span></div>Expenditures related to general and administration activities are recognized as an expense in the period in which they are incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance income and finance cost</a></td>
<td class="text">Finance income and finance cost <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income consists of changes in the fair value of derivative financial liabilities and interest income. Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset&#8217;s net carrying amount on initial recognition. </span></div>Finance cost consists of changes in the fair value of derivative financial liabilities, interest expense related to lease liabilities and borrowings, accretion of borrowings and amortization of deferred debt issue costs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text">Foreign currency translation <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements are presented in U.S. Dollars, which is the Group&#8217;s presentation currency. The Group maintains the financial statements of each entity within the Group in its respective functional currency. The majority of the Group&#8217;s expenses are incurred in U.S. Dollars and Icelandic Krona, and the majority of the Company&#8217;s cash and cash equivalents are held in a combination of Icelandic Krona, Euros and U.S. Dollars. Transactions in currencies other than the Group&#8217;s presentation currency (foreign currencies) are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non- monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognized in profit or loss in the period in which they arise. </span></div>Exchange differences arising on translation of a foreign controlled subsidiary are recognized in other comprehensive income or loss and accumulated in a translation reserve within equity. The cumulative translation amount is reclassified to profit or loss if and when the net investment in the foreign controlled subsidiary is disposed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group measures certain financial liabilities at fair value through profit or loss (FVTPL) at each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure the fair values of such financial liabilities, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques, as follows: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 1: quoted prices in active markets for identical assets and liabilities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (e.g., prices) or indirectly (e.g., derived from prices); and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 3: inputs for the asset or liability that are unobservable. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amounts of cash and cash equivalents, restricted cash, trade receivables, other current assets, contract assets, trade and other payables and other current liabilities in the Group&#8217;s consolidated statements of financial position approximate their fair value because of the short maturities and nature of these instruments. </span></div>For liabilities that are measured at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by reassessing the inputs used in determining fair value at the end of each reporting period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Goodwill and other intangible assets</a></td>
<td class="text">Goodwill and other intangible assets <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Goodwill and business combinations</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisitions are first reviewed to determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not meet the definition of a business, the Group will account for the transaction as an asset acquisition. If the definition of a business combination is met, the Group will account for the transaction using the acquisition method of accounting. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange fo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">r control of the acquiree. Acquisition-related costs are recognized in the consolidated statements of profit or loss and other comprehensive income or loss as incurred.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of the purchase price of the business combination over the Group&#8217;s interest in the net fair value of the identifiable assets, liabilities, contingent liabilities, the amount of any noncontrolling interests in the acquiree and the fair value of the acquirer&#8217;s previously held equity interest in the acquiree. Goodwill is reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the initial accounting for a business combination is incomplete by the end of the reporting period in which the business combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period, or as additional assets or liabilities are recognized, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group did not complete any business combinations during the years ended 31&#160;December 2023. Refer to Note 1.1 for the Business Combination completed during the year ended 31&#160;December 2022.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other intangible assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other intangible assets consist of software, customer relationships, and intellectual property rights. Intangible assets acquired in a business combination are identified and recognized separately from goodwill if they satisfy the definition of an intangible asset and their fair values can be reliably measured. The cost of intangible assets is their fair value at the acquisition date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with finite useful lives are reported at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over an asset&#8217;s estimated useful life. The estimated useful life and amortization method are reviewed at each balance sheet date, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The following useful lives are used in the calculation of amortization: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"></td><td style="width:78.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intellectual property rights*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10 years</span></td></tr></table></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">From launch date</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with indefinite useful lives are reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text">Income tax <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax includes the current tax and deferred tax charge recorded in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Current tax</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current tax expense is based on taxable profit for the year. Taxable profit differs from &#8216;profit before tax&#8217; as reported in the consolidated statements of profit or loss and other comprehensive income or loss because it excludes items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group&#8217;s current tax expense is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accruals for tax contingencies are made when it is not probable that a tax authority will accept the tax position, based upon management&#8217;s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Accruals for tax contingencies are measured using either the most likely amount or the expected value amount depending on which method the entity expects to better predict the resolution of the uncertainty. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Deferred tax</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax is provided in full for all temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit, except to the extent the temporary difference arises from: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The initial recognition of an asset or a liability in a transaction that is not a business combination and that affects neither the taxable profit nor accounting profit; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The initial recognition of residual goodwill (for deferred tax liabilities only); or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Investments in subsidiaries, branches, associates and joint ventures, where the Group is able to control the timing of the reversal of the temporary difference and it is not probable that it will reverse in the foreseeable future. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and deferred tax assets reflects the tax consequences that would follow from the manner in which the Group expects, at the balance sheet date, to recover or settle the carrying amount of the assets and liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax is charged or credited to the consolidated statements of profit or loss and other comprehensive income or loss, except when the tax arises from a business combination or it relates to items charged or credited directly to equity, in which case the deferred tax is also taken directly to equity. </span></div>Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis in that taxation authority.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment is recognized as an asset when it is probable that future economic benefits associated with the asset will flow to the Group and the cost of the asset can be measured in a reliable manner. Property, plant and equipment which qualifies for recognition as an asset are initially measured at cost. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cost of property, plant and equipment includes an asset&#8217;s purchase price and any directly attributable costs of bringing the asset to working condition for its intended use. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation is calculated and recognized as an expense on a straight-line basis over an asset&#8217;s estimated useful life. The estimated useful lives, residual values and depreciation method are reviewed at each balance sheet date, with the effect of any changes in estimate accounted for on a prospective basis. The following useful lives are used in the calculation of depreciation: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"></td><td style="width:78.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5-20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3-15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5 years</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of the Group&#8217;s property, plant and equipment assets have been pledged to secure borrowings as further described in Note 21. Significant disposals of pledged assets are subject to lender approval. Upon disposal or retirement of an asset, the difference between the sales proceeds, if applicable, and the carrying amount of the asset is recognized in the consolidated statements of profit or loss and other comprehensive income or loss at the time of disposal or retirement. </span></div>At the end of each reporting period, or sooner if events triggering an interim impairment assessment occur, the Group reviews the carrying amounts of its property, plant and equipment to determine whether there is any indication that the value of such assets are impaired. Triggering events that warrant an interim impairment assessment include, but are not limited to, the technical obsolescence of equipment or failure of such equipment to meet regulatory requirements. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss and the carrying amount of the asset is reduced to its recoverable amount, which is the higher of fair value less costs of disposal and value in use.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text">Inventories <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories, which consist of raw materials and supplies, work in progress and finished goods are stated at the lower of cost or net realizable value. Net realizable value is the expected sales price less completion costs and costs to be incurred in marketing, selling and distributing the inventory. Cost is calculated using the weighted average cost method or the first-in,first-out method, depending on the nature of the inventory. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories include direct costs for raw materials and supplies and, as applicable, direct and indirect labor and overhead expenses that have been incurred to bring inventories to their present location and condition.  </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the net realizable value is lower than the carrying amount, a write-down of inventory is recognized for the amount by which the carrying amount exceeds net realizable value.</span></div>The Group does not pledge inventories as collateral to secure its liabilities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text">Financial assets <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Recognition of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets are recognized when the Group becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets, other than financial assets measured at FVTPL, are added to or deducted from the fair value of the financial assets, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets at FVTPL are recognized immediately in profit or loss. There were no transaction costs related to the acquisition of financials assets in 2023, 2022, or 2021. All of the Group&#8217;s financial assets are measured at amortized cost as of 31&#160;December 2023 and 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial assets measured at amortized cost</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets measured at amortized cost are debt instruments that give rise to contractual cash flows that are solely payments of principal and interest on the principal amount outstanding. The Group&#8217;s financial assets measured at amortized cost are trade receivables, certain other current assets, receivables from related parties, restricted cash and cash and cash equivalents. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income is recognized by applying the effective interest rate, except for short-term receivables when the effect of discounting is immaterial. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Impairment of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognizes a loss allowance for expected credit losses ("ECL") on its trade receivables and other debt instruments that are measured at amortized cost. In addition, although contract assets are not financial assets, a loss allowance for ECL are also recognized for such assets. ECL is based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group always recognizes lifetime ECL for trade receivables and contract assets. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group&#8217;s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecasted direction of conditions at the reporting date, including time value of money where appropriate. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group writes off a financial asset when there is no reasonable expectation of recovery, such as information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. A trade receivable or contract asset that is considered uncollectible is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognized in profit or loss. The Group did not write off any trade receivables or contract assets during the years ended 31&#160;December 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group estimates impairment for related party receivables on an individual basis. No impairment is recognized for restricted cash or cash and cash equivalents as management has estimated that the effects of any calculated ECL would be immaterial. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derecognition of financial assets</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Group neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Group recognizes its retained interest in the asset as well as an associated liability. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received. </span></div>On derecognition of a financial asset, the difference between the asset&#8217;s carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognized in other comprehensive income or loss and accumulated in equity is recognized in profit or loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text">Financial liabilities <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s financial liabilities consist of trade and other payables, certain other current liabilities loans and borrowings, lease liabilities, derivative financial instruments, long-term incentive plans, share appreciation right plans and other long-term liability to a related party. All financial liabilities are initially measured at fair value. Loans and borrowings are recorded net of directly attributable transaction costs and less the value attributable to any embedded derivative financial instruments, if applicable. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group derecognizes financial liabilities when, and only when, the Group&#8217;s obligations are discharged, cancelled, substantially modified or have expired. Additionally, management elected, as part of its accounting policy, to recognize the difference between the carrying amount of the financial liabilities and the fair value of the consideration paid for the extinguishment in the consolidated statement of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities subsequently measured at amortized cost</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After initial recognition, financial liabilities other than derivative financial instruments and awards issued pursuant to long-term incentive plans are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that discounts all estimated future cash payments through the expected life of the financial liability, or a shorter period if appropriate, to the amortized cost of a financial liability. The effective interest rate includes the effects of any discount or premium on acquisition of the financial liability, as well as any fees or costs incurred upon acquisition. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial liabilities subsequently measured at FVTPL</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivative financial instruments </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain rights and features pursuant to borrowing arrangements and other contracts may provide the counterparty with one or more financial instruments that need to be evaluated and potentially accounted for separately by the Group. These financial instruments are either embedded in a host instrument or are treated as a separate financial instrument if they are contractually transferable independent from the host instrument. Such rights and features pursuant to the Group&#8217;s contracts with both third parties and related parties include earn out rights, conversion rights and warrant rights. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity conversion features within host debt instruments that meet the definition of a derivative and have economic and risk characteristics that are not closely related to the host instrument are embedded derivatives that are separated from the host instrument and accounted for separately. As part of the accounting for embedded derivatives or separate financial instruments, management considers the appropriate accounting classification under IAS 32. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Embedded derivatives and separate financial instruments that meet the fixed-for-fixed criteria are classified as equity and initially measured at fair value. Warrant rights that provide the holder with an option to purchase ordinary shares at a specified price or pursuant to a specified formula are generally separate derivative financial instruments that are accounted for as derivative liabilities. Earn Out Shares grant the holder with a variable number of Ordinary Shares based on certain vesting conditions tied to the stock price and are accounted for as derivative liabilities. In the event that the fair value of any derivative liabilities, determined using unobservable inputs, exceeds the transaction price of a borrowing arrangement, the Group records a deferred loss at the inception of the borrowing arrangement for the difference between the fair value of the derivative liabilities and the transaction price of the borrowing arrangement. Such deferred losses are recognized over the term of the related borrowing arrangement using the straight-line method of amortization. The deferred loss is netted against derivative financial liabilities on the consolidated statements of financial position. Amortization of the deferred loss is recognized as a component of &#8220;Finance costs&#8221; in the consolidated statements of profit or loss and other comprehensive income or loss. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recognized derivative liabilities related to the Predecessor Earn Out Shares, OACB Earn Out Shares and assumed OACB warrants. Additionally, the Group recognized an embedded derivative for the conversion feature associated with the Tranche A Convertible Bonds, as further described in Note 21. These features are liability-classified, rather than equity-classified, because the Group is obligated to issue a variable number of ordinary shares to the holder upon conversion or exercise of the feature. Therefore, these derivative liabilities were initially recorded at fair value and remeasured to fair value at each reporting period with gains and losses arising from changes in the fair value recognized in finance income or finance costs, as appropriate. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of the derivative liabilities were determined using a valuation approach that incorporated a range of inputs that are both observable and unobservable in nature. The inputs used in the initial and subsequent fair value measurements predominantly relate to (i) the price of the Group&#8217;s Ordinary Shares (ii) the volatility of the Group&#8217;s Ordinary Shares, (ii) a risky discount rate corresponding to the credit risk associated with the repayment of the host debt instruments, and (iii) the probabilities of each derivative being exercised by the holder and the timing of such exercises. The probabilities are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group will derecognize any derivative liabilities if and when the rights are exercised by the holders or the time period during which the rights can be exercised expires. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Liabilities to related parties </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Group&#8217;s liabilities to related parties arose from its acquisition of rights for the commercialization of the Group&#8217;s biosimilar Adalimumab product in certain territories in Asia from Lotus Pharmaceutical Co. Ltd., a </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related party, during the year ended 31&#160;December 2021. Pursuant to the terms of the asset acquisition, the Group made an upfront payment of $1.9 million and is required to pay $7.4 million upon the commercial launch of Adalimumab in China which became due on 31 December 2023. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Long-term incentive plans </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Share appreciation rights</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group issued to certain current and former employees share appreciation rights ("SARs") that require settlement in connection with the occurrence of specified, future triggering events. Grants occurred from 2015 through 2020. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. The individuals retain their vested awards upon termination of employment with the Group. Settlement amounts are determined by the change in the Group&#8217;s market value from the grant date of the SAR until the triggering events occur. The SARs do not expire at a specific date. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the terms of the SAR agreements, management determined that the Group cannot avoid paying cash to settle the awards and, therefore, SARs are liability-classified in the consolidated statements of financial position. Accordingly, SARs were recorded at fair value and were subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. The fair value of the SARs was determined using the Black-Scholes-Merton pricing model. In connection with the closing of the Business Combination, the Company reached a settlement agreement for share appreciation rights previously awarded to certain current and former employees. The remaining share appreciation rights were settled through the issuance of fully vested RSUs under the Management Incentive Plan on 1 December 2022. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Employee incentive plan</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group also sponsors an employee incentive plan for certain qualifying employees. Under the plans, such employees are entitled to cash payments upon achievement of key milestones, such as a research and development milestone or the occurrence of an exit event. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. Since the Group cannot avoid paying cash to settle the awards, the employee incentive plan is liability-classified in the consolidated statements of financial position. Accordingly, awards issued pursuant to the employee incentive plan are recorded at fair value and are subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. Employee incentive plan liabilities are presented as either current or non-current on the consolidated statements of financial position based on the anticipated timing of settlement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the employee incentive plan awards is determined by estimating the probability of success in reaching the specified milestones and other levers, such as the anticipated timing of potential milestone achievement. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Management Incentive Plan</span></div>The Group can issue share options, restricted share units (&#8220;RSUs&#8221;), and other share-based awards under the Company&#8217;s new incentive plan (the &#8220;Management Incentive Plan&#8221;) which was approved by the Board in June 2022. Awards issued under the Management Incentive Plan are accounted for in accordance with IFRS 2. Share-based payments are classified as equity-settled share-based payments as the Company intends to settle the awards with equity and has the commercial substance to do so. Share-based payments are measured at the grant date fair value of the instruments issued and recognized over the expected vesting periods. The number of shares expected to vest are reviewed and adjusted at the end of each reporting period such that the amount of expense recognized shall be based on the number of equity instruments that will eventually vest.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock', window );">Litigation and other contingencies</a></td>
<td class="text">Litigation and other contingencies <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group may, from time to time, become involved in legal proceedings arising out of the normal course of its operations. For instance, as a developer and manufacturer of biosimilars, the Group may be subject to lawsuits alleging patent infringement or other similar claims filed by the reference product sponsor. Similarly, the Group may utilize patent challenge procedures to challenge the validity, enforceability or infringement of the reference product </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sponsor&#8217;s patents. Other parties may also file patent infringement claims against the Group alleging that the Group&#8217;s products or manufacturing process techniques infringe their patents. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group establishes reserves for specific legal matters when it determines that the likelihood of an unfavorable outcome is probable and the loss is reasonably estimable. When such conditions are not met for a specific legal matter, no reserve is established. Although management currently believes that resolving claims against the Group, including claims where an unfavorable outcome is reasonably possible, will not have a material impact on the liquidity, results of operations, or financial condition of the Group, these matters are subject to inherent uncertainties and management&#8217;s view of these matters may change in the future. It is possible that an unfavorable outcome of a lawsuit or other contingency could have a material impact on the liquidity, results of operations, or financial condition of the Group. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount of loss can be reasonably estimated. Accruals are based only on information available at the time of the assessment, due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Group&#8217;s results of operations in a given period. </span></div>The Group maintains liability insurance coverages for various claims and exposures. The Group&#8217;s insurance coverage limits its maximum exposure on claims; however, the Group is responsible for any uninsured portion of losses. Management believes that present insurance coverage is sufficient to cover potential exposures.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for those with a lease term of twelve months or less and leases of low value assets. For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The Group&#8217;s leased assets consist of various real estate, fleet and equipment leases. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets reflect the initial measurement of the lease liability, lease payments made at or before the lease commencement date and any initial direct costs less lease incentives that may have been received by the Group. These assets are subsequently measured at cost less accumulated depreciation, impairment losses and remeasurements of the underlying lease liability. Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the underlying asset. If a lease transfers ownership of the underlying asset to the Group or the lease includes a purchase option that the Group is reasonably certain to exercise, the related right-of-use asset is depreciated over the useful life of the underlying asset. Depreciation starts at the commencement date of the lease. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate, which is the rate of interest that the Group would need to pay to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term in a similar economic environment based on information available at the commencement date of the lease. The lease payments included in the measurement of the lease liability comprise fixed payments (including in-substance fixed payments) less any incentives, variable lease payments that depend on an index or rate, expected residual guarantees and the exercise price of purchase options reasonably certain to be exercised by the Group. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability, using the effective interest method, and by reducing the carrying amount to reflect payments made during the lease term. The Group remeasures the lease liability if the lease term has changed, when lease payments based on an index or rate change or when a lease contract is modified and the modification is not accounted for as a separate lease. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable payments that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs. </span></div>As a practical expedient, lessees are not required to separate non-lease components from lease components, and instead account for any lease and associated non-lease components as a single lease component. The Group has used this practical expedient.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text">Loss per share <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of the Predecessor Earn Out Shares and OACB Earn Out Shares have equal dividend and participation rights to the ordinary shareholders. However, these participating securities are classified as liabilities and as such, the shares held are not included in the weighted average number of ordinary shares outstanding in the basic loss per share calculation. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The calculation of basic loss per share is based on the loss for the year attributable to ordinary shareholders of the Group and the weighted average number of ordinary shares outstanding during the period. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted loss per share is computed by dividing the loss for the year attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding in the basic loss per share calculation, both of which are adjusted for the effects of all dilutive potential ordinary shares. Antidilutive effects of potential ordinary shares, which result in an increase in earnings per share or a reduction in loss per share, are not recognized in the computation of diluted loss per share.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">New accounting standards</a></td>
<td class="text">New accounting standards <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">New standards and interpretations adopted and effective during the periods</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following new IFRS standards have been adopted by the Group effective 1 January 2023: </span></div><div style="margin-top:5.1pt;padding-left:27.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IFRS 17 - Insurance Contracts</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2017, the IASB issued IFRS 17, Insurance Contracts, which replaces IFRS 4, Insurance Contracts. This standard sets out principles for the recognition, measurement, presentation and disclosure of insurance contracts that are within the scope of IFRS 17. In June 2020, the IASB issued Amendments to IFRS 17, which addresses concerns and implementation challenges that were identified after IFRS 17, Insurance Contracts, was published in 2017. The amendments are effective for annual periods beginning on or after 1 January 2023. IFRS 17 requires fundamental accounting changes to how insurance contracts are measured and accounted for. It introduces the general measurement model, based on a risk-adjusted present value of future cash flows that will arise as the insurance contract is fulfilled. This new measurement model aims to provide relevant information of the future cash flows. The general measurement model is modified for the measurement of reinsurance contracts held, direct participating contracts, and investment contracts with discretionary participation features. Also, while the general measurement model applies to all groups of insurance contracts in scope of IFRS 17, a simplified approach (a premium allocation approach) may be used to measure contracts that meet certain criteria. IFRS 17 also includes new disclosure requirements, providing more clarity and transparency for users of financial statements. The adoption of the standard did not have a material impact on the consolidated financial statements of the Group.</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:27.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 1 (Amendment) - Disclosure of Accounting Policies</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued Disclosure of Accounting Policies (Amendments to IAS 1) and IFRS Practice Statement 2 Making Materiality Judgements. The amendments replace the requirement for entities to disclose their significant accounting policies with the requirement to disclose their material accounting policy information. The amendments also include guidance to help entities apply the definition of material in making decisions about accounting policy disclosures.  The adoption of these amendments did not have a material impact on the consolidated financial statements of the Group.</span></div><div><span><br/></span></div><div style="padding-left:27.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 8 (Amendments) - Definition of Accounting Estimates</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments on IAS 8 to help entities to distinguish between accounting policies and accounting estimates. The amendments clarify how companies distinguish changes in accounting policies from changes in accounting estimates, with a primary focus on the definition of and clarifications on accounting estimates. The distinction between the two is important because changes in accounting policies are applied retrospectively, while changes in accounting estimates are applied prospectively. The amendments further clarify that accounting estimates are monetary amounts in the financial statements and are subject to measurement uncertainty. The amendments also clarify the relationship between accounting policies and accounting estimates by specifying that a company develops accounting estimates to achieve the objective set out by an accounting policy. The amendments are reflected in all financial statements and disclosures of the Group. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.</span></div><div style="margin-top:7.95pt;padding-left:27.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IAS 12 (Amendments) - Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments on IAS 12, which clarifies how companies shall account for deferred tax on transactions such as leases and decommissioning obligations, with a focus on reducing diversity in practice. The amendments narrow the scope of the initial recognition exemption in paragraphs 15 and 24 of IAS 12 so that it does not apply to transactions that give rise to equal and offsetting temporary differences. As a result, companies will need to recognize deferred tax assets and a deferred tax liability for temporary differences arising on initial recognition of a lease and a decommissioning provision. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.</span></div><div style="margin-top:6pt;padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 12 (Amendments) - International Tax Reform&#8212;Pillar Two Model Rules</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, the OECD released technical guidance on its 15% global minimum tax agreed as the second &#8216;pillar&#8217; of a project to address the tax challenges arising from digitalisation of the economy. This guidance elaborates on the application and operation of the Global Anti-Base Erosion (GloBE) Rules agreed and released in December 2021 which lay out a co-ordinated system to ensure that multinational enterprises with revenues above &#8364;750 million pay tax of at least 15% on the income arising in each of the jurisdictions in which they operate. In May 2023, the IASB issued amendments to IAS12 Income Taxes to introduce a temporary exception to the requirements to recognise and disclose information about deferred tax assets and liabilities related to Pillar Two income taxes. As the Company does not meet the revenue thresholds, this guidance had no impact on the Group's consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">New and revised IFRS standards in issue but not yet effective</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following new standards are not yet adopted by or effective for the Group and have not been applied in preparing these consolidated financial statements. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 1 (Amendments) &#8211; Classification of Liabilities as Current or Non-Current </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IASB issued amendments to IAS 1, which affect the presentation of liabilities as current or non-current in the statement of financial position. The amendment does not impact the amount or timing of recognition of any asset, liability, income or expenses, or the information disclosed about those items. The amendments clarify that the classification of liabilities as current or non-current is based on rights that are in existence at the end of the reporting period, specify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, explain that rights are in existence if covenants are complied with at the end of the reporting period, and introduce a definition of &#8216;settlement&#8217; to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. The Group currently evaluates the impact of these amendments on the consolidated financial statements. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IAS 1 (Amendments) &#8211; Non-current Liabilities with Covenants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These amendments clarify how conditions with which an entity must comply within twelve months after the reporting period affect the classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these conditions. The amendments also respond to stakeholders&#8217; concerns about the classification of such a liability as current or non-current. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group currently evaluates the impact of these amendments on the consolidated financial statements.</span></div><div style="margin-top:1pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IFRS 16 (Amendment) - Lease Liability in a Sale and Leaseback</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This amendment adds subsequent measurement requirements for sale and leaseback transactions. This amendment includes requirements for sale and leaseback transactions in IFRS 16 to explain how an entity accounts for a sale and leaseback after the date of the transaction. Sale and leaseback transactions where some or all the lease payments are variable lease payments that do not depend on an index or rate are most likely to be impacted. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group anticipates that the application of this amendment will not have a material impact on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for cost of product revenue explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for critical accounting judgments and key sources of estimation uncertainty explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for litigation and other contingencies explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investments in joint ventures. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417223408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsAbstract', window );"><strong>General information about financial statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock', window );">Schedule of fair value of shares issued and non-cash share listing expense</a></td>
<td class="text">The fair value of shares issued was estimated based on a market price of $9.38 per share as of 15&#160;June 2022. <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(in 000s) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class A Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">976,505</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class B Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,250,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Alvotech Shares issued to OACB shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,226,505</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of Shares issued to OACB as of 15 June 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$56,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of OACB Earn Out Shares issued to OACB as of 15 June 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Estimated fair market value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,160&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjusted net liabilities of OACB as of 15 June 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18,251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Difference &#8211; being the share listing expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,411&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Schedule of subsidiaries and joint ventures</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2 Information about subsidiaries and joint ventures </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:37.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Entity name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Principal </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">activity</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issued and </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">paid capital </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(presented in </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">whole shares)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Place of </span></div><div style="margin-bottom:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">establishment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proportion of ownership </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">and voting power held by </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Alvotech </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31.12.2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31.12.2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech hf</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,893,650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Germany GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,182</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Germany</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Swiss AG</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153,930</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Switzerland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Hannover GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,983</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Germany</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Malta Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,450</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Malta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech USA Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">USA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech UK Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">UK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Manco ehf</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Group Serv.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">215,390</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech Biosciences India Private Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignafelagi&#240; S&#230;mundur hf</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Real estate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,965,337</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Iceland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech &amp; CCHN Biopharmaceutical Co. Ltd*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Biopharm.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,000,021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span>Alvotech &amp; CCHN Biopharmaceutical Co. Ltd. is an unconsolidated joint venture (see Note 27).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_GeneralInformationAboutFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_GeneralInformationAboutFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of fair value of shares issued and non-cash share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B4<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411184960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure Of Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock', window );">Summary of Useful Lives of Amortization</a></td>
<td class="text">The following useful lives are used in the calculation of amortization: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"></td><td style="width:78.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intellectual property rights*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10 years</span></td></tr></table></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">From launch date</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock', window );">Summary of Useful Lives of Depreciation</a></td>
<td class="text">The following useful lives are used in the calculation of depreciation: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"></td><td style="width:78.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5-20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3-15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5 years</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of estimated useful lives of property plant and equipment explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of estimated useful lives other intangible assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412180304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Summary Of Detailed Information About Revenue From Customers Based On Geographical Market</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from customers based on the geographic market in which the revenue is earned, which predominantly aligns with the rights conveyed to the Group&#8217;s customers pursuant to its out-license contracts, is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Europe</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Asia and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">91,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,029&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock', window );">Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current assets, excluding financial instruments and deferred tax assets, based on the location of the asset is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.272%"><tr><td style="width:1.0%"></td><td style="width:63.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Europe</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">415,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">334,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Asia and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">426,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">338,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory', window );">Summary Of Detailed Information About Revenue From Transactions With Individual Customers</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from transactions with individual customers that exceeds ten percent or more of the Group&#8217;s total revenue is as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"><tr><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">% Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about noncurrent assets excluding financial instruments and deferred tax assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of major customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414785328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Summary Of The Groups' Revenue From Contracts With Customers</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Groups&#8217; revenue from contracts with customers, disaggregated by the type of good or service and timing of transfer of control of such goods and services to customers: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue (point in time revenue recognition)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License revenue (point in time revenue recognition)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Development and other service revenue (over time revenue recognition)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">91,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,029&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Summary Of Reconciliation Of Contract Assets And Contract Liabilities</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contract assets and liabilities </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Contract </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Assets </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Contract </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liabilities </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract asset additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts transferred to trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer prepayments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December  2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">93,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract asset additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,634&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts transferred to trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition of contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(42,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,101)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31 December 2023</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,049&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132,444&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue and other operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411581408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Salaries And Other Employee Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract', window );"><strong>Disclosure Of Salaries And Other Employee Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock', window );">Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group</a></td>
<td class="text">The aggregate salary and other employee expenses incurred by the Group for these employees were as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Salary expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">92,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Defined contribution plan expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term incentive plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share-based payments (see Note 23)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other employee expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Temporary labor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">164,909&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>Defined contribution plan expense consists of costs incurred by the Group for employees of certain subsidiaries that are required by local laws to participate in pension schemes. These pension schemes are not sponsored or administered by the Group. Pursuant to the requirements of the schemes, the Group is required to contribute a certain percentage of its payroll costs to the pension schemes. Such contributions are charged to the consolidated statements of profit or loss and other comprehensive income or loss as they are incurred in accordance with the rules of the pension schemes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock', window );">Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salaries and other employee expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total salary and other employee expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">164,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109,520&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about aggregate salary and other employee expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about salaries and other employee expenses included in consolidated statements of profit or loss explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of salaries and other employee expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408518912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income And Finance Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfFinanceIncomeAbstract', window );"><strong>Disclosure Of Finance Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExplanatory', window );">Summary Of Detailed Information About Finance Income</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income earned during the years ended 31&#160;December 2023, 2022 and 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in the fair value of derivatives (see Note 28)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income from cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">556&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,823&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,549&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,568&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceCostExplanatory', window );">Summary Of Detailed Information About Finance Cost</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance costs incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in the fair value of derivatives (see Note 28)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on debt and borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">129,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">106,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consenting fee (see Note 21)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss on remeasurement of bonds (see Note 21)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities (see Note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of deferred debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">267,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">188,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of finance income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance cost. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414090944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Depreciation, Amortization And Impairment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract', window );"><strong>Disclosure Of Depreciation Amortization And Imapirment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock', window );">Summary Of Detailed Information About Depreciation Amortization And Impairment</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation, amortization and impairment expenses incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and impairment of property, plant and equipment (see Note 12)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation of right of use assets (see Note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization and impairment of intangible assets (see Note 15)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock', window );">Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation, amortization and impairment expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total depreciation, amortization and impairment expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of depreciation amortization and imapirment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about depreciation amortization and impairment expense included in consolidated statements profit or loss and other comprehensive income or loss explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about depreciation amortization and impairment explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430483766448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Fees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfAuditFeesAbstract', window );"><strong>Disclosure Of Audit Fees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock', window );">Summary Of Detailed Information About Audit Fees</a></td>
<td class="text"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financial Statement audit fees</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other fees, including tax services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total fees</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfAuditFeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of audit fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfAuditFeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about audit fees explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411109104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure Of Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock', window );">Schedule of taxation recognized in the consolidated statements of profit or loss and other comprehensive income or loss</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxation recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct taxes - current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct taxes &#8211; prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total current tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(89,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(54,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(48,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(100,565)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,967)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(48,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(99,318)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,067)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(47,694)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock', window );">Schedule of the reconciling items between the statutory rate and the effective tax rate</a></td>
<td class="text">The reconciling items between the statutory rate and the effective tax rate are as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effect of tax rate in foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-recognition of tax losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock', window );">Schedule of the movement in net deferred taxes</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The movement in net deferred taxes during the years ended 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">170,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax credited to profit or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">309,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">309,807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(53)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(309)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock', window );">Schedule of deferred tax recognized in the consolidated statements of financial position</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount of deferred tax recognized in the consolidated statements of financial position as of 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets attributable to temporary differences in respect of tax losses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">301,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">205,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets attributable to other temporary differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities attributable to other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">309,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">209,187&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock', window );">Schedule of expiration of unused tax losses</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These tax losses expire as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"><tr><td style="width:1.0%"></td><td style="width:78.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024-2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027-2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">289,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Later</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,155,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,513,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about deferred tax recognized in the consolidated statements of financial position explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about effective tax rate reconciliation explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about expiration of unused tax losses explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about major components of income tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about reconciliation of changes in deferred tax liability asset explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411371184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of Basic and Diluted Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The calculation of basic and diluted loss per share for the years ended 31&#160;December 2023, 2022, and 2021 is as follows (in thousands, except for share and per share amounts):</span></div><div style="margin-top:12pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Earnings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss for the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(551,731)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(513,580)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(101,504)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of ordinary shares outstanding</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">227,256,469&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">197,721,710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,673,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.43)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.60)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.92)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411171824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant And Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Summary of property, plant and equipment</a></td>
<td class="text">Movements within property, plant and equipment during the years ended 31&#160;December 2023 and 2022 are as follows: <div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"><tr><td style="width:1.0%"></td><td style="width:28.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Facility</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;Equipment </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Furniture, <br/>fixtures and <br/>leasehold <br/>improvements </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Computer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">equipment </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">271,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">176,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">304,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,583&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,063&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">729&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">236,779&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"><tr><td style="width:1.0%"></td><td style="width:28.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Facility</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;Equipment </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Furniture, <br/>fixtures and <br/>leasehold <br/>improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Computer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">equipment </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">88,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">271,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,002&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">114,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,365&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">440&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">220,594&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412531168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Schedule of quantitative information about right-of-use assets</a></td>
<td class="text">The carrying amounts of the Group&#8217;s right-of-use assets and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjustments for indexed leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition due to acquisition of Alvotech Facility (see Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(88,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">119,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock', window );">Schedule of detailed information about classes of right of use assets</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s right-of-use assets as of 31&#160;December 2023 and 2022 are comprised of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fleet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">119,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock', window );">Schedule of detailed information about lease liabilities</a></td>
<td class="text">The Group&#8217;s lease liabilities and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"></td><td style="width:64.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adjustments for indexed leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Installment payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derecognition due to acquisition of Alvotech Facility (see Note 12)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(80,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,632&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,369&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock', window );">Schedule of detailed information about lease cost</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amounts recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 in relation to the Group&#8217;s lease arrangements are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Depreciation expense from right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fleet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total depreciation expense from right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,869)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,699)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,840)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,022)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency difference on lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from extinguishment of lease agreement (see Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total amount recognized in profit and loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,713)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,068)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,378)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock', window );">Schedule of detailed information about maturity analysis for lease liabilities</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The maturity analysis of undiscounted lease payments as of 31&#160;December 2023 and 2022 is as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less than one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">89,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">155,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about classes of right of use assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about lease cost explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about lease liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about maturity analysis for lease liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430495016496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclousreOfGoodwillAbstract', window );"><strong>Disclosure of Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory', window );">Summary of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s goodwill balances as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(724)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclousreOfGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclousre of goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclousreOfGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408482128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Summary of Detailed Information About Intangible Assets</a></td>
<td class="text">Movements in intangible assets during the years ended 31&#160;December 2023 and 2022 are as follows: <div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Software </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Customer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">relationships </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Intellectual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">property </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Retirement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Software </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Customer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">relationships </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Intellectual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">property </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,684&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net carrying amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,341&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">311&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory', window );">Summary of Impairment Loss and Reversal of Impairment Loss</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense for amortization of the Group&#8217;s intangible assets is included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">324&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">944&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">733&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">923&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of impairment loss and the reversal of impairment loss. [Refer: Impairment loss; Reversal of impairment loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408482128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash And Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text">Cash and cash equivalents as of 31&#160;December 2023 and 2022 are as follows: <div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents denominated in US dollars</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents denominated in other currencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock', window );">Summary of Restricted Cash</a></td>
<td class="text">Movements in restricted cash balances during the years ended 31&#160;December 2023 and 2022 are as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,187&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about cash and cash equivalents explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about restricted cash and cash equivalents explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411147616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s inventory balances as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inventory reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about inventories explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411372896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock', window );">Summary of Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other current assets as of 31&#160;December 2023 and 2022 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value-added tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,035&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds receivable from Convertible Bonds (see Note 21)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">851&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other short-term receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,871&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,949&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other current assets explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414838160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of Share Capital and Share Premium</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share capital and share premium of the Group&#8217;s Ordinary Shares issued as of 31&#160;December 2023, and 2022 are as follows (in thousands, except for share amounts): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266,821,844</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,231,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252,160,087</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,060,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total share capital and share premium</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266,821,844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,231,969&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252,160,087</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,060,558&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock', window );">Summary of Movements in Ordinary Shares, Share Capital and Share Premium</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s Class A and Class B ordinary shares, share capital and share premium during the years ended 31&#160;December 2023, 2022, and 2021 are as follows (in thousands, except for share amounts): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ordinary </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Predecessor </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Ordinary </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">capital </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Share </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">premium </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,259,139</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">166,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">166,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share issue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,222,660</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">833,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">833,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,481,799</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,000,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,000,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Elimination of Predecessor Ordinary Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13,481,799)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(135)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of Ordinary Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186,576,505</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">PIPE Financing (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,493,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">174,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">174,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Transaction costs arising on share issue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,330,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(227,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(227,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares (Note 1.1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">SARs Settlement (Note 22)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,510,582</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of related party loans with Ordinary Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252,160,087</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,058,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,060,558&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capital contribution</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,834,061</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested earn-out shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Penny warrants (Note 28)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,479,962</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Public warrants (Note 28)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">553,552</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of RSUs with shares (Note 23)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">838,919</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of SARs with shares (Note 22)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,044,737)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266,821,844</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,229,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,231,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about movements in ordinary shares, share capital and share premium explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412317488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfOtherReservesTableTextBlock', window );">Schedule of Other Reserves</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other reserves as of 31&#160;December 2023 and 2022 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity component of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share based payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ScheduleOfOtherReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Reserves</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ScheduleOfOtherReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412552608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Summary of consolidated statements of financial position</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s debt consists of interest-bearing borrowings from financial institutions, related parties and third parties. Outstanding borrowings, net of transaction costs, presented on the consolidated statements of financial position as current and non-current as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">530,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">155,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total outstanding borrowings, net of debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current portion of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total non-current borrowings</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">922,134&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">744,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock', window );">Summary of movements in the group's outstanding borrowings</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s outstanding borrowings during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">400,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of deferred debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accretion/derecognition of borrowings discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Recognition of new borrowings discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(43,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Proceeds from new borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">275,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">467,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loans from related party converted to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Repayments of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(99,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(83,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of deferred debt issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency exchange difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below details the changes in the Group&#8217;s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group&#8217;s consolidated cash flow statement as cash flows from financing activities.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">1 January <br/>2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Financing Cash flows (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Capitalized loan cost changes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair value changes, including accretion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other changes (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign exchange impact</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds and Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(36,071)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">236,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds (including related party)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">530,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,968&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,556&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">170,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(35,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Other changes include interest accruals and effects of payments including $3.5&#160;million in cash received from borrowings from the 2022 Convertible Bonds and transaction cost of $9&#160;million paid in 2023.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.242%"><tr><td style="width:1.0%"></td><td style="width:19.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 January <br/>2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing Cash flows (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized loan cost changes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value changes, including accretion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other changes (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion to Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-cash movements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2022 Convertible Bonds and Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(40,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds (including related party)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">394,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">70,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,069&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34,308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">530,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Facility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings, net </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">400,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">268,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Other changes include interest accruals and payments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock', window );">Schedule of maturities of outstanding borrowings</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of principal amounts on the Group&#8217;s outstanding borrowings as of 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within two years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">867,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">696,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Within four years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,857&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure&#160;of movements in outstanding borrowings explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Maturities of outstanding borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411108496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfLongtermIncentivePlansAbstract', window );"><strong>Disclosure Of Longterm incentive plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Schedule of movements in the group's employee incentive plan liabilities</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Movements in the Group&#8217;s employee incentive plan liabilities during the years ended 31&#160;December 2023 and 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December prior to reclassification</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">659&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassified to other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(659)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">544&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfLongtermIncentivePlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Longterm incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfLongtermIncentivePlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408484000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share Based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Summary of Movements in RSUs</a></td>
<td class="text">Movements in RSUs during the year ended 31&#160;December 2023 are as follows:<div style="margin-top:12pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.030%"><tr><td style="width:1.0%"></td><td style="width:41.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">RSUs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,979,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">New grants during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">820,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$8.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,659,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,587,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$7.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,466,374)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(679,562)</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,745,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$7.04&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,979,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$6.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss', window );">Summary of Share-based payment expense</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group recogniz</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ed $18.0 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.3&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of shar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e-based payment expense during the years ended 31&#160;December 2023 and 2022, respectively, as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"><tr><td style="width:1.0%"></td><td style="width:64.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,991&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,033&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,317&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share based payment arrangements abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430494555504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of related party transactions</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions as of and for the year ended 31&#160;December 2023 are as follows:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"></td><td style="width:39.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Purchased service /</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Sold service</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Receivables</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Payables/ </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">borrowings</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ATP Holdings ehf. - Sister company (a)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Consulting ehf. &#8211; Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki-Art ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen UK - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">581&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Finance B.V. - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus International Pte. Ltd. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">539&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo Limited - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo UK - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki Invest ehf - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Floki Holdings S.&#224; r.l. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Spain SL - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Norwich Clinical Services Ltd - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company (d)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,732&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki fasteignir ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,781&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">597&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">896&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,956&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). In relation to the private placement of Tranche A Convertible Bonds in July, the Company paid underwriters fee to APT Holding amounting to $3.3&#160;million. The underwriter&#8217;s fee is accounted for as a transaction cost that is amortized through profit and loss over the life of the instrument.  </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Payables to Lotus Pharmaceuticals Co. Ltd. consists of the other current liability as further described in Note 2. This other current liability is presented as &#8220;Liabilities to related party&#8221; on the consolidated statements of financial position. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The amount receivable from Alvotech &amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Refer to Note 13 for the details of the new lease. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions as of and for the year ended 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"></td><td style="width:39.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchased service / <br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sold service</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Receivables</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payables/ <br/>borrowings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Consulting ehf. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ATP Holdings ehf. - Sister company (a)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">765&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company (e)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus International Pte. Ltd. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Korea co. Ltd - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Adalvo Limited - Sister company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">603&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Spain SL - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Norwich Clinical Services Ltd - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Pharma Pvt Ltd - Sister Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fl&#243;ki fasteignir ehf. - Sister company</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">L41 ehf.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lambhagavegur 7 ehf. (d)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">818&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">163,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities including discount and accretion (see Note 21). </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#8220;Other long-term liability to related party&#8221; on the consolidated statements of financial position. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The amount receivable from Alvotech &amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Lambahagavegur is no longer a related party as it was sold during the year ended 31&#160;December 2023. </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. was acquired as part of the Share Purchase Agreement, with ATP Holdings ehf., on 16 November 2022. The related party transactions reflect activity until the acquisition date. See Note 12 and Note 21 for further details.  </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions for the year ended 31&#160;December 2021 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"><tr><td style="width:1.0%"></td><td style="width:59.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchased service / <br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sold <br/>service</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company (a) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Pharma Partners S.&#224; r.l. &#8211; Sister company (a) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Aztiq AB &#8211; Sister company (a) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Aztiq Fj&#225;rfestingar ehf. (a) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company  </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,762&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Iceland ehf.  - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen ehf.  - Sister company  </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen UK - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lotus Pharmaceuticals Co. Ltd. - Sister company (b) </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Emerging Markets - Sister company </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Korea co. Ltd - Sister company </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Inc. - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Malta Sh. Services - Sister company </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvogen Pharma Pvt Ltd - Sister Company </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">HRJ&#193;F ehf - Sister company  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">L41 ehf. </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lambhagavegur 7 ehf. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,940&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,715&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt">The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span>Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#8220;Other long-term liability to related party&#8221; on the consolidated statements of financial position.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock', window );">Schedule of information about Board of Directors remuneration</a></td>
<td class="text">The Board of Directors&#8217; remuneration is shown in the table below. <div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"><tr><td style="width:1.0%"></td><td style="width:45.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors&#8217; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Board fees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension <br/>contribution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">year-end**</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman, Chairman of the board*</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies, Vice-Chairman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,143,713</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant, Board Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#193;rni Har&#240;arson, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua, Board Member*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick, Board Member</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver, Board Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,582</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman, Board Member*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">421&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">416&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,175,459</span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Waived their board compensation (both cash and equity)</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Direct share ownership </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Key employees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Salaries and benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Termination benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long- term benefits</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman CEO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Executive Team Members (9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">372&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"><tr><td style="width:1.0%"></td><td style="width:45.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors&#8217; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Board fees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long-term benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Shares at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">year-end**</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Robert Wessman, Chairman of the board</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Davies, Vice-Chairman</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,133,131</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ann Merchant, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#193;rni Har&#240;arson, Board Member (from 16.6.2022)*</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Faysal Kalmoua, Board Member*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda McGoldrick, Board Member (from 16.6.2022)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Graver, Board Member (from 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tomas Ekman, Board Member*</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Hirofumi Imai, Board member (until 16.6.2022)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">927&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,133,131</span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt">Waived their board compensation (both cash and equity)</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Direct share ownership </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Key employees</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Salaries and benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pension contribution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Termination benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other long- term benefits</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mark Levick CEO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Executive Team Members (9)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">820&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">608&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about board of directors and key managerial personnel explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411137184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentLiabilitiesAbstract', window );"><strong>Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock', window );">Schedule of composition of other current liabilities</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The composition of other current liabilities as of 31&#160;December 2023 and 2022 is as follows: </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unpaid salary and salary related expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued vacation leave</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee incentive plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62,720&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other current liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412354080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interests In Joint Ventures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesAbstract', window );"><strong>Disclosure of joint ventures [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock', window );">Schedule of Information About Joint Venture</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"><tr><td style="width:1.0%"></td><td style="width:33.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%;text-decoration:underline">Name of entity</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Place of business</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Ownership interest </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Alvotech &amp; CCHN Biopharmaceutical Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock', window );">Schedule of Changes in Groups Investment in a Joint Venture</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the change in the Group&#8217;s investment in a joint venture during the years ended 31&#160;December 2023 and 2022: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 1 January</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share in losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment loss on investment in joint venture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Translation difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at 31 December</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about changes in investment in joint venture explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about joint venture explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417794208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Summary of Financial Assets Measured at Cost</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets as of 31&#160;December 2023 and 2022, all of which are measured at amortized cost, are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,035&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Receivables from related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other long-term assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,484</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Summary of Financial Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial liabilities as of 31&#160;December 2023 and 2022 are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Borrowings (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">960,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">764,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative financial liabilities (measured at FVTPL)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">380,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other long-term liability to related party (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term incentive plan (measured at FVTPL)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade and other payables (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities (measured at amortized cost)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Liabilities to related parties (measured at amortized cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,748,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,297,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock', window );">Summary of Material Differences Between the Fair Value and Carrying Amount</a></td>
<td class="text">Material differences between the fair values and carrying amounts of these borrowings are identified as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">559,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">155,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">82,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">862,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">944,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">530,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">535,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Convertible Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">693,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">720,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock', window );">Summary of Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables illustrate the fair value measurement hierarchy of the Group&#8217;s financial instruments measured at fair value on a recurring basis as of 31&#160;December 2023 and 2022: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Bond Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">349,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">349,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">356,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bond Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Bond Interest Rate Feature (included in other current assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Predecessor Earn Out Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">276,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">276,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Earn Out Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OACB Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">286,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">381,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Disclosure of Fair Value Measurement of Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of Level 3 financial instruments:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.818%"><tr><td style="width:1.0%"></td><td style="width:49.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Senior Bond Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Tranche A Conversion Feature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Senior Bond Interest Rate Feature</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 January  2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer to Level 1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(45,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">118,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Summary of Assumptions and Inputs</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the Tranche A Conversion Feature: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.787%"><tr><td style="width:1.0%"></td><td style="width:55.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$11.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Conversion price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risky yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the Predecessor Earn Out Shares: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,330,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,330,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$11.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions and inputs that were used for the model in valuing the OACB Earn Out Shares: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 December <br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Number of shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">625,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,250,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$11.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Volatility rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock', window );">Summary of Interest Rate Sensitivity Analysis</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides an interest rate sensitivity analysis for the effect on loss before tax: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-rate financial instruments +100</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(89)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-rate financial instruments -100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock', window );">Summary of Impact on the Groups Operations</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below are the foreign currencies that have the most significant impact on the Group&#8217;s operations. </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"><tr><td style="width:1.0%"></td><td style="width:23.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.455%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Closing rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Average rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock', window );">Summary of Groups Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2023 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>assets </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,735)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">144,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(141,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Group&#8217;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net <br/>assets </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GBP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ISK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CHF</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock', window );">Summary of Analysis Assumes that all Other Variables</a></td>
<td class="text">The analysis assumes that all other variables, such as interest rates, remain constant. <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">EUR </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">GBP </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">ISK </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">CHF </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">INR </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Year ended 31 December 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">-10% weakening</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">+10% strengthening</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Year ended 31 December 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">-10% weakening</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">+10% strengthening</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureExplanatory', window );">Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets</a></td>
<td class="text">The maximum credit risk exposure for the Group&#8217;s financial assets as of 31&#160;December 2023 and 2022 is as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"><tr><td style="width:1.0%"></td><td style="width:64.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,848&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,498&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock', window );">Summary of Contractual Maturities of Financial Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of financial assets and liabilities as of 31&#160;December 2023 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one<br/>year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">One to two<br/>years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,468&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">142,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">142,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,101,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,167,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">121,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">253,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,631,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,951,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of financial assets and liabilities as of 31&#160;December 2022 are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one<br/>year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">One to two<br/>years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">106,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,671&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136,498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-interest bearing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">112,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fixed-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">896,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,008,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">380,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">380,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable-interest bearing - Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">92,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">175,382&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,344,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,593,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of assets and liabilities denominated in foreign currencies explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of carrying amount and financial amount of certain borrowings explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of currency risk sensitivity analysis on profit before tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of fair value of derivative financial instruments explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of foreign exchange rate explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of contractual maturities of financial assets and financial liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCreditRiskExposureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the credit risk exposure. Credit risk exposure is the credit risk inherent in an entity&#8217;s financial assets and commitments to extend credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCreditRiskExposureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413009888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract', window );"><strong>Disclosure In Entirety Of Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplement cash flow information for the years ended 31&#160;December 2023, 2022, and 2021 is included below (see Note 21 for non-cash movements in borrowings).</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"><tr><td style="width:1.0%"></td><td style="width:50.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of property, plant and equipment in trade payables and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,812&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of intangibles in trade payables and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets obtained through new operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Purchase of Facility through Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-cash issuance of Aztiq Convertible Bond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity issued through conversion of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">346,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Acquisition of other intangible assets through financing agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of RSUs with shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Settlement of SARs with shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in entirety of supplemental cash flow information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of supplemental cash flow information [Text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430443510048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 26, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 23, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 23, 2024 </div>
<div>$ / shares </div>
<div>kr / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 20, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ProceedsFromTheCapitalReorganization', window );">Proceeds from the capital reorganization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,827<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ReorganizationShareListingExpense', window );">Reorganization, share listing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FairValueOfSharesIssuedMarketPricePerShare', window );">Fair value of shares issued, market price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,559<span></span>
</td>
<td class="nump">186,742<span></span>
</td>
<td class="nump">84,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,731<span></span>
</td>
<td class="nump">513,580<span></span>
</td>
<td class="nump">101,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,205,845)<span></span>
</td>
<td class="num">(1,654,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,157<span></span>
</td>
<td class="nump">$ 66,427<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">$ 31,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsLiabilities', window );">Current assets less current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 833,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AztiqPharmaPartnersSarlMember', window );">Aztiq Pharma Partners Sarl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.90%<span></span>
</td>
<td class="nump">40.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvogenMember', window );">Alvogen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.70%<span></span>
</td>
<td class="nump">35.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_OtherSubsidiariesMember', window );">Other Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.40%<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder', window );">Maximum percentage of ownership interest held by each shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=alvo_BusinessCombinationAndPipeFinancingMember', window );">Business Combination and PIPE Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ExpenseCapitalized', window );">Expense capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=alvo_OacbWarrantsMember', window );">OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,916,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember', window );">OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares) | shares</a></td>
<td class="nump">10,127,132<span></span>
</td>
<td class="nump">10,127,132<span></span>
</td>
<td class="nump">10,127,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Common stock par or stated value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price (in dollar per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.41<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted in share-based payment arrangement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | OACB Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted in share-based payment arrangement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CommonStockSharesSubscribed', window );">Common stock, shares subscribed (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CommonStockSubscriptionPricePerShare', window );">Common stock, subscription (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CommonStockValueSubscriptions', window );">Common stock, value, subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfSharesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant or right | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | OACB Warrants | Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GeneralInformationAboutFinancialStatementsLineItems', window );"><strong>General Information About Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfSharesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant or right | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CommonStockSharesSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, shares subscribed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CommonStockSharesSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CommonStockSubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, subscription price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CommonStockSubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CommonStockValueSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, value, subscriptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CommonStockValueSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ExpenseCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ExpenseCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_FairValueOfSharesIssuedMarketPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares issued, market price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_FairValueOfSharesIssuedMarketPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_GeneralInformationAboutFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_GeneralInformationAboutFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of ownership interest held by each shareholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfSharesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares called by each warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfSharesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ProceedsFromTheCapitalReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the capital reorganization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ProceedsFromTheCapitalReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ReorganizationShareListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reorganization, share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ReorganizationShareListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets less the amount of current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AztiqPharmaPartnersSarlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AztiqPharmaPartnersSarlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_OtherSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_OtherSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=alvo_BusinessCombinationAndPipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=alvo_BusinessCombinationAndPipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=alvo_OacbWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=alvo_OacbWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_PredecessorEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_PredecessorEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AgreementsTypeAxis=alvo_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AgreementsTypeAxis=alvo_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430473746656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General Information - Schedule of fair value of shares issued and non-cash share listing expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems', window );"><strong>Schedule of fair value of shares issued and noncash share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2', window );">Total Alvotech Shares issued to OACB shareholders (in shares) | shares</a></td>
<td class="nump">7,226,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2', window );">Estimated fair market value</a></td>
<td class="nump">$ 65,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2', window );">Adjusted net liabilities of OACB as of 15 June 2022</a></td>
<td class="num">(18,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ReorganizationShareListingExpense', window );">Difference &#8211; being the share listing expense</a></td>
<td class="nump">$ 83,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems', window );"><strong>Schedule of fair value of shares issued and noncash share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2', window );">Total Alvotech Shares issued to OACB shareholders (in shares) | shares</a></td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2', window );">Estimated fair market value</a></td>
<td class="nump">$ 9,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems', window );"><strong>Schedule of fair value of shares issued and noncash share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2', window );">Estimated fair market value</a></td>
<td class="nump">$ 56,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Class A Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems', window );"><strong>Schedule of fair value of shares issued and noncash share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2', window );">Total Alvotech Shares issued to OACB shareholders (in shares) | shares</a></td>
<td class="nump">976,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Class B Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems', window );"><strong>Schedule of fair value of shares issued and noncash share listing expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2', window );">Total Alvotech Shares issued to OACB shareholders (in shares) | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted net liabilities recognized amount in accordance with IFRS 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares issued recognized accordance with IFRS 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares issued recognized accordance with IFRS 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ReorganizationShareListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reorganization, share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ReorganizationShareListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of fair value of shares issued and non-cash share listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassesOfCommonStockAxis=alvo_ClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassesOfCommonStockAxis=alvo_ClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassesOfCommonStockAxis=alvo_ClassBCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassesOfCommonStockAxis=alvo_ClassBCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413283344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information - Disclosure of Subsidiaries and Joint Ventures (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember', window );">Alvotech &amp; CCHN Biopharmaceutical Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">110,000,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechHfMember', window );">Alvotech hf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">3,893,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechGermanyGmbhMember', window );">Alvotech Germany GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">31,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechSwissAgMember', window );">Alvotech Swiss AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">153,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechHannoverGmbhMember', window );">Alvotech Hannover GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">29,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechMaltaLtdMember', window );">Alvotech Malta Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">80,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechUsaIncMember', window );">Alvotech USA Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechUkLtdMember', window );">Alvotech UK Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechMancoEhfMember', window );">Alvotech Manco ehf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">215,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechBiosciencesIndiaPrivateLtdMember', window );">Alvotech Biosciences India Private Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">96,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_FasteignafelagiSmundurHfMember', window );">Fasteignafelagi&#240; S&#230;mundur hf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued and paid capital (presented in whole shares) (in shares)</a></td>
<td class="nump">12,965,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership and voting power held by Alvotech</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechHfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechHfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechGermanyGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechGermanyGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechSwissAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechSwissAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechHannoverGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechHannoverGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechMaltaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechMaltaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechUsaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechUsaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechUkLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechUkLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechMancoEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechMancoEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechBiosciencesIndiaPrivateLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_AlvotechBiosciencesIndiaPrivateLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_FasteignafelagiSmundurHfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=alvo_FasteignafelagiSmundurHfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430448680672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segement</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss on investment in joint venture</a></td>
<td class="nump">$ 21,519<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfOperatingSegments1', window );">Number of operating segments | segement</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">$ 217,956<span></span>
</td>
<td class="nump">$ 163,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalCo.LtdMember', window );">Lotus pharmaceutical co. ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Segments 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430480827472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Useful Lives of Amortization (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful lives of amortization</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful lives of amortization</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CustomerrelatedIntangibleAssetsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful lives of amortization</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntellectualPropertyRightsMember', window );">Intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful lives of amortization</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CustomerrelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CustomerrelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntellectualPropertyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntellectualPropertyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416107488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Useful Lives of Depreciation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityMember', window );">Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of depreciation</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityEquipmentMember', window );">Facility equipment | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of depreciation</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityEquipmentMember', window );">Facility equipment | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of depreciation</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of depreciation</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of depreciation</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of depreciation</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of depreciation</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430449146064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary Of Detailed Information About Revenue From Customers Based On Geographical Market (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segement</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfOperatingSegments1', window );">Number of operating segments | segement</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">$ 91,434<span></span>
</td>
<td class="nump">$ 83,029<span></span>
</td>
<td class="nump">$ 36,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">63,510<span></span>
</td>
<td class="nump">39,433<span></span>
</td>
<td class="nump">20,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember', window );">North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">18,306<span></span>
</td>
<td class="nump">30,780<span></span>
</td>
<td class="nump">11,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=alvo_AsiaAndOtherMember', window );">Asia and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">$ 9,618<span></span>
</td>
<td class="nump">$ 12,816<span></span>
</td>
<td class="nump">$ 4,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Segments 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=alvo_AsiaAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=alvo_AsiaAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430444385280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets, excluding financial instruments and deferred tax assets</a></td>
<td class="nump">$ 426,947<span></span>
</td>
<td class="nump">$ 338,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets, excluding financial instruments and deferred tax assets</a></td>
<td class="nump">415,659<span></span>
</td>
<td class="nump">334,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember', window );">North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets, excluding financial instruments and deferred tax assets</a></td>
<td class="nump">5,094<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=alvo_AsiaAndOtherMember', window );">Asia and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Non-current assets, excluding financial instruments and deferred tax assets</a></td>
<td class="nump">$ 6,194<span></span>
</td>
<td class="nump">$ 3,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=alvo_AsiaAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=alvo_AsiaAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416600592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary Of Detailed Information About Revenue From Transactions With Individual Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=alvo_CustomerAMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 9,430<span></span>
</td>
<td class="nump">$ 17,940<span></span>
</td>
<td class="nump">$ 10,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
<td class="nump">27.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=alvo_CustomerBMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 46,954<span></span>
</td>
<td class="nump">$ 38,376<span></span>
</td>
<td class="nump">$ 18,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">51.40%<span></span>
</td>
<td class="nump">46.20%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=alvo_CustomerCMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 8,876<span></span>
</td>
<td class="nump">$ 12,840<span></span>
</td>
<td class="nump">$ 1,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=alvo_CustomerDMember', window );">Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 16,556<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">18.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMajorCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMajorCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=alvo_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=alvo_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=alvo_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=alvo_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=alvo_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=alvo_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=alvo_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=alvo_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416119520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary Of The Groups' Revenue From Contracts With Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">$ 91,434<span></span>
</td>
<td class="nump">$ 83,029<span></span>
</td>
<td class="nump">$ 36,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=alvo_ProductRevenueMember', window );">Product revenue (point in time revenue recognition) | Goods or services transferred at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">48,699<span></span>
</td>
<td class="nump">24,836<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=alvo_LicenseRevenueMember', window );">License revenue (point in time revenue recognition) | Goods or services transferred at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">12,177<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=alvo_DevelopmentAndOtherServiceRevenueMember', window );">Development and other service revenue (over time revenue recognition) | Goods or services transferred over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">$ 30,558<span></span>
</td>
<td class="nump">$ 57,769<span></span>
</td>
<td class="nump">$ 35,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=alvo_ProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=alvo_ProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=alvo_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=alvo_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=alvo_DevelopmentAndOtherServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=alvo_DevelopmentAndOtherServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430449038464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary Of Reconciliation Of Contract Assets And Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=alvo_ContractAssetMember', window );">Contract Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractAssetsRollForward', window );"><strong>Contract Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Beginning balance asset</a></td>
<td class="nump">$ 28,656<span></span>
</td>
<td class="nump">$ 19,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets', window );">Contract asset additions</a></td>
<td class="nump">19,634<span></span>
</td>
<td class="nump">29,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables', window );">Amounts transferred to trade receivables</a></td>
<td class="num">(2,412)<span></span>
</td>
<td class="num">(19,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Ending balance asset</a></td>
<td class="nump">46,049<span></span>
</td>
<td class="nump">28,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractLiabilitiesRollForward', window );"><strong>Contract Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment', window );">Foreign currency adjustment</a></td>
<td class="nump">171<span></span>
</td>
<td class="num">(915)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=alvo_ContractLiabilitiesMember', window );">Contract Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractLiabilitiesRollForward', window );"><strong>Contract Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Beginning balance liabilities</a></td>
<td class="nump">93,932<span></span>
</td>
<td class="nump">74,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables', window );">Amounts transferred to trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability', window );">Derecognition of contract liability</a></td>
<td class="num">(42,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractLiabilityCustomerPrepayments', window );">Customer prepayments</a></td>
<td class="nump">100,555<span></span>
</td>
<td class="nump">46,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities', window );">Revenue recognized</a></td>
<td class="num">(23,101)<span></span>
</td>
<td class="num">(26,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment', window );">Foreign currency adjustment</a></td>
<td class="nump">3,147<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Ending balance liabilities</a></td>
<td class="nump">$ 132,444<span></span>
</td>
<td class="nump">$ 93,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract assets additions amounts transferred to trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract assets liabilities foreign currency adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Liabilities Additions Amounts Transferred to Trade Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Liabilities Additions Derecognition of contract liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractLiabilityCustomerPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract liability C\customer prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractLiabilityCustomerPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity&#8217;s future performance).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in contract liabilities resulting from cumulative catch-up adjustments to revenue arising from a change in the measure of progress. [Refer: Increase (decrease) through cumulative catch-up adjustments to revenue, contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in contract assets resulting from cumulative catch-up adjustments to revenue. [Refer: Contract assets; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=alvo_ContractAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=alvo_ContractAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=alvo_ContractLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=alvo_ContractLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416726528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractAssets', window );">Non-current contract assets</a></td>
<td class="nump">$ 10,856<span></span>
</td>
<td class="nump">$ 3,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Current contract assets</a></td>
<td class="nump">35,193<span></span>
</td>
<td class="nump">25,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current contract liabilities</a></td>
<td class="nump">73,261<span></span>
</td>
<td class="nump">57,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current contract liabilities</a></td>
<td class="nump">59,183<span></span>
</td>
<td class="nump">$ 36,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_NotLaterThanFiveYearsMember', window );">Not later than five years | Performance obligations satisfied over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Transaction price allocated to remaining performance obligations</a></td>
<td class="nump">$ 383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod', window );">Period of revenue recognition</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NoncurrentContractAssetsMaterializePeriod', window );">Non-current contract assets materialize period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod', window );">Noncurrent contract liabilities revenue recognition period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NoncurrentContractAssetsMaterializePeriod', window );">Non-current contract assets materialize period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod', window );">Noncurrent contract liabilities revenue recognition period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NoncurrentContractAssetsMaterializePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-current contract assets materialize period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NoncurrentContractAssetsMaterializePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-current contract liabilities revenue recognition period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Price Allocated To Remaining Performance Obligations, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 120<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=alvo_NotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=alvo_NotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430470850176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Salaries And Other Employee Expenses - Additional Information (Details) - Individuals<br> Individuals in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract', window );"><strong>Disclosure Of Salaries And Other Employee Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageNumberOfEmployees', window );">Average number of individuals employed</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of salaries and other employee expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of personnel employed by the entity during a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416251152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Salaries And Other Employee Expenses - Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract', window );"><strong>Disclosure Of Salaries And Other Employee Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salary expense</a></td>
<td class="nump">$ 107,067<span></span>
</td>
<td class="nump">$ 92,082<span></span>
</td>
<td class="nump">$ 67,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Defined contribution plan expense</a></td>
<td class="nump">11,518<span></span>
</td>
<td class="nump">10,052<span></span>
</td>
<td class="nump">7,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermBenefits', window );">Long-term incentive plan expense</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">5,481<span></span>
</td>
<td class="nump">17,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments (see Note 23)</a></td>
<td class="nump">18,033<span></span>
</td>
<td class="nump">10,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Other employee expense</a></td>
<td class="nump">19,718<span></span>
</td>
<td class="nump">11,670<span></span>
</td>
<td class="nump">10,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TemporaryLabourExpense', window );">Temporary labor</a></td>
<td class="nump">8,495<span></span>
</td>
<td class="nump">5,838<span></span>
</td>
<td class="nump">6,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee benefits expense</a></td>
<td class="nump">$ 164,909<span></span>
</td>
<td class="nump">$ 135,440<span></span>
</td>
<td class="nump">$ 109,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of salaries and other employee expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TemporaryLabourExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary labour expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TemporaryLabourExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term employee benefits other than post-employment benefits and termination benefits. Such benefits may include long-term paid absences, jubilee or other long-service benefits, long-term disability benefits, long-term profit-sharing and bonuses and long-term deferred remuneration. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 158<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_158&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416120320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Salaries And Other Employee Expenses - Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems', window );"><strong>Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total salary and other employee expenses</a></td>
<td class="nump">$ 164,909<span></span>
</td>
<td class="nump">$ 135,440<span></span>
</td>
<td class="nump">$ 109,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_CostOfProductRevenueMember', window );">Cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems', window );"><strong>Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total salary and other employee expenses</a></td>
<td class="nump">76,908<span></span>
</td>
<td class="nump">42,501<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_ResearchAndDevelopmentExpensesMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems', window );"><strong>Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total salary and other employee expenses</a></td>
<td class="nump">44,339<span></span>
</td>
<td class="nump">52,962<span></span>
</td>
<td class="nump">71,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_GeneralAndAdministrativeExpensesMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems', window );"><strong>Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total salary and other employee expenses</a></td>
<td class="nump">$ 43,662<span></span>
</td>
<td class="nump">$ 39,977<span></span>
</td>
<td class="nump">$ 37,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about salaries and other emloyee expenses included in consolidated statements of profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_CostOfProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_CostOfProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417023632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income And Finance Costs - Summary Of Detailed Information About Finance Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DetailsOfFinanceIncomeAbstract', window );"><strong>Details Of Finance Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Changes in the fair value of derivatives (see Note 28)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,637<span></span>
</td>
<td class="nump">$ 51,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income from cash and cash equivalents</a></td>
<td class="nump">4,547<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnOtherFinancialAssets', window );">Other interest income</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">$ 4,823<span></span>
</td>
<td class="nump">$ 2,549<span></span>
</td>
<td class="nump">$ 51,568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DetailsOfFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Details of finance income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DetailsOfFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on other financial assets. [Refer: Interest income; Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414295232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income And Finance Costs - Summary Of Detailed Information About Finance Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfFinanceIncomeAbstract', window );"><strong>Disclosure Of Finance Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Changes in the fair value of derivatives (see Note 28)</a></td>
<td class="nump">$ 132,333<span></span>
</td>
<td class="nump">$ 96,981<span></span>
</td>
<td class="nump">$ 2,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest on debt and borrowings</a></td>
<td class="nump">129,327<span></span>
</td>
<td class="nump">71,452<span></span>
</td>
<td class="nump">106,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ConsentingFee', window );">Consenting fee (see Note 21)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,430<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LossOnRemeasurementOfBonds', window );">Loss on remeasurement of bonds (see Note 21)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,511<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities (see Note 13)</a></td>
<td class="nump">3,840<span></span>
</td>
<td class="nump">6,022<span></span>
</td>
<td class="nump">6,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AmortizationOfDeferredDebtIssuanceCosts', window );">Amortization of deferred debt issue costs</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="nump">$ 267,157<span></span>
</td>
<td class="nump">$ 188,419<span></span>
</td>
<td class="nump">$ 117,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AmortizationOfDeferredDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of deferred debt issuancecCosts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AmortizationOfDeferredDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ConsentingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consenting fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ConsentingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of finance income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LossOnRemeasurementOfBonds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on remeasurement of bonds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LossOnRemeasurementOfBonds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430480823600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract', window );"><strong>Disclosure Of Depreciation Amortization And Imapirment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment', window );">Depreciation and impairment of property, plant and equipment (see Note 12)</a></td>
<td class="nump">$ 14,353<span></span>
</td>
<td class="nump">$ 9,807<span></span>
</td>
<td class="nump">$ 10,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right of use assets (see Note 13)</a></td>
<td class="nump">8,913<span></span>
</td>
<td class="nump">9,869<span></span>
</td>
<td class="nump">8,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AmortizationAndImpairmentOfIntangibleAssets', window );">Amortization and impairment of intangible assets (see Note 15)</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">4,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">$ 25,989<span></span>
</td>
<td class="nump">$ 23,164<span></span>
</td>
<td class="nump">$ 24,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AmortizationAndImpairmentOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization And Impairment Of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AmortizationAndImpairmentOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Impairment Of Property Plant And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of depreciation amortization and imapirment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense, amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss. [Refer: Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416106992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems', window );"><strong>Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total depreciation, amortization and impairment expense</a></td>
<td class="nump">$ 25,989<span></span>
</td>
<td class="nump">$ 23,164<span></span>
</td>
<td class="nump">$ 24,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_CostOfProductRevenueMember', window );">Cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems', window );"><strong>Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total depreciation, amortization and impairment expense</a></td>
<td class="nump">15,582<span></span>
</td>
<td class="nump">10,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_ResearchAndDevelopmentExpensesMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems', window );"><strong>Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total depreciation, amortization and impairment expense</a></td>
<td class="nump">6,886<span></span>
</td>
<td class="nump">9,757<span></span>
</td>
<td class="nump">21,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_GeneralAndAdministrativeExpensesMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems', window );"><strong>Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Total depreciation, amortization and impairment expense</a></td>
<td class="nump">$ 3,521<span></span>
</td>
<td class="nump">$ 3,354<span></span>
</td>
<td class="nump">$ 2,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed information about depreciation amortization and impairment expense included in consolidated statements profit or loss and other comprehensive income or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense, amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss. [Refer: Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_CostOfProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_CostOfProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=alvo_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411108976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Fees - Summary Of Detailed Information About Audit Fees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfAuditFeesAbstract', window );"><strong>Disclosure Of Audit Fees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Financial Statement audit fees</a></td>
<td class="nump">$ 2,876<span></span>
</td>
<td class="nump">$ 2,615<span></span>
</td>
<td class="nump">$ 5,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForTaxServices', window );">Other fees, including tax services</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total fees</a></td>
<td class="nump">$ 3,339<span></span>
</td>
<td class="nump">$ 3,291<span></span>
</td>
<td class="nump">$ 5,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfAuditFeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of audit fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfAuditFeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForAuditServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for auditing services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForAuditServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForTaxServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for tax services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForTaxServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430448666576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Schedule Of Taxation Recognized In The Consolidated Statements Of Profit Or Loss And Other Comprehensive Income Or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CurrentTaxAbstract', window );"><strong>Current tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Direct taxes - current</a></td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Direct taxes &#8211; prior year</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Total current tax</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DeferredTaxAbstract', window );"><strong>Deferred tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Current</a></td>
<td class="num">(89,847)<span></span>
</td>
<td class="num">(54,236)<span></span>
</td>
<td class="num">(48,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods', window );">Prior year</a></td>
<td class="num">(10,718)<span></span>
</td>
<td class="nump">15,269<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods', window );">Total deferred tax</a></td>
<td class="num">(100,565)<span></span>
</td>
<td class="num">(38,967)<span></span>
</td>
<td class="num">(48,891)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total income tax benefit</a></td>
<td class="num">$ (99,318)<span></span>
</td>
<td class="num">$ (38,067)<span></span>
</td>
<td class="num">$ (47,694)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CurrentTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CurrentTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DeferredTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DeferredTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax expense income and adjustments for deferred tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for the deferred tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430420222256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods', window );">Prior year deferred tax impact</a></td>
<td class="num">$ (10,718)<span></span>
</td>
<td class="nump">$ 15,269<span></span>
</td>
<td class="num">$ (477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">15.30%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">309,807<span></span>
</td>
<td class="nump">209,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses expire</a></td>
<td class="nump">1,513,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IS', window );">ICELAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses expire</a></td>
<td class="nump">1,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_LU', window );">LUXEMBOURG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses expire</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember', window );">Other temporary differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">3,562<span></span>
</td>
<td class="nump">2,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TemporaryDifferenceMember', window );">Temporary differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">$ 309,800<span></span>
</td>
<td class="nump">$ 209,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfIncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfIncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for the deferred tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_LU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_LU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TemporaryDifferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_TemporaryDifferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430418094512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Schedule Of The Reconciling Items Between The Statutory Rate And The Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure Of Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Tax rate</a></td>
<td class="nump">24.90%<span></span>
</td>
<td class="nump">24.90%<span></span>
</td>
<td class="nump">24.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfForeignTaxRates', window );">Effect of tax rate in foreign jurisdictions</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="num">(8.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Permanent differences</a></td>
<td class="num">(6.70%)<span></span>
</td>
<td class="num">(8.90%)<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses', window );">Non-recognition of tax losses</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other items</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">15.30%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TaxRateEffectOfNonrecognitionOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect of non-recognition&#160;of tax losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TaxRateEffectOfNonrecognitionOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408425760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Schedule Of The Movement In Net Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DeferredTaxLiabilityAssetRollForward', window );"><strong>Deferred tax liability (asset) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="nump">$ 209,187<span></span>
</td>
<td class="nump">$ 170,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Deferred tax credited to profit or loss</a></td>
<td class="nump">100,567<span></span>
</td>
<td class="nump">38,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="nump">309,754<span></span>
</td>
<td class="nump">209,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">309,807<span></span>
</td>
<td class="nump">209,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Deferred tax credited to profit or loss</a></td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">$ (309)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DeferredTaxLiabilityAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liability (asset)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DeferredTaxLiabilityAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416664672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Tax - Schedule Of Deferred Tax Recognized In The Consolidated Statements Of Financial Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">$ 309,807<span></span>
</td>
<td class="nump">$ 209,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Deferred tax liabilities attributable to other temporary differences</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax assets</a></td>
<td class="nump">309,754<span></span>
</td>
<td class="nump">209,187<span></span>
</td>
<td class="nump">$ 170,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Unused tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">301,375<span></span>
</td>
<td class="nump">205,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember', window );">Other temporary differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">11,941<span></span>
</td>
<td class="nump">6,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Deferred tax liabilities attributable to other temporary differences</a></td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="num">$ (2,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411975728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Tax - Schedule Of Expiration Of Unused Tax Losses (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses expire</a></td>
<td class="nump">$ 1,513,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TaxYearsAxis=alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember', window );">2024-2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses expire</a></td>
<td class="nump">68,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TaxYearsAxis=alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember', window );">2027-2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses expire</a></td>
<td class="nump">289,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TaxYearsAxis=alvo_LaterPeriodMember', window );">Later</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure of income tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses expire</a></td>
<td class="nump">$ 1,155,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfIncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfIncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TaxYearsAxis=alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TaxYearsAxis=alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TaxYearsAxis=alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TaxYearsAxis=alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TaxYearsAxis=alvo_LaterPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TaxYearsAxis=alvo_LaterPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411985744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented', window );">Number of potential ordinary shares that are antidilutive in period presented</a></td>
<td class="nump">86,745,377<span></span>
</td>
<td class="nump">148,857,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Antidilutive securities excluded from computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential ordinary shares that are antidilutive in the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430419629232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Summary of Basic and Diluted Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">$ (551,731)<span></span>
</td>
<td class="num">$ (513,580)<span></span>
</td>
<td class="num">$ (101,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares outstanding basic (in shares)</a></td>
<td class="nump">227,256,469<span></span>
</td>
<td class="nump">197,721,710<span></span>
</td>
<td class="nump">110,673,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares outstanding diluted (in shares)</a></td>
<td class="nump">227,256,469<span></span>
</td>
<td class="nump">197,721,710<span></span>
</td>
<td class="nump">110,673,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (in dollars per share)</a></td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (2.60)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (in dollars per share)</a></td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (2.60)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430421429072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant And Equipment - Summary Of Property, Plant And Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">$ 220,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">236,779<span></span>
</td>
<td class="nump">$ 220,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityMember', window );">Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">114,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">111,766<span></span>
</td>
<td class="nump">114,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityEquipmentMember', window );">Facility Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">117,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FurnitureFixturesAndLeaseholdImprovementsMember', window );">Furniture, fixtures and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">6,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">7,063<span></span>
</td>
<td class="nump">6,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">271,707<span></span>
</td>
<td class="nump">122,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="nump">2,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">31,369<span></span>
</td>
<td class="nump">153,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1,392)<span></span>
</td>
<td class="num">(2,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="nump">572<span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">304,908<span></span>
</td>
<td class="nump">271,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Facility Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">145,150<span></span>
</td>
<td class="nump">88,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="nump">25,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">29,351<span></span>
</td>
<td class="nump">35,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1,233)<span></span>
</td>
<td class="num">(2,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="nump">679<span></span>
</td>
<td class="num">(1,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">176,718<span></span>
</td>
<td class="nump">145,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Furniture, fixtures and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">9,598<span></span>
</td>
<td class="nump">32,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(25,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">10,878<span></span>
</td>
<td class="nump">9,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(136)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="num">(51,113)<span></span>
</td>
<td class="num">(43,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">895<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="nump">347<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">14,353<span></span>
</td>
<td class="nump">9,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="num">(68,129)<span></span>
</td>
<td class="num">(51,113)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="num">(359)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">2,875<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="num">(3,234)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation | Facility Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="num">(46,002)<span></span>
</td>
<td class="num">(33,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="nump">3,330<span></span>
</td>
<td class="nump">5,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">10,572<span></span>
</td>
<td class="nump">8,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="num">(59,497)<span></span>
</td>
<td class="num">(46,002)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation | Furniture, fixtures and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="num">(3,233)<span></span>
</td>
<td class="num">(8,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(5,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="nump">40<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="num">(3,815)<span></span>
</td>
<td class="num">(3,233)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Depreciation | Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PropertyPlantAndEquipmentRollForward', window );"><strong>Property, Plant and Equipment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="num">(1,519)<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Reclassification of assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Translation difference</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="num">$ (1,583)<span></span>
</td>
<td class="num">$ (1,519)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_PropertyPlantAndEquipmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_PropertyPlantAndEquipmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FacilityEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FurnitureFixturesAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=alvo_FurnitureFixturesAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430449040480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant And Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity', window );">Property, plant and equipment, pledged as security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127.4<span></span>
</td>
<td class="nump">$ 122.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AssetsAcquisitionAxis=alvo_SaemundurMember', window );">Saemundur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AssetAcquisitionsConsiderationTransferred', window );">Asset acquisition consideration transferred</a></td>
<td class="nump">$ 115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond', window );">Asset acquisition consideration transferred Convertible Bond</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed', window );">Asset acquisition consideration transferred Loans Assumed</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AssetsAcquisitionAxis=alvo_SaemundurMember', window );">Saemundur | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AssetAcquisitionConsiderationTransferredSettlements', window );">Asset acquisition consideration transferred Settlements</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LossOnExtinguishmentOfTheLeaseLiability', window );">Loss on extinguishment of the lease liability</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AssetAcquisitionConsiderationTransferredConvertibleBond">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred Convertible Bond.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AssetAcquisitionConsiderationTransferredConvertibleBond</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AssetAcquisitionConsiderationTransferredLoansAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred Loans Assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AssetAcquisitionConsiderationTransferredLoansAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AssetAcquisitionConsiderationTransferredSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred Settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AssetAcquisitionConsiderationTransferredSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AssetAcquisitionsConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AssetAcquisitionsConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LossOnExtinguishmentOfTheLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on extinguishment of the lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LossOnExtinguishmentOfTheLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment pledged as security for liabilities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 74<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_74_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AssetsAcquisitionAxis=alvo_SaemundurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AssetsAcquisitionAxis=alvo_SaemundurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_FacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_FacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430420343536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Leases Assets About Right-Of-Use Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RightOfUsedAssetsRollForward', window );"><strong>Right Of Used Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Beginning balance</a></td>
<td class="nump">$ 47,501<span></span>
</td>
<td class="nump">$ 126,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets', window );">Adjustments for indexed leases</a></td>
<td class="nump">7,354<span></span>
</td>
<td class="nump">10,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">New leases</a></td>
<td class="nump">74,109<span></span>
</td>
<td class="nump">9,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CancellationsRightOfUseAssets', window );">Cancelled leases</a></td>
<td class="num">(139)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DecreaseThroughDerecognitionRightOfUseAssets', window );">Derecognition due to acquisition of Alvotech Facility (see Note 12)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(88,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ReclassificationRightOfUseAssets', window );">Reclassification</a></td>
<td class="num">(443)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(8,913)<span></span>
</td>
<td class="num">(9,869)<span></span>
</td>
<td class="num">$ (8,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TranslationDifferenceRightOfUseAssets', window );">Translation difference</a></td>
<td class="nump">333<span></span>
</td>
<td class="num">(274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Ending balance</a></td>
<td class="nump">$ 119,802<span></span>
</td>
<td class="nump">$ 47,501<span></span>
</td>
<td class="nump">$ 126,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdjustmentsForIndexedLeasesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for indexed leases right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdjustmentsForIndexedLeasesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CancellationsRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancellations, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CancellationsRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DecreaseThroughDerecognitionRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Derecognition, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DecreaseThroughDerecognitionRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ReclassificationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ReclassificationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RightOfUsedAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right Of Used Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RightOfUsedAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TranslationDifferenceRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Translation difference right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TranslationDifferenceRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430415920992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 119,802<span></span>
</td>
<td class="nump">$ 47,501<span></span>
</td>
<td class="nump">$ 126,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Lease liabilities</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alvo_FasteignafelagidEyjolfurHf.Member', window );">Fasteignafelagid Eyjolfur hf. | ICELAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AreaOfProperty', window );">Area of property | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 68,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AreaOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AreaOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense relating to short-term leases and low value leases for which recognition exemption has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WeightedAverageRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WeightedAverageRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alvo_FasteignafelagidEyjolfurHf.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alvo_FasteignafelagidEyjolfurHf.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416669824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Classes of Right-Of-Use Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems', window );"><strong>Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 119,802<span></span>
</td>
<td class="nump">$ 47,501<span></span>
</td>
<td class="nump">$ 126,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=alvo_FacilitiesMember', window );">Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems', window );"><strong>Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">110,692<span></span>
</td>
<td class="nump">41,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=alvo_FleetMember', window );">Fleet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems', window );"><strong>Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems', window );"><strong>Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 8,721<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about classes of right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_FleetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_FleetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430473753280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LeaseLiabilitiesRollForward', window );"><strong>Lease Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at 1 January</a></td>
<td class="nump">$ 40,532<span></span>
</td>
<td class="nump">$ 122,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases', window );">Adjustments for indexed leases</a></td>
<td class="nump">7,405<span></span>
</td>
<td class="nump">10,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases</a></td>
<td class="nump">72,882<span></span>
</td>
<td class="nump">7,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LeaseLiabilitiesCancelledLease', window );">Cancelled leases</a></td>
<td class="num">(167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Installment payments</a></td>
<td class="num">(7,260)<span></span>
</td>
<td class="num">(7,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerecognitionDueToAssetsAcquisition', window );">Derecognition due to acquisition of Alvotech Facility (see Note 12)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(80,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LeaseLiabilitiesForeignCurrencyAdjustment', window );">Foreign currency adjustment</a></td>
<td class="nump">1,932<span></span>
</td>
<td class="num">(11,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LeaseLiabilitiesTranslationDifference', window );">Translation difference</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at 31 December</a></td>
<td class="nump">115,315<span></span>
</td>
<td class="nump">40,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current liabilities</a></td>
<td class="num">(9,683)<span></span>
</td>
<td class="num">(5,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">$ 105,632<span></span>
</td>
<td class="nump">$ 35,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DerecognitionDueToAssetsAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition due to assets acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DerecognitionDueToAssetsAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities adjustments for indexed leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LeaseLiabilitiesCancelledLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liabilities, Cancelled Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LeaseLiabilitiesCancelledLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LeaseLiabilitiesForeignCurrencyAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities foreign currency adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LeaseLiabilitiesForeignCurrencyAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LeaseLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LeaseLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LeaseLiabilitiesTranslationDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities translation difference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LeaseLiabilitiesTranslationDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414797696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary Of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems', window );"><strong>Disclosure Of Detailed Information About Lease Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right of use assets (see Note 13)</a></td>
<td class="num">$ (8,913)<span></span>
</td>
<td class="num">$ (9,869)<span></span>
</td>
<td class="num">$ (8,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="num">(3,840)<span></span>
</td>
<td class="num">(6,022)<span></span>
</td>
<td class="num">(6,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ForeignCurrencyDifferenceOnLeaseLiability', window );">Foreign currency difference on lease liability</a></td>
<td class="num">(1,932)<span></span>
</td>
<td class="nump">11,682<span></span>
</td>
<td class="nump">3,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LossFromExtinguishmentOfLeaseLiabilities', window );">Loss from extinguishment of lease agreement (see Note 12)</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(3,859)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LeaseCostRecognizedInProfitAndLoss', window );">Total amount recognized in profit and loss</a></td>
<td class="num">(14,713)<span></span>
</td>
<td class="num">(8,068)<span></span>
</td>
<td class="num">(11,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">119,802<span></span>
</td>
<td class="nump">47,501<span></span>
</td>
<td class="nump">126,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=alvo_FacilitiesMember', window );">Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems', window );"><strong>Disclosure Of Detailed Information About Lease Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right of use assets (see Note 13)</a></td>
<td class="num">(7,631)<span></span>
</td>
<td class="num">(9,423)<span></span>
</td>
<td class="num">(8,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">110,692<span></span>
</td>
<td class="nump">41,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=alvo_FleetMember', window );">Fleet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems', window );"><strong>Disclosure Of Detailed Information About Lease Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right of use assets (see Note 13)</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems', window );"><strong>Disclosure Of Detailed Information About Lease Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right of use assets (see Note 13)</a></td>
<td class="num">(1,102)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="num">$ (433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 8,721<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ForeignCurrencyDifferenceOnLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency difference on lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ForeignCurrencyDifferenceOnLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LeaseCostRecognizedInProfitAndLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease cost recognized in profit and loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LeaseCostRecognizedInProfitAndLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LossFromExtinguishmentOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss from extinguishment of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LossFromExtinguishmentOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_FleetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_FleetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417848032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturity Analysis For Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">$ 155,372<span></span>
</td>
<td class="nump">$ 48,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">14,637<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">One to five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">51,053<span></span>
</td>
<td class="nump">20,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Gross lease liabilities</a></td>
<td class="nump">$ 89,682<span></span>
</td>
<td class="nump">$ 22,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about maturity analysis for lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413172656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Summary of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GoodwillBalancesRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Balance as of 1 January</a></td>
<td class="nump">$ 11,643<span></span>
</td>
<td class="nump">$ 12,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill', window );">Translation difference</a></td>
<td class="nump">415<span></span>
</td>
<td class="num">(724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Balance as of 31 December</a></td>
<td class="nump">$ 12,058<span></span>
</td>
<td class="nump">$ 11,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_GoodwillBalancesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Balances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_GoodwillBalancesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430409158560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfGoodwillLineItems', window );"><strong>Disclosure of Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Growth rate used to extrapolate cash flow projections</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate applied to cash flow projections</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfGoodwillLineItems', window );"><strong>Disclosure of Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill', window );">Impairment loss recognised in profit or loss, goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_d_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_e_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_d_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430415976032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible assets - Summary of Detailed Information About Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 25,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">19,076<span></span>
</td>
<td class="nump">25,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">10,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">13,076<span></span>
</td>
<td class="nump">10,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CustomerrelatedIntangibleAssetsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember', window );">Intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">30,865<span></span>
</td>
<td class="nump">26,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassification of assets</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">10,094<span></span>
</td>
<td class="nump">7,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment</a></td>
<td class="num">(1,779)<span></span>
</td>
<td class="num">(2,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Retirement</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Translation difference</a></td>
<td class="nump">162<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">25,344<span></span>
</td>
<td class="nump">30,865<span></span>
</td>
<td class="nump">26,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">13,684<span></span>
</td>
<td class="nump">8,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassification of assets</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">4,094<span></span>
</td>
<td class="nump">7,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment</a></td>
<td class="num">(1,779)<span></span>
</td>
<td class="num">(2,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Retirement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Translation difference</a></td>
<td class="nump">72<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">17,073<span></span>
</td>
<td class="nump">13,684<span></span>
</td>
<td class="nump">8,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">2,181<span></span>
</td>
<td class="nump">2,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassification of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Retirement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Translation difference</a></td>
<td class="nump">90<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">2,271<span></span>
</td>
<td class="nump">2,181<span></span>
</td>
<td class="nump">2,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Reclassification of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Retirement</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Translation difference</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=alvo_AmortizationMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">5,213<span></span>
</td>
<td class="nump">4,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Translation difference</a></td>
<td class="nump">111<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">6,268<span></span>
</td>
<td class="nump">5,213<span></span>
</td>
<td class="nump">4,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=alvo_AmortizationMember', window );">Amortization | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Translation difference</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="nump">626<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=alvo_AmortizationMember', window );">Amortization | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Translation difference</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">2,271<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=alvo_AmortizationMember', window );">Amortization | Intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward', window );"><strong>Intangible Assets Other Than Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Translation difference</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IntangibleAssetsOtherThanGoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Other Than Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IntangibleAssetsOtherThanGoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CustomerrelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CustomerrelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=alvo_AmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=alvo_AmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430448666320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible assets - Summary of Impairment Loss and Reversal of Impairment Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="nump">$ 944<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CostOfSalesMember', window );">Cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_ResearchAndDevelopmentMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_GeneralAndAdministrativeMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_GeneralAndAdministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_GeneralAndAdministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414722496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible assets - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alvo_AVT23Member', window );">AVT23 | Kashiv</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PaymentForContractualCommitment', window );">Payment for contract commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Contractual capital commitments</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractualCapitalCommitmentContingentLiability', window );">Commitment, contingent liability</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ContractualCapitalCommitmentsTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alvo_AVT23Member', window );">AVT23 | Kashiv | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PaymentForContractualCommitment', window );">Payment for contract commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntangibleAssetsWithFiniteLivedMember', window );">Intangible assets with finite lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntangibleAssetsWithFiniteLivedMember', window );">Intangible assets with finite lived | Cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntangibleAssetsWithFiniteLivedMember', window );">Intangible assets with finite lived | General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntellectualPropertyRightsMember', window );">Intellectual property rights | AVT23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill', window );">Derecognition of intangible asset</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractualCapitalCommitmentContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Capital Commitment, Contingent Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractualCapitalCommitmentContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ContractualCapitalCommitmentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Capital Commitments, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ContractualCapitalCommitmentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition, Intangible Assets Other Than Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DerecognitionIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_PaymentForContractualCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Contractual Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_PaymentForContractualCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 130<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_130_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 130<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_130_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alvo_AVT23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alvo_AVT23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alvo_KashivMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alvo_KashivMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntangibleAssetsWithFiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntangibleAssetsWithFiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncomeStatementsLocationAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncomeStatementsLocationAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncomeStatementsLocationAxis=alvo_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncomeStatementsLocationAxis=alvo_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntellectualPropertyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntellectualPropertyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430449034560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash And Cash Equivalents - Summary of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,157<span></span>
</td>
<td class="nump">$ 66,427<span></span>
</td>
<td class="nump">$ 17,556<span></span>
</td>
<td class="nump">$ 31,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Cash and cash equivalents denominated in US dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">10,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember', window );">Cash and cash equivalents denominated in other currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,691<span></span>
</td>
<td class="nump">$ 56,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfCashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfCashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430473745552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash And Cash Equivalents - Summary of Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CashAndCashEquivalentsRollForward', window );"><strong>Cash And Cash Equivalents [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents', window );">Balance at 1 January</a></td>
<td class="nump">$ 25,187<span></span>
</td>
<td class="nump">$ 10,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdditionRestrictedCashAndCashEquivalents', window );">Additions during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_InterestIncomeOnCash', window );">Interest income</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents', window );">Balance at 31 December</a></td>
<td class="nump">$ 26,132<span></span>
</td>
<td class="nump">$ 25,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdditionRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition restricted cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdditionRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CashAndCashEquivalentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CashAndCashEquivalentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_InterestIncomeOnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income on cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_InterestIncomeOnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430449035344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Raw materials and supplies</a></td>
<td class="nump">$ 51,524<span></span>
</td>
<td class="nump">$ 41,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work in progress</a></td>
<td class="nump">33,068<span></span>
</td>
<td class="nump">29,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">2,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_InventoryReserves', window );">Inventory reserves</a></td>
<td class="num">(10,403)<span></span>
</td>
<td class="num">(2,062)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Balance at 31 December</a></td>
<td class="nump">$ 74,433<span></span>
</td>
<td class="nump">$ 71,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_InventoryReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_InventoryReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430448577296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfInventoriesLineItems', window );"><strong>Disclosure of Inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory write-down</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfInventoryWritedown', window );">Reversal of inventory write-down</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember', window );">Cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfInventoriesLineItems', window );"><strong>Disclosure of Inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod', window );">Cost of inventories recognised as expense</a></td>
<td class="nump">$ 42,800<span></span>
</td>
<td class="nump">$ 20,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfInventoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfInventoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories recognised as an expense during the period. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfInventoryWritedown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfInventoryWritedown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408526208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Assets - Summary of Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">Value-added tax</a></td>
<td class="nump">$ 8,801<span></span>
</td>
<td class="nump">$ 6,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">22,035<span></span>
</td>
<td class="nump">20,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ProceedsReceivableFromConvertibleBonds', window );">Proceeds receivable from Convertible Bonds (see Note 21)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerivaiveAssets', window );">Derivative asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other short-term receivables</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">1,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Total</a></td>
<td class="nump">$ 31,871<span></span>
</td>
<td class="nump">$ 32,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DerivaiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivaive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DerivaiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ProceedsReceivableFromConvertibleBonds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds receivable from convertible bonds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ProceedsReceivableFromConvertibleBonds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430448650224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentAssetsLineItems', window );"><strong>Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">$ 31,871<span></span>
</td>
<td class="nump">$ 31,871<span></span>
</td>
<td class="nump">$ 32,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alvo_AVT23Member', window );">AVT23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentAssetsLineItems', window );"><strong>Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerecognitionPrepaidDevelopmentCosts', window );">Derecognition, prepaid development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alvo_AVT23Member', window );">AVT23 | Intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentAssetsLineItems', window );"><strong>Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill', window );">Derecognition of intangible asset</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DerecognitionIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition, Intangible Assets Other Than Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DerecognitionIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DerecognitionPrepaidDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition, Prepaid Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DerecognitionPrepaidDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alvo_AVT23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alvo_AVT23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntellectualPropertyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=alvo_IntellectualPropertyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416016464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2023</div></th>
<th class="th"><div>Jun. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Gross private placement equity offering fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,141,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,821,844<span></span>
</td>
<td class="nump">252,160,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_StockIssuedUnderPipeFinancingShares', window );">Stock issued under PIPE financing shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CommonStockHeldBySubsidiaries', window );">Common stock held by subsidiary (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,905,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,157,000<span></span>
</td>
<td class="nump">66,427,000<span></span>
</td>
<td class="nump">$ 17,556,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,689,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember', window );">Cash and cash equivalents denominated in other currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,691,000<span></span>
</td>
<td class="nump">$ 56,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares', window );">Warrants issuable as a percentage of fully diluted ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassAAndClassBOrdinarySharesMember', window );">Class A and Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_SharesAuthorizedValue', window );">Shares authorized value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,961,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Common stock par or stated value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Gross private placement equity offering fee</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Common stock par or stated value per share (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 137,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_SaleOfStockIssuePricePerShare', window );">Sale of stock issue price (in dollars per share)</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Exchange of Predecessor Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalReorganizationEventSharesIssued', window );">Capital reorganization event shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Exchange of Class A OACB Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalReorganizationSharesIssued', window );">Capital reorganization shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_PredecessorEarnoutSharesMember', window );">Predecessor Earn Out Shares | Exchange of Predecessor Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalReorganizationEventSharesIssued', window );">Capital reorganization event shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassAOacbOrdinarySharesMember', window );">Class A OACB Ordinary Shares | Exchange of Class A OACB Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassBOacbOrdinarySharesMember', window );">Class B OACB Ordinary Shares | Exchange of Class A OACB Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares | Exchange of Class A OACB Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalReorganizationSharesIssued', window );">Capital reorganization shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CapitalReorganizationEventSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital reorganization event shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CapitalReorganizationEventSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CapitalReorganizationSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital reorganization shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CapitalReorganizationSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CommonStockHeldBySubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock held by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CommonStockHeldBySubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_SaleOfStockIssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock issue price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_SaleOfStockIssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_SharesAuthorizedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares authorized value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_SharesAuthorizedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_StockIssuedUnderPipeFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued under PIPE financing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_StockIssuedUnderPipeFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuable as a percentage of fully diluted ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 107<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassAAndClassBOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassAAndClassBOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_SaleOfStockAxis=alvo_PrivatePlacementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_SaleOfStockAxis=alvo_PrivatePlacementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_StockExchangeDescriptionAxis=alvo_ExchangeOfPredecessorOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_StockExchangeDescriptionAxis=alvo_ExchangeOfPredecessorOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_StockExchangeDescriptionAxis=alvo_ExchangeOfClassAOacbOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_StockExchangeDescriptionAxis=alvo_ExchangeOfClassAOacbOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_PredecessorEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=alvo_PredecessorEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassAOacbOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassAOacbOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassBOacbOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=alvo_ClassBOacbOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=alvo_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417034496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Summary of Share Capital and Share Premium (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares</a></td>
<td class="nump">266,821,844<span></span>
</td>
<td class="nump">252,160,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ShareCapitalAndSharePremium', window );">Share capital and share premium</a></td>
<td class="nump">$ 1,231,969<span></span>
</td>
<td class="nump">$ 1,060,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares</a></td>
<td class="nump">266,821,844<span></span>
</td>
<td class="nump">252,160,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ShareCapitalAndSharePremium', window );">Share capital and share premium</a></td>
<td class="nump">$ 1,231,969<span></span>
</td>
<td class="nump">$ 1,060,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ShareCapitalAndSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital and share premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ShareCapitalAndSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430444376976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Movements in Ordinary Shares, Share Capital and Share Premium (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning Balance (in shares)</a></td>
<td class="nump">252,160,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance</a></td>
<td class="num">$ (564,416)<span></span>
</td>
<td class="num">$ (135,612)<span></span>
</td>
<td class="num">$ (867,243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssuanceOfOrdinaryShares', window );">Issuance of Ordinary, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,576,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseThroughPipeFinancingShares', window );">PIPE Financing, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfPredecessorEarnOutShares', window );">Predecessor Earn Out Shares, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfOacbEarnOutShares', window );">OACB Earn Out Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares', window );">SARs Settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,510,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares', window );">Settlement of related party loans with Ordinary Shares, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalContributionSharesIssued', window );">Capital contribution (in shares)</a></td>
<td class="nump">11,834,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestedEarnoutSharesIssued', window );">Vested earn-out shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance (in shares)</a></td>
<td class="nump">266,821,844<span></span>
</td>
<td class="nump">252,160,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance</a></td>
<td class="num">$ (932,493)<span></span>
</td>
<td class="num">$ (564,416)<span></span>
</td>
<td class="num">$ (135,612)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_PredecessorOrdinarySharesMember', window );">Predecessor Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,481,799<span></span>
</td>
<td class="nump">7,259,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfEquityShares', window );">Share issue (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,222,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_EliminationOfPredecessorOrdinaryShares', window );">Elimination of Predecessor Ordinary Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,481,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,481,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PennyWarrantsMember', window );">Penny Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="nump">2,479,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="nump">553,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="nump">838,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_ShareAppreciationRightsMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="num">(1,044,737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance</a></td>
<td class="nump">$ 2,126<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfEquities', window );">Share issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_EliminationOfPredecessorOrdinaryValue', window );">Elimination of Predecessor Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssuanceOfOrdinaryValue', window );">Issuance of Ordinary Shares (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseThroughPipeFinancingValue', window );">PIPE Financing (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue', window );">SARs Settlement (Note 22)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue', window );">Settlement of related party loans with Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalContributionValue', window );">Capital contribution</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestedEarnoutSharesValue', window );">Vested earn-out shares</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance</a></td>
<td class="nump">2,279<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital | Penny Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance</a></td>
<td class="nump">1,058,432<span></span>
</td>
<td class="nump">1,000,118<span></span>
</td>
<td class="nump">166,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfEquities', window );">Share issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_EliminationOfPredecessorOrdinaryValue', window );">Elimination of Predecessor Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssuanceOfOrdinaryValue', window );">Issuance of Ordinary Shares (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseThroughPipeFinancingValue', window );">PIPE Financing (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs arising on share issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfPredecessorEarnOutSharesValue', window );">Predecessor Earn Out Shares (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(227,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfOacbEarnOutSharesValue', window );">OACB Earn Out Shares (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue', window );">SARs Settlement (Note 22)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue', window );">Settlement of related party loans with Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalContributionValue', window );">Capital contribution</a></td>
<td class="nump">132,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestedEarnoutSharesValue', window );">Vested earn-out shares</a></td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance</a></td>
<td class="nump">1,229,690<span></span>
</td>
<td class="nump">1,058,432<span></span>
</td>
<td class="nump">1,000,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium | Penny Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">27,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">7,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">5,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="num">(9,526)<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=alvo_IssuedCapitalAndSharePremiumMember', window );">Issued capital and share premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning Balance</a></td>
<td class="nump">1,060,558<span></span>
</td>
<td class="nump">1,000,253<span></span>
</td>
<td class="nump">166,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfEquities', window );">Share issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_EliminationOfPredecessorOrdinaryValue', window );">Elimination of Predecessor Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssuanceOfOrdinaryValue', window );">Issuance of Ordinary Shares (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseThroughPipeFinancingValue', window );">PIPE Financing (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs arising on share issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfPredecessorEarnOutSharesValue', window );">Predecessor Earn Out Shares (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(227,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfOacbEarnOutSharesValue', window );">OACB Earn Out Shares (Note 1.1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue', window );">SARs Settlement (Note 22)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue', window );">Settlement of related party loans with Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalContributionValue', window );">Capital contribution</a></td>
<td class="nump">132,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestedEarnoutSharesValue', window );">Vested earn-out shares</a></td>
<td class="nump">8,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending Balance</a></td>
<td class="nump">1,231,969<span></span>
</td>
<td class="nump">$ 1,060,558<span></span>
</td>
<td class="nump">$ 1,000,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=alvo_IssuedCapitalAndSharePremiumMember', window );">Issued capital and share premium | Penny Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">27,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=alvo_IssuedCapitalAndSharePremiumMember', window );">Issued capital and share premium | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">7,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=alvo_IssuedCapitalAndSharePremiumMember', window );">Issued capital and share premium | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="nump">5,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=alvo_IssuedCapitalAndSharePremiumMember', window );">Issued capital and share premium | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesCapitalRollForward', window );"><strong>Issue of Shares Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital</a></td>
<td class="num">$ (9,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CapitalContributionSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CapitalContributionSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CapitalContributionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CapitalContributionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_EliminationOfPredecessorOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Elimination of predecessor ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_EliminationOfPredecessorOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_EliminationOfPredecessorOrdinaryValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Elimination of predecessor ordinary value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_EliminationOfPredecessorOrdinaryValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncreaseThroughPipeFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase through PIPE financing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncreaseThroughPipeFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncreaseThroughPipeFinancingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase through PIPE financing value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncreaseThroughPipeFinancingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssuanceOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssuanceOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssuanceOfOrdinaryValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssuanceOfOrdinaryValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfEquities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of equities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfEquities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfOacbEarnOutShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of OACB earn out shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfOacbEarnOutShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfOacbEarnOutSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of OACB earn out shares value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfOacbEarnOutSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfPredecessorEarnOutShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of predecessor earn out shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfPredecessorEarnOutShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfPredecessorEarnOutSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of predecessor earn out shares value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfPredecessorEarnOutSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfSharesCapitalRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of Shares capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfSharesCapitalRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of shares on settlement of related party loans shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of shares on settlement of related party loans value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of shares on settlement of share appreciation rights shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of shares on settlement of share appreciation rights value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_VestedEarnoutSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vested Earnout Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_VestedEarnoutSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_VestedEarnoutSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vested Earnout Shares Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_VestedEarnoutSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=alvo_PredecessorOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=alvo_PredecessorOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_ShareAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_ShareAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=alvo_IssuedCapitalAndSharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=alvo_IssuedCapitalAndSharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430449149072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments', window );">Equity component of convertible bonds</a></td>
<td class="nump">$ 21,391<span></span>
</td>
<td class="nump">$ 16,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Share based payments</a></td>
<td class="nump">21,520<span></span>
</td>
<td class="nump">14,548<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="nump">$ 42,911<span></span>
</td>
<td class="nump">$ 30,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing components of convertible instruments classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417867328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Summary of consolidated statements of financial position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">$ 862,544<span></span>
</td>
<td class="nump">$ 693,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">97,615<span></span>
</td>
<td class="nump">71,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total outstanding borrowings, net of debt issue costs</a></td>
<td class="nump">960,159<span></span>
</td>
<td class="nump">764,570<span></span>
</td>
<td class="nump">$ 400,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Less: current portion of borrowings</a></td>
<td class="num">(38,025)<span></span>
</td>
<td class="num">(19,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Total non-current borrowings</a></td>
<td class="nump">922,134<span></span>
</td>
<td class="nump">744,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember', window );">Senior Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">549,411<span></span>
</td>
<td class="nump">530,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total outstanding borrowings, net of debt issue costs</a></td>
<td class="nump">549,411<span></span>
</td>
<td class="nump">530,506<span></span>
</td>
<td class="nump">394,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_A2022ConvertibleBondsMember', window );">2022 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">155,914<span></span>
</td>
<td class="nump">32,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember', window );">Aztiq Convertible Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">80,663<span></span>
</td>
<td class="nump">65,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember', window );">Alvogen Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Loans received</a></td>
<td class="nump">76,556<span></span>
</td>
<td class="nump">64,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total outstanding borrowings, net of debt issue costs</a></td>
<td class="nump">$ 76,556<span></span>
</td>
<td class="nump">$ 64,588<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_A2022ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_A2022ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430371365184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Additional Information (Details)<br> $ / shares in Units, kr in Billions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>ISK (kr)</div>
</th>
<th class="th">
<div>Jul. 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2022 </div>
<div>USD ($) </div>
<div>tranch</div>
</th>
<th class="th">
<div>Dec. 09, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 12, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2022 </div>
<div>USD ($) </div>
<div>Loan</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 24, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 24, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>tranche </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 09, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of bonds | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 862,544,000<span></span>
</td>
<td class="nump">$ 693,328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity', window );">Property, plant and equipment, pledged as security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,400,000<span></span>
</td>
<td class="nump">122,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfTranches', window );">Number of tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,831,000<span></span>
</td>
<td class="nump">$ 193,678,000<span></span>
</td>
<td class="nump">$ 113,821,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares', window );">Settlement of related party loans with Ordinary Shares, (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ExtinguishmentOfBorrowings', window );">Extinguishment of borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ExtinguishmentOfBorrowingsAccruedInterest', window );">Extinguishment of borrowings accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,159,000<span></span>
</td>
<td class="nump">$ 764,570,000<span></span>
</td>
<td class="nump">400,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,367,000<span></span>
</td>
<td class="nump">34,714,000<span></span>
</td>
<td class="nump">$ 37,496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Matured On March 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Matured on August 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Matured on august 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Matured on March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Matured on March 2024 | Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Financial assets pledged as collateral for liabilities or contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Secured Overnight Financing Rate | Matured On March 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Secured Overnight Financing Rate | Matured on august 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember', window );">Landsbankinn hf | Secured Overnight Financing Rate | Matured on March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties | ATP Holding ehf.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of bonds</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares', window );">Warrants issuable as a percentage of fully diluted ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondsMember', window );">Senior Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,411,000<span></span>
</td>
<td class="nump">$ 530,506,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity', window );">Property, plant and equipment, pledged as security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_WeightedAverageMember', window );">Weighted average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.73%<span></span>
</td>
<td class="nump">12.41%<span></span>
</td>
<td class="nump">14.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember', window );">Convertible Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRedemptionConversionPrice', window );">Borrowings redemption conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember', window );">Senior Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549,411,000<span></span>
</td>
<td class="nump">$ 530,506,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,411,000<span></span>
</td>
<td class="nump">530,506,000<span></span>
</td>
<td class="nump">$ 394,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_TrancheAConvertibleDebtMember', window );">Tranche A Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of bonds</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsConversionFeatureFairValue', window );">Borrowings conversion feature fair value</a></td>
<td class="nump">$ 45,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_TrancheBConvertibleDebtMember', window );">Tranche B Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DebtSecurities', window );">Debt instruments issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember', window );">Aztiq Convertible Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,663,000<span></span>
</td>
<td class="nump">65,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRedemptionConversionPrice', window );">Borrowings redemption conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember', window );">Aztiq Convertible Bond | Aztiq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember', window );">Aztiq Convertible Bond | Financial liabilities at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember', window );">Aztiq Convertible Bond | Aztiq Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqFacilityLoansMember', window );">Aztiq Facility Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AssetAcquisitionConsiderationLoansAssumed', window );">Asset acquisition consideration loans assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember', window );">Alvogen Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRepurchasedFaceAmount', window );">Borrowings repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares', window );">Settlement of related party loans with Ordinary Shares, (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,556,000<span></span>
</td>
<td class="nump">64,588,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Loans received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,556,000<span></span>
</td>
<td class="nump">64,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember', window );">Alvogen Facility | Borrowings Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember', window );">Alvogen Facility | Borrowings Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqFacilityMember', window );">Aztiq Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRepurchasedFaceAmount', window );">Borrowings repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares', window );">Settlement of related party loans with Ordinary Shares, (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqFacilityMember', window );">Aztiq Facility | Borrowings Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqFacilityMember', window );">Aztiq Facility | Borrowings Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityAndAztiqFacilityMember', window );">Alvogen Facility and Aztiq Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRepurchasedFaceAmount', window );">Borrowings repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue', window );">Settlement of related party loans with Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenLoanMember', window );">Alvogen Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfSeparateInstallments', window );">Number of separate installments | Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_LoanAgreementMember', window );">Loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AggregateBorrowingsIndebtedness', window );">Aggregate borrowings indebtedness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenSubordinatedLoanMember', window );">Alvogen Subordinated Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPayable', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenLoanWarrantsMember', window );">Alvogen Loan Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare', window );">Percnetage of warrants issued representing fully diluted ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_FacilityLoansMember', window );">Facility Loans | Final Maturity in December 2029 | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_FacilityLoansMember', window );">Facility Loans | Final Maturity in December 2027 | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_FacilityLoansMember', window );">Facility Loans | Arion banki hf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRepurchaseAmount', window );">Borrowings repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_FacilityLoansMember', window );">Facility Loans | Landsbankinn hf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfLoans', window );">Number of loans | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ProceedsFromBorrowingsNetOfTransactionCosts', window );">Proceeds from borrowings net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_FacilityLoansMember', window );">Facility Loans | Bottom of range | Landsbankinn hf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_FacilityLoansMember', window );">Facility Loans | Top of range | Landsbankinn hf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_OtherBorrowingsFinancialInstitutionMember', window );">Other Borrowings Financial Institution | USD SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Borrowings, variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures', window );">Repayment of bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PremiumPaymentOnBonds', window );">Premium payment on bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ExtensionPremiumToBondHolders', window );">Extension premium to bond holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdditionalExtensionPremiumToBondholders', window );">Additional extension premium to bondholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PrepaymentPenaltyPercentageOnBonds', window );">Prepayment penalty percentage on bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities', window );">Gain losses recognized in profit or loss excluding exchange differences fair value measurement liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_MinimumAmountOfRestrictedCashToBeMaintained', window );">Minimum amount of restricted cash to be maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two | Consent Fees To Bondholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Consent fees to bond holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue', window );">Gain (loss) on extinguishment of debt including change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CarryingValueOfDebtExtinguished', window );">Carrying value of debt extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AccruedInterestOnDebtExtinguished', window );">Accrued interest on debt extiguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NetCashProceedsFromTheTransaction', window );">Net cash proceeds from the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue', window );">Recognition of derivative liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Contingently Issuable Penny Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsExercisePricePerShare', window );">Class of warrants or rights exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Contingently Issuable Penny Warrants | Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares', window );">Warrants issuable as a percentage of fully diluted ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Contingently Issuable Penny Warrants | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares', window );">Warrants issuable as a percentage of fully diluted ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Senior Bond Interest Rate Feature (included in other current assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RecognitionOfDerivativeAsset', window );">Recognition of derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue', window );">Recognition of derivative liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Before The Terms Of The Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | After The Terms Of The Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Principal Component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Interest Component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Issued To A New Bond Holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Issued To The Existing Noteholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Issued To The Existing And A New Bond Holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuesFairValueMeasurementLiabilities', window );">Issues fair value measurement liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 397,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 397,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Substantial Modification Of Convertible Bonds And Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Fair value changes, including accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities', window );">Gain losses recognized in profit or loss excluding exchange differences fair value measurement liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Reduction In Interest Rate If Additional Shares Are Issued Within Six Months | Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingSharesIssuancePeriodForInterestDecrease', window );">Shares issuance period for interest decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember', window );">Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Increase In The Face Value Of The Bonds | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStockAxis=alvo_ClassACommonStockMember', window );">Class A Shareholders | BCA Framework Agreement | Convertible Ordinary Shares | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants', window );">Stock shares issued during the period exercise of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,522,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Public warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities', window );">Stock shares issued during the period conversion of convertible securities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,306,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStockAxis=alvo_ClassACommonStockMember', window );">Class A Shareholders | BCA Framework Agreement | Convertible Ordinary Shares | Ordinary Shares | Payment Of In Kind Accrued Interest As A Result Of Warrant Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants', window );">Stock shares issued during the period exercise of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,137,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Public warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStockAxis=alvo_ClassACommonStockMember', window );">Class A Shareholders | BCA Framework Agreement | Convertible Shareholder Loan | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_GainLossOnExtinguishmentOfDebt', window );">Gain loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStockAxis=alvo_ClassACommonStockMember', window );">Class A Shareholders | BCA Framework Agreement | Convertible Shareholder Loan | Ordinary Shares | Finance Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Fair value changes, including accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStockAxis=alvo_ClassACommonStockMember', window );">Class A Shareholders | Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities', window );">Stock shares issued during the period conversion of convertible securities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStockAxis=alvo_ClassACommonStockMember', window );">Class A Shareholders | Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Ordinary Shares | Principal And Accrued Interest Component.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingConversionPeriodPriorToExtinguishment', window );">Conversion period prior to extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium', window );">Prepayment period with additional premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfStockAxis=alvo_ClassACommonStockMember', window );">Class A Shareholders | Convertible Bond Agreement Two Thousand And Eighteen | Convertible Bond | Ordinary Shares | Premium Component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AccruedInterestOnDebtExtinguished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AccruedInterestOnDebtExtinguished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdditionalExtensionPremiumToBondholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional extension premium to bondholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdditionalExtensionPremiumToBondholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AggregateBorrowingsIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate borrowings indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AggregateBorrowingsIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AssetAcquisitionConsiderationLoansAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration loans assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AssetAcquisitionConsiderationLoansAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingConversionPeriodPriorToExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Conversion Period Prior To Extinguishment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingConversionPeriodPriorToExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingPrepaymentPeriodWithAdditionalPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Prepayment Period With Additional Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingPrepaymentPeriodWithAdditionalPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingSharesIssuancePeriodForInterestDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Shares Issuance Period For Interest Decrease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingSharesIssuancePeriodForInterestDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingsConversionFeatureFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings conversion feature fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingsConversionFeatureFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingsRedemptionConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings redemption conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingsRedemptionConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingsRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings repurchase amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingsRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingsRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings repurchased face amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingsRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CarryingValueOfDebtExtinguished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CarryingValueOfDebtExtinguished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassOfWarrantsOrRightsExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassOfWarrantsOrRightsExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ExtensionPremiumToBondHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extension premium to bond holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ExtensionPremiumToBondHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ExtinguishmentOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ExtinguishmentOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ExtinguishmentOfBorrowingsAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of borrowings accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ExtinguishmentOfBorrowingsAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_GainLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_GainLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on extinguishment of debt including change in fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of shares on settlement of related party loans shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of shares on settlement of related party loans value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_MinimumAmountOfRestrictedCashToBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of restricted cash to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_MinimumAmountOfRestrictedCashToBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NetCashProceedsFromTheTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash proceeds from the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NetCashProceedsFromTheTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfSeparateInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Separate Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfSeparateInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percnetage of warrants issued representing fully diluted ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_PremiumPaymentOnBonds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premium payment on bonds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_PremiumPaymentOnBonds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_PrepaymentPenaltyPercentageOnBonds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment penalty percentage on bonds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_PrepaymentPenaltyPercentageOnBonds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ProceedsFromBorrowingsNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from borrowings net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ProceedsFromBorrowingsNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RecognitionOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RecognitionOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RecognitionOfDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RecognitionOfDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock shares issued during the period conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock shares issued during the period exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuable as a percentage of fully diluted ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAdjustmentToInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of instruments issued by the entity that represent indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) excluding exchange differences, recognised in profit or loss, on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest recognised as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuesFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in fair value measurement of liabilities resulting from issues of those liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuesFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment pledged as security for liabilities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 74<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_74_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LenderNameAxis=alvo_LandsbankinnHfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LenderNameAxis=alvo_LandsbankinnHfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_MaturityMonthAndYearAxis=alvo_MaturedOnMarch2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_MaturityMonthAndYearAxis=alvo_MaturedOnMarch2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_MaturityMonthAndYearAxis=alvo_MaturedOnAugust2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_MaturityMonthAndYearAxis=alvo_MaturedOnAugust2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_MaturityMonthAndYearAxis=alvo_MaturedOnAugust2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_MaturityMonthAndYearAxis=alvo_MaturedOnAugust2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_MaturityMonthAndYearAxis=alvo_MaturedOnApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_MaturityMonthAndYearAxis=alvo_MaturedOnApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_VariableRatesAxis=alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_VariableRatesAxis=alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alvo_ATPHoldingEhf.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alvo_ATPHoldingEhf.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_TrancheAConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_TrancheAConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_TrancheBConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_TrancheBConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AztiqConvertibleBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alvo_AztiqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alvo_AztiqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_AztiqConversionFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_AztiqConversionFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqFacilityLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AztiqFacilityLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingsTrancheAxis=alvo_BorrowingsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingsTrancheAxis=alvo_BorrowingsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingsTrancheAxis=alvo_BorrowingsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingsTrancheAxis=alvo_BorrowingsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AztiqFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AztiqFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityAndAztiqFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityAndAztiqFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AlvogenLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenSubordinatedLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AlvogenSubordinatedLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenLoanWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AlvogenLoanWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_FacilityLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_FacilityLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=alvo_FinalMaturityInDecember2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=alvo_FinalMaturityInDecember2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RiskExposuresAxis=alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RiskExposuresAxis=alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=alvo_FinalMaturityInDecember2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=alvo_FinalMaturityInDecember2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LenderNameAxis=alvo_ArionBankiHfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LenderNameAxis=alvo_ArionBankiHfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_OtherBorrowingsFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_OtherBorrowingsFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=alvo_UsdSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=alvo_UsdSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AgreementOneAxis=alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AgreementOneAxis=alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NatureOfFeesAxis=alvo_ConsentFeesToBondholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NatureOfFeesAxis=alvo_ConsentFeesToBondholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AgreementOneAxis=alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AgreementOneAxis=alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_ContingentlyIssuablePennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_ContingentlyIssuablePennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TrancheAxis=alvo_TrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TrancheAxis=alvo_TrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TrancheAxis=alvo_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TrancheAxis=alvo_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_SeniorBondInterestRateFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_SeniorBondInterestRateFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_SeniorBondWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_SeniorBondWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DetailsAxis=alvo_BeforeTheTermsOfTheSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DetailsAxis=alvo_BeforeTheTermsOfTheSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DetailsAxis=alvo_AfterTheTermsOfTheSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DetailsAxis=alvo_AfterTheTermsOfTheSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ComponentOfBondsPayableAxis=alvo_PrincipalComponentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ComponentOfBondsPayableAxis=alvo_PrincipalComponentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ComponentOfBondsPayableAxis=alvo_InterestComponentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ComponentOfBondsPayableAxis=alvo_InterestComponentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdditionalBondsIssuanceAxis=alvo_IssuedToANewBondHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdditionalBondsIssuanceAxis=alvo_IssuedToANewBondHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdditionalBondsIssuanceAxis=alvo_IssuedToTheExistingNoteholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdditionalBondsIssuanceAxis=alvo_IssuedToTheExistingNoteholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdditionalBondsIssuanceAxis=alvo_IssuedToTheExistingAndANewBondHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdditionalBondsIssuanceAxis=alvo_IssuedToTheExistingAndANewBondHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_EventAxis=alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_EventAxis=alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_EventAxis=alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_EventAxis=alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_EventAxis=alvo_IncreaseInTheFaceValueOfTheBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_EventAxis=alvo_IncreaseInTheFaceValueOfTheBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassOfStockAxis=alvo_ClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassOfStockAxis=alvo_ClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AgreementAxis=alvo_BcaFrameworkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AgreementAxis=alvo_BcaFrameworkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_EventAxis=alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_EventAxis=alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleShareholderLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleShareholderLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncomeStatementsLocationAxis=alvo_FinanceIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncomeStatementsLocationAxis=alvo_FinanceIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ComponentOfDebtConvertedIntoEquityAxis=alvo_PrincipalAndAccruedInterestComponent.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ComponentOfDebtConvertedIntoEquityAxis=alvo_PrincipalAndAccruedInterestComponent.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ComponentOfDebtConvertedIntoEquityAxis=alvo_PremiumComponentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ComponentOfDebtConvertedIntoEquityAxis=alvo_PremiumComponentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414741952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Summary of movements in the group's outstanding borrowings (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRollForward', window );"><strong>Borrowings [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Beginning Borrowings</a></td>
<td class="nump">$ 764,570<span></span>
</td>
<td class="nump">$ 400,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PaymentsForDebtIssueCost', window );">Recognition of deferred debt issue costs</a></td>
<td class="num">(6,115)<span></span>
</td>
<td class="num">(2,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AccretionderecognitionOfBorrowingsDiscount', window );">Accretion/derecognition of borrowings discount</a></td>
<td class="nump">15,770<span></span>
</td>
<td class="nump">35,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RecognitionOfNewBorrowingsDiscount', window );">Recognition of new borrowings discount</a></td>
<td class="num">(50,953)<span></span>
</td>
<td class="num">(43,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities', window );">Proceeds from new borrowings</a></td>
<td class="nump">275,311<span></span>
</td>
<td class="nump">467,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LoansFromRelatedPartyConvertedToEquity', window );">Loans from related party converted to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities', window );">Repayments of borrowings</a></td>
<td class="num">(99,367)<span></span>
</td>
<td class="num">(83,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DebtInstrumentIncreaseAccruedInterests', window );">Accrued interest</a></td>
<td class="nump">58,212<span></span>
</td>
<td class="nump">40,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AmortizationOfDeferredDebtIssueCosts', window );">Amortization of deferred debt issue costs</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign currency exchange difference</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Ending Borrowings</a></td>
<td class="nump">$ 960,159<span></span>
</td>
<td class="nump">$ 764,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AccretionderecognitionOfBorrowingsDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion/derecognition of borrowings discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AccretionderecognitionOfBorrowingsDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AmortizationOfDeferredDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of deferred debt issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AmortizationOfDeferredDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DebtInstrumentIncreaseAccruedInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument increase accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DebtInstrumentIncreaseAccruedInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LoansFromRelatedPartyConvertedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loans from related party converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LoansFromRelatedPartyConvertedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_PaymentsForDebtIssueCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for debt issue cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_PaymentsForDebtIssueCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from borrowing, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RecognitionOfNewBorrowingsDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of new borrowings discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RecognitionOfNewBorrowingsDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of borrowing, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430446400240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Summary of non-cash changes in the group&#8217;s outstanding borrowings (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRollForward', window );"><strong>Borrowings [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Beginning Borrowings</a></td>
<td class="nump">$ 764,570<span></span>
</td>
<td class="nump">$ 400,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Financing Cash flows</a></td>
<td class="nump">170,460<span></span>
</td>
<td class="nump">268,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease', window );">Capitalized loan cost changes</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="num">(2,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement', window );">Fair value changes, including accretion</a></td>
<td class="num">(35,183)<span></span>
</td>
<td class="num">(8,176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherChanges', window );">Other changes</a></td>
<td class="nump">57,580<span></span>
</td>
<td class="nump">41,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign currency exchange difference</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity', window );">Conversion to Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherNonCashMovements', window );">Other non-cash movements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Ending Borrowings</a></td>
<td class="nump">960,159<span></span>
</td>
<td class="nump">764,570<span></span>
</td>
<td class="nump">$ 400,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Gross private placement equity offering fee</a></td>
<td class="nump">4,141<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Payments for debt issue costs</a></td>
<td class="nump">9,004<span></span>
</td>
<td class="nump">12,102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleLoanNotesMember', window );">2022 Convertible Bonds and Aztiq Convertible Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRollForward', window );"><strong>Borrowings [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Beginning Borrowings</a></td>
<td class="nump">98,234<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Financing Cash flows</a></td>
<td class="nump">145,358<span></span>
</td>
<td class="nump">55,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease', window );">Capitalized loan cost changes</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="num">(2,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement', window );">Fair value changes, including accretion</a></td>
<td class="num">(36,071)<span></span>
</td>
<td class="num">(40,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherChanges', window );">Other changes</a></td>
<td class="nump">27,603<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign currency exchange difference</a></td>
<td class="num">(204)<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity', window );">Conversion to Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherNonCashMovements', window );">Other non-cash movements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Ending Borrowings</a></td>
<td class="nump">236,577<span></span>
</td>
<td class="nump">98,234<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceeds from current borrowings</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Payments for debt issue costs</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember', window );">Senior Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRollForward', window );"><strong>Borrowings [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Beginning Borrowings</a></td>
<td class="nump">530,506<span></span>
</td>
<td class="nump">394,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Financing Cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease', window );">Capitalized loan cost changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement', window );">Fair value changes, including accretion</a></td>
<td class="nump">888<span></span>
</td>
<td class="nump">32,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherChanges', window );">Other changes</a></td>
<td class="nump">18,017<span></span>
</td>
<td class="nump">34,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign currency exchange difference</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherNonCashMovements', window );">Other non-cash movements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Ending Borrowings</a></td>
<td class="nump">549,411<span></span>
</td>
<td class="nump">530,506<span></span>
</td>
<td class="nump">394,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_OtherBorrowingsMember', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRollForward', window );"><strong>Borrowings [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Beginning Borrowings</a></td>
<td class="nump">71,242<span></span>
</td>
<td class="nump">6,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Financing Cash flows</a></td>
<td class="nump">25,102<span></span>
</td>
<td class="nump">33,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease', window );">Capitalized loan cost changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement', window );">Fair value changes, including accretion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherChanges', window );">Other changes</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign currency exchange difference</a></td>
<td class="nump">1,279<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherNonCashMovements', window );">Other non-cash movements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Ending Borrowings</a></td>
<td class="nump">97,615<span></span>
</td>
<td class="nump">71,242<span></span>
</td>
<td class="nump">6,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember', window );">Alvogen Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BorrowingsRollForward', window );"><strong>Borrowings [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Beginning Borrowings</a></td>
<td class="nump">64,588<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Financing Cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease', window );">Capitalized loan cost changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement', window );">Fair value changes, including accretion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherChanges', window );">Other changes</a></td>
<td class="nump">11,968<span></span>
</td>
<td class="nump">4,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign currency exchange difference</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity', window );">Conversion to Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashChangesInOtherNonCashMovements', window );">Other non-cash movements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Ending Borrowings</a></td>
<td class="nump">$ 76,556<span></span>
</td>
<td class="nump">$ 64,588<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BorrowingsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BorrowingsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_InterestCostsCapitalizedPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Costs Capitalized, Period Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_InterestCostsCapitalizedPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NonCashChangesInOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Changes in Other Changes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NonCashChangesInOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NonCashChangesInOtherNonCashMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Changes in Other non-cash movements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NonCashChangesInOtherNonCashMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities reclassified into equity. [Refer: Equity; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 80A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in profit or loss for liabilities measured at fair value that are attributable to the change in unrealised gains or losses relating to those liabilities held at the end of the reporting period. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from current borrowings obtained. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleLoanNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleLoanNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_SeniorBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_OtherBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_OtherBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_AlvogenFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414710288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Schedule of maturities of outstanding borrowings (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="nump">$ 960,159<span></span>
</td>
<td class="nump">$ 764,570<span></span>
</td>
<td class="nump">$ 400,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="nump">38,025<span></span>
</td>
<td class="nump">19,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Within two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="nump">867,273<span></span>
</td>
<td class="nump">3,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Within three years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">696,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Within four years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="nump">37,857<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_ThereafterMember', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="nump">$ 12,072<span></span>
</td>
<td class="nump">$ 40,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=alvo_ThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=alvo_ThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430418653952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Payment to employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,736<span></span>
</td>
<td class="nump">$ 7,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset', window );">Increase decrease through other current liabilities and income net defined benefit liability asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total salary and other employee expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,909<span></span>
</td>
<td class="nump">$ 135,440<span></span>
</td>
<td class="nump">$ 109,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement', window );">Number of share options after tax witholding in share based payment arrangement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,465,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_ShareAppreciationRightsMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue', window );">Settlement of cash option as a liability fairvalue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue', window );">Decrease in equity from share-based payment transactions, cash settlement, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset', window );">Increase (decrease) in net defined benefit liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liabilities from share-based payment transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_ShareAppreciationRightsMember', window );">SARs | Selling, General And Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total salary and other employee expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">increase in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=alvo_FormerEmployeesMember', window );">Former Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination', window );">Number of year for issuing Shares after the closing of the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Payment to employee</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=alvo_FormerEmployeesMember', window );">Former Employees | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,755,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=alvo_ExistingEmployeesMember', window );">Existing Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination', window );">Number of year for issuing Shares after the closing of the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Payment to employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset', window );">Increase decrease through other current liabilities and income net defined benefit liability asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=alvo_ExistingEmployeesMember', window );">Existing Employees | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease In Equity From Share-Based Payment Transactions, Cash Settlement, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through other current liabilities and income net defined benefit liability asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities From Share-Based Payment Transactions, Cash Settlement, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options After Tax Witholding In Share based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of year for issuing Shares after the closing of the Business Combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_ShareAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_ShareAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=alvo_FormerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=alvo_FormerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=alvo_ExistingEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=alvo_ExistingEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430411114608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Incentive Plans - Schedule Of Movements In The Group's Employee Incentive Plan Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward', window );"><strong>Liability Asset Of Defined Benefit Plans [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning balance</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 14,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset', window );">Additions</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">5,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Payments</a></td>
<td class="num">(11,736)<span></span>
</td>
<td class="num">(7,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Prior to reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward', window );"><strong>Liability Asset Of Defined Benefit Plans [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning balance</a></td>
<td class="nump">12,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Ending balance</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">12,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember', window );">Reclassified to other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward', window );"><strong>Liability Asset Of Defined Benefit Plans [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning balance</a></td>
<td class="num">(11,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Ending balance</a></td>
<td class="num">$ (659)<span></span>
</td>
<td class="num">$ (11,773)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LiabilityAssetOfDefinedBenefitPlansRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Asset Of Defined Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LiabilityAssetOfDefinedBenefitPlansRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430412600800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Movements in RSUs (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">6,979,482<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">New grants during the year (in shares) | shares</a></td>
<td class="nump">820,602<span></span>
</td>
<td class="nump">7,659,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (in shares) | shares</a></td>
<td class="num">(1,587,929)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (in shares) | shares</a></td>
<td class="num">(2,466,374)<span></span>
</td>
<td class="num">(679,562)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">3,745,781<span></span>
</td>
<td class="nump">6,979,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract', window );"><strong>Weighted Average Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding', window );">Beginning Outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">8.79<span></span>
</td>
<td class="nump">6.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">7.11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">6.67<span></span>
</td>
<td class="nump">6.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding', window );">Ending Outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.04<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number And Weighted Average Fair Value Of Other Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value Of Equity Instruments Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value Per Share Other Equity Instruments Forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value per share other equity instruments granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value per share other equity instruments outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value per share other equity instruments vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430448693168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense from share-based payment transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,033<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Period of Requirements for Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416804432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of share-based payment expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense from share-based payment transactions</a></td>
<td class="nump">$ 18,033<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncomeStatementsLocationAxis=ifrs-full_CostOfSalesMember', window );">Cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense from share-based payment transactions</a></td>
<td class="nump">3,319<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncomeStatementsLocationAxis=alvo_ResearchAndDevelopmentExpensesMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense from share-based payment transactions</a></td>
<td class="nump">3,991<span></span>
</td>
<td class="nump">2,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncomeStatementsLocationAxis=alvo_GeneralAndAdministrativeExpensesMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense from share-based payment transactions</a></td>
<td class="nump">$ 10,723<span></span>
</td>
<td class="nump">$ 5,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncomeStatementsLocationAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncomeStatementsLocationAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncomeStatementsLocationAxis=alvo_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncomeStatementsLocationAxis=alvo_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncomeStatementsLocationAxis=alvo_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncomeStatementsLocationAxis=alvo_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414836608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>litigation_case</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LitigationAbstract', window );"><strong>Litigation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfLitigations', window );">Number of litigations | litigation_case</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LegalCost', window );">Legal expenses | $</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LegalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LegalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LitigationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LitigationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfLitigations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Litigations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfLitigations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430448370640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">168 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_LoansToRelatedParties', window );">Loans to related parties | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember', window );">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfLeaseAgreements', window );">Number of lease agreements</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember', window );">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company | April 2023 Lease Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember', window );">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company | Remaining 15 Lease Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alvo_FlokiFasteignirEhf.Member', window );">Fl&#243;ki Fasteignir ehf.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfLeaseAgreementsEnteredInto', window );">Number of lease agreements entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfLeasesTerminated', window );">Number of leases terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alvo_FlokiArtEhf.Member', window );">Fl&#243;ki-Art ehf.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WeightedAverageRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loans to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfLeaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Lease Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfLeaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfLeaseAgreementsEnteredInto">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Lease Agreements Entered Into</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfLeaseAgreementsEnteredInto</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfLeasesTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Leases Terminated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfLeasesTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WeightedAverageRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WeightedAverageRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LeaseFacilityAxis=alvo_April2023LeaseFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LeaseFacilityAxis=alvo_April2023LeaseFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_LeaseFacilityAxis=alvo_Remaining15LeaseFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_LeaseFacilityAxis=alvo_Remaining15LeaseFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alvo_FlokiFasteignirEhf.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alvo_FlokiFasteignirEhf.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alvo_FlokiArtEhf.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alvo_FlokiArtEhf.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413726864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Summary of Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">$ 32,781<span></span>
</td>
<td class="nump">$ 21,141<span></span>
</td>
<td class="nump">$ 39,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="nump">3,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">217,956<span></span>
</td>
<td class="nump">163,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Gross private placement equity offering fee</a></td>
<td class="nump">4,141<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenLuxHoldingsSRLMember', window );">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">11,968<span></span>
</td>
<td class="nump">5,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">76,556<span></span>
</td>
<td class="nump">64,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AtpHoldingsEhfMember', window );">ATP Holdings ehf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">9,193<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">49,560<span></span>
</td>
<td class="nump">81,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Gross private placement equity offering fee</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqFjrfestingarEhfMember', window );">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember', window );">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,189<span></span>
</td>
<td class="nump">7,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiEyjolfurEhfMember', window );">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqConsultingEhfMember', window );">Aztiq Consulting ehf. &#8211; Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiArtEhfMember', window );">Fl&#243;ki-Art ehf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenIcelandEhf.SisterCompanyMember', window );">Alvogen Iceland ehf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">465<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">2,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEhf.SisterCompanyMember', window );">Alvogen ehf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenUKSisterCompanyMember', window );">Alvogen UK - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenFinanceB.VMember', window );">Alvogen Finance B.V. - Sister Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">3,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember', window );">Lotus Pharmaceuticals Co. Ltd. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">7,440<span></span>
</td>
<td class="nump">7,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusInternationalPteltdMember', window );">Lotus International Pte. Ltd. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEmergingMarketsSisterCompanyMember', window );">Alvogen Emerging Markets - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenKoreaCo.LtdSisterCompanyMember', window );">Alvogen Korea co. Ltd - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenInc.SisterCompanyMember', window );">Alvogen Inc. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember', window );">Alvotech and CCHT Biopharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AdalvoLimitedMember', window );">Adalvo Limited - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AdalvoUKMember', window );">Adalvo UK - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiInvestEhfMember', window );">Fl&#243;ki Invest ehf - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiHoldingsS.aR.lMember', window );">Floki Holdings S.&#224; r.l. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_L41EhfMember', window );">L41 ehf.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenMaltaSh.ServicesSisterCompanyMember', window );">Alvogen Malta Sh. Services - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenSpainSlMember', window );">Alvogen Spain SL - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_NorwichClinicalServicesLtdMember', window );">Norwich Clinical Services Ltd - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignaflagiEyjlfurhfMember', window );">Fasteignaf&#233;lagi&#240; Eyj&#243;lfur ehf - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">69,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiFasteignirEhfMember', window );">Fl&#243;ki fasteignir ehf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="nump">$ 11,466<span></span>
</td>
<td class="nump">8,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenPharmaPvtLtdSisterCompanyMember', window );">Alvogen Pharma Pvt Ltd - Sister Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_Lambahagavegur7EhfMember', window );">Lambahagavegur 7 ehf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Payables/ borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the rendering of services in related party transactions. [Refer: Revenue; Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesReceivedRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of services received in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesReceivedRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenLuxHoldingsSRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenLuxHoldingsSRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AtpHoldingsEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AtpHoldingsEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqFjrfestingarEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqFjrfestingarEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiEyjolfurEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiEyjolfurEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqConsultingEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqConsultingEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiArtEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiArtEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenIcelandEhf.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenIcelandEhf.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEhf.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEhf.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenUKSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenUKSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenFinanceB.VMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenFinanceB.VMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusInternationalPteltdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusInternationalPteltdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEmergingMarketsSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEmergingMarketsSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenKoreaCo.LtdSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenKoreaCo.LtdSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenInc.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenInc.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AdalvoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AdalvoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AdalvoUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AdalvoUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiInvestEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiInvestEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiHoldingsS.aR.lMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiHoldingsS.aR.lMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_L41EhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_L41EhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenMaltaSh.ServicesSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenMaltaSh.ServicesSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenSpainSlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenSpainSlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_NorwichClinicalServicesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_NorwichClinicalServicesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignaflagiEyjlfurhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignaflagiEyjlfurhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiFasteignirEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FlokiFasteignirEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenPharmaPvtLtdSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenPharmaPvtLtdSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_Lambahagavegur7EhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_Lambahagavegur7EhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416891472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Schedule of Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">$ 32,781<span></span>
</td>
<td class="nump">$ 21,141<span></span>
</td>
<td class="nump">$ 39,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="nump">3,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember', window );">Alvogen Lux Holdings S.&#224; r.l. &#8211; Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember', window );">Aztiq Pharma Partners S.&#224; r.l. &#8211; Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenAztiqABSisterCompanyMember', window );">Alvogen Aztiq AB &#8211; Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqFjrfestingarEhfMember', window );">Aztiq Fj&#225;rfestingar ehf. &#8211; Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember', window );">Fasteignaf&#233;lagi&#240; S&#230;mundur hf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,189<span></span>
</td>
<td class="nump">7,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenIcelandEhf.SisterCompanyMember', window );">Alvogen Iceland ehf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">465<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">2,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEhf.SisterCompanyMember', window );">Alvogen ehf. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenUKSisterCompanyMember', window );">Alvogen UK - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember', window );">Lotus Pharmaceuticals Co. Ltd. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEmergingMarketsSisterCompanyMember', window );">Alvogen Emerging Markets - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenKoreaCo.LtdSisterCompanyMember', window );">Alvogen Korea co. Ltd - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenInc.SisterCompanyMember', window );">Alvogen Inc. - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenMaltaSh.ServicesSisterCompanyMember', window );">Alvogen Malta Sh. Services - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenPharmaPvtLtdSisterCompanyMember', window );">Alvogen Pharma Pvt Ltd - Sister Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_HRJAFEhfSisterCompanyMember', window );">HRJ&#193;F ehf - Sister company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_L41EhfMember', window );">L41 ehf.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_Lambhagavegur7EhfMember', window );">Lambhagavegur 7 ehf.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Purchased service / interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions', window );">Sold service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of information about board of directors remuneration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the rendering of services in related party transactions. [Refer: Revenue; Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesReceivedRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of services received in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesReceivedRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenAztiqABSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenAztiqABSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqFjrfestingarEhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AztiqFjrfestingarEhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FasteignafelagiSmundurHf.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenIcelandEhf.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenIcelandEhf.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEhf.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEhf.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenUKSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenUKSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEmergingMarketsSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenEmergingMarketsSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenKoreaCo.LtdSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenKoreaCo.LtdSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenInc.SisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenInc.SisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenMaltaSh.ServicesSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenMaltaSh.ServicesSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenPharmaPvtLtdSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AlvogenPharmaPvtLtdSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_HRJAFEhfSisterCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_HRJAFEhfSisterCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_L41EhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_L41EhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_Lambhagavegur7EhfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_Lambhagavegur7EhfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413691872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Schedule of Information About Board of Directors Remuneration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 9,456<span></span>
</td>
<td class="nump">$ 5,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">266,821,844<span></span>
</td>
<td class="nump">252,160,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Salaries and benefits</a></td>
<td class="nump">$ 6,511<span></span>
</td>
<td class="nump">$ 6,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CompensationStatusAxis=alvo_NetCompensationExpenseMember', window );">Net Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">1,175,459<span></span>
</td>
<td class="nump">1,133,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_RobertWessmanMember', window );">Robert Wessman, Chairman of the board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Salaries and benefits</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_RobertWessmanMember', window );">Robert Wessman, Chairman of the board | Compensation Waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_RichardDaviesMember', window );">Richard Davies, Vice-Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">1,143,713<span></span>
</td>
<td class="nump">1,133,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AnnMerchantMember', window );">Ann Merchant, Board Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_ArniHararsonMember', window );">&#193;rni Har&#240;arson, Board Member* | Compensation Waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FaysalKalmouaMember', window );">Faysal Kalmoua, Board | Compensation Waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LindaMcgoldrickMember', window );">Linda McGoldrick, Board Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LisaGraverMember', window );">Lisa Graver, Board Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_ThomasEkmanMember', window );">Tomas Ekman, Board Member*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_ThomasEkmanMember', window );">Tomas Ekman, Board Member* | Compensation Waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_MarkLevickCeoMember', window );">Mark Levick CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Salaries and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_OtherExecutiveTeamMember', window );">Other Executive Team Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="nump">9,456<span></span>
</td>
<td class="nump">5,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Salaries and benefits</a></td>
<td class="nump">5,020<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_HirofumiImaiBoardMember', window );">Hirofumi Imai, Board member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems', window );"><strong>Schedule of Information About Board of Directors Remuneration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DirectorFees', window );">Board fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long- term benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DirectorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Director Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DirectorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of information about board of directors remuneration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CompensationStatusAxis=alvo_NetCompensationExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CompensationStatusAxis=alvo_NetCompensationExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_RobertWessmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_RobertWessmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CompensationStatusAxis=alvo_CompensationWaivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CompensationStatusAxis=alvo_CompensationWaivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_RichardDaviesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_RichardDaviesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AnnMerchantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_AnnMerchantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_ArniHararsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_ArniHararsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FaysalKalmouaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_FaysalKalmouaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LindaMcgoldrickMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LindaMcgoldrickMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LisaGraverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_LisaGraverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_ThomasEkmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_ThomasEkmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_MarkLevickCeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_MarkLevickCeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_OtherExecutiveTeamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_OtherExecutiveTeamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_HirofumiImaiBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=alvo_HirofumiImaiBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413046288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Liabilities - Schedule of Composition of Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentLiabilitiesAbstract', window );"><strong>Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses', window );">Unpaid salary and salary related expenses</a></td>
<td class="nump">$ 31,340<span></span>
</td>
<td class="nump">$ 15,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CurrentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CurrentAccruedVacation', window );">Accrued vacation leave</a></td>
<td class="nump">6,075<span></span>
</td>
<td class="nump">5,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CurrentEmployeeIncentivePlan', window );">Employee incentive plan</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">12,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">21,313<span></span>
</td>
<td class="nump">18,720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 62,720<span></span>
</td>
<td class="nump">$ 54,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CurrentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CurrentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current accrued salary and salary related expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CurrentAccruedVacation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current accrued vacation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CurrentAccruedVacation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CurrentEmployeeIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current employee incentive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CurrentEmployeeIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430415619072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interests In Joint Ventures - Schedule of Information About Joint Venture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesLineItems', window );"><strong>Disclosure of joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Carrying Amount</a></td>
<td class="nump">$ 18,494<span></span>
</td>
<td class="nump">$ 48,568<span></span>
</td>
<td class="nump">$ 55,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember', window );">Alvotech &amp; CCHN Biopharmaceutical Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesLineItems', window );"><strong>Disclosure of joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture', window );">Place of business</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Carrying Amount</a></td>
<td class="nump">$ 18,494<span></span>
</td>
<td class="nump">$ 48,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of a joint venture. [Refer: Principal place of business; Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414980976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interests In Joint Ventures - Schedule of Changes in Groups Investment in a Joint Venture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_InvestmentsAccountedForUsingEquityMethodRollForward', window );"><strong>Investments Accounted For Using Equity Method [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Balance at 1 January</a></td>
<td class="nump">$ 48,568<span></span>
</td>
<td class="nump">$ 55,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod', window );">Share in losses</a></td>
<td class="num">(7,153)<span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
<td class="num">$ (2,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss on investment in joint venture</a></td>
<td class="num">(21,519)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax', window );">Translation difference</a></td>
<td class="num">(1,402)<span></span>
</td>
<td class="num">(4,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Balance at 31 December</a></td>
<td class="nump">$ 18,494<span></span>
</td>
<td class="nump">$ 48,568<span></span>
</td>
<td class="nump">$ 55,307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_InvestmentsAccountedForUsingEquityMethodRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments Accounted For Using Equity Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_InvestmentsAccountedForUsingEquityMethodRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of gains losses of joint ventures on exchange differences on translation net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416499360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interests In Joint Ventures - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesAbstract', window );"><strong>Disclosure of joint ventures [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities', window );">Dividends received from joint ventures</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommitmentsInRelationToJointVentures', window );">Commitments in relation to joint ventures</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures', window );">Commitments of joint venture partners in relation to joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures', window );">Contingent liabilities incurred in relation to interests in joint ventures</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments of joint venture partners in relation to joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsInRelationToJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The commitments that the entity has relating to its joint ventures as specified in paragraphs B18-B20 of IFRS 12. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsInRelationToJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities incurred in relation to interests in joint ventures. [Refer: Contingent liabilities [member]; Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow representing dividends received from joint ventures, classified as investing activities. [Refer: Joint ventures [member]; Dividends received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430417222000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Financial Assets Measured at Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,157<span></span>
</td>
<td class="nump">$ 66,427<span></span>
</td>
<td class="nump">$ 17,556<span></span>
</td>
<td class="nump">$ 31,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">26,132<span></span>
</td>
<td class="nump">25,187<span></span>
</td>
<td class="nump">$ 10,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">41,292<span></span>
</td>
<td class="nump">32,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentAsset', window );">Other current assets</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">5,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties', window );">Receivables from related parties</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherNoncurrentAsset', window );">Other long-term assets</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets</a></td>
<td class="nump">$ 80,848<span></span>
</td>
<td class="nump">$ 136,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherNoncurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non-current asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherNoncurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables due from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430467183024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Financial Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (measured at amortized cost)</a></td>
<td class="nump">$ 960,159<span></span>
</td>
<td class="nump">$ 764,570<span></span>
</td>
<td class="nump">$ 400,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivative financial liabilities (measured at FVTPL)</a></td>
<td class="nump">520,553<span></span>
</td>
<td class="nump">380,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPayablesToRelatedParties', window );">Other long-term liability to related party (measured at amortized cost)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan', window );">Long-term incentive plan (measured at FVTPL)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables (measured at amortized cost)</a></td>
<td class="nump">80,563<span></span>
</td>
<td class="nump">49,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities (measured at amortized cost)</a></td>
<td class="nump">115,315<span></span>
</td>
<td class="nump">40,532<span></span>
</td>
<td class="nump">$ 122,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Liabilities to related parties</a></td>
<td class="nump">9,851<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OtherCurrentLiability', window );">Other current liabilities</a></td>
<td class="nump">61,873<span></span>
</td>
<td class="nump">53,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities</a></td>
<td class="nump">$ 1,748,314<span></span>
</td>
<td class="nump">$ 1,297,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial liabilities at amortized cost and financial liabilities at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OtherCurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OtherCurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408612576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Material Differences Between the Fair Value and Carrying Amount (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems', window );"><strong>Disclosure in tabular form of carrying amount and financial amount of certain borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">$ 862,544<span></span>
</td>
<td class="nump">$ 693,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BondsIssuedAtFairValue', window );">Fair Value</a></td>
<td class="nump">944,102<span></span>
</td>
<td class="nump">720,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondsMember', window );">Senior Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems', window );"><strong>Disclosure in tabular form of carrying amount and financial amount of certain borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">549,411<span></span>
</td>
<td class="nump">530,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BondsIssuedAtFairValue', window );">Fair Value</a></td>
<td class="nump">559,867<span></span>
</td>
<td class="nump">535,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_AztiqConvertibleBondMember', window );">Aztiq Convertible Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems', window );"><strong>Disclosure in tabular form of carrying amount and financial amount of certain borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">80,663<span></span>
</td>
<td class="nump">65,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BondsIssuedAtFairValue', window );">Fair Value</a></td>
<td class="nump">84,756<span></span>
</td>
<td class="nump">65,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_A2022ConvertibleBondsMember', window );">2022 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems', window );"><strong>Disclosure in tabular form of carrying amount and financial amount of certain borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">155,914<span></span>
</td>
<td class="nump">32,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BondsIssuedAtFairValue', window );">Fair Value</a></td>
<td class="nump">217,419<span></span>
</td>
<td class="nump">52,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_AlvogenFacilityMember', window );">Alvogen Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems', window );"><strong>Disclosure in tabular form of carrying amount and financial amount of certain borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bonds issued</a></td>
<td class="nump">76,556<span></span>
</td>
<td class="nump">64,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_BondsIssuedAtFairValue', window );">Fair Value</a></td>
<td class="nump">$ 82,060<span></span>
</td>
<td class="nump">$ 66,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_BondsIssuedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonds issued at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_BondsIssuedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of carrying amount and financial amount of certain borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_AztiqConvertibleBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_AztiqConvertibleBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_A2022ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_A2022ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_AlvogenFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_AlvogenFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430517043008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">$ 520,553<span></span>
</td>
<td class="nump">$ 381,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">45,623<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">356,100<span></span>
</td>
<td class="nump">286,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">118,830<span></span>
</td>
<td class="nump">84,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">19,715<span></span>
</td>
<td class="nump">45,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">19,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember', window );">Tranche A Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">118,830<span></span>
</td>
<td class="nump">38,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember', window );">Tranche A Conversion Feature | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember', window );">Tranche A Conversion Feature | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember', window );">Tranche A Conversion Feature | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">118,830<span></span>
</td>
<td class="nump">38,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondInterestRateFeatureMember', window );">Senior Bond Interest Rate Feature (included in other current assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondInterestRateFeatureMember', window );">Senior Bond Interest Rate Feature (included in other current assets) | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondInterestRateFeatureMember', window );">Senior Bond Interest Rate Feature (included in other current assets) | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondInterestRateFeatureMember', window );">Senior Bond Interest Rate Feature (included in other current assets) | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember', window );">Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">349,900<span></span>
</td>
<td class="nump">276,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember', window );">Predecessor Earn Out Shares | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember', window );">Predecessor Earn Out Shares | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">349,900<span></span>
</td>
<td class="nump">276,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember', window );">Predecessor Earn Out Shares | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember', window );">OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">25,908<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember', window );">OACB Warrants | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">25,908<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember', window );">OACB Warrants | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember', window );">OACB Warrants | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of fair value of derivative financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondInterestRateFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondInterestRateFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430413493824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Provides a Reconciliation of Level 3 Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerivativeFinancialLiabilitiesRollForward', window );"><strong>Derivative Financial Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Revaluation</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerivativeFinancialLiabilitiesRollForward', window );"><strong>Derivative Financial Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Beginning balances</a></td>
<td class="nump">45,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Revaluation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities', window );">Transfer to Level 1</a></td>
<td class="num">(45,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettlementsFairValueMeasurementLiabilities', window );">Extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Ending balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 45,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Tranche A Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerivativeFinancialLiabilitiesRollForward', window );"><strong>Derivative Financial Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Beginning balances</a></td>
<td class="nump">38,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuesFairValueMeasurementLiabilities', window );">Issues fair value measurement liabilities</a></td>
<td class="nump">45,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Revaluation</a></td>
<td class="nump">35,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Ending balances</a></td>
<td class="nump">118,830<span></span>
</td>
<td class="nump">38,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Senior Bond Interest Rate Feature (included in other current assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerivativeFinancialLiabilitiesRollForward', window );"><strong>Derivative Financial Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Beginning balances</a></td>
<td class="nump">851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettlementsFairValueMeasurementLiabilities', window );">Extinguishment</a></td>
<td class="num">(851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Ending balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 | Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DerivativeFinancialLiabilitiesRollForward', window );"><strong>Derivative Financial Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities', window );">Transfer to Level 1</a></td>
<td class="num">$ (19,700)<span></span>
</td>
<td class="num">$ (45,300)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DerivativeFinancialLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DerivativeFinancialLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuesFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in fair value measurement of liabilities resulting from issues of those liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuesFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SettlementsFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in the fair value measurement of liabilities resulting from settlements. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SettlementsFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondInterestRateFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondInterestRateFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430421555072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>Dec. 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,553<span></span>
</td>
<td class="nump">$ 381,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseInOutstandingBondsFairValue', window );">Increase in outstanding bonds fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid', window );">(Loss) / gain on extinguishment of financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(27,311)<span></span>
</td>
<td class="nump">$ 151,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsOutstanding', window );">Class of warrants or rights outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,363,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,157<span></span>
</td>
<td class="nump">188,419<span></span>
</td>
<td class="nump">117,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,390<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,882,583<span></span>
</td>
<td class="nump">$ 1,392,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,821,844<span></span>
</td>
<td class="nump">252,160,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,821,844<span></span>
</td>
<td class="nump">252,160,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PennyWarrantsMember', window );">Penny Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,479,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember', window );">Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Convertible Bond Agreement Two Thousand And Eighteen | Contingently Issuable Penny Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsExercisePricePerShare', window );">Class of warrants or rights exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember', window );">Convertible Bond | Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two | Tranche B | Convertible Bond Agreement Two Thousand And Eighteen | Contingently Issuable Penny Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares', window );">Warrants issuable as a percentage of fully diluted ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember', window );">Convertible Bond | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember', window );">Convertible Bond | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,715<span></span>
</td>
<td class="nump">$ 45,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares', window );">Warrants issuable as a percentage of fully diluted ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,479,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsOutstanding', window );">Class of warrants or rights outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,718,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_TrancheOfSeniorBondWarrantsPercentage', window );">Tranche of senior bond warrants percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Revaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember', window );">Tranche A Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,830<span></span>
</td>
<td class="nump">38,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember', window );">Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,900<span></span>
</td>
<td class="nump">276,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AggregatePeriodForDeterminingTheSharePrice', window );">Aggregate period for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_SharesPrice', window );">Shares price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ThresholdDaysForDeterminingTheSharePrice', window );">Number of threshold days for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days for determining the share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember', window );">OACB Earn Out Shares | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_SharesPrice', window );">Shares price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember', window );">OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,908<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsOutstanding', window );">Class of warrants or rights outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,916,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsExercisePricePerShare', window );">Class of warrants or rights exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553.552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember', window );">OACB Warrants | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfSharesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant or right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,100<span></span>
</td>
<td class="nump">286,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 | Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities', window );">Transfers out of Level 3 of fair value hierarchy, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
<td class="nump">45,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 | Tranche A Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 | Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,900<span></span>
</td>
<td class="nump">276,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 | OACB Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 | OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,830<span></span>
</td>
<td class="nump">84,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities', window );">Transfers out of Level 3 of fair value hierarchy, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettlementsFairValueMeasurementLiabilities', window );">Extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Revaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Tranche A Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,830<span></span>
</td>
<td class="nump">38,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Revaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Predecessor Earn Out Shares | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AggregatePeriodForDeterminingTheSharePrice', window );">Aggregate period for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_SharesPrice', window );">Shares price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ThresholdDaysForDeterminingTheSharePrice', window );">Number of threshold days for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days for determining the share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestingPercentageOfShares', window );">Vesting percentage of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Predecessor Earn Out Shares | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_SharesPrice', window );">Shares price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ThresholdDaysForDeterminingTheSharePrice', window );">Number of threshold days for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days for determining the share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestingPercentageOfShares', window );">Vesting percentage of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | OACB earnout shares | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestingPercentageOfShares', window );">Vesting percentage of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | OACB earnout shares | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_VestingPercentageOfShares', window );">Vesting percentage of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | OACB Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AggregatePeriodForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate period for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AggregatePeriodForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassOfWarrantsOrRightsExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassOfWarrantsOrRightsExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassOfWarrantsOrRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassOfWarrantsOrRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncreaseInOutstandingBondsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Outstanding Bonds Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncreaseInOutstandingBondsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfSharesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares called by each warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfSharesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_SharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_SharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ThresholdDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ThresholdDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TrancheOfSeniorBondWarrantsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tranche of Senior Bond Warrants, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TrancheOfSeniorBondWarrantsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_VestingPercentageOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting percentage of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_VestingPercentageOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuable as a percentage of fully diluted ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 11<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_11&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SettlementsFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in the fair value measurement of liabilities resulting from settlements. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SettlementsFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_PennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=alvo_ConvertibleBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AgreementOneAxis=alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AgreementOneAxis=alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AgreementAxis=alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_ContingentlyIssuablePennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=alvo_ContingentlyIssuablePennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TrancheAxis=alvo_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TrancheAxis=alvo_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_TrancheAConversionFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TrancheAxis=alvo_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TrancheAxis=alvo_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TrancheAxis=alvo_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TrancheAxis=alvo_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_OacbEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_OacbEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430414731920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Assumptions and Inputs (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">266,821,844<span></span>
</td>
<td class="nump">252,160,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember', window );">Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">38,330,000<span></span>
</td>
<td class="nump">38,330,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_OacbEarnoutSharesMember', window );">OACB earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares at year-end (in shares)</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=alvo_StockPriceMember', window );">Stock price | Embedded derivative liabilities associated with convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">11.48<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=alvo_StockPriceMember', window );">Stock price | Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">11.48<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=alvo_StockPriceMember', window );">Stock price | OACB earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">11.48<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=alvo_ConversionPriceOfBondsMember', window );">Conversion price | Embedded derivative liabilities associated with convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility rate | Embedded derivative liabilities associated with convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.575<span></span>
</td>
<td class="nump">0.450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility rate | Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.550<span></span>
</td>
<td class="nump">0.450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility rate | OACB earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.550<span></span>
</td>
<td class="nump">0.450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Risk-free interest rate | Embedded derivative liabilities associated with convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.042<span></span>
</td>
<td class="nump">0.042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Risk-free interest rate | Predecessor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.0397<span></span>
</td>
<td class="nump">0.0405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Risk-free interest rate | OACB earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.0397<span></span>
</td>
<td class="nump">0.0405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=alvo_DividendYieldMember', window );">Dividend yield | Embedded derivative liabilities associated with convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=alvo_RiskyYieldMember', window );">Risky yield | Embedded derivative liabilities associated with convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.163<span></span>
</td>
<td class="nump">0.193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_PredecessorEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_OacbEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_OacbEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=alvo_StockPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=alvo_StockPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=alvo_ConversionPriceOfBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=alvo_ConversionPriceOfBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=alvo_DividendYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=alvo_DividendYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=alvo_RiskyYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=alvo_RiskyYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430416768416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Interest Rate Sensitivity Analysis (Details) - Interest rate risk - Variable interest rate financial liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems', window );"><strong>Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Effect on financial statement</a></td>
<td class="num">$ (89)<span></span>
</td>
<td class="num">$ (186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Effect on financial statement</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible decrease in an unobservable input. [Refer: Tax income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_VariableInterestRateFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_VariableInterestRateFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430517041504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Impact on the Groups Operations (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems', window );"><strong>Disclosure in tabular form of foreign exchange rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate</a></td>
<td class="nump">1.105<span></span>
</td>
<td class="nump">1.061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">1.091<span></span>
</td>
<td class="nump">1.052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PercentageChangeInForeignExchangeRate', window );">Change</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems', window );"><strong>Disclosure in tabular form of foreign exchange rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate</a></td>
<td class="nump">1.275<span></span>
</td>
<td class="nump">1.204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">1.266<span></span>
</td>
<td class="nump">1.233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PercentageChangeInForeignExchangeRate', window );">Change</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ISK', window );">ISK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems', window );"><strong>Disclosure in tabular form of foreign exchange rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate</a></td>
<td class="nump">0.007<span></span>
</td>
<td class="nump">0.007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">0.007<span></span>
</td>
<td class="nump">0.007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PercentageChangeInForeignExchangeRate', window );">Change</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems', window );"><strong>Disclosure in tabular form of foreign exchange rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate</a></td>
<td class="nump">1.188<span></span>
</td>
<td class="nump">1.071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">1.156<span></span>
</td>
<td class="nump">1.047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PercentageChangeInForeignExchangeRate', window );">Change</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_INR', window );">INR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems', window );"><strong>Disclosure in tabular form of foreign exchange rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate</a></td>
<td class="nump">0.012<span></span>
</td>
<td class="nump">0.012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">0.012<span></span>
</td>
<td class="nump">0.013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_PercentageChangeInForeignExchangeRate', window );">Change</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of foreign exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_PercentageChangeInForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in foreign exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_PercentageChangeInForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ISK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ISK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_INR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_INR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430371356816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Groups Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems', window );"><strong>Disclosure in tabular form of assets and liabilities denominated in foreign currencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="nump">$ 950,090<span></span>
</td>
<td class="nump">$ 828,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="nump">1,882,583<span></span>
</td>
<td class="nump">1,392,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems', window );"><strong>Disclosure in tabular form of assets and liabilities denominated in foreign currencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="nump">36,568<span></span>
</td>
<td class="nump">36,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="nump">46,303<span></span>
</td>
<td class="nump">26,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="num">(9,735)<span></span>
</td>
<td class="nump">9,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems', window );"><strong>Disclosure in tabular form of assets and liabilities denominated in foreign currencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="nump">3,479<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="num">(3,410)<span></span>
</td>
<td class="num">(1,427)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ISK', window );">ISK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems', window );"><strong>Disclosure in tabular form of assets and liabilities denominated in foreign currencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="nump">3,247<span></span>
</td>
<td class="nump">49,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="nump">144,812<span></span>
</td>
<td class="nump">109,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="num">(141,565)<span></span>
</td>
<td class="num">(60,023)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems', window );"><strong>Disclosure in tabular form of assets and liabilities denominated in foreign currencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="nump">7,488<span></span>
</td>
<td class="nump">7,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="num">(7,153)<span></span>
</td>
<td class="num">(7,236)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_INR', window );">INR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems', window );"><strong>Disclosure in tabular form of assets and liabilities denominated in foreign currencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Liabilities</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="num">$ (369)<span></span>
</td>
<td class="num">$ (506)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of assets and liabilities denominated in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ISK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ISK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_INR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_INR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408649968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Analysis Assumes that all Other Variables (Details) - Currency risk - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems', window );"><strong>Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Variable increase</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Variable decrease</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems', window );"><strong>Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="num">$ (974)<span></span>
</td>
<td class="num">$ (991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems', window );"><strong>Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="num">(341)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">ISK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems', window );"><strong>Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="num">(14,156)<span></span>
</td>
<td class="num">(6,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="nump">14,156<span></span>
</td>
<td class="nump">6,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems', window );"><strong>Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="num">(715)<span></span>
</td>
<td class="num">(724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">INR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems', window );"><strong>Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities', window );">Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of currency risk sensitivity analysis on profit before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible decrease in an unobservable input. [Refer: Tax income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ISK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ISK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_INR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_INR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430408684752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfCreditRiskLineItems', window );"><strong>Disclosure Of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">$ 80,848<span></span>
</td>
<td class="nump">$ 136,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=alvo_CashEquivalentsAndCashMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfCreditRiskLineItems', window );"><strong>Disclosure Of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">11,157<span></span>
</td>
<td class="nump">66,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=alvo_RestrictedCashMember', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfCreditRiskLineItems', window );"><strong>Disclosure Of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">26,132<span></span>
</td>
<td class="nump">25,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfCreditRiskLineItems', window );"><strong>Disclosure Of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">$ 43,559<span></span>
</td>
<td class="nump">$ 44,884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaximumExposureToCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35K<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35K_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaximumExposureToCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_CashEquivalentsAndCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_CashEquivalentsAndCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430421099920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Contractual Maturities of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">$ 80,848<span></span>
</td>
<td class="nump">$ 136,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,951,502<span></span>
</td>
<td class="nump">1,593,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_NonInterestBearingFinancialLiabilitiesMember', window );">Non-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">142,436<span></span>
</td>
<td class="nump">112,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_FixedInterestBearingBorrowingsMember', window );">Fixed-interest bearing - Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,167,494<span></span>
</td>
<td class="nump">1,008,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_DerivativesMember', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">520,553<span></span>
</td>
<td class="nump">380,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_VariableInterestBearingBorrowingsMember', window );">Variable-interest bearing - Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">121,019<span></span>
</td>
<td class="nump">92,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=alvo_NonInterestBearingFinancialAssetsMember', window );">Non-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">43,223<span></span>
</td>
<td class="nump">40,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=alvo_VariableInterestBearingFinancialAssetsMember', window );">Variable-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">37,625<span></span>
</td>
<td class="nump">96,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">54,380<span></span>
</td>
<td class="nump">106,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">253,740<span></span>
</td>
<td class="nump">175,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year | Non-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">142,436<span></span>
</td>
<td class="nump">104,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year | Fixed-interest bearing - Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">66,309<span></span>
</td>
<td class="nump">45,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year | Variable-interest bearing - Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">44,995<span></span>
</td>
<td class="nump">25,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year | Non-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">43,223<span></span>
</td>
<td class="nump">40,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within one year | Variable-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">11,157<span></span>
</td>
<td class="nump">66,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">One to two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,631,936<span></span>
</td>
<td class="nump">74,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">One to two years | Non-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">One to two years | Fixed-interest bearing - Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,101,185<span></span>
</td>
<td class="nump">66,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">One to two years | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">520,553<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">One to two years | Variable-interest bearing - Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">10,198<span></span>
</td>
<td class="nump">8,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">One to two years | Non-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">One to two years | Variable-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">26,468<span></span>
</td>
<td class="nump">29,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">65,826<span></span>
</td>
<td class="nump">1,344,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember', window );">Thereafter | Non-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember', window );">Thereafter | Fixed-interest bearing - Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">896,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember', window );">Thereafter | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">380,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember', window );">Thereafter | Variable-interest bearing - Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">65,826<span></span>
</td>
<td class="nump">59,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember', window );">Thereafter | Non-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember', window );">Thereafter | Variable-interest bearing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">$ 26,468<span></span>
</td>
<td class="nump">$ 29,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of contractual maturities of financial assets and financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_NonInterestBearingFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_NonInterestBearingFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_FixedInterestBearingBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_FixedInterestBearingBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_VariableInterestBearingBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=alvo_VariableInterestBearingBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_NonInterestBearingFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_NonInterestBearingFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=alvo_VariableInterestBearingFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=alvo_VariableInterestBearingFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=alvo_LaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430446397328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems', window );"><strong>Disclosure In Entirety of Supplemental Cash Flow Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid', window );">Acquisition of property, plant and equipment in trade payables and other current liabilities</a></td>
<td class="nump">$ 2,266<span></span>
</td>
<td class="nump">$ 4,131<span></span>
</td>
<td class="nump">$ 3,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid', window );">Acquisition of intangibles in trade payables and other current liabilities</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">4,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities', window );">Right-of-use assets obtained through new operating leases</a></td>
<td class="nump">74,109<span></span>
</td>
<td class="nump">9,583<span></span>
</td>
<td class="nump">18,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond', window );">Purchase of Facility through Aztiq Convertible Bond</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,005<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NonCashIssuanceOfConvertibleBond', window );">Non-cash issuance of Aztiq Convertible Bond</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_OrdinarySharesValueIssuedConversionOfBorrowings', window );">Equity issued through conversion of borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,200<span></span>
</td>
<td class="nump">346,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements', window );">Acquisition of other intangible assets through financing agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems', window );"><strong>Disclosure In Entirety of Supplemental Cash Flow Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares', window );">Settlement of liability with shares</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_ShareAppreciationRightsMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems', window );"><strong>Disclosure In Entirety of Supplemental Cash Flow Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares', window );">Settlement of liability with shares</a></td>
<td class="nump">$ 13,767<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquistion Of Other Intangible Assets Through Financing Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition of the loan facilities through convertible bond.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital expenditure intangible assets incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital expenditure tangible assets incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Entirety of Supplemental Cash Flow Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through settlement of liability with shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NonCashIssuanceOfConvertibleBond">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash issuance of convertible bond.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NonCashIssuanceOfConvertibleBond</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_OrdinarySharesValueIssuedConversionOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares value issued conversion of borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_OrdinarySharesValueIssuedConversionOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use assets obained through new operating lease liabilites.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_ShareAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_ShareAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140430466828144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 26, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 23, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 20, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 26, 2024 </div>
<div>kr / shares</div>
</th>
<th class="th">
<div>Dec. 07, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 833,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,390<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember', window );">Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,479,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember', window );">OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from the issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsExercisePricePerShare', window );">Class of warrants or rights exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from the issuance of common stock | $</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_SaleOfStockIssuePricePerShare', window );">Sale of stock issue price (in dollars per share) | (per share)</a></td>
<td class="nump">$ 16.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfSharesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant or right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="nump">10,127,132<span></span>
</td>
<td class="nump">10,127,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Increase in share capital | $</a></td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Common stock par or stated value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Major ordinary share transactions | Senior Bond Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,501,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Major ordinary share transactions | OACB Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_ClassOfWarrantsOrRightsExercisePricePerShare', window );">Class of warrants or rights exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvo_NumberOfSharesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant or right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Major ordinary share transactions | Tranche two | OACB Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares | Major ordinary share transactions | Tranche one | OACB Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase decrease in shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alvo_HumiraMember', window );">Humira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_ClassOfWarrantsOrRightsExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_ClassOfWarrantsOrRightsExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_NumberOfSharesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares called by each warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_NumberOfSharesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_SaleOfStockIssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock issue price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_SaleOfStockIssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_SeniorBondWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialLiabilitiesAxis=alvo_EarnoutWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TrancheAxis=alvo_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TrancheAxis=alvo_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=alvo_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvo_TrancheAxis=alvo_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvo_TrancheAxis=alvo_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alvo_HumiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alvo_HumiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>166
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M6NO>"L(XZ/V2<W4PS %#M\[^ E!+ P04    "  BA'18+FQ;Y&(&   2&@
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M'^3C+V+?(6;]+67=]7^3Q\$V-W=<[CHMFWUC<]U4[?#)/^\#<=  T4 #O&^
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M$*6R- #O5P8P)7RA!;K?^+W\%U!+ P04    "  BA'18@G?5FQTF  !'A@
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M7):#@_6'=@CX^-#4+L#U(]7=(,OYIH+SPR9KD$2721(E$.\OBWP#@@8D!GS
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MMM[J[#&96/%6$X5*X"W8'!4R ],:;ZGDL@ \5X)4D9^F)#WFI1C+EJA.?V
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M5HHW[5!76H>)V4/?FXSG&Z79W5#O$/2EPA 3)HN$;4)/HVH:BNUQG)U\"B[
ME/"O+J&Q":72_*]4<DC6E)Q[%*/!6V\[(W(ZK*WMQDI>>R1B,LE$[O.(GI&$
M7!M.Z:DJE9 D(62<G:RI]3-.Y;_6]H-E#=3K2%T-W/J!U4A?TPW*NED%TM+G
M/B6V';=K($\V&%%&C@:PX?;J<D/I_8 LFJ>/41<?7&E;:"B>1),,6)Q&)R]L
MN_*4Q7DCU5.)64=3,X2J4VCW5CZQ-=9-K(4H,9 DG>&7ZV_@9@)8ZNC_82^A
M48H1P,\_,2$VH>G04GU11(144:9+ T0E:Y@> DQQ0#2=RO,,@5J*D>6/R1G9
M/Z8:-PY-AGZHO+,TDGG%J#K*HW*A%,]B6P[*?LT2I5O*H_N99O7:P,X2-B_M
M@#,.#7*R.ME /&@KRR4*2)) D7?.PQ:E?4XY6>6"))FW5(RW*GX&6\PG*\Q^
M)03,T1<,)X&^T:["A!G%8\IE:\XVC%,;X/"".?*+I/ J!T?'&*2N-RW!MY'7
M=M>#HJ90'!N.\*^Z%)<0A:S47! U(W6?M[MSM-,E!C6P]4<,,TN3MF.3<.3.
MS5U,2SG&F+,(>-5$VD-#/U8:P8>@]?U&>T'R/M>IE6+ART6F:1*)O5,8M3^R
M8]R[IVQNI'PO&$->4@9L'V"818VC"6"A+;3@C#3K9CRX 5%+%ESMGD5WK='*
M20KAS*],-<#R,@HGWS\K#NW-_,.TM^(OI4DU'0>X;X]^"] U#H0[9YL4T'C6
ML@+ZH+Y'Q<;*SG\PI*R%->-#3$(0;7:$.="?I=QCZA16.SBVU&AH#F.JU S6
M<^,<)X/;>:1(M X5JP&,V4X[_N;:!$D;1[(\7R9+TJVDD8>CVFT&2NL:9%VQ
MT5&>@,P1*.Q1EFD%Z"4AU,#\+F]:P')]E/84(BJ;^T&,U"\)%!LNY]@4"Y&)
M_A&48\D!U7UJ/=NH=TT\SZR$G'--R9[ZUB+'2*U["9LLE99;1514>.+0P6(Q
M^VW6/I;W#U>^XGY7-3\=FS)SNK@,,X0PZK4."SU4-!KJDJ4O=D<5.B]&N$,O
M5>I&P)0H3X?BR==(7>]?716/O\D&K/1H8?Q7\2=&"Y>)5T<@:I)MU FG4"\]
MTS;WM3+.]<+$D$@]^"#<N"!@JNY0/,#BV48K4> ZM22]-0*>OCA)F!)E,^AY
M[072O5E P9J' 71/DDVKK,F))%I;MWNN[:O='H6;L?O4*LH/F<I%DRFDXB8"
MIIR?^@@0Q;&)Z_-$GAE%2RRR7[Z_$9/\!JQQN;YX)!.IHJ6?!O^(63[Z/O."
M\D!$/L?G<YU1R23E7F9<?<USKM('+%'+\7RBD?8W%41YZ1!)ZK%69"V*S9U9
MK]&D.&87C\R-GW'0D:JK*;1<Q]X-TK/#;K],7=J@- .GG4H09&/@1#C5"7.'
M0T\!:S6G%/@X&RMBBGG)5&)$%Y+$>QQHX#Z5%%J/?MI"EZO42@0-+^;YL=KO
M8N1R? F]&$7T5S32&E(_HX;A1E6PU6WK2%M$:+\99:T2LI0G#(?5.'%B0HC@
M9W;M#4X,6=$5.F7Y] 7?BS':LU:\RFUZF>TE,@6XZZ)XUZ)SV4B:=BOI]_K7
M3'ZZ:UQ5&%W_.*I';_%F"H$-\6":BN><Y/>;APH<IONHH#0KZ=+^>AFD%$M2
M5'RC;YGM.1ZA-.HOM*,PK$MHCTMW\'X+MXG#.XK_[F";U$TTWF \$XCHG<IZ
M\!_H)0%-11S3M![/#1='K(?4.Y[LA\/O&!0+F\3ERJB[]/A40T>*CV9)W?.>
MBB]V.>W ,@\FDK^/7,]7I1/2,',*9C_Q8!]-TABTMZ-)I 4*<Q95O.[46J=9
M;W"E7(\UHF"Z'-'41JF:II5,8!50E=['P(X!Q$)/^ *[SYOST5X\!V,T8:Z(
M'9N_-2AC\]WL>4-Q!PR5@@U0,;!CS$2XHL) AG'2-#6>R4<$MQM+B617)*#1
M:- 65NHQ=91@PCA\#L"T[_-^9KQ8"![ST;-;J7N.EI818UP2JD=(^2L[NV@"
MTCV"C21OMY)'D%!OMK%$^U0H\4P*B;>D[(-](TV D4HA;EZ<\71VM'VD =1J
MT^[PNP]-"6Z>TT3:X+)XERC)-*H'*Y'YXS SF3%362-.8,T].L,7[_[QX?OO
M'N##LSR]MO!XS>YQZ5:,V&],F:=V-98: FL[KK3GRBK.292F&)/GO&'!)I8P
MV J#C>MOR+GACC NS 5+B(0Q,Z%MY6?1D- TH*)(#>D<R?AYL+,5*"<$QZ&V
M9@F'3UK$4R;0S)^CBIY\-J<)5N02(<1R@@53Y%A^\D?_BWJ-0Y#Z4QF,9@H?
M*!<K?<M@+4U?&IK)T_8*F?&Q6F,/ H;9C,:Q,0/W8/F ,R*]=H9Z#AX\#G!8
M1E,Y!1P-%&H>>XQP<J]V0/OM34C3^;[#K8J+I\7/0YM7<?  ;+EW&1M%7<3;
M?/BH0>*ST;*73Q4XHU7SC2(5&(SI[)-(NI%.5UI,%^M1OG#K_7HEJSW@#O?Q
MEV2&:M!'GLRG[S&XCR.XRQ D@.TEST[?8?MXR9)9V?$2^.5J6O,8IRAIF[W,
M+1E57>J;R6\_E;=<-&FR1;*&%4ZS.>]?6=^(S/N)\\ ]-0$:@M7^1*T8.&#J
M[8B=*\F>SQI9R"D&K R2KGEG4._=G,;.Y2OY<H# @4O:Q:%+-G"T"-)8NE13
M0X$<Z2>JHMQ+O#BR, PWIGEW*2Z=\:3N2P&2M$3Y>7..]-'CXD]M6Y$WG"YT
M&O/*'HK1#V,CA^+5EILM8XJ6 YQQ@ 6*(<511%%9!,DF"M?K?$.J9O/]@'YN
M'FZ!JQ:=-&FW*&=!BX5UXSVJENPK#,%*2'OGTYB8M-BD,L!V\(PL:8G#2%P_
MH20"L;1)YG!0\4W_J_9-99IFUX7I>NISF@9"4VI NF$9K#GNL#,(RGHKMEHY
MB9@;T,[)OAXI47-+%B*;0%^-Q(SRE,VQ2V2%:NPZF9J7@8#E_^HPRAQ"#1>,
MYY1'#]<,GBZRPGF[ZMJR01Y@7!C%\INGYTL;A8]\VSEQ,(/$=K:F?.LT@+#!
MB$A6K3E+ G'>12[9[3Q"-96G([UU5$B9),MH4I;IJIT,4$HQ.8S7-VVC%K=4
M0.OU-?/W/ 5''NFL#ZZEQA0(&)'&>&F#7IF90X)N/.VNIW 39LF:@2>]JE?A
M!)F<<J'$3A7;?#1VR:($RZPV.JX*;_;5=#!<'A"-A@:C;7-KRMWR:-TX4H?$
MX:H@,9TM7CG?&'W-XF/ZN7H/V/7#94DJ!^-&Y@IJ)BP)];&+)"%O\450I(GU
M8S^) D8$4JJE90FHH4Y7I0#F9* ?+ZN/FG!JK'X(V?P_'W*[^(:*15#$(0[V
MJ7A%DDI2AR(5DVH?Z>2+.+DJA6(P1AQI$UWYVZ@P-&AJQCM)[?R"B"9YP(E:
MD6%B!7#J+S<",L]_@>6I!B_OTL%%0FJ=BSVIR;[E,$1>96F.D,&)U]&2^)FN
M1SZ8#F<UJ3?K&9HA5/0K%;$;1W3)R-3+!?&*$S9<--ZXFRR9Q+5M>-$T]>_.
MV=G<7!CC2E8-5QJ17V%0X6,#*FDEOC4/HJ00O[.YAS )\953%SCF,O7"43+.
MFV?WS%IB==F.1^3_#<>37ZPOXI6^UH7?&.I(S2GC&=2S&UQJI=W4QESZW"0H
M4\E++"S4X7]8S24=:_-%U5H+_WZR030(ERT?BD>;05=Y^ZV.50&]08[@/JJ%
M'0?4M)1TQ@!LYLM!Q@Y/F(P>54LLU19QNFJ^;B'WGA9(= XY5,A)$%,,8C=@
M;.,Z<I%.P)1QRR36;;PNRY5,@GGC\B90:_;Y<7T/M?=T)94RX2\":3LZJM&)
MLK$=3 +VSN73][*OIJD=,9ZS,7P:1Y-)W@7_7AF/R(YEM9RQ4TO%Y+%B7?/&
MD;[-'!@Z'Y!K3*)(_]+T3J*O&@::@TO3_S)$6Y!']D@T/&3X(>;G$X2?&8\^
ML15,FZXQ"60B#$6$:*S"F'!L1,DJ=.X!BP=Y6EP)QQ>/SY^(X'HSR_K%U_+U
M^SNX_S^+BT?RF,9GWM&D*RHK9#&]P +8R[7,!O\V_?YM^OV&IM_E^N)+($3R
MZW"^J_EG7C,MR],,6"HU,4-AN80K34OXW<:#OS%0?!A!%0M2+!K+3T0\LIV=
M1PVWDW_)D6OYK0FBIJ^>R5<;ZBO"U?0'/V@,AFBDW\N]UL"C[WFX'8^5=YS8
M2\_JN:.HUD/C#W<X*B+F"+[LR4*)K)<\@2B28N[MN7E6"[@W41D)%,'WG32K
MZCATJC1S#;<R46^!#'*Y1LM&O_B\3X%!D&T' D^\ :1%]>MC*I:&-YNB'6[U
MS:<W$ED/H(0[+CO@$!C^;AEQ#GRKP>*5;79/D[WS^$3\F3N24+%Z!J3_C78.
M[$6\I*9VEB3Q-2W+G0%-VFG9.Z$^M_LA0B-J?#&2A:!%ID.;A%6B>!-SCK^L
M'-63<7*6);Z8,'QA5+S!KTIO6$_#Z&!S'W^L!\X0B_XI[Y1&9*S!DC?R)?O#
M-*@4^L,EY*9BM:,[8OE?=YLEDC4*/F-5F$GJXSS0+%_/E\S$-K".._DJI?L-
M_=Q,9H( QP_IDG,!%7\L;SQ\U,V>C+/G++%2,NR#\>1'\\AM)G6<.,U"O';(
MTI*?TL@/%>@LY<;0TTCN-KB?^<%,^O39?2".@P"BHX-U*KGVL7>&E?D/GN'Y
M=/'1K]?87YT#5H8S;P^<5I29+'R=^6_)K'@BG(W2XG1^SM3:7Q*R\ZU<-N5F
M^0Y)$,_+):W_YX5B8AF547#.%../^&5<;F8F@=BHNDH7(YVU;TUG-9;<.[\\
MR]L049 A'Y7*#J:USE'I<[7*U'*1QF83Q"@8?P_]\&$4P&EWR\0SL6L$;UE#
MLHA6'L80(S(<86$W)-7ESTWU9OH1V;C2:YAS\BA81 8P]SH@;F<]HSR=,1)C
M=Y'&4O%[%*?"QK-B=;2PH;$[US0FR;RT7AR\/"JVS41,F&F4*>FWP?J(>XS[
M?79WB7V 8JK3;Z7,('R.3FQH_AY943$$ *#H$,R<.@VYRL]O?\'PLZA 3B;2
MQ!MHNVQ&<ZRN38XUGGNL<[5- YUX5.-V>,)O;/E&-9A&KR.2D[);TDG4\"K5
MMSQ=@POZ9D"/Y17XVPR4?%DE/MV605N/<B101UU??@2PI@LL,,3(JN"?6-I1
M?Y4<[]8T ?CH?SG\1=!KG^1<*/D+T;_1)%3S0_.'0$$5_Q PBPS?Y\;Z F 4
M%,)L&H>Z?)/X+-^0G,8G./Q_N17P,]]..I"C9;)87+_4=38[/-/TKRU7WJL[
MG5X8E]Y[KL2H.8W(TGS]F:,Q!5%_XDZG/UBC)LO:9[\I9U4SPI:'6^_LO$R^
M^B0<,LJXDCE O4E"OEG36XR5;## 'M/\*B%PI(Q,6>3$1_8[?!2$IW#*6]M=
M.LK43\9)FEZ2WS7N>LT_."#VI-:PD<HWT/Z.D=C[Q6#_]7"F/<?3XIUV9'^I
M<<CX22*;)^>7^NT;<DPP6!N_?2Q??8<]#/B+IQ@,Q#GX+-X?GU]HH/3=T#5>
M?U /G*1/W&D4XZ@ZT7BN$O]NPA9A97YS' S,O5:';FEHC.F9F/L==MB8$DSX
MLV%79@BEQ@-94<FRQHPQ(>^:!BS$P1\R)20&%(G%<:BRFIA*JIS*--:^=45I
M9"OW?+LJ4+XN&WFJ8NH.:V\D2'^W0H]\&-S\N>]9V(^F;-N26;RCQ,#SA_W+
MYP]]@/]LX7]PE?!?8K&W95^^?'YTH+S?N+I&70\(>'%V<68^1>O\Q=FKBZ>O
M+L\>PIOI\9?/3^7>_15T/[:<U&X'KSY:?_WDC$/T^D??GG!)_"V@OCW2/W'2
M@^OP ?A^UP+QR!^X 0I! N_E_P%02P,$%     @ (H1T6&>8+?%1#   LR0
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M:UAKU4*CY.;"HFZ!=I*+1E2T#R!45&<N30;V6U%MH=-J)VKTR$.SH*8&LEO
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M1$B$@9Y<<D :9H^&/XPO@,\.9] 99#V+^""U8Y'O,<B15_$\'H[;Y/7*''O
MC'KO3,#%VK^F#50"(-9/SFZW>[#?U._4_?7ZM?^!:^AM6$XKD(Z'L\F@!L;V
MPZK2OUJ7R@*;_')#@%OM+N!\I91M/YR [M\8U_\!4$L#!!0    ( "*$=%C$
M-#N*M@0  "8+   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;+56VV[<
M-A#]E8$"!"F@>'6_./8"MI.F!9K&L-WVH>@#5YI=$:%$A:2\WK_OD)*UMF-O
M_=('>TEJYLR9*WFRE>J;;A -W+6BTZ=>8TQ_O%CHJL&6Z2/98T=?UE*US-!6
M;1:Z5\AJI]2*110$V:)EO/.6)^[L4BU/Y& $[_!2@1[:EJG=.0JY/?5"[_[@
MBF\:8P\6RY.>;? :S1_]I:+=8D:I>8N=YK(#A>M3[RP\/D^LO!/XD^-6/UB#
M]60EY3>[^;4^]0)+" 56QB(P^KG%"Q3" A&-[Q.F-YNTB@_7]^@_.]_)EQ73
M>"'%7[PVS:E7>%#CF@W"7,GM+SCYDUJ\2@KM_L-VE,TB#ZI!&]E.RL2@Y=WX
MR^ZF.#Q0*((7%*))(7*\1T..Y4=FV/)$R2TH*TUH=N%<==I$CG<V*==&T5=.
M>F9YS013'#6<=35\-0TJ^-3V0NX0X=,=I5ZC/ED8LF3E%]6$>CZB1B^@AA%\
MD9UI-'SJ:JP? RR(XLPSNN=Y'AU$_(C5$<2A#U$0Q0?PXMGOV.'%+^%Q70FI
M!X7P=0VOB0+\?;;21E$9_?-<0$9SR?/F;&L=ZYY5>.I1[VA4M^@MW[X)L^##
M 6>2V9GD$/H^B8SH2T<?[^GC@20>1'V>\VM,P4V#P&Y145=#-[0K$I)KX%W-
M;WD],*'O=6I8[8! X+.20P_UH'BW<0<[9(K$;/50VH'2CP['IM\50>0["K0*
M8<LTE&7I0Y$6XW&6I#[-#-VCZWJQ.QI);38*-\P@:.O'[J 7O*L&I9YRI#EH
M=QIG#0U;I#(B#FLI:,CI8\?2D1SY78_&)F0(@]P/LAS*R ^*"++<3^*87%Q3
M FJHJ'$47PUN:/6"=;/>N_ G"$,_#0N"\(,T@MS/R@1^D]WFO4'56LK868<?
M*^8%I'Y2A!#F?IFF<-TPA>_M,*NA9SN:L4;#.TW._RXI-E%,=@H_(%)D)PYS
M>/NFB,+HP]0:3T,%8>GGEE3H9WE@=:(\@1L2D\KZ+=B*@E;X29D2CR(N(//#
M+ 'Z\\N@A# F=HE5+/TT"IR?_QT-^J*Y)N)46I6TBY<3MD^5%49EZ+:B>VBE
M><W'<C8-,T!1H:+Y/O )1,B*":*_I>^2(J4,KWAORX?4^^EF<O<D:E=@1.O)
ML</LI '=$U]I@8D/JVF4$WE\RO8(+@>E!]89:]$>3WS&'!%[>S9A^P^\Y'K/
MG#3GL%%=S@[WJ&QYV*ZT[4AXE'Q%-3O%;[+X@V/70]4\2L3H5455M!G-636;
M#REX3>&I01OZF3GW2JZYL8[3R'TX.BK9TFAIK,%;&U3:XU[,9@5WSM:<6FXO
M\DJJFE&ITUUIFC%*@\ Y/#\Z\)JA-9D1@QTY%IA,_5]^O30H+B@/$W ]5(92
M>HO=0 V<4:,4D$1^&H1S-UY1O3%%N;&&:Q(5LK?<]CXEB1_'):217V8T+6AV
M% 5\QHY&LW!:]X6HF)L:>\78ST@C+OTRSR&FL1%'<",-J;UB<K[4V,]==8L'
M;Y<6J:#L"TU3!(?.C,^8^71^!)Z-;Y^]^/B"_$+UR*DX!:Y)-3C*4P_4^"H;
M-T;V[B6TDH;>56[9T$,6E16@[VM)XV_:6 /STWCY+U!+ P04    "  BA'18
MTQ?TD7@#   ("   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RM55&/
MVS8,_BN$"Q0K8)PMV7%\UR1 [KIB!=KUT&+;P[ 'Q:9CH;:42O*EW:\?)2>^
M7''),& OMD21'S^2$KG8:_/%MH@.OO6=LLNH=6YWDR2V:K$7]DKO4-%)HTTO
M'&W--K$[@Z(.1GV7\#0MDEY(%:T6079O5@L]N$XJO#=@A[X7YOLM=GJ_C%AT
M%'R2V]9Y0;):[,06/Z/[;7=O:)=,*+7L45FI%1ALEM&:W=SF7C\H_"YQ;T_6
MX"/9:/W%;][5RRCUA+##RGD$0;\'O,.N\T!$X^L!,YI<>L/3]1'];8B=8MD(
MBW>Z^T/6KEU&900U-F+HW">]_P4/\<P\7J4[&[ZP'W7S-()JL$[W!V-BT$LU
M_L6W0QY.#,IS!OQ@P /OT5%@^48XL5H8O0?CM0G-+T*HP9K(2>6+\MD9.I5D
MYU9OI1*J0GBG*MTCK%4-1]&=MLXN$D=>O&Y2'1!O1T1^!I%Q^*"5:RW\K&JL
MGP(D1&_BR(\<;_E%Q#=874'&8N ISR[@95/,6<#+SN%)6W7:#@;A8P,_9.#/
M]<8Z0Y?EK^="'X'SYX'] [JQ.U'A,J(78M$\8+1Z^8(5Z>L+M/.)=GX)?2J5
M'(D**E5S$%7G2G41\7F^_^8&?E! 81364 ]&JBVX%N$[B2R@KSZ5#:A\V&_0
MA/*%(O* 2@L&TH*PT.B.NH.]"2JC1CB]:X7:HB57 ;@1TL"#Z 8$W=#;,_)!
M^$=MX2>+"+]JA\#+5_#R1<D9?PTL+K(YS%@\RZ^IO@XI2'?DW1C=0R5L&\B$
M!7X="+%#15'F9$2VLP)8"1_)NR'#IPA\7D#F%4BY]+R#'^^N**<LC3DCB\&8
M_YJF^#%/@B[K_Y\HEO$XRS*X+N+KDE$ 99H_)HJ:9HT;%TALM*'K2M0M,'X=
M9WP.<Q;G,PXL+2CNDMJ%LI0Y'UU#/DX<L<>*S.,\2Z?=>VTMA.;>H_#OD;J]
M\XPW6M7V# 1Y8VS:G9+M" 2ADV(C.^GDDVA9]@JRN,Q3LO=9*^*<$KCNM7'R
M;Q$&1,A4@V.9?-S2VN%80+I*LSF0"56W+( 7\YB1@)5EG+-K8&P>9P6#YYYY
M<M*=>S3;,(,LX0[*C8UZDDYC;CUV]T?U<49^$&8KE:5(&S)-K^:S",PX=\:-
MT[O0ZS?:T>0(RY9&-1JO0.>-IF0<-M[!-/Q7_P!02P,$%     @ (H1T6)-K
MD:A^ P  6@@  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULG5;;CMLV
M$/V5@0($74!8290MRQO;P%YZR4.:Q29M'XH^T-+8(D*1"DFM=_OU'5*VUTZ]
M1MH7BY>9,Y<SG/%LH\T7VR Z>&JELO.H<:Z[2A);-=AR>ZD[5'2STJ;ECK9F
MG=C.(*^#4BL3EJ9%TG*AHL4LG-V;Q4SW3@J%]P9LW[;</-^@U)MYE$6[@P>Q
M;IP_2!:SCJ_Q$[K?NGM#NV2/4HL6E15:@<'5/+K.KFY&7CX(_"YP8P_6X"-9
M:OW%;][7\RCU#J'$RGD$3I]'O$4I/1"Y\76+&>U->L7#]0[]IQ [Q;+D%F^U
M_$/4KIE'900UKG@OW8/>_(+;>,8>K]+2AE_8#+)%$4'56Z?;K3)YT HU?/G3
M-@\'"F7ZB@+;*K#@]V H>'G''5_,C-Z \=*$YA<AU*!-S@GE2?GD#-T*TG.+
M.R0N*\%]BF*X;K5QXN^P@VM5P_NVX\(0"6Z6.#+GE9)J"WTS0+-7H#,&'[1R
MC84?58WU,4!"?NZ=93MG;]A9Q#NL+B'/8F IR\_@Y?O@\X"7OX8G;"6U[0W"
MQQ4<IN)4)G@W9 +^O%Y:9ZB>_CJ5E,'DZ+1)_\:N;,<KG$=DS:)YQ&CQ]DU6
MI._.!#3:!S0ZA_X-F_PP!DXQB+-LGH4^[?AWVX/OE\0G:C@6+0A5]<9@#75O
MA%J#:Q">D1L+Z.N)"H%0*VR7:$)!A+)@<<"C50:<>.465EI2Z[%702C(#-='
M?'_CA%Y!9ZCS&?<<0R<Y'7D)_-J++@C\8!'A5^T0,G8!V2C.QSE,XS*=0);&
M15$<PQ.>\?W!+WKKW;+H["%*?@%E/,T"2#&E=3&='E?AOUT4RG&U%DMY"G!\
M 2R>4,1Y/"I+&!%X 6P<3\LI4+*R8@1L%+,R^S_<^-02/[+W1&R$:X0*_%1:
M62U%S1V=6T<?KV>W^5P)<ML /3D;D#6I&-)IR7[C&_UC0-4MOHB]SM^MMCNB
MZKYR-"(>4?4^\GA<,D]#2IR\?5.RC+V#!ZI9;JHF&*Y)5.KN.*8B+LN"TC\9
M3X!E\802]#,J-%P&'5Y3^Q7^X?LY\J*6QV-R)J<"H(3&XVP"G[4CG?J_9O4T
M.:>Z0G+0[ULTZS#5+"6R5VYH_?O3_>"\'N;%B_@P=3]PLQ;*@L05J::7DW$T
M5.INXW07IL=2.YI%8=G0\$?C!>A^I:G:MAMO8/]W8O$/4$L#!!0    ( "*$
M=%@K]QA$"0,  !P'   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;(U5
M36^C,!#]*R-6VE,4 B0T[2:1^JG=0]6JW8_#:@\N#&#5V*QMFO;?[]@00J4T
MVHMAQO/>O!GC8;55^ME4B!9>:R'-.JBL;<["T&05ULQ,58.2=@JE:V;)U&5H
M&HTL]Z!:A/%LEH8UXS+8K+SO7F]6JK6"2[S78-JZ9OKM H7:KH,HV#D>>%E9
MYP@WJX:5^(CV1W.OR0H'EIS7* U7$C06Z^ \.KN8NW@?\)/CUHS>P57RI-2S
M,[[EZV#F!*' S#H&1H\7O$0A'!')^-MS!D-*!QR_[]AO?.U4RQ,S>*G$+Y[;
M:ATL \BQ8*VP#VK[%?MZ%HXO4\+X%;9=;)(&D+7&JKH'DX*:R^[)7OL^C #+
MV0> N ?$7G>7R*N\8I9M5EIM0;MH8G,OOE2/)G%<ND-YM)IV.>'LYKS-N84;
M1+,*+?$Y;YCUV(L.&W^ C6*X5=)6!JYECOE[@I"$#&KBG9J+^"CC%6932*()
MQ+,X.<*7#-4EGB_YB(^;3"C3:H2[ O:UPN_S)V,U?1)_#I7=D<X/D[IK<F8:
MEN$ZH'M@4+]@L/G\*4IG7XY(G@^2Y\?8^P,I/CB0H]C#RO:$OJMNB=T2P0V7
M3&:<"7BTS")=-0ML%#U9GJ2TIM$"%I/%+(8[6Z'VFQ/@,A,4*TNP[!5<+IX1
M:)[&D!(L2E+XKBQQ>ZYDDB2GM,:G$7&ER?)0<C/.GBFZ^,:"*CJ;Y@]0^CZ$
MO*K5P*1L78J!RXRX9 [*"VZT*M"X,>(B=DK)^\+ILZ5*7#+9CXDMMY5/Y*A:
MJ_2;9])8MH)YL^#4]]( "4)9TN3R^<8=>2=8XXL;3KUB+BUJ7H\D<]F-5DH^
M_8\.[_RXS_(^0]9J[4^25%?40:5Y]JY'HX0[+M\$!WZ\OG2E<G<Y?,"^H9-1
M6:0G4W4C.%'BQ-LL=_(F/JVS&T&'0^*G<.A2A*.)5:,N_5QVA]Y*VPVOP3N,
M_O-NXNW#N__&+=,EEP8$%@2=34\6 >AN%G>&58V??T_*TC3UKQ7]OE"[ -HO
ME+([PR48?HB;?U!+ P04    "  BA'18*&KJ .H'  !A%   &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6RM6&EOVS@:_BN$9SIP -76Y4-I$B!I.[M=
MS!%,LSL?%ON!EJB86TGTD%2<S*_?YR4E6W:<'H,%#$NBWOMX^%(76Z4_F;40
MECW656,N1VMK-^?3J<G7HN9FHC:BP9M2Z9I;/.K[J=EHP0O'5%?3. SGTYK+
M9G1UX=9N]=6%:FTE&W&KF6GKFNNG&U&I[>4H&O4+O\G[M:6%Z=7%AM^+C\+^
M<W.K\33=22ED+1HC5<.T*"]'U]'Y34KTCN!?4FS-X)Z1)RNE/M'#A^)R%))!
MHA*Y)0D<EP?Q5E05"8(9?W0R1SN5Q#B\[Z7_Z'R'+RMNQ%M5_2X+N[X<+4>L
M$"5O*_N;VOY==/[,2%ZN*N/^V=;3)O,1RUMC5=TQPX):-O[*'[LX#!B6X0L,
M<<<0.[N](F?E.V[YU8566Z:)&M+HQKGJN&&<;"@I'ZW&6PD^>_6AR54MV!U_
MO)A:R*/5:=[QWGC>^ 7>*&8_J\:N#7O?%*(X%#"%(3MKXMZ:F_BS$M^)?,*2
M*&!Q&">?D9?LO$N<O.0E>=+DE3*M%NS7DNU]9?^^7AFK41+_.>6V%YJ>%DIM
M<FXV/!>7(_2!$?I!C*Y^^"Z:AV\^8W*Z,SG]G/0O).2K>"T<!#^WOG%R==_(
M/T7!9,/L6K!<-495LN 6:\;B@B:SAJF2;;0JI65*,T3-,-X43(%%@Z>&KVMJ
MQ@<!04Y/3U:T6C;W3O:3X-HP0>6 /#+D4]0K\%,^75;CP$G%7<0D-!A6J@K(
M8,[9VU9K&.+,)WI'[BG?2;CAW@C#7J,O/&44).$"_V$T8XMP?DCVPW?+.(K>
MP"<)0\DP-IZ'9VP<1;,SEF81NU.65SMAI#8*XG3!LC#$790M8'\I\+9P+WO[
MQLLL6*8+2)JE09S,<9,N@S1*S]CM0%<4!HMH><:B61#/,] LP.)5%D.Q( R#
MV1PVC9-ED,T77MXRBWIRN4_K2C2",C3.LB AZ<03>IY%,,]@PQW2,/#Y0)>L
M4;>6,OU]%$X6 )2JHB(A]*Z>4"L5JL$PJY 5#4!KNNCD3SO6QN4<1(5H% #)
M51$JZT,.YJ:0.?ND5<,GSHX2+ H%P<N24+@KDJ$C7UD[?='$G8UD(O%TU>TJ
M'5[Q0W<Y#'4F\SQOZ[9RMM(+[T) Y5?S!IL/=8 CQP\D:VX9C-OB/5IBQ5>5
M\(ND\[0P[#YM5< O5K858ME:61UV74V..B>=XK+5KK4*87(M5X)XT0@N<,"K
M+?TUBK3IEE?4)]JI0_M2))$4*?YR[_GT")^6!Y\237%U6CIA%-%H-DE>L3%Q
MG[/Y)'OE)$7G+(DGX:LSZF$8+8B)>T?Y9E/)W(7LI_81)JA6WTNS=E#3HAR>
MO"8(SY7>*.UQ"A9XHRBE\*TBMR2PR2 N=BN$EWXDA/RQISWAB-\07HX@Y:ZG
MB]-)QEX=7=X[>63C3A[RV#?%?Q%T@U(GPPU:<)(RA&(<=]?E)*;KK<#4T%!A
M%1+BJ(V0L/$<?>>I,KHF(;A^4<WKHU(>5-8XFLP<2S)9NBN2$M+-KZZ ?)!B
M6B(;G-1Q. %\O'\>%<HGZ.;.R\0S4=1K]>"; &XV:)IA'WU]F>W;] C;]\&_
MX8")'*D!?+-_\*;%*(@W61 M >6+$&"Y/,3='#?2-9LZWJ \="X8 6>4#64/
M+4L@?3%+=UK>/<,(XVB6V$R()LWFAS25Y"L4I*6&&\\2RD28G;'?7:-:]T_^
M,DTC("5/E:5#GO(0CU;>/F"%M.L.%PSOH'U85 '[</V1181V?[38U R1&H=Z
M*T)WW#<4$5Y:01-VONY5?GF/+X'9Z"_L*QME7+GYOJ-!B7)\VF+L055+*><K
M5(IO+J?<ZWW#UD"!!Z$#I[[8SUW',>CBO7IB.:RZITYVN.=$[CU;"6JVH6O>
M2EZKMGD>V6^:<IY'@&H5+_Y".9^J)6XM +VU?MO 1B5J@CEX.@0"2;.9V0Q@
MIFOW),1<LYA!/B:'+/PJ%7Y*.ZTHBH(LC=@\6";QRW7]+1+'";HN)L0+L@2#
MRR]'@#%LJF'C71]2]>J?V)H3RHOC:=7M]6YS@#VZ0-I@B)5N(QW:P]$YM%9J
M54,%J@C9]7V$>M%6_MD]>:< (@_2..RF!.\ED<Y:<*I;AX4X[DE7&/X@!M;>
M(K.6&S-YV2&:L)+)?#=@D9[O"9O[A5,>?Z$(@[Y> .C5TS/E?MCY?T;R 4^J
M-8-X.1/HP(,[5$:EGH3H1SD?S$$=YUQK"?5HY"W7N\;\FU;MQC?SZ6%M(&(P
MD Y6>R/W4Z<?; :C''6_+(0^GM_*UA(H$;;DW! T=#L*M"LJ&JP0.--RT:(U
MW1&HM:\QTM#A!UHU8*YI,: ADX3&_('+:M<U'H4= /DAL=]]>]M/YGB"">!4
M-*09YO$P-H,H[.<LD@_E4CL^X'%?D)#4XKSX"973[2):<#>@OE!(KH+##!/'
M80UC:;9;.K3O&^OWSF]I>X_$XT8^']K2U_B;LSF.1!C;<+^@A8S%.(;-PR7[
MB=,VA//:C. RQ=TL2H(%%%\[>X[FX%T)NE:Q[H#5-JTY'.;="0F"TIVKV[7$
M5@2'W5%8$GU'%$8[(CJ"G#X=[&O5QS%*]G%]D6.?U\FI+PO3P6<?@-.]^[A%
M!F*']%^ =JN[[V?7_K/1GMQ_?/N98T8''E:B!"N.AK.1GV;Z!ZLV[B/22ED@
MH;M="XX.(P*\+Y6R_0,IV'U5O/H?4$L#!!0    ( "*$=%AKJ*Q:G 0   L+
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;)U6VV[C-A#]E8$*%#$@
MV))\3V,#<7:W6V O0=)M'HH^T-+(8I<2M205)_WZSE"RU]DX1MH7FY>9PS/#
M,R->;+7Y:@M$!P^EJNPB*)RKSP<#FQ98"MO7-5:TDVM3"D=3LQG8VJ#(O%.I
M!DD430:ED%6PO/!KUV9YH1NG9(77!FQ3EL(\KE#I[2*(@]W"C=P4CA<&RXM:
M;/ 6W9?ZVM!LL$?)9(F5E;H"@_DBN(S/5R.V]P9_2-S:@S%P)&NMO_+DMVP1
M1$P(%::.$03]W>,5*L5 1.-;AQGLCV3'P_$._9V/G6)9"XM76MW)S!6+8!9
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MM3.@\UHI>UBX ,?_!,L?4$L#!!0    ( "*$=%BD>)5J*P,  -L&   9
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MFL535D"1Q:<G&7RGQTFIH3.Z)KDLY'F<GLR!G<;%-(6/0@FZQ1746E<66%$
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M:AJ!Z?IT-W&Z";UQJQUUVC"LZ&E#XQW(OM-TP_J)W^#\6"Z_ 5!+ P04
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ME28P7@1)S.Y2Q%$LS](56BFR_(WX%D09[^2?<*@VJW=[98A3(%>\G(9ZQEO
MBZBEG7L=JVY- 8JTR]8[)"M@QRQ_0$"(R*X6,V?;+1 2M[CBS3WGTG> $#W@
MKM)]V9I=@(]YYKJ>8P9)N#6NW9U%@\&EZ@>V:5:QNS1OM6'H:B,9X@TQ/]UL
MR(,)!CZ2.LC7O-W 'SV/BE^1QJ-O0[^LUN(.+:8%,06X7*7*Y@.A[K*RK8'<
M '0Y#=/S('J";-AR*[OD6L=3U#ZRE+8 =L( *-BH6%S=<X;]%,[YEX*%,?M7
M6W"I-,H'R$%<+V$/N:+GY168'XR=[YJ=8<57BDX7)[%K-Q3O$<B OF7M'JYN
MR1FM'BR%EGX)UZ 63,XJ!JPQ6\S'C/Z4W6@GT75/:]@&RIH])D5,,#>,#$L
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M4G>V3/3AD(/#CAB>'_3+X%AV/=!*#K+EPAP41._VCLA]9PZ/7@FPC$Q:Z1?
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M %1G3MAX$?D]8#KT6V//K9]^V_/JEG[@#O$/4$_\"IR^JG]#[UK\=)RY7?P
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M*77VM!>..,V+TZ6_+"VTHZN7?\SHKHN&)]#WI:;BK5_807M[OOH'4$L#!!0
M   ( "*$=%@K\_"V@00  .<)   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y
M+GAM;(56;6_;. S^*T16#!O@)7Y+['1I@+:[[>Z 78OVUGTXW ?%9F)AMN5)
M<M/LUQ\I)V[:IKDOME[(AP])D=)LK?0/4R!:>*C*VIP-"FN;T]'(9 56P@Q5
M@S7M+)6NA*6I7HU,HU'D3JDJ1Z'O3T:5D/5@/G-KUWH^4ZTM98W7&DQ;54)O
M+K!4Z[-!,-@MW,A587EA-)\U8H6W:+\UUYIFHQXEEQ761JH:-"[/!N?!Z47,
M\D[@3N+:[(V!/5DH]8,G?^1G Y\)88F9901!OWN\Q+)D(*+Q<XLYZ$VRXOYX
MA_[9^4Z^+(3!2U5^E[DMS@;I ')<BK:T-VK].V[]&3->IDKCOK#N9,<DG+7&
MJFJK3 PJ67=_\;"-PYY"ZK^B$&X50L>[,^18?A)6S&=:K4&S-*'QP+GJM(F<
MK#DIMU;3KB0].[\MA,8/%^17#M=B0^&V9C:RA,S[HVR+<M&AA*^@!"%\5;4M
M#/Q6YY@_!1@1I9Y7N.-U$1Y%_(39$*+ @] /HR-X4>]GY/"BU_"DR4IE6HUP
MM03G-3SQ&LZU%O4*703@G_.%L9J.S+^'@M&9B@^;XC(Z-8W(\&Q =6)0W^-@
M_O9-,/$_'G$D[AV)CZ%O$[9PU)LC"3N*<ICC(6BXJB$ R@96"]2<C= #6R#<
M8-U6J(6KK4M55=):1!"M+926OPA"U+F3_*)5V\"*HFMI]>;VFP&K *NF5!M$
MXP$^8-9R<=*8E7*IJ6:5-IV2K%>@N;B<WI7.94WMH\NA 55G"*3JQ#)5YY(9
M&> $5VB'S(TZF.F(X@./$:B;=4RDH1JVJ*FTB%SG>]N0)#.G-O6#^F*C)=E0
M2[?VW'Y+!UZ7&[;.VV(M=,ZLW"P7UBDZ/YQO6P(YJ'L*)\OLN#>HI<H]6!<R
M*YC7"FN*;UEN0% *R/7XPP:%?A24MN"M;C4KY7+Y#,Q9-.W"X,^6CWC%-4IX
M6RF/NJJA[L4*2ZTJ2KJV,I.-X,1G%+<2W:8 /B$<A#[ 0RKX^VVQR+J+9=[J
M71@<)>1>0$7\Y/A$+C/"4 I*NA',:;?(!ZM#^>X:*2F>4X3H7H#/0FJX$V6+
M_R]PU5ICR6O'VE+8_A1UR]F:>--DZL5I"">381+"VS=I&(0?^_]?='^X++UT
M(PU];^*38CI,II!XD_'4\^.8@28IT-VP1,ETGNN]"[QQFGC3</H>3I)A$+PP
M>D=Y.*08>O%DXD5)_-X92>#=A,B/)Z&;1_YS-_=#''E)//:2-&";?OS"\;_[
MBJ0B4ZM:_@*B<!*D0Y_NE[)T5V7-*_XPZE?H#)N"4_JT/?3U],P%\VKN";GK
M(73T&G17<KGQ7CD/E\I8-MUHE;>9)9U[ZCI(/D;!%"B\?&:H>PE-%>,Z!PF4
MJMFG9DAZ.@T@I&\,7[J:<L(BIZ*7W.:9Q:-\X'L),1A[J1] D'I^%/%:%"1P
MJ'^/]BY?:H@K]\3@\FEKV]W#_6K_BCGO+N]'\>X)]%7HE:3>5>*25/UA,AYT
MG6\WL:IQ5_E"67H8N&%!+S'4+$#[2Z7L;L(&^K?=_#]02P,$%     @ (H1T
M6,2"E-\E!   Z0@  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULC59M
M;]LV$/XK!S4H6L"P9#EI@L0VX#3K5J %@J;M/@S[0$LGB0A%:B1EQ_]^=Z0L
M>T"2[HO-MWOX/'?'.RUVQCZZ!M'#4ZNT6R:-]]UUFKJBP5:XJ>E0TTYE;"L\
M36V=NLZB*(-1J](\RSZDK9 Z62W"VKU=+4SOE=1X;\'U;2OL_A:5V2V367)8
M^";KQO-"NEITHL8']#^Z>TNS=$0I98O:2:/!8K5,UK/KVW,^'P[\E+AS)V-@
M)1MC'GGRN5PF&1-"A85G!$%_6_R(2C$0T?AGP$S&*]GP='Q _Q2TDY:-</C1
MJ#]EZ9ME<I5 B97HE?]F=G_@H.>"\0JC7/B%73R;YPD4O?.F'8R)02MU_!=/
M@Q].#*ZR%PSRP2 /O.-%@>6=\&*UL&8'ED\3&@^"U&!-Y*3FH#QX2[N2[/SJ
MB_2R%NR@1>H)CU?38K"]C;;Y"[:S'+X:[1L'O^D2R_\"I$1D9),?V-SFKR+>
M83&%^6P">9;/7\&;C^KF 6_^2W7PUWKCO*4D^/LYH1'F_'D8?AC7KA,%+A/*
M?(=VB\GJ[9O9A^SF%9+G(\GSU]!_$8+_:PO?&X3?K>D[V D'4F^-VF)) ZA,
M;T&-)QV\$TJ!)I:E=*UT#LOW?,X3P@\M/5D]>.'1@2BW:!V"-[#>;.A)@+#2
M25T#O6\P53 I<4MONZ.7&I;6:FL\%LW;-U?Y[/+&P?KG]RR'SIJR+_P$A"Z#
M6255 *I P$8:96I9.*)9T(NG>[J.AE'93OHFDIL^3.&3,64 N;-]#>N2'H7D
MR(:C#O&142W6O1+>V#TC6;,5"MXQ!+/*LYM!S=%]+FS,;MY/1P% @M &%Y)^
M-AZL HUU;1&#YD!OV/JL*8&9W#"_E0%*L[P]?/%E/$U)U%%9"GX-WJ'J>E1(
MU?$1_13N>^MZH<,QWG3HO8IW%J;MC!X\_B*U2=CJA/62@\G+)8,Y+SMV#QZ0
MASP@)W$X*#D*)63K)G1/STZ(TR"L(T':2W$X<TB<D&3A^I-,FT2Y*,B;3&//
M%VY06)#>@=E1;B)&W,(XZBXABP^$J]X2LCTA;JF:4PF.@"9L5M:T4*#UU(#@
MA&=)S4N7 V)\%U(7O>6 AI1XDE334>WA+)MF5%J5(L83.+N:7AYF >AL-I]>
MC"MTB<*:U.-3QXGJH.PM9QS[8$_*'*4-%4.J8D#5#-L-<>1J%FI:'M.?1E3C
MAB2@IJ3V$P:FVD+28R)30H2S*26&Y/:GXKHW(:CD@Q,W4\B=+#'ZPC?240IY
M"EN,_R#>T8NGQ&$/:$^RQ3$B0N_9 BV']8@+=+>3I)SB%0'=]+EZEYZTGQ9M
M'9JLB[D3.]&X.O;Q=6Q?Q^/Q(^"KL+6D"J6P(M-L>GF1@(V--4Z\Z4(SVQA/
MK3$,&_H60<L':+\RE)_#A"\8OVY6_P)02P,$%     @ (H1T6/M(OE-K$
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M8_FFR-WBZT9JDQY,-2D6F(]6]=?$:J](L%I/O%5N]_H":T015DW&C/XH^:1
MA.5Q=VO*EC=%GF 7%=5&;'A%;)B#D4I22JY(2Y$*C%O@G#N*\N%YG"<A4A6
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M,,!L#WZ^$%>UF3@24W5M[,%3=O#7M>&_Z.HX=$5AP>NXD#0T- HUESIV;YA
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MR(.V$#!<++%U.)B.3YBV7[VT'S*U,5]WA%4R%9M?UX*'0M,"_'VI@.:+#W1
M]?W7=_\/4$L#!!0    ( "*$=%AADPF0IP(   (&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;)6436_;, R&_PKA 3L9]7?29DF I.VP 2M6M.MV
M&'90;"86*DN>I#3MOQ\E.UX&) %VL2F1?/32,CG=*?UL:D0+KXV09A;4UK:3
M*#)EC0TS%ZI%29ZUT@VSM-2;R+0:6>63&A&E<3R*&L9E,)_ZO7L]GZJM%5SB
MO0:S;1JFWY8HU&X6),%^XX%O:NLVHOFT91M\1/O4WFM:10.EX@U*PY4$C>M9
ML$@FR]S%^X#O''?FP 97R4JI9[?X7,V"V E"@:5U!$:O%[Q&(1R(9/SNF<%P
MI$L\M/?TC[YVJF7%#%XK\8-7MIX%EP%4N&9;81_4[A/V]12.5RIA_!-V76PV
M#J#<&JN:/ID4-%QV;_;:?X>#A,OX1$+:)Z1>=W>05WG#+)M/M=J!=M%$<X8O
MU6>3."[=I3Q:35Y.>7;^U=:HX7JK-4H+7SA;<<$M1S.-+.%=4%3VJ&6'2D^@
MDA3NE+2U@5M98?4O(")=@[AT+VZ9GB7>8'D!61)"&J?9&5XV%)MY7O:_Q<+/
MQ<I83;_(KV-U=]3\.-6US<2TK,190'UA4+]@,'__+AG%'\YHS@?-^3EZK[GL
M-8OS%W06=5SH23Y\JQ%*U;3*<-] :@WJ9# SSI\E0'>&S8JBW)T!DY4S4N ^
M9*T$30$SZ9S>\21;QBLP3-!,\/&]J5$PBQ7@*PT@0T?0CY#E,21%.$IC6)2E
MWI*;2XM4C(4LS#)BAFE^-3A?6,F\=H'L!6$4QN,"BC!."[AM6J'>$ E04C$T
M&J 53,*HN((D#7-B[2F#@I04)!DDE^&8%(Q2_RKR,,['<.RJHX.^;%!O_/0Q
M]%&WTG8M.NP. V[1]?7?\&XZWC&]X=)0(6M*C2_&10"ZFSC=PJK6=_E*69H9
MWJQI2*-V >1?*V7W"W? ,/;G?P!02P,$%     @ (H1T6'O[RMC;!@  E!
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULM5C;CMLX$OT5PC,;= ."
M;VTGG?0%Z/;L;!),+DAG,@^+?: EVF)"D1J2LN._WU-%R983IS&SP+[8LD16
MG:HZ=8KR]=;Y+Z%4*HJOE;'A9E#&6+\8C4)>JDJ&H:N5Q9.5\Y6,^.G7HU![
M)0O>5)G1=#Q^.JJDMH/;:[[WWM]>NR8:;=5[+T)35=+O[I5QVYO!9-#=^*#7
M9:0;H]OK6J[5@XJ_U^\]?HWV5@I=*1NTL\*KU<W@;O+B?D;K><$GK;:A=RTH
MDJ5S7^C'J^)F,"9 RJ@\D@6)KXU:*&/($&#\V=H<[%W2QOYU9_U7CAVQ+&50
M"V?^T$4L;P:7 U&HE6Q,_."V+U4;SYSLY<X$_A3;M'8V'HB\"=%5[68@J+1-
MW_)KFX?>ALL?;9BV&Z:,.SEBE+_(*&^OO=L*3ZMAC2XX5-X-<-I241ZBQU.-
M??'VE8W*JQ"#>&7%:Z=M%)^4C0WN78\B'-"R4=X:NT_&IC\P-IF*-\[&,HA_
MVD(5QP9&0+:'-^W@W4\?M?B+RH?B8I*)Z7AZ\8B]BWVX%VSOXD?V=,B-"PA/
MN)7XS/%NVGC%O^4R1 ^>_.=4Z,GP[+1AZIT7H9:YNAF@.8+R&S6X??+3Y.GX
MZA'8LSWLV6/6>U72]AO4IZ#^S\:(! ^JCJI:*H^<3RXS<6<V+JJ\%.5JF F)
M]ET&76AT,*4PEDK\R[NFSH1BNP6L1H=U1Y:%7'NET,P1_(ZE6)32KO.RL>(E
MVD8\D55])=ZBAS_"DW7&K7? 4H#_7@/6&;LXQRW0X8Q\/OGI<CH=7QT[J:6/
M5GE^-KG*Q&"Q>/EV<"Z A^0+H*S:FIW((5\12(]WXTO'72_@A(ILB'OMZE)"
M!7+51)U+(Q8.V?@M%H_@:7$(Y[O'KS\MWK5WSX?B(_;5C:]=4%TJ:8'0@1 7
M:@/)1%XK:9L56,EIM(6 I!FQU"[H2AOI1>U=T>2IG&1C4:+@, F1_:)B<M,Y
MGCR["J(V"(,\+IM 2P-YE"8XWIZ[QL947&US!WA>DH .Q5M9\;:4*/'^.S/O
MMLA^*'5-'&".B87T?J?M6MQ59)?[F#ZFO:N_FW *4(KY6/PC?8"EL^<S,;O,
MYD\O4U:] VR6?>!SW\.B%&-=H(ADNC[> T2$VI.H!U$J4XCE[L#VH7@C+886
M,UIMI&F84-M288D_K-OG_-B>1"E#LUKI7),!D)/<;]!66"-Q3<.*@I9+;2C7
MQ ?M,<G8M,=0VTALY)FF([4(,P/J%=5:Y\(M/RN>=X&"858U%FQ!^-*8W5#<
MA0-(43BLLRZ*TB%.">9\=I[<MJP\ I^=VIA#]CV&%WEBXQ(@ R9C=B(7V@)7
MY-2!LAWE9<[,0Q8I'42I->]5?S8$I4)F79'8O'(&APE>()=&M;E3*:2<I$5U
MS?"8YV\UJFA\YW2GI \@.J88QH_ &.HD$:2E5!-Q7_0X?"^-M&@'&<5$O$;'
MDCZVC)S/LXOQ,_%04MGA%P,HD*@]RR;SBW-Q-LWFS\<0MZJ6VC,X6B% Q&.\
MQVC/II-L/GE^SMHRF5Z)CU[:8+A709;5"DPG1&>3;#:>PLTLF\RPO(>T']GW
M3=266!=<89!/@4\(?H=[E&Y;!+'RKDH5_(O)XTD^S;H<3H8]5Z4D\OT\'XYQ
MTC&&XLA=5>F4 +1 6V<LRF4H$^GTLN&(\9AQ2&;\-V['&5I30V&V>(PL%]_"
M/8T6Z!Z2R)I=(O+)>;,'/OX_(V>-_EOP/Y[H<=E6T2LZM).9 ];P.)H#]X?B
MU\:3UE7.JY.2L/=#P<(+\UHG02/!@HA)EA5XU#R]>L>2QR XWR+XH]1H?@*A
M6%&M$T&OK8:LDCB2,:_Y\!]:-2)W3%DN ,U4TECO23%2^'PZ(>]9&G.$%'C2
MR$FRS=)*J(TCB59?6\7I--"K=9/:,' !@NK?VE.!5.X((JB@OO((HI+(6D=8
M9[10OM -9@#*A&NGC+2]7F3=/9&P#.EEBBX5"@T[AAB#S;'-W98^&FB"CR!$
MFB:H)2K-^HNX7(69@N]")ZA=1N 2JNUI;'4=DE@ M<!M4!((]0E=BR>G +U>
M%8+E*^#=)["OI8I;I>SAE$ 4Y#,"2K!L=MB5?]D_Q9'[<GP5>I/>?M^X_;[
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MSZL:T@?F->+Z/,UO1!S:(& LEJ%O!4L;$]58(=G7D?J,49I >_7AQ[??W8C
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M6P%Y\XZ&..[)?P__"<BI?1IU:X^#Y]Z&'.T3S9#^7/OGT=F#.S71N-7]#82
MB.>%5A!&P@\MS_;$=6PMO>"&B1;&PJ,-9W&-#\>^83IYEDMK]GTKPO*N'=_!
M< P@"GE>0,<!0*7KI>4$W@T3A5IZ R\$E!!&Y?^,"*<',"X3P7=M.I(2.+Z@
MCM-0R8U#W?V!AQ4Y=(A%T8#:K2,(DAU; 43D.K0M$%W1 $2CEOZ 2.!ZH2:!
M(P('+P8V;MQQ*021"5M[&&O>QH01D^4&"L(!) S?028?]<5<Y_!8P>9(0GT.
MN@WGI_<OQ:'J"J0SRDFPEHZ:E">-/V.[?D3ZY-02<:E'09U)O%1P;_JI=/M
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M=Z[4SJBY:*L]_Y[*JFH1?_#7+9(%6=,+>+ZNX%7U!4W0_\#.L_\%4$L#!!0
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M:&5E=#,V+GAM;.U837/;.!+]*RC-5":ITNC+MO)EN\IVG(VSX\05.3.'K3E
M9$M$# (, $K6_/I]#9"TE-BN[.YA][ '6R31W7C=_;H;Y.':NAM?$ 5Q6VKC
MCWI%"-6KX=!G!972#VQ%!BL+ZTH9<.N60U\YDGE4*O5P,AI-AZ54IG=\&)]=
MN>-#6P>M#%TYX>NRE&YS2MJNCWKC7OO@DUH6@1\,CP\KN:09A<_5E</=L+.2
MJY*,5]8(1XNCWLGXU>D^RT>!WQ6M_=:U8$_FUM[PS45^U!LQ(-*4!;8@\;.B
M,]*:#0'&U\9FK]N2%;>O6^MOH^_P92X]G5G]A\I#<=1[T1,Y+62MPR>[?D>-
M/P=L+[/:Q_]BG62G+WLBJWVP9:,,!*4RZ5?>-G'84G@Q>D!ATBA,(NZT443Y
M1@9Y?.CL6CB6AC6^B*Y&;8!3AI,R"PZK"GKA>%;//7VMR01QOL)_?S@,,,N+
MPZPQ<9I,3!XP,9Z(2VM"X<6YR2G?-3 $G@[4I 5U.GG4XAO*!F)OW!>3T63O
M$7M[G9-[T=[>0_:4S[3UM2-A%\)8\ZO,OR"VRBP%1:^%7 1R8%EE77Q<D5,V
M%_^0<Q\<J//G?7%)N^[?ORN7TRM?R8R.>J@73VY%O>,G/XVGH]>/^+3?^;3_
MF/7MQ-&#B?L738CK@L3?G*TK/)"ZEH%RE.NW4J& R+) =L2E=!E?3/;[>$PB
MATJ\R*SQ5JL\FE@H(TVFI!8^X$$9K:P)Z9 KJ;2<:RA9,2>AO*\I'XB/1HP/
MQ%N:NQJM8FN#,UM6TFR$-,;6)H-Q%40A/5(GT;  ET+0<0LAEX[:S50HQ'M;
M )013V19O>[NE!'O)6SVQ9DT,I<PG?-#WNW\_$2@\8F3WZ]' "#%7%FO2D!V
M#'@6"%=2/ 67Z$:9NI3S9P/QB9:UEL$"N*PJ9Q'*.RN-:4^H8G=#P,;HI>:.
MND$(R(BEDR9P%"ZC!!O1*I/<Q?R6(8GX9;5S<%!O0%B3,W%A7N:Y8F%LN]1V
MCI]FJSY6,UVW<NSAY\%L($[TR@;*BE\\\E:6Y#A7ZJ^XHZBD"P:U 844H+YX
M?W)Y):X*B:[8%UHB#QSYSKTFCM!-]$B%O#\0OT51KL%.-H8>:4?4@\I4%?F2
MBI'AU14 ,5PP#FF!Y@?9N/:.I$92+PSJ&NPB,$"5\]KYE/S**3S3*E9Y]!QH
M-@V0<Q.0'&20]U@HY]']:H=)!RQM6H");BL,#P;DA;<\0[RHK/>*"7L'$F+*
MI6!%_@-E)$]K<58C@1$5<_G*<:RC]!FAV2PXM22>SJ[.GL7L-JSJBW6A$"W@
M ';-,N]KW7J  IGL_5B!A$*&N/3VS4DB6R0E5F87E[^=?'AS(9XB7UJ5D;_8
M[4O"UV=_.3M@(_(HS9)BJ>X6P;NZ5(R6H?,N 4P.,06(@\PQ'84K"*:#58BD
M0_< .Y&1+S7:B8(]E2N+Q,/;[>6D6GGK%&)[SY(T-QMT=6:'KZS)-SJMGCE4
M]I.?7DS&SU][D2M/F-JM4JTSXERMN$7IG9VT1)=K-O1WSPN5.YD#*631#*NJ
MCOJI3S1&5\2K Y QCJQ^$Q2Q1@"MZ1A1X(A /ORZ=$PBGC*QAC*JX2 HC;3D
M=19\6YPXT.B\GYJ7EYK\3M7R*"/I0(F?QY/!!&G1&ED;B&LT;Z9-6]9=+'B4
M!5HBF&U1MTFC6_0%GZ+R;0/ /AU1VOT1#>8/=W.?R#C]43)2=(6MCD?]\>1Y
M?[PW$1\=FA+KSA 12ET.S(M,O54EDY\'4E3[>3R=XB@4G15/#7&MVXPH]\WJ
MJ%U]UF='&\W/LS=B-!B->;0+S]L@PV"10$)!;C3DU#*2C<'^CB#@7,S^+B;]
MR<'H[KEH"@MH<?HS',58)8+#S)G_KD8'<<0V3JZ!DH=>3AJ1=QR=U)$NS HT
ML0YQ<+8$+EHI6WMD.LW'6&-H>YL$ R.$="[FFWLRCN&-\L+V_6X1?=!D5E"Q
M2&BNT3Z]3!TIX/C,E<!Q2*G^('TNOXJ+#$T)A#]O7$PC>G)?TCUA^#-&R7.!
MX_GQY.Q4G$MGQ,<ZM-ZSBW %ERBAK8G$+L9^#L7IY* _&HV^I4?"O2UX'W_N
MP=)&7&89^!B/)DRTV.7HEE'4RA==\]HZN&@E45\J;%J8.P><K6,-]$#'!4XE
ML(SVY&.?L%!Q7%O(9<&O-*@TS&);4BOV2$#3@-J*YQ6X0AEYM*I_*ZSCE_WQ
M]#^,["ZH_^G ;IUS46![8X'W"RKGT$O->H;F#N%39LH?TO'I2Q16YX0"C*^/
MJ3+IEONBC^=;Y=#;HR3LGP!*$_ ^#CL'(_R]?/E=Y.*!MRE@M=4L[GIPM,\Y
M:^8%SG1HGG<;76^U5 <?% ]Q'M E=TC'X90EQY\-9-(7,40Q-Q"W2Z/^HF9&
MWY7\0TF*QWD87:5I^7W&5$N77"T6\(T),Z>PYB-L].=K'=.:/&8D&3S9L']=
M+_^133IR=3[D_SVNM+QHL,?.UG#&=PS)=RDB''\:Z(9:QZ.M>3,>8*ZT1&C$
ML3^?'79I%(=/8S=%OS7G&PK>5_#[J/CI]+MJ;Y("GNQ,T/W!BW:"[G+N_TSZ
M<2;=]XH_W/I.@T/6,GZ-XG<NE&SZ9-,][3YXG:3O/'?BZ6L9WJR6"J^#FA90
M'0V>'_02;]J;8*OXU6=N0[!EO"SPBDF.!;"^L#@,-#>\0?<9\/B?4$L#!!0
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M4A'$6#DI1HW)LEK8/<.T6R&,BO;:+5*@NF$#-AF"S3A@4L;]QXFCJ8EJ5=P
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M<E[\-?\)&<*)H8BREYC1VV9_2G0/597ATYOZ^@:>PSFO:6RFQD7OO) (\!T
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MW52E"SAE.PT%Z3*9,N6IWW3E,;*?&C3A1[N.$OP%6H+)]"2_. RJ&XLQ*-%
MPYFN2U?ALO4O[@F3ZD&"1KT,$]$<L](-9B_EGQRSN/^-$(Y*8KK<)DAA+<42
MV>5(T&.(OX'+"Y(OO02WQ\;/<-(UYVGO)798_IB<.^O"%%+'9LA^&+=UY:/0
M(PT8V41Y4(R36%?,]$ ZKQZA #FQ)3_BHK7FKS,UC<,X8(]C@UBK"C4 -,K%
M EBR)'&6R#=G_08I>PS-492".)0W%/NW*OX!<E<=)"[_2)"*+2UH.@+>HFEN
MX63T'(/?6OVS?>K& .461(]?Q5VWK6#K:&_4\5PP,0;W5]$=]>UN *9,9C<6
M$N%?^U+4/R2H$E]!&(88=];NSE F%WO3R)(>(7$6)GT*(9U1=>;N8AJVD9Z<
M/X#GC<$>"O46500_ H>O2<.C(XT2+Z<2B5]?'"]'=K?:ET0 90G>/[ 2/%1?
MLV@1?+L@^-3B'F!9 $TJ*@A-%M:WA0:7$1==I\GQ>+0DK>VK9Z::-1HE2>::
M_,AX=OHQ$LQZ>%;< #W+ODQSZ_D%EZBZWN#LVT.]@=4UU:X>V+.D"[6]EEN
M#TK$T]-8.7.B!V4-HDDW,3$WM-$6<DM_%OR,(75595X ;#1.G,P,A_93RB\:
M.!>+';]M_E#$,H=BF5L8HYTFD>4RSR@)SL#R;!XLR6A(XM%X4!G-K=*K 5&:
MIBG%DR6SM0F39B5]'C4B7#4@?Q7G&&!T/5)[,@>5S<-6C- OSA)O&F<[%!.1
M"?^1(\?P HKQU-BU)!U*M$S0+$,H-ON5@NST@S\<1[4>1&PBMUGLTZ0 PB.;
M"?(K@=].JFS)8A ,-&9T6V\YA5)%S8IS_G*\N.PS@) D_V),#6ITGUX4WU?
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MCN>^7[E*CB)B96K"K2S,P&P1<0MUJG.48V2IF0)%Q#*$T_K )!0.CU$UZ=R
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MDDC&D;F+K?L_C%+.^YN7%E0N4]:)0_K_!\(ZAZAI,$SHKX7^ G;;*67"1$@
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M)+<!_P;016,V!31Y +PID08D*$^8_-_[^U'_G.R;#&.WY%I-3))U(_4PUN-
M2SMA#62S/DU-FLY6*B9B_,+9,U$[BZQ7L8N!:!G'&U2-28?$J-!#*#;5_@%D
M;:KK B$CXG#QK'@95\,"Z/3\'ZC+RY!I\E/;G.F?"WQ?M5RS&X9HQ<BLB7%K
M\5PS62UJS/3%.G-Y2!'C#D D(,$\PWJG6RK(I ?W22L@._]VR.715E8KC>#Q
M6*&HLA7\8/<E=3F=5:0LUF,SN8H''H_S<OG*8!Q>@[EO0/ZHN'O4\Y;1*DZ;
M6JG0S2,D*\)&$PW?IB3QA'K^JG5;K&:C;>9)T+!P!RJ$396#43E%\N'3-EDF
M",<.$^PYX[H<?)6':%LUMCL \E"JS$[MW!!;6/)[P*[%G6&T,M8PA:N&=2IG
M116I?(\WAQXX;OL;-D/I&>:EU4"QT._*%8EL=V0L76DYN*A:",=."G6E@GB4
M@#B%J 5-]"/-XY^)]%QACDO$T8\8^#0,462ERT[0\I5B=Q:BG+&R/%0V6R1B
M/SEL\.2+UO[28.-=.GELR[#D#?I,:)>!\6'L!X:LDWE8HLA</KX<?'D*.$7R
MTD<SYA3KLB;91=J#QES8EB=F^8C=)F535?XSMB'[S<\JD<^47(H=E<6#K* ?
M7$!"Z');8TW-!Y;,$;&4>&,NS#_IVOGL/P\RR7;^16),YGC''T, $GIRKDK)
M*Z*GZW+SGN7HL'.0SGW(5F2#B>0TRH+2X?8VG-<<S]/!S;#_6T?"U>LV*=B4
MZ3(B3H!!T>![S7B:#AEPQ,<"NHG.PPG-+(23EGKAQMKM((UA[ZI[XO<>%#YU
MH#AF3!L[:2-0@A>E>G\<O(:L59? YNEO*Y&I80D/3,RZ'YYS(0F?4%OF[\NA
M_.Z;0]5=5R^K_;YG)O;M(^S'8+\BW\-.M%\_OWST"7P97O_NFV-Y78$>?(TY
M&_MJ!Y\^/?_R\T?,VO6/H3WBD!@W,K0'^B<V$:TZ? &>[]IVT#]P FPH2\O[
M[O\ 4$L#!!0    ( "*$=%B53L'NQ00  ,@+   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;)56VW+;-A#]E1TE]3@95B)(4Y9B6S.R?&V;QF,E[4.G
M#Q"Y$I&   N 5MRO[X*D:<56%/?!)H#%GCT+G%WA>*W-%YLC.OA:2&5/>KES
MY;O!P*8Y%MSV=8F*+$MM"NYH:E8#6QKD6>U4R$$4AL-!P87J38[KM1LS.=:5
MDT+AC0%;%04W]Z<H]?JDQWH/"[=BE3N_,)@<EWR%<W2?RAM#LT&'DHD"E15:
M@<'E26_*WITF?G^]X0^!:[LQ!I_)0NLO?G*=G?1"3P@EILXC</K<X0RE]$!$
MXY\6L]>%](Z;XP?TBSIWRF7!+<ZT_%-D+C_IC7J0X9)7TMWJ]16V^=0$4RUM
M_1_6S=[#I =I99TN6F=B4 C5?/G7]APV'$;A=QRBUB&J>3>!:I9GW/')L=%K
M,'XWH?E!G6KM3>2$\I<R=X:L@OS<Y!(5&BY!J.:"_4GM?^0+B?;-\<!1!+]O
MD+9HIPU:]!TT%L%[K5QNX5QEF'T+,"!J';_H@=]IM!/Q#-,^Q"R *(SB'7AQ
MEV]<X\7_(U^^(+7"4BBN4D$VZ[A#$IZS\-=T89TAZ?R][3":4 ?;0_ER>F=+
MGN))C^K%HKG#WF3O%1N&1SL2.>@2.=B%/IE3>6:51-!+6')AX([+JI[9G%,X
M$-96F %7&2BM?DZYS1L32&&=4"O KU3:%K=EMC/V]LP^YKB3R)I;0 I,ATXS
M7TD9^,,G-9LOU'U*(]+:[?6X'X^@1-/2)3]:90G\4BGT.HCZ,&^@]X6", SM
M&_@PG9TVJ[F6&1H+,\FMA>FWB^/#89"$26M\XI$$A.7_&K1S;A1\(&6TP5@0
M)8WYHW8DDZF\TP[3_,'>YNETXVXWH0^#*&HB7WQS1-M=GV<,KY-A$ [#)^Y;
M>?X8;!PPRN*\NXSZVMIK:+"'24 ZA6GVF5H0[5!DD8(OA!1.H.UB;P'?9R,Z
M*/8&SL1RB085W>K>JU'$V!$LT.O.D5*V*A%&<7# &.PHCZ0KC^3%Y6&KA169
MX,8S]_7P60M%F5*%5W1@V_2_&YSU([A^UD!^$(9:HA/N'A0O$&Z,H%Y3DHKJ
MGR6_?OU8KR47&:2\%%YF^W6)*7\+I/8U*:H]/5+]C>1-S5!A4<\6-O=MB]!U
MJ4U-C6QZ32W/YJ*LL4FS_L1+O:8"RU%2*=X_2CEF?1;U?:]]'$:/YGP)IT*7
M%+V@KAR,QG$P3$*X3E%Z;%)5GX3UT^.@\[Q$.BQU#Y?%XFH3@P5L%'76'0#S
MM?#E?+GAS)(X&,>A-[E_T?R(PA572M]1UD\X1.-@/(I?PN$]EX[#;RZ#2Z.K
M$N;4^?HP"H,#.H3&N,/[TWQ*JDDW$PCKQ5T^OSX+Q^+$+^^DJ5(-2)>UZ1>Q
M)(C'+[HL8FA3X2O7$F.2M-?K';6*FLP#?Q@/ \;B=L=SN M.K4.L%%]2P)78
M>Q4=A$<PIV\<'A65RBKC!76+)'*L?W.!1<&86D\<'[Z$YAXORB.8S:Y^[SA1
M.51.I(0XTWW/]NWF<;.PZ? 1@UE./_>0M) /W[?;.L]@XW55H%G5;T@+J:Z4
M:QY:W6KW3)TVK[/'[<T;]STW*Z$L2%R2:]CWKT+3O!N;B=-E_59;:$<OOWJ8
MTU,;C=] ]J6FU-N)#] ]WB?_ 5!+ P04    "  BA'18IO8'!O,"   3!P
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MRYR^6FB\ ]DSK=UFXPG:[^#D+U!+ P04    "  BA'18,G7X_VX$  "L"@
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MLG:3K)2*BI]+6[T K\1*&NH3VZJYQC-0*/F$+V3,*K_\1:MZ^_'#, KS<W/
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M]'/J=]W<C1K!JJV_CRR4)1_\YYJNDZC= =I?*F7W@C/075"G?P-02P,$%
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M?R2ZV_MC[$[&/\[N4&ML/QZC>/Q%:_A$EXY! UR6G=:4?-5I+M=@:X1G9-H
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MT.CL?!* [EW<!Z1:[YRU(NM#/ZWMPX?:)=C]2BG:!Z[ \)3F?P%02P,$%
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MIPW."8F'\MEJ6!6@9Q?O9*%J3I;LADR7;%5Q<W(VMP",R_.B [EL08('0&A
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MK5"#SY]R1MD78"3+*(PH92<PRDYPG0H&EU6E@\'.N8)P01%?X)V"YB'3>5H
M9NG".%EO3XXH89PC&@L_E*?AE_ "+WBTLG5U3Z72LYFR*CBWL4RS D:Y"*9X
M6&1LU_TWP@\"9"G)D!"-29[EZ #'VN9Q0HHX1Q-,@%+W5[XO)D?1DA3AT#*P
M#W[2 OTDE/)C9.2$\WA'1D2A]/7M#.F)P#(XEF8I,!ZBA[+R?2IF/%L+L=8P
M+\2'"@822=Q+SY/LH'[!T01$09(BPT5.1? ZYY#FA+("?L=_W%):^Q+*0#9F
MV?H/XH%)EZ8X9H0Q"AF)4PX9(C&.$<+8_J\5P081\AR#%P/'3"@ZGT+>,D82
MD1Y5$8(D>8H:=N/)L+\9M[6QR4 >*C -I12GN,B BA#_O<7!0H&^!=WL?Q!?
M+*0XZ<H*DT/0;AVCV?MQ84<]%$>5"=M),Y)CUN8DI0DB):%Z."G84?H*4N0"
M1MWP5HA73$)9YB3#!RD-"260>Q[8[I-5%-E>6;O]#V0M>D%'5*R?K4-Z'GXK
M_EO5A.@D)$TH% 6A20XI/JH"$JQAQO"E*!+8]T<[WNFG&F6?NJ[101ENZUNK
M87=H3"_[?FQ[O.]J;Z5]TIC+M9JA:7R:B0ALWRGV"V\677<V-1Y[O6XZQ^9:
MV7  O\^,\9M%N&!HUR?_ E!+ P04    "  BA'18.IK@+.P%  #($   &0
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M5N9A1&D33+P40N\F=H/QJ4W_ %!+ P04    "  BA'18A$^2F+\$  !=#
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MHFXY[L@R1P*CY-NR_,GGVBBDTE_'"M.&C8Z'M>UUK=<\A[&'_:-!;<";?/Q
MX^#F#*BH Q6=\SYY:KO*(OJT1W3?0S1UB'H;/76(CL$X&^@XC >Y 6Q5K)"H
MCY2M:)2HEP2Y1EZ!*TW 4@/W%'/-H9HC!>W>$EX7]H41KJPM6<@23PU]39[D
MPFRM\,ZU!.HK*!TPO1)K;7%A8V.G-[PD:X5GEC*O1-F6U.19&I3>26W(+2]Y
MG:-O0RCYB=>-+9D+34,_3B/"?)I20H=^$ 0D#/PT'I(9Y"4"$0N1M[7$&N^
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M"%^$1F#!)9R?12Q@=Q"Z0^:38DE@,P+:8GIW- RZHU6YD/I*HZP.<BD(K)K
M'?JWYB%&-P&$S+T=W,*Q^_4.>K%"N;831]'I;FK=MF6_VP^U6=O+?\/;B?C
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M/IND=A/@_5)!<MH'YZ#[$!O_!U!+ P04    "  BA'18C1@CZI4"  "6!0
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MB=HYD+U6RNX%EV!<Q?D_4$L#!!0    ( "*$=%BGH!L+:@<  %T5   9
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MP.R$&GN6\&MK<*%U<:R60(W,A*9QRVK-.BCG$OTAX%ROK5KL,^C]'XH:,(T
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MI-B$=,U$;K<=\SPT&5E1Z/8QQG9\!PSK6IX]?@35A<3=OJ<9=PWS66#/<9^
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M"2UK$,F 8]3=/D&PU"%>QR1!0J"]+_BRCL0O[(ZP?)F).QV,4YJAJC0EJ8W
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M>*5Y=O>LLL5LR4VI@/G<CWP6>3Q"/Z$@>1RQ'D#H%A#ZZP'Q-C&W29J0=+M
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ML!P=(1FS9%NB=EF0MX(-V04L079UBCM#6#5W#7POIB;#_<HPJ[O7OUTS,13
MM1AZ@:!K[*ZHGORA .A_.?^ 9QE2#^GY= T"NBK%]#!&CS<W_Z:0ZH4[KMKQ
MN/CUDD;!8@^<0^(O-/'P_!"E6LWDW361"+EU5;B*?K>3*T/+0PW=F+;9[*6
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MF\C4&MG*.U4B2N-X%%6,RV ^]6OW>CY5C15<XKT&TU05T[L;%&H["Y)@O_#
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M8H[03F-*DZ/3UFP8ZIH-=[=BT..?4*:_#RZ&_%ZM'!T>M'X#U5Q4\U#-1[4
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M0#4'U5Q4\U#-1[4 U4)4BU MIC0Y?6VUA66]Y,DZ"ZW-0#4'U5Q4\U#-1[4
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MWM3,EUCDA$E$(=.AP=%8ISK1E*%-1_'*EGYK6ZC89J%+=Q!F@GZ?<:ZV';-
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MQHVW,3^< <U N07V?BZE>9JX![0MK?$_4$L#!!0    ( "*$=%C'O1<\_0,
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M'29 (F#*0-[?4"H.)^H![0:;_S]02P,$%     @ (H1T6!M)&=96 P  )PX
M !D   !X;"]W;W)K<VAE971S+W-H965T-S(N>&ULQ5==;],P%/TK5I@02&/Y
M[L=H(Y4-! ^P:1WP@'CPDIO&(HF#[:SCWW.=I"%9L\*D3+RT=N)S?,_Q<60O
MMES\D F (G=9FLNED2A5G)JF#!/(J#SA!>3X)N8BHPJ[8F/*0@"-*E"6FHYE
M3<R,LMP(%M6S2Q$L>*E2EL.E(++,,BI^O8&4;Y>&;>P>7+%-HO0#,U@4= -K
M4)^+2X$]LV6)6 :Y9#PG N*EL;)/SVQ' ZH17QAL9:=-M)0;SG_HSH=H:5BZ
M(D@A5)J"XM\MG$&::B:LXV=#:K1S:F"WO6-_5XE',3=4PAE/O[)()4MC9I (
M8EJFZHIOWT,CR-=\(4]E]4NVS5C+(&$I%<\:,%:0L;S^IW>-$1V [3T <!J
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MHB6;NBG-+-%2/BG4NB\%D_\2B1.S)5[+513@ 6\I$Z18@S_!LMH#X*\5B+%
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MR%0I;S<8I9BI /G_BE)Q'*@7-,>GLU]02P,$%     @ (H1T6,78%J#@ P
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MWAQ>-#>2E?5V_H%)-<#JRPQP"EP'J.=KQN3^1K_ '"$M_P-02P,$%     @
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M,E7M85471B[+;:!9Z43*TP6P%)0=@,_G4IJG"SM!O9,X^1=02P,$%     @
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M*&N [S.)*=TL[ ?:$7_Y!5!+ P04    "  BA'18L8"0LF,#   Y"@  &0
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MU1 #)NM"I>YH4=JG>R$T%@*VN<;:#J0QP/FEP&QJ.F:!MEJ<_0-02P,$%
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MI7AN;E."$R*T 3S?<JX>!GJ!IG6X^@]02P,$%     @ (H1T6$'O*:#C @
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M@2AD"NF<3-0/P9MK0=.1K#)'\2V3ZF WS5Q=I8#K">I[QIB\[^C3O;N<Q;\
M4$L#!!0    ( "*$=%C^Q_QBU0(  #D(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#DQ+GAM;*U6;6_3,!#^*U:0$$BP-&]M-]I([3+$)(:J3< 'Q <WN3;6
M'#O83CO^/6<G"]W65INT+XWMW//<W>/+72=;J6YU"6#(7<6%GGJE,?69[^N\
MA(KJ$UF#P#<KJ2IJ<*O6OJX5T,*!*NZ'@\'0KR@37CIQ9PN53F1C.!.P4$0W
M5475WSEPN9UZ@7=_<,W6I;$'?CJIZ1INP'RO%PIW?L]2L J$9E(0!:NI-PO.
MLL3:.X,?#+9Z9TUL)DLI;^WFLIAZ QL0<,B-9:#XV, Y<&Z),(P_':?7N[3
MW?4]^V>7.^:RI!K.)?_)"E-.O;%'"EC1AIMKN?T"73XNP%QR[7[)MK4=H7'>
M:".K#HP15$RT3WK7Z; #"(8' &$'"!\#X@. J -$SP7$'2!VRK2I.!TR:F@Z
M47)+E+5&-KMP8CHTIL^$O?8;H_ M0YQ)OTJMR0(4N2FI O*1S(J"V1NAG%R*
MMJSL_;S+P%#&]7LTT=943WR#_BV+GW>^YJVO\("O("174IA2DPM10/&0P,?
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M-<#W*XEWTVVL@_[?0OH/4$L#!!0    ( "*$=%A%4X[75 ,  )\*   9
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M%ZFG^2Z!I25=]IX8\]W2]HJQ88F.H8B@KX!%%<VB9-!7"'LJ)]%#4-S$/LV
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M6L',KMU3F%NE3U3N&:X1''8H[XRNL#/(XJ*FR&B1YE<76Z&UB//D 2CV-E,
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M2!Z_@*D ^3RD5+Q,5(-?'NC\_U!+ P04    "  BA'18ADIU4)\"  #W!@
M&@   'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&ULK55M;],P$/XK5IC0D-CR
MVFP:;:2UY56:-*T;?$!\<)-+8\VQB^TTX]_CES2T)2L@\26QSW?//<_9/H];
M+AYE!:#04TV9G'B54NLKWY=Y!366YWP-3*^47-18Z:E8^7(M !<VJ*9^% 2I
M7V/"O&QL;;<B&_-&4<+@5B#9U#46/Z9 >3OQ0F]KN".K2AF#GXW7> 4+4 _K
M6Z%G?H]2D!J8))PA >7$NPZO9JGQMPZ?";1R9XR,DB7GCV;RL9AX@2$$%')E
M$+#^;6 &E!H@3>-[A^GU*4W@[GB+_LYJUUJ66,*,TR^D4-7$N_10 25NJ+KC
M[0?H](P,7LZIM%_4.M\T]5#>2,7K+E@SJ ES?_S4U6$G('PN(.H"HL. Y)F
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MJOU4=,UYLJ&,P3NX3!)J4DL8+ IW/TRBSZY0$<KD6VWR<'\%9Z_?3GRE0QL
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M%,9 [Z><J^W$!*B?1]%O4$L#!!0    ( "*$=%B(,@5,GPD  #-5   :
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MJRPIFK_.6V?K3IS5:U%FNZYQY<$N3MO_T:]=(HX:>.R=!J1K0/0&_CL-:->
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MM!>AJG$L-36)1":17&6<Z@Z#E6),-8ZEIJ98(K4',F6_P:K3..YRU-/'*OA
M@]-R"13V) M[, SW&*U\(R>NGA'3Q$@;AQT9&Z@$7 \FW*J+B:0N3[Q&B;//
ML[W(R]^<O*XCV$<K4&YP5\)4XUAJ:BHE<'OL.J,5$DQW*<94XUAJ:HHEZ7LP
MZO<;K4(3$ +7-7HG*LYCJ:F)D4#O@43;9[R:&5EAEJ285I;<<=B;L=%*P/9@
MPEYF16F-$9.7EZAJ'$M-K0-*_";N508G@H357?D14XUCJ:DIELA/8.3O-3AU
M&@H3N#,6:/W08D:8YVJ_A3CLT=B()9\3$$X7CV*51$41;^)56RW/-EUEW1HZ
ML?QP<_7:(7S(P9?$)>B:2+HF,%W?K]=Q\^//F@^3JJM\S/7ZH<4L9#.]  <[
M,C90R<L$YN5/NWT4YSN16L=E8H+PC1>&<SU2BQD)@T /]1+$3"0Q$YB8'T49
MY^+=4,V2\(V-/N"##+[,+T&^1)(O@6O-7_(H+=HRA[..-QN1B_>&/TO1F1E#
M@&ETX[&9?AE< D6)1%$"H^AIXB(FAY* &NL#%C/+C,!M:LJ,H,8AR9' Y%BS
ME/.[ Q71887!<SYJH1=+3<V>)%$ROPY6H9(KJAK'4E/7?"6Y4KAPW NKJ*UV
MS&9Z7[.8S<(PU+H:[-#8@"5'4I@CAU$5-4G10E7P(0<O4U\".ZG$3@IC)TA5
MU*1,WX0JBY4%JF _QL9YM-T!ID<8JJC)A3:HLIE9H IV96RHDA\IS(\P5-'3
MM598?_ %?@G$I!(Q*8R8_7F*FK@9&GW?@J1$K^C 'HV-6!(D/7>W K608^B&
M5 _68F9.!-QBIDP$:A@2"BD,A1U,]5_\@_4&[T5"+6EBJ:FYE&!*K[-)@:+2
M*ZH:QU)34RSIE2+L5*#F5@7BS?35/YL5)7.]VUT")7V)DCZ,DL/(RC=A49]U
MX.,-WNEV">[T)7?Z,'>"6.6;F&DD Y4QL=349$C&]&'&A-G+-_'1R 9J'1-+
M3<V&)%$?)E$8SWP3,8ULH&X.P%)3LW&T41:&U?YXYIO@.C=28RN.^GJU"W9I
M;,B22'V82$_SF6]2)B&A/DW8K(S)A-NLCB<3-0@)F3X,F1V=#=WR *L.!0A4
M-8ZEIF94\JX?7H71?%0,1E7C6&IJBB4&^W!]MM^V_%[+]LM^9ASV:&S$DDI]
MF$H'4IH)GD;8J.50+#7UA@3)L ',L""E!2:R6C9Y6*ST2P!V8FR0$D4#&$5A
M^@I.L^AI$PZ[,#9$"9C!J;5S"*D"$S"MRXCP089>VEAJ:DHD908P9?;GJN T
M<9XVX; [8\.5&!F<N\<T,-'0UIU-*]NH?M),#>/H%JDS[Y%"W3&*JL:QU-34
M22 -KK-C-$ E5%0UCJ6FIE@2:H"P8S0PU]8#XNFE98N5'\SUQ4/8G['Q2EP,
M8%P<,(9:8-#8U&\QNO$\(^9+ &,@@3& @?'D"&0BHN4V3=/(<I_F)=B/2?9C
MY]Y#Q2P 2/2M,TN+E7F]<XN5<KVK04BV8R?*C$=GZ\3&$UAIZ+B&JL:QU-0L
M2GQDU[DUBJ'>&H6JQK'4U!1+'&4(MT8QRZU1U->G#HL5F1NC"^S/V'@ECS*L
MLB8S49(88XRMK&E$?(FJ)I/HRLY#5V;6(:O15 _4-/*)$>@E0),=/0O@[(<!
MF OB=*[#S=)F95SMW&*E7.UJ$!+E&(QRVL31?Y$=UAT\QJ%6%['4U)Q*7&37
M661GJ(OLJ&H<2TU-L:13AK#(SBS/ YB%^B]]FQ5C^MX6V)^Q#^.0D!K"D-I_
M&@DMNS'UF=-B<^.Y>LBP2V-#ED@;]D=::Z"6FWX\?<*T&NE%'-B1L8%*Z@SA
MHN7I>20T"Y>694"+E7FY<YO5\>6N!B&Y+CQQ4XXZCPQ=#H35!S]3!G5A'$M-
MS:PDR-"_RFP28F[F7**J<2PU-<4264,867O-)J&)I/I4<MJ$PYZ,C50R:XAU
M4U%H\J81[DD3#KLS-MRCAUCUIUMKD&;UT0CRI F'G1@;I,3-\-S;U#L!!H5Y
MTH2#)JWOTZ.G25:_(EZ:IW(6SBI[3<OV 8N'3P]/_KQOGG>I??[@?>3M\SNE
M3/LXT9^BO.JLA9.(327I?J@[5-X^H;-]4V;[YIF5SUE9_91I7FY%M!9Y;5!]
MO\FR\MN;^@"'YZ0N_@!02P,$%     @ (H1T6 T+/%G" P  *1(  !H   !X
M;"]W;W)K<VAE971S+W-H965T,3 T+GAM;,U8VV[C-A#]%4)=%+O -KI:CE-;
M0!+U$F 7#9)N^U#T@9'&%K$4J9*4G?[]DI0B6[8B)("PR(LM4C.',V=X*)++
M'1=?90&@T&-)F5PYA5+5A>O*K( 2RS-> =-OUER46.FFV+BR$H!SZU12-_"\
MV"TQ84ZRM'VW(EGR6E'"X%8@69<E%O]? >6[E>,[3QUW9%,HT^$FRPIOX![4
ME^I6Z);;H>2D!"8)9TC >N5<^A>I'QH':_$7@9T\>$8FE0?.OYK&3;YR/!,1
M4,B4@<#Z;PO70*E!TG'\UX(ZW9C&\?#Y"?U7F[Q.Y@%+N.;T;Y*K8N6<.RB'
M-:ZINN.[WZ%-:&;P,DZE_46[UM9S4%9+Q<O664=0$M;\X\>6B ,'/W[&(6@=
M@F.'Z!F'L'4(7^H0M0Z19:9)Q?*08H63I> [)(RU1C,/EDSKK=,GS-3]7@G]
MEF@_E?RA"A#HABG,-N2! L)2@I+H)W3?S 3$U^BFK# 1NMH*?>)2(LQR= =;
M$!+3H??O4U"84/E!PWRY3]'[=Q_0.T08^K/@M=3><NDJ';P)P<W:0*^:0(-G
M O4#])DS54CT"\LA[P.X.NLN]> I]:M@%#&%[ R%_D<4>$$X$-#UR]V# ??T
MY>[^2#9A5\C0XH7/X1&942YK :8B C+.,D()MNK2/5FA*PS25(&<5-L4=,-Y
MOB.4HG\,-"(*2OGO4)V:.*+A.,PZ=2$KG,'*T0N1!+$%)_GQ!S_V?A[B>$JP
M="*P'O]1QW\TAIY<EEPH(BW?'P<HYE9H2E>A8WJ(W&:0V YBUNQMLHBBI;L]
MY.S49AZ&?9MT "?8V_0RG'49SD8SO.92F9E4"9[7F=)S; NLAJ$L1H%>.T6F
M!$LG NL1&'<$QF]$HO&4_$\)EDX$UN-_WO$__QX2;0:9'4@K],^/)'IJ$\W]
M(XF>VGC# CWO\CL?S>].,X9%5MBYDFMU4E[9CS(\ZFVBA,&O[BCD:Z?*E&#I
M1& ]*A<=E8LW(M7%E/Q/"99.!-;CW_?V^U+O>XBU'>509<=:'3#QCJ0Z8!(&
MT;!:_8.MMS^:XF_ 0.@=M)DO.->;>R*5P.8<-*K8<=373IE)T=*IT/J,!GM&
M@S<BVS:0J8HP)5HZ%5J_"/N#B#^ZSYY,N>')%C8^^<X.& 5Q<*S>4Z/98G&D
M7O?@#%V"V-B["(DR7C/5G"F[WNZ^X]*>\H_ZK\P]B#V;[V&:2Y3/6&P(DXC"
M6D-Z9W.]GHCF7J)I*%[9D_H#5_K<;Q\+P#D(8Z#?KSE73PTS0'<[E'P#4$L#
M!!0    ( "*$=%A66FF&A@4  )(L   :    >&PO=V]R:W-H965T<R]S:&5E
M=#$P-2YX;6S%FMMNXS80AE^%4!?%+K"-+?F00VT#B25M@R)HL-G=7A2]H*6Q
M3:PDJB1M)T ?OJ0L2Y:C,'8[16YL'3C?4/Q'(VK$T8:+[W()H,ACFF1R["R5
MRJ\Z'1DM(:7RC.>0Z3-S+E*J]*Y8=&0N@,:%49ITO&YWV$DIRYS)J#AV+R8C
MOE()R^!>$+E*4RJ>;B#AF['C.KL#G]EBJ<R!SF24TP4\@/J:WPN]UZDH,4LA
MDXQG1,!\[%R[5Z'7,P9%BV\,-G)OFYA+F7'^W>S<QF.G:WH$"43*(*C^6\,4
MDL20=#_^*J%.Y=,8[F_OZ&%Q\?IB9E3"E">_LU@MQ\Z%0V*8TU6B/O/-+U!>
MT,#P(I[(XI=LRK9=AT0KJ7A:&NL>I"S;_M/'<B#V#-S^"P9>:> =&@Q?,.B5
M!KUC/?1+@_ZQ!H/28'!LEX:EP; 8^^U@%2/M4T4G(\$W1)C6FF8V"KD*:SW
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MCMOC#?IME3OF,J,:)I(_L\SD(V?@D SF=,G-HUQ_AR:?GL5+)=?5+UG7MOW
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M8,P*F1(*MQR)(LLP?YE"RLJ)Y5KKA3NR3*1>L(-QCI=P#_(AO^5J9C<L,<F
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MK7UW:)<.;:U,047KX&.!QT-&UX@I:XFF!EI,[2WIQT2=^XU@\FDL_<3XFXB
MH5G.&!"!)IR#X.@#FH1AK,X%)^B"%&^7.J5C'P2.$WXB3>YN?'1\=(*.4$S0
M;41SCDG(A[:042EL.R@CF!41>&]$X'KHDA(1<?2)A!!N ]B23L7)>^8T]1H1
M?0C.4,L]19[CM>H"^C]W?W]WKX%-JSJAEL9K'7)"/[Y**W0A(.4_:T*<%I#M
M>DB52\YYA@,863)9<& KL,;OW[E=YV.=7";!?$-@6U*V*RG;3>BEE$$I)=92
MUJE7H'0UBDJ<JW'+[??<H;W:E&4O*[_&RANT!Y75%I%.1:332&1R?UO[:DX;
MW0X]=Y-@OB&P+;FZE5Q=\U>H:U)*DV"^(; M*7N5E+W&-\\'!@%=$OUU.$5R
MAPS'H?S2KF0)D:5*WX#R^FO5B'RHH@589_->=1SGU>4SM..64OU*J;Z19-/?
M(>+V=YC,^CMII,;*;XSH'_D.*KZ#O^<D]%O6"T)6<;*LRV7QD#%9H3+QA)BJ
MOVKY-Z(>^E:8!/,-@6VIZ3HOA9EC/FF5F(;4-(KFFT+;UG.CT'7WSUR(+F39
M*C!9QO,$BMM9JZ>[>^_DM7M].YNW/E@H0VB%4/9&<Y "6^HFB\LLG1-1] G5
M:M7(373[8K^8%UW@)6;+F'"4P$*Z.F<]F;58T5@5$T$SW6K,J9"-BQY&LAD%
MI@SD\P6EXGFB-JC:V_$?4$L#!!0    ( "*$=%A"[$IHQ0D  #)N   :
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M;7.BP>+LWH#)F3M.7_F&^C%0&H72&)3&431=>*T?XYQWV4G?:OJO+KRAEZ9
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M[WX(ONN1?GVLGINN?7.Y;+L.]*>Q7!U.]GI_LO3,R1+:G539/C;!AW(MUBK
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M_B*.]3=><BRC*E]2;G,XS7][?HD>U_!"E=O<K%>YH#2)C;5 L,RJ*SY))9W
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M\P!U?LV8?-C)OR;4GYN6_P%02P,$%     @ (H1T6"Y:?Z&!=@  _<T* !H
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M-_-F/O_GY@?6_=^_.]M\3<U#<[?:()/U__O4_*-Y>-A8ZZ_D7\_L=W]<=?/
M]L=;77_Z]M??SIO)LOG'_*&8WJ_>__V[F^^4^^;MY/%A%<]_,YOG;^ERX]W-
M'Y9/_U?Y[?ESS[Y3[AZ7J_F'YP>OOX(/T]F7_S_Y]_-O1>L!X_%7'C!^?L#X
M\ 'G7WG ^?,#SE][A8OG!UP</N#V*P^X?'[ Y6NO</7\@*N#!YQ_[7NX?G[
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M-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!M135,E3+4:U
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MN(VQ'!OBPJ:X8#&^W\9V0^%ONX?"'W_7XKIF/?W"T8:%CHE'-175-%334<U
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MY[&<SW(!RX4L%[%<S'()RZ4LE[%<SG(%RY4L5[%<S7+25T%.*(GPW@K6@YN
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MN2SGL9S/<@'+A2P7L5S,<@G+I2R7L5S.<@7+E2Q7L5S-<B*P!_< @8N P$U
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M9[*<Q7(VRSDLY[*<QW(^RP4L%[)<Q'(QRR4LE[)<QG(YRQ4L5[)<Q7(URXG
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M7);S6,YGN8#E0I:+6"YFN83E4I;+6"YGN8+E2I:K6*YF.1E*'\?G0]:#@X#
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M8;%>+QYW+^^;R6VSW/[ YOMWB\5Z_\7V )\7RW_O_OCO_@]02P,$%     @
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M9>O+#/]M@#0&>'\MA'X9F =T_U^6_P!02P,$%     @ (H1T6".[=%.0"
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MQ1)QM=0==;86PH1VDTPB)I$>??1(-.,)>R7O9&FG20EGF]HJ,:SU36_0V^W
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MU2Y>;>O58N7X[JBV:@@QK(48=@IQ32C)BJPMQ$[@OB'V21;V1-80;%0+-OH
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MO "/ZZ@&]V'-?=C)?<FE,IN9"QX7D=+GWA98 6TL.X&>NE\]@35J'M4UCUZ
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M15Q[*S:],&(:M"J?5/K:%Y*K4Z)P,KXADN387,%;-,TRHI>8HNO*/BE]<)J
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MB0DPY7FSKV==VEDCV;'^@#P"%5V9<&8W/50+5%J$16NKL5/-^J^:%6]J];0
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M54"4+R64.XKGQ5/W.ZX43XO-%= 8A#E!_[[@7&UWC(/ZU9#I#U!+ P04
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M?G"*I?-E5JY7V?)V]?JB;OQK1[F8;GUY]^R+=\ 7YCF?RF4]6SF_+&_SVR[
M11/8/CIO%]T[#T3D^?3<\=E/CN=ZOL&A2?_+/</EO/_E#(C&W[]7_@;//X17
MK*;S<K6N\O;-J>6WXVM>/^5Y^U5\?L<>MF_G?UH,IZCSQ>J_IC?D><# /& [
MZ;Q:/633_,U9,ZNL\NHQ/[MZ^8)%[J4IF91@G BLD^A@G^@ 0K^Z7E?363.9
MW#HM<C'-G8OFHUWGS4BU*8O/:-$&K9UI'Z]\+TZ:M_Q13H]NY3$6*%;<@)6F
M@;NWZ@04[@,*P8!NROD^%E, SU>'TJ!A&BONZS8)2Q3G=1L_9J'9]VCO>P3Z
M_CF?YL5C]G6>&Z>42'<KC137=1L6!JKOH!<#/W#Q/L88_L!EWS<!7CA?RZJY
MMEC>&X.-M4 \%J>A&J]NQB+?2U(E8M"G@1$G^X@3,.)_5N5JY3Q4S3M;Y\[#
MO!FGH1.UD_^U+NJV^-SE59,%YRXW?F 3+<) ^RI-="-7R0!DT0DKW8>5@F&]
MG3^6]\T\_'']M_-K\Z5KWTCGYOSE"\\++IWJ?'[NO'R1--_[2^>F6#4SBC,M
M%P_9\KLI2' HV\F9$HP3@752S%Q!6=Q3U\'MB$2Y)D7C5&C=;$L$D9$6PRU<
M9_9A::1,MQ.#61A(M6(;.^C;T-@]$;MW5-W<7@Y,,1/<A,-.# U2L$H&<BFL
MP&ZO!F-$33CLP] 8!:%C"*/K66"W,'(D<11J!=9@%@5AHE(*V*FA00O2QV#6
M]_;+M2A"^>SNO%W=H54'!K6>"BG1.!5:-Z&"B;+HY(6'B'9NLTV)QJG0NMD6
MG)@AI-BV\.BT-V6IKWYU#>38"P/UFSL&-V:"'#.8':-U!Z6V$]R$PTX,#5)0
M909S9:SNI'B,NDDS6ZM1CD%6/4%6/9">]:X\6YC.DJ99V:DA&\P2P^<7=FIH
MT((S>C!G/')UY^G<T/==+15$W'";L3&8IB>8I@<SS;?_JXN_G/=_MBO%\+*Z
M:^:X)D%9]5RW^Z\9X6%LZPDI&J="ZZ98\%SOY-NG'NG^*2D:IT+K9ELP;H]V
M#]73*;7VA==-/!:I,Y]NQ+P#NSJ>H-+><1NHGK[S&:C>ZR9J009-NIX+SNH=
MM7WJZ7NC6MI1$P[[,/2S)IBB1[-]ZNG<3PO6L,6J13L&.?0$.?1@<O@^:XI
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M.;GGV+FYF6RXN)$I@$*_,LKDU$J5RD]M6\8I9%CV> Y,KRRYR+#20[&R92X
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MU9\#($R 7E]R_6JH!^8&S0=&\!M02P,$%     @ (H1T6'R9C$YD P  <0H
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MQ5YS5L*#)&I?%%3^\QZX.,XLUWJ^\<@V6VUNV.ET1S?P!/K+[D'BR&Y5<E9
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M"?:$K$\V]4"+7?7IOA(:#P+5Y18/@R - )^OA=#/ W,::(^7Z;]02P,$%
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M$;*^S=0#+<KJ?+\2&FX+U>,6;H!4&@-XOQ9"/P_,E:&]4RZ_ U!+ P04
M"  BA'18M</?WR@$  #S$P  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,S<N
M>&ULS5A=;]LV%/TKA%8,+;!%HCYH.;,-) Z"]:% T*S=P[ '6KZVB4JD2U)V
MLU\_4E8DRY*5&M%#7FQ]W'-T[M&]TA4G>R&_J0V 1C^RE*NIL]%Z>^VZ*ME
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M<M .?VVG\W8KY'0> EJ%.%JA5K<R.2[8^U'T(;;+0L"U<$2A;TC*?%1J9N6
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M@2LF.)*P&#LW^'I&!JE!-N(/!EM5N48IE2<A?J8W]^'8\5*/(() IQ#4_-O
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MA-CG.)8#*3D0.P<>OK4J<@0K"=+8!^KYJGM7*@]LEQYE]TXKQVA =(-F@F]
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M=(!YOQ!"[V_2"8J?1";_ 5!+ P04    "  BA'18%,.PE$\5  ")*P$ &@
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MI24H3:$TC=(,17,U9@W<.6_@RLC1PND;LX,UT@?:#=9(1V>G49JA:$ZP%];
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M-" Z<!>_9<VU8;?\&!8 :J,^X&0!H.XHB],LSF"XC@"BE@!DB]3>SXS=4'V
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M6FQGWL>\JO*;W8_76;K*BJ9!_?>7>5X]_*$9X"XO_MA-^^+_ 5!+ P04
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MER<B7Q<WLB]R(?*T.%P1+'6C N3KRSP7/T_4O?'[WT+,_P=02P,$%     @
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MMLZ^DBY=]>!J8M7"M[&9LM04_3"G9PNU"Z#]3"F[GK@#FH<P_@=02P,$%
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MA=;\,6K4 +I,#2#KE(?3::N6[79>V/$C !DU@"Y3 \@ZY>&DK0;L=MZXXS6
MC!I YZH!9%,#T&NK@7[\<RO J 'TBAKXS7H"T._UUBH?"JT9HU$#Z/W5 !I4
M#0R%UDR040/H,C6 [%,>HG8MOVK7)&C4 +I,#2#[E/\OP0Z[CA\%R*@!=*X:
M0%8UX+750#_^6RO /3EQS0C?%0?1 D0LI[(\K*R?UH?=U\41;^OY"EZMRR-K
M U.>H'_&?)=0 5*R59#>*%1[S\M#Z?)&LGUQKOO$I&19<1D3O"%<&ZCOMXS)
MEQN]0/VO@>6_4$L#!!0    ( "*$=%C5A)<DB00  ,@9   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$T-"YX;6S-F6UOVS80Q[\*H15#"RR12#UGMH$F6=I@
M6Q'$R_9BV O:IF.BDNB2=-Q]^Y&RHD=*;6(-\)M$LNY._SO=^4?*DSWCG\6&
M$ F^IDDFIM9&RNV%;8OEAJ18G+,MR=25->,IENJ4/]IBRPE>Y4YI8B/'">P4
MT\R:3?+/[OALPG8RH1FYXT#LTA3S?R])PO93"UK/']S3QXW4']BSR18_DCF1
M#]L[KL[L,LJ*IB03E&6 D_74>@\OKE"L'7*+/RG9B]HQT*DL&/NL3VY74\O1
MBDA"EE*'P.K?$[DB2:(C*1U?BJ!6>4_M6#]^CGZ3)Z^266!!KECR%UW)S=2*
M++ B:[Q+Y#W;?R1%0KZ.MV2)R/^"?6'K6&"Y$Y*EA;-2D-+L\!]_+0I1<X!>
MCP,J'-#W.KB%@YLG>E"6IW6-)9Y-.-L#KJU5-'V0UR;W5MG03#_&N>3J*E5^
M<G9#,YPM*4[ ;28DWZDG) 4X _/#8P5L#3YPMML*\%X(HB[A; 5^HWA!$RHI
M$>#M-9&8)N*=<GJ87X.W;]Z!-X!FX(\-VPEE+2:V5$+U[>QE(>KR( KUB+HF
MRW/@PI\ <I!K<+_Z?G?4=+=5><H:H;)&*(_G]L6C8IDPL>-$YR7Q8I=@#O0(
MZ?+@JBY)K2XKDC'UO+ D*^VEK%5'9>J1<DY4P97%W_H^@$J2BG],-3J(\LRB
M]'A?B"U>DJFEYE<0_D2LV8\_P,#YV52QD8(UZN>6]7.'HL\.G6-*\> 7Y'[Z
M"^=I%ON.$SL3^ZDNOFL6H<CSW-*L(<LK97F#LFI=;-)V</9K-X51A/S(;8DS
MV+DQBOS8K,XOU?F#ZGYYN#>I&G1Z:5.,%*R17U#F%YSB4 5CUF^D8(WZA67]
MPE<.5=AI2#?P@ZC5MB8K#SGFIHU*4=$Q(Q5U[ND%KM,>J*X5"GSHF97%I;)X
M4-DGM2+"O26+.[<\BT/7;PGK6L6Q$YAU0:<"L#.H[,/EG9&0@UXO[=2QHC5S
MK"TRX"D.>Z%JK!J.%*U9PVH1 @<9/3#PA6.],8.XU;L&&PAA3^]68(?#9/_&
MO!?>C2\9+^Q(ZUI!WXUZM%5TA\-X'YYXV,7VF>O!]LK#9 8]%/:(J^ .A^E^
M.__5J&I4O(\5K9EC!7AXDH2'HR)^K&C-&E:0AZ^E/#0 ''EANW^[5E[L13TP
MA17GX5&@AUV&0\^+(&K+,]@Y:@O0-U\5[>$QN(<&WD,/^D&;^";#P,DWI29]
MJ((^&H;^U<<;XY9O5.B/%:V98P5]=)+01Z-"?ZQHS1K6WCR\%OJH"W2WLV(U
M& 4]^U)401\=!7W4Q7GH1>WMA\G*=?P>;17TT3'01P::AVJMT=9F,D-NSTH?
M5=!'WX#^)^.6?MCKQ0W[?T ?5=!')PE]-"KTQXK6K&$%??1:Z*,NSF'09K[)
MJ&>ECRK@HZ. C[H@]VL#4P@S&,$>U*,*]>@8U!?.]7>'9VYG=V2R\CM;>[OV
MFEW_QO$[YH\T$R A:^7FG(<J,W[XV>!P(MDV?_.^8%*R-#_<$+PB7!NHZVO&
MY/.)?IE?_G@S^P]02P,$%     @ (H1T6 U23W+#!   3AT  !H   !X;"]W
M;W)K<VAE971S+W-H965T,30U+GAM;-U9VV[C-A#]%4)=% F01!)]BU/;0.QL
MND&[31!OM@]%'VB)MHE(I)>DXN3O2TJR+C:EQ(!:V'V)16GFZ,PA9S0A!VO&
MG\428PE>PX"*H;64<G5EV\);XA")"[;"5#V9,QXBJ89\88L5Q\B/G<+ AH[3
MM4-$J#4:Q/<>^&C (AD0BA\X$%$8(OXVQ@%;#RW7VMQX)(NEU#?LT6"%%GB*
MY=/J@:N1G:'X),14$$8!Q_.A=>U>36!'.\06WPE>B\(UT*',&'O6@SM_:#F:
M$0ZP)S4$4C\O>(*#0",I'C]24"M[IW8L7F_0;^/@53 S)/"$!7\27RZ'UJ4%
M?#Q'42 ?V?H+3@.*"7HL$/%?L$YM'0MXD9 L3)T5@Y#0Y!>]ID(4'-QNA0-,
M'>"V0[O"H94ZM.) $V9Q6#=(HM& LS7@VEJAZ8M8F]A;14.HGL:IY.HI47YR
M=$LHHAY! ;BC0O)(S9 4X!Q,DVD%; ZN*0K>!!'@6JC)Q@+()9( !0&XETO,
MP7?$"9H%ZL')#9:(!.)4 4PBSC'UW@ GXEF-GZ8WX.33*?@$" 7?EBP2B/IB
M8$L5A*9B>RGA<4(85A!V(?C*J%P*\)GZV"\#V"KZ3 *XD6 ,:Q%OL'<!6NX9
M@ YL&0A-/NX.:^BTLAEIQ7BM*CPBO(")B&,U)> ;FD4!XD"O67 _SV5]U+).
M=3ZI/"#R+9^F>PH>.)L3"<98Y3E6&*_@K]_5:\"=Q*'XVR1ZPJEMYJ1KR958
M(0\/+54L!.8OV!K]_)/;=7XQ"=806$F^=B9?NPY]M%F-:IEYJJX);(HV@7"=
M&$-7NI>1<^$.[)=B%.\8E=AU,G:=C['S<36[SD?8O6-48M?-V'5KV7U^>C3Q
MJ77:=VTT!%:*KY?%USO U.HU*5]#8"7Y+C/Y+FN7QUV:4>!DLWI/=3&?(\+!
M"PHB#$)U4ZFK/R+ 5V/)@+9C5*WY-[!B0I!B:FKOB+*9)IKF["J29\K'8PM*
M!/:UQ2I1G'&@YDZ<@5DBO42O9R!0V40"-4_8^"E)XND6<N2\WVMO99+)J%^1
M2?U,JOY_(]7&_5^7*HFG4U!A5RF#3950KI,W($ZM5+^.'XQ=0*W7OFG3%%HY
MQD*3Y1Y@X4E)-25A0VAE"6$N(?R?%9\TH&*ZG+?:V]]QDY7;;E5D5=Y$NK5-
MUA$6H#2@HA &M7:-JL7*6T:WOF>\F_YF9%3KM7?^-(16CC%O/-W.(9:@VG9X
M;PD;0BM+F'?';GU[?(0EJ&LJ+FZGNYU6!KNNX\"*Q,K[;;>V'SW&*M0S%!B#
M8+MF-7KE#;9;WV%/OMP:2=5Z[9U%#:&58\P[8[=_B(6HME_?6\*&T,K[57G+
M#.M;YN,K1&E I0+3<SM;666T@FUS5L&\^X:UK>D15J$TH*(0!K4,1I5BY7TV
M?*?/_L.X!U3OM6_^-(56CC%OCN$A;K'"1O=8FT(K2YBWS/"=EOGX2E#;\.]8
M;SNG#$:=BBT.F/?>L'[7]P@+4&=G4VQ7JUV;':GLPLE4B/DB/K 3P&,1E<D)
M378W.Q2\CH_"MNZ/W:M)<K27PR0GC5\17Q J0(#G"M*YZ"E:/#F\2P:2K>+S
MKQF3DH7QY1(C'W-MH)[/&9.;@7Y!=H0Z^@=02P,$%     @ (H1T6+LY_0DP
M P  3PT  !H   !X;"]W;W)K<VAE971S+W-H965T,30V+GAM;+5776_:,!3]
M*U9639VT-=\A=!"IA76KM*H5K-O#M <W7(C5)$YM!]B_GYV$0&A [92^%#NY
MY_2>XP.Y&:PH>^01@$#K)$[Y4(N$R,YUG8<1))B?T0Q2>6=.68*%W+*%SC,&
M>%: DEBW#,/3$TQ2+1@4U^Y8,*"YB$D*=PSQ/$DP^WL),5T--5/;7)B01234
M!3T89'@!4Q#WV1V3.[UFF9$$4DYHBAC,A]J%>3XR+04H*GX26/&=-5)2'BA]
M5)OKV5 S5$<00R@4!98?2QA!'"LFV<=31:K5_U,!=]<;]JM"O!3S@#F,:/R+
MS$0TU'P-S6".\UA,Z.H;5()<Q1?2F!=_T:JJ-304YES0I ++#A*2EI]X71FQ
M S"= P"K E@O!=@5P"Z$EIT5LL98X&# Z HQ52W9U*+PID!+-215QS@53-XE
M$B>"*Y+B-"0X1M<I%RR7)R0X^H2FY;$B.D<B G2#UR3)$S1B,","30A_1%_6
M&>4Y@TW-5T;SC*,MXP7G(,E.QR PB?D'27L_':/3DP_H!)$4_8AHSG$ZXP-=
M2"FJ(3VLVKXLV[8.M#V&\ S9YD=D&9;= A^]'&XUX;HTL';1JEVT"C[[$!_A
M85R:<3MOF/3[NRQ%UP(2_J=-9LGKM/.J[_ YSW (0TU^23FP)6C!^W>F9WQN
M$]T16<,"N[; /L8>;!("FU0(BL+2"":-:-->$GH%H?JY60:^X3O^0%_NBGI>
M9=J>T]^6-=IUZG:=H^V.,(^0S!X*U0*><K+$L<I^6Z-'J5Y[2!V1-52[M6KW
MC7+J=FE!1V0-"[S: J_KG):$[FX"3=/M[>7T>97G.5:O/::]NMO>T6XG('^4
M22B@#&I;=T<)7GLR'9$UM/JU5O^-PNEW:4%'9 T+^K4%_:[#V7\6.\LS;6LO
MG"U5KND?"*=I;(<'XVB_M_*YSQ NGO.M#_&C\->>3%=L3;$[DY+Y1OFLB+NR
MH2.VI@W;4<<\.D;\3T8KQMUGN&.[;G\OI&UECN\[>RG5=Z9=]:IQ@]F"I!S%
M,)<XXZPG8\[*Z;W<")H5 _ #%7*<+I:1?.,!I@KD_3FE8K-1,W7]#A7\ U!+
M P04    "  BA'18_"WWN\H(  !\5P  &@   'AL+W=O<FMS:&5E=',O<VAE
M970Q-#<N>&ULS9QM;]NV%L>_BN -PP;<U1*?U24&V@3%+;"MQ;J'%\-]H3A,
M+,R6,DE..N!^^$O9KH\H4728>PSH3>N'P[\.#_]2?B9%73R5U5_U2NLF^KQ9
M%_7E;-4T#Z_G\WJYTINL?E4^Z,)\<U=6FZPQ;ZO[>?U0Z>QVUVBSGI,X%O--
MEA>SQ<7NLX_5XJ+<-NN\T!^KJ-YN-EGUSUN]+I\N9\GLRP>_Y/>KIOU@OKAX
MR.[U)]W\]O"Q,N_F1Y7;?*.+.B^+J-)WE[,WR>LKI=H&NXC?<_U4=UY';5=N
MRO*O]LW[V\M9W&:DUWK9M!*9^>]17^GUNE4R>?Q]$)T=C]DV[+[^HOYNUWG3
MF9NLUE?E^H_\MEE=SM0LNM5WV7;=_%(^_5L?.L1;O66YKG?_1D^'V'@6+;=U
M4VX.C4T&F[S8_Y]]/A2BTR!A(PW(H0%Y;@-Z:$!W'=UGMNO6==9DBXNJ?(JJ
M-MJHM2]VM=FU-KW)BW88/S65^38W[9K%N[S(BF6>K:/W1=U46S-"31U]'WW:
M#VM4WD579=%4IMQ;$_13UFRKO,EUW7X#C=_4M3;MLN(V^C'/;O+U/N;;:]UD
M^;K^SBC^]NDZ^O;K[Z*OH[R(?EV5V]I$UQ?SQO2BS66^/&3\=I\Q&<GX6B]?
M133Y5T1B0AW-KY[?G-C-YZ9VQP*28P')3H^.Z>7U<EW6VTI''T9K]<%1JS>F
M5O!AMVI__FB.$;UO]*;^CZL^^X28.Z'VO']=/V1+?3DS)W:MJT<]6WSS52+B
M'US50A*S:D>/M:,^]<6O96.Z?G<L0K:KC*O+>QVQTVFO3(\+%2NF+N:/W;X,
MHQ(J6 IA5I;LF"4+RG(-0^5*=2_&NTFD/.$QZ27KB.,I325Q9\N/V7)OMC^7
MQ?=YT6@S6DUTH[,J+^Y=:7I50DV$)&9U6!P[+*9V @K,VB&)6;63Q]I)3&O+
MH649853TG.T(2PCEL=O8ZIBK\N;Z+O^L;P?6-G]8WI:5D3*OG3E[14/'"DG,
MZG]Z['\Z-9^GF+5#$K-JE\2 .3&FTP]JMH>%9"GK>=T5&,<J5<+M]J0#9HDW
MXVM=Y8]9"[DGD_4*A8X3EIK=;<"I9'(\E: "%9::73] JB2,J4YYAP[\RTG,
M.>W[?!A'E0'P$5I) *X2/UW];B[CV<U:AU_9_<+!PX:D9I<!J"WAD[,]*@)B
MJ=GU PA,O)P4;'LQO&R3)$[2ONV'<2EA,1MQ/7!7X@>OYU*Z7R9XC)#4[$X#
MP"5J<AY'Q3\L-;M^ (")EY$"?BX?A+JV9920P47=$1:S> 34"< 6\</6Z#7=
M.9OAU0J>SD!2LWL.T$:2J5F<H-(?EII=O\YDFI>. BQ^$+* 1 K">Q9WA*4B
M'IL2(H!9Q(]9?^3-*B^BT@S-/\;;S@R]"L$#@Z1F]Q<PC;#)&1N5[[#4[/H!
MWQ'_M%R L?F0R)EA[;ZQAV%)+!21(\X&DB*H)$6&A$0XE6R0KX.X)*=JY <$
M 90B?I3JG8G1?Z/GPI5?.-A@YX K G!%)@=7!!6NL-3L^@%<D3"X.F7[(3HY
MYT)=<;$)&YD>HL!8U,]80]N_<(+4?YS04<12LZL"_$4GQU\4E;^PU.SZ 7_1
M,/XZ<1;0(5T)0>/^KVA'&..2C_RIHIWEPR (,^? \R=-_=+!PW8..J- 9W1R
M=$91Z0Q+S:X?T!D-H[-3WAFR5Q]WO"%VED!FU$]F0[N_?/+4?ZC@X3O'(B8%
M!*1R<O9'94<L-;M^P([4O[0::G\UO)RS-.W_]':$$4YX.G(: *E1/ZF]'/C]
MPL&#=HX5308 R.*IF9ZAHB*6FET_0$7F7U]]_B_R@]"IV517V/AL*@,F8WXF
M"[CL.[-'7=W$4K-K <3'Z.1,CPJ*6&IV_3JWLH7=R^8QO>/^M"3I,/NA/\,P
M(=C8+!0#(F-^(OM@QJ0IH^:IW)G>G2+J B:6FMUA@#LVN=O8&"H#8JG9]0,&
M9&&WLGF</;P_K4_OWA [08 LA@I9;$A/B:!).IAA<@1*1MG($C4#S&)^S.J?
M@0&<Y5<.-M8Y.(L#9_')<19'Y2PL-;M^P%D\C+-.^)X/*:I_=GI#["P!LK@?
MLAQN?^%\JO] P8-W#M[BP%M\<KS%47D+2\VN'_ 61]T[P%W0%2>)ZO^V=@2V
M$Z\CR]J\LWD@#+N"IE3]VL$C=PX>X\!C?'(\QE%Y#$O-KA_P&$?=6L"'Q.6\
M#]41-W;M!S+C?C)SF/[E$ZO^8P4/XCD613DP()_<G@..RHY8:O;.)&!'@;KK
M0+@V$R1I?YN;(TS%=&1%60"H"3^H_1_ [U<.WA%UCC50 2@H)K<#0: R(Y::
M73]@1H&UJU,,-Q7T6=\;8B<(4";\4!9RO7>FC;KTB:5F%P.(3TQNXX% Y40L
M-;M^G=VG8;?+>=P^O -NX'9?B)T@@)@X 6(K8^CLSMC:F13J.B:6FMU5 #DQ
MN7O@!"KN8:G9]0/<$U@;#,3PMC8BF!B0BB,L%3)Q>UH"5TE4KI)#8!)<D<&^
M90=^4<8(&T$K"6@E3\R!'<_! *CR:X9:"TO-K@! E9P<5$E4J,)2L^L'4"51
MMW7*TV3E")&I&EDVD !7\L2,5]?J+YQ"]1\B>.3. 5@2 $M.#K D*F!AJ=GU
M \"2J/L1Y&G*<H2H5*1D[,]2YVD:ST6MH'E3OVKP<)V#P20PF)P<@TE4!L-2
ML^L'#"91]R'((6$-[#X,\6W=5T!AZ@2%=>W^\AE3_U&"']%RCM5.!:2G)K<!
M0:%R(I::73_@1(6Z 4$Y-B XR-X1QM,D'KD550&5J1-4]A*N]VL&C]<Y%C@5
MX)Z:W,X#A4J'6&IV_8 .%=:^4'5ZTX$WQ$X0\$N=P*]G7>2=":,N9V*IV64
MM%.3VV*@4+$02\VN7^?A;6%WOWE\OA?J/L71-;7D"G-,+<T[CT9MGTO[4U;=
MYT4=K?6=:1>_:G_<5/M'O>[?-.7#[FFI-V73E)O=RY7.;G75!ICO[\JR^?*F
M?0#K\8&[B_\!4$L#!!0    ( "*$=%@,$EVQE00  *D3   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$T."YX;6S%6-MNXS80_15"712[P":Z6K93VT 2;=
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MQ=/B,B;PX2(T -ZO.5?[&SU ?3JW^ ]02P,$%     @ (H1T6)!IU=ZV"@
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M=?O>&H_O[;6A%!UQ>Z89PY\UHV?TM<^?+.WU*^G-V_PX,-2;4V"SAD\!K1-
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MLR0(HLB. &9W$ 08 F<CCF .P .&!$%Y']R['WGU?<K;_O=Y\@102P,$%
M  @ (H1T6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70
MGC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8
M_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(
M7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1
MH2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^
M %!+ P04    "  BA'18<JJ933\)   &80  #P   'AL+W=O<FMB;V]K+GAM
M;,6=76_;N!*&_XK@JSW YL3RAV0738$T27NR2+=!'/2V8&S:)E86O924C_[Z
M0TEQ,F-+[^[-R%>-Y:_'I#0/.2*G'Y^L^^O!VK^"YTV29F>]=9YO/YR>9O.U
MWJCLOW:K4__,TKJ-ROU#MSK-MDZK1;;6.M\DIX-^/SK=*)/V/GW<?=:M.Z4/
M;*[GN;&I/U@>^&'T4_;^?/DP>#29>3")R5_.>M7?B>X%&Y.:C?FE%V>]?B_(
MUO;I?]:97S;-53*;.YLD9[VP?N*'=KF9'QR>E9#WZB&KCN3JX4YYD+->U/<?
MN#0NRZM75)^O/..C]B^N'Q6Y_6*27+M+E>NOSA9;DZ[*C_&_XI3\C*H==O_6
MC?C!_9MFM,NEF>M+.R\V.LWK=G0Z*0'3;&VV62](U4:?]2[LHW;!K5KI\D?Y
M;[E>U#\P]V2DN=P'XY]PUXN*48[GO%B8/+A.ZS?[9PG6 & -9+$N_&.;F(7_
M]D4P*R'*-V2!70;^%%P2R"& '!X-\HM)%8$< <C1T2 O5+8FD&, .3X>Y%K1
M<S("D)$LY%>=:J>2P#1>+#$ BV7!9L5FH]Q+\'T9S,PJ-?YM*LV#\_G<%FEN
M".0$0$YD(?_T8M@1I:NRD].%<HN,T$T!W52X"?6J?$5PI[?6E8 T.O=1>.[+
M@MWI1YT63!;0%L*ZF*E$.:.SX#Q=!-_SM7?9U6:;V!>M@ZOG+<5$]@B%]5&&
MWW2NO=?F=J,KV-VA"YOE%!/Y(Q06R*7VHZ^YJ9[X/3C?E*?>K^I1A4PQD4%"
M88748X0O6M.+-42Z"(5]\=JO]^J9$B$WA,)RN+%9%MSZRV&V5HY=KD@,H; 9
M_%AIZP?3+[\'MTFE!']67?U=F&WY/@J)Q! *F^%&JXR?6D@$H; )OEJ[>#))
M0L?!2  #80'40?;:3Y/25?G5@<HR/T>A>$@( V$AE&/(ZK2J_BC/K4>5E&,W
M"@@G$L(JN$Z]0'-;2HLBH; _$ [[=9=>%,Z50X[S@_Y$L7X@'.NK\.4[<VO\
MO)Q"H7 _$ [W=8,YG6GWR+L1A?R!<,C_;)VS3WZLR(A0N!\(A_L;FZY.[K7;
ME ,?_U+SJ*O SP!1J!\(A_KJ[#KY[./](KA5+YO]0($"_T X\-^8W*SV9W5#
M%/J'XF/_I)H0WRH_+F3G_1"%_*%PR.?AZ\:H*M>W!XA"_E \Y.?:!XL\\Y=!
M\(<UGO*'?T?A."+,' DKH)Z-&)5XQ"QWQ?Z5,$0.&$H[H-ANDRH#X_DJKW])
M[--;DI!B(BL,A:TP*QXR_7=1GH17C_OMA\0P%!8#S,?\'%!,9(NAL"T:\EG!
M;_?*0V3_H8Q(&$-I8<"F'%),Y(YAU^FCIH8<(9>,NLDC-7(AF8R.F5!BU\H(
M*65TS(02QT1:&1TSH<0QX2V)SA)*C><CDLJHL\Q2(QK2RJC3%%,C'M+)Z)BY
MIN WBHF,,NHDV]38>L@@HX[23DU@8R2.\7'R3SM.BHD\,CY6'JH&I9C((^/N
MLE&-/8WD,3Y"6JH1$JECW&5^JI$.WL;N-%'5B(<,,NXL8]6(ANPQ/E;JZO#Z
M1?88'R&!U=B6R"5C89?LY8V:^"*DE*@3I30DD [Z.D)*B825 M)()2C%1$J)
M.IF:[*62&OL<R242E@O,*;&9283T$@GKI2DG<A*<+_Q\Q?_)^AQY)A+VS [S
MFF'._"<O"C]$HYAPP51'*Z8XYJ7)YHG-"D<QD7NBCM9/V<8DTXAB(O=$'>7"
MFC''%!/9)Y+.A4',B"Z90Q**A25TF++S%]![MI%B(@G%TODQA,GB9HPD% M+
M"&/2/&V,+!0+6VB7!65=?;_60;4FG$YF8V2A6-A"C9AW>FZ]YQ-#+10C"\7"
M%GK'?!,D-2?%1!:*I6_'P!0S.S?A(EYI"T%,:J$862B6MA#$I!:*D85B80OA
MA#WM] FRT$380AB3=OH$66@B;"%\7X&U)K+01-A"&).U)K+01-A"Y/8'B_"7
M.E<FH8M')\A"$V$+D5LA9&Y1"E,]*[ZM %EHTMT=&R:BUTD'Q406F@A;J+TU
M_?#CCG4ZLM!$V$(0\QMU^@1N)A&V4"OFI5YJ1V>6$V2AB;"%6C&OGK?&T7-S
MBBPT%;;0WIW%_<N(8B(+384M=(!)IIJ?%=M)A"PT%;80OA%Z0C&1A:;"%H*8
M;&8Y11::"EOH]7XMZ^S78^4M*HJ)+#05MM ;YJ&!]I:43I&%IM)K"!I:\R(I
M;^E6FRTI)K+05/IN4%NGUW<+*":RT+2;M01L$%=CEKO,6&O"O8W2*YL;6O.;
MR@MG\A=_V1/,L(_W.@I[Z&T1!$-].\I X2[(OK")"&C3]<Y X3[(OK"+VE9O
MO#8P X4[(?N=+#YH 64V"OMP+V1?V$?MH-69P$#A%LF^])[ZUA4Q59LR4+AS
MLB_L) BZU_5P,V5??&[TOGB'1:CZ"08*-U3VQ6='%/0@0C%0N->R+VRFQB5'
M[TU+0?$N?.EM^"V@NZ9EH'A_OO3](K8^ZB SST"AF:2WZ.^#TMN&_BD&"LTD
MO4D?@'ZSC[PR S23]#;]_<5G=3J1+0$)\:Y]Z6W[9/T9:\=Y7?Z%@4(E2>_F
M9Z PIQCB_?W2&_S;6G3CSTS_5@8*E22]R;\--+7IR9SE;D*\_5]Z_S\'W:7L
MRB:M9DP4%-8%"*4+ [2OF*Q.608*E21=(@"!^@9FH+AH3!=*VE_<V3P:@?4#
M0ND" BV@3:,16$P@[*2:0%N+\J$]+# 02E<8>-_\_8\!']8<"*6+#NRO[=T;
MX3%0:";I6@2'H"3JL_M=(2Q)$$K7)&@ )5'_CH%",TD7*,"@UQ04EBT(I>L6
MM*_O/@CXL)!!*%W) *WP]J@,%)KIB!4-@A,>1V%9@U"ZK@%NT7,&"LTD7>.@
M>=7\6Y!BH-!,TE4.(.A>UT,S25<]P*!#!@K-)%WW (..&"@TDW3Q@U;0.NPS
M4&@FZ?(';:"O0Q,*"HL@A-)5$'#7CQDH-)-T600,&C%0:*9N"B.T@<8,%)I)
MNC0"!ITP4%QL\YAF^CEEH-!,TJ42$.C/*EW_#@K-)%TX 8.&#!2:2;J$ MXD
MQQ0*:RB$TD44#DHO\7DH X5FJLLJG%8OSSY]7.BE2?7B3_\EF3\^5\G\U@7E
M/Z_)C'&9'%P627+ACWU/;ZQ:[,KX[_X+@D__!U!+ P04    "  BA'18+,7-
MS/T#  !,5P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=P[;AM)
M&$7AK0A<@%FWJKH> \O1)$X-;X"06P]8$@F2 ]N['\$*I/MC@DD,GDAH$BS=
MZ -!]N''+^OC[ORP?S[=/QQ.5S^?'I]/UYO[\_GPUW9[NKE?GW:G#_O#^OSR
MS.W^^+0[OUP>[[:'W<WWW=VZS2FU[?']&9M/']^?>?7UUV']/R?N;V\?;M:_
M]S?_/*W/Y_\X>/MC?_Q^NE_7\^;JZ^YXMYZO-]N?CV\/G[:__^C#R\F;J\_?
MKC?'S]^TV5YZ4+9!^?*#B@TJEQ]4;5"]_*#%!BV7']1L4+O\H&Z#^N4'#1LT
M+C]HVJ!Y^4%*+F,"3 I8 [26<RV UW*P!1!;3K8 9LO1%D!M.=L"N"V'6P"Y
MY70+8+<<;P'TSJYW!NB=7>\,T#N'-]L O;/KG0%Z9]<[ _3.KG<&Z)U=[PS0
M.[O>&:!W=KTS0._L>F> WL7U+@"]B^M= 'H7U[L ]"[APQ* WL7U+@"]B^M=
M 'H7U[L ]"ZN=P'H75SO M"[N-X%H'=UO2M [^IZ5X#>U?6N +VKZUT!>M?P
M83= [^IZ5X#>U?6N +VKZUT!>E?7NP+TKJYW!>B]N-X+0._%]5X >B^N]P+0
M>W&]%X#>B^N] /1>PI>5 +T7UWL!Z+VXW@M [\7U7@!Z+Z[W M"[N=X-H'=S
MO1M [^9Z-X#>S?5N +V;Z]T >C?7NP'T;N%F$X#>S?5N +V;Z]T >C?7NP'T
M[JYW!^C=7>\.T+N[WAV@=W>].T#O[GIW@-[=]>X O;OKW0%Z]W"S($#O[GIW
M@-[=]>X O8?K/0!Z#]=[ /0>KO< Z#U<[P'0>[C> Z#W<+T'0._A>@^ WL/U
M'@"]1[C9&Z#W<+T'0._I>D^ WM/UG@"]I^L] 7I/UWL"])ZN]P3H/5WO"=![
MNMX3H/=TO2= [^EZ3X#>,\0Z +V58JX#\%LI!#L)(+A22'82P'"E$.TD@.)*
M(=M) ,>50KB3 )(KA70G 2Q7"O%. FBN%/*=!/!<*00\B2!Z## 9!69,, FB
MQP@346'&#!/18<80$U%BQA03T6+&&!-18\8<$]%CQB 3463&))/09"I$F2)4
MF0I9I@A=IG+,Z@FBAS13A#93(<X4H<Y4R#-%Z#,5 DT1"DV%1%.$1E,ATA2A
MTE3(-$7H-!5"31%*38544X164R'6%*'65(D_E4(0/02;(A2;"LFF",VF0K0I
M0K6ID&V*T&TJA)LBE)L*Z:8([:9"O"E"O:F0;XK0;RH$G"(4G H)IP@-IVK\
M^2N"Z"'C%*'C5 @Y12@Y%5).$5I.A9A3A)I3(>?4'^TY3^=?C^OI;='KM0_X
MH_7F^>6UZ]O__WWY^F#@^C78W+Z?<?KT+U!+ P04    "  BA'18K^7A%_,"
M   M4P  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V\MNVD 8AN%;06PC\'P^
MNPK9M-VV6?0&7!B"A4_R3%)R]QW(06J5HD94ZKL)"A[//]C2LWNOOSV.ULT.
M7=N[U7SG_?@ABMQZ9[O:+8?1]N'*=IBZVH=_I[MHK-?[^LY&L3%YM!YZ;WN_
M\,<]YC?7G^RVOF_][/,A?.V:H5_-)]NZ^>SCT\+CK-6\'L>V6=<^7(\>^LUO
M4Q;/$Y;ASM,:MVM&=Q46S*,W)QRO_'G \WU?'^PT-1L[NZTG_Z7NPJKHT$;.
M/[;6+<]O\<89A^VV6=O-L+[OPBU+-TZVWKB=M;YKET^;7IV?[,,3MD]_=?'\
MTS;G!H:5M],PNO#&)OO^<2^OY'CW8@P;V<DWYW_BZ\2P]<6_SQ[?]L9N_G)V
M>+P_AFE_>A\N.GU<_HQ_?<>O^[_S'#'D' GD'"GD'!GD'#GD' 7D'"7D'!7D
M'#*4@U!$%85444P5!5515!6%55%<%056462-*;+&%%ECBJPQ1=:8(FM,D36F
MR!I39(TILL8461.*K E%UH0B:T*1-:'(FE!D32BR)A19$XJL"476E")K2I$U
MI<B:4F1-*;*F%%E3BJPI1=:4(FM*D36CR)I19,THLF8463.*K!E%UHPB:T:1
M-:/(FE%DS2FRYA19<XJL.476G")K3I$UI\B:4V3-*;+F%%D+BJP%1=:"(FM!
MD;6@R%I09"THLA8460N*K 5%UI(B:TF1M:3(6E)D+2FREA192XJL)476DB)K
M29&UHLA:462M*+)6%%DKBJP51=:*(FM%D;6BR%I19)6AT"I#L56&@JL,15<9
M"J\R%%]E*,#*4(25H1 K@S$6E&-AC.4$69PBBY-D<9HL3I3%J;(X61:FRQ(F
MS!*FS!(FS1*FS1(FSA*FSA(FSQ*FSQ(FT!*FT!(FT1*FT1(FTA*FTA(FTQ*F
MTQ(FU!*FU!(FU1*FU1(FUA*FUA(FUQ*FUQ(FV!*FV!(FV1*FV1(FVM)_K;:^
M#\/^'X\_?2Z[NNE?YD?'3=W-3U!+ 0(4 Q0    ( "*$=%@'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ (H1T6$H@EFOM    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ (H1T6)E<G",0!@  G"<  !,
M     ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  BA'18
MM7S+!O4&  #K(@  &               @($,"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ (H1T6,GLNNLZ @  N04  !@
M     ("!-P\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M "*$=%@N;%OD8@8  !(:   8              " @:<1  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  BA'18+EM7SU<'  "7(P  &
M            @($_&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ (H1T6 )1@I=I"P  K#@  !@              ("!S!\  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "*$=%@O.BX!Y T  .S&
M   8              " @6LK  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  BA'18!E!:[3<4  #O-P  &               @(&%.0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ (H1T6()WU9L=
M)@  1X8  !@              ("!\DT  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( "*$=%AGF"WQ40P  +,D   8              "
M@45T  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  BA'18
MRK3PZ0D%   2"P  &0              @(',@   >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( "*$=%C4AAIX>P8  -(0   9
M      " @0R&  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ (H1T6,0T.XJV!   )@L  !D              ("!OHP  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  BA'18TQ?TD7@#   ("
M&0              @(&KD0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( "*$=%B3:Y&H?@,  %H(   9              " @5J5  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ (H1T6"OW&$0)
M P  ' <  !D              ("!#YD  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  BA'18*&KJ .H'  !A%   &0
M@(%/G   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "*$
M=%AKJ*Q:G 0   L+   9              " @7"D  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ (H1T6'6\_#@=!P  LQ$  !D
M         ("!0ZD  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  BA'18(^&:6]8&  "P$   &0              @(&7L   >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "*$=%@; -J;1P0  "X*
M   9              " @:2W  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ (H1T6/HRUF7R!P  !A4  !D              ("!(KP
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  BA'1846?4
M:6H#   ?"   &0              @(%+Q   >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( "*$=%BD>)5J*P,  -L&   9
M  " @>S'  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M(H1T6%:51JA8 P  . <  !D              ("!3LL  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  BA'18*BJ;OQP(   F%0  &0
M            @('=S@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( "*$=%A06DSO@P(  ) %   9              " @3#7  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ (H1T6*]^*[X+'0
M97   !D              ("!ZMD  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  BA'186\6-8Q$&  !)#P  &0              @($L
M]P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "*$=%@K
M\_"V@00  .<)   9              " @73]  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ (H1T6,2"E-\E!   Z0@  !D
M     ("!+ (! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "*$=%@!4YXQK0,  )D(   9              "
M@?TW 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ (H1T
M6#57<(K9!P  $A0  !D              ("!X3L! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  BA'1832F./)!!  !^^0  &0
M        @('Q0P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( "*$=%B53L'NQ00  ,@+   9              " @;B% 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ (H1T6*;V!P;S @  $P<
M !D              ("!M(H! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  BA'18,G7X_VX$  "L"@  &0              @('>C0$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "*$=%BLE0J5
M/P0  (,*   9              " @8.2 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ (H1T6)1.");Z P  8 D  !D
M ("!^98! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  B
MA'18O=N]II\#  # "   &0              @($JFP$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "*$=%@[0F7GRP,  )@)   9
M          " @0"? 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#
M%     @ (H1T6![OLTUS @  5@4  !D              ("! J,! 'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  BA'18=+0Z-SH%  #)
M#@  &0              @(&LI0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+ 0(4 Q0    ( "*$=%BNY_A,Y0(  $8&   9              " @1VK
M 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ (H1T6&VA
MB ""!   N@L  !D              ("!.:X! 'AL+W=O<FMS:&5E=',O<VAE
M970T."YX;6Q02P$"% ,4    "  BA'18.IK@+.P%  #($   &0
M    @('RL@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M "*$=%@\KI3#<P(  '8%   9              " @16Y 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ (H1T6(1/DIB_!   70P  !D
M             ("!O[L! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  BA'18T 8OH_0"  !6!P  &0              @(&UP $ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( "*$=%ARG0>!K@(
M , %   9              " @>## 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ (H1T6*\V&^7  @  ]@4  !D              ("!
MQ<8! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  BA'18
M\1O*6B(%  "4#0  &0              @(&\R0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( "*$=%B-&"/JE0(  )8%   9
M      " @17/ 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ (H1T6*>@&PMJ!P  714  !D              ("!X=$! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  BA'18K7NF5? "  !U!@
M&0              @(&"V0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( "*$=%@RO/O(GP,  'H(   9              " @:G< 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ (H1T6/%$O, <
M"P  %B@  !D              ("!?^ ! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    "  BA'18"WU0GK<"   ,!@  &0
M@('2ZP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( "*$
M=%C&_UK28P,  *L'   9              " @<#N 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ (H1T6+:55AO8"P  AB8  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( "*$=%A-8P[ZG@,  !\.   9
M  " @<H; @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
M(H1T6$F:=6(* P  & P  !D              ("!GQ\" 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    "  BA'18]8%?/HT#  #>$@  &0
M            @('@(@( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( "*$=%C'O1<\_0,  &P3   9              " @:0F @!X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ (H1T6!M)&=96 P
M)PX  !D              ("!V"H" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX
M;6Q02P$"% ,4    "  BA'18LI+OMB@$  !*%0  &0              @(%E
M+@( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( "*$=%C%
MV!:@X ,  $X2   9              " @<0R @!X;"]W;W)K<VAE971S+W-H
M965T-S0N>&UL4$L! A0#%     @ (H1T6.HM''$L!   7A$  !D
M     ("!VS8" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4
M"  BA'18)7&:=# $  !5%   &0              @($^.P( >&PO=V]R:W-H
M965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( "*$=%AP=>]LF (  .P&   9
M              " @:4_ @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L!
M A0#%     @ (H1T6+<!H9^^ P  ^PL  !D              ("!=$(" 'AL
M+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    "  BA'18OWA.H^$#
M  !5$P  &0              @(%I1@( >&PO=V]R:W-H965T<R]S:&5E=#<Y
M+GAM;%!+ 0(4 Q0    ( "*$=%@ER8J2*0,  % )   9              "
M@8%* @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ (H1T
M6-PA]AK" P  [@L  !D              ("!X4T" 'AL+W=O<FMS:&5E=',O
M<VAE970X,2YX;6Q02P$"% ,4    "  BA'18L8"0LF,#   Y"@  &0
M        @(':40( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0
M   ( "*$=%@,E;9[\@,  $84   9              " @715 @!X;"]W;W)K
M<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ (H1T6$'O*:#C @  3 @
M !D              ("!G5D" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q0
M2P$"% ,4    "  BA'18E77!S:L#  #0#   &0              @(&W7 (
M>&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( "*$=%CB( ];
M:@0  -\8   9              " @9E@ @!X;"]W;W)K<VAE971S+W-H965T
M.#8N>&UL4$L! A0#%     @ (H1T6'>&H5)H P  B@L  !D
M ("!.F4" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    "  B
MA'18>+!WC>X"  "F"   &0              @('9: ( >&PO=V]R:W-H965T
M<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( "*$=%A-E4RGL ,  !H1   9
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M970Y,RYX;6Q02P$"% ,4    "  BA'18HXY0V.0#   Z$P  &0
M    @('A@P( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    (
M "*$=%AAN..YX@,  $X.   9              " @?R' @!X;"]W;W)K<VAE
M971S+W-H965T.34N>&UL4$L! A0#%     @ (H1T6%F&];") P  %PX  !D
M             ("!%8P" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"
M% ,4    "  BA'18,,E _D\#   B$0  &0              @('5CP( >&PO
M=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( "*$=%AI@OC"V ,
M %@,   9              " @5N3 @!X;"]W;W)K<VAE971S+W-H965T.3@N
M>&UL4$L! A0#%     @ (H1T6%&V\>WI!   IQ@  !D              ("!
M:I<" 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    "  BA'18
MI605L"<#  #<#0  &@              @(&*G ( >&PO=V]R:W-H965T<R]S
M:&5E=#$P,"YX;6Q02P$"% ,4    "  BA'18ADIU4)\"  #W!@  &@
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M:&5E=#$P-2YX;6Q02P$"% ,4    "  BA'18$CHI$"(#  !!$   &@
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M:&5E=#$Q,"YX;6Q02P$"% ,4    "  BA'182U_6ZE$#  #J#@  &@
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M:&5E=#$Q-2YX;6Q02P$"% ,4    "  BA'18#'KI'*4$  !Z&@  &@
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M:&5E=#$R,"YX;6Q02P$"% ,4    "  BA'18,%>%:F4'  "./   &@
M        @(%C=P, >&PO=V]R:W-H965T<R]S:&5E=#$R,2YX;6Q02P$"% ,4
M    "  BA'18*L"D:+@#  #2#@  &@              @($ ?P, >&PO=V]R
M:W-H965T<R]S:&5E=#$R,BYX;6Q02P$"% ,4    "  BA'18I[.6.J0#  "!
M#0  &@              @('P@@, >&PO=V]R:W-H965T<R]S:&5E=#$R,RYX
M;6Q02P$"% ,4    "  BA'18\Q1%>U4#  #F#P  &@              @(',
MA@, >&PO=V]R:W-H965T<R]S:&5E=#$R-"YX;6Q02P$"% ,4    "  BA'18
M2V\/_6\#  #<#@  &@              @(%9B@, >&PO=V]R:W-H965T<R]S
M:&5E=#$R-2YX;6Q02P$"% ,4    "  BA'18)(#H3:@"  #:!P  &@
M        @($ C@, >&PO=V]R:W-H965T<R]S:&5E=#$R-BYX;6Q02P$"% ,4
M    "  BA'18/.D4&\X$   F(@  &@              @('@D , >&PO=V]R
M:W-H965T<R]S:&5E=#$R-RYX;6Q02P$"% ,4    "  BA'18 <:'?5(3   J
MS0  &@              @('FE0, >&PO=V]R:W-H965T<R]S:&5E=#$R."YX
M;6Q02P$"% ,4    "  BA'18EC%[?#D)  !95@  &@              @(%P
MJ0, >&PO=V]R:W-H965T<R]S:&5E=#$R.2YX;6Q02P$"% ,4    "  BA'18
M7Y!S,J4)  #<3P  &@              @('AL@, >&PO=V]R:W-H965T<R]S
M:&5E=#$S,"YX;6Q02P$"% ,4    "  BA'18EIK;O^<"  !P"   &@
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M:&5E=#$S-2YX;6Q02P$"% ,4    "  BA'18H@JIH=(#  !?#@  &@
M        @($GS@, >&PO=V]R:W-H965T<R]S:&5E=#$S-BYX;6Q02P$"% ,4
M    "  BA'18M</?WR@$  #S$P  &@              @($QT@, >&PO=V]R
M:W-H965T<R]S:&5E=#$S-RYX;6Q02P$"% ,4    "  BA'18(#&2[$8(   2
M50  &@              @(&1U@, >&PO=V]R:W-H965T<R]S:&5E=#$S."YX
M;6Q02P$"% ,4    "  BA'18D>@2*L,$   >&0  &@              @($/
MWP, >&PO=V]R:W-H965T<R]S:&5E=#$S.2YX;6Q02P$"% ,4    "  BA'18
M%,.PE$\5  ")*P$ &@              @($*Y , >&PO=V]R:W-H965T<R]S
M:&5E=#$T,"YX;6Q02P$"% ,4    "  BA'180>!<QNT%   7,0  &@
M        @(&1^0, >&PO=V]R:W-H965T<R]S:&5E=#$T,2YX;6Q02P$"% ,4
M    "  BA'18O$(^#\@"   4!P  &@              @(&V_P, >&PO=V]R
M:W-H965T<R]S:&5E=#$T,BYX;6Q02P$"% ,4    "  BA'18C(7 /3T$   F
M&   &@              @(&V @0 >&PO=V]R:W-H965T<R]S:&5E=#$T,RYX
M;6Q02P$"% ,4    "  BA'18U827)(D$  #(&0  &@              @($K
M!P0 >&PO=V]R:W-H965T<R]S:&5E=#$T-"YX;6Q02P$"% ,4    "  BA'18
M#5)/<L,$  !.'0  &@              @('L"P0 >&PO=V]R:W-H965T<R]S
M:&5E=#$T-2YX;6Q02P$"% ,4    "  BA'18NSG]"3 #  !/#0  &@
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( "*$=%ARJIE-/PD   9A   /
M      "  8 Q! !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  BA'18+,7-
MS/T#  !,5P  &@              @ 'L.@0 >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  BA'18K^7A%_,"   M4P  $P
M    @ $A/P0 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     G0"= '0K  !%
%0@0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>924</ContextCount>
  <ElementCount>616</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>288</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss</Role>
      <ShortName>Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - General information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/Generalinformation</Role>
      <ShortName>General information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary Of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - New Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/NewAccountingStandards</Role>
      <ShortName>New Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Salaries And Other Employee Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SalariesAndOtherEmployeeExpenses</Role>
      <ShortName>Salaries And Other Employee Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Finance Income And Finance Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinanceIncomeAndFinanceCosts</Role>
      <ShortName>Finance Income And Finance Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Depreciation, Amortization And Impairment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/DepreciationAmortizationAndImpairment</Role>
      <ShortName>Depreciation, Amortization And Impairment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Audit Fees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/AuditFees</Role>
      <ShortName>Audit Fees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Property, Plant And Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant And Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Other Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherIntangibleassets</Role>
      <ShortName>Other Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Cash And Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash And Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Other reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/Otherreserves</Role>
      <ShortName>Other reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Long-Term Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LongTermIncentivePlans</Role>
      <ShortName>Long-Term Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Interests In Joint Ventures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/InterestsInJointVentures</Role>
      <ShortName>Interests In Joint Ventures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary Of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - General information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/GeneralinformationTables</Role>
      <ShortName>General information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/Generalinformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Summary Of Significant Accounting Policies (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesTable</Role>
      <ShortName>Summary Of Significant Accounting Policies (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/SegmentReporting</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/Revenue</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Salaries And Other Employee Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesTables</Role>
      <ShortName>Salaries And Other Employee Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/SalariesAndOtherEmployeeExpenses</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Finance Income And Finance Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsTables</Role>
      <ShortName>Finance Income And Finance Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/FinanceIncomeAndFinanceCosts</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Depreciation, Amortization And Impairment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentTables</Role>
      <ShortName>Depreciation, Amortization And Impairment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/DepreciationAmortizationAndImpairment</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Audit Fees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/AuditFeesTables</Role>
      <ShortName>Audit Fees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/AuditFees</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/IncomeTax</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/LossPerShare</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Property, Plant And Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant And Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/Leases</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/Goodwill</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Other Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherIntangibleassetsTables</Role>
      <ShortName>Other Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/OtherIntangibleassets</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Cash And Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash And Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/CashAndCashEquivalents</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/Inventories</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/OtherCurrentAssets</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/ShareCapital</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Other reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherreservesTables</Role>
      <ShortName>Other reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/Otherreserves</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/Borrowings</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Long-Term Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LongTermIncentivePlansTables</Role>
      <ShortName>Long-Term Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/LongTermIncentivePlans</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/ShareBasedPayments</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/RelatedParties</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Interests In Joint Ventures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/InterestsInJointVenturesTables</Role>
      <ShortName>Interests In Joint Ventures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/InterestsInJointVentures</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/FinancialInstruments</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - General information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails</Role>
      <ShortName>General information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - General Information - Schedule of fair value of shares issued and non-cash share listing expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails</Role>
      <ShortName>General Information - Schedule of fair value of shares issued and non-cash share listing expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - General Information - Disclosure of Subsidiaries and Joint Ventures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails</Role>
      <ShortName>General Information - Disclosure of Subsidiaries and Joint Ventures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Useful Lives of Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Useful Lives of Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Segment Reporting - Summary Of Detailed Information About Revenue From Customers Based On Geographical Market (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails</Role>
      <ShortName>Segment Reporting - Summary Of Detailed Information About Revenue From Customers Based On Geographical Market (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Segment Reporting - Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails</Role>
      <ShortName>Segment Reporting - Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Segment Reporting - Summary Of Detailed Information About Revenue From Transactions With Individual Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails</Role>
      <ShortName>Segment Reporting - Summary Of Detailed Information About Revenue From Transactions With Individual Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Revenue - Summary Of The Groups' Revenue From Contracts With Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails</Role>
      <ShortName>Revenue - Summary Of The Groups' Revenue From Contracts With Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Revenue - Summary Of Reconciliation Of Contract Assets And Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails</Role>
      <ShortName>Revenue - Summary Of Reconciliation Of Contract Assets And Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Revenue - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RevenueAdditionalinformationDetails</Role>
      <ShortName>Revenue - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Salaries And Other Employee Expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesAdditionalInformationDetails</Role>
      <ShortName>Salaries And Other Employee Expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Salaries And Other Employee Expenses - Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails</Role>
      <ShortName>Salaries And Other Employee Expenses - Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Salaries And Other Employee Expenses - Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails</Role>
      <ShortName>Salaries And Other Employee Expenses - Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Finance Income And Finance Costs - Summary Of Detailed Information About Finance Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails</Role>
      <ShortName>Finance Income And Finance Costs - Summary Of Detailed Information About Finance Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Finance Income And Finance Costs - Summary Of Detailed Information About Finance Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails</Role>
      <ShortName>Finance Income And Finance Costs - Summary Of Detailed Information About Finance Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails</Role>
      <ShortName>Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails</Role>
      <ShortName>Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Audit Fees - Summary Of Detailed Information About Audit Fees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails</Role>
      <ShortName>Audit Fees - Summary Of Detailed Information About Audit Fees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Income Tax - Schedule Of Taxation Recognized In The Consolidated Statements Of Profit Or Loss And Other Comprehensive Income Or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails</Role>
      <ShortName>Income Tax - Schedule Of Taxation Recognized In The Consolidated Statements Of Profit Or Loss And Other Comprehensive Income Or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Income Tax - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails</Role>
      <ShortName>Income Tax - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Income Tax - Schedule Of The Reconciling Items Between The Statutory Rate And The Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails</Role>
      <ShortName>Income Tax - Schedule Of The Reconciling Items Between The Statutory Rate And The Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Income Tax - Schedule Of The Movement In Net Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails</Role>
      <ShortName>Income Tax - Schedule Of The Movement In Net Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Income Tax - Schedule Of Deferred Tax Recognized In The Consolidated Statements Of Financial Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails</Role>
      <ShortName>Income Tax - Schedule Of Deferred Tax Recognized In The Consolidated Statements Of Financial Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Income Tax - Schedule Of Expiration Of Unused Tax Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails</Role>
      <ShortName>Income Tax - Schedule Of Expiration Of Unused Tax Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LossPerShareAdditionalInformationDetails</Role>
      <ShortName>Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Loss Per Share - Summary of Basic and Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails</Role>
      <ShortName>Loss Per Share - Summary of Basic and Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Property, Plant And Equipment - Summary Of Property, Plant And Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant And Equipment - Summary Of Property, Plant And Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Property, Plant And Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant And Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Leases - Summary of Leases Assets About Right-Of-Use Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails</Role>
      <ShortName>Leases - Summary of Leases Assets About Right-Of-Use Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Leases - Summary of Classes of Right-Of-Use Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails</Role>
      <ShortName>Leases - Summary of Classes of Right-Of-Use Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Leases - Summary of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Leases - Summary Of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails</Role>
      <ShortName>Leases - Summary Of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Leases - Summary of Maturity Analysis For Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Maturity Analysis For Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Goodwill - Summary of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/GoodwillSummaryofGoodwillDetails</Role>
      <ShortName>Goodwill - Summary of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/GoodwillAdditionalInformationDetails</Role>
      <ShortName>Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Other Intangible assets - Summary of Detailed Information About Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails</Role>
      <ShortName>Other Intangible assets - Summary of Detailed Information About Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Other Intangible assets - Summary of Impairment Loss and Reversal of Impairment Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails</Role>
      <ShortName>Other Intangible assets - Summary of Impairment Loss and Reversal of Impairment Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Other Intangible assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails</Role>
      <ShortName>Other Intangible assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Cash And Cash Equivalents - Summary of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails</Role>
      <ShortName>Cash And Cash Equivalents - Summary of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Cash And Cash Equivalents - Summary of Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails</Role>
      <ShortName>Cash And Cash Equivalents - Summary of Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails</Role>
      <ShortName>Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Inventories - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/InventoriesAdditionalInformationDetails</Role>
      <ShortName>Inventories - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - Other Current Assets - Summary of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails</Role>
      <ShortName>Other Current Assets - Summary of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - Other Current Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails</Role>
      <ShortName>Other Current Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9954546 - Disclosure - Share Capital - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails</Role>
      <ShortName>Share Capital - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9954547 - Disclosure - Share Capital - Summary of Share Capital and Share Premium (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails</Role>
      <ShortName>Share Capital - Summary of Share Capital and Share Premium (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9954548 - Disclosure - Share Capital - Summary of Movements in Ordinary Shares, Share Capital and Share Premium (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails</Role>
      <ShortName>Share Capital - Summary of Movements in Ordinary Shares, Share Capital and Share Premium (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9954549 - Disclosure - Other reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherreservesDetails</Role>
      <ShortName>Other reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alvotech.com/role/OtherreservesTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9954550 - Disclosure - Borrowings - Summary of consolidated statements of financial position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails</Role>
      <ShortName>Borrowings - Summary of consolidated statements of financial position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9954551 - Disclosure - Borrowings - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails</Role>
      <ShortName>Borrowings - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>9954552 - Disclosure - Borrowings - Summary of movements in the group's outstanding borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails</Role>
      <ShortName>Borrowings - Summary of movements in the group's outstanding borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>9954553 - Disclosure - Borrowings - Summary of non-cash changes in the group???s outstanding borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails</Role>
      <ShortName>Borrowings - Summary of non-cash changes in the group???s outstanding borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>9954554 - Disclosure - Borrowings - Schedule of maturities of outstanding borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails</Role>
      <ShortName>Borrowings - Schedule of maturities of outstanding borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>9954555 - Disclosure - Long-Term Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Long-Term Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>9954556 - Disclosure - Long-Term Incentive Plans - Schedule Of Movements In The Group's Employee Incentive Plan Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails</Role>
      <ShortName>Long-Term Incentive Plans - Schedule Of Movements In The Group's Employee Incentive Plan Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>9954557 - Disclosure - Share-Based Payments - Summary of Movements in RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails</Role>
      <ShortName>Share-Based Payments - Summary of Movements in RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>9954558 - Disclosure - Share-Based Payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>9954559 - Disclosure - Share-Based Payments - Summary of share-based payment expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails</Role>
      <ShortName>Share-Based Payments - Summary of share-based payment expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>9954560 - Disclosure - Litigation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/LitigationAdditionalInformationDetails</Role>
      <ShortName>Litigation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>9954561 - Disclosure - Related Parties - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails</Role>
      <ShortName>Related Parties - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>9954562 - Disclosure - Related Parties - Summary of Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Parties - Summary of Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>9954563 - Disclosure - Related Parties - Schedule of Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Parties - Schedule of Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>9954564 - Disclosure - Related Parties - Schedule of Information About Board of Directors Remuneration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails</Role>
      <ShortName>Related Parties - Schedule of Information About Board of Directors Remuneration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>9954565 - Disclosure - Other Current Liabilities - Schedule of Composition of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Current Liabilities - Schedule of Composition of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>9954566 - Disclosure - Interests In Joint Ventures - Schedule of Information About Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails</Role>
      <ShortName>Interests In Joint Ventures - Schedule of Information About Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>9954567 - Disclosure - Interests In Joint Ventures - Schedule of Changes in Groups Investment in a Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails</Role>
      <ShortName>Interests In Joint Ventures - Schedule of Changes in Groups Investment in a Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>9954568 - Disclosure - Interests In Joint Ventures - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails</Role>
      <ShortName>Interests In Joint Ventures - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>9954569 - Disclosure - Financial Instruments - Summary of Financial Assets Measured at Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails</Role>
      <ShortName>Financial Instruments - Summary of Financial Assets Measured at Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>9954570 - Disclosure - Financial Instruments - Summary of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails</Role>
      <ShortName>Financial Instruments - Summary of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>9954571 - Disclosure - Financial Instruments - Summary of Material Differences Between the Fair Value and Carrying Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails</Role>
      <ShortName>Financial Instruments - Summary of Material Differences Between the Fair Value and Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>9954572 - Disclosure - Financial Instruments - Summary of Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Summary of Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>9954573 - Disclosure - Financial Instruments - Schedule of Provides a Reconciliation of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Schedule of Provides a Reconciliation of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>9954574 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>9954575 - Disclosure - Financial Instruments - Summary of Assumptions and Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails</Role>
      <ShortName>Financial Instruments - Summary of Assumptions and Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>9954576 - Disclosure - Financial Instruments - Summary of Interest Rate Sensitivity Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails</Role>
      <ShortName>Financial Instruments - Summary of Interest Rate Sensitivity Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>142</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>9954577 - Disclosure - Financial Instruments - Summary of Impact on the Groups Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails</Role>
      <ShortName>Financial Instruments - Summary of Impact on the Groups Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>143</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>9954578 - Disclosure - Financial Instruments - Summary of Groups Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails</Role>
      <ShortName>Financial Instruments - Summary of Groups Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>144</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>9954579 - Disclosure - Financial Instruments - Summary of Analysis Assumes that all Other Variables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails</Role>
      <ShortName>Financial Instruments - Summary of Analysis Assumes that all Other Variables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>145</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>9954580 - Disclosure - Financial Instruments - Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails</Role>
      <ShortName>Financial Instruments - Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>146</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>9954581 - Disclosure - Financial Instruments - Summary of Contractual Maturities of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Financial Instruments - Summary of Contractual Maturities of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>147</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>9954582 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>148</Position>
    </Report>
    <Report instance="alvo-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>9954583 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>149</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 10 fact(s) appearing in ix:hidden were eligible for transformation: alvo:NumberOfConsecutiveTradingDays, alvo:ThresholdDaysForDeterminingTheSharePrice, alvo:VestingPercentageOfShares -  alvo-20231231.htm 4</Log>
    <Log type="Warning">[EXG.9.7.4.tooManyCells] Presentation group http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails with 27 axes could have more than 156042641 billion cells.  Split up this presentation group and see EXG 9.7.4 to see how to reduce the number of combinations by selecting fewer members for each axis. - alvo-20231231.htm  - alvo-20231231.htm </Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" original="alvo-20231231.htm">alvo-20231231.htm</File>
    <File>alvo-20231231.xsd</File>
    <File>alvo-20231231_cal.xml</File>
    <File>alvo-20231231_def.xml</File>
    <File>alvo-20231231_lab.xml</File>
    <File>alvo-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>alvo-20231231_g1.jpg</File>
    <File>alvo-20231231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="2012">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>173
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "alvo-20231231.htm": {
   "nsprefix": "alvo",
   "nsuri": "http://www.alvotech.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "alvo-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "alvo-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "alvo-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alvo-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "alvo-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alvo-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 377,
   "keyCustom": 239,
   "axisStandard": 43,
   "axisCustom": 24,
   "memberStandard": 65,
   "memberCustom": 199,
   "hidden": {
    "total": 14,
    "http://www.alvotech.com/20231231": 10,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 924,
   "entityCount": 1,
   "segmentCount": 288,
   "elementCount": 1183,
   "unitCount": 15,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 2012,
    "http://xbrl.sec.gov/dei/2023": 48
   },
   "report": {
    "R1": {
     "role": "http://www.alvotech.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.alvotech.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
     "longName": "0000003 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss",
     "shortName": "Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
     "longName": "0000004 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:OtherNoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
     "longName": "0000006 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.alvotech.com/role/Generalinformation",
     "longName": "0000007 - Disclosure - General information",
     "shortName": "General information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.alvotech.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "0000008 - Disclosure - Summary Of Significant Accounting Policies",
     "shortName": "Summary Of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.alvotech.com/role/NewAccountingStandards",
     "longName": "0000009 - Disclosure - New Accounting Standards",
     "shortName": "New Accounting Standards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFirstTimeAdoptionExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFirstTimeAdoptionExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.alvotech.com/role/SegmentReporting",
     "longName": "0000010 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.alvotech.com/role/Revenue",
     "longName": "0000011 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpenses",
     "longName": "0000012 - Disclosure - Salaries And Other Employee Expenses",
     "shortName": "Salaries And Other Employee Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.alvotech.com/role/FinanceIncomeAndFinanceCosts",
     "longName": "0000013 - Disclosure - Finance Income And Finance Costs",
     "shortName": "Finance Income And Finance Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.alvotech.com/role/DepreciationAmortizationAndImpairment",
     "longName": "0000014 - Disclosure - Depreciation, Amortization And Impairment",
     "shortName": "Depreciation, Amortization And Impairment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.alvotech.com/role/AuditFees",
     "longName": "0000015 - Disclosure - Audit Fees",
     "shortName": "Audit Fees",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfAuditFeesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfAuditFeesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.alvotech.com/role/IncomeTax",
     "longName": "0000016 - Disclosure - Income Tax",
     "shortName": "Income Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.alvotech.com/role/LossPerShare",
     "longName": "0000017 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.alvotech.com/role/PropertyPlantAndEquipment",
     "longName": "0000018 - Disclosure - Property, Plant And Equipment",
     "shortName": "Property, Plant And Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.alvotech.com/role/Leases",
     "longName": "0000019 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.alvotech.com/role/Goodwill",
     "longName": "0000020 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.alvotech.com/role/OtherIntangibleassets",
     "longName": "0000021 - Disclosure - Other Intangible assets",
     "shortName": "Other Intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.alvotech.com/role/CashAndCashEquivalents",
     "longName": "0000022 - Disclosure - Cash And Cash Equivalents",
     "shortName": "Cash And Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.alvotech.com/role/Inventories",
     "longName": "0000023 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.alvotech.com/role/OtherCurrentAssets",
     "longName": "0000024 - Disclosure - Other Current Assets",
     "shortName": "Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.alvotech.com/role/ShareCapital",
     "longName": "0000025 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.alvotech.com/role/Otherreserves",
     "longName": "0000026 - Disclosure - Other reserves",
     "shortName": "Other reserves",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.alvotech.com/role/Borrowings",
     "longName": "0000027 - Disclosure - Borrowings",
     "shortName": "Borrowings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.alvotech.com/role/LongTermIncentivePlans",
     "longName": "0000028 - Disclosure - Long-Term Incentive Plans",
     "shortName": "Long-Term Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfLongTermIncentivePlansExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfLongTermIncentivePlansExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.alvotech.com/role/ShareBasedPayments",
     "longName": "0000029 - Disclosure - Share-Based Payments",
     "shortName": "Share-Based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.alvotech.com/role/Litigation",
     "longName": "0000030 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfLitigationSettlementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfLitigationSettlementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.alvotech.com/role/RelatedParties",
     "longName": "0000031 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.alvotech.com/role/OtherCurrentLiabilities",
     "longName": "0000032 - Disclosure - Other Current Liabilities",
     "shortName": "Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.alvotech.com/role/InterestsInJointVentures",
     "longName": "0000033 - Disclosure - Interests In Joint Ventures",
     "shortName": "Interests In Joint Ventures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfJointVenturesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfJointVenturesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.alvotech.com/role/FinancialInstruments",
     "longName": "0000034 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.alvotech.com/role/SupplementalCashFlowInformation",
     "longName": "0000035 - Disclosure - Supplemental Cash Flow Information",
     "shortName": "Supplemental Cash Flow Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.alvotech.com/role/SubsequentEvents",
     "longName": "0000036 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary Of Significant Accounting Policies (Policies)",
     "shortName": "Summary Of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.alvotech.com/role/GeneralinformationTables",
     "longName": "9954472 - Disclosure - General information (Tables)",
     "shortName": "General information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesTable",
     "longName": "9954473 - Disclosure - Summary Of Significant Accounting Policies (Table)",
     "shortName": "Summary Of Significant Accounting Policies (Table)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.alvotech.com/role/SegmentReportingTables",
     "longName": "9954474 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.alvotech.com/role/RevenueTables",
     "longName": "9954475 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesTables",
     "longName": "9954476 - Disclosure - Salaries And Other Employee Expenses (Tables)",
     "shortName": "Salaries And Other Employee Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsTables",
     "longName": "9954477 - Disclosure - Finance Income And Finance Costs (Tables)",
     "shortName": "Finance Income And Finance Costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentTables",
     "longName": "9954478 - Disclosure - Depreciation, Amortization And Impairment (Tables)",
     "shortName": "Depreciation, Amortization And Impairment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.alvotech.com/role/AuditFeesTables",
     "longName": "9954479 - Disclosure - Audit Fees (Tables)",
     "shortName": "Audit Fees (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.alvotech.com/role/IncomeTaxTables",
     "longName": "9954480 - Disclosure - Income Tax (Tables)",
     "shortName": "Income Tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.alvotech.com/role/LossPerShareTables",
     "longName": "9954481 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.alvotech.com/role/PropertyPlantAndEquipmentTables",
     "longName": "9954482 - Disclosure - Property, Plant And Equipment (Tables)",
     "shortName": "Property, Plant And Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.alvotech.com/role/LeasesTables",
     "longName": "9954483 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.alvotech.com/role/GoodwillTables",
     "longName": "9954484 - Disclosure - Goodwill (Tables)",
     "shortName": "Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.alvotech.com/role/OtherIntangibleassetsTables",
     "longName": "9954485 - Disclosure - Other Intangible assets (Tables)",
     "shortName": "Other Intangible assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.alvotech.com/role/CashAndCashEquivalentsTables",
     "longName": "9954486 - Disclosure - Cash And Cash Equivalents (Tables)",
     "shortName": "Cash And Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.alvotech.com/role/InventoriesTables",
     "longName": "9954487 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.alvotech.com/role/OtherCurrentAssetsTables",
     "longName": "9954488 - Disclosure - Other Current Assets (Tables)",
     "shortName": "Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.alvotech.com/role/ShareCapitalTables",
     "longName": "9954489 - Disclosure - Share Capital (Tables)",
     "shortName": "Share Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.alvotech.com/role/OtherreservesTables",
     "longName": "9954490 - Disclosure - Other reserves (Tables)",
     "shortName": "Other reserves (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:ScheduleOfOtherReservesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:ScheduleOfOtherReservesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.alvotech.com/role/BorrowingsTables",
     "longName": "9954491 - Disclosure - Borrowings (Tables)",
     "shortName": "Borrowings (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.alvotech.com/role/LongTermIncentivePlansTables",
     "longName": "9954492 - Disclosure - Long-Term Incentive Plans (Tables)",
     "shortName": "Long-Term Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.alvotech.com/role/ShareBasedPaymentsTables",
     "longName": "9954493 - Disclosure - Share-Based Payments (Tables)",
     "shortName": "Share-Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.alvotech.com/role/RelatedPartiesTables",
     "longName": "9954494 - Disclosure - Related Parties (Tables)",
     "shortName": "Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.alvotech.com/role/OtherCurrentLiabilitiesTables",
     "longName": "9954495 - Disclosure - Other Current Liabilities (Tables)",
     "shortName": "Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.alvotech.com/role/InterestsInJointVenturesTables",
     "longName": "9954496 - Disclosure - Interests In Joint Ventures (Tables)",
     "shortName": "Interests In Joint Ventures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsTables",
     "longName": "9954497 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.alvotech.com/role/SupplementalCashFlowInformationTables",
     "longName": "9954498 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
     "longName": "9954499 - Disclosure - General information - Additional Information (Details)",
     "shortName": "General information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-68",
      "name": "alvo:ProceedsFromTheCapitalReorganization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-68",
      "name": "alvo:ProceedsFromTheCapitalReorganization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails",
     "longName": "9954500 - Disclosure - General Information - Schedule of fair value of shares issued and non-cash share listing expense (Details)",
     "shortName": "General Information - Schedule of fair value of shares issued and non-cash share listing expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-68",
      "name": "alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-68",
      "name": "alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails",
     "longName": "9954501 - Disclosure - General Information - Disclosure of Subsidiaries and Joint Ventures (Details)",
     "shortName": "General Information - Disclosure of Subsidiaries and Joint Ventures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-109",
      "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954502 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "alvo:UpfrontPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails",
     "longName": "9954503 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Amortization (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Useful Lives of Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails",
     "longName": "9954504 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Depreciation (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Useful Lives of Depreciation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-126",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-126",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails",
     "longName": "9954505 - Disclosure - Segment Reporting - Summary Of Detailed Information About Revenue From Customers Based On Geographical Market (Details)",
     "shortName": "Segment Reporting - Summary Of Detailed Information About Revenue From Customers Based On Geographical Market (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "alvo:NumberOfOperatingSegments1",
      "unitRef": "segement",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails",
     "longName": "9954506 - Disclosure - Segment Reporting - Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets (Details)",
     "shortName": "Segment Reporting - Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails",
     "longName": "9954507 - Disclosure - Segment Reporting - Summary Of Detailed Information About Revenue From Transactions With Individual Customers (Details)",
     "shortName": "Segment Reporting - Summary Of Detailed Information About Revenue From Transactions With Individual Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-150",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-150",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails",
     "longName": "9954508 - Disclosure - Revenue - Summary Of The Groups' Revenue From Contracts With Customers (Details)",
     "shortName": "Revenue - Summary Of The Groups' Revenue From Contracts With Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-162",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails",
     "longName": "9954509 - Disclosure - Revenue - Summary Of Reconciliation Of Contract Assets And Contract Liabilities (Details)",
     "shortName": "Revenue - Summary Of Reconciliation Of Contract Assets And Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-175",
      "name": "ifrs-full:ContractAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "ifrs-full:ContractAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.alvotech.com/role/RevenueAdditionalinformationDetails",
     "longName": "9954510 - Disclosure - Revenue - Additional information (Details)",
     "shortName": "Revenue - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentContractAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesAdditionalInformationDetails",
     "longName": "9954511 - Disclosure - Salaries And Other Employee Expenses - Additional Information (Details)",
     "shortName": "Salaries And Other Employee Expenses - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AverageNumberOfEmployees",
      "unitRef": "individuals",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AverageNumberOfEmployees",
      "unitRef": "individuals",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails",
     "longName": "9954512 - Disclosure - Salaries And Other Employee Expenses - Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group (Details)",
     "shortName": "Salaries And Other Employee Expenses - Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails",
     "longName": "9954513 - Disclosure - Salaries And Other Employee Expenses - Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss (Details)",
     "shortName": "Salaries And Other Employee Expenses - Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails",
     "longName": "9954514 - Disclosure - Finance Income And Finance Costs - Summary Of Detailed Information About Finance Income (Details)",
     "shortName": "Finance Income And Finance Costs - Summary Of Detailed Information About Finance Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsOnChangeInFairValueOfDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsOnChangeInFairValueOfDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails",
     "longName": "9954515 - Disclosure - Finance Income And Finance Costs - Summary Of Detailed Information About Finance Costs (Details)",
     "shortName": "Finance Income And Finance Costs - Summary Of Detailed Information About Finance Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:LossesOnChangeInFairValueOfDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:LossesOnChangeInFairValueOfDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails",
     "longName": "9954516 - Disclosure - Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment (Details)",
     "shortName": "Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails",
     "longName": "9954517 - Disclosure - Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss (Details)",
     "shortName": "Depreciation, Amortization And Impairment - Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails",
     "longName": "9954518 - Disclosure - Audit Fees - Summary Of Detailed Information About Audit Fees (Details)",
     "shortName": "Audit Fees - Summary Of Detailed Information About Audit Fees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails",
     "longName": "9954519 - Disclosure - Income Tax - Schedule Of Taxation Recognized In The Consolidated Statements Of Profit Or Loss And Other Comprehensive Income Or Loss (Details)",
     "shortName": "Income Tax - Schedule Of Taxation Recognized In The Consolidated Statements Of Profit Or Loss And Other Comprehensive Income Or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
     "longName": "9954520 - Disclosure - Income Tax - Additional Information (Details)",
     "shortName": "Income Tax - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-203",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails",
     "longName": "9954521 - Disclosure - Income Tax - Schedule Of The Reconciling Items Between The Statutory Rate And The Effective Tax Rate (Details)",
     "shortName": "Income Tax - Schedule Of The Reconciling Items Between The Statutory Rate And The Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails",
     "longName": "9954522 - Disclosure - Income Tax - Schedule Of The Movement In Net Deferred Taxes (Details)",
     "shortName": "Income Tax - Schedule Of The Movement In Net Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails",
     "longName": "9954523 - Disclosure - Income Tax - Schedule Of Deferred Tax Recognized In The Consolidated Statements Of Financial Position (Details)",
     "shortName": "Income Tax - Schedule Of Deferred Tax Recognized In The Consolidated Statements Of Financial Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NetDeferredTaxAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-194",
      "name": "ifrs-full:NetDeferredTaxAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails",
     "longName": "9954524 - Disclosure - Income Tax - Schedule Of Expiration Of Unused Tax Losses (Details)",
     "shortName": "Income Tax - Schedule Of Expiration Of Unused Tax Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-200",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.alvotech.com/role/LossPerShareAdditionalInformationDetails",
     "longName": "9954525 - Disclosure - Loss Per Share - Additional Information (Details)",
     "shortName": "Loss Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "alvo:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "alvo:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails",
     "longName": "9954526 - Disclosure - Loss Per Share - Summary of Basic and Diluted Loss Per Share (Details)",
     "shortName": "Loss Per Share - Summary of Basic and Diluted Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ifrs-full:AdjustedWeightedAverageShares",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
     "longName": "9954527 - Disclosure - Property, Plant And Equipment - Summary Of Property, Plant And Equipment (Details)",
     "shortName": "Property, Plant And Equipment - Summary Of Property, Plant And Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-235",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails",
     "longName": "9954528 - Disclosure - Property, Plant And Equipment - Additional Information (Details)",
     "shortName": "Property, Plant And Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-263",
      "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails",
     "longName": "9954529 - Disclosure - Leases - Summary of Leases Assets About Right-Of-Use Assets (Details)",
     "shortName": "Leases - Summary of Leases Assets About Right-Of-Use Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:AdjustmentsForIndexedLeasesRightOfUseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.alvotech.com/role/LeasesAdditionalInformationDetails",
     "longName": "9954530 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails",
     "longName": "9954531 - Disclosure - Leases - Summary of Classes of Right-Of-Use Assets (Details)",
     "shortName": "Leases - Summary of Classes of Right-Of-Use Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails",
     "longName": "9954532 - Disclosure - Leases - Summary of Lease Liabilities (Details)",
     "shortName": "Leases - Summary of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:LeaseLiabilitiesAdjustmentsForIndexedLeases",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails",
     "longName": "9954533 - Disclosure - Leases - Summary Of Lease Cost (Details)",
     "shortName": "Leases - Summary Of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:ForeignCurrencyDifferenceOnLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails",
     "longName": "9954534 - Disclosure - Leases - Summary of Maturity Analysis For Lease Liabilities (Details)",
     "shortName": "Leases - Summary of Maturity Analysis For Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.alvotech.com/role/GoodwillSummaryofGoodwillDetails",
     "longName": "9954535 - Disclosure - Goodwill - Summary of Goodwill (Details)",
     "shortName": "Goodwill - Summary of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "ifrs-full:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails",
     "longName": "9954536 - Disclosure - Goodwill - Additional Information (Details)",
     "shortName": "Goodwill - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
     "longName": "9954537 - Disclosure - Other Intangible assets - Summary of Detailed Information About Intangible Assets (Details)",
     "shortName": "Other Intangible assets - Summary of Detailed Information About Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-312",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails",
     "longName": "9954538 - Disclosure - Other Intangible assets - Summary of Impairment Loss and Reversal of Impairment Loss (Details)",
     "shortName": "Other Intangible assets - Summary of Impairment Loss and Reversal of Impairment Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-332",
      "name": "ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
     "longName": "9954539 - Disclosure - Other Intangible assets - Additional Information (Details)",
     "shortName": "Other Intangible assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-346",
      "name": "alvo:PaymentForContractualCommitment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-346",
      "name": "alvo:PaymentForContractualCommitment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails",
     "longName": "9954540 - Disclosure - Cash And Cash Equivalents - Summary of Cash and Cash Equivalents (Details)",
     "shortName": "Cash And Cash Equivalents - Summary of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-350",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails",
     "longName": "9954541 - Disclosure - Cash And Cash Equivalents - Summary of Restricted Cash (Details)",
     "shortName": "Cash And Cash Equivalents - Summary of Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:NoncurrentRestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:AdditionRestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails",
     "longName": "9954542 - Disclosure - Inventories - Summary of Inventories (Details)",
     "shortName": "Inventories - Summary of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails",
     "longName": "9954543 - Disclosure - Inventories - Additional Information (Details)",
     "shortName": "Inventories - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InventoryWritedown2011",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InventoryWritedown2011",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails",
     "longName": "9954544 - Disclosure - Other Current Assets - Summary of Other Current Assets (Details)",
     "shortName": "Other Current Assets - Summary of Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
     "longName": "9954545 - Disclosure - Other Current Assets - Additional Information (Details)",
     "shortName": "Other Current Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:OtherCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-356",
      "name": "alvo:DerecognitionPrepaidDevelopmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
     "longName": "9954546 - Disclosure - Share Capital - Additional information (Details)",
     "shortName": "Share Capital - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:PaymentsForShareIssueCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-68",
      "name": "alvo:StockIssuedUnderPipeFinancingShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails",
     "longName": "9954547 - Disclosure - Share Capital - Summary of Share Capital and Share Premium (Details)",
     "shortName": "Share Capital - Summary of Share Capital and Share Premium (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "alvo:ShareCapitalAndSharePremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails",
     "longName": "9954548 - Disclosure - Share Capital - Summary of Movements in Ordinary Shares, Share Capital and Share Premium (Details)",
     "shortName": "Share Capital - Summary of Movements in Ordinary Shares, Share Capital and Share Premium (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "alvo:IssuanceOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.alvotech.com/role/OtherreservesDetails",
     "longName": "9954549 - Disclosure - Other reserves (Details)",
     "shortName": "Other reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "alvo:ScheduleOfOtherReservesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "alvo:ScheduleOfOtherReservesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
     "longName": "9954550 - Disclosure - Borrowings - Summary of consolidated statements of financial position (Details)",
     "shortName": "Borrowings - Summary of consolidated statements of financial position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:BondsIssued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:OtherBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
     "longName": "9954551 - Disclosure - Borrowings - Additional Information (Details)",
     "shortName": "Borrowings - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-439",
      "name": "ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures",
      "unitRef": "isk",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-439",
      "name": "ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures",
      "unitRef": "isk",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails",
     "longName": "9954552 - Disclosure - Borrowings - Summary of movements in the group's outstanding borrowings (Details)",
     "shortName": "Borrowings - Summary of movements in the group's outstanding borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:PaymentsForDebtIssueCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R119": {
     "role": "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails",
     "longName": "9954553 - Disclosure - Borrowings - Summary of non-cash changes in the group\u2019s outstanding borrowings (Details)",
     "shortName": "Borrowings - Summary of non-cash changes in the group\u2019s outstanding borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R120": {
     "role": "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails",
     "longName": "9954554 - Disclosure - Borrowings - Schedule of maturities of outstanding borrowings (Details)",
     "shortName": "Borrowings - Schedule of maturities of outstanding borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-283",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R121": {
     "role": "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
     "longName": "9954555 - Disclosure - Long-Term Incentive Plans - Additional Information (Details)",
     "shortName": "Long-Term Incentive Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "121",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R122": {
     "role": "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails",
     "longName": "9954556 - Disclosure - Long-Term Incentive Plans - Schedule Of Movements In The Group's Employee Incentive Plan Liabilities (Details)",
     "shortName": "Long-Term Incentive Plans - Schedule Of Movements In The Group's Employee Incentive Plan Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "122",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R123": {
     "role": "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails",
     "longName": "9954557 - Disclosure - Share-Based Payments - Summary of Movements in RSUs (Details)",
     "shortName": "Share-Based Payments - Summary of Movements in RSUs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "123",
     "firstAnchor": {
      "contextRef": "c-547",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-548",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R124": {
     "role": "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails",
     "longName": "9954558 - Disclosure - Share-Based Payments - Additional Information (Details)",
     "shortName": "Share-Based Payments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "124",
     "firstAnchor": {
      "contextRef": "c-546",
      "name": "alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-546",
      "name": "alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R125": {
     "role": "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails",
     "longName": "9954559 - Disclosure - Share-Based Payments - Summary of share-based payment expense (Details)",
     "shortName": "Share-Based Payments - Summary of share-based payment expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "125",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-552",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R126": {
     "role": "http://www.alvotech.com/role/LitigationAdditionalInformationDetails",
     "longName": "9954560 - Disclosure - Litigation - Additional Information (Details)",
     "shortName": "Litigation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "126",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "alvo:NumberOfLitigations",
      "unitRef": "litigation_case",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "alvo:NumberOfLitigations",
      "unitRef": "litigation_case",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R127": {
     "role": "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails",
     "longName": "9954561 - Disclosure - Related Parties - Additional information (Details)",
     "shortName": "Related Parties - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "127",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "alvo:LoansToRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "alvo:LoansToRelatedParties",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "alvo:LoansToRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R128": {
     "role": "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails",
     "longName": "9954562 - Disclosure - Related Parties - Summary of Related Party Transactions (Details)",
     "shortName": "Related Parties - Summary of Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "128",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ServicesReceivedRelatedPartyTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R129": {
     "role": "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
     "longName": "9954563 - Disclosure - Related Parties - Schedule of Related Party Transactions (Details)",
     "shortName": "Related Parties - Schedule of Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "129",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ServicesReceivedRelatedPartyTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-654",
      "name": "ifrs-full:ServicesReceivedRelatedPartyTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R130": {
     "role": "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails",
     "longName": "9954564 - Disclosure - Related Parties - Schedule of Information About Board of Directors Remuneration (Details)",
     "shortName": "Related Parties - Schedule of Information About Board of Directors Remuneration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "130",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R131": {
     "role": "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails",
     "longName": "9954565 - Disclosure - Other Current Liabilities - Schedule of Composition of Other Current Liabilities (Details)",
     "shortName": "Other Current Liabilities - Schedule of Composition of Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "131",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "alvo:CurrentAccruedSalaryAndSalaryRelatedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "alvo:CurrentAccruedSalaryAndSalaryRelatedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R132": {
     "role": "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails",
     "longName": "9954566 - Disclosure - Interests In Joint Ventures - Schedule of Information About Joint Venture (Details)",
     "shortName": "Interests In Joint Ventures - Schedule of Information About Joint Venture (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "132",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-713",
      "name": "ifrs-full:PrincipalPlaceOfBusinessOfJointVenture",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R133": {
     "role": "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails",
     "longName": "9954567 - Disclosure - Interests In Joint Ventures - Schedule of Changes in Groups Investment in a Joint Venture (Details)",
     "shortName": "Interests In Joint Ventures - Schedule of Changes in Groups Investment in a Joint Venture (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "133",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R134": {
     "role": "http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails",
     "longName": "9954568 - Disclosure - Interests In Joint Ventures - Additional Information (Details)",
     "shortName": "Interests In Joint Ventures - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "134",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R135": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails",
     "longName": "9954569 - Disclosure - Financial Instruments - Summary of Financial Assets Measured at Cost (Details)",
     "shortName": "Financial Instruments - Summary of Financial Assets Measured at Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "135",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "alvo:OtherCurrentAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R136": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails",
     "longName": "9954570 - Disclosure - Financial Instruments - Summary of Financial Liabilities (Details)",
     "shortName": "Financial Instruments - Summary of Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "136",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "alvo:OtherCurrentLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R137": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails",
     "longName": "9954571 - Disclosure - Financial Instruments - Summary of Material Differences Between the Fair Value and Carrying Amount (Details)",
     "shortName": "Financial Instruments - Summary of Material Differences Between the Fair Value and Carrying Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "137",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:BondsIssued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "alvo:BondsIssuedAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R138": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
     "longName": "9954572 - Disclosure - Financial Instruments - Summary of Fair Value on a Recurring Basis (Details)",
     "shortName": "Financial Instruments - Summary of Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "138",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-744",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R139": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
     "longName": "9954573 - Disclosure - Financial Instruments - Schedule of Provides a Reconciliation of Level 3 Financial Instruments (Details)",
     "shortName": "Financial Instruments - Schedule of Provides a Reconciliation of Level 3 Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "139",
     "firstAnchor": {
      "contextRef": "c-782",
      "name": "ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-726",
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R140": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
     "longName": "9954574 - Disclosure - Financial Instruments - Additional Information (Details)",
     "shortName": "Financial Instruments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "140",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-472",
      "name": "alvo:IncreaseInOutstandingBondsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R141": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails",
     "longName": "9954575 - Disclosure - Financial Instruments - Summary of Assumptions and Inputs (Details)",
     "shortName": "Financial Instruments - Summary of Assumptions and Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "141",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-735",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R142": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails",
     "longName": "9954576 - Disclosure - Financial Instruments - Summary of Interest Rate Sensitivity Analysis (Details)",
     "shortName": "Financial Instruments - Summary of Interest Rate Sensitivity Analysis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "142",
     "firstAnchor": {
      "contextRef": "c-820",
      "name": "ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-820",
      "name": "ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R143": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails",
     "longName": "9954577 - Disclosure - Financial Instruments - Summary of Impact on the Groups Operations (Details)",
     "shortName": "Financial Instruments - Summary of Impact on the Groups Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "143",
     "firstAnchor": {
      "contextRef": "c-822",
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-822",
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R144": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
     "longName": "9954578 - Disclosure - Financial Instruments - Summary of Groups Assets and Liabilities (Details)",
     "shortName": "Financial Instruments - Summary of Groups Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "144",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-822",
      "name": "ifrs-full:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    },
    "R145": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
     "longName": "9954579 - Disclosure - Financial Instruments - Summary of Analysis Assumes that all Other Variables (Details)",
     "shortName": "Financial Instruments - Summary of Analysis Assumes that all Other Variables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "145",
     "firstAnchor": {
      "contextRef": "c-842",
      "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-842",
      "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R146": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails",
     "longName": "9954580 - Disclosure - Financial Instruments - Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets (Details)",
     "shortName": "Financial Instruments - Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "146",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:MaximumExposureToCreditRisk",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:MaximumExposureToCreditRisk",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R147": {
     "role": "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails",
     "longName": "9954581 - Disclosure - Financial Instruments - Summary of Contractual Maturities of Financial Assets and Liabilities (Details)",
     "shortName": "Financial Instruments - Summary of Contractual Maturities of Financial Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "147",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alvo:DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R148": {
     "role": "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails",
     "longName": "9954582 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)",
     "shortName": "Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "148",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "alvo:DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "alvo:DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R149": {
     "role": "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "9954583 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "149",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:IssueOfEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-919",
      "name": "alvo:SaleOfStockIssuePricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alvo-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "alvo_A2022ConvertibleBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "A2022ConvertibleBondsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Convertible Bonds",
        "label": "2022 Convertible Bonds [Member]",
        "documentation": "2022 Convertible Bonds"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ATPHoldingEhf.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ATPHoldingEhf.Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATP Holding ehf.",
        "label": "ATP Holding ehf. [Member]",
        "documentation": "ATP Holding ehf."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AVT23Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AVT23Member",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AVT23",
        "label": "AVT23 [Member]",
        "documentation": "AVT23"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AccretionderecognitionOfBorrowingsDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AccretionderecognitionOfBorrowingsDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion/derecognition of borrowings discount",
        "label": "AccretionDerecognition Of Borrowings Discount",
        "documentation": "Accretion/derecognition of borrowings discount."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AccruedInterestOnDebtExtinguished": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AccruedInterestOnDebtExtinguished",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest on debt extiguished",
        "label": "Accrued Interest On Debt Extinguished",
        "documentation": "Accrued interest on debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Accumulated depreciation and amortisation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r64",
      "r354",
      "r361",
      "r365",
      "r366"
     ]
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "alvo_AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of other intangible assets through financing agreements",
        "label": "Acquistion Of Other Intangible Assets Through Financing Agreements",
        "documentation": "Acquistion Of Other Intangible Assets Through Financing Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AdalvoLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdalvoLimitedMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adalvo Limited - Sister company",
        "label": "Adalvo Limited [Member]",
        "documentation": "Adalvo Limited member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AdalvoUKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdalvoUKMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adalvo UK - Sister company",
        "label": "Adalvo UK [Member]",
        "documentation": "Adalvo UK"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AdditionOfTheLoanFacilitiesThroughConvertibleBond": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdditionOfTheLoanFacilitiesThroughConvertibleBond",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of Facility through Aztiq Convertible Bond",
        "label": "Addition Of The Loan Facilities Through Convertible Bond",
        "documentation": "Addition of the loan facilities through convertible bond."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AdditionRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdditionRestrictedCashAndCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions during the year",
        "label": "Addition Restricted Cash and Cash Equivalents",
        "documentation": "Addition restricted cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AdditionalBondsIssuanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdditionalBondsIssuanceAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Bonds Issuance [Axis]",
        "label": "Additional Bonds Issuance [Axis]",
        "documentation": "Additional bonds issuance [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AdditionalBondsIssuanceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdditionalBondsIssuanceDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Bonds Issuance [Domain]",
        "label": "Additional Bonds Issuance [Domain]",
        "documentation": "Additional bonds issuance."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AdditionalExtensionPremiumToBondholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdditionalExtensionPremiumToBondholders",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional extension premium to bondholders",
        "label": "Additional Extension Premium To Bondholders",
        "documentation": "Additional extension premium to bondholders."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "New leases",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted net liabilities of OACB as of 15 June 2022",
        "label": "Adjusted Net Liabilities Recognized Amount In Accordance With Ifrs 2",
        "documentation": "Adjusted net liabilities recognized amount in accordance with IFRS 2."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding diluted (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriod",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Direct taxes \u2013 prior year",
        "label": "Adjustments for current tax of prior periods"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase) / decrease in contract assets",
        "label": "Adjustments for decrease (increase) in contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in contract assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in other assets",
        "label": "Adjustments for decrease (increase) in other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxOfPriorPeriods",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails": {
       "parentTag": "alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prior year",
        "terseLabel": "Prior year deferred tax impact",
        "label": "Adjustments for deferred tax of prior periods"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for the deferred tax of prior periods."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "alvo_AdjustmentsForExtinguishmentOfLiabilityLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdjustmentsForExtinguishmentOfLiabilityLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on extinguishment of SARs liability",
        "label": "Adjustments For Extinguishment Of Liability Losses Gains",
        "documentation": "Adjustments for extinguishment of liability losses gains."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance costs",
        "label": "Adjustments for finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Finance income",
        "label": "Adjustments for finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "alvo_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of other intangible assets",
        "label": "Adjustments For Impairment Loss Reversal Of Impairment Loss Recognise In Profit Or Loss Intangible Assets",
        "documentation": "Adjustments for impairment loss reversal of impairment loss recognise in profit or loss intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of property, plant and equipment",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncomeTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit",
        "label": "Adjustments for income tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in contract liabilities",
        "label": "Adjustments for increase (decrease) in contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term incentive plan expense",
        "label": "Adjustments for increase (decrease) in employee benefit liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "alvo_AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase / (decrease) in liabilities with related parties",
        "label": "Adjustments For Increase Decrease In Liabilities To Related Parties",
        "documentation": "Adjustments for increase decrease in liabilities to related parties"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) / increase in other liabilities",
        "label": "Adjustments for increase (decrease) in other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in trade and other payables",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "alvo_AdjustmentsForIndexedLeasesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdjustmentsForIndexedLeasesRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for indexed leases",
        "label": "Adjustments For Indexed Leases Right Of Use Assets",
        "documentation": "Adjustments for indexed leases right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for non-cash items:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "alvo_AdjustmentsForSharelistingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AdjustmentsForSharelistingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-listing expense",
        "label": "Adjustments For Sharelisting Expense",
        "documentation": "Adjustments for share-listing expense."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of net loss of joint venture",
        "label": "Adjustments for undistributed profits of investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for undistributed profits of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate difference",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r370"
     ]
    },
    "alvo_AfterTheTermsOfTheSecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AfterTheTermsOfTheSecondAmendmentMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After The Terms Of The Second Amendment",
        "label": "After The Terms Of The Second Amendment [member]",
        "documentation": "After the terms of the second amendment."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AggregateBorrowingsIndebtedness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AggregateBorrowingsIndebtedness",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate borrowings indebtedness",
        "label": "Aggregate Borrowings Indebtedness",
        "documentation": "Aggregate borrowings indebtedness."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AggregatePeriodForDeterminingTheSharePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AggregatePeriodForDeterminingTheSharePrice",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate period for determining the share price",
        "label": "Aggregate Period For Determining The Share Price",
        "documentation": "Aggregate period for determining the share price."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands [member]",
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r179",
      "r192",
      "r193",
      "r196",
      "r197",
      "r199",
      "r205",
      "r226",
      "r281",
      "r315",
      "r319"
     ]
    },
    "alvo_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AgreementAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement [Axis]",
        "label": "Agreement [Axis]",
        "documentation": "Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AgreementDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement [Domain]",
        "label": "Agreement [Domain]",
        "documentation": "Agreement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AgreementOneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AgreementOneAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement One [Axis]",
        "label": "Agreement One [Axis]",
        "documentation": "Agreement one."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AgreementOneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AgreementOneDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement One [Domain]",
        "label": "Agreement One [Domain]",
        "documentation": "Agreement one."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AgreementsTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AgreementsTypeAxis",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements Type [Axis]",
        "label": "Agreements Type [Axis]",
        "documentation": "Agreements type."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AgreementsTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AgreementsTypeDomain",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements Type [Domain]",
        "label": "Agreements Type [Domain]",
        "documentation": "Agreements Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All levels of fair value hierarchy [member]",
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r163"
     ]
    },
    "alvo_AlvogenAztiqABSisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenAztiqABSisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Aztiq AB \u2013 Sister company",
        "label": "Alvogen Aztiq AB \u2013 Sister company [Member]",
        "documentation": "Alvogen Aztiq AB member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenEhf.SisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenEhf.SisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen ehf. - Sister company",
        "label": "Alvogen ehf. - Sister company [Member]",
        "documentation": "Alvogen ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenEmergingMarketsSisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenEmergingMarketsSisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Emerging Markets - Sister company",
        "label": "Alvogen Emerging Markets - Sister company [Member]",
        "documentation": "Alvogen Emerging Markets member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenFacilityAndAztiqFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenFacilityAndAztiqFacilityMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Facility and Aztiq Facility",
        "label": "Alvogen Facility and Aztiq Facility [member]",
        "documentation": "Alvogen Facility and Aztiq Facility [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenFacilityMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Facility",
        "label": "Alvogen Facility [Member]",
        "documentation": "Alvogen facility."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenFinanceB.VMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenFinanceB.VMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Finance B.V. - Sister Company",
        "label": "Alvogen Finance B.V [Member]",
        "documentation": "Alvogen Finance B.V"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenIcelandEhf.SisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenIcelandEhf.SisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Iceland ehf. - Sister company",
        "label": "Alvogen Iceland ehf. - Sister company [Member]",
        "documentation": "Alvogen Iceland ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenInc.SisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenInc.SisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Inc. - Sister company",
        "label": "Alvogen Inc. - Sister company [Member]",
        "documentation": "Alvogen Inc member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenKoreaCo.LtdSisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenKoreaCo.LtdSisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Korea co. Ltd - Sister company",
        "label": "Alvogen Korea co. Ltd - Sister company [Member]",
        "documentation": "Alvogen Korea co .Ltd member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenLoanMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Loan",
        "label": "Alvogen Loan [member]",
        "documentation": "Alvogen Loan [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenLoanWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenLoanWarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Loan Warrants",
        "label": "Alvogen Loan Warrants [member]",
        "documentation": "Alvogen Loan Warrants [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenLuxHoldingsS.aR.lSisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenLuxHoldingsS.aR.lSisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Lux Holdings S.\u00e0 r.l. \u2013 Sister company",
        "label": "Alvogen Lux Holdings S.\u00e0 r.l \u2013 Sister company [Member]",
        "documentation": "Alvogen Lux Holdings S.\u00e0 r.l."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenLuxHoldingsSRLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenLuxHoldingsSRLMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Lux Holdings S.\u00e0 r.l. \u2013 Sister company",
        "label": "Alvogen Lux Holdings S r l [Member]",
        "documentation": "Alvogen Lux Holdings S r l member"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenMaltaSh.ServicesSisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenMaltaSh.ServicesSisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Malta Sh. Services - Sister company",
        "label": "Alvogen Malta Sh. Services - Sister company [Member]",
        "documentation": "Alvogen Malta Sh Services member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen",
        "label": "Alvogen [Member]",
        "documentation": "Alvogen."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenPharmaPvtLtdSisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenPharmaPvtLtdSisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Pharma Pvt Ltd - Sister Company",
        "label": "Alvogen Pharma Pvt Ltd - Sister Company [Member]",
        "documentation": "Alvogen Pharma Pvt Ltd member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenSpainSlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenSpainSlMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Spain SL - Sister company",
        "label": "Alvogen Spain SL [Member]",
        "documentation": "Alvogen Spain SL member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenSubordinatedLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenSubordinatedLoanMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Subordinated Loan",
        "label": "Alvogen Subordinated Loan [member]",
        "documentation": "Alvogen Subordinated Loan [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvogenUKSisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvogenUKSisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen UK - Sister company",
        "label": "Alvogen UK - Sister company [Member]",
        "documentation": "Alvogen UK member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechAndCchnBiopharmaceuticalCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechAndCchnBiopharmaceuticalCoLtdMember",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech and CCHT Biopharmaceutical Co., Ltd.",
        "verboseLabel": "Alvotech &amp; CCHN Biopharmaceutical Co., Ltd",
        "label": "Alvotech and CCHN Biopharmaceutical Co Ltd [Member]",
        "documentation": "Alvotech and CCHN Biopharmaceutical Co Ltd member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechBiosciencesIndiaPrivateLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechBiosciencesIndiaPrivateLtdMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech Biosciences India Private Ltd",
        "label": "Alvotech Biosciences India Private Ltd [Member]",
        "documentation": "Alvotech Biosciences India Private Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechCchnBiopharmaceuticalCo.LtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechCchnBiopharmaceuticalCo.LtdMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech &amp; CCHN Biopharmaceutical Co. Ltd",
        "label": "Alvotech CCHN Biopharmaceutical Co. Ltd [Member]",
        "documentation": "Alvotech &amp; CCHN Biopharmaceutical Co. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechGermanyGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechGermanyGmbhMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech Germany GmbH",
        "label": "Alvotech Germany GmbH [Member]",
        "documentation": "Alvotech Germany GmbH."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechHannoverGmbhMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechHannoverGmbhMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech Hannover GmbH",
        "label": "Alvotech Hannover GmbH [Member]",
        "documentation": "Alvotech Hannover GmbH."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechHfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechHfMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech hf",
        "label": "Alvotech Hf [Member]",
        "documentation": "Alvotech hf."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechMaltaLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechMaltaLtdMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech Malta Ltd",
        "label": "Alvotech Malta Ltd [Member]",
        "documentation": "Alvotech Malta Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechMancoEhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechMancoEhfMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech Manco ehf",
        "label": "Alvotech Manco ehf [Member]",
        "documentation": "Alvotech Manco ehf."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechSwissAgMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechSwissAgMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech Swiss AG",
        "label": "Alvotech Swiss AG [Member]",
        "documentation": "Alvotech Swiss AG."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechUkLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechUkLtdMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech UK Ltd",
        "label": "Alvotech UK Ltd [Member]",
        "documentation": "Alvotech UK Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AlvotechUsaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AlvotechUsaIncMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvotech USA Inc",
        "label": "Alvotech USA Inc [Member]",
        "documentation": "Alvotech USA Inc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two",
        "label": "Amendment To Outstanding Bonds January To June Two Thousand And Twenty Two [member]",
        "documentation": "Amendment to outstanding bonds january to june two thousand and twenty two [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two",
        "label": "Amendment To Outstanding Bonds November Sixteenth Two Thousand And Twenty Two [member]",
        "documentation": "Amendment to outstanding bonds november sixteenth two thousand and twenty two [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization",
        "terseLabel": "Amortisation, intangible assets other than goodwill",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "alvo_AmortizationAndImpairmentOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AmortizationAndImpairmentOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails": {
       "parentTag": "ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and impairment of intangible assets (see Note 15)",
        "label": "Amortization And Impairment Of Intangible Assets",
        "documentation": "Amortization And Impairment Of Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AmortizationMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Amortization [member]",
        "documentation": "Amortization."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AmortizationOfDeferredDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AmortizationOfDeferredDebtIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred debt issue costs",
        "label": "Amortization Of Deferred Debt Issuance Costs",
        "documentation": "Amortization of deferred debt issuancecCosts."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AmortizationOfDeferredDebtIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AmortizationOfDeferredDebtIssueCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred debt issue costs",
        "label": "Amortization Of Deferred Debt Issue Costs",
        "documentation": "Amortization of deferred debt issue costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables/ borrowings",
        "label": "Amounts payable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r88"
     ]
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Amounts receivable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r88"
     ]
    },
    "alvo_AnnMerchantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AnnMerchantMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ann Merchant, Board Member",
        "label": "Ann Merchant [Member]",
        "documentation": "Ann Merchant."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare",
     "presentation": [
      "http://www.alvotech.com/role/LossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share",
        "label": "Antidilutive securities excluded from computation of earnings per share",
        "documentation": "Antidilutive securities excluded from computation of earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax rate",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "alvo_April2023LeaseFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "April2023LeaseFacilityMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2023 Lease Facility",
        "label": "April 2023 Lease Facility [Member]",
        "documentation": "April 2023 Lease Facility"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AreaOfProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AreaOfProperty",
     "presentation": [
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of property",
        "label": "Area of Property",
        "documentation": "Area of Property"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ArionBankiHfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ArionBankiHfMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arion banki hf",
        "label": "Arion banki hf [member]",
        "documentation": "Arion banki hf [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ArniHararsonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ArniHararsonMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u00c1rni Har\u00f0arson, Board Member*",
        "label": "Arni Hararson [Member]",
        "documentation": "\u00c1rni Har\u00f0arson"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AsiaAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AsiaAndOtherMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails",
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia and Other",
        "label": "Asia And Other [Member]",
        "documentation": "Asia and other."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AssetAcquisitionConsiderationLoansAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AssetAcquisitionConsiderationLoansAssumed",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition consideration loans assumed",
        "label": "Asset Acquisition Consideration Loans Assumed",
        "documentation": "Asset acquisition consideration loans assumed."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AssetAcquisitionConsiderationTransferredConvertibleBond": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AssetAcquisitionConsiderationTransferredConvertibleBond",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition consideration transferred Convertible Bond",
        "label": "Asset Acquisition Consideration Transferred Convertible Bond",
        "documentation": "Asset acquisition consideration transferred Convertible Bond."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AssetAcquisitionConsiderationTransferredLoansAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AssetAcquisitionConsiderationTransferredLoansAssumed",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition consideration transferred Loans Assumed",
        "label": "Asset Acquisition Consideration Transferred Loans Assumed",
        "documentation": "Asset acquisition consideration transferred Loans Assumed."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AssetAcquisitionConsiderationTransferredSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AssetAcquisitionConsiderationTransferredSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition consideration transferred Settlements",
        "label": "Asset Acquisition Consideration Transferred Settlements",
        "documentation": "Asset acquisition consideration transferred Settlements."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AssetAcquisitionsConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AssetAcquisitionsConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition consideration transferred",
        "label": "Asset Acquisitions Consideration Transferred",
        "documentation": "Asset acquisition consideration transferred."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AssetAcquisitionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AssetAcquisitionsDomain",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisitions [Domain]",
        "documentation": "Asset Acquisition [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r162",
      "r163",
      "r168",
      "r254",
      "r257"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AssetsAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AssetsAcquisitionAxis",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Assets Acquisition [Axis]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AssetsAndLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAndLiabilitiesAxis",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities [axis]",
        "label": "Assets and liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_AssetsAndLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAndLiabilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities [member]",
        "label": "Assets and liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "alvo_AtpHoldingsEhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AtpHoldingsEhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATP Holdings ehf. - Sister company",
        "label": "ATP Holdings ehf [Member]",
        "documentation": "ATP Holdings ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails",
      "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [axis]",
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341"
     ]
    },
    "alvo_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.alvotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.alvotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.alvotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330"
     ]
    },
    "ifrs-full_AuditorsRemuneration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AuditorsRemuneration",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total fees",
        "label": "Auditor's remuneration"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_AuditorsRemunerationForAuditServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AuditorsRemunerationForAuditServices",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statement audit fees",
        "label": "Auditor's remuneration for audit services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_AuditorsRemunerationForTaxServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AuditorsRemunerationForTaxServices",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/AuditFeesSummaryOfDetailedInformationAboutAuditFeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other fees, including tax services",
        "label": "Auditor's remuneration for tax services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for tax services."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective tax rate",
        "label": "Average effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average rate",
        "label": "Average foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_AverageNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageNumberOfEmployees",
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average number of individuals employed",
        "label": "Average number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The average number of personnel employed by the entity during a period."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_AztiqConsultingEhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqConsultingEhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq Consulting ehf. \u2013 Sister company",
        "label": "Aztiq Consulting ehf [Member]",
        "documentation": "Aztiq Consulting ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AztiqConversionFeatureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqConversionFeatureMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq Conversion Feature",
        "label": "Aztiq Conversion Feature [member]",
        "documentation": "Aztiq Conversion Feature [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AztiqConvertibleBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqConvertibleBondMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq Convertible Bond",
        "label": "Aztiq Convertible Bond [member]",
        "documentation": "Aztiq Convertible Bond[Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AztiqFacilityLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqFacilityLoansMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq Facility Loans",
        "label": "Aztiq Facility Loans [member]",
        "documentation": "Aztiq Facility Loans [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AztiqFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqFacilityMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq Facility",
        "label": "Aztiq Facility [member]",
        "documentation": "Aztiq Facility [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AztiqFjrfestingarEhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqFjrfestingarEhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq Fj\u00e1rfestingar ehf. \u2013 Sister company",
        "label": "Aztiq Fjrfestingar ehf [Member]",
        "documentation": "Aztiq Fjrfestingar ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AztiqMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq",
        "label": "Aztiq [Member]",
        "documentation": "Aztiq."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AztiqPharmaPartnersS.aR.l.SisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqPharmaPartnersS.aR.l.SisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq Pharma Partners S.\u00e0 r.l. \u2013 Sister company",
        "label": "Aztiq Pharma Partners S.\u00e0 r.l. \u2013 Sister company [Member]",
        "documentation": "Aztiq Pharma Partners S.\u00e0 r.l. member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_AztiqPharmaPartnersSarlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "AztiqPharmaPartnersSarlMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aztiq Pharma Partners Sarl",
        "label": "Aztiq Pharma Partners Sarl [Member]",
        "documentation": "Aztiq Pharma Partners S.a r.l."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BankBorrowingsUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BankBorrowingsUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails": {
       "parentTag": "alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r317",
      "r320"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic loss per share (in dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "alvo_BcaFrameworkAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BcaFrameworkAgreementMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCA Framework Agreement",
        "label": "BCA Framework Agreement [member]",
        "documentation": "BCA framework agreement [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BeforeTheTermsOfTheSecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BeforeTheTermsOfTheSecondAmendmentMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Before The Terms Of The Second Amendment",
        "label": "Before The Terms Of The Second Amendment [member]",
        "documentation": "Before the terms of the second amendment [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BondsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BondsIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Bonds issued",
        "terseLabel": "Bonds issued",
        "label": "Bonds issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of bonds issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_BondsIssuedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BondsIssuedAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Bonds Issued At Fair Value",
        "documentation": "Bonds issued at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BondsIssuedUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BondsIssuedUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails": {
       "parentTag": "alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to bonds issued. [Refer: Bonds issued]"
       }
      }
     },
     "auth_ref": [
      "r317",
      "r320"
     ]
    },
    "alvo_BorrowingConversionPeriodPriorToExtinguishment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingConversionPeriodPriorToExtinguishment",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion period prior to extinguishment",
        "label": "Borrowing, Conversion Period Prior To Extinguishment",
        "documentation": "Borrowing, Conversion Period Prior To Extinguishment"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingPrepaymentPeriodWithAdditionalPremium": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingPrepaymentPeriodWithAdditionalPremium",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment period with additional premium",
        "label": "Borrowing, Prepayment Period With Additional Premium",
        "documentation": "Borrowing, Prepayment Period With Additional Premium"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingSharesIssuancePeriodForInterestDecrease": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingSharesIssuancePeriodForInterestDecrease",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuance period for interest decrease",
        "label": "Borrowing, Shares Issuance Period For Interest Decrease",
        "documentation": "Borrowing, Shares Issuance Period For Interest Decrease"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total outstanding borrowings, net of debt issue costs",
        "terseLabel": "Borrowings (measured at amortized cost)",
        "periodStartLabel": "Beginning Borrowings",
        "periodEndLabel": "Ending Borrowings",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_BorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings [abstract]",
        "label": "Borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsAdjustmentToInterestRateBasis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, variable interest rate",
        "label": "Borrowings, adjustment to interest rate basis"
       }
      },
      "en": {
       "role": {
        "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [axis]",
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "ifrs-full_BorrowingsByNameMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [member]",
        "label": "Borrowings by name [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "alvo_BorrowingsConversionFeatureFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsConversionFeatureFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings conversion feature fair value",
        "label": "Borrowings Conversion Feature Fair Value",
        "documentation": "Borrowings conversion feature fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "alvo_BorrowingsRedemptionConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsRedemptionConversionPrice",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings redemption conversion price (in dollars per share)",
        "label": "Borrowings Redemption Conversion Price",
        "documentation": "Borrowings redemption conversion price."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingsRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings repurchase amount",
        "label": "Borrowings Repurchase Amount",
        "documentation": "Borrowings repurchase amount."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingsRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings repurchased face amount",
        "label": "Borrowings Repurchased Face Amount",
        "documentation": "Borrowings repurchased face amount."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsRollForward",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings [Roll Forward]",
        "label": "Borrowings [Roll Forward]",
        "documentation": "Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingsTrancheAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsTrancheAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings Tranche [Axis]",
        "label": "Borrowings Tranche [Axis]",
        "documentation": "Borrowings Tranche [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingsTrancheDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsTrancheDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings Tranche [Domain]",
        "label": "Borrowings Tranche [Domain]",
        "documentation": "Borrowings Tranche [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingsTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsTrancheOneMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings Tranche One",
        "label": "Borrowings Tranche One [member]",
        "documentation": "Borrowings Tranche One [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_BorrowingsTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BorrowingsTrancheTwoMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings Tranche Two",
        "label": "Borrowings Tranche Two [member]",
        "documentation": "Borrowings Tranche Two [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r199",
      "r210",
      "r300",
      "r302",
      "r379"
     ]
    },
    "alvo_BusinessCombinationAndPipeFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "BusinessCombinationAndPipeFinancingMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination and PIPE Financing",
        "label": "Business Combination and PIPE Financing [Member]",
        "documentation": "Business combination and pipe financing."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations [axis]",
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "currency_CHF": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CHF",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CHF",
        "label": "Switzerland, Francs"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CancellationsRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CancellationsRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled leases",
        "label": "Cancellations, Right Of Use Assets",
        "documentation": "Cancellations, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CapitalContributionSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CapitalContributionSharesIssued",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution (in shares)",
        "label": "Capital Contribution Shares Issued",
        "documentation": "Capital Contribution Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CapitalContributionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CapitalContributionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution",
        "label": "Capital Contribution Value",
        "documentation": "Capital Contribution Value"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CapitalExpenditureIntangibleAssetsIncurredButNotPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CapitalExpenditureIntangibleAssetsIncurredButNotPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of intangibles in trade payables and other current liabilities",
        "label": "Capital Expenditure Intangible Assets Incurred But Not Paid",
        "documentation": "Capital expenditure intangible assets incurred but not paid."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CapitalExpenditureTangibleAssetsIncurredButNotPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CapitalExpenditureTangibleAssetsIncurredButNotPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of property, plant and equipment in trade payables and other current liabilities",
        "label": "Capital Expenditure Tangible Assets Incurred But Not Paid",
        "documentation": "Capital expenditure tangible assets incurred but not paid."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CapitalReorganizationEventSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CapitalReorganizationEventSharesIssued",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reorganization event shares issued (in shares)",
        "label": "Capital Reorganization Event Shares Issued",
        "documentation": "Capital reorganization event shares issued."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CapitalReorganizationSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CapitalReorganizationSharesIssued",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reorganization shares issued (in shares)",
        "label": "Capital Reorganization Shares Issued",
        "documentation": "Capital reorganization shares issued."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r60",
      "r113",
      "r118",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r221",
      "r232",
      "r233"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [member]",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r118",
      "r122",
      "r124",
      "r125",
      "r221",
      "r232",
      "r233"
     ]
    },
    "alvo_CarryingValueOfDebtExtinguished": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CarryingValueOfDebtExtinguished",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value of debt extinguished",
        "label": "Carrying Value Of Debt Extinguished",
        "documentation": "Carrying value of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAdvancesAndLoansFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAdvancesAndLoansFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from loans from related parties",
        "label": "Cash advances and loans from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from advances and loans from related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year",
        "periodEndLabel": "Cash and cash equivalents at the end of the year",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r135",
      "r158"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents [abstract]",
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CashAndCashEquivalentsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CashAndCashEquivalentsRollForward",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash And Cash Equivalents [Roll Forward]",
        "label": "Cash And Cash Equivalents [Roll Forward]",
        "documentation": "Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CashEquivalentsAndCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CashEquivalentsAndCashMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash Equivalents And Cash [Member]",
        "documentation": "Cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash generated from financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r136"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r136"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r136"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operations",
        "label": "Cash flows from (used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating cash flow before movement in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r372"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Installment payments",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashRepaymentsOfAdvancesAndLoansFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of loans from related parties",
        "label": "Cash repayments of advances and loans from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of advances and loans from related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails",
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [axis]",
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_ChangesInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "increase in equity",
        "label": "Increase (decrease) in equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "alvo_ChangesInInventoryReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ChangesInInventoryReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in inventory reserves",
        "label": "Changes In Inventory Reserves",
        "documentation": "Changes In Inventory Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassAAndClassBOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassAAndClassBOrdinarySharesMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A and Class B Ordinary Shares",
        "label": "Class A and Class B Ordinary Shares [Member]",
        "documentation": "Class A and class B ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassACommonStockMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Shareholders",
        "label": "Class A Common Stock [Member]",
        "documentation": "Class\u00a0A common stock."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassAOacbOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassAOacbOrdinarySharesMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A OACB Ordinary Shares",
        "label": "Class A OACB Ordinary Shares [Member]",
        "documentation": "Class A OACB ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassBCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassBCommonStockMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Shareholders",
        "label": "Class B Common Stock [Member]",
        "documentation": "Class\u00a0B common stock."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassBOacbOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassBOacbOrdinarySharesMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B OACB Ordinary Shares",
        "label": "Class B OACB Ordinary Shares [Member]",
        "documentation": "Class B OACB ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassOfStock1Domain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassOfStock1Domain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Domain]",
        "label": "Class Of Stock 1 [Domain]",
        "documentation": "Class Of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassOfStockAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Axis]",
        "label": "Class Of Stock [Axis]",
        "documentation": "Class of stock [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassOfStocksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassOfStocksAxis",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of stocks [axis]",
        "label": "Class Of Stocks [Axis]",
        "documentation": "Class of stocks."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassOfStocksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassOfStocksDomain",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stocks [Domain]",
        "label": "Class Of Stocks [Domain]",
        "documentation": "Class Of Stocks [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassOfWarrantsOrRightsExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassOfWarrantsOrRightsExercisePricePerShare",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrants or rights exercise price per share (in dollars per share)",
        "label": "Class Of Warrants Or Rights Exercise Price Per Share",
        "documentation": "Class of warrants or rights exercise price per share."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassOfWarrantsOrRightsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassOfWarrantsOrRightsOutstanding",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrants or rights outstanding (in shares)",
        "label": "Class Of Warrants Or Rights Outstanding",
        "documentation": "Class of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails",
      "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails",
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails",
      "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r105",
      "r170",
      "r190"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails",
      "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails",
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails",
      "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [member]",
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r170",
      "r190"
     ]
    },
    "alvo_ClassesOfCommonStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassesOfCommonStockAxis",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of common stock [axis]",
        "label": "Classes of common stock [Axis]",
        "documentation": "Classes of common stock axis."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ClassesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ClassesOfCommonStockMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of Common Stock [member]",
        "label": "Classes of Common Stock [Member]",
        "documentation": "Classes Of Common Stock Member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [axis]",
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r235",
      "r237",
      "r238"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments, class [member]",
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r235",
      "r237",
      "r238"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [axis]",
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r265",
      "r266"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of current inventories [abstract]",
        "label": "Classes of current inventories [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital [member]",
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing rate",
        "label": "Closing foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_CommitmentsInRelationToJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommitmentsInRelationToJointVentures",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments in relation to joint ventures",
        "label": "Commitments in relation to joint ventures"
       }
      },
      "en": {
       "role": {
        "documentation": "The commitments that the entity has relating to its joint ventures as specified in paragraphs B18-B20 of IFRS 12. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "alvo_CommitmentsOfJointVenturePartnersInRelationToJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CommitmentsOfJointVenturePartnersInRelationToJointVentures",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments of joint venture partners in relation to joint ventures",
        "label": "Commitments Of Joint Venture Partners In Relation To Joint Ventures",
        "documentation": "Commitments of joint venture partners in relation to joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CommonStockHeldBySubsidiaries": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CommonStockHeldBySubsidiaries",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock held by subsidiary (in shares)",
        "label": "Common Stock Held By Subsidiaries",
        "documentation": "Common stock held by subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CommonStockSharesSubscribed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CommonStockSharesSubscribed",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares subscribed (in shares)",
        "label": "Common Stock, Shares Subscribed",
        "documentation": "Common stock, shares subscribed."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CommonStockSubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CommonStockSubscriptionPricePerShare",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, subscription (in dollars per share)",
        "label": "Common Stock, Subscription Price Per Share",
        "documentation": "Common stock, subscription price per share."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CommonStockValueSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CommonStockValueSubscriptions",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value, subscriptions",
        "label": "Common Stock, Value, Subscriptions",
        "documentation": "Common stock, value, subscriptions."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CompensationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CompensationStatusAxis",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Status [Axis]",
        "label": "Compensation Status [Axis]",
        "documentation": "Compensation Status"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CompensationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CompensationStatusDomain",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Status [Domain]",
        "label": "Compensation Status [Domain]",
        "documentation": "Compensation Status [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CompensationWaivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CompensationWaivedMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Waived",
        "label": "Compensation Waived [Member]",
        "documentation": "Compensation Waived"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ComponentOfBondsPayableAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ComponentOfBondsPayableAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component Of Bonds Payable [Axis]",
        "label": "Component Of Bonds Payable [Axis]",
        "documentation": "Component of bonds payable [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ComponentOfBondsPayableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ComponentOfBondsPayableDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component Of Bonds Payable [Domain]",
        "label": "Component Of Bonds Payable [Domain]",
        "documentation": "Component of bonds payable."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ComponentOfDebtConvertedIntoEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ComponentOfDebtConvertedIntoEquityAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component Of Debt Converted Into Equity [Axis]",
        "label": "Component Of Debt Converted Into Equity [Axis]",
        "documentation": "Component of debt converted into equity [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ComponentOfDebtConvertedIntoEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ComponentOfDebtConvertedIntoEquityDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component Of Debt Converted Into Equity [Domain]",
        "label": "Component Of Debt Converted Into Equity [Domain]",
        "documentation": "Component of debt converted into equity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Item that will be reclassified to profit or loss in subsequent periods:",
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total comprehensive loss",
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r36",
      "r143",
      "r145",
      "r156",
      "r296"
     ]
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer equipment",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "alvo_ConsentFeesToBondholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConsentFeesToBondholdersMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consent Fees To Bondholders",
        "label": "Consent Fees To Bondholders [member]",
        "documentation": "Consent fees to bondholders [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ConsentingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConsentingFee",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consenting fee (see Note 21)",
        "label": "Consenting Fee",
        "documentation": "Consenting fee."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent liabilities incurred in relation to interests in joint ventures",
        "label": "Contingent liabilities incurred in relation to interests in joint ventures"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities incurred in relation to interests in joint ventures. [Refer: Contingent liabilities [member]; Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "alvo_ContingentlyIssuablePennyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContingentlyIssuablePennyWarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingently Issuable Penny Warrants",
        "label": "Contingently Issuable Penny Warrants [member]",
        "documentation": "Contingently issuable penny warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ContractAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractAssetMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Assets",
        "label": "Contract Asset [Member]",
        "documentation": "Contract asset."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance asset",
        "periodEndLabel": "Ending balance asset",
        "label": "Contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity\u2019s future performance)."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r175"
     ]
    },
    "alvo_ContractAssetsAdditionsAmountsTransferredToTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractAssetsAdditionsAmountsTransferredToTradeReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts transferred to trade receivables",
        "label": "Contract Assets Additions Amounts Transferred to Trade Receivables",
        "documentation": "Contract assets additions amounts transferred to trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ContractAssetsLiabilitiesForeignCurrencyAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractAssetsLiabilitiesForeignCurrencyAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency adjustment",
        "label": "Contract Assets Liabilities Foreign Currency Adjustment",
        "documentation": "Contract assets liabilities foreign currency adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ContractAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractAssetsRollForward",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Assets",
        "label": "Contract Assets [Roll Forward]",
        "documentation": "Contract Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance liabilities",
        "periodEndLabel": "Ending balance liabilities",
        "label": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r175"
     ]
    },
    "alvo_ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amounts transferred to trade receivables",
        "label": "Contract Liabilities Additions Amounts Transferred to Trade Receivables",
        "documentation": "Contract Liabilities Additions Amounts Transferred to Trade Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ContractLiabilitiesAdditionsDerecognitionOfContractLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractLiabilitiesAdditionsDerecognitionOfContractLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Derecognition of contract liability",
        "label": "Contract Liabilities Additions Derecognition of contract liability",
        "documentation": "Contract Liabilities Additions Derecognition of contract liability"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ContractLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractLiabilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Liabilities",
        "label": "Contract Liabilities [Member]",
        "documentation": "Contract liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ContractLiabilitiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractLiabilitiesRollForward",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Liabilities",
        "label": "Contract Liabilities [Roll Forward]",
        "documentation": "Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ContractLiabilityCustomerPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractLiabilityCustomerPrepayments",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer prepayments",
        "label": "Customer prepayments",
        "documentation": "Contract liability C\\customer prepayments."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ContractualCapitalCommitmentContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractualCapitalCommitmentContingentLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment, contingent liability",
        "label": "Contractual Capital Commitment, Contingent Liability",
        "documentation": "Contractual Capital Commitment, Contingent Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractualCapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractualCapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual capital commitments",
        "label": "Contractual capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_ContractualCapitalCommitmentsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ContractualCapitalCommitmentsTerm",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "label": "Contractual Capital Commitments, Term",
        "documentation": "Contractual Capital Commitments, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContributionsToPlanNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContributionsToPlanNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "alvo_ConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConversionPrice",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price (in dollars per share)",
        "label": "Conversion Price",
        "documentation": "Conversion Price."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ConversionPriceOfBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConversionPriceOfBondsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Conversion Price Of Bonds [Member]",
        "documentation": "Conversion price of bonds."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ConvertibleBondAgreementTwoThousandAndEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConvertibleBondAgreementTwoThousandAndEighteenMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Bond Agreement Two Thousand And Eighteen",
        "label": "Convertible Bond Agreement Two Thousand And Eighteen [member]",
        "documentation": "Convertible bond agreement two thousand and eighteen."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ConvertibleBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConvertibleBondMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Bond",
        "label": "Convertible Bond [member]",
        "documentation": "Convertible bond [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ConvertibleLoanNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConvertibleLoanNotesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Convertible Bonds and Aztiq Convertible Bond",
        "label": "Convertible Loan Notes [Member]",
        "documentation": "Convertible Loan Notes"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ConvertibleOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConvertibleOrdinarySharesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Ordinary Shares",
        "label": "Convertible Ordinary Shares [member]",
        "documentation": "Convertible ordinary shares [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ConvertibleShareholderLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ConvertibleShareholderLoanMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Shareholder Loan",
        "label": "Convertible Shareholder Loan [member]",
        "documentation": "Convertible shareholder loan [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property rights",
        "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of inventories recognised as expense",
        "label": "Cost of inventories recognised as expense during period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of inventories recognised as an expense during the period. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "alvo_CostOfProductRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CostOfProductRevenueMember",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails",
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "label": "Cost Of Product Revenue [Member]",
        "documentation": "Cost of product revenue."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of product revenue",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r43"
     ]
    },
    "ifrs-full_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "label": "Cost of sales [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to goods or services sold. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency risk",
        "label": "Currency risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r250"
     ]
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Current accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "alvo_CurrentAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CurrentAccruedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued interest",
        "label": "Current Accrued Interest",
        "documentation": "Current accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CurrentAccruedSalaryAndSalaryRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CurrentAccruedSalaryAndSalaryRelatedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unpaid salary and salary related expenses",
        "label": "Current Accrued Salary And Salary Related Expenses",
        "documentation": "Current accrued salary and salary related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CurrentAccruedVacation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CurrentAccruedVacation",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued vacation leave",
        "label": "Current Accrued Vacation",
        "documentation": "Current accrued vacation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r152",
      "r296"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets less current liabilities",
        "label": "Current assets (liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets less the amount of current liabilities."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_CurrentContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract assets",
        "terseLabel": "Current contract assets",
        "label": "Current contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract assets. [Refer: Contract assets]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract liabilities",
        "terseLabel": "Current contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "alvo_CurrentEmployeeIncentivePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CurrentEmployeeIncentivePlan",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee incentive plan",
        "label": "Current Employee Incentive Plan",
        "documentation": "Current employee incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "negatedLabel": "Current liabilities",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r154",
      "r296"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPortionOfLongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPortionOfLongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current maturities of borrowings",
        "negatedLabel": "Less: current portion of borrowings",
        "label": "Current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_CurrentTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CurrentTaxAbstract",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax",
        "label": "Current Tax [Abstract]",
        "documentation": "Current Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Direct taxes - current",
        "label": "Current tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax",
        "label": "Current tax expense (income) and adjustments for current tax of prior periods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Current tax liabilities, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value-added tax",
        "label": "Current value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "alvo_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A",
        "label": "Customer A [Member]",
        "documentation": "Customer A."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer B",
        "label": "Customer B [Member]",
        "documentation": "Customer B."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CustomerCMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer C",
        "label": "Customer C [Member]",
        "documentation": "Customer C"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_CustomerDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "CustomerDMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer D",
        "label": "Customer D [Member]",
        "documentation": "Customer D"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CustomerrelatedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CustomerrelatedIntangibleAssetsMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer-related intangible assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing assets related to customers. Such assets may include customer lists, order or production backlog, customer contracts and related customer relationships as well as non-contractual customer relationships."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "alvo_DebtInstrumentIncreaseAccruedInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DebtInstrumentIncreaseAccruedInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Debt Instrument Increase Accrued Interests",
        "documentation": "Debt instrument increase accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DebtSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instruments issued",
        "label": "Debt instruments issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of instruments issued by the entity that represent indebtedness."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "alvo_DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in equity from share-based payment transactions, cash settlement, fair value",
        "label": "Decrease In Equity From Share-Based Payment Transactions, Cash Settlement, Fair Value",
        "documentation": "Decrease In Equity From Share-Based Payment Transactions, Cash Settlement, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DecreaseThroughDerecognitionRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DecreaseThroughDerecognitionRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Derecognition due to acquisition of Alvotech Facility (see Note 12)",
        "label": "Decrease Through Derecognition, Right Of Use Assets",
        "documentation": "Decrease Through Derecognition, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DeferredTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DeferredTaxAbstract",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax",
        "label": "Deferred Tax [Abstract]",
        "documentation": "Deferred Tax."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "verboseLabel": "Deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21",
      "r50"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails": {
       "parentTag": "alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current",
        "label": "Deferred tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "alvo_DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax",
        "label": "Deferred Tax Expense Income and Adjustments For Deferred Tax Of Prior Periods",
        "documentation": "Deferred tax expense income and adjustments for deferred tax of prior periods."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax credited to profit or loss",
        "label": "Deferred tax expense (income) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21",
      "r50"
     ]
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Deferred tax liability (asset)",
        "negatedPeriodEndLabel": "Deferred tax liability (asset)",
        "negatedTotalLabel": "Net deferred tax assets",
        "label": "Deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "alvo_DeferredTaxLiabilityAssetRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DeferredTaxLiabilityAssetRollForward",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability (asset) [Roll Forward]",
        "label": "Deferred tax liability (asset) [Roll Forward]",
        "documentation": "Deferred tax liability (asset)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails",
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss",
        "terseLabel": "Total depreciation, amortization and impairment expense",
        "label": "Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense, amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss. [Refer: Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_DepreciationAndImpairmentOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DepreciationAndImpairmentOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails": {
       "parentTag": "ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and impairment of property, plant and equipment (see Note 12)",
        "label": "Depreciation And Impairment Of Property Plant And Equipment",
        "documentation": "Depreciation And Impairment Of Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r63"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "calculation": {
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails": {
       "parentTag": "ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails": {
       "parentTag": "alvo_LeaseCostRecognizedInProfitAndLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentDetails",
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails",
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation of right of use assets (see Note 13)",
        "negatedTerseLabel": "Depreciation",
        "negatedLabel": "Depreciation of right of use assets (see Note 13)",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "alvo_DerecognitionDueToAssetsAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DerecognitionDueToAssetsAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Derecognition due to acquisition of Alvotech Facility (see Note 12)",
        "label": "Derecognition Due To Assets Acquisition",
        "documentation": "Derecognition due to assets acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DerecognitionIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DerecognitionIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognition of intangible asset",
        "label": "Derecognition, Intangible Assets Other Than Goodwill",
        "documentation": "Derecognition, Intangible Assets Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DerecognitionPrepaidDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DerecognitionPrepaidDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognition, prepaid development costs",
        "label": "Derecognition, Prepaid Development Costs",
        "documentation": "Derecognition, Prepaid Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DerivaiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DerivaiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset",
        "label": "Derivaive Assets",
        "documentation": "Derivaive assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "alvo_DerivativeFinancialLiabilitiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DerivativeFinancialLiabilitiesRollForward",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Liabilities [Roll Forward]",
        "label": "Derivative Financial Liabilities [Roll Forward]",
        "documentation": "Derivative Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails": {
       "parentTag": "alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_DerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativesMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities",
        "label": "Derivatives [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r297",
      "r301",
      "r313",
      "r321"
     ]
    },
    "alvo_DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "label": "Description of accounting policy for cost of product revenue explanatory [Policy Text Block]",
        "documentation": "Description of accounting policy for cost of product revenue explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Critical accounting judgments and key sources of estimation uncertainty",
        "label": "Description of accounting policy for critical accounting judgments and key sources of estimation uncertainty explanatory [Policy Text Block]",
        "documentation": "Description of accounting policy for critical accounting judgments and key sources of estimation uncertainty explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income and finance cost",
        "label": "Description of accounting policy for finance income and costs [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets",
        "label": "Description of accounting policy for financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Description of accounting policy for financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and other intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentsInJointVentures",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in joint ventures",
        "label": "Description of accounting policy for investments in joint ventures [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investments in joint ventures. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "alvo_DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation and other contingencies",
        "label": "Description of accounting policy for litigation and other contingencies explanatory [Policy Text Block]",
        "documentation": "Description of accounting policy for litigation and other contingencies explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for measuring inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reporting",
        "label": "Description of accounting policy for segment reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate applied to cash flow projections",
        "label": "Discount rate applied to cash flow projections"
       }
      },
      "en": {
       "role": {
        "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r110"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting standards",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Growth rate used to extrapolate cash flow projections",
        "label": "Growth rate used to extrapolate cash flow projections"
       }
      },
      "en": {
       "role": {
        "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109"
     ]
    },
    "alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossLineItems",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Line Items]",
        "label": "Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Line Items]",
        "documentation": "Detailed information about depreciation amortization and impairment expense included in consolidated statements profit or loss and other comprehensive income or loss."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossTable",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Table]",
        "label": "Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss [Table]",
        "documentation": "Detailed information about depreciation amortization and impairment expense included in consolidated statements profit or loss and other comprehensive income or loss."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DetailsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DetailsAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Details [Axis]",
        "label": "Details [Axis]",
        "documentation": "Details [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DetailsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DetailsDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Details [Domain]",
        "label": "Details [Domain]",
        "documentation": "Details [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DetailsOfFinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DetailsOfFinanceIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Details Of Finance Income [Abstract]",
        "label": "Details Of Finance Income [Abstract]",
        "documentation": "Details of finance income."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DevelopmentAndOtherServiceRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DevelopmentAndOtherServiceRevenueMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and other service revenue (over time revenue recognition)",
        "label": "Development and Other Service Revenue [Member]",
        "documentation": "Research and development and other service revenue."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted loss per share (in dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "alvo_DirectorFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DirectorFees",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board fees",
        "label": "Director Fees",
        "documentation": "Director Fees"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInEntiretyOfSupplementalCashFlowInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Entirety Of Supplemental Cash Flow Information [Abstract]",
        "label": "Disclosure In Entirety Of Supplemental Cash Flow Information [Abstract]",
        "documentation": "Disclosure in entirety of supplemental cash flow information."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information",
        "label": "Disclosure In Entirety Of Supplemental Cash Flow Information Explanatory [Text Block]",
        "documentation": "Disclosure in entirety of supplemental cash flow information [Text block]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInEntiretyOfSupplementalCashFlowInformationLineItems",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Entirety of Supplemental Cash Flow Information [Line Items]",
        "label": "Disclosure In Entirety of Supplemental Cash Flow Information [Line Items]",
        "documentation": "Disclosure In Entirety of Supplemental Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInEntiretyOfSupplementalCashFlowInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInEntiretyOfSupplementalCashFlowInformationTable",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure in Entirety of Supplemental Cash Flow Information [Table]",
        "label": "Disclosure in Entirety of Supplemental Cash Flow Information [Table]",
        "documentation": "Disclosure in Entirety of Supplemental Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Groups Assets and Liabilities",
        "label": "Disclosure In Tabular Form Of Assets And Liabilities Denominated In Foreign Currencies Explanatory [Table Text Block]",
        "documentation": "Disclosure in tabular form of assets and liabilities denominated in foreign currencies explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure in tabular form of assets and liabilities denominated in foreign currencies [line items]",
        "label": "Disclosure In Tabular Form Of Assets And Liabilities Denominated In Foreign Currencies [Line Items]",
        "documentation": "Disclosure in tabular form of assets and liabilities denominated in foreign currencies."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Tabular Form Of Assets And Liabilities Denominated In Foreign Currencies [Table]",
        "label": "Disclosure In Tabular Form Of Assets And Liabilities Denominated In Foreign Currencies [Table]",
        "documentation": "Disclosure in tabular form of assets and liabilities denominated in foreign currencies."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Material Differences Between the Fair Value and Carrying Amount",
        "label": "Disclosure In Tabular Form Of Carrying Amount And Financial Amount Of Certain Borrowings Explanatory [Table Text Block]",
        "documentation": "Disclosure in tabular form of carrying amount and financial amount of certain borrowings explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure in tabular form of carrying amount and financial amount of certain borrowings [line items]",
        "label": "Disclosure In Tabular Form Of Carrying Amount And Financial Amount Of Certain Borrowings [Line Items]",
        "documentation": "Disclosure in tabular form of carrying amount and financial amount of certain borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Tabular Form Of Carrying Amount And Financial Amount Of Certain Borrowings [Table]",
        "label": "Disclosure In Tabular Form Of Carrying Amount And Financial Amount Of Certain Borrowings [Table]",
        "documentation": "Disclosure in tabular form of carrying amount and financial amount of certain borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Analysis Assumes that all Other Variables",
        "label": "Disclosure in Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax Explanatory [Table Text Block]",
        "documentation": "Disclosure in tabular form of currency risk sensitivity analysis on profit before tax explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]",
        "label": "Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Line Items]",
        "documentation": "Disclosure in tabular form of currency risk sensitivity analysis on profit before tax."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Table]",
        "label": "Disclosure In Tabular Form Of Currency Risk Sensitivity Analysis On Profit Before Tax [Table]",
        "documentation": "Disclosure in tabular form of currency risk sensitivity analysis on profit before tax."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value on a Recurring Basis",
        "label": "Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments Explanatory [Table Text Block]",
        "documentation": "Disclosure in tabular form of fair value of derivative financial instruments explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]",
        "label": "Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Line Items]",
        "documentation": "Disclosure in tabular form of fair value of derivative financial instruments."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Table]",
        "label": "Disclosure In Tabular Form Of Fair Value Of Derivative Financial Instruments [Table]",
        "documentation": "Disclosure in tabular form of fair value of derivative financial instruments."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Impact on the Groups Operations",
        "label": "Disclosure In Tabular Form Of Foreign Exchange Rate Explanatory [Table Text Block]",
        "documentation": "Disclosure in tabular form of foreign exchange rate explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfForeignExchangeRateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfForeignExchangeRateLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure in tabular form of foreign exchange rate [line items]",
        "label": "Disclosure In Tabular Form Of Foreign Exchange Rate [Line Items]",
        "documentation": "Disclosure in tabular form of foreign exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfForeignExchangeRateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfForeignExchangeRateTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Tabular Form Of Foreign Exchange Rate [Table]",
        "label": "Disclosure In Tabular Form Of Foreign Exchange Rate [Table]",
        "documentation": "Disclosure in tabular form of foreign exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Interest Rate Sensitivity Analysis",
        "label": "Disclosure In Tabular Form Of Interest Rate Sensitivity Analysis Impact On Profit Before Tax Explanatory [Table Text Block]",
        "documentation": "Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax [line items]",
        "label": "Disclosure In Tabular Form Of Interest Rate Sensitivity Analysis Impact On Profit Before Tax [Line Items]",
        "documentation": "Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure In Tabular Form Of Interest Rate Sensitivity Analysis Impact On Profit Before Tax [Table]",
        "label": "Disclosure In Tabular Form Of Interest Rate Sensitivity Analysis Impact On Profit Before Tax [Table]",
        "documentation": "Disclosure in tabular form of interest rate sensitivity analysis impact on profit before tax."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Cash Flow Information",
        "label": "Disclosure In Tabular Form Of Supplemental Cash Flow Information Explanatory [Table Text Block]",
        "documentation": "Disclosure in tabular form of supplemental cash flow information [Text block]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfAuditFeesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfAuditFeesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Audit Fees [Abstract]",
        "label": "Disclosure Of Audit Fees [Abstract]",
        "documentation": "Disclosure of audit fees."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfAuditFeesExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfAuditFeesExplanatoryTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/AuditFees"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit fees",
        "label": "Disclosure Of Audit Fees Explanatory [Text Block]",
        "documentation": "Disclosure of audit fees explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of consolidation",
        "label": "Disclosure of basis of consolidation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBorrowingsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/Borrowings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Disclosure of borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash And Cash Equivalents",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "alvo_DisclosureOfCashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfCashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Cash and Cash Equivalents [Line Items]",
        "label": "Disclosure of Cash and Cash Equivalents [Line Items]",
        "documentation": "Disclosure of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Cash and Cash Equivalents [Table]",
        "label": "Disclosure of Cash and Cash Equivalents [Table]",
        "documentation": "Disclosure of cash and cash Equivalents,"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [abstract]",
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share Capital and Share Premium",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [line items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Contractual Maturities of Financial Assets and Liabilities",
        "label": "Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure of contractual maturities of financial assets and financial liabilities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]",
        "label": "Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Line Items]",
        "documentation": "Disclosure of contractual maturities of financial assets and financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Table]",
        "label": "Disclosure Of Contractual Maturities Of Financial Assets And Financial Liabilities [Table]",
        "documentation": "Disclosure of contractual maturities of financial assets and financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCreditRiskExposureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCreditRiskExposureExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of the Maximum Credit Risk Exposure of the Groups Financial Assets",
        "label": "Disclosure of credit risk exposure [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the credit risk exposure. Credit risk exposure is the credit risk inherent in an entity\u2019s financial assets and commitments to extend credit."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "alvo_DisclosureOfCreditRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfCreditRiskLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Credit Risk [Line Items]",
        "label": "Disclosure Of Credit Risk [Line Items]",
        "documentation": "Disclosure of credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfCreditRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfCreditRiskTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Credit Risk [Table]",
        "label": "Disclosure Of Credit Risk [Table]",
        "documentation": "Disclosure of credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDepreciationAmortizationAndImapirmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDepreciationAmortizationAndImapirmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Depreciation Amortization And Imapirment [Abstract]",
        "label": "Disclosure Of Depreciation Amortization And Imapirment [Abstract]",
        "documentation": "Disclosure of depreciation amortization and imapirment."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation, amortization and impairment",
        "label": "Disclosure Of Depreciation Amortization And Impairment Explanatory [Text Block]",
        "documentation": "Disclosure of depreciation amortization and imapirment explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Aggregate Salary And Other Employee Expenses Incurred By The Group",
        "label": "Disclosure Of Detailed Information About Aggregate Salary And Other Employee Expenses [Table Text Block]",
        "documentation": "Disclosure of detailed information about aggregate salary and other employee expenses"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/AuditFeesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Audit Fees",
        "label": "Disclosure Of Detailed Information About Audit Fees Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about audit fees explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of information about Board of Directors remuneration",
        "label": "Disclosure Of Detailed Information About Board Of Directors And Key Managerial Personnel Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about board of directors and key managerial personnel explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of consolidated statements of financial position",
        "label": "Disclosure of detailed information about borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [line items]",
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [table]",
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "alvo_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash and Cash Equivalents",
        "label": "Disclosure of Detailed Information About Cash and Cash Equivalents Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about cash and cash equivalents explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Groups Investment in a Joint Venture",
        "label": "Disclosure Of Detailed Information About Changes In Investment In Joint Venture Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about changes in investment in joint venture explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of detailed information about classes of right of use assets",
        "label": "Disclosure Of Detailed Information About Classes Of Right Of Use Assets Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about classes of right of use assets explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Line Items]",
        "label": "Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Line Items]",
        "documentation": "Disclosure of detailed information about classes of right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsTable",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Table]",
        "label": "Disclosure Of Detailed Information About Classes Of Right Of Use Assets [Table]",
        "documentation": "Disclosure of detailed information about classes of right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of deferred tax recognized in the consolidated statements of financial position",
        "label": "Disclosure of Detailed Information About Deferred Tax Recognized in the Consolidated Statements of Financial Position Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about deferred tax recognized in the consolidated statements of financial position explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss",
        "label": "Disclosure Of Detailed Information About Depreciation Amortization And Impairment Expense Included In Consolidated Statements Profit Or Loss And Other Comprehensive Income Or Loss Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about depreciation amortization and impairment expense included in consolidated statements profit or loss and other comprehensive income or loss explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Depreciation Amortization And Impairment",
        "label": "Disclosure Of Detailed Information About Depreciation Amortization And Impairment Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about depreciation amortization and impairment explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the reconciling items between the statutory rate and the effective tax rate",
        "label": "Disclosure Of Detailed Information About Effective Tax Rate Reconciliation Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about effective tax rate reconciliation explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of expiration of unused tax losses",
        "label": "Disclosure Of Detailed Information About Expiration Of Unused Tax Losses Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about expiration of unused tax losses explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Detailed Information About Intangible Assets",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "alvo_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Inventories",
        "label": "Disclosure of Detailed Information About Inventories Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about inventories explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information About Joint Venture",
        "label": "Disclosure Of Detailed Information About Joint Venture Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about joint venture explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of detailed information about lease cost",
        "label": "Disclosure of Detailed Information About Lease Cost Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about lease cost explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutLeaseCostLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutLeaseCostLineItems",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Lease Cost [Line Items]",
        "label": "Disclosure Of Detailed Information About Lease Cost [Line Items]",
        "documentation": "Disclosure of detailed information about lease cost."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutLeaseCostTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutLeaseCostTable",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Lease Cost [Table]",
        "label": "Disclosure Of Detailed Information About Lease Cost [Table]",
        "documentation": "Disclosure of detailed information about lease cost ."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of detailed information about lease liabilities",
        "label": "Disclosure Of Detailed Information About Lease Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about lease liabilities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of taxation recognized in the consolidated statements of profit or loss and other comprehensive income or loss",
        "label": "Disclosure of Detailed Information About Major Components Of Income Tax Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about major components of income tax explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of detailed information about maturity analysis for lease liabilities",
        "label": "Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about maturity analysis for lease liabilities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesLineItems",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities [Line Items]",
        "label": "Disclosure Of Detailed Information About Maturity Analysis For Lease Liabilities [Line Items]",
        "documentation": "Disclosure of detailed information about maturity analysis for lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesTable",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Maturity Analysis For Lease liabilities [Table]",
        "label": "Disclosure Of Detailed Information About Maturity Analysis For Lease liabilities [Table]",
        "documentation": "Disclosure of detailed information about maturity analysis for lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Ordinary Shares, Share Capital and Share Premium",
        "label": "Disclosure of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about movements in ordinary shares, share capital and share premium explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets",
        "label": "Disclosure Of Detailed Information About Noncurrent Assets Excluding Financial Instruments And Deferred Tax Assets Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about noncurrent assets excluding financial instruments and deferred tax assets explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Current Assets",
        "label": "Disclosure of Detailed Information About Other Current Assets Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about other current assets explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of composition of other current liabilities",
        "label": "Disclosure Of Detailed Information About Other Current Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about other current liabilities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of property, plant and equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "alvo_DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the movement in net deferred taxes",
        "label": "Disclosure Of Detailed Information About Reconciliation Of Changes In Deferred Tax Liability Asset Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about reconciliation of changes in deferred tax liability asset explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Cash",
        "label": "Disclosure of Detailed Information about Restricted Cash and Cash Equivalents Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about restricted cash and cash equivalents explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossLineItems",
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Line Items]",
        "label": "Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Line Items]",
        "documentation": "Disclosure of detailed information about salaries and other emloyee expenses included in consolidated statements of profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutSalariesAndOtherEmloyeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossTable",
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Table]",
        "label": "Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss [Table]",
        "documentation": "Disclosure of detailed information about salaries and other emloyee expenses included in consolidated statements of profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss",
        "label": "Disclosure Of Detailed Information About Salaries And Other Employee Expenses Included In Consolidated Statements Of Profit Or Loss Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about salaries and other employee expenses included in consolidated statements of profit or loss explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of The Groups' Revenue From Contracts With Customers",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails",
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails",
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails",
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails",
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reporting",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "alvo_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Useful Lives of Depreciation",
        "label": "Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory [Table Text Block]",
        "documentation": "Disclosure of estimated useful lives of property plant and equipment explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Useful Lives of Amortization",
        "label": "Disclosure Of Estimated Useful Lives Other Intangible Assets Explanatory [Table Text Block]",
        "documentation": "Disclosure of estimated useful lives other intangible assets explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent events",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Fair Value Measurement of Liabilities",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_DisclosureOfFinanceCostExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceCostExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Finance Cost",
        "label": "Disclosure of finance cost [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance cost. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "alvo_DisclosureOfFinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfFinanceIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Finance Income [Abstract]",
        "label": "Disclosure Of Finance Income [Abstract]",
        "documentation": "Disclosure of finance income."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income and finance costs",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Finance Income",
        "label": "Disclosure of finance income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Assets Measured at Cost",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [abstract]",
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r235",
      "r243"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Liabilities",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFirstTimeAdoptionExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/NewAccountingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting standards",
        "label": "Disclosure of first-time adoption [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for the entity's first-time adoption of International Financial Reporting Standards."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "Disclosure of general and administrative expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/Generalinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General information",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails",
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [line items]",
        "label": "Disclosure of geographical areas [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails",
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [table]",
        "label": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "ifrs-full_DisclosureOfGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGoodwillExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Disclosure of goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "alvo_DisclosureOfGoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfGoodwillLineItems",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Goodwill [Line Items]",
        "label": "Disclosure of Goodwill [Line Items]",
        "documentation": "Disclosure of goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfGoodwillTable",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Goodwill [Table]",
        "label": "Disclosure of Goodwill [Table]",
        "documentation": "Disclosure of goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Impairment Loss and Reversal of Impairment Loss",
        "label": "Disclosure of impairment loss and reversal of impairment loss [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of impairment loss and the reversal of impairment loss. [Refer: Impairment loss; Reversal of impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of impairment loss and reversal of impairment loss [table]",
        "label": "Disclosure of impairment loss and reversal of impairment loss [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to impairment loss and the reversal of impairment loss."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "alvo_DisclosureOfIncomeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfIncomeTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Income Tax [Abstract]",
        "label": "Disclosure Of Income Tax [Abstract]",
        "documentation": "Disclosure of income tax."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "alvo_DisclosureOfIncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfIncomeTaxLineItems",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of income tax [Line Items]",
        "label": "Disclosure of income tax [Line Items]",
        "documentation": "Disclosure of income tax ."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfIncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfIncomeTaxTable",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of income tax [Table]",
        "label": "Disclosure of income tax [Table]",
        "documentation": "Disclosure of income tax."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [abstract]",
        "label": "Disclosure of detailed information about intangible assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Intangible assets",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "alvo_DisclosureOfInventoriesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfInventoriesLineItems",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Inventories [Line Items]",
        "label": "Disclosure of Inventories [Line Items]",
        "documentation": "Disclosure of inventories."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfInventoriesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfInventoriesTable",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Inventories [Table]",
        "label": "Disclosure of Inventories [Table]",
        "documentation": "Disclosure of inventories."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIssuedCapitalExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Disclosure of issued capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of joint ventures [abstract]",
        "label": "Disclosure of joint ventures [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfJointVenturesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfJointVenturesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVentures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interests in joint ventures",
        "label": "Disclosure of joint ventures [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of joint ventures. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfJointVenturesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfJointVenturesLineItems",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of joint ventures [line items]",
        "label": "Disclosure of joint ventures [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfJointVenturesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfJointVenturesTable",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of joint ventures [table]",
        "label": "Disclosure of joint ventures [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to joint ventures."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195"
     ]
    },
    "alvo_DisclosureOfLitigationSettlementsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfLitigationSettlementsExplanatoryTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation",
        "label": "Disclosure Of Litigation Settlements Explanatory [Text Block]",
        "documentation": "Disclosure of litigation settlements explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfLongTermIncentivePlansExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfLongTermIncentivePlansExplanatoryTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term incentive plans",
        "label": "Disclosure Of Long Term Incentive Plans Explanatory [Text Block]",
        "documentation": "Disclosure of long-term incentive plans."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfLongtermIncentivePlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfLongtermIncentivePlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Longterm incentive plans [Abstract]",
        "label": "Disclosure Of Longterm incentive plans [Abstract]",
        "documentation": "Longterm incentive plans."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMajorCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMajorCustomersLineItems",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of major customers [line items]",
        "label": "Disclosure of major customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMajorCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMajorCustomersTable",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of major customers [table]",
        "label": "Disclosure of major customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the entity's major customers."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of movements in the group's employee incentive plan liabilities",
        "label": "Disclosure of net defined benefit liability (asset) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [line items]",
        "label": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [table]",
        "label": "Disclosure of net defined benefit liability (asset) [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "alvo_DisclosureOfNewAccountingStandardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfNewAccountingStandardsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of New Accounting Standards [Abstract]",
        "label": "Disclosure Of New Accounting Standards [Abstract]",
        "documentation": "Disclosure of new accounting standards."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [abstract]",
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in RSUs",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [abstract]",
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Disclosure of other current assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Disclosure of other current liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherLiabilitiesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/Otherreserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other reserves",
        "label": "Disclosure of other liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Property Plant And Equipment [Abstract]",
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of quantitative information about right-of-use assets",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]",
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]",
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Goodwill",
        "label": "Disclosure of reconciliation of changes in goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in intangible assets and goodwill [line items]",
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]",
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "alvo_DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Disclosure of Revenue and other operating income Explanatory [Text Block]",
        "documentation": "Disclosure of revenue and other operating income explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Revenue From Customers Based On Geographical Market",
        "label": "Disclosure of revenue from contracts with customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182"
     ]
    },
    "alvo_DisclosureOfSalariesAndOtherEmployeeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfSalariesAndOtherEmployeeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Salaries And Other Employee Expenses [Abstract]",
        "label": "Disclosure Of Salaries And Other Employee Expenses [Abstract]",
        "documentation": "Disclosure of salaries and other employee expenses."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries and other employee expenses",
        "label": "Disclosure Of Salaries And Other Employee Expenses Explanatory [Text Block]",
        "documentation": "Disclosure of salaries and other employee expenses explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSegmentsMajorCustomersExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Detailed Information About Revenue From Transactions With Individual Customers",
        "label": "Disclosure of major customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of major customers."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "alvo_DisclosureOfShareBasedPaymentArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfShareBasedPaymentArrangementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Share Based Payment Arrangements [Abstract]",
        "label": "Disclosure Of Share Based Payment Arrangements [Abstract]",
        "documentation": "Disclosure of share based payment arrangements abstract."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of subsidiaries and joint ventures",
        "label": "Disclosure of subsidiaries [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of subsidiaries [line items]",
        "label": "Disclosure of subsidiaries [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of subsidiaries [table]",
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assumptions and Inputs",
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]",
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]",
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to significant unobservable inputs used in the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Summary Of Significant Accounting Policies [Abstract]",
        "label": "Disclosure Of Summary Of Significant Accounting Policies [Abstract]",
        "documentation": "Disclosure of summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of summary of significant accounting policies [Table]",
        "label": "Disclosure of summary of significant accounting policies [Table]",
        "documentation": "Disclosure of summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of related party transactions",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [line items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "alvo_DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of movements in the group's outstanding borrowings",
        "label": "Disclosureof Movements In Outstanding Borrowings Explanatory [Table Text Block]",
        "documentation": "Disclosure\u00a0of movements in outstanding borrowings explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumLineItems",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclousre of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium [Line Items]",
        "label": "Disclousre of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium [Line Items]",
        "documentation": "Disclousre of detailed information about movements in ordinary shares, share capital and share premium."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclousreOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumTable",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclousre of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium [Table]",
        "label": "Disclousre of Detailed Information About Movements in Ordinary Shares, Share Capital and Share Premium [Table]",
        "documentation": "Disclousre of detailed information about movements in ordinary shares, share capital and share premium."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_DisclousreOfGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DisclousreOfGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Goodwill [Abstract]",
        "label": "Disclosure of Goodwill [Abstract]",
        "documentation": "Disclousre of goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Retirement",
        "label": "Disposals and retirements, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals",
        "label": "Disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "alvo_DividendYieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "DividendYieldMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Dividend Yield [Member]",
        "documentation": "Dividend yield."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends",
        "label": "Dividends recognised as distributions to owners"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividends received from joint ventures",
        "label": "Dividends received from joint ventures, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow representing dividends received from joint ventures, classified as investing activities. [Refer: Joint ventures [member]; Dividends received]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r332"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "EUR",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EUR",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Basic and Diluted Loss Per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareLineItems",
     "presentation": [
      "http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share [line items]",
        "label": "Earnings per share [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareTable",
     "presentation": [
      "http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share [table]",
        "label": "Earnings per share [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "alvo_EarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "EarnoutSharesMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OACB Earn Out Shares",
        "label": "Earnout Shares [Member]",
        "documentation": "Earnout shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_EarnoutWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "EarnoutWarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OACB Warrants",
        "label": "Earnout Warrants [Member]",
        "documentation": "Earnout warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of movements in exchange rates on cash held",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130"
     ]
    },
    "alvo_EliminationOfPredecessorOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "EliminationOfPredecessorOrdinaryShares",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elimination of Predecessor Ordinary Shares (in shares)",
        "label": "Elimination of Predecessor Ordinary Shares",
        "documentation": "Elimination of predecessor ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_EliminationOfPredecessorOrdinaryValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "EliminationOfPredecessorOrdinaryValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elimination of Predecessor Ordinary Shares",
        "label": "Elimination of Predecessor Ordinary Value",
        "documentation": "Elimination of predecessor ordinary value"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Embedded derivative liabilities associated with convertible bonds",
        "label": "Embedded Derivative Liabilities Associated With Convertible Bonds [Member]",
        "documentation": "Embedded derivative liabilities associated with convertible bonds."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails",
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee benefits expense",
        "terseLabel": "Total salary and other employee expenses",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r43",
      "r268"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for business combinations [member]",
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r222"
     ]
    },
    "ifrs-full_EntitysTotalForJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForJointVenturesMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails",
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for joint ventures [member]",
        "label": "Entity's total for joint ventures [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint ventures' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r161"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails",
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for related parties [member]",
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for subsidiaries [member]",
        "label": "Entity's total for subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r160"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r27",
      "r142",
      "r144",
      "r162",
      "r163",
      "r168"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [member]",
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails",
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_EventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "EventAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Event [Axis]",
        "label": "Event [Axis]",
        "documentation": "Event [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_EventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "EventDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Event [Domain]",
        "label": "Event [Domain]",
        "documentation": "Event."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ExcerciseOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExcerciseOfWarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Of Warrants",
        "label": "Excercise Of Warrants [Member]",
        "documentation": "Excercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ExchangeOfClassAOacbOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExchangeOfClassAOacbOrdinarySharesMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Class A OACB Ordinary Shares",
        "label": "Exchange of Class A OACB Ordinary Shares [Member]",
        "documentation": "Exchange of class A OACB ordinary dhares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ExchangeOfPredecessorOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExchangeOfPredecessorOrdinarySharesMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Predecessor Ordinary Shares",
        "label": "Exchange of Predecessor Ordinary Shares [Member]",
        "documentation": "Exchange of predecessor ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ExistingEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExistingEmployeesMember",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Existing Employees",
        "label": "Existing Employees [Member]",
        "documentation": "Existing employees member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ExpenseCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExpenseCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense capitalized",
        "label": "Expense Capitalized",
        "documentation": "Expense capitalized."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense from share-based payment transactions",
        "label": "Expense from share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments (see Note 23)",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used",
        "documentation": "Expense relating to short-term leases and low value leases for which recognition exemption has been used."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share-based payment expense",
        "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "presentation": [
      "http://www.alvotech.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Reconciliation Of Contract Assets And Contract Liabilities",
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "alvo_ExtensionPremiumToBondHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExtensionPremiumToBondHolders",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension premium to bond holders",
        "label": "Extension Premium To Bond Holders",
        "documentation": "Extension premium to bond holders."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ExtinguishmentOfBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExtinguishmentOfBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of borrowings",
        "label": "Extinguishment Of Borrowings",
        "documentation": "Extinguishment of borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ExtinguishmentOfBorrowingsAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ExtinguishmentOfBorrowingsAccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of borrowings accrued interest",
        "label": "Extinguishment Of Borrowings Accrued Interest",
        "documentation": "Extinguishment of borrowings accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FacilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails",
      "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities",
        "label": "Facilities [Member]",
        "documentation": "Facilities member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FacilityEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FacilityEquipmentMember",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Facility equipment",
        "terseLabel": "Facility Equipment",
        "label": "Facility Equipment [Member]",
        "documentation": "Facility Equipment."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FacilityLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FacilityLoansMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Loans",
        "label": "Facility Loans [member]",
        "documentation": "Facility Loans [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FacilityMember",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Facility",
        "terseLabel": "Facility",
        "label": "Facility [Member]",
        "documentation": "Facility."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FairValueOfSharesIssuedMarketPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FairValueOfSharesIssuedMarketPricePerShare",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares issued, market price (in dollars per share)",
        "label": "Fair Value Of Shares Issued, Market Price Per Share",
        "documentation": "Fair value of shares issued, market price per share."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Alvotech Shares issued to OACB shareholders (in shares)",
        "label": "Fair Value of Shares Issued Recognized Accordance With IFRS 2",
        "documentation": "Fair value of shares issued recognized accordance with IFRS 2."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair market value",
        "label": "Fair Value of Shares Issued Recognized amount in Accordance With IFRS 2",
        "documentation": "Fair value of shares issued recognized accordance with IFRS 2."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FasteignafelagiEyjolfurEhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FasteignafelagiEyjolfurEhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fasteignaf\u00e9lagi\u00f0 Eyj\u00f3lfur ehf - Sister company",
        "label": "Fasteignaf\u00e9lagi\u00f0 Eyj\u00f3lfur ehf [Member]",
        "documentation": "Fasteignaf\u00e9lagi\u00f0 Eyj\u00f3lfur ehf"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FasteignafelagiSmundurHf.SisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FasteignafelagiSmundurHf.SisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails",
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fasteignaf\u00e9lagi\u00f0 S\u00e6mundur hf. - Sister company",
        "label": "Fasteignaf\u00e9lagi\u00f0 S\u00e6mundur hf. - Sister company [Member]",
        "documentation": "Fasteignaf\u00e9lagi\u00f0 S\u00e6mundur hf. member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FasteignafelagiSmundurHfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FasteignafelagiSmundurHfMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fasteignafelagi\u00f0 S\u00e6mundur hf",
        "label": "Fasteignafelagi Smundur hf [Member]",
        "documentation": "Fasteignafelagi\u00f0 S\u00e6mundur hf."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FasteignafelagidEyjolfurHf.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FasteignafelagidEyjolfurHf.Member",
     "presentation": [
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fasteignafelagid Eyjolfur hf.",
        "label": "Fasteignafelagid Eyjolfur hf. [Member]",
        "documentation": "Fasteignafelagid Eyjolfur hf."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FasteignaflagiEyjlfurhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FasteignaflagiEyjlfurhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fasteignaf\u00e9lagi\u00f0 Eyj\u00f3lfur ehf - Sister company",
        "label": "Fasteignaflagi Eyjlfurhf [Member]",
        "documentation": "Fasteignaflagi Eyjlfurhf member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FaysalKalmouaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FaysalKalmouaMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Faysal Kalmoua, Board",
        "label": "Faysal Kalmoua [Member]",
        "documentation": "Faysal Kalmoua."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consent fees to bond holders",
        "label": "Fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "alvo_FinalMaturityInDecember2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FinalMaturityInDecember2027Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final Maturity in December 2027",
        "label": "Final Maturity in December 2027 [Member]",
        "documentation": "Final Maturity in December 2027"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FinalMaturityInDecember2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FinalMaturityInDecember2029Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final Maturity in December 2029",
        "label": "Final Maturity in December 2029 [Member]",
        "documentation": "Final Maturity in December 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance costs",
        "totalLabel": "Finance costs",
        "terseLabel": "Finance costs",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income",
        "totalLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "alvo_FinanceIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FinanceIncomeMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income",
        "label": "Finance Income [Member]",
        "documentation": "Finance income [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r227",
      "r232",
      "r233",
      "r237",
      "r312"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial assets",
        "label": "Financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsHeldForManagingLiquidityRisk",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets held for managing liquidity risk (for example, financial assets that are readily saleable or expected to generate cash inflows to meet cash outflows on financial liabilities). [Refer: Liquidity risk [member]; Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets pledged as collateral for liabilities or contingent liabilities",
        "label": "Financial assets pledged as collateral for liabilities or contingent liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_FinancialAssetsTypeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsTypeMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, type [member]",
        "label": "Financial assets, type [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated types of financial assets. It also represents the standard value for the 'Types of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249"
     ]
    },
    "alvo_FinancialAssetsUndiscountedNonInterestBearingLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FinancialAssetsUndiscountedNonInterestBearingLoansReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "auth_ref": []
    },
    "alvo_FinancialAssetsUndiscountedVariableInterestBearingLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FinancialAssetsUndiscountedVariableInterestBearingLoansReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails": {
       "parentTag": "ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at amortised cost, category",
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "alvo_FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial liabilities",
        "label": "Financial Liabilities At Amortized Cost And Financial Liabilities At Fair Value Through Profit Or Loss",
        "documentation": "Financial liabilities at amortized cost and financial liabilities at fair value through profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, at fair value",
        "periodStartLabel": "Beginning balances",
        "periodEndLabel": "Ending balances",
        "label": "Financial liabilities, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesCategoryMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, category [member]",
        "label": "Financial liabilities, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, class [member]",
        "label": "Financial liabilities, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r265",
      "r266"
     ]
    },
    "ifrs-full_FinancialLiabilitiesReclassifiedIntoEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesReclassifiedIntoEquity",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Conversion to Equity",
        "label": "Financial liabilities reclassified into equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities reclassified into equity. [Refer: Equity; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_FinancialLiabilitiesTypeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesTypeMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, type [member]",
        "label": "Financial liabilities, type [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated types of financial liabilities. It also represents the standard value for the 'Types of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r359"
     ]
    },
    "alvo_FixedInterestBearingBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FixedInterestBearingBorrowingsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed-interest bearing - Borrowings",
        "label": "Fixed-Interest Bearing Borrowings [Member]",
        "documentation": "Fixed-Interest Bearing Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FixturesAndFittingsMember",
     "presentation": [
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Fixtures and fittings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "alvo_FleetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FleetMember",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails",
      "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fleet",
        "label": "Fleet [Member]",
        "documentation": "Fleet member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FlokiArtEhf.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FlokiArtEhf.Member",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fl\u00f3ki-Art ehf.",
        "label": "Fl\u00f3ki-Art ehf. [Member]",
        "documentation": "Fl\u00f3ki-Art ehf."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FlokiArtEhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FlokiArtEhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fl\u00f3ki-Art ehf. - Sister company",
        "label": "Floki Art ehf [Member]",
        "documentation": "Floki Art ehf"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FlokiFasteignirEhf.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FlokiFasteignirEhf.Member",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fl\u00f3ki Fasteignir ehf.",
        "label": "Fl\u00f3ki Fasteignir ehf. [Member]",
        "documentation": "Fl\u00f3ki Fasteignir ehf."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FlokiFasteignirEhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FlokiFasteignirEhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fl\u00f3ki fasteignir ehf. - Sister company",
        "label": "Floki Fasteignir ehf [Member]",
        "documentation": "Floki Fasteignir ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FlokiHoldingsS.aR.lMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FlokiHoldingsS.aR.lMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floki Holdings S.\u00e0 r.l. - Sister company",
        "label": "Floki Holdings S.\u00e0 r.l [Member]",
        "documentation": "Floki Holdings S.\u00e0 r.l"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FlokiInvestEhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FlokiInvestEhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fl\u00f3ki Invest ehf - Sister company",
        "label": "Floki Invest ehf [Member]",
        "documentation": "Floki Invest ehf"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignCountriesMember",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents denominated in other currencies",
        "label": "Foreign countries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261"
     ]
    },
    "alvo_ForeignCurrencyDifferenceOnLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ForeignCurrencyDifferenceOnLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails": {
       "parentTag": "alvo_LeaseCostRecognizedInProfitAndLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency difference on lease liability",
        "label": "Foreign Currency Difference On Lease Liability",
        "documentation": "Foreign currency difference on lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FormerEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FormerEmployeesMember",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Employees",
        "label": "Former Employees [Member]",
        "documentation": "Former employees."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_FurnitureFixturesAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "FurnitureFixturesAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, fixtures and leasehold improvements",
        "label": "Furniture, Fixtures and Leasehold Improvements [Member]",
        "documentation": "Furniture, Fixtures and Leasehold Improvements."
       }
      }
     },
     "auth_ref": []
    },
    "currency_GBP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "GBP",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GBP",
        "label": "United Kingdom, Pounds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) / gain on extinguishment of financial liabilities",
        "negatedLabel": "Loss/(Gain) on extinguishment of financial liabilities",
        "label": "Gain (loss) arising from difference between carrying amount of financial liability extinguished and consideration paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "alvo_GainLossOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GainLossOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain loss on extinguishment of debt",
        "label": "Gain Loss On Extinguishment Of Debt",
        "documentation": "Gain loss on extinguishment of debt."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on extinguishment of debt including change in fair value",
        "label": "Gain Loss On Extinguishment Of Debt Including Change In Fair Value",
        "documentation": "Gain loss on extinguishment of debt including change in fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value changes, including accretion",
        "label": "Gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate differences",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78"
     ]
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value changes, including accretion",
        "label": "Gains (losses) recognised in profit or loss attributable to change in unrealised gains or losses for liabilities held at end of period, fair value measurement"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in profit or loss for liabilities measured at fair value that are attributable to the change in unrealised gains or losses relating to those liabilities held at the end of the reporting period. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain losses recognized in profit or loss excluding exchange differences fair value measurement liabilities",
        "label": "Gains (losses) recognised in profit or loss excluding exchange differences, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) excluding exchange differences, recognised in profit or loss, on the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation",
        "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ifrs-full_GainsOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in the fair value of derivatives (see Note 28)",
        "label": "Gains on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "terseLabel": "General and administrative expense",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_GeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expenses [Member]",
        "documentation": "General and administrative expenses."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_GeneralAndAdministrativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GeneralAndAdministrativeMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative [Member]",
        "documentation": "General and administrative."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_GeneralInformationAboutFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GeneralInformationAboutFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General information about financial statements [Abstract]",
        "label": "General information about financial statements [Abstract]",
        "documentation": "General information about financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_GeneralInformationAboutFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GeneralInformationAboutFinancialStatementsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information About Financial Statements [Line Items]",
        "label": "General Information About Financial Statements [Line Items]",
        "documentation": "General information about financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_GeneralInformationAboutFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GeneralInformationAboutFinancialStatementsTable",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General information about financial statements [Table]",
        "label": "General information about financial statements [Table]",
        "documentation": "General information about financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails",
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r280",
      "r305",
      "r309"
     ]
    },
    "ifrs-full_GeographicalAreasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails",
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [member]",
        "label": "Geographical areas [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r280",
      "r305",
      "r309"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods or services transferred at point in time",
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodsOrServicesTransferredOverTimeMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods or services transferred over time",
        "label": "Goods or services transferred over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/GoodwillSummaryofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Balance as of 1 January",
        "periodEndLabel": "Balance as of 31 December",
        "label": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r106",
      "r111",
      "r221"
     ]
    },
    "alvo_GoodwillBalancesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GoodwillBalancesRollForward",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillSummaryofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill Balances [Roll Forward]",
        "documentation": "Goodwill Balances"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodwillMember",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r113",
      "r123",
      "r126",
      "r221",
      "r233",
      "r237",
      "r312"
     ]
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross lease liabilities",
        "label": "Gross lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r316"
     ]
    },
    "alvo_GrossPipeFinancingFeesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GrossPipeFinancingFeesPaid",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross PIPE Financing fees paid",
        "label": "Gross Pipe Financing Fees Paid",
        "documentation": "Gross pipe financing fees paid."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_GrossProceedsFromThePipeFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "GrossProceedsFromThePipeFinancing",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross proceeds from the PIPE Financing",
        "label": "Gross Proceeds From The Pipe Financing",
        "documentation": "Gross proceeds from the pipe financing."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_HRJAFEhfSisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "HRJAFEhfSisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HRJ\u00c1F ehf - Sister company",
        "label": "HRJ\u00c1F ehf - Sister company [Member]",
        "documentation": "HRJAF ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_HirofumiImaiBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "HirofumiImaiBoardMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hirofumi Imai, Board member",
        "label": "Hirofumi Imai, Board [Member]",
        "documentation": "Hirofumi Imai, Board"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility rate",
        "label": "Historical volatility for shares, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "alvo_HumiraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "HumiraMember",
     "presentation": [
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Humira",
        "label": "Humira [Member]",
        "documentation": "Humira"
       }
      }
     },
     "auth_ref": []
    },
    "currency_INR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "INR",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INR",
        "label": "India, Rupees"
       }
      }
     },
     "auth_ref": []
    },
    "country_IS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "IS",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICELAND",
        "label": "ICELAND"
       }
      }
     },
     "auth_ref": []
    },
    "currency_ISK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "ISK",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ISK",
        "label": "Iceland, Kronur"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329",
      "r330"
     ]
    },
    "ifrs-full_ImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Impairment loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss on investment in joint venture",
        "negatedTerseLabel": "Impairment loss on investment in joint venture",
        "label": "Impairment loss recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r103"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss, goodwill",
        "label": "Impairment loss recognised in profit or loss, goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit or loss [abstract]",
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IncomeStatementsLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncomeStatementsLocationAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income statement location [axis]",
        "label": "Income Statements Location [Axis]",
        "documentation": "Income statement location."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IncomeStatementsLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncomeStatementsLocationDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statements Location [Domain]",
        "label": "Income Statements Location [Domain]",
        "documentation": "Income Statements Location [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTaxationRecognizedInTheConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit",
        "totalLabel": "Total income tax benefit",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r46",
      "r47",
      "r48",
      "r90",
      "r159",
      "r253"
     ]
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax paid",
        "label": "Income taxes paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified to other current liabilities",
        "label": "Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy and corrections of prior period errors."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r137",
      "r138",
      "r140"
     ]
    },
    "ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in allowance for receivables",
        "label": "Increase (decrease) in allowance account for credit losses of financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the allowance account used to record the impairment of financial assets due to credit losses. [Refer: Financial assets; Allowance account for credit losses of financial assets]"
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase / (decrease) in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect on financial statement",
        "verboseLabel": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities",
        "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible decrease in an unobservable input. [Refer: Tax income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect on financial statement",
        "verboseLabel": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities",
        "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities, recognised in profit or loss before tax, due to a reasonably possible increase in an unobservable input. [Refer: Tax income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in net defined benefit liability (asset)",
        "label": "Increase (decrease) in net defined benefit liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase decrease in shares issued (in shares)",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_IncreaseDecreaseThroughCapitalReorganization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseDecreaseThroughCapitalReorganization",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Reorganization",
        "label": "Increase (Decrease) Through Capital Reorganization",
        "documentation": "Increase (decrease) through capital reorganization."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recognition of equity component of convertible bonds",
        "label": "Increase (decrease) through conversion of convertible instruments, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Increase (decrease) through cumulative catch-up adjustments to revenue arising from change in measure of progress, contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in contract liabilities resulting from cumulative catch-up adjustments to revenue arising from a change in the measure of progress. [Refer: Increase (decrease) through cumulative catch-up adjustments to revenue, contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfReconciliationOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract asset additions",
        "label": "Increase (decrease) through cumulative catch-up adjustments to revenue, contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in contract assets resulting from cumulative catch-up adjustments to revenue. [Refer: Contract assets; Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency exchange difference",
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public warrants exercised",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Cash flows",
        "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/GoodwillSummaryofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation difference",
        "label": "Increase (decrease) through net exchange differences, goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation difference",
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation difference",
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "alvo_IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase decrease through other current liabilities and income net defined benefit liability asset",
        "label": "Increase Decrease Through Other Current Liabilities and Income Net Defined Benefit Liability Asset",
        "documentation": "Increase decrease through other current liabilities and income net defined benefit liability asset."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IncreaseDecreaseThroughPipeFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseDecreaseThroughPipeFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Financing",
        "label": "Increase (Decrease) Through PIPE Financing",
        "documentation": "Increase (decrease) through pipe financing."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IncreaseDecreaseThroughSettlementOfLiabilityWithShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseDecreaseThroughSettlementOfLiabilityWithShares",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of liability with shares",
        "label": "Increase (Decrease) Through Settlement Of Liability With Shares",
        "documentation": "Increase (decrease) through settlement of liability with shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of related party loans with Ordinary Shares",
        "label": "Increase (Decrease) Through Settlement Of Related Party Loans With Ordinary Shares",
        "documentation": "Increase (decrease) through settlement of related party loans with ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of share-based payments",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution",
        "label": "Increase (decrease) through transactions with owners, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of assets",
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of assets",
        "label": "Increase (decrease) through transfers, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "alvo_IncreaseInOutstandingBondsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseInOutstandingBondsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in outstanding bonds fair value",
        "label": "Increase In Outstanding Bonds Fair Value",
        "documentation": "Increase In Outstanding Bonds Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IncreaseInTheFaceValueOfTheBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseInTheFaceValueOfTheBondsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase In The Face Value Of The Bonds",
        "label": "Increase In The Face Value Of The Bonds [member]",
        "documentation": "Increase In the face value Of the bonds [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New leases",
        "label": "Increase through new leases, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294"
     ]
    },
    "alvo_IncreaseThroughPipeFinancingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseThroughPipeFinancingShares",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Financing, (in shares)",
        "label": "Increase Through PIPE Financing Shares",
        "documentation": "Increase through PIPE financing shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IncreaseThroughPipeFinancingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IncreaseThroughPipeFinancingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Financing (Note 1.1)",
        "label": "Increase Through PIPE Financing Value",
        "documentation": "Increase through PIPE financing value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r118"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets other than goodwill [member]",
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r119",
      "r284",
      "r307"
     ]
    },
    "alvo_IntangibleAssetsOtherThanGoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IntangibleAssetsOtherThanGoodwillRollForward",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets Other Than Goodwill [Roll Forward]",
        "label": "Intangible Assets Other Than Goodwill [Roll Forward]",
        "documentation": "Intangible Assets Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IntangibleAssetsWithFiniteLivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IntangibleAssetsWithFiniteLivedMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets with finite lived",
        "label": "Intangible Assets With Finite Lived [Member]",
        "documentation": "Intangible assets with finite lived."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IntellectualPropertyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IntellectualPropertyRightsMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property rights",
        "label": "Intellectual Property Rights [Member]",
        "documentation": "Intellectual Property Rights"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_InterestComponentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "InterestComponentMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Component",
        "label": "Interest Component [member]",
        "documentation": "Interest component [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_InterestCostsCapitalizedPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "InterestCostsCapitalizedPeriodIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized loan cost changes",
        "label": "Interest Costs Capitalized, Period Increase (Decrease)",
        "documentation": "Interest Costs Capitalized, Period Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on debt and borrowings",
        "label": "Interest expense on borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails": {
       "parentTag": "alvo_LeaseCostRecognizedInProfitAndLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails",
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities (see Note 13)",
        "negatedLabel": "Interest expense on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "alvo_InterestIncomeOnCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "InterestIncomeOnCash",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income",
        "label": "Interest Income On Cash",
        "documentation": "Interest income on cash."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income from cash and cash equivalents",
        "label": "Interest income on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_InterestIncomeOnOtherFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnOtherFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other interest income",
        "label": "Interest income on other financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on other financial assets. [Refer: Interest income; Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_InterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payable",
        "label": "Interest payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest recognised as a liability."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_InterestRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateMeasurementInputMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Interest rate, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an interest rate used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate risk",
        "label": "Interest rate risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r250"
     ]
    },
    "ifrs-full_InterestRateTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateTypesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate types [member]",
        "label": "Interest rate types [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Balance at 31 December",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r73",
      "r271"
     ]
    },
    "alvo_InventoryReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "InventoryReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory reserves",
        "label": "Inventory Reserves",
        "documentation": "Inventory reserves."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InventoryWritedown2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InventoryWritedown2011",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-down",
        "label": "Inventory write-down"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r75"
     ]
    },
    "alvo_InvestmentsAccountedForUsingEquityMethodRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "InvestmentsAccountedForUsingEquityMethodRollForward",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Accounted For Using Equity Method [Roll Forward]",
        "label": "Investments Accounted For Using Equity Method [Roll Forward]",
        "documentation": "Investments Accounted For Using Equity Method"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInJointVenturesAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails",
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in joint venture",
        "verboseLabel": "Carrying Amount",
        "periodStartLabel": "Balance at 1 January",
        "periodEndLabel": "Balance at 31 December",
        "label": "Investments in joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "alvo_IssuanceOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssuanceOfOrdinaryShares",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Ordinary, (in shares)",
        "label": "Issuance of Ordinary Shares",
        "documentation": "Issuance of ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssuanceOfOrdinaryValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssuanceOfOrdinaryValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Ordinary Shares (Note 1.1)",
        "label": "Issuance of Ordinary Value",
        "documentation": "Issuance of ordinary value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfConvertibleInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of convertible instruments",
        "label": "Issue of convertible instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The change in equity resulting from the issuing of convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "alvo_IssueOfEquities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfEquities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share issue",
        "label": "Issue Of Equities",
        "documentation": "Issue of equities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in share capital",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "alvo_IssueOfEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfEquityShares",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue (in shares)",
        "label": "Issue of Equity Shares",
        "documentation": "Issue of equity shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfOacbEarnOutShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfOacbEarnOutShares",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OACB Earn Out Shares (in shares)",
        "label": "Issue of OACB Earn Out Shares, Shares",
        "documentation": "Issue of OACB earn out shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfOacbEarnOutSharesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfOacbEarnOutSharesValue",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OACB Earn Out Shares (Note 1.1)",
        "label": "Issue of OACB Earn Out Shares Value",
        "documentation": "Issue of OACB earn out shares value."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfPredecessorEarnOutShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfPredecessorEarnOutShares",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor Earn Out Shares, (in shares)",
        "label": "Issue of Predecessor Earn Out Shares",
        "documentation": "Issue of predecessor earn out shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfPredecessorEarnOutSharesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfPredecessorEarnOutSharesValue",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor Earn Out Shares (Note 1.1)",
        "label": "Issue of Predecessor Earn Out Shares Value",
        "documentation": "Issue of predecessor earn out shares value."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfSharesCapitalRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfSharesCapitalRollForward",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of Shares Capital [Roll Forward]",
        "label": "Issue of Shares capital [Roll Forward]",
        "documentation": "Issue of Shares capital"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfSharesOnSettlementOfRelatedPartyLoansShares",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of related party loans with Ordinary Shares, (in shares)",
        "label": "Issue of Shares on Settlement of Related Party Loans Shares",
        "documentation": "Issue of shares on settlement of related party loans shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfSharesOnSettlementOfRelatedPartyLoansValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfSharesOnSettlementOfRelatedPartyLoansValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of related party loans with Ordinary Shares",
        "label": "Issue of Shares on Settlement of Related Party Loans Value",
        "documentation": "Issue of shares on settlement of related party loans value."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfSharesOnSettlementOfShareAppreciationRightsShares",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SARs Settlement (in shares)",
        "label": "Issue of Shares on Settlement of Share Appreciation Rights Shares",
        "documentation": "Issue of shares on settlement of share appreciation rights shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssueOfSharesOnSettlementOfShareAppreciationRightsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssueOfSharesOnSettlementOfShareAppreciationRightsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SARs Settlement (Note 22)",
        "label": "Issue of Shares on Settlement of Share Appreciation Rights Value",
        "documentation": "Issue of shares on settlement of share appreciation rights value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "alvo_IssuedCapitalAndSharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssuedCapitalAndSharePremiumMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued capital and share premium",
        "label": "Issued Capital and Share Premium [Member]",
        "documentation": "Issued capital and share premium."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "alvo_IssuedToANewBondHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssuedToANewBondHolderMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued To A New Bond Holder",
        "label": "Issued To A New Bond Holder [member]",
        "documentation": "Issued to a new bond holder [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssuedToTheExistingAndANewBondHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssuedToTheExistingAndANewBondHolderMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued To The Existing And A New Bond Holder",
        "label": "Issued To The Existing And A New Bond Holder [member]",
        "documentation": "Issued to the existing and a new bond holder [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_IssuedToTheExistingNoteholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "IssuedToTheExistingNoteholderMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued To The Existing Noteholder",
        "label": "Issued To The Existing Noteholder [member]",
        "documentation": "Issued to the existing noteholder."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuesFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuesFairValueMeasurementLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issues fair value measurement liabilities",
        "label": "Issues, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in fair value measurement of liabilities resulting from issues of those liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_JointVenturesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "JointVenturesAxis",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails",
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint ventures [axis]",
        "label": "Joint ventures [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r161"
     ]
    },
    "alvo_KashivMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "KashivMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kashiv",
        "label": "Kashiv [Member]",
        "documentation": "Kashiv"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long- term benefits",
        "label": "Key management personnel compensation, other long-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension contribution",
        "label": "Key management personnel compensation, post-employment benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries and benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination benefits",
        "label": "Key management personnel compensation, termination benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "alvo_L41EhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "L41EhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "L41 ehf.",
        "label": "L41 ehf [Member]",
        "documentation": "L41 ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "country_LU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "LU",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LUXEMBOURG",
        "label": "LUXEMBOURG"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_Lambahagavegur7EhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "Lambahagavegur7EhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lambahagavegur 7 ehf",
        "label": "Lambahagavegur 7 ehf [Member]",
        "documentation": "Lambahagavegur 7 ehf member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_Lambhagavegur7EhfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "Lambhagavegur7EhfMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lambhagavegur 7 ehf.",
        "label": "Lambhagavegur 7 ehf [Member]",
        "documentation": "Lambhagavegur 7 ehf"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LandsbankinnHfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LandsbankinnHfMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Landsbankinn hf",
        "label": "Landsbankinn hf [member]",
        "documentation": "Landsbankinn hf."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LaterPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LaterPeriodMember",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Later",
        "label": "Later period [Member]",
        "documentation": "Later period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r205",
      "r315",
      "r318",
      "r320"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One to five years",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r320"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Within two years",
        "terseLabel": "One to two years",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r205",
      "r315",
      "r320",
      "r341"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Within four years",
        "label": "Later than three years and not later than four years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r205",
      "r315",
      "r320",
      "r341"
     ]
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Within three years",
        "label": "Later than two years and not later than three years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r205",
      "r315",
      "r320",
      "r341"
     ]
    },
    "alvo_LaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LaterThanTwoYearsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Later Than Two Years [Member]",
        "documentation": "Later than two years."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LeaseCostRecognizedInProfitAndLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LeaseCostRecognizedInProfitAndLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total amount recognized in profit and loss",
        "label": "Lease Cost Recognized In Profit And Loss",
        "documentation": "Lease cost recognized in profit and loss."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LeaseFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LeaseFacilityAxis",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Facility [Axis]",
        "label": "Lease Facility [Axis]",
        "documentation": "Lease Facility"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LeaseFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LeaseFacilityDomain",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Facility [Domain]",
        "label": "Lease Facility [Domain]",
        "documentation": "Lease Facility [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails",
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at 1 January",
        "periodEndLabel": "Balance at 31 December",
        "verboseLabel": "Lease liabilities (measured at amortized cost)",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "alvo_LeaseLiabilitiesAdjustmentsForIndexedLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LeaseLiabilitiesAdjustmentsForIndexedLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for indexed leases",
        "label": "Lease Liabilities Adjustments For Indexed Leases",
        "documentation": "Lease liabilities adjustments for indexed leases."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LeaseLiabilitiesCancelledLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LeaseLiabilitiesCancelledLease",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled leases",
        "label": "Lease Liabilities, Cancelled Lease",
        "documentation": "Lease Liabilities, Cancelled Lease"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LeaseLiabilitiesForeignCurrencyAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LeaseLiabilitiesForeignCurrencyAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency adjustment",
        "label": "Lease Liabilities Foreign Currency Adjustment",
        "documentation": "Lease liabilities foreign currency adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LeaseLiabilitiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LeaseLiabilitiesRollForward",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liabilities [Roll Forward]",
        "label": "Lease Liabilities [Roll Forward]",
        "documentation": "Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LeaseLiabilitiesTranslationDifference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LeaseLiabilitiesTranslationDifference",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation difference",
        "label": "Lease Liabilities Translation Difference",
        "documentation": "Lease liabilities translation difference."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "alvo_LegalCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LegalCost",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LitigationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal expenses",
        "label": "Legal cost",
        "documentation": "Legal cost."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LenderNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LenderNameAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Lender name [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LenderNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LenderNameDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Domain]",
        "label": "Lender Name [Domain]",
        "documentation": "Lender name."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r163"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Levels of fair value hierarchy [axis]",
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r163"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r162",
      "r163",
      "r168",
      "r254",
      "r258"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of cash option as a liability fairvalue",
        "label": "Liabilities From Share-Based Payment Transactions, Cash Settlement, Fair Value",
        "documentation": "Liabilities From Share-Based Payment Transactions, Cash Settlement, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesFromSharebasedPaymentTransactions2011",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities from share-based payment transactions",
        "label": "Liabilities from share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Net defined benefit liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "alvo_LiabilityAssetOfDefinedBenefitPlansRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LiabilityAssetOfDefinedBenefitPlansRollForward",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Asset Of Defined Benefit Plans [Roll Forward]",
        "label": "Liability Asset Of Defined Benefit Plans [Roll Forward]",
        "documentation": "Liability Asset Of Defined Benefit Plans"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LicenceFeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LicenceFeeIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and other revenue",
        "label": "Licence fee income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from licence fees."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_LicenseRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LicenseRevenueMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue (point in time revenue recognition)",
        "label": "License revenue [Member]",
        "documentation": "License revenue."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LindaMcgoldrickMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LindaMcgoldrickMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Linda McGoldrick, Board Member",
        "label": "Linda McGoldrick [Member]",
        "documentation": "Linda McGoldrick."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LineItemsByFunctionMember",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails",
      "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line items by function [member]",
        "label": "Line items by function [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341"
     ]
    },
    "alvo_LisaGraverMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LisaGraverMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lisa Graver, Board Member",
        "label": "Lisa Graver [Member]",
        "documentation": "Lisa Graver."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LitigationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LitigationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation [Abstract]",
        "label": "Litigation [Abstract]",
        "documentation": "Litigation."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement",
        "label": "Loan agreement [Member]",
        "documentation": "Loan agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LoansFromRelatedPartyConvertedToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LoansFromRelatedPartyConvertedToEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans from related party converted to equity",
        "label": "Loans From Related Party Converted To Equity",
        "documentation": "Loans from related party converted to equity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans received",
        "label": "Loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_LoansToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LoansToRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans to related parties",
        "label": "Loans to related parties",
        "documentation": "Loans to related parties."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "verboseLabel": "Total non-current borrowings",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "alvo_LossFromExtinguishmentOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LossFromExtinguishmentOfLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails": {
       "parentTag": "alvo_LeaseCostRecognizedInProfitAndLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss from extinguishment of lease agreement (see Note 12)",
        "label": "Loss From Extinguishment Of Lease Liabilities",
        "documentation": "Loss from extinguishment of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LossOnExtinguishmentOfTheLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LossOnExtinguishmentOfTheLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of the lease liability",
        "label": "Loss on Extinguishment of the lease liability",
        "documentation": "Loss on extinguishment of the lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LossOnRemeasurementOfBonds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LossOnRemeasurementOfBonds",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on remeasurement of bonds (see Note 21)",
        "label": "Loss On Remeasurement Of Bonds",
        "documentation": "Loss on remeasurement of bonds."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LossesOnChangeInFairValueOfDerivatives",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinanceIncomeAndFinanceCostsSummaryOfDetailedInformationAboutFinanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in the fair value of derivatives (see Note 28)",
        "label": "Losses on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LossesOnDisposalsOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of property, plant and equipment",
        "label": "Losses on disposals of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The losses on the disposal of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "alvo_LotusInternationalPteltdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LotusInternationalPteltdMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lotus International Pte. Ltd. - Sister company",
        "label": "Lotus International PteLtd [Member]",
        "documentation": "Lotus International Pte\u00a0Ltd member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LotusPharmaceuticalCo.LtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LotusPharmaceuticalCo.LtdMember",
     "presentation": [
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lotus pharmaceutical co. ltd",
        "label": "Lotus pharmaceutical co. ltd [Member]",
        "documentation": "Lotus pharmaceutical co. ltd."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_LotusPharmaceuticalsCo.Ltd.SisterCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "LotusPharmaceuticalsCo.Ltd.SisterCompanyMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lotus Pharmaceuticals Co. Ltd. - Sister company",
        "label": "Lotus Pharmaceuticals Co. Ltd. - Sister company [Member]",
        "documentation": "Lotus Pharmaceuticals CoLtd member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ifrs-full_MajorCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customers [member]",
        "label": "Customers [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorOrdinaryShareTransactionsMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major ordinary share transactions",
        "label": "Major ordinary share transactions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "alvo_MarkLevickCeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MarkLevickCeoMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mark Levick CEO",
        "label": "Mark Levick CEO [Member]",
        "documentation": "Mark Levick CEO ."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_MaturedOnApril2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MaturedOnApril2024Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matured on March 2024",
        "label": "Matured On April 2024 [Member]",
        "documentation": "Matured On April 2024"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_MaturedOnAugust2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MaturedOnAugust2029Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matured on August 2029",
        "label": "Matured On August 2029 [Member]",
        "documentation": "Matured on august 2029"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_MaturedOnAugust2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MaturedOnAugust2030Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matured on august 2030",
        "label": "Matured On August 2030 [Member]",
        "documentation": "Matured On August 2030"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_MaturedOnMarch2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MaturedOnMarch2029Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matured On March 2029",
        "label": "Matured On March 2029 [Member]",
        "documentation": "Matured On March 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r179",
      "r192",
      "r193",
      "r196",
      "r197",
      "r199",
      "r205",
      "r226",
      "r240",
      "r281",
      "r315"
     ]
    },
    "alvo_MaturityMonthAndYearAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MaturityMonthAndYearAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity Month and Year [Axis]",
        "label": "Maturity Month and Year [Axis]",
        "documentation": "Maturity month and year [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_MaturityMonthAndYearDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MaturityMonthAndYearDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity Month and Year [Domain]",
        "label": "Maturity Month and Year [Domain]",
        "documentation": "Maturity Month and year."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaximumExposureToCreditRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaximumExposureToCreditRisk",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum exposure to credit risk",
        "label": "Maximum exposure to credit risk"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_MaximumPercentageOfOwnershipInterestHeldByEachShareholder": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MaximumPercentageOfOwnershipInterestHeldByEachShareholder",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of ownership interest held by each shareholder",
        "label": "Maximum Percentage Of Ownership Interest Held By Each Shareholder",
        "documentation": "Maximum percentage of ownership interest held by each shareholder."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_MinimumAmountOfRestrictedCashToBeMaintained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "MinimumAmountOfRestrictedCashToBeMaintained",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum amount of restricted cash to be maintained",
        "label": "Minimum Amount Of Restricted Cash To Be Maintained",
        "documentation": "Minimum amount of restricted cash to be maintained."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NatureOfFeesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NatureOfFeesAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature Of Fees [Axis]",
        "label": "Nature Of Fees [Axis]",
        "documentation": "Nature of fees [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NatureOfFeesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NatureOfFeesDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature Of Fees [Domain]",
        "label": "Nature Of Fees [Domain]",
        "documentation": "Nature of fees."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetAssetsLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net assets",
        "label": "Assets (liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r341"
     ]
    },
    "alvo_NetCashProceedsFromTheTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NetCashProceedsFromTheTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash proceeds from the transaction",
        "label": "Net Cash Proceeds From The Transaction",
        "documentation": "Net cash proceeds from the transaction."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NetCompensationExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NetCompensationExpenseMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Compensation Expense",
        "label": "Net Compensation Expense [Member]",
        "documentation": "Net Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails": {
       "parentTag": "ifrs-full_DeferredTaxLiabilityAsset",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "verboseLabel": "Deferred tax assets",
        "label": "Net deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_NetDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails": {
       "parentTag": "ifrs-full_DeferredTaxLiabilityAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheMovementInNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "negatedLabel": "Deferred tax credited to profit or loss",
        "negatedTerseLabel": "Deferred tax liabilities attributable to other temporary differences",
        "label": "Net deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "alvo_NonCashChangesInOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NonCashChangesInOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other changes",
        "label": "Non Cash Changes in Other Changes",
        "documentation": "Non Cash Changes in Other Changes"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NonCashChangesInOtherNonCashMovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NonCashChangesInOtherNonCashMovements",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-cash movements",
        "label": "Non Cash Changes in Other non-cash movements",
        "documentation": "Non Cash Changes in Other non-cash movements"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NonCashIssuanceOfConvertibleBond": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NonCashIssuanceOfConvertibleBond",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash issuance of Aztiq Convertible Bond",
        "label": "Non Cash Issuance Of Convertible Bond",
        "documentation": "Non cash issuance of convertible bond."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NonInterestBearingFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NonInterestBearingFinancialAssetsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-interest bearing",
        "label": "Non Interest Bearing Financial Assets [Member]",
        "documentation": "Non Interest Bearing Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NonInterestBearingFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NonInterestBearingFinancialLiabilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-interest bearing",
        "label": "Non-Interest Bearing Financial Liabilities [Member]",
        "documentation": "Non-Interest Bearing Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NonInterestBearingUndiscountedCashFlowsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NonInterestBearingUndiscountedCashFlowsLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails": {
       "parentTag": "alvo_FinancialLiabilitiesDerivativesAndNonDerivativesUndiscontinuedCashFlows",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [member]",
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r153",
      "r296"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets, excluding financial instruments and deferred tax assets",
        "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "ifrs-full_NoncurrentContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract assets",
        "terseLabel": "Non-current contract assets",
        "label": "Non-current contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract assets. [Refer: Contract assets]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "alvo_NoncurrentContractAssetsMaterializePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NoncurrentContractAssetsMaterializePeriod",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current contract assets materialize period",
        "label": "Noncurrent Contract Assets Materialize Period",
        "documentation": "Non-current contract assets materialize period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract liabilities",
        "terseLabel": "Non-current contract liabilities",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NoncurrentContractLiabilitiesRevenueRecognitionPeriod",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent contract liabilities revenue recognition period",
        "label": "Noncurrent Contract Liabilities Revenue Recognition Period",
        "documentation": "Non-current contract liabilities revenue recognition period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial liabilities",
        "verboseLabel": "Derivative financial liabilities (measured at FVTPL)",
        "label": "Non-current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/LeasesSummaryofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Non-current liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r155",
      "r296"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentPayablesToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentPayablesToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liability to related party",
        "verboseLabel": "Other long-term liability to related party (measured at amortized cost)",
        "label": "Non-current payables to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term incentive plan",
        "verboseLabel": "Long-term incentive plan (measured at FVTPL)",
        "label": "Non-current net defined benefit liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_NoncurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofRestrictedCashDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "periodStartLabel": "Balance at 1 January",
        "periodEndLabel": "Balance at 31 December",
        "label": "Non-current restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsDetails",
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North America",
        "label": "North America [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NorwichClinicalServicesLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NorwichClinicalServicesLtdMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Norwich Clinical Services Ltd - Sister company",
        "label": "Norwich Clinical Services Ltd [Member]",
        "documentation": "Norwich Clinical Services Ltd member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not later than five years",
        "label": "Not Later Than Five Years [Member]",
        "documentation": "Not later than five years"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/LeasesSummaryofMaturityAnalysisForLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "verboseLabel": "Within one year",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r192",
      "r193",
      "r205",
      "r315",
      "r320"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument face value",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberAndWeightedAverageFairValueOfOtherEquityInstrumentsRollForward",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Number And Weighted Average Fair Value Of Other Equity Instruments [Roll Forward]",
        "documentation": "Number And Weighted Average Fair Value Of Other Equity Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consecutive trading days for determining the share",
        "label": "Number Of Consecutive Trading Days",
        "documentation": "Number of consecutive trading days."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of instruments granted in share-based payment arrangement (in shares)",
        "label": "Number of instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311"
     ]
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New grants during the year (in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r377"
     ]
    },
    "alvo_NumberOfLeaseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfLeaseAgreements",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of lease agreements",
        "label": "Number Of Lease Agreements",
        "documentation": "Number Of Lease Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NumberOfLeaseAgreementsEnteredInto": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfLeaseAgreementsEnteredInto",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of lease agreements entered into",
        "label": "Number Of Lease Agreements Entered Into",
        "documentation": "Number Of Lease Agreements Entered Into"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NumberOfLeasesTerminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfLeasesTerminated",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of leases terminated",
        "label": "Number Of Leases Terminated",
        "documentation": "Number Of Leases Terminated"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NumberOfLitigations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfLitigations",
     "presentation": [
      "http://www.alvotech.com/role/LitigationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of litigations",
        "label": "Number Of Litigations",
        "documentation": "Number Of Litigations"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NumberOfLoans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfLoans",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of loans",
        "label": "Number Of Loans",
        "documentation": "Number Of Loans"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NumberOfOperatingSegments1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfOperatingSegments1",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number Of Operating Segments 1",
        "documentation": "Number Of Operating Segments 1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested during the year (in shares)",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited during the year (in shares)",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in shares)",
        "periodStartLabel": "Outstanding (in shares)",
        "periodEndLabel": "Outstanding (in shares)",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented",
     "presentation": [
      "http://www.alvotech.com/role/LossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of potential ordinary shares that are antidilutive in period presented",
        "label": "Number of potential ordinary shares that are antidilutive in period presented"
       }
      },
      "en": {
       "role": {
        "documentation": "Number of potential ordinary shares that are antidilutive in the period presented."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "alvo_NumberOfSeparateInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfSeparateInstallments",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of separate installments",
        "label": "Number of Separate Installments",
        "documentation": "Number of Separate Installments"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options after tax witholding in share based payment arrangement (in shares)",
        "label": "Number Of Share Options After Tax Witholding In Share based Payment Arrangement",
        "documentation": "Number Of Share Options After Tax Witholding In Share based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options exercisable (in shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options granted (in shares)",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "alvo_NumberOfSharesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfSharesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by each warrant or right",
        "label": "Number Of Shares Called By Each Warrant Or Right",
        "documentation": "Number of shares called by each warrant or right."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and paid capital (presented in whole shares) (in shares)",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails",
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares at year-end (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "alvo_NumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfTranches",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Number Of Tranches",
        "documentation": "Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of year for issuing Shares after the closing of the Business Combination",
        "label": "Number of year for issuing Shares after the closing of the Business Combination",
        "documentation": "Number of year for issuing Shares after the closing of the Business Combination."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_OacbEarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OacbEarnoutSharesMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OACB earnout shares",
        "label": "OACB earnout shares [member]",
        "documentation": "OACB earnout shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_OacbWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OacbWarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OACB Warrants",
        "label": "OACB Warrants [Member]",
        "documentation": "OACB warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/CoverPage",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r348"
     ]
    },
    "alvo_OrdinarySharesValueIssuedConversionOfBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OrdinarySharesValueIssuedConversionOfBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity issued through conversion of borrowings",
        "label": "Ordinary Shares Value Issued Conversion Of Borrowings",
        "documentation": "Ordinary shares value issued conversion of borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Other borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_OtherBorrowingsFinancialInstitutionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherBorrowingsFinancialInstitutionMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Borrowings Financial Institution",
        "label": "Other Borrowings Financial Institution [member]",
        "documentation": "Other Borrowings Financial Institution [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_OtherBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherBorrowingsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Other Borrowings [Member]",
        "documentation": "Other Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income / (loss)",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exchange rate differences on translation of foreign operations",
        "terseLabel": "Foreign currency translation differences",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r40"
     ]
    },
    "alvo_OtherCurrentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherCurrentAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Current Asset",
        "documentation": "Other current asset."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "totalLabel": "Total",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "alvo_OtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets [Abstract]",
        "label": "Other Current Assets [Abstract]",
        "documentation": "Other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_OtherCurrentAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherCurrentAssetsLineItems",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets [Line Items]",
        "label": "Other Current Assets [Line Items]",
        "documentation": "Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_OtherCurrentAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherCurrentAssetsTable",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets [Table]",
        "label": "Other Current Assets [Table]",
        "documentation": "Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/OtherCurrentLiabilitiesScheduleofCompositionofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "alvo_OtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherCurrentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Liabilities [Abstract]",
        "label": "Other Current Liabilities [Abstract]",
        "documentation": "Other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_OtherCurrentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherCurrentLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Current Liability",
        "documentation": "Other current liability."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other short-term receivables",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ifrs-full_OtherEmployeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEmployeeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other employee expense",
        "label": "Other employee expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "alvo_OtherExecutiveTeamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherExecutiveTeamMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Executive Team Members",
        "label": "Other Executive Team [Member]",
        "documentation": "Other Executive Team."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-operating (loss) / profit",
        "label": "Other gains (losses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338"
     ]
    },
    "ifrs-full_OtherLongtermBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherLongtermBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term incentive plan expense",
        "label": "Other long-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of long-term employee benefits other than post-employment benefits and termination benefits. Such benefits may include long-term paid absences, jubilee or other long-service benefits, long-term disability benefits, long-term profit-sharing and bonuses and long-term deferred remuneration. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "alvo_OtherNoncurrentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherNoncurrentAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Noncurrent Asset",
        "documentation": "Other non-current asset."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails",
      "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Other property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.alvotech.com/role/OtherreservesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/OtherreservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other reserves",
        "totalLabel": "Other reserves",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "ifrs-full_OtherReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReservesMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other reserves",
        "label": "Other reserves [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r33"
     ]
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "alvo_OtherShareBasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherShareBasedPaymentsMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Share Based Payments",
        "label": "Other Share Based Payments [Member]",
        "documentation": "Other Share Based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_OtherSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "OtherSubsidiariesMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Subsidiaries",
        "label": "Other Subsidiaries [Member]",
        "documentation": "Other subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other items",
        "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_OtherTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTemporaryDifferencesMember",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other temporary differences",
        "label": "Other temporary differences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par or stated value per share (in dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "alvo_PaymentForContractualCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PaymentForContractualCommitment",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for contract commitment",
        "label": "Payment For Contractual Commitment",
        "documentation": "Payment For Contractual Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Of In Kind Accrued Interest As A Result Of Warrant Exercise",
        "label": "Payment Of In Kind Accrued Interest As A Result Of Warrant Exercise [member]",
        "documentation": "Payment of in kind accrued interest as a result of warrant exercise [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_PaymentsForDebtIssueCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PaymentsForDebtIssueCost",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Recognition of deferred debt issue costs",
        "label": "Payments For Debt Issue Cost",
        "documentation": "Payments for debt issue cost."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForDebtIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsForDebtIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transaction cost from borrowings",
        "terseLabel": "Payments for debt issue costs",
        "label": "Payments for debt issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for debt issue costs."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross private placement equity offering fee",
        "terseLabel": "Gross private placement equity offering fee",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to employee",
        "negatedLabel": "Payments",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "alvo_PennyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PennyWarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penny Warrants",
        "label": "Penny Warrants [Member]",
        "documentation": "Penny Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_PercentageChangeInForeignExchangeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PercentageChangeInForeignExchangeRate",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofImpactontheGroupsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change",
        "label": "Percentage Change In Foreign Exchange Rate",
        "documentation": "Percentage change in foreign exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of entity's revenue",
        "label": "Percentage of entity's revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable decrease",
        "label": "Percentage of reasonably possible decrease in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable increase",
        "label": "Percentage of reasonably possible increase in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting equity interests acquired",
        "label": "Percentage of voting equity interests acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "alvo_PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percnetage of warrants issued representing fully diluted ordinary share",
        "label": "Percnetage of Warrants Issued Representing Fully Diluted Ordinary Share",
        "documentation": "Percnetage of warrants issued representing fully diluted ordinary share."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PerformanceObligationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PerformanceObligationsAxis",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations [axis]",
        "label": "Performance obligations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_PerformanceObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PerformanceObligationsMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations [member]",
        "label": "Performance obligations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_PerformanceObligationsSatisfiedOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PerformanceObligationsSatisfiedOverTimeMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations satisfied over time",
        "label": "Performance obligations satisfied over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for performance obligations satisfied over time. An entity satisfies a performance obligation over time, if one of the following criteria is met: (a) the customer simultaneously receives and consumes the benefits provided by the entity\u2019s performance as the entity performs; (b) the entity\u2019s performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced; or (c) the entity\u2019s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. [Refer: Performance obligations [member]]"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan expense",
        "label": "Post-employment benefit expense, defined contribution plans"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "alvo_PredecessorEarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PredecessorEarnoutSharesMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor Earn Out Shares",
        "label": "Predecessor Earnout Shares [member]",
        "documentation": "Predecessor earnout shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_PredecessorOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PredecessorOrdinarySharesMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor Ordinary Shares",
        "label": "Predecessor Ordinary Shares [Member]",
        "documentation": "Predecessor ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_PremiumComponentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PremiumComponentMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premium Component",
        "label": "Premium Component [member]",
        "documentation": "Premium component [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_PremiumPaymentOnBonds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PremiumPaymentOnBonds",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premium payment on bonds",
        "label": "Premium Payment On Bonds",
        "documentation": "Premium payment on bonds."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_PrepaymentPenaltyPercentageOnBonds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PrepaymentPenaltyPercentageOnBonds",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment penalty percentage on bonds",
        "label": "Prepayment Penalty Percentage On Bonds",
        "documentation": "Prepayment penalty percentage on bonds."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Presentation of leases for lessee [abstract]",
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PreviouslyStatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PreviouslyStatedMember",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior to reclassification",
        "label": "Previously stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r137",
      "r138",
      "r140"
     ]
    },
    "alvo_PrincipalAndAccruedInterestComponent.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PrincipalAndAccruedInterestComponent.Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal And Accrued Interest Component.",
        "label": "Principal And Accrued Interest Component. [member]",
        "documentation": "Principal and accrued interest component [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_PrincipalComponentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PrincipalComponentMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Component",
        "label": "Principal Component [member]",
        "documentation": "Principal component [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PrincipalPlaceOfBusinessOfJointVenture": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PrincipalPlaceOfBusinessOfJointVenture",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Place of business",
        "label": "Principal place of business of joint venture"
       }
      },
      "en": {
       "role": {
        "documentation": "The principal place of business of a joint venture. [Refer: Principal place of business; Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r94",
      "r148"
     ]
    },
    "alvo_PrivatePlacementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PrivatePlacementsMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placements [Member]",
        "documentation": "Private placements."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ProceedsFromBorrowingClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ProceedsFromBorrowingClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from new borrowings",
        "label": "Proceeds From Borrowing Classified As Financing Activities",
        "documentation": "Proceeds from borrowing, classified as financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from new borrowings",
        "label": "Proceeds from borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "alvo_ProceedsFromBorrowingsNetOfTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ProceedsFromBorrowingsNetOfTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from borrowings net of transaction costs",
        "label": "Proceeds from Borrowings Net of Transaction Costs",
        "documentation": "Proceeds from borrowings net of transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromCurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromCurrentBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from current borrowings",
        "label": "Proceeds from current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of bonds",
        "label": "Proceeds from issue of bonds, notes and debentures"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock",
        "label": "Proceeds from issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingOtherEquityInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from private placement equity offering",
        "label": "Proceeds from issuing other equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds on issue of equity shares",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of property, plant and equipment",
        "label": "Proceeds from sales of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "alvo_ProceedsFromTheCapitalReorganization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ProceedsFromTheCapitalReorganization",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from the Capital Reorganization",
        "terseLabel": "Proceeds from the capital reorganization",
        "label": "Proceeds From The Capital Reorganization",
        "documentation": "Proceeds from the capital reorganization."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ProceedsReceivableFromConvertibleBonds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ProceedsReceivableFromConvertibleBonds",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsSummaryofOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds receivable from Convertible Bonds (see Note 21)",
        "label": "Proceeds Receivable From Convertible Bonds",
        "documentation": "Proceeds receivable from convertible bonds."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ProductRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ProductRevenueMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue (point in time revenue recognition)",
        "label": "Product revenue [Member]",
        "documentation": "Product revenue."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [axis]",
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r304"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.alvotech.com/role/OtherCurrentAssetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [member]",
        "label": "Products and services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r304"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss for the year",
        "terseLabel": "Loss for the year",
        "negatedTerseLabel": "Net loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r35",
      "r128",
      "r143",
      "r145",
      "r254",
      "r256",
      "r296",
      "r308"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r268",
      "r269",
      "r322",
      "r323"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r349"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r60"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant And Equipment",
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r284",
      "r307"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentPledgedAsSecurity",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, pledged as security",
        "label": "Property, plant and equipment, pledged as security"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment pledged as security for liabilities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "alvo_PropertyPlantAndEquipmentRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PropertyPlantAndEquipmentRollForward",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Roll Forward]",
        "label": "Property, Plant and Equipment [Roll Forward]",
        "documentation": "Property, Plant and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInJointVenture": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInJointVenture",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails",
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofInformationAboutJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership and voting power held by Alvotech",
        "verboseLabel": "Ownership interest",
        "label": "Proportion of ownership interest in joint venture"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r92",
      "r95",
      "r149"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest in subsidiary",
        "verboseLabel": "Proportion of ownership and voting power held by Alvotech",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r92",
      "r95",
      "r147"
     ]
    },
    "alvo_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Warrants",
        "label": "Public Warrants [Member]",
        "documentation": "Public Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of intangible assets",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r199",
      "r210",
      "r300",
      "r302",
      "r379"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [member]",
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r199",
      "r210",
      "r300",
      "r302",
      "r379"
     ]
    },
    "ifrs-full_RawMaterialsAndConsumablesUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RawMaterialsAndConsumablesUsed",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials and supplies",
        "label": "Raw materials and consumables used"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r268"
     ]
    },
    "alvo_ReclassificationRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ReclassificationRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification",
        "label": "Reclassification, Right-of-Use Assets",
        "documentation": "Reclassification, Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_RecognitionOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RecognitionOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of derivative asset",
        "label": "Recognition Of Derivative Asset",
        "documentation": "Recognition of derivative asset."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_RecognitionOfDerivativeLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RecognitionOfDerivativeLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of derivative liabilities at fair value",
        "label": "Recognition Of Derivative Liabilities At Fair Value",
        "documentation": "Recognition of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_RecognitionOfNewBorrowingsDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RecognitionOfNewBorrowingsDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Recognition of new borrowings discount",
        "label": "Recognition Of New Borrowings Discount",
        "documentation": "Recognition of new borrowings discount."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction In Interest Rate If Additional Shares Are Issued Within Six Months",
        "label": "Reduction In Interest Rate If Additional Shares Are Issued Within Six Months [member]",
        "documentation": "Reduction In Interest Rate If Additional Shares Are Issued Within Six Months [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transactions [abstract]",
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_Remaining15LeaseFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "Remaining15LeaseFacilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining 15 Lease Facilities",
        "label": "Remaining 15 Lease Facilities [Member]",
        "documentation": "Remaining 15 Lease Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ReorganizationShareListingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ReorganizationShareListingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reorganization, share listing expense",
        "verboseLabel": "Difference \u2013 being the share listing expense",
        "label": "Reorganization, Share Listing Expense",
        "documentation": "Reorganization, share listing expense."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBondsNotesAndDebentures",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of bonds",
        "label": "Repayments of bonds, notes and debentures"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "alvo_RepaymentsOfBorrowingClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RepaymentsOfBorrowingClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsSummaryofmovementsinthegroupsoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of borrowings",
        "label": "Repayments Of Borrowing, Classified As Financing Activities",
        "documentation": "Repayments of borrowing, classified as financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of borrowings",
        "terseLabel": "Repayments of borrowings",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "alvo_RepaymentsOfPrincipalPortionOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RepaymentsOfPrincipalPortionOfLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of principal portion of lease liabilities",
        "label": "Repayments Of Principal Portion Of Lease Liabilities",
        "documentation": "Repayments of principal portion of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails",
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails",
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "alvo_ResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://www.alvotech.com/role/DepreciationAmortizationAndImpairmentSummaryOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossDetails",
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofsharebasedpaymentexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research And Development Expenses [Member]",
        "documentation": "Research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsSummaryofImpairmentLossandReversalofImpairmentLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development [Member]",
        "documentation": "Research and development."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfEquityComponentOfConvertibleInstruments",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/OtherreservesDetails": {
       "parentTag": "ifrs-full_OtherReserves",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherreservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity component of convertible bonds",
        "label": "Reserve of equity component of convertible instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing components of convertible instruments classified as equity."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation reserve",
        "label": "Reserve of exchange differences on translation"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r270"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/OtherreservesDetails": {
       "parentTag": "ifrs-full_OtherReserves",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/OtherreservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payments",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_RestatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestatedMember",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currently stated [member]",
        "label": "Currently stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r137",
      "r138",
      "r140",
      "r198",
      "r343"
     ]
    },
    "alvo_RestrictedCashInConnectionWithAmendedBondAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RestrictedCashInConnectionWithAmendedBondAgreement",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted cash in connection with amended bond agreement",
        "label": "Restricted Cash In Connection With Amended Bond Agreement",
        "documentation": "Restricted cash in connection with amended bond agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_RestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RestrictedCashMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryoftheMaximumCreditRiskExposureoftheGroupsFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted cash",
        "documentation": "Restricted cash member."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted share units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing restricted share units."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r270"
     ]
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansScheduleOfMovementsInTheGroupsEmployeeIncentivePlanLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retrospective application and retrospective restatement [axis]",
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r137",
      "r138",
      "r140"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromTransactionsWithIndividualCustomersDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r157",
      "r223",
      "r252",
      "r255",
      "r259",
      "r260",
      "r263",
      "r268",
      "r269",
      "r296"
     ]
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails",
      "http://www.alvotech.com/role/SegmentReportingSummaryOfDetailedInformationAboutRevenueFromCustomersBasedOnGeographicalMarketDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from contracts with customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174"
     ]
    },
    "alvo_RevenueFromContractsWithCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RevenueFromContractsWithCustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Revenue and other Operating Income [Abstract]",
        "label": "Revenue from contracts with customers [Abstract]",
        "documentation": "Disclosure of revenue and other operating income."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromRenderingOfServicesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromRenderingOfServicesRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sold service",
        "label": "Revenue from rendering of services, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the rendering of services in related party transactions. [Refer: Revenue; Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue",
        "label": "Revenue from sale of goods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "ifrs-full_ReversalOfInventoryWritedown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReversalOfInventoryWritedown",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of inventory write-down",
        "label": "Reversal of inventory write-down"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r76"
     ]
    },
    "alvo_RichardDaviesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RichardDaviesMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Richard Davies, Vice-Chairman",
        "label": "Richard Davies [Member]",
        "documentation": "Richard Davies."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained through new operating leases",
        "label": "Right Of Use Assets Obtained Through New Operating Lease Liabilities",
        "documentation": "Right of use assets obained through new operating lease liabilites."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_RightOfUsedAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RightOfUsedAssetsRollForward",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right Of Used Assets [Roll Forward]",
        "label": "Right Of Used Assets [Roll Forward]",
        "documentation": "Right Of Used Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails",
      "http://www.alvotech.com/role/LeasesSummaryOfLeaseCostDetails",
      "http://www.alvotech.com/role/LeasesSummaryofClassesofRightOfUseAssetsDetails",
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r189"
     ]
    },
    "ifrs-full_RiskExposuresAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RiskExposuresAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk variables [axis]",
        "label": "Risk variables [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_RiskExposuresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RiskExposuresMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk variables [member]",
        "label": "Risk variables [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk variables. It also represents the standard value for the 'Risk variables' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "alvo_RiskyYieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RiskyYieldMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risky yield",
        "label": "Risky Yield [Member]",
        "documentation": "Risky yield."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_RobertWessmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "RobertWessmanMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Robert Wessman, Chairman of the board",
        "label": "Robert Wessman [Member]",
        "documentation": "Robert Wessman ."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SaemundurMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SaemundurMember",
     "presentation": [
      "http://www.alvotech.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Saemundur",
        "label": "Saemundur [Member]",
        "documentation": "Saemundur."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "documentation": "Sale of stock."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SaleOfStockDomain",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Domain]",
        "label": "Sale Of Stock [Domain]",
        "documentation": "Sale Of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SaleOfStockIssuePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SaleOfStockIssuePricePerShare",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock issue price (in dollars per share)",
        "label": "Sale Of Stock Issue Price Per Share",
        "documentation": "Sale of stock issue price per share."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseLineItems",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of fair value of shares issued and noncash share listing expense [line items]",
        "label": "Schedule Of Fair Value Of Shares Issued And NonCash Share Listing Expense [Line Items]",
        "documentation": "Schedule of fair value of shares issued and non-cash share listing expense."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTable",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of fair value of shares issued and noncash share listing expense [table]",
        "label": "Schedule Of Fair Value Of Shares Issued And NonCash Share Listing Expense [Table]",
        "documentation": "Schedule of fair value of shares issued and non-cash share listing expense."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of fair value of shares issued and non-cash share listing expense",
        "label": "Schedule of fair value of shares issued and noncash share listing expense [Table Text Block]",
        "documentation": "Schedule of fair value of shares issued and non-cash share listing expense."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ScheduleOfInformationAboutBoardOfDirectorsRemunerationLineItems",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails",
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information About Board of Directors Remuneration [Line Items]",
        "label": "Schedule of Information About Board of Directors Remuneration [Line Items]",
        "documentation": "Schedule of information about board of directors remuneration."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ScheduleOfInformationAboutBoardOfDirectorsRemunerationTable",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails",
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information About Board of Directors Remuneration [Table]",
        "label": "Schedule of Information About Board of Directors Remuneration [Table]",
        "documentation": "Schedule of information about board of directors remuneration."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of maturities of outstanding borrowings",
        "label": "Schedule of Maturities Of Outstanding Borrowings Explanatory [Table Text Block]",
        "documentation": "Schedule of Maturities of outstanding borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ScheduleOfOtherReservesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ScheduleOfOtherReservesTableTextBlock",
     "presentation": [
      "http://www.alvotech.com/role/OtherreservesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Reserves",
        "label": "Schedule of Other Reserves [Table Text Block]",
        "documentation": "Schedule of Other Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate. [member]",
        "documentation": "Secured overnight financing rate (SOFR) overnight index swap rate [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails",
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General And Administrative Expense",
        "label": "Selling, general and administrative expense [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount of expense relating to selling, general and administrative activities of the entity. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341"
     ]
    },
    "alvo_SeniorBondInterestRateFeatureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SeniorBondInterestRateFeatureMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Bond Interest Rate Feature (included in other current assets)",
        "label": "Senior Bond Interest Rate Feature [member]",
        "documentation": "Senior bond interest rate feature [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SeniorBondWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SeniorBondWarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Bond Warrants",
        "label": "Senior Bond Warrants [Member]",
        "documentation": "Senior bond warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SeniorBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SeniorBondsMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofconsolidatedstatementsoffinancialpositionDetails",
      "http://www.alvotech.com/role/BorrowingsSummaryofnoncashchangesinthegroupsoutstandingborrowingsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Bonds",
        "label": "Senior Bonds [Member]",
        "documentation": "Senior bonds."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ServicesReceivedRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ServicesReceivedRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofRelatedPartyTransactionsDetails",
      "http://www.alvotech.com/role/RelatedPartiesSummaryofRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased service / interest",
        "label": "Services received, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of services received in related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_SettlementsFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SettlementsFairValueMeasurementLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Extinguishment",
        "label": "Settlements, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in the fair value measurement of liabilities resulting from settlements. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "alvo_ShareAppreciationRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ShareAppreciationRightsMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails",
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SARs",
        "label": "Share appreciation rights [Member]",
        "documentation": "Share appreciation rights mmeber"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ShareCapitalAndSharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ShareCapitalAndSharePremium",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and share premium",
        "label": "Share Capital and Share Premium",
        "documentation": "Share capital and share premium."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transaction costs arising on share issue",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "alvo_ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation difference",
        "label": "Share Of Gains Losses Of Joint Ventures On Exchange Differences On Translation Net Of Tax",
        "documentation": "Share of gains losses of joint ventures on exchange differences on translation net of tax."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofProfitorLossandOtherComprehensiveIncomeorLoss",
      "http://www.alvotech.com/role/InterestsInJointVenturesScheduleofChangesinGroupsInvestmentinaJointVentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of net loss of joint venture",
        "verboseLabel": "Share in losses",
        "label": "Share of profit (loss) of joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangements [member]",
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "alvo_SharesAuthorizedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SharesAuthorizedValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized value",
        "label": "Shares Authorized Value",
        "documentation": "Shares authorized value."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SharesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SharesPrice",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares price (in dollars per share)",
        "label": "Shares Price",
        "documentation": "Share price."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationDisclosureofSubsidiariesandJointVenturesDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [axis]",
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r160"
     ]
    },
    "ifrs-full_SignificantUnobservableInputLiabilities": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantUnobservableInputLiabilities",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable input, liabilities",
        "label": "Significant unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails",
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of cash flows [abstract]",
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [abstract]",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of financial position [abstract]",
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.alvotech.com/role/OtherIntangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_StockExchangeDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "StockExchangeDescriptionAxis",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Exchange Description [Axis]",
        "label": "Stock Exchange Description [Axis]",
        "documentation": "Stock exchange description."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_StockExchangeDescriptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "StockExchangeDescriptionDomain",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Exchange Description [Domain]",
        "label": "Stock Exchange Description [Domain]",
        "documentation": "Stock Exchange Description [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_StockIssuedUnderPipeFinancingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "StockIssuedUnderPipeFinancingShares",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued under PIPE financing shares (in shares)",
        "label": "Stock Issued Under PIPE Financing Shares",
        "documentation": "Stock issued under PIPE financing shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_StockPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "StockPriceMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price",
        "label": "Stock Price [Member]",
        "documentation": "Stock price."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock shares issued during the period conversion of convertible securities (in shares)",
        "label": "Stock Shares Issued During The Period Conversion Of Convertible Securities",
        "documentation": "Stock shares issued during the period conversion of convertible securities."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_StockSharesIssuedDuringThePeriodExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "StockSharesIssuedDuringThePeriodExerciseOfWarrants",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock shares issued during the period exercise of warrants (in shares)",
        "label": "Stock Shares Issued During The Period Exercise Of Warrants",
        "documentation": "Stock shares issued during the period exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SubscriptionAgreementsMember",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Agreements",
        "label": "Subscription Agreements [Member]",
        "documentation": "Subscription agreements."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Substantial Modification Of Convertible Bonds And Derivative Liabilities",
        "label": "Substantial Modification Of Convertible Bonds And Derivative Liabilities [member]",
        "documentation": "Substantial modification of convertible bonds and derivative liabilities [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Permanent differences",
        "label": "Tax rate effect of expense not deductible in determining taxable profit (tax loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_TaxRateEffectOfForeignTaxRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxRateEffectOfForeignTaxRates",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of tax rate in foreign jurisdictions",
        "label": "Tax rate effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "alvo_TaxRateEffectOfNonrecognitionOfTaxLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TaxRateEffectOfNonrecognitionOfTaxLosses",
     "calculation": {
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfTheReconcilingItemsBetweenTheStatutoryRateAndTheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-recognition of tax losses",
        "label": "Tax Rate Effect Of Nonrecognition of Tax Losses",
        "documentation": "Tax rate effect of non-recognition\u00a0of tax losses"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TaxYearsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TaxYearsAxis",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax years [Axis]",
        "label": "Tax years [Axis]",
        "documentation": "Tax years."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TaxYearsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TaxYearsDomain",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax years [Domain]",
        "label": "Tax years [Domain]",
        "documentation": "Tax years."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceMember",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences",
        "label": "Temporary differences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for differences between the carrying amount of an asset or liability in the statement of financial position and its tax base. Temporary differences may be either: (a) taxable temporary differences; or (b) deductible temporary differences. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]",
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "alvo_TemporaryLabourExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TemporaryLabourExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary labor",
        "label": "Temporary Labour Expense",
        "documentation": "Temporary labour expense."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ThereafterMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsScheduleofmaturitiesofoutstandingborrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Thereafter [Member]",
        "documentation": "Thereafter Member."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ThomasEkmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ThomasEkmanMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesScheduleofInformationAboutBoardofDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tomas Ekman, Board Member*",
        "label": "Tomas Ekman [Member]",
        "documentation": "Tomas Ekman."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_ThresholdDaysForDeterminingTheSharePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "ThresholdDaysForDeterminingTheSharePrice",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of threshold days for determining the share price",
        "label": "Threshold Days For Determining The Share Price",
        "documentation": "Threshold days for determining the share price."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [axis]",
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesMember",
     "presentation": [
      "http://www.alvotech.com/role/RevenueSummaryOfTheGroupsRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [member]",
        "label": "Timing of transfer of goods or services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails",
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r199",
      "r210",
      "r300",
      "r302",
      "r379"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "verboseLabel": "Trade and other payables (measured at amortized cost)",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities to related parties",
        "label": "Current payables to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFinancialAssetsMeasuredatCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables from related parties",
        "label": "Current receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables due from related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ifrs-full_TradeReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeReceivablesMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Trade receivables [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r236",
      "r312",
      "r341"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheAConversionFeatureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheAConversionFeatureMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A Conversion Feature",
        "label": "Tranche A Conversion Feature [Member]",
        "documentation": "Tranche A conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheAConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheAConvertibleDebtMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A Convertible Debt",
        "label": "Tranche A Convertible Debt [Member]",
        "documentation": "Tranche A Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheAMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A",
        "label": "Tranche A [member]",
        "documentation": "Tranche A [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche [axis]",
        "label": "Tranche [Axis]",
        "documentation": "Tranche."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheBConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheBConvertibleDebtMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B Convertible Debt",
        "label": "Tranche B Convertible Debt [Member]",
        "documentation": "Tranche B Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheBMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B",
        "label": "Tranche B [member]",
        "documentation": "Tranche B."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche [Domain]",
        "label": "Tranche [Domain]",
        "documentation": "Tranche [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheOfSeniorBondWarrantsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheOfSeniorBondWarrantsPercentage",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche of senior bond warrants percentage",
        "label": "Tranche of Senior Bond Warrants, Percentage",
        "documentation": "Tranche of Senior Bond Warrants, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche one",
        "label": "Tranche One [Member]",
        "documentation": "Tranche one."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche two",
        "label": "Tranche Two [Member]",
        "documentation": "Tranche two."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Transaction costs",
        "documentation": "Transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price allocated to remaining performance obligations",
        "label": "Transaction price allocated to remaining performance obligations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "alvo_TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod",
     "presentation": [
      "http://www.alvotech.com/role/RevenueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of revenue recognition",
        "label": "Transaction Price Allocated To Remaining Performance Obligations, Period",
        "documentation": "Transaction Price Allocated To Remaining Performance Obligations, Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transfer to Level 1",
        "terseLabel": "Transfers out of Level 3 of fair value hierarchy, liabilities",
        "label": "Transfers out of Level 3 of fair value hierarchy, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "alvo_TranslationDifferenceRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TranslationDifferenceRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/LeasesSummaryofLeasesAssetsAboutRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation difference",
        "label": "Translation Difference Right Of Use Assets",
        "documentation": "Translation difference right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TwoLeaseFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TwoLeaseFacilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Lease Facilities",
        "label": "Two Lease Facilities [Member]",
        "documentation": "Two Lease Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TwoThousandTwentyFourToTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TwoThousandTwentyFourToTwoThousandTwentySixMember",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024-2026",
        "label": "Two Thousand Twenty Four to Two Thousand Twenty Six [Member]",
        "documentation": "Two Thousand Twenty Four to Two Thousand Twenty Six"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_TwoThousandTwentySevenToTwoThousandTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "TwoThousandTwentySevenToTwoThousandTwentyNineMember",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027-2029",
        "label": "Two Thousand Twenty Seven to Two Thousand Twenty Nine [Member]",
        "documentation": "Two thousand twenty six to two thousand twenty eight."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of financial assets [axis]",
        "label": "Types of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249"
     ]
    },
    "ifrs-full_TypesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsScheduleofProvidesaReconciliationofLevel3FinancialInstrumentsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofFairValueonaRecurringBasisDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofGroupsAssetsandLiabilitiesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofMaterialDifferencesBetweentheFairValueandCarryingAmountDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of financial liabilities [axis]",
        "label": "Types of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r204",
      "r225",
      "r229",
      "r230"
     ]
    },
    "ifrs-full_TypesOfRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAnalysisAssumesthatallOtherVariablesDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks [member]",
        "label": "Risks [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r204",
      "r225",
      "r229",
      "r230"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.alvotech.com/role/GeneralInformationScheduleoffairvalueofsharesissuedandnoncashsharelistingexpenseDetails",
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails",
      "http://www.alvotech.com/role/LongTermIncentivePlansAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails",
      "http://www.alvotech.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.alvotech.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.alvotech.com/role/CashAndCashEquivalentsSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents denominated in US dollars",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [axis]",
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r376"
     ]
    },
    "ifrs-full_UnobservableInputsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofAssumptionsandInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [member]",
        "label": "Unobservable inputs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r376"
     ]
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxAdditionalInformationDetails",
      "http://www.alvotech.com/role/IncomeTaxScheduleOfExpirationOfUnusedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses expire",
        "label": "Unused tax losses for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesMember",
     "presentation": [
      "http://www.alvotech.com/role/IncomeTaxScheduleOfDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses",
        "label": "Unused tax losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "alvo_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Upfront payment",
        "documentation": "Upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_UsdSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "UsdSofrMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD SOFR",
        "label": "USD SOFR [member]",
        "documentation": "USD SOFR [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives of amortization",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://www.alvotech.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life of depreciation",
        "label": "Useful life measured as period of time, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "alvo_VariableInterestBearingBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VariableInterestBearingBorrowingsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable-interest bearing - Borrowings",
        "label": "Variable Interest Bearing Borrowings [Member]",
        "documentation": "Variable Interest Bearing Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VariableInterestBearingFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VariableInterestBearingFinancialAssetsMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofContractualMaturitiesofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable-interest bearing",
        "label": "Variable-Interest Bearing Financial Assets [Member]",
        "documentation": "Variable-Interest Bearing Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VariableInterestRateFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VariableInterestRateFinancialLiabilitiesMember",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsSummaryofInterestRateSensitivityAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest rate financial liabilities",
        "label": "Variable Interest Rate Financial Liabilities [Member]",
        "documentation": "Variable interest rate financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VariableRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VariableRatesAxis",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rates [Axis]",
        "documentation": "Variable rate [Axis]."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VariableRatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VariableRatesDomain",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rates [Domain]",
        "label": "Variable Rates [Domain]",
        "documentation": "Variable Rates [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VestedEarnOutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VestedEarnOutSharesMember",
     "presentation": [
      "http://www.alvotech.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested Earn-Out Shares",
        "label": "Vested Earn-Out Shares [Member]",
        "documentation": "Vested Earn-Out Shares"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VestedEarnoutSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VestedEarnoutSharesIssued",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested earn-out shares (in shares)",
        "label": "Vested Earnout Shares Issued",
        "documentation": "Vested Earnout Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VestedEarnoutSharesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VestedEarnoutSharesValue",
     "crdr": "credit",
     "presentation": [
      "http://www.alvotech.com/role/ShareCapitalSummaryofMovementsinOrdinarySharesShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested earn-out shares",
        "label": "Vested Earnout Shares Value",
        "documentation": "Vested Earnout Shares Value"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VestingPercentageOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VestingPercentageOfShares",
     "presentation": [
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage of shares",
        "label": "Vesting Percentage Of Shares",
        "documentation": "Vesting percentage of shares."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_VestingPeriodOfRequirementsForShareBasedPaymentArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "VestingPeriodOfRequirementsForShareBasedPaymentArrangement",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Vesting Period of Requirements for Share-Based Payment Arrangement",
        "documentation": "Vesting Period of Requirements for Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.alvotech.com/role/SalariesAndOtherEmployeeExpensesSummaryOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesIncurredByTheGroupDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary expense",
        "label": "Wages and salaries"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "alvo_WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails",
      "http://www.alvotech.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.alvotech.com/role/ShareCapitalAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issuable as a percentage of fully diluted ordinary shares",
        "label": "Warrants Issuable As A Percentage Of Fully Diluted Ordinary Shares",
        "documentation": "Warrants issuable as a percentage of fully diluted ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.alvotech.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing warrants."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "alvo_WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "WeightedAverageFairValueOfEquityInstrumentsOutstandingAbstract",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value",
        "label": "Weighted Average Fair Value Of Equity Instruments Outstanding [Abstract]",
        "documentation": "Weighted Average Fair Value Of Equity Instruments Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Weighted Average Fair Value Per Share Other Equity Instruments Forfeited",
        "documentation": "Weighted Average Fair Value Per Share Other Equity Instruments Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Weighted Average Fair Value Per Share Other Equity Instruments Granted",
        "documentation": "Weighted average fair value per share other equity instruments granted."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Outstanding (in dollars per share)",
        "periodEndLabel": "Ending Outstanding (in dollars per share)",
        "label": "Weighted Average Fair Value Per Share Other Equity Instruments Outstanding",
        "documentation": "Weighted average fair value per share other equity instruments outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "alvo_WeightedAverageFairValuePerShareOtherEquityInstrumentsVested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "WeightedAverageFairValuePerShareOtherEquityInstrumentsVested",
     "presentation": [
      "http://www.alvotech.com/role/ShareBasedPaymentsSummaryofMovementsinRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Weighted Average Fair Value Per Share Other Equity Instruments Vested",
        "documentation": "Weighted average fair value per share other equity instruments vested."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.alvotech.com/role/BorrowingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average",
        "label": "Weighted average [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r199",
      "r300",
      "r302",
      "r379"
     ]
    },
    "alvo_WeightedAverageRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.alvotech.com/20231231",
     "localname": "WeightedAverageRemainingLeaseTerm",
     "presentation": [
      "http://www.alvotech.com/role/LeasesAdditionalInformationDetails",
      "http://www.alvotech.com/role/RelatedPartiesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease remaining lease term",
        "label": "Weighted-Average Remaining Lease Term",
        "documentation": "Lessee operating lease remaining lease term."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePrice2019",
     "presentation": [
      "http://www.alvotech.com/role/GeneralinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average share price (in dollar per share)",
        "label": "Weighted average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.alvotech.com/role/LossPerShareSummaryofBasicandDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding basic (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_WorkInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WorkInProgress",
     "crdr": "debit",
     "presentation": [
      "http://www.alvotech.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Current work in progress"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r359"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "107",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_107&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "80A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_80A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "74",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_74_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "d",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_d_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_d_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_e_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_e_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRIC",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=19&code=ifrs-tx-2023-en-r&anchor=para_11&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS01_g20-33_TI",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_23_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d_vi&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11E",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11E&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B51&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2023-03-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2023-03-23"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_118_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "158",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_158&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>174
<FILENAME>0001628280-24-012230-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-012230-xbrl.zip
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M)OWN!!ZU[LGCE2LV@0*P%K^<<FHQ_PD?M7:%,DQ@%S'_HAPP:58]=!%S*ZD
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M];SI]53AQ$RO%SO4Q,PN'TA8AIE</? 0!C.W>$C#/69J3:_.25MUJBFJ3N/
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MNY.G]2F?,9.*T^!7D(8S"@^HHXF(*1P]<.ZKU69>41MB/DN/L@>FBXAI/9Q
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M1(CD"5].KK-1( (E3_AR<IZ- C$L$K[U<_]@_O@"8/3I%8!H%=.'-@I$KR!
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MI8FG8[Q*)WP;UE':>P!5FV1]0J&I#]-@SLVL/;0$Q:#N[-Z[]FXSE:#@HZY
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MTU.F('QQ:GHE]DAT'9V+,>=I4HZ76<R'%_DE>)XM83A-<575+_M]0>0*CUS
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MF=)+[O>+(TLC1&A!':),R3VB9I@E<J[0?'B'(?_RUQGQQ/U3B:ZE[5:09NA
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M&EB@UTW=U>&YF$UJV9 )0VBBE%_A#.!J71NV -&U0#R(N(AID6N8);ZSS1R
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MW1N6./0V/0FE(@AM>$ O-GFY#3.PSBGU&L\0)O+3C,66(,=,E4I2MN<S(K5
MQIBB[47>-(>1:Y>5+%UC80+'M1-)VU)W4#YPR^,W$T4Q%7F2'<;'>Q&;A%L\
M%XD.F9SH]#.%<0N+E*@=RM;7'</U-S2C>A=YS01?(I7FJ_I&%OJH-(:]W,@]
M*4"A&*JM*R,4$Q(!]RPYQEU=JXZ6SC[.U:9&/E5RF/:*D%:*3!034P[_KFBD
MKBJK8 XOJ;,[["=%;'K4+D[31CG3HK9PDA-D!V<CC"];\JWA1I)1(C$TH<;)
MII=JBC/@E+8Y$%[C/7*F93,UTVR?^ZPY"N.MV%NGG+F,JNYE*H&LY5JH6$>+
M&8Q&F%%Z NL-(.+OBG%GD%3 2@P.7]@ET?REE!!)LV:;='J"427RE87 H>CH
M4N%MFJ4T<(DYB'XIC16_SZ#,?2=M719:9%7V99_0;BQ#6ZY2'327]*$XXN'9
M\I1_K5S=38-,U=':\:24V$&=IW:V 12J7 *V> !=MV8:)G(+B((,X_"(ACHA
M&AT!0MBR<$%.U SLKGK"COWOGX7GEMY!U$CT.-D<[I"E\TF&1(ELWYV(;GZM
MNO21.ID$?=%$TFI!ZB_6I2C9X5;="1#S6TP4<JGL)6C:QU/KP@XA74%"IQR[
M-\6V3JCXN8IRFK_?:OZ 88Y9H'" 5TCIU4Y1--57U&]%^5$4L/>[I:9RJN!]
M!T=T>9K5>YO5F&GTP0OB#M:Q>E.V[V;?!ENYCTQ K\QEG+T%G^;Z,'N$UWOR
MU9MO7[W%/Y]^=<8L&K/V"N+#[:'MBNV,/I#U<FP$R@G'[:R5JZ4!MI+(Y:RA
MP#=&FRDK$QG,DNNXT67<=YLHQ,$"1+WD=@:RK.UV7^EU*;&(RS)08D%Q740B
M*0\IPR4V NKO))?!:4TJZ)Q6['VN6)?6%0$:[[A=%9LE8BM>6)R?$4?2+8\3
M7O!^.Q !]S-J[P\F\/Z4PB5#3L<<HQ6^4,#:"XR1\6:" ](D"?TH& ^IZTF5
M#>[-47B-BSPS5]?\U1 AG](DM+>$I2X4G7!58H0607E#(%XV>[DH-G3YQ>R5
M:/:TL\LU5_[_\/+5Y1_.@.;+9O]0L/,+8R&[]/R**RB2&ZF!$]X;.?LFA;#7
M B9K-3WN/.0;35XWFX.4W2V76!+6=2N9'8\4L%_/\CEU9/?3YTK^BF(;%*I<
M^9\!ARP/)X%Y[:2AF?FX"Y$OBR.DA5Y^0OQIOK&,D"FKA,NNUX4K2*(1^88>
M J32E!:RG9->.6\A0J;@W2I7965(+]!'D$'U?/<R7'V0R/!NHL8AT+-V$5Z>
MCI*PNE<-J<%#%)3/GG(EVIBL)A]A$'LFE:IZCTUY4?W*X(^8"&AT&2C#13[T
M1$29;1'0$$=BH#]]923411U,#/1P/K);M@?]]24M?R!9]1\?NA?&ZLRW; 4V
M?B BEQRE+55U$</<4$D7N>&V6.P[>^*4?FY17I<NW[@KPG<8U]<6Y;_V@S08
M%\XYH= *6=RURFURJI0-?)(.8U1)6274BHM-D3=Z!*SV6*</%Q5[R?)]<JR
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M97O,/%D[026-1L-D_M8E'9OBV/8,J[SN](3DR[! 0N@&#QK'.9_;R$_6T+O
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M5U6Q$1)_:_@#T8!LI*9@DF.$)%L$>';-\%:YM,YBX003&,RN0PW&#SB#PTT
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M<^ *%I:5\>4H';7HD?L_U7N_[QZT#.]-9N6(G>8&9RAKIDQ(NA@B/BV<;2+
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MY#.)OSG,I0?Q/HOHGI!4M7S#'_5Y^HN(20>J )Y1RI!QD"&T%.\WJU@+U(/
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M)X$ H9  &P?_YZJY$!*=L8M;O9+&R=A,-1D>@[D,OJ^@PR5)I/M4WEL';#@
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M+S!B=#A9S_W._,U5LU>\1UO:O/_L(6,J_$(^TF,&#=>HRGB*AEB,DI3+22F
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M+=&XANC[<2=\2*EM#CVRV1K%A^%ERAQBQA6K6,>$?8DEY!WLPX0D91Q3@!;
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MM0[:)8!"AZ3Q8);RUCM:&.DS!>[)M*IN2!H%6!!*B*1?CZ >@QE,+MAH1H5
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ME@'=D5PR2R41\1M@5/:52#]'-@-Q=0I<*EQ)ZU5E1S%]I1+NXZ")]MCD@.W
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MR)APUG@Q]:W:$"'$A[3H/L?ZQ BFM6_"\UV>(X==:\1)[E? 6?./NRGZI/\
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MW0KZK2),8T>$.I#M=(8U"R/+VHA!^1\)XLS4OF8 TB8SN2"\K !^*&>*3T
MGF$YE*B7!%(C/?Q]$&DBSP.I4I5W32GYT!9V2MFC4CW"4Q"L&@3#2T1Z$80D
M5)J-28OH5R'X*I!3Y7KV5PTZ@W\T; 5 + $N%%J_BJLT0X_G7\3I,N $IG3X
M.!$L))S\0MIU<L+[.STRNGR\VE1*[ 8#1_\:X"/8I92LZJ.&B$&IP<556*Y$
M%;;5-T9HC&7&C$+XV%T%*2?G<NCYF/3I/I+0[3D#5H1F[11")QC=:0_7V_.$
MJ7@)2:2BW0@ H3<Z?BU/(]-Y4/R=6#9Q:@G)+UY>!#H8:YV\L+CQAN'-E!M@
M!PK'^D@W5693NIH>7A< -]> 4NFB77X'%?[ H%-/M-LG![A",N)LZS",E>K6
MX(%5FYF1]>UL7D-:2?WJ!0=KY%QPXQ>B =X*'B\S$4M\^^']C$-+1/&C7*<1
MS?][*3)]2/[BMTZ*Q'!&$W Z @2Q0JR/W]8-'M)8VN4(67HCV-YB'M0$YT1J
MO]8B,&5#[9PS7R=A";'=SE 5SJ""-C-$OWOG_:\IUH;*#XAQLY(CPZ^'MK-W
M-MA7M>&4I)-F3DO==&1B_^,*HL\^?2B(7NZI/4:8-,*2] B".-H?C\?"CWN@
M0Y+H7Q\"28R9T1]BILL[EHDK:'\*.&O=$&UECH.D(Q@M2^825;T3:B#PW4T4
M_/OH?^PS!![!+'AM>!; R<Q'=R!W@;\H?YY(%F/"J['+P>"L!,8% $[P,B2+
M2A\Q):1)0AE\FBCTY^QSB.##RUD %P?R>B&WG=?+(G2BO >IC<8?ZCIQ? JL
M>JI:8R!YC1+8CL!WT;>#'#ZBAK?D=,V8$A=QD=*8@BTC$7MA]- 8L[;.W=KI
MQ6RXF=8PDPB95N2GN6[;[R2GB@M5U6U F<9/'2#WV#6=&B'M(A=&!@PDIUN'
M_)C@ <A)J?K8VD57V(3P^XT/Y_9 KTC8-^$=/4K1.T*K-$6N.B37]+\D=DTF
MY\PL]V06\:L)W;K0>P8U(67,-:M^NG.+"I%A$$+YT'$>$(>-JLU(-J,@VT;5
MG)2J)KT:.6-\7\I5 9;Y%S8V84TY;S:)VA<CA74C+-4C+%$PIGYV\Y$M.S]$
MV(S=YM#BDF1RX0!W;!QP)[-O)Y]";Q^L1U/[E3SXDEV'1IB",Y24_";894PR
M1!4.O=K6Y2TV7VK 1.J<.##1*2#OOI!"%V8*#.]KW:Q]>/:;:570AS&3 &GL
MP<W9U,BM!UQ-5 62-(AFF23TH^^9FI;*>4*W#L9 ^S'BX=#?_+U_OB4D^E:S
M%V9@L=N&.VV^?_GB)K37  ;"+VS(#B?EJX"'AJW:,F_&KB;<%:Y)^7*6R/ZH
MHGQ(/TJ(PM?43XCFEHX=)3(!LP+O7L$KE.,2988.!-Z7&R-U4G@2<*;@G9.G
M?8\CJ]OT\GA(" ^':"6L=Q9D )D4")F"8="."LXI'BXO0K5\P(*8 9O%^S<P
M2Z=\R)2OA:0GU<I,98\I%XC??7BIQ*2+':?/5X,#>5/SQJ)$RDAS@;@]V>!$
M#A9',2$G3K0LFE[N X^;E92]9?H<6/98Y4>2MN4)6/Y4[21:PO9U[4LBB)[/
MBL#Q78_(J^@G ^QE37IT=E@35O F\:LD#6NJ%/"B?MG<Y:6CAKEXJZ&' SLS
MZ<C(+2V(I6EAV66LB(:A916RX$M,#$A*BAV]SS%R/<E8CUIOG&BQ.-Z/M;3,
MO-1\N-?[G=3XK;>TT@*\^!,O.64_&07,2L'Y_70>4UZZ@IN9.P>R3ICAL3'I
MR H$0008]Z5)ZFM4B0]35*;&VS@6G0[TV1'  .*/:,"DX<S<]<06,:8CYJ<G
M^V_-DB[S22R(]C+'>(3KV3>Q^$7:3FO[;2<1*[-'$1-IE"U_S#RBT5(9:8$6
MB#'*)?EX@P>!)0IMNX.!**4O\U'40([I,$COI"PG:8T&_3(L]>U9S"PN$@>4
M^/$B]<4E0X[+54&E4_N7SAK!:-"B#30VN!.EBC-X^BT?6[JYLR1HTPIN;&*$
MT0E+U=X'C/DL!@^O7;2ZNH04X03N!1#[E0X361YMR4_.M]A<3BU-?U#L>JS>
M-87H@<*Y7Q;<DS OF;*>T!S&T,FSDH=$3>&!&<G@.:88TI2<CYULHFRK0M:#
MW#O%6<A#_SXU!>/7#%??Y  =$2WXP\0*@B";=,*Z9/TW >S7G[SJ]>P-XYAC
MX=KW/>7_,"6$_V@!A!A '0]R*'F:MD-D M3=< H>.Y&!$V6/?.$]:^'N),?B
M2B@OKR_L?/K%F>.(! L:TOL"4@H8MC LDFV;.%5D>)3]<T3G%-Q.:1>)(**:
MC&/T:6!F=^-]G=P'BI5PXR7NA2\$4Q^AQ1KI]C64ACNP3SE2YL$&YS0%3=GQ
M=5/OB=HBZDLCGQ ",FFN&"':QV6#!!JZ7#!$:44';/@H"K&:V\H57XCB0+T4
M!"O"I9?-ML[['4L\GOP-,BF5N/2TYB;RHSMB9!ZE0J$LXWF;] 1/4< A'E)1
MXYA<"-LI[6T_#KYL4YH!'PIR?L,T$R%[DG<__.@5[0;%O 0HFC><O=7%#J:T
M<VM.FYM9DC&??+J'4KF6RI\\E,J/F?X_:5J&K4.,_T ,.K?V^V@6?8D[)UCU
M\9UC$B 3 CEW6*";+8D'AY*1+;8+A_I.R$/#IETCE8\1VSXM[;/(=V1@BR&[
MI#XK:06(Y&(O.HNYR<,%&PN)"J9VYCRJP3:&HY#1KV@\!O;Y?<Q&.BLQUG3/
M"I9EO><'1S VT.0& 3+0S.N;BJ!I4# CD=E+2WF/830BYFG.KH1)"'K19X^N
M(:*@N@L#I(Y^BXM867SFQZ5*Z%@OC.L.F3C0Z_@HW.U$I(A[-U/^_F'63;)$
M 6V,R>HR/U!4SX6:P-[XS:OG+VX,RUM (OS*<#G50[RX3-!;?;\%&KHE-LUR
M&D6=7 !Q@K=6W&%ZUX_0E0D+SQH9=+\"14I+9#>HU05\85;LP8:<S._CG6Z8
M:'@D3H.@F2[[P!9!_<"&"A2=/*A2MG!GHH*,@EEOMZ%&\PD0"5R>90HSQZ4G
MT2%?@E@I<@.'R4OF0:>'\D2A=&2A)?[!D%[T+H;?S%VWA[)5?F2TR=L=I2QZ
M!(M'2-X>*_AHZ;8Y)B$(X&ONC43AD"G"I8?9>C2\?BMW_)*=4GTF^MJLIA2O
M5EK%X\L5<<;^8/,F'*M55-]ET PG^7F18E?]M23Y+W'UV!>18ZL5X+?J#5%"
ME&)@K:IA;; J#[SK+'N?EB8 KH&NB"$=,(" 6.5,0'/#??HHGN'8;(]TZA-.
MH#P0!4;0'!_8EL<92M#$S"S@81%9W'%[ E8R;POB%MQPRW23*U=FU'EFWH98
M=S7?BNA,;@)>8[=,&_A?-"]0"[*+]%]#CM?>A8)89'2(W&,^ ]%4Z.!'4V_X
MRKGI"@5]S2)8%>#\H2*8;=+QRR'XUG.AV9,2P9'!FVTAP\@#&)LF&0T5CC=]
M(Q6<44I"&:3=\S%>PX#^*>O%K:!(#,L#AN!^A!>WN([SBLDB[32.4;M&MD3R
M%US)TQ9*H//@1ZC[#K>B%4Q4XG7P^M-QCDFCR<Y<G(%YU;@=:M8SI&EIZ9/,
MZXV9X6PV;PJWDE1,Y=9U5T0C+E.E9R +M=&&:>O=!ESH!3HTTHK2^^BGU*83
M93L OEOJM@68!EW7_Q5J^K N,%FO#$!3M6=5*Y&"<+3!A+TPMTEALAOU> YQ
MG*OS KV4%S%>CSR49,6C@;LM=L.!X]. &JD;QIP9IH.P%:]GWV!K/&L"6CLV
MO-])0[8@$GEB,R!%39Y70P=DNE>Z0+3*7)_ 5M%@+<R8"\XB3QK&25.G74T
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MIR0S>3SY(7V6RWHRKUTV.Z:R373F*B[DU'1]P1W;*-C,&6&M-ODODRF4+B'
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MUYVA^TB&SA&TCM=AT"5$* =!IN93HG4P/DA$[RIL5%@Y>J?9/EQTD R(:5J
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M+8=9_.V\7A%<8#;1X^>0/J1:V.T\^0K??G8\^>__.GGRY==$E^XN\A9F@Q6
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M_O'[Y-;'DV]H='6"SX?_]A_DOAU:#/:M+Z8,; '$M,G7Y=P=C&Q':9[VLKH
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MF_8MLYEUJ,P9EDBJZN3**]+%O^R((U^.Y"4.;YN3?OQI.OZ*@<:L -<@MRA
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MK>%$4,\K\CMM2&'P2:B7V0W$(9O7T!S@+%%8P<=NM#':Q="CL6$$RLOKPB;
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MZ?3!@T=?G#QX^L7S9Q_P*(\GWQ8SS%# A=10$]2TKARD+PAR%22.W)-MNM8
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ME^6T1-W"HAXZKBTXWH-DQRUG/U)FEU9U)0^5V,P8%X3E:!561^5-FO5M<:T
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MZEORB.1N<;L]S^28%%>Y6@_W-N31?&(A,$P5L:F=GC[Z.CS@9%F7?VH<[*L
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MTZ@1PMY\!"1TG_*/C?.O IHZ^=).)HWC8,QCM>1JW%\E>9-$.Z_;9O<E#*/
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M*V!6(X89T(I:6_;A79@M^ O9(K4EBEF._B1#I(7S=)RO@@R[BD!#/,QBU/@
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MWQX>C@ZB!7*@X [Y]O#!Z)'^D[[Q[<'>Z-A_0 "DY.QK"G1P?+!Q%]P63)N
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MN+5K?D!_1-:(\J#<"&7:&/N"52*$VTA19H6&<OOLX'LN<>%C"YB'I <R9L;
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MK-[!]IU0J79"3*.!Q)/Q#>*.R1,OIG,(X2%7X^-C=L/A6FCK7XV@H=X5 <;
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MVL)U=O</: _MPK:9K)KR'"'\(V%U8!?O)QAVG4* K6/X+ [>%_3DG$\D4/O
M$Z*4L#[9H%NT-WKHW:)M6S?BZ;0UXT8'TR^=KBM*TX3^13]=X_(R!IM/!)^F
MR;'PEQO.]QA &3D?+M](H8G($FDBF2!F9+AVL9<*2]:[J.53JT@6FW/MG*%R
M*>GAU8%\3%A<UW)?Y/+9Y@&43NZ:SLUM>NUNR:,RDV.*IVG51-IT32*-9HY/
M5]HZ:8)TZ.XD[5PMXSYF.NAZUQ-/XHMDP#0[V1F?9J6IT0<376G3Y"DW7)W!
M\<W],8Y;QW3'.[7)'II,%W\<_036JH9E1*@?_5?LTXTNC^@3C3X%&2N6 P_W
M7+./)HGH4YN22K3^CXA]65?GV!W^Q.1'%#"P9:RW<U<.-^7P1W?E\"TP9E>Y
M>_<WNGO/8:1;Y^S1H*.=9):#AU4AJ86X>E7*NKC8OCEKJ6-6,WN:F6&I8%+Z
M2"#(@(4+KN 4E3YJ%[XP#10=V3/**V@'-[N'_W[^PPN*F):$R]YGOBJP5)@-
M@#.<1":G):M:S%Q#.1KTB5[.7PT=TVX^T680GR0KZ6[^-:5.&;2@/ -K',U!
M=Q*W*5FK%"_/0IC3U'>HQ^ZWZ31=B/&=9LDX11>TPOI&":?3-06C;M-J>:*=
M]?V#RE1.UNT17Q*2MB@Z5NQ">SK'F #/T46-+%]PCJ!/#]=EW_JGEOV# _(/
M,D0ULACGG,4#LTK# "VTU$T[7;GSG>HY,9]V11BV^\.<CQ=RU);D0JI. FL1
M=F]%=[C^F_R"-9Q/L'2'&RT==6O]SQGF '!IOZD@4-HZR]<=OT_,4A@AR4AX
M52B?0\5!&'%98S0<1^.VL=WU+.?C_%%* CN!2A,@QJZ1=EDN);D-O^0L/75Z
M820BG7HH'!I84S1M,H)..'XP&(V3JYG,9EFAH$X5-=,<+%_@UY-??GX9.S/,
MCTZA$M)FM!.PCY56?\[A(9/=)Q%J#B/AWIKB#<6S0?%F<89Q/4]ZS]@N*49N
M&!\QJQ(1D:\AUJ-.]DJI%)BZ06#%1!Y !8MDFCEM#[I&W59G"*C"NJMCE\+I
M<.+6JR5/,>,N8KL0-@^/]&K8)6;E%?[U(JE]_!]-6JY=7#BB\SK)^89R$[P"
MS\90)N#^Z&![$P&??DH<?OPIL6V3Q8^;.594=W(MY\109:$XGG2^<=@8*@N"
M]X'Y89(:3O(5$T#(A$HK29@$<7+R+FI-B[,$:<YIESC*"I_;-_*[H@AFL5G"
M6$$;SE%A4."E[YFZ1^GB'(8JL@//U#7WL9IHQ @>W!(3,MOWNA$H,>D@:-1+
M9GK=RU*9/"A#BB[CSIN?[Y&?(>+'#(1<41,11%NI=#@FH6-";=_)1"Q_,L-T
M*;M#/:NX1.8LF%5P2ULP5!'\,X6=277_[9OCTXWN'7=D>1=OM^_C)=&;GSN>
MXR%WGU>\]_2@\*\BF:+:GH@-\D&@T@1#R3'GO$K\XC!N>F.3*(7P">%$W T1
MRS@P#N%QP7#H'.G<\^ :]PR6BWHFG>>VV Y,>LDXN/1;TN,R0_@:SUC8&R$0
M@D5.5L(XY]Y""1+N,)Q=9"VC7:%K.9:%'$NY&IP*\F;D_/Z9^Y*(/TS7\F4)
M_Y *UA8OZZL\]N/-I:@,U38S+K+*SR?5]CGM.O;O@J>(=LY*A2_%'K_T[I<7
MGX9,6G,W]DT^'7;TZ\D:D%&_!F4K3K4?&#T6^D"(G:1<J)--4VR%BP:$V8P]
M9C!4D[9)BA2AU_#@H_ )L^)W 6$/WR&X%N=_8,/II:009!C.*&#$M)$3=7'=
MTHP8S8A&$?U[@3MM+A_!M%(&FTP._I$R0Z).ZVHI>B_K]KC;K8& TN@9 ^&<
M+?X.$9@T$_9L.T6F:]Y>0:]$#S7U_!Q#S9-,[B8+$2S[+\B+[NG=;Y"Q(+/0
M\2A"(W],=WB5K+JBGE<<'V&2A624Z(QD9=F>R::@*3#;:O:/ \-$0%L\3D,G
M95%.F=N&Z$,N,&H: NYU< SZ"&N.^L#E=AZ3<Y/^@J %B$YWZ"1'AB)<W<]>
M[NT_O+?Q^/B?,D^R:KNFX9M_\:BC';A2GOWA80R%-XI<'R0*-%P0$$.=GCWG
MA5IW^$O#Q8AS5V'70%(W<\SQ3N:DGQ'5L(2=824N;3J@GK[][1XWG"0U*:OF
MJ^5(YI7EI\H"91,<$*G+^*8B()1*=P_$(EH,M+'ET(.]O4.#1@BL!3Z_UB/Y
M87Y.ZCF\S2?PSHDG"E[!RY=/HYUO^ _?W&.:JUTE"Z15),(@[DK4(U,3]/W@
M@8=\J17D8B+<^[>"4N14//PY0'?96B4N@?^;)JSJ\!OK@J7F_'#W-=:*:K<"
MOV)*8I&H<RR';*(<F56J?0%\JFCM=]HI(+@Z+=EXGI/U"=^_77'SP=Y=<7,K
M["$;_P#NN-8+.AE.0O !KSX*'Y,N/>4P$S&;%3UH?>S'R$!&AAP<.D &'#:6
MY]I[#$T)5C8QK 0=]P%]#1T2=P$V<Z%29M.*#S)<&.J<]4%4?7#H#[UPOC3Z
MW;:C4%SRX,4SVH;3C#:Q1MVY+%CIN$6]R"5#Z_$S;#37---5*==LVZ)(%NFT
MUSU%W54Q!V6#Q?2B65UD9;0#!UKI3F_3C;7VFS^GJZ9JIW#F+L%AKMR7K_?.
M;AE7J$A>O3;8^>UG#7V23,[/6$T"%L,3ISVQ57UC\!A]G8 =)Z1QS]DF)/_M
M4#-[_EMR/U=+80L5%R_">A*R*V,7BM0A10X$7;-%@O20A,T'MXB@YI*U-#(/
M-7CSDQ0)^PLL7?$N]@.E(,W?=YXNY,=Z56"C)4S#E+47(M5>D-%25VI2H\:7
M4(0K59#OEX$O/Z:CI<340-W$5F"D$AD.3XW<N8. ,<%T9(BZ-9?EV),)8/[3
M2H6 <1<X=@VJQR@#4+B0&'.TPER<3:IRG%%)$69:U>>EC8586#'EX84/**O.
MC:NJ%QT^"5L_/.:HEM@V>,3MIM.S-&18Y>95/_^481#*SZE*$X3R,V$V*<\+
M)@YS5 >#/6LW 34KFCF.%C#^#'49Z@F<MR7][FJ0BT.T!&@7#G)48Z939AV9
MW<XI(L]@3U/"+!A2I8Y8RZ-6N0C*DB I*?/+ZZ<T?).TGL1IWKDH,9N.IY%7
M*BK;!B4::6!<-CSAW<;7PD=.,1V3U:0%S'JYU);/*@K1&<%]*Q('GKCLM]-6
MF9-"AJ2#:E0'D6<)$/).A89HBMA70GA5BLUP-#Z= %M[:+#:W=W0O(2=]DDA
M6HU^L:*3EO,%")4OI>N>X(:RRDECV( @19U.%$7=5TKY2S0S]\XG1_NX92?4
MU@@!V3D.D#38ELJBI5+")FR.ZD'0&N\L3\<_+15/ CZKK\\GV'*9K[@^G0]-
MB-@;=SIV<$%P:B!S3X8 ;\+J;"%ACYWO$E\A]3QP#RYFDHQR$L\[Q$'HQ^\R
M"V^?R3^6M0)?N([*DBWM::RW;+D06'$/!;PM1Q2NIJ]_7U@Z*5=N5*8F.%/&
MZ="JSI%(<]5?GW4LRFNLZ%-U^GD'%"!4ZA>BSQ7=29%$>!TUI32E%*Q4VHT+
M)^YDSC,^BM[/LSP5L2=F^S05 V=BD3:*<Y?ZH5FT?R!*L(UCNR"V#2>FQ&<:
MRGI_>S Z5D11'-PL9-2(VKJE$09Y,&3OAGL060[?D3PC>RMP!2XQ"?#M_M[>
M: \_?4 _+!3%)("3F*1SJ*[M!6+@?AXOIS3V]$(\A0:)U3.PQ*3D8AJTWZQ^
MS+C&+DL9;HFD.G4=#IE^P[.SO^?5;JE( \<?. D$,:.N9Z<&@[+I6U<\1LZE
MOI98J/K'NQS%L::4'R /@;KGD*.V=@(UF$(V3%Q6.FR9K(A=NZ,4B'M[G N_
M/%R-Q1*8@IOHO?#=9ZCB0\Y-"A;)>7,IRIS1FE!B72K=HHB?$6? D<1.YEN3
M2*':F9):@J]7KQ&0XX#+"ZMU[* ^'CTI%P-BMCML0QE9HOU?'<G*8'!.:(RD
MNN@V=,;Y"(!7^4I4T^1N(VQ\3KFM'EOZO<G6AE\Y>LV%<'LLP'8,O3.ZN)LF
MT66C*DB[1(^48LA:'MV)3W?TV#IR;'1"[.)A8;76NC8Q*V88&%;M1 0O4>6*
M!X(X?_HE:OUY"3>J9I#IN$Q6L970I"]WY>>8/@IU-3LZ<P)M@\\/"-VE,)<T
M-T9M;?OV.A\H=D987=#!;3(5]_%VMB%F8/Z4U^TR_IWE-A,)"0S>93&OEWXE
MK- +4CGIQ"V*?I9!^*P(OC\?U5,S'A^S:-4IYV#4\VB]F3*9]*<(>+"8N (Z
M#5IBGK5ZI_' LR4FSE$=2G1K-'TS#\Y0-PYTFQLS7AW8\+AYB]2P*"GL5Z/E
M:M3Z\3ZDUK@A=.K-W2DJ. NT.Z/H1[ 5%WS\XIO.-GCU.FU)X+/I 9_8I]5]
M/3"L8KUG=]<::*IG^W?5L]O6,;,^'_]6<<Y;E@G L7N,=AUH"ZCTGZ@2.;I6
M&U2$=?#U<E:2J6LP<@/?[]PSAWA"!/H]R70K(VZW*A^()D2!7!WYBXZGLN-H
M>K8ERMF2^JFF-@>$\9KRDI((0Q0V0CTK&64A0]D@H\<TM4B/^6AOP_B"]R!T
M^W6[@"]0QET@9'!]<.U@^(_O&/"_()^T+/RO+$0C["FI4=FR.[<<4A(+PAEY
M#(]D[.JTPRYF[X*13+#<R@;",JYOA(U(!P_W8GCBJ(;-CB+&:2J,&<+@5'O1
M5O$T8I^!ZRO)P5--\4J-B(G^FJ[.?T\NLO,X.IVD#/8)6<NT/<5 0-V-M-=%
MZD#Y:E(JQ+=7- *W@'LG?D@K#*P>4XNS[GN4G#V377^&N[A@3W8V2S).D662
MM>KR'8DT?>'GP8L2=.0'_+XG?P,O9_BN,(-/L-0@,,)+G!?EY>Z\O!35P5KX
ML>75XEI0D;5 4([CW:*I2AB*)&=%WP ^.B#&25]PD%;KT2L%V"S+\UT,[["E
ML)Y'/[QZ,_"2AS5R7?HG:S3BYB<)%6^<F&(@6HAH!2%(3Y<&0NSH5^#GWPGP
M2? /$H)7E7(9/&9S^HIU@O1UO0F;V.Z$V8:E"GD(F&!:8#8):0_SU2XA!CLB
MQ9'(=:]I6U,ZS:<_OG92Q 2&)?BS?M<21>-_>Y+'\(K1#A! F28DK;AK_XXL
M[VO(45$WBO@&WW_- R7J<O-;,>$@\+WL0H2\$Y6L\WI@&W!2>)B66>V&@<6[
M#$&_Q="%JJ_7NUD*,OT(&G;+NYZN@G\J+3L7RZV(@/LE&4>I8;]G%:42TWDY
MJW?7:7IN'69+_A10SM=*?46I"$<&Q-*F*U>T9D1OE[+><,$/40%*GB447(J[
M7%D(&#8(US6\@$*T;\FZ##.OT6LJ9UR]X!JB;?GN]#[((PX<\#4NDL97D A,
MB!*S1=1C2>PU1X1DD[V'EXY31X0XBIZL(O3JF9'P4#P,9*@Z:XL!J5OI4#B(
M R+, 5;2V-(M&50S/M;^(Q\3,$,MPZ'O%*Z^K."IOC.1CJGGV=*(SGXE8*86
M5A:X'0?BY-HIRPRL.GP"4DLI:I=(ET8.GTPE1C(+CB&/ZBS%[N/EW*A"=R)5
M%Z$K7RO1?N[\]O9>'+U]=_+L)-IY_AO\_*+]/8O>4!T^>EJ.XNAE,XUVB% ,
M_OH4XN_D._K?Z(<VG\F/K](I##+:,5O%@/Y#%M?O^#]PL9].P.>46^WP;H/?
M/OOY[8_1SKLDNT0*LQ^Q5>[G$EOLGB:+<3G%:[^"RX+SB_2PL"X2.%_ <I\6
M4S#]]%OX$?_S!,Q,GH!]83?J37*>(=H [O%_3MY&.Z^RZ13,W?-$=,/<N$[&
MTRPZ'5?)/%O 2%K8["OX]<_) JEC=YBX%G[Q"N*,E\FX)HK+# ;[,AOCO]ZU
M3=IR/O5M@@F(G8"K%N^ Q_$?[MF9-G?T,\SV9M;<;CL%7"IL)K1O6@X@,+#@
M9V/@D1.63?%-1A\$VY7A-)C$01A%)3*) K+%N*UJ!LXY7FC/<^ :1*B"!ML'
MNXA9ICJMNT;6DD=3P.4C!E[<=F$+V$X&2^3IE\D*#3W<-)]27GY:*HU!>5E0
M**#4MM2'PP=SA0RHTU@9K!'_I;WV>M"3](/9HIRJAG""-J:>[W5JLEV$07'4
M"'2ZI77CBK"]=^$_P9V;$_:2[DZ.+^?7I^42KO!5#XH3"ML/]Z-GZ:33")HN
MEGFYXNSC/F9KEC3>H?0C?N3A\3\TL81'#)7TT7>;<E&.D3/]L-XZ\*$:,FT?
M]8"%R%UL@"N[$CC&%.WA90CBT-.%3.94S\6!+3)F^F':RG0"UC'(A-TM_R^X
M_)^__4&R2=6R)%04ADA8<V0K_'43IN])7('7;,;X>4L<HX9:#Y2,H:X>%1#B
M0X:?$**#52F"!#/84PE> ^O8LDR1H8+DZFBS,'P,!^00A9=4DB>\!J65'&3#
M0SOZ7?/<\+1D#ED1FB 6K#FBVXFSYR*KRH('$T,<16>E3V(27D833/ 678)I
M5L$3D'])M1=23HV10RQKW/&-!VX$<7PB)Q:IL-(,!+>5NC7=&0:;A"1/BJV!
M;5O4B.,C4 $))K454PGYH=X :=';U5^OKRJ H?AT-=.,(3<"ZE-.HC%F#S5=
MB?0 B938V2)FVOV ,HBSY*)D3*'6LR7GJ_X1O0;<ECSC76Q&7DY<\$KB13;M
MWH-GH!%VV7=*0H>)9J2@<S<-W[V\\#$S7+0LA\+A!XPH6Y+G)H^J^=."^\ZP
M*@VKK$@OJ3R,<(^SE5(-)RXXT2+%&'<==1GGW&TR!R?N$C'XM'-\J8ZP3HD%
M+MAMUCL3<>RX$7!DSHOC;A*I#EHDG%#D#.SPF#@Q$.$I[Z!C79"CE !8%C 7
MBR#WC+27<VJ)<=/8@1S2M)#8I?16,B0"!LHH,#\F#_2ZPUD8G,7!'<[BUC1D
M7(FST%KLMN$LNN<!X2435\HSD-5 &9<-KMA;5P*CDY6L1=*$\.8>(,/D=TTO
MSGL/G6/HI&NPYEA3<T4Z# ^\D[M#Q$Z7#XIQV#:1D$*"=+_Y-K= 2[$?0C '
MIF=E)C,W3S -PF!]ZUM1^0&U(FO?",!?(0/(9;B06J<GJ\ Y9ZD@NKJT4WVO
MEZE&.RQI]A=H7J)6QCG2DQ1G:=V)U((@;LNVUJODO-.!(<71?A>:[U0=[FE2
M=/\UFYH$&=^OF&]H8Z&J%:,=99C4?V46>+YR#;!-@E26IUZ')$C1X=8MSN!W
M^C#8^$A *99T )]#F@A#\ !L*IA_ 98:4"]L:EQ-H^BM-+HH'YK?-_!^.2=
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MU&UGX /5K0NI2]2P>B9SQNVC8*Y4*2+X9)[]D3EX:D^"/$"\V&2?[\7!2;[
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MUZ301G9<52W\E-N,);S\(+O.#;0'T0*^,W?$@$4)UFDHZ1OF>W'H7[-8<.4
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M@NLL5;I5_Y&OY2"/HE-U0,4IQ[#R$_;-\&!\8GP<1D55FBW&$%"E(BM@MO]
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M_C-9+!_KO^+(]J%U8R^B]V?.(+:&M#'1S/D=VR[AE\0R7F)W'5SC%V7 X:F
MQZY;Y+I+.]XNBW+E+"_/$:84;:])('0[%M954NU4_7=UA9].7KW9TKJ"&;J8
M)/1[8*5F):]';QD/'H$_4>;II,W%YR-N;Y1LI_.<O<-0N!T>L*5-!'_F2:,=
M8QR@H)81QA 6L;_N[($1VD<8"B^&.^@]",WZP@$^-J@K?JP_;/W0S^ 1>U\
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M[_MWM?=-I_U7>BVNB.#HC5%GC:.Z]3GU6%)-*V8],@N^*0UH"\W757W56+]
M_%SH^@9B0=AC[(&!Z!.P0<JT7:@XR]/=:7:6>:6B0/BDOXG#7& /8H.&2--@
M>,[V4EK"%>E!GZ6I\,N0778+H7Y!]X@XW(B2$\ L(K/V]P.,_;'BO^X11XD%
MT]%A[L5_"+7$\1W$T_"R"+?4@F4G&4=<EC$"%CAMR*V=IN%%[;K/)Y)2)S.%
M$BENRUV#685Z@P3&'$7/O=NB@,@!L:' 3'(ERP/T7(?\8*:4GU(U*<$>4T:3
M]1@<.*.C-Q76XF29;!)DM,",!LZJVG/U3SCV$7%$S0[P9(N8=AS1;--/!/:3
M^>:\ RX)&H'+Q.B;LBMQT-^]9FWD=LL0NQ3Z7R  .@IP'.LCH/7/;*.@JZ,>
M3D1Y4H$#SV7'7DZ:<V<+QT($TJ&L"7Q>/F;)@=8.RW,"72>8"N,E&&Z94\U@
M+> >?+UEBTC+01)=&4R7_D<L=5E[L5/2C=@8\>"G<W+Q]9Y_\_#F:X<Q,*;;
M-=&]&?H[1WIK#<+-HKUL@<EKEOW[#-'>C0S<#2.QOJ,KW)>WS=/U;J/W=+O'
M@UX?>^(5D4KN$OJ 5-GFXJ]\7?P.EI^SWT*M.?\OKF.HOC3^S8M-BQ(=VN!E
M6V&!GDF.DGS2BOGV T?L:3OT<H;2;00E*!B+K[>+0Q\/ U<(#/UA2$K3JE<3
M*&*;A\>;^8>+P?&$4:H?Y]>PQA547!D(*7"^\_(2Y@)>NQT-M7+@F-;'&L'Y
M]7EB#AVNJZ>$E/)AG_J5;YQ>*WWJ6"@2R<&!4(3\':)+%*V-0_W X7ZL:Y%Z
MO:X36[A>*'/OF\4;O;*F:Q3S05BG25_C*^P[(>'%-6N;*4@VSU!1LJ\?;BFU
M)AREW 5%GQ@4B?W_E)#H%@&I7DC-@MKMN$ ^""$ET"BM^V_W1P]L#7S@*+A!
M9'A+T#!/F3J$-M.6!7[O4Q3)1<PMB7[/RDE+Z&W#%1X+A$%HQ>ES2S@0T3]G
MNWF6EV-D)^1R/N]S6 WE)0K?,9T1>$GH$5'="*TEQ%[<<:'\30F"+O'0<;F#
MZ:I(D+A?^5=IAB]"&G.^)?:(I(H,F*5$KNBJL4'K)%74R_^?O7=M;MO*TD;_
M"JO?=^;(59!BR9?$[3-3)=]B=\<3E>UTSCE?W@))D$(, AR E,S\^K/7LRY[
M;0"4Y<RD8V94-34=4R2PK^OZK&=5$U*A5M>&%^3K?(9_5%7#<O$IRPRYU:AC
MKQF 5GQ:5TU0F^0"*IV"E(JC2"]HWA)(-!@!L[8)G[T#*.9%#\"&ZC5CJ5G:
MJ]I\7<Y)EBVJXE,YE:IE?2Z! -?E50/10415S9KLT6U=ZDW":A(31!"[#75M
M,BZ 6 :3<+&[<R 0]+@?TAV2]CV^:&?(?TI+T-]<<@&3),Q'^.]E0[7>E%2<
MS8+%V^8&0^DQ]U &\#@:+0E;O1I^A(*NFLZREG!\N7;*J,6"O*5:3@X)\M+6
MDV7P]>6]*_TQY48DK AV#/H,'0>#JJ=UY9*$U>&)93*BM)AK,KO,"3@3GM1M
MREGG4D%VHPC3V84;4$2FIO MW',X SA^"HS5T].CD0YFT"K>N> -6=%:%7:1
MC?^_?H72\0M=;"CJ/]*KQE5EUA<U=! &B[0R]^@*7,,1[2;GJV41'(-G37&)
MMN1M<-*6114>N9I\OYJ^SBA2%Z3B-\2T\ZJL@D1_'GX:'%KR)UX%.5K499#B
M?P]R,)M<+,)(@\/X/NSU-MRF\-MB3;;C\R:XB=LN$VA]D/V_<JH?IVC%CB(?
MN*:-'+QGY 4-^0%3<HS7VU79YI.C?)YKGXJ3R=L@+&+C -\D))QGJ;.W$BXJ
M,386O>3<AI,O;1LFC^Y/5LMO5C_H^]RP7# [F[S\"4;?M$&U15QI\M6:E1;T
M)RHQR%>WJ+(\"4HOE^:E31WN6IR-F(G#8NC8AY8'#V0A1N^&3>AO0_3IVL%+
MQVS>9WHZAMNIH_7[&0'4QKI$@9I7+\Z_>!!X[.B99&Z"9S^<&YJ$GA^I-Y_;
MVK!.B&()6TG(EJ+XR'D'@,5FA(LTVWQ>,/LRC>B+!ZW";=^JT:1LY4!L>?:@
MSRE%*T\S6M(Y%8.)L_^ZJ!8B[M4J]JHE@19(JQ7TCVS8+$IQFSZS#,PW32@=
MUQK<IV]<13%!YVM-U!&K05$O-Y?1#_L*%>5OD.\/OQ;Y_K?PG"!_;R/@G7P)
MY_&8D*IY1K&LU6Y&'[YHZN7Q^3=OB_*7<O*^*#_F@P/,EQ+:X#:R^V%/=B<R
M^_VF")\%H;WM-L7'LI9B%DJCW.%%#"]R=H<7^1JY&L)X.=8'8^+SEH,>]G@9
M3NSJTK6BJ'J^V12KM>8 Y\%M 9$KQ;A2XB@72K#::'68JCSX:'BIOE*8D=C2
M04D R&>.PZ_G[7;)CAVF :^<'>^;& L=.V$89\'H,C&DNIXAA%"6%HEQX3CS
M??XYU,#CKT4-O"N"B"_:9D01#*5_%/GGU:;I(.4GSZDTYT5.M;H#J\69H_\H
M\_"4[IO;*X''-RD!&[<%0E^&-21+?E&54\HRK#?WP*:<3BMS,TX*'X-S_E%N
MD,0DTEO!CW>$QO1E9DX[1CRW5JHB1[CT=9:(_X;S^N!K.:\XE(.SJB?M1@=S
M<#J_+^9%V*]W01QOR/-<G4\_H<93'5>B!JDK>@+M.R'[;G-N']QT;B_:IBKS
M;_Z?)3WL*&QVTZG]@J.Z8XE*QLSGE4/R,*\A_AR'[M'7<NCVV<J9FK5L$]_F
M<#RZZ7#(>TRDC731%.2DDV?RHXS$&1 PY6*G2GT0PK1'B^-E_'E!T>>2D!PU
M#(PFL:X].;+G,2</E2J<>@%?H7J*0[8Q=-L90MKH^^-?V>.9&LQ">N>TZ.:#
M-0]K&H3ZHK2$UR-[BPL=ZVS#>_XD=^3LP1\*PW%WY/N" #(4;QK>DC3D<TLY
M>G:C'+77V3Z/,AS\!J$JS_'B=,2*B-/](BN"'WYX6<@W'I]X\=G6@%]G/I(D
MY[1E/JA]%-0MR2UD*06B$*3,IN FPCE]#I>S(^I<"L$6$A@T,F(?Z&IJ)\UP
MBOQY/D8^M)A+2);2_=O69*(P2%.@DN0C@2+H>?05ES7,KYJ2_KY K%.271E:
MDS"2'2"6,.-OV.>*Q%J[2$W+64/A7+B1^1DQ\;*=*PC)ZTBZ7+JXLS20JKK&
M,2H+!0<7/#N#.N_1EER5RZ;EOLNR$>&GK%%VX8_A7/ -+Q'?7[=EL:%XJ-+E
M_EP(+@;Q3LK42CBS6(3;N.DB$S1GI'2$!.]@)D5>?)R$I/00XZ>O6<0R?%8P
M_I"7AX!=K?Z6H#M=MP5/,@-A$!J57Z@?K1LY9V16+K\..C]<@PHU[MRZ&T$H
M(:.3-QA6&"M:4C:7AD^"J-N4*W2,%NYA4!9:#H])E>.(@XK<LB-SQ$'IDEP[
M).\^Y:LU93Y1'+T-WMR\Q,TX.#*BO_S[SY?4<I4W/4RS7*/1 P$4PH:O**+2
M=@FT>OQBE-W@&JH1$[?9%9+LNTG,?$;!G"V:E/1($\9?[D43< SUHIQS]2QR
MZ(Z_NK'K@TS[=;WOHL?^-^Y"]#G>Q]*SN&P$5F6;3%_'\[\$8&##I)QV2PW$
MCP4@($@M5 LD]%:P[V3\*+^-5B5J=8"3%<@].HE)V\)L8N>63%;*V> (JXS&
M/WA/E-F-8V;8.4J'D$@(CV$:QZZ8M>"C3C!K;/HW0@9P@\RDBY/(%@?FP+Z+
M#(@T1,BI &X&HE&M4Q)"AT3\'MRMXZTS3P/L)&#\N/%41H2)H"EN.)N*'AJ<
M+CT2;'-ZJA.W&XQEW!32WPNW:;&3%@7<,WU>MF%\E5#LA_$L';B;\=!K/N50
MOHK/4RI[@%7=S97#.SYQ1A1;J<LT[XIPSX;%+ETLD.?<W2[H/:8%X08 N%<0
M,C-*[&W(^.ZVK?AG.D:%E"KL5'#%9!:'/WB)#T@G3'*^ENYA](MDTJ0EW4/1
MWT&CO3)*?7'TU4AG=T50WA,F$<9RR>[I54*Z6?EDHBH,8_M9A&E+AXS^MO]6
M:U>-#/BMLMYRES0].VP<UL'79<6_7\CRX7ES0?SUY;+N1\%I&@0EXW X3:,(
MRK39%47GV(G2SA8R61.8YJVS5)4UMU7T/0C$C%2HC:W8H3D>[R) X0=#$AT^
MX]?W!!+D,R(SU&V]$+%VKCG[ W.RW,R$-YG+%3@*M"B(%J?*F-D&$R9(9#6I
MZ/Q;#J@NK8I+K(%:=&UD&@S3I?(<Z!&!L10)12DI2[27XAA25Q '2Y:VS]PP
M?58620\WY 9U*3_".I]]S)?X'O$CY,N"(/RSIIU_+(HU/H>+C__*Y\2"7G;X
M!W>"A.2P4A[\R]BE$_:%X$L!\;CH^Z=F/;!CT$G)WL"!XO"@*32V/J9B]8QW
MROF"-:<D.RTO1)CC+$P+N<G[JTI8?(S/C3UH:->W^OS6#CXQP823>D4R[CI(
MUTIQLU3S\Y_;4L0<>9I4$"0]*3SV%I43X&*S(C_RDK;![+Y)Z/W/@P4\N(,%
M'&I!.$&[3"M<"!S\P+0#M6@2FT2"IJ-V?-H@R21]^&YQ+#11W>;8:@),@8[*
M,JEE ]:O,]Y#)U09<ZG]$EF$7@"<K*T!WA?M%?6D.I]M\.6+U^_/!6_'"FWR
MJFGFV>1%NV4+_'G3K8)XG]DO7KUZ\?S<.XVB"85TAY3A?N&XA$[][<HM[52V
M1X.I1O"ZS-27V*6FLU)EAMTPD"$U4J6B/7%&VH)T&C\N^1[#!M7I&E.";D]>
M<7\@X?2EC@!]W0(\H:@+-KFEA!7'*-<P*\>[@JH)-O6.09C6GXJ.6-BK7[;$
M*(E.7K5Z.ZIWZ12UP2_I&$W)DXG>US,=<>QAGSA@X>G/?CCOF+MLWN;7PHEF
MVACAO2NI$IF &C@X>K4B1I4/TQDLZ& ;'IAS05E5(':5V;T*VQS<*?=!5Y2_
M4A$+.<6_;&V&"PJ>A.>65V5%\Y'2*?+RVI(*W=RG<D?"+>#-(_^&0H.@F8R&
M!H(YXO/RTJE)N./VV;'\F:<YCX2?E!22LCF+2'83)CZD)UG<M;,<(S4.^%02
M@6,^F>< _X:W7$I;UIQ]>CK2VVJIUJ?$YI(1XUO%%=<+4E1VPRNG.Q+^F,_%
MTEEM:SE_X4I0L?D-!I6R.."Z'V#TQIF6>M'F7KI.BP63AU'94.279?>?A4=L
M,)8N#[4/!-T_;+R.*;WINY>%9-8(BXSC *^?._UP<#NL?ME="N?'HJ#"R?6V
MU2HB$ K.=I,CJ_ZA&.&]V!>=AYE%89.$-T='N]FMZ>J!+OV*2#RZ<=E,ZLKN
M:45M@6-;]+PN5VBL!VI"#'X[)99$;8HHBXK>>$KTN]2*,%KA.91-%"^0+F_^
MXX5E)Z@#RS0(^96OUY9-@K2TL26/QPF^W*XHM46;IZU_!1<^#SNOMX> PL=2
M]T8\]'TOZDLVJ+<AEOUWW=FIWT?'A40\18_?9_S#-AS7D\F+F%%",5B^0<:9
M6USMTI\E*B/N+%?NKDAC2*MRK:3C&!T\#KL%M$YP7]+.-!2PF\<.).'I1<;Z
M*P@JF7\=]$>UL?F[WGPB40Y/4%SX<[\12EVN;W"WH""6:/,:S0R\+%9HJ9TE
MG0M9>G\J9XB$)L4Q>I/LR%$#R8Y3]OT"M91BE$]C+'_,9_UM8$5'1W [V\2_
M#::'N^8-$S7OO%YA:RB>-A^57@;[T2_.FH9=PGL]K^E6ZW5F,;&12*I*"91E
MLAT#XNC] H,T(NZV3 VX1<U]L;"AMSEA5'::R09PLB\NR"ZH!/\C*[=IPC8=
M!2%+-Q5OFU"+3(D@! N 8N;T79L7HK565,O;PEV0BY/EB5FYVMINL ,Q\FU2
M%1_A)*@8B.>'SP&'6/B#WNUS<0[-\1AED-^V(9?2R#D>=A(2D=D)+Z?U[$CE
MIRWER>2'!E'I=C5R^*)QZG4*S2B8WF*Y7,GL8TDR);^:L*'X+!-!CP"X[_%.
M&U1V\<P=GBQ*;\\>99AH]V$HD R895DK27M8$+D)%*B:/+A_/ ]?N<Y+G#GA
MCTC7,%ZG3/[""FR?!N9>M$O*-VWK2J49W?0Z^&,+AE90(2ZQ7K5LBX)3HN.F
MJO0L>H[+Y^:IRR"]G'/J0K,FFRM+GJBWF5Z)M1.Z,GQX"?X8PC/0)9=%A+@=
MG4Z<S0E3<5V7G: (A@>>+X*87=@Y77Z-(=-,"6.CU+-A.V0+>.D/[XP^[YTX
ML2K9W'#N:23;O4F\A]\2JS8!&)K6%:(';1G+_KKMFF(:5HGHZOKBLYOV9-(?
MFZHAT8F\5_V0[YCV"R^"DK,M5Q4'N_7[YQ=.KO;P)OXQU .N-:2H2Z2&68BJ
M89>_HVC(0M+]T!^-< SU#IT<>=)-OE4U"V<)9DB4@@,QDC.&:"9O(7@EE0ZH
MP;N#;+%B>'Y)3EV]F!B@S5<%X"6,@=2NRRYLXNR2C2=;(L^%O'%@M>3G8D61
M:&;Z'!F8'"+.9K(V#(L$LS\>"; L6!C??HJ&)!)#N<GJ(#J$O#6[*-S6D\DS
M<0)A7C.DZ]D/&BP+OV&2(>= 20OP&J$7$!3:_@3'OU"+3A*<R3$+A^;P+OL'
ME:KY3MU84%U1 (P\"&G.GM>"ZA*M'!NH],^OY-Q+ZHRB")D8%.E_6^K7I6?O
MM)!^%?$N4Q^+=AX7F2->SD="&W@JK< )"C*%R#?6&X$W=1^M#TI/MLNI2UUE
MYAD78Y3[J,=CB B ="U&HUPXY-'B6GCYYCN7>5D%T[)_@G/NX5)NMB) VP)H
MPFD3A L[TN^>L12*]>%D2KQ[%MGL?&YJN">0LN5&$>J7P?"EI@&R_KK?997N
M>,5^C_9#[\<[<<W>/8LL7KV-H;%1*+4K+'<7*?3B$JN6=\1\''[;=[BX43-2
M=&43'(4E<#B)!S/*LBQQ#>O&[FA1"CE\%.[M;%>2T\2A.QRJP[OG?<5)\0=A
MM*$0L" YA_0+N.*QY,'B(>I81!W^X-'I47Z/UO3RFC:R+9Q@3>[TYK(M"/,"
M.8_+>)DCBCR5?A?\;Y9)5]2$<HV<2"% 1-(N;VKJ6AD.UFF6!&J4.;N4F(>&
M2Y77U[:<?$%LZ*ZGJ$W1V5P)5AF4EIR*Z,ZS8OQFTQ#7C_*EJ1_W,8R3G/S,
M>W;8@=RB^ 2^8G5*9#Y=,V/&*-RM<)1)&M&9G#>*!LM(KD;.'^+$H\@%08!F
M2#,FROE$EN@L:/5M$B",IAW 8LQ:(TL3GK_6. >@0(HH'BK_L2!9@M[UC(UA
M%D2TR*L%QB;*/JTW5$JD?\Q[2#<*]I$O2R"&SJT560ILE=!MO,NI^YSZP[N<
M^M=8:O]FP:&5'NO/O @'G+GANOTW6:))$Z>-Y/R')RY*;NBFESU&,JE3)3Y\
M,#!&2$I"=E-DF7&?4V:%C!WQAN$D>XH%*-U59&$2%CLHA'H+1D0*CIFA%;5!
M4,7+@H#:ZTOYA.H%Z(H/@DXPNI7P[J;),$Z6972,\B/6WFV538X%FJUX MKQ
MBR^B;C#%7ER.] D)QXV/?*H+Q X8*G,JK0<\AD7*XB<,@AJ_]V5H3 P"FVL)
MCKZE:95<TJ+0/R2L%R],5+N.<7F806(E+H4N&3DRQ^K<;'S&8\0>9[R<2WQ7
M^747+;EIX<^L<]; ][LV?)DLJ)%<'YZ!]5[\]J%+WPDW41HC 6F%B]S!.S 2
M.BT,=.3@R;78$P!F[Y\N ;[%Y$=\I%I!H2%HC:O*+\,5H<R0"]G'1"H\]!?4
MK7*CY(4"0J&'OH;A)' 4NZ6)%] #S\0Z'ZLA@FA;KX5TG,C.^LL77AJ.S+'"
M*HV8[P"3UN>(MG+.S4?0+'4WR".,W#D2*.[&.;,]S>?8:?"R(XU8#7(G<A%+
M0DK0MDLCZM& BZ+FJ;X!?@*1F=$0--_AB+X$'>6E)]"@+M#B^<^;=IAI/1'G
MGPOMZGGBI-"#Z?6E!P-P\,> 0GWQ'6.Y8WEU]E#IF0@2:3KHAMR/@\%$9%62
M#\+.EY5%3Z">?%V7&U[D5':9H6P\DZ.M@UT>!_+$ZSH)5B.G,N^EOK,!. &J
M[UY_Q3B#S/FWCC/9AW<'WR8)L&31J)Z";@KJPQH#!2)2W*_2D8SHY$@ZD<R^
M?WO1:0L6X>[GQJMAR5#D&&O$%@[BYZ!_\<C%6!&-CTMY%7:8#L3=;?ZYA34U
MF(D[JOV3Q7*0?PL67OC>>SYOTGP>%$D2]DS7B*9-;RXY3Z3WA.\IAV(69;N*
MQYG^0E$;%S\-/^9. =NNG\?LPND'W1,*SMIM)PST!6DV)_JDQ4-G55"K+9 1
MA"M<UE*H$@M@X@6]J8;&"3/&)W;:=P:6,C,/$X(4S)E566S#O[0;B.M9S?SZ
M(M@X(\+!-LS*;P;)VG*C.$2QW_C]JV;#9F[+%6O>T!<HFJOU.KQ[R=B&3@Q"
M4CXJ-T7[6/Q>DL!JNFOS$,WS!!-T@&&B)MYX-K,F5!SU*I-&'WDX,]6F/%;2
M]GE341##@9I(#=%[BA[DHZ:31@U>,["E3HQ7+8V"24P'.K5&1.8P=XE$#.A+
MK;>-:U=@PH'IL$6UBMH."T,+'U1YV7:;F(=)GS:L8D?NT>V#ENBQ<R'TGPM.
M?'DE%1Y**LV$#X4>.R2,1\+#Y88/A.,>%TNM<!1Q=O"N;%9DE85Y/KX?-.*N
MXTM=HI/$K"C7&S..B"E5*H]31,O(-.+:P$3I.$EP/ _?NY3WFKR/'#8;V,>T
M\E(,+B,<G/VD%).[]Q ?03 -+?E@$5697M _E!;<7':QG?O<&DZXS1F?$'7]
M<& ;1A/BF06U!*+UTMLU/$:9/T28'M[,J7S6C?.8J&>T+%9=Q/4J_X5BDYI)
MS%1&2]6H?\9TIV)?.%C& R+TRR =R)D1-XPDE;-0R;JDI%8SFU$Y,5J6D-,C
M[7>0RZBJ?D</D (+V0/)0?;1)/40U%*[9++]"+.A"3__\1]O7AR?/ID0R4NP
M#V>9CB+Z68)\G0=K<T>-V\,::9.JPY5"?(*0G^B&1QI@1G>0?6&%"&C)'3J.
MB@A7H:HNB?NT%@[*)#44M'_9D>%!,6IRC;@_W^G94Q_HH@T)0Y!N.;",%-)3
MYK4W0PAJ3!P@^A!.R- >9AZ;R&X$&2,$@YWG2@43!K5/5@9YMZWFD)9<'S!7
M#A;SQD'S$#TJH72QE8B&I29J4?<N,8+>8!BU-UP>3N^4&Q?S8 I/*2-,'W.
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M=MHFAULYE;6P2Z4GFG;J\,R$B\1D1HMKY/RY"XF6_FUKK@,-7PL^S$I-BS&
M5&J_(^1:$QOTK%S#JZ>$0BN]>!;@8$6-2*LT4GCR/AU.^0JZ$''M$6]@9UO:
M-'?]/LU[G7:R@M@PO%3RL\3,OT.._VZ05K6LZ(@QGW6DDXZ6III,9 Y9FTW#
M3MU!R'_W[7$ZV  -L0NTVQ80C=UMR.^V(<PGOV!*PIYSG8UYUW=[\;OMQ;K*
M9_U8TZ!I9STAT_1N%WZW74![3Z0* :?C/INN'S&W&T3OFD^]1KMWE^/WU1S!
MKK<V?\%V)M[/NQ7_W5:<PDO!+/IE6\\D[,E!SF G+8J2?5/^!.Z/CW>:Z<Q_
M;X/152R02K[;K=]SMX:Q9R;&MWCSX?F1/]U$WJLXGY(ZD9(O#X^NH+6!/=EM
M.WCIW/2K^4@96XGP\&<D0Y*: (,SLG'ZIP@D_HBK^#J2^?] S>0I#.%"B.]\
MZ.K XHG6 ?&ZT.;"L7 (:/$$&ROX;G$_2)'72ZH?L_BA<<N-U:(;KBBI=0LR
M;]M:9V-DD;:@*9]2R2'*S8(-(>FF'L.R:[,@(04-$_G\F!!#:')J2>&4>N4;
M^""<U2GQ74&=?..WN@@VO2X,>$Z#UA%JHWE*5L5F#8J%BKU ,HV;):FR37G\
ML9Q]G.:SCUFX1?F6&?CR*?I!+(+M2K7 >;GJ*+%;7N7")DZ2*5;(7.XZM/ +
MRU-WEP3:J_2LQJ4YP*39![=SY[16?Y>UPO$A]B7M=WW^]_=6#QE1,70J8]4M
MG]D-L,HDKRB&AJ@E%HIP)XLMA4@;*L&2[-4Z1X\U>4NXZ-M:SJ-U[>1D:<5!
MLUK_%4XV97OYXYG\-Z#+L[R[E![-'\L:@5C*0H,)A=7_Z) WS5\GE,("L#(M
M)^9VP>&B=!X#MFVI9!B,P90":]N\7GK"L?@%)IFCM=H4*Q2J%.T5451',$]8
M!UP:RU3."T&-Y;9#O6N_;//5T\G1]!X5<\TN!=_,W>48!WJ%6NG>2\-/9O=D
MN!%;-'R$#'GO4PB -[\7>=A^TV-.)F^D\SEE.JNJ6(9YQI*;\3-)&K2IB"A4
MM&7!W7GCV>%.6A3O#P,B8H#N1(_8._<U/6%E4M@I3$@X-DR^@0Q]6*]NP1-"
MMZ"QL^8#P\MRP8F=15LXN.4= LH04-_=(:"^1FZ<58$6S,B-;)$X:(MI;EWJ
M%:=.\FM&[ N=5+<\)PRTMIULFWR.CMH$;]P*E#8H$7^MKLIVL^6F1/4.T$&[
M7,*WT>=U<.*Z7 ">+O<[EO,X(< ]L<MZ46T+[<0=I$6Y)OR10Q)1+2 ]^9?M
M?+GBS&E$+$(=M ?90R@B%Y+*KF(MYEZT7M!LA8"GEWD[I9PF,]]#-5NS=]%0
M:\I[EC/M@.*KFK6)*4O/*P"X"MUYJCH- KDW@.2M9MTY3"GL,I2R6J<M'@@#
M+5@I$\2&%8KDM_,Z%Q2[9FKE]"Z:Z+79"4<?HGPP0S(/J[ 6_[G-04(@G=%1
M,L?'S4V&%(Z;"WK9*M06Y-8%&T71%X[N+V=_$9.0*@V4)YD6I,5[@_A>'BMV
M)?VG'9A9GZ^$%(I&KN/-Q[:?->?8YD<Z!RJ;MP)=;0(7CJGN;*>C>SJY]$P!
MT.+2/8Q92^+@#(NEB,9NUH8UJ,.Q1E,%L]RYP2;'"E!GD<\$O) XV]I>7=KE
MT+"M\OGP;FS:'5X<)PC4@D@0*9TL!6_JU,C>ZFU$G>)ZS:S'SH&SVQ'\K]5T
MVW:\VO!X "3LMBVGEVD%B1ABPH2HZ?>C+=JTXFZ-&*5<NFG-,\(E6^N-43_N
M*F]WCE^">R/M#/A*E]5PE[%H--:TXRK)T=FYJZ+#DU697*/K(\W)2R,>N:[<
MX1V35UR7#18'PJ RB%] ?LYUH+E>7)P_/^="=_9S?7E+,WF+3B\M#';^[U(:
MR0@T5NH9Q#2W8P?%7O+)R\6/AJT;/.QM!<'+;QONS2M\^3G_F0KHU<=\]?Q<
M?<R327H5(&B>GR<=>@#QV7B,@XIELC,Z(6\PORV:#G4SJ8)^"<,B]A88"1R-
MF9$Y K>U*N;+PCTNFXB?Y-KS;D36ZLDJ@W6OCY+/8@!D>ZBUEA)<=X$2W. ^
M&/H5'3(+#(Q7A<1X -A*:N75(N(??8[\Q7A\Y&QED[#FZ"FT[<;.F3<,M"29
M:JU<I(EP5*RJXY$,HU9]-&VY^X+$LUP<BYQ[.N3AF$TV^4K9XB$.HP U$U7"
M<#4!5.4 ^4%\'Q^<P,P%[25(;'[J-?48K(HI.BZ)(HB8[\):9!1;[I/#:/)2
MJH0P[K#S],6JU(Z>Z>09O.L8!G*ZZ(7#RPO@W-43.$"\-A'D("2"'\[99612
MT"7-BH9O>#<FYA,PL/)8N.]!9D_)=E*1(8HELC?%S&9\-2H3*HR1*3S,6;$>
MM90RU5A>YP)#X5LKI@D4R*-[@40\E\ Z@HC*2@D6 "+$"G?$&;YGS^4RZ<@]
MH6LGK0:VLJ2Q_6I7;#:5E5;UR MU@=R)A%WI47_SXJK9"!=O+GUV"VZC)].T
M0H$PA[1_+D>/Q1U2ZSE"#/4/ T!K9$WIA54A'PY3V.EYXZ1$-(LF%V1[RPVB
MB1(DD_*]\I'0P)P^>?+8M-GK-Q?GIL]B%[G(M*PO,X\@->5N+4S3X&KQ"4X%
MBG+"W0YZ?K567Y;_!NZ);A:.O)P=W;^=/QER9_3J(: W);<I(\G'A.!@)!EJ
M_G"+-I2H0.3 "W1-^ZW*KA#R'6V&BE0M_S7H:Y)%US5L3D'[J-""F)A+T)=!
MJLTB^\S@,RG(KH1?SW.F!*4!,&:PI:85M:UN5?S>L,:K:?'KKUJ T6W"BUGV
M$?%)8A$/!N*BX%.*C,Q8IL9#D-3TL ;T#Z38.:4):4#[AD=[PLY[QA&:7(>*
M*"S]]W8-_86X9DFI$3D/Y/X5"$WGUGH3KA=7FGQ40A?74/IS^AG&MJ5ZPGAJ
M\>5-'\R+JA00;C9Q>CR(UVQD5R$C"90;P\AID:G[R2H'.NRWFY/H%6J^R_"J
M\LG$7?_O-#GE^5]J=G)) >2,_/T@D^M]UJRVB"73.0+^M 2MT+9H*\NQ"CF7
MN$3G])W&(.9%SQB(UL*8>ARKR]2W75AV\$*?_U[3A-Z]\1^:7K 2* U*I?C^
M6*[)U])5M6G#>^[5*35F:ONE224*D%SE9<4<9SBQZO=ET>N3H_;\LJSF86TM
M0"K*\$U4AJ(2CIA;DH\F4>=:-.P>1TZ!0\OK>BM]'"(-I.OY'']OVV,X'4VZ
M=#$P;-Q Z?8=C:1MYHVP9=%Y#I8T9</79&0&F8=_K1MN)]]I9.FRI.YO2K(U
M=AP6'.ZFQ3\RZ]<.0+"W2UA@_+R: B<23J1IAXG<X[0X=26'*=9T:P),2+')
M<-'BZI!";,,!6DM=+:D)WEW*X:#;-UJ>4%@G/=9<?5*NZ*30I> [&PY.4&/M
M 5IJB7BXMB;/#KK _+MCZ7PG$,)"31M109^'+WP>I@ E@,(I52OB2]H%BN?_
M0S&[K.D>,ZW7R_#$8!5Q0?1SQ=;*[[P,>?WFP\OGKR,SL=M=J7#D>B_#)&0
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MP\J2C!<?)G?4O-TSW6Z@454!4V2,4%D[S7%)ILP57X1-J9KEMH@UV*@*DK[
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MPMN[Y\I,QL#8')/AB*L;*3<!(0EBHQ6'!RW/"@XN:HME1[(PU]1!LB($=&/
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M=3I9-LT\R;N-=5!+6A5.F[F5'IV[U8%[9R1=$W).A-F:_<GQOBJ9)7*$0)B
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M)N)*GS5SJAAYP$E=>-UAH722/_(>;3'L6,B37TBIBA8I<*]'? ]S0+-X4;E
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M!;'/[1GP?B90 E)6W')?#AL9.YD*3K>:KN27/*$;S1,FC*Q]M,;T28FP%AJ
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M7/D<=9R?J'Y,'HU*E=<680AG@#]",>=U(JZV'6<SHGPO$OP GE>8AI\Z/U,
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MPB'#8V.IUO@\>M,_^Z&?/!AMS\1J'<8/0KQ5XW/8<Z>C]NO0YTF<,=RM!R.
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M/UZ__ZYZ6>Z9Z= @E?I:(Q?O M<%2;?SHM)ZK,(I%@SRNQ0,F+R1FH//X1'
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M]BN'/XJ ,RS/OU%FX"Q?W(A,.JW1N^KJ#U/679;$Y#'%&"V98)S7Q9J0'JD
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MZ=CV0FHD<2Y[XT/N7ML%Z40WK )_DVCT=4" ;ZR[:K_KN7UO:AMX-I(Z@][
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M]%S=J#Z R+ PNHOS*:A2T,NXQ.=T8](%/A-@RR&Z'MVG\"I7U^O\^V+^-<K
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M>9WIKYK?HIXH1FX^"T=?P0\25R&7L,&FY22[:Z)YG*QC[E;A%Q)/\JZ.*1#
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M0$,P\.)NJ'FIRZ%3FE3SP-47*>*:Z.L'AKE 5-@[1'09PE[)DPAQA<UH<#&
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M00U%\/!HF^0G9DK!0%HIU0NU'-I5EDFT5S,'6DO9LM!6=]Y+CY,U<G/]4H[
M?N<[">Y=+>)%KI,7;#O;IDLC[X9-.N>-$M.75]\*)I"G^-@R@^1WZ66D]49@
MYGA2R8R<L2H8I>%<9;T_U5VBQ[R5?.Y( I!9B!MD+"36A!,6*3@OS9")3-,
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MU)L"YUJ$I$F2)@@$$VJ7:)#<_T?,;JW+Z64I$C;/!S62YY:T6F0M?1NX>!4
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M)L%YV2ACAS280QB&K<3BM^0&:0$.%BWX>&YF<JL&<_B7>?+"/'EJ/UE E:"
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M<^S>O2-JEIR-407B7-1;=89M-3,'T."7"K(WI/%SZQN^\$;EE5W.]C\X:+;
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M$BP!+@IG5]I,=M<P0@MA#/*ZS<;FUUTEU#[F#>4Q.\T&"RI^<7T5+RBAX6_
ML;Y2JS?0+[3Z]W-7_]1]U1:KME13+:T& $([[(JG@+;(;L; OT#_K@JYLTJ$
MFIZNM<X2YPW5Q3)#6%Q*3^EV5M=8$>T0/W&'%#4+NXY8\R:7"O-D"]J7D3,5
MO*2B4[MLFEAP[20#K(%G-3_0EG+A>)4E'QY,AIV?&,13,^!NCJR+9YD1GO(2
M>BS09Q*R,\4.S10)4S%%EI!$XJE?-YP_2KUGD*J5Z]'V>9$0E>(=R9I:3N5Q
M+*D? ^GA>493"5&6,Y^P4!]LEBJHUSH!.4] /JP3D.?II2^T+Q@B 7+W$3$0
M4W-Y#82Z;? PX7!8E5:JK*K2+,=&)=P:10++46?G ?4(1)]XJM$*1%B V"BA
MVE=XV0BY[BYO_%*0DZ0YE_M1S=8A9O>ZN*.4&Y^<@;[NOP(BB60Z]FQR->PR
MS$8G0FJ9KR"0R95 @DO=(IS4@Q,?R;12,-,K";MFB=36*NE5>D+=)9X(/*7&
M]5 #TNUEC$)J=?VV7 BZQQ!^BK>61Z73I51!EM3CU"UYRZR&9+H/F8)-&\!
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M(/PI W[B>'\FXA :@YG2<(3>)4%?]M5IT^WDH[,1H7FK(T9):.HE8.G0K&P
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M\L#(YT#N9]P7?J)3;<RUIA41KHUVI;P58??9T)6$&690K83%@IV)18^CG+F
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M4IQ+R,+'[)1J*?&B2PPKCPU9G$?1]4/>?8N>E8KTC'OKB+C.(69X83>O/M,
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M8%K'!EV3,'BJ#W*J^;D,Q,T9&.:ON/TXI.1*=HBB_EARJ/'+;*YNB"8%<42
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MJ.+AWTG6$>7Y/:"[2R*[I?E+'2,4VGK+F'8+J#I%>T\_"P75VO33H%I$=>/
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M=Y=$1('K -LF[*51UQME ;:*DG8DAM:FI!:U7JPV#KQA49E(X4NL&[D>EOI
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M#27ED+,[P3]>GK)&5>50M=4D<BI4#2J&JC=@_% "95PA4: 5A#OLT";RA^_
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MC%[M7M!^#6*'T\M/(;TW[5ZSCWM!-P7H[X,4$HC'>+%B*F#Q!&(8 ]2\<^#
M75>>*8CVP+T]FXXY@/]8P;/(\L2?\&NH@,:XE3^B$/\P!A$Q?O9C.K>\!\'!
M"\9+Y%TYYIKA\!X::TVL?,"<(3^5DWGSVQ>IZ5CPU@^_D0AT.^,ONH8]8/;/
MSY^MZ5P4(KT-ON)6IVRO<%!3M+\"[[-#YL6FUU:B\;0;E[['<F;7"QCE KXP
M)E;H@(2CDAZ+[TA,&QT1'Y7:(3S&=\[ZTXI[!,ACFC(JQ GC!PQD_Y (D4&6
M<WHIT@-X:=$ITLM 1RA^<L*X,&;7XT ZQ0>26;.984%"U,JK/X*NT0T#NG@7
M.*B1^<J'?$L%R.D>("$%@FV;@CR2LN 9_Z>46RJ=9-I/[=U=X$\9L\,O@;\
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MF<,Y),4D^QO7AQG3-T#S O^)-&-@)T#ZY@:):/#J)6C83CR $\2?</D_F30
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M"1R9OS!,/I\[=@" ]?"W<.66RQ4];]%6BT$?&7X+8@&#S^%GTBL;SX+.@3W
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MV\KO6[>5/T%Z!9[?,GG)?F?%1R]X9SW.ZMM.ZI8J3!?I7@X%W 'I(FU#N+I
MOU^Z#GU"^CY%0GO2 9,PB:^, LCAUL#9>C9%J+QKW'SY>M]XCW(N5Q&E5S<]
M2G+!E8=_]N$_.,35_<^-]](?@M,)*,[#I;6)'_/)PIBPF$@&L\A0!/E.&(BK
MW"AVV_XR2KZ+_32_>SRBX?/OC??UD\6O8%/@2GHV/W!@ZW@ N<V'C>!:#.KN
MC)0P#!(@RX '-\-%ZYKCVR'_U80]H&+IH6[&[01MXU^6)TUJ705+<EMAAV>K
M@,PX-MS9P)F(6"'A09SY?N2IHL=6]!;%1<9O\YX5+. L4WN0?.5X?"N2U5N/
MEN.2G(*K9U: :BD.6Q!-ME&UJ2@B-A"\SJYT8YV99NZ$0+8I\&OJ@RH\X:$M
M[ ?:%F@_A=*L#"LB#?$6)A^JH8;\FB>O7# +^8E-5E[+$;Z"IO'/S,N!$0C?
M#IS@1#7")4])"HA+=FQAUC > /ODZH^-QSCU!]\7= 5V_M&9RAC[W0QBPAW+
MB2JYRS^AO!L 9?G]_E.#)\,C":-Y\6?(O<V]53RLS:+L$#0?A?CSE4?QF>3?
M?4(2Z'@V^8WMLZBDT&EVCB%O)#K,&O&P6\3HVQN$BZDZXI[B1;M0O&B?E7CA
M>(E3E<=4K)=!DE =.T[^DN8W-^%4ZL_04Q'*/#1*>;D6YCHTU4WG#GODS@-/
M??3#?CP\7WKF%;4N-"%V!G$AH=<N'=/N-?NX%Y0<Y3]A8/"C\!TXWB.0+,8^
MZET_U:[S$ <_1$L[L"D*;R-;.<4J8$(E23,@!J\"3_CQ>*+7H^\^<O\#"?+I
M\Z):&?K,3G=3,AZZ5<A]M/P"86 I]X7@9^+LZJ=^_#=#? F=+H^7Q6PN8V']
M 3(;15_1[QY]4OH29P]%!'-,FC)Z<PV-24A]>A04I137%VPM"G@X&(\'PP "
ME!J5P["=0/JA N:R1VX&BC"46&2_I%Z\\AP,R"-1,QW?*P7+D&2[>*P9N<LI
ML\ )IJL%*B38;0L5;LRRI( UZ?:&2XVZC;*-L0LIO5!\.MFN#>NF#53".#5/
M/-E-QU/#,3)R3GR",H<=ODX?IG2"2>F?!J$L&B<$93P4(?N)FY2/SX,],2'
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MK,_\LF#AQ$]:8V/Y).G77#_^A)(@+SSN(AU.N2#CC.^U_@M5@R6\%IG7I?S
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M\<8K+[XKZ">+$ZOA0\M[<":RT'*Z0UO>Z*'N9UKN5"HPQRTL, ARP?WV$?O
MK1=)N#^S0D=$8'+U':- I*TE-['0-V1E U)\)TQ)N,5[A5! N1:NQ\?8V^G)
M$AT485(\,I4:$P\C6W:BC\;<?RK^,;U;[E\2)2^CL0$K_@)8U@1^ 1(R#S:6
M$XW7:MF 9VK8)'?#5"*VU*LG\XBSB\A%2/BI)11-_6,2>IZT9)-NF;A>M8P<
MPA UZLD1\?XE/!? +]X4$4R$VHDRL?K=DF])7'YA=QE2P>)K=+'^&I%"16K8
M:B'-0,JNJIZU5/NQV"^>VV(>T(/-ZT3K8G0RXBX#<67IXII85A*Y*47<6-YN
M,\;;*N)GU6A)'NK#B72.OPN(8(8,%421Y08R+4^$XS9568^'&I<S=U0)*9_5
MPU2XV$[,)Q7YG5;=J4;%DD<VK*U)^)RJ?9]N+&<[-F_K)*U9C.O;1;*9%18
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M!,HNEGR@N(P;:BHA8TI+R?H)R9_670F*DA0\.%->1(J>BJJ!/XGE08Q2I%;
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M],8KL6ZR74&FYLGN-SX.H"LN:Z)T'$E7,=FC:,F91-H,CAYIPX4"^ 3#V3V
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M?A7H@$6+@3ES%1-+#63LCHJSM$D_S);;7Q,,L$;<M;DC#G-- ILF$&>H)(O
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MWR.*/(>8D$O7./&E*7.]GISU&FG=L1QU$C;*E$M9>G^Z2V\1\+P]Y./,G>>
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MBG6U</>2J7H8.]6Z2!6-%TQA$ FQ3G+-QS.8,C])=C37?_;"P&<>>WSEO_/
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MVG'?G.@L4R_YII+8EZ=-M&9+_B5AD>8DZQBNJQ9^=FLJ6U\G*YM5=?GI>'2
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M C',HAC)HW%KOTA K'\0V^O=G 1BQF!BRH;=-$WG K2 +BU,\BEAZ7D^1K3
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M8L[RT]W>D'5+Y7K_<^6%7.CO'_XF8M:=P+B?HJ7;ETG1BG)+V,4A<"^5-V6
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M?6W82Z.'O<0<!=V2P7C)MEV.?^0O<N0=,%QMPFCC^.M87>'KMW]$LO3-]3V
MSYL 1NN?3AC"!^"G]_]>>_]"_07R>/&N 3\@LP3PXH_A\Y_OW[[)?!UZ"SUR
MHPB>C%N#]'FSEM@8L6M7^GSA-]*OX''.7%@H[HP3+Z+I)F)K0&+"$*K"(&S]
M!M8-%J3[DRO'Q.GN^44\J[0#LA1YR.9(5S)]-D!+$ 72CV"SG.&H;I8D>>/
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M&[JT4G9W8H "3GV$TVG% &UQ-W%I<&JXZ=47T#C"IJ?U9=.[Y<N(#E4!;^6
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M^LE.H.0)>]P)$3D",A<@[4$/20E7P)[2;Z\Y).WXEFS*5_>>;,F-NT"Y;*_
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M)-&<S+3>;LWCNI]</'QJD[LZPT?";L_:0/JF,_CT"A^E-K6J.WS$R4PUS6'
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M., 6P3W<_6JS[-([T87KI^>A2.V&HA]Q*#(R>1Q",K2(?Y)BED0L/'0PSM>
MY'9,=3F&(2[G]CW444V.53B[Z1E>X;"6A3%2(V2=YZ03'GEEX]O/SO:YF.)R
M7^G4.U_XLE:CW*]$2WE;F,0BX-%&L3<A,5#H0*A/./BM14_2HK4]+=6"*4Q-
MP6Q+M2#7$\(T9C60ITK+1Y6_KO3%_\ &U690U?P674@IS-$R,W0FI1COU%N1
M4C0DYFB<:S/LU:''4 -HU,_W& M6D99T6NK ^M7<F02EI^U 1IDV688^UF 4
M*QJ9?'LY+IW)?YB.83J&Z1BF8VITS%57GV7OTTV43!\$.2--=B]SYJLMPS&'
M.?%E005S7--X0Q)YHZ A9Y?=8]Q6AQ<\[ %@K^8V[;V[<1?DG_=4&;4M>Y %
MC81Q9&S[WE<IV5@(UI@*JE)!]3[_?E00DDFI$@] XP4CG]O(5-"Y5%!5Z\E>
M59!!ZJ%A_U65<>L-PHA[\/"J$%3'4YK?'SL6QXU4J(H5ZZDL.[.S9<=*5H]$
MC].G\A2%P^VWL91',WU2H4_:%F@<J$]$L;.9QO3)D3B8>M4GTN'&V.54PM<T
MX!IH_LN=RXD"]\5^]+?H@*.Y*K0CT?.&5D\^;]8VUM188,0AH1T8<VMK3FOI
MHX(\;[FT2;82YJV <1T$N^K%UE766FV5=4R1B,2(1#?=+6,78ILT0RT%8>17
MDO6Z$GJ:QA/ZL.#13$CU9><Y%M!3W%MOI(;TBT=KQ<@\#RJ<ET5E,E,*&D/N
M30U[W>%<LO5Q?*HR[K"RN-*DT5:%<;*HUA;&P?:$"-.M/U]A<V3 Z[Q#/5]-
MMBL,$ [().?U'G^L<@+H-A.G:D$M9JJT#ZO;XLI$S M<V&L'%!DFK2.!+]RC
M7AQO&ZS?XJRS_7K&E;TF%<<W,,C0GJ^2K+5@^Q@X"P<^RB=O<G]8[MSC[-5R
MRMU$)=';=4A9%.+R8XMT/R8_3^N2][5 +/Y9S0$K":]MG6 5,7(L=H28RZ3%
M65Q"C;P$:RMJ#HN?_FZ[6"*,;*?<ORP?9 [ &3@N[&CZ5V"C.=<+L=+[V?/I
M>]XC*/RHAMB+RJ3)R&T7OO$:/\RW-\B%X)+2UU*$N,04RH.CLM(L'C BPR),
M'S< #8P\64^ FB]8??G)P4:*BWW-%0'GG91"#O)[%.BF7^+T1%K-N: /W$-$
M?!G?SPFM[%M\E>TBC?)VD:SQ(VO\R!H_7D'CQPJ"%*F8($4>19[[P\H)2.&_
M-9]'3=C15L<7W-1)'1WG8 C4'-91;<T\#=]@!UIJ/RR=$$L:UG@?0,,YHB>"
MD]NW5[8;X,/A0/>>[?AC4SCV:3N"@)-$FC1OD)$NMW[$795T<9P>4.30N#OD
M']X+G<M7-WM"5]R<Z_M'RJ+1L$BBLMGSJ=&3+$:\[]EZB 84+'Q=9*!3O<MU
M%%5(4QT[-;8LJM"GDFGTDY4O3DV];4E ::F *E_NH,RIH53WU&1CBL:D*N?M
M/3JRQ-$D56[HF8Y[J7P])5-?SD:FJ5.&OI<C ]V^HX.A;J1YYVP?Q[V/L6E_
MPGT<7N$,R8MB#;6CU?AHP0UY;F.@1N3^;KEQU%%D2?_*+ZDV5D=*8+VJQ6R;
MOJR74>P=@=!*%LW)3.<EU>1%.9^$Q3*8SY,R(XIU<7G*\ER4!B,)L*/R")*1
M&9Y.AR>I*9Y:YEQ)XF0F:AJO*WTU]&2(NPC$R7IC%=86<A*%G"&.0<FU-K*7
MY'\78633VR')>SG(D"A>BF'+2!?+>6^^K2WG,:Y7:^.XC.V51%2C+$RJ60ZD
M>I1D0O$J2;RFY0^UHVULU7E2L+$7>&2(58GBZ9UU4OEIZ8-!@8V3NIX)%?KW
M")8&0T8C9)AMD-'6GE G,T.6>5GO7,')L#,\[,BZ?$SP:!0\2O?[3S_@84Y=
MXM2512Z=J=/)K3LJ>VH GMM1K5=K^[.,J_X8SED)$^Y!N1@BKYO#\LY>^*DA
M"1T<L$@*(9<USCQQ<W,&BUYA<32G%FE) 1/E1;$O(A&&G $A1]9KV\T?"!U9
MB*$CJ7UY1)G3\V!0?%X[I/UWU 2ZJM'<KUA@P(E3\;<N7J4+X8X8@./T0E;R
MU]8V;9XO+8!9@);*W)53R+Y;IG!]2,U[RLB5Q4HCMY-L=/6-7!1G1SDNBBR=
M'#/ (9"(F@47'%I2L8V<V^W>9';@7KB+0EHKH%5Y_0_'E]S+'8R![#) )NLE
M1"=M4%;3C2N-/B5ESPP;@=?L+R:L&"ZE9NG9-J_++!F71=FV/6-=B!X7_3"N
MI+3=J&*[:XU72[K\#C)Y>5S[?NQ@0I<<NDL_LO(&>*40%9Q137Q'A$+=T+1C
M9]*-S!EYO:BKR\'I!7781%OFQ>.S]C/8C0-VU?9Y;[@S '<J+_06FQN.57Y!
M#O1LGVSF)#^:(>[.?=L*[(<5+-C3JH\NZ;)9V26=^?8''R5A3J1#+?(*:2KU
M4BH8NM69EY(!K('Q70^PEN:0@H$W7>%UE2&0(;")'=X_!"4*05/N*WUZ.";Y
M!3G*'W),\Y;O!&B=PPM!QRH_YC)ESF?F?#[9>@[,T\%V]%0)/27&Y2[_=-??
MXQMM@8!M/MH?Z?)DIO)J02%F\]P>!KH+ 5VI/=D[ZI3AH^ZJG;JI-.C/EN]R
M=]NPWS3H4=DV?2=4V)F\)5Q@6-\#G;B*.IG)!B_+PN"<N*/:XP&X:D=XO!QF
MI59HRN%ZF4:X.QTMSJ(4\AKU=:!?29O,)$GGU0(%UCK%G*%J2*@J,"E/!RM]
M.+"Z9G_DW<WMQ[[-R"L@+VAB1MY9\\>.]J-!VGJK/9J/UTA,,0#WYPB/DDY.
MSG%YE4:X.\<S'W-JZ\ #WIS,3%[L=+PS, T03.VLQI[0I I#0=,UNQZ_WWP+
MN.]V&*YIEVAJ)TH2\S9V,!,C;BMWMZ[1:S>;C0]?)L64WW ,P8%FI"I.9C*O
MB@*O&GFO/O-",B_D0'*F:@NUVHE+:;*H*H% ])6IQWQ:0T)0 ^+C]@AJ:ZS(
M "^!ES2=0>SR(%9?8'42C"D$8[(P$);N:_:AIBQB;\GY-/>"VUA^^,:M/7@P
M]^J$JWU>!.9:[==FCG)>[G'9?\=5/]1:5C'_!9:$.5V9TW4PLM*CM9P3E'([
M60-1Z*L;%?/B#0D[!]K)9=AI:[WH8+U(O,C =8G@.MA"[@M=!D&75'!\,P[?
M$^.FO)&$Q$@(VIK&Q@D;)JCF9":IH*,U,(2-O">#,1!<@D/YHNHI6IU1\I$X
MY#4!Y(87I<X\8&VQ/G"OX/4B33D6TD32K4 U>$7NRPO(T#9VM.FUQ8F'PDTB
M< -S0%7[:N\WG *Q"W)'WUH;)[36!!B^\[C%_6%T FUM;;'*#1TM\6UJA:G%
M32ZWB];&MH8<ZR)OR H(F#@HI_.%[/X W-%7>R8I)1W@RD2IU!^M*2@F?37U
M.KNMPW#5$5<E+>1J<-76[D%R=%GB-08\!KS8R*[JHMT?\C2*/%T>/*GX-;NX
M_VD'F.]A6[[[SMN&E,7KL/2.,:;%]FE7TZ7$>@$OKA<HLJ@+6L:DC6F]O&4,
M2W8>CV_ZP@^12JNX0!#*K6+D8A]&%B!#R,GLVW*$M+4RS,G,X.7NP7(&H>%!
MJ-I2[0U#ND Q-! U=,W>WWO;==^X5\OW+3>,J1PD@S$YE-BCBEZ;5!&3-7^R
MZ9]?W3C-(MMW[4#GKRYBQ%C13=XL(-UC"<?C\?!>^&&BJ'6AQ2BW+XXP%AP4
M$F85#2,MCX&C5W!H+<'1UL20 3DZ+ZI]=3ICZ!D0>F2CY#;<&WP4"A]#&09\
MKMEA>K]]7#OSOFS4,7K76MJHJG!V&Q6+XE295U5&(,%\JL.0E2(CI#;YK=Y"
MU9@W]3*Q4>()Z\W"T"<SG=?$@13D,_#T:Y^6^.)[0X]!T=-79BWSH/9$Y_#M
M^S\B_H8@38XKR<RC6F:MEC$XG,Y:Q9"6;/"FF'<6,'\J\Z<.Y%!1:VO0:JU5
M P-OP_!H,&STBHW:JK%N]@;8,\AR8S)?_ 6"1S:D(Z-'0O2(@CP,]%RS,S5K
MK1*&W@)K]8HH>LO)K$OXQO+.U3T^ZY/9K89,2BP5A=?E/.-"+UO('*W,']('
M"[Q:1P+?QHC%LJ[SMP%B".D7(75-)WHS1E3L#: 6,&XP!(T:07@>G@A"&H%0
M09T5ZT4V!*XPN0?^ KK&^W5O%U+>WM9%>T(B,0,[_6D:#R89;RCY])L!D!M<
M-#0&X,?M89E'<KZU.=ZT6B?-H:>9@0GEDMY7IF0_4C)PER##:"%&CT639YBD
MM:5D\IK9%TTKP^G5XA1]",<!JBD0H,HB;VKC5J@U5XN%$VS6UAM.SR['-?M4
MMT^Q31C I]@F#.!39!/^$EJ/:QO^7#@OLUB[PMT33HPY_3?J><?=6O2N"!^+
MG_=L^4^.2_2DMLGZ-20=CM;3'UIJ=&BEAQR?(Y(IP*$TNUF_>*$]7W%_6.[<
MX^S5<LIS%A=L'P-GX6!S(&_))1\B[WJO;L!UN=\+678B[_G9<[^'WOS'W^SU
MXN/;]_BWG0.:Y9A8NRKQIJ 6YB[N]SSB'#>9W93[OITG<4KX#[P9VK"!"QP$
M%ZYL;KD-M_AZ$&R)8PC69O^!<+C:],.PHM83#81^A0_#%KS8W/T:(&"Y"\Z#
MC_B<36P >,X2=M=]"J9YB'')84X@B8##R3JV*NF";BZLA6 IABA8EBFIFBD;
MNB;KMKSX/TE7#%TW!5T@?=M3W\\#5C3.!E!)F%*CI?J__Y,1Q3R'S[YU]<D)
MYFLO@.VZ6][A6O_N6(_.V@D!59]_@N"[5NCY;RGD2!2TL/#VXB:,7\1GVX"S
M#3P]]+?V9$:>QL%>V_X++$->2:2WJ]&HB1Q\GZ_LQ78=#_=;]/P'U$</\*6/
M:Y"0U'#E_7&523J=1)6JBNRX=VBNG5-7/8#4S+WGC1<X9 (@7EYVL:T 7Y1%
MBHF,1Y9(%;9Q /'$SRV]]=I[#=[GQ:< _E+V[H'2:ONP"N0T2,QG:@C#:JRM
M36"_C__R(3Y)')?,B7SI0_3XR*96"_S:^'OT[0^OSB)<O=?UJ2*1FT9D"T0_
M3-\5I\(OT6F6>5U3IH*F%;XE3,7"U\L>):I34"*M'E7^NFI(_0U*KWQ4C?W4
MT"M;X46E@#C-;=1H=!EM&(2XT*EG>[5<<XR*>A&HVG2CI"LX!<CX4'<]>NZB
MG/NO"ZGF%7AQ:ODEHE,ZCO/>QKMPM[S=[<%7-X 3&@W!AO9LVMN#9>(B#W;M
ML1DW1^MYO$IDUM:5'A^92$.L\7"Y& $RKSHA%R^FW*,5D![ ;V2W#SH0QIOE
M<QR=3Q:6K.M]M*SMA4@CZEV5&-GA!4*IN9+N THZZ&.%5Y4+J=AE\<B3:K6,
MTZD]^(S)3)%X4^S93&6A\^N#:JW6[ A5<S*3!5XU.O-BG#]XGH]69:-3^Z[I
M"N]GF0]X]C^/_E]FC9VHW1]3Y9!N]Y22"%S-0R+<*NBQC3W1[WUL!.V\V)&C
M5A2$7[(>]6CWA=U7K$?8[&U8_I4B?_,YO.[<EW>RF5V.]'^;!YQD14C"3"M_
MYUI\LM\]^K;UXYVUA%F^M]:OUEN &$YO'>Q;-"H=<;2_:*5+LUSVLC1ZP=)0
M ($J\7PB3^]); \_!6.R!C,6;N6CXORO^@T""Y&$D]!'B-U@Z$W0:BS=9P(H
M5HP&7.B1J"J,FRA1[,O.?7%<RYT[UIK['L(+Q' NB)=F9Q.)*IW/:0,\@.>I
M0#'=)L)C&E-3*'YK+P*RI\0T.L=BJZ;JV,I9-D7'S4#CR>+1X\D?/=_W7C%>
M7Q1)AF'E(\GP8CZ2O'M.?12Y*+(;/;3HMZ1)P]AS\0P_V:'EK.W%5Y=:5_"C
M-X_>-JR;>6Z*(XDZ_Q4,NPTI3- _!&!^/H:X7H$3A"3@C(D@OAV --L6YFEP
MC[N=6_K>,[=,%)'C!J$3DB9; <\1NX'XW7Q,/" QZG#E^,DK4RY5RI)Z+,^Y
M-HGEA#Y,+;*:YQZ,A^<V& YW\;'P6DABYBF=&.PT(7Q]-[ DJFX%W'SK^Q@K
MPN$ 1-XE_VX27D=O8BJ^7JMO68"=!=C'&65F 7868)]]MUW'\[F/+([>I1JB
MUO](UK<-38F<,CN0_4<Q>:5O]R.+DH\==[5-(#KA3@;<H2^Q>Y\I%@,_*FB(
MX9I*?.B@SJ\C=(E5\L>4'&38457>%#MGC[# ]Q#14QO$Z80>=3*3)5Y1.A_W
MPPAUCUFSWOPG=/Z=4ZU=#.6+EXU:WO].LJ%-9H; :]I J# 9D6JOX#%KVU)U
M H\^F6DJKYL# <\UFZQ8EOADN]P7:XYE:V_,6*V0BMIF&+][,)9O]MQV7@Z1
M"VR&H?&JRAKQ7"1\:HF/.L+'!+6J\*IQ(:F98U:KM'IW%VACEFK'G-%=2+BU
M7(C"9&9BDR%&^G^!\&F6Q]D%/B*<RB(O*7UE<C)K]6!@/'BAM>:\ZEP&DE>!
MY!DV367H8M)>;7IT@TC:X1(E@4+6A#Z:6K?:IN&;P%<+MP:.W,/A)N.U"@QC
MO:_RMW-QU5VTR?R['03ODYRQC>?'Y"Q7:T6WZSM0)T&W=&7OZ<+>+7_WW*?0
M]I^[2)8RF<D&+TAYR[HY@3PSJ@>(IEI]? PT8:F_R9MBEW8$S,;NQ\9.Y^MV
M5,#90Y.5(;93VWT(%K;YD"1>[$ZBT=]>CL889X!M=S+T 5CL*:\HO*:.&[ -
MN%[+"YM.6;E"GOC> <7OS&MK6:H*%M,9&H3B=.6MD:ETC9&-1C4<0ZK9^8K%
M,*YK4ZD@_26Q$.;C-H"/!@%WZST_.BXMEKIY\FU*P_IK8-L<Z3\I3L7?>"R?
MT?.E+B)/GI4M"4HM6<"1A'U[@65!M"CQX^T-!W+P;+]Z_H_4#_IVL%V'Z US
M:*6._=/VYTY *C"CRAW8E0"&R7.OEN];;LB32IOEEGK1B$I"/LO FSNDOB>9
M[+QJ1Z?<#7PK&@"=$"W8(8.)^&M)M<_M&A[.W7!>3&0;$>!Z<V)E+)H5^.3
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M,11@_>;OX:!_A6$$MINR#HS);.EM_1"/[07<^?:K9O#8ITL8NZ[Q['6"7."
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MRU0G,U,3>/A;OV5=7?9P^"8] ^JIBUY-[4A%KR<&:E$'D0Q!R!C(.)!:AG[
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M:\NU0L]_>R!N$'CFQ[4W_[%3C88PX6S0F!MX?.AO[<DA$SHUMF[A$ZB_8;-
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MRI)^^G*[N29/OD<ALR@55^=1U4[?Z-JFW=6LJMI'BWSPQB)W:QFMKY0?\NS
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MN)CA1WHU"*GS_<H9PWC?.MZ+\QHA#\^2;F#<R?U-!0:P^OH;7W(\KN0ES3R
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M$#*8O 60TQ"_!6-R&C,6,@E1E?RT>X',3O^!A20'8_(>M9"/\2I.OVB0\XD
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MIW)TO6^:/4W1RJI]0^M)5>5VZ#W@ A4EG.C6]BR14H,R:TLX*922T<A\$[5
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ML.-@3+PGRC3ALLS^,YXXN+A9/>,(!"_*G&TRC-U(",84'AWY#FQ\ ,H9A D
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MA#(4N'%_>A4#$7TFEXCR_#TVZSM_ .$!_Q\Q>]]Y[#M[ &'^O_S$7<?O.W$
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M=L?W$-U0.:[%/4;?LQ=I)!VAI'_4Y0N+7![#K#.'YO;7^0U0[=LV<:^_(U]
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M?*"ZSA"AQTHIH8NTOSA^S#W0J?';HB"K^@.W+?&)"$2%L-)@S:_,\[7]2#-
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M56GU+Z$CQ>@1A3INQT':#K"C<]1>31)#PK!292'Z ZT<TL:'Q>-!MVT/];(
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MGJ+SUQQ4P%5_O=ZRNQ"0F+ 6;B/M41C;[T;\L2M,O@MFSY%G%FY81)VORO:
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M=H+\N9/Z^QN84PQKO'3^\9?_#U!+ P04    "  DA'18EHZ:I4TN  #^W0$
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M^<L/]<4$64@N-H#_9YL7O[P<=PK'Z?1X/<WOZ/?MZ^L@^T\!?EWA+.-&+.<
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MUKJ^MG]^)V)>;M[B/V"/W/')+3:[?0;1;->Z5?@@\:!)?@H"4['V7.= JL"
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M3=<]E(0OIM_'I;$^8V?66.<=941*70)V7I9\JD!4N7 4E4-HLM62LGN,$]6
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M[CC)&Q*\4B1(97+B6E,]7!6%_; _CY3C"KJSN\]7?0Y["4L^"7,5_6@#=/#
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MN \-NV*"^\BP_YA@]I8FQSRQ5.*4K-&X_6F*7BMN?,))K04[_9C@@;QVE.<
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M^ M.N^ >K\':H6QNWD^I2D4_5YIV0G3,.AJD0X@<USTJ,PF9*>*5BR8F%M*
M3=8&UI(6G=8&4))]&*B=%?-K,_\%,:VZ2'^&_P)_VQQ0 =,Y4Y+0OBZI898X
MR2@1(0*G)CB([;)('QGD*/=?ZC#1]"#&OIK.+(+GDPCOPGBTW#-7]_*80ILW
M9*(XYR4WEN+6B/,'IR$'"5'3X1S,W3B_8Z.C$GF]Y!AOQ[:^S=L"W? UY1]!
M?+2R\I48;JDZ'>CII[C\8R@I]2YSW&VY$;@@<\>(I3D1KJRD0N!;]3#G\J24
MY^D2\T?1G7U8&5!G/N(?LSS:*+$6@'/%:"(I*UWN/OA2R4T0L,KI;!.B/O8F
MMP/Z42IE5V.^I5+5H*T7N^G79A(7"2[S!Y=I5!8Q&^^(@_)J,1E(H#P2'X$&
M@^^<IL/UD]J%\AN^D]+MD+D*;?W<0=X*2ZO@K;*!F!1E"3QZXAV:BU)P<+:\
M;2 'TZ:M$+];5>I.6'U_?;MR_ZUXGR,_'OT3<)4=-8MKCQ)T*:$1!#H;2A@2
M& HB\&24BD;'T*X22>LAOS,UZ9&/7@+&FU#OIDAFS;GTVI6^XT"DU9E85&>$
M%W4*06CEASMK>A3J=Z9F?1#8SXWCW=BH<*5=;B!96%I:;BN"UET@U$M$)HWV
M=KCBU+MQ?K>:58FZBA=E=BRN=Q/<E\+Y<'O#:[70BBR!9T!'@5HT\V*TB#AH
MHG/V43$.7+=K9W30\-^9#@W$4\7;)'=2 ,KM4@1;($U'$5Z,%[]5[II^@"+Z
MT>1\N\MZ)H1EBL=,E++E0D&*B-UPG IS-D1)71JP6=+!\_C.E'5PZBM><%F\
M:(?#7KUS/OKD3?+$1EJ,4#1'K16,&,M9I#D&8$]> :F"Y#O3O.'9VU0]T\,M
MHX]^[*?ERO6J =[KRZMQ\Q7@]9>KT@MQ=E/*?GEI!]+;VWL\+T)S/7_J 6\G
M<7R=RN\A+;-F/$I%8!_G^'5QIW%Q83&/YN^FOS2S+JT GNE,*MRE>J8SN\=1
MQ^M;RWZ,=U_OUE/I,)/;)2$F<!&$)\:42A2\5*)PN"1DGYU0'A<%;ULMJ\>;
M0[=.HT/#7A4O5S&D*"*)EGGT3;P@SMK2WH0GIVQ*V;;;S8Z#O^_+7]_26W&_
ML^KS5Z?G<[7LQ7P^'87KI1FSGO[/7W\MF6OPJ?ET :/IF^O)PNQ8' Q#X-FH
M& FE5!=:T(!UTI/ J6=*Y4SU<%<+]D4_=";0-Z./F_F&?>I%+Z?Z-RO'SU_7
MP%9'P6V@#9Y+M!/NT3HV],KXAH+5I6M@C=(6(,6<B;<N$>E9(D$R0'>.,2V!
M&VN'"^ ,K$E/MW%X+HJT#TOUZP7.YHM5N?2-O]_1/07-K.2.9!;0#Z<@B84<
M2#0AQ$!=SL*TLCMWCW&,^$@E'IKZ0JS=\>$#S "?=H&;]2L$-6ZNRB:\UO2;
MIM8^&>\B,9DM6AIS8F,$(ABX(,$+KMK5>VPSVHGP75VPM=_JO\($IGZ,^%ZD
M2Y3Q;#Y=5,MZ )%ZR:-1EC!NH)26-,2K%(E5WHD0!?-1MN*^W7@GPGX/PNTE
M$V(=P/H9\:+-/5OA.].*!4-+82PTNXET.A O79D];FX<'59XN*[W:!3L #EP
M9;%O+'Q0E^-A>N"^@JLIQ&6/UQ>7S70^^N?R^TEZ>WGE1],BI2>#M*V>LA+"
M4XS<Y6--ZLOF$@>X*#;DY_* YA(ZQ]Q/9.858O0G(HGZ,?WG-M/;Y2D)GZ4J
M%8,3P^4)C"#> R/*ZQ2=MCD]+.2T*_C\;.?8[4S@N4UK&53C7@1'M24IE$Z$
ME";B,BO=,)CTPE'(OEU1T.<YOV'.%)[;U ][*^^?.3RW.>VOKM_PF0374NL8
MH-RE-VCK\9)E*!EA)H+"]\Y;\:\SB>?]#AZ@K]W/+/;1FX$CS&V@_>O,HE_&
M]P@U'T+7P!K%+#";I"+.%YQ> K& 1!OG/ ]64,^'N\?ZS9]9]*5(^[ TX)F%
M!:4=I89 %*7_$GYQ.3"2J8M99\:]:9<K\ZV<6>S%0\LSBWV$>)0SBZ223J6W
MJDE)$,F4(#;R3$0*7N+_BMMV3NFW=V9Q,-_5!7NL,XO 5/12$,5B":LG1ARS
M@C!'$Y=6E4SEDSVS.)C]'H3;RYG%IET_V[3KBQU>5JSIS(_?Y8<_7US F15S
M_ZYA?P;)<2U0JP682&0.BJ#'#*C:8!73-H8A2^KW-<VASTV>FWO6+43RW/1P
MF).9I?P^^2^W?4C>5NFBTN[!%<X5#IA![53\&PBW&JA+SR%K<8EFN 9(Q5 #
MG4S$(\E,J=*:IV7H_-%QJJ6TWSQZ&>/04D:E52)H$Y2";@'ATX2S075U$$06
M#VMS[P/_.*GA'5G:F;[=073/)YSY"2ZOFJF??GTURAE*QROX;7*- (J\<.E:
M''W?_.3E%/!=6Q;ALBQQB)83$:DK#>1QU74""'7!4*MU #]<;9>#IW'TI.LN
M6K1Y]W,0-GN)#1T$?>V[M@ _>#RRPX2.%;$<2'WJJ&T'[I^= OL8K0.%J$W
M221NB=60"3,T"Y5B5FRX(B+/3G&?#)!^BWJ[#^6]Z.O"I]HR@S7 8% <UGJB
M70D(4I^)I=H0ZYR/R446%!M,)Y\ >XR S6#D;ZA=3>;ZZ?:RB6V=?YL$TZ62
MDTB1%O,F$BO0&V81E(? A(;A C([87Y?ZE2'K8IKU&PZ/[L)!?T5FO.IO[H8
M13]>MBH0BJ%*.Z(3H'9S:XFWD1..FDV5]93!8UT&LY^%!5,XRD)[?H+Q?%;^
MMO!B%RKR*(!3\!CJ2;AB0'@!:NG7WH7T:O$&M0+5PL9O3?\N(,/:YA6):OJ2
M<NTW?R<XXW+.,@/17,22@*-*A69+8O:&EEJ 5#_6SN694K_#NAV:^7V$6Y'Q
MV%Q/YM.O9V\_GC'O-%"=2 RVM'*WC(2$ICDM-8",8S9S^PB],XA_.F\^_[1Z
MXI+AU5]N";X=;[A-OJ+@FTY2JVCLK1'\\MN9Y(R:&"5A2NK2K(X2%W0F+O.L
MDDN2N\<2'/?C[9??3H&W/:763]NL](_KV7QQVO:FF;X"-/VF"]NR)(B,FNFR
M,!<N-0%-0!5Q8FAD$AFD*=U>*!J!Z$9DHX2U ^:OM@-]Q)MDE4X;^N6I%Z_O
MQ6>8^G-XC4Y$+&D&"/$#[E]G'%\2DW@BR>+,)6A/T$,5Q#F75;"2*C=<^>4=
M($]*82KPT,N*\RO,[ZCOW4J\CD5M6"Z)1]'@6LH8?J<YB=Y2'IED4J3!5&0G
MS%-2DCI<])0.=(-KU96@=*_@M"1S,*^(C%"Z6]!R9S8!!),B=<.%(C?@G9):
M=)-]+[77'T3!< _\.YIA%[\V#['>9M^<&=SYP,1 P)<FEI&7_LG,DN1#<H%Q
M)N5P-LL!$S@EE>J;OYV5V?O)E_H8+R!=CQ<U V[PKZ#_LR1^?;J 7<4 WHPF
M?A)'?OR^F8UJY5GU JAF?E;_$NN8U[6]C/)! ?G;EX:6OKG>9:*I26B.9T="
MJ01CC:,>]U">O1]NSZHVKPK;>U<LR["WT#E0C;N1D5ZB->L4<<JC?"FZ.QIM
M6?5HM.B9R7>0S+BCZ_D6>V-X93B%W#OIE8T6[3$39"EC9$J1EYQ(!JMU$EQP
M.EQC\V\F]^ZX:E<Q66\?^I]=KE,;\/]*UNLS66\O]:F:]'0(]\].@3DXX2SN
M<R($=$Z\18^8^40B=TXRQT&&X2R[9Z>X/2;K'4]O]Z&\%WU]@'2=Z"4D,UQR
M H8I(K5 G]Q23XR-H(RSU#Z\$CM<F./;S*3:B^BG0AT'L-3+P<Q3^8)HLUB>
ME216 B>21D:"HIHH 88KQFBDPZG1B65Z=E.HFLP-<*2S;D;MK1'!6B)T*8*:
M5":>:TVXHH8Z&HSF _80WX+PV!VZCNIR=Z:LGX;TN\^C#/,QXWJIHU%+:#8%
MAMH>HG?6!?VP$\YIGPT^>Y4ZE+Q>%J@MN+XN=/Y,*Z$90Y7/"F>+MJ5&:"P3
M)ZV5TD=TX <,(.Z"^5WK51WR=AY2]WU ]/K+U6BZ:L+X0&AU#WY:#-3/@<Z^
M,QS@ G[V$H1$0\C)TD@RJ-*JPTHB>41=L6AP!_:4B(]X 5^(3'EI&V!<-B6+
M2^$+XV4IPR2X\MFZEM7YG_<%_'U8:GL!?Q_1'?L08-DTU7_Y+_#397 #)RP8
M0RN>ZP0ECY<2KX0G*62T\4TTPL56Q-]]ZG.[J[(714T-4=4N6+4&LDH";@-E
M>S#["?:.<=FDHZ2W\=5!3#TS9P3S5B9#$C7HF#N5< 7*BCB=0XZ<01;AV3"V
M(ZC:'V'[2*<Z47\TGRZ:ZYF?I$]_X!K[]4US/?W4;/SXX^C+*@QB6"F0)CG)
M5HC2=262$&S)QQ?,92&#-NVJUNP]],")6EU8:@83<>WRD)NP2N7*+7!_1?MB
M?256N1PIS81S&DLK^^)XND2B]4&D4$HXY\-4XNG!3T4I*HNY]CKQBY_#ZO;#
M"DUVSD8; @E24#0OC"(^<T9R(14XZ/SP=OD.TC<>_8U2VDU$O61W'Y(.:K/(
M47@@CI<>C%ES8K64A!MA8@8GC!PNH/S-I_,>XGL-Q]\PY0\+>'PO/E[X*:QZ
M#S7Y9S\;15SE7HW&UW-(=S_3(5YSZ% 5(C959EDMN?:UGTY&D_.;T6XULF@$
MY\P3,$4/O0O$)\,(S2D:-"UR2L.EZ^^$6:$YWX-'+YUB!]9'D2T!7=(:)*[&
M0:9 -# -/%'+^7 U4;9"'"XQM8Z.;&F9UUGRQXX8W<YE65EV65=6>*:8UL0;
M5@K]ZT@\SYDH[UC("=#CRX.ISBVN8QQ:]*4Y!TJ[ET/2O\/H_ +7[-4-S\4\
M<7Y&ERKME,023Y.&6Q(L"X1;'66YS.<&+-2U%>(IZ4-W#GJ\S0]I.[Q$/:"[
M[M$ 0R]"1L]1<W'*P%FT6BNAS' J\BC44U*5>ISTXHDM#,'UW.^:@6=203("
M. $E,I$Z6&)I8L1 ]I$;:JT9SB+9"?.45*4.%[W<OUWY"5O!"9P;PTV1F*AQ
MTBXG8AUND(9&A;)07K !+V;O!GI*JE*+CV'NS:+Y= 73^=?W8S^9OYBDU_]]
M/;JZU_%WYR<Z^-P51JW@?M>>>R_77'="N-77134C2R41W'DBA1>EGB@Z3, #
MBQF8T</UCM\/>]WKJCO'6[J3*D'$M[ETA'2E0:0*^)VVA.E(K:1:X*;^O.1T
MQ&NGE?7N\:NE%8E[/G& EWXZ_8I;P(O+4E7L18S7E]?C<H&^51\;_,M?I[AW
M/'C*XA"9"J.I*[V@2LF/K!EQI3\8E\!R3D+9.-SMTKYF^3PNG]94S(TWX%DH
M2"_>[GU,Z\L0+5 -?K%T&])CW1A]'OKPA)IV(',X50LQI"BY)2 XHI,IDZ"Y
M(]XQ(1(-+K#AZI4-IV)/WNW\EC1L'PY[T:PM<UUG56AMJ&"26)W1YX^E[KJ7
M@7 3I K*VB2'"^OOA'D,I[H[DQO*48>&?BIJ[GB!)NGN.[1NXQJTYD"!>"-,
MN69J2E1!$HZV KX\6N0XW+7T?9"?B![U1E8_V]K8E_2-1RS0Q;KKA4J>%8LS
M>(8N6+F_Q;PA0=!HN +O['!*U0[S]V#8UR>OEQ.&G?#6"VP+@(-;[$^ /IKQ
MW@/GVPZ[JQ/6R_+U%%#!>#;: @G&E&+8#-\T%0)!Q(ERS]&6'#0Q8GB->MI6
M?PX*M0]/M?.'W_BXN%&ZKM2 ]*E2X)117ZZ4 L>-/SE"=;DW 9:QA_?,=R0/
MWW_N,:R;JE)OZHBL]J6 -92'<[.&25H*;K!8]#6R4LC:X5L)@@4F@K=A/QI[
M?%N?#9]=A%C]M;R>HD31B'HS^E+^*!?,?P$_@XMF7((%T^;SLCKL.J-=&J-H
MZ7O@,V)5J']!\7+CO-PJ9#PQ0=L1OM_ IZ4(/0J]%]/R97-Y=3V'Z4,)Q)AE
M5J6#ITVEV))!QTIG37P6Z&2Q(-B );%V@#P5S:G+1L7DE85*[YSQAV8\?M-,
M__#3=&8I#6 E*^7%2Q*6L"1(QH@7G#K+HA:4MUH\VHQV[%H>/1VY]B/M7@)J
M.U&>)9>%T.4BFQ2I7(41Q =#2Z$2)(KJ&.APF4P[80Y\D:@^J>T=A+T8Z<7'
M?#N)T[(%OH+EGY\NILWU^<6GJ9_,,DQGNZ$[)S.(B"]00'HE4YR$D"@*QS%A
M<Y+<#W> ?O T3D_9AF&T%WOG14H+X<^6)0$O_&0%_N?K&:[>LQENP6$T6<28
M'YE'5EQPB_,(F2)Z3R/Q2KM21DE:W.A5=,.91W7F='IJ>@2N>\H<GETU,S]^
M#*.G28',) "@'V%Y25@-'.W%+)-%HS'Q05,+G\![>KI6F:.=2<4];,2_POSU
MEXAOQSG<J8SZR#R8I0)"N?6N),Y#!^*YU$184*E$._2 96[KS.GT]/$(7&_J
MK*I1=_+V"'@W3) I1*\Y<;%<C&=*D>"H(3D$YU2F5KCA:INV@GQZ&E>?J4V%
MTGVZKBYF'H+ !5E0=)0R[O/.12 @%&A'*?KMPZ6=/Z$XP]PM61M0?OQVDIOI
MI>_8:^VP@?J\0=)^AL>Z-!*,M%8D1Y*SI:*TP1=&H.G  ]H3$G3@#^L9'OLR
MQ"]'N31"@V%4FDR 9G0O9:0D>*]+%V>3-==!P7 GU2=P:60?O>MT:60?XHY]
M:62QERY+O;^(.(UE+\5E9JWW3HG RE%?)!(@$IN31]U@E/KL@VA9*&WKX[^)
M9*R]F&RJ2K3VX>D"T1U -P4X6V#:JT[ICH&.4+"T @D;G%:2X%#L,L4UD\H0
MRU%MI::*.)\5T8F'R$(RG+>K?SDHJX\5-1V(U'T$5YO,CQ[^?_:^M+N-Y-CR
M%X6=^_*1W2W9FFFW-))LG_G$DRN),0GH :"ZY5\_D5BX8&,5*JM @OW.>VJ)
MTJN\%3<J8\G(B-N[<;R;KD]@K==1:P(R:PZ",X'QC.0@I0Z6A])=1C4B<>/!
M T=L540]J22G7@X1[POG5DJZT,R@=<I1E^0JQF \Y.)UR-(D2*!NHMLQX)"2
M'0#/U@[7HZ6?,I6GH-:7VQK &OZFXBZH)Z]V/I;,Y]2C Q/]WL=X L_9F&A*
M EA4:/#*+T9P#REG'UGFD@[8MVE !6E>O-RS?K0AH.?Z9)IU-AG-IBMS;X3E
M%O"-&?C,A--.FZ1B(__@]/7)%61]H"JYC:#ZJ3)"^XA&S5VAR?O79#X:7Q5#
M-__Q 6/Z:9JM_-IIBI>!96(\FCC")4.+5QQ:GQ4HDZ4B+!:7:;C4;5/8KZ".
MK5L6J!\":U? ;WG:/^/_C?#!BV3PNJAE@5+A-Y&(P"\BE/[+)()71@.AU* V
M$*T;7FUHO.29JDB/<N\[5[ /)/[\.TIJA [X3Y-QO$17.S#/4(^30,Q2&[ J
M2@B(F#+4YV3,4;K2$,!;TIP^.*D8QK3"_.L$?XO_^.X6%3^9+'S2#HCBQ93S
M""8R!JCVCE(E)4VNJA(]7OU/#>K 1NTJ_*: OZ3Y?'G8,;O,5E)"M0;JB"EG
M[;B!ALP@B)Q((M$HW6PTTQ&+_ZD\QW-1L?AK.;UD,IM]'+_[HSA@B/FZ(/J8
MOUZGQ<VD^XF@EQR=K:QCN4)?AHQJ=/A]S E"- :QAFQBLYF)#1<\9QWI0^:]
M%%CM%<*GFQ2O4KR8?4GA;EJP*A4HD=8"9\27H6@9K$$=3HD3S] WBYH-%V4U
MQGVF:M8[A7O+K^I.D"G?PZQVI5&#I]:8"],2>R\U1/_G#ED?S7'5[^D1@ L_
MN9M_+@W3)_ENEI89H@>-(S%Q3PBZPDJA/7*1@+6&EDM"Q"H294C#7:WI_#IU
M*XW:0%B>N%!*?=8D PDH0Y%DF>I7[O,G)30U2>9XFN*CUJ]RFGJD_G7X<(E2
MOXR?NFII-IU?_ESZ<Z7I-X=VXC=WFQ:9_D111BHZ"$J6*:?*@47TH )WD7NA
M'#FDMMG-_()Y7&"AL7]--_-9^=-B,UZHY;ZU7\9!:L^\3RK*OV)>J^#YG+[=
M3<,UVJ^+JVE:Z-DFQ%7!01.0#0Y9FRI+8V##'JG6X7 R% $GTQ87RN0O'4 S
MAV )4^"SC. DQC.2BVP\>?U:LN=<]81*TD;N]0]89_,TNAJ[G&[<U2B^^_'_
M)C?Y;OKW_)=U@R-1FEPE##L6\S1"+$>)QH-E&(L@M$QY>,ZE;[;4<,%>C_Q,
M>A-NQ;.S\OY?T'0NWOIO:7(U==^N1\'=+#1>:2=9**-*N2R-;:@$YX4!Q!*I
M5AR#S4.7:9KN WL!O#7_H@X3%0\]%J"6?NMC2*O/H0FHBD[%7B##.Q&5B)KT
M)>7*GL-^<"39% 6"TSYRW!%%N1-H-?!H8O;96N<.#:M]H=0?\ R&9+Z-<"LR
M'HKQF_ZX_/ %#1Y7N'.5P=BZ%*%J-$C9,> ,MS.>J=#V$+VS%/YR-?G^U]43
MEPRO_O! \,-ZP]K]2H*?=)):[3J8C?&*GU-YH='X:I'E_)JFMY<NYTSP=8!0
M(LKT  \^&@7E])P8EY*TS0X4GUWJU#G[X1)2/8B^>H'4-+F'8PQ\2XQ82%!@
M%2LW$$H]A4@$2MFYYP9=V89:\/2Y;XSR#D+MI7!Z\Q4ODU7!<:% QT#0* 4#
MUD5T@@/)-C!M.1VNS<<FNK>C+)48JEW.].Z/;^CRX$YUX\H1]]?)E^O)=%ZV
MJM6AV*KOZ>QC_G7R^[_<S=T*]?O)]-]H,*\_IS"Y6I+V[H]T^ZW\YN]N]E-*
MXW_.4KQDJ12A,P_*86@KB,I@>"J_*&UMT)&;9KM,WTC?CBJ^/.+W5EGU<$2]
M&C8ZR:NJ^TE>2/=C_N=:NIW/JYLO4>WP^LBWZGB2O="DQTJ\7"3%306^O^&P
MB>I!D[.)U'D:47\S^LU!H@V5>I$(<U$E@JK4[#Y''3R==M5.$%8346@T-)((
MVI9>\C*A8#1^35JC4<CXV=,X@#@&.4L^E18]V0\'INS49\F'KXY1)2-'KP1"
M#BA%(QQ8CTXMDX2G$'1F]F3W[$Z1%3Z)AC2ZT=N&J0$O:C:!]>>-WDYD-KRQ
M>0P3 RH*X3(&%SQPGSQZB2Z *R=?AC%KO<5M>W-:Q7DHR%$W>OO0CS8$]'2C
M=Y368'221/J8(1CG2\<##39;"MKDJ(6D*E/:R.G9?/++N=7;2MX[;O4>)ZSJ
MTX9N4EH/M:"",N(# ^U+%QJK*5@A#3B5=& T^J1T,](>'GH.?!TIHEXVWT7G
M[.=FGGC/K55"0!+1E"E'!-^26. .$0K!,TMJL+VX">+7K24]LM-+[Y:MO"5/
MR93Y1N"L*FTE\/4-,0:,M,;*3)E0P]TC.5UF^=3A:R6&]IJ(_G)P'_/BCS]/
M9O-:.;<=CZR=8WL.]5 YM7L4#^H3(C/&)P>!Z02"^@S&) U$ZFBRH8)O3OOJ
MD#3:7K_WG-G]DJMPFE%+3;D I6THLT<X6E1:&J8XH9UARM!F?1S:K_UB<F(=
MM:!U#JP#!2\[YX46U6872HV&8?@F+H$W)H!2E%AA0K;Q!*.]7T'.JXM&-,IQ
MM6%FP-1%$UA_YK@ZD=DPAW$,$P,JBO*9DXC^>N*X*2\\=\<5A:!HI$%RHP?T
MDU]ZCJL/_6A#0.\Y+I:2R"(ET-)J],EY><$D@4D=G U*<=.L%\S+S7&UDO?!
M'%<;8?69X[(>S9?"3\ID7BI[F01+2 :%,94Q,B>;FLU%?9$YKN/Y.E)$)\QQ
MH0L2:"I[HT;O1,0 CG@'DA(6+;Z#<L.=-[RN'-<Q6M(C.[WDN!X//]K*IH00
MN/ 4-R-;1@ +3J!  JF9SYD(F?AP@X4.(7V!N:]*86H/3/72\G3=&7-59?=Q
M_*1=$-JW2V)2)-QYM&PLETZ9&2RW%F)I;4?Q?\6 4ZJ>A?L6-*HN9]7]R,FT
M7!_]^6Y:9OW]>)CZMX'SQV4T91P %Z#1.0)A<?_T1%+<MJ.E.EC!-B<H[?-5
MFBYYOMK1H^AK5W*73F7O45";O<JVM%@YC*5D5F!"0B/KC$ Y! /12!N,B\0'
MWD@_FJYXYNK1B^!K]YV\?^%5V?9_BTS0'<NCXH>55[@TF3&FHP3.A041\=T]
MXP:,1M?=<,]#PXK3Y]<Z=XVH*^Q>A@AO^4R94F.80.,6T7$2'G<QPVP$EGGP
M1CI/!_1NWZ)'VXF1O3TE^[Q!\0\W7[0CO!B[FQ^S4;D:LKGIU;M+T6*Q^K<J
MCGW3H<Z"&^![4-.HG#""ETM"F8/(S(*76D$B5.<4J*6\60:R-K+>SX\;@%D>
M8AF7$Q$$'3EIT-//)I0V+ FR]M23Y$2VS7SHFJA>S)ES;]K6^C2Z%T)?SCGU
M_>N5DY% ,<#4D0 )%H,+KQ(8KQD08UV4G'*MARO/>XSLQ9Y,]Z,=6X;[:)9Z
M28-?7%U-TY6;I_@51?B3&\=U K<)M,$/K/?"/=6A]?%L;BE&72H&UA;F'2&)
M99#&:!#29O"41*!9).T-84(.UUEX8"UY]N1Z$"5IPT ORO';9/XK IM^O7;C
MC^/T?Y-;#QTUE"9A<9MD2I R!H&!3YGBABF#)$%Y1H93CKTP3W%V5HG.+36I
MPT4OAQV;N"[&\3':]Z/OBQ^OY1"MB=1;"B)F@9\+->#*U%I\-,]1L8Q?T6"Z
MTP[[.2E4CZSULAGM12:T$EY+##"<*_KO-#AM!$CA/>6$9$/#\/KT%C2G"Q.]
M'-__;3J9S;;R[K@]&ND- UX*"H3+#HS%,#018D.,/(K-SA(]*LA.B"\PO=E[
MC%^3M6'NKOQM,HF_CVYN:@\Y:?3<"CG-]OAKIR_7"!ZES)U)E%,/7#%23DPU
M^& (!,F5=M2%R-1S\GM^F6J)Q?63EVD#P61*3)'2YTV4ZU49+-,E_6_*<%Y%
M9,.JP+U+#)[RZ\;0WOS=\7)[.<FX7=7*1CAO8BBC!&GQBH@!FT@ BVYWIEY8
MM(%O^M)(!^(;W0UI0\" )?]-8/UY-Z03F0UK_X]A8D!%T8218$4$1S1^%@XQ
M>A<9QE9.XO]P9]API^XO_6Y('_K1AH!>]&*]0Z[+Z+FFTF0#L5QV$-HE<-)B
M:(8.-O7&!X0X7+#R!-O+*45O1=IVO'&\Q'O)G_V29F$Z6C301(,YG?P^O_Z,
M(7;IHOEU\NZ/^=1]F]S@#WYVL^OW-Y/?/TTG_R^%\L]GEYPE&TDRP!//&,EC
M.&^<IV""YCH1[]F0$^N.?Y$31L!U7-[AZ>Q?%XN42D_[ G]V\>W;S:B\PB[<
MVE!'*&<0'$OEGE8 IX('S?!;S)Y'&H9K,GW<.YRK!O9#8B^F\,/M-S>:+D;J
M3F:S5?'D[*%X\N.T_'PMK4MAM3+12W!)<PPI$#EZ"!&] \L0K5=:#W>7JQWV
M,U*V'DG;FR.NFM9;W$S[,)Z[\=4(@U2W<#3N*__VY4<?_A\Z-XVN"Z!"HK!'
MB?0R.KDHW;C<'';++>_G:P229A_&FY NQG%;_9VV+"3T^H)9W&L4 9U)9D'&
MK)3.P7@VG,==[;7JCE(^!LHRY1.\%B+J!"RA*1%&8KBFC0(C);%$9Z'5<%5K
M55[I-*.5A]/QPR.6A]&$%Y3U==/IC]'XZN*V.%$7(=S=WA7O/3Z^@(I_.9V/
M9LO?C^.#22Q"**=;&T\IR8P<J+*%B+RX#92"P;"3*G!64)O1$TM\N ^CK[=\
M&>,;!]+9[8S32]"=?I*93S"M$BE-4 V?]-Z!]&0Y[Q>A#\^H:0<RAU,UQJC*
MT7L(P8<RB#F!2:&47"9-A>8Z:'&&*O9\UOP5:5@;#OO)O&^_ZUKYA;=<90R&
M21#XMB:"RSE =#(123PW=KB2LKTP3Y*/[\SD[O*?SC14'Y:X^$C^N_A(UEV\
M/>4^4@F9H/J+Q- 9H.63D,)H$BU5E#P7Z^]Y]JNFLH:\^CURW?3S%@F.4L%X
M7Q)5]CBB&&<L2?")\])0GX!EV4(@-$H3HN7Q!%-O&F%_XWYV?SSW4J;Z+,QU
M5_D&0 =WJ!N"/WE=20^ZL*ME4&]$]G/"TA"PI5HJJSS0S-'\ADS!$>J@-/"E
MECA"<GH;&M>\4.4E*5P;_OHQO9/;;W?S-/TRR?/?W33=-_CSQE%O(1FG\>V)
M!1NX!"NEP*W>1T6'*\7?C?$4KE@OM&Z;R>Z<]%)S\//=;#ZY3=-I6H2JF\*X
M[R_J"/J?&B0-Y72:H6=*=0:MF#;"$>N&],Z:0#YC3:K.6$^;T+<?T])59_8)
M88X7?N?J;#/B&TQ'[F;=D731?&?V)4V_CT(J_PQ_NAB,O/R+^V)2S:FR!F@L
M$8VS%IPA!+@(-C-F\%N1 VY?==_NC-7UE'I0N\_?LR+[/+FY>3^9X@X?+XT2
MS)/(P#.,PT5$/7(L$9#9N)R-MUHVZ^G69M533U(?_JBT7V+ZZE![&.TE]<8D
MI0+DQ3>G?02?2P\R39P)Z*GBE_=R8H"!*ZKZ([N]S]^*J9["RC M]S=_2<O_
M?KV>3NZNKK].W7B6TW3V_"L()Z5FD0,G/BUO>WII VAJ@R"*Z&#-@,K6\77.
M61F'9+J7[-OZ^NL#MM5+_'0W0RLPFV&<Y$?CA?%H\#[!$>>H8N"<QX#>%M?$
M"@]>\!"%%TZ1X6[PU'VW\U7C$^I Q<Z^;8MP&[R(9@*!)^ 4!2ITZ25C(CH_
M"EWLR+4@:4";7^>ESE>+3\%Z+\V(T7O_-IFYF^*1?T[ST711Q=< N5(DY7)0
M1%V9NTLQ)"O-(4 ;9E&NSM(!\]3'OL7Y*N@@O.YM?=R#1_M;FK_[(RSBR8<Q
M  W>!\&+,B,:"$NQE#-P,#)D%*B6+EE'#1VN7JGNNYVO]IY0![9U6E5P?!_5
M?3T/EW M58X4K-(H.X=B,\83T,YGD:..R0R7ZVP%_7PULC\&MQ5.#Y%C(C)$
M4F:39ZH,.LZ(TY R,59Z*U,VF@WI;S93K $OGSUU\%PQHM\QR'8WFW_5V^VS
MU@AZOW[6328O\/Y9%.AU>R<A>LN*KU/*Y)2#H$U2S$;OV(!7^%_F_;.GS%X\
MD+[Y5\MR,LM5Y.7>/,7MMIS/,+"^7&=.AO)@>13R-)?.VKW':[QIUD:;#]\T
MZY'S%W2]K%WU$#591B4$9%XFT"F!IC+R!(D8GKC-(>?AKKR_QA+5/I6J:UUJ
M&W)/6AW8!.B?=:G#Z<+198+'$'E2S8OE$#YK!%R..T7I3N)R,J!RBHH)3ZT?
MK@CLK.I2AU&X-OSU5!(VFW_,7]S-_8AY3QAE@91N2PA$,(F[N^8>O'7"<FX0
MZ7 IY"UX+[DHJQ69.XJRNC!1^[K7YS1+^+1K] A^08_@9O)X++D,+E-" YA(
M*0B=!7X;)H&-T1I)N&8^/!=F/[O*N3%=5ZRUQRG_+8W3U-T@KHMXBY*>S4N9
MW_=U331W*B6'>V!V1(,@48 AW($CCG).J;))-F+\\#IGR7E%T?93_]$JB<JY
M\"*5V0BD-$5+I<LD41*8-)$32J+)PTTK>:%I\)>71^B/XV%&#>Q,@=:>.]!^
MD;Z2NX--)-B3%-C0D <ME*@&-DL-.I7!%@SW/\N4 D^UC2Q)+<UPY[:-(%?.
MNVXLL\R*.*8E)[E<U+4"34.F8+SSP%@D/GNE568O0BHGS*+6T:EG,J2=V7FU
MB5"=B90!?9(</'H1V>=RRLF!>^HY24H)\V<BM&?=Z9KO;,/A2;-.38#^F>\<
M3A>.3C\=0^1I-4\Q- F(56NB\'LDI>5]D( 1E O2!D8V6\Z<J\;5SG<.I' M
M^*N=XMC$^._1_/I]X2+]BM%X7(?C,63O7 +%;03!C2MS'3T0$E+@-GBBQ'.!
M1//E7G+"HQ57AR[^=1=T[>PF(DPW-RG,[S9ONJZ3/4E$*A!7$@*_!A7+"&.,
MA25QF5N*<;&B3;7@X$KGJ@#UQ%M_&\#8.WV9N_FR^/K7\L^+Q!=M_71@,D?$
ME+)>3NPTTF4P.<I RF 4;QKROG^5<W-XZXJU_OWPW<!^67PNC:#M]F5;,K]<
M;UCWLS(S3?CN(-:AOO0U1.8X44&#-2*#$ ;142HA!($6B(@L2-,]?GC&][A_
M)R2\A30'.LF6/(=DA0'KG2U3>#GX1/%W(2':H!(5 W;(.=U)=G7Z&IQ=MY%]
M;>]NWX';NS^^X>=S#]&9C*_E*$3T/4!89<&5UI[:::N"<B%OSKEH>:;Y=+W7
MSW=?PJVX'<RF\TOT..-=F'^<KKO6E&W/.^8(YP*RE@:U4$OPPKLR4LP9+2-E
M]-"M].QF?D$%+K#8!OZ:;N:S\J>%/BQT8=_:Y^;N59%QQ5O?C_"4H],5HME*
MT9N :I"K;*D VT"&=?SJ<+1->"4!]_/%[P G*369TPQ6FC++$J-7*SB%P(.A
M+")T?L@%>*&L[W'^!B2]C5QKN_47__K*^'T"F^H@T'WE5J.9$4R!"<Y BDEQ
MRJG-I-G$^4</'<Y05Y3QI(* *OIAY<U^+FW4T_2;F\Y__.9NEZIHK(G$:0]2
ME)<RQH-E5@$5,3$$&FPX=!.IZ0>Y:^USM,.=95RQ?47!\SE]NYN&:S=+%U?3
MM/ \-R&NM+L)R(IVN3&PX>UT=PXG0Q%0V6XW!ZMD3#*X!$:4:OR,O_AL+42A
M(S>,<.D/G?N]$BTY8-=/I"1MY%[;SO]O-[L>?5^//O$TT:B*,8P$1)*X0:HL
MP06)%HZ())AK9.@?/W582]^3U"<U1%;9]-^G';Z$-';3T62IKH*B[R$94%9F
M)B$\, [-72#96&NR]>S0S9*F'_'.Q<_1^'>7<L5600M *QS_',^^I3#*HQ37
MQJ8!J(K6?B^0X:U[!9(F?4FXLCG?#T[BCD9I.=QW4J*&.PU.)@N41Q6TI]JP
M0[US7BCM!\SU4*RW$6Q/;+^?3%-PL_4E)N^$9DX$8.A_E+*.!,Y$!E9'9U(D
M*M : =[NU8<UZ)5HV4%T!YGVTQS[22N RT!$--:7>HT00=C$P=(@(!J'JARI
ME'&X#BU/L9WZDD]?9>X=&*A]O/9+FBX[:S:[3.1T4ME'"DQS6=)8'AQW&4@T
M04>I*=E,P>[QW-NM>UZ*T+?@:\=NG]R/HJNXC_T\&<^G;E$*]O/D]G8T+S^_
MU*BDA@<.G"K47Q,5;I!!0Y8I2A9M)IN#0_8HQ3,+G:$6U!1M+_=)'\-RWT;S
MQ^AFEYFRS)SF0+.RJ)5)@V$N@O*2,!4$=YN5E;T691R >EZZTP<_%0]Q%ZI]
M"%GYN]'XJAC D?.CF]'\QR5A)N+[.G2@8RX#51GX@!+)A/CH\*^8RXUVD98+
MGY=F]"[ZBF<,SV*=?4W3VTLGA):E0Q5CQ(/(1(*SP4%*Q,5D/<7]L;-B+)9Z
M8ZK07KQ[4TQ5[X?_[&:EIT;YS[O_N1M]=S<%['V/S/)SM_77':Z*=UJOPJWQ
M>N_;\0+YTC%]I)"[D3VHI8J6B<PI).7*:(@8RN2R#"Q&'XA2Q+AFGV:+1;N%
M.\^NL\SBLD UCR:"MT:7ECT,@_3LP.5H(Z'2RMSLXE##!?N^QMTKLT_CFAXD
M?.J+W$^2@']+DZNI^W8]"FYYV0XWT$3P=2#%XJ/+TD$Q6 O6,\*UDC*D0V-?
M6Y^$; (8^C2D/YIW'8=T$G?M+.E2C1Y#6N4(FX"J>22R#\@)CT2Z$37I2\J#
MJ4"0(5N*CIE7S(#@Z$Q9I3)D*Y3G7LK(P^NCOLFQR #,MQ%N1<9#.=*?_KC\
MYY=+;Z.U6A(,H 6ZR20E<+ZD[:,,0K L:3I4M#)+X2]7D^]_73UQR?#J#P\$
M/ZPW\.%''<%/.DFME\..<O@RNAHO:C.FH_L;#9'B+I'+;5B:RU!)C*P,IVBE
MDI4D<$&C'6ZNW6Z,KUD#JLJ_GPMF.WV62\.HLY1H?-F [HK/'@PZNT"%I-;F
M+)CSPR4T=V(<^.I1WT%#54J&Z5_W8?P=D4V*.M?N6M?TT16R#D>]1>T$PR,0
M#VJ4J1=")PH8*%@0M)@/7Q1 4\H,=3K$9O< GENI6BKAT<.788\0,;BRH5&!
ML8\0SL!B!J&P6C#&7$R;<U/;O<)ID@:=V=J;*>@DP%.G!QYUYIRCD?-WRY:@
MZTN4/_WXS<WQ+;].OEZGT?3]W3C<7^ NH3'U*#(9@P#!! <OI &EI.$J6$ZR
M'LS>M$5_\L1#-ZW9[JO:)WN]>#'W7^%//]; [AOR/ ]M\*YN>^&>JH];OXQO
M*5A=N@;6*.L2>NTV@^=,(<0@P5"A$&=D1- DE3N4WWC5FO1L?[87HTAM6!JJ
M<P<U)F@DTIE0<@ 17]5P#UD':VD6_/!M_;/IW%&=OB:=.UK(OI?\RQ+2(T/]
M,,C[8K;Z4'ZYFX[&5Y_2=#2)ER[0$(@CB+@,1P[*H01D!)U9$B900N-PDUG;
MHC]A;%[--Q^(NWY*FU=8?_Q[.IJG./E]S BEET)E0GGF8(.PI>0:OX)H)4BI
MB,[*"S_@M-_=&,]+<RKPT(MQ>C0/;POA)=-""5-.*04"$YX$<%YR,,YX[@C1
M.@WGX!Q">EZZ4HV3O?6O]8=7_'PWG2+4B_XF5S1?H=;8BB/?J49&<'O]!^7R
M*@KMA ":,P;RPC,P@AB@*2DIC2'9Q.<D^MPBG?* V\]=YB*41X>-E<M"K"3#
M0S!@J5>0>?2\'(Q:W:S[Z)X%!LG^U6+F2>*OAL1.G?/;VY['*I.UP<W0F6+C
MT.*!L1S?2:GD"#I!+)Y+;[)Z9#[7C*R-4 =K1]4$U!MJ1M:*HT9]J8X1\&#L
M.VZ]#!Z='LX6E_9<&>$5068IHS!"<UNC_\$+;T96G_0V<NVS&5G@Z%U2CKL6
M*0<(CF/4(K)&SS8%9R/7+C[KR;W49F2M9+RO&5D; ?636FHW$\,(JAW%6 N5
M-"->'\'FI$#ZF'Q()'DQ7'CWLH<J53?L@Y#6R_W'IN,5F@#]<XK2<+IP]%";
M8X@\[12EX"@3:'T-CP*_1^8!=V "B2CNLB*1RC^G*+U@A6O#7P]3E [/=LDR
M9\6R!+X<5!O19W HD6R2HE$Z*TVS3FVO>G1.&X9:C<YI(]X3=_[@RM"4 T/M
M9Z)\# J\<18R4^@-9&_YYC;SRCI_])?OZE'2O2K%IVGZYD:/9]N7$\$9 F2"
MTIC A8Q!7]0:; P9>,X\<1FD:]B^L<EJ9Z< -:3:B\.Q_>J726>2T,4'R\IH
M+V-P?S+$@8_:>:FR3FRX<OAM?*]<-ZJ)?IB3KR_7;II6300>SH=&5<Z\&C^[
MPFG7<>_1RVSV>X?T,:8'I6*><>2ZW+I1 1T/*L%Z:5$'C,E!2!+E<"F+YKCK
M3FG?N=8R%1&2RCD[!&L637'+$31ZYL"L=LIEZX(<KK*L&>;3S&NOJ&>'A[97
M(NO4IWL[0L8GN\8R.F1>$94@9XH;-#$)O$\"4O+,V1"2WYPM.T0^<1/FRVB5
M7$LM]J<3.]'33R'L+FCW2:;GP0V>+3P ^.09PF[T-E.;#MP,KD#6*0P.,X5@
M:"Q#@ 1NUDDC4B9%\J4V:L![JD,K3O-$WX!ZTX:2VGF\!:Z+<GFV_.:GC],X
M&KOICP7*^RO7O+27Y0J2]0I$-@J,-@$45<031I,6S:+V!HN=(IM7C9M)CX+M
MY2!T)ZIL&#52$LA<+N;#BC*S4P'Q4E(>1!DH,5SH?J8Z4I&#ZDU[IRFFD&:S
MR?2=FXXG=_,GT%B,B@CK@0=\1Z$I!1MB6I1B6\N4IJE9=>+A=<Z!Y-KBK#T3
M?;E'?73![U1"SI7/@@3(5G(01BNPQB5PRD2M)*$F-^RK>G"=LV&ZHCBKM]1=
M&J%]T+P3 GT;"3G:C+X-+>=4TH!W)G-&K*1*-V=Z[SKGQ70=<=;NBKMKCTDB
MA4C1D/#$2G>5C*XKEV6.A/3.4YJI"8WH/>=]NJO@*@Y16N#Y,I^$_[S[(UR[
M\57Z)<W"=/3M_A(PD5H3IS08)=!SY-: ,;;,@4 G$C6,4-KL3/70*F>9 :HK
MV]H6>1^P5?EE$VB[LS\MZ3]%?7AE9IKPW4&LM;WN9R!&[W,H.Y'TZ"L*:R7X
M3!UN3%X9YER2O-FDC%,POB?K<CK"VTBS-M%K5!_SH\A@MQM!)4]$<+ LXMOC
MG@9&& N4N4ARIB3Y9MVL&B\Y\+%X398FO8NX=L7, \IG @='K9(Z"V .HT,1
MA00;.0/C!>,Q<D-$L]%)35<\.S6H*.#J^[Z[08 +$2S;NVB;8A8>\!49Q@[.
M@\GHQ')%\>>!\"R:!=T;#SYC9ZZ#!&O'V8^PK+2W"9IV+MOF$J?PTKJ(? ]W
M'>35XS>Y0L6(3B)PLBRLPS@R@;4^0F24*7107-B\FWM:]@YZ7/V1UT9,]=/6
MH^]NGC[=N+ HY;B/X5,6U'@*)&8'B(Z#4SX#U5I:':22636B;L\"0QO+;D*?
M5)98+\=27_%?HHUXCY9Z'$:EWF@Y;ZHTG%V$!2%Z0ET&%74$D94!ZQT%J:@1
M%&TXDW:P$ZIGP)ZEW>V'JHJIT > NY 5T"M=;X)O\'J:PYA/55)3E>KM=N_U
M>>JEMN89G%)%YQB)0(H=%1$_5E?2S\Q[I0T7)HE#(WU>OQX]6V%S4C5J0T]U
MKS*-1Y/I3Y-Q_+>;3MV#O<W*^F!,*&8[E%:+%+S)&8).EC#'N):^F7.Y9X53
MG-'4)&)26XH5O9;#\VR8)TZQI-":<HW*S!EX;R+:6NEDI)YKX@YL!Z]NPM<@
MWD<]D5<\LSL\"J4)J+<VY:L548UF/1TCY<&F?#$F=+:$0.0E3#,:P6EI( :.
M(9L-U,=##?M?*/5'3?GJ@?D6PNW'+=P]K<@S93()"FS@)90V JQ3 M 8I9""
M,U*KX=S!%STMJA6%3:=%M9%_[?.=Y1'#Q=W\>C(=_3?%?[F;.S1X,2E#K8(4
MRED#TQQ,\ K*=+M N(FA82W.SL>?>@YU#]?%*LFRET35;W=%.*NW7<.;I7C)
M45^-]@P"R1*=4671K:$:B(RH?R%)K@_Y?76_^WTHSU!9*E/3BZGXY'XLLJVX
M92W ?9C-[M+R)K_0S"@G&2@A91G6KL&6'OQ6,LN"RBQ2-IC:[,=YUHI3B9Y>
M>HI]<M/%SO<I+;%=EA;7V48#-C-26C]X< (W1!--9N5VB1?#]:??1'?F:M*!
MBNKEW<MW^YQ0=FX\^N^B&<&[TA-]N?TM=#A>9DM17YD':BF^-D5'R#,,NWV2
MPM-DT=%J6.;=:+TSY+\O:?=R]/'4!'Z\F\_F;AQ'XZM+&G6*KEQ L*'4U96^
M^$13T)SY6 JBA!\N2[T7YAGJ3VUR:A>=[U3M)UJ=",9," 6T3A:$++52#I5<
M.Q-29D$&VF$/>;/;Q]$RWM8 U;T.>8GCGV-\WJ?1M[3*Y8^OEB@OG6=669.
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MOZ/?7:#5^ZT_1K,*BIO@:94SWE[C!#GC;F+?1V 'D=5./>Z Y8P.2F4'QHL
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M*7/0I5.-*T/(T&-P@OJX<:EOB,;^^^">OQO6%W<UQU UQ+CZ")J@/-WLD?W
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M;7-C><?:W.>_]S]&<W\Y^G^0%@-/5A=[)H*W.2A/O"B9JM+C[[+%WVEOG*<
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M=O1@R;H]0_F2ZD>YC\9I3PGEI9.D\9EXQ5%NZ2(O25@^#9>!^]+K1U\ (0>
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MB:)!H(Q""3=<[FB;A,<=NML;DUZ2D%>E6NY)'>0:/$[7+NNAXG/[X_DL1?8
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M6-Y9S2U8[:&CVGOZ8XF$5MXK&8BB$?<@65I)(/&(EAR4B%90LU76WZ&.X![
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M29E]H%]:T>W"K<^JYS(!\Q"R.MK"QTEZ:(/XY^L_:NWG-U!_FLYFT]_I+VN
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MID_79.2]^>,3.<O7\]I%@MZZ-E]=7M^\G2PF1Z2?[N:_3.?O\#I=!N=4YL*
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M1TQ1:]*,T(?JFEJ/\))EX]<Y9N_7SG"8Y=6ME[UDMOI>_=;I<GL>RYGH2CX
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MO@RJL9776-E[C4,%'K3@:"3WUR/:T) -/"#>G,H]5)52YI19I:%A8!USN97
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MYUQ]FTS:(+ELYTV:L!H/:!.$YV,JL8L9.XHJ!BO,D/$HW_;'Y'A7@=C01F-
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M[@=(X8%(V(ZVNU..^9$X?QY8:RZR@!S$Y!X>4*+_@C7& _$^17Y@V'PK-)4
M(9)S4OMH/N/H3"89#:S(*==YE@0<H08[/F=G?F0L[BGZG\);_RX$7)G+0N4,
MX.<%&_6=K+A1TY'1?#\T?[RZL'G.,<(B"7&[^S7 .N^Z8I<7B\P(J^<(^5XY
M9/XY^?B2?E7(O.4DR5I1V+P4#]^7WO9= I'4?00O44M5-,^\\\C2L-LNO+;2
MP/*8K;+F6KC.;TQ42>>T-EN>?[K09Y"FCM[*S3=?'=M'E S3&ETWOCUDS"L;
MB5NSHO1W26QAM6#;@63YWD:K++_<E35NX(P6J!DPIN;L1FP&^5>]L$ /W6IN
M2/KV="MIO>]:"PM OG6E[F7P[N'F%6QH"6 QB5'N\ YM%?2Y 8^PW5Y(Y\KO
M<A6S6@P1#]QWA !)ZG36;!5=XCP1<CSOO5)'C<.*G78;,B0@0?/"5V<88D3/
M>GWV7=$F<8VGHE]GD#1WJ SQBZ:.4[ZP>,&J>T6M1%N1G;8 8]Z5&AK:*.E;
M;^F1.A:"K/:J/'X>9U&7;//CKM;F.V</9.S]!:[4/:HP+4N,ZSRCI4B%;45\
M=%395C^$?DA?^I<BP+,5NL-G ]_[3H6+-!HMSC@#TM3"+)!._08]$K0W"I R
M)T0OE(6KU>Q7U>#22NQCAK<;[SHM)(]&E^SBV$8WM]RRK>AHQ:K[F)."K#4S
M.+E-"">6?1],>-'BU,K"H?L,U7A@R+W$4XP >:17AR9JPS$F\6L*&;=0OCJH
MMA6L.$L>5DI.E1"_L21**JIH5U2$69YGB\D77#3R^SZ:0G?O K&W94-NE[3-
MIZES,4!77PS_3$$F%>FPW(/Y$Q^U$;')29]=C^KKQO+-D<Y%[K2TE4F<%W)T
MKUDXI44MD%8++J(IFU 9QA]&+C>7-U<U!,V,KK'):(LOF%=\+(_<EMD2*(E%
M4JP:)6>P[O9)XFC:7.VYS<?+J'X3O>[)&G/1D''@>>M]/%!M>5!:I(1F/4B=
M7DKP'U7W(VG4)V6Q]90I2N(035?C'WNW%" 7W]\.H\;*9DYJ6"%/T/R]5M41
M9UF[+9PW>N#D60:)(T3D(7S\:GIH_9A=MGNZUU9US326)E,4^A]Q,=&U,/E%
M'UPH8F"-&QK6K_ZFR&K>9@HS'\T>&3/[Z&,KN,TDN+C#S/L]\GWB=(C4RC.(
M=*<JA0I*&Z>>%(O;Z\+%QC>D(IO/XH$>T6]X8 9,EM]V="#F[V'=HJ=/M7?$
MOV!9P(A5FXL])C2$K;PL30,7]<IJ]L0%MFB?\I<\&=O"L4_\$1QX5I$MV&6&
M>UB.M\)>C_DWJ+WM9L!P5L2,^J>P("#YH:P22_D;2^O!!N8=/$#M*SR:E]"9
MK3*27<'.'7A?Z_AEM2N)%66PC^]$UV,2P%.BF>';Y@*[5L:YPA1'57UH(QM'
M^AZ1%Z/BJR_&MVL4W-+ML4WF+D^/6>.]UA/,'D$_.2CK#N<EWZT?VLYRT)6%
MBSJ)I!N[O^Y^['Y<U]+%GGA#>*+_7F7JO(_QIBA_TN&[A,^PZ1K$5AX$=S*E
MFK'?/T1'OF>)<4*&+40SJM4\B%G>M"'U-WQ^&"KG+N>VG&MCZT\_*&:<46DP
MKN(@T<:^"Y%5)U<;XF1&BY^\=5]-_5[J+B_RN7C[_%DAKB25, C[:Q&BKA)/
M&)DOAU!HP5I-E!!7A36_+<4758D;XZ*OJ&0U"&H0@>RQ)I*=\$,>T(Q[/ZSQ
M0*[S:?'PLP0L'OY290BW:A^2K,/W+]3A@0G[^E)&) \V:&_VF!S$NHU*@NF[
M*G3 [YO^K_>SW:?&D@WMZI=?RKDLA()UL+#)R,:>H"I9D7V?_*9<C9*% ZT+
M]\JGT.@N?D2 O.@\@J6;.VB>.YV)="Q&A;Q8_HR\7?!8\*[]GDK=H( CO:2#
MH4-<P%2N,1/;\"L_I0Y7*.JC..R(1X$/#S2#Y/4O]_A50<B^N=QA?C":<?H,
MA !.%8B5=CP3J3@X#RG]S-OY7/!D5E=[>&@>Y1A(_$2J4EY"S+:OYT%E%-'5
M]2LB![$']6,@;)-QZ8,UK^M\V?&Z]NE3 2C2T@X/[&KY/L #?B"V8!,5V53?
M(9MX].JJ:IL'-\J$!)7/7*ZM4?,*O"![ELDDIK9@'I442I3=E;6*_DAO9545
M1<]W+<>E$T)8!\<8,L-/:#/H8;-&,#QP^>X?+P=L"FS,#6T^JJH*DK6WT5&C
MNY9Y,UKQTX.[GP"70!/K=J?#"XT$( GI/ZFLS<$#P7%%8#!(H_5/]O+QP,X#
MRS69O)H%83JO6[!6II*5?81_CN.64!6D<F=$+OP>T>>WXV_J]_<RJ71^J41\
MYND;:\P@8Q=#))+T*YW+,R^_7LAD6R'<#H8O&@Y"U[]RG !ZN<_AH3AAS+-^
MI2&')=RX^N/J&$GS#?Z%D',$'&M^I^=+A6+)83X&>*"%X@ /,&52IAF@9E+F
M2:L=5'OYJZM<N2DN+7:VGS?4M@A252O1-0_%L>F1U\N__\#WK#RPMW3 /Q/@
M9\$QJH5 FXIA<R''>" *3!1DV6T<,Z-0E+(?'NBT(3*"AOHSA?&:TGSART]B
M[+TP^4&55%Z"KVR  )&"!\[UMP:8$B"GQ?T'SVM63Y">!!N>72C@RV&O>[!+
MG_*K,M" WY"QV_8<F(O->&!!C&!T548^YL4C^J2WMA2).;[<USA5S#\]Z$7"
MD6Y>%L>(+MP9)SBFCP-5+R=RLFF!!X@E9[%/ FCGE[%!E=!C<F/8QLBT?AQF
MJ"O5/"HD-']5Q"YA&F:G=-50+++V/M]6CQ":A&C-?HR7*!%3"*:SY7;SO>\\
M.R5-$)RBMR>(%'@@,Z(/$YPW;<]^9G2C^)TDHRNB7H7F%5DY*WD\9-ED*1E-
M9%0Q),B9@.R/\.PXQ_6H6.15)L>A=R;5S:Q:\W_"OU;W^BE6F[DUW(<=DA:-
MNZ]$<@?%R%SC1*F56$W[7D<U[02Z9!G=4=1A2Q"22.;<6G_3PR/=_]7/_OH?
M @S6VCT"EIAO,$6XHR$\<,@7(,L&U:X>?/JNHB)0L.21:7G'A=:"7<+B,;)_
M+JQ&G.'TX"[,MIGO,[_  XKQL;^L1X\C7+S$L]/3B"3'C'2L<OC%O9@E^Z+E
M"FK5B)BSLD),]7$#S,#T+S?8-\K@"[T+N+J:'?%.S#8(]R&S^PQUIW _XI%\
M:]#H2X3HER@ RTL4]PL3;TS[E'YE#,N#E)=5J\?XS*LO5\3VV@K.M'=B>!+[
MNJ44YIAG_QB!@+O9Q9KF^@'W"VX]HV-WXV=N5K\-N?F,_J)!K$4$JJ?8]U$V
M1O^F-I67ASV;Q]AMM_H&&ZYX6!4)X+NAG5*[?+FEWZQJ]9]);TL*G$/-7/9)
M-WJ/CW5W"%P%@I1MGY8Q)GNT,M[A)8FZR?Y,P=QD*3T7R<%N-ZH@$8_KM6\X
MGJ4XB9=.1<B/Z9Z]@LBV)3"WC7H#R.Z7&?UQ(1R_SB&3LD(Y///;4RZO+UJO
M5(NCI'7I+!^L(6%_V$DUK$"T.2Z\/P*^70(]/0) .-8!PDQ]S:#P"7/BD"UL
MAP)46'KUU-E_0)DQV69H[1#'W2*GT&;N(/NDZ)L)36$WVR/4GYHD!!"L4'C[
M13E01#<Z7EMG+F2?.P<D:>\Y[):RS,&QX51@)M34P ,:3TJ_XQ;\^+N;+V!O
M#LC)(HNBH;H-28,[@O=T9FD1FG%I/6%R5\YPOL ,0,J^F3AAA:C.P@;NPE$T
M,-RE6(P).PTXEVS8'#<X?17 368Y=$-.S2X)$<5A$\QM^,"3OJVP6YK8K9@)
M1^NEBS10SU%MK]Z<L0BA6%(7FG-]Y=EWM7MYV<G(^A_H/7),=,CIXO8H?SVH
M-O.YMD:**"I=BBC7N%02QPAY"5_AG<6<!0U&K?:3G@!9OF4%;E@/%,US\@+<
MFF]/"F"M<ZCD$Q*0+1'PX(%Y?K(N<[K&ZX5>PB:55?!X^Y2-O!BIT<&G%72<
M!#O>(*@C.0[IQ<R/=D H5BFQU],/OIN-:HZ)R35]BB0Q>/CB@XM1)4&;%]7/
M7%C\.XX#[1$.5C4<U!=']NP%10VK9&VY-.I&1==/,IY* MI<G%%'+TRA6$%M
M4CPP,)2-!^:>PA84V3357*@0G/&7O@0.%UJM73<9^Z6'VJ\CF,;@I'+"!>)U
MZ5W.$=WCM?<J^F/Y/O5$.3[LO2"RR/I*Z4IU)17)A!?L?OVPKG%DT7K8I:KG
M6]Q3,_>-JX6;)6MX$M+5WT>C+5IL[DM&BED).!,T1UD>NVJ!7ETX-WO$[ ;#
M4L1B;8@*L^J<,$;I%'C@7;[:Z7^.@2 0^ZL@0.8/+%4O])<9&\*)<@R;&6T^
M<I&J_9@P<./LOTBL ['X^U0V&8R.5Z;+()4](1Y+\^7")")9S(,5R$.<Z&WB
M--FCG\2RID;Q];82$Y\W#J(@DM>M@X<S5Y=D^LJCA?(S$7X-QA5#I3P?J[@4
MGGYFH3/Q_ R(W %7ESW7?\12*8QE4L8#':?I7JTE8U?2QAPC"FYU1*;:FQE?
ME5I4W]*;^CO),I-F!BUB-8P)#)&N/97EBJ2=^\3D'L4ERO/+$>)I?7QGWE4/
M+47@>&S/W[KD1F/V:9VG[T##F#]&E:A@N7"/>J$_=!W.?@DU,/-L=G44#XCL
M027%,E#IOE#.0C1C2!A7W/XZ#.2'/L.II,\IWZ%I.[P3X9%"\5<W;JAE)ZK4
M\N\_B=^ZM<1;NRA:(.]%K/_-(Z>JF/M-?,#B"?]O3F'L!'['C>K(ZMGHB>8:
MV?(AJ*14$=%\:- P(&><&0C&.2\,\Y[8G;[-UQXTK"L(!^82L"-]"EM8ZS>4
M]0D%@A%'_@Z,A:(83 V:J/6H)M"Q>,-7/<=L^K/[$ZZ@F:.KW*[[!3&$(3US
MS,!>Q.EA#:0_#:Q;V!0/?.CHQWTV'7G>WS;AB$3E1^1\"'\"UU1%ERR\0IHI
M9MOP?."A(U@9U@^=]%5'.XQ77[KPJ"KR0<C,8N_G_4*NQPQ*= \3G8L_)U$<
MN 9H0WQ4,(%%-LFI#J&1W"&R:44O )^; B57IG[;)RISC9$9@!3>5=?X[SS\
M;N:)UKY?,^"K-D>AA4Z593'5<Q5KT3C39C"5R<->W ME!M&/K*@%3-H,YL?[
MLTA%M@YZ$/5:UU"A)R3ZN),:S*DG%;5R[-+_3_E><51OH_WU)>X==2433ZQ0
MV1G8P /8]N3I6SCJ&R_B 24PO. ..#J"\9.029S?Z=L\2#@>@8DLPPN^'?A_
MZ9#)P3&JGPRA]OO>@'L-LTKT8HCZ1LGRJ[WGE_2@*?2,6*XC\Q.BIWA@NQ46
M_ P/_*P1]CL3ZT! (Y\Y/1BA. D]1IV^;^2?'TM"%69$^;J9$W7+5.:;LETM
MIV(C;O6DJ :L]& @'&<Z9)Q@M%%E4F-R+MF8_@Y_JIIO6YJ+'^P4W-Y9/"HG
M?BKZ3/Y6F7XF.1[ J.W"CT@G\,#LR]/C&DB.09!2LH#%J#\MEO]&!-#_L\JB
M#VULC?:L=XOO%K1F < 1@796P/F 3T&B_&)>UFHZP&"Q(AXHLP15#64%7(<A
M60:A*_16>"!@]70%DCFP ;[/(&@.8?EO1P!]H&ZG6Z#N!\DXHGR,/E4>!J8!
M919?^9KVQ(*9/I)DAQ9(V?KH$OOH4#]7/T.1S/<Q^AI!CP+[Q_G31\2FG@/[
M8@1CL%;9[%W<Y_+^$Y]\C"[HQG^Y2M>_7:77C>/%CJ%@\ :'355=%;PNZ8N#
MP81%"JV/9F"2;S;0E:[J5::$\3AJ\'*@-2J/U:Z/T(^^&/DNBB.Q.2] _.?Y
M%R*G^23T3$7[#+64!>L)J;X;B?WUH2!/JPZ+^IC2(MOC1=B*^/08&2H!I^2]
M?1(B!-LW C;@%9O*JK/6D6[6O!Y4R:OJ0FGVU[G4G5@JG98N6D'LO6.]*_[\
M]W+]_?=UV<] QH3DK*%A8O+>;"); H\^IK)$0N6H6;J1@:?P;*2&-.VC(V@Y
M-?W"[!'++DBVZ#)PLJ!#I\N#P X'"XX6=;"PJ)H!TR4'ELO_9RG;UQ<+*X+?
M7WDU:%VFJX9^U'X$[JW] %\S""?LC-"]'GA<)KEVJ/?T;%@C4YZ=Y))$8PI+
MG\UO[^/9DCDM%_)+W-R[3O]C,=X5) <-/+AH[PT;X.=;)E73^C_OR5;!G_Q>
MC'^FM:&MHP3DF"Q(1HY,;U=\K4:K6#O^Z-V15*16NE+WN3^201>A%8G$ W1)
ME@\A^Q1CNM"IPF8>6%?_2^B&K .VSU.,8!%*Z7^I(Q,CK%G>A)J->%P7;"(#
M>SCUYHDJ%T;^3&D"CF$SX*L;%5WL<< 4'D#33R54TGCKA]H9A8:-M:<F;@R8
M]KWSBNCT>AP@_<B!V^[.TWL<5[ZS:!<QDWIRH&H$9, ]A\YG8,]/P]#TO;ZR
MF*!4MI BMN40[#W:_D)M&:H-EH3?'&JAKHBT_/49F0&L++>(H;J7H-ND<9J>
M3;( L]1(MOSGHG"#8_KBAFUF#*[+J*&6WUWAMW*ZJB26FP[HE'MNWZ^)?I(0
M&2)[XYY)I01E=-MCDH%$@%GF P68FZC!U$3VK T7#%H!9(8AZW@@K$P&#0F3
M,Y^G(K-G=C^:$EQT#HGM*=]9>*O>>SN?N\B:R62^Z1[R:^Y[.QGZKOTZZ[J:
MIMKJ&/VHBTG<KXJ?G0>8K "4[  )%<8XB6-7& ,R?F)&<ZR*">J@O4^XW8S3
ME$%6WJA-Q\=0F$9>0RMI7.X6.CM1*).5Z5[@R=JZ_<MA^&*]ERNNH^\>'KA=
M>43LZ?8_((S_7G.>I84O++=R[+-5XYZ<WA[^V7^^SU(W2\!:F\8<-RP']=;(
M'*";FU"$(1F5B$XFH02 G2!Y3:4+X7H,C9SA""&;<'+*#G0P4Q;J\-C)5FV3
MQ38"7MR6WK0:9;Y0U&QL%9NN[=9BO6T)BT9S376=:<@5SDK'3%9KUH,.:SMS
M,BRUDZ<K_??NZJ0=:6*4ND?14AN7;[?26C#<")@TCTAGB<LU*#-"+J3>8N(,
MSW'X]HHCF!B;$W7P_B[V,>I[4V2_3\&EI[:>AR+=Q_3,2DDLSZ CT*=6VE5J
MDF!JHIA8RY@,\FE@&;=\CMB2#>0@IY.IN8"X4>K_UBXF U74DMK:[Y>W1C-E
M_)EUP*3I[7RC*U>27ZDBU*U[HTFDH0EPF/ U07W-R4',:,@6+G%7O^IF9)JM
M</18:+[*.'\0G!,O9GI+)#&HW>,:S:(E/?=#E#>EW_N0-%1DFZ:/?;'MF&>0
MU63U$F*%FOO1[=<]1+]Q%>SGJZ'4VN)681/M,_)!=38E,P_UJ"=HHX+9ZOJ;
M &\2Y]1D;+(V)6R\[CUL52_#=/H7@2+;])_]@L__)2]NW\8<@I0EU &><OH/
M?N&SZ!](JF/*2=AUTS[ 2ZAJ+H.US7W>^IO_R..QU,23#0H'S^_/TXKW)Y/
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MAFJ4.R2=C\F3)R>+0J]F"*(L%8IF+U<4N'*O5.T%9J;)@BD,]$9E@:T*O<#
M:R!Z5UBE!M3OT%5[63"RGI+OU00#0*F<4*T. .0-8H9EB*HLJPU)*0 &636Z
MO$!P%?A_KZ3TFH"&5[G:<%@=['!M6+=C*H[UAJ9:>[-3*:HW,!79;-Z&@GD"
M!P0$ 0AL^ ;A_?\WGXZ$7VCP6S;N*2!*#(9 ZN19DW6RIC T;!G]"-:/$LFN
M/5EP",$'+<@4>#/:37%47A);/PME ^4F& Y# *,_!V,CRBUAJ$925>6A;AFP
ML?$.&VSOP6E)X=5&]9"-L-9Q; *6+-8J>865Y.HOC G#?VBL416&@_74OO6I
MIV\SAG62AG/P8$/BS>(0AA.==6TT]&-,16'8BX:LY :F=4,_QK4N*/NC+L\&
MOLTB]>9\4H4M"$,P58*M-!U+E'/^>(&VTP47G:#M/IIVPK8874UYBG7>0[59
M#]7P.4.U$$U;8V4Y3$,(W7GL-* ??EQTQYSIV# S>&*T'8:LM+/L+N<QOTQ[
MDET&$<[3/C!9B+GL=,IE+Z3<]D+98X]E_8Y&P6,O%().6@TX&FJ@ ^BTTR$G
MW1C^B3EI:]1%DQ&G/91TVV-)5[.1]S2KG+=)BM__-%Q>>X,+.VDD"R1D/<54
MW!U7.W,=P!\0_\(?F 2*Q@IT"*A+-USQKLJT+T['0G&@FHMF.]I[Z6'M8BYZ
MPQ-STPV?!VR+UT&7@7I@KN!S;DJW;@]I!] 6[ OG<\34()AV  %.NA!S@#&P
M(P!("8'#"L7!_KM]<5\SQK@\+LPE<5E7*J1YBO9FNAF3HO9N;C*]Q5 S)Y&.
M>*M0=\FQ=CQ9U@.MK"7J"*=B2IF(M,-%/I7S)IU(S>?SJR&_HUC(%?U@Z_0$
MPIAA)F W6E8XZNH HI$DDLNDW3*;1IM\1J;2.:RHL16SFD_C]:PECO(*;Q4R
MFDWTHI!HB;B*6=8K^2H!R=H*EU3(4<83C*P)V4JN ZCG%3\F*'B@I 72%8V0
M-%VO50V6J*MQL+] ?9_3'@/F$LNZ', @\L-[5G0Y[0Y7(I1RN5/Q<-%7R#4+
M.5>K ZCFO0UWR!NW)L(.-^.7N+JK[7?&G84BFTBUTE+6%G38+=%$6/"["DT^
M56X4.BK[2SFW1^++O#ME(?5(N]$J:!U !(JVB_Y$V0PE4W@T+O/9-*/E,VY4
MR*!Q.5?A53:M&7D/6LMC/Z5^!Q!RROYT6L:E7$6K<4J.$,MZI*RQK*('*KI.
MM$Q#A^HP"PS-.6P1KF$3<Y)TFK1 \2A)*_XD1;.*@9D"VP&,F68NEL@P:"Z-
M NW:\7BP+9;<^:;F) ,%&U=$&@' AGI3P4*Y;0E5F]F4O\Q7]*@6L6>0#"[
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M) 4"12NO5#)PQ9^!RTC%GD%Q*)GGZJTJ:50*7L@*N?(.)<YF&8&'2=PN*AU
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MFU,@CH/;=338]D9AT&&0K58%2(_XM7 $=<-F6_,$3'?0)%,@1<? 8;%TF*=
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M.X @]WI=" R67E1!!LX"(Y"]L!+,IW"C1#:#GJ8_JJ8C2EQ.^3&\G6B%;+1
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M=;3GE*<OK?_[!ELK-"<GW[LX 'WXS-3J W?][JWQPI_F3-K^]GNYLP_QB?^
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M,;:-\R='SNT#< ZT5X!O50*T[$XRFMJ,6ZW&C/D'P3)YX.^GW<S1_R (CY<
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MJ YXZ0Z?8WC\7HK-4EZK#ZNZC'%]VH^M-]7K-2W$M7J;%Y+KAUI^D@^;5=V
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MIV-+OC-A[L:Y$\,],-W>$Z99D^I==7S!U'E/./L3Y'T']6ZDJ5]?6;=4)5G
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MVAI]=0WFK3:>QWL'H6]!K"^!Z9!MJ)ZJAWMJ@CT]A]5+'>U9>)[*GNN9C'&
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M48%QHAC)A'VKIEY1$[->*QM<@?T>$T:\PZSNQ\J"Z$9#P(WBSAOO$W+VH^#
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MUM8%&R_N79V[?][-J0M6'.T^7;K>-S"Y*=9BP^L:A)]E\37G<OL]#.( 21%
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MKJ3*J](P]:J4"YE1CC*20HFICJ1#'$&*8O-3K!@5":)9Y);"=4;2Q)E<G53
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MDIPS)#"5, LC A&+,:08,4@Y#[%(L(JQU3=VH!Y3I_YL'AY,-<1UFUX":U7
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MW+4N.FCX"SH&@SZ'/[>&RX')G]T"Q>< WT;S+CL)CHIZF<FP5//S(3>^*\Q
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M$#]*Q;=RV9$-]G0M;EC/0C.N*V83V%(KG,KJTD;UK- 6M\AS".]V:7P @1U
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MA) 46;1I/!K:L[8X1 BM-36+]7,,@(%^<!;+3C-T$MW(X/TDB2QT@;-D;EK
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M_(-L-D1'\FX^%G?WZM]/VWI+2JYTS0JR-)&1D(!B% ,H909H'*5 $IIQPH7
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M,,5IDK/4H^;*1. &E5W9P_OO[/'I+Q;@7WH G@A?A_EE(LP\-P1??(OGH;)
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MM5U@R]OU-[7=KJK3[<W/;IZ>"B66U=?Q=7G_L"VKO(*%B&&FD(0 9IA;VE.
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MMJ._?>9TC_WV7A<PG[9=3>J=R:^;E4V0^(T5<@%5CF,6*\!BV^H+9^9?!&K
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ME3(V^V?I7[T@!%A7^IH8+C_VJI6I?)X&,'N\^#>K4+3>G'&*+,\U6HW)9@-
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M$-KC05I!0*#6((6"2YIQA5*GF(^KP*D9R0J.;JI0;?WOMU&K1E3KX=/BPP%
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M[FO-;,I(=8H+5,I%3[5V$3NH9ZL_-">]',L\C/!V7.,Z<V#N1[I#X1ZU9LQ
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M/'!:BI*S-]4]+C>KO%!N529 GL81@ RE@"0" 3EOF(8HC2GE.GO+)!7/F\9
M-_C<D=,TQZ>!F=;KSL0U4]CZDFJO?2U)3MBM C>DE44.T%4LY^MMH_YV*%L^
M/?8BBUE+O&&5ZCUL>V2_8O_:-=LV$?M=53]-XK[>?*HQX](V;>-TI2FJ? ?-
M*DM(G-(\!AF.8N4&C0%!7,B3D#0+<1'"*-;J:#*3#^_7L'T5!%4P2M%O3X!=
M]9F'G@730[8=WKJ':N\H&IIR!W94[2QU0_NLK(0-MA8GYEG(>#\AVW&W\(EX
M%H3/3\#SAK,X\9ZI4/&^?!AB6#:W*YQ0(E"N^CY*@P/"H@ DRN79-HHPC:(0
MQE0K5%";HN_KG>OW;X,],8-#D19:&N=,UQB8::!#(9LW>XW3<Q#XA<;@4.@:
M(KN3WU3-GP?)RA#(M[EU=;@SD7OR!*<UT'+'-!.YCLYB1B]::,!1O:P;<8C@
M:R_35Q$L\@3A%% .*8!9SJ0YEQ-0%+!(,\J2F&D=NBY2\JSQGA0%&T6BMN$>
M!NM\$BX-U><*!#.5-Y;_1@2C8.8KE_(;Z#=7.-CIM0O?@RMEIB/DI!*;'& Y
MY:4CQY'2TGIA5FUQ->P6EVM56545[&WG_XI4N^WKM9K#YD9\4'EA-^+O34>W
M+V@<I:)(LDB (L52I86< 1R*1)IUF!<%%R)/M JC.N)GN1OD=MUW+ 8C'H.6
MR:#G4CW5\JE^D)SN:V/,J$1M/54:ZG39";"^+O[C86]5]WN).9A=Z;O5]_U<
ME*.YP.U<T'XNY%-U.Q?RAUW3[PL>2GO/A4RSF+<UF9<HWST7DS,%NV</:^M/
M?5[*X(HTVQK3[2HAD$4BHBKM,%*]+51MW@(!1AG/*22<%89.T_/$/&\UK^?7
M5ID 2M?;Z49\,T5_0O+@,^[).HWQN2R==[?D! L+^QXO@_'<P:CQCIM;D^YL
MSKL<E56"8)S$ZD9$J&21F E 2)(#B#,:8DA0C*/5AM^JZJZ?[*](CHAJ?>]%
M][T_(ZW][?<D^T2K>3<?QYC9W6^80^#D%D/HP3#[DN*D> M?11SS\*(7#B?A
MN'2M</HE*]=9']\I+8=755U77\K-;6M+M+>Q5\W>07=%Y?&WR]W.8!IFE'/
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M^5?\MMQLNM[<ZS8!SZ">SUF 4AQF<4%C$",N >)) K"J_):E:4YB&D:L@#U
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M<.R^::8#P#1;:\ZA]!(-.!T@<Z9-IXN1K3/Y) :[NI:T^]KA0V@&$BAG-,H
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MH S"B$8BUMX8=*EZW@<Z-@))/6@941I+_:7C)=@S8Z"2M/'4T.X^4#)3YKH
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M:;U@TT:OC[;X=M4T?-NVC"DWG+V2JE&4V_=R<IL/U7HM#Y'2.&8KFJ"4<21
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MI^!QN=EIB>=]ZYOF8N&-4 N2Y]NBWFLV#F,YZ6L%79M%/?1I'BZ0TSB+$8U
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M"3ZI\?5&6DY=&TEVI&O-WK2-E]B? &_$Z[;2>G.]>?OOG=3=!S=80E"!*,U
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M;?GP[6KO76X:6-/1KS%S0','-'M[U23GW4"SG(]I);4BRLZAQA\<8,>+?/Z
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M\8PS2P]'>)E4T9.2G,S]//V&@]YZGCCQOMJ(XJ;LTBK8TP7_YV/=='6LXRC
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M;=N,SY':$JX=$^H'_5UK-@#3?#BV&S@)I(E!LS \EJ;,&)FV^VJ/3+OB6P[
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MV)9'<%6!$9>@91/T?.H_:DZ!8@L,O+95P3IN]>^MLLN7F"L#);GZ#-BIU.7
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M8/]=3?&CFM#65PAD0DFDS,\D$%PY:!F"..,(YECFE*9"YH&19IJ@X5DMM?3
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ML\0)^J^B%!MRIY4+OR_*HF[T ?XW\>[/!U'68E0EY#I7!E&<10E,"$H@8ED
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M2'FU4\M7X!O9%+KQAZXYTS(!-HJ+&4>8DXB:FGH><+)3VF.(=O>M=#!A#R=
M-1N>#D%-)%_S9'22GY<[+C6!:?(,U6@ !_OQXN]743R<JY @D1'"$,5$J9*
M*2<;<0QE$*9!CJ(\Q>;E;4<#>]84+24+ V0LLH&IYBB(W5)NB;B4V!\+8V$B
M.0KE9O=,3Y"=47.$\4E+9?S\>N;'$2[W;(IC?U^BH[OZF=S<;$174W![ET!7
MVWE3E6T61OV/HKE]HY1)=:^6VLATN28XRC!)=6%K*B B.(8DY3F,!0E2C*C(
M,\LV6$NQYEF!?'F\O]>5XI7G<W4KP*^;ZO&A_C]@N :E601;'H%F$FRYG-,
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M[!_UGQM1_C]5>SW\EX\-_U+4:A&\J>X?2/G4?Y(9XHE,< :#-E$OE,H=B;F
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M98KS-$D8MBJ,<A<]>['33ASX2K5 YR;DUB#:OI]S0./V_KJ@XL,,[&C@_$S
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M4'WHQ3KO$H\A5C".>48+J(@A)\@E@BS7V$6,D @1E*8R<B4G"(69%]O *=3
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MY-GM"#GGUVW@LTZS!P;%,=M^B 2H!@*.75>3,^M;G[2[@\GS9]]ME%DZ">\
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M:%Y_OU.?"TR0K0-^)=C=7/&@9,=[UQ@USX+_!O"MNH":AK>]PH!N-0[IE6<
M<G;_'%+GA3WU#'"_]-ES")FG/\&'JE9RM3&]$$9)OV."DJR(4LBEJ:M)20(+
MA27,2<2*2%*116S@(;@.UZ3 4CTK#W+(5W#M=:BK4P:(QW:?P+![/$E:S\?*
M;CL]MEY[.;3G8F17VTGXF?C8'9%[939V6VU_*BYV1XA=F=A=A_?8R=^/Y(<Z
MOKTROK:*;UL]V:8_K]1?&]E5<G]<E?)R(^^;&\F0X#&-H:2&TUE_:"#A(H=4
M>V*>YBS!Q+[':!B=ELMIC)= #L6\^JI65_.7OYI^2_V)!Z,P:#5VV0D/-&\6
M=07+SX9W:N-_\40X%"LL/R%^90R'.2<Q3,QJ;V)H.S%\5^[>;M"8OSR:3G:M
MQJ$*WL/"-EK^$$C4<H418;$Y*)D(/+1W,<4@HANX/0L2B0@7<99"AHDI3(LR
MR%">0%&(G!(FHCAW/()X1,K<);&[=V<X0N=P1&@<'^N*A&E6.Q85N!KL4PUP
MVJ#Y-_2/R%YZ3_ZT^4>VU4<N]D[N]O2I5^I2?W3*6T-NV U_+E-H:,BXB%)(
M8I1";%J-$$D9S+(HR3#+$(YB5VI";VT\,@!N+_\%URN&9DOLN=JJU[\:SCE;
M;]RM,[2S8NF7C]WCZGV!X.*)UZGXS)]F]=9PZ:3J5"B/I% G#^E==2 ;7J\>
M.BK8"\Y-/R<MX5.U7O&G#U7]C..E[8BR;@.L_8,L&>)$H +!1&F?B)-,PH+G
M,<PQ3U-1X#A5KIP+(?2:.41ZP4JTV6GA7$P09!ZL"PJ61M=QY;U3KPW'M@J"
MAU9#DQ<U_W\2_?F.((4$;O[*@B#:+EU=$!+B(Q4&08?W2(S^N:Z:9G_/[/I.
M?EH]R+[@O[R]087DL3G'+6/C35E!("M2!H5$L9((9T64V<6:=@)G#R=;#<Q&
M]-[^M-E.^G3YZ3>P5<,A-W8>0XO\8QA<O!Q<!\AVP]X(;QL2&/$S >*0!PP*
MC%^*[]03\V  4H,>H3)XU@:/)N?.C[)<WLW:HH.4FOU=ON%FN]O4U@>HU>:C
MEG:E_MNT=/M;W]&M=\A2:#?\UT9+[+:N?I>;NTK<8(H(3E0,(\[T(ESF"C*N
M8TU5($IRA?(XLVH2%4B?F</+5C<3_QBN\+5Y'_3?#QK@N0:9T]#/B,@8I3E,
MTS2!.$T)I#'"4&5Q6D1<D#S'-]]DS:J?$/]]O1QG8%6VZ+NW&YP&MVTLOQB$
M;I^X[=/[T"H&?C$8_NG%(]P,T;T4;53_:#0<2B'N6QU#QN]!P)H];I^FY<+Q
M>A!(7\;I88;UH2#H*R>^R =:ZUC7E$W0];JMF[C!F2)1%!<P90)#C!,*69QQ
M2) L.$YQ3 MN3SDP(FGF;\NN]JCIA;=U1X-TEY/S8W!91.&A0'#S3CO[![G@
M<@;[79@" N'@R0S@B8<C'8"%C>/'_\<&6/"XOX4=A\?[;6[PH:I\;#;5O:S?
M]^<8918IE5 &$Q:;@_BY\4Q4QVE2L1B3J!!I:L]0>3CXW/O-O33PWH6-\9G]
M%OYF@E6.^\E;@WP(29Y;YD(OZ6^A)ZOD^:ESI) \;L$X<^2S>Q8DC#RN[2%/
MY(EK9BJLO'@4J\T'>="QN3T>=2U_;-Z:K/@-3K-$QD)'GY&((4:FX;+$"$8J
MPPG&3'".@A96GM=I[O6T%;%DJR8P>@:NU;.8$POWM3S2CELWMD63.YS!GIK@
M:ZLH,)J"M^/;-[--0^"2R;#3,7/))&VG19EID3MUERR5M(=K<JFDA:B?JU32
M'AOG4DF'H=T^6DV]N?FB']?V1,$7+DM:KZJ.3SW&-$V4A#(5!<0*)Y!%BL*T
MT'_F^O.495:U_2<ES/U!Z44YL8B?AF/<^P<QTC&%9VF?M0\X:\.1S)JB#6NM
MT#>W2;7_E.M-8_[5OO3M"W]ZW$5>W[-F#2_C^0LGG%KOTV1OI2F,N*8_;O1"
M,#?M+6&"A8 X,OQL*LJ@R'(5"1%E2<;=>J<>D>+TBKDW436R &N%@0W]X9Z#
M/P:,;69]HKEN+]NG@S3YSN3 IZ]/&;3$*>H7LI<_#7W*_*.GFD]>'(+BY_][
MI.5F9<*X;_+YM[@]K5"IQ^&T0L<6@U#$258H2"G!YBA<!AG#I@0YS3*1I/]_
M=5?7X[:-1=_[*P0LL-L"X4(B*8G$ @629F8W0#8I,NF^]&' SQFUBCV5[:3S
M[Y>4K!E[;-DD)<J[#TTG$TOW\L@ZO+R7/%=Q[K1BF\B?R)/K?L3ZQXYW1Z+6
M]G0/6&KP?+IG"E4?_V?D2BVS(1^\>HL#^D@AGV"H9A7Q\??R@@(^P9">%N\)
MO^VHE-B[Q94QVZCUXT=]LWEXJ-M0B]56K?RZ7G[;<V6U;IA8W]+4L*<T<5)&
M% 28% 6@,F6 2,(ETS3-H%/C]/&NS$>I[Q9)[YW-T^SZU_5 L![N96U^[9T,
M2\B$/!BO=%ADN(-Y]/\"Z:",5V3$1R>ZJD6B>N1MH7L7^;9GA;;([\QKTV>Y
M1D#DF-P*L7")G-8() 9266/N&'S8=WOO=G/D+RN;13MV: U!4MAH'!0PUP!K
MR 'C4 &ERD(IG/'4UE9\5MYNAB,OQC^H=??B;%:=(HW7H;5QD+H&UM,#Y5GU
M[8EENVGY^RU6/T0_X><W\OC'C=W<F?L$LA=(1PXE^UT?$,NV@CT?S'AV.IO>
M4J[S/"<$\+RP(6IN?H(Z!S)'2",N4O,KYQ#UF(7(D6?7N;A>+NZ E8CU.D4\
MC(I#?#AVK'XO?S?,9W.= LS887H$9V.'&Q9S=<->+!=@K^GR5.'4J4&=C)*.
M7CA?\'/*[[V8YN0' RCDA3[Y-:N:_[!ZHWY63;>K]K0FV&U*F<1:":!SA %&
M- 5,%AG0C,B\H&4&/32W1CH3F9B>50ZMJJ%<UC5K5LF#^3JW:GN. H>3H.[
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MC<X*Y_R8F1<<83ED!M<+A[AA]]F^-S_]^%W_&_.'/2_PXW?_!5!+ P04
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M6;)#(Z/B>H%A$XP9PC2S'HQ1>',5667"@N.A",S)G8:(K=6Z(>'E9%2/EN3
M"/B-_O;BW>?Y[";E9ZR+CE-\Q8A.<H5$ &^T@:P3CY$ES^-I'L7#%;LAX>4D
M44^2Z,!H^(#I:D%(YB)^G*XN<&*RC3JY""ZAK@D:.N R(TF@X]YS%CR>=N7R
M<,5N:'@YV=.3)#HP&CXN0GWA_N';99Q?3*Q1(8>80+M QQJ2&)SQA&H350S"
M9^U/NURYMURWZK"7DPT]7I8C,0F__)$^A]DG7+LXPCGO7+*0%1I03A*<7?!0
MBN!2)9\,IB9F87O5;I!X.=G.DR4[BH#S]?SRLF;VY^F?FZ<8;Z]6M8U#1?ND
MF"P5A<@@DR-N@J'(F=QC2%EIG;25&%M<R!ZBH1MJ7EKJLYG41_*([N9!QMO%
M^]H$Y1X[662TF?PGYW6@>$J0-ZU- JN\%%%R;>0#8W/X3=V!M;J!Y64D/\\A
MWE%8G'_@Q<5_G\U_GWW 0&$WYC?+Y17YV=FY>DU4@-G(@025("2-D).2+D8Z
M7UF+I/F>Y;M!YZ5E1%O(>A2@^<_YQ17I8[&N;EDLR0U/R(UV8 HCU/OL( I$
M<,5A4MIYE+H!6!XLVPTD+RTS>HIL1P&.Z\+K305<]=)))U?+21(N\J(<B%#O
MA[PQ$'GTD*73R++4@;>XV-^]>C>HO)Q4:3-)CP(Q;V;TM9!6TZ_X<UB%:[8F
MJ? D$0LH*^MU$7E>GKPMV@B**><XQ?XMCJ#=JW=#S,M)J3:3]"@0L[:-K\,*
M/\T7WR8YZR!="<"1@CLEH@4G9:I]^I@,Q;!R\*'W<RI5;Q?MAH^7DV@]5:ZC
M@,4OE[CX1(;P+XOY[ZO/UZ78$PK17#$8(//J7AD1B0V;R!ZB=D6&E$Z\BCFP
M>#>8O)P,;"LYCP,N?]R][=B\ YH(IZTM!'19^Q^HJ 6$XAP0 ZHH8SP/+<Z<
MQRMW>Y[Y<E*T320\,$K>I+)X=96G]"]>K5:XW.CCUXOP:>(3$RFI#)Z.2%!.
M:0A"9X@AB^!LT;J<=I6S?^UN2'DYF=M&4A[)2ZM?I[,/J\O5+XO%?/%Z3D2D
M6VZ,MMDP9("LWE.(HFM]"S$G.$=C+(IT6I3\- W=L/-R\K>-I3X2#+U*J=9%
M;2*Z60Z+/+$N!AMB 8NZUE26!)$,*" W*!6S*3C?!#N/U^Z&F9>1QFTHY5%X
M,-M/#B<)??1:(VA3&_0H"N""R BYJ.092Y*7%O=#VVMVP\9+R],>+=518.(U
M"641+M[,,O[QW_';A GRL2A6 YG(["GC)1!' ESPPAMIO0PMHN,'RW9#QDM+
MSIXBVY$<+IN&&!MG_%?ZL^5$)!]U[?G&!".16,^)?HG@>&%6<</)UVKDESQ8
MNAM(7DY:MHV,A^[131SD-1?5?7(*7632@"F"S!_GII901,B"DQE,ANSA:16,
M]Y;K!HB7DW4]7I:CLA:U?<X&QU8A^CH21="OH#!8B-YHDD8AWTEEZ;%-E[,'
M"W<#QLM)M[:0;S.(_/N/CZ1*'/[SV%DNZV!^2UKWZ>TVTN71-YI,=CE,V8D#
M7M8E(@]7N!T4DI"YI)$#TV0 E#><(!,I(%4"B7/O'7M2* =7.,GD;](OZYHY
MHY+FS"$4;B6H8 O$8BUD;[&D'-&>6)FZM=B /92;*.J>J3]2AD.?]ANR?YTN
M+M_D"1:R6QHU,*/)GV5)@Y/*@XG9R<2ED>RT%V[WEANP"_*YU'^$',<!@-^N
M1X--F&%)">F(;6&);5<%( ,8GX4N%.>4>%HT\&#!8?I2GA4$1\ERK*?YZ_EL
M.;^8YCIY[[8%ZW)>WBWF9</L<AEF^>WJ,RYJSF2!GW&VG'[%VJSD$C?_X!@7
MH,W"C2;"-9?!B<[&7??US1*W5-UA6$E%WT_ UP\GN4D0$\6>V0?II?,LI4,=
MJMMVO]]#Y.DM_]_C5YQ=X:^TL3^$"WQ;_C*?Y^5$8D;)L@3)*;Y2,@ERHR4#
MF7GF3&9I[:%BL[;,[Z9Q&-^G+6X>SP)HH(]1C)+X;9IPEO!7O-["DR"5M D+
MR(*UN"&EVOV>_D^:X&(L%.[UMYT>4C>,(W5N+)VD@U&@:'T@7&^)B5:^<",8
M9.88.14E@7=%@N:),6%RT?G0%5[CB39;E WC@9T;/4?+?A3(>3U?KMZ6:D*7
MI$2'T:L NA0RGC%X\ 8=R.2E%M&D?+#355O@;!$V3,/P<^/F6,D_'S9^ YL9
M?JI^92/@O"<M$!&?7\WRSP3^B_F7*IM?_OA"#BE94,T*4P3\6&J#?%3T._2F
M3G$V/$6="SN4W&GM%QT@=9AVX^=WCUII9R1P^PO.<!$NB)]7^7(ZNQ[6\15O
M6&):4:!;[SA<(L.;"0?!U(GJ*+02+#$E#F43V@+N"6*'Z5]^;LBUU-!(0+<)
MNVM,7>.,MU^P<C3[]*J^:YBNIF2XK3 ^><[ 82+#;06'D!$A:Q%2$3XXU]^1
M^22YP_1#/S?PVFKI>*]LO@H7C8"W?AW^MMQQ]K;\M_ETMOI/DMH5J>VZI SS
MK_/%WY?$["__ZVJZ^O977'V>YTDIEI6L!)A<V16Z-CFK(WU#+3 *69*5[PV4
M)[$R3*?V<P.V/^V.(L1X<_DE3!=5?I77]YCFG^ATP/QFMI' VW76<F)D*4IP
M#T4J0SYPEN!"DE!0H6%."H8]YA$[T3Q,S_ASP_,,^AH%#G^=SL(LW>1X%)+U
MK^-"59TMJ;R($"(WH"D.4XXVD;/].8SW2!NHI?RY876\^,>$GAJU5X<B^XB"
M;+#4LK8*3.3+TN^R0%[[$*> _4W\W:9LH-[R/6'G^<(?22#QES"=+:O5Q.7;
MV4WGJ)^GA0BJF6?ZP_7SM8NPF?ZTQ^+:F&H'8^*4D[%5=3IND*C!*BDBF>*H
M?7]^71.6!NIP?_90N'=UC\)$5K8KY:\6T^JUUFCLCNF?</4[XNQU6"R^U>CL
MLKJX;\MF9T\I<IJ&.+U8/^6LT=O5=/D9\ZM9KE?BTXR;423OPC1/7' 8?%*0
MT;KZ_-<#Q6\:N R!*6=XB/TYBOWP/%![_S[VR<@ ,XJ-M+Y2VC(B$\N"]3%:
MB#EF4,G5EZJ" >;*B$^<F_Z<U8?4#315H)=[O6.5,(HLTEV"X2<L\P5^#'],
MLO'>E."J)&0=C5"('1/!&,.$%ES17PZ0L+PE<* I!/WE*(]3Q2CPM!$-D7Z=
MTJ]]]*>S*S*^UTE7LKP3F[0S*I1:,;%^>R+!)56%A2(3CX;UZ*1VH7B@Z09G
MS^*T5M9(0JF[G33A.?$2# >'I?8?JR]F53!0,BH1A5;QX).Q<]FR@88D]&?"
MGB7X45BN?06SMZ+AJ%1,V@(R4>=QDY)#[1@CF&1*:A[8P5&29W"P#E [T.R%
M7ARN5DH:A1]?F9G/:@GWV[*/NX^?P^H?TXN+G_ ]IMKW=UJFF#_.MU,!?T,*
M?,B4WTI".&29<0L!:V\CR0Q$:2PHFX(USN1X<,!#ZTJM\W Y=.%R6SSNJ/\:
M 3A&L4WV<7_#V5,9M$DF2Z-C=."M74_U$N"X%.!)#@D#.3&Q/Y_S5&Z&AOTX
M<-GY=#@+2([>%E]Q$>=-SX\'[$[0%T/^EP&&EJ2(A5/4B Z$IYA12(]XL(E&
M>]/_@,"AGPB,%+ZGJG(4AOJ7L)A1 +E\AXMU#<NM;'*RJ3#CZ/Q#!8KQ#-[G
M3 <CG8?6,\9Z3,GOHW*@(57G=IN;*&44\/HI+*?IAIVZ!V]8FOCBC4)O(6F6
MZE48L>(RA^"$%$E[]+H_H[>7S*%/[C9(> 2P-FH9!<)^GEY<K3#O9":3(+S-
M"(SVW::N+H0HP3#'<HZ,DX/0&\8.$#KT 7LFE+52S4M[WGY[G_ENOFE??)^1
MTYZP/_[X69^I/\%+LZ?HMVN^?;SD+1R-Y+$X2?Z^YX:\*V' :U_ 6(),'><J
MQ*$NN(VKH#M0?+IY>[5<XFIYY['RHKS7#)SC#%3DCOQ+&4 *C%QGE++'6^/[
MM U]5#9'T&.#=H(R1G%6_FT^2YNQ'0\YT09+<)S$8FWM19G ^5+K-XLV0AFK
M4G\]#_91.33 3M'^(R@U4<4H0$41]A=<K+Z]NPC$S"S7EPWKIXD38Y3,T1I(
M2D=0"45M9N-J"TOT@D7'#C:Z;WZ9MYO,H6'5!@F[[O8:J&44"%N/2IR7JR5N
M)#1)%FTR7H-/GM7HFJRX("^5"2:=5(;;@QW-VP+K(75#._-GPM-)2A@%C&H[
MF=^G]!L9C$C%($2'"(I"6PCUK;2+1<H@,>:[J_SS5YM>4S5T)XTSP>8HH8\"
M+F](_+-/TWAQ#?AUYOGCYS"[9<ER[H+@ F+)A:+CPNNPD3I&W$55M%3>]?=D
MY$ERAVZY<2: M573*)!W)ZE:X55E=&URZT@LSUFJ+7W#=2=PZ1 ,Q30L"B^X
MZ:\Z:A^50W??.!/.FBAE))>0;V9?<;E:9WC>S)[Q3EDG1F<^LGI?1ONG1)(E
MBQXHXO&L[B27L4>#=Q030W?J.)L9/+]*1V$<U_;]H1 GLA@KE-)@=:W;B46
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M =96'U%H#M'1$2RYRH$[FU'U=VH=HG3H#$,/3S":*6H4!]HU-[=[SW+'K6?
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MM\#+Z=7E#0\AV"0S@^+7CTQL)*D@@O!99\%59+J_@^TQ?4,_=&N(H!.%/PH
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M<9,#<58'B)'B(**1X#"H*&PFS[\_U^,Q?6TMU-WW[UV,>Y>U"81<42C*L:I
M3#Z"#5IFJ9VS=IBD^4YRA[9*)V+HL+TY74%CM32_S6>?/N+B\LTLT>>F7[$6
MF1Y7@KG[2XW>RSQ-9>N7=W7-U:,U;\&5G4Y,9PZ23BTZS(R%D!@=9L+;^G8S
M!/ZDR)ZY9K-WN;O%N;NOCW$J%>^ IXKQ$CWX8 T(+G0)3#O-Y5%L=EM_\)*H
MYEC8^WSW3$H9J^%91\4_;<UB/*YCW..OM,M1':"N>5>XA^N]J@/4/CT8Y2%$
MTLY8.F$*G6I*1 8!Z3^9,)X9JU/FSW_ZVVGIMO[.HSF<VTMNG[ E,R8T^?*"
MU4;XQB3PF4? [%-BUD8MAKF1Z\K!2.Q7>W@=]I?.HN"Q6K+?* 3]=/0@K*V?
M;N,J[:&FA<6Z^_;6.P(?G">01,$5*"X->#0"C,PB*UW*HSOS/2;I\;?;N3NW
MG[X;:+W[8*V%SE@<Q0FNV'4N%H(BOG2,(A;#74S/;SS9>?D!C<6)FMWOU)Q%
M]&.U!%LSTH\L,'KPA48MN/=3U2R%LST>?GMJ\5VEFG8*,TO @ZCO$Y,!\HO)
MTBN5+%,E\=S?)*.GJ&WK[FROMGWX.4\(#T:"]X)V&$D(@A,9,!4C"H^2Y6&N
MU_80/'2*IRG&#CLP+50V5BNU7?.PE4,_M?1H^U/-ZX_VTMFZ"&G["N.V46G@
M'E$CH)"1POLZ_I43RH+1PBOCY*-$;(=*I!T+G:\<:<]528S!Y* KD .=N;;V
M#O+>@R^<%Z$"$V689R9/TSZ2PJ13X=*].JF!"L=JD-[,: %<KI9O9O]M/IVM
M_I,^2OP?6:&]YUN-RK6[4'J6,J9[Z]TU#O297&5RDYE"1^KG GR($KC3R65D
MBN5AFI_L)+>M@;NWQ+V>928Z5F@G*.$"J&(E!&UH=_CL$@4SSHMA+L[V43RT
M8]469X=M6A.MC=62W8Y"?C,CP5T=G=;>^9V&$P,.47@6Z[5KV;NW I)%8T*
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MZDO ]5KNN]LB/+S;+D+7NEYR<'RN_<(=Z<33MM;*>1EL%@W;O'4F:^CV52-
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MP,OIU>6!.1Y287(Z@RBUGUY(&D(6'#23Z(3%%!YF4T^I[6I)^M YE?."_07
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M9#W::.W]%Q&,]O6E-58?R^=,WE;)8&V*/%I6@A_NW'B,RG'Z3(Q@FGI14Q.
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M>7H;J5L<"'['*JI9\-4.H5(:Y:"X1%LH!PXQUL9(F4OC.)?1N5'AUDCIXA
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M]$A)]MWOC@V+7C4VZT=\K6C^OBR<Y8K5!HT\U;V1N 27/!T%*'GD,@87#X/
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M]@/S/BJ24XDA(!CI,RCI @0I(C"6,$F?(C/J)6NR^W*M036(G)^KASV?Z1.
M$5Y=85I?'_9BV,?K4&6NB Y4BDZ>R4A7!+E?FH4B/2=7S/"N"'IVI=;QGC'
MTQ^KV^.&W#[\3 +:IO&_K_]ZE=6FJZM-0I=,-&"A7WBPX'0HX$K6B=6)7-%U
MQ,S3J[3&RS#65;_,G2I*?EU\"[/Y11%!,I,L>*<**.6("LXUI*1(4S)5%.NJ
M6YY;IVE=?%^2[(*/$]@Z"4/[X5NQEB6A5PY\#)[L/3)V(W+Z74*B+AGD:L3F
M9=-XP>]=]!W>[(^10VME\]0#X;N_ON-\=4-2<(78$#ADNEQ!>>,AU); -EAO
MD@FI'#92.O(]]OYZ3;L8](Z5H1C=$#NKY?J"S+%\G=8?EOL&9%4]QR "DU)!
ML=H1XJV&J&*H _:"LSISP9_K*U#"*FXV2PMLU,^_X]5Z5?^TP=(&1T^MW?HQ
M?QC;IA=.3P,I]3%L1\%J=YPTYZY(7L!K5R?-DDO@E>209')<9")1/G=E'0F7
MAQMH<RGU(].' #F3P:WOHC?_^"+DWF$LW"9%=IWTEO2@$@9<"@XPHY%<<E^8
MZ'3AW/EH<V&?*Y]%#\QJK K>UCD#N"26K7_^$;YM8>^\RRS8"%I5)C@7P0MO
M@*N,@@A+/CU7A])5"SRV=IM6&6-<&F=SNC%2/N'WZV7Z&E;XYG*)&V/LD*3=
M&3(ZHTX!P:F:XEWHEUB\AZQLEDXPJ>-S3PE=X=-Y0^WTS/DR7PPM@-:7S/\.
MJZ^S'_O!-)$CSZ9JW\Q H::S98J&D#2I5*90B=#IEKG[U7;B'TABBS[8UUB;
MW#ATGQ/.PW*VV!X-Q>FBU *XJ).TB!QP@;1L8L5Y[XJ/XKF:AZZ:X]'%VS2P
M&>/F.9_7K<&RV_??YZOOF&9EAGEOKM'!X;P^2P6MB27!0M#H@<MLDHW<.O%<
M@XW.@'EJ ^UT2P]"7?3-X8G Y+?%$E-8[<LP8E!6!)5 T-U:7S(1@LL"O,W!
M868F\3ZLV<=7;PB0?D3Z"$C.X.\D(O7/:=KW-TG!FAGMB[9@L4A0 AV9:<8
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M9\.4CR 3\419SL&GC)NR8>^%L1R[Y<(]O\YD^IOVJ8!Z9&UKE&QUZ8>0XJ.
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M?K[^]HV4[^(>#\,\;_[X<8G?9M??>FJ'>\Q2O7?'/9G.!LUR>4E"R>Q "D'
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MV2J0,=<^N[5FN@1.=I8V14B=2^J6IM=MO=:U(..V<NQ?!--'U>[<B9ABR:6
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M,"EEP7GBC-/)(/=<%-[,.;SWV;[%WXJ<IJTPK6]Q_S/,QE6M_CP"9$YB%LR
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MA[O#P:_@,%GFO>5VFN1AY3]Q?K.)S4]N56-S&>E3O'8050I\J?ZVX[KV:Y/
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M[-UE^<LM%5;P$GA]);&UZ,4G"]Y+"XK%DJ4+.>MFO4JV+M%CB5 'B&F%L8.
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MU;J_Q/.-0D.N[:A-!!%B!$4_0N2<F">-TB@Q\+R3:=U"9]:>L\\/O;A:9/A
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MH986F)4A6>9-:EC2OL?B@S5<]P+//7_^V*(8A/VZ[_7A61&YMA.RL7838+E
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M7UU>/DW2S7ES1K'(%0<3+'%,)TU:6 G(7AN&V6>_KL6.B,\.&Q[;9^\3(X\
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M043KH%ATT9O@I7K)4<Q-@CM;%QRY,QO[VEZGT*&L=?8"DJYS?I(A!B;&P(M
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M@QRZ;]A0Y#;-6E \@*RMGBU0DI9_:40B5Z(BSB@IPMF*:S(GA>16DO8R%OC
M^IK$-(Z*;DA(%RITH$7C +7QX8XT835':.>-XD3E:%/08%.\<45L!;8[&/R6
M 4U$PL7U(/XXP1X6B+-# O%H3(XX.;Y,9Q^1H32A! OL*C2!GIQ^.9J]%,_G
MA^3Y2!\?%EPU(<TH'Z HZ&AC 1I;['M-R;KV[4$8\?+A/B40!R[$?'>Q%<I,
MXQ_??A]*X^O90'U>\>7.G&5=!QE($*(;4)^ -=K@!>!-'!+>8J:_C]'<106U
M"VVC$49V<;=_!Q/JC\GSQE+@=_G^#B3@WIE+6%QRMRY@2$8\ !-$*)Y!9^Z0
MIS(<4O(&5'LO>F]^\G5F?!T2#ZJIG[R$ICZ<UHD.O\F&08C0*N,\AHY.J[?(
MA*AH[W@G]YJBM5X<&R-O;*2] %CZ >55H4;"8T2=&6X#&PJ)F@4)IXA?3 )'
MO(M_J3'K<@/^VTA4G PH&AT.N-VKOQOW;U9YWRK%J*$.SX10)[KERB4@*-H"
MNFZ@E\!OJ"*"ZZ@QMN+AK*P[4OA=4&O;W7B;^@"5<8$+':R9[&%89E))'^8C
MO(S%E @UV6%!=DV%X$ 7!4M:9GWPY.4EU=L#[*S?8EDM+!)&@C&'0'"(FG"N
MV<(KB15/ZH51"Z"RI_EU>SQK6TZ$JE9F!3BZ+$TD0GX'O BVKZ_;_0-_4O8>
M/18?A_V3V[P\.4Y?#V;#01(?[_\.Y>D@"+KA##,'; ^-4+QV,.V^S+#4U(JO
MIE('5<*B62LL,]Z;:DJ/]1=4KW*NVN>E(1GB</O$?SSN3\:D_]Q;_"^ZC=OW
M ?KA?8 S+W;'+OJ#B]&CHX-^^NC89Z5>]L_3\[W$G@6-H];H%X>X>G,T.NH6
MM)"?#NM;MB:"Z ;*@ONNB5YY O",T: ?5W=K:6OZ,[?JY'B,*1X^[SU%OF/H
MGG$<L% 9/^><-ELHF0;]<\0_"P=%K#/U.3GO3W'8<W+(NU)"L?LFS%_#,X\^
M9W_85Z>?>77HU:['SD+Y>* Z;;\A5AL7'EI-XS'M G;>&=ND8:@_@\T2GF$B
M-GYWR1=>,VL_XQMO9^%-N_\#4$L#!!0    ( "2$=%CZS,/680<  +0F   8
M    86QV;RTR,#(S,3(S,7AE>'@Q,C(N:'1M[5IM;]LX$OY^OX*78-,4D!W+
ML>O$=@-T^P+T@'U!N\!^/%#B*")"D5J2LN/]]3=#RF]QTGJWZ,7)78$ZDD@.
MY^7A,R-2T])7ZFI: A=7_YC^L]-A[TS>5* ]RRUP#X(U3NIK]KL =\,ZG;;7
M6U,OK+PN/>OW^@/VN[$W<L9CNY=>P=52SO0LWD_/PB33S(C%U53(&9/B]9',
M>_S5>7\XZ@O(!P,^X*,41J*778C1\)(/BG^G1S@4N\<QSB\4O#ZJI.Z40/./
M!\/:3^92^'*<]GH_'(5^5]/":(^361P<+Z.,'4D>;GV'*WFMQ\&>HSATV9P;
M9>SXN!?^3:BE4_!*JL7XQ6^R L=^ACG[9"JN7R2.:]=Q8&41.SKY)Z!.J%ZX
MG4=]1RA'20U+_=-TB$J_ORUE)CU+^]T^VU9YTVQNK]%R;^IQVD>Y&\KGZ&JP
MCZ3]6[!>%C+G7AK-L@7S);!?K=2YK+EB'Z3F>(E7OQ38"RRK&^L:CHIZ\["U
MAV+=9\@;*[U$B>]O\Y+K:V!O<L\^-0H?I>>\DPY.^4O&M6#I4,2[@[>*.\:%
MJ6F%;T8#C0U!/._UF2E"(#]SFW$-KO/+K8)%,!U;^KW>_DC][C8.[K7Q8\+^
M94"QGXSE&*N$Y0&HA$_N3XZ'%Y.]+'BU7&I2"PS9N#]Z-(O2+OO(2CX#9F$F
M88[1\Z7$4&K=X/JR4!N+X='L@[$5QJCS@6+U1LV,A[QDIQ3/D^.+?K\W65K^
MG<P($L?2(]3S?2C$5#77B^^LU!=]&_R23EXB,"[W!T;-A< $V5%0^/%P< <J
MG4?$2K_[>-[<=DMZV1V2&W[D#@&+Z*P6[$:;N0)Q#4E$< M=85 %;;#\P!FX
MU(CL!6NTMPV@!5B0A-H$,<U9A7>6LDK!B9(L,Y4,'!;Z[730D(-SW"ZH2\5O
M()#;2J;#9P*5P2E5*&Q:]LNEQ4(&NVD<CIH(3%_S4N)B<@W]K,?/P4(KA RH
MI%-8\5#Q-)>^1 -=C>1*LY/<&E4S LV<X3 1D^;*#0&"3Q^!YT\'@<"*596R
MCFD2DKK!9KO1+G6![!J+':QQ5"-0)N)F(X )8DY:M6 UAIT02TA6:@W)%@WN
MSM2(>B%)<$(]&H4=$(<&P1*F<T&?G+N2%<K,W1*D+7LR3D^BTJABL@$TM]1D
M1]5G@K7!P6'MMW5@*+6DHXEKH=26(40-IJV(*60?&;<0D(&1EID""B(#A&.F
MI"NI.W6KD!:)&NE>2)<KXQH<1X1IC8H0J:W)0>!CQTX1% (08C'R#Y6PPU/8
M*&'I+MY*JE%UA";)9T18&XB-(")=]IZHV)JHP(G(SBT<8S-5.:%&^UO8O$@/
M")L;[P./#LYA]S(E1[P#A^\@&*J0QKZ.HX0R;,X;M_\02G49(";:F6+R-(U%
M <A*,^D"T6$OT$$.E>5KBMRD60N*!Y"UV;,%2M+R+[5(Y$I4Q!DE1=BX<$WF
MI)#<2M)>Q@0?6%^3F,91T@T+TH4,'6C1.$!M?'C=2UC-$=IYHSA1.=H4-%@G
M;QP12X'-"@:O,J".2+@X'L3?)]C# G%V2" ^'Y C3HXOT\E'9"A-*,$$NPA%
MH">G7YY/GHOG\T/R?*2/]S.NFK#,:#U 4="^P0PTEMAWBI)5[MN#,.+M_75*
M( X<B.O=Q5(H,XU_>/I]*(VO>@/5><77*W.6+2O(0((0W8#ZQ+=&G. 9X$T<
M$M[B2G\7H[F+"BH7VD(CM.SB;O\*)N0?D^>-I<#O\OT6).#.IDL87'*W2F!(
M1CP $T1(GD%G[I"G,FQ2\@94^RYZIW_R;69\&Q(/JJ@?/H>B/FS7B25^DS6#
M$*%5QGD,'6T%;Y )4='>\4[N%$4KO3@61M[82'L!L/0 Y54A1\)#1)T9;@,;
M"HF:!0FGB%]<!(YX%_]28;9<&_!'(U%Q,J!H=-@]=B__7[A_M\S[1BE&!74X
M<$&=Z)4KEX"@:!/HJH"> [^AC AN28VQ% ][9<LMA;\$M;;<C:^I]U 9%SC0
MP8K)[H=E)I7TH3_"RUA<$B$G.TS(KJD0'.BB8$G+K/?NO#RG?'N E?4;3*N%
M1<)(,.80" Y1$_8U6W@E,>-)/3-J!I3V-+]NMV=MRXE0U<HL %OGI8E$R+?
MBV#[]KS=/?!CJ'?HL7C:]!.W>7ERG+[J3?J]))Z=_P7E:2,(ELT9KARP'31"
M\=K!>'DQP513*[X82QU4"8,FK;#,>&^J,9V9SRA?Y5RUAY%A,<3F]CA],.@.
M!Z3_U%O\+Y83MX?MW7#8?N;%;MM%MW=Q_F!KKYL^V/9%J9?=43K:2^Q9T#AJ
MC7YQB*O71^='RP$MY,?]^I:MB""Z@5;!CFM,_0C(&: U/RZV$VEK]U,VZ>1X
M@(L[_&X=SF[9N&?\>BQDQ"_YI5TE81'5:"SM#C&R<O)D//9?\-*3\<7;4D*Q
M^T')_X!;'CQ/O]]1IU_X_.;EKKO.0I:X)PEM?F55&Q?.IL9Q-W8&.]]=K5==
M2#.]]1">X=)K_.Z0KWRJU?[&K\;.PM=J_P%02P,$%     @ )(1T6)RTVAR*
M!   5A4  !@   !A;'9O+3(P,C,Q,C,Q>&5X>#$S,2YH=&WM6&UOVS80_KY?
MP3E8ZP"6+<FOD9T 05Z #N@Z-!WR<:"DDT6$(C623NS^^ATIR;'C)$L^9.ZZ
M!H$CYWBG>^ZY%Y*SW!3\9)8#34]^FOWL>>1<)HL"A"&) FH@)0O-Q)Q<IZ!O
MB.?5J\YDN5)LGAL2^N& 7$MUPVYI)3?,<#AI[,QZU?=9S[UD%LMT=3)+V2UA
MZ7&+C8;^*/3'B3\9C@9^-HG#(!Z-D_%PY,?C /I_!BU4Q>65CC8K#L>M@@DO
M!_O^:# LS?2.I2:/ M__I>76G<PR*0R^3*%R]5C9V+%D8&D\RME<1 Y/JU)M
MQ(GD4D4'OON96HF7T8+Q5?3^"RM D]_@CGR6!17O.YH*[6E0+*L6:O85T"=T
MSWV]J_P=HQW.!#3^!\$0G;Y8YBQFA@3];D"V7=Z$3=4<D1M91D&(=C><3S#4
MH/;D_1DHPS*64,.D(/&*F!S([XJ)A)64DXLE) O#;H%\RG 5*$)%NB&_9(+B
M(SXU\G*A]((B$".?CL:W@CZ8D#^Z5]VS+KF"Q$4@Z _]#J&:T%26MH;^4W@:
M%$?^B,C,<7E%54P%:._3DL.*G";&2D+?#U^<K&\.9O HF ^")%*(&M(=,[D#
M="K$ O/M,Y12(19!+J4J$)!W:8&=\EMI(,E)VZY]=S )0W_: 'TC%,YBQ PF
M0/*2DI-%2<7JC9UZ-K0N+L'TD&12N:!F3"<8U!5014"DF/?GD$ 1@WIW$(S\
M:3_HV''1=Z61,8X+UH1@TBT4,PS=L\WA8IGD5,P!!TU1,*TM>?AK5Z8XE4@.
M"I"H37XJ+ANG.N1#!T'BNPVY!JT1;8><Y0RR1]I1G>5U3)T#OTK@Y*-4E(-N
M%'?[U+9B9ZO.[]N"13^>/M\57E5T'0(4L],& 9MM4G5?C)S)J>E8:U8]!NT4
M<J;)C9!W&.XYO#L83J8OJMD1YD!)TQ2'O\<A,]%PT$P<AMP*$WGA>&]EW0X.
M]Y?ZVW$)AMW^P ;B"P:];BC9@G,D!M."6U[66:[@KP538/=%VG)S/S#:])!@
M&07#=GJX3H#[FEC70YT%P5%_4.52X2H->3V:VL3]#J@-OTUJF< ^5U1;'!PI
MAJ)JBO]U5#6\4Z:0^%*!MA1WK)AR3E -O<'&@8(2.4=)U3";AH(&4^9,V^:#
MJQ:\RA!9@G+OU ^:3?=%@W>R-QK/$7+5;3Y2E>35! C]3G5@>,6NP="80R..
MI4I!>0B"TU)#U#Q,4Z9+3E<1$\X5IS2MC<72&%E$]J!P:WLE#JEZG^5ROA+7
M9XB!W_6K8X3!LX-)FQ?7)XRN$_5,NBL[FG2/_*?%?C=8RWK.=F4?$6CD\[C5
M;S4*=0Y&8;DDP?8VWZ;E#@A9[H'C@=L!#,93[3X?S-HUOR^ 6W/J*"\1@^0L
M)=;YZ2L#41&YIU@\L;=X32 >P"7N[V.XMUJU\^_?3(DG=ZJ/!Z;]S$'P<#<\
M/5>Z/SK#]],9-K?2_]>^L'-T^-$7VL]< +VF+VS> Y92NUU4I(!3VVAV;@;O
MD\M5OG^O0F/,L(795?F'R\3ZL[K7[+G[U+\!4$L#!!0    ( "2$=%@$5C2F
MI0(  #0(   8    86QV;RTR,#(S,3(S,7AE>'@Q-3$N:'1MU5;;;MI $'WO
M5TR)FKQ@X@L8, 0IY1*A-B0"HCQ6:WN,M[%WK=TU*?WZKB^D(A51VCY$V8>5
M1S-G9L[H#,LP5FDR&L9(PM&'X4?#@ D/\A29@D @41A"+BG;P'V(\@$,HXX:
M\VPGZ"968)MV&^ZY>*!;4OD550F.]GF&YY4]/"^+#'T>[D;#D&Z!AA<-VNN[
MD=/I=3I!E[2MOM5OFVA&?=LEG:[?[>$WJZ&A.KS"2+5+\**14F;$6-3WNF:K
MXV9J\$A#%7N6:7YJ'(82L='1/E>*IUXO4]H=<:9T)T)GKCZK G^6.<"Z3]B]
MWR?!PT;PG(5&P!,NO).H/(/:<LLS*"!&1%*:[+RS-4U1P@(?8<E3PLZ:DC!I
M2!0TJ@(E_8F>96E*I?FXIVD.$LIP3]OJ%T3'-XO5=+&&FQG,%Y/I[51?VEQ.
MK^:K]70YG<#MW>>O\S%<CL<W=XOU?'$%L_GR^I#W2],:*/RA#)+0#?.^YU+1
M:/=V0V@_'X+=T4.X1P@XDX5F%0<5(U 6<)%Q013E#/P="(Q0( L*%RQQ0Z6J
MG2NE15[J?<%;X#B.8;MNKV>!]LVX2&%E]("P\#A*/L$LQVU6W]V.95DEK#(=
MV[6?,LX,!W@$/!>Z+]VE@K!<M&LB@ECO4[/<J:9V)KJ:WKV:540980$EB9Y\
M75X6B2Z3+5>HH23+D(@"H5FJF$JX9"S7\<NJS+X!VS1F$'%19MUI"" +=0,3
M###U48!CE3TXK5?JQ'UIJUZQBWM_K1BS/(>*&6L)^H+^GU).3]K=@2QO33;A
M5"D$C*,6P#_W_.;R/R3R?GE\.3VQV\X@(UN^R443YH'6O]Z@]\OH<*&/\GCV
MD&5<TN)'QJOV?XM'G[::N?D;0GS)DUP=A_SU:UC?U:M]7OY;^ 502P,$%
M  @ )(1T6("'F<;U&   8J@  !<   !A;'9O+3(P,C,Q,C,Q>&5X>#DW+FAT
M;>T]:W/;MI;?]U=PT]E>>T=6)<N.'3OM3&Z2=C/;FW3B[-[]UH%(2$)#$BQ
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M058&A_G8Q@G0QG_<M!G>VA.2A!LQ]I)BKLM ]R.T="!#D$QN!N0:G8MYBDH
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M4$L! A0#%     @ )(1T6+1+>0__% 8 "O%! !$              ( !
M &%L=F\M,C R,S$R,S$N:'1M4$L! A0#%     @ )(1T6'=?5Q]G0@  $T8#
M !$              ( !+A4& &%L=F\M,C R,S$R,S$N>'-D4$L! A0#%
M  @ )(1T6):.FJ5-+@  _MT! !4              ( !Q%<& &%L=F\M,C R
M,S$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( "2$=%B8>(?[HPL! /;@"P 5
M          "  42&!@!A;'9O+3(P,C,Q,C,Q7V1E9BYX;6Q02P$"% ,4
M"  DA'1854->*"1#  ![7   %               @ $:D@< 86QV;RTR,#(S
M,3(S,5]G,2YJ<&=02P$"% ,4    "  DA'18=EOA'/@J   K3@  %
M        @ %PU0< 86QV;RTR,#(S,3(S,5]G,BYJ<&=02P$"% ,4    "  D
MA'184O:''F@_ @!H;Q8 %0              @ &:  @ 86QV;RTR,#(S,3(S
M,5]L86(N>&UL4$L! A0#%     @ )(1T6"._F_W9=P$ [OL0 !4
M     ( !-4 * &%L=F\M,C R,S$R,S%?<')E+GAM;%!+ 0(4 Q0    ( "2$
M=%AUX*579@<  ' G   8              "  4&X"P!A;'9O+3(P,C,Q,C,Q
M>&5X>#$R,2YH=&U02P$"% ,4    "  DA'18^LS#UF$'  "T)@  &
M        @ '=OPL 86QV;RTR,#(S,3(S,7AE>'@Q,C(N:'1M4$L! A0#%
M  @ )(1T6)RTVAR*!   5A4  !@              ( !=,<+ &%L=F\M,C R
M,S$R,S%X97AX,3,Q+FAT;5!+ 0(4 Q0    ( "2$=%@$5C2FI0(  #0(   8
M              "  33,"P!A;'9O+3(P,C,Q,C,Q>&5X>#$U,2YH=&U02P$"
M% ,4    "  DA'18@(>9QO48  !BJ   %P              @ $/SPL 86QV
J;RTR,#(S,3(S,7AE>'@Y-RYH=&U02P4&      T #0!K P  .>@+

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>alvo-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alvo="http://www.alvotech.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alvo-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:ClassOfStocksAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:ClassOfStocksAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:VestedEarnOutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:VestedEarnOutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:VestedEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:OtherShareBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:OtherShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementsTypeAxis">alvo:SubscriptionAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:OacbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:ClassesOfCommonStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:ClassesOfCommonStockAxis">alvo:ClassBCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">alvo:BusinessCombinationAndPipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechGermanyGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechGermanyGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechGermanyGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechSwissAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechSwissAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechSwissAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHannoverGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHannoverGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechHannoverGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMaltaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMaltaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMaltaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUkLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUkLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechUkLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMancoEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMancoEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechMancoEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechBiosciencesIndiaPrivateLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechBiosciencesIndiaPrivateLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvotechBiosciencesIndiaPrivateLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:FasteignafelagiSmundurHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:FasteignafelagiSmundurHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:FasteignafelagiSmundurHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechCchnBiopharmaceuticalCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechCchnBiopharmaceuticalCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechCchnBiopharmaceuticalCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AztiqPharmaPartnersSarlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AztiqPharmaPartnersSarlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:AlvogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:OtherSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">alvo:OtherSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-23</startDate>
            <endDate>2024-02-23</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">alvo:AsiaAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">alvo:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:DevelopmentAndOtherServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:DevelopmentAndOtherServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">alvo:DevelopmentAndOtherServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">alvo:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:NotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:NotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:CostOfProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:CostOfProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:CostOfProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:TemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TaxYearsAxis">alvo:TwoThousandTwentyFourToTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TaxYearsAxis">alvo:TwoThousandTwentySevenToTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TaxYearsAxis">alvo:LaterPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:LU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FacilityEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">alvo:FurnitureFixturesAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AssetsAcquisitionAxis">alvo:SaemundurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AssetsAcquisitionAxis">alvo:SaemundurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AssetsAcquisitionAxis">alvo:SaemundurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagidEyjolfurHf.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagidEyjolfurHf.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:FleetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">alvo:AmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntangibleAssetsWithFiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntangibleAssetsWithFiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntangibleAssetsWithFiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntangibleAssetsWithFiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">alvo:IntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:KashivMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:KashivMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:KashivMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:KashivMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:AVT23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:ClassAAndClassBOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfPredecessorOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfPredecessorOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfClassAOacbOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:ClassAOacbOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfClassAOacbOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:ClassBOacbOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfClassAOacbOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:StockExchangeDescriptionAxis">alvo:ExchangeOfClassAOacbOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:SaleOfStockAxis">alvo:PrivatePlacementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-10</startDate>
            <endDate>2023-02-10</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:SaleOfStockAxis">alvo:PrivatePlacementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-10</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">alvo:PredecessorOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">alvo:IssuedCapitalAndSharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:A2022ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:A2022ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:BcaFrameworkAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-07</startDate>
            <endDate>2021-12-07</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:BcaFrameworkAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:EventAxis">alvo:PaymentOfInKindAccruedInterestAsAResultOfWarrantExerciseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-07</startDate>
            <endDate>2021-12-07</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:BcaFrameworkAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:FinanceIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleShareholderLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:BcaFrameworkAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleShareholderLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ComponentOfDebtConvertedIntoEquityAxis">alvo:PrincipalAndAccruedInterestComponent.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ComponentOfDebtConvertedIntoEquityAxis">alvo:PremiumComponentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ClassOfStockAxis">alvo:ClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AdditionalBondsIssuanceAxis">alvo:IssuedToANewBondHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AdditionalBondsIssuanceAxis">alvo:IssuedToTheExistingNoteholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AdditionalBondsIssuanceAxis">alvo:IssuedToTheExistingAndANewBondHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AdditionalBondsIssuanceAxis">alvo:IssuedToTheExistingAndANewBondHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-24</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:EventAxis">alvo:SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:EventAxis">alvo:SubstantialModificationOfConvertibleBondsAndDerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ComponentOfBondsPayableAxis">alvo:PrincipalComponentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:ComponentOfBondsPayableAxis">alvo:InterestComponentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:NatureOfFeesAxis">alvo:ConsentFeesToBondholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:EventAxis">alvo:ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:EventAxis">alvo:ReductionInInterestRateIfAdditionalSharesAreIssuedWithinSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsJanuaryToJuneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:EventAxis">alvo:IncreaseInTheFaceValueOfTheBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:DetailsAxis">alvo:BeforeTheTermsOfTheSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:DetailsAxis">alvo:AfterTheTermsOfTheSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ContingentlyIssuablePennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ContingentlyIssuablePennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:ContingentlyIssuablePennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:AgreementAxis">alvo:ConvertibleBondAgreementTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:AgreementOneAxis">alvo:AmendmentToOutstandingBondsNovemberSixteenthTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <instant>2022-12-20</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-20</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-20</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-20</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-25</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-07-24</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alvo:ATPHoldingEhf.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheAConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:TrancheBConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">alvo:AztiqConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alvo:AztiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:BorrowingsTrancheAxis">alvo:BorrowingsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-22</startDate>
            <endDate>2022-02-22</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:BorrowingsTrancheAxis">alvo:BorrowingsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-22</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:BorrowingsTrancheAxis">alvo:BorrowingsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:BorrowingsTrancheAxis">alvo:BorrowingsTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AztiqFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityAndAztiqFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityAndAztiqFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-11</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-11</startDate>
            <endDate>2022-04-11</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenSubordinatedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenSubordinatedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenLoanWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenSubordinatedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-20</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:ArionBankiHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-09</startDate>
            <endDate>2022-12-09</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:FinalMaturityInDecember2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RiskExposuresAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:FacilityLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:FinalMaturityInDecember2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RiskExposuresAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsFinancialInstitutionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">alvo:UsdSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsFinancialInstitutionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">alvo:UsdSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsFinancialInstitutionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">alvo:UsdSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:VariableRatesAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnMarch2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:VariableRatesAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-05</instant>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:VariableRatesAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-05</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnAugust2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnApril2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:VariableRatesAxis">alvo:SecuredOvernightFinancingRateSofrOvernightIndexSwapRate.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:LenderNameAxis">alvo:LandsbankinnHfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:MaturityMonthAndYearAxis">alvo:MaturedOnApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleLoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:SeniorBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:OtherBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:ThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:ThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:FormerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:FormerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:FormerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:FormerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:ExistingEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:ExistingEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">alvo:ExistingEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:IncomeStatementsLocationAxis">alvo:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:LeaseFacilityAxis">alvo:April2023LeaseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FlokiFasteignirEhf.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FlokiFasteignirEhf.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alvo:LeaseFacilityAxis">alvo:Remaining15LeaseFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvo:FlokiArtEhf.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsSRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsSRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AtpHoldingsEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AtpHoldingsEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqConsultingEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqConsultingEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiArtEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiArtEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenUKSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenUKSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenFinanceB.VMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenFinanceB.VMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusInternationalPteltdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusInternationalPteltdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiInvestEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiInvestEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiHoldingsS.aR.lMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiHoldingsS.aR.lMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenSpainSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenSpainSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:NorwichClinicalServicesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:NorwichClinicalServicesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignaflagiEyjlfurhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignaflagiEyjlfurhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiFasteignirEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiFasteignirEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsSRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsSRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqConsultingEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqConsultingEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AtpHoldingsEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AtpHoldingsEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiEyjolfurEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiEyjolfurEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusInternationalPteltdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusInternationalPteltdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenKoreaCo.LtdSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenKoreaCo.LtdSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AdalvoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenSpainSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenSpainSlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:NorwichClinicalServicesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:NorwichClinicalServicesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenPharmaPvtLtdSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenPharmaPvtLtdSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiFasteignirEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FlokiFasteignirEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:L41EhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:L41EhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:Lambahagavegur7EhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:Lambahagavegur7EhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenLuxHoldingsS.aR.lSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqPharmaPartnersS.aR.l.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenAztiqABSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AztiqFjrfestingarEhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FasteignafelagiSmundurHf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenIcelandEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEhf.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenUKSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LotusPharmaceuticalsCo.Ltd.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenEmergingMarketsSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenKoreaCo.LtdSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenInc.SisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenMaltaSh.ServicesSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AlvogenPharmaPvtLtdSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:HRJAFEhfSisterCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:L41EhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:Lambhagavegur7EhfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RichardDaviesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RichardDaviesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AnnMerchantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AnnMerchantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ArniHararsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ArniHararsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FaysalKalmouaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FaysalKalmouaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LindaMcgoldrickMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LindaMcgoldrickMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LisaGraverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LisaGraverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ThomasEkmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ThomasEkmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:NetCompensationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:NetCompensationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:OtherExecutiveTeamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RobertWessmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RichardDaviesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:RichardDaviesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AnnMerchantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:AnnMerchantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ArniHararsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ArniHararsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FaysalKalmouaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:CompensationWaivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:FaysalKalmouaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LindaMcgoldrickMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LindaMcgoldrickMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LisaGraverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:LisaGraverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ThomasEkmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:ThomasEkmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:HirofumiImaiBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:HirofumiImaiBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:NetCompensationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:CompensationStatusAxis">alvo:NetCompensationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:MarkLevickCeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">alvo:OtherExecutiveTeamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">alvo:AlvotechAndCchnBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:A2022ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:AztiqConvertibleBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:A2022ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:AlvogenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondInterestRateFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">alvo:ConvertibleBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:TrancheAConversionFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:ConversionPriceOfBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:ConversionPriceOfBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:DividendYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:DividendYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:RiskyYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EmbeddedDerivativeLiabilitiesAssociatedWithConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:RiskyYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:PredecessorEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c-810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">alvo:StockPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-07</instant>
        </period>
    </context>
    <context id="c-819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:VariableInterestRateFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:VariableInterestRateFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ISK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:CashEquivalentsAndCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:CashEquivalentsAndCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-877">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:NonInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-891">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">alvo:VariableInterestBearingFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-894">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:NonInterestBearingFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:FixedInterestBearingBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">alvo:LaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">alvo:VariableInterestBearingBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:OacbEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:ShareAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alvo:HumiraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="c-917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="c-918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="c-919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="c-920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="c-921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alvo:TrancheAxis">alvo:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">alvo:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="c-922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:SeniorBondWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="c-923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="c-924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001898416</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialLiabilitiesAxis">alvo:EarnoutWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares2">
        <measure>alvo:shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="iskPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:ISK</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segement">
        <measure>alvo:segement</measure>
    </unit>
    <unit id="individuals">
        <measure>alvo:Individuals</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="tranche">
        <measure>alvo:tranche</measure>
    </unit>
    <unit id="tranch">
        <measure>alvo:tranch</measure>
    </unit>
    <unit id="isk">
        <measure>iso4217:ISK</measure>
    </unit>
    <unit id="loan">
        <measure>alvo:Loan</measure>
    </unit>
    <unit id="agreement">
        <measure>alvo:agreement</measure>
    </unit>
    <unit id="litigation_case">
        <measure>alvo:litigation_case</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-42">0001898416</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-43">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-44">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-45">2023</dei:DocumentFiscalYearFocus>
    <alvo:ThresholdDaysForDeterminingTheSharePrice contextRef="c-797" id="f-2302">P10D</alvo:ThresholdDaysForDeterminingTheSharePrice>
    <alvo:NumberOfConsecutiveTradingDays contextRef="c-797" id="f-2303">P20D</alvo:NumberOfConsecutiveTradingDays>
    <alvo:ThresholdDaysForDeterminingTheSharePrice contextRef="c-798" id="f-2305">P10D</alvo:ThresholdDaysForDeterminingTheSharePrice>
    <alvo:NumberOfConsecutiveTradingDays contextRef="c-798" id="f-2306">P20D</alvo:NumberOfConsecutiveTradingDays>
    <alvo:ThresholdDaysForDeterminingTheSharePrice contextRef="c-807" id="f-2320">P10D</alvo:ThresholdDaysForDeterminingTheSharePrice>
    <alvo:NumberOfConsecutiveTradingDays contextRef="c-807" id="f-2321">P20D</alvo:NumberOfConsecutiveTradingDays>
    <alvo:VestingPercentageOfShares
      contextRef="c-797"
      decimals="2"
      id="f-2505"
      unitRef="number">0.50</alvo:VestingPercentageOfShares>
    <alvo:VestingPercentageOfShares
      contextRef="c-798"
      decimals="2"
      id="f-2506"
      unitRef="number">0.50</alvo:VestingPercentageOfShares>
    <alvo:VestingPercentageOfShares
      contextRef="c-910"
      decimals="2"
      id="f-2507"
      unitRef="number">0.50</alvo:VestingPercentageOfShares>
    <alvo:VestingPercentageOfShares
      contextRef="c-911"
      decimals="2"
      id="f-2508"
      unitRef="number">0.50</alvo:VestingPercentageOfShares>
    <dei:DocumentType contextRef="c-1" id="f-1">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c-1" id="f-2">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-5">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c-1" id="f-7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">001-41421</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-9">ALVOTECH</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-10">N4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-11">9</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-12">Rue de Bitbourg</dei:EntityAddressAddressLine2>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">1273</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-14">Luxembourg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-15">LU</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c-2" id="f-16">Robert Wessman</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c-2" id="f-17">S&#xe6;mundargata 15-19</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-2" id="f-18">102</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-2" id="f-19">Reykjav&#xed;k</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-2" id="f-20">IS</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-2" id="f-21">354</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-2" id="f-22">422 4500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-3" id="f-23">Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-24">ALVO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-25">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-26">Warrants</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-27">ALVOW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-28">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-29" unitRef="shares">266821844</dei:EntityCommonStockSharesOutstanding>
    <alvo:ClassOfWarrantsOrRightsOutstanding contextRef="c-5" decimals="INF" id="f-30" unitRef="shares">10363094</alvo:ClassOfWarrantsOrRightsOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-31">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-32">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-33">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-34">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-35">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-36">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-37">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-38">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-39">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c-1" id="f-40">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c-1" id="f-41">false</dei:EntityShellCompany>
    <dei:AuditorName contextRef="c-1" id="f-46">Deloitte ehf.</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-47">K&#xf3;pavogur, Iceland</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-48">1490</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="c-1" id="f-49">1490</dei:AuditorFirmId>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-3" id="f-50" unitRef="usd">48699000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-6" decimals="-3" id="f-51" unitRef="usd">24836000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-7" decimals="-3" id="f-52" unitRef="usd">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:LicenceFeeIncome contextRef="c-1" decimals="-3" id="f-53" unitRef="usd">42735000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome contextRef="c-6" decimals="-3" id="f-54" unitRef="usd">58193000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome contextRef="c-7" decimals="-3" id="f-55" unitRef="usd">36772000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-3" id="f-56" unitRef="usd">1948000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-6" decimals="-3" id="f-57" unitRef="usd">1988000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-7" decimals="-3" id="f-58" unitRef="usd">2912000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-3" id="f-59" unitRef="usd">160856000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">64095000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-7" decimals="-3" id="f-61" unitRef="usd">0</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-62" unitRef="usd">210827000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-63" unitRef="usd">180622000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-64" unitRef="usd">191006000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-65" unitRef="usd">76559000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">186742000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-67" unitRef="usd">84134000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-3" id="f-68" unitRef="usd">-354860000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-6" decimals="-3" id="f-69" unitRef="usd">-346442000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-7" decimals="-3" id="f-70" unitRef="usd">-235456000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-1" decimals="-3" id="f-71" unitRef="usd">-7153000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">-2590000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-7" decimals="-3" id="f-73" unitRef="usd">-2418000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-74" unitRef="usd">21519000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-6" decimals="-3" id="f-75" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-7" decimals="-3" id="f-76" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-3" id="f-77" unitRef="usd">4823000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">2549000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-7" decimals="-3" id="f-79" unitRef="usd">51568000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-80" unitRef="usd">267157000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-6" decimals="-3" id="f-81" unitRef="usd">188419000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-7" decimals="-3" id="f-82" unitRef="usd">117361000</ifrs-full:FinanceCosts>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-83" unitRef="usd">-5183000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-6" decimals="-3" id="f-84" unitRef="usd">10566000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-7" decimals="-3" id="f-85" unitRef="usd">2681000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">0</ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid>
    <ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid contextRef="c-6" decimals="-3" id="f-87" unitRef="usd">-27311000</ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid>
    <ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid contextRef="c-7" decimals="-3" id="f-88" unitRef="usd">151788000</ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid>
    <ifrs-full:OtherGainsLosses contextRef="c-1" decimals="-3" id="f-89" unitRef="usd">-296189000</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">-205205000</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c-7" decimals="-3" id="f-91" unitRef="usd">86258000</ifrs-full:OtherGainsLosses>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-92" unitRef="usd">-651049000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">-551647000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-7" decimals="-3" id="f-94" unitRef="usd">-149198000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">-99318000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-6" decimals="-3" id="f-96" unitRef="usd">-38067000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-7" decimals="-3" id="f-97" unitRef="usd">-47694000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">-551731000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">-513580000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">-101504000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">-86000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">-6111000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-7" decimals="-3" id="f-103" unitRef="usd">-305000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">-551817000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">-519691000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-7" decimals="-3" id="f-106" unitRef="usd">-101809000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">-2.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">-2.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-6"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">-2.60</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-6"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">-2.60</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-7"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">-0.92</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-7"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-0.92</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">236779000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-114" unitRef="usd">220594000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">119802000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-8" decimals="-3" id="f-116" unitRef="usd">47501000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">12058000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-8" decimals="-3" id="f-118" unitRef="usd">11643000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">19076000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-8" decimals="-3" id="f-120" unitRef="usd">25652000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentContractAssets contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">10856000</ifrs-full:NoncurrentContractAssets>
    <ifrs-full:NoncurrentContractAssets contextRef="c-8" decimals="-3" id="f-122" unitRef="usd">3286000</ifrs-full:NoncurrentContractAssets>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">18494000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-8" decimals="-3" id="f-124" unitRef="usd">48568000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">2244000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-8" decimals="-3" id="f-126" unitRef="usd">5780000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">26132000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-128" unitRef="usd">25187000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:DeferredTaxAssets contextRef="c-5" decimals="-3" id="f-129" unitRef="usd">309807000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-8" decimals="-3" id="f-130" unitRef="usd">209496000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-5" decimals="-3" id="f-131" unitRef="usd">755248000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-8" decimals="-3" id="f-132" unitRef="usd">597707000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c-5" decimals="-3" id="f-133" unitRef="usd">74433000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-8" decimals="-3" id="f-134" unitRef="usd">71470000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables contextRef="c-5" decimals="-3" id="f-135" unitRef="usd">41292000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-8" decimals="-3" id="f-136" unitRef="usd">32972000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentContractAssets contextRef="c-5" decimals="-3" id="f-137" unitRef="usd">35193000</ifrs-full:CurrentContractAssets>
    <ifrs-full:CurrentContractAssets contextRef="c-8" decimals="-3" id="f-138" unitRef="usd">25370000</ifrs-full:CurrentContractAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-5" decimals="-3" id="f-139" unitRef="usd">31871000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-8" decimals="-3" id="f-140" unitRef="usd">32949000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">896000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c-8" decimals="-3" id="f-142" unitRef="usd">1548000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-143" unitRef="usd">11157000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-144" unitRef="usd">66427000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="c-5" decimals="-3" id="f-145" unitRef="usd">194842000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-8" decimals="-3" id="f-146" unitRef="usd">230736000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c-5" decimals="-3" id="f-147" unitRef="usd">950090000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-8" decimals="-3" id="f-148" unitRef="usd">828443000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital contextRef="c-5" decimals="-3" id="f-149" unitRef="usd">2279000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-8" decimals="-3" id="f-150" unitRef="usd">2126000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c-5" decimals="-3" id="f-151" unitRef="usd">1229690000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-8" decimals="-3" id="f-152" unitRef="usd">1058432000</ifrs-full:SharePremium>
    <ifrs-full:OtherReserves contextRef="c-5" decimals="-3" id="f-153" unitRef="usd">42911000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-8" decimals="-3" id="f-154" unitRef="usd">30582000</ifrs-full:OtherReserves>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c-5" decimals="-3" id="f-155" unitRef="usd">-1528000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c-8" decimals="-3" id="f-156" unitRef="usd">-1442000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:RetainedEarnings contextRef="c-5" decimals="-3" id="f-157" unitRef="usd">-2205845000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c-8" decimals="-3" id="f-158" unitRef="usd">-1654114000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-159" unitRef="usd">-932493000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-3" id="f-160" unitRef="usd">-564416000</ifrs-full:Equity>
    <ifrs-full:LongtermBorrowings contextRef="c-5" decimals="-3" id="f-161" unitRef="usd">922134000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-8" decimals="-3" id="f-162" unitRef="usd">744654000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-5" decimals="-3" id="f-163" unitRef="usd">520553000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-8" decimals="-3" id="f-164" unitRef="usd">380232000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentPayablesToRelatedParties contextRef="c-5" decimals="-3" id="f-165" unitRef="usd">0</ifrs-full:NoncurrentPayablesToRelatedParties>
    <ifrs-full:NoncurrentPayablesToRelatedParties contextRef="c-8" decimals="-3" id="f-166" unitRef="usd">7440000</ifrs-full:NoncurrentPayablesToRelatedParties>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-5" decimals="-3" id="f-167" unitRef="usd">105632000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-8" decimals="-3" id="f-168" unitRef="usd">35369000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan contextRef="c-5" decimals="-3" id="f-169" unitRef="usd">0</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan contextRef="c-8" decimals="-3" id="f-170" unitRef="usd">544000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-5" decimals="-3" id="f-171" unitRef="usd">73261000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-8" decimals="-3" id="f-172" unitRef="usd">57017000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-173" unitRef="usd">53000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-8" decimals="-3" id="f-174" unitRef="usd">309000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-5" decimals="-3" id="f-175" unitRef="usd">1621633000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-8" decimals="-3" id="f-176" unitRef="usd">1225565000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-5" decimals="-3" id="f-177" unitRef="usd">80563000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-8" decimals="-3" id="f-178" unitRef="usd">49188000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-5" decimals="-3" id="f-179" unitRef="usd">9683000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-8" decimals="-3" id="f-180" unitRef="usd">5163000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">38025000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="c-8" decimals="-3" id="f-182" unitRef="usd">19916000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">9851000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="c-8" decimals="-3" id="f-184" unitRef="usd">1131000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <ifrs-full:CurrentContractLiabilities contextRef="c-5" decimals="-3" id="f-185" unitRef="usd">59183000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-8" decimals="-3" id="f-186" unitRef="usd">36915000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-187" unitRef="usd">925000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-188" unitRef="usd">934000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-189" unitRef="usd">62720000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-8" decimals="-3" id="f-190" unitRef="usd">54047000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-5" decimals="-3" id="f-191" unitRef="usd">260950000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-8" decimals="-3" id="f-192" unitRef="usd">167294000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c-5" decimals="-3" id="f-193" unitRef="usd">1882583000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-8" decimals="-3" id="f-194" unitRef="usd">1392859000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-5" decimals="-3" id="f-195" unitRef="usd">950090000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-8" decimals="-3" id="f-196" unitRef="usd">828443000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-551731000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-6" decimals="-3" id="f-198" unitRef="usd">-513580000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-3" id="f-199" unitRef="usd">-101504000</ifrs-full:ProfitLoss>
    <alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">0</alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains>
    <alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains contextRef="c-6" decimals="-3" id="f-201" unitRef="usd">-4803000</alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains>
    <alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains contextRef="c-7" decimals="-3" id="f-202" unitRef="usd">0</alvo:AdjustmentsForExtinguishmentOfLiabilityLossesGains>
    <alvo:AdjustmentsForSharelistingExpense contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">0</alvo:AdjustmentsForSharelistingExpense>
    <alvo:AdjustmentsForSharelistingExpense contextRef="c-6" decimals="-3" id="f-204" unitRef="usd">83411000</alvo:AdjustmentsForSharelistingExpense>
    <alvo:AdjustmentsForSharelistingExpense contextRef="c-7" decimals="-3" id="f-205" unitRef="usd">0</alvo:AdjustmentsForSharelistingExpense>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">78000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c-6" decimals="-3" id="f-207" unitRef="usd">5492000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c-7" decimals="-3" id="f-208" unitRef="usd">17955000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">24210000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-6" decimals="-3" id="f-210" unitRef="usd">20409000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-7" decimals="-3" id="f-211" unitRef="usd">18196000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">0</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-213" unitRef="usd">0</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-214" unitRef="usd">2092000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">1779000</alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets>
    <alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets contextRef="c-6" decimals="-3" id="f-216" unitRef="usd">2755000</alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets>
    <alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets contextRef="c-7" decimals="-3" id="f-217" unitRef="usd">3993000</alvo:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecogniseInProfitOrLossIntangibleAssets>
    <ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">-18500000</ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets contextRef="c-6" decimals="-3" id="f-219" unitRef="usd">0</ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets contextRef="c-7" decimals="-3" id="f-220" unitRef="usd">0</ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets>
    <alvo:ChangesInInventoryReserves contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">8341000</alvo:ChangesInInventoryReserves>
    <alvo:ChangesInInventoryReserves contextRef="c-6" decimals="-3" id="f-222" unitRef="usd">0</alvo:ChangesInInventoryReserves>
    <alvo:ChangesInInventoryReserves contextRef="c-7" decimals="-3" id="f-223" unitRef="usd">0</alvo:ChangesInInventoryReserves>
    <ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">365000</ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-225" unitRef="usd">0</ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-226" unitRef="usd">0</ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">21519000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-6" decimals="-3" id="f-228" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-7" decimals="-3" id="f-229" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">-7153000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-6" decimals="-3" id="f-231" unitRef="usd">-2590000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-7" decimals="-3" id="f-232" unitRef="usd">-2418000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">4823000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-6" decimals="-3" id="f-234" unitRef="usd">2549000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-7" decimals="-3" id="f-235" unitRef="usd">51568000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">267157000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-6" decimals="-3" id="f-237" unitRef="usd">188419000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-7" decimals="-3" id="f-238" unitRef="usd">117361000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">0</ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid>
    <ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid contextRef="c-6" decimals="-3" id="f-240" unitRef="usd">-27311000</ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid>
    <ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid contextRef="c-7" decimals="-3" id="f-241" unitRef="usd">151788000</ifrs-full:GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">18033000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">10317000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-7" decimals="-3" id="f-244" unitRef="usd">0</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">5183000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-6" decimals="-3" id="f-246" unitRef="usd">-10566000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-7" decimals="-3" id="f-247" unitRef="usd">-2681000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">-99318000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="c-6" decimals="-3" id="f-249" unitRef="usd">-38067000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="c-7" decimals="-3" id="f-250" unitRef="usd">-47694000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">-283554000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-6" decimals="-3" id="f-252" unitRef="usd">-228861000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-7" decimals="-3" id="f-253" unitRef="usd">-193220000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">-11304000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-6" decimals="-3" id="f-255" unitRef="usd">-32412000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">-29412000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">-8320000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-6" decimals="-3" id="f-258" unitRef="usd">-3576000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-7" decimals="-3" id="f-259" unitRef="usd">-28813000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">2161000</alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties>
    <alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties contextRef="c-6" decimals="-3" id="f-261" unitRef="usd">56000</alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties>
    <alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">-453000</alvo:AdjustmentsForIncreaseDecreaseInLiabilitiesToRelatedParties>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">-17393000</ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets contextRef="c-6" decimals="-3" id="f-264" unitRef="usd">-9218000</ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets contextRef="c-7" decimals="-3" id="f-265" unitRef="usd">15286000</ifrs-full:AdjustmentsForDecreaseIncreaseInContractAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">-802000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c-6" decimals="-3" id="f-267" unitRef="usd">-17194000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="c-7" decimals="-3" id="f-268" unitRef="usd">-4363000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">31772000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-6" decimals="-3" id="f-270" unitRef="usd">16442000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-7" decimals="-3" id="f-271" unitRef="usd">14318000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">35396000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-6" decimals="-3" id="f-273" unitRef="usd">19396000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities contextRef="c-7" decimals="-3" id="f-274" unitRef="usd">21470000</ifrs-full:AdjustmentsForIncreaseDecreaseInContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">-5182000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c-6" decimals="-3" id="f-276" unitRef="usd">-21384000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c-7" decimals="-3" id="f-277" unitRef="usd">5160000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">-257226000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-6" decimals="-3" id="f-279" unitRef="usd">-276751000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-7" decimals="-3" id="f-280" unitRef="usd">-200027000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">3649000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-6" decimals="-3" id="f-282" unitRef="usd">568000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-7" decimals="-3" id="f-283" unitRef="usd">16000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">57254000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-6" decimals="-3" id="f-285" unitRef="usd">35372000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">28004000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">1354000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities contextRef="c-6" decimals="-3" id="f-288" unitRef="usd">834000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities contextRef="c-7" decimals="-3" id="f-289" unitRef="usd">155000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">-312185000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-291" unitRef="usd">-312389000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">-228170000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">33234000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-6" decimals="-3" id="f-294" unitRef="usd">37880000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-295" unitRef="usd">20462000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">133000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-6" decimals="-3" id="f-297" unitRef="usd">379000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-298" unitRef="usd">0</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">13239000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-6" decimals="-3" id="f-300" unitRef="usd">11122000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-301" unitRef="usd">20171000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <alvo:RestrictedCashInConnectionWithAmendedBondAgreement contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">0</alvo:RestrictedCashInConnectionWithAmendedBondAgreement>
    <alvo:RestrictedCashInConnectionWithAmendedBondAgreement contextRef="c-6" decimals="-3" id="f-303" unitRef="usd">14914000</alvo:RestrictedCashInConnectionWithAmendedBondAgreement>
    <alvo:RestrictedCashInConnectionWithAmendedBondAgreement contextRef="c-7" decimals="-3" id="f-304" unitRef="usd">0</alvo:RestrictedCashInConnectionWithAmendedBondAgreement>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">-46340000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-306" unitRef="usd">-63537000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-307" unitRef="usd">-40633000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">99367000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-6" decimals="-3" id="f-309" unitRef="usd">34714000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-7" decimals="-3" id="f-310" unitRef="usd">37496000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">8269000</alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities>
    <alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities contextRef="c-6" decimals="-3" id="f-312" unitRef="usd">11147000</alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities>
    <alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities contextRef="c-7" decimals="-3" id="f-313" unitRef="usd">7350000</alvo:RepaymentsOfPrincipalPortionOfLeaseLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">278831000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-6" decimals="-3" id="f-315" unitRef="usd">193678000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-7" decimals="-3" id="f-316" unitRef="usd">113821000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsForDebtIssueCosts contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">9004000</ifrs-full:PaymentsForDebtIssueCosts>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">136879000</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments contextRef="c-6" decimals="-3" id="f-319" unitRef="usd">0</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments contextRef="c-7" decimals="-3" id="f-320" unitRef="usd">0</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">4141000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-6" decimals="-3" id="f-322" unitRef="usd">0</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-7" decimals="-3" id="f-323" unitRef="usd">0</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">6390000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-6" decimals="-3" id="f-325" unitRef="usd">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-7" decimals="-3" id="f-326" unitRef="usd">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-6" decimals="-3" id="f-328" unitRef="usd">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-7" decimals="-3" id="f-329" unitRef="usd">185856000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForDebtIssueCosts contextRef="c-6" decimals="-3" id="f-330" unitRef="usd">12102000</ifrs-full:PaymentsForDebtIssueCosts>
    <ifrs-full:PaymentsForDebtIssueCosts contextRef="c-7" decimals="-3" id="f-331" unitRef="usd">0</ifrs-full:PaymentsForDebtIssueCosts>
    <alvo:GrossProceedsFromThePipeFinancing contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">0</alvo:GrossProceedsFromThePipeFinancing>
    <alvo:GrossProceedsFromThePipeFinancing contextRef="c-6" decimals="-3" id="f-333" unitRef="usd">-174930000</alvo:GrossProceedsFromThePipeFinancing>
    <alvo:GrossProceedsFromThePipeFinancing contextRef="c-7" decimals="-3" id="f-334" unitRef="usd">0</alvo:GrossProceedsFromThePipeFinancing>
    <alvo:GrossPipeFinancingFeesPaid contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">0</alvo:GrossPipeFinancingFeesPaid>
    <alvo:GrossPipeFinancingFeesPaid contextRef="c-6" decimals="-3" id="f-336" unitRef="usd">5562000</alvo:GrossPipeFinancingFeesPaid>
    <alvo:GrossPipeFinancingFeesPaid contextRef="c-7" decimals="-3" id="f-337" unitRef="usd">0</alvo:GrossPipeFinancingFeesPaid>
    <alvo:ProceedsFromTheCapitalReorganization contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">0</alvo:ProceedsFromTheCapitalReorganization>
    <alvo:ProceedsFromTheCapitalReorganization contextRef="c-6" decimals="-3" id="f-339" unitRef="usd">9827000</alvo:ProceedsFromTheCapitalReorganization>
    <alvo:ProceedsFromTheCapitalReorganization contextRef="c-7" decimals="-3" id="f-340" unitRef="usd">0</alvo:ProceedsFromTheCapitalReorganization>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">0</ifrs-full:CashAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties contextRef="c-6" decimals="-3" id="f-342" unitRef="usd">160000000</ifrs-full:CashAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties contextRef="c-7" decimals="-3" id="f-343" unitRef="usd">0</ifrs-full:CashAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">0</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties contextRef="c-6" decimals="-3" id="f-345" unitRef="usd">50000000</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties contextRef="c-7" decimals="-3" id="f-346" unitRef="usd">0</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">301319000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-348" unitRef="usd">424910000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-349" unitRef="usd">254831000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">-57206000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-6" decimals="-3" id="f-351" unitRef="usd">48984000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-7" decimals="-3" id="f-352" unitRef="usd">-13972000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-353" unitRef="usd">66427000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-9" decimals="-3" id="f-354" unitRef="usd">17556000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-10" decimals="-3" id="f-355" unitRef="usd">31689000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">1936000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-357" unitRef="usd">-113000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-358" unitRef="usd">-161000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-359" unitRef="usd">11157000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-360" unitRef="usd">66427000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-9" decimals="-3" id="f-361" unitRef="usd">17556000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Equity contextRef="c-11" decimals="-3" id="f-362" unitRef="usd">73000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-3" id="f-363" unitRef="usd">166740000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-3" id="f-364" unitRef="usd">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-14" decimals="-3" id="f-365" unitRef="usd">4974000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-15" decimals="-3" id="f-366" unitRef="usd">-1039030000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-3" id="f-367" unitRef="usd">-867243000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-16" decimals="-3" id="f-368" unitRef="usd">-101504000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-3" id="f-369" unitRef="usd">-101504000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-17" decimals="-3" id="f-370" unitRef="usd">-305000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-7" decimals="-3" id="f-371" unitRef="usd">-305000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-17" decimals="-3" id="f-372" unitRef="usd">-305000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-16" decimals="-3" id="f-373" unitRef="usd">-101504000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-7" decimals="-3" id="f-374" unitRef="usd">-101809000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity contextRef="c-18" decimals="-3" id="f-375" unitRef="usd">62000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-19" decimals="-3" id="f-376" unitRef="usd">833378000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-7" decimals="-3" id="f-377" unitRef="usd">833440000</ifrs-full:IssueOfEquity>
    <ifrs-full:Equity contextRef="c-20" decimals="-3" id="f-378" unitRef="usd">135000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-21" decimals="-3" id="f-379" unitRef="usd">1000118000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-22" decimals="-3" id="f-380" unitRef="usd">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-3" id="f-381" unitRef="usd">4669000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-3" id="f-382" unitRef="usd">-1140534000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-383" unitRef="usd">-135612000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-25" decimals="-3" id="f-384" unitRef="usd">-513580000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-6" decimals="-3" id="f-385" unitRef="usd">-513580000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-26" decimals="-3" id="f-386" unitRef="usd">-6111000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-6" decimals="-3" id="f-387" unitRef="usd">-6111000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-26" decimals="-3" id="f-388" unitRef="usd">-6111000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-25" decimals="-3" id="f-389" unitRef="usd">-513580000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-6" decimals="-3" id="f-390" unitRef="usd">-519691000</ifrs-full:ComprehensiveIncome>
    <alvo:IncreaseDecreaseThroughPipeFinancing contextRef="c-27" decimals="-3" id="f-391" unitRef="usd">175000</alvo:IncreaseDecreaseThroughPipeFinancing>
    <alvo:IncreaseDecreaseThroughPipeFinancing contextRef="c-28" decimals="-3" id="f-392" unitRef="usd">169193000</alvo:IncreaseDecreaseThroughPipeFinancing>
    <alvo:IncreaseDecreaseThroughPipeFinancing contextRef="c-6" decimals="-3" id="f-393" unitRef="usd">169368000</alvo:IncreaseDecreaseThroughPipeFinancing>
    <ifrs-full:IssueOfEquity contextRef="c-29" decimals="-3" id="f-394" unitRef="usd">35000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-30" decimals="-3" id="f-395" unitRef="usd">30267000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-31" decimals="-3" id="f-396" unitRef="usd">30302000</ifrs-full:IssueOfEquity>
    <alvo:IncreaseDecreaseThroughCapitalReorganization contextRef="c-27" decimals="-3" id="f-397" unitRef="usd">1731000</alvo:IncreaseDecreaseThroughCapitalReorganization>
    <alvo:IncreaseDecreaseThroughCapitalReorganization contextRef="c-28" decimals="-3" id="f-398" unitRef="usd">-173296000</alvo:IncreaseDecreaseThroughCapitalReorganization>
    <alvo:IncreaseDecreaseThroughCapitalReorganization contextRef="c-6" decimals="-3" id="f-399" unitRef="usd">-171565000</alvo:IncreaseDecreaseThroughCapitalReorganization>
    <alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares contextRef="c-27" decimals="-3" id="f-400" unitRef="usd">50000</alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares>
    <alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares contextRef="c-28" decimals="-3" id="f-401" unitRef="usd">32150000</alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares>
    <alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares contextRef="c-6" decimals="-3" id="f-402" unitRef="usd">32200000</alvo:IncreaseDecreaseThroughSettlementOfRelatedPartyLoansWithOrdinaryShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-32" decimals="-3" id="f-403" unitRef="usd">14548000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-6" decimals="-3" id="f-404" unitRef="usd">14548000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-32" decimals="-3" id="f-405" unitRef="usd">16034000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-6" decimals="-3" id="f-406" unitRef="usd">16034000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:Equity contextRef="c-33" decimals="-3" id="f-407" unitRef="usd">2126000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-34" decimals="-3" id="f-408" unitRef="usd">1058432000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-35" decimals="-3" id="f-409" unitRef="usd">30582000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-36" decimals="-3" id="f-410" unitRef="usd">-1442000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-37" decimals="-3" id="f-411" unitRef="usd">-1654114000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-3" id="f-412" unitRef="usd">-564416000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-38" decimals="-3" id="f-413" unitRef="usd">-551731000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">-551731000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-39" decimals="-3" id="f-415" unitRef="usd">-86000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">-86000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-39" decimals="-3" id="f-417" unitRef="usd">-86000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-38" decimals="-3" id="f-418" unitRef="usd">-551731000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-419" unitRef="usd">-551817000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c-40" decimals="-3" id="f-420" unitRef="usd">118000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c-41" decimals="-3" id="f-421" unitRef="usd">132618000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">132736000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IssueOfEquity contextRef="c-42" decimals="-3" id="f-423" unitRef="usd">6000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-43" decimals="-3" id="f-424" unitRef="usd">8300000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-44" decimals="-3" id="f-425" unitRef="usd">8306000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-45" decimals="-3" id="f-426" unitRef="usd">25000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-46" decimals="-3" id="f-427" unitRef="usd">27159000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-47" decimals="-3" id="f-428" unitRef="usd">27184000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-48" decimals="-3" id="f-429" unitRef="usd">6000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-49" decimals="-3" id="f-430" unitRef="usd">7612000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-50" decimals="-3" id="f-431" unitRef="usd">7618000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-51" decimals="-3" id="f-432" unitRef="usd">16985000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-52" decimals="-3" id="f-433" unitRef="usd">16985000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-53" decimals="-3" id="f-434" unitRef="usd">8000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-54" decimals="-3" id="f-435" unitRef="usd">5095000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-55" decimals="-3" id="f-436" unitRef="usd">-5781000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-56" decimals="-3" id="f-437" unitRef="usd">-678000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-57" decimals="-3" id="f-438" unitRef="usd">-10000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-58" decimals="-3" id="f-439" unitRef="usd">-9526000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-59" decimals="-3" id="f-440" unitRef="usd">-4231000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-60" decimals="-3" id="f-441" unitRef="usd">-13767000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-61" decimals="-3" id="f-442" unitRef="usd">5356000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">5356000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:Equity contextRef="c-62" decimals="-3" id="f-444" unitRef="usd">2279000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-63" decimals="-3" id="f-445" unitRef="usd">1229690000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-64" decimals="-3" id="f-446" unitRef="usd">42911000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-65" decimals="-3" id="f-447" unitRef="usd">-1528000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-66" decimals="-3" id="f-448" unitRef="usd">-2205845000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-449" unitRef="usd">-932493000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-450">General information &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Alvotech (the &#x201c;Parent&#x201d; or the &#x201c;Company&#x201d; or &#x201c;Alvotech&#x201d;), previously known as Alvotech Lux Holdings S.A.S., the surviving company after the Business Combination (as defined below) with, among other parties, Alvotech Holdings S.A. (the &#x201c;Predecessor&#x201d;), is a Luxembourg public limited company (soci&#xe9;t&#xe9; anonyme) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg and is registered with the Luxembourg Trade and Companies&#x2019; Register under number B 258884. The Company was incorporated on 23 August 2021. These consolidated financial statements were approved by the Group&#x2019;s Board of Directors, and authorized for issue, on 20 March 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company and its subsidiaries (collectively referred to as the &#x201c;Group&#x201d;) are a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide. The Group has commercialized a certain biosimilar product and has multiple biosimilar molecules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.1 Capital Reorganization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 15 June 2022 (the &#x201c;Closing Date&#x201d;), the Company consummated the capital reorganization with Alvotech Holdings S.A. and OACB (the &#x201c;Business Combination&#x201d; or &#x201c;Capital Reorganization&#x201d;) pursuant to the business combination agreement, dated as of 7 December 2021, as amended by an amendment agreement dated 18 April 2022 and 7 June 2022 (the &#x201c;Business Combination Agreement&#x201d;), by and among the Company, Oaktree Acquisition Corp. II (&#x201c;OACB&#x201d;) and the Predecessor. The closing of the Business Combination resulted in the following transactions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;OACB merged with and into the Company, whereby (i) all of the outstanding ordinary shares of OACB (&#x201c;OACB Ordinary Shares&#x201d;) were exchanged for ordinary shares of Alvotech (&#x201c;Ordinary Shares&#x201d;) on a one-for-one basis, pursuant to a share capital increase of Alvotech and (ii) all of the outstanding warrants of OACB ceased to represent a right to acquire OACB Ordinary Shares and now represent a right to be issued one Ordinary Share, with Alvotech as the surviving company in the merger. Prior to the merger OACB shares were redeemed, resulting in $9.8 million of cash proceeds from the OACB trust account; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Alvotech redeemed and canceled the initial shares held by the initial sole shareholder of Alvotech pursuant to a share capital reduction of Alvotech; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The legal form of Alvotech changed from a simplified joint stock company (soci&#xe9;t&#xe9; par actions simplifi&#xe9;e) to a public limited liability company (soci&#xe9;t&#xe9; anonyme) under Luxembourg law; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The Predecessor merged with and into the Parent, whereby all outstanding ordinary shares of the Predecessor (&#x201c;Predecessor Ordinary Shares&#x201d;) were exchanged for Ordinary Shares, pursuant to a share capital increase of Alvotech, with Alvotech as the surviving company in the merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Concurrently with the execution of the Business Combination Agreement, OACB and Alvotech entered into subscription agreements (&#x201c;Subscription Agreements&#x201d;) with certain investors (the &#x201c;PIPE Financing&#x201d;). On 15&#160;June 2022, immediately prior to the closing of the Business Combination, the PIPE Financing was closed, pursuant to the Subscription Agreements, in which subscribers collectively subscribed for 17,493,000 Ordinary Shares at $10.00 per share for an aggregate subscription price equal to $174.9 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the Business Combination, Predecessor shareholders were granted a total of 38,330,000 Ordinary Shares subject to certain vesting conditions (&#x201c;Predecessor Earn Out Shares&#x201d;). Former OACB shareholders were granted a total of 1,250,000 Ordinary Shares subject to certain vesting conditions (&#x201c;OACB Earn Out Shares&#x201d;). Additionally, as part of the Business Combination the Company assumed the 10,916,647 outstanding warrants (&#x201c;OACB Warrants&#x201d;), on substantially the same contractual terms and conditions as were in effect immediately prior to the Business Combination. See Note 28 for further details. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Business Combination was accounted for as a capital reorganization. Under this method of accounting, OACB was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes, with Alvotech Holdings S.A. being the accounting acquirer and accounting predecessor. Accordingly, the capital reorganization was treated as the equivalent of Alvotech issuing shares at the closing of the Business Combination for the net assets of OACB as of the Closing Date, accompanied by a recapitalization. The capital reorganization, which was not within the scope of IFRS 3 since OACB did not meet the definition of a business in accordance with that guidance, was accounted for within the scope of IFRS 2. In accordance with IFRS 2, Alvotech recorded a one-time non-cash share listing expense of $83.4 million, recognized as a general and administrative expense, based on the excess of the fair value of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Alvotech shares issued, at the Closing Date, over the fair value of OACB&#x2019;s identifiable net assets acquired. The fair value of shares issued was estimated based on a market price of $9.38 per share as of 15&#160;June 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;(in 000s) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class A Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;976,505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class B Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Alvotech Shares issued to OACB shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,226,505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value of Shares issued to OACB as of 15 June 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$56,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value of OACB Earn Out Shares issued to OACB as of 15 June 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Estimated fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adjusted net liabilities of OACB as of 15 June 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Difference &#x2013; being the share listing expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Business Combination and PIPE Financing, the Company incurred $28.5 million of transaction costs, which represent legal, financial advisory, and other professional fees in connection with the Business Combination and PIPE Financing, during the year ended December&#160;31, 2022. Of this amount, $5.6 million represented equity issuance costs related to PIPE Financing that were capitalized in share premium. The remaining $22.9 million was recognized as general and administrative expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2 Information about subsidiaries and joint ventures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.137%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Entity name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Principal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;activity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Issued and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;paid capital &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(presented in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;whole shares)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Place of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;establishment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Proportion of ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;and voting power held by &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Alvotech &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31.12.2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31.12.2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech hf&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,893,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Iceland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Germany GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,182&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Swiss AG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;153,930&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Hannover GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,983&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Malta Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Group Serv.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,450&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Malta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech USA Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech UK Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Group Serv.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Manco ehf&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Group Serv.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;215,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Iceland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Biosciences India Private Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignafelagi&#xf0; S&#xe6;mundur hf&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,965,337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Iceland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech &amp;amp; CCHN Biopharmaceutical Co. Ltd*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,000,021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt"&gt;Alvotech &amp;amp; CCHN Biopharmaceutical Co. Ltd. is an unconsolidated joint venture (see Note 27). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.3 Information about shareholders &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant shareholders of the Company are Aztiq Pharma Partners S.&#xe0; r.l. (Aztiq) and Alvogen Lux Holdings S.&#xe0; r.l. (Alvogen), with 37.9% and 33.7% ownership interest as of 31&#160;December 2023, and  40.7% and 35.8% ownership interest as of 31&#160;December 2022, respectively. The remaining 28.4% ownership interest is held by various entities, with no single shareholder holding more than 2.4% ownership interest as of 31&#160;December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The remaining 23.5% ownership interest was held by various entities, with no single shareholder holding more than 2.4% ownership interest as of 31&#160;December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.4 Going concern &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group has primarily funded its operations with proceeds from the issuance of ordinary shares and the issuance of loans and borrowings to both related parties and third parties. The Group has also incurred recurring losses since its inception, including net losses of $551.7&#160;million, $513.6 million, and $101.5 million for the years ended 31&#160;December 2023, 2022, and 2021, respectively, and had an accumulated deficit of $2,205.8&#160;million as of 31&#160;December 2023. The Group has not generated positive operational cash flow, largely due to the continued focus on biosimilar product development and expansion efforts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of 31&#160;December 2023, the Group had cash and cash equivalents, excluding restricted cash, of $11.2&#160;million and current assets less current liabilities of ($66.1) million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, the development of and regulatory approval of commercially viable biosimilar products, the need to raise adequate additional financing necessary to fund the development and commercialization of its biosimilar products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company announced in February 2024 that the U.S. Food and Drug Administration ("FDA") has approved SIMLANDI (adalimumab) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn&#x2019;s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. Teva is Alvotech&#x2019;s strategic partner for the exclusive commercialization of SIMLANDI in the United States. SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA, and will qualify for interchangeable exclusivity for the 40mg/0.4ml injection. This approval is an important milestone for the Company to access the U.S. market with a unique positioning. The Company expects to launch AVT02 with its partner Teva in the United States during the first half of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Additionally, in February 2024, the Company announced it has reached settlement agreements with Johnson &amp;amp; Johnson in Japan, Canada and in the European Economic Area (EEA) for AVT04, a biosimilar to Stelara (ustekinumab). Regulatory approval for AVT04 in these markets has already been granted. Market applications for AVT04 are currently pending in additional global markets, including in the U.S. Market entry of AVT04 in Canada started in March 2024. Launch of AVT04 in Japan is anticipated after the upcoming round of National Health Insurance reimbursement price listings, in May 2024. Entry to the first European markets is expected as soon as possible after the expiration date of the European Supplementary Protection Certificate for Stelara, which is in late July 2024. These approvals represent another significant milestone for the Company to tap into the Stelara market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The closing of the private placement equity offering in February 2024 provided the Group with gross proceeds of $166&#160;million (net proceeds of $160&#160;million) that is expected to be used to finance general corporate purposes and working capital, to strengthen its production capacity, and to support expected biosimilars launches. As part of the transaction, the Group sold 10,127,132 Ordinary Shares, par value USD 0.01 per share, at a purchase price of $16.41 per share, or ISK 2,250 per share, at foreign exchange rates on 23 February 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, the Group expects to continue to source its financing during the development of its biosimilar products from existing out-license contracts with commercial partners. In light of these conditions and events management evaluated whether there is substantial doubt about the Group&#x2019;s ability to continue as a going concern for at least one year after the date that the consolidated financial statements are issued. Based on the cash on hand, funding received, and projected future cash flows, management concluded that the Group has the ability to continue as a going concern for at least one year after the date that the consolidated financial statements are issued. As such, the consolidated financial statements have been prepared on a going concern basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;However, although management continues to pursue these plans, there is no assurance that the Group will be successful in obtaining sufficient funding on terms acceptable to the Group to fund continuing operations, if at all. If financing is obtained, the terms of such financing may adversely affect the holdings or the rights of the Group&#x2019;s shareholders. The ability to obtain funding, therefore, is outside of management&#x2019;s control and is a material uncertainty that may cast significant doubt upon the Group&#x2019;s ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <alvo:NumberOfSharesCalledByEachWarrantOrRight
      contextRef="c-67"
      decimals="INF"
      id="f-451"
      unitRef="shares">1</alvo:NumberOfSharesCalledByEachWarrantOrRight>
    <alvo:NumberOfSharesCalledByEachWarrantOrRight
      contextRef="c-67"
      decimals="INF"
      id="f-452"
      unitRef="shares">1</alvo:NumberOfSharesCalledByEachWarrantOrRight>
    <alvo:ProceedsFromTheCapitalReorganization contextRef="c-68" decimals="-5" id="f-453" unitRef="usd">9800000</alvo:ProceedsFromTheCapitalReorganization>
    <alvo:CommonStockSharesSubscribed
      contextRef="c-69"
      decimals="INF"
      id="f-454"
      unitRef="shares">17493000</alvo:CommonStockSharesSubscribed>
    <alvo:CommonStockSubscriptionPricePerShare
      contextRef="c-69"
      decimals="INF"
      id="f-455"
      unitRef="usdPerShare">10.00</alvo:CommonStockSubscriptionPricePerShare>
    <alvo:CommonStockValueSubscriptions contextRef="c-69" decimals="-5" id="f-456" unitRef="usd">174900000</alvo:CommonStockValueSubscriptions>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-70"
      decimals="INF"
      id="f-457"
      unitRef="shares">38330000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-71"
      decimals="INF"
      id="f-458"
      unitRef="shares">1250000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-72"
      decimals="INF"
      id="f-459"
      unitRef="shares2">10916647</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <alvo:ReorganizationShareListingExpense contextRef="c-68" decimals="-5" id="f-460" unitRef="usd">83400000</alvo:ReorganizationShareListingExpense>
    <alvo:ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock contextRef="c-1" id="f-461">The fair value of shares issued was estimated based on a market price of $9.38 per share as of 15&#160;June 2022. &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;(in 000s) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class A Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;976,505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class B Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Alvotech Shares issued to OACB shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,226,505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value of Shares issued to OACB as of 15 June 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$56,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value of OACB Earn Out Shares issued to OACB as of 15 June 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Estimated fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adjusted net liabilities of OACB as of 15 June 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Difference &#x2013; being the share listing expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:ScheduleOfFairValueOfSharesIssuedAndNoncashShareListingExpenseTableTextBlock>
    <alvo:FairValueOfSharesIssuedMarketPricePerShare
      contextRef="c-73"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">9.38</alvo:FairValueOfSharesIssuedMarketPricePerShare>
    <alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2
      contextRef="c-74"
      decimals="INF"
      id="f-463"
      unitRef="shares">976505</alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2>
    <alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2
      contextRef="c-75"
      decimals="INF"
      id="f-464"
      unitRef="shares">5000000</alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2>
    <alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2
      contextRef="c-76"
      decimals="INF"
      id="f-465"
      unitRef="shares">1250000</alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2>
    <alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2
      contextRef="c-68"
      decimals="INF"
      id="f-466"
      unitRef="shares">7226505</alvo:FairValueOfSharesIssuedRecognizedAccordanceWithIfrs2>
    <alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2 contextRef="c-77" decimals="-3" id="f-467" unitRef="usd">56060000</alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2>
    <alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2 contextRef="c-76" decimals="-3" id="f-468" unitRef="usd">9100000</alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2>
    <alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2 contextRef="c-68" decimals="-3" id="f-469" unitRef="usd">65160000</alvo:FairValueOfSharesIssuedRecognizedAmountInAccordanceWithIfrs2>
    <alvo:AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2 contextRef="c-68" decimals="-3" id="f-470" unitRef="usd">-18251000</alvo:AdjustedNetLiabilitiesRecognizedAmountInAccordanceWithIfrs2>
    <alvo:ReorganizationShareListingExpense contextRef="c-68" decimals="-3" id="f-471" unitRef="usd">83411000</alvo:ReorganizationShareListingExpense>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination contextRef="c-78" decimals="-5" id="f-472" unitRef="usd">28500000</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <alvo:ExpenseCapitalized contextRef="c-78" decimals="-5" id="f-473" unitRef="usd">5600000</alvo:ExpenseCapitalized>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-78" decimals="-5" id="f-474" unitRef="usd">22900000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="c-1" id="f-475">&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2 Information about subsidiaries and joint ventures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.137%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Entity name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Principal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;activity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Issued and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;paid capital &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(presented in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;whole shares)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Place of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;establishment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Proportion of ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;and voting power held by &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Alvotech &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31.12.2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31.12.2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech hf&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,893,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Iceland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Germany GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,182&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Swiss AG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;153,930&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Hannover GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,983&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Malta Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Group Serv.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,450&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Malta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech USA Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;USA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech UK Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Group Serv.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Manco ehf&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Group Serv.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;215,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Iceland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech Biosciences India Private Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignafelagi&#xf0; S&#xe6;mundur hf&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,965,337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Iceland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech &amp;amp; CCHN Biopharmaceutical Co. Ltd*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biopharm.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,000,021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;*&lt;/span&gt;Alvotech &amp;amp; CCHN Biopharmaceutical Co. Ltd. is an unconsolidated joint venture (see Note 27).</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-79"
      decimals="INF"
      id="f-476"
      unitRef="shares">3893650</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-80" decimals="4" id="f-477" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-81" decimals="4" id="f-478" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-82"
      decimals="INF"
      id="f-479"
      unitRef="shares">31182</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-83" decimals="4" id="f-480" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-84" decimals="4" id="f-481" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-85"
      decimals="INF"
      id="f-482"
      unitRef="shares">153930</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-86" decimals="4" id="f-483" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-87" decimals="4" id="f-484" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-88"
      decimals="INF"
      id="f-485"
      unitRef="shares">29983</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-89" decimals="4" id="f-486" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-90" decimals="4" id="f-487" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-91"
      decimals="INF"
      id="f-488"
      unitRef="shares">80450</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-92" decimals="4" id="f-489" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-93" decimals="4" id="f-490" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-94"
      decimals="INF"
      id="f-491"
      unitRef="shares">10</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-95" decimals="4" id="f-492" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-96" decimals="4" id="f-493" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-97"
      decimals="INF"
      id="f-494"
      unitRef="shares">135</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-98" decimals="4" id="f-495" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-99" decimals="4" id="f-496" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-100"
      decimals="INF"
      id="f-497"
      unitRef="shares">215390</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-101" decimals="4" id="f-498" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-102" decimals="4" id="f-499" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-103"
      decimals="INF"
      id="f-500"
      unitRef="shares">96113</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-104" decimals="4" id="f-501" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-105" decimals="4" id="f-502" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-106"
      decimals="INF"
      id="f-503"
      unitRef="shares">12965337</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-107" decimals="4" id="f-504" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-108" decimals="4" id="f-505" unitRef="number">1.0000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-109"
      decimals="INF"
      id="f-506"
      unitRef="shares">110000021</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-110" decimals="4" id="f-507" unitRef="number">0.5000</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-111" decimals="4" id="f-508" unitRef="number">0.5000</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-112"
      decimals="INF"
      id="f-509"
      unitRef="number">0.379</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-113"
      decimals="INF"
      id="f-510"
      unitRef="number">0.337</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-114"
      decimals="INF"
      id="f-511"
      unitRef="number">0.407</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-115"
      decimals="INF"
      id="f-512"
      unitRef="number">0.358</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-116"
      decimals="INF"
      id="f-513"
      unitRef="number">0.284</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <alvo:MaximumPercentageOfOwnershipInterestHeldByEachShareholder
      contextRef="c-116"
      decimals="INF"
      id="f-514"
      unitRef="number">2.4</alvo:MaximumPercentageOfOwnershipInterestHeldByEachShareholder>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-117"
      decimals="INF"
      id="f-515"
      unitRef="number">0.235</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <alvo:MaximumPercentageOfOwnershipInterestHeldByEachShareholder
      contextRef="c-117"
      decimals="INF"
      id="f-516"
      unitRef="number">2.4</alvo:MaximumPercentageOfOwnershipInterestHeldByEachShareholder>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-5" id="f-517" unitRef="usd">-551700000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-6" decimals="-5" id="f-518" unitRef="usd">-513600000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-5" id="f-519" unitRef="usd">-101500000</ifrs-full:ProfitLoss>
    <ifrs-full:RetainedEarnings contextRef="c-5" decimals="-5" id="f-520" unitRef="usd">-2205800000</ifrs-full:RetainedEarnings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-5" id="f-521" unitRef="usd">11200000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssetsLiabilities contextRef="c-5" decimals="-5" id="f-522" unitRef="usd">-66100000</ifrs-full:CurrentAssetsLiabilities>
    <ifrs-full:IssueOfEquity contextRef="c-118" decimals="-6" id="f-523" unitRef="usd">166000000</ifrs-full:IssueOfEquity>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-119" decimals="-6" id="f-524" unitRef="usd">160000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-120"
      decimals="INF"
      id="f-525"
      unitRef="shares">10127132</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c-121"
      decimals="INF"
      id="f-526"
      unitRef="usdPerShare">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-120"
      decimals="2"
      id="f-527"
      unitRef="usdPerShare">16.41</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-120"
      decimals="0"
      id="f-528"
      unitRef="iskPerShare">2250</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c-1" id="f-529">Summary of significant accounting policies &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1 Basis of preparation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements of the Group have been prepared in accordance and in compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), which comprise all standards and interpretations approved by the IASB, and as adopted by the European Union ("EU"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All amendments to IFRSs issued by the IASB that are effective for annual periods that begin on or after 1 January 2023 have been adopted as further described within the footnotes to the consolidated financial statements. The Group has not adopted any standards or amendments to standards in issue that are available for early adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and financial liabilities which have been measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The consolidated financial statements are presented in U.S. Dollar ("USD") and all values are rounded to the nearest thousand unless otherwise indicated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.2 Basis of consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;has power over the investee; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;is exposed, or has rights, to variable returns from its involvement with the investee; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;has the ability to use its power to affect its returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company&#x2019;s voting rights in an investee are sufficient to give it power, including: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the size of the Company&#x2019;s holding of voting rights relative to the size and dispersion of holdings of the other vote holders; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;potential voting rights held by the Company, other vote holders or other parties; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;rights arising from other contractual arrangements; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders&#x2019; meetings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income or loss from the date the Company gains control until the date when the Company ceases to control the subsidiary. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All intra-group transactions, balances, income and expenses are eliminated in full in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3 Investments in joint ventures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To the extent the Group concludes that it does not control, and thus consolidate, a joint venture, the Group accounts for its interest in joint ventures using the equity method of accounting. As such, investments in a joint venture are initially recognized at cost and the carrying amount is subsequently adjusted for the Group&#x2019;s share of the profit or loss of the joint venture, as well as any distributions received from the joint venture. The Group carries its ownership interest in a joint venture as &#x201c;Investment in joint venture&#x201d; on the consolidated statements of financial position. The Group&#x2019;s profit or loss includes its share of the profit or loss of the joint venture and, to the extent applicable, other comprehensive income or loss for the Group includes its share of other comprehensive income or loss of the joint venture. The Group&#x2019;s share of a joint venture&#x2019;s profit or loss in a particular year is presented as &#x201c;Share of net loss of joint venture&#x201d; in the consolidated statements of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying amount of equity-accounted investments is assessed for impairment as a single asset. Impairment losses are incurred only if there is objective evidence of impairment as a result of loss events that have an impact on estimated future cash flows and that can be reliably estimated. Losses expected as a result of future events are not recognized. The Group  recognized an impairment loss of $21.5&#160;million related to its investment in the joint venture for the year ended 31&#160;December 2023. No impairment losses were recognized in 2022 or 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.4 Critical accounting judgments and key sources of estimation uncertainty &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of the consolidated financial statements in conformity with IFRS requires Group management to make judgments, estimates and assumptions about the reported amounts of assets, liabilities, income and expenses that are not readily apparent from other sources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and other factors that are considered to be relevant. Judgments and assumptions involving key estimates are primarily made in relation to the measurement and recognition of revenue, the impairment of the investment in the joint venture, the valuation of derivative financial liabilities, the valuation of restricted share units (&#x201c;RSUs&#x201d;), and the valuation of deferred tax assets. Apart from those involving estimations, critical accounting judgments include the Group&#x2019;s evaluation as to whether it controls its joint venture in China  and material uncertainties with respect to the Group&#x2019;s going concern assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Existing circumstances and assumptions may change due to events arising that are beyond the Group&#x2019;s control. Therefore, actual results may differ from these estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.5 Segment reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group operates and manages its business as one operating segment based on the manner in which the Chief Executive Officer, the Group&#x2019;s chief operating decision maker, assesses performance and allocates resources across the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.6 Revenue recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Product revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue from the sale of its biosimilar product to commercial partners, identified as the customer, when control is transferred, and the performance obligations have been satisfied. This is when the title passes to the customer, which is upon shipment of the product. At that point, the commercial partner has full discretion over the channel and price to sell the products. Revenue is recognized based on the net selling price from the commercial partners, which is considered to be the transaction price and includes estimated rebates, returns and chargebacks, and other forms of variable consideration recognized by the customer. Variable consideration is accounted for by the Company only to the extent that it is highly probable that a significant reversal in the revenue recognized will not occur. Variable consideration, which includes any adjustments to the net selling price, is estimated based on the most likely amount method on a contract-by-contract basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Out-licensing revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A significant part of the Group&#x2019;s revenue is generated from long-term out-license contracts which provide the customer with an exclusive right to market and sell products in a particular territory once such products are approved for commercialization. These contracts typically include the Group&#x2019;s promises to continue development of the underlying compound and to provide supply of the product to the customer upon commercialization. The Group concludes that the license, development services and commercial supply are separate performance obligations. This is because customers generally have the capabilities to perform the necessary development, manufacturing and commercialization activities on their own or with readily available resources and have the requisite expertise in the industry and the territory for which the license has been granted. Further, the intellectual property is generally in a later phase of development at the time the license is granted such that any subsequent development activities performed by the Group are not expected to significantly modify or transform the intellectual property. The fact that the Group is contractually obligated to perform development activities for and provide commercial supply to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;customer does not impact this conclusion. The Group&#x2019;s promise to provide commercial supply to its customers is contingent upon the achievement of regulatory approval in the particular territory for which the license has been granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consideration to which the Group is entitled pursuant to these contracts generally includes upfront payments and payments based upon the achievement of development and regulatory milestones. All contracts include a potential refund obligation whereby the Group must refund the consideration paid by the customer in the event of a technical failure or the occurrence of certain other matters that result in partial or full cancellation of the contract. As such, the entire transaction price is comprised of variable consideration, which is estimated using the most likely amount method due to the binary nature of the outcomes under these contracts. Such variable consideration is included in the transaction price only when it is highly probable that doing so will not result in a significant reversal of cumulative revenue recognized when the underlying uncertainty associated with the variable consideration is subsequently resolved. The Group does not account for a significant financing component since a substantial amount of consideration promised by the customer is variable and the amount or timing of that consideration varies on the basis of a future event that is not substantially within the control of either party. Certain contracts also include commercialization milestones upon the first commercial sale of a product in a particular territory, as well as royalties. Commercialization milestones and royalties are accounted for as sales-based royalties; therefore, such amounts are not included in the transaction price and recognized as revenue until the underlying sale that triggers the milestone or royalty occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upfront payments, when applicable, are received in advance of transferring control of all goods and services. Therefore, a portion of upfront payments is recorded as a contract liability upon receipt. Due to the existence of refund provisions, upfront payments and certain development milestone payments are generally included in the transaction price upon submission of the first clinical trial application to the respective regulatory agency, since it is at this point in time that a significant reversal of cumulative revenue recognized related to such payments is no longer highly probable. Other development and regulatory milestones may not be included in the transaction price until such milestones are achieved due to the degree of uncertainty associated with achieving these milestones. Contract liabilities are presented on the consolidated statements of financial position as either current or non-current based upon forecasted performance. In certain contracts, the Group may transfer control of goods and services, and thus recognize revenue, prior to having the right to invoice the customer. In these circumstances, the Group recognizes contract assets for revenue recognized, and subsequently reclasses the contract asset to trade receivables upon issuing an invoice and the right to consideration is only conditional on the passage of time. Contract assets are presented on the consolidated statements of financial position as either current or non-current based upon the expected timing of settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The standalone selling prices of the development services and the license to intellectual property are not directly observable and, therefore, are estimated. The standalone selling price of the development services is estimated based on the expected costs to be incurred during the development period, using various data points such as the underlying development budget, contractual milestones and performance completed at the time of entering into the contract with a customer. The standalone selling price of the license is estimated using the residual approach on the basis that the Group licenses intellectual property for a broad range of amounts and has not previously licensed intellectual property on a standalone basis. Therefore, the Group first allocates the transaction price to the development services and subsequently allocates the remainder of the transaction price to the license. If the product is still in early phase of development and the constraint on variable consideration has not been resolved, all the transaction price is allocated to the development service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The standalone selling price of the commercial supply is directly observable and the stated prices in the Group&#x2019;s supply contracts reflect the standalone selling price of such goods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The licenses to intellectual property are right of use licenses on the basis that the ongoing development work performed by the Group does not significantly affect the intellectual property to which the customer has rights. Therefore, control of the license transfers to the customer at the point in time when the right to use the license is granted to the customer. The license is generally granted to the customer at the time the contract is executed with the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group satisfies its performance obligation related to the development services over time as the Group&#x2019;s performance enhances the value of the licensed intellectual property controlled by the customer throughout the performance period. The Group recognizes revenue using a cost-based input measure since this measure best reflects the progress of the development services and, therefore, the pattern of transfer of control of the services to the customer. In certain instances, the Group may subcontract services to other parties for which the Group is ultimately responsible. Costs incurred for such subcontracted services are included in the Group&#x2019;s measure of progress for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;satisfying its performance obligation. Changes in the total estimated costs to be incurred in measuring the Group&#x2019;s progress toward satisfying its performance obligation may result in adjustments to cumulative revenue recognized at the time the change in estimate occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon the achievement of regulatory approval and the commencement of commercial sale of its products, the Group will satisfy its performance obligation related to commercial supply at the point in time when control of the manufactured product is transferred to the customer. Transfer of control for such goods will occur in accordance with the stated shipping terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group does not incur incremental costs of obtaining a contract with a customer that would require capitalization. Costs to fulfill performance obligations are not incurred in advance of performance and, as such, are expensed when incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other revenue primarily consists of clinical trial support services rendered by the Group for its customers, which is recognized as the service is provided. Revenue for such services is presented in the consolidated statements of profit or loss and other comprehensive income or loss net of any discounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.7 Cost of product revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cost of product revenue includes the cost of inventory sold, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as shipping and freight costs and royalty costs related to in-license agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.8 Research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development expenses primarily consist of personnel costs, material and other lab supply costs, facility costs and internal and external costs related to the execution of studies and other development program advancement initiatives. Such expenses also include costs incurred in preparation for commercial launch, such as designing and developing commercial-scale manufacturing capabilities and processes, quality control processes, production asset validation and other related activities. The costs also include amortization, depreciation and impairment losses related to software, property, plant and equipment, and right-of-use assets used in research and development activities and pre-commercial manufacturing and quality control activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;An internally generated intangible asset arising from the Group&#x2019;s development is recognized only if the Group can demonstrate: the technical feasibility of completing the intangible asset so that it will be available for use or sale; the intent to complete the intangible asset and use or sell it; how the intangible asset will generate probable future economic benefits; the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and the ability to measure reliably the expenditure attributable to the intangible asset during its development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amount initially recognized for internally-generated intangible assets is the sum of the expenditures incurred from the date when the intangible asset first meets the aforementioned recognition criteria. If an internally-generated intangible asset cannot be recognized, the related development expenditure is charged to profit or loss in the period in which it is incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expenditures related to research and development activities are generally recognized as an expense in the period in which they are incurred. The Company did not capitalize any development expenses as intangible assets during the years ended 31&#160;December 2023, 2022, and 2021 as not all the criteria in paragraph 57 of IAS 38 have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.9 General and administrative expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administration expenses primarily consist of personnel-related costs, including salaries and other related compensation expense, for corporate and other administrative and operational functions including finance, human resources, information technology and legal, as well as facility-related costs. These costs relate to the operation of the business and are not related to research and development initiatives. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expenditures related to general and administration activities are recognized as an expense in the period in which they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.10 Finance income and finance cost &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finance income consists of changes in the fair value of derivative financial liabilities and interest income. Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset&#x2019;s net carrying amount on initial recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finance cost consists of changes in the fair value of derivative financial liabilities, interest expense related to lease liabilities and borrowings, accretion of borrowings and amortization of deferred debt issue costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.11 Foreign currency translation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements are presented in U.S. Dollars, which is the Group&#x2019;s presentation currency. The Group maintains the financial statements of each entity within the Group in its respective functional currency. The majority of the Group&#x2019;s expenses are incurred in U.S. Dollars and Icelandic Krona, and the majority of the Company&#x2019;s cash and cash equivalents are held in a combination of Icelandic Krona, Euros and U.S. Dollars. Transactions in currencies other than the Group&#x2019;s presentation currency (foreign currencies) are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non- monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognized in profit or loss in the period in which they arise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exchange differences arising on translation of a foreign controlled subsidiary are recognized in other comprehensive income or loss and accumulated in a translation reserve within equity. The cumulative translation amount is reclassified to profit or loss if and when the net investment in the foreign controlled subsidiary is disposed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.12 Fair value measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group measures certain financial liabilities at fair value through profit or loss (FVTPL) at each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure the fair values of such financial liabilities, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques, as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 1: quoted prices in active markets for identical assets and liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (e.g., prices) or indirectly (e.g., derived from prices); and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 3: inputs for the asset or liability that are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying amounts of cash and cash equivalents, restricted cash, trade receivables, other current assets, contract assets, trade and other payables and other current liabilities in the Group&#x2019;s consolidated statements of financial position approximate their fair value because of the short maturities and nature of these instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For liabilities that are measured at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by reassessing the inputs used in determining fair value at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.13 Goodwill and other intangible assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Goodwill and business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquisitions are first reviewed to determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not meet the definition of a business, the Group will account for the transaction as an asset acquisition. If the definition of a business combination is met, the Group will account for the transaction using the acquisition method of accounting. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange fo&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;r control of the acquiree. Acquisition-related costs are recognized in the consolidated statements of profit or loss and other comprehensive income or loss as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill represents the excess of the purchase price of the business combination over the Group&#x2019;s interest in the net fair value of the identifiable assets, liabilities, contingent liabilities, the amount of any noncontrolling interests in the acquiree and the fair value of the acquirer&#x2019;s previously held equity interest in the acquiree. Goodwill is reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If the initial accounting for a business combination is incomplete by the end of the reporting period in which the business combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period, or as additional assets or liabilities are recognized, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group did not complete any business combinations during the years ended 31&#160;December 2023. Refer to Note 1.1 for the Business Combination completed during the year ended 31&#160;December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other intangible assets consist of software, customer relationships, and intellectual property rights. Intangible assets acquired in a business combination are identified and recognized separately from goodwill if they satisfy the definition of an intangible asset and their fair values can be reliably measured. The cost of intangible assets is their fair value at the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets with finite useful lives are reported at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over an asset&#x2019;s estimated useful life. The estimated useful life and amortization method are reviewed at each balance sheet date, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The following useful lives are used in the calculation of amortization: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intellectual property rights*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;From launch date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets with indefinite useful lives are reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.14 Income tax &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Income tax includes the current tax and deferred tax charge recorded in the consolidated statements of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Current tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The current tax expense is based on taxable profit for the year. Taxable profit differs from &#x2018;profit before tax&#x2019; as reported in the consolidated statements of profit or loss and other comprehensive income or loss because it excludes items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group&#x2019;s current tax expense is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accruals for tax contingencies are made when it is not probable that a tax authority will accept the tax position, based upon management&#x2019;s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Accruals for tax contingencies are measured using either the most likely amount or the expected value amount depending on which method the entity expects to better predict the resolution of the uncertainty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Deferred tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax is provided in full for all temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit, except to the extent the temporary difference arises from: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The initial recognition of an asset or a liability in a transaction that is not a business combination and that affects neither the taxable profit nor accounting profit; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The initial recognition of residual goodwill (for deferred tax liabilities only); or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Investments in subsidiaries, branches, associates and joint ventures, where the Group is able to control the timing of the reversal of the temporary difference and it is not probable that it will reverse in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and deferred tax assets reflects the tax consequences that would follow from the manner in which the Group expects, at the balance sheet date, to recover or settle the carrying amount of the assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax is charged or credited to the consolidated statements of profit or loss and other comprehensive income or loss, except when the tax arises from a business combination or it relates to items charged or credited directly to equity, in which case the deferred tax is also taken directly to equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis in that taxation authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.15 Property, plant and equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment is recognized as an asset when it is probable that future economic benefits associated with the asset will flow to the Group and the cost of the asset can be measured in a reliable manner. Property, plant and equipment which qualifies for recognition as an asset are initially measured at cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The cost of property, plant and equipment includes an asset&#x2019;s purchase price and any directly attributable costs of bringing the asset to working condition for its intended use. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation is calculated and recognized as an expense on a straight-line basis over an asset&#x2019;s estimated useful life. The estimated useful lives, residual values and depreciation method are reviewed at each balance sheet date, with the effect of any changes in estimate accounted for on a prospective basis. The following useful lives are used in the calculation of depreciation: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facility equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5-20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain of the Group&#x2019;s property, plant and equipment assets have been pledged to secure borrowings as further described in Note 21. Significant disposals of pledged assets are subject to lender approval. Upon disposal or retirement of an asset, the difference between the sales proceeds, if applicable, and the carrying amount of the asset is recognized in the consolidated statements of profit or loss and other comprehensive income or loss at the time of disposal or retirement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At the end of each reporting period, or sooner if events triggering an interim impairment assessment occur, the Group reviews the carrying amounts of its property, plant and equipment to determine whether there is any indication that the value of such assets are impaired. Triggering events that warrant an interim impairment assessment include, but are not limited to, the technical obsolescence of equipment or failure of such equipment to meet regulatory requirements. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss and the carrying amount of the asset is reduced to its recoverable amount, which is the higher of fair value less costs of disposal and value in use. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.16 Inventories &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories, which consist of raw materials and supplies, work in progress and finished goods are stated at the lower of cost or net realizable value. Net realizable value is the expected sales price less completion costs and costs to be incurred in marketing, selling and distributing the inventory. Cost is calculated using the weighted average cost method or the first-in,first-out method, depending on the nature of the inventory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories include direct costs for raw materials and supplies and, as applicable, direct and indirect labor and overhead expenses that have been incurred to bring inventories to their present location and condition.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If the net realizable value is lower than the carrying amount, a write-down of inventory is recognized for the amount by which the carrying amount exceeds net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group does not pledge inventories as collateral to secure its liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.17 Financial assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Recognition of financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial assets are recognized when the Group becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets, other than financial assets measured at FVTPL, are added to or deducted from the fair value of the financial assets, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets at FVTPL are recognized immediately in profit or loss. There were no transaction costs related to the acquisition of financials assets in 2023, 2022, or 2021. All of the Group&#x2019;s financial assets are measured at amortized cost as of 31&#160;December 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial assets measured at amortized cost are debt instruments that give rise to contractual cash flows that are solely payments of principal and interest on the principal amount outstanding. The Group&#x2019;s financial assets measured at amortized cost are trade receivables, certain other current assets, receivables from related parties, restricted cash and cash and cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest income is recognized by applying the effective interest rate, except for short-term receivables when the effect of discounting is immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Impairment of financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group recognizes a loss allowance for expected credit losses ("ECL") on its trade receivables and other debt instruments that are measured at amortized cost. In addition, although contract assets are not financial assets, a loss allowance for ECL are also recognized for such assets. ECL is based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group always recognizes lifetime ECL for trade receivables and contract assets. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group&#x2019;s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecasted direction of conditions at the reporting date, including time value of money where appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group writes off a financial asset when there is no reasonable expectation of recovery, such as information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. A trade receivable or contract asset that is considered uncollectible is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognized in profit or loss. The Group did not write off any trade receivables or contract assets during the years ended 31&#160;December 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group estimates impairment for related party receivables on an individual basis. No impairment is recognized for restricted cash or cash and cash equivalents as management has estimated that the effects of any calculated ECL would be immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Derecognition of financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Group neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Group recognizes its retained interest in the asset as well as an associated liability. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On derecognition of a financial asset, the difference between the asset&#x2019;s carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognized in other comprehensive income or loss and accumulated in equity is recognized in profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.18 Financial liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s financial liabilities consist of trade and other payables, certain other current liabilities loans and borrowings, lease liabilities, derivative financial instruments, long-term incentive plans, share appreciation right plans and other long-term liability to a related party. All financial liabilities are initially measured at fair value. Loans and borrowings are recorded net of directly attributable transaction costs and less the value attributable to any embedded derivative financial instruments, if applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group derecognizes financial liabilities when, and only when, the Group&#x2019;s obligations are discharged, cancelled, substantially modified or have expired. Additionally, management elected, as part of its accounting policy, to recognize the difference between the carrying amount of the financial liabilities and the fair value of the consideration paid for the extinguishment in the consolidated statement of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial liabilities subsequently measured at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;After initial recognition, financial liabilities other than derivative financial instruments and awards issued pursuant to long-term incentive plans are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that discounts all estimated future cash payments through the expected life of the financial liability, or a shorter period if appropriate, to the amortized cost of a financial liability. The effective interest rate includes the effects of any discount or premium on acquisition of the financial liability, as well as any fees or costs incurred upon acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial liabilities subsequently measured at FVTPL&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Derivative financial instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain rights and features pursuant to borrowing arrangements and other contracts may provide the counterparty with one or more financial instruments that need to be evaluated and potentially accounted for separately by the Group. These financial instruments are either embedded in a host instrument or are treated as a separate financial instrument if they are contractually transferable independent from the host instrument. Such rights and features pursuant to the Group&#x2019;s contracts with both third parties and related parties include earn out rights, conversion rights and warrant rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equity conversion features within host debt instruments that meet the definition of a derivative and have economic and risk characteristics that are not closely related to the host instrument are embedded derivatives that are separated from the host instrument and accounted for separately. As part of the accounting for embedded derivatives or separate financial instruments, management considers the appropriate accounting classification under IAS 32. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Embedded derivatives and separate financial instruments that meet the fixed-for-fixed criteria are classified as equity and initially measured at fair value. Warrant rights that provide the holder with an option to purchase ordinary shares at a specified price or pursuant to a specified formula are generally separate derivative financial instruments that are accounted for as derivative liabilities. Earn Out Shares grant the holder with a variable number of Ordinary Shares based on certain vesting conditions tied to the stock price and are accounted for as derivative liabilities. In the event that the fair value of any derivative liabilities, determined using unobservable inputs, exceeds the transaction price of a borrowing arrangement, the Group records a deferred loss at the inception of the borrowing arrangement for the difference between the fair value of the derivative liabilities and the transaction price of the borrowing arrangement. Such deferred losses are recognized over the term of the related borrowing arrangement using the straight-line method of amortization. The deferred loss is netted against derivative financial liabilities on the consolidated statements of financial position. Amortization of the deferred loss is recognized as a component of &#x201c;Finance costs&#x201d; in the consolidated statements of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group recognized derivative liabilities related to the Predecessor Earn Out Shares, OACB Earn Out Shares and assumed OACB warrants. Additionally, the Group recognized an embedded derivative for the conversion feature associated with the Tranche A Convertible Bonds, as further described in Note 21. These features are liability-classified, rather than equity-classified, because the Group is obligated to issue a variable number of ordinary shares to the holder upon conversion or exercise of the feature. Therefore, these derivative liabilities were initially recorded at fair value and remeasured to fair value at each reporting period with gains and losses arising from changes in the fair value recognized in finance income or finance costs, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of the derivative liabilities were determined using a valuation approach that incorporated a range of inputs that are both observable and unobservable in nature. The inputs used in the initial and subsequent fair value measurements predominantly relate to (i) the price of the Group&#x2019;s Ordinary Shares (ii) the volatility of the Group&#x2019;s Ordinary Shares, (ii) a risky discount rate corresponding to the credit risk associated with the repayment of the host debt instruments, and (iii) the probabilities of each derivative being exercised by the holder and the timing of such exercises. The probabilities are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group will derecognize any derivative liabilities if and when the rights are exercised by the holders or the time period during which the rights can be exercised expires. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Liabilities to related parties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The majority of the Group&#x2019;s liabilities to related parties arose from its acquisition of rights for the commercialization of the Group&#x2019;s biosimilar Adalimumab product in certain territories in Asia from Lotus Pharmaceutical Co. Ltd., a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related party, during the year ended 31&#160;December 2021. Pursuant to the terms of the asset acquisition, the Group made an upfront payment of $1.9 million and is required to pay $7.4 million upon the commercial launch of Adalimumab in China which became due on 31 December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Long-term incentive plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Share appreciation rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group issued to certain current and former employees share appreciation rights ("SARs") that require settlement in connection with the occurrence of specified, future triggering events. Grants occurred from 2015 through 2020. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. The individuals retain their vested awards upon termination of employment with the Group. Settlement amounts are determined by the change in the Group&#x2019;s market value from the grant date of the SAR until the triggering events occur. The SARs do not expire at a specific date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the terms of the SAR agreements, management determined that the Group cannot avoid paying cash to settle the awards and, therefore, SARs are liability-classified in the consolidated statements of financial position. Accordingly, SARs were recorded at fair value and were subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. The fair value of the SARs was determined using the Black-Scholes-Merton pricing model. In connection with the closing of the Business Combination, the Company reached a settlement agreement for share appreciation rights previously awarded to certain current and former employees. The remaining share appreciation rights were settled through the issuance of fully vested RSUs under the Management Incentive Plan on 1 December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Employee incentive plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group also sponsors an employee incentive plan for certain qualifying employees. Under the plans, such employees are entitled to cash payments upon achievement of key milestones, such as a research and development milestone or the occurrence of an exit event. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. Since the Group cannot avoid paying cash to settle the awards, the employee incentive plan is liability-classified in the consolidated statements of financial position. Accordingly, awards issued pursuant to the employee incentive plan are recorded at fair value and are subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. Employee incentive plan liabilities are presented as either current or non-current on the consolidated statements of financial position based on the anticipated timing of settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the employee incentive plan awards is determined by estimating the probability of success in reaching the specified milestones and other levers, such as the anticipated timing of potential milestone achievement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Management Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group can issue share options, restricted share units (&#x201c;RSUs&#x201d;), and other share-based awards under the Company&#x2019;s new incentive plan (the &#x201c;Management Incentive Plan&#x201d;) which was approved by the Board in June 2022. Awards issued under the Management Incentive Plan are accounted for in accordance with IFRS 2. Share-based payments are classified as equity-settled share-based payments as the Company intends to settle the awards with equity and has the commercial substance to do so. Share-based payments are measured at the grant date fair value of the instruments issued and recognized over the expected vesting periods. The number of shares expected to vest are reviewed and adjusted at the end of each reporting period such that the amount of expense recognized shall be based on the number of equity instruments that will eventually vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.19 Litigation and other contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group may, from time to time, become involved in legal proceedings arising out of the normal course of its operations. For instance, as a developer and manufacturer of biosimilars, the Group may be subject to lawsuits alleging patent infringement or other similar claims filed by the reference product sponsor. Similarly, the Group may utilize patent challenge procedures to challenge the validity, enforceability or infringement of the reference product &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;sponsor&#x2019;s patents. Other parties may also file patent infringement claims against the Group alleging that the Group&#x2019;s products or manufacturing process techniques infringe their patents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group establishes reserves for specific legal matters when it determines that the likelihood of an unfavorable outcome is probable and the loss is reasonably estimable. When such conditions are not met for a specific legal matter, no reserve is established. Although management currently believes that resolving claims against the Group, including claims where an unfavorable outcome is reasonably possible, will not have a material impact on the liquidity, results of operations, or financial condition of the Group, these matters are subject to inherent uncertainties and management&#x2019;s view of these matters may change in the future. It is possible that an unfavorable outcome of a lawsuit or other contingency could have a material impact on the liquidity, results of operations, or financial condition of the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount of loss can be reasonably estimated. Accruals are based only on information available at the time of the assessment, due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Group&#x2019;s results of operations in a given period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group maintains liability insurance coverages for various claims and exposures. The Group&#x2019;s insurance coverage limits its maximum exposure on claims; however, the Group is responsible for any uninsured portion of losses. Management believes that present insurance coverage is sufficient to cover potential exposures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.20 Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for those with a lease term of twelve months or less and leases of low value assets. For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The Group&#x2019;s leased assets consist of various real estate, fleet and equipment leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets reflect the initial measurement of the lease liability, lease payments made at or before the lease commencement date and any initial direct costs less lease incentives that may have been received by the Group. These assets are subsequently measured at cost less accumulated depreciation, impairment losses and remeasurements of the underlying lease liability. Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the underlying asset. If a lease transfers ownership of the underlying asset to the Group or the lease includes a purchase option that the Group is reasonably certain to exercise, the related right-of-use asset is depreciated over the useful life of the underlying asset. Depreciation starts at the commencement date of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate, which is the rate of interest that the Group would need to pay to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term in a similar economic environment based on information available at the commencement date of the lease. The lease payments included in the measurement of the lease liability comprise fixed payments (including in-substance fixed payments) less any incentives, variable lease payments that depend on an index or rate, expected residual guarantees and the exercise price of purchase options reasonably certain to be exercised by the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability, using the effective interest method, and by reducing the carrying amount to reflect payments made during the lease term. The Group remeasures the lease liability if the lease term has changed, when lease payments based on an index or rate change or when a lease contract is modified and the modification is not accounted for as a separate lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable payments that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As a practical expedient, lessees are not required to separate non-lease components from lease components, and instead account for any lease and associated non-lease components as a single lease component. The Group has used this practical expedient. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.21 Loss per share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Holders of the Predecessor Earn Out Shares and OACB Earn Out Shares have equal dividend and participation rights to the ordinary shareholders. However, these participating securities are classified as liabilities and as such, the shares held are not included in the weighted average number of ordinary shares outstanding in the basic loss per share calculation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The calculation of basic loss per share is based on the loss for the year attributable to ordinary shareholders of the Group and the weighted average number of ordinary shares outstanding during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted loss per share is computed by dividing the loss for the year attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding in the basic loss per share calculation, both of which are adjusted for the effects of all dilutive potential ordinary shares. Antidilutive effects of potential ordinary shares, which result in an increase in earnings per share or a reduction in loss per share, are not recognized in the computation of diluted loss per share.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-530">Basis of preparation &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements of the Group have been prepared in accordance and in compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), which comprise all standards and interpretations approved by the IASB, and as adopted by the European Union ("EU"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All amendments to IFRSs issued by the IASB that are effective for annual periods that begin on or after 1 January 2023 have been adopted as further described within the footnotes to the consolidated financial statements. The Group has not adopted any standards or amendments to standards in issue that are available for early adoption. &lt;/span&gt;&lt;/div&gt;The consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and financial liabilities which have been measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The consolidated financial statements are presented in U.S. Dollar ("USD") and all values are rounded to the nearest thousand unless otherwise indicated.</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="c-1" id="f-531">Basis of consolidation &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;has power over the investee; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;is exposed, or has rights, to variable returns from its involvement with the investee; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;has the ability to use its power to affect its returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company&#x2019;s voting rights in an investee are sufficient to give it power, including: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the size of the Company&#x2019;s holding of voting rights relative to the size and dispersion of holdings of the other vote holders; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;potential voting rights held by the Company, other vote holders or other parties; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;rights arising from other contractual arrangements; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders&#x2019; meetings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income or loss from the date the Company gains control until the date when the Company ceases to control the subsidiary. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. &lt;/span&gt;&lt;/div&gt;All intra-group transactions, balances, income and expenses are eliminated in full in consolidation.</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentsInJointVentures contextRef="c-1" id="f-532">Investments in joint ventures &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To the extent the Group concludes that it does not control, and thus consolidate, a joint venture, the Group accounts for its interest in joint ventures using the equity method of accounting. As such, investments in a joint venture are initially recognized at cost and the carrying amount is subsequently adjusted for the Group&#x2019;s share of the profit or loss of the joint venture, as well as any distributions received from the joint venture. The Group carries its ownership interest in a joint venture as &#x201c;Investment in joint venture&#x201d; on the consolidated statements of financial position. The Group&#x2019;s profit or loss includes its share of the profit or loss of the joint venture and, to the extent applicable, other comprehensive income or loss for the Group includes its share of other comprehensive income or loss of the joint venture. The Group&#x2019;s share of a joint venture&#x2019;s profit or loss in a particular year is presented as &#x201c;Share of net loss of joint venture&#x201d; in the consolidated statements of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;The carrying amount of equity-accounted investments is assessed for impairment as a single asset. Impairment losses are incurred only if there is objective evidence of impairment as a result of loss events that have an impact on estimated future cash flows and that can be reliably estimated. Losses expected as a result of future events are not recognized. The Group  recognized an impairment loss of $21.5&#160;million related to its investment in the joint venture for the year ended 31&#160;December 2023. No impairment losses were recognized in 2022 or 2021.</ifrs-full:DescriptionOfAccountingPolicyForInvestmentsInJointVentures>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-1" decimals="-5" id="f-533" unitRef="usd">21500000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-6" decimals="-5" id="f-534" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-7" decimals="-5" id="f-535" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <alvo:DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock contextRef="c-1" id="f-536">Critical accounting judgments and key sources of estimation uncertainty &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of the consolidated financial statements in conformity with IFRS requires Group management to make judgments, estimates and assumptions about the reported amounts of assets, liabilities, income and expenses that are not readily apparent from other sources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and other factors that are considered to be relevant. Judgments and assumptions involving key estimates are primarily made in relation to the measurement and recognition of revenue, the impairment of the investment in the joint venture, the valuation of derivative financial liabilities, the valuation of restricted share units (&#x201c;RSUs&#x201d;), and the valuation of deferred tax assets. Apart from those involving estimations, critical accounting judgments include the Group&#x2019;s evaluation as to whether it controls its joint venture in China  and material uncertainties with respect to the Group&#x2019;s going concern assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Existing circumstances and assumptions may change due to events arising that are beyond the Group&#x2019;s control. Therefore, actual results may differ from these estimates. &lt;/span&gt;&lt;/div&gt;The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.</alvo:DescriptionOfAccountingPolicyForCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="c-1" id="f-537">Segment reporting The Group operates and manages its business as one operating segment based on the manner in which the Chief Executive Officer, the Group&#x2019;s chief operating decision maker, assesses performance and allocates resources across the Group.</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <alvo:NumberOfOperatingSegments1
      contextRef="c-5"
      decimals="INF"
      id="f-538"
      unitRef="segement">1</alvo:NumberOfOperatingSegments1>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c-1" id="f-539">Revenue recognition &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Product revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue from the sale of its biosimilar product to commercial partners, identified as the customer, when control is transferred, and the performance obligations have been satisfied. This is when the title passes to the customer, which is upon shipment of the product. At that point, the commercial partner has full discretion over the channel and price to sell the products. Revenue is recognized based on the net selling price from the commercial partners, which is considered to be the transaction price and includes estimated rebates, returns and chargebacks, and other forms of variable consideration recognized by the customer. Variable consideration is accounted for by the Company only to the extent that it is highly probable that a significant reversal in the revenue recognized will not occur. Variable consideration, which includes any adjustments to the net selling price, is estimated based on the most likely amount method on a contract-by-contract basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Out-licensing revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A significant part of the Group&#x2019;s revenue is generated from long-term out-license contracts which provide the customer with an exclusive right to market and sell products in a particular territory once such products are approved for commercialization. These contracts typically include the Group&#x2019;s promises to continue development of the underlying compound and to provide supply of the product to the customer upon commercialization. The Group concludes that the license, development services and commercial supply are separate performance obligations. This is because customers generally have the capabilities to perform the necessary development, manufacturing and commercialization activities on their own or with readily available resources and have the requisite expertise in the industry and the territory for which the license has been granted. Further, the intellectual property is generally in a later phase of development at the time the license is granted such that any subsequent development activities performed by the Group are not expected to significantly modify or transform the intellectual property. The fact that the Group is contractually obligated to perform development activities for and provide commercial supply to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;customer does not impact this conclusion. The Group&#x2019;s promise to provide commercial supply to its customers is contingent upon the achievement of regulatory approval in the particular territory for which the license has been granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consideration to which the Group is entitled pursuant to these contracts generally includes upfront payments and payments based upon the achievement of development and regulatory milestones. All contracts include a potential refund obligation whereby the Group must refund the consideration paid by the customer in the event of a technical failure or the occurrence of certain other matters that result in partial or full cancellation of the contract. As such, the entire transaction price is comprised of variable consideration, which is estimated using the most likely amount method due to the binary nature of the outcomes under these contracts. Such variable consideration is included in the transaction price only when it is highly probable that doing so will not result in a significant reversal of cumulative revenue recognized when the underlying uncertainty associated with the variable consideration is subsequently resolved. The Group does not account for a significant financing component since a substantial amount of consideration promised by the customer is variable and the amount or timing of that consideration varies on the basis of a future event that is not substantially within the control of either party. Certain contracts also include commercialization milestones upon the first commercial sale of a product in a particular territory, as well as royalties. Commercialization milestones and royalties are accounted for as sales-based royalties; therefore, such amounts are not included in the transaction price and recognized as revenue until the underlying sale that triggers the milestone or royalty occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upfront payments, when applicable, are received in advance of transferring control of all goods and services. Therefore, a portion of upfront payments is recorded as a contract liability upon receipt. Due to the existence of refund provisions, upfront payments and certain development milestone payments are generally included in the transaction price upon submission of the first clinical trial application to the respective regulatory agency, since it is at this point in time that a significant reversal of cumulative revenue recognized related to such payments is no longer highly probable. Other development and regulatory milestones may not be included in the transaction price until such milestones are achieved due to the degree of uncertainty associated with achieving these milestones. Contract liabilities are presented on the consolidated statements of financial position as either current or non-current based upon forecasted performance. In certain contracts, the Group may transfer control of goods and services, and thus recognize revenue, prior to having the right to invoice the customer. In these circumstances, the Group recognizes contract assets for revenue recognized, and subsequently reclasses the contract asset to trade receivables upon issuing an invoice and the right to consideration is only conditional on the passage of time. Contract assets are presented on the consolidated statements of financial position as either current or non-current based upon the expected timing of settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The standalone selling prices of the development services and the license to intellectual property are not directly observable and, therefore, are estimated. The standalone selling price of the development services is estimated based on the expected costs to be incurred during the development period, using various data points such as the underlying development budget, contractual milestones and performance completed at the time of entering into the contract with a customer. The standalone selling price of the license is estimated using the residual approach on the basis that the Group licenses intellectual property for a broad range of amounts and has not previously licensed intellectual property on a standalone basis. Therefore, the Group first allocates the transaction price to the development services and subsequently allocates the remainder of the transaction price to the license. If the product is still in early phase of development and the constraint on variable consideration has not been resolved, all the transaction price is allocated to the development service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The standalone selling price of the commercial supply is directly observable and the stated prices in the Group&#x2019;s supply contracts reflect the standalone selling price of such goods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The licenses to intellectual property are right of use licenses on the basis that the ongoing development work performed by the Group does not significantly affect the intellectual property to which the customer has rights. Therefore, control of the license transfers to the customer at the point in time when the right to use the license is granted to the customer. The license is generally granted to the customer at the time the contract is executed with the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group satisfies its performance obligation related to the development services over time as the Group&#x2019;s performance enhances the value of the licensed intellectual property controlled by the customer throughout the performance period. The Group recognizes revenue using a cost-based input measure since this measure best reflects the progress of the development services and, therefore, the pattern of transfer of control of the services to the customer. In certain instances, the Group may subcontract services to other parties for which the Group is ultimately responsible. Costs incurred for such subcontracted services are included in the Group&#x2019;s measure of progress for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;satisfying its performance obligation. Changes in the total estimated costs to be incurred in measuring the Group&#x2019;s progress toward satisfying its performance obligation may result in adjustments to cumulative revenue recognized at the time the change in estimate occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon the achievement of regulatory approval and the commencement of commercial sale of its products, the Group will satisfy its performance obligation related to commercial supply at the point in time when control of the manufactured product is transferred to the customer. Transfer of control for such goods will occur in accordance with the stated shipping terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group does not incur incremental costs of obtaining a contract with a customer that would require capitalization. Costs to fulfill performance obligations are not incurred in advance of performance and, as such, are expensed when incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Other revenue&lt;/span&gt;&lt;/div&gt;Other revenue primarily consists of clinical trial support services rendered by the Group for its customers, which is recognized as the service is provided. Revenue for such services is presented in the consolidated statements of profit or loss and other comprehensive income or loss net of any discounts.</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <alvo:DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock contextRef="c-1" id="f-540">Cost of product revenue Cost of product revenue includes the cost of inventory sold, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as shipping and freight costs and royalty costs related to in-license agreements.</alvo:DescriptionOfAccountingPolicyForCostOfProductRevenueExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c-1" id="f-541">Research and development expenses &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development expenses primarily consist of personnel costs, material and other lab supply costs, facility costs and internal and external costs related to the execution of studies and other development program advancement initiatives. Such expenses also include costs incurred in preparation for commercial launch, such as designing and developing commercial-scale manufacturing capabilities and processes, quality control processes, production asset validation and other related activities. The costs also include amortization, depreciation and impairment losses related to software, property, plant and equipment, and right-of-use assets used in research and development activities and pre-commercial manufacturing and quality control activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;An internally generated intangible asset arising from the Group&#x2019;s development is recognized only if the Group can demonstrate: the technical feasibility of completing the intangible asset so that it will be available for use or sale; the intent to complete the intangible asset and use or sell it; how the intangible asset will generate probable future economic benefits; the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and the ability to measure reliably the expenditure attributable to the intangible asset during its development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amount initially recognized for internally-generated intangible assets is the sum of the expenditures incurred from the date when the intangible asset first meets the aforementioned recognition criteria. If an internally-generated intangible asset cannot be recognized, the related development expenditure is charged to profit or loss in the period in which it is incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expenditures related to research and development activities are generally recognized as an expense in the period in which they are incurred. The Company did not capitalize any development expenses as intangible assets during the years ended 31&#160;December 2023, 2022, and 2021 as not all the criteria in paragraph 57 of IAS 38 have been met.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="c-1" id="f-542">General and administrative expenses &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administration expenses primarily consist of personnel-related costs, including salaries and other related compensation expense, for corporate and other administrative and operational functions including finance, human resources, information technology and legal, as well as facility-related costs. These costs relate to the operation of the business and are not related to research and development initiatives. &lt;/span&gt;&lt;/div&gt;Expenditures related to general and administration activities are recognized as an expense in the period in which they are incurred.</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="c-1" id="f-543">Finance income and finance cost &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finance income consists of changes in the fair value of derivative financial liabilities and interest income. Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset&#x2019;s net carrying amount on initial recognition. &lt;/span&gt;&lt;/div&gt;Finance cost consists of changes in the fair value of derivative financial liabilities, interest expense related to lease liabilities and borrowings, accretion of borrowings and amortization of deferred debt issue costs.</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c-1" id="f-544">Foreign currency translation &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements are presented in U.S. Dollars, which is the Group&#x2019;s presentation currency. The Group maintains the financial statements of each entity within the Group in its respective functional currency. The majority of the Group&#x2019;s expenses are incurred in U.S. Dollars and Icelandic Krona, and the majority of the Company&#x2019;s cash and cash equivalents are held in a combination of Icelandic Krona, Euros and U.S. Dollars. Transactions in currencies other than the Group&#x2019;s presentation currency (foreign currencies) are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non- monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognized in profit or loss in the period in which they arise. &lt;/span&gt;&lt;/div&gt;Exchange differences arising on translation of a foreign controlled subsidiary are recognized in other comprehensive income or loss and accumulated in a translation reserve within equity. The cumulative translation amount is reclassified to profit or loss if and when the net investment in the foreign controlled subsidiary is disposed.</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c-1" id="f-545">Fair value measurements &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group measures certain financial liabilities at fair value through profit or loss (FVTPL) at each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure the fair values of such financial liabilities, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques, as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 1: quoted prices in active markets for identical assets and liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (e.g., prices) or indirectly (e.g., derived from prices); and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 3: inputs for the asset or liability that are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying amounts of cash and cash equivalents, restricted cash, trade receivables, other current assets, contract assets, trade and other payables and other current liabilities in the Group&#x2019;s consolidated statements of financial position approximate their fair value because of the short maturities and nature of these instruments. &lt;/span&gt;&lt;/div&gt;For liabilities that are measured at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by reassessing the inputs used in determining fair value at the end of each reporting period.</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-546">Goodwill and other intangible assets &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Goodwill and business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquisitions are first reviewed to determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not meet the definition of a business, the Group will account for the transaction as an asset acquisition. If the definition of a business combination is met, the Group will account for the transaction using the acquisition method of accounting. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange fo&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;r control of the acquiree. Acquisition-related costs are recognized in the consolidated statements of profit or loss and other comprehensive income or loss as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill represents the excess of the purchase price of the business combination over the Group&#x2019;s interest in the net fair value of the identifiable assets, liabilities, contingent liabilities, the amount of any noncontrolling interests in the acquiree and the fair value of the acquirer&#x2019;s previously held equity interest in the acquiree. Goodwill is reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If the initial accounting for a business combination is incomplete by the end of the reporting period in which the business combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period, or as additional assets or liabilities are recognized, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group did not complete any business combinations during the years ended 31&#160;December 2023. Refer to Note 1.1 for the Business Combination completed during the year ended 31&#160;December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other intangible assets consist of software, customer relationships, and intellectual property rights. Intangible assets acquired in a business combination are identified and recognized separately from goodwill if they satisfy the definition of an intangible asset and their fair values can be reliably measured. The cost of intangible assets is their fair value at the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets with finite useful lives are reported at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over an asset&#x2019;s estimated useful life. The estimated useful life and amortization method are reviewed at each balance sheet date, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The following useful lives are used in the calculation of amortization: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intellectual property rights*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;From launch date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets with indefinite useful lives are reviewed for impairment at least annually, and whenever there is an indication that the asset may be impaired. An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. The value in use calculation is performed using discounted expected future cash flows. The discount rate applied to these cash flows is based on the weighted average cost of capital and reflects current market assessments of the time value of money.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <alvo:DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-547">The following useful lives are used in the calculation of amortization: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intellectual property rights*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;From launch date&lt;/span&gt;&lt;/div&gt;</alvo:DisclosureOfEstimatedUsefulLivesOtherIntangibleAssetsExplanatoryTableTextBlock>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-122" id="f-548">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-123" id="f-549">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-124" id="f-550">P7Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-125" id="f-551">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c-1" id="f-552">Income tax &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Income tax includes the current tax and deferred tax charge recorded in the consolidated statements of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Current tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The current tax expense is based on taxable profit for the year. Taxable profit differs from &#x2018;profit before tax&#x2019; as reported in the consolidated statements of profit or loss and other comprehensive income or loss because it excludes items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group&#x2019;s current tax expense is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accruals for tax contingencies are made when it is not probable that a tax authority will accept the tax position, based upon management&#x2019;s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Accruals for tax contingencies are measured using either the most likely amount or the expected value amount depending on which method the entity expects to better predict the resolution of the uncertainty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Deferred tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax is provided in full for all temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit, except to the extent the temporary difference arises from: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The initial recognition of an asset or a liability in a transaction that is not a business combination and that affects neither the taxable profit nor accounting profit; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The initial recognition of residual goodwill (for deferred tax liabilities only); or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Investments in subsidiaries, branches, associates and joint ventures, where the Group is able to control the timing of the reversal of the temporary difference and it is not probable that it will reverse in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and deferred tax assets reflects the tax consequences that would follow from the manner in which the Group expects, at the balance sheet date, to recover or settle the carrying amount of the assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax is charged or credited to the consolidated statements of profit or loss and other comprehensive income or loss, except when the tax arises from a business combination or it relates to items charged or credited directly to equity, in which case the deferred tax is also taken directly to equity. &lt;/span&gt;&lt;/div&gt;Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis in that taxation authority.</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-553">Property, plant and equipment &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment is recognized as an asset when it is probable that future economic benefits associated with the asset will flow to the Group and the cost of the asset can be measured in a reliable manner. Property, plant and equipment which qualifies for recognition as an asset are initially measured at cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The cost of property, plant and equipment includes an asset&#x2019;s purchase price and any directly attributable costs of bringing the asset to working condition for its intended use. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation is calculated and recognized as an expense on a straight-line basis over an asset&#x2019;s estimated useful life. The estimated useful lives, residual values and depreciation method are reviewed at each balance sheet date, with the effect of any changes in estimate accounted for on a prospective basis. The following useful lives are used in the calculation of depreciation: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facility equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5-20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain of the Group&#x2019;s property, plant and equipment assets have been pledged to secure borrowings as further described in Note 21. Significant disposals of pledged assets are subject to lender approval. Upon disposal or retirement of an asset, the difference between the sales proceeds, if applicable, and the carrying amount of the asset is recognized in the consolidated statements of profit or loss and other comprehensive income or loss at the time of disposal or retirement. &lt;/span&gt;&lt;/div&gt;At the end of each reporting period, or sooner if events triggering an interim impairment assessment occur, the Group reviews the carrying amounts of its property, plant and equipment to determine whether there is any indication that the value of such assets are impaired. Triggering events that warrant an interim impairment assessment include, but are not limited to, the technical obsolescence of equipment or failure of such equipment to meet regulatory requirements. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss and the carrying amount of the asset is reduced to its recoverable amount, which is the higher of fair value less costs of disposal and value in use.</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <alvo:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock contextRef="c-1" id="f-554">The following useful lives are used in the calculation of depreciation: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facility equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5-20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-126" id="f-555">P40Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-127" id="f-556">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-128" id="f-557">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-129" id="f-558">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-130" id="f-559">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-131" id="f-560">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-132" id="f-561">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c-1" id="f-562">Inventories &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories, which consist of raw materials and supplies, work in progress and finished goods are stated at the lower of cost or net realizable value. Net realizable value is the expected sales price less completion costs and costs to be incurred in marketing, selling and distributing the inventory. Cost is calculated using the weighted average cost method or the first-in,first-out method, depending on the nature of the inventory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories include direct costs for raw materials and supplies and, as applicable, direct and indirect labor and overhead expenses that have been incurred to bring inventories to their present location and condition.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If the net realizable value is lower than the carrying amount, a write-down of inventory is recognized for the amount by which the carrying amount exceeds net realizable value.&lt;/span&gt;&lt;/div&gt;The Group does not pledge inventories as collateral to secure its liabilities.</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="c-1" id="f-563">Financial assets &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Recognition of financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial assets are recognized when the Group becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets, other than financial assets measured at FVTPL, are added to or deducted from the fair value of the financial assets, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets at FVTPL are recognized immediately in profit or loss. There were no transaction costs related to the acquisition of financials assets in 2023, 2022, or 2021. All of the Group&#x2019;s financial assets are measured at amortized cost as of 31&#160;December 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial assets measured at amortized cost are debt instruments that give rise to contractual cash flows that are solely payments of principal and interest on the principal amount outstanding. The Group&#x2019;s financial assets measured at amortized cost are trade receivables, certain other current assets, receivables from related parties, restricted cash and cash and cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest income is recognized by applying the effective interest rate, except for short-term receivables when the effect of discounting is immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Impairment of financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group recognizes a loss allowance for expected credit losses ("ECL") on its trade receivables and other debt instruments that are measured at amortized cost. In addition, although contract assets are not financial assets, a loss allowance for ECL are also recognized for such assets. ECL is based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group always recognizes lifetime ECL for trade receivables and contract assets. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group&#x2019;s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecasted direction of conditions at the reporting date, including time value of money where appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group writes off a financial asset when there is no reasonable expectation of recovery, such as information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. A trade receivable or contract asset that is considered uncollectible is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognized in profit or loss. The Group did not write off any trade receivables or contract assets during the years ended 31&#160;December 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group estimates impairment for related party receivables on an individual basis. No impairment is recognized for restricted cash or cash and cash equivalents as management has estimated that the effects of any calculated ECL would be immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Derecognition of financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Group neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Group recognizes its retained interest in the asset as well as an associated liability. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received. &lt;/span&gt;&lt;/div&gt;On derecognition of a financial asset, the difference between the asset&#x2019;s carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognized in other comprehensive income or loss and accumulated in equity is recognized in profit or loss.</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="c-1" id="f-564">Financial liabilities &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s financial liabilities consist of trade and other payables, certain other current liabilities loans and borrowings, lease liabilities, derivative financial instruments, long-term incentive plans, share appreciation right plans and other long-term liability to a related party. All financial liabilities are initially measured at fair value. Loans and borrowings are recorded net of directly attributable transaction costs and less the value attributable to any embedded derivative financial instruments, if applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group derecognizes financial liabilities when, and only when, the Group&#x2019;s obligations are discharged, cancelled, substantially modified or have expired. Additionally, management elected, as part of its accounting policy, to recognize the difference between the carrying amount of the financial liabilities and the fair value of the consideration paid for the extinguishment in the consolidated statement of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial liabilities subsequently measured at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;After initial recognition, financial liabilities other than derivative financial instruments and awards issued pursuant to long-term incentive plans are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that discounts all estimated future cash payments through the expected life of the financial liability, or a shorter period if appropriate, to the amortized cost of a financial liability. The effective interest rate includes the effects of any discount or premium on acquisition of the financial liability, as well as any fees or costs incurred upon acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial liabilities subsequently measured at FVTPL&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Derivative financial instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain rights and features pursuant to borrowing arrangements and other contracts may provide the counterparty with one or more financial instruments that need to be evaluated and potentially accounted for separately by the Group. These financial instruments are either embedded in a host instrument or are treated as a separate financial instrument if they are contractually transferable independent from the host instrument. Such rights and features pursuant to the Group&#x2019;s contracts with both third parties and related parties include earn out rights, conversion rights and warrant rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equity conversion features within host debt instruments that meet the definition of a derivative and have economic and risk characteristics that are not closely related to the host instrument are embedded derivatives that are separated from the host instrument and accounted for separately. As part of the accounting for embedded derivatives or separate financial instruments, management considers the appropriate accounting classification under IAS 32. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Embedded derivatives and separate financial instruments that meet the fixed-for-fixed criteria are classified as equity and initially measured at fair value. Warrant rights that provide the holder with an option to purchase ordinary shares at a specified price or pursuant to a specified formula are generally separate derivative financial instruments that are accounted for as derivative liabilities. Earn Out Shares grant the holder with a variable number of Ordinary Shares based on certain vesting conditions tied to the stock price and are accounted for as derivative liabilities. In the event that the fair value of any derivative liabilities, determined using unobservable inputs, exceeds the transaction price of a borrowing arrangement, the Group records a deferred loss at the inception of the borrowing arrangement for the difference between the fair value of the derivative liabilities and the transaction price of the borrowing arrangement. Such deferred losses are recognized over the term of the related borrowing arrangement using the straight-line method of amortization. The deferred loss is netted against derivative financial liabilities on the consolidated statements of financial position. Amortization of the deferred loss is recognized as a component of &#x201c;Finance costs&#x201d; in the consolidated statements of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group recognized derivative liabilities related to the Predecessor Earn Out Shares, OACB Earn Out Shares and assumed OACB warrants. Additionally, the Group recognized an embedded derivative for the conversion feature associated with the Tranche A Convertible Bonds, as further described in Note 21. These features are liability-classified, rather than equity-classified, because the Group is obligated to issue a variable number of ordinary shares to the holder upon conversion or exercise of the feature. Therefore, these derivative liabilities were initially recorded at fair value and remeasured to fair value at each reporting period with gains and losses arising from changes in the fair value recognized in finance income or finance costs, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of the derivative liabilities were determined using a valuation approach that incorporated a range of inputs that are both observable and unobservable in nature. The inputs used in the initial and subsequent fair value measurements predominantly relate to (i) the price of the Group&#x2019;s Ordinary Shares (ii) the volatility of the Group&#x2019;s Ordinary Shares, (ii) a risky discount rate corresponding to the credit risk associated with the repayment of the host debt instruments, and (iii) the probabilities of each derivative being exercised by the holder and the timing of such exercises. The probabilities are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group will derecognize any derivative liabilities if and when the rights are exercised by the holders or the time period during which the rights can be exercised expires. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Liabilities to related parties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The majority of the Group&#x2019;s liabilities to related parties arose from its acquisition of rights for the commercialization of the Group&#x2019;s biosimilar Adalimumab product in certain territories in Asia from Lotus Pharmaceutical Co. Ltd., a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related party, during the year ended 31&#160;December 2021. Pursuant to the terms of the asset acquisition, the Group made an upfront payment of $1.9 million and is required to pay $7.4 million upon the commercial launch of Adalimumab in China which became due on 31 December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Long-term incentive plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Share appreciation rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group issued to certain current and former employees share appreciation rights ("SARs") that require settlement in connection with the occurrence of specified, future triggering events. Grants occurred from 2015 through 2020. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. The individuals retain their vested awards upon termination of employment with the Group. Settlement amounts are determined by the change in the Group&#x2019;s market value from the grant date of the SAR until the triggering events occur. The SARs do not expire at a specific date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the terms of the SAR agreements, management determined that the Group cannot avoid paying cash to settle the awards and, therefore, SARs are liability-classified in the consolidated statements of financial position. Accordingly, SARs were recorded at fair value and were subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. The fair value of the SARs was determined using the Black-Scholes-Merton pricing model. In connection with the closing of the Business Combination, the Company reached a settlement agreement for share appreciation rights previously awarded to certain current and former employees. The remaining share appreciation rights were settled through the issuance of fully vested RSUs under the Management Incentive Plan on 1 December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Employee incentive plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group also sponsors an employee incentive plan for certain qualifying employees. Under the plans, such employees are entitled to cash payments upon achievement of key milestones, such as a research and development milestone or the occurrence of an exit event. The awards include a combination of vesting conditions, such as service and performance conditions, as well as non-vesting conditions depending on the particular award. Since the Group cannot avoid paying cash to settle the awards, the employee incentive plan is liability-classified in the consolidated statements of financial position. Accordingly, awards issued pursuant to the employee incentive plan are recorded at fair value and are subsequently remeasured each reporting period with the change in fair value reflected as a gain or loss in the consolidated statements of profit or loss and other comprehensive income or loss, as appropriate. Employee incentive plan liabilities are presented as either current or non-current on the consolidated statements of financial position based on the anticipated timing of settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the employee incentive plan awards is determined by estimating the probability of success in reaching the specified milestones and other levers, such as the anticipated timing of potential milestone achievement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Management Incentive Plan&lt;/span&gt;&lt;/div&gt;The Group can issue share options, restricted share units (&#x201c;RSUs&#x201d;), and other share-based awards under the Company&#x2019;s new incentive plan (the &#x201c;Management Incentive Plan&#x201d;) which was approved by the Board in June 2022. Awards issued under the Management Incentive Plan are accounted for in accordance with IFRS 2. Share-based payments are classified as equity-settled share-based payments as the Company intends to settle the awards with equity and has the commercial substance to do so. Share-based payments are measured at the grant date fair value of the instruments issued and recognized over the expected vesting periods. The number of shares expected to vest are reviewed and adjusted at the end of each reporting period such that the amount of expense recognized shall be based on the number of equity instruments that will eventually vest.</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <alvo:UpfrontPayment contextRef="c-133" decimals="-5" id="f-565" unitRef="usd">1900000</alvo:UpfrontPayment>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-134" decimals="-5" id="f-566" unitRef="usd">7400000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <alvo:DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock contextRef="c-1" id="f-567">Litigation and other contingencies &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group may, from time to time, become involved in legal proceedings arising out of the normal course of its operations. For instance, as a developer and manufacturer of biosimilars, the Group may be subject to lawsuits alleging patent infringement or other similar claims filed by the reference product sponsor. Similarly, the Group may utilize patent challenge procedures to challenge the validity, enforceability or infringement of the reference product &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;sponsor&#x2019;s patents. Other parties may also file patent infringement claims against the Group alleging that the Group&#x2019;s products or manufacturing process techniques infringe their patents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group establishes reserves for specific legal matters when it determines that the likelihood of an unfavorable outcome is probable and the loss is reasonably estimable. When such conditions are not met for a specific legal matter, no reserve is established. Although management currently believes that resolving claims against the Group, including claims where an unfavorable outcome is reasonably possible, will not have a material impact on the liquidity, results of operations, or financial condition of the Group, these matters are subject to inherent uncertainties and management&#x2019;s view of these matters may change in the future. It is possible that an unfavorable outcome of a lawsuit or other contingency could have a material impact on the liquidity, results of operations, or financial condition of the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount of loss can be reasonably estimated. Accruals are based only on information available at the time of the assessment, due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Group&#x2019;s results of operations in a given period. &lt;/span&gt;&lt;/div&gt;The Group maintains liability insurance coverages for various claims and exposures. The Group&#x2019;s insurance coverage limits its maximum exposure on claims; however, the Group is responsible for any uninsured portion of losses. Management believes that present insurance coverage is sufficient to cover potential exposures.</alvo:DescriptionOfAccountingPolicyForLitigationAndOtherContingenciesExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c-1" id="f-568">Leases &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for those with a lease term of twelve months or less and leases of low value assets. For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The Group&#x2019;s leased assets consist of various real estate, fleet and equipment leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets reflect the initial measurement of the lease liability, lease payments made at or before the lease commencement date and any initial direct costs less lease incentives that may have been received by the Group. These assets are subsequently measured at cost less accumulated depreciation, impairment losses and remeasurements of the underlying lease liability. Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the underlying asset. If a lease transfers ownership of the underlying asset to the Group or the lease includes a purchase option that the Group is reasonably certain to exercise, the related right-of-use asset is depreciated over the useful life of the underlying asset. Depreciation starts at the commencement date of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate, which is the rate of interest that the Group would need to pay to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term in a similar economic environment based on information available at the commencement date of the lease. The lease payments included in the measurement of the lease liability comprise fixed payments (including in-substance fixed payments) less any incentives, variable lease payments that depend on an index or rate, expected residual guarantees and the exercise price of purchase options reasonably certain to be exercised by the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability, using the effective interest method, and by reducing the carrying amount to reflect payments made during the lease term. The Group remeasures the lease liability if the lease term has changed, when lease payments based on an index or rate change or when a lease contract is modified and the modification is not accounted for as a separate lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable payments that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs. &lt;/span&gt;&lt;/div&gt;As a practical expedient, lessees are not required to separate non-lease components from lease components, and instead account for any lease and associated non-lease components as a single lease component. The Group has used this practical expedient.</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c-1" id="f-569">Loss per share &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Holders of the Predecessor Earn Out Shares and OACB Earn Out Shares have equal dividend and participation rights to the ordinary shareholders. However, these participating securities are classified as liabilities and as such, the shares held are not included in the weighted average number of ordinary shares outstanding in the basic loss per share calculation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The calculation of basic loss per share is based on the loss for the year attributable to ordinary shareholders of the Group and the weighted average number of ordinary shares outstanding during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted loss per share is computed by dividing the loss for the year attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding in the basic loss per share calculation, both of which are adjusted for the effects of all dilutive potential ordinary shares. Antidilutive effects of potential ordinary shares, which result in an increase in earnings per share or a reduction in loss per share, are not recognized in the computation of diluted loss per share.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-571">New accounting standards &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;New standards and interpretations adopted and effective during the periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following new IFRS standards have been adopted by the Group effective 1 January 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5.1pt;padding-left:27.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;IFRS 17 - Insurance Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2017, the IASB issued IFRS 17, Insurance Contracts, which replaces IFRS 4, Insurance Contracts. This standard sets out principles for the recognition, measurement, presentation and disclosure of insurance contracts that are within the scope of IFRS 17. In June 2020, the IASB issued Amendments to IFRS 17, which addresses concerns and implementation challenges that were identified after IFRS 17, Insurance Contracts, was published in 2017. The amendments are effective for annual periods beginning on or after 1 January 2023. IFRS 17 requires fundamental accounting changes to how insurance contracts are measured and accounted for. It introduces the general measurement model, based on a risk-adjusted present value of future cash flows that will arise as the insurance contract is fulfilled. This new measurement model aims to provide relevant information of the future cash flows. The general measurement model is modified for the measurement of reinsurance contracts held, direct participating contracts, and investment contracts with discretionary participation features. Also, while the general measurement model applies to all groups of insurance contracts in scope of IFRS 17, a simplified approach (a premium allocation approach) may be used to measure contracts that meet certain criteria. IFRS 17 also includes new disclosure requirements, providing more clarity and transparency for users of financial statements. The adoption of the standard did not have a material impact on the consolidated financial statements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.05pt;padding-left:27.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;IAS 1 (Amendment) - Disclosure of Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The IASB issued Disclosure of Accounting Policies (Amendments to IAS 1) and IFRS Practice Statement 2 Making Materiality Judgements. The amendments replace the requirement for entities to disclose their significant accounting policies with the requirement to disclose their material accounting policy information. The amendments also include guidance to help entities apply the definition of material in making decisions about accounting policy disclosures.  The adoption of these amendments did not have a material impact on the consolidated financial statements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;IAS 8 (Amendments) - Definition of Accounting Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The IASB issued amendments on IAS 8 to help entities to distinguish between accounting policies and accounting estimates. The amendments clarify how companies distinguish changes in accounting policies from changes in accounting estimates, with a primary focus on the definition of and clarifications on accounting estimates. The distinction between the two is important because changes in accounting policies are applied retrospectively, while changes in accounting estimates are applied prospectively. The amendments further clarify that accounting estimates are monetary amounts in the financial statements and are subject to measurement uncertainty. The amendments also clarify the relationship between accounting policies and accounting estimates by specifying that a company develops accounting estimates to achieve the objective set out by an accounting policy. The amendments are reflected in all financial statements and disclosures of the Group. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7.95pt;padding-left:27.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;IAS 12 (Amendments) - Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The IASB issued amendments on IAS 12, which clarifies how companies shall account for deferred tax on transactions such as leases and decommissioning obligations, with a focus on reducing diversity in practice. The amendments narrow the scope of the initial recognition exemption in paragraphs 15 and 24 of IAS 12 so that it does not apply to transactions that give rise to equal and offsetting temporary differences. As a result, companies will need to recognize deferred tax assets and a deferred tax liability for temporary differences arising on initial recognition of a lease and a decommissioning provision. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;IAS 12 (Amendments) - International Tax Reform&#x2014;Pillar Two Model Rules&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2022, the OECD released technical guidance on its 15% global minimum tax agreed as the second &#x2018;pillar&#x2019; of a project to address the tax challenges arising from digitalisation of the economy. This guidance elaborates on the application and operation of the Global Anti-Base Erosion (GloBE) Rules agreed and released in December 2021 which lay out a co-ordinated system to ensure that multinational enterprises with revenues above &#x20ac;750 million pay tax of at least 15% on the income arising in each of the jurisdictions in which they operate. In May 2023, the IASB issued amendments to IAS12 Income Taxes to introduce a temporary exception to the requirements to recognise and disclose information about deferred tax assets and liabilities related to Pillar Two income taxes. As the Company does not meet the revenue thresholds, this guidance had no impact on the Group's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;New and revised IFRS standards in issue but not yet effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following new standards are not yet adopted by or effective for the Group and have not been applied in preparing these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;IAS 1 (Amendments) &#x2013; Classification of Liabilities as Current or Non-Current &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The IASB issued amendments to IAS 1, which affect the presentation of liabilities as current or non-current in the statement of financial position. The amendment does not impact the amount or timing of recognition of any asset, liability, income or expenses, or the information disclosed about those items. The amendments clarify that the classification of liabilities as current or non-current is based on rights that are in existence at the end of the reporting period, specify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, explain that rights are in existence if covenants are complied with at the end of the reporting period, and introduce a definition of &#x2018;settlement&#x2019; to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. The Group currently evaluates the impact of these amendments on the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;IAS 1 (Amendments) &#x2013; Non-current Liabilities with Covenants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These amendments clarify how conditions with which an entity must comply within twelve months after the reporting period affect the classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these conditions. The amendments also respond to stakeholders&#x2019; concerns about the classification of such a liability as current or non-current. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group currently evaluates the impact of these amendments on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;IFRS 16 (Amendment) - Lease Liability in a Sale and Leaseback&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;This amendment adds subsequent measurement requirements for sale and leaseback transactions. This amendment includes requirements for sale and leaseback transactions in IFRS 16 to explain how an entity accounts for a sale and leaseback after the date of the transaction. Sale and leaseback transactions where some or all the lease payments are variable lease payments that do not depend on an index or rate are most likely to be impacted. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group anticipates that the application of this amendment will not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfFirstTimeAdoptionExplanatory contextRef="c-1" id="f-570">New accounting standards &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;New standards and interpretations adopted and effective during the periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following new IFRS standards have been adopted by the Group effective 1 January 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5.1pt;padding-left:27.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;IFRS 17 - Insurance Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2017, the IASB issued IFRS 17, Insurance Contracts, which replaces IFRS 4, Insurance Contracts. This standard sets out principles for the recognition, measurement, presentation and disclosure of insurance contracts that are within the scope of IFRS 17. In June 2020, the IASB issued Amendments to IFRS 17, which addresses concerns and implementation challenges that were identified after IFRS 17, Insurance Contracts, was published in 2017. The amendments are effective for annual periods beginning on or after 1 January 2023. IFRS 17 requires fundamental accounting changes to how insurance contracts are measured and accounted for. It introduces the general measurement model, based on a risk-adjusted present value of future cash flows that will arise as the insurance contract is fulfilled. This new measurement model aims to provide relevant information of the future cash flows. The general measurement model is modified for the measurement of reinsurance contracts held, direct participating contracts, and investment contracts with discretionary participation features. Also, while the general measurement model applies to all groups of insurance contracts in scope of IFRS 17, a simplified approach (a premium allocation approach) may be used to measure contracts that meet certain criteria. IFRS 17 also includes new disclosure requirements, providing more clarity and transparency for users of financial statements. The adoption of the standard did not have a material impact on the consolidated financial statements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.05pt;padding-left:27.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;IAS 1 (Amendment) - Disclosure of Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The IASB issued Disclosure of Accounting Policies (Amendments to IAS 1) and IFRS Practice Statement 2 Making Materiality Judgements. The amendments replace the requirement for entities to disclose their significant accounting policies with the requirement to disclose their material accounting policy information. The amendments also include guidance to help entities apply the definition of material in making decisions about accounting policy disclosures.  The adoption of these amendments did not have a material impact on the consolidated financial statements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;IAS 8 (Amendments) - Definition of Accounting Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The IASB issued amendments on IAS 8 to help entities to distinguish between accounting policies and accounting estimates. The amendments clarify how companies distinguish changes in accounting policies from changes in accounting estimates, with a primary focus on the definition of and clarifications on accounting estimates. The distinction between the two is important because changes in accounting policies are applied retrospectively, while changes in accounting estimates are applied prospectively. The amendments further clarify that accounting estimates are monetary amounts in the financial statements and are subject to measurement uncertainty. The amendments also clarify the relationship between accounting policies and accounting estimates by specifying that a company develops accounting estimates to achieve the objective set out by an accounting policy. The amendments are reflected in all financial statements and disclosures of the Group. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7.95pt;padding-left:27.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;IAS 12 (Amendments) - Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The IASB issued amendments on IAS 12, which clarifies how companies shall account for deferred tax on transactions such as leases and decommissioning obligations, with a focus on reducing diversity in practice. The amendments narrow the scope of the initial recognition exemption in paragraphs 15 and 24 of IAS 12 so that it does not apply to transactions that give rise to equal and offsetting temporary differences. As a result, companies will need to recognize deferred tax assets and a deferred tax liability for temporary differences arising on initial recognition of a lease and a decommissioning provision. The adoption of the amendments did not have a material impact on the consolidated financial statements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;IAS 12 (Amendments) - International Tax Reform&#x2014;Pillar Two Model Rules&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2022, the OECD released technical guidance on its 15% global minimum tax agreed as the second &#x2018;pillar&#x2019; of a project to address the tax challenges arising from digitalisation of the economy. This guidance elaborates on the application and operation of the Global Anti-Base Erosion (GloBE) Rules agreed and released in December 2021 which lay out a co-ordinated system to ensure that multinational enterprises with revenues above &#x20ac;750 million pay tax of at least 15% on the income arising in each of the jurisdictions in which they operate. In May 2023, the IASB issued amendments to IAS12 Income Taxes to introduce a temporary exception to the requirements to recognise and disclose information about deferred tax assets and liabilities related to Pillar Two income taxes. As the Company does not meet the revenue thresholds, this guidance had no impact on the Group's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;New and revised IFRS standards in issue but not yet effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following new standards are not yet adopted by or effective for the Group and have not been applied in preparing these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;IAS 1 (Amendments) &#x2013; Classification of Liabilities as Current or Non-Current &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The IASB issued amendments to IAS 1, which affect the presentation of liabilities as current or non-current in the statement of financial position. The amendment does not impact the amount or timing of recognition of any asset, liability, income or expenses, or the information disclosed about those items. The amendments clarify that the classification of liabilities as current or non-current is based on rights that are in existence at the end of the reporting period, specify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, explain that rights are in existence if covenants are complied with at the end of the reporting period, and introduce a definition of &#x2018;settlement&#x2019; to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. The Group currently evaluates the impact of these amendments on the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;IAS 1 (Amendments) &#x2013; Non-current Liabilities with Covenants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These amendments clarify how conditions with which an entity must comply within twelve months after the reporting period affect the classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these conditions. The amendments also respond to stakeholders&#x2019; concerns about the classification of such a liability as current or non-current. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group currently evaluates the impact of these amendments on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;IFRS 16 (Amendment) - Lease Liability in a Sale and Leaseback&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;This amendment adds subsequent measurement requirements for sale and leaseback transactions. This amendment includes requirements for sale and leaseback transactions in IFRS 16 to explain how an entity accounts for a sale and leaseback after the date of the transaction. Sale and leaseback transactions where some or all the lease payments are variable lease payments that do not depend on an index or rate are most likely to be impacted. The amendment is effective for annual periods beginning on or after 1 January 2024. The Group anticipates that the application of this amendment will not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFirstTimeAdoptionExplanatory>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c-1" id="f-572">Segment reporting &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As disclosed in Note 2, the Group operates and manages its business as one operating segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A significant portion of the Group&#x2019;s revenue is generated from long-term out-license contracts which provide the customer with exclusive rights to a particular territory, which generally span multiple countries or a particular continent, as well as the Group&#x2019;s promises to continue development of the underlying compound and to provide supply of the product to the customer upon commercialization. Therefore, based on the nature of the customer agreements, revenue information is not currently available on a country-by-country basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue from customers based on the geographic market in which the revenue is earned, which predominantly aligns with the rights conveyed to the Group&#x2019;s customers pursuant to its out-license contracts, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Asia and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;91,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-current assets, excluding financial instruments and deferred tax assets, based on the location of the asset is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;415,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;334,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Asia and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;426,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;338,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue from transactions with individual customers that exceeds ten percent or more of the Group&#x2019;s total revenue is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.254%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;% Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;% Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;% Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <alvo:NumberOfOperatingSegments1
      contextRef="c-5"
      decimals="INF"
      id="f-573"
      unitRef="segement">1</alvo:NumberOfOperatingSegments1>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-574">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue from customers based on the geographic market in which the revenue is earned, which predominantly aligns with the rights conveyed to the Group&#x2019;s customers pursuant to its out-license contracts, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Asia and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;91,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-135" decimals="-3" id="f-575" unitRef="usd">63510000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-136" decimals="-3" id="f-576" unitRef="usd">39433000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-137" decimals="-3" id="f-577" unitRef="usd">20509000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-138" decimals="-3" id="f-578" unitRef="usd">18306000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-139" decimals="-3" id="f-579" unitRef="usd">30780000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-140" decimals="-3" id="f-580" unitRef="usd">11660000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-141" decimals="-3" id="f-581" unitRef="usd">9618000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-142" decimals="-3" id="f-582" unitRef="usd">12816000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-143" decimals="-3" id="f-583" unitRef="usd">4603000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-3" id="f-584" unitRef="usd">91434000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-6" decimals="-3" id="f-585" unitRef="usd">83029000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-7" decimals="-3" id="f-586" unitRef="usd">36772000</ifrs-full:RevenueFromContractsWithCustomers>
    <alvo:DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-587">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-current assets, excluding financial instruments and deferred tax assets, based on the location of the asset is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;415,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;334,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Asia and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;426,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;338,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutNoncurrentAssetsExcludingFinancialInstrumentsAndDeferredTaxAssetsExplanatoryTableTextBlock>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-144" decimals="-3" id="f-588" unitRef="usd">415659000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-145" decimals="-3" id="f-589" unitRef="usd">334837000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-146" decimals="-3" id="f-590" unitRef="usd">5094000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-147" decimals="-3" id="f-591" unitRef="usd">240000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-148" decimals="-3" id="f-592" unitRef="usd">6194000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-149" decimals="-3" id="f-593" unitRef="usd">3715000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-5" decimals="-3" id="f-594" unitRef="usd">426947000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-8" decimals="-3" id="f-595" unitRef="usd">338792000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory contextRef="c-1" id="f-596">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue from transactions with individual customers that exceeds ten percent or more of the Group&#x2019;s total revenue is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.254%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;% Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;% Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;% Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory>
    <ifrs-full:Revenue contextRef="c-150" decimals="-3" id="f-597" unitRef="usd">9430000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-150" decimals="3" id="f-598" unitRef="number">0.103</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-151" decimals="-3" id="f-599" unitRef="usd">17940000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-151" decimals="3" id="f-600" unitRef="number">0.216</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-152" decimals="-3" id="f-601" unitRef="usd">10070000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-152" decimals="3" id="f-602" unitRef="number">0.274</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-153" decimals="-3" id="f-603" unitRef="usd">46954000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-153" decimals="3" id="f-604" unitRef="number">0.514</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-154" decimals="-3" id="f-605" unitRef="usd">38376000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-154" decimals="3" id="f-606" unitRef="number">0.462</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-155" decimals="-3" id="f-607" unitRef="usd">18369000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-155" decimals="3" id="f-608" unitRef="number">0.500</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-156" decimals="-3" id="f-609" unitRef="usd">8876000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-156" decimals="3" id="f-610" unitRef="number">0.097</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-157" decimals="-3" id="f-611" unitRef="usd">12840000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-157" decimals="3" id="f-612" unitRef="number">0.155</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-158" decimals="-3" id="f-613" unitRef="usd">1590000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-158" decimals="3" id="f-614" unitRef="number">0.043</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-159" decimals="-3" id="f-615" unitRef="usd">16556000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-159" decimals="3" id="f-616" unitRef="number">0.181</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-160" decimals="-3" id="f-617" unitRef="usd">0</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-160" decimals="3" id="f-618" unitRef="number">0</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue contextRef="c-161" decimals="-3" id="f-619" unitRef="usd">0</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-161" decimals="3" id="f-620" unitRef="number">0</ifrs-full:PercentageOfEntitysRevenue>
    <alvo:DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock contextRef="c-1" id="f-621">Revenue &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Disaggregated revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Groups&#x2019; revenue from contracts with customers, disaggregated by the type of good or service and timing of transfer of control of such goods and services to customers: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Product revenue (point in time revenue recognition)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;License revenue (point in time revenue recognition)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Development and other service revenue (over time revenue recognition)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;91,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Reassessment of variable consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to revenue in the period of change. The Group updates variable consideration estimates on a quarterly basis. The quarterly changes in estimates did not result in material adjustments to the Group&#x2019;s previously reported revenue or trade receivables during the years ended 31&#160;December 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Contract assets and liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Contract &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Assets &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Contract &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liabilities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31 December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contract asset additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amounts transferred to trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(19,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(26,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31 December  2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;93,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contract asset additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amounts transferred to trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derecognition of contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(42,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The net increase in contract assets as of 31&#160;December 2023 is due to revenue recognized when the performance obligation has been met which is offset by the transfer of such amounts to trade receivables on the basis that the Group&#x2019;s right to that consideration is no longer contingent on its performance. The net increase in contract liabilities as of 31&#160;December 2023 is due to customer prepayments in advance of the Group&#x2019;s performance. As of 31&#160;December 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, $10.9 million and $35.2 million are recorded as non-current contract assets and current contract assets, respectively. Non-current contract assets will materialize over the next 2 to 3 years. As of 31&#160;December 2023, $73.3 million and $59.2 million are recorded as non-current contract liabilities and current contract liabilities, respectively. Non-current contract liabilities will&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; be recognized as revenue over the next 2 to 6 years as either services are rendered or contractual milestones are achieved, depending on the performance obligation to which the payment relates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Remaining performance obligations &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Due to the long-term nature of the Group&#x2019;s out-license contracts, the Group&#x2019;s obligations pursuant to such contracts represent partially unsatisfied performance obligations at year-end. The revenues under existing out-license contracts with original expected durations of more than one year are estimated &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;to be $383.0 million. The&lt;/span&gt; Group expects to recognize the majority of these revenues over the next 5 years.</alvo:DisclosureOfRevenueAndOtherOperatingIncomeExplanatoryTextBlock>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-622">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Groups&#x2019; revenue from contracts with customers, disaggregated by the type of good or service and timing of transfer of control of such goods and services to customers: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Product revenue (point in time revenue recognition)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;License revenue (point in time revenue recognition)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Development and other service revenue (over time revenue recognition)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;91,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-162" decimals="-3" id="f-623" unitRef="usd">48699000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-163" decimals="-3" id="f-624" unitRef="usd">24836000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-164" decimals="-3" id="f-625" unitRef="usd">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-165" decimals="-3" id="f-626" unitRef="usd">12177000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-166" decimals="-3" id="f-627" unitRef="usd">424000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-167" decimals="-3" id="f-628" unitRef="usd">1453000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-168" decimals="-3" id="f-629" unitRef="usd">30558000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-169" decimals="-3" id="f-630" unitRef="usd">57769000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-170" decimals="-3" id="f-631" unitRef="usd">35319000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-3" id="f-632" unitRef="usd">91434000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-6" decimals="-3" id="f-633" unitRef="usd">83029000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-7" decimals="-3" id="f-634" unitRef="usd">36772000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory contextRef="c-1" id="f-635">&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Contract assets and liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Contract &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Assets &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Contract &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liabilities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31 December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contract asset additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amounts transferred to trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(19,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(26,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31 December  2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;93,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contract asset additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amounts transferred to trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derecognition of contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(42,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Customer prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <ifrs-full:ContractAssets contextRef="c-171" decimals="-3" id="f-636" unitRef="usd">19438000</ifrs-full:ContractAssets>
    <ifrs-full:ContractLiabilities contextRef="c-172" decimals="-3" id="f-637" unitRef="usd">74536000</ifrs-full:ContractLiabilities>
    <ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets contextRef="c-173" decimals="-3" id="f-638" unitRef="usd">29823000</ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets>
    <alvo:ContractAssetsAdditionsAmountsTransferredToTradeReceivables contextRef="c-173" decimals="-3" id="f-639" unitRef="usd">19690000</alvo:ContractAssetsAdditionsAmountsTransferredToTradeReceivables>
    <alvo:ContractLiabilityCustomerPrepayments contextRef="c-174" decimals="-3" id="f-640" unitRef="usd">46127000</alvo:ContractLiabilityCustomerPrepayments>
    <ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities contextRef="c-174" decimals="-3" id="f-641" unitRef="usd">-26782000</ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities>
    <alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment contextRef="c-173" decimals="-3" id="f-642" unitRef="usd">-915000</alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment>
    <alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment contextRef="c-174" decimals="-3" id="f-643" unitRef="usd">51000</alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment>
    <ifrs-full:ContractAssets contextRef="c-175" decimals="-3" id="f-644" unitRef="usd">28656000</ifrs-full:ContractAssets>
    <ifrs-full:ContractLiabilities contextRef="c-176" decimals="-3" id="f-645" unitRef="usd">93932000</ifrs-full:ContractLiabilities>
    <ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets contextRef="c-177" decimals="-3" id="f-646" unitRef="usd">19634000</ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractAssets>
    <alvo:ContractAssetsAdditionsAmountsTransferredToTradeReceivables contextRef="c-177" decimals="-3" id="f-647" unitRef="usd">2412000</alvo:ContractAssetsAdditionsAmountsTransferredToTradeReceivables>
    <alvo:ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables contextRef="c-178" decimals="-3" id="f-648" unitRef="usd">0</alvo:ContractLiabilitiesAdditionsAmountsTransferredToTradeReceivables>
    <alvo:ContractLiabilitiesAdditionsDerecognitionOfContractLiability contextRef="c-178" decimals="-3" id="f-649" unitRef="usd">42089000</alvo:ContractLiabilitiesAdditionsDerecognitionOfContractLiability>
    <alvo:ContractLiabilityCustomerPrepayments contextRef="c-178" decimals="-3" id="f-650" unitRef="usd">100555000</alvo:ContractLiabilityCustomerPrepayments>
    <ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities contextRef="c-178" decimals="-3" id="f-651" unitRef="usd">-23101000</ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueArisingFromChangeInMeasureOfProgressContractLiabilities>
    <alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment contextRef="c-177" decimals="-3" id="f-652" unitRef="usd">171000</alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment>
    <alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment contextRef="c-178" decimals="-3" id="f-653" unitRef="usd">3147000</alvo:ContractAssetsLiabilitiesForeignCurrencyAdjustment>
    <ifrs-full:ContractAssets contextRef="c-179" decimals="-3" id="f-654" unitRef="usd">46049000</ifrs-full:ContractAssets>
    <ifrs-full:ContractLiabilities contextRef="c-180" decimals="-3" id="f-655" unitRef="usd">132444000</ifrs-full:ContractLiabilities>
    <ifrs-full:NoncurrentContractAssets contextRef="c-5" decimals="-5" id="f-656" unitRef="usd">10900000</ifrs-full:NoncurrentContractAssets>
    <ifrs-full:CurrentContractAssets contextRef="c-5" decimals="-5" id="f-657" unitRef="usd">35200000</ifrs-full:CurrentContractAssets>
    <alvo:NoncurrentContractAssetsMaterializePeriod contextRef="c-181" id="f-658">P2Y</alvo:NoncurrentContractAssetsMaterializePeriod>
    <alvo:NoncurrentContractAssetsMaterializePeriod contextRef="c-182" id="f-659">P3Y</alvo:NoncurrentContractAssetsMaterializePeriod>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-5" decimals="-5" id="f-660" unitRef="usd">73300000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-5" decimals="-5" id="f-661" unitRef="usd">59200000</ifrs-full:CurrentContractLiabilities>
    <alvo:NoncurrentContractLiabilitiesRevenueRecognitionPeriod contextRef="c-181" id="f-662">P2Y</alvo:NoncurrentContractLiabilitiesRevenueRecognitionPeriod>
    <alvo:NoncurrentContractLiabilitiesRevenueRecognitionPeriod contextRef="c-182" id="f-663">P6Y</alvo:NoncurrentContractLiabilitiesRevenueRecognitionPeriod>
    <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations contextRef="c-183" decimals="-5" id="f-664" unitRef="usd">383000000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
    <alvo:TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod contextRef="c-184" id="f-665">P5Y</alvo:TransactionPriceAllocatedToRemainingPerformanceObligationsPeriod>
    <alvo:DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock contextRef="c-1" id="f-666">Salaries and other employee expenses &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The average number of individuals employed by the Group during the years ended 31&#160;December 2023, 2022, and 2021 was 999, 858, and 645, respectively. The aggregate salary and other employee expenses incurred by the Group for these employees were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Salary expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;92,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;67,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Defined contribution plan expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Long-term incentive plan expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share-based payments (see Note 23)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other employee expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Temporary labor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;164,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19.43pt"&gt;Defined contribution plan expense consists of costs incurred by the Group for employees of certain subsidiaries that are required by local laws to participate in pension schemes. These pension schemes are not sponsored or administered by the Group. Pursuant to the requirements of the schemes, the Group is required to contribute a certain percentage of its payroll costs to the pension schemes. Such contributions are charged to the consolidated statements of profit or loss and other comprehensive income or loss as they are incurred in accordance with the rules of the pension schemes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Salaries and other employee expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total salary and other employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;164,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfSalariesAndOtherEmployeeExpensesExplanatoryTextBlock>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="c-1"
      decimals="-3"
      id="f-667"
      unitRef="individuals">999000</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="c-6"
      decimals="-3"
      id="f-668"
      unitRef="individuals">858000</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="c-7"
      decimals="-3"
      id="f-669"
      unitRef="individuals">645000</ifrs-full:AverageNumberOfEmployees>
    <alvo:DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock contextRef="c-1" id="f-670">The aggregate salary and other employee expenses incurred by the Group for these employees were as follows: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Salary expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;92,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;67,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Defined contribution plan expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Long-term incentive plan expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share-based payments (see Note 23)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other employee expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Temporary labor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;164,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;Defined contribution plan expense consists of costs incurred by the Group for employees of certain subsidiaries that are required by local laws to participate in pension schemes. These pension schemes are not sponsored or administered by the Group. Pursuant to the requirements of the schemes, the Group is required to contribute a certain percentage of its payroll costs to the pension schemes. Such contributions are charged to the consolidated statements of profit or loss and other comprehensive income or loss as they are incurred in accordance with the rules of the pension schemes.</alvo:DisclosureOfDetailedInformationAboutAggregateSalaryAndOtherEmployeeExpensesTableTextBlock>
    <ifrs-full:WagesAndSalaries contextRef="c-1" decimals="-3" id="f-671" unitRef="usd">107067000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c-6" decimals="-3" id="f-672" unitRef="usd">92082000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c-7" decimals="-3" id="f-673" unitRef="usd">67433000</ifrs-full:WagesAndSalaries>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c-1" decimals="-3" id="f-674" unitRef="usd">11518000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c-6" decimals="-3" id="f-675" unitRef="usd">10052000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c-7" decimals="-3" id="f-676" unitRef="usd">7694000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:OtherLongtermBenefits contextRef="c-1" decimals="-3" id="f-677" unitRef="usd">78000</ifrs-full:OtherLongtermBenefits>
    <ifrs-full:OtherLongtermBenefits contextRef="c-6" decimals="-3" id="f-678" unitRef="usd">5481000</ifrs-full:OtherLongtermBenefits>
    <ifrs-full:OtherLongtermBenefits contextRef="c-7" decimals="-3" id="f-679" unitRef="usd">17955000</ifrs-full:OtherLongtermBenefits>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-3" id="f-680" unitRef="usd">18033000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-6" decimals="-3" id="f-681" unitRef="usd">10317000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-7" decimals="-3" id="f-682" unitRef="usd">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:OtherEmployeeExpense contextRef="c-1" decimals="-3" id="f-683" unitRef="usd">19718000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-6" decimals="-3" id="f-684" unitRef="usd">11670000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-7" decimals="-3" id="f-685" unitRef="usd">10274000</ifrs-full:OtherEmployeeExpense>
    <alvo:TemporaryLabourExpense contextRef="c-1" decimals="-3" id="f-686" unitRef="usd">8495000</alvo:TemporaryLabourExpense>
    <alvo:TemporaryLabourExpense contextRef="c-6" decimals="-3" id="f-687" unitRef="usd">5838000</alvo:TemporaryLabourExpense>
    <alvo:TemporaryLabourExpense contextRef="c-7" decimals="-3" id="f-688" unitRef="usd">6164000</alvo:TemporaryLabourExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-1" decimals="-3" id="f-689" unitRef="usd">164909000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-6" decimals="-3" id="f-690" unitRef="usd">135440000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-7" decimals="-3" id="f-691" unitRef="usd">109520000</ifrs-full:EmployeeBenefitsExpense>
    <alvo:DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock contextRef="c-1" id="f-692">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Salaries and other employee expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total salary and other employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;164,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutSalariesAndOtherEmployeeExpensesIncludedInConsolidatedStatementsOfProfitOrLossExplanatoryTableTextBlock>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-185" decimals="-3" id="f-693" unitRef="usd">76908000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-186" decimals="-3" id="f-694" unitRef="usd">42501000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-187" decimals="-3" id="f-695" unitRef="usd">0</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-188" decimals="-3" id="f-696" unitRef="usd">44339000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-189" decimals="-3" id="f-697" unitRef="usd">52962000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-190" decimals="-3" id="f-698" unitRef="usd">71588000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-191" decimals="-3" id="f-699" unitRef="usd">43662000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-192" decimals="-3" id="f-700" unitRef="usd">39977000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-193" decimals="-3" id="f-701" unitRef="usd">37932000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-1" decimals="-3" id="f-702" unitRef="usd">164909000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-6" decimals="-3" id="f-703" unitRef="usd">135440000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-7" decimals="-3" id="f-704" unitRef="usd">109520000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c-1" id="f-705">Finance income and finance costs &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finance income earned during the years ended 31&#160;December 2023, 2022 and 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in the fair value of derivatives (see Note 28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest income from cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finance costs incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in the fair value of derivatives (see Note 28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on debt and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;129,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;106,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Consenting fee (see Note 21)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss on remeasurement of bonds (see Note 21)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on lease liabilities (see Note 13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of deferred debt issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;267,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;188,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <ifrs-full:DisclosureOfFinanceIncomeExplanatory contextRef="c-1" id="f-706">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finance income earned during the years ended 31&#160;December 2023, 2022 and 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in the fair value of derivatives (see Note 28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest income from cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExplanatory>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives contextRef="c-1" decimals="-3" id="f-707" unitRef="usd">0</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives contextRef="c-6" decimals="-3" id="f-708" unitRef="usd">1637000</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives contextRef="c-7" decimals="-3" id="f-709" unitRef="usd">51549000</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-710" unitRef="usd">4547000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-711" unitRef="usd">556000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-712" unitRef="usd">18000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnOtherFinancialAssets contextRef="c-1" decimals="-3" id="f-713" unitRef="usd">276000</ifrs-full:InterestIncomeOnOtherFinancialAssets>
    <ifrs-full:InterestIncomeOnOtherFinancialAssets contextRef="c-6" decimals="-3" id="f-714" unitRef="usd">356000</ifrs-full:InterestIncomeOnOtherFinancialAssets>
    <ifrs-full:InterestIncomeOnOtherFinancialAssets contextRef="c-7" decimals="-3" id="f-715" unitRef="usd">1000</ifrs-full:InterestIncomeOnOtherFinancialAssets>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-3" id="f-716" unitRef="usd">4823000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-6" decimals="-3" id="f-717" unitRef="usd">2549000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-7" decimals="-3" id="f-718" unitRef="usd">51568000</ifrs-full:FinanceIncome>
    <ifrs-full:DisclosureOfFinanceCostExplanatory contextRef="c-1" id="f-719">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finance costs incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in the fair value of derivatives (see Note 28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on debt and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;129,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;106,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Consenting fee (see Note 21)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss on remeasurement of bonds (see Note 21)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on lease liabilities (see Note 13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of deferred debt issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;267,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;188,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceCostExplanatory>
    <ifrs-full:LossesOnChangeInFairValueOfDerivatives contextRef="c-1" decimals="-3" id="f-720" unitRef="usd">132333000</ifrs-full:LossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:LossesOnChangeInFairValueOfDerivatives contextRef="c-6" decimals="-3" id="f-721" unitRef="usd">96981000</ifrs-full:LossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:LossesOnChangeInFairValueOfDerivatives contextRef="c-7" decimals="-3" id="f-722" unitRef="usd">2804000</ifrs-full:LossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-1" decimals="-3" id="f-723" unitRef="usd">129327000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-6" decimals="-3" id="f-724" unitRef="usd">71452000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-7" decimals="-3" id="f-725" unitRef="usd">106548000</ifrs-full:InterestExpenseOnBorrowings>
    <alvo:ConsentingFee contextRef="c-1" decimals="-3" id="f-726" unitRef="usd">0</alvo:ConsentingFee>
    <alvo:ConsentingFee contextRef="c-6" decimals="-3" id="f-727" unitRef="usd">7430000</alvo:ConsentingFee>
    <alvo:ConsentingFee contextRef="c-7" decimals="-3" id="f-728" unitRef="usd">0</alvo:ConsentingFee>
    <alvo:LossOnRemeasurementOfBonds contextRef="c-1" decimals="-3" id="f-729" unitRef="usd">0</alvo:LossOnRemeasurementOfBonds>
    <alvo:LossOnRemeasurementOfBonds contextRef="c-6" decimals="-3" id="f-730" unitRef="usd">6511000</alvo:LossOnRemeasurementOfBonds>
    <alvo:LossOnRemeasurementOfBonds contextRef="c-7" decimals="-3" id="f-731" unitRef="usd">0</alvo:LossOnRemeasurementOfBonds>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-3" id="f-732" unitRef="usd">3840000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-6" decimals="-3" id="f-733" unitRef="usd">6022000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-7" decimals="-3" id="f-734" unitRef="usd">6423000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <alvo:AmortizationOfDeferredDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-735" unitRef="usd">1657000</alvo:AmortizationOfDeferredDebtIssuanceCosts>
    <alvo:AmortizationOfDeferredDebtIssuanceCosts contextRef="c-6" decimals="-3" id="f-736" unitRef="usd">23000</alvo:AmortizationOfDeferredDebtIssuanceCosts>
    <alvo:AmortizationOfDeferredDebtIssuanceCosts contextRef="c-7" decimals="-3" id="f-737" unitRef="usd">1586000</alvo:AmortizationOfDeferredDebtIssuanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-738" unitRef="usd">267157000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-6" decimals="-3" id="f-739" unitRef="usd">188419000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-7" decimals="-3" id="f-740" unitRef="usd">117361000</ifrs-full:FinanceCosts>
    <alvo:DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock contextRef="c-1" id="f-741">Depreciation, amortization and impairment &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation, amortization and impairment expenses incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation and impairment of property, plant and equipment (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation of right of use assets (see Note 13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization and impairment of intangible assets (see Note 15)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation, amortization and impairment expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total depreciation, amortization and impairment expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDepreciationAmortizationAndImpairmentExplanatoryTextBlock>
    <alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock contextRef="c-1" id="f-742">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation, amortization and impairment expenses incurred during the years ended 31&#160;December 2023, 2022, and 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation and impairment of property, plant and equipment (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation of right of use assets (see Note 13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization and impairment of intangible assets (see Note 15)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExplanatoryTableTextBlock>
    <alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-743" unitRef="usd">14353000</alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment>
    <alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-744" unitRef="usd">9807000</alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment>
    <alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-745" unitRef="usd">10666000</alvo:DepreciationAndImpairmentOfPropertyPlantAndEquipment>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-3" id="f-746" unitRef="usd">8913000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-6" decimals="-3" id="f-747" unitRef="usd">9869000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-7" decimals="-3" id="f-748" unitRef="usd">8699000</ifrs-full:DepreciationRightofuseAssets>
    <alvo:AmortizationAndImpairmentOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-749" unitRef="usd">2723000</alvo:AmortizationAndImpairmentOfIntangibleAssets>
    <alvo:AmortizationAndImpairmentOfIntangibleAssets contextRef="c-6" decimals="-3" id="f-750" unitRef="usd">3488000</alvo:AmortizationAndImpairmentOfIntangibleAssets>
    <alvo:AmortizationAndImpairmentOfIntangibleAssets contextRef="c-7" decimals="-3" id="f-751" unitRef="usd">4916000</alvo:AmortizationAndImpairmentOfIntangibleAssets>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-752" unitRef="usd">25989000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-6" decimals="-3" id="f-753" unitRef="usd">23164000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-7" decimals="-3" id="f-754" unitRef="usd">24281000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock contextRef="c-1" id="f-755">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation, amortization and impairment expenses are included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total depreciation, amortization and impairment expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndImpairmentExpenseIncludedInConsolidatedStatementsProfitOrLossAndOtherComprehensiveIncomeOrLossExplanatoryTableTextBlock>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-185" decimals="-3" id="f-756" unitRef="usd">15582000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-186" decimals="-3" id="f-757" unitRef="usd">10053000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-187" decimals="-3" id="f-758" unitRef="usd">0</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-188" decimals="-3" id="f-759" unitRef="usd">6886000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-189" decimals="-3" id="f-760" unitRef="usd">9757000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-190" decimals="-3" id="f-761" unitRef="usd">21764000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-191" decimals="-3" id="f-762" unitRef="usd">3521000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-192" decimals="-3" id="f-763" unitRef="usd">3354000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-193" decimals="-3" id="f-764" unitRef="usd">2517000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-765" unitRef="usd">25989000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-6" decimals="-3" id="f-766" unitRef="usd">23164000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-7" decimals="-3" id="f-767" unitRef="usd">24281000</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <alvo:DisclosureOfAuditFeesExplanatoryTextBlock contextRef="c-1" id="f-768">Audit fees &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financial Statement audit fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other fees, including tax services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial Statements audit fees consist of fees for the audit of our annual financial statements and other professional services provided in connection with the statutory and regulatory filings or engagements, including fees for the review of our interim financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:28.34pt;text-indent:-0.01pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other fees, including tax services, include fees for review of our current and historical financial information included in our SEC registration statements, fees for tax compliance, tax advice, and tax planning. &lt;/span&gt;&lt;/div&gt;Audit fees for 2021 included fees for the audit of the consolidated financial statements for 2019 and 2020.</alvo:DisclosureOfAuditFeesExplanatoryTextBlock>
    <alvo:DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock contextRef="c-1" id="f-769">&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financial Statement audit fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other fees, including tax services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutAuditFeesExplanatoryTableTextBlock>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c-1" decimals="-3" id="f-770" unitRef="usd">2876000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c-6" decimals="-3" id="f-771" unitRef="usd">2615000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c-7" decimals="-3" id="f-772" unitRef="usd">5502000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForTaxServices contextRef="c-1" decimals="-3" id="f-773" unitRef="usd">462000</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemunerationForTaxServices contextRef="c-6" decimals="-3" id="f-774" unitRef="usd">676000</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemunerationForTaxServices contextRef="c-7" decimals="-3" id="f-775" unitRef="usd">136000</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemuneration contextRef="c-1" decimals="-3" id="f-776" unitRef="usd">3339000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration contextRef="c-6" decimals="-3" id="f-777" unitRef="usd">3291000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration contextRef="c-7" decimals="-3" id="f-778" unitRef="usd">5638000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-779">Income tax &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Taxation recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Current tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Direct taxes - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Direct taxes &#x2013; prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total current tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(89,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(54,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(48,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(100,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(48,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(99,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(47,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The prior year deferred tax impact of $10.7 million mainly relates to foreign currency impact on losses denominated in Icelandic krona. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The factors affecting the tax benefit during the years ended 31&#160;December 2023 and 2022 relate to the recognition of a deferred tax asset on accumulated tax losses, as management assessed that it was probable that the accumulated tax losses would be fully utilized in the coming years, as further described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There were no accruals for tax contingencies during the years ended 31&#160;December 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effective tax rate for the year of 15.3% (2022: 6.9%, 2021: 32.0%) is lower than the applicable Luxembourgish statutory rate of corporation tax. The reconciling items between the statutory rate and the effective tax rate are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effect of tax rate in foreign jurisdictions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-recognition of tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The movement in net deferred taxes during the years ended 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;209,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;170,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax credited to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;309,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;209,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;309,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;209,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Where there is a right of offset of deferred tax balances within the same tax jurisdiction, IAS 12 requires these to be presented after such offset in the consolidated statements of financial position. The closing deferred tax balances included above are after offset; however, the disclosure of deferred tax assets by category below are presented before such offset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amount of deferred tax recognized in the consolidated statements of financial position as of 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets attributable to temporary differences in respect of tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;301,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets attributable to other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities attributable to other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;309,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;209,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A deferred tax liability has been recognized in relation to ordinary timing differences arising from depreciation, amortization, other provisions and difference in measurement basis of customer relationships. A deferred tax liability of $3.6&#160;million and $2.9 million has been recognized as of 31&#160;December 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A deferred tax asset has been recognized in relation to ordinary timing differences arising from various provisions, reserves, employee benefits and tax losses carried forward in the Group. The deferred tax asset on tax losses relates to tax losses arising in Iceland, and management considers probable that future forecasted profit associated with product and out-licensing revenue will be available to offset the cumulative tax losses as of 31&#160;December 2023. No deferred tax asset is recognized on tax losses arising in Luxembourg as their recoverability is unlikely to be realized. A deferred tax asset of $309.8&#160;million and $209.5 million is recognized as of 31&#160;December 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These tax losses expire as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024-2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027-2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;289,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Later&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,155,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,513,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 2023, the Group has total unused tax losses of $1,514 million which is comprised of $1,501 million of accumulated tax losses in Iceland and $13 million accumulated tax losses in Luxembourg.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <alvo:DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock contextRef="c-1" id="f-780">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Taxation recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Current tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Direct taxes - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Direct taxes &#x2013; prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total current tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(89,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(54,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(48,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(100,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(48,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(99,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(47,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutMajorComponentsOfIncomeTaxExplanatoryTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-1" decimals="-3" id="f-781" unitRef="usd">1307000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-6" decimals="-3" id="f-782" unitRef="usd">1015000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-7" decimals="-3" id="f-783" unitRef="usd">706000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c-1" decimals="-3" id="f-784" unitRef="usd">-60000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c-6" decimals="-3" id="f-785" unitRef="usd">-115000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c-7" decimals="-3" id="f-786" unitRef="usd">491000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="c-1" decimals="-3" id="f-787" unitRef="usd">1247000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="c-6" decimals="-3" id="f-788" unitRef="usd">900000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="c-7" decimals="-3" id="f-789" unitRef="usd">1197000</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-1" decimals="-3" id="f-790" unitRef="usd">-89847000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-6" decimals="-3" id="f-791" unitRef="usd">-54236000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-7" decimals="-3" id="f-792" unitRef="usd">-48414000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods contextRef="c-1" decimals="-3" id="f-793" unitRef="usd">-10718000</ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods>
    <ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods contextRef="c-6" decimals="-3" id="f-794" unitRef="usd">15269000</ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods>
    <ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods contextRef="c-7" decimals="-3" id="f-795" unitRef="usd">-477000</ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods>
    <alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods contextRef="c-1" decimals="-3" id="f-796" unitRef="usd">-100565000</alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods>
    <alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods contextRef="c-6" decimals="-3" id="f-797" unitRef="usd">-38967000</alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods>
    <alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods contextRef="c-7" decimals="-3" id="f-798" unitRef="usd">-48891000</alvo:DeferredTaxExpenseIncomeAndAdjustmentsForDeferredTaxOfPriorPeriods>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-799" unitRef="usd">-99318000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-6" decimals="-3" id="f-800" unitRef="usd">-38067000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-7" decimals="-3" id="f-801" unitRef="usd">-47694000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods contextRef="c-1" decimals="-5" id="f-802" unitRef="usd">-10700000</ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-1" decimals="3" id="f-803" unitRef="number">0.153</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-6" decimals="3" id="f-804" unitRef="number">0.069</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-7" decimals="3" id="f-805" unitRef="number">0.320</ifrs-full:AverageEffectiveTaxRate>
    <alvo:DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock contextRef="c-1" id="f-806">The reconciling items between the statutory rate and the effective tax rate are as follows: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effect of tax rate in foreign jurisdictions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-recognition of tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutEffectiveTaxRateReconciliationExplanatoryTableTextBlock>
    <ifrs-full:ApplicableTaxRate contextRef="c-1" decimals="3" id="f-807" unitRef="number">0.249</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-6" decimals="3" id="f-808" unitRef="number">0.249</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-7" decimals="3" id="f-809" unitRef="number">0.249</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-1" decimals="3" id="f-810" unitRef="number">-0.034</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-6" decimals="3" id="f-811" unitRef="number">-0.024</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-7" decimals="3" id="f-812" unitRef="number">-0.082</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="c-1" decimals="3" id="f-813" unitRef="number">-0.067</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="c-6" decimals="3" id="f-814" unitRef="number">-0.089</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="c-7" decimals="3" id="f-815" unitRef="number">0.304</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <alvo:TaxRateEffectOfNonrecognitionOfTaxLosses contextRef="c-1" decimals="3" id="f-816" unitRef="number">-0.015</alvo:TaxRateEffectOfNonrecognitionOfTaxLosses>
    <alvo:TaxRateEffectOfNonrecognitionOfTaxLosses contextRef="c-6" decimals="3" id="f-817" unitRef="number">-0.038</alvo:TaxRateEffectOfNonrecognitionOfTaxLosses>
    <alvo:TaxRateEffectOfNonrecognitionOfTaxLosses contextRef="c-7" decimals="3" id="f-818" unitRef="number">-0.150</alvo:TaxRateEffectOfNonrecognitionOfTaxLosses>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-1" decimals="3" id="f-819" unitRef="number">0.020</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-6" decimals="3" id="f-820" unitRef="number">-0.029</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-7" decimals="3" id="f-821" unitRef="number">-0.001</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-1" decimals="3" id="f-822" unitRef="number">0.153</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-6" decimals="3" id="f-823" unitRef="number">0.069</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-7" decimals="3" id="f-824" unitRef="number">0.320</ifrs-full:AverageEffectiveTaxRate>
    <alvo:DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock contextRef="c-1" id="f-825">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The movement in net deferred taxes during the years ended 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;209,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;170,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax credited to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;309,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;209,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;309,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;209,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-8" decimals="-3" id="f-826" unitRef="usd">-209187000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-9" decimals="-3" id="f-827" unitRef="usd">-170268000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-828" unitRef="usd">-100567000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-6" decimals="-3" id="f-829" unitRef="usd">-38919000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-5" decimals="-3" id="f-830" unitRef="usd">-309754000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-8" decimals="-3" id="f-831" unitRef="usd">-209187000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:NetDeferredTaxAssets contextRef="c-5" decimals="-3" id="f-832" unitRef="usd">309807000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets contextRef="c-8" decimals="-3" id="f-833" unitRef="usd">209496000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-834" unitRef="usd">53000</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c-8" decimals="-3" id="f-835" unitRef="usd">309000</ifrs-full:NetDeferredTaxLiabilities>
    <alvo:DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock contextRef="c-1" id="f-836">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amount of deferred tax recognized in the consolidated statements of financial position as of 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets attributable to temporary differences in respect of tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;301,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets attributable to other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities attributable to other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;309,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;209,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutDeferredTaxRecognizedInTheConsolidatedStatementsOfFinancialPositionExplanatoryTableTextBlock>
    <ifrs-full:NetDeferredTaxAssets contextRef="c-194" decimals="-3" id="f-837" unitRef="usd">301375000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets contextRef="c-195" decimals="-3" id="f-838" unitRef="usd">205290000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets contextRef="c-196" decimals="-3" id="f-839" unitRef="usd">11941000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets contextRef="c-197" decimals="-3" id="f-840" unitRef="usd">6832000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c-196" decimals="-3" id="f-841" unitRef="usd">3562000</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c-197" decimals="-3" id="f-842" unitRef="usd">2935000</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-5" decimals="-3" id="f-843" unitRef="usd">-309754000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-8" decimals="-3" id="f-844" unitRef="usd">-209187000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c-196" decimals="-5" id="f-845" unitRef="usd">3600000</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c-197" decimals="-5" id="f-846" unitRef="usd">2900000</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets contextRef="c-198" decimals="-5" id="f-847" unitRef="usd">309800000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-199" decimals="-5" id="f-848" unitRef="usd">209500000</ifrs-full:DeferredTaxAssets>
    <alvo:DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock contextRef="c-1" id="f-849">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These tax losses expire as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024-2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027-2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;289,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Later&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,155,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,513,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutExpirationOfUnusedTaxLossesExplanatoryTableTextBlock>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-200" decimals="-3" id="f-850" unitRef="usd">68821000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-201" decimals="-3" id="f-851" unitRef="usd">289608000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-202" decimals="-3" id="f-852" unitRef="usd">1155294000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-5" decimals="-3" id="f-853" unitRef="usd">1513723000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-5" decimals="-6" id="f-854" unitRef="usd">1514000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-203" decimals="-6" id="f-855" unitRef="usd">1501000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-204" decimals="-6" id="f-856" unitRef="usd">13000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-857">Loss per share &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic loss per share is computed by dividing loss for the year by the weighted average number of ordinary shares outstanding during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted loss per share is computed by adjusting the calculation of basic loss per share for the effects of dilutive potential ordinary shares from financial instruments that may be converted or exercised into ordinary shares of the Group. For the years ended 31&#160;December 2023 and 2022, 86,745,377 and 148,857,998, respectively, potential ordinary shares pursuant to the RSUs, Senior Bond Warrants, Aztiq Convertible Bond, 2022 Convertible Bonds, OACB Warrants, Predecessor Earn Out Shares, and OACB Earn Out Shares (as defined and discussed in Notes 21 and 28) were excluded in the calculation of diluted loss per share, since the effect of doing so would result in a reduction of loss per share and thus be antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; For the year ended 31&#160;December 2021, there were no potential ordinary shares pursuant to such agreements as all conversion, warrant and funding rights associated with these agreements had been exercised or otherwise expired (refer to Note 22 for further details). Therefore, the calculation of diluted loss per share did not differ from the calculation of basic loss per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The calculation of basic and diluted loss per share for the years ended 31&#160;December 2023, 2022, and 2021 is as follows (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(551,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(513,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(101,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average number of ordinary shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;227,256,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;197,721,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,673,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented contextRef="c-1" decimals="0" id="f-858" unitRef="shares">86745377</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented contextRef="c-6" decimals="0" id="f-859" unitRef="shares">148857998</ifrs-full:NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented>
    <alvo:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare contextRef="c-7" decimals="0" id="f-860" unitRef="shares">0</alvo:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c-1" id="f-861">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The calculation of basic and diluted loss per share for the years ended 31&#160;December 2023, 2022, and 2021 is as follows (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(551,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(513,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(101,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average number of ordinary shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;227,256,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;197,721,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,673,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-862" unitRef="usd">-551731000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-6" decimals="-3" id="f-863" unitRef="usd">-513580000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-3" id="f-864" unitRef="usd">-101504000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="0" id="f-865" unitRef="shares">227256469</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-866" unitRef="shares">227256469</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-6" decimals="0" id="f-867" unitRef="shares">197721710</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-6" decimals="0" id="f-868" unitRef="shares">197721710</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-7" decimals="0" id="f-869" unitRef="shares">110673309</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-7" decimals="0" id="f-870" unitRef="shares">110673309</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-871"
      unitRef="usdPerShare">-2.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-872"
      unitRef="usdPerShare">-2.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-6"
      decimals="2"
      id="f-873"
      unitRef="usdPerShare">-2.60</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-6"
      decimals="2"
      id="f-874"
      unitRef="usdPerShare">-2.60</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-7"
      decimals="2"
      id="f-875"
      unitRef="usdPerShare">-0.92</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-7"
      decimals="2"
      id="f-876"
      unitRef="usdPerShare">-0.92</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-877">Property, plant and equipment &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment consists of facility and computer equipment, furniture, fixtures and leasehold improvements. Movements within property, plant and equipment during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;Equipment &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Furniture, &lt;br/&gt;fixtures and &lt;br/&gt;leasehold &lt;br/&gt;improvements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Computer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;equipment &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;176,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;304,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;236,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;Equipment &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Furniture, &lt;br/&gt;fixtures and &lt;br/&gt;leasehold &lt;br/&gt;improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Computer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;equipment &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;88,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;153,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;99,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;220,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 16 November 2022, the Group entered into a share purchase agreement (the &#x201c;Share Purchase Agreement&#x201d;) relating to shares in Fasteignaf&#xe9;lagi&#xf0; S&#xe6;mundur hf. (&#x201c;Saemundur&#x201d;) with ATP Holdings ehf., an affiliate of Aztiq. Pursuant to the Share Purchase Agreement, Alvotech purchased 99.99% of the shares in Saemundur through the issuance the Aztiq Convertible Bond, as defined and discussed in Note 21, and the assumption of debt. At the time of closing, Saemundur&#x2019;s only asset was the property where Alvotech&#x2019;s Reykjavik manufacturing and research facility (the &#x201c;Facility&#x201d;) are located. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Share Purchase Agreement was accounted for as an asset acquisition under IFRS 3 as all of the fair value of the gross assets acquired from Saemundur were concentrated in the Alvotech Facility. As a result, the purchase price was determined to be $115.0 million, which consists of $80.0 million related to the fair value of the Aztiq Convertible Bond, $30.0 million in loans assumed by the Company, and $5.0 million associated with the settlement of the pre-existing relationship with Saemundur. The entire purchase price was allocated to the Facility as it was the only asset acquired. Additionally, the Company recognized a $3.9 million loss on the extinguishment of the lease liability related to the Facility. See Note 21 for further details. &lt;/span&gt;&lt;/div&gt;The Group pledged $127.4 million and $122.4 million of property, plant and equipment as collateral to secure bank loans with third parties as of 31&#160;December 2023 and 2022, respectively.</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-878">Movements within property, plant and equipment during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;Equipment &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Furniture, &lt;br/&gt;fixtures and &lt;br/&gt;leasehold &lt;br/&gt;improvements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Computer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;equipment &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;176,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;304,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;236,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;Equipment &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Furniture, &lt;br/&gt;fixtures and &lt;br/&gt;leasehold &lt;br/&gt;improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Computer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;equipment &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;88,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;153,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;99,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;220,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-205" decimals="-3" id="f-879" unitRef="usd">115000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-206" decimals="-3" id="f-880" unitRef="usd">145150000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-207" decimals="-3" id="f-881" unitRef="usd">9598000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-208" decimals="-3" id="f-882" unitRef="usd">1959000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-209" decimals="-3" id="f-883" unitRef="usd">271707000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-210" decimals="-3" id="f-884" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-211" decimals="-3" id="f-885" unitRef="usd">2771000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-212" decimals="-3" id="f-886" unitRef="usd">-112000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-213" decimals="-3" id="f-887" unitRef="usd">-7000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-214" decimals="-3" id="f-888" unitRef="usd">2652000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-210" decimals="-3" id="f-889" unitRef="usd">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-211" decimals="-3" id="f-890" unitRef="usd">29351000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-212" decimals="-3" id="f-891" unitRef="usd">1500000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-213" decimals="-3" id="f-892" unitRef="usd">518000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-214" decimals="-3" id="f-893" unitRef="usd">31369000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-210" decimals="-3" id="f-894" unitRef="usd">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-211" decimals="-3" id="f-895" unitRef="usd">1233000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-212" decimals="-3" id="f-896" unitRef="usd">23000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-213" decimals="-3" id="f-897" unitRef="usd">136000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-214" decimals="-3" id="f-898" unitRef="usd">1392000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-210" decimals="-3" id="f-899" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-211" decimals="-3" id="f-900" unitRef="usd">679000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-212" decimals="-3" id="f-901" unitRef="usd">-85000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-213" decimals="-3" id="f-902" unitRef="usd">-22000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-214" decimals="-3" id="f-903" unitRef="usd">572000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-215" decimals="-3" id="f-904" unitRef="usd">115000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-216" decimals="-3" id="f-905" unitRef="usd">176718000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-217" decimals="-3" id="f-906" unitRef="usd">10878000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-218" decimals="-3" id="f-907" unitRef="usd">2312000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-219" decimals="-3" id="f-908" unitRef="usd">304908000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-220" decimals="-3" id="f-909" unitRef="usd">-359000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-221" decimals="-3" id="f-910" unitRef="usd">-46002000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-222" decimals="-3" id="f-911" unitRef="usd">-3233000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-223" decimals="-3" id="f-912" unitRef="usd">-1519000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-224" decimals="-3" id="f-913" unitRef="usd">-51113000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-225" decimals="-3" id="f-914" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-226" decimals="-3" id="f-915" unitRef="usd">3330000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-227" decimals="-3" id="f-916" unitRef="usd">-112000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-228" decimals="-3" id="f-917" unitRef="usd">-7000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-229" decimals="-3" id="f-918" unitRef="usd">3211000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-225" decimals="-3" id="f-919" unitRef="usd">2875000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-226" decimals="-3" id="f-920" unitRef="usd">10572000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-227" decimals="-3" id="f-921" unitRef="usd">676000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-228" decimals="-3" id="f-922" unitRef="usd">230000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-229" decimals="-3" id="f-923" unitRef="usd">14353000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-225" decimals="-3" id="f-924" unitRef="usd">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-226" decimals="-3" id="f-925" unitRef="usd">-737000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-227" decimals="-3" id="f-926" unitRef="usd">-22000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-228" decimals="-3" id="f-927" unitRef="usd">-136000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-229" decimals="-3" id="f-928" unitRef="usd">-895000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-225" decimals="-3" id="f-929" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-226" decimals="-3" id="f-930" unitRef="usd">330000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-227" decimals="-3" id="f-931" unitRef="usd">40000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-228" decimals="-3" id="f-932" unitRef="usd">-23000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-229" decimals="-3" id="f-933" unitRef="usd">347000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-230" decimals="-3" id="f-934" unitRef="usd">-3234000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-231" decimals="-3" id="f-935" unitRef="usd">-59497000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-232" decimals="-3" id="f-936" unitRef="usd">-3815000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-233" decimals="-3" id="f-937" unitRef="usd">-1583000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-234" decimals="-3" id="f-938" unitRef="usd">-68129000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-235" decimals="-3" id="f-939" unitRef="usd">111766000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-236" decimals="-3" id="f-940" unitRef="usd">117221000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-237" decimals="-3" id="f-941" unitRef="usd">7063000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-238" decimals="-3" id="f-942" unitRef="usd">729000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-943" unitRef="usd">236779000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-239" decimals="-3" id="f-944" unitRef="usd">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-240" decimals="-3" id="f-945" unitRef="usd">88510000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-241" decimals="-3" id="f-946" unitRef="usd">32395000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-242" decimals="-3" id="f-947" unitRef="usd">1551000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-243" decimals="-3" id="f-948" unitRef="usd">122456000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-244" decimals="-3" id="f-949" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-245" decimals="-3" id="f-950" unitRef="usd">25486000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-246" decimals="-3" id="f-951" unitRef="usd">-25486000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-247" decimals="-3" id="f-952" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-248" decimals="-3" id="f-953" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-244" decimals="-3" id="f-954" unitRef="usd">115000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-245" decimals="-3" id="f-955" unitRef="usd">35156000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-246" decimals="-3" id="f-956" unitRef="usd">2706000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-247" decimals="-3" id="f-957" unitRef="usd">357000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-248" decimals="-3" id="f-958" unitRef="usd">153219000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-244" decimals="-3" id="f-959" unitRef="usd">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-245" decimals="-3" id="f-960" unitRef="usd">2959000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-246" decimals="-3" id="f-961" unitRef="usd">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-247" decimals="-3" id="f-962" unitRef="usd">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-248" decimals="-3" id="f-963" unitRef="usd">2959000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-244" decimals="-3" id="f-964" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-245" decimals="-3" id="f-965" unitRef="usd">-1043000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-246" decimals="-3" id="f-966" unitRef="usd">-17000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-247" decimals="-3" id="f-967" unitRef="usd">51000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-248" decimals="-3" id="f-968" unitRef="usd">-1009000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-205" decimals="-3" id="f-969" unitRef="usd">115000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-206" decimals="-3" id="f-970" unitRef="usd">145150000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-207" decimals="-3" id="f-971" unitRef="usd">9598000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-208" decimals="-3" id="f-972" unitRef="usd">1959000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-209" decimals="-3" id="f-973" unitRef="usd">271707000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-249" decimals="-3" id="f-974" unitRef="usd">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-250" decimals="-3" id="f-975" unitRef="usd">-33853000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-251" decimals="-3" id="f-976" unitRef="usd">-8614000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-252" decimals="-3" id="f-977" unitRef="usd">-1459000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-253" decimals="-3" id="f-978" unitRef="usd">-43926000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-254" decimals="-3" id="f-979" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-255" decimals="-3" id="f-980" unitRef="usd">5985000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-256" decimals="-3" id="f-981" unitRef="usd">-5985000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-257" decimals="-3" id="f-982" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-258" decimals="-3" id="f-983" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-254" decimals="-3" id="f-984" unitRef="usd">359000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-255" decimals="-3" id="f-985" unitRef="usd">8752000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-256" decimals="-3" id="f-986" unitRef="usd">621000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-257" decimals="-3" id="f-987" unitRef="usd">75000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-258" decimals="-3" id="f-988" unitRef="usd">9807000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-254" decimals="-3" id="f-989" unitRef="usd">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-255" decimals="-3" id="f-990" unitRef="usd">-2597000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-256" decimals="-3" id="f-991" unitRef="usd">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-257" decimals="-3" id="f-992" unitRef="usd">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-258" decimals="-3" id="f-993" unitRef="usd">-2597000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-254" decimals="-3" id="f-994" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-255" decimals="-3" id="f-995" unitRef="usd">9000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-256" decimals="-3" id="f-996" unitRef="usd">-17000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-257" decimals="-3" id="f-997" unitRef="usd">-15000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-258" decimals="-3" id="f-998" unitRef="usd">-23000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-220" decimals="-3" id="f-999" unitRef="usd">-359000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-221" decimals="-3" id="f-1000" unitRef="usd">-46002000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-222" decimals="-3" id="f-1001" unitRef="usd">-3233000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-223" decimals="-3" id="f-1002" unitRef="usd">-1519000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-224" decimals="-3" id="f-1003" unitRef="usd">-51113000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-259" decimals="-3" id="f-1004" unitRef="usd">114641000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-260" decimals="-3" id="f-1005" unitRef="usd">99148000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-261" decimals="-3" id="f-1006" unitRef="usd">6365000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-262" decimals="-3" id="f-1007" unitRef="usd">440000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-1008" unitRef="usd">220594000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="c-263"
      decimals="4"
      id="f-1009"
      unitRef="number">0.9999</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <alvo:AssetAcquisitionsConsiderationTransferred contextRef="c-264" decimals="-5" id="f-1010" unitRef="usd">115000000</alvo:AssetAcquisitionsConsiderationTransferred>
    <alvo:AssetAcquisitionConsiderationTransferredConvertibleBond contextRef="c-264" decimals="-5" id="f-1011" unitRef="usd">80000000</alvo:AssetAcquisitionConsiderationTransferredConvertibleBond>
    <alvo:AssetAcquisitionConsiderationTransferredLoansAssumed contextRef="c-264" decimals="-5" id="f-1012" unitRef="usd">30000000</alvo:AssetAcquisitionConsiderationTransferredLoansAssumed>
    <alvo:AssetAcquisitionConsiderationTransferredSettlements contextRef="c-265" decimals="-5" id="f-1013" unitRef="usd">5000000</alvo:AssetAcquisitionConsiderationTransferredSettlements>
    <alvo:LossOnExtinguishmentOfTheLeaseLiability contextRef="c-265" decimals="-5" id="f-1014" unitRef="usd">3900000</alvo:LossOnExtinguishmentOfTheLeaseLiability>
    <ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity contextRef="c-5" decimals="-5" id="f-1015" unitRef="usd">127400000</ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity>
    <ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity contextRef="c-8" decimals="-5" id="f-1016" unitRef="usd">122400000</ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c-1" id="f-1017">Leases &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s leased assets consist of facilities, fleet and equipment pursuant to both arrangements with third parties and related parties. The carrying amounts of the Group&#x2019;s right-of-use assets and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adjustments for indexed leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;New leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derecognition due to acquisition of Alvotech Facility (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(88,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;119,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group entered into lease agreement with Fasteignafelagid Eyjolfur hf. in April 2023 for a facility expansion in Iceland with remaining lease terms of approximately 15 years as of 31 December 2023. The building is 140,000 square feet and is currently in construction. The expansion is close to being finalized and is expected to be completed in 2024. The lease amount is in substance fixed and is based on construction cost, adjusted monthly. Righ-of-use asset as of 31&#160;December 2023 amounts to $68.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s right-of-use assets as of 31&#160;December 2023 and 2022 are comprised of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fleet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;119,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The Group&#x2019;s lease liabilities and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adjustments for indexed leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;New leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Installment payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derecognition due to acquisition of Alvotech Facility (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(80,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;105,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amounts recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 in relation to the Group&#x2019;s lease arrangements are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Depreciation expense from right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fleet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total depreciation expense from right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency difference on lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss from extinguishment of lease agreement (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total amount recognized in profit and loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The maturity analysis of undiscounted lease payments as of 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;89,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;155,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Group&#x2019;s lease liabilities as of 31&#160;December 2023 and 2022 do not include $0.7 million and  $0.1 million, respectively, of costs for short-term leases and low value leases.</ifrs-full:DisclosureOfLeasesExplanatory>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c-1" id="f-1018">The carrying amounts of the Group&#x2019;s right-of-use assets and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adjustments for indexed leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;New leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derecognition due to acquisition of Alvotech Facility (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(88,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;119,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="c-8" decimals="-3" id="f-1019" unitRef="usd">47501000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-9" decimals="-3" id="f-1020" unitRef="usd">126801000</ifrs-full:RightofuseAssets>
    <alvo:AdjustmentsForIndexedLeasesRightOfUseAssets contextRef="c-1" decimals="-3" id="f-1021" unitRef="usd">7354000</alvo:AdjustmentsForIndexedLeasesRightOfUseAssets>
    <alvo:AdjustmentsForIndexedLeasesRightOfUseAssets contextRef="c-6" decimals="-3" id="f-1022" unitRef="usd">10201000</alvo:AdjustmentsForIndexedLeasesRightOfUseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-1" decimals="-3" id="f-1023" unitRef="usd">74109000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-6" decimals="-3" id="f-1024" unitRef="usd">9583000</ifrs-full:AdditionsToRightofuseAssets>
    <alvo:CancellationsRightOfUseAssets contextRef="c-1" decimals="-3" id="f-1025" unitRef="usd">139000</alvo:CancellationsRightOfUseAssets>
    <alvo:CancellationsRightOfUseAssets contextRef="c-6" decimals="-3" id="f-1026" unitRef="usd">0</alvo:CancellationsRightOfUseAssets>
    <alvo:DecreaseThroughDerecognitionRightOfUseAssets contextRef="c-1" decimals="-3" id="f-1027" unitRef="usd">0</alvo:DecreaseThroughDerecognitionRightOfUseAssets>
    <alvo:DecreaseThroughDerecognitionRightOfUseAssets contextRef="c-6" decimals="-3" id="f-1028" unitRef="usd">88941000</alvo:DecreaseThroughDerecognitionRightOfUseAssets>
    <alvo:ReclassificationRightOfUseAssets contextRef="c-1" decimals="-3" id="f-1029" unitRef="usd">443000</alvo:ReclassificationRightOfUseAssets>
    <alvo:ReclassificationRightOfUseAssets contextRef="c-6" id="f-1030" unitRef="usd" xsi:nil="true"/>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-3" id="f-1031" unitRef="usd">8913000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-6" decimals="-3" id="f-1032" unitRef="usd">9869000</ifrs-full:DepreciationRightofuseAssets>
    <alvo:TranslationDifferenceRightOfUseAssets contextRef="c-1" decimals="-3" id="f-1033" unitRef="usd">333000</alvo:TranslationDifferenceRightOfUseAssets>
    <alvo:TranslationDifferenceRightOfUseAssets contextRef="c-6" decimals="-3" id="f-1034" unitRef="usd">-274000</alvo:TranslationDifferenceRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-5" decimals="-3" id="f-1035" unitRef="usd">119802000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-8" decimals="-3" id="f-1036" unitRef="usd">47501000</ifrs-full:RightofuseAssets>
    <alvo:WeightedAverageRemainingLeaseTerm contextRef="c-266" id="f-1037">P15Y</alvo:WeightedAverageRemainingLeaseTerm>
    <alvo:AreaOfProperty contextRef="c-267" decimals="-3" id="f-1038" unitRef="sqft">140000</alvo:AreaOfProperty>
    <ifrs-full:RightofuseAssets contextRef="c-267" decimals="-5" id="f-1039" unitRef="usd">68500000</ifrs-full:RightofuseAssets>
    <alvo:DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-1040">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s right-of-use assets as of 31&#160;December 2023 and 2022 are comprised of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fleet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;119,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutClassesOfRightOfUseAssetsExplanatoryTableTextBlock>
    <ifrs-full:RightofuseAssets contextRef="c-268" decimals="-3" id="f-1041" unitRef="usd">110692000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-269" decimals="-3" id="f-1042" unitRef="usd">41702000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-270" decimals="-3" id="f-1043" unitRef="usd">389000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-271" decimals="-3" id="f-1044" unitRef="usd">339000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-272" decimals="-3" id="f-1045" unitRef="usd">8721000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-273" decimals="-3" id="f-1046" unitRef="usd">5460000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-5" decimals="-3" id="f-1047" unitRef="usd">119802000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-8" decimals="-3" id="f-1048" unitRef="usd">47501000</ifrs-full:RightofuseAssets>
    <alvo:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-1049">The Group&#x2019;s lease liabilities and the movements during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adjustments for indexed leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;New leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Installment payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derecognition due to acquisition of Alvotech Facility (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(80,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;105,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:LeaseLiabilities contextRef="c-8" decimals="-3" id="f-1050" unitRef="usd">40532000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-9" decimals="-3" id="f-1051" unitRef="usd">122140000</ifrs-full:LeaseLiabilities>
    <alvo:LeaseLiabilitiesAdjustmentsForIndexedLeases contextRef="c-1" decimals="-3" id="f-1052" unitRef="usd">7405000</alvo:LeaseLiabilitiesAdjustmentsForIndexedLeases>
    <alvo:LeaseLiabilitiesAdjustmentsForIndexedLeases contextRef="c-6" decimals="-3" id="f-1053" unitRef="usd">10247000</alvo:LeaseLiabilitiesAdjustmentsForIndexedLeases>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-1054" unitRef="usd">72882000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-6" decimals="-3" id="f-1055" unitRef="usd">7458000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <alvo:LeaseLiabilitiesCancelledLease contextRef="c-1" decimals="-3" id="f-1056" unitRef="usd">167000</alvo:LeaseLiabilitiesCancelledLease>
    <alvo:LeaseLiabilitiesCancelledLease contextRef="c-6" decimals="-3" id="f-1057" unitRef="usd">0</alvo:LeaseLiabilitiesCancelledLease>
    <ifrs-full:CashOutflowForLeases contextRef="c-1" decimals="-3" id="f-1058" unitRef="usd">7260000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-6" decimals="-3" id="f-1059" unitRef="usd">7655000</ifrs-full:CashOutflowForLeases>
    <alvo:DerecognitionDueToAssetsAcquisition contextRef="c-1" decimals="-3" id="f-1060" unitRef="usd">0</alvo:DerecognitionDueToAssetsAcquisition>
    <alvo:DerecognitionDueToAssetsAcquisition contextRef="c-6" decimals="-3" id="f-1061" unitRef="usd">80075000</alvo:DerecognitionDueToAssetsAcquisition>
    <alvo:LeaseLiabilitiesForeignCurrencyAdjustment contextRef="c-1" decimals="-3" id="f-1062" unitRef="usd">1932000</alvo:LeaseLiabilitiesForeignCurrencyAdjustment>
    <alvo:LeaseLiabilitiesForeignCurrencyAdjustment contextRef="c-6" decimals="-3" id="f-1063" unitRef="usd">-11682000</alvo:LeaseLiabilitiesForeignCurrencyAdjustment>
    <alvo:LeaseLiabilitiesTranslationDifference contextRef="c-1" decimals="-3" id="f-1064" unitRef="usd">-9000</alvo:LeaseLiabilitiesTranslationDifference>
    <alvo:LeaseLiabilitiesTranslationDifference contextRef="c-6" decimals="-3" id="f-1065" unitRef="usd">99000</alvo:LeaseLiabilitiesTranslationDifference>
    <ifrs-full:LeaseLiabilities contextRef="c-5" decimals="-3" id="f-1066" unitRef="usd">115315000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-8" decimals="-3" id="f-1067" unitRef="usd">40532000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-5" decimals="-3" id="f-1068" unitRef="usd">9683000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-8" decimals="-3" id="f-1069" unitRef="usd">5163000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-5" decimals="-3" id="f-1070" unitRef="usd">105632000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-8" decimals="-3" id="f-1071" unitRef="usd">35369000</ifrs-full:NoncurrentLeaseLiabilities>
    <alvo:DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock contextRef="c-1" id="f-1072">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amounts recognized in the consolidated statements of profit or loss and other comprehensive income or loss during the years ended 31&#160;December 2023, 2022, and 2021 in relation to the Group&#x2019;s lease arrangements are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Depreciation expense from right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fleet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total depreciation expense from right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency difference on lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss from extinguishment of lease agreement (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total amount recognized in profit and loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutLeaseCostExplanatoryTableTextBlock>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-274" decimals="-3" id="f-1073" unitRef="usd">7631000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-275" decimals="-3" id="f-1074" unitRef="usd">9423000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-276" decimals="-3" id="f-1075" unitRef="usd">8228000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-277" decimals="-3" id="f-1076" unitRef="usd">180000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-278" decimals="-3" id="f-1077" unitRef="usd">119000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-279" decimals="-3" id="f-1078" unitRef="usd">38000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-280" decimals="-3" id="f-1079" unitRef="usd">1102000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-281" decimals="-3" id="f-1080" unitRef="usd">327000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-282" decimals="-3" id="f-1081" unitRef="usd">433000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-3" id="f-1082" unitRef="usd">8913000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-6" decimals="-3" id="f-1083" unitRef="usd">9869000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-7" decimals="-3" id="f-1084" unitRef="usd">8699000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-3" id="f-1085" unitRef="usd">3840000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-6" decimals="-3" id="f-1086" unitRef="usd">6022000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-7" decimals="-3" id="f-1087" unitRef="usd">6423000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <alvo:ForeignCurrencyDifferenceOnLeaseLiability contextRef="c-1" decimals="-3" id="f-1088" unitRef="usd">-1932000</alvo:ForeignCurrencyDifferenceOnLeaseLiability>
    <alvo:ForeignCurrencyDifferenceOnLeaseLiability contextRef="c-6" decimals="-3" id="f-1089" unitRef="usd">11682000</alvo:ForeignCurrencyDifferenceOnLeaseLiability>
    <alvo:ForeignCurrencyDifferenceOnLeaseLiability contextRef="c-7" decimals="-3" id="f-1090" unitRef="usd">3744000</alvo:ForeignCurrencyDifferenceOnLeaseLiability>
    <alvo:LossFromExtinguishmentOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-1091" unitRef="usd">28000</alvo:LossFromExtinguishmentOfLeaseLiabilities>
    <alvo:LossFromExtinguishmentOfLeaseLiabilities contextRef="c-6" decimals="-3" id="f-1092" unitRef="usd">3859000</alvo:LossFromExtinguishmentOfLeaseLiabilities>
    <alvo:LossFromExtinguishmentOfLeaseLiabilities contextRef="c-7" decimals="-3" id="f-1093" unitRef="usd">0</alvo:LossFromExtinguishmentOfLeaseLiabilities>
    <alvo:LeaseCostRecognizedInProfitAndLoss contextRef="c-1" decimals="-3" id="f-1094" unitRef="usd">14713000</alvo:LeaseCostRecognizedInProfitAndLoss>
    <alvo:LeaseCostRecognizedInProfitAndLoss contextRef="c-6" decimals="-3" id="f-1095" unitRef="usd">8068000</alvo:LeaseCostRecognizedInProfitAndLoss>
    <alvo:LeaseCostRecognizedInProfitAndLoss contextRef="c-7" decimals="-3" id="f-1096" unitRef="usd">11378000</alvo:LeaseCostRecognizedInProfitAndLoss>
    <alvo:DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-1097">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The maturity analysis of undiscounted lease payments as of 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;89,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;155,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutMaturityAnalysisForLeaseLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-283" decimals="-3" id="f-1098" unitRef="usd">14637000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-284" decimals="-3" id="f-1099" unitRef="usd">6000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-285" decimals="-3" id="f-1100" unitRef="usd">51053000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-286" decimals="-3" id="f-1101" unitRef="usd">20160000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-287" decimals="-3" id="f-1102" unitRef="usd">89682000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-288" decimals="-3" id="f-1103" unitRef="usd">22274000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-5" decimals="-3" id="f-1104" unitRef="usd">155372000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-8" decimals="-3" id="f-1105" unitRef="usd">48434000</ifrs-full:GrossLeaseLiabilities>
    <alvo:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c-1" decimals="-5" id="f-1106" unitRef="usd">700000</alvo:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <alvo:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c-6" decimals="-5" id="f-1107" unitRef="usd">100000</alvo:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:DisclosureOfGoodwillExplanatory contextRef="c-1" id="f-1108">Goodwill &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s goodwill balances as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance as of 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance as of 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill is recognized at the Group level, which is determined to be the smallest cash-generating unit. The recoverable amount of the cash-generating unit is determined based on a value in use calculation which uses cash flow projections based on the financial forecast for the period 2024-2030 which reflect the recent business developments of the Group and has been approved by management and the Board of Directors. The Group determined that the terminal growth rate and the discount rate are the key assumptions used in determining the current estimate of value in use. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash flows beyond 2030 have been extrapolated using a negative 5% terminal rate in both the 2023 and 2022 value in use calculations, respectively. A discount rate of 25.0% (2022: 27.6%) per annum was used in determining the current estimate of value in use. Since the recoverable amount of the cash-generating unit was substantially in excess of its carrying amount as of 31&#160;December 2023 and 2022, management believes that any reasonably possible change in the key assumptions on which the recoverable amount of the cash-generating unit is based would not cause the carrying amount of the cash-generating unit to exceed its recoverable amount. &lt;/span&gt;&lt;/div&gt;There were no goodwill impairment charges recognized in the consolidated statements of profit or loss and other comprehensive income or loss in any prior periods.</ifrs-full:DisclosureOfGoodwillExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory contextRef="c-1" id="f-1109">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s goodwill balances as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance as of 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance as of 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory>
    <ifrs-full:Goodwill contextRef="c-8" decimals="-3" id="f-1110" unitRef="usd">11643000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-9" decimals="-3" id="f-1111" unitRef="usd">12367000</ifrs-full:Goodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill contextRef="c-1" decimals="-3" id="f-1112" unitRef="usd">415000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill contextRef="c-6" decimals="-3" id="f-1113" unitRef="usd">-724000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill>
    <ifrs-full:Goodwill contextRef="c-5" decimals="-3" id="f-1114" unitRef="usd">12058000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-8" decimals="-3" id="f-1115" unitRef="usd">11643000</ifrs-full:Goodwill>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections contextRef="c-5" decimals="3" id="f-1116" unitRef="number">0.05</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections contextRef="c-8" decimals="3" id="f-1117" unitRef="number">0.05</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="c-5" decimals="3" id="f-1118" unitRef="number">0.250</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="c-8" decimals="3" id="f-1119" unitRef="number">0.276</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill contextRef="c-289" decimals="INF" id="f-1120" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill contextRef="c-290" decimals="INF" id="f-1121" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c-1" id="f-1122">Other Intangible assets &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other intangible assets consist of software, customer relationships, and licensed intellectual property rights. Movements in intangible assets during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Software &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Customer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;relationships &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Intellectual &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;property &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Retirement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Software &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Customer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;relationships &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Intellectual &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;property &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions during the year ended 31&#160;December 2023 were primarily comprised of licensed intellectual property rights from Kashiv as detailed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expense for amortization of the Group&#x2019;s intangible assets is included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At 31&#160;December 2023 and 2022, the Group performed a review of its intangible assets and determined certain software development had been abandoned. In assessing recoverable amount, the Group determined the market for resale was non-existent. Management therefore determined to fully impair the assets, resulting in an impairment charge of $1.8 million and $2.8 million during the years ended 31&#160;December 2023 and 2022, respectively. The impairment charge was recognized as an expense within &#x201c;General and administrative expense&#x201d;. For the year ended 31&#160;December 2022, the impairment was recognized as an expense as follows: $2.1 million in "Cost of product revenue" and $0.7 million in "General and administrative expense".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At 31&#160;December 2023, following the termination of the agreement with Biosana, the Group derecognized $15.0&#160;million of other intangible assets relating to intellectual property rights for the co-development and commercialization of AVT23. A corresponding receivable was recognized to reflect the claim against Biosana for full reimbursement. See further information on the receivable in Note 18.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Alvotech entered into an exclusive product licensing and supply agreement with Kashiv for the development and commercialization of AVT23 in September 2023. Under the terms of the agreement, Kashiv granted Alvotech an exclusive right for AVT23 which will be produced using Kashiv&#x2019;s proprietary process technology and commercialized by Alvotech in specific territories. In exchange, Alvotech made an upfront payment of $3.0&#160;million upon the signing of the agreement, with an additional $3.0&#160;million due upon the beginning of Phase 3 which coincides with the clinical trial application ("CTA") submission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, Alvotech may be obligated to pay Kashiv up to an aggregate of $25&#160;million (including the $6&#160;million upfront payments mentioned above), payable upon the achievement of various development and regulatory milestones, as well as certain tiered royalty payments up to an aggregate of $15&#160;million based on commercial sales of AVT23. The agreement terminates 10 years after the launch of AVT23 and is subject to certain customary termination rights.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c-1" id="f-1123">Movements in intangible assets during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Software &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Customer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;relationships &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Intellectual &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;property &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassification of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Retirement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Software &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Customer &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;relationships &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Intellectual &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;property &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-291" decimals="-3" id="f-1124" unitRef="usd">13684000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-292" decimals="-3" id="f-1125" unitRef="usd">2181000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-293" decimals="-3" id="f-1126" unitRef="usd">15000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-209" decimals="-3" id="f-1127" unitRef="usd">30865000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-294" decimals="-3" id="f-1128" unitRef="usd">1002000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-295" decimals="-3" id="f-1129" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-296" decimals="-3" id="f-1130" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-214" decimals="-3" id="f-1131" unitRef="usd">1002000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-294" decimals="-3" id="f-1132" unitRef="usd">4094000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-295" decimals="-3" id="f-1133" unitRef="usd">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-296" decimals="-3" id="f-1134" unitRef="usd">6000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-214" decimals="-3" id="f-1135" unitRef="usd">10094000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-294" decimals="-3" id="f-1136" unitRef="usd">1779000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-295" decimals="-3" id="f-1137" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-296" decimals="-3" id="f-1138" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-214" decimals="-3" id="f-1139" unitRef="usd">1779000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-294" decimals="-3" id="f-1140" unitRef="usd">0</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-295" decimals="-3" id="f-1141" unitRef="usd">0</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-296" decimals="-3" id="f-1142" unitRef="usd">15000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-214" decimals="-3" id="f-1143" unitRef="usd">15000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-294" decimals="-3" id="f-1144" unitRef="usd">72000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-295" decimals="-3" id="f-1145" unitRef="usd">90000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-296" decimals="-3" id="f-1146" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-214" decimals="-3" id="f-1147" unitRef="usd">162000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-297" decimals="-3" id="f-1148" unitRef="usd">17073000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-298" decimals="-3" id="f-1149" unitRef="usd">2271000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-299" decimals="-3" id="f-1150" unitRef="usd">6000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-219" decimals="-3" id="f-1151" unitRef="usd">25344000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-300" decimals="-3" id="f-1152" unitRef="usd">3343000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-301" decimals="-3" id="f-1153" unitRef="usd">1870000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-302" decimals="-3" id="f-1154" unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-303" decimals="-3" id="f-1155" unitRef="usd">5213000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-304" decimals="-3" id="f-1156" unitRef="usd">626000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-305" decimals="-3" id="f-1157" unitRef="usd">318000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-306" decimals="-3" id="f-1158" unitRef="usd">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-307" decimals="-3" id="f-1159" unitRef="usd">944000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-304" decimals="-3" id="f-1160" unitRef="usd">28000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-305" decimals="-3" id="f-1161" unitRef="usd">83000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-306" decimals="-3" id="f-1162" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-307" decimals="-3" id="f-1163" unitRef="usd">111000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-308" decimals="-3" id="f-1164" unitRef="usd">3997000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-309" decimals="-3" id="f-1165" unitRef="usd">2271000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-310" decimals="-3" id="f-1166" unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-311" decimals="-3" id="f-1167" unitRef="usd">6268000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-312" decimals="-3" id="f-1168" unitRef="usd">13076000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-313" decimals="-3" id="f-1169" unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-314" decimals="-3" id="f-1170" unitRef="usd">6000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-5" decimals="-3" id="f-1171" unitRef="usd">19076000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-315" decimals="-3" id="f-1172" unitRef="usd">8777000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-316" decimals="-3" id="f-1173" unitRef="usd">2329000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-317" decimals="-3" id="f-1174" unitRef="usd">15000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-243" decimals="-3" id="f-1175" unitRef="usd">26106000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-318" decimals="-3" id="f-1176" unitRef="usd">7682000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-295" decimals="-3" id="f-1177" unitRef="usd">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-319" decimals="-3" id="f-1178" unitRef="usd">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-248" decimals="-3" id="f-1179" unitRef="usd">7682000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-318" decimals="-3" id="f-1180" unitRef="usd">2755000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-295" decimals="-3" id="f-1181" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-319" decimals="-3" id="f-1182" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-248" decimals="-3" id="f-1183" unitRef="usd">2755000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-318" decimals="-3" id="f-1184" unitRef="usd">-20000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-320" decimals="-3" id="f-1185" unitRef="usd">-148000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-319" decimals="-3" id="f-1186" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-248" decimals="-3" id="f-1187" unitRef="usd">-168000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-291" decimals="-3" id="f-1188" unitRef="usd">13684000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-292" decimals="-3" id="f-1189" unitRef="usd">2181000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-293" decimals="-3" id="f-1190" unitRef="usd">15000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-209" decimals="-3" id="f-1191" unitRef="usd">30865000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-321" decimals="-3" id="f-1192" unitRef="usd">2933000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-322" decimals="-3" id="f-1193" unitRef="usd">1664000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-323" decimals="-3" id="f-1194" unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-324" decimals="-3" id="f-1195" unitRef="usd">4597000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-325" decimals="-3" id="f-1196" unitRef="usd">423000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-326" decimals="-3" id="f-1197" unitRef="usd">310000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-327" decimals="-3" id="f-1198" unitRef="usd">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-328" decimals="-3" id="f-1199" unitRef="usd">733000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-325" decimals="-3" id="f-1200" unitRef="usd">-13000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-326" decimals="-3" id="f-1201" unitRef="usd">-104000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-327" decimals="-3" id="f-1202" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-328" decimals="-3" id="f-1203" unitRef="usd">-117000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-300" decimals="-3" id="f-1204" unitRef="usd">3343000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-301" decimals="-3" id="f-1205" unitRef="usd">1870000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-302" decimals="-3" id="f-1206" unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-303" decimals="-3" id="f-1207" unitRef="usd">5213000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-329" decimals="-3" id="f-1208" unitRef="usd">10341000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-330" decimals="-3" id="f-1209" unitRef="usd">311000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-331" decimals="-3" id="f-1210" unitRef="usd">15000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-8" decimals="-3" id="f-1211" unitRef="usd">25652000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory contextRef="c-1" id="f-1212">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expense for amortization of the Group&#x2019;s intangible assets is included within the consolidated statements of profit or loss and other comprehensive income or loss as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-332" decimals="-3" id="f-1213" unitRef="usd">318000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-333" decimals="-3" id="f-1214" unitRef="usd">471000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-334" decimals="-3" id="f-1215" unitRef="usd">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-335" decimals="-3" id="f-1216" unitRef="usd">8000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-336" decimals="-3" id="f-1217" unitRef="usd">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-337" decimals="-3" id="f-1218" unitRef="usd">324000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-338" decimals="-3" id="f-1219" unitRef="usd">618000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-339" decimals="-3" id="f-1220" unitRef="usd">262000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-340" decimals="-3" id="f-1221" unitRef="usd">599000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-1222" unitRef="usd">944000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-6" decimals="-3" id="f-1223" unitRef="usd">733000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-7" decimals="-3" id="f-1224" unitRef="usd">923000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLoss contextRef="c-341" decimals="-5" id="f-1225" unitRef="usd">1800000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss contextRef="c-342" decimals="-5" id="f-1226" unitRef="usd">2800000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss contextRef="c-343" decimals="-5" id="f-1227" unitRef="usd">2100000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss contextRef="c-344" decimals="-5" id="f-1228" unitRef="usd">700000</ifrs-full:ImpairmentLoss>
    <alvo:DerecognitionIntangibleAssetsOtherThanGoodwill contextRef="c-345" decimals="-5" id="f-1229" unitRef="usd">15000000</alvo:DerecognitionIntangibleAssetsOtherThanGoodwill>
    <alvo:PaymentForContractualCommitment contextRef="c-346" decimals="-5" id="f-1230" unitRef="usd">3000000</alvo:PaymentForContractualCommitment>
    <alvo:PaymentForContractualCommitment contextRef="c-347" decimals="-5" id="f-1231" unitRef="usd">3000000</alvo:PaymentForContractualCommitment>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-348" decimals="-6" id="f-1232" unitRef="usd">25000000</ifrs-full:ContractualCapitalCommitments>
    <alvo:PaymentForContractualCommitment contextRef="c-349" decimals="-6" id="f-1233" unitRef="usd">6000000</alvo:PaymentForContractualCommitment>
    <alvo:ContractualCapitalCommitmentContingentLiability contextRef="c-348" decimals="-6" id="f-1234" unitRef="usd">15000000</alvo:ContractualCapitalCommitmentContingentLiability>
    <alvo:ContractualCapitalCommitmentsTerm contextRef="c-346" id="f-1235">P10Y</alvo:ContractualCapitalCommitmentsTerm>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c-1" id="f-1236">Cash and cash equivalents &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents include both cash in banks and on hand. Cash and cash equivalents as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents denominated in US dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents denominated in other currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Restricted cash relates to cash that may only be used pursuant to certain of the Group&#x2019;s borrowing arrangements. Therefore, these deposits are not available for general use by the Group. Movements in restricted cash balances during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s restricted cash is available for use after one year or later.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <alvo:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock contextRef="c-1" id="f-1237">Cash and cash equivalents as of 31&#160;December 2023 and 2022 are as follows: &lt;div style="margin-top:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents denominated in US dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents denominated in other currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatoryTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c-350" decimals="-3" id="f-1238" unitRef="usd">1466000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-351" decimals="-3" id="f-1239" unitRef="usd">10377000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-352" decimals="-3" id="f-1240" unitRef="usd">9691000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-353" decimals="-3" id="f-1241" unitRef="usd">56050000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-1242" unitRef="usd">11157000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-1243" unitRef="usd">66427000</ifrs-full:CashAndCashEquivalents>
    <alvo:DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock contextRef="c-1" id="f-1244">Movements in restricted cash balances during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutRestrictedCashAndCashEquivalentsExplanatoryTableTextBlock>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-1245" unitRef="usd">25187000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c-9" decimals="-3" id="f-1246" unitRef="usd">10087000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <alvo:AdditionRestrictedCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-1247" unitRef="usd">0</alvo:AdditionRestrictedCashAndCashEquivalents>
    <alvo:AdditionRestrictedCashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-1248" unitRef="usd">14914000</alvo:AdditionRestrictedCashAndCashEquivalents>
    <alvo:InterestIncomeOnCash contextRef="c-1" decimals="-3" id="f-1249" unitRef="usd">945000</alvo:InterestIncomeOnCash>
    <alvo:InterestIncomeOnCash contextRef="c-6" decimals="-3" id="f-1250" unitRef="usd">186000</alvo:InterestIncomeOnCash>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-1251" unitRef="usd">26132000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-1252" unitRef="usd">25187000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c-1" id="f-1253">Inventories &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s inventory balances as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Inventory reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The increase in inventory from 31&#160;December 2022 to 31&#160;December 2023 is due to the expansion of the commercial launch of certain of the Group&#x2019;s biosimilar products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group recognised $42.8 million and $20.9 million within cost of goods sold during the years ended 31&#160;December 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;During the years ended 31&#160;December 2023, 2022, and 2021, write-down of inventories amounted to $10.4&#160;million, $2.1 million and $1.2 million, respectively, due to product expiration and results from quality control inspections. There were no reversals of inventory write-downs during the years ended 31&#160;December 2023, 2022, and 2021.</ifrs-full:DisclosureOfInventoriesExplanatory>
    <alvo:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock contextRef="c-1" id="f-1254">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s inventory balances as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Inventory reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock>
    <ifrs-full:RawMaterialsAndConsumablesUsed contextRef="c-1" decimals="-3" id="f-1255" unitRef="usd">51524000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed contextRef="c-6" decimals="-3" id="f-1256" unitRef="usd">41961000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:WorkInProgress contextRef="c-5" decimals="-3" id="f-1257" unitRef="usd">33068000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-8" decimals="-3" id="f-1258" unitRef="usd">29450000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods contextRef="c-5" decimals="-3" id="f-1259" unitRef="usd">244000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-8" decimals="-3" id="f-1260" unitRef="usd">2121000</ifrs-full:FinishedGoods>
    <alvo:InventoryReserves contextRef="c-1" decimals="-3" id="f-1261" unitRef="usd">10403000</alvo:InventoryReserves>
    <alvo:InventoryReserves contextRef="c-6" decimals="-3" id="f-1262" unitRef="usd">2062000</alvo:InventoryReserves>
    <ifrs-full:Inventories contextRef="c-5" decimals="-3" id="f-1263" unitRef="usd">74433000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-8" decimals="-3" id="f-1264" unitRef="usd">71470000</ifrs-full:Inventories>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="c-354" decimals="-3" id="f-1265" unitRef="usd">42800000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="c-355" decimals="-3" id="f-1266" unitRef="usd">20900000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:InventoryWritedown2011 contextRef="c-1" decimals="-5" id="f-1267" unitRef="usd">10400000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011 contextRef="c-6" decimals="-5" id="f-1268" unitRef="usd">2100000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011 contextRef="c-7" decimals="-5" id="f-1269" unitRef="usd">1200000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="c-7" decimals="-6" id="f-1270" unitRef="usd">0</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="c-1" decimals="-6" id="f-1271" unitRef="usd">0</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="c-6" decimals="-6" id="f-1272" unitRef="usd">0</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory contextRef="c-1" id="f-1273">Other current assets &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The composition of other current assets as of 31&#160;December 2023 and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value-added tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Proceeds receivable from Convertible Bonds (see Note 21)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other short-term receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year, the Group terminated the co-development agreement with Biosana for AVT23 and derecognized $15.0&#160;million of other intangible assets and $3.5&#160;million of prepaid development costs. A receivable of $18.5&#160;million was recognized under other current assets which was fully reserved due to the uncertainty that it would be collected.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <alvo:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-1274">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The composition of other current assets as of 31&#160;December 2023 and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value-added tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Proceeds receivable from Convertible Bonds (see Note 21)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other short-term receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="c-5" decimals="-3" id="f-1275" unitRef="usd">8801000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="c-8" decimals="-3" id="f-1276" unitRef="usd">6468000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-5" decimals="-3" id="f-1277" unitRef="usd">22035000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-8" decimals="-3" id="f-1278" unitRef="usd">20601000</ifrs-full:CurrentPrepaidExpenses>
    <alvo:ProceedsReceivableFromConvertibleBonds contextRef="c-5" decimals="-3" id="f-1279" unitRef="usd">0</alvo:ProceedsReceivableFromConvertibleBonds>
    <alvo:ProceedsReceivableFromConvertibleBonds contextRef="c-8" decimals="-3" id="f-1280" unitRef="usd">3520000</alvo:ProceedsReceivableFromConvertibleBonds>
    <alvo:DerivaiveAssets contextRef="c-5" decimals="-3" id="f-1281" unitRef="usd">0</alvo:DerivaiveAssets>
    <alvo:DerivaiveAssets contextRef="c-8" decimals="-3" id="f-1282" unitRef="usd">851000</alvo:DerivaiveAssets>
    <ifrs-full:OtherCurrentReceivables contextRef="c-5" decimals="-3" id="f-1283" unitRef="usd">1035000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c-8" decimals="-3" id="f-1284" unitRef="usd">1509000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c-5" decimals="-3" id="f-1285" unitRef="usd">31871000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-8" decimals="-3" id="f-1286" unitRef="usd">32949000</ifrs-full:OtherCurrentAssets>
    <alvo:DerecognitionIntangibleAssetsOtherThanGoodwill contextRef="c-345" decimals="-5" id="f-1287" unitRef="usd">15000000</alvo:DerecognitionIntangibleAssetsOtherThanGoodwill>
    <alvo:DerecognitionPrepaidDevelopmentCosts contextRef="c-356" decimals="-5" id="f-1288" unitRef="usd">3500000</alvo:DerecognitionPrepaidDevelopmentCosts>
    <ifrs-full:OtherCurrentAssets contextRef="c-357" decimals="-5" id="f-1289" unitRef="usd">18500000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:DisclosureOfIssuedCapitalExplanatory contextRef="c-1" id="f-1290">Share capital &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all liabilities. Equity instruments issued by a Group entity are recognized in the amount of the proceeds received, net of direct issue costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prior to the Capital Reorganization the Group&#x2019;s equity consisted of Class A and Class B ordinary shares (together the &#x201c;Predecessor Ordinary Shares&#x201d;). The Group&#x2019;s authorized share capital was $99.7 million, consisting of the equivalent of 99,961,829 Class A or Class B ordinary shares with a par value of $0.01 per share. All share capital issued as of 31&#160;December 2023 and 2022 was fully paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Capital Reorganization resulted in the following share capital activity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;All of the outstanding Predecessor Ordinary Shares were exchanged for 180,600,000 Ordinary Shares and 38,330,000 Predecessor Earn Out Shares; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;976,505 of Class A OACB Ordinary Shares were exchanged for Ordinary Shares; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;6,250,000 of Class B OACB Ordinary Shares were exchanged for 5,000,000 Ordinary Shares and 1,250,000 OACB Earn Out Shares; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;17,493,000 Ordinary Shares were issued in the PIPE Financing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No dividends were paid or declared during the years ended 31&#160;December 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share capital and share premium of the Group&#x2019;s Ordinary Shares issued as of 31&#160;December 2023, and 2022 are as follows (in thousands, except for share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;capital and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;premium&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;capital and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;premium&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ordinary Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;266,821,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,231,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252,160,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,060,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total share capital and share premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;266,821,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,231,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252,160,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,060,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 10 February 2023, the Company completed a private placement equity offering for gross proceeds of $137.0&#160;million, and transaction costs of $4.1&#160;million, of its ordinary shares, par value $0.01 per share, at a purchase price of $11.57 per share. The shares were delivered from previously issued ordinary shares held by Alvotech&#x2019;s subsidiary, Alvotech Manco ehf. As a result of proceeds raised from the private placement offering, the Company extinguished the derivative financial liability related to the Senior Bond Warrants since the Company has not anymore the obligation to issue the penny warrants representing 1.0% of the fully diluted ordinary share capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;This was accounted for as an extinguishment of a derivative financial liability in the consolidated statements of profit or loss and other comprehensive income or loss. See Notes 21 and 28 for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Movements in the Group&#x2019;s Class A and Class B ordinary shares, share capital and share premium during the years ended 31&#160;December 2023, 2022, and 2021 are as follows (in thousands, except for share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.971%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.971%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Ordinary &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Predecessor &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Ordinary &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;capital &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;premium &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,259,139&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;166,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;166,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,222,660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;833,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;833,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,481,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,000,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,000,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Elimination of Predecessor Ordinary Shares (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13,481,799)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Issuance of Ordinary Shares (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;186,576,505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;PIPE Financing (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,493,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;174,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;174,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Transaction costs arising on share issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Predecessor Earn Out Shares (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,330,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(227,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(227,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Earn Out Shares (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;SARs Settlement (Note 22)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,510,582&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of related party loans with Ordinary Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252,160,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,058,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,060,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capital contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,834,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested earn-out shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Penny warrants (Note 28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,479,962&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Public warrants (Note 28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;553,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of RSUs with shares (Note 23)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;838,919&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of SARs with shares (Note 22)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,044,737)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;266,821,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,229,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,231,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Alvotech Manco ehf., a subsidiary of Alvotech hf., owns 22,905,618 Ordinary Shares in Alvotech. Such shares are intended for the future issuance of Ordinary Shares under the Management Incentive Plan and other equity offerings.</ifrs-full:DisclosureOfIssuedCapitalExplanatory>
    <alvo:SharesAuthorizedValue contextRef="c-358" decimals="-5" id="f-1291" unitRef="usd">99700000</alvo:SharesAuthorizedValue>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c-358"
      decimals="INF"
      id="f-1292"
      unitRef="shares">99961829</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="c-358"
      decimals="2"
      id="f-1293"
      unitRef="usdPerShare">0.01</ifrs-full:ParValuePerShare>
    <alvo:CapitalReorganizationEventSharesIssued
      contextRef="c-359"
      decimals="INF"
      id="f-1294"
      unitRef="shares">180600000</alvo:CapitalReorganizationEventSharesIssued>
    <alvo:CapitalReorganizationEventSharesIssued
      contextRef="c-360"
      decimals="INF"
      id="f-1295"
      unitRef="shares">38330000</alvo:CapitalReorganizationEventSharesIssued>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-361"
      decimals="INF"
      id="f-1296"
      unitRef="shares">976505</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-362"
      decimals="INF"
      id="f-1297"
      unitRef="shares">6250000</ifrs-full:NumberOfSharesOutstanding>
    <alvo:CapitalReorganizationSharesIssued
      contextRef="c-363"
      decimals="INF"
      id="f-1298"
      unitRef="shares">5000000</alvo:CapitalReorganizationSharesIssued>
    <alvo:CapitalReorganizationSharesIssued
      contextRef="c-364"
      decimals="INF"
      id="f-1299"
      unitRef="shares">1250000</alvo:CapitalReorganizationSharesIssued>
    <alvo:StockIssuedUnderPipeFinancingShares
      contextRef="c-68"
      decimals="INF"
      id="f-1300"
      unitRef="shares">17493000</alvo:StockIssuedUnderPipeFinancingShares>
    <ifrs-full:DividendsPaid contextRef="c-1" decimals="INF" id="f-1301" unitRef="usd">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="c-6" decimals="INF" id="f-1302" unitRef="usd">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="c-7" decimals="INF" id="f-1303" unitRef="usd">0</ifrs-full:DividendsPaid>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-1304">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share capital and share premium of the Group&#x2019;s Ordinary Shares issued as of 31&#160;December 2023, and 2022 are as follows (in thousands, except for share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;capital and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;premium&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;capital and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;premium&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ordinary Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;266,821,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,231,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252,160,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,060,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total share capital and share premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;266,821,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,231,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252,160,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,060,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-365"
      decimals="INF"
      id="f-1305"
      unitRef="shares">266821844</ifrs-full:NumberOfSharesIssued>
    <alvo:ShareCapitalAndSharePremium contextRef="c-365" decimals="-3" id="f-1306" unitRef="usd">1231969000</alvo:ShareCapitalAndSharePremium>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-366"
      decimals="INF"
      id="f-1307"
      unitRef="shares">252160087</ifrs-full:NumberOfSharesIssued>
    <alvo:ShareCapitalAndSharePremium contextRef="c-366" decimals="-3" id="f-1308" unitRef="usd">1060558000</alvo:ShareCapitalAndSharePremium>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-5"
      decimals="INF"
      id="f-1309"
      unitRef="shares">266821844</ifrs-full:NumberOfSharesIssued>
    <alvo:ShareCapitalAndSharePremium contextRef="c-5" decimals="-3" id="f-1310" unitRef="usd">1231969000</alvo:ShareCapitalAndSharePremium>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-8"
      decimals="INF"
      id="f-1311"
      unitRef="shares">252160087</ifrs-full:NumberOfSharesIssued>
    <alvo:ShareCapitalAndSharePremium contextRef="c-8" decimals="-3" id="f-1312" unitRef="usd">1060558000</alvo:ShareCapitalAndSharePremium>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-367" decimals="-5" id="f-1313" unitRef="usd">137000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-367" decimals="-3" id="f-1314" unitRef="usd">4100000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ParValuePerShare
      contextRef="c-368"
      decimals="INF"
      id="f-1315"
      unitRef="usdPerShare">0.01</ifrs-full:ParValuePerShare>
    <alvo:SaleOfStockIssuePricePerShare
      contextRef="c-368"
      decimals="INF"
      id="f-1316"
      unitRef="usdPerShare">11.57</alvo:SaleOfStockIssuePricePerShare>
    <alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares
      contextRef="c-369"
      decimals="INF"
      id="f-1317"
      unitRef="number">0.010</alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares>
    <alvo:DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock contextRef="c-1" id="f-1318">&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Movements in the Group&#x2019;s Class A and Class B ordinary shares, share capital and share premium during the years ended 31&#160;December 2023, 2022, and 2021 are as follows (in thousands, except for share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.971%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.971%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Ordinary &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Predecessor &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Ordinary &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;capital &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;premium &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,259,139&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;166,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;166,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,222,660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;833,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;833,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,481,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,000,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,000,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Elimination of Predecessor Ordinary Shares (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13,481,799)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Issuance of Ordinary Shares (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;186,576,505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;PIPE Financing (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,493,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;174,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;174,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Transaction costs arising on share issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Predecessor Earn Out Shares (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,330,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(227,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(227,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Earn Out Shares (Note 1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;SARs Settlement (Note 22)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,510,582&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of related party loans with Ordinary Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252,160,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,058,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,060,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capital contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,834,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested earn-out shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Penny warrants (Note 28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,479,962&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Public warrants (Note 28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;553,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of RSUs with shares (Note 23)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;838,919&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of SARs with shares (Note 22)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,044,737)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;266,821,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,229,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,231,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutMovementsInOrdinarySharesShareCapitalAndSharePremiumExplanatoryTableTextBlock>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-370"
      decimals="INF"
      id="f-1319"
      unitRef="shares">7259139</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-11" decimals="-3" id="f-1320" unitRef="usd">73000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-3" id="f-1321" unitRef="usd">166740000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-371" decimals="-3" id="f-1322" unitRef="usd">166813000</ifrs-full:Equity>
    <alvo:IssueOfEquityShares
      contextRef="c-372"
      decimals="INF"
      id="f-1323"
      unitRef="shares">6222660</alvo:IssueOfEquityShares>
    <alvo:IssueOfEquities contextRef="c-18" decimals="-3" id="f-1324" unitRef="usd">62000</alvo:IssueOfEquities>
    <alvo:IssueOfEquities contextRef="c-19" decimals="-3" id="f-1325" unitRef="usd">833378000</alvo:IssueOfEquities>
    <alvo:IssueOfEquities contextRef="c-373" decimals="-3" id="f-1326" unitRef="usd">833440000</alvo:IssueOfEquities>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-374"
      decimals="INF"
      id="f-1327"
      unitRef="shares">13481799</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-20" decimals="-3" id="f-1328" unitRef="usd">135000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-21" decimals="-3" id="f-1329" unitRef="usd">1000118000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-375" decimals="-3" id="f-1330" unitRef="usd">1000253000</ifrs-full:Equity>
    <alvo:EliminationOfPredecessorOrdinaryShares
      contextRef="c-376"
      decimals="INF"
      id="f-1331"
      unitRef="shares">-13481799</alvo:EliminationOfPredecessorOrdinaryShares>
    <alvo:EliminationOfPredecessorOrdinaryValue contextRef="c-27" decimals="-3" id="f-1332" unitRef="usd">-135000</alvo:EliminationOfPredecessorOrdinaryValue>
    <alvo:EliminationOfPredecessorOrdinaryValue contextRef="c-28" decimals="-3" id="f-1333" unitRef="usd">135000</alvo:EliminationOfPredecessorOrdinaryValue>
    <alvo:EliminationOfPredecessorOrdinaryValue contextRef="c-377" decimals="-3" id="f-1334" unitRef="usd">0</alvo:EliminationOfPredecessorOrdinaryValue>
    <alvo:IssuanceOfOrdinaryShares
      contextRef="c-6"
      decimals="INF"
      id="f-1335"
      unitRef="shares">186576505</alvo:IssuanceOfOrdinaryShares>
    <alvo:IssuanceOfOrdinaryValue contextRef="c-27" decimals="-3" id="f-1336" unitRef="usd">1866000</alvo:IssuanceOfOrdinaryValue>
    <alvo:IssuanceOfOrdinaryValue contextRef="c-28" decimals="-3" id="f-1337" unitRef="usd">63169000</alvo:IssuanceOfOrdinaryValue>
    <alvo:IssuanceOfOrdinaryValue contextRef="c-377" decimals="-3" id="f-1338" unitRef="usd">65035000</alvo:IssuanceOfOrdinaryValue>
    <alvo:IncreaseThroughPipeFinancingShares
      contextRef="c-6"
      decimals="INF"
      id="f-1339"
      unitRef="shares">17493000</alvo:IncreaseThroughPipeFinancingShares>
    <alvo:IncreaseThroughPipeFinancingValue contextRef="c-27" decimals="-3" id="f-1340" unitRef="usd">175000</alvo:IncreaseThroughPipeFinancingValue>
    <alvo:IncreaseThroughPipeFinancingValue contextRef="c-28" decimals="-3" id="f-1341" unitRef="usd">174755000</alvo:IncreaseThroughPipeFinancingValue>
    <alvo:IncreaseThroughPipeFinancingValue contextRef="c-377" decimals="-3" id="f-1342" unitRef="usd">174930000</alvo:IncreaseThroughPipeFinancingValue>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-28" decimals="-3" id="f-1343" unitRef="usd">5562000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-377" decimals="-3" id="f-1344" unitRef="usd">5562000</ifrs-full:ShareIssueRelatedCost>
    <alvo:IssueOfPredecessorEarnOutShares
      contextRef="c-6"
      decimals="INF"
      id="f-1345"
      unitRef="shares">38330000</alvo:IssueOfPredecessorEarnOutShares>
    <alvo:IssueOfPredecessorEarnOutSharesValue contextRef="c-28" decimals="-3" id="f-1346" unitRef="usd">-227500000</alvo:IssueOfPredecessorEarnOutSharesValue>
    <alvo:IssueOfPredecessorEarnOutSharesValue contextRef="c-377" decimals="-3" id="f-1347" unitRef="usd">-227500000</alvo:IssueOfPredecessorEarnOutSharesValue>
    <alvo:IssueOfOacbEarnOutShares
      contextRef="c-6"
      decimals="INF"
      id="f-1348"
      unitRef="shares">1250000</alvo:IssueOfOacbEarnOutShares>
    <alvo:IssueOfOacbEarnOutSharesValue contextRef="c-28" decimals="-3" id="f-1349" unitRef="usd">-9100000</alvo:IssueOfOacbEarnOutSharesValue>
    <alvo:IssueOfOacbEarnOutSharesValue contextRef="c-377" decimals="-3" id="f-1350" unitRef="usd">-9100000</alvo:IssueOfOacbEarnOutSharesValue>
    <alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsShares
      contextRef="c-6"
      decimals="INF"
      id="f-1351"
      unitRef="shares">3510582</alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsShares>
    <alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue contextRef="c-27" decimals="-3" id="f-1352" unitRef="usd">35000</alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue>
    <alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue contextRef="c-28" decimals="-3" id="f-1353" unitRef="usd">30267000</alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue>
    <alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue contextRef="c-377" decimals="-3" id="f-1354" unitRef="usd">30302000</alvo:IssueOfSharesOnSettlementOfShareAppreciationRightsValue>
    <alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares
      contextRef="c-6"
      decimals="INF"
      id="f-1355"
      unitRef="shares">5000000</alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares>
    <alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue contextRef="c-27" decimals="-3" id="f-1356" unitRef="usd">50000</alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue>
    <alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue contextRef="c-28" decimals="-3" id="f-1357" unitRef="usd">32150000</alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue>
    <alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue contextRef="c-377" decimals="-3" id="f-1358" unitRef="usd">32200000</alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-8"
      decimals="INF"
      id="f-1359"
      unitRef="shares">252160087</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-33" decimals="-3" id="f-1360" unitRef="usd">2126000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-34" decimals="-3" id="f-1361" unitRef="usd">1058432000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-378" decimals="-3" id="f-1362" unitRef="usd">1060558000</ifrs-full:Equity>
    <alvo:CapitalContributionSharesIssued
      contextRef="c-1"
      decimals="INF"
      id="f-1363"
      unitRef="shares">11834061</alvo:CapitalContributionSharesIssued>
    <alvo:CapitalContributionValue contextRef="c-40" decimals="-3" id="f-1364" unitRef="usd">118000</alvo:CapitalContributionValue>
    <alvo:CapitalContributionValue contextRef="c-41" decimals="-3" id="f-1365" unitRef="usd">132618000</alvo:CapitalContributionValue>
    <alvo:CapitalContributionValue contextRef="c-379" decimals="-3" id="f-1366" unitRef="usd">132736000</alvo:CapitalContributionValue>
    <alvo:VestedEarnoutSharesIssued
      contextRef="c-1"
      decimals="INF"
      id="f-1367"
      unitRef="shares">0</alvo:VestedEarnoutSharesIssued>
    <alvo:VestedEarnoutSharesValue contextRef="c-40" decimals="-3" id="f-1368" unitRef="usd">6000</alvo:VestedEarnoutSharesValue>
    <alvo:VestedEarnoutSharesValue contextRef="c-41" decimals="-3" id="f-1369" unitRef="usd">8300000</alvo:VestedEarnoutSharesValue>
    <alvo:VestedEarnoutSharesValue contextRef="c-379" decimals="-3" id="f-1370" unitRef="usd">8306000</alvo:VestedEarnoutSharesValue>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-47"
      decimals="INF"
      id="f-1371"
      unitRef="shares">2479962</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-45" decimals="-3" id="f-1372" unitRef="usd">25000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-46" decimals="-3" id="f-1373" unitRef="usd">27159000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-380" decimals="-3" id="f-1374" unitRef="usd">27184000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-50"
      decimals="INF"
      id="f-1375"
      unitRef="shares">553552</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-48" decimals="-3" id="f-1376" unitRef="usd">6000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-49" decimals="-3" id="f-1377" unitRef="usd">7612000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-381" decimals="-3" id="f-1378" unitRef="usd">7618000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-56"
      decimals="INF"
      id="f-1379"
      unitRef="shares">838919</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-53" decimals="-3" id="f-1380" unitRef="usd">8000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-54" decimals="-3" id="f-1381" unitRef="usd">5095000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-382" decimals="-3" id="f-1382" unitRef="usd">5103000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-60"
      decimals="INF"
      id="f-1383"
      unitRef="shares">-1044737</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-57" decimals="-3" id="f-1384" unitRef="usd">-10000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-58" decimals="-3" id="f-1385" unitRef="usd">-9526000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-383" decimals="-3" id="f-1386" unitRef="usd">-9536000</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-5"
      decimals="INF"
      id="f-1387"
      unitRef="shares">266821844</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-62" decimals="-3" id="f-1388" unitRef="usd">2279000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-63" decimals="-3" id="f-1389" unitRef="usd">1229690000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-384" decimals="-3" id="f-1390" unitRef="usd">1231969000</ifrs-full:Equity>
    <alvo:CommonStockHeldBySubsidiaries contextRef="c-5" decimals="0" id="f-1391" unitRef="shares">22905618</alvo:CommonStockHeldBySubsidiaries>
    <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory contextRef="c-1" id="f-1392">Other reserves &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The composition of other reserves as of 31&#160;December 2023 and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity component of convertible bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
    <alvo:ScheduleOfOtherReservesTableTextBlock contextRef="c-1" id="f-1393">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The composition of other reserves as of 31&#160;December 2023 and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity component of convertible bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:ScheduleOfOtherReservesTableTextBlock>
    <ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments contextRef="c-5" decimals="-3" id="f-1394" unitRef="usd">21391000</ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments>
    <ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments contextRef="c-8" decimals="-3" id="f-1395" unitRef="usd">16034000</ifrs-full:ReserveOfEquityComponentOfConvertibleInstruments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c-5" decimals="-3" id="f-1396" unitRef="usd">21520000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c-8" decimals="-3" id="f-1397" unitRef="usd">14548000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:OtherReserves contextRef="c-5" decimals="-3" id="f-1398" unitRef="usd">42911000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-8" decimals="-3" id="f-1399" unitRef="usd">30582000</ifrs-full:OtherReserves>
    <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="c-1" id="f-1400">Borrowings &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s debt consists of interest-bearing borrowings from financial institutions, related parties and third parties. Outstanding borrowings, net of transaction costs, presented on the consolidated statements of financial position as current and non-current as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;530,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 Convertible Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;155,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total outstanding borrowings, net of debt issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: current portion of borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(19,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total non-current borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;922,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;744,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Convertible shareholder loans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Business Combination Agreement (see Note 1.1), on 7&#160;December 2021, the Group&#x2019;s shareholders entered into the BCA Framework Agreement resulting in the exercise of the conversion, warrant, and funding rights associated with the convertible shareholder loans. As a result, the following issuances of Class A ordinary shares occurred: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;1,522,103 shares from the exercise of warrant and funding rights in exchange for $101.3 million of cash;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;1,137,248 shares from the exercise of warrant rights in exchange for the settlement of $73.7 million of accrued payment-in-kind interest; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;2,306,555 shares resulting from the conversion of $166.8 million of outstanding principal and accrued payment-in-kind interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with these exercises, for the year ended 31 December 2021, the Group recognized finance income of $48.7 million resulting from the remeasurement of the derivative liabilities at the date of extinguishment and a $149.2 million gain on extinguishment of financial liabilities, which primarily reflects the difference between the carrying amount of the pre-transaction convertible shareholder loans and the related derivative financial liabilities and the fair value of the ordinary shares issued. In addition, the gain on extinguishment of financial liabilities includes transaction costs incurred as part of the extinguishment, the acceleration of previously deferred debt issue costs incurred in connection with the issuance of the convertible shareholder loans and the acceleration of previously unamortized accretion of the convertible shareholder loans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 24&#160;June 2021, holders of the Group&#x2019;s convertible bonds converted $100.7 million of principal and accrued interest and $4.8 million of additional premium offered by the Group to the bondholders into 455,687 Class A ordinary shares. Following the conversion, certain bondholders elected to redeem their remaining bonds for cash, resulting in the payment of $55.3 million in outstanding principal and accrued interest plus an additional $6.1 million of premium that the bondholders elected to be paid in cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The remaining unconverted and unredeemed bonds were replaced with new bonds with an extended maturity of June 2025 and the elimination of conversion rights, among other amendments to the terms and conditions. The Group offered the holders of the replaced bonds an extension premium of $8.1 million for their agreement to extend the maturity of the replaced bonds to June 2025, as well as an additional premium of $2.6 million, both of which were granted to the bondholders in the form of additional bonds. The Group also issued an additional $113.8 million of bonds to one previous bondholder and one new bondholder. On the date of issuance, the fair value and the nominal value of the bonds was $358.8 million and $397.4 million, respectively. The difference between the nominal value and fair value was recognized as a discount that will be amortized over the term of the bonds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group determined that the 24 June 2021 transaction was a substantial modification to its convertible bonds and the associated derivative financial liability and accounted for the transaction as an extinguishment. As a result, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Group recognized a gain on extinguishment of financial liabilities of $2.6 million during the year ended 31 December 2021, primarily driven by the difference between the fair value of the post-transaction bonds and the carrying amount of the pre-transaction bonds. The gain on extinguishment of financial liabilities also includes the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Transaction costs and fees incurred as part of the extinguishment; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The acceleration of previously deferred debt issue costs incurred in connection with the issuance of the pre-transaction bonds; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The acceleration of previously unamortized accretion of the pre-transaction bonds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prior to the extinguishment of the convertible bonds and as noted above, the bondholders had the option to convert the bonds into Class A ordinary shares up to fourteen days prior to maturity. This conversion right was separately accounted for as a derivative financial liability. During the period from 1 January 2021 to 24 June 2021, there was no change in fair value of the derivative financial liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of 31 December 2021, the carrying amount of the bonds was $363.1 million. Accrued interest on the bonds as of 31 December 2021 is $31.0 million. The Group has the option, at any time, to prepay all or any part of the outstanding bonds. If the Group elects to prepay the bonds within the first three years of the bond agreement, the bondholders are entitled to be paid an additional premium of at least 2.0% of the outstanding principal at the time of such prepayment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January and June of 2022, the Group amended the terms of the outstanding bonds. The amendments resulted in the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Following the close of the Business Combination, the interest rate will range from 7.5% to 10.0% depending on the amount of aggregate net proceeds, as defined by the terms of the amended bond agreement; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;A $7.4&#160;million consent fee, recognized as finance costs, paid to the bondholders who did not vote against the Business Combination Agreement; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The requirement for Alvotech to maintain a minimum of $25.0 million of restricted cash in a separate liquidity account; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;A decrease in the interest rate to 7.5%, following the closing of the Business Combination, if the Company issues additional shares within six months of the Closing Date, resulting in the Company exceeding the amount of aggregate net proceeds, as defined in the bond agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As a result of the closing of the Business Combination, there was a change in future cash flows on the bonds related to the increase in interest rate from 7.5% to 10.0%. The Company remeasured the carrying value in accordance with IFRS 9 to the present value of the revised cash flows and recognized a $6.5 million loss on the remeasurement of the bonds. The outstanding bonds were subsequently amended as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Senior Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 16&#160;November 2022, the Group amended and upsized the outstanding bonds by $70.0 million. The amended bond agreement (the &#x201c;Senior Bonds&#x201d;) resulted in the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;An increase in principal from $455.7&#160;million at the time of the amendment, to $525.7 million;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;An increase in the interest rate, resulting in a range from 10.75% to 12.0% depending on the occurrence of certain events, as defined by the terms of the agreement. The Group accounted for this interest rate feature (the &#x201c;Senior Bond Interest Rate Feature&#x201d;) as an embedded derivative, classified as an other current asset in the consolidated statement of financial position as of 31 December 2022; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Amended the terms of the related party loans from Alvogen, setting forth subordination conditions; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Contingently issuable penny warrants (exercise price of $0.01) to the bondholders (the &#x201c;Senior Bond Warrants&#x201d;) if certain events occur, issuable in two tranches representing 1.5% and 1.0% of the fully diluted ordinary share capital, as defined in the Senior Bonds agreement (see Note 28). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group determined that the 16 November 2022 transaction was a substantial modification to its bonds and accounted for the transaction as an extinguishment. As a result, the Group recognized a loss on extinguishment of financial liabilities of $40.9 million, including $12.1 million of transaction costs, during the year ended 31 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 2022, primarily driven by the difference between the fair value of the post-transaction Senior Bonds and the Senior Bond Warrants and the carrying amount of the pre-transaction bonds. The loss on extinguishment of financial liabilities includes the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Extinguishment of bonds with a carrying value of $440.1&#160;million, including $4.8 million of accrued interest;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Net cash proceeds of $57.9&#160;million, including transaction costs paid of $12.1 million;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Recognition of a $4.6&#160;million derivative asset for the Senior Bond Interest Rate Feature;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Recognition of $528.2&#160;million and $15.4 million representing the fair value of the new Senior Bonds and Senior Bond Warrants (see Note 28), respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As a result of proceeds raised from the private placement offering executed in February 2023, the Company extinguished the liability related to the senior bond warrants since the Company has not anymore the obligation to issue the penny warrants representing the 1.0% Senior Bond Warrants (see Note 28 for further information).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of 31&#160;December 2023, the carrying amount of the Senior Bonds is $549.4&#160;million, compared to $530.5&#160;million as of 31&#160;December 2022. The Group has the option, at any time, to prepay all or any part of the outstanding bonds in exchange for the payment of the redemption premium pursuant to the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group has pledged its intellectual property as collateral for the Senior Bonds. Additionally, the Group has pledged the Facility of up to $600&#160;million over the Facility as collateral for the Senior Bonds (2nd lien pledge), as further described in Note 12.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;2022 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 20&#160;December 2022, the Group issued two tranches of convertible bonds (the &#x201c;2022 Convertible Bonds&#x201d;). Tranche A is ISK denominated with a principal balance of $59.1 million, of which $3.5 million in cash proceeds were received in February 2023, and carries an annual payment-in-kind interest rate of 15% per year, while Tranche B is USD denominated with a principal balance of $0.6 million and carries an annual payment-in-kind interest rate of 12.5% per year. The maturity date of the Convertible Bonds is the later of the (i) 20 December 2025 or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Holders of both the Tranche A and Tranche B of the 2022 Convertible Bonds, may elect, at their sole discretion, to convert all or part of the principal amount and accrued interest into Alvotech Ordinary Shares at a conversion price of $10.00 per share on 31 December 2023, 30 June 2024, or upon mandatory or optional redemption of the bonds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The conversion features (the &#x201c;Tranche A Conversion Feature&#x201d; and &#x201c;Tranche B Conversion Feature&#x201d;) for both the Tranche A and Tranche B of the 2022 Convertible Bonds were determined to be embedded derivatives as the economic characteristics and risks are not closely related to the debt host. The Group classified the Tranche A Conversion Feature as a liability due to the variability created by conversion rates resulting from the tranche being denominated in ISK and was determined to have a fair value of $24.9 million at issuance date (see Note 28 for further details). The Group classified the Tranche B Conversion Feature as equity due to the conversion price having preservation and passage of time adjustments that meet the fixed-for-fixed criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8.4pt;padding-left:27.5pt;padding-right:7.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%"&gt;On 25 January 2023, the Company issued an additional $10.0&#160;million of Tranche B Convertible Bonds. The Tranche B Conversion Feature associated with this additional issuance was determined to have a fair value of $1.4&#160;million at issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8.4pt;padding-left:27.5pt;padding-right:7.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%"&gt;On 24 July 2023, Alvotech announced that Teva and Alvotech have agreed to expand their existing partnership agreement. As part of the agreement, Teva acquired Tranche B Convertible Bonds in principal amount of $40&#160;million. The Tranche B Conversion Feature associated with this additional issuance was determined to have a fair value of $3.9&#160;million at issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:7.75pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:28.34pt;padding-right:7.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 31 July 2023, Alvotech completed a private placement of Tranche A Convertible Bonds for a total principal amount of $100&#160;million, or approximately ISK 13&#160;billion at current exchange rates. As part of this private placement, ATP Holdings ehf., an affiliated of Aztiq, acquired Tranche A Convertible Bonds in principal amount of $30&#160;million. The Tranche A Conversion Feature associated with these additional issuances was determined to have a fair value of $45.6&#160;million at issuance date (see Note 28 for further details). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of 31&#160;December 2023, the carrying amount of the Tranche A and Tranche B of the 2022 Convertible Bonds is $107.1 million and $48.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"&gt;Aztiq Convertible Bond &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 16 November 2022, the Group issued a convertible bond (also known as the &#x201c;Aztiq Convertible Bond&#x201d;) to ATP Holdings ehf, an affiliate of Aztiq, for the Share Purchase Agreement and the acquisition of the Alvotech Facility (See Note 12). The Aztiq Convertible Bond has a principal amount of $80.0 million and carries an interest rate of 12.50% per annum. Interest is payable in six-month intervals and is capitalized and added to the outstanding principal amount of the bonds. The maturity date of the convertible bond is the later of the (i) 16 November 2025 or (ii) 91 days after the earlier of the full redemption or the final maturity date of the Senior Bonds. Bondholders have the right to convert their outstanding bonds into ordinary shares of Alvotech on 30 December 2023, 30 June 2024, or when the bond has been called or put up for mandatory or optional redemption, for a conversion price is $10.00 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The conversion feature (the &#x201c;Aztiq Conversion Feature&#x201d;) was determined to be an embedded derivative as the economic characteristics and risks are not closely related to the debt host. The Group classified the Aztiq Conversion Feature as equity due to the conversion price having preservation and passage of time adjustments that meet fixed-for-fixed criteria. As a result, the Group recognized the following related to the Aztiq Convertible Bond: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;$64.0&#160;million related to the debt host;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;$16.0&#160;million related to the Aztiq Conversion Feature; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;$30.0&#160;million related to the loans (the &#x201c;Facility Loans&#x201d;) on the building, which were assumed by the Group as part of the asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.35pt;padding-left:28.34pt;padding-right:7.9pt;text-align:justify;text-indent:-0.05pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.35pt;padding-left:28.34pt;padding-right:7.9pt;text-indent:-0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%"&gt;In April 2023, we were communicated that ATP Holdings ehf. sold a portion of the Aztiq Convertible Bond to Mitsui &amp;amp; Co., Ltd. ("Mitsui"), a global trading and investment company headquartered in Japan, and Shinhan Healthcare fund 5 ("Shinhan"), a fund established under the laws of the Republic of Korea.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of 31&#160;December 2023, the carrying amount of the Aztiq Convertible Bond was  $80.7&#160;million and includes $15.1 million held by ATP Holdings ehf. The carrying amount of the Aztiq Convertible Bond was $65.8&#160;million as of 31&#160;December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Alvogen Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with an undertaking by Alvotech shareholders to ensure that Alvotech was sufficiently funded through the closing of the Business Combination by providing at least $50.0 million for the operations of the Group, Alvogen and Aztiq provided interest free loan advances to Alvotech. On 22&#160;February 2022, Alvotech borrowed $15.0 million under the facility from Alvogen, as lender. On 29&#160;March 2022, Alvotech withdrew an additional amount of $10.0 million under the facility, for aggregate indebtedness of $25.0 million. On 11&#160;March 2022, Alvotech borrowed $15.0 million under the facility from Aztiq, as lender. On 31&#160;March 2022, Alvotech withdrew an additional amount of $10.0 million under the facility, for aggregate indebtedness of $25.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 12 July 2022, the Company entered into settlement agreements with both Aztiq and Alvogen for the $25.0 million in related party loans provided by each party. As a result of the settlement agreements, Aztiq and Alvogen each received 2,500,000 Ordinary Shares. The settlement was accounted for as an extinguishment of financial liabilities. In accordance with IFRS 9, the difference between the fair value of the consideration paid for the settlement, which was determined to be $32.2 million, and the extinguished financial liabilities of $50.0 million was recognized as a gain on the extinguishment of financial liabilities in the consolidated statement of profit or loss and other comprehensive income or loss.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 11&#160;April 2022, Alvotech entered into a loan agreement with Alvogen, as lender, for a loan of up to $40.0 million bearing an interest rate of 10% per annum. The loan was drawable in two separate installments of $20.0 million each. On 12&#160;April 2022, Alvotech withdrew the first installment of $20.0 million. Alvotech withdrew a second installment of $20.0 million on 9&#160;May 2022 for aggregate indebtedness of $40.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 1&#160;June 2022, Alvotech also entered into a loan agreement with Alvogen, as lender, for a loan of $20.0 million bearing an interest rate of 10% per annum. Alvotech withdrew the entire loan amount of $20.0 million on 1&#160;June 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the 16 November 2022 Senior Bonds amendment, Alvotech entered into a subordinated loan agreement with Alvogen (the &#x201c;Alvogen Facility&#x201d;). As part of the subordinated loan agreement, the Group agreed to the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Rollover the $63.3&#160;million outstanding, which includes $3.3 million of accrued interest, under the Alvogen loans, into the new subordinated loan agreement, and withdraw an additional $50.0 million in loans;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The interest rate was increased from 10% per annum to 17.5% per annum on the outstanding amounts under the loan facility;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;A repayment date of 91 days after the full redemption or the final maturity date of the Senior Bonds; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Contingently issuable penny warrants to the bondholders (the &#x201c;Alvogen Facility Warrants&#x201d;) if certain events occur, representing 4.0% of the fully diluted ordinary share capital, as defined in the Alvogen Facility agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group determined that the 16 November 2022 transaction was a substantial modification to its related party loans and accounted for the transaction as an extinguishment. As a result, the Group recognized the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Extinguishment of bonds with a carrying value of $63.2&#160;million, including $3.2 million of accrued interest;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Net cash proceeds of $50.0&#160;million; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Recognition of $113.2&#160;million and $1.3 million representing the fair value of the new Alvogen Facility and Alvogen Facility Warrants, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 20&#160;December 2022, the Company repaid $50.0 million under the Alvogen Facility, with proceeds from the 2022 Convertible Bonds. As a result, Alvotech extinguished the liability to issue the Alvogen Facility Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of 31&#160;December 2023, the carrying amount of the Alvogen Facility is $76.6&#160;million, compared to $64.6&#160;million as of 31&#160;December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Facility Loans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As noted above, the Group assumed the Facility Loans as part of the asset acquisition for the Facility. On 9&#160;December 2022, the Group extinguished the assumed loans from Arion banki hf., with an outstanding balance of $30.9 million, with two new loans from Landsbankinn hf. for $48.8 million, with variable interest rate, currently 8.3% and 9.3% per annum. The refinancing resulted in net cash proceeds of $17.2 million after transaction costs paid. The Group has pledged the facility as collateral to secure these loans (1st lien pledge), as further described in Note 12.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.35pt;padding-left:27.5pt;padding-right:7.9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.35pt;padding-left:27.5pt;padding-right:7.9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%"&gt;These two loans were denominated in Icelandic Krona and included a conversion clause to convert them into USD. The conversion of these two loans took place in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27.5pt;padding-right:7.65pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%"&gt;Under the terms of the loan agreements after conversion, the first loan includes annuity payments that are due monthly with a final maturity in December 2029 and a variable interest rate of USD &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%"&gt;Secured Overnight Funding Rate ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%"&gt;SOFR") plus a margin of 4.75%. The second loan is a bullet loan with a final maturity in December 2027 and a variable interest rate of USD SOFR plus a margin of 3.75%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.55pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27.5pt;padding-right:7.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:128%"&gt;The Group determined that conversion to USD of the two loans was a substantial modification to loan agreements and accounted for the transaction as an extinguishment. No gain or loss was recognized as part of the extinguishment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of 31&#160;December 2023, the carrying amount of the Facility Loans is $48.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Other borrowings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2015 and 2016, the Group entered into several term loan agreements with a financial institution for a total principal amount of $25.9 million. The loan agreements set forth terms and conditions between the Group and the financial institution, inclusive of certain representations and non-financial covenants. Per the terms of the loan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;agreements, the loans mature throughout 2024, depending on the issuance date of each loan. Interest on the loans is based on variable interest rate of USD SOFR plus a margin of 4.95%, payable on a monthly basis. Interest accrued and unpaid at the end of each interest period increases the principal obligations owed by the Group to the financial institution. As of 31&#160;December 2023, the outstanding balance on the loans is $0.5&#160;million, compared to a balance of $3.2&#160;million as of 31&#160;December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 22 February 2022, the Group entered into a credit facility agreement with Landsbankinn hf. with the ability to draw down an amount up to $8&#160;million. The credit facility is in place to help finance equipment purchases in the future. Per the terms of the credit facility, any borrowings are required to be paid by 1 August 2024 and have a variable interest rate of USD SOFR plus a margin of 4.95%. As of 31&#160;December 2023, the outstanding balance on the credit facility was $7.8&#160;million, compared to $13.9&#160;million as of 31&#160;December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 22 February 2022, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $3.2 million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in March 2029. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $2.5&#160;million, compared to $2.9&#160;million as of 31&#160;December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 5 August 2022, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $1.8 million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in August 2029. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $1.6&#160;million, compared to $1.8&#160;million as of 31&#160;December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 4 August 2023, the Group entered into a loan agreement with Landsbankinn hf. for a principal amount of $11.5&#160;million. The loan is in place to help finance equipment purchases. Per the terms of the loan agreement, annuity payments are due monthly with a final maturity in August 2030. The loan has a variable interest rate of USD SOFR plus a margin of 4.25%. As of 31&#160;December 2023, the outstanding balance on the loan was $11.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group is in compliance with all representations and non-financial covenants required by these agreements. In addition, the Group has pledged equipment as collateral to secure these borrowings, as further described in Note 12. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 14 December 2023, the Group entered into a qualified receivable financing agreement with Landsbankinn hf. for a principal amount of $25.0&#160;million. The qualified receivable financing arrangement has a variable interest rate of USD SOFR plus a margin of 3.50% and a maturity of April 2024. As of 31&#160;December 2023, the outstanding balance on the loan was $25.0&#160;million. The Group has pledged $25&#160;million of its trade receivables to secure this financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Movements in the Group&#x2019;s outstanding borrowings during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings, net at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;400,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Recognition of deferred debt issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accretion/derecognition of borrowings discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Recognition of new borrowings discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(50,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(43,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Proceeds from new borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;275,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;467,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loans from related party converted to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Repayments of borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(99,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(83,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of deferred debt issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings, net at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted-average interest rates of outstanding borrowings for the years ended 31&#160;December 2023, 2022, and 2021 are 12.73%, 12.41%, and 14.83%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below details the changes in the Group&#x2019;s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group&#x2019;s consolidated cash flow statement as cash flows from financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;1 January &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Financing Cash flows (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Capitalized loan cost changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Fair value changes, including accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Other changes (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 Convertible Bonds and Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;98,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(36,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;236,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds (including related party)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;530,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;170,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(35,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Other changes include interest accruals and effects of payments including $3.5&#160;million in cash received from borrowings from the 2022 Convertible Bonds and transaction cost of $9&#160;million paid in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.318%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.746%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 January &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing Cash flows (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized loan cost changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value changes, including accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other changes (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Conversion to Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-cash movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 Convertible Bonds and Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(40,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;98,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds (including related party)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;394,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;70,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;530,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;400,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;268,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;113,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Other changes include interest accruals and payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual maturities of principal amounts on the Group&#x2019;s outstanding borrowings as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Within two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;867,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Within three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;696,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Within four years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="c-1" id="f-1401">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s debt consists of interest-bearing borrowings from financial institutions, related parties and third parties. Outstanding borrowings, net of transaction costs, presented on the consolidated statements of financial position as current and non-current as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;530,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 Convertible Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;155,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total outstanding borrowings, net of debt issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: current portion of borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(19,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total non-current borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;922,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;744,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:BondsIssued contextRef="c-385" decimals="-3" id="f-1402" unitRef="usd">549411000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-386" decimals="-3" id="f-1403" unitRef="usd">530506000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-387" decimals="-3" id="f-1404" unitRef="usd">155914000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-388" decimals="-3" id="f-1405" unitRef="usd">32441000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-389" decimals="-3" id="f-1406" unitRef="usd">80663000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-390" decimals="-3" id="f-1407" unitRef="usd">65793000</ifrs-full:BondsIssued>
    <ifrs-full:LoansReceived contextRef="c-391" decimals="-3" id="f-1408" unitRef="usd">76556000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived contextRef="c-392" decimals="-3" id="f-1409" unitRef="usd">64588000</ifrs-full:LoansReceived>
    <ifrs-full:OtherBorrowings contextRef="c-5" decimals="-3" id="f-1410" unitRef="usd">97615000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-8" decimals="-3" id="f-1411" unitRef="usd">71242000</ifrs-full:OtherBorrowings>
    <ifrs-full:Borrowings contextRef="c-5" decimals="-3" id="f-1412" unitRef="usd">960159000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-3" id="f-1413" unitRef="usd">764570000</ifrs-full:Borrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="c-5" decimals="-3" id="f-1414" unitRef="usd">38025000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="c-8" decimals="-3" id="f-1415" unitRef="usd">19916000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-5" decimals="-3" id="f-1416" unitRef="usd">922134000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-8" decimals="-3" id="f-1417" unitRef="usd">744654000</ifrs-full:LongtermBorrowings>
    <alvo:StockSharesIssuedDuringThePeriodExerciseOfWarrants
      contextRef="c-393"
      decimals="INF"
      id="f-1418"
      unitRef="shares">1522103</alvo:StockSharesIssuedDuringThePeriodExerciseOfWarrants>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-393" decimals="-5" id="f-1419" unitRef="usd">101300000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <alvo:StockSharesIssuedDuringThePeriodExerciseOfWarrants
      contextRef="c-394"
      decimals="INF"
      id="f-1420"
      unitRef="shares">1137248</alvo:StockSharesIssuedDuringThePeriodExerciseOfWarrants>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-394" decimals="-5" id="f-1421" unitRef="usd">73700000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <alvo:StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities
      contextRef="c-393"
      decimals="INF"
      id="f-1422"
      unitRef="shares">2306555</alvo:StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="c-393" decimals="-5" id="f-1423" unitRef="usd">166800000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-395" decimals="-5" id="f-1424" unitRef="usd">48700000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <alvo:GainLossOnExtinguishmentOfDebt contextRef="c-396" decimals="-5" id="f-1425" unitRef="usd">149200000</alvo:GainLossOnExtinguishmentOfDebt>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="c-397" decimals="-5" id="f-1426" unitRef="usd">100700000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="c-398" decimals="-5" id="f-1427" unitRef="usd">4800000</ifrs-full:IssueOfConvertibleInstruments>
    <alvo:StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities
      contextRef="c-399"
      decimals="INF"
      id="f-1428"
      unitRef="shares">455687</alvo:StockSharesIssuedDuringThePeriodConversionOfConvertibleSecurities>
    <ifrs-full:RepaymentsOfBondsNotesAndDebentures contextRef="c-400" decimals="-5" id="f-1429" unitRef="usd">55300000</ifrs-full:RepaymentsOfBondsNotesAndDebentures>
    <alvo:PremiumPaymentOnBonds contextRef="c-400" decimals="-5" id="f-1430" unitRef="usd">6100000</alvo:PremiumPaymentOnBonds>
    <alvo:ExtensionPremiumToBondHolders contextRef="c-400" decimals="-5" id="f-1431" unitRef="usd">8100000</alvo:ExtensionPremiumToBondHolders>
    <alvo:AdditionalExtensionPremiumToBondholders contextRef="c-400" decimals="-5" id="f-1432" unitRef="usd">2600000</alvo:AdditionalExtensionPremiumToBondholders>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures contextRef="c-401" decimals="-5" id="f-1433" unitRef="usd">113800000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures contextRef="c-402" decimals="-5" id="f-1434" unitRef="usd">113800000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:IssuesFairValueMeasurementLiabilities contextRef="c-403" decimals="-5" id="f-1435" unitRef="usd">358800000</ifrs-full:IssuesFairValueMeasurementLiabilities>
    <ifrs-full:NotionalAmount contextRef="c-404" decimals="-5" id="f-1436" unitRef="usd">397400000</ifrs-full:NotionalAmount>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities contextRef="c-405" decimals="-5" id="f-1437" unitRef="usd">2600000</ifrs-full:GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities>
    <alvo:BorrowingConversionPeriodPriorToExtinguishment contextRef="c-397" id="f-1438">P14D</alvo:BorrowingConversionPeriodPriorToExtinguishment>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-406" decimals="-6" id="f-1439" unitRef="usd">0</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:BondsIssued contextRef="c-407" decimals="-5" id="f-1440" unitRef="usd">363100000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-408" decimals="-5" id="f-1441" unitRef="usd">31000000</ifrs-full:BondsIssued>
    <alvo:BorrowingPrepaymentPeriodWithAdditionalPremium contextRef="c-397" id="f-1442">P3Y</alvo:BorrowingPrepaymentPeriodWithAdditionalPremium>
    <alvo:PrepaymentPenaltyPercentageOnBonds
      contextRef="c-409"
      decimals="3"
      id="f-1443"
      unitRef="number">0.020</alvo:PrepaymentPenaltyPercentageOnBonds>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-410"
      decimals="INF"
      id="f-1444"
      unitRef="number">0.075</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-411"
      decimals="INF"
      id="f-1445"
      unitRef="number">0.100</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:FeeAndCommissionExpense contextRef="c-412" decimals="-5" id="f-1446" unitRef="usd">7400000</ifrs-full:FeeAndCommissionExpense>
    <alvo:MinimumAmountOfRestrictedCashToBeMaintained contextRef="c-413" decimals="-5" id="f-1447" unitRef="usd">25000000.0</alvo:MinimumAmountOfRestrictedCashToBeMaintained>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-414"
      decimals="INF"
      id="f-1448"
      unitRef="number">0.075</ifrs-full:BorrowingsInterestRate>
    <alvo:BorrowingSharesIssuancePeriodForInterestDecrease contextRef="c-415" id="f-1449">P6M</alvo:BorrowingSharesIssuancePeriodForInterestDecrease>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-410"
      decimals="INF"
      id="f-1450"
      unitRef="number">0.075</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-411"
      decimals="2"
      id="f-1451"
      unitRef="number">0.100</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities contextRef="c-416" decimals="-5" id="f-1452" unitRef="usd">6500000</ifrs-full:GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementLiabilities>
    <ifrs-full:NotionalAmount contextRef="c-417" decimals="-5" id="f-1453" unitRef="usd">70000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-418" decimals="-5" id="f-1454" unitRef="usd">455700000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-419" decimals="-5" id="f-1455" unitRef="usd">525700000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-420"
      decimals="INF"
      id="f-1456"
      unitRef="number">0.1075</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-421"
      decimals="INF"
      id="f-1457"
      unitRef="number">0.120</ifrs-full:BorrowingsInterestRate>
    <alvo:ClassOfWarrantsOrRightsExercisePricePerShare
      contextRef="c-422"
      decimals="2"
      id="f-1458"
      unitRef="usdPerShare">0.01</alvo:ClassOfWarrantsOrRightsExercisePricePerShare>
    <alvo:NumberOfTranches
      contextRef="c-5"
      decimals="INF"
      id="f-1459"
      unitRef="tranche">2</alvo:NumberOfTranches>
    <alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares
      contextRef="c-423"
      decimals="INF"
      id="f-1460"
      unitRef="number">0.015</alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares>
    <alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares
      contextRef="c-424"
      decimals="INF"
      id="f-1461"
      unitRef="number">0.010</alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares>
    <alvo:GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue contextRef="c-425" decimals="-5" id="f-1462" unitRef="usd">40900000</alvo:GainLossOnExtinguishmentOfDebtIncludingChangeInFairValue>
    <alvo:TransactionCosts contextRef="c-425" decimals="-5" id="f-1463" unitRef="usd">12100000</alvo:TransactionCosts>
    <alvo:CarryingValueOfDebtExtinguished contextRef="c-426" decimals="-5" id="f-1464" unitRef="usd">440100000</alvo:CarryingValueOfDebtExtinguished>
    <alvo:AccruedInterestOnDebtExtinguished contextRef="c-425" decimals="-5" id="f-1465" unitRef="usd">4800000</alvo:AccruedInterestOnDebtExtinguished>
    <alvo:NetCashProceedsFromTheTransaction contextRef="c-425" decimals="-5" id="f-1466" unitRef="usd">57900000</alvo:NetCashProceedsFromTheTransaction>
    <alvo:TransactionCosts contextRef="c-425" decimals="-5" id="f-1467" unitRef="usd">12100000</alvo:TransactionCosts>
    <alvo:RecognitionOfDerivativeAsset contextRef="c-427" decimals="-5" id="f-1468" unitRef="usd">4600000</alvo:RecognitionOfDerivativeAsset>
    <alvo:RecognitionOfDerivativeLiabilitiesAtFairValue contextRef="c-428" decimals="-5" id="f-1469" unitRef="usd">528200000</alvo:RecognitionOfDerivativeLiabilitiesAtFairValue>
    <alvo:RecognitionOfDerivativeLiabilitiesAtFairValue contextRef="c-425" decimals="-5" id="f-1470" unitRef="usd">15400000</alvo:RecognitionOfDerivativeLiabilitiesAtFairValue>
    <alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares
      contextRef="c-369"
      decimals="INF"
      id="f-1471"
      unitRef="number">0.010</alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares>
    <ifrs-full:BondsIssued contextRef="c-385" decimals="-5" id="f-1472" unitRef="usd">549400000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-386" decimals="-5" id="f-1473" unitRef="usd">530500000</ifrs-full:BondsIssued>
    <ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity contextRef="c-429" decimals="-3" id="f-1474" unitRef="usd">600000000</ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity>
    <alvo:NumberOfTranches
      contextRef="c-430"
      decimals="INF"
      id="f-1475"
      unitRef="tranch">2</alvo:NumberOfTranches>
    <ifrs-full:NotionalAmount contextRef="c-431" decimals="-5" id="f-1476" unitRef="usd">59100000</ifrs-full:NotionalAmount>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-432" decimals="-5" id="f-1477" unitRef="usd">3500000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-431"
      decimals="INF"
      id="f-1478"
      unitRef="number">0.15</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-433" decimals="-5" id="f-1479" unitRef="usd">600000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-433"
      decimals="INF"
      id="f-1480"
      unitRef="number">0.125</ifrs-full:BorrowingsInterestRate>
    <alvo:BorrowingsRedemptionConversionPrice
      contextRef="c-434"
      decimals="INF"
      id="f-1481"
      unitRef="usdPerShare">10.00</alvo:BorrowingsRedemptionConversionPrice>
    <alvo:BorrowingsConversionFeatureFairValue contextRef="c-431" decimals="-5" id="f-1482" unitRef="usd">24900000</alvo:BorrowingsConversionFeatureFairValue>
    <ifrs-full:DebtSecurities contextRef="c-435" decimals="-5" id="f-1483" unitRef="usd">10000000</ifrs-full:DebtSecurities>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-435" decimals="-5" id="f-1484" unitRef="usd">1400000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures contextRef="c-436" decimals="-6" id="f-1485" unitRef="usd">40000000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-437" decimals="-5" id="f-1486" unitRef="usd">3900000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures contextRef="c-438" decimals="-6" id="f-1487" unitRef="usd">100000000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures contextRef="c-439" decimals="-8" id="f-1488" unitRef="isk">13000000000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures contextRef="c-440" decimals="-6" id="f-1489" unitRef="usd">30000000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <alvo:BorrowingsConversionFeatureFairValue contextRef="c-441" decimals="-5" id="f-1490" unitRef="usd">45600000</alvo:BorrowingsConversionFeatureFairValue>
    <ifrs-full:BondsIssued contextRef="c-442" decimals="-5" id="f-1491" unitRef="usd">107100000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-443" decimals="-5" id="f-1492" unitRef="usd">48800000</ifrs-full:BondsIssued>
    <ifrs-full:NotionalAmount contextRef="c-444" decimals="-5" id="f-1493" unitRef="usd">80000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-444"
      decimals="INF"
      id="f-1494"
      unitRef="number">0.1250</ifrs-full:BorrowingsInterestRate>
    <alvo:BorrowingsRedemptionConversionPrice
      contextRef="c-444"
      decimals="2"
      id="f-1495"
      unitRef="usdPerShare">10.00</alvo:BorrowingsRedemptionConversionPrice>
    <ifrs-full:NotionalAmount contextRef="c-445" decimals="-5" id="f-1496" unitRef="usd">64000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-446" decimals="-5" id="f-1497" unitRef="usd">16000000</ifrs-full:NotionalAmount>
    <alvo:AssetAcquisitionConsiderationLoansAssumed contextRef="c-447" decimals="-5" id="f-1498" unitRef="usd">30000000</alvo:AssetAcquisitionConsiderationLoansAssumed>
    <ifrs-full:BondsIssued contextRef="c-389" decimals="-5" id="f-1499" unitRef="usd">80700000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-448" decimals="-3" id="f-1500" unitRef="usd">15100000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-390" decimals="-5" id="f-1501" unitRef="usd">65800000</ifrs-full:BondsIssued>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-449" decimals="-5" id="f-1502" unitRef="usd">50000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-450" decimals="-5" id="f-1503" unitRef="usd">15000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-451" decimals="-5" id="f-1504" unitRef="usd">10000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-452" decimals="-5" id="f-1505" unitRef="usd">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-453" decimals="-5" id="f-1506" unitRef="usd">15000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-454" decimals="-5" id="f-1507" unitRef="usd">10000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-455" decimals="-5" id="f-1508" unitRef="usd">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <alvo:BorrowingsRepurchasedFaceAmount contextRef="c-456" decimals="-5" id="f-1509" unitRef="usd">25000000</alvo:BorrowingsRepurchasedFaceAmount>
    <alvo:BorrowingsRepurchasedFaceAmount contextRef="c-457" decimals="-5" id="f-1510" unitRef="usd">25000000</alvo:BorrowingsRepurchasedFaceAmount>
    <alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares
      contextRef="c-458"
      decimals="INF"
      id="f-1511"
      unitRef="shares">2500000</alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares>
    <alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares
      contextRef="c-459"
      decimals="INF"
      id="f-1512"
      unitRef="shares">2500000</alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansShares>
    <alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue contextRef="c-460" decimals="-5" id="f-1513" unitRef="usd">32200000</alvo:IssueOfSharesOnSettlementOfRelatedPartyLoansValue>
    <alvo:BorrowingsRepurchasedFaceAmount contextRef="c-461" decimals="-5" id="f-1514" unitRef="usd">50000000</alvo:BorrowingsRepurchasedFaceAmount>
    <ifrs-full:NotionalAmount contextRef="c-462" decimals="INF" id="f-1515" unitRef="usd">40000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-462"
      decimals="INF"
      id="f-1516"
      unitRef="number">0.10</ifrs-full:BorrowingsInterestRate>
    <alvo:NumberOfSeparateInstallments
      contextRef="c-462"
      decimals="INF"
      id="f-1517"
      unitRef="loan">2</alvo:NumberOfSeparateInstallments>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-463" decimals="-5" id="f-1518" unitRef="usd">20000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-464" decimals="-5" id="f-1519" unitRef="usd">20000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-464" decimals="-5" id="f-1520" unitRef="usd">20000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <alvo:AggregateBorrowingsIndebtedness contextRef="c-465" decimals="-5" id="f-1521" unitRef="usd">40000000</alvo:AggregateBorrowingsIndebtedness>
    <ifrs-full:NotionalAmount contextRef="c-466" decimals="-5" id="f-1522" unitRef="usd">20000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-467"
      decimals="INF"
      id="f-1523"
      unitRef="number">0.10</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-468" decimals="-5" id="f-1524" unitRef="usd">20000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:NotionalAmount contextRef="c-469" decimals="-5" id="f-1525" unitRef="usd">63300000</ifrs-full:NotionalAmount>
    <ifrs-full:InterestPayable contextRef="c-469" decimals="-5" id="f-1526" unitRef="usd">3300000</ifrs-full:InterestPayable>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-470" decimals="-5" id="f-1527" unitRef="usd">50000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-466"
      decimals="INF"
      id="f-1528"
      unitRef="number">0.10</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-469"
      decimals="INF"
      id="f-1529"
      unitRef="number">0.175</ifrs-full:BorrowingsInterestRate>
    <alvo:PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare
      contextRef="c-471"
      decimals="INF"
      id="f-1530"
      unitRef="number">0.040</alvo:PercnetageOfWarrantsIssuedRepresentingFullyDilutedOrdinaryShare>
    <alvo:ExtinguishmentOfBorrowings contextRef="c-472" decimals="-5" id="f-1531" unitRef="usd">63200000</alvo:ExtinguishmentOfBorrowings>
    <alvo:ExtinguishmentOfBorrowingsAccruedInterest contextRef="c-472" decimals="-5" id="f-1532" unitRef="usd">3200000</alvo:ExtinguishmentOfBorrowingsAccruedInterest>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-470" decimals="-5" id="f-1533" unitRef="usd">50000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:Borrowings contextRef="c-469" decimals="-5" id="f-1534" unitRef="usd">113200000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-471" decimals="-5" id="f-1535" unitRef="usd">1300000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-473" decimals="-5" id="f-1536" unitRef="usd">50000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:LoansReceived contextRef="c-391" decimals="-5" id="f-1537" unitRef="usd">76600000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived contextRef="c-392" decimals="-5" id="f-1538" unitRef="usd">64600000</ifrs-full:LoansReceived>
    <alvo:BorrowingsRepurchaseAmount contextRef="c-474" decimals="-5" id="f-1539" unitRef="usd">30900000</alvo:BorrowingsRepurchaseAmount>
    <alvo:NumberOfLoans
      contextRef="c-475"
      decimals="INF"
      id="f-1540"
      unitRef="agreement">2</alvo:NumberOfLoans>
    <ifrs-full:NotionalAmount contextRef="c-476" decimals="-5" id="f-1541" unitRef="usd">48800000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-477"
      decimals="INF"
      id="f-1542"
      unitRef="number">0.083</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-478"
      decimals="INF"
      id="f-1543"
      unitRef="number">0.093</ifrs-full:BorrowingsInterestRate>
    <alvo:ProceedsFromBorrowingsNetOfTransactionCosts contextRef="c-479" decimals="-5" id="f-1544" unitRef="usd">17200000</alvo:ProceedsFromBorrowingsNetOfTransactionCosts>
    <alvo:NumberOfLoans
      contextRef="c-475"
      decimals="INF"
      id="f-1545"
      unitRef="agreement">2</alvo:NumberOfLoans>
    <alvo:NumberOfLoans
      contextRef="c-475"
      decimals="INF"
      id="f-1546"
      unitRef="agreement">2</alvo:NumberOfLoans>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis
      contextRef="c-480"
      decimals="4"
      id="f-1547"
      unitRef="number">0.0475</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis
      contextRef="c-481"
      decimals="4"
      id="f-1548"
      unitRef="number">0.0375</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <alvo:NumberOfLoans
      contextRef="c-475"
      decimals="INF"
      id="f-1549"
      unitRef="agreement">2</alvo:NumberOfLoans>
    <ifrs-full:Borrowings contextRef="c-475" decimals="-5" id="f-1550" unitRef="usd">48500000</ifrs-full:Borrowings>
    <ifrs-full:NotionalAmount contextRef="c-482" decimals="-5" id="f-1551" unitRef="usd">25900000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis
      contextRef="c-483"
      decimals="INF"
      id="f-1552"
      unitRef="number">0.0495</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <ifrs-full:Borrowings contextRef="c-483" decimals="-5" id="f-1553" unitRef="usd">500000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-484" decimals="-5" id="f-1554" unitRef="usd">3200000</ifrs-full:Borrowings>
    <ifrs-full:NotionalAmount contextRef="c-485" decimals="-6" id="f-1555" unitRef="usd">8000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis
      contextRef="c-486"
      decimals="INF"
      id="f-1556"
      unitRef="number">0.0495</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <ifrs-full:Borrowings contextRef="c-487" decimals="-5" id="f-1557" unitRef="usd">7800000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-488" decimals="-5" id="f-1558" unitRef="usd">13900000</ifrs-full:Borrowings>
    <ifrs-full:NotionalAmount contextRef="c-489" decimals="-5" id="f-1559" unitRef="usd">3200000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis
      contextRef="c-490"
      decimals="INF"
      id="f-1560"
      unitRef="number">0.0425</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <ifrs-full:Borrowings contextRef="c-491" decimals="-5" id="f-1561" unitRef="usd">2500000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-492" decimals="-5" id="f-1562" unitRef="usd">2900000</ifrs-full:Borrowings>
    <ifrs-full:NotionalAmount contextRef="c-493" decimals="-5" id="f-1563" unitRef="usd">1800000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis
      contextRef="c-494"
      decimals="INF"
      id="f-1564"
      unitRef="number">0.0425</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <ifrs-full:Borrowings contextRef="c-495" decimals="-5" id="f-1565" unitRef="usd">1600000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-496" decimals="-5" id="f-1566" unitRef="usd">1800000</ifrs-full:Borrowings>
    <ifrs-full:NotionalAmount contextRef="c-497" decimals="-5" id="f-1567" unitRef="usd">11500000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis
      contextRef="c-494"
      decimals="INF"
      id="f-1568"
      unitRef="number">0.0425</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <ifrs-full:Borrowings contextRef="c-498" decimals="-5" id="f-1569" unitRef="usd">11000000</ifrs-full:Borrowings>
    <ifrs-full:NotionalAmount contextRef="c-499" decimals="-5" id="f-1570" unitRef="usd">25000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis
      contextRef="c-500"
      decimals="INF"
      id="f-1571"
      unitRef="number">0.0350</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <ifrs-full:Borrowings contextRef="c-499" decimals="-5" id="f-1572" unitRef="usd">25000000</ifrs-full:Borrowings>
    <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="c-501" decimals="-3" id="f-1573" unitRef="usd">25000000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <alvo:DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock contextRef="c-1" id="f-1574">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Movements in the Group&#x2019;s outstanding borrowings during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings, net at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;400,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Recognition of deferred debt issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accretion/derecognition of borrowings discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Recognition of new borrowings discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(50,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(43,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Proceeds from new borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;275,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;467,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loans from related party converted to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Repayments of borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(99,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(83,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of deferred debt issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign currency exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings, net at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below details the changes in the Group&#x2019;s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group&#x2019;s consolidated cash flow statement as cash flows from financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;1 January &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Financing Cash flows (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Capitalized loan cost changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Fair value changes, including accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Other changes (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 Convertible Bonds and Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;98,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(36,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;236,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds (including related party)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;530,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;170,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(35,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Other changes include interest accruals and effects of payments including $3.5&#160;million in cash received from borrowings from the 2022 Convertible Bonds and transaction cost of $9&#160;million paid in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.318%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.746%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 January &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing Cash flows (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized loan cost changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value changes, including accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other changes (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Conversion to Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-cash movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2022 Convertible Bonds and Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(40,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;98,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds (including related party)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;394,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;70,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;530,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;400,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;268,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;113,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The cash flows from bank loans, loans from related parties and other borrowings make up the net amount of proceeds from borrowings and repayments of borrowings in the cash flow statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Other changes include interest accruals and payments.&lt;/span&gt;&lt;/div&gt;</alvo:DisclosureofMovementsInOutstandingBorrowingsExplanatoryTableTextBlock>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-3" id="f-1575" unitRef="usd">764570000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-9" decimals="-3" id="f-1576" unitRef="usd">400911000</ifrs-full:Borrowings>
    <alvo:PaymentsForDebtIssueCost contextRef="c-1" decimals="-3" id="f-1577" unitRef="usd">6115000</alvo:PaymentsForDebtIssueCost>
    <alvo:PaymentsForDebtIssueCost contextRef="c-6" decimals="-3" id="f-1578" unitRef="usd">2889000</alvo:PaymentsForDebtIssueCost>
    <alvo:AccretionderecognitionOfBorrowingsDiscount contextRef="c-1" decimals="-3" id="f-1579" unitRef="usd">15770000</alvo:AccretionderecognitionOfBorrowingsDiscount>
    <alvo:AccretionderecognitionOfBorrowingsDiscount contextRef="c-6" decimals="-3" id="f-1580" unitRef="usd">35065000</alvo:AccretionderecognitionOfBorrowingsDiscount>
    <alvo:RecognitionOfNewBorrowingsDiscount contextRef="c-1" decimals="-3" id="f-1581" unitRef="usd">50953000</alvo:RecognitionOfNewBorrowingsDiscount>
    <alvo:RecognitionOfNewBorrowingsDiscount contextRef="c-6" decimals="-3" id="f-1582" unitRef="usd">43241000</alvo:RecognitionOfNewBorrowingsDiscount>
    <alvo:ProceedsFromBorrowingClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-1583" unitRef="usd">275311000</alvo:ProceedsFromBorrowingClassifiedAsFinancingActivities>
    <alvo:ProceedsFromBorrowingClassifiedAsFinancingActivities contextRef="c-6" decimals="-3" id="f-1584" unitRef="usd">467196000</alvo:ProceedsFromBorrowingClassifiedAsFinancingActivities>
    <alvo:LoansFromRelatedPartyConvertedToEquity contextRef="c-1" decimals="-3" id="f-1585" unitRef="usd">0</alvo:LoansFromRelatedPartyConvertedToEquity>
    <alvo:LoansFromRelatedPartyConvertedToEquity contextRef="c-6" decimals="-3" id="f-1586" unitRef="usd">-50000000</alvo:LoansFromRelatedPartyConvertedToEquity>
    <alvo:RepaymentsOfBorrowingClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-1587" unitRef="usd">99367000</alvo:RepaymentsOfBorrowingClassifiedAsFinancingActivities>
    <alvo:RepaymentsOfBorrowingClassifiedAsFinancingActivities contextRef="c-6" decimals="-3" id="f-1588" unitRef="usd">83951000</alvo:RepaymentsOfBorrowingClassifiedAsFinancingActivities>
    <alvo:DebtInstrumentIncreaseAccruedInterests contextRef="c-1" decimals="-3" id="f-1589" unitRef="usd">58212000</alvo:DebtInstrumentIncreaseAccruedInterests>
    <alvo:DebtInstrumentIncreaseAccruedInterests contextRef="c-6" decimals="-3" id="f-1590" unitRef="usd">40424000</alvo:DebtInstrumentIncreaseAccruedInterests>
    <alvo:AmortizationOfDeferredDebtIssueCosts contextRef="c-1" decimals="-3" id="f-1591" unitRef="usd">1657000</alvo:AmortizationOfDeferredDebtIssueCosts>
    <alvo:AmortizationOfDeferredDebtIssueCosts contextRef="c-6" decimals="-3" id="f-1592" unitRef="usd">23000</alvo:AmortizationOfDeferredDebtIssueCosts>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-1593" unitRef="usd">1075000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-6" decimals="-3" id="f-1594" unitRef="usd">1032000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:Borrowings contextRef="c-5" decimals="-3" id="f-1595" unitRef="usd">960159000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-3" id="f-1596" unitRef="usd">764570000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-502"
      decimals="4"
      id="f-1597"
      unitRef="number">0.1273</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-503"
      decimals="4"
      id="f-1598"
      unitRef="number">0.1241</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-504"
      decimals="4"
      id="f-1599"
      unitRef="number">0.1483</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:Borrowings contextRef="c-505" decimals="-3" id="f-1600" unitRef="usd">98234000</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-506" decimals="-3" id="f-1601" unitRef="usd">145358000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-506" decimals="-3" id="f-1602" unitRef="usd">1657000</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-506" decimals="-3" id="f-1603" unitRef="usd">-36071000</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-506" decimals="-3" id="f-1604" unitRef="usd">27603000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-506" decimals="-3" id="f-1605" unitRef="usd">-204000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:Borrowings contextRef="c-507" decimals="-3" id="f-1606" unitRef="usd">236577000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-386" decimals="-3" id="f-1607" unitRef="usd">530506000</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-508" decimals="-3" id="f-1608" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-508" decimals="-3" id="f-1609" unitRef="usd">0</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-508" decimals="-3" id="f-1610" unitRef="usd">888000</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-508" decimals="-3" id="f-1611" unitRef="usd">18017000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-508" decimals="-3" id="f-1612" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:Borrowings contextRef="c-385" decimals="-3" id="f-1613" unitRef="usd">549411000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-509" decimals="-3" id="f-1614" unitRef="usd">71242000</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-510" decimals="-3" id="f-1615" unitRef="usd">25102000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-510" decimals="-3" id="f-1616" unitRef="usd">0</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-510" decimals="-3" id="f-1617" unitRef="usd">0</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-510" decimals="-3" id="f-1618" unitRef="usd">-8000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-510" decimals="-3" id="f-1619" unitRef="usd">1279000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:Borrowings contextRef="c-511" decimals="-3" id="f-1620" unitRef="usd">97615000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-392" decimals="-3" id="f-1621" unitRef="usd">64588000</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-512" decimals="-3" id="f-1622" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-512" decimals="-3" id="f-1623" unitRef="usd">0</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-512" decimals="-3" id="f-1624" unitRef="usd">0</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-512" decimals="-3" id="f-1625" unitRef="usd">11968000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-512" decimals="-3" id="f-1626" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:Borrowings contextRef="c-391" decimals="-3" id="f-1627" unitRef="usd">76556000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-3" id="f-1628" unitRef="usd">764570000</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-1629" unitRef="usd">170460000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-1" decimals="-3" id="f-1630" unitRef="usd">1657000</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-1" decimals="-3" id="f-1631" unitRef="usd">-35183000</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-1" decimals="-3" id="f-1632" unitRef="usd">57580000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-1633" unitRef="usd">1075000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:Borrowings contextRef="c-5" decimals="-3" id="f-1634" unitRef="usd">960159000</ifrs-full:Borrowings>
    <ifrs-full:ProceedsFromCurrentBorrowings contextRef="c-506" decimals="-5" id="f-1635" unitRef="usd">3500000</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:PaymentsForDebtIssueCosts contextRef="c-506" decimals="-5" id="f-1636" unitRef="usd">9000000</ifrs-full:PaymentsForDebtIssueCosts>
    <ifrs-full:Borrowings contextRef="c-513" decimals="-3" id="f-1637" unitRef="usd">0</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-514" decimals="-3" id="f-1638" unitRef="usd">55852000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-514" decimals="-3" id="f-1639" unitRef="usd">-2865000</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-514" decimals="-3" id="f-1640" unitRef="usd">-40245000</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-514" decimals="-3" id="f-1641" unitRef="usd">1528000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-514" decimals="-3" id="f-1642" unitRef="usd">444000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity contextRef="c-514" decimals="-3" id="f-1643" unitRef="usd">0</ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity>
    <alvo:NonCashChangesInOtherNonCashMovements contextRef="c-514" decimals="-3" id="f-1644" unitRef="usd">83520000</alvo:NonCashChangesInOtherNonCashMovements>
    <ifrs-full:Borrowings contextRef="c-505" decimals="-3" id="f-1645" unitRef="usd">98234000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-515" decimals="-3" id="f-1646" unitRef="usd">394129000</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-516" decimals="-3" id="f-1647" unitRef="usd">70000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-516" decimals="-3" id="f-1648" unitRef="usd">0</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-516" decimals="-3" id="f-1649" unitRef="usd">32069000</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-516" decimals="-3" id="f-1650" unitRef="usd">34308000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-516" decimals="-3" id="f-1651" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <alvo:NonCashChangesInOtherNonCashMovements contextRef="c-516" decimals="-3" id="f-1652" unitRef="usd">0</alvo:NonCashChangesInOtherNonCashMovements>
    <ifrs-full:Borrowings contextRef="c-386" decimals="-3" id="f-1653" unitRef="usd">530506000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-517" decimals="-3" id="f-1654" unitRef="usd">6782000</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-518" decimals="-3" id="f-1655" unitRef="usd">33112000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-518" decimals="-3" id="f-1656" unitRef="usd">0</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-518" decimals="-3" id="f-1657" unitRef="usd">0</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-518" decimals="-3" id="f-1658" unitRef="usd">762000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-518" decimals="-3" id="f-1659" unitRef="usd">588000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <alvo:NonCashChangesInOtherNonCashMovements contextRef="c-518" decimals="-3" id="f-1660" unitRef="usd">29998000</alvo:NonCashChangesInOtherNonCashMovements>
    <ifrs-full:Borrowings contextRef="c-509" decimals="-3" id="f-1661" unitRef="usd">71242000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-519" decimals="-3" id="f-1662" unitRef="usd">0</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-520" decimals="-3" id="f-1663" unitRef="usd">110000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-520" decimals="-3" id="f-1664" unitRef="usd">0</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-520" decimals="-3" id="f-1665" unitRef="usd">0</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-520" decimals="-3" id="f-1666" unitRef="usd">4588000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-520" decimals="-3" id="f-1667" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity contextRef="c-520" decimals="-3" id="f-1668" unitRef="usd">50000000</ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity>
    <alvo:NonCashChangesInOtherNonCashMovements contextRef="c-520" decimals="-3" id="f-1669" unitRef="usd">0</alvo:NonCashChangesInOtherNonCashMovements>
    <ifrs-full:Borrowings contextRef="c-392" decimals="-3" id="f-1670" unitRef="usd">64588000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-9" decimals="-3" id="f-1671" unitRef="usd">400911000</ifrs-full:Borrowings>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-6" decimals="-3" id="f-1672" unitRef="usd">268964000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <alvo:InterestCostsCapitalizedPeriodIncreaseDecrease contextRef="c-6" decimals="-3" id="f-1673" unitRef="usd">-2865000</alvo:InterestCostsCapitalizedPeriodIncreaseDecrease>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement contextRef="c-6" decimals="-3" id="f-1674" unitRef="usd">-8176000</ifrs-full:GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForLiabilitiesHeldAtEndOfPeriodFairValueMeasurement>
    <alvo:NonCashChangesInOtherChanges contextRef="c-6" decimals="-3" id="f-1675" unitRef="usd">41186000</alvo:NonCashChangesInOtherChanges>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-6" decimals="-3" id="f-1676" unitRef="usd">1032000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity contextRef="c-6" decimals="-3" id="f-1677" unitRef="usd">50000000</ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity>
    <alvo:NonCashChangesInOtherNonCashMovements contextRef="c-6" decimals="-3" id="f-1678" unitRef="usd">113518000</alvo:NonCashChangesInOtherNonCashMovements>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-3" id="f-1679" unitRef="usd">764570000</ifrs-full:Borrowings>
    <alvo:ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock contextRef="c-1" id="f-1680">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual maturities of principal amounts on the Group&#x2019;s outstanding borrowings as of 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Within two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;867,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Within three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;696,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Within four years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:ScheduleOfMaturitiesOfOutstandingBorrowingsExplanatoryTableTextBlock>
    <ifrs-full:Borrowings contextRef="c-283" decimals="-3" id="f-1681" unitRef="usd">38025000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-284" decimals="-3" id="f-1682" unitRef="usd">19916000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-521" decimals="-3" id="f-1683" unitRef="usd">867273000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-522" decimals="-3" id="f-1684" unitRef="usd">3804000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-523" decimals="-3" id="f-1685" unitRef="usd">4932000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-524" decimals="-3" id="f-1686" unitRef="usd">696646000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-525" decimals="-3" id="f-1687" unitRef="usd">37857000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-526" decimals="-3" id="f-1688" unitRef="usd">3374000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-527" decimals="-3" id="f-1689" unitRef="usd">12072000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-528" decimals="-3" id="f-1690" unitRef="usd">40830000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-5" decimals="-3" id="f-1691" unitRef="usd">960159000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-3" id="f-1692" unitRef="usd">764570000</ifrs-full:Borrowings>
    <alvo:DisclosureOfLongTermIncentivePlansExplanatoryTextBlock contextRef="c-1" id="f-1693">Long-term incentive plans &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Share appreciation rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prior to 2020, the Group granted SARs to three former employees. During the year ended 31&#160;December 2021 and 2020, the Group granted SARs to one and two current employees, respectively. There were no new granted SARs in the years ended 31&#160;December 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Settlement of SARs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the closing of the Business Combination, the Company reached a settlement agreement for share appreciation rights previously awarded to certain current and former employees. The rights were settled as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;two former employees will each receive 1,755,291 Ordinary Shares to be issued one year after the Closing Date. In accordance with IFRS 2, the settlements were accounted for as a modification of a share-based payment transaction that changes the awards classification from cash-settled to equity-settled; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;one former employee will receive a $1.5 million cash payment in July 2022; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;one current employee can elect to receive a cash payment of $1.5 million or 150,000 Ordinary Shares to be issued one year after the Closing Date. The Company recognized the cash settlement option as a liability with a fair value of $0.8 million and the share settlement option as equity with a fair value of $0.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The settlement agreements resulted in a net $36.8 million decrease in the SARs liability, a $31.0 million increase in equity equal to the fair value of the Ordinary Shares issued to the two former employees, a $1.5 million increase in other current liabilities, and income of $4.3 million in "General and administrative expense" recognized for the difference between the extinguished liabilities and the fair value of consideration paid to the current and former employees. As of 31&#160;December 2022, the Company recognized $0.7 million as an other current liability related to the remaining SARs liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All liabilities described above have been fully settled in 2023 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Shares were delivered to the two former employees, on a net basis after tax withholding, resulting in a total of 2,465,845 shares which has been reflected accordingly in Note 19.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The employee who could choose between receiving $1.5&#160;million or 150,000 Ordinary Shares elected to receive the cash payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Employee incentive plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Movements in the Group&#x2019;s employee incentive plan liabilities during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December prior to reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassified to other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfLongTermIncentivePlansExplanatoryTextBlock>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-6" decimals="0" id="f-1694" unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-1" decimals="0" id="f-1695" unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfEmployees
      contextRef="c-529"
      decimals="0"
      id="f-1696"
      unitRef="number">2</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-530"
      decimals="0"
      id="f-1697"
      unitRef="shares">1755291</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <alvo:NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination contextRef="c-531" id="f-1698">P1Y</alvo:NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="c-532" decimals="-5" id="f-1699" unitRef="usd">1500000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:NumberOfEmployees
      contextRef="c-533"
      decimals="0"
      id="f-1700"
      unitRef="number">1</ifrs-full:NumberOfEmployees>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="c-534" decimals="-5" id="f-1701" unitRef="usd">1500000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-535"
      decimals="0"
      id="f-1702"
      unitRef="shares">150000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <alvo:NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination contextRef="c-534" id="f-1703">P1Y</alvo:NumberOfYearForIssuingSharesAfterTheClosingOfTheBusinessCombination>
    <alvo:LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue contextRef="c-536" decimals="-5" id="f-1704" unitRef="usd">800000</alvo:LiabilitiesFromShareBasedPaymentTransactionsCashSettlementFairValue>
    <alvo:DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue contextRef="c-537" decimals="-5" id="f-1705" unitRef="usd">700000</alvo:DecreaseInEquityFromShareBasedPaymentTransactionsCashSettlementFairValue>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset contextRef="c-537" decimals="-5" id="f-1706" unitRef="usd">-36800000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ChangesInEquity contextRef="c-538" decimals="-5" id="f-1707" unitRef="usd">31000000</ifrs-full:ChangesInEquity>
    <alvo:IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-5" id="f-1708" unitRef="usd">1500000</alvo:IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-539" decimals="-5" id="f-1709" unitRef="usd">4300000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-536" decimals="-5" id="f-1710" unitRef="usd">700000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:NumberOfEmployees
      contextRef="c-529"
      decimals="0"
      id="f-1711"
      unitRef="number">2</ifrs-full:NumberOfEmployees>
    <alvo:NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement contextRef="c-1" decimals="0" id="f-1712" unitRef="shares">2465845</alvo:NumberOfShareOptionsAfterTaxWitholdingInShareBasedPaymentArrangement>
    <alvo:IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset contextRef="c-534" decimals="-5" id="f-1713" unitRef="usd">1500000</alvo:IncreaseDecreaseThroughOtherCurrentLiabilitiesAndIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-535"
      decimals="0"
      id="f-1714"
      unitRef="shares">150000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory contextRef="c-1" id="f-1715">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Movements in the Group&#x2019;s employee incentive plan liabilities during the years ended 31&#160;December 2023 and 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December prior to reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Reclassified to other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-540" decimals="-3" id="f-1716" unitRef="usd">12317000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-9" decimals="-3" id="f-1717" unitRef="usd">14935000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-3" id="f-1718" unitRef="usd">78000</ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset contextRef="c-6" decimals="-3" id="f-1719" unitRef="usd">5075000</ifrs-full:ContributionsToPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-3" id="f-1720" unitRef="usd">11736000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="c-6" decimals="-3" id="f-1721" unitRef="usd">7693000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-541" decimals="-3" id="f-1722" unitRef="usd">659000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-540" decimals="-3" id="f-1723" unitRef="usd">12317000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-542" decimals="-3" id="f-1724" unitRef="usd">-659000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-543" decimals="-3" id="f-1725" unitRef="usd">-11773000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-5" decimals="-3" id="f-1726" unitRef="usd">0</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-8" decimals="-3" id="f-1727" unitRef="usd">544000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c-1" id="f-1728">Share-based payments &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 1 December 2022, the Renumeration Committee authorized and the Group granted RSUs to employees, executives, and directors granting rights to Ordinary Shares once vesting conditions are met. Compensation expense for RSUs is determined based upon the market price of the Ordinary Shares underlying the awards on the date of grant and expensed over the vesting period, which is generally a 1 to 4-year period, with a 1-year cliff vesting period &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and subsequent monthly vesting, resulting from participants completing a service condition. Movements in RSUs during the year ended 31&#160;December 2023 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Average &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Average &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,979,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;New grants during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;820,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$8.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,659,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,587,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$7.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,466,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(679,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,745,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,979,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group recogniz&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ed $18.0 million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.3&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; of shar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;e-based payment expense during the years ended 31&#160;December 2023 and 2022, respectively, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement contextRef="c-544" id="f-1729">P1Y</alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement>
    <alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement contextRef="c-545" id="f-1730">P4Y</alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement>
    <alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement contextRef="c-546" id="f-1731">P1Y</alvo:VestingPeriodOfRequirementsForShareBasedPaymentArrangement>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c-1" id="f-1732">Movements in RSUs during the year ended 31&#160;December 2023 are as follows:&lt;div style="margin-top:12pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Average &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Average &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,979,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;New grants during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;820,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$8.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,659,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,587,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$7.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,466,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(679,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,745,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,979,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-547"
      decimals="INF"
      id="f-1733"
      unitRef="shares">6979482</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding
      contextRef="c-547"
      decimals="2"
      id="f-1734"
      unitRef="usdPerShare">6.72</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-548"
      decimals="INF"
      id="f-1735"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding
      contextRef="c-548"
      decimals="2"
      id="f-1736"
      unitRef="usdPerShare">0</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-549"
      decimals="INF"
      id="f-1737"
      unitRef="shares">820602</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted
      contextRef="c-549"
      decimals="2"
      id="f-1738"
      unitRef="usdPerShare">8.79</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-550"
      decimals="INF"
      id="f-1739"
      unitRef="shares">7659044</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted
      contextRef="c-550"
      decimals="2"
      id="f-1740"
      unitRef="usdPerShare">6.68</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-549"
      decimals="INF"
      id="f-1741"
      unitRef="shares">1587929</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited
      contextRef="c-549"
      decimals="2"
      id="f-1742"
      unitRef="usdPerShare">7.11</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-550"
      decimals="INF"
      id="f-1743"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited
      contextRef="c-550"
      decimals="2"
      id="f-1744"
      unitRef="usdPerShare">0</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsForfeited>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-549"
      decimals="INF"
      id="f-1745"
      unitRef="shares">2466374</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsVested
      contextRef="c-549"
      decimals="2"
      id="f-1746"
      unitRef="usdPerShare">6.67</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsVested>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-550"
      decimals="INF"
      id="f-1747"
      unitRef="shares">679562</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsVested
      contextRef="c-550"
      decimals="2"
      id="f-1748"
      unitRef="usdPerShare">6.30</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsVested>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-551"
      decimals="INF"
      id="f-1749"
      unitRef="shares">3745781</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding
      contextRef="c-551"
      decimals="2"
      id="f-1750"
      unitRef="usdPerShare">7.04</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-547"
      decimals="INF"
      id="f-1751"
      unitRef="shares">6979482</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding
      contextRef="c-547"
      decimals="2"
      id="f-1752"
      unitRef="usdPerShare">6.72</alvo:WeightedAverageFairValuePerShareOtherEquityInstrumentsOutstanding>
    <ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss contextRef="c-1" id="f-1753">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group recogniz&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ed $18.0 million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.3&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; of shar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;e-based payment expense during the years ended 31&#160;December 2023 and 2022, respectively, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-1" decimals="-5" id="f-1754" unitRef="usd">18000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-6" decimals="-5" id="f-1755" unitRef="usd">10300000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-552" decimals="-3" id="f-1756" unitRef="usd">3319000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-553" decimals="-3" id="f-1757" unitRef="usd">1522000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-554" decimals="-3" id="f-1758" unitRef="usd">3991000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-555" decimals="-3" id="f-1759" unitRef="usd">2994000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-556" decimals="-3" id="f-1760" unitRef="usd">10723000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-557" decimals="-3" id="f-1761" unitRef="usd">5801000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-1" decimals="-3" id="f-1762" unitRef="usd">18033000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-6" decimals="-3" id="f-1763" unitRef="usd">10317000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <alvo:DisclosureOfLitigationSettlementsExplanatoryTextBlock contextRef="c-1" id="f-1764">Litigation &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group was involved in four litigations (all now dismissed) in the United States adverse to AbbVie arising out of the development of Alvotech&#x2019;s AVT02 product, and the filing of a biologics license application with the U.S. Food and Drug Administration seeking regulatory approval (the &#x201c;AbbVie Litigations&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Alvotech entered into the AbbVie U.S. Agreement with AbbVie Inc. and AbbVie Biotechnology Ltd with respect to AVT02 for the U.S. market. Pursuant to the settlement component of the AbbVie U.S. Agreement, the parties agreed to stipulate to the dismissal of all claims, counterclaims and potential claims in the four U.S. litigations, with each party to bear its own fees and costs. The parties further agreed to release each other from certain claims and demands. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group incurred approximately $0.0 million, $8.7 million and $13.5 million in legal expenses during the years ended 31&#160;December 2023, 2022, and 2021, respectively, in preparation for, and/or in relation to, these litigations. Aside from this matter, the Group is not currently a party to any material litigation or similar matters.&lt;/span&gt;&lt;/div&gt;</alvo:DisclosureOfLitigationSettlementsExplanatoryTextBlock>
    <alvo:NumberOfLitigations
      contextRef="c-5"
      decimals="INF"
      id="f-1765"
      unitRef="litigation_case">4</alvo:NumberOfLitigations>
    <alvo:NumberOfLitigations
      contextRef="c-5"
      decimals="INF"
      id="f-1766"
      unitRef="litigation_case">4</alvo:NumberOfLitigations>
    <alvo:LegalCost contextRef="c-1" decimals="-5" id="f-1767" unitRef="usd">0</alvo:LegalCost>
    <alvo:LegalCost contextRef="c-6" decimals="-5" id="f-1768" unitRef="usd">8700000</alvo:LegalCost>
    <alvo:LegalCost contextRef="c-7" decimals="-5" id="f-1769" unitRef="usd">13500000</alvo:LegalCost>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c-1" id="f-1770">Related parties &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Related parties are those parties which have considerable influence over the Group, directly or indirectly, including a parent company, owners or their families, large investors, key management personnel and their families and parties that are controlled by or dependent on the Group, such as affiliates and joint ventures. Key management personnel include the Group&#x2019;s executive officers and directors, since these individuals have the authority and responsibility for planning, directing and controlling the activities of the Group. Interests in subsidiaries are set out in Note 1. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Transactions with related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A related party transaction is a transfer of resources, services or obligations between the Group and a related party, regardless of whether a price is charged. The Group engages with related parties for both purchased and sold services, loans and other borrowings and other activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group entered into lease agreement with Fasteignaf&#xe9;lagi&#xf0; Eyj&#xf3;lfur hf. in April 2023 for a new facility in Iceland with remaining lease terms of approximately 15 years as of 31 December 2023 (see Note 13). The Group also entered into seventeen separate lease agreements with Fl&#xf3;ki Fasteignir ehf. (HRJAF ehf.) throughout 2020, 2021 and 2023 for a group of apartment buildings in Iceland used for temporary housing of employees and third party &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;contractors. Two of the leases were terminated during the year ended 31&#160;December 2021. The remaining lease terms for the other fifteen leases approximate 7 years, on average, as of 31&#160;December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group entered into office sublease sharing agreement with Alvogen UK Ltd. in August 2023. The agreement was effective from 1 January 2023 and shall terminate upon the expiration or termination of the Lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group entered into art lease agreement with Fl&#xf3;ki-Art ehf. in January 2023, as a result of the Share Purchase Agreement (see Note 12). The leased asset is located in S&#xe6;mundargata 15-19, Reykjavik. The remaining lease term for the leased asset is 15 years, as of 31 December 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group provides and receives certain support services through arrangements with Aztiq, Alvogen, and Alvogen Malta (Outlicensing) Ltd. (Adalvo). Services provided to Alvogen consist of finance, administrative, legal and human resource services. Services received from Alvogen primarily consist of marketing, salary processing, and information technology support services. Services received from Adalvo primarily consist of legal, regulatory, supply chain management, and portfolio and market intelligence services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchased service includes rental fees and service expenses, as described above. Rental fees and service expenses with related parties are presented as &#x201c;General and administrative expenses&#x201d; or &#x201c;Research and development expenses&#x201d; in the consolidated statements of profit or loss and other comprehensive income or loss, depending on the nature of the service performed and expense incurred by the Group. Rental liabilities from lease arrangements with related parties are presented as a component of &#x201c;Lease liabilities&#x201d; on the consolidated statements of financial position. Service payables are presented as &#x201c;Liabilities to related parties&#x201d; on the consolidated statements of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest includes interest expense on borrowings. Interest expenses on loans from related parties are presented as &#x201c;Finance costs&#x201d; in the consolidated statements of profit or loss and other comprehensive income or loss. Borrowings are presented as &#x201c;Borrowings&#x201d; and &#x201c;Current maturities of borrowings&#x201d; on the consolidated statements of financial position. See Note 21 for further details on the borrowing arrangements with related parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sold service includes services provided to related parties, as described above. Income from related parties for such services are presented as &#x201c;Other income&#x201d; in the consolidated statements of profit or loss and other comprehensive income or loss. Amounts receivable for such activities are presented as &#x201c;Receivables from related parties&#x201d; on the consolidated statements of financial position. The Group has not recorded bad debt provisions for its receivables from related parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Related party transactions as of and for the year ended 31&#160;December 2023 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Purchased service /&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Sold service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Payables/ &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Lux Holdings S.&#xe0; r.l. &#x2013; Sister company (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ATP Holdings ehf. - Sister company (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Fj&#xe1;rfestingar ehf. &#x2013; Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Consulting ehf. &#x2013; Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fl&#xf3;ki-Art ehf. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Iceland ehf.  - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen ehf.  - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen UK - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Finance B.V. - Sister Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus Pharmaceuticals Co. Ltd. - Sister company (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus International Pte. Ltd. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Emerging Markets - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Inc. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adalvo Limited - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adalvo UK - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fl&#xf3;ki Invest ehf - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Floki Holdings S.&#xe0; r.l. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Malta Sh. Services - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Spain SL - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Norwich Clinical Services Ltd - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignaf&#xe9;lagi&#xf0; Eyj&#xf3;lfur ehf - Sister company (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fl&#xf3;ki fasteignir ehf. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;217,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). In relation to the private placement of Tranche A Convertible Bonds in July, the Company paid underwriters fee to APT Holding amounting to $3.3&#160;million. The underwriter&#x2019;s fee is accounted for as a transaction cost that is amortized through profit and loss over the life of the instrument.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Payables to Lotus Pharmaceuticals Co. Ltd. consists of the other current liability as further described in Note 2. This other current liability is presented as &#x201c;Liabilities to related party&#x201d; on the consolidated statements of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The amount receivable from Alvotech &amp;amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Refer to Note 13 for the details of the new lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Related party transactions as of and for the year ended 31&#160;December 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Purchased service / &lt;br/&gt;interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sold service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payables/ &lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Lux Holdings S.&#xe0; r.l. &#x2013; Sister company (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Fj&#xe1;rfestingar ehf. &#x2013; Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Consulting ehf. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ATP Holdings ehf. - Sister company (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignaf&#xe9;lagi&#xf0; S&#xe6;mundur hf. - Sister company (e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignaf&#xe9;lagi&#xf0; Eyj&#xf3;lfur ehf - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Iceland ehf.  - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen ehf.  - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus Pharmaceuticals Co. Ltd. - Sister company (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus International Pte. Ltd. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Emerging Markets - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Korea co. Ltd - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Inc. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adalvo Limited - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Malta Sh. Services - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Spain SL - Sister Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Norwich Clinical Services Ltd - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Pharma Pvt Ltd - Sister Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fl&#xf3;ki fasteignir ehf. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;L41 ehf.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lambhagavegur 7 ehf. (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;163,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities including discount and accretion (see Note 21). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#x201c;Other long-term liability to related party&#x201d; on the consolidated statements of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The amount receivable from Alvotech &amp;amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Lambahagavegur is no longer a related party as it was sold during the year ended 31&#160;December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;Fasteignaf&#xe9;lagi&#xf0; S&#xe6;mundur hf. was acquired as part of the Share Purchase Agreement, with ATP Holdings ehf., on 16 November 2022. The related party transactions reflect activity until the acquisition date. See Note 12 and Note 21 for further details.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Related party transactions for the year ended 31&#160;December 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Purchased service / &lt;br/&gt;interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sold &lt;br/&gt;service&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Lux Holdings S.&#xe0; r.l. &#x2013; Sister company (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Pharma Partners S.&#xe0; r.l. &#x2013; Sister company (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Aztiq AB &#x2013; Sister company (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Fj&#xe1;rfestingar ehf. (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignaf&#xe9;lagi&#xf0; S&#xe6;mundur hf. - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Iceland ehf.  - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen ehf.  - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen UK - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus Pharmaceuticals Co. Ltd. - Sister company (b) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Emerging Markets - Sister company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Korea co. Ltd - Sister company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Inc. - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Malta Sh. Services - Sister company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Pharma Pvt Ltd - Sister Company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;HRJ&#xc1;F ehf - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;L41 ehf. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lambhagavegur 7 ehf. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#x201c;Other long-term liability to related party&#x201d; on the consolidated statements of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Commitments and guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group does not have any contractual commitments with its related parties other than the receivables, loans and payables previously disclosed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Key management personnel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At 31&#160;December 2023 and 2022 there are no loans to the members of the Board of Directors and the CEO. In addition, there were no transactions carried out between the Group and members of the Board of Directors nor the CEO in the years ended 31&#160;December 2023 and 2022. The Board of Directors&#x2019; remuneration is shown in the table below. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Board of Directors&#x2019; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Board fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension &lt;br/&gt;contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Shares at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;year-end**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Robert Wessman, Chairman of the board*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Richard Davies, Vice-Chairman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,143,713&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ann Merchant, Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,582&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#xc1;rni Har&#xf0;arson, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Faysal Kalmoua, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Linda McGoldrick, Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,582&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lisa Graver, Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,582&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tomas Ekman, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,175,459&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt"&gt;Waived their board compensation (both cash and equity)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt"&gt;Direct share ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Key employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Pension contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Other long- term benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Robert Wessman CEO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Executive Team Members (9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Board of Directors&#x2019; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Board fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Pension &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Shares at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;year-end**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Robert Wessman, Chairman of the board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Richard Davies, Vice-Chairman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,133,131&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ann Merchant, Board Member (from 16.6.2022)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#xc1;rni Har&#xf0;arson, Board Member (from 16.6.2022)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Faysal Kalmoua, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Linda McGoldrick, Board Member (from 16.6.2022)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lisa Graver, Board Member (from 16.6.2022)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tomas Ekman, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Hirofumi Imai, Board member (until 16.6.2022)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,133,131&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt"&gt;Waived their board compensation (both cash and equity)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt"&gt;Direct share ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Key employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Pension contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Other long- term benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mark Levick CEO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Executive Team Members (9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <alvo:WeightedAverageRemainingLeaseTerm contextRef="c-558" id="f-1771">P15Y</alvo:WeightedAverageRemainingLeaseTerm>
    <alvo:NumberOfLeaseAgreementsEnteredInto
      contextRef="c-559"
      decimals="INF"
      id="f-1772"
      unitRef="agreement">17</alvo:NumberOfLeaseAgreementsEnteredInto>
    <alvo:NumberOfLeasesTerminated
      contextRef="c-560"
      decimals="INF"
      id="f-1773"
      unitRef="agreement">2</alvo:NumberOfLeasesTerminated>
    <alvo:NumberOfLeaseAgreements
      contextRef="c-561"
      decimals="INF"
      id="f-1774"
      unitRef="agreement">15</alvo:NumberOfLeaseAgreements>
    <alvo:WeightedAverageRemainingLeaseTerm contextRef="c-562" id="f-1775">P7Y</alvo:WeightedAverageRemainingLeaseTerm>
    <alvo:WeightedAverageRemainingLeaseTerm contextRef="c-563" id="f-1776">P15Y</alvo:WeightedAverageRemainingLeaseTerm>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-1777">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Related party transactions as of and for the year ended 31&#160;December 2023 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Purchased service /&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Sold service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Payables/ &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Lux Holdings S.&#xe0; r.l. &#x2013; Sister company (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ATP Holdings ehf. - Sister company (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Fj&#xe1;rfestingar ehf. &#x2013; Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Consulting ehf. &#x2013; Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fl&#xf3;ki-Art ehf. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Iceland ehf.  - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen ehf.  - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen UK - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Finance B.V. - Sister Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus Pharmaceuticals Co. Ltd. - Sister company (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus International Pte. Ltd. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Emerging Markets - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Inc. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adalvo Limited - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adalvo UK - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fl&#xf3;ki Invest ehf - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Floki Holdings S.&#xe0; r.l. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Malta Sh. Services - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Spain SL - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Norwich Clinical Services Ltd - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignaf&#xe9;lagi&#xf0; Eyj&#xf3;lfur ehf - Sister company (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fl&#xf3;ki fasteignir ehf. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;217,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). In relation to the private placement of Tranche A Convertible Bonds in July, the Company paid underwriters fee to APT Holding amounting to $3.3&#160;million. The underwriter&#x2019;s fee is accounted for as a transaction cost that is amortized through profit and loss over the life of the instrument.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Payables to Lotus Pharmaceuticals Co. Ltd. consists of the other current liability as further described in Note 2. This other current liability is presented as &#x201c;Liabilities to related party&#x201d; on the consolidated statements of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The amount receivable from Alvotech &amp;amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Refer to Note 13 for the details of the new lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Related party transactions as of and for the year ended 31&#160;December 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Purchased service / &lt;br/&gt;interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sold service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payables/ &lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Lux Holdings S.&#xe0; r.l. &#x2013; Sister company (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Fj&#xe1;rfestingar ehf. &#x2013; Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Consulting ehf. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ATP Holdings ehf. - Sister company (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignaf&#xe9;lagi&#xf0; S&#xe6;mundur hf. - Sister company (e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignaf&#xe9;lagi&#xf0; Eyj&#xf3;lfur ehf - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Iceland ehf.  - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen ehf.  - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus Pharmaceuticals Co. Ltd. - Sister company (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus International Pte. Ltd. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Emerging Markets - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Korea co. Ltd - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Inc. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech and CCHT Biopharmaceutical Co., Ltd. (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Adalvo Limited - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Malta Sh. Services - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Spain SL - Sister Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Norwich Clinical Services Ltd - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Pharma Pvt Ltd - Sister Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fl&#xf3;ki fasteignir ehf. - Sister company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;L41 ehf.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lambhagavegur 7 ehf. (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;163,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities including discount and accretion (see Note 21). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#x201c;Other long-term liability to related party&#x201d; on the consolidated statements of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The amount receivable from Alvotech &amp;amp; CCHN Biopharmaceutical Co., Ltd. relates to amounts due for reference drugs used in research and development studies and certain consulting fees incurred by the Group. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt"&gt;Lambahagavegur is no longer a related party as it was sold during the year ended 31&#160;December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;Fasteignaf&#xe9;lagi&#xf0; S&#xe6;mundur hf. was acquired as part of the Share Purchase Agreement, with ATP Holdings ehf., on 16 November 2022. The related party transactions reflect activity until the acquisition date. See Note 12 and Note 21 for further details.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Related party transactions for the year ended 31&#160;December 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Purchased service / &lt;br/&gt;interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sold &lt;br/&gt;service&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Lux Holdings S.&#xe0; r.l. &#x2013; Sister company (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Pharma Partners S.&#xe0; r.l. &#x2013; Sister company (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Aztiq AB &#x2013; Sister company (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Aztiq Fj&#xe1;rfestingar ehf. (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fasteignaf&#xe9;lagi&#xf0; S&#xe6;mundur hf. - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Iceland ehf.  - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen ehf.  - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen UK - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lotus Pharmaceuticals Co. Ltd. - Sister company (b) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Emerging Markets - Sister company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Korea co. Ltd - Sister company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Inc. - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Malta Sh. Services - Sister company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvogen Pharma Pvt Ltd - Sister Company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;HRJ&#xc1;F ehf - Sister company  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;L41 ehf. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lambhagavegur 7 ehf. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.91pt"&gt;The full amount of purchased service relates to interest expenses from long-term liabilities and the full amount of payables / loans are interest-bearing long-term liabilities (see Note 21). &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(b)&lt;/span&gt;Payables to Lotus Pharmaceuticals Co. Ltd. consists of the long-term liability as further described in Note 2. This long-term liability is presented as &#x201c;Other long-term liability to related party&#x201d; on the consolidated statements of financial position.</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-564" decimals="-3" id="f-1778" unitRef="usd">11968000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-564" decimals="-3" id="f-1779" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-565" decimals="-3" id="f-1780" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-565" decimals="-3" id="f-1781" unitRef="usd">76556000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-566" decimals="-3" id="f-1782" unitRef="usd">9193000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-566" decimals="-3" id="f-1783" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-567" decimals="-3" id="f-1784" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-567" decimals="-3" id="f-1785" unitRef="usd">49560000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-568" decimals="-3" id="f-1786" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-568" decimals="-3" id="f-1787" unitRef="usd">4000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-569" decimals="-3" id="f-1788" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-569" decimals="-3" id="f-1789" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-570" decimals="-3" id="f-1790" unitRef="usd">178000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-570" decimals="-3" id="f-1791" unitRef="usd">69000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-571" decimals="-3" id="f-1792" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-571" decimals="-3" id="f-1793" unitRef="usd">54000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-572" decimals="-3" id="f-1794" unitRef="usd">88000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-572" decimals="-3" id="f-1795" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-573" decimals="-3" id="f-1796" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-573" decimals="-3" id="f-1797" unitRef="usd">422000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-574" decimals="-3" id="f-1798" unitRef="usd">19000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-574" decimals="-3" id="f-1799" unitRef="usd">1000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-575" decimals="-3" id="f-1800" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-575" decimals="-3" id="f-1801" unitRef="usd">484000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-576" decimals="-3" id="f-1802" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-576" decimals="-3" id="f-1803" unitRef="usd">152000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-577" decimals="-3" id="f-1804" unitRef="usd">16000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-577" decimals="-3" id="f-1805" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-578" decimals="-3" id="f-1806" unitRef="usd">273000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-578" decimals="-3" id="f-1807" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-579" decimals="-3" id="f-1808" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-579" decimals="-3" id="f-1809" unitRef="usd">581000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-580" decimals="-3" id="f-1810" unitRef="usd">3382000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-580" decimals="-3" id="f-1811" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-581" decimals="-3" id="f-1812" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-581" decimals="-3" id="f-1813" unitRef="usd">65000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-582" decimals="-3" id="f-1814" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-582" decimals="-3" id="f-1815" unitRef="usd">29000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-583" decimals="-3" id="f-1816" unitRef="usd">29000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-583" decimals="-3" id="f-1817" unitRef="usd">7440000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-584" decimals="-3" id="f-1818" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-584" decimals="-3" id="f-1819" unitRef="usd">2000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-585" decimals="-3" id="f-1820" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-585" decimals="-3" id="f-1821" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-586" decimals="-3" id="f-1822" unitRef="usd">108000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-586" decimals="-3" id="f-1823" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-587" decimals="-3" id="f-1824" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-587" decimals="-3" id="f-1825" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-588" decimals="-3" id="f-1826" unitRef="usd">305000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-588" decimals="-3" id="f-1827" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-589" decimals="-3" id="f-1828" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-589" decimals="-3" id="f-1829" unitRef="usd">284000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-590" decimals="-3" id="f-1830" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-590" decimals="-3" id="f-1831" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-591" decimals="-3" id="f-1832" unitRef="usd">758000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-591" decimals="-3" id="f-1833" unitRef="usd">539000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-592" decimals="-3" id="f-1834" unitRef="usd">402000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-592" decimals="-3" id="f-1835" unitRef="usd">189000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-593" decimals="-3" id="f-1836" unitRef="usd">86000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-593" decimals="-3" id="f-1837" unitRef="usd">337000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-594" decimals="-3" id="f-1838" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-594" decimals="-3" id="f-1839" unitRef="usd">49000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-595" decimals="-3" id="f-1840" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-595" decimals="-3" id="f-1841" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-596" decimals="-3" id="f-1842" unitRef="usd">680000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-596" decimals="-3" id="f-1843" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-597" decimals="-3" id="f-1844" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-597" decimals="-3" id="f-1845" unitRef="usd">251000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-598" decimals="-3" id="f-1846" unitRef="usd">40000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-598" decimals="-3" id="f-1847" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-599" decimals="-3" id="f-1848" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-599" decimals="-3" id="f-1849" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-600" decimals="-3" id="f-1850" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-600" decimals="-3" id="f-1851" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-601" decimals="-3" id="f-1852" unitRef="usd">7000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-601" decimals="-3" id="f-1853" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-602" decimals="-3" id="f-1854" unitRef="usd">14000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-602" decimals="-3" id="f-1855" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-603" decimals="-3" id="f-1856" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-603" decimals="-3" id="f-1857" unitRef="usd">15000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-604" decimals="-3" id="f-1858" unitRef="usd">642000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-604" decimals="-3" id="f-1859" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-605" decimals="-3" id="f-1860" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-605" decimals="-3" id="f-1861" unitRef="usd">170000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-606" decimals="-3" id="f-1862" unitRef="usd">3807000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-606" decimals="-3" id="f-1863" unitRef="usd">102000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-607" decimals="-3" id="f-1864" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-607" decimals="-3" id="f-1865" unitRef="usd">69732000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-608" decimals="-3" id="f-1866" unitRef="usd">1682000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-608" decimals="-3" id="f-1867" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-609" decimals="-3" id="f-1868" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-609" decimals="-3" id="f-1869" unitRef="usd">11466000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-1" decimals="-3" id="f-1870" unitRef="usd">32781000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-1" decimals="-3" id="f-1871" unitRef="usd">597000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-5" decimals="-3" id="f-1872" unitRef="usd">896000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-5" decimals="-3" id="f-1873" unitRef="usd">217956000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-566" decimals="-3" id="f-1874" unitRef="usd">3300000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-610" decimals="-3" id="f-1875" unitRef="usd">5415000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-610" decimals="-3" id="f-1876" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-611" decimals="-3" id="f-1877" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-611" decimals="-3" id="f-1878" unitRef="usd">64588000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-612" decimals="-3" id="f-1879" unitRef="usd">216000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-612" decimals="-3" id="f-1880" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-613" decimals="-3" id="f-1881" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-613" decimals="-3" id="f-1882" unitRef="usd">20000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-614" decimals="-3" id="f-1883" unitRef="usd">442000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-614" decimals="-3" id="f-1884" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-615" decimals="-3" id="f-1885" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-615" decimals="-3" id="f-1886" unitRef="usd">25000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-616" decimals="-3" id="f-1887" unitRef="usd">1254000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-616" decimals="-3" id="f-1888" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-617" decimals="-3" id="f-1889" unitRef="usd">765000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-617" decimals="-3" id="f-1890" unitRef="usd">81254000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-618" decimals="-3" id="f-1891" unitRef="usd">7189000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-618" decimals="-3" id="f-1892" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-619" decimals="-3" id="f-1893" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-619" decimals="-3" id="f-1894" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-620" decimals="-3" id="f-1895" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-620" decimals="-3" id="f-1896" unitRef="usd">196000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-621" decimals="-3" id="f-1897" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-621" decimals="-3" id="f-1898" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-622" decimals="-3" id="f-1899" unitRef="usd">465000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-622" decimals="-3" id="f-1900" unitRef="usd">174000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-623" decimals="-3" id="f-1901" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-623" decimals="-3" id="f-1902" unitRef="usd">484000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-624" decimals="-3" id="f-1903" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-624" decimals="-3" id="f-1904" unitRef="usd">68000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-625" decimals="-3" id="f-1905" unitRef="usd">1000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-625" decimals="-3" id="f-1906" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-626" decimals="-3" id="f-1907" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-626" decimals="-3" id="f-1908" unitRef="usd">3000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-627" decimals="-3" id="f-1909" unitRef="usd">2000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-627" decimals="-3" id="f-1910" unitRef="usd">7440000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-628" decimals="-3" id="f-1911" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-628" decimals="-3" id="f-1912" unitRef="usd">4000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-629" decimals="-3" id="f-1913" unitRef="usd">3000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-629" decimals="-3" id="f-1914" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-630" decimals="-3" id="f-1915" unitRef="usd">98000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-630" decimals="-3" id="f-1916" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-631" decimals="-3" id="f-1917" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-631" decimals="-3" id="f-1918" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-632" decimals="-3" id="f-1919" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-632" decimals="-3" id="f-1920" unitRef="usd">1000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-633" decimals="-3" id="f-1921" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-633" decimals="-3" id="f-1922" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-634" decimals="-3" id="f-1923" unitRef="usd">585000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-634" decimals="-3" id="f-1924" unitRef="usd">266000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-635" decimals="-3" id="f-1925" unitRef="usd">12000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-635" decimals="-3" id="f-1926" unitRef="usd">222000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-636" decimals="-3" id="f-1927" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-636" decimals="-3" id="f-1928" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-637" decimals="-3" id="f-1929" unitRef="usd">758000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-637" decimals="-3" id="f-1930" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-638" decimals="-3" id="f-1931" unitRef="usd">1218000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-638" decimals="-3" id="f-1932" unitRef="usd">106000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-639" decimals="-3" id="f-1933" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-639" decimals="-3" id="f-1934" unitRef="usd">349000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-640" decimals="-3" id="f-1935" unitRef="usd">603000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-640" decimals="-3" id="f-1936" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-641" decimals="-3" id="f-1937" unitRef="usd">7000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-641" decimals="-3" id="f-1938" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-642" decimals="-3" id="f-1939" unitRef="usd">117000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-642" decimals="-3" id="f-1940" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-643" decimals="-3" id="f-1941" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-643" decimals="-3" id="f-1942" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-644" decimals="-3" id="f-1943" unitRef="usd">301000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-644" decimals="-3" id="f-1944" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-645" decimals="-3" id="f-1945" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-645" decimals="-3" id="f-1946" unitRef="usd">31000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-646" decimals="-3" id="f-1947" unitRef="usd">1159000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-646" decimals="-3" id="f-1948" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-647" decimals="-3" id="f-1949" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-647" decimals="-3" id="f-1950" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-648" decimals="-3" id="f-1951" unitRef="usd">1516000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-648" decimals="-3" id="f-1952" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-649" decimals="-3" id="f-1953" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-649" decimals="-3" id="f-1954" unitRef="usd">8876000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-650" decimals="-3" id="f-1955" unitRef="usd">26000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-650" decimals="-3" id="f-1956" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-651" decimals="-3" id="f-1957" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-651" decimals="-3" id="f-1958" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-652" decimals="-3" id="f-1959" unitRef="usd">537000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-652" decimals="-3" id="f-1960" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-653" decimals="-3" id="f-1961" unitRef="usd">0</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-653" decimals="-3" id="f-1962" unitRef="usd">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-6" decimals="-3" id="f-1963" unitRef="usd">21141000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-6" decimals="-3" id="f-1964" unitRef="usd">818000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-8" decimals="-3" id="f-1965" unitRef="usd">1548000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-8" decimals="-3" id="f-1966" unitRef="usd">163289000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-654" decimals="-3" id="f-1967" unitRef="usd">9383000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-654" decimals="-3" id="f-1968" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-655" decimals="-3" id="f-1969" unitRef="usd">16048000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-655" decimals="-3" id="f-1970" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-656" decimals="-3" id="f-1971" unitRef="usd">297000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-656" decimals="-3" id="f-1972" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-657" decimals="-3" id="f-1973" unitRef="usd">120000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-657" decimals="-3" id="f-1974" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-658" decimals="-3" id="f-1975" unitRef="usd">7762000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-658" decimals="-3" id="f-1976" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-659" decimals="-3" id="f-1977" unitRef="usd">454000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-659" decimals="-3" id="f-1978" unitRef="usd">2308000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-660" decimals="-3" id="f-1979" unitRef="usd">6000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-660" decimals="-3" id="f-1980" unitRef="usd">2000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-661" decimals="-3" id="f-1981" unitRef="usd">299000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-661" decimals="-3" id="f-1982" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-662" decimals="-3" id="f-1983" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-662" decimals="-3" id="f-1984" unitRef="usd">312000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-663" decimals="-3" id="f-1985" unitRef="usd">238000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-663" decimals="-3" id="f-1986" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-664" decimals="-3" id="f-1987" unitRef="usd">0</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-664" decimals="-3" id="f-1988" unitRef="usd">9000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-665" decimals="-3" id="f-1989" unitRef="usd">89000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-665" decimals="-3" id="f-1990" unitRef="usd">654000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-666" decimals="-3" id="f-1991" unitRef="usd">1216000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-666" decimals="-3" id="f-1992" unitRef="usd">151000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-667" decimals="-3" id="f-1993" unitRef="usd">491000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-667" decimals="-3" id="f-1994" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-668" decimals="-3" id="f-1995" unitRef="usd">1415000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-668" decimals="-3" id="f-1996" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-669" decimals="-3" id="f-1997" unitRef="usd">29000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-669" decimals="-3" id="f-1998" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-670" decimals="-3" id="f-1999" unitRef="usd">713000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-670" decimals="-3" id="f-2000" unitRef="usd">0</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions contextRef="c-7" decimals="-3" id="f-2001" unitRef="usd">39940000</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions contextRef="c-7" decimals="-3" id="f-2002" unitRef="usd">3715000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <alvo:LoansToRelatedParties contextRef="c-8" decimals="-3" id="f-2003" unitRef="usd">0</alvo:LoansToRelatedParties>
    <alvo:LoansToRelatedParties contextRef="c-5" decimals="-3" id="f-2004" unitRef="usd">0</alvo:LoansToRelatedParties>
    <alvo:DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock contextRef="c-1" id="f-2005">The Board of Directors&#x2019; remuneration is shown in the table below. &lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Board of Directors&#x2019; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Board fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension &lt;br/&gt;contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Shares at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;year-end**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Robert Wessman, Chairman of the board*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Richard Davies, Vice-Chairman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,143,713&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ann Merchant, Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,582&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#xc1;rni Har&#xf0;arson, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Faysal Kalmoua, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Linda McGoldrick, Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,582&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lisa Graver, Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,582&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tomas Ekman, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,175,459&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt"&gt;Waived their board compensation (both cash and equity)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt"&gt;Direct share ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Key employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Pension contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Other long- term benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Robert Wessman CEO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Executive Team Members (9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Board of Directors&#x2019; fee for the year and shares at year end (board fees in thousands and shares in whole amounts).&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Board fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Pension &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Shares at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;year-end**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Robert Wessman, Chairman of the board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Richard Davies, Vice-Chairman&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,133,131&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ann Merchant, Board Member (from 16.6.2022)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#xc1;rni Har&#xf0;arson, Board Member (from 16.6.2022)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Faysal Kalmoua, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Linda McGoldrick, Board Member (from 16.6.2022)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lisa Graver, Board Member (from 16.6.2022)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tomas Ekman, Board Member*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Hirofumi Imai, Board member (until 16.6.2022)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,133,131&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22pt"&gt;Waived their board compensation (both cash and equity)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt"&gt;Direct share ownership &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Key employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Pension contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Other long- term benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mark Levick CEO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10.37pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Executive Team Members (9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutBoardOfDirectorsAndKeyManagerialPersonnelExplanatoryTableTextBlock>
    <alvo:DirectorFees contextRef="c-671" decimals="-3" id="f-2006" unitRef="usd">0</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-671" decimals="-3" id="f-2007" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-671" decimals="-3" id="f-2008" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-672"
      decimals="INF"
      id="f-2009"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-673" decimals="-3" id="f-2010" unitRef="usd">156000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-673" decimals="-3" id="f-2011" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-673" decimals="-3" id="f-2012" unitRef="usd">104000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-674"
      decimals="INF"
      id="f-2013"
      unitRef="shares">1143713</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-675" decimals="-3" id="f-2014" unitRef="usd">113000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-675" decimals="-3" id="f-2015" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-675" decimals="-3" id="f-2016" unitRef="usd">104000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-676"
      decimals="INF"
      id="f-2017"
      unitRef="shares">10582</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-677" decimals="-3" id="f-2018" unitRef="usd">0</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-677" decimals="-3" id="f-2019" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-677" decimals="-3" id="f-2020" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-678"
      decimals="INF"
      id="f-2021"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-679" decimals="-3" id="f-2022" unitRef="usd">0</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-679" decimals="-3" id="f-2023" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-679" decimals="-3" id="f-2024" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-680"
      decimals="INF"
      id="f-2025"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-681" decimals="-3" id="f-2026" unitRef="usd">81000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-681" decimals="-3" id="f-2027" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-681" decimals="-3" id="f-2028" unitRef="usd">104000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-682"
      decimals="INF"
      id="f-2029"
      unitRef="shares">10582</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-683" decimals="-3" id="f-2030" unitRef="usd">71000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-683" decimals="-3" id="f-2031" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-683" decimals="-3" id="f-2032" unitRef="usd">104000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-684"
      decimals="INF"
      id="f-2033"
      unitRef="shares">10582</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-685" decimals="-3" id="f-2034" unitRef="usd">0</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-685" decimals="-3" id="f-2035" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-685" decimals="-3" id="f-2036" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-686"
      decimals="INF"
      id="f-2037"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-687" decimals="-3" id="f-2038" unitRef="usd">421000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-687" decimals="-3" id="f-2039" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-687" decimals="-3" id="f-2040" unitRef="usd">416000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-688"
      decimals="INF"
      id="f-2041"
      unitRef="shares">1175459</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-689" decimals="-3" id="f-2042" unitRef="usd">1491000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-689" decimals="-3" id="f-2043" unitRef="usd">26000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-689" decimals="-3" id="f-2044" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-689" decimals="-3" id="f-2045" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-690" decimals="-3" id="f-2046" unitRef="usd">5020000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-690" decimals="-3" id="f-2047" unitRef="usd">346000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-690" decimals="-3" id="f-2048" unitRef="usd">52000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-690" decimals="-3" id="f-2049" unitRef="usd">9456000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-1" decimals="-3" id="f-2050" unitRef="usd">6511000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-1" decimals="-3" id="f-2051" unitRef="usd">372000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-1" decimals="-3" id="f-2052" unitRef="usd">52000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-1" decimals="-3" id="f-2053" unitRef="usd">9456000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <alvo:DirectorFees contextRef="c-691" decimals="-3" id="f-2054" unitRef="usd">740000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-691" decimals="-3" id="f-2055" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-691" decimals="-3" id="f-2056" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-692"
      decimals="INF"
      id="f-2057"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-693" decimals="-3" id="f-2058" unitRef="usd">68000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-693" decimals="-3" id="f-2059" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-693" decimals="-3" id="f-2060" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-694"
      decimals="INF"
      id="f-2061"
      unitRef="shares">1133131</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-695" decimals="-3" id="f-2062" unitRef="usd">43000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-695" decimals="-3" id="f-2063" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-695" decimals="-3" id="f-2064" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-696"
      decimals="INF"
      id="f-2065"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-697" decimals="-3" id="f-2066" unitRef="usd">0</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-697" decimals="-3" id="f-2067" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-697" decimals="-3" id="f-2068" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-698"
      decimals="INF"
      id="f-2069"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-699" decimals="-3" id="f-2070" unitRef="usd">0</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-699" decimals="-3" id="f-2071" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-699" decimals="-3" id="f-2072" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-700"
      decimals="INF"
      id="f-2073"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-701" decimals="-3" id="f-2074" unitRef="usd">38000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-701" decimals="-3" id="f-2075" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-701" decimals="-3" id="f-2076" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-702"
      decimals="INF"
      id="f-2077"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-703" decimals="-3" id="f-2078" unitRef="usd">38000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-703" decimals="-3" id="f-2079" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-703" decimals="-3" id="f-2080" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-704"
      decimals="INF"
      id="f-2081"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-705" decimals="-3" id="f-2082" unitRef="usd">0</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-705" decimals="-3" id="f-2083" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-705" decimals="-3" id="f-2084" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-706"
      decimals="INF"
      id="f-2085"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-707" decimals="-3" id="f-2086" unitRef="usd">0</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-707" decimals="-3" id="f-2087" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-707" decimals="-3" id="f-2088" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-708"
      decimals="INF"
      id="f-2089"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <alvo:DirectorFees contextRef="c-709" decimals="-3" id="f-2090" unitRef="usd">927000</alvo:DirectorFees>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-709" decimals="-3" id="f-2091" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-709" decimals="-3" id="f-2092" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-710"
      decimals="INF"
      id="f-2093"
      unitRef="shares">1133131</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-711" decimals="-3" id="f-2094" unitRef="usd">892000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-711" decimals="-3" id="f-2095" unitRef="usd">162000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-711" decimals="-3" id="f-2096" unitRef="usd">1157000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-711" decimals="-3" id="f-2097" unitRef="usd">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-712" decimals="-3" id="f-2098" unitRef="usd">5400000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-712" decimals="-3" id="f-2099" unitRef="usd">446000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-712" decimals="-3" id="f-2100" unitRef="usd">820000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-712" decimals="-3" id="f-2101" unitRef="usd">5015000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-6" decimals="-3" id="f-2102" unitRef="usd">6292000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-6" decimals="-3" id="f-2103" unitRef="usd">608000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-6" decimals="-3" id="f-2104" unitRef="usd">1977000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="c-6" decimals="-3" id="f-2105" unitRef="usd">5015000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory contextRef="c-1" id="f-2106">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other current liabilities &lt;/span&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The composition of other current liabilities as of 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unpaid salary and salary related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued vacation leave&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee incentive plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory>
    <alvo:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-2107">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The composition of other current liabilities as of 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unpaid salary and salary related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued vacation leave&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee incentive plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</alvo:DisclosureOfDetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock>
    <alvo:CurrentAccruedSalaryAndSalaryRelatedExpenses contextRef="c-5" decimals="-3" id="f-2108" unitRef="usd">31340000</alvo:CurrentAccruedSalaryAndSalaryRelatedExpenses>
    <alvo:CurrentAccruedSalaryAndSalaryRelatedExpenses contextRef="c-8" decimals="-3" id="f-2109" unitRef="usd">15620000</alvo:CurrentAccruedSalaryAndSalaryRelatedExpenses>
    <alvo:CurrentAccruedInterest contextRef="c-5" decimals="-3" id="f-2110" unitRef="usd">3333000</alvo:CurrentAccruedInterest>
    <alvo:CurrentAccruedInterest contextRef="c-8" decimals="-3" id="f-2111" unitRef="usd">2249000</alvo:CurrentAccruedInterest>
    <alvo:CurrentAccruedVacation contextRef="c-5" decimals="-3" id="f-2112" unitRef="usd">6075000</alvo:CurrentAccruedVacation>
    <alvo:CurrentAccruedVacation contextRef="c-8" decimals="-3" id="f-2113" unitRef="usd">5025000</alvo:CurrentAccruedVacation>
    <alvo:CurrentEmployeeIncentivePlan contextRef="c-5" decimals="-3" id="f-2114" unitRef="usd">659000</alvo:CurrentEmployeeIncentivePlan>
    <alvo:CurrentEmployeeIncentivePlan contextRef="c-8" decimals="-3" id="f-2115" unitRef="usd">12433000</alvo:CurrentEmployeeIncentivePlan>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-2116" unitRef="usd">21313000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-8" decimals="-3" id="f-2117" unitRef="usd">18720000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-2118" unitRef="usd">62720000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-8" decimals="-3" id="f-2119" unitRef="usd">54047000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:DisclosureOfJointVenturesExplanatory contextRef="c-1" id="f-2120">Interests in joint ventures &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2018, Alvotech hf., a subsidiary of the Group, entered into a joint venture agreement with Changchun High &amp;amp; New Technology Industries (Group) Inc. (the &#x201c;joint venture partner&#x201d;, "CCHN") to form a newly created joint venture entity, Alvotech &amp;amp; CCHN Biopharmaceutical Co., Ltd. (the &#x201c;joint venture&#x201d; or &#x201c;JVCO&#x201d;). The purpose of the JVCO is to develop, manufacture and sell biosimilar products in the Chinese market. The JVCO&#x2019;s place of business is also the country of incorporation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%;text-decoration:underline"&gt;Name of entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Place of business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Ownership interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech &amp;amp; CCHN Biopharmaceutical Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The proportion of ownership interest is the same as the proportion of voting rights held by the Group. Management evaluated whether the Group&#x2019;s voting rights are sufficient for providing a practical ability to direct the relevant activities and strategic objectives of JVCO unilaterally. As the Group does not hold a majority of the voting rights, the Group does not control JVCO. As a result, the Group&#x2019;s investment in JVCO is accounted for using the equity method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides the change in the Group&#x2019;s investment in a joint venture during the years ended 31&#160;December 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share in losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment loss on investment in joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(21,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Group did not receive any dividends from JVCO during the years ended 31&#160;December 2023, 2022, and 2021. The Group had a $5.0 million commitment to provide a cash contribution to JVCO as of 31&#160;December 2020, which was paid during the year ended 31&#160;December 2021. Similarly, the joint venture partner had a $50.0 million commitment to provide a cash contribution to JVCO as of 31&#160;December 2020, which was also paid during the year ended 31&#160;December 2021. The Group does not have any remaining commitments to JVCO as of 31&#160;December 2023 and 2022. Furthermore, the Group does not have any contingent liabilities relating to its interests in JVCO as of 31&#160;December 2023 or 2022. While there are no significant restrictions resulting from contractual arrangements with JVCO, entities in China are subject to local exchange control regulations. These regulations provide for restrictions on exporting capital from those countries, other than dividends&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;. As of 31 December 2023, it had become clear that there were uncertainties around the economic conditions in China. Accordingly, the Group recorded an impairment loss on its investment in JVCO based on discussions between Alvotech and CCHN to buy back Alvotech&#xb4;s interest in the joint venture. The Group estimated the recoverable amount using value in use where the recoverable amount is estimated as the future cash flows expected to arise from dividends to be received from the investment and from its ultimate disposal.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfJointVenturesExplanatory>
    <alvo:DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock contextRef="c-1" id="f-2121">&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%;text-decoration:underline"&gt;Name of entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Place of business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Ownership interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Alvotech &amp;amp; CCHN Biopharmaceutical Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutJointVentureExplanatoryTableTextBlock>
    <ifrs-full:PrincipalPlaceOfBusinessOfJointVenture contextRef="c-713" id="f-2122">China</ifrs-full:PrincipalPlaceOfBusinessOfJointVenture>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="c-713"
      decimals="2"
      id="f-2123"
      unitRef="number">0.50</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="c-714"
      decimals="2"
      id="f-2124"
      unitRef="number">0.50</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-715" decimals="-3" id="f-2125" unitRef="usd">18494000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-716" decimals="-3" id="f-2126" unitRef="usd">48568000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <alvo:DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock contextRef="c-1" id="f-2127">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides the change in the Group&#x2019;s investment in a joint venture during the years ended 31&#160;December 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 1 January&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share in losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment loss on investment in joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(21,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Translation difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at 31 December&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfDetailedInformationAboutChangesInInvestmentInJointVentureExplanatoryTableTextBlock>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-8" decimals="-3" id="f-2128" unitRef="usd">48568000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-9" decimals="-3" id="f-2129" unitRef="usd">55307000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-1" decimals="-3" id="f-2130" unitRef="usd">-7153000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-6" decimals="-3" id="f-2131" unitRef="usd">-2590000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-2132" unitRef="usd">21519000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-6" decimals="-3" id="f-2133" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <alvo:ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c-1" decimals="-3" id="f-2134" unitRef="usd">-1402000</alvo:ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax>
    <alvo:ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c-6" decimals="-3" id="f-2135" unitRef="usd">-4149000</alvo:ShareOfGainsLossesOfJointVenturesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-5" decimals="-3" id="f-2136" unitRef="usd">18494000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-8" decimals="-3" id="f-2137" unitRef="usd">48568000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities contextRef="c-6" decimals="-3" id="f-2138" unitRef="usd">0</ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities>
    <ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-2139" unitRef="usd">0</ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities>
    <ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-2140" unitRef="usd">0</ifrs-full:DividendsReceivedFromJointVenturesClassifiedAsInvestingActivities>
    <ifrs-full:CommitmentsInRelationToJointVentures contextRef="c-10" decimals="-5" id="f-2141" unitRef="usd">5000000</ifrs-full:CommitmentsInRelationToJointVentures>
    <alvo:CommitmentsOfJointVenturePartnersInRelationToJointVentures contextRef="c-10" decimals="-5" id="f-2142" unitRef="usd">50000000</alvo:CommitmentsOfJointVenturePartnersInRelationToJointVentures>
    <ifrs-full:CommitmentsInRelationToJointVentures contextRef="c-5" decimals="-3" id="f-2143" unitRef="usd">0</ifrs-full:CommitmentsInRelationToJointVentures>
    <ifrs-full:CommitmentsInRelationToJointVentures contextRef="c-8" decimals="-3" id="f-2144" unitRef="usd">0</ifrs-full:CommitmentsInRelationToJointVentures>
    <ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures contextRef="c-8" decimals="-3" id="f-2145" unitRef="usd">0</ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures>
    <ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures contextRef="c-5" decimals="-3" id="f-2146" unitRef="usd">0</ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-2147">Financial instruments &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Accounting classification and carrying amounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial assets as of 31&#160;December 2023 and 2022, all of which are measured at amortized cost, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Receivables from related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 2.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,484&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial liabilities as of 31&#160;December 2023 and 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative financial liabilities (measured at FVTPL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;380,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other long-term liability to related party (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Long-term incentive plan (measured at FVTPL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Trade and other payables (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Liabilities to related parties (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,748,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,297,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;It is management&#x2019;s estimate that the carrying amounts of financial assets and financial liabilities carried at amortized cost approximate their fair value, with the exception of the Senior Bonds, Aztiq Convertible Bond, 2022 Convertible Bonds, and Alvogen Facility, since any applicable interest receivable or payable is either close to current market rates or the instruments are short-term in nature. Material differences between the fair values and carrying amounts of these borrowings are identified as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;559,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Convertible Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;155,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;217,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;82,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;862,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;530,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;535,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Convertible Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;693,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;720,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables illustrate the fair value measurement hierarchy of the Group&#x2019;s financial instruments measured at fair value on a recurring basis as of 31&#160;December 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Senior Bond Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tranche A Conversion Feature&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Predecessor Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;349,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;349,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;356,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bond Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tranche A Conversion Feature&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bond Interest Rate Feature (included in other current assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Predecessor Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;276,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;276,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;286,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;381,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a reconciliation of Level 3 financial instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Senior Bond Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Tranche A Conversion Feature&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Senior Bond Interest Rate Feature&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 January  2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfer to Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(45,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group recognized the transfer of the Senior Bond Warrants from Level 3 to Level 1 for $19.7&#160;million (2022: $45.3 million) during the year ended 31&#160;December 2023 due to the lift of the lock-up period for the un-exercised Senior Bond Warrants. The Group did not recognize any transfer of assets or liabilities between levels of the fair value hierarchy during the years ended 31&#160;December 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 16 November 2022, the Group amended and upsized the outstanding bonds by $70.0&#160;million. The amended bond agreement of the Senior Bonds resulted in, among other things, an increase in the interest rate, resulting in a range from 10.75% to 12.0% depending on the occurrence of certain events, as defined by the terms of the agreement (see Note 21). The Group accounted for this interest rate feature (the &#x201c;Senior Bond Interest Rate Feature&#x201d;) as an embedded derivative, classified as an "Other current assets" in the consolidated statement of financial position as of 31 December 2022. Since the conditions to adjust the coupon rate have not been met as of 31 March 2023 per the terms of the agreement, the interest rate on the Senior Bonds is now fixed and the embedded derivative previously recorded has been extinguished during the year ended 31&#160;December 2023, resulting in a loss on extinguishment of $0.9&#160;million recorded in finance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Senior Bond Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As noted in Note 21, as a result of proceeds raised from the private placement offering executed in February 2023, the Company extinguished the derivative financial liability related to the senior bond warrants since the Company has not anymore the obligation to issue the 1.0% Senior Bond Warrants, resulting in a gain on extinguishment of $6.5 million. In January and February 2023, the Senior Bond Warrant holders (also known as penny warrant holders) elected to exercise their warrants. As a result, 2,479,962 ordinary shares were issued in exchange for the exercising of the penny warrants. The Company received an immaterial amount of cash and recognized the transaction as an extinguishment of the derivative financial liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the Senior Bond Warrants was derived from the publicly quoted trading price of the Ordinary Shares at the valuation date. As of 31&#160;December 2023, the Company had 1,718,845 warrants with an exercise price of $0.01, representing the 1.5% tranche of Senior Bond Warrants. The Senior Bond Warrants had a fair value of $19.7&#160;million as of 31&#160;December 2023. The change in fair resulted in $8.1 million of finance costs for the year ended 31&#160;December 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Tranche A Conversion Feature &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As noted in Note 21, in connection with the Convertible Bonds the Group classified the Tranche A Conversion Feature as an embedded derivative liability due to the variability created by conversion rates resulting from the tranche being denominated in ISK. The conversion feature had a fair value of $118.8&#160;million as of 31&#160;December 2023. The change in fair resulted in $35.2&#160;million of finance costs for the year ended 31&#160;December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the Tranche A Conversion Feature was determined using a lattice model that incorporated inputs and assumptions as further described below. The inputs and assumptions associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the assumptions and inputs that were used for the model in valuing the Tranche A Conversion Feature: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.725%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.482%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$11.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Volatility rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risky yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;Predecessor Earn Out Shares &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the Business Combination, Predecessor shareholders were granted a total of 38,330,000 Ordinary Shares subject to certain vesting conditions (&#x201c;Predecessor Earn Out Shares&#x201d;). One half of the Predecessor Earn Out Shares will vest if, at any time during the five years following the closing of the Business Combination, the Alvotech ordinary share price is at or above a volume weighted average price (&#x201c;VWAP&#x201d;) of $15.00 per share for any &lt;span style="-sec-ix-hidden:f-2302"&gt;ten&lt;/span&gt; trading days within any &lt;span style="-sec-ix-hidden:f-2303"&gt;twenty&lt;/span&gt;-trading day period, with the other half vesting at a VWAP of $20.00 per share for any &lt;span style="-sec-ix-hidden:f-2305"&gt;ten&lt;/span&gt; trading days within any &lt;span style="-sec-ix-hidden:f-2306"&gt;twenty&lt;/span&gt;-trading day period. The Predecessor Earn Out Shares are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The Predecessor Earn Out Shares had a fair value of $349.9 million as of 31&#160;December 2023, resulting in $73.7&#160;million of finance costs during the year ended 31&#160;December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the Predecessor Earn Out Shares was determined using Monte Carlo analysis that incorporated inputs and assumptions as further described below. The inputs and assumptions associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the assumptions and inputs that were used for the model in valuing the Predecessor Earn Out Shares: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,330,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,330,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$11.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Volatility rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;OACB Earn Out Shares &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Former OACB shareholders were granted a total of 1,250,000 Ordinary Shares subject to certain vesting conditions (&#x201c;OACB Earn Out Shares&#x201d;). One half of the OACB Earn Out Shares will vest if, at any time during the five years following the closing of the Business Combination, the Alvotech ordinary share price is at or above a VWAP of $12.50 per share for any &lt;span style="-sec-ix-hidden:f-2320"&gt;ten&lt;/span&gt; trading days within any &lt;span style="-sec-ix-hidden:f-2321"&gt;twenty&lt;/span&gt;-trading day period, with the other half vesting at a VWAP of $15.00 per share.  On 17 February 2023, the first half of OACB Earn Out Shares vested resulting in the issuance of 625,000 ordinary shares by the Group. The OACB Earn Out Shares are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The OACB Earn Out Shares had a fair value of $6.2 million as of 31&#160;December 2023, resulting in $4.0&#160;million of finance costs during the year ended 31&#160;December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the OACB Earn Out Shares was determined using a Monte Carlo analysis that incorporated inputs and assumptions as further described below. Assumptions and inputs associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the assumptions and inputs that were used for the model in valuing the OACB Earn Out Shares: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;625,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,250,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$11.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Volatility rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"&gt;OACB Warrants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, as part of the Business Combination the Company assumed the 10,916,647 outstanding OACB Warrants, on substantially the same contractual terms and conditions as were in effect immediately prior to the Business Combination, including an exercise price of $11.50. Each warrant entitles the holder to purchase one Alvotech ordinary share.  During 2023, holders of the OACB warrants exercised their warrant rights for an exercise price of $11.50 for the rights to one ordinary share per warrant. The exercises resulted in the issuance of 553.552 ordinary shares and cash proceeds of approximately $6.3&#160;million. The OACB warrants are accounted for as derivative financial liabilities in accordance with IAS 32 and will be subject to ongoing mark-to-market adjustments through the consolidated statement of profit or loss and other comprehensive income or loss. The OACB warrants had a fair value of $25.9&#160;million as of 31&#160;December 2023. The fair value of the warrants was derived from the publicly quoted trading price at the valuation date. The change in fair value of the OACB Warrants resulted in $17.0&#160;million of finance costs during the year ended 31&#160;December 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Capital management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The capital structure of the Group consists of equity, debt and cash. For the foreseeable future, the Board of Directors will maintain a capital structure that supports the Group&#x2019;s strategic objectives through managing the budgeting process, maintaining strong investor relations and managing the financial risks of the Group, as further described below. No changes were made in the objectives, policies or processes for managing capital during the years ended 31&#160;December 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Financial risk management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s corporate treasury function provides services across the organization, coordinates access to domestic and international financial markets, monitors and manages the financial risks relating to the Group&#x2019;s operations through internal risk reports which analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Interest rate risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group&#x2019;s exposure to the risk of fluctuations in market interest rates primarily relates to the cash in bank and borrowings that are subject to floating interest rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides an interest rate sensitivity analysis for the effect on loss before tax: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-rate financial instruments +100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-rate financial instruments -100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Foreign currency risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group uses the US dollar as its reporting currency and conducts business on a global basis in various currencies. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Icelandic and UK market currencies, as well as in the Swiss franc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Below are the foreign currencies that have the most significant impact on the Group&#x2019;s operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.481%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ISK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;INR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2023 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;assets &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ISK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;144,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(141,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;INR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Net &lt;br/&gt;assets &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ISK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(60,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;INR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reasonable possible strengthening or weakening of the Group&#x2019;s significant foreign currencies against the USD would affect the measurement of financial instruments denominated in a foreign currency and affect profit or loss and equity by the amount shown in the sensitivity analysis table below. The analysis assumes that all other variables, such as interest rates, remain constant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;EUR &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;GBP &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;ISK &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;CHF &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;INR &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Year ended 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;-10% weakening&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;+10% strengthening&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Year ended 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;-10% weakening&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;+10% strengthening&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Credit risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Credit risk it the risk that a counterparty will not fulfill its contractual obligations under a financial instrument contract, leading to a financial loss for the Group. The maximum credit risk exposure for the Group&#x2019;s financial assets as of 31&#160;December 2023 and 2022 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s cash and cash equivalents and restricted cash are deposited with high-quality financial institutions. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Group has not experienced any losses on its deposits of cash and cash equivalents and restricted cash yet monitors the credit rating of these financial institutions on a periodic basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other assets primarily consist of other current assets, as described in Note 18, and trade receivables and contract assets recognized in connection with the Group&#x2019;s performance pursuant to its contracts with customers, all of which are large multinational pharmaceutical companies. In 2023, the Group recognized a receivable of $18.5&#160;million in other current assets following the termination of the co-development agreement with Biosana which was fully reserved as of 31&#160;December 2023 due to the uncertainty of its collection (see Note 18). There are no other significant amounts past due as of 31&#160;December 2023 and 2022 and the Group concludes that any expected credit losses with respect to these assets, except as described above, is immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Liquidity risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual maturities of financial assets and liabilities as of 31&#160;December 2023 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Within one&lt;br/&gt;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;One to two&lt;br/&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;142,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;142,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fixed-interest bearing - Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,101,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,167,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-interest bearing - Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;121,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;253,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,631,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,951,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual maturities of financial assets and liabilities as of 31&#160;December 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Within one&lt;br/&gt;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;One to two&lt;br/&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;106,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;112,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fixed-interest bearing - Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;896,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,008,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;380,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;380,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-interest bearing - Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;92,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;175,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,344,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,593,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Refer to Note 13 for the maturity analysis of the Group&#x2019;s undiscounted lease payments.</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c-1" id="f-2148">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial assets as of 31&#160;December 2023 and 2022, all of which are measured at amortized cost, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Receivables from related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 2.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,484&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-2149" unitRef="usd">11157000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-2150" unitRef="usd">66427000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-2151" unitRef="usd">26132000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-2152" unitRef="usd">25187000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentTradeReceivables contextRef="c-5" decimals="-3" id="f-2153" unitRef="usd">41292000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-8" decimals="-3" id="f-2154" unitRef="usd">32972000</ifrs-full:CurrentTradeReceivables>
    <alvo:OtherCurrentAsset contextRef="c-5" decimals="-3" id="f-2155" unitRef="usd">1035000</alvo:OtherCurrentAsset>
    <alvo:OtherCurrentAsset contextRef="c-8" decimals="-3" id="f-2156" unitRef="usd">5880000</alvo:OtherCurrentAsset>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c-5" decimals="-3" id="f-2157" unitRef="usd">896000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c-8" decimals="-3" id="f-2158" unitRef="usd">1548000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <alvo:OtherNoncurrentAsset contextRef="c-5" decimals="-3" id="f-2159" unitRef="usd">336000</alvo:OtherNoncurrentAsset>
    <alvo:OtherNoncurrentAsset contextRef="c-8" decimals="-3" id="f-2160" unitRef="usd">4484000</alvo:OtherNoncurrentAsset>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c-5" decimals="-3" id="f-2161" unitRef="usd">80848000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c-8" decimals="-3" id="f-2162" unitRef="usd">136498000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c-1" id="f-2163">&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial liabilities as of 31&#160;December 2023 and 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Borrowings (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;960,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;764,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative financial liabilities (measured at FVTPL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;380,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other long-term liability to related party (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Long-term incentive plan (measured at FVTPL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Trade and other payables (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Liabilities to related parties (measured at amortized cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,748,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,297,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:Borrowings contextRef="c-5" decimals="-3" id="f-2164" unitRef="usd">960159000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-3" id="f-2165" unitRef="usd">764570000</ifrs-full:Borrowings>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-5" decimals="-3" id="f-2166" unitRef="usd">520553000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-8" decimals="-3" id="f-2167" unitRef="usd">380232000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentPayablesToRelatedParties contextRef="c-5" decimals="-3" id="f-2168" unitRef="usd">0</ifrs-full:NoncurrentPayablesToRelatedParties>
    <ifrs-full:NoncurrentPayablesToRelatedParties contextRef="c-8" decimals="-3" id="f-2169" unitRef="usd">7440000</ifrs-full:NoncurrentPayablesToRelatedParties>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan contextRef="c-5" decimals="-3" id="f-2170" unitRef="usd">0</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan contextRef="c-8" decimals="-3" id="f-2171" unitRef="usd">544000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-5" decimals="-3" id="f-2172" unitRef="usd">80563000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-8" decimals="-3" id="f-2173" unitRef="usd">49188000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:LeaseLiabilities contextRef="c-5" decimals="-3" id="f-2174" unitRef="usd">115315000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-8" decimals="-3" id="f-2175" unitRef="usd">40532000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="c-5" decimals="-3" id="f-2176" unitRef="usd">9851000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="c-8" decimals="-3" id="f-2177" unitRef="usd">1131000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <alvo:OtherCurrentLiability contextRef="c-5" decimals="-3" id="f-2178" unitRef="usd">61873000</alvo:OtherCurrentLiability>
    <alvo:OtherCurrentLiability contextRef="c-8" decimals="-3" id="f-2179" unitRef="usd">53664000</alvo:OtherCurrentLiability>
    <alvo:FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c-5" decimals="-3" id="f-2180" unitRef="usd">1748314000</alvo:FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <alvo:FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c-8" decimals="-3" id="f-2181" unitRef="usd">1297301000</alvo:FinancialLiabilitiesAtAmortizedCostAndFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <alvo:DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock contextRef="c-1" id="f-2182">Material differences between the fair values and carrying amounts of these borrowings are identified as follows: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;559,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Convertible Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;155,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;217,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;82,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;862,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;530,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;535,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Convertible Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alvogen Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;693,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;720,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureInTabularFormOfCarryingAmountAndFinancialAmountOfCertainBorrowingsExplanatoryTableTextBlock>
    <ifrs-full:BondsIssued contextRef="c-429" decimals="-3" id="f-2183" unitRef="usd">549411000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-429" decimals="-3" id="f-2184" unitRef="usd">559867000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-717" decimals="-3" id="f-2185" unitRef="usd">80663000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-717" decimals="-3" id="f-2186" unitRef="usd">84756000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-718" decimals="-3" id="f-2187" unitRef="usd">155914000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-718" decimals="-3" id="f-2188" unitRef="usd">217419000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-719" decimals="-3" id="f-2189" unitRef="usd">76556000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-719" decimals="-3" id="f-2190" unitRef="usd">82060000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-5" decimals="-3" id="f-2191" unitRef="usd">862544000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-5" decimals="-3" id="f-2192" unitRef="usd">944102000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-720" decimals="-3" id="f-2193" unitRef="usd">530506000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-720" decimals="-3" id="f-2194" unitRef="usd">535167000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-721" decimals="-3" id="f-2195" unitRef="usd">65793000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-721" decimals="-3" id="f-2196" unitRef="usd">65772000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-722" decimals="-3" id="f-2197" unitRef="usd">32441000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-722" decimals="-3" id="f-2198" unitRef="usd">52463000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-723" decimals="-3" id="f-2199" unitRef="usd">64588000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-723" decimals="-3" id="f-2200" unitRef="usd">66883000</alvo:BondsIssuedAtFairValue>
    <ifrs-full:BondsIssued contextRef="c-8" decimals="-3" id="f-2201" unitRef="usd">693328000</ifrs-full:BondsIssued>
    <alvo:BondsIssuedAtFairValue contextRef="c-8" decimals="-3" id="f-2202" unitRef="usd">720285000</alvo:BondsIssuedAtFairValue>
    <alvo:DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock contextRef="c-1" id="f-2203">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables illustrate the fair value measurement hierarchy of the Group&#x2019;s financial instruments measured at fair value on a recurring basis as of 31&#160;December 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Senior Bond Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tranche A Conversion Feature&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Predecessor Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;349,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;349,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;356,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bond Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tranche A Conversion Feature&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Senior Bond Interest Rate Feature (included in other current assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Predecessor Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;276,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;276,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Earn Out Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;OACB Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;286,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;381,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureInTabularFormOfFairValueOfDerivativeFinancialInstrumentsExplanatoryTableTextBlock>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-724" decimals="-3" id="f-2204" unitRef="usd">19715000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-725" id="f-2205" unitRef="usd" xsi:nil="true"/>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-726" decimals="-3" id="f-2206" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-727" decimals="-3" id="f-2207" unitRef="usd">19715000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-728" decimals="-3" id="f-2208" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-729" decimals="-3" id="f-2209" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-730" decimals="-3" id="f-2210" unitRef="usd">118830000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-731" decimals="-3" id="f-2211" unitRef="usd">118830000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-732" decimals="-3" id="f-2212" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-733" decimals="-3" id="f-2213" unitRef="usd">349900000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-734" decimals="-3" id="f-2214" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-735" decimals="-3" id="f-2215" unitRef="usd">349900000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-736" decimals="-3" id="f-2216" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-737" decimals="-3" id="f-2217" unitRef="usd">6200000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-738" decimals="-3" id="f-2218" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-739" decimals="-3" id="f-2219" unitRef="usd">6200000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-740" decimals="-3" id="f-2220" unitRef="usd">25908000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-741" decimals="-3" id="f-2221" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-742" decimals="-3" id="f-2222" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-743" decimals="-3" id="f-2223" unitRef="usd">25908000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-744" decimals="-3" id="f-2224" unitRef="usd">45623000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-745" decimals="-3" id="f-2225" unitRef="usd">356100000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-746" decimals="-3" id="f-2226" unitRef="usd">118830000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-5" decimals="-3" id="f-2227" unitRef="usd">520553000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-747" decimals="-3" id="f-2228" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-748" decimals="-3" id="f-2229" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-749" decimals="-3" id="f-2230" unitRef="usd">45325000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-750" decimals="-3" id="f-2231" unitRef="usd">45325000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-751" decimals="-3" id="f-2232" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-752" decimals="-3" id="f-2233" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-753" decimals="-3" id="f-2234" unitRef="usd">38055000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-754" decimals="-3" id="f-2235" unitRef="usd">38055000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-755" decimals="-3" id="f-2236" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-756" decimals="-3" id="f-2237" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-757" decimals="-3" id="f-2238" unitRef="usd">851000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-758" decimals="-3" id="f-2239" unitRef="usd">851000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-759" decimals="-3" id="f-2240" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-760" decimals="-3" id="f-2241" unitRef="usd">276200000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-761" decimals="-3" id="f-2242" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-762" decimals="-3" id="f-2243" unitRef="usd">276200000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-763" decimals="-3" id="f-2244" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-764" decimals="-3" id="f-2245" unitRef="usd">10500000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-765" decimals="-3" id="f-2246" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-766" decimals="-3" id="f-2247" unitRef="usd">10500000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-767" decimals="-3" id="f-2248" unitRef="usd">10152000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-768" decimals="-3" id="f-2249" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-769" decimals="-3" id="f-2250" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-770" decimals="-3" id="f-2251" unitRef="usd">10152000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-771" decimals="-3" id="f-2252" unitRef="usd">10152000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-772" decimals="-3" id="f-2253" unitRef="usd">286700000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-773" decimals="-3" id="f-2254" unitRef="usd">84231000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-8" decimals="-3" id="f-2255" unitRef="usd">381083000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c-1" id="f-2256">&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a reconciliation of Level 3 financial instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Senior Bond Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Tranche A Conversion Feature&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Senior Bond Interest Rate Feature&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 January  2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfer to Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(45,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-749" decimals="-3" id="f-2257" unitRef="usd">45325000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-753" decimals="-3" id="f-2258" unitRef="usd">38055000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-757" decimals="-3" id="f-2259" unitRef="usd">851000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:IssuesFairValueMeasurementLiabilities contextRef="c-774" decimals="-3" id="f-2260" unitRef="usd">45555000</ifrs-full:IssuesFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-775" decimals="-3" id="f-2261" unitRef="usd">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-774" decimals="-3" id="f-2262" unitRef="usd">35220000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities contextRef="c-775" decimals="-3" id="f-2263" unitRef="usd">45325000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:SettlementsFairValueMeasurementLiabilities contextRef="c-775" decimals="-3" id="f-2264" unitRef="usd">0</ifrs-full:SettlementsFairValueMeasurementLiabilities>
    <ifrs-full:SettlementsFairValueMeasurementLiabilities contextRef="c-776" decimals="-3" id="f-2265" unitRef="usd">851000</ifrs-full:SettlementsFairValueMeasurementLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-726" decimals="-3" id="f-2266" unitRef="usd">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-730" decimals="-3" id="f-2267" unitRef="usd">118830000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-777" decimals="-3" id="f-2268" unitRef="usd">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities contextRef="c-778" decimals="-3" id="f-2269" unitRef="usd">19700000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-725" id="f-2270" unitRef="usd" xsi:nil="true"/>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities contextRef="c-779" decimals="-3" id="f-2271" unitRef="usd">45300000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities>
    <alvo:IncreaseInOutstandingBondsFairValue contextRef="c-472" decimals="-5" id="f-2272" unitRef="usd">70000000</alvo:IncreaseInOutstandingBondsFairValue>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-780"
      decimals="4"
      id="f-2273"
      unitRef="number">0.1075</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-781"
      decimals="3"
      id="f-2274"
      unitRef="number">0.120</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:SettlementsFairValueMeasurementLiabilities contextRef="c-776" decimals="-5" id="f-2275" unitRef="usd">900000</ifrs-full:SettlementsFairValueMeasurementLiabilities>
    <alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares
      contextRef="c-369"
      decimals="INF"
      id="f-2276"
      unitRef="number">0.010</alvo:WarrantsIssuableAsAPercentageOfFullyDilutedOrdinaryShares>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-782" decimals="-5" id="f-2277" unitRef="usd">6500000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-782"
      decimals="INF"
      id="f-2278"
      unitRef="shares">2479962</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <alvo:ClassOfWarrantsOrRightsOutstanding
      contextRef="c-727"
      decimals="INF"
      id="f-2279"
      unitRef="shares">1718845</alvo:ClassOfWarrantsOrRightsOutstanding>
    <alvo:ConversionPrice
      contextRef="c-727"
      decimals="INF"
      id="f-2280"
      unitRef="usdPerShare">0.01</alvo:ConversionPrice>
    <alvo:TrancheOfSeniorBondWarrantsPercentage
      contextRef="c-782"
      decimals="3"
      id="f-2281"
      unitRef="number">0.015</alvo:TrancheOfSeniorBondWarrantsPercentage>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-727" decimals="-5" id="f-2282" unitRef="usd">19700000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinanceCosts contextRef="c-782" decimals="-5" id="f-2283" unitRef="usd">-8100000</ifrs-full:FinanceCosts>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-731" decimals="-5" id="f-2284" unitRef="usd">118800000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinanceCosts contextRef="c-783" decimals="-5" id="f-2285" unitRef="usd">35200000</ifrs-full:FinanceCosts>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory contextRef="c-1" id="f-2286">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the assumptions and inputs that were used for the model in valuing the Tranche A Conversion Feature: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.725%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.482%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$11.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Conversion price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Volatility rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risky yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the assumptions and inputs that were used for the model in valuing the Predecessor Earn Out Shares: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,330,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,330,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$11.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Volatility rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the assumptions and inputs that were used for the model in valuing the OACB Earn Out Shares: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31 December &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;625,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,250,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$11.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Volatility rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-784"
      decimals="2"
      id="f-2287"
      unitRef="number">11.48</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-785"
      decimals="2"
      id="f-2288"
      unitRef="number">10.00</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-786"
      decimals="2"
      id="f-2289"
      unitRef="number">10.00</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-787"
      decimals="2"
      id="f-2290"
      unitRef="number">10.00</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-788"
      decimals="3"
      id="f-2291"
      unitRef="number">0.575</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-789"
      decimals="3"
      id="f-2292"
      unitRef="number">0.450</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-790"
      decimals="3"
      id="f-2293"
      unitRef="number">0.042</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-791"
      decimals="3"
      id="f-2294"
      unitRef="number">0.042</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-792"
      decimals="3"
      id="f-2295"
      unitRef="number">0.000</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-793"
      decimals="3"
      id="f-2296"
      unitRef="number">0.000</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-794"
      decimals="3"
      id="f-2297"
      unitRef="number">0.163</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-795"
      decimals="3"
      id="f-2298"
      unitRef="number">0.193</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-796"
      decimals="INF"
      id="f-2299"
      unitRef="shares">38330000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <alvo:AggregatePeriodForDeterminingTheSharePrice contextRef="c-797" id="f-2300">P5Y</alvo:AggregatePeriodForDeterminingTheSharePrice>
    <alvo:SharesPrice
      contextRef="c-797"
      decimals="2"
      id="f-2301"
      unitRef="usdPerShare">15.00</alvo:SharesPrice>
    <alvo:SharesPrice
      contextRef="c-798"
      decimals="2"
      id="f-2304"
      unitRef="usdPerShare">20.00</alvo:SharesPrice>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-735" decimals="-3" id="f-2307" unitRef="usd">349900000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinanceCosts contextRef="c-799" decimals="-5" id="f-2308" unitRef="usd">73700000</ifrs-full:FinanceCosts>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-735"
      decimals="INF"
      id="f-2309"
      unitRef="shares">38330000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-762"
      decimals="INF"
      id="f-2310"
      unitRef="shares">38330000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-800"
      decimals="2"
      id="f-2311"
      unitRef="number">11.48</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-801"
      decimals="2"
      id="f-2312"
      unitRef="number">10.00</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-802"
      decimals="3"
      id="f-2313"
      unitRef="number">0.550</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-803"
      decimals="3"
      id="f-2314"
      unitRef="number">0.450</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-804"
      decimals="4"
      id="f-2315"
      unitRef="number">0.0397</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-805"
      decimals="4"
      id="f-2316"
      unitRef="number">0.0405</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-806"
      decimals="INF"
      id="f-2317"
      unitRef="shares">1250000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <alvo:AggregatePeriodForDeterminingTheSharePrice contextRef="c-807" id="f-2318">P5Y</alvo:AggregatePeriodForDeterminingTheSharePrice>
    <alvo:SharesPrice
      contextRef="c-807"
      decimals="2"
      id="f-2319"
      unitRef="usdPerShare">12.50</alvo:SharesPrice>
    <alvo:SharesPrice
      contextRef="c-808"
      decimals="2"
      id="f-2322"
      unitRef="usdPerShare">15.00</alvo:SharesPrice>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-809"
      decimals="INF"
      id="f-2323"
      unitRef="shares">625000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-739" decimals="-3" id="f-2324" unitRef="usd">6200000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinanceCosts contextRef="c-806" decimals="-5" id="f-2325" unitRef="usd">4000000</ifrs-full:FinanceCosts>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-810"
      decimals="INF"
      id="f-2326"
      unitRef="shares">625000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-811"
      decimals="INF"
      id="f-2327"
      unitRef="shares">1250000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-812"
      decimals="2"
      id="f-2328"
      unitRef="number">11.48</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-813"
      decimals="2"
      id="f-2329"
      unitRef="number">10.00</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-814"
      decimals="3"
      id="f-2330"
      unitRef="number">0.550</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-815"
      decimals="3"
      id="f-2331"
      unitRef="number">0.450</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-816"
      decimals="4"
      id="f-2332"
      unitRef="number">0.0397</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-817"
      decimals="4"
      id="f-2333"
      unitRef="number">0.0405</ifrs-full:SignificantUnobservableInputLiabilities>
    <alvo:ClassOfWarrantsOrRightsOutstanding
      contextRef="c-818"
      decimals="INF"
      id="f-2334"
      unitRef="shares">10916647</alvo:ClassOfWarrantsOrRightsOutstanding>
    <alvo:ClassOfWarrantsOrRightsExercisePricePerShare
      contextRef="c-818"
      decimals="2"
      id="f-2335"
      unitRef="usdPerShare">11.50</alvo:ClassOfWarrantsOrRightsExercisePricePerShare>
    <alvo:NumberOfSharesCalledByEachWarrantOrRight
      contextRef="c-67"
      decimals="INF"
      id="f-2336"
      unitRef="shares">1</alvo:NumberOfSharesCalledByEachWarrantOrRight>
    <alvo:ClassOfWarrantsOrRightsExercisePricePerShare
      contextRef="c-743"
      decimals="2"
      id="f-2337"
      unitRef="usdPerShare">11.50</alvo:ClassOfWarrantsOrRightsExercisePricePerShare>
    <alvo:NumberOfSharesCalledByEachWarrantOrRight
      contextRef="c-67"
      decimals="INF"
      id="f-2338"
      unitRef="shares">1</alvo:NumberOfSharesCalledByEachWarrantOrRight>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-743"
      decimals="INF"
      id="f-2339"
      unitRef="shares">553.552</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-819" decimals="-5" id="f-2340" unitRef="usd">6300000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:Liabilities contextRef="c-743" decimals="-5" id="f-2341" unitRef="usd">25900000</ifrs-full:Liabilities>
    <ifrs-full:FinanceCosts contextRef="c-819" decimals="-5" id="f-2342" unitRef="usd">17000000</ifrs-full:FinanceCosts>
    <alvo:DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock contextRef="c-1" id="f-2343">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides an interest rate sensitivity analysis for the effect on loss before tax: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-rate financial instruments +100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-rate financial instruments -100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureInTabularFormOfInterestRateSensitivityAnalysisImpactOnProfitBeforeTaxExplanatoryTableTextBlock>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-820" decimals="-3" id="f-2344" unitRef="usd">-89000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-821" decimals="-3" id="f-2345" unitRef="usd">-186000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-820" decimals="-3" id="f-2346" unitRef="usd">89000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-821" decimals="-3" id="f-2347" unitRef="usd">186000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <alvo:DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock contextRef="c-1" id="f-2348">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Below are the foreign currencies that have the most significant impact on the Group&#x2019;s operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.481%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ISK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;INR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureInTabularFormOfForeignExchangeRateExplanatoryTableTextBlock>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-822"
      decimals="3"
      id="f-2349"
      unitRef="number">1.105</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-823"
      decimals="3"
      id="f-2350"
      unitRef="number">1.061</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-824"
      decimals="3"
      id="f-2351"
      unitRef="number">1.091</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-825"
      decimals="3"
      id="f-2352"
      unitRef="number">1.052</ifrs-full:AverageForeignExchangeRate>
    <alvo:PercentageChangeInForeignExchangeRate
      contextRef="c-824"
      decimals="3"
      id="f-2353"
      unitRef="number">0.041</alvo:PercentageChangeInForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-826"
      decimals="3"
      id="f-2354"
      unitRef="number">1.275</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-827"
      decimals="3"
      id="f-2355"
      unitRef="number">1.204</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-828"
      decimals="3"
      id="f-2356"
      unitRef="number">1.266</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-829"
      decimals="3"
      id="f-2357"
      unitRef="number">1.233</ifrs-full:AverageForeignExchangeRate>
    <alvo:PercentageChangeInForeignExchangeRate
      contextRef="c-828"
      decimals="3"
      id="f-2358"
      unitRef="number">0.059</alvo:PercentageChangeInForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-830"
      decimals="3"
      id="f-2359"
      unitRef="number">0.007</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-831"
      decimals="3"
      id="f-2360"
      unitRef="number">0.007</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-832"
      decimals="3"
      id="f-2361"
      unitRef="number">0.007</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-833"
      decimals="3"
      id="f-2362"
      unitRef="number">0.007</ifrs-full:AverageForeignExchangeRate>
    <alvo:PercentageChangeInForeignExchangeRate
      contextRef="c-832"
      decimals="3"
      id="f-2363"
      unitRef="number">0.051</alvo:PercentageChangeInForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-834"
      decimals="3"
      id="f-2364"
      unitRef="number">1.188</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-835"
      decimals="3"
      id="f-2365"
      unitRef="number">1.071</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-836"
      decimals="3"
      id="f-2366"
      unitRef="number">1.156</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-837"
      decimals="3"
      id="f-2367"
      unitRef="number">1.047</ifrs-full:AverageForeignExchangeRate>
    <alvo:PercentageChangeInForeignExchangeRate
      contextRef="c-836"
      decimals="3"
      id="f-2368"
      unitRef="number">0.109</alvo:PercentageChangeInForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-838"
      decimals="3"
      id="f-2369"
      unitRef="number">0.012</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-839"
      decimals="3"
      id="f-2370"
      unitRef="number">0.012</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-840"
      decimals="3"
      id="f-2371"
      unitRef="number">0.012</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-841"
      decimals="3"
      id="f-2372"
      unitRef="number">0.013</ifrs-full:AverageForeignExchangeRate>
    <alvo:PercentageChangeInForeignExchangeRate
      contextRef="c-840"
      decimals="3"
      id="f-2373"
      unitRef="number">0.001</alvo:PercentageChangeInForeignExchangeRate>
    <alvo:DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock contextRef="c-1" id="f-2374">&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2023 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;assets &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ISK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;144,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(141,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;INR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group&#x2019;s assets and liabilities that are denominated in foreign currencies as of 31&#160;December 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Net &lt;br/&gt;assets &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ISK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(60,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;INR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureInTabularFormOfAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatoryTableTextBlock>
    <ifrs-full:Assets contextRef="c-822" decimals="-3" id="f-2375" unitRef="usd">36568000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-822" decimals="-3" id="f-2376" unitRef="usd">46303000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-822" decimals="-3" id="f-2377" unitRef="usd">-9735000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-826" decimals="-3" id="f-2378" unitRef="usd">69000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-826" decimals="-3" id="f-2379" unitRef="usd">3479000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-826" decimals="-3" id="f-2380" unitRef="usd">-3410000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-830" decimals="-3" id="f-2381" unitRef="usd">3247000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-830" decimals="-3" id="f-2382" unitRef="usd">144812000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-830" decimals="-3" id="f-2383" unitRef="usd">-141565000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-834" decimals="-3" id="f-2384" unitRef="usd">335000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-834" decimals="-3" id="f-2385" unitRef="usd">7488000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-834" decimals="-3" id="f-2386" unitRef="usd">-7153000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-838" decimals="-3" id="f-2387" unitRef="usd">167000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-838" decimals="-3" id="f-2388" unitRef="usd">536000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-838" decimals="-3" id="f-2389" unitRef="usd">-369000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-823" decimals="-3" id="f-2390" unitRef="usd">36420000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-823" decimals="-3" id="f-2391" unitRef="usd">26514000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-823" decimals="-3" id="f-2392" unitRef="usd">9906000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-827" decimals="-3" id="f-2393" unitRef="usd">111000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-827" decimals="-3" id="f-2394" unitRef="usd">1538000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-827" decimals="-3" id="f-2395" unitRef="usd">-1427000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-831" decimals="-3" id="f-2396" unitRef="usd">49484000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-831" decimals="-3" id="f-2397" unitRef="usd">109507000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-831" decimals="-3" id="f-2398" unitRef="usd">-60023000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-835" decimals="-3" id="f-2399" unitRef="usd">69000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-835" decimals="-3" id="f-2400" unitRef="usd">7305000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-835" decimals="-3" id="f-2401" unitRef="usd">-7236000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:Assets contextRef="c-839" decimals="-3" id="f-2402" unitRef="usd">11000</ifrs-full:Assets>
    <ifrs-full:Liabilities contextRef="c-839" decimals="-3" id="f-2403" unitRef="usd">517000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-839" decimals="-3" id="f-2404" unitRef="usd">-506000</ifrs-full:NetAssetsLiabilities>
    <alvo:DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock contextRef="c-1" id="f-2405">The analysis assumes that all other variables, such as interest rates, remain constant. &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;EUR &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;GBP &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;ISK &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;CHF &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;INR &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Year ended 31 December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;-10% weakening&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;+10% strengthening&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Year ended 31 December 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;-10% weakening&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:10pt;text-indent:-10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;+10% strengthening&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureInTabularFormOfCurrencyRiskSensitivityAnalysisOnProfitBeforeTaxExplanatoryTableTextBlock>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="c-842"
      decimals="2"
      id="f-2406"
      unitRef="number">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-843" decimals="-3" id="f-2407" unitRef="usd">-974000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-844" decimals="-3" id="f-2408" unitRef="usd">-341000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-845" decimals="-3" id="f-2409" unitRef="usd">-14156000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-846" decimals="-3" id="f-2410" unitRef="usd">-715000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-847" decimals="-3" id="f-2411" unitRef="usd">-37000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="c-842"
      decimals="2"
      id="f-2412"
      unitRef="number">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-843" decimals="-3" id="f-2413" unitRef="usd">974000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-844" decimals="-3" id="f-2414" unitRef="usd">341000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-845" decimals="-3" id="f-2415" unitRef="usd">14156000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-846" decimals="-3" id="f-2416" unitRef="usd">715000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-847" decimals="-3" id="f-2417" unitRef="usd">37000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="c-848"
      decimals="2"
      id="f-2418"
      unitRef="number">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-849" decimals="-3" id="f-2419" unitRef="usd">-991000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-850" decimals="-3" id="f-2420" unitRef="usd">-143000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-851" decimals="-3" id="f-2421" unitRef="usd">-6002000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-852" decimals="-3" id="f-2422" unitRef="usd">-724000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-853" decimals="-3" id="f-2423" unitRef="usd">-51000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="c-848"
      decimals="2"
      id="f-2424"
      unitRef="number">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-849" decimals="-3" id="f-2425" unitRef="usd">991000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-850" decimals="-3" id="f-2426" unitRef="usd">143000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-851" decimals="-3" id="f-2427" unitRef="usd">6002000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-852" decimals="-3" id="f-2428" unitRef="usd">724000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities contextRef="c-853" decimals="-3" id="f-2429" unitRef="usd">51000</ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputRecognisedInProfitOrLossBeforeTaxLiabilities>
    <ifrs-full:DisclosureOfCreditRiskExposureExplanatory contextRef="c-1" id="f-2430">The maximum credit risk exposure for the Group&#x2019;s financial assets as of 31&#160;December 2023 and 2022 is as follows: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCreditRiskExposureExplanatory>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c-854" decimals="-3" id="f-2431" unitRef="usd">11157000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c-855" decimals="-3" id="f-2432" unitRef="usd">66427000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c-856" decimals="-3" id="f-2433" unitRef="usd">26132000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c-857" decimals="-3" id="f-2434" unitRef="usd">25187000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c-858" decimals="-3" id="f-2435" unitRef="usd">43559000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c-859" decimals="-3" id="f-2436" unitRef="usd">44884000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c-5" decimals="-3" id="f-2437" unitRef="usd">80848000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c-8" decimals="-3" id="f-2438" unitRef="usd">136498000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:OtherCurrentAssets contextRef="c-357" decimals="-5" id="f-2439" unitRef="usd">18500000</ifrs-full:OtherCurrentAssets>
    <alvo:DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-2440">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual maturities of financial assets and liabilities as of 31&#160;December 2023 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Within one&lt;br/&gt;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;One to two&lt;br/&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;142,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;142,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fixed-interest bearing - Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,101,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,167,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-interest bearing - Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;121,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;253,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,631,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,951,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual maturities of financial assets and liabilities as of 31&#160;December 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.909%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Within one&lt;br/&gt;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;One to two&lt;br/&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;106,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-interest bearing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;112,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fixed-interest bearing - Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;896,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,008,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;380,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;380,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable-interest bearing - Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;92,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;175,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,344,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,593,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureOfContractualMaturitiesOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:FinancialAssets contextRef="c-860" decimals="-3" id="f-2441" unitRef="usd">43223000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-861" decimals="-3" id="f-2442" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-862" decimals="-3" id="f-2443" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-863" decimals="-3" id="f-2444" unitRef="usd">43223000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-864" decimals="-3" id="f-2445" unitRef="usd">11157000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-865" decimals="-3" id="f-2446" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-866" decimals="-3" id="f-2447" unitRef="usd">26468000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-867" decimals="-3" id="f-2448" unitRef="usd">37625000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-283" decimals="-3" id="f-2449" unitRef="usd">54380000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-521" decimals="-3" id="f-2450" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-868" decimals="-3" id="f-2451" unitRef="usd">26468000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-5" decimals="-3" id="f-2452" unitRef="usd">80848000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c-869" decimals="-3" id="f-2453" unitRef="usd">142436000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-870" decimals="-3" id="f-2454" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-871" decimals="-3" id="f-2455" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-872" decimals="-3" id="f-2456" unitRef="usd">142436000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-873" decimals="-3" id="f-2457" unitRef="usd">66309000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-874" decimals="-3" id="f-2458" unitRef="usd">1101185000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-875" decimals="-3" id="f-2459" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-876" decimals="-3" id="f-2460" unitRef="usd">1167494000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-877" decimals="-3" id="f-2461" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-878" decimals="-3" id="f-2462" unitRef="usd">520553000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-879" decimals="-3" id="f-2463" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-880" decimals="-3" id="f-2464" unitRef="usd">520553000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-881" decimals="-3" id="f-2465" unitRef="usd">44995000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-882" decimals="-3" id="f-2466" unitRef="usd">10198000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-883" decimals="-3" id="f-2467" unitRef="usd">65826000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-884" decimals="-3" id="f-2468" unitRef="usd">121019000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-283" decimals="-3" id="f-2469" unitRef="usd">253740000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-521" decimals="-3" id="f-2470" unitRef="usd">1631936000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-868" decimals="-3" id="f-2471" unitRef="usd">65826000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-5" decimals="-3" id="f-2472" unitRef="usd">1951502000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialAssets contextRef="c-885" decimals="-3" id="f-2473" unitRef="usd">40400000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-886" decimals="-3" id="f-2474" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-887" decimals="-3" id="f-2475" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-888" decimals="-3" id="f-2476" unitRef="usd">40400000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-889" decimals="-3" id="f-2477" unitRef="usd">66427000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-890" decimals="-3" id="f-2478" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-891" decimals="-3" id="f-2479" unitRef="usd">29671000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-892" decimals="-3" id="f-2480" unitRef="usd">96098000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-284" decimals="-3" id="f-2481" unitRef="usd">106827000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-522" decimals="-3" id="f-2482" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-893" decimals="-3" id="f-2483" unitRef="usd">29671000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-8" decimals="-3" id="f-2484" unitRef="usd">136498000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c-894" decimals="-3" id="f-2485" unitRef="usd">104366000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-895" decimals="-3" id="f-2486" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-896" decimals="-3" id="f-2487" unitRef="usd">7984000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-897" decimals="-3" id="f-2488" unitRef="usd">112350000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-898" decimals="-3" id="f-2489" unitRef="usd">45757000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-899" decimals="-3" id="f-2490" unitRef="usd">66308000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-900" decimals="-3" id="f-2491" unitRef="usd">896921000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-901" decimals="-3" id="f-2492" unitRef="usd">1008986000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-902" decimals="-3" id="f-2493" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-903" decimals="-3" id="f-2494" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-904" decimals="-3" id="f-2495" unitRef="usd">380232000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-905" decimals="-3" id="f-2496" unitRef="usd">380232000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-906" decimals="-3" id="f-2497" unitRef="usd">25259000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-907" decimals="-3" id="f-2498" unitRef="usd">8036000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-908" decimals="-3" id="f-2499" unitRef="usd">59109000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-909" decimals="-3" id="f-2500" unitRef="usd">92404000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-284" decimals="-3" id="f-2501" unitRef="usd">175382000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-522" decimals="-3" id="f-2502" unitRef="usd">74344000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-893" decimals="-3" id="f-2503" unitRef="usd">1344246000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-8" decimals="-3" id="f-2504" unitRef="usd">1593972000</ifrs-full:FinancialLiabilities>
    <alvo:DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock contextRef="c-1" id="f-2509">Supplemental cash flow information &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplement cash flow information for the years ended 31&#160;December 2023, 2022, and 2021 is included below (see Note 21 for non-cash movements in borrowings).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Non-cash investing and financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Acquisition of property, plant and equipment in trade payables and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Acquisition of intangibles in trade payables and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use assets obtained through new operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Purchase of Facility through Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-cash issuance of Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity issued through conversion of borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;346,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Acquisition of other intangible assets through financing agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of RSUs with shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of SARs with shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureInEntiretyOfSupplementalCashFlowInformationExplanatoryTextBlock>
    <alvo:DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock contextRef="c-1" id="f-2510">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplement cash flow information for the years ended 31&#160;December 2023, 2022, and 2021 is included below (see Note 21 for non-cash movements in borrowings).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Non-cash investing and financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Acquisition of property, plant and equipment in trade payables and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Acquisition of intangibles in trade payables and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use assets obtained through new operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Purchase of Facility through Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-cash issuance of Aztiq Convertible Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity issued through conversion of borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;346,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Acquisition of other intangible assets through financing agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of RSUs with shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Settlement of SARs with shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alvo:DisclosureInTabularFormOfSupplementalCashFlowInformationExplanatoryTableTextBlock>
    <alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid contextRef="c-1" decimals="-3" id="f-2511" unitRef="usd">2266000</alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid>
    <alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid contextRef="c-6" decimals="-3" id="f-2512" unitRef="usd">4131000</alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid>
    <alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid contextRef="c-7" decimals="-3" id="f-2513" unitRef="usd">3812000</alvo:CapitalExpenditureTangibleAssetsIncurredButNotPaid>
    <alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid contextRef="c-1" decimals="-3" id="f-2514" unitRef="usd">930000</alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid>
    <alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid contextRef="c-6" decimals="-3" id="f-2515" unitRef="usd">4075000</alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid>
    <alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid contextRef="c-7" decimals="-3" id="f-2516" unitRef="usd">0</alvo:CapitalExpenditureIntangibleAssetsIncurredButNotPaid>
    <alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-2517" unitRef="usd">74109000</alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities>
    <alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities contextRef="c-6" decimals="-3" id="f-2518" unitRef="usd">9583000</alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities>
    <alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities contextRef="c-7" decimals="-3" id="f-2519" unitRef="usd">18871000</alvo:RightOfUseAssetsObtainedThroughNewOperatingLeaseLiabilities>
    <alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond contextRef="c-1" decimals="-3" id="f-2520" unitRef="usd">0</alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond>
    <alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond contextRef="c-6" decimals="-3" id="f-2521" unitRef="usd">115005000</alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond>
    <alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond contextRef="c-7" decimals="-3" id="f-2522" unitRef="usd">0</alvo:AdditionOfTheLoanFacilitiesThroughConvertibleBond>
    <alvo:NonCashIssuanceOfConvertibleBond contextRef="c-1" decimals="-3" id="f-2523" unitRef="usd">0</alvo:NonCashIssuanceOfConvertibleBond>
    <alvo:NonCashIssuanceOfConvertibleBond contextRef="c-6" decimals="-3" id="f-2524" unitRef="usd">80000000</alvo:NonCashIssuanceOfConvertibleBond>
    <alvo:NonCashIssuanceOfConvertibleBond contextRef="c-7" decimals="-3" id="f-2525" unitRef="usd">0</alvo:NonCashIssuanceOfConvertibleBond>
    <alvo:OrdinarySharesValueIssuedConversionOfBorrowings contextRef="c-1" decimals="-3" id="f-2526" unitRef="usd">0</alvo:OrdinarySharesValueIssuedConversionOfBorrowings>
    <alvo:OrdinarySharesValueIssuedConversionOfBorrowings contextRef="c-6" decimals="-3" id="f-2527" unitRef="usd">32200000</alvo:OrdinarySharesValueIssuedConversionOfBorrowings>
    <alvo:OrdinarySharesValueIssuedConversionOfBorrowings contextRef="c-7" decimals="-3" id="f-2528" unitRef="usd">346043000</alvo:OrdinarySharesValueIssuedConversionOfBorrowings>
    <alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements contextRef="c-1" decimals="-3" id="f-2529" unitRef="usd">0</alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements>
    <alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements contextRef="c-6" decimals="-3" id="f-2530" unitRef="usd">0</alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements>
    <alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements contextRef="c-7" decimals="-3" id="f-2531" unitRef="usd">461000</alvo:AcquistionOfOtherIntangibleAssetsThroughFinancingAgreements>
    <alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares contextRef="c-549" decimals="-3" id="f-2532" unitRef="usd">678000</alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares>
    <alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares contextRef="c-550" decimals="-3" id="f-2533" unitRef="usd">0</alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares>
    <alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares contextRef="c-912" decimals="-3" id="f-2534" unitRef="usd">0</alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares>
    <alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares contextRef="c-537" decimals="-3" id="f-2535" unitRef="usd">13767000</alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares>
    <alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares contextRef="c-913" decimals="-3" id="f-2536" unitRef="usd">0</alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares>
    <alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares contextRef="c-914" decimals="-3" id="f-2537" unitRef="usd">0</alvo:IncreaseDecreaseThroughSettlementOfLiabilityWithShares>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-2538">Subsequent events &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Group evaluated subsequent events through 20 March 2024, the date the consolidated financial statements were available to be issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 15 February 2024, the Company announced it has reached settlement agreements with Johnson &amp;amp; Johnson in Japan, Canada and in the EEA for AVT04, a biosimilar to Stelara (ustekinumab). Regulatory approval for AVT04 in these markets has already been granted. Market applications for AVT04 are currently pending in additional global markets, including in the U.S. Alvotech's commercialization partner in Canada, JAMP Pharma, launched AVT04 in Canada on March 1, 2024. Launch of AVT04 in Japan is anticipated after the upcoming round of National Health Insurance reimbursement price listings, in May 2024. Entry to the first European markets is expected as soon as possible after the expiration date of the European Supplementary Protection Certificate (SPC) for Stelara, which is in late July 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 23 February 2024, the Company announced that the FDA has approved SIMLANDI (adalimumab) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn&#x2019;s disease, adult ulcerative colitis, adult plaque psoriasis, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest-grossing pharmaceutical products in the world, with sales in the U.S. of nearly $12.2&#160;billion. Teva is Alvotech&#x2019;s strategic partner for the exclusive commercialization of SIMLANDI in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 26 February 2024, the Company announced the sale of 10,127,132 Ordinary Shares for an approximate value of $166&#160;million (net proceeds of $160&#160;million), par value USD 0.01 per share, at a purchase price of $16.41 per share, or ISK 2,250 per share at the foreign exchange rates on 23 February 2024. The Shares will be delivered to the Investors from previously issued treasury shares held by Alvotech&#x2019;s subsidiary, Alvotech Manco ehf. The Transaction took place on the Nasdaq Iceland Exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 12 February 2024, the second tranche of OACB Earn Out Shares vested resulting in the issuance of 625,000 Ordinary Shares. The issuance of Ordinary Shares for the second tranche will be accounted for as an extinguishment of a financial liability in the consolidated statements of profit or loss and other comprehensive income or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On 12 February 2024, the first tranche of Predecessor Earn Out Shares vested resulting in the issuance of 19,165,000 Ordinary Shares. The issuance of Ordinary Shares for the first tranche will be accounted for as an extinguishment of a financial liability in the consolidated statements of profit or loss and other comprehensive income or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subsequent to 31&#160;December 2023, Senior Bond Warrant holders elected to exercise their warrants. As a result,  1,501,599 Ordinary Shares were issued in exchange for the exercising of the penny warrants. The Company received an immaterial amount of cash and will recognize the transaction as an extinguishment of the derivative financial liabilities. The difference between the equity issued and carrying value of the derivative financial liabilities will be recognized in the consolidated statements of profit or loss and other comprehensive income or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subsequent to 31&#160;December 2023, holders of the OACB Warrants exercised their warrant rights for an exercise price of $11.50 for the rights to one Ordinary Share per warrant. The exercises result in the issuance of 419,660 Ordinary Shares and cash proceeds of $4.8&#160;million. The Company will recognize the transaction as an extinguishment of the derivative financial liabilities. The difference between the equity issued and carrying value of the derivative financial liabilities will be recognized in the consolidated statements of profit or loss and other comprehensive income or loss.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:Revenue contextRef="c-915" decimals="-8" id="f-2539" unitRef="usd">12200000000</ifrs-full:Revenue>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-916"
      decimals="INF"
      id="f-2540"
      unitRef="shares">10127132</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-916" decimals="-6" id="f-2541" unitRef="usd">166000000</ifrs-full:IssueOfEquity>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-917" decimals="-6" id="f-2542" unitRef="usd">160000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-918"
      decimals="INF"
      id="f-2543"
      unitRef="usdPerShare">0.01</ifrs-full:ParValuePerShare>
    <alvo:SaleOfStockIssuePricePerShare
      contextRef="c-919"
      decimals="INF"
      id="f-2544"
      unitRef="usdPerShare">16.41</alvo:SaleOfStockIssuePricePerShare>
    <alvo:SaleOfStockIssuePricePerShare
      contextRef="c-919"
      decimals="INF"
      id="f-2545"
      unitRef="iskPerShare">2250</alvo:SaleOfStockIssuePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-920"
      decimals="INF"
      id="f-2546"
      unitRef="shares">625000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-921"
      decimals="INF"
      id="f-2547"
      unitRef="shares">19165000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-922"
      decimals="INF"
      id="f-2548"
      unitRef="shares">1501599</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <alvo:ClassOfWarrantsOrRightsExercisePricePerShare
      contextRef="c-923"
      decimals="2"
      id="f-2549"
      unitRef="usdPerShare">11.50</alvo:ClassOfWarrantsOrRightsExercisePricePerShare>
    <alvo:NumberOfSharesCalledByEachWarrantOrRight
      contextRef="c-923"
      decimals="INF"
      id="f-2550"
      unitRef="shares">1</alvo:NumberOfSharesCalledByEachWarrantOrRight>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c-924"
      decimals="INF"
      id="f-2551"
      unitRef="shares">419660</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-924" decimals="-5" id="f-2552" unitRef="usd">4800000</ifrs-full:ProceedsFromExerciseOfWarrants>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
